FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Bhojraj, S
   Libby, R
AF Bhojraj, S
   Libby, R
TI RETRACTED: Capital market pressure, disclosure frequency-induced
   earnings/cash flow conflict, and managerial myopia (Retracted article.
   See vol. 90, pg. 1715, 2015)
SO ACCOUNTING REVIEW
LA English
DT Article; Retracted Publication
DE managerial myopia; capital market pressures; financial reporting;
   disclosure frequency
ID RESEARCH-AND-DEVELOPMENT; VOLUNTARY DISCLOSURE; MANAGEMENT; BEHAVIOR;
   DECISIONS; FORECASTS; EFFICIENT; FIRMS
AB We examine the effects of increased capital market pressure and disclosure frequency-induced earnings/cash flow conflict on myopic behavior. In our experiments, experienced financial managers choose between projects where a conflict exists between near-term earnings and total cash flow. Managers more often choose projects that they believe will maximize short-term earnings (and price) as opposed to total cash flows in response to increased capital market pressure resulting from a pending stock issuance, holding constant agency frictions and other stock market pressures. When faced with increased capital market pressure, changes in disclosure frequency cause managers to behave more or less myopically depending on the impact of the change on the pattern of earnings and the resulting earnings/cash flow conflict. Our study provides insights into managers' beliefs about stock market pressures, mandatory reporting, and the availability of alternative communications channels, and contributes to literature on managerial myopia and earnings management, as well as current debates over disclosure frequency.
C1 Cornell Univ, Ithaca, NY 14853 USA.
RP Bhojraj, S (reprint author), Cornell Univ, Ithaca, NY 14853 USA.
RI alrefaei, hessa/F-1443-2015
CR BABER WR, 1991, ACCOUNT REV, V66, P818
   Baginski SP, 2002, ACCOUNT REV, V77, P25, DOI 10.2308/accr.2002.77.1.25
   Bar-Gill O., 2003, MISREPORTING CORPORA
   Bartov E, 2002, J ACCOUNT ECON, V33, P173, DOI 10.1016/S0165-4101(02)00045-9
   BHOJRAJ S, 2003, MANAGERIAL CHARACTER
   Bruno F, 1966, NOT FITOSOC, V3, P1
   Bushee BJ, 1998, ACCOUNT REV, V73, P305
   BUTLER M, 2003, EFFECT REPORTING FRE
   Cloyd CB, 1996, J ACCOUNTING RES, V34, P23, DOI 10.2307/2491330
   DECHOW PM, 1991, J ACCOUNT ECON, V14, P51, DOI 10.1016/0167-7187(91)90058-S
   EVANS C, 2003, ACCOUNTANCY      APR
   FASB-Financial Accounting Standards Board, 2000, EL DISTR BUS REP INF
   GRAHAM JR, 2004, EC IMPLICATIONS CORP
   Healy P. M., 1999, ACCOUNT HORIZ, V13, P365, DOI DOI 10.2308/ACCH.1999.13.4.365
   HEALY PM, 1985, J ACCOUNT ECON, V7, P85, DOI 10.1016/0165-4101(85)90029-1
   HUNTON JA, 2003, ASSESSING IMPACT MOR
   JACOBSON R, 1993, J ACCOUNT ECON, V16, P383, DOI 10.1016/0165-4101(93)90033-C
   JONES JJ, 1991, J ACCOUNTING RES, V29, P193, DOI 10.2307/2491047
   Kasznik R, 1999, J ACCOUNTING RES, V37, P57, DOI 10.2307/2491396
   Kennedy J, 1998, J ACCOUNTING RES, V36, P257, DOI 10.2307/2491477
   Libby R, 2000, ACCOUNT REV, V75, P383, DOI 10.2308/accr.2000.75.4.383
   LIBBY R, 2002, ACCOUNT ORG SOC, V27, P775
   LYS T, 1995, J FINANC ECON, V39, P353, DOI 10.1016/0304-405X(95)00831-X
   Roychowdhury S., 2003, MANAGEMENT EARNINGS
   *SEC, 2000, 3442728 SEC
   Securities and Exchange Commission (SEC), 1969, DISCL INV REAPPR FED
   STEIN JC, 1989, Q J ECON, V104, P655, DOI 10.2307/2937861
   TEOH SH, 1998, REV ACCOUNT STUD, V3, P175, DOI DOI 10.1023/A:1009688619882
NR 28
TC 56
Z9 57
U1 4
U2 32
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0001-4826
EI 1558-7967
J9 ACCOUNT REV
JI Account. Rev.
PD JAN
PY 2005
VL 80
IS 1
BP 1
EP 20
DI 10.2308/accr.2005.80.1.1
PG 20
WC Business, Finance
SC Business & Economics
GA 894IN
UT WOS:000226784700001
DA 2018-12-27
ER

PT J
AU Yang, XY
   Feng, YF
   Tian, G
   Ge, YC
   Ge, X
   Di, Y
   Zhang, YL
   Sun, B
   Xiao, FS
AF Yang, XY
   Feng, YF
   Tian, G
   Ge, YC
   Ge, X
   Di, Y
   Zhang, YL
   Sun, B
   Xiao, FS
TI RETRACTED: Design and size control of uniform zeolite nanocrystals
   synthesized in adjustable confined voids formed by recyclable
   monodisperse polymer spheres (Retracted Article. See vol 45, pg 5729,
   2006)
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Retracted Publication
DE hydrothermal synthesis; nanocrystals; nanotechnology; polymers; zeolites
ID CATALYTIC CRACKING; POROUS STRUCTURES; BUILDING-BLOCKS; CRYSTAL SIZE;
   MFI ZEOLITE; IN-SITU; GAS-OIL; COMPLEXES; MECHANISM; GROWTH
C1 Jilin Univ, Dept Chem, Changchun 730012, Peoples R China.
   Jilin Univ, Key Lab Inorgan Synth & Preparat Chem, Changchun 730012, Peoples R China.
RP Xiao, FS (reprint author), Jilin Univ, Dept Chem, Changchun 730012, Peoples R China.
EM fsxiao@mail.jlu.edu.cn
CR AGUIAR EFS, 1998, MICROPOR MESOPOR MAT, V25, P185
   Boudreau LC, 1999, J MEMBRANE SCI, V152, P41, DOI 10.1016/S0376-7388(98)00166-5
   Breck DW, 1974, ZEOLITE MOL SIEVES S
   Bronich TK, 1997, MACROMOLECULES, V30, P3519, DOI 10.1021/ma970197o
   CAMBLOR MA, 1989, APPL CATAL, V55, P65, DOI 10.1016/S0166-9834(00)82317-9
   Camblor MA, 1998, J CATAL, V179, P537, DOI 10.1006/jcat.1998.2249
   Camblor MA, 1997, STUD SURF SCI CATAL, V105, P341
   Chen X, 2002, POLYMER, V43, P4147, DOI 10.1016/S0032-3861(02)00262-8
   Corkery RW, 1997, ZEOLITES, V18, P379, DOI 10.1016/S0144-2449(97)81256-0
   Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785
   Dong AG, 2002, ADV MATER, V14, P926, DOI 10.1002/1521-4095(20020618)14:12<926::AID-ADMA926>3.0.CO;2-1
   GABELICA Z, 1985, ACTA CHIM HUNG, V119, P275
   Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538
   Huang LM, 2000, J AM CHEM SOC, V122, P3530, DOI 10.1021/ja994240u
   Huang LM, 2001, MICROPOR MESOPOR MAT, V48, P73, DOI 10.1016/S1387-1811(01)00332-8
   JACOBS PA, 1981, J CHEM SOC CHEM COMM, P591, DOI 10.1039/c39810000591
   Kabanov AV, 1998, J AM CHEM SOC, V120, P9941, DOI 10.1021/ja981922t
   Kirschhock C. E. A., 2001, ANGEW CHEM, V113, P2707
   Kirschhock CEA, 2001, ANGEW CHEM INT EDIT, V40, P2637, DOI 10.1002/1521-3773(20010716)40:14<2637::AID-ANIE2637>3.0.CO;2-7
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Madsen C, 1999, CHEM COMMUN, P673, DOI 10.1039/a901228a
   Mintova S, 2002, ANGEW CHEM INT EDIT, V41, P2558, DOI 10.1002/1521-3773(20020715)41:14<2558::AID-ANIE2558>3.0.CO;2-0
   Mintova S, 1999, SCIENCE, V283, P958, DOI 10.1126/science.283.5404.958
   MINTOVA S, 2002, ANGEW CHEM, V114, P2670
   MITSUI O, 1985, Patent No. 3441072
   NOTARI B, 1987, INNOVATION ZEOLITE M, V37, P413
   Pauling L., 1960, NATURE CHEM BOND STR
   PERSSON AE, 1994, ZEOLITES, V14, P557, DOI 10.1016/0144-2449(94)90191-0
   RAJAGOPALAN K, 1986, APPL CATAL, V23, P69, DOI 10.1016/S0166-9834(00)81453-0
   Raman NK, 1996, CHEM MATER, V8, P1682, DOI 10.1021/cm960138+
   SCHOEMAN BJ, 1993, J CHEM SOC CHEM COMM, P994, DOI 10.1039/c39930000994
   SCHOEMAN BJ, 1994, ZEOLITES, V14, P208, DOI 10.1016/0144-2449(94)90157-0
   SCHOEMAN BJ, 1994, ZEOLITES, V14, P110, DOI 10.1016/0144-2449(94)90004-3
   Solomatin SV, 2003, LANGMUIR, V19, P8069, DOI 10.1021/la0300151
   Valkenberg MH, 2002, CATAL REV, V44, P321, DOI 10.1081/CR-120003497
   VANDERPOL AJHP, 1992, APPL CATAL A-GEN, V92, P113, DOI 10.1016/0926-860X(92)80310-9
   Wakihara T, 2003, J AM CHEM SOC, V125, P12388, DOI 10.1021/ja0363765
   Wang HT, 2000, CHEM COMMUN, P2333, DOI 10.1039/b006518h
   Wang HT, 2003, J AM CHEM SOC, V125, P9928, DOI 10.1021/ja036071q
   Wang HT, 2002, CHEM COMMUN, P1708, DOI 10.1039/b204854j
   Wang HT, 2002, J MATER CHEM, V12, P3640, DOI 10.1039/b207394c
   YAMAMURA M, 1994, ZEOLITES, V14, P643, DOI 10.1016/0144-2449(94)90121-X
   YANAGISAWA T, 1990, B CHEM SOC JPN, V63, P988, DOI 10.1246/bcsj.63.988
   Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E
   YING JY, 1999, ANGEW CHEM, V111, P58
   Zhang BJ, 2000, CHEM COMMUN, P781, DOI 10.1039/b001528h
   Zhang G, 2003, J COLLOID INTERF SCI, V263, P467, DOI 10.1016/S0021-9797(03)00340-0
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zones SI, 1996, CURR OPIN SOLID ST M, V1, P107, DOI 10.1016/S1359-0286(96)80018-0
NR 49
TC 20
Z9 20
U1 7
U2 48
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2005
VL 44
IS 17
BP 2563
EP 2568
DI 10.1002/anie.200462187
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 922WY
UT WOS:000228871800020
PM 15782369
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Ito, M
AF Fujii, Y
   Tanaka, H
   Ito, M
TI RETRACTED: A randomized clinical trial of a single dose of ramosetron
   for the prevention of vomiting after strabismus surgery in children - A
   dose-ranging study (Retracted article. See vol. 130, pg. 952, 2012)
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
ID GRANISETRON
AB Background: Postoperative vomiting (POV) after pediatric strabismus surgery remains a major problem.
   Objective: To evaluate the efficacy and safety of a single dose of ramosetron, a new serotonin antagonist, for preventing POV in children undergoing strabismus surgery.
   Method: In a prospective, randomized, double-masked, placebo-controlled study, 80 children (38 boys and 42 girls), aged 4 to 10 years, scheduled for strabismus surgery, received intravenously either placebo or ramosetron at I of 3 different doses (3 mug/kg, 6 mug/kg, or 12 mug/kg) (n=20 each) at the end of the surgical procedure. A standard general anesthetic technique was used.
   Main Outcome Measures: Emetic episodes were recorded and safety assessments performed during the first and second 24-hour periods (ie, 0-24 and 24-48 hours) after receiving anesthesia.
   Results: The rate of patients who were emesis-free (defined as no retching and no vomiting), during the 0- to 24-hour period after anesthesia was 35% with 3 mug/kg of ramosetron (P=.37), 90% with 6 mug/kg of ramosetron (P=.001), and 90% with 12 mug/kg of ramosetron (P=.001) compared with placebo (25%). The corresponding rate during the 24- to 48-hour period after anesthesia was 40% (P=.371), 90% (P=.001), and 90% (P=.001), respectively, compared with placebo (30%). No clinically important adverse events were observed in any group.
   Conclusions: A 6-mug/kg dose of ramosetron is sufficient, but a 3-mug/kg dose is insufficient for preventing POV during the 0- to 48-hour period after anesthesia in children undergoing strabismus surgery. Increasing the dose to 12 mug/kg of ramosetron provides no demonstrable additional benefit.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Ophthalmol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   FLEISHER LA, 1996, CLIN ANESTH, P443
   FUJIHARA A, 1994, CLIN REP, V28, P2337
   Fujii Y, 2001, BRIT J OPHTHALMOL, V85, P670, DOI 10.1136/bjo.85.6.670
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   LERMAN J, 1986, ANESTHESIOLOGY, V65, P322
   McCormick C., 2002, ASA NEWSL, V66, P19
   Munro HM, 1999, CAN J ANAESTH, V46, P45, DOI 10.1007/BF03012513
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 10
TC 9
Z9 9
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2005
VL 123
IS 1
BP 25
EP 28
DI 10.1001/archopht.123.1.25
PG 4
WC Ophthalmology
SC Ophthalmology
GA 886RL
UT WOS:000226245900002
PM 15642807
DA 2018-12-27
ER

PT J
AU Sato, Y
   Kanoko, T
   Satoh, K
   Iwamoto, J
AF Sato, Y
   Kanoko, T
   Satoh, K
   Iwamoto, J
TI RETRACTED: Menatetrenone and vitamin D2 with calcium supplements prevent
   nonvertebral fracture in elderly women with Alzheimer's disease
   (Retracted article. See vol. 106, pg. 213, 2018)
SO BONE
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; fracture; menatetrenone; vitamin D; vitamin K
ID BONE-MINERAL DENSITY; HIP FRACTURE; STROKE PATIENTS;
   PSYCHIATRIC-ILLNESS; PARKINSONS-DISEASE; CIRCULATING LEVELS;
   HYPOVITAMINOSIS D; K INTAKE; OSTEOPOROSIS; AMELIORATION
AB A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer's disease (AD), who are prone to falls and may have osteoporosis. We previously showed deficiency of vitamins D and K1 causes reduced bone mineral density (BMD) in female AD patients. The present study was undertaken to address the possibility that treatment with vitamin K2 (menatetrenone,MK-4) may maintain BMD and reduce the incidence of nonvertebral fractures in elderly female patients with AD. In a random and prospective study of AD patients, 100 patients received 45 mg menatetrenone, 1000 IU ergocalciferol and 600 mg calcium daily for 2 years, and the remaining 100 (untreated group) did not. At baseline, patients of both groups showed vitamin D and K1 deficiencies. They also had high serum levels of parathyroid hormone (PTH) and Glu osteocalcin (OC) and low serum ionized calcium, indicating that vitamin D deficiency stimulates compensatory PTH secretion. During the 2-year Study period, BMD in the second metacarpals increased by 2.3% in the treated group and decreased by 5.2% in the untreated group (P < 0.0001). Serum levels of vitamin K2 and 25-hydroxyvitamin D increased by 284.9% and 147.9%, respectively, in the treated group. Correspondingly, a significant decrease in Glu OC and PTH were observed, in association with an increased calcium levels, in the treated group. Twenty-two patients in the untreated group sustained nonvertebral fractures (15 with hip fractures, two fractures each at the distal forearm and the proximal femur, each one fracture at the proximal humerus, ribs, and pelvis), and three fractures (2 with hip fractures, one fracture at the proximal femur) Occurred among the treated patients (P = 0.0003; odds ratio = 7.5). Treatment with MK-4 and vitamin D2 with calcium supplements increases the BMD in elderly female patients with AD and leads to the prevention of nonvertebral fractures. (C) 2004 Elsevier Inc. All rights reserved.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Futase Social Insurance Hosp, Dept Neurol, Iizuka, Fukuoka 8200054, Japan.
   Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 0368562, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 0368562, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo 1608582, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR BITENSKY L, 1988, J BONE JOINT SURG BR, V70, P663
   Booth SL, 2003, AM J CLIN NUTR, V77, P512
   BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492
   BURNS A, 1989, PSYCHOL MED, V19, P383, DOI 10.1017/S0033291700012423
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   Feskanich D, 1999, AM J CLIN NUTR, V69, P74
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Francis RM, 1996, OSTEOPOROSIS INT, V6, P284, DOI 10.1007/BF01623386
   Guirguis-Blake J, 2003, J FAM PRACTICE, V52, P431
   HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268
   HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497
   HODGES SJ, 1993, J BONE MINER RES, V8, P1241
   HODGES SJ, 1991, BONE, V12, P387, DOI 10.1016/8756-3282(91)90027-G
   Holmes J, 2000, PSYCHOL MED, V30, P921, DOI 10.1017/S0033291799002548
   Johansson C, 1996, AGING CLIN EXP RES, V8, P189, DOI 10.1007/BF03339676
   KIPEN E, 1995, J AM GERIATR SOC, V43, P1088, DOI 10.1111/j.1532-5415.1995.tb07005.x
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   LANGENBERG JP, 1984, J CHROMATOGR, V289, P377, DOI 10.1016/S0021-9673(00)95103-3
   Lark RK, 2001, AM J CLIN NUTR, V73, P602
   Matsueda M, 2000, Am J Orthop (Belle Mead NJ), V29, P691
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MELTON LJ, 1994, J AM GERIATR SOC, V42, P614, DOI 10.1111/j.1532-5415.1994.tb06859.x
   Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P2448, DOI 10.1001/jama.284.19.2448-JLT1115-4-1
   Nightingale S, 2001, LANCET, V357, P1264, DOI 10.1016/S0140-6736(00)04421-4
   Orimo H, 1998, J BONE MINER METAB, V16, P106, DOI 10.1007/s007740050034
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x
   Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919
   Sato Y, 2002, BONE, V31, P114, DOI 10.1016/S8756-3282(02)00783-4
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 1999, AM J PHYS MED REHAB, V78, P457, DOI 10.1097/00002060-199909000-00008
   Sato Y, 1997, STROKE, V28, P736, DOI 10.1161/01.STR.28.4.736
   SATO Y, IN PRESS ARCH PHYS M
   SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9
   SZULC P, 1994, J BONE MINER RES, V9, P1591
   van Staa TP, 2002, BONE, V31, P508, DOI 10.1016/S8756-3282(02)00848-7
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Vergnaud P, 1997, J CLIN ENDOCR METAB, V82, P719, DOI 10.1210/jc.82.3.719
   VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1
NR 45
TC 42
Z9 45
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD JAN
PY 2005
VL 36
IS 1
BP 61
EP 68
DI 10.1016/j.bone.2004.09.018
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 893QE
UT WOS:000226733500008
PM 15664003
DA 2018-12-27
ER

PT J
AU Schmidt, SC
   Langrehr, JM
   Hintze, RE
   Neuhaus, P
AF Schmidt, SC
   Langrehr, JM
   Hintze, RE
   Neuhaus, P
TI RETRACTED: Long-term results and risk factors influencing outcome of
   major bile duct injuries following cholecystectomy (Retracted Article.
   See vol 93, pg 1562, 2006)
SO BRITISH JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
ID HEPATIC-ARTERY INJURIES; LAPAROSCOPIC CHOLECYSTECTOMY; BILIARY
   STRICTURES; SURGICAL THERAPY; MANAGEMENT; HEPATICOJEJUNOSTOMY; LESIONS;
   REPAIR; CLASSIFICATION; COMPLICATIONS
AB Background: Major bile duct injuries usually need operative repair and remain a challenge even for surgeons who specialize in hepatobiliary surgery. The purpose of this study was to evaluate management and short- and long-term outcomes of patients with major complications after cholecystectomy. Methods: Data were analysed for 54 patients who underwent operation for major bile duct injuries after cholecystectomy between January 1990 and January 2002. Univariate and multivariate analyses were performed to identify risk factors for the development of biliary complications. Results: Complete follow-up data were available for all 54 patients (median duration 61.9 (range 2.6-154.3) months). All underwent Roux-en-Y hepaticojejunostomy. Three patients (6 per cent) died from biliary tract complications during follow-up. Long-term biliary complications occurred in ten patients (19 per cent). Nine patients developed biliary stricture of whom five developed secondary biliary cirrhosis. A successful long-term result was achieved in 50 (93 per cent) of 54 patients, including those who required subsequent procedures. Biliary reconstruction in the presence of peritonitis (P = 0.002), combined vascular and bile duct injuries (P = 0.029), and injury at or above the level of the biliary bifurcation (P = 0.012) were significant independent predictors of poor outcome. Conclusion: Successful repair of bile duct injuries after cholecystectomy can be achieved in specialized hepatobiliary units.
C1 Humboldt Univ, Dept Gen Visceral & Transplantat Surg, Div Cent Interdisciplinary Endoscopy, D-13353 Berlin, Germany.
   Humboldt Univ, Dept Gastroenterol & Hepatol, Div Cent Interdisciplinary Endoscopy, D-13353 Berlin, Germany.
RP Schmidt, SC (reprint author), Humboldt Univ, Dept Gen Visceral & Transplantat Surg, Div Cent Interdisciplinary Endoscopy, Charite Campus Virchow Clin,Augustenburger Pl 1, D-13353 Berlin, Germany.
EM sven.schmidt@charite.de
CR Adamsen S, 1997, J AM COLL SURGEONS, V184, P571
   Ahrendt SA, 2001, WORLD J SURG, V25, P1360, DOI 10.1007/s00268-001-0124-2
   BACHA EA, 1994, LANCET, V344, P896, DOI 10.1016/S0140-6736(94)92873-8
   Bachellier P, 2001, WORLD J SURG, V25, P1335, DOI 10.1007/s00268-001-0120-6
   Bismuth H, 2001, WORLD J SURG, V25, P1241, DOI 10.1007/s00268-001-0102-8
   Bismuth H, 1982, BILIARY TRACT, P209
   BISMUTH H, 1981, TRAUMATISMES OPERATO, V1
   BLUMGART LH, 1994, SURG CLIN N AM, V74, P845, DOI 10.1016/S0039-6109(16)46385-1
   BLUMGART LH, 1984, BRIT J SURG, V71, P836, DOI 10.1002/bjs.1800711110
   Buell JF, 2002, ARCH SURG-CHICAGO, V137, P703, DOI 10.1001/archsurg.137.6.703
   CSENDES A, 1992, HEPATO-GASTROENTEROL, V39, P333
   Fletcher DR, 1999, ANN SURG, V229, P449, DOI 10.1097/00000658-199904000-00001
   Gupta N, 1998, ARCH SURG-CHICAGO, V133, P176, DOI 10.1001/archsurg.133.2.176
   HALASZ NA, 1991, ARCH SURG-CHICAGO, V126, P137
   HEPP J, 1985, WORLD J SURG, V9, P507, DOI 10.1007/BF01655291
   Johnson SR, 2000, SURGERY, V128, P668, DOI 10.1067/msy.2000.108422
   Koffron A, 2001, SURGERY, V130, P722, DOI 10.1067/msy.2001.116682
   Lillemoe KD, 1997, ANN SURG, V225, P459, DOI 10.1097/00000658-199705000-00003
   LINDENAUER SM, 1973, SURGERY, V73, P875
   MADARIAGA JR, 1994, J AM COLL SURGEONS, V179, P321
   Mirza DF, 1997, BRIT J SURG, V84, P786, DOI 10.1002/bjs.1800840614
   Murr MM, 1999, ARCH SURG-CHICAGO, V134, P604, DOI 10.1001/archsurg.134.6.604
   Nealon WH, 1996, ANN SURG, V223, P639, DOI 10.1097/00000658-199606000-00002
   Neuhaus P, 2000, CHIRURG, V71, P166, DOI 10.1007/s001040051033
   PELLEGRINI CA, 1984, AM J SURG, V147, P175, DOI 10.1016/0002-9610(84)90054-0
   PITT HA, 1989, ANN SURG, V210, P417, DOI 10.1097/00000658-198910000-00001
   Robertson AJ, 1998, TRANSPLANT INT, V11, P449, DOI 10.1007/s001470050173
   ROSLYN JJ, 1993, ANN SURG, V218, P129, DOI 10.1097/00000658-199308000-00003
   Savader SJ, 1997, ANN SURG, V225, P268, DOI 10.1097/00000658-199703000-00005
   STEWART L, 1995, ARCH SURG-CHICAGO, V130, P1123
   STRASBERG SM, 1995, J AM COLL SURGEONS, V180, P101
   Sutherland F, 1999, ARCH SURG-CHICAGO, V134, P299, DOI 10.1001/archsurg.134.3.299
   Tocchi A, 1996, ANN SURG, V224, P162, DOI 10.1097/00000658-199608000-00008
   Wherry DC, 1996, ANN SURG, V224, P145, DOI 10.1097/00000658-199608000-00006
NR 34
TC 121
Z9 147
U1 5
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-1323
J9 BRIT J SURG
JI Br. J. Surg.
PD JAN
PY 2005
VL 92
IS 1
BP 76
EP 82
DI 10.1002/bjs.4775
PG 7
WC Surgery
SC Surgery
GA 892RL
UT WOS:000226667600014
PM 15521078
DA 2018-12-27
ER

PT J
AU Yang, ZF
   Ho, DW
   Lam, CT
   Luk, JM
   Lum, CT
   Yu, WC
   Poon, RT
   Fan, ST
AF Yang, ZF
   Ho, DW
   Lam, CT
   Luk, JM
   Lum, CT
   Yu, WC
   Poon, RT
   Fan, ST
TI RETRACTED: Identification of brain-derived neurotrophic factor as a
   novel functional protein in hepatocellular carcinoma (Retracted article.
   See vol. 78, pg. 3400, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID LIPIODOL CHEMOEMBOLIZATION; GENE-THERAPY; RAT MODEL; TRKB; EXPRESSION;
   HSP90; TRANSPLANTATION; NEUROBLASTOMA; TECHNOLOGY; ADENOVIRUS
AB This study aims to identify a novel molecule that may contribute to hepatocarcinogenesis in a rat orthotopic hepatocellular carcinoma model. The hepatocellular carcinoma model was generated by injection of tumor cells into the left lobe of the liver. Proteomic approaches, including ProteinChip and two-dimensional electrophoresis, were used to identify proteins from serially collected rat serum samples. By both ProteinChip and two-dimensional electrophoresis techniques, the level of a 27-kDa protein was found to be augmented in serum samples during tumor development, decreased after left lobectomy, and reincreased at the time of tumor recurrence. The protein was identified to be brain-derived neurotrophic factor (BDNF). By using specific primers and monoclonal antibody, the expression pattern of BDNF was confirmed in tumor tissue but not in the adjacent nontumorous liver tissue. In addition, the truncated isoform of BDNF receptor-tyrosine protein kinase receptor B was only found in tumor tissue. An in vitro study showed that exogenous BDNF could induce tumor cell proliferation predominantly in relatively small numbers of inoculated cells. Administration of BDNF to tumor cell lines induced significantly increased expression of heat shock protein 90 (Usp90) and cyclin D1, and blocking the activity of Hsp90 could reverse the up-regulation of cyclin D1 induced by BDNF. The present study revealed that BDNF and its receptor were uniquely expressed in tumor tissue and cell lines of hepatocellular carcimona but not in nontumorous liver tissue and normal cell line. BDNF could stimulate tumor cell proliferation in a Hsp90-dependent manner.
C1 Univ Hong Kong, Ctr Study Liver Dis, Pokfulam, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China.
RP Poon, RT (reprint author), Hong Kong Queen Mary Hosp, Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM poontp@hkucc.hku.hk
RI Fan, Sheung Tat/C-4138-2009; Luk, John/A-4085-2008; Poon,
   Ronnie/C-4383-2009
OI Luk, John/0000-0002-6323-7940; 
CR Anderson SC, 1998, CLIN CANCER RES, V4, P1649
   Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456
   Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200
   Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585
   Diogenes MJ, 2004, J NEUROSCI, V24, P2905, DOI 10.1523/JNEUROSCI.4454-03.2004
   Edsjo A, 2003, LAB INVEST, V83, P813, DOI 10.1097/01.LAB.0000074895.48776.D8
   Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100
   Goggi J, 2003, BRAIN RES, V968, P156, DOI 10.1016/S0006-8993(03)02234-0
   *GROUP ET TRAIT CA, 1995, NEW ENGL J MED, V332, P1256, DOI DOI 10.1056/NEJM199505113321903
   Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401
   Haapasalo A, 2002, J BIOL CHEM, V277, P43160, DOI 10.1074/jbc.M205202200
   Ho R, 2002, CANCER RES, V62, P6462
   Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200
   Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
   Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Melle C, 2004, INT J ONCOL, V24, P885
   Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529
   Noga O, 2003, CLIN EXP ALLERGY, V33, P649, DOI 10.1046/j.1365-2222.2003.01586.x
   Raoul JL, 1997, HEPATOLOGY, V26, P1156
   Rosty C, 2002, CANCER RES, V62, P1868
   Schmitz V, 2001, HEPATOLOGY, V34, P72, DOI 10.1053/jhep.2001.25757
   Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399
   Tokuyama W, 1998, MOL BRAIN RES, V62, P206, DOI 10.1016/S0169-328X(98)00261-7
   Zeindl-Eberhart E, 2004, HEPATOLOGY, V39, P540, DOI 10.1002/hep.20060
NR 27
TC 75
Z9 90
U1 2
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2005
VL 65
IS 1
BP 219
EP 225
PG 7
WC Oncology
SC Oncology
GA 884JF
UT WOS:000226080200028
PM 15665298
DA 2018-12-27
ER

PT J
AU Knight, KR
   Shinkel, TA
   Cowan, PJ
   Romeo-Meeuw, R
   d'Apice, AJF
   Morrison, WA
AF Knight, KR
   Shinkel, TA
   Cowan, PJ
   Romeo-Meeuw, R
   d'Apice, AJF
   Morrison, WA
TI RETRACTED: Transgenic expression of human complement regulators reduces
   skeletal muscle ischaemia/reperfusion injury in mice (Retracted article.
   See vol. 115, pg. 263, 2008)
SO CLINICAL SCIENCE
LA English
DT Article; Retracted Publication
DE complement activation; ischaemia/reperfusion; pathophysiology;
   transgenic mice
ID ISCHEMIA-REPERFUSION INJURY; RECOMBINANT SOLUBLE CD46; MEMBRANE ATTACK
   COMPLEX; MATRIX IN-VITRO; ISCHEMIA/REPERFUSION INJURY;
   ENDOTHELIAL-CELLS; INHIBITING ACTIVITIES; FUNCTIONAL-ANALYSIS;
   ACTIVATION; NEUTROPHILS
AB This study aimed to explore the hypothesis that activated complement components contribute significantly to I/R (ischaemia/reperfusion) injury in skeletal muscle. After 50, 70 and 90 min of tourniquet ischaemia and 24 h of reperfusion, viability of the medial gastrocnemius muscle in CBA-C57BL/6 wild-type mice, assessed histochemically by reduction of NBT (Nitro Blue Tetrazolium) dye, was 60, 21 and 8% respectively. Skeletal muscle viability after 70 min of ischaemia and 24 h of reperfusion in transgenic mice expressing a combination of human CD46, CD55 and CD59. all inhibitors of complement activation, was 45% compared with 24% in ischaemic reperfused wild-type mice (P = 0.008; n = 6 per group). Muscle from sham-treated transgenic mice and wildtype littermates had no significant loss of viability relative to normal contralateral gastrocnemius muscle. A significant reduction in myeloperoxidase activity (a measure of neutrophil infiltration), xanthine oxidase activity (a source of free radicals) and water content (a measure of oedema) was observed in ischaemic reperfused muscle from transgenic mice compared with ischaemic reperfused wild-type muscle (P < 0.05). Haematoxylin and eosin-stained histological sections also showed less damage and less apparent leucocyte infiltration in muscles from ischaemic reperfused transgenic mice than those from wild-type animals given the same degree of injury. Muscles from sham-treated transgenic and wild-type controls were almost identical with normal muscle. It is concluded that complement activation contributes to the pathogenesis of I/R injury in murine skeletal muscle, resulting in increased neutrophil infiltration into the injured muscle, increased free radical production and vascular permeability during reperfusion, and a net detrimental effect on muscle viability.
C1 St Vincents Hosp, Bernard O Brien Inst Microsurg, Fitzroy, Vic 3065, Australia.
   Univ Melbourne, St Vincents Hosp, Dept Surg, Fitzroy, Vic 3065, Australia.
   St Vincents Hosp, Immunol Res Ctr, Fitzroy, Vic 3065, Australia.
   Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
RP Knight, KR (reprint author), Bernard O Brien Inst Microsurg, 42 Fitzroy St, Fitzroy, Vic 3065, Australia.
EM knightkr@svhm.org.au
OI Cowan, Peter/0000-0001-9016-4954
CR Andoh A, 2001, DIGESTION, V63, P103, DOI 10.1159/000051920
   Barker JE, 2001, J PATHOL, V194, P109, DOI 10.1002/path.845
   BENGTSON A, 1987, BRIT J SURG, V74, P697, DOI 10.1002/bjs.1800740816
   BISHOP MJ, 1991, AM REV RESPIR DIS, V143, P386, DOI 10.1164/ajrccm/143.2.386
   BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V
   CARDEN DL, 1988, PHYSIOLOGIST, V31, pA30
   Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408
   Christiansen D, 1996, IMMUNOLOGY, V87, P348
   Christiansen D, 1996, EUR J IMMUNOL, V26, P578, DOI 10.1002/eji.1830260312
   Collard CD, 1997, CIRCULATION, V96, P326
   Fleming SD, 2003, CLIN IMMUNOL, V106, P55, DOI 10.1016/S1521-6616(02)00021-9
   GOLDMAN G, 1990, ANN SURG, V211, P196, DOI 10.1097/00000658-199002000-00012
   GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504
   Grunenfelder J, 2002, J INVEST SURG, V15, P281, DOI 10.1080/08941930290086065
   Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x
   HEIDEMAN M, 1988, ARCH SURG-CHICAGO, V123, P188
   HICKEY MJ, 1992, J SURG RES, V53, P369, DOI 10.1016/0022-4804(92)90063-6
   Hindmarsh EJ, 1998, J IMMUNOL, V160, P6128
   Hindmarsh EJ, 1998, EUR J IMMUNOL, V28, P1052, DOI 10.1002/(SICI)1521-4141(199803)28:03<1052::AID-IMMU1052>3.3.CO;2-N
   HOU J, 2000, ZHONGGUO YIXUE KEXUE, V2, P80
   Jordan JE, 2001, CIRCULATION, V104, P1413, DOI 10.1161/hc3601.095578
   KNIGHT KR, 1991, CLIN SCI, V80, P235, DOI 10.1042/cs0800235
   Kyriakides C, 1999, AM J PHYSIOL-CELL PH, V277, pC1263, DOI 10.1152/ajpcell.1999.277.6.C1263
   LABBE R, 1988, J SURG RES, V44, P45, DOI 10.1016/0022-4804(88)90121-7
   Lazarus B, 2000, J PATHOL, V191, P443, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH666>3.0.CO;2-L
   MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321
   PEMBERTON M, 1993, J IMMUNOL, V150, P5104
   RUBIN BB, 1990, AM J PHYSIOL, V259, pH525
   Rubin BB, 1996, J APPL PHYSIOL, V80, P369
   Scoazec JY, 1997, GASTROENTEROLOGY, V112, P908, DOI 10.1053/gast.1997.v112.pm9041253
   Shinkel TA, 1998, TRANSPLANTATION, V66, P1401, DOI 10.1097/00007890-199812150-00001
   STAHL GL, 1995, CIRC RES, V76, P575, DOI 10.1161/01.RES.76.4.575
   Stahl GL, 2003, AM J PATHOL, V162, P449, DOI 10.1016/S0002-9440(10)63839-4
   Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517
   VANDENBERG CW, 1994, J IMMUNOL, V152, P4095
   Ward PA, 1996, AM J PATHOL, V149, P1079
   Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343
   WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562
   Wheeler SF, 2002, GLYCOBIOLOGY, V12, P261, DOI 10.1093/glycob/12.4.261
   Zhang BM, 1997, CLIN SCI, V93, P167, DOI 10.1042/cs0930167
NR 41
TC 4
Z9 4
U1 3
U2 10
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD JAN
PY 2005
VL 108
IS 1
BP 47
EP 53
DI 10.1042/CS20040236
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 885GN
UT WOS:000226145200005
PM 15341509
DA 2018-12-27
ER

PT J
AU Sjostrand, M
   Gudbjornsdottir, S
   Strindberg, L
   Lonnroth, P
AF Sjostrand, M
   Gudbjornsdottir, S
   Strindberg, L
   Lonnroth, P
TI RETRACTED: Delayed transcapillary delivery of insulin to muscle
   interstitial fluid after oral glucose load in obese subjects (Retracted
   Article. See vol 54, pg 2266, 2005)
SO DIABETES
LA English
DT Article; Retracted Publication
ID MEDIATED CAPILLARY RECRUITMENT; HUMAN SKELETAL-MUSCLE; BLOOD-FLOW;
   IN-VIVO; RESISTANCE; TRANSPORT; RATS; NIDDM; HYPERINSULINEMIA;
   MICRODIALYSIS
AB Obese subjects exhibit a delay in insulin action and delivery of insulin to muscle interstitial fluid during glucose/insulin infusion. The aim of the present study was to follow the distribution of insulin to skeletal muscle after an oral glucose load in obese subjects. We conducted an oral glucose tolerance test (OGTT) in 10 lean and 10 obese subjects (BMI 23 +/- 0.6 vs. 33 +/- 1.2 kg/m(2); P < 0.001). Insulin measurements in muscle interstitial fluid were combined with forearm arteriovenous catheterization and blood flow measurements. In the obese group, interstitial insulin was significantly (35-55%) lower than plasma insulin (P < 0.05) during the 1st h after the OGTT, whereas in lean subjects, no significant difference was found between interstitial and plasma insulin levels during the same time period. The permeability surface area product for glucose, representing capillary recruitment, increased in the lean group (P +/- 0.05) but not in the obese group (NS). Obese subjects had a significantly higher plasma insulin level at 90-120 min after oral glucose (398 +/- 57 vs. 224 +/- 37 pmol/l in control subjects; P < 0.05). The significant gradient between plasma insulin and muscle interstitial insulin during the first hour after OGTT suggests a slow delivery of insulin in obese subjects. The hindered transcapillary transport of insulin may be attributable to a defect in insulin-mediated capillary recruitment.
C1 Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden.
RP Sjostrand, M (reprint author), Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden.
EM mikaela.sjostrand@medic.gu.se
CR ADER M, 1994, AM J PHYSIOL, V266, pE17
   BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124
   BEARD JC, 1987, J CLIN ENDOCR METAB, V65, P59, DOI 10.1210/jcem-65-1-59
   Bergman R N, 1990, Horm Metab Res Suppl, V24, P49
   CASTILLO C, 1994, J CLIN INVEST, V93, P10, DOI 10.1172/JCI116932
   Clerk LH, 2002, DIABETES, V51, P1138, DOI 10.2337/diabetes.51.4.1138
   Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404
   DELA F, 1995, DIABETES, V44, P221, DOI 10.2337/diabetes.44.2.221
   GARVEY WT, 1985, J CLIN INVEST, V76, P22, DOI 10.1172/JCI111950
   Gautier JF, 2001, DIABETES, V50, P1828, DOI 10.2337/diabetes.50.8.1828
   Getty L, 1998, DIABETES, V47, P1941, DOI 10.2337/diabetes.47.12.1941
   GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909
   Gudbjornsdottir S, 2003, J CLIN ENDOCR METAB, V88, P4559, DOI 10.1210/jc.2003-030434
   Herkner H, 2003, EUR J CLIN INVEST, V33, P141, DOI 10.1046/j.1365-2362.2003.01106.x
   Holmang A, 1997, DIABETES, V46, P1799, DOI 10.2337/diabetes.46.11.1799
   Holmang A, 2001, ACTA PHYSIOL SCAND, V171, P427, DOI 10.1046/j.1365-201X.2001.00801.x
   JANSSON PAE, 1993, DIABETES, V42, P1469, DOI 10.2337/diabetes.42.10.1469
   Kalliokoski KK, 2003, INT J SPORTS MED, V24, P400
   LAAKSO M, 1990, DIABETES, V39, P965, DOI 10.2337/diabetes.39.8.965
   LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644
   LAAKSO M, 1992, DIABETES, V41, P1076, DOI 10.2337/diabetes.41.9.1076
   LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088
   LONNROTH P, 1987, AM J PHYSIOL, V253, pE228
   Mather KJ, 2002, DIABETES, V51, P3517, DOI 10.2337/diabetes.51.12.3517
   Miles PDG, 1998, J CLIN INVEST, V101, P202, DOI 10.1172/JCI1256
   Mokshagundam SPL, 1996, METABOLISM, V45, P951, DOI 10.1016/S0026-0495(96)90261-9
   Niklasson M, 1998, DIABETOLOGIA, V41, P1467, DOI 10.1007/s001250051093
   Niklasson M, 2000, J APPL PHYSIOL, V88, P2116
   Nolan JJ, 1997, DIABETES, V46, P994, DOI 10.2337/diabetes.46.6.994
   PAASKE WP, 1977, ACTA PHYSIOL SCAND, V101, P1, DOI 10.1111/j.1748-1716.1977.tb05977.x
   PRAGER R, 1986, J CLIN INVEST, V78, P472, DOI 10.1172/JCI112599
   SCHMITZ O, 1986, ACTA ENDOCRINOL-COP, V113, P559, DOI 10.1530/acta.0.1130559
   SIGGAARDANDERSE.J, 1970, DANISH MED B      S1, V17, P1
   Sjostrand M, 1999, AM J PHYSIOL-ENDOC M, V276, pE151
   Sjostrand M, 2002, DIABETES, V51, P2742, DOI 10.2337/diabetes.51.9.2742
   Strindberg L, 2000, SCAND J CLIN LAB INV, V60, P205, DOI 10.1080/003655100750044857
   Ueda S, 1998, J CLIN ENDOCR METAB, V83, P2126, DOI 10.1210/jc.83.6.2126
   Vincent MA, 2002, DIABETES, V51, P42, DOI 10.2337/diabetes.51.1.42
   Wallis MG, 2002, DIABETES, V51, P3492, DOI 10.2337/diabetes.51.12.3492
   Wascher TC, 2000, DIABETES, V49, P803, DOI 10.2337/diabetes.49.5.803
   WAUGH WH, 1977, CLIN CHEM, V23, P639
   YALOW RS, 1988, AM J MED, V85, P22, DOI 10.1016/0002-9343(88)90394-4
   YALOW RS, 1965, ANN NY ACAD SCI, V131, P357, DOI 10.1111/j.1749-6632.1965.tb34803.x
   YANG YJ, 1989, J CLIN INVEST, V84, P1620, DOI 10.1172/JCI114339
   Yki-Jarvinen H, 1998, DIABETOLOGIA, V41, P369, DOI 10.1007/s001250050919
   Youd JM, 2000, DIABETES, V49, P1904, DOI 10.2337/diabetes.49.11.1904
NR 46
TC 18
Z9 18
U1 3
U2 7
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD JAN
PY 2005
VL 54
IS 1
BP 152
EP 157
DI 10.2337/diabetes.54.1.152
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 886SA
UT WOS:000226247500020
PM 15616023
OA Bronze
DA 2018-12-27
ER

PT J
AU Takahashi, N
   Nakamura, T
AF Takahashi, N
   Nakamura, T
TI RETRACTED: Nano-crystalline quartz prepared by AP-CVD (Retracted
   article. See vol. 13, pg. S13, 2010)
SO ELECTROCHEMICAL AND SOLID STATE LETTERS
LA English
DT Article; Retracted Publication
ID VAPOR-PHASE EPITAXY; ATMOSPHERIC-PRESSURE; NANOCRYSTALS; NANOWIRES;
   FILMS
AB The preparation of the nano-crystalline quartz by atmospheric pressure chemical vapor deposition (AP-CVD) with the reaction of Si(OC2H5)(4), O-2, and HCl. Scanning electron microscopy and electron diffraction observations of the crystals deposited onto a Si(100) substrate showed that they showed quartz single crystal with nano-pillar morphology. (C) 2005 The Electrochemical Society.
C1 Shizuoka Univ, Dept Mat Sci & Technol, Hamamatsu, Shizuoka 4328561, Japan.
RP Takahashi, N (reprint author), Shizuoka Univ, Dept Mat Sci & Technol, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328561, Japan.
EM tntakah@ipc.shizuoka.ac.jp
CR Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0
   Bertone JF, 2003, NANO LETT, V3, P655, DOI 10.1021/nl025854r
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Dang HY, 2003, NANOTECHNOLOGY, V14, P738, DOI 10.1088/0957-4484/14/7/308
   Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047
   Heath JR, 1999, ACCOUNTS CHEM RES, V32, P388, DOI 10.1021/ar990059e
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   *JCPDS, 1999, 331161 JCPDS
   Morales AM, 1998, SCIENCE, V279, P208, DOI 10.1126/science.279.5348.208
   Takahashi N, 2003, ELECTROCHEM SOLID ST, V6, pH25, DOI 10.1149/1.1613072
   Takahashi N, 2002, J MATER CHEM, V12, P719, DOI 10.1039/b108850p
   Takahashi N, 2003, CHEM MATER, V15, P2889, DOI 10.1021/cm021712m
   Wickham JN, 2000, PHYS REV LETT, V84, P923, DOI 10.1103/PhysRevLett.84.923
NR 13
TC 2
Z9 2
U1 3
U2 12
PU ELECTROCHEMICAL SOC INC
PI PENNINGTON
PA 65 SOUTH MAIN STREET, PENNINGTON, NJ 08534 USA
SN 1099-0062
EI 1944-8775
J9 ELECTROCHEM SOLID ST
JI Electrochem. Solid State Lett.
PY 2005
VL 8
IS 5
BP C72
EP C73
DI 10.1149/1.1874652
PG 2
WC Electrochemistry; Materials Science, Multidisciplinary
SC Electrochemistry; Materials Science
GA 915SM
UT WOS:000228326600011
DA 2018-12-27
ER

PT J
AU Hamalainen, P
   Hall, M
   Howcroft, B
AF Hamalainen, P
   Hall, M
   Howcroft, B
TI RETRACTED: A framework for market discipline in bank regulatory design
   (Retracted article. See vol. 36, pg. 1039, 2009)
SO JOURNAL OF BUSINESS FINANCE & ACCOUNTING
LA English
DT Article; Retracted Publication
DE bank regulation; mandatory subordinated debt; market discipline
ID DEPOSIT INSURANCE
AB Given current debates on the future direction of regulatory design, the first objective of this paper is to contextualise the issues surrounding bank market discipline. Accordingly, the paper raises awareness of the current key themes within incentive-based regulatory design and analyses the theory underlying market discipline. This leads to the creation of a theoretical framework of market discipline, which provides a powerful tool for understanding the conditions necessary for effective market discipline and for assessing the findings of market discipline-related empirical research. The second objective is to emphasise the suitability of the theoretical framework for debates on contemporary market discipline and aiding future bank regulatory policy design, in particular, how to incorporate suitable, incentive mechanisms in international banking regulation.
C1 Univ Loughborough, Sch Business, Loughborough LE11 3TU, Leics, England.
   Univ Loughborough, Dept Econ, Loughborough LE11 3TU, Leics, England.
   Univ Loughborough, Banking Ctr, Loughborough LE11 3TU, Leics, England.
RP Hamalainen, P (reprint author), Univ Loughborough, Sch Business, Loughborough LE11 3TU, Leics, England.
EM P.K.Hamalainen@lboro.ac.uk
CR AVERY RB, 1988, J MONEY CREDIT BANK, V20, P597, DOI 10.2307/1992286
   Barth J. R., 1991, GREAT SAVINGS LOAN D
   *BAS COMM BANK SUP, 1998, ENH BANK TRANS
   Basel Committee on Banking Supervision, 1997, COR PRINC EFF BANK S
   Basel Committee on Banking Supervision, 2001, NEW BAS CAP ACC
   Basel Committee on Banking Supervision (Basel), 2000, NEW CAP AD FRAM PILL
   Berger A. N., 1991, P C BANK STRUCT COMP, P419
   Billett MT, 1998, J FINANC ECON, V48, P333, DOI 10.1016/S0304-405X(98)00014-2
   Bliss R. R., 2001, PRUDENTIAL SUPERVISI, P107
   *BOARD GOV FED RES, 2000, STAFF STUD, V173
   *BOARD GOV FED RES, 1999, STAFF STUD, V172
   BRUNI F, 1995, COPING FINANCIAL FRA, P109
   Calomiris CW, 1999, J BANK FINANC, V23, P1499, DOI 10.1016/S0378-4266(99)00028-X
   CALOMIRIS CW, 1997, POSTMODERN SAFETY NE
   CARRINGTON T, 1984, WALL STREET J   0820, pA2
   Crockett A, 2002, J BANK FINANC, V26, P977, DOI 10.1016/S0378-4266(01)00265-5
   DIAMOND DW, 1983, J POLIT ECON, V91, P401, DOI 10.1086/261155
   Dowd K., 1992, EXPERIENCE FREE BANK
   *EUR SHAD FIN REG, 1999, IMPR BAS COMM NEW CA
   European Shadow Financial Regulatory Committee, 2000, INT RAT CAP STAND SU
   Evanoff DD, 2001, CONTEMP ECON POLICY, V19, P444, DOI 10.1093/cep/19.4.444
   EVANOFF DD, 1993, YALE J REGULATION, V10, P344
   *FIN SERV AUTH, 2000, FSA RESP CRUICKSH RE
   *FIN SERV AUTH, 2000, FIN SERV AUTH NEW RE
   *FIN SERV AUTH, 2000, RESP FIN SERV AUTH C
   Flannery MJ, 1998, J MONEY CREDIT BANK, V30, P273, DOI 10.2307/2601102
   Flannery MJ, 1996, J FINANC, V51, P1347, DOI 10.2307/2329397
   GARTEN HA, 1986, YALE J REGULATION, V4, P129
   HALL MJB, 1989, BANCA NAZ LAVORO Q R, V169, P207
   HALL MJB, 2001, INT LIB CRITICAL WRI, V1
   HALL MJB, 2001, BANCA NAZL LAVORO Q, V217, P111
   HORVITZ PM, 1983, AM BANKER       0715, P3
   JONES DS, 1995, J BANK FINANC, V19, P491, DOI 10.1016/0378-4266(94)00135-P
   Kaufman GG, 1997, RES FIN SERV, V9, P35
   KUPIEC PH, 1997, FINANCE EC DISCUSSIO, V97
   Lane T., 1993, IMF STAFF PAPERS, P53
   LLEWELLYN DT, 2000, IMF CENTR BANK SEM W
   MAYES D, 2000, 10 FIN SERV AUTH
   MEYER LH, 1999, C REF BANK CAP STAND
   MORGAN DP, 2000, UNPUB BOND MARKET DI
   MORGAN DP, 2000, UNPUB RATING BANKS R
   OHARA M, 1990, J FINANC, V45, P1587, DOI 10.2307/2328751
   Park S, 1998, J MONEY CREDIT BANK, V30, P347, DOI 10.2307/2601105
   Peria MSM, 2001, J FINANC, V56, P1029, DOI 10.1111/0022-1082.00354
   SHORT H, 1997, CORPORATE GOVERNANCE, P18
   SWINDLE CS, 1995, J FINANC SERV RES, V9, P123
   *US DEP TREAS, 1991, MOD FIN SYST REC SAF
   US Shadow Financial Regulatory Committee, 2000, REF BANK CAP REG
   WALL LD, 1989, EC REV           JUL, P2
NR 49
TC 12
Z9 13
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-686X
EI 1468-5957
J9 J BUS FINAN ACCOUNT
JI J. Bus. Finan. Account.
PD JAN-MAR
PY 2005
VL 32
IS 1-2
BP 183
EP 209
DI 10.1111/j.0306-686X.2005.00592.x
PG 27
WC Business, Finance
SC Business & Economics
GA 949NL
UT WOS:000230795300007
DA 2018-12-27
ER

PT J
AU El-Remessy, AB
   Bartoli, M
   Platt, DH
   Fulton, D
   Caldwell, RB
AF El-Remessy, AB
   Bartoli, M
   Platt, DH
   Fulton, D
   Caldwell, RB
TI RETRACTED: Oxidative stress inactivates VEGF survival signaling in
   retinal endothelial cells via PI 3-kinase tyrosine nitration(Retracted
   article.See vol.129,2016)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE peroxynitrite; high glucose; apoptosis; endothelial cells; p38 MAP
   kinase; tyrosine nitration; Akt-1
ID ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; STREPTOZOTOCIN-DIABETIC
   RATS; SMOOTH-MUSCLE-CELLS; HIGH D-GLUCOSE; GROWTH-FACTOR; MEDIATED
   APOPTOSIS; POLYOL PATHWAY; PEROXYNITRITE; EXPRESSION
AB In diabetic retinopathy, endothelial cell apoptosis is paradoxically increased despite upregulation of the potent pro-survival factor VEGF We tested the hypothesis that elevated glucose levels disrupt VEGF's pro-survival function via peroxynitrite-mediated alteration of the Akt-1/p38 MAP kinase signaling pathway by studies of retinal endothelial cells in vitro. High glucose or exogenous peroxynitrite caused significant increases in apoptosis in the presence or absence of VEGF Treatment with a peroxynitrite decomposition catalyst blocked these effects, implying a causal role of peroxynitrite. Peroxynitrite or high glucose treatment also increased phosphorylation of p38 MAP kinase, whereas phosphorylation of Akt-1 was significantly decreased in basal or VEGF-stimulated conditions. High glucose- or peroxynitrite-treated cells also showed significant increases in tyrosine nitration on the p85 subunit of PI 3-kinase that blocked PI 3-kinase and Akt-1 kinase activity. Inhibiting peroxynitrite formation or blocking tyrosine nitration of p85 restored the activity of PI 3-kinase and Akt-1 kinase, blocked phosphorylation of p38 MAP kinase and normalized pro-survival function. Transfecting the cells with constitutively active Akt-1 or inhibiting activity of p38 MAP kinase completely masked the pro-apoptotic effects of high glucose and exogenous peroxynitrite, suggesting an interaction between the Akt-1 and p38 MAP kinase pathways. In conclusion, high glucose treatment blocks the pro-survival effect of VEGF and causes accelerated endothelial cell apoptosis via the action of peroxynitrite in causing tyrosine nitration of PI 3-kinase, inhibiting activity of Akt-1 kinase and increasing the activity of p38 MAP kinase.
C1 Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
RP El-Remessy, AB (reprint author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.
EM aelremessy@mcg.edu
FU NEI NIH HHS [EY11766, EY04618]
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323
   Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.0.CO;2-1
   Behzadian MA, 2003, INVEST OPHTH VIS SCI, V44, pU403
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   Cardier JE, 2002, MICROVASC RES, V63, P10, DOI 10.1006/mvre.2001.2360
   Ceriello A, 2001, DIABETOLOGIA, V44, P834
   Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076
   Cosentino F, 1997, CIRCULATION, V96, P25
   Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9
   Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899
   El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5
   Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje
   Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581
   Ido Y, 2002, DIABETES, V51, P159, DOI 10.2337/diabetes.51.1.159
   Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Karasu C, 2000, EUR J PHARMACOL, V392, P163, DOI 10.1016/S0014-2999(00)00140-0
   Kern TS, 2000, INVEST OPHTH VIS SCI, V41, P3972
   Kim NH, 2000, J ENDOCRINOL, V165, P617, DOI 10.1677/joe.0.1650617
   Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219
   Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096
   Misko TP, 1998, J BIOL CHEM, V273, P15646, DOI 10.1074/jbc.273.25.15646
   Miwa K, 2003, DIABETES RES CLIN PR, V60, P1, DOI 10.1016/S0168-8227(02)00248-6
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Morishita R, 1997, DIABETOLOGIA, V40, P1053, DOI 10.1007/s001250050787
   Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472
   Nishikawa T, 2000, NATURE, V404, P787
   Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   Quagliaro L, 2003, DIABETES, V52, P2795, DOI 10.2337/diabetes.52.11.2795
   SALGO MG, 1995, BIOCHEM BIOPH RES CO, V215, P1111, DOI 10.1006/bbrc.1995.2578
   Schroeder P, 2003, BIOCHEM BIOPH RES CO, V307, P69, DOI 10.1016/S0006-291X(03)01132-X
   Schroeder P, 2001, BIOCHEM BIOPH RES CO, V285, P782, DOI 10.1006/bbrc.2001.5210
   Shaw S, 2003, J BIOL CHEM, V278, P30634, DOI 10.1074/jbc.M305008200
   SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907
   Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506
   Turko IV, 2001, AM J PHYSIOL-HEART C, V281, pH2289
   van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860
   Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497
   Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479
   Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200
   Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198
NR 53
TC 120
Z9 125
U1 4
U2 7
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD JAN 1
PY 2005
VL 118
IS 1
BP 243
EP 252
DI 10.1242/jcs.01612
PG 10
WC Cell Biology
SC Cell Biology
GA 896JX
UT WOS:000226931500023
PM 15615788
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Motlekar, NA
   Srivenugopal, KS
   Wachtel, MS
   Youan, BBC
AF Motlekar, NA
   Srivenugopal, KS
   Wachtel, MS
   Youan, BBC
TI RETRACTED: Oral delivery of low-molecular-weight heparin using sodium
   caprate as absorption enhancer reaches therapeutic levels (Retracted
   Article. See vol 16, pg 723, 2008)
SO JOURNAL OF DRUG TARGETING
LA English
DT Article; Retracted Publication
DE sodium caprate; low molecular weight heparin; Caco-2 cell monolayer;
   absorption enhancer; ardeparin; oral absorption
ID CACO-2 CELL MONOLAYERS; IN-VIVO EVALUATION; INTESTINAL-ABSORPTION; TIGHT
   JUNCTIONS; HYDROPHILIC COMPOUNDS; RECTAL ABSORPTION; DRUG ABSORPTION;
   FATTY-ACIDS; PERMEABILITY; VITRO
AB The primary objective of this study was to evaluate sodium caprate as an oral penetration enhancer for low molecular weight heparin (LMWH), ardeparin. In vitro studies using Caco-2 cell monolayer indicated that 0.0625% of sodium caprate gave approximately 2-fold enhancement of ardeparin compared to negative control with almost 100% cell survival as evaluated by MTT cytotoxicity assay. In vivo studies in rats with ardeparin (1200 IU/kg) and sodium caprate (100 mg/kg) led to a relative bioavailability of 27% with plasma anti-factor Xa levels within the therapeutic range (>0.2 IU/ml). Moreover, under these conditions, histological examination provided evidence that there was no damage to the gastrointestinal wall. Regional permeability studies using rat intestine indicated the colon as the region of maximum permeation. These results suggest that, at the dose administered, sodium caprate acts as a relatively safe and efficient absorption enhancer in the quest for alternatives for the oral delivery of LMWH.
C1 Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
   Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Div Anat Pathol, Lubbock, TX 79430 USA.
   Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Div Res, Lubbock, TX 79430 USA.
RP Youan, BBC (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.
EM bibotti.youan@ttuhsc.edu
FU NIGMS NIH HHS [R15 GM069397, GM 069397-01A2]
CR ANDERBERG EK, 1993, PHARMACEUT RES, V10, P857, DOI 10.1023/A:1018909210879
   Arnold J, 2002, J PHARM SCI, V91, P1707, DOI 10.1002/jps.10171
   ASADA H, 1995, J PHARM SCI-US, V84, P682, DOI 10.1002/jps.2600840604
   Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
   Bertini S, 2005, BIOMACROMOLECULES, V6, P168, DOI 10.1021/bm049693s
   BIANCHINI P, 1995, HAEMOSTASIS, V25, P288
   Boneu B, 2000, THROMB RES, V100, pV113
   Cano-Cebrian Maria Jose, 2005, Current Drug Delivery, V2, P9, DOI 10.2174/1567201052772834
   Chao AC, 1999, INT J PHARM, V191, P15, DOI 10.1016/S0378-5173(99)00213-6
   Cho SY, 2002, ARCH PHARM RES, V25, P86, DOI 10.1007/BF02975268
   Hui OY, 2002, J MED CHEM, V45, P2857, DOI 10.1021/jm020001x
   KASKEL FJ, 1987, AM J PHYSIOL, V252, pF188
   KAZUHIKO KITAO KIN, 1984, Patent No. 4485033
   Knipp GT, 1997, J PHARM SCI, V86, P1105, DOI 10.1021/js9700309
   Lennernas H, 2002, J PHARM PHARMACOL, V54, P499, DOI 10.1211/0022357021778772
   Leone-Bay A, 1998, J MED CHEM, V41, P1163, DOI 10.1021/jm970811m
   LINDGREN E, 1998, CONS ECOL, V2, P5
   Lindmark T, 1997, PHARMACEUT RES, V14, P930, DOI 10.1023/A:1012112219578
   LINDMARK T, 1995, J PHARMACOL EXP THER, V275, P958
   LOBENBERG R, 2000, ORAL DRUG ABSORPTION, P137
   Lutz KL, 1997, J PHARM SCI, V86, P977, DOI 10.1021/js970134j
   MADARA JL, 1988, AM J PHYSIOL, V254, pG416
   MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125
   Mitragotri S, 2001, PHARMACEUT RES, V18, P1151, DOI 10.1023/A:1010979010907
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   MURANISHI S, 1990, CRIT REV THER DRUG, V7, P1
   NIEDUSZYNSKI I, 1989, HEPARIN CHEM BIOL PR, P51
   Nissan A, 2000, HAEMOSTASIS, V30, P225
   Quan YS, 1998, BIOL PHARM BULL, V21, P615
   Raoof AA, 2002, EUR J PHARM SCI, V17, P131, DOI 10.1016/S0928-0987(02)00162-8
   Ross Benjamin P., 2005, Current Drug Delivery, V2, P277, DOI 10.2174/1567201054367968
   Salartash K, 2000, ANN SURG, V231, P789, DOI 10.1097/00000658-200006000-00002
   SAWADA T, 1991, PHARMACEUT RES, V8, P1365, DOI 10.1023/A:1015840921203
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Sethia S, 2004, J PHARM SCI-US, V93, P2985, DOI 10.1002/jps.20199
   SHIMAZAKI T, 1990, DIGEST DIS SCI, V43, P641
   Soderholm JD, 1998, DIGEST DIS SCI, V43, P1547, DOI 10.1023/A:1018823100761
   TAKAHASHI K, 1994, PHARMACEUT RES, V11, P1401, DOI 10.1023/A:1018983620622
   TANAKA TM, 2000, HACHIOJI
   TEIEN AN, 1976, THROMB RES, V8, P413, DOI 10.1016/0049-3848(76)90034-7
   Thanou M, 2001, J PHARM SCI, V90, P38, DOI 10.1002/1520-6017(200101)90:1<38::AID-JPS5>3.3.CO;2-V
   Thanou M, 2001, ADV DRUG DELIVER REV, V52, P117, DOI 10.1016/S0169-409X(01)00231-9
   TOMITA M, 1995, J PHARMACOL EXP THER, V272, P739
   Uchiyama T, 1999, J PHARM PHARMACOL, V51, P1241, DOI 10.1211/0022357991776976
   Ward P. D., 2000, PHARM SCI TECHNOL TO, V3, P346, DOI DOI 10.1016/S1461-5347(00)00302-3
   Watson CJ, 2001, AM J PHYSIOL-CELL PH, V281, pC388
   Yamamoto A, 1997, J PHARM PHARMACOL, V49, P1057, DOI 10.1111/j.2042-7158.1997.tb06041.x
NR 47
TC 39
Z9 41
U1 3
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2005
VL 13
IS 10
BP 573
EP 583
DI 10.1080/10611860500471906
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 999JE
UT WOS:000234384800005
PM 16390818
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Field, K
AF Field, Kenneth
TI RETRACTED: Mapping the British Motor Sport Industry in Northamptonshire
   (Retracted article. See vol. 8, pg. 195, 2012)
SO JOURNAL OF MAPS
LA English
DT Article; Retracted Publication
AB This paper provides a brief overview of the preparation of the first ever small-scale map of motor sport companies in Northamptonshire, the UK's 'home of motor sport'. It describes the construction of the map and gives the reader an insight into the perceptual and design choices made in map construction as well as providing an overview of the scope of motor sport in the county.
C1 Kingston Univ, Sch Earth Sci & Geog, Kingston upon Thames KT1 2EE, Surrey, England.
RP Field, K (reprint author), Kingston Univ, Sch Earth Sci & Geog, Penrhyn Rd, Kingston upon Thames KT1 2EE, Surrey, England.
EM ken.field@kingston.ac.uk
CR Henry N, 1996, AREA, V28, P25
   *MOT RES ASS, 2003, PUNCH ITS WEIG UNPUB
NR 2
TC 1
Z9 1
U1 3
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1744-5647
J9 J MAPS
JI J. Maps
PY 2005
SI SI
BP 38
EP 45
PG 8
WC Geography; Geography, Physical
SC Geography; Physical Geography
GA V04ND
UT WOS:000207064200007
DA 2018-12-27
ER

PT J
AU Wang, WD
   Chen, ZT
   Li, DZ
   Cao, ZH
   Pu, P
   Fu, SZ
   Chen, J
   Sun, SL
   Chen, XP
AF Wang, WD
   Chen, ZT
   Li, DZ
   Cao, ZH
   Pu, P
   Fu, SZ
   Chen, J
   Sun, SL
   Chen, XP
TI RETRACTED: Detecting normal cell radiosensitivity via assay of DNA
   damage in lymphocytes for individualizing radiotherapy in head and neck
   cancer patients (Retracted article. See vol. 89, pg. 124, 2015)
SO ONCOLOGY
LA English
DT Article; Retracted Publication
DE head and neck cancer; lymphocytes; radiosensitivity; double-strand
   breaks; predictive assay
ID NORMAL TISSUE RADIOSENSITIVITY; IN-VITRO RADIOSENSITIVITY; DOUBLE-STRAND
   BREAKS; SKIN FIBROBLASTS; INTRINSIC RADIOSENSITIVITY; CHROMOSOMAL
   RADIOSENSITIVITY; RADIATION SENSITIVITY; PERIPHERAL-BLOOD; TUMOR-CELLS;
   PREDICTION
AB Purpose: The purpose of this study was to determine whether the distribution of radiosensitivities in normal tissues of head and neck cancer patients, measured using a DNA damage assay on lymphocytes, is likely to provide sufficient discrimination to enable reliable identification of patients with abnormal sensitivities. Material and Methods: Radiosensitivity was assessed in 307 lymphocyte samples from unselected head and neck cancer patients and was quantified as the initial number of DNA double-strand breaks (dsb) induced per Gray and per DNA unit (200 Mbp). Results: The existence of an inter-individual variation in the radiosensitivity parameter is described by the range (0.41-9.38 dsb/Gy/DNA unit) of the values found. We detected 37 patients who developed severe skin reactions during radiotherapy treatment and we compared their radiosensitivity values with the remaining patients treated. Radiosensitivity values of >7.20 dsb/Gy/DNA unit should theoretically correspond to highly radiosensitive patients. Conclusions: Our results suggest that initial DNA damage measured on lymphocytes offers an approach to predict the acute response of human normal tissues prior to radiotherapy. Copyright (C) 2005 S. Karger AG, Basel.
C1 Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400037, Peoples R China.
   Third Mil Med Univ, Dept Med Stat, Chongqing, Peoples R China.
   Chongqing Med Univ, Tumor Hosp, Dept Oncol, Chongqing, Peoples R China.
RP Wang, WD (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400037, Peoples R China.
EM wwdlr@yahoo.com
CR Alsbeih G, 2000, INT J RADIAT ONCOL, V46, P143, DOI 10.1016/S0360-3016(99)00409-5
   Barber JBP, 2000, RADIOTHER ONCOL, V55, P179, DOI 10.1016/S0167-8140(99)00158-9
   Bentzen SM, 1997, RADIOTHER ONCOL, V43, P121, DOI 10.1016/S0167-8140(97)01899-9
   BURNET NG, 1992, LANCET, V339, P1570, DOI 10.1016/0140-6736(92)91833-T
   Burnet NG, 1998, INT J CANCER, V79, P606, DOI 10.1002/(SICI)1097-0215(19981218)79:6<606::AID-IJC9>3.0.CO;2-Y
   DEALMODOVAR JMR, 1994, BRIT J CANCER, V69, P457, DOI 10.1038/bjc.1994.83
   DEALMODOVAR JMR, 1994, INT J RADIAT BIOL, V65, P641, DOI 10.1080/09553009414550751
   Dikomey E, 2000, INT J RADIAT ONCOL, V46, P481, DOI 10.1016/S0360-3016(99)00335-1
   GEARA FB, 1992, CANCER RES, V52, P6348
   GREEN MHL, 1991, INT J RADIAT BIOL, V59, P749, DOI 10.1080/09553009114550661
   Harney J, 2004, RADIOTHER ONCOL, V70, P319, DOI 10.1016/j.radonc.2004.01.015
   Honkanen J, 1998, J CANCER RES CLIN, V124, P415, DOI 10.1007/s004320050193
   JOHNSON NL, 1994, CONTINUOUS UNIVARIAT, P317
   Kiltie AE, 1999, RADIOTHER ONCOL, V51, P55, DOI 10.1016/S0167-8140(99)00030-4
   KUSHIRO J, 1990, RADIAT RES, V122, P326, DOI 10.2307/3577763
   Muller WU, 2001, RADIAT ENVIRON BIOPH, V40, P83, DOI 10.1007/s004110000087
   Nunez MI, 1998, INT J CANCER, V76, P354, DOI 10.1002/(SICI)1097-0215(19980504)76:3<354::AID-IJC12>3.0.CO;2-B
   Nunez MI, 1996, RADIOTHER ONCOL, V39, P155, DOI 10.1016/0167-8140(96)01732-X
   Ozsahin M, 1997, INT J RADIAT ONCOL, V38, P429, DOI 10.1016/S0360-3016(97)00038-2
   Peacock J, 2000, RADIOTHER ONCOL, V55, P173, DOI 10.1016/S0167-8140(00)00173-0
   RAMSAY J, 1995, INT J RADIAT ONCOL, V31, P339, DOI 10.1016/0360-3016(94)00478-4
   Scott D, 2000, STRAHLENTHER ONKOL, V176, P229, DOI 10.1007/s000660050005
   Stausbol-Gron B, 1999, BRIT J CANCER, V79, P1074, DOI 10.1038/sj.bjc.6690172
   Tucker SL, 1996, RADIOTHER ONCOL, V38, P103, DOI 10.1016/0167-8140(95)01669-4
   TUCKER SL, 1992, EUR J CANCER, V28A, P1783, DOI 10.1016/0959-8049(92)90004-L
   West CML, 1998, INT J RADIAT BIOL, V73, P409
   West CML, 2001, INT J RADIAT ONCOL, V51, P10, DOI 10.1016/S0360-3016(01)01575-9
NR 27
TC 3
Z9 3
U1 3
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2005
VL 69
IS 3
BP 208
EP 213
DI 10.1159/000088332
PG 6
WC Oncology
SC Oncology
GA 972YU
UT WOS:000232490500003
PM 16166813
DA 2018-12-27
ER

PT J
AU Singh, D
   Chander, V
   Chopra, K
AF Singh, D
   Chander, V
   Chopra, K
TI RETRACTED: Protective effect of catechin on ischemia-reperfusion-induced
   renal injury in rats (Retracted Article. See vol 60, pg 750, 2008)
SO PHARMACOLOGICAL REPORTS
LA English
DT Article; Retracted Publication
DE ischemia-reperfusion; oxidative stress; catechin
ID LOW-DENSITY-LIPOPROTEIN; SUPEROXIDE-DISMUTASE; OXIDANT STRESS;
   ANTIOXIDANT ACTIVITY; FLAVONOIDS; FAILURE; DAMAGE; TRANSPLANTATION;
   GLUTATHIONE; DYSFUNCTION
AB There is increasing evidence to suggest that toxic oxygen radicals play a role in the pathogenesis of ischemia/reperftision (I/R) injury in the kidney. This study was designed to investigate the effects of catechin, a bioflavonoid, in I/R-induced renal failure in rats. The protective effect of catechin against the damage inflicted by reactive oxygen species (ROS) during renal I/R was investigated in Sprague Dawley rats using histopathological and biochemical parameters. In one set of experiments, animals were unilaterally nephrectomized, and subjected to 45 min of left renal pedicle occlusion, and in another set both the renal pedicles were occluded for 45 min followed by 24 It of reperfusion. Catechin (40 mg/kg, po) was administered twice daily for 4 days and 2 h prior to ischemia. At the end of the reperfusion period, rats were sacrificed. Thiobarbituric acid reactive substances (TBARS), reduced glutathione levels, glutathione reductase, catalase, and superoxide dismutase activities were determined in renal tissue. Serum creatinine and blood urea nitrogen concentrations were measured for the evaluation of renal function. Ischemic control animals demonstrated severe deterioration of renal function, renal morphology and a significant renal oxidative stress. Pretreatment of animals with catechin markedly attenuated renal dysfunction, morphological alterations, reduced elevated TBARS levels and restored the depleted renal antioxidant enzymes. The findings imply that ROS play a causal role in I/R-induced renal injury, and catechin exerts renoprotective effects probably by the radical scavenging and antioxidant activities.
C1 Panjab Univ, Inst Pharmaceut Sci, Div Pharmacol, Chandigarh 160014, India.
RP Singh, D (reprint author), Panjab Univ, Inst Pharmaceut Sci, Div Pharmacol, Chandigarh 160014, India.
EM devindercpsingh@yahoo.co.uk
CR ALMOND PS, 1993, TRANSPLANT P, V25, P936
   BAKER GL, 1985, ANN SURG, V202, P628, DOI 10.1097/00000658-198511000-00016
   BARNES JL, 1981, LAB INVEST, V45, P378
   BAUD L, 1993, BRIT MED BULL, V49, P621, DOI 10.1093/oxfordjournals.bmb.a072635
   BIRD JE, 1988, J CLIN INVEST, V81, P1630, DOI 10.1172/JCI113498
   Bomzon A, 1997, SEMIN NEPHROL, V17, P549
   BULKLEY G B, 1987, British Journal of Cancer, V55, P66
   Calomme M, 1996, PLANTA MED, V62, P222, DOI 10.1055/s-2006-957864
   Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6
   CARPENTER CB, 1995, KIDNEY INT, V48, pS40
   Chatterjee PK, 1999, KIDNEY INT, V56, P973, DOI 10.1046/j.1523-1755.1999.00644.x
   Chatterjee PK, 2000, FASEB J, V14, P641
   Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x
   Claiborne A, 1985, CRC HDB METHODS OXYG, P283
   COLE E, 1995, CLIN TRANSPLANT, V9, P282
   Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9
   DELALASTRA CA, 1992, J PHARM PHARMACOL, V44, P929
   DOSLUOGLU HH, 1993, TRANSPLANT INT, V6, P138
   FINN WF, 1981, J LAB CLIN MED, V98, P21
   Ishikawa T, 1997, AM J CLIN NUTR, V66, P261
   JAESCHKE H, 1990, METHOD ENZYMOL, V186, P752
   JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485
   KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4
   MARTIN MJ, 1993, PHYTOTHER RES, V7, P150, DOI 10.1002/ptr.2650070211
   Matsuzaki Y, 1996, JPN J CANCER RES, V87, P170, DOI 10.1111/j.1349-7006.1996.tb03155.x
   Mirossay L, 1999, PHYSIOL RES, V48, P375
   MOHANDAS J, 1984, CANCER RES, V44, P5086
   Morpurgo E, 1996, TRANSPLANTATION, V62, P1221, DOI 10.1097/00007890-199611150-00006
   Noreen Y, 1998, PLANTA MED, V64, P520, DOI 10.1055/s-2006-957506
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Perez RM, 1998, PHYTOMEDICINE, V5, P55, DOI 10.1016/S0944-7113(98)80060-3
   Pirsch JD, 1996, TRANSPLANTATION, V61, P1581, DOI 10.1097/00007890-199606150-00006
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649
   SCHILLER HJ, 1991, KLIN WOCHENSCHR, V69, P1083, DOI 10.1007/BF01645163
   Singh D, 2003, TOXICOLOGY, V191, P143, DOI 10.1016/S0300-483X(03)00259-2
   TANNER G A, 1976, Kidney International Supplement, V6, pS65
   vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0
   VARLEY H, 1988, PRACTICAL CLIN BIOCH, P236
   Williams P, 1997, J PHARMACOL TOX MET, V37, P1, DOI 10.1016/S1056-8719(96)00141-4
   Yamamura S, 1998, PHYTOCHEMISTRY, V48, P131, DOI 10.1016/S0031-9422(97)01112-6
   Yamanaka N, 1997, FEBS LETT, V401, P230, DOI 10.1016/S0014-5793(96)01455-X
NR 42
TC 45
Z9 47
U1 1
U2 1
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD JAN-FEB
PY 2005
VL 57
IS 1
BP 70
EP 76
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 926IT
UT WOS:000229117600008
PM 15849379
DA 2018-12-27
ER

PT J
AU Kim, DW
AF Kim, DW
TI RETRACTED: Efficient induction of dopaminergic neurons form embryonic
   stem cells for application to Parkinson's disease (Retracted Article)
SO YONSEI MEDICAL JOURNAL
LA English
DT Correction; Retracted Publication
C1 Yonsei Univ, Coll Med, Dept Physiol, Seoul, South Korea.
RP Kim, DW (reprint author), Yonsei Univ, Coll Med, Dept Physiol, Seoul, South Korea.
CR Kim DW, 2004, YONSEI MED J, V45, P1203, DOI 10.3349/ymj.2004.45.6.1203
NR 1
TC 20
Z9 23
U1 3
U2 4
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD DEC 31
PY 2004
VL 45
IS 6
BP 1203
EP 1203
DI 10.3349/ymj.2004.45.6.1203
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 885QN
UT WOS:000226172100035
PM 15250046
OA Bronze
DA 2018-12-27
ER

PT J
AU Shimizu, KK
   Cork, JM
   Caicedo, AL
   Mays, CA
   Moore, RC
   Olsen, KM
   Ruzsa, S
   Coop, G
   Bustamante, CD
   Awadalla, P
   Purugganan, MD
AF Shimizu, KK
   Cork, JM
   Caicedo, AL
   Mays, CA
   Moore, RC
   Olsen, KM
   Ruzsa, S
   Coop, G
   Bustamante, CD
   Awadalla, P
   Purugganan, MD
TI RETRACTED: Darwinian selection on a selfing locus (Retracted Article.
   See vol 320, pg 176, 2008)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID ARABIDOPSIS-THALIANA; S-LOCUS; A-LYRATA; INCOMPATIBILITY; GENE; LIGAND;
   BRASSICACEAE; POPULATIONS; DIVERSITY; EVOLUTION
AB The shift to self-pollination is one of the most prevalent evolutionary transitions in flowering plants. In the selfing plant Arabidopsis thaliana, pseudogenes at the SCR and SRK self-incompatibility loci are believed to underlie the evolution of self-fertilization. Positive directional selection has driven the evolutionary fixation of pseudogene alleles of SCR, leading to substantially reduced nucleotide variation. Coalescent simulations indicate that this adaptive event may have occurred very recently and is possibly associated with the post-Pleistocene expansion of A. thaliana from glacial refugia. This suggests that ancillary morphological innovations associated with self-pollination can evolve rapidly after the inactivation of the self-incompatibility response.
C1 N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA.
   Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.
   Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
RP Purugganan, MD (reprint author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.
EM michaelp@unity.ncsu.edu
OI Olsen, Kenneth/0000-0002-8338-3638
CR ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56
   BAKER HG, 1955, EVOLUTION, V9, P347, DOI 10.1111/j.1558-5646.1955.tb01544.x
   Bergelson J, 1998, GENETICS, V148, P1311
   Bustamante CD, 2002, NATURE, V416, P531, DOI 10.1038/416531a
   Charles R, 2003, J DENT RES, V82, P101
   Charlesworth D, 1998, HEREDITY, V81, P1, DOI 10.1038/sj.hdy.6884000
   Charlesworth D, 2003, GENETICS, V164, P1519
   Charlesworth D, 2003, PHILOS T R SOC B, V358, P1051, DOI 10.1098/rstb.2003.1296
   Chookajorn T, 2004, P NATL ACAD SCI USA, V101, P911, DOI 10.1073/pnas.2637116100
   Coop G, 2004, THEOR POPUL BIOL, V66, P219, DOI 10.1016/j.tpb.2004.06.006
   Darwin C, 1876, EFFECTS CROSS SELF F
   Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000
   HUDSON RR, 1994, GENETICS, V136, P1329
   JAIN SK, 1976, ANNU REV ECOL SYST, V7, P469, DOI 10.1146/annurev.es.07.110176.002345
   Kachroo A, 2001, SCIENCE, V293, P1824, DOI 10.1126/science.1062509
   Koch MA, 2000, MOL BIOL EVOL, V17, P1483, DOI 10.1093/oxfordjournals.molbev.a026248
   Kusaba M, 2001, PLANT CELL, V13, P627, DOI 10.1105/tpc.13.3.627
   McVean G, 2002, GENETICS, V160, P1231
   Nasrallah ME, 2002, SCIENCE, V297, P247, DOI 10.1126/science.1072205
   OKane SL, 1997, NOVON, V7, P323, DOI 10.2307/3391949
   Olsen KM, 2002, GENETICS, V160, P1641
   Runions CJ, 2000, AM J BOT, V87, P1439, DOI 10.2307/2656870
   Sato K, 2002, GENETICS, V162, P931
   Sharbel TF, 2000, MOL ECOL, V9, P2109, DOI 10.1046/j.1365-294X.2000.01122.x
   Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]
   Stebbins G. L., 1950, VARIATION EVOLUTION
   Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104
   Yoshida K, 2003, GENES GENET SYST, V78, P11, DOI 10.1266/ggs.78.11
NR 28
TC 81
Z9 90
U1 2
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 17
PY 2004
VL 306
IS 5704
BP 2081
EP 2084
DI 10.1126/science.1103776
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 881CM
UT WOS:000225841000059
PM 15604405
DA 2018-12-27
ER

PT J
AU Xu, R
   Hanson, SR
   Zhang, ZW
   Yang, YY
   Schultz, PG
   Wong, CH
AF Xu, R
   Hanson, SR
   Zhang, ZW
   Yang, YY
   Schultz, PG
   Wong, CH
TI RETRACTED: Site-specific incorporation of the mucin-type
   N-acetylgalactosamine-alpha-O-threonine into protein in Escherichia coli
   (Retracted Article. See vol 131, pg 13883, 2009)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID GENETIC-CODE; GLYCOPROTEINS; GLYCOSYLATION; GENERATION
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Schultz, PG (reprint author), Scripps Res Inst, Dept Chem, 10550 Torrey Pines Rd, La Jolla, CA 92037 USA.
EM wong@scripps.edu
CR Arslan T, 1997, J AM CHEM SOC, V119, P10877, DOI 10.1021/ja971927a
   Chin JW, 2002, J AM CHEM SOC, V124, P9026, DOI 10.1021/ja027007w
   Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b
   Grogan MJ, 2002, ANNU REV BIOCHEM, V71, P593, DOI 10.1146/annurev.biochem.71.110601.135334
   GRUNDLER G, 1984, LIEBIGS ANN CHEM, P1826
   Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166
   Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022
   Kobayashi T, 2003, NAT STRUCT BIOL, V10, P425, DOI 10.1038/nsb934
   Liu HT, 2003, J AM CHEM SOC, V125, P1702, DOI 10.1021/ja029433n
   Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144
   Santoro SW, 2002, NAT BIOTECHNOL, V20, P1044, DOI 10.1038/nbt742
   Sears P, 2001, SCIENCE, V291, P2344, DOI 10.1126/science.1058899
   Sears P, 1998, CELL MOL LIFE SCI, V54, P223, DOI 10.1007/s000180050146
   Wang L, 2001, CHEM BIOL, V8, P883, DOI 10.1016/S1074-5521(01)00063-1
   Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077
   Wang L, 2003, P NATL ACAD SCI USA, V100, P56, DOI 10.1073/pnas.0234824100
   Wang L, 2000, J AM CHEM SOC, V122, P5010, DOI 10.1021/ja000595y
   Wu AM, 2004, FEBS LETT, V562, P51, DOI 10.1016/S0014-5793(04)00180-2
   Zhang ZW, 2002, ANGEW CHEM INT EDIT, V41, P2840, DOI 10.1002/1521-3773(20020802)41:15<2840::AID-ANIE2840>3.0.CO;2-#
   Zhang ZW, 2004, SCIENCE, V303, P371, DOI 10.1126/science.1089509
NR 20
TC 52
Z9 53
U1 5
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 8
PY 2004
VL 126
IS 48
BP 15654
EP 15655
DI 10.1021/ja044711z
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 876OD
UT WOS:000225505700010
PM 15571382
DA 2018-12-27
ER

PT J
AU Pereira, JH
   de Oliveira, JS
   Canduri, F
   Dias, MVB
   Palma, MS
   Basso, LA
   de Azevedo, WF
   Santos, DS
AF Pereira, JH
   de Oliveira, JS
   Canduri, F
   Dias, MVB
   Palma, MS
   Basso, LA
   de Azevedo, WF
   Santos, DS
TI RETRACTED: Interaction of shikimic acid with shikimate kinase (Retracted
   Article. See vol 334, pg 967, 2005)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE drug design; Mycobacterium tuberculosis; shikimate kinase; structure;
   shikimic acid
ID ESCHERICHIA-COLI K-12; ADENYLATE KINASE; 3-DIMENSIONAL STRUCTURE;
   CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; CATALYSIS; BINDING;
   DOMAIN; AROL; PURIFICATION
AB The crystal structure of shikimate kinase from Mycobacterium tuberculosis (MtSK) complexed with MgADP and shikimic acid (shikimate) has been determined at 2.3 Angstrom resolution, clearly revealing the amino acid residues involved in shikimate binding. In MtSK, the Glu61 strictly conserved in SK forms a hydrogen bond and salt-bridge with Arg58 and assists in positioning the guanidinium group of Arg58 for shikimate binding. The carboxyl group of shikimate interacts with Arg58, Gly81, and Arg136, and hydroxyl groups with Asp34 and Gly80. The crystal structure of MtSK-MgADP-shikimate will provide crucial information for elucidation of the mechanism of SK-catalyzed reaction and for the development of a new generation of drugs against tuberculosis. (C) 2004 Elsevier Inc. All rights reserved.
C1 UNESP, Dept Phys, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
   Univ Fed Rio Grande do Sul, Dept Biol Mol & Biotecnol, Rede Brasileira Pesquisa Tuberculose Grp Microbio, BR-91501970 Porto Alegre, RS, Brazil.
   Ctr Appl Toxinol, Inst Butantan, BR-05503900 Sao Paulo, Brazil.
   UNESP, Lab Struct Biol & Zoochem, CEIS, Dept Biol,Inst Biosci, BR-13506900 Rio Claro, SP, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa & Desenvolvimento Biol Mol & Func, BR-90619900 Porto Alegre, RS, Brazil.
RP Santos, DS (reprint author), UNESP, Dept Phys, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
EM walterfa@df.ibilce.unesp.br; diogenes@pucrs.br
RI Santos, Diogenes/A-6647-2008; Canduri, Fernanda/K-7120-2013
OI Santos, Diogenes/0000-0003-4971-463X; Dias, Marcio/0000-0002-5312-0191;
   Basso, Luiz/0000-0003-0903-2407
CR BRUNGER AT, 1992, XPLOR VERSION 3 1 SY
   Cerasoli E, 2003, BBA-PROTEINS PROTEOM, V1648, P43, DOI 10.1016/S1570-9639(03)00110-9
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   DEFEYTER RC, 1986, J BACTERIOL, V165, P331, DOI 10.1128/jb.165.1.331-333.1986
   DEFEYTER RC, 1986, J BACTERIOL, V165, P233, DOI 10.1128/jb.165.1.233-239.1986
   DHALIWAL B, 2004, FEBS LETT
   DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1
   ELY B, 1979, J BACTERIOL, V138, P933
   GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048
   Gu YJ, 2002, J MOL BIOL, V319, P779, DOI 10.1016/S0022-2836(02)00339-X
   Gu YJ, 2001, ACTA CRYSTALLOGR D, V57, P1870, DOI 10.1107/S0907444901014032
   Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8
   Idziak C, 1997, BIOCHEM SOC T, V25, pS627, DOI 10.1042/bst025s627
   JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219
   JENCKS WP, 1975, CATALSIS CHEM ENZYMO
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Krell T, 2001, PROTEIN SCI, V10, P1137, DOI 10.1110/ps.52501
   Krell T, 1998, J MOL BIOL, V278, P983, DOI 10.1006/jmbi.1998.1755
   LASKOWSKI RA, 1994, PROCHECK V 3 0 PROGR
   Leipe DD, 2003, J MOL BIOL, V333, P781, DOI 10.1016/j.jmb.2003.08.040
   LESLIE AGW, 1992, MOSFLM VERSION 6 11
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094
   MILLAR G, 1986, BIOCHEM J, V237, P427, DOI 10.1042/bj2370427
   Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4
   MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   Polikarpov I, 1998, J SYNCHROTRON RADIAT, V5, P72, DOI 10.1107/S0909049597014684
   Romanowski MJ, 2002, PROTEINS, V47, P558, DOI 10.1002/prot.10099
   Schlauderer GJ, 1996, PROTEIN SCI, V5, P434
   Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X
   STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G
   Vinella D, 1996, J BACTERIOL, V178, P3818, DOI 10.1128/jb.178.13.3818-3828.1996
   VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
   WHIPP MJ, 1995, J BACTERIOL, V177, P1627, DOI 10.1128/jb.177.6.1627-1629.1995
   WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8
NR 36
TC 6
Z9 6
U1 4
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 3
PY 2004
VL 325
IS 1
BP 10
EP 17
DI 10.1016/j.bbrc.2004.09.217
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 871YU
UT WOS:000225173400003
PM 15522194
DA 2018-12-27
ER

PT J
AU Zhang, P
AF Zhang, P
TI RETRACTED:
   trans-bis{1-[3-(cyclohexylamino)propyliminomethyl]-2-naphtholato}copper(
   II) dichloride dihydrate (Retracted article. See vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title centrosymmetric mononuclear copper( II) compound, [ Cu( C(20)H(26)N(2)O) (2)] Cl(2) . 2H(2)O, the Cu(II) atom is coordinated by two N atoms and two O atoms from two Schiff base ligands. The coordination geometry is slightly distorted square planar. In the crystal structure, the ions and molecules are linked together by intermolecular O - H ... Cl and N - H ... Cl hydrogen bonds.
C1 Xianyang Teachers Coll, Dept Chem, Xianyang 712000, Peoples R China.
RP Zhang, P (reprint author), Xianyang Teachers Coll, Dept Chem, Xianyang 712000, Peoples R China.
EM zhangping419@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 1998, SMART VERS 5 628
   [Anonymous], 1998, SAINT VERS 6 02
   BHATIA SC, 1981, J CHEM SOC DALTON, P1773, DOI 10.1039/dt9810001773
   Chang S, 1998, ORGANOMETALLICS, V17, P3460, DOI 10.1021/om970910y
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXS97
   SHELDRICK GM, 1997, SHELXTL VERS 5 1
   SHELDRICK GM, 1997, SHELXL97
   You ZL, 2004, ACTA CRYSTALLOGR E, V60, pM1114, DOI 10.1107/S1600536804016563
NR 10
TC 7
Z9 7
U1 3
U2 11
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2004
VL 60
BP M1808
EP M1810
DI 10.1107/S1600536804028296
PN 12
PG 3
WC Crystallography
SC Crystallography
GA 876FJ
UT WOS:000225481600030
DA 2018-12-27
ER

PT J
AU Kim, JD
   Kang, KH
AF Kim, JD
   Kang, KH
TI RETRACTED: Isolation of Lactobacillus sakei strain KJ-2008 and its
   removal of characteristic malodorous gases under anaerobic culture
   conditions (Retracted article. See vol. 77, 2013)
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE deodorization; malodorous gases; piggery slurry; lactic acid bacterium
ID THIOSPHAERA-PANTOTROPHA; AEROBIC DENITRIFICATION; ACTIVATED-SLUDGE;
   HYDROGEN-SULFIDE; BIOFILTER; AMMONIA; BIOTREATMENT; BACTERIA; AIR
AB A number of different sources, such as composts, leachates, and pig feces samples were collected from different pig farms in Korea. Several microorganisms were screened for their ability to deodorize the malodorous gases. As a result, a novel malodorous gas-deodorizing bacterial strain KJ-2008 was isolated due to the most abundant of nitrate-supplemented minimal media under anaerobic conditions. Crimp-sealed serum bottles containing nitrate-supplemented minimal medium (MM-NO3-) in airtight conditions were inoculated with KJ-2008. Nitrate concentration decreased rapidly after 20h incubation and nitrite production reached almost zero during the time the experimental was carried out. Taxonomic identification including 16S rDNA base sequencing and phylogenetic analysis indicated that the isolate KJ-2008 had a 99.8% homology in its 16S rDNA base sequence with Lactobacillus sakei. Among the volatile fatty acids, acetic acid contained in large amounts in fresh piggery slurry decreased about 40% after 50h incubation of the strain KJ-2008. n-Butyric acid, n-valeric acid, and iso-valeric acid gradually decreased, and iso-butyric acid and capronic acid dramatically eliminated at initial time with the treatment. Moreover, NH3 removal efficiency reached a maximum of 98.5% after 50h of incubation. The concentration of H2S did not change.
C1 Sungkyunkwan Univ, Dept Food & Biotechnol, Suwon 440746, South Korea.
   Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea.
RP Kang, KH (reprint author), Sungkyunkwan Univ, Dept Food & Biotechnol, Suwon 440746, South Korea.
EM khkang@skku.edu
CR CHOI MY, 1992, J MICROBIOL BIOTECHN, V2, P273
   Chung YC, 2001, CHEMOSPHERE, V43, P1043, DOI 10.1016/S0045-6535(00)00211-3
   Chung YC, 1996, J BIOTECHNOL, V52, P31, DOI 10.1016/S0168-1656(96)01622-7
   Chung YC, 1998, ENVIRON PROG, V17, P70, DOI 10.1002/ep.670170211
   Chung YC, 1997, BIOTECHNOL PROGR, V13, P794, DOI 10.1021/bp970065e
   EATON A, 1995, STANDARD METHODS EXA
   EIKUM AS, 1986, ODOR PRESERVATION CO
   Felsenstein J, 1993, PHYLIP PHYLOGENETIC
   Gerhardt P., 1994, METHODS GEN MOL BACT, P1
   GOLUEKE CG, 1977, BIOL RECLAMATION SOL, P50
   HENRY JG, 1980, J WATER POLLUT CON F, V52, P2523
   Kim NJ, 2000, BIOTECHNOL LETT, V22, P1295, DOI 10.1023/A:1005605706932
   KIM NS, 1993, J MICROBIOL BIOTECHN, V3, P214
   Kim YK, 2001, J MICROBIOL BIOTECHN, V11, P570
   LESON G, 1991, J AIR WASTE MANAGE, V41, P1045, DOI 10.1080/10473289.1991.10466898
   Murray R. G. E., 1994, P21
   Nigam P, 2000, BIORESOURCE TECHNOL, V72, P219, DOI 10.1016/S0960-8524(99)00123-6
   PROSSER JI, 1989, ADV MICROB PHYSIOL, V30, P125
   ROBERTSON LA, 1990, ANTON LEEUW INT J G, V57, P139, DOI 10.1007/BF00403948
   Ryer-Powder J. E., 1991, Plant/Operations Progress, V10, P228, DOI 10.1002/prsb.720100411
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   STACKEBRANDT E, 1993, HDB NEW BACTERIAL SY, P152
   Stouthamer A.H., 1988, BIOL ANAEROBIC MICRO, P245
   Su JJ, 2001, J APPL MICROBIOL, V90, P457, DOI 10.1046/j.1365-2672.2001.01265.x
   Vinderola CG, 2000, FOOD RES INT, V33, P97, DOI 10.1016/S0963-9969(00)00011-9
   YANG YH, 1994, J AIR WASTE MANAGE, V44, P863, DOI 10.1080/1073161X.1994.10467287
   Yoon JH, 1997, INT J SYST BACTERIOL, V47, P111, DOI 10.1099/00207713-47-1-111
   ZUMFT WG, 1988, S SOC GEN MICROBIOL, V42, P245
NR 28
TC 4
Z9 7
U1 3
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD DEC
PY 2004
VL 68
IS 12
BP 2427
EP 2435
DI 10.1271/bbb.68.2427
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA 886TC
UT WOS:000226250500002
PM 15618611
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
AF Fujii, Y
TI RETRACTED: Pretreatment with flurbiprofen axetil and venous occlusion to
   reduce pain during injection of propofol (Retracted article. See vol.
   60, pg. 607, 2013)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Letter; Retracted Publication
CR Karasawa F, 2000, J Anesth, V14, P135, DOI 10.1007/s005400070020
   Picard P, 2000, ANESTH ANALG, V90, P963
   SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   Yull DN, 2000, ANAESTHESIA, V55, P284, DOI 10.1046/j.1365-2044.2000.01320.x
NR 5
TC 6
Z9 8
U1 6
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD DEC
PY 2004
VL 51
IS 10
BP 1047
EP 1048
DI 10.1007/BF03018498
PG 2
WC Anesthesiology
SC Anesthesiology
GA 880QG
UT WOS:000225803700021
PM 15574561
DA 2018-12-27
ER

PT J
AU Lee, HC
AF Lee, HC
TI RETRACTED: Recent advance in hepatic insulin gene therapy (Retracted
   Article. See vol 69, pg 311, 2005)
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 12th Japan-Korea Symposium on Diabetes Mellitus
CY MAY 09-10, 2003
CL Nagoya, JAPAN
DE gene therapy; SIA (single chain insulin analogue); AAV (adeno-associated
   virus)
ID PYRUVATE-KINASE GENE; ADENOASSOCIATED VIRUS; DIABETES-MELLITUS;
   CYCLIC-AMP; INTEGRATION; EXPRESSION; PROMOTER; GLUCOSE; CELLS; SITE
AB The development of type I diabetes results from the almost total destruction of insulin-producing pancreatic cells by autoimmune responses specific to cells, Standard insulin therapy may not maintain blood glucose concentrations within the relatively narrow range that occurs in the presence of normal pancreatic cells. We used a recombinant adeno-associated virus (rAAV) that expresses a single-chain insulin analogue (SIA), which possesses biologically active insulin activity without enzymatic conversion, under the control of hepatocyte-specific L-type pyruvate kinase (LPK) promoter, which regulates SIA expression in response to blood glucose levels. Here, we show that SIA produced from the gene construct rAAV-LPK-SIA caused remission of diabetes in streptozotocin-induced diabetic rats and autoimmune diabetic mice for a prolonged time without any apparent side effects. This new SIA gene therapy may have potential therapeutic value for the cure of autoimmune diabetes in humans. (C) 2004 Published by Elsevier Ireland Ltd.
C1 Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea.
RP Lee, HC (reprint author), Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM endohclee@yumc.yonsei.ac.kr
CR BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871
   CAMERON NE, 1991, AM J PHYSIOL, V261, pE1
   CHEN RH, 1995, FEBS LETT, V365, P223, DOI 10.1016/0014-5793(95)00472-L
   Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427
   Cuif MH, 1997, FEBS LETT, V417, P81, DOI 10.1016/S0014-5793(97)01260-X
   CUIF MH, 1993, J BIOL CHEM, V268, P13769
   DECAUX JF, 1989, J BIOL CHEM, V264, P11584
   FROST SC, 1985, J BIOL CHEM, V260, P2646
   GIRAUD C, 1994, P NATL ACAD SCI USA, V91, P10039, DOI 10.1073/pnas.91.21.10039
   HEATH WF, 1992, J BIOL CHEM, V267, P419
   KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x
   Levine F, 1999, MOL MED TODAY, V5, P165, DOI 10.1016/S1357-4310(98)01425-7
   MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97
   POLLET RJ, 1977, J BIOL CHEM, V252, P5828
   Roth J, 1975, Methods Enzymol, V37, P66
   SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2
   STUDIER FW, 1990, METHOD ENZYMOL, V185, P60
   YOON JW, 1976, NATURE, V264, P178, DOI 10.1038/264178a0
NR 18
TC 2
Z9 2
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD DEC
PY 2004
VL 66
SU 1
BP S3
EP S10
DI 10.1016/j.diabres.2003.10.029
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 880YI
UT WOS:000225826000002
PM 15563976
DA 2018-12-27
ER

PT J
AU Targownik, LE
   Spiegel, BM
   Sack, J
   Hines, OJ
   Dulai, GS
   Gralnek, IM
   Farrell, JJ
AF Targownik, LE
   Spiegel, BM
   Sack, J
   Hines, OJ
   Dulai, GS
   Gralnek, IM
   Farrell, JJ
TI RETRACTED: Colonic stent vs. emergency surgery for management of acute
   left-sided malignant colonic obstruction: a decision analysis (Retracted
   Article. See vol 27, pg 448, 2008)
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Review; Retracted Publication
ID LARGE-BOWEL OBSTRUCTION; EXPANDING METALLIC STENTS; QUALITY-OF-LIFE;
   ACUTE COLORECTAL OBSTRUCTION; PALLIATIVE TREATMENT; PRIMARY RESECTION;
   INTESTINAL-OBSTRUCTION; PRIMARY ANASTOMOSIS; SURGICAL-TREATMENT;
   DESCENDING COLON
AB Background: Acute colonic obstruction because of malignancy is often a surgical emergency. Surgical decompression with colostomy with or without resection and eventual re-anastomosis is the traditional treatment of choice. Endoscopic colonic stent insertion effectively decompresses the obstructed colon, allowing for surgery to be performed electively. This study sought to determine the cost-effectiveness of colonic stent vs. surgery for emergent management of acute malignant colonic obstruction.
   Methods: Decision analysis was used to calculate the cost-effectiveness of two competing strategies in a hypothetical patient presenting with acute, complete, malignant colonic obstruction: (1) emergent colonic stent followed by elective surgical resection and re-anastomosis; (2) emergent surgical resection followed by diversion (Hartmann's procedure) or primary anastomosis. Cost estimates were obtained from a third-party payer perspective. Primary outcome measures were mortality, stoma requirement, and total number of operative procedures.
   Results: Colonic stent resulted in 23% fewer operative procedures per patient (1.01 vs. 1.32 operations per patient), an 83% reduction in stoma requirement (7% vs. 43%), and lower procedure-related mortality (5% vs. 11%). Colonic stent was associated with a lower mean cost per patient ($45,709 vs. $49,941).
   Conclusions: Colonic stent insertion followed by elective surgery appears more effective and less costly than emergency surgery under base-case conditions. This finding remains robust over a wide range of assumptions for clinical inputs in sensitivity analysis. Our findings suggest that colonic stent insertion should be offered, whenever feasible, as a bridge to elective surgery in patients presenting with malignant colonic obstruction.
C1 Univ Calif Los Angeles, Sch Med, Div Digest Dis, Ctr Hlth Sci, Los Angeles, CA 90095 USA.
   Univ Manitoba, Fac Med, Dept Internal Med, Div Gastroenterol, Winnipeg, MB, Canada.
   Univ Calif Los Angeles, Ctr Hlth Sci, Div Digest Dis, CURE Digest Dis Res Ctr,Ctr Study Digest Healthca, Los Angeles, CA 90024 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Sect Gastrointestinal Surg, Los Angeles, CA USA.
RP Farrell, JJ (reprint author), Univ Calif Los Angeles, Sch Med, Div Digest Dis, Ctr Hlth Sci, Los Angeles, CA 90095 USA.
FU NCRR NIH HHS [K23 RR 16188]; NIDDK NIH HHS [DK 07180]
CR Adamsen S, 2000, DAN MED BULL, V47, P225
   ANDERSON KR, 1995, J UROLOGY, V154, P1934, DOI 10.1016/S0022-5347(01)66829-0
   ARNAUD JP, 1994, DIS COLON RECTUM, V37, P685, DOI 10.1007/BF02054412
   Arnell T, 1998, AM SURGEON, V64, P986
   Aviv RI, 2002, CLIN RADIOL, V57, P347, DOI 10.1053/crad.2001.0844
   Baron TH, 1998, GASTROINTEST ENDOSC, V47, P277, DOI 10.1016/S0016-5107(98)70327-X
   Ben Soussan E, 2001, GASTROEN CLIN BIOL, V25, P463
   Binkert CA, 1998, RADIOLOGY, V206, P199, DOI 10.1148/radiology.206.1.9423673
   Boorman P, 1999, ANN ROY COLL SURG, V81, P251
   BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109
   Boyle P., 1998, MANAGEMENT COLORECTA, P19
   BUCHANAN GN, 2000, COLORECTAL DIS, V2, P277
   Campbell KL, 1997, DIS COLON RECTUM, V40, P1391, DOI 10.1007/BF02050829
   Camunez F, 2000, RADIOLOGY, V216, P492, DOI 10.1148/radiology.216.2.r00au12492
   Canon CL, 1997, AM J ROENTGENOL, V168, P199, DOI 10.2214/ajr.168.1.8976946
   Chen HS, 2000, SURGERY, V127, P370, DOI 10.1067/msy.2000.104674
   Choo IW, 1998, RADIOLOGY, V206, P415, DOI 10.1148/radiology.206.2.9457194
   Cole SJ, 2000, COLORECTAL DIS, V2, P282
   Dauphine CE, 2002, ANN SURG ONCOL, V9, P574
   Davidson R, 1998, SURG ENDOSC-ULTRAS, V12, P353, DOI 10.1007/s004649900670
   De Gregorio MA, 1998, RADIOLOGY, V209, P117, DOI 10.1148/radiology.209.1.9769821
   DEANS GT, 1994, BRIT J SURG, V81, P1270, DOI 10.1002/bjs.1800810905
   DeFriend D, 1996, BRIT J HOSP MED, V56, P326
   Desroches E, 1999, ANN CHIR, V53, P1029
   Diaz LP, 1999, CARDIOVASC INTER RAD, V22, P29, DOI 10.1007/s002709900325
   Dixon A R, 1990, J R Coll Surg Edinb, V35, P166
   Dohmoto M, 1997, SURG ENDOSC-ULTRAS, V11, P758, DOI 10.1007/s004649900444
   Dohmoto M., 1991, ENDOSCOPIA DIGESTIVA, V3, P1507
   Dominitz JA, 1997, AM J GASTROENTEROL, V92, P2171
   Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552
   DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203
   Farrell JJ, 2001, SEMINARS INTERVENTIO, V18, P327
   Fava M, 1999, REV MED CHILE, V127, P1207
   FENG YS, 1987, DIS COLON RECTUM, V30, P29, DOI 10.1007/BF02556917
   GANDRUP P, 1992, EUR J SURG, V158, P427
   GARCIAVALDECASAS JC, 1991, DIS COLON RECTUM, V34, P759, DOI 10.1007/BF02051066
   GREENBURG AG, 1985, AM J SURG, V150, P65, DOI 10.1016/0002-9610(85)90011-X
   Harris GJC, 2001, AM J SURG, V181, P499, DOI 10.1016/S0002-9610(01)00622-5
   HUDDY SPJ, 1988, ANN ROY COLL SURG, V70, P40
   IRVIN TT, 1977, BRIT J SURG, V64, P741, DOI 10.1002/bjs.1800641015
   Isbister WH, 1996, AUST NZ J SURG, V66, P602, DOI 10.1111/j.1445-2197.1996.tb00828.x
   ITABASHI M, 1993, DIS COLON RECTUM, V36, P508, DOI 10.1007/BF02050019
   Keymilng M, 2003, ENDOSCOPY, V35, P234, DOI 10.1055/s-2003-37265
   Khot UP, 2002, BRIT J SURG, V89, P1096, DOI 10.1046/j.1365-2168.2002.02148.x
   Knopfle E, 2001, CHIRURG, V72, P1137
   Knopfle E, 1998, ROFO-FORTSCHR RONTG, V168, P380, DOI 10.1055/s-2007-1015146
   KORUTH NM, 1985, BRIT J SURG, V72, P703, DOI 10.1002/bjs.1800720910
   KORUTH NM, 1985, BRIT J SURG, V72, P708, DOI 10.1002/bjs.1800720911
   KRONBORG O, 1995, INT J COLORECTAL DIS, V10, P1, DOI 10.1007/BF00337576
   Lamah M, 1998, J ROY COLL SURG EDIN, V43, P318
   Law WL, 2000, DIS COLON RECTUM, V43, P1522, DOI 10.1007/BF02236731
   LEITMAN IM, 1992, SURG GYNECOL OBSTET, V174, P513
   Liberman H, 2000, AM J SURG, V180, P407, DOI 10.1016/S0002-9610(00)00492-X
   Lobato RF, 1999, INT SURG, V84, P159
   LONDONOSCHIMMER EE, 1994, DIS COLON RECTUM, V37, P916, DOI 10.1007/BF02052598
   Mainar A, 1999, RADIOLOGY, V210, P65, DOI 10.1148/radiology.210.1.r99ja0665
   Mainar A, 1996, RADIOLOGY, V198, P761, DOI 10.1148/radiology.198.3.8628867
   Martinez-Santos C, 2002, DIS COLON RECTUM, V45, P401, DOI 10.1007/s10350-004-6190-4
   Massa M., 1995, Annali Italiani di Chirurgia, V66, P467
   Mauro MA, 2000, RADIOLOGY, V215, P659, DOI 10.1148/radiology.215.3.r00jn30659
   Mella J, 1997, BRIT J SURG, V84, P1731
   MILESKI WJ, 1990, SURG GYNECOL OBSTET, V171, P17
   Mitry E, 2002, BEST PRACT RES CL GA, V16, P253, DOI 10.1053/bega.2002.0284
   Miyayama S, 2000, AM J ROENTGENOL, V175, P1631, DOI 10.2214/ajr.175.6.1751631
   MOCHIZUKI H, 1993, SURG TODAY, V23, P771, DOI 10.1007/BF00311618
   Nugent KP, 1999, DIS COLON RECTUM, V42, P1569, DOI 10.1007/BF02236209
   Nyam DCNK, 1996, BRIT J SURG, V83, P786, DOI 10.1002/bjs.1800830618
   OHMAN U, 1982, AM J SURG, V143, P742, DOI 10.1016/0002-9610(82)90050-2
   Osaka H, 2000, Gan To Kagaku Ryoho, V27, P1970
   OSMAN HS, 2000, COLORECTAL DIS, V2, P233, DOI DOI 10.1046/J.1463-1318.2000.00140.X]
   Park JJ, 1999, DIS COLON RECTUM, V42, P1575, DOI 10.1007/BF02236210
   PEARCE NW, 1992, BRIT J SURG, V79, P839, DOI 10.1002/bjs.1800790844
   PHILLIPS RKS, 1985, BRIT J SURG, V72, P296, DOI 10.1002/bjs.1800720417
   Pikarsky A J, 2000, Surg Endosc, V14, P372
   RADCLIFFE AG, 1983, SURG GYNECOL OBSTET, V156, P721
   RAIJMAN I, 1995, ENDOSCOPY, V27, P273, DOI 10.1055/s-2007-1005684
   Repici A, 2000, GASTROINTEST ENDOSC, V52, P735, DOI 10.1067/mge.2000.109803
   Repse S., 1996, Annali Italiani di Chirurgia, V67, P205
   REY JF, 1995, ENDOSCOPY, V27, P501, DOI 10.1055/s-2007-1005755
   RIEDL S, 1995, CHIRURG, V66, P597
   Rocca R, 2000, GASTROINTEST ENDOSC, V51, pAB105, DOI 10.1016/S0016-5107(00)14184-7
   Rupp K D, 1995, Eur J Surg Oncol, V21, P644, DOI 10.1016/S0748-7983(95)95563-1
   Saida Y, 1996, DIS COLON RECTUM, V39, P552, DOI 10.1007/BF02058710
   SERPELL JW, 1989, BRIT J SURG, V76, P965, DOI 10.1002/bjs.1800760932
   Smothers L, 2003, DIS COLON RECTUM, V46, P24, DOI 10.1097/01.DCR.0000044719.17980.4C
   Sommeling CA, 1997, ACTA CHIR BELG, V97, P217
   Soonawalla Z, 1998, AM J ROENTGENOL, V171, P633, DOI 10.2214/ajr.171.3.9725287
   Spinelli P, 1993, Bildgebung, V60 Suppl 1, P48
   SPRANGERS MAG, 1995, DIS COLON RECTUM, V38, P361, DOI 10.1007/BF02054222
   STAMATAKIS JD, 2000, NATL AUDIT BOWEL OBS
   Tack J, 1998, GASTROINTEST ENDOSC, V48, P267, DOI 10.1016/S0016-5107(98)70189-0
   Tamim WZ, 2000, ARCH SURG-CHICAGO, V135, P434, DOI 10.1001/archsurg.135.4.434
   TAN SG, 1991, ARCH SURG-CHICAGO, V126, P748
   Tejero E, 1997, DIS COLON RECTUM, V40, P432, DOI 10.1007/BF02258387
   Tominaga K, 2001, GASTROINTEST ENDOSC, V53, P524, DOI 10.1067/mge.2001.112184
   Turegano-Fuentes F, 1998, BRIT J SURG, V85, P232
   UMPLEBY HC, 1984, DIS COLON RECTUM, V27, P299, DOI 10.1007/BF02555634
   van Geldere D, 2002, J AM COLL SURGEONS, V194, P40, DOI 10.1016/S1072-7515(01)01131-0
   VIGDER L, 1985, ARCH SURG-CHICAGO, V120, P825
   Vrazas JI, 2002, ANZ J SURG, V72, P392, DOI 10.1046/j.1445-2197.2002.02426.x
   Wallis F, 1998, CLIN RADIOL, V53, P251, DOI 10.1016/S0009-9260(98)80121-9
   WELCH JP, 1974, AM J SURG, V127, P492, DOI 10.1016/0002-9610(74)90302-X
   WHITTLE J, 1992, AM J SURG, V163, P572, DOI 10.1016/0002-9610(92)90559-A
   Wholey MH, 1998, AM J SURG, V175, P194, DOI 10.1016/S0002-9610(97)00285-7
   WONG RW, 1994, J SURG RES, V57, P289, DOI 10.1006/jsre.1994.1147
   Xinopoulos D, 2002, HEPATO-GASTROENTEROL, V49, P359
   Zollikofer CL, 2000, EUR RADIOL, V10, P329, DOI 10.1007/s003300050053
NR 107
TC 109
Z9 117
U1 3
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD DEC
PY 2004
VL 60
IS 6
BP 865
EP 874
AR PII S0016-5107(04)02225-4
DI 10.1016/S0016-5107(04)02225-4
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 883NI
UT WOS:000226019200002
PM 15604999
DA 2018-12-27
ER

PT J
AU Hanna, J
   Gonen-Gross, T
   Fitchett, J
   Rowe, T
   Daniels, M
   Arnon, TI
   Gazit, R
   Joseph, A
   Schjetne, KW
   Steinle, A
   Porgador, A
   Mevorach, D
   Goldman-Wohl, D
   Yagel, S
   LaBarre, MJ
   Buckner, JH
   Mandelboim, O
AF Hanna, J
   Gonen-Gross, T
   Fitchett, J
   Rowe, T
   Daniels, M
   Arnon, TI
   Gazit, R
   Joseph, A
   Schjetne, KW
   Steinle, A
   Porgador, A
   Mevorach, D
   Goldman-Wohl, D
   Yagel, S
   LaBarre, MJ
   Buckner, JH
   Mandelboim, O
TI RETRACTED: Novel APC-like properties of human NK cells directly regulate
   T cell activation (Retracted article. See vol. 125, pg. 1763, 2015)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID NATURAL-KILLER-CELLS; VIRUS-INFECTED CELLS; DENDRITIC CELLS; ANTIGEN
   PRESENTATION; EXPRESSION; RECEPTOR; IMMUNITY; INTERNALIZATION;
   CYTOTOXICITY; RECOGNITION
AB Initiation of the adaptive immune response is dependent on the priming of naive T cells by APCs. Proteomic analysis of unactivated and activated human NK cell membrane-enriched fractions demonstrated that activated NK cells can efficiently stimulate T cells, since they upregulate MHC class II molecules and multiple ligands for TCR costimulatory molecules. Furthermore, by manipulating antigen administration, we show that NK cells possess multiple independent unique pathways for antigen uptake. These results highlight NK cell-mediated cytotoxicity and specific ligand recognition by cell surface-activating receptors on NK cells as unique mechanisms for antigen capturing and presentation. in addition, we analyzed the T cell-activating potential of human NK cells derived from different clinical conditions, such as inflamed tonsils and noninfected and CMV-infected uterine decidual samples, and from transporter-associated processing antigen 2-deficient patients. This in vivo analysis revealed that proinflammatory, but not immune-suppressive, microenvironmental requirements can selectively dictate upregulation of T cell-activating molecules on NK cells. Taken together, these observations offer new and unexpected insights into the direct interactions between NK and T cells and suggest novel APC-like activating functions for human NK cells.
C1 Hebrew Univ Jerusalem, Lautenberg Ctr Gen & Tumor Immunol, Hadassah Med Sch, IL-91120 Jerusalem, Israel.
   Biogen Inc, San Diego, CA USA.
   Univ Oslo, Inst Immunol, Oslo, Norway.
   Interfak Inst Zellbiol, Immunol Abt, Tubingen, Germany.
   Ben Gurion Univ Negev, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.
   Hadassah Univ Hosp, Cellular & Mol Immunol Lab, Dept Med, IL-91120 Jerusalem, Israel.
   Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel.
   Benaroya Res Inst, Seattle, WA USA.
RP Mandelboim, O (reprint author), Hebrew Univ Jerusalem, Lautenberg Ctr Gen & Tumor Immunol, Hadassah Med Sch, IL-91120 Jerusalem, Israel.
EM oferman@md2.huji.ac.il
RI HANNA, JACOB/K-1339-2012; Gazit, Roi/J-3352-2017; Steinle,
   Alexander/E-6131-2012
OI HANNA, JACOB/0000-0003-2042-9974; 
CR Andre P, 2004, EUR J IMMUNOL, V34, P961, DOI 10.1002/eji.200324705
   Arnon TI, 2004, BLOOD, V103, P664, DOI 10.1182/blood-2003-05-1716
   Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369
   Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507
   Celestin J, 2001, J IMMUNOL, V167, P6097, DOI 10.4049/jimmunol.167.11.6097
   Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012
   Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148
   Crotzer VL, 2004, J EXP MED, V199, P981, DOI 10.1084/jem.20031105
   Falk K, 2000, EUR J IMMUNOL, V30, P3012, DOI 10.1002/1521-4141(200010)30:10<3012::AID-IMMU3012>3.0.CO;2-Q
   Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876
   Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455
   Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149
   Gebe JA, 2001, J IMMUNOL, V167, P3250, DOI 10.4049/jimmunol.167.6.3250
   Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517
   Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X
   Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957
   Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305
   Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110
   Markel G, 2004, BLOOD, V103, P1770, DOI 10.1182/blood-2003-06-2114
   Markel G, 2002, J CLIN INVEST, V110, P943, DOI 10.1172/JCI200215643
   Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4
   Muntasesll A, 2002, J IMMUNOL, V169, P5052, DOI 10.4049/jimmunol.169.9.5052
   Orange JS, 2002, NAT IMMUNOL, V3, P1006, DOI 10.1038/ni1102-1006
   Pende D, 2002, CANCER RES, V62, P6178
   Perkins AC, 1999, NUCL MED COMMUN, V20, P1, DOI 10.1097/00006231-199901000-00001
   Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371
   Rothenfusser S, 2004, BLOOD, V103, P2162, DOI 10.1182/blood-2003-04-1091
   Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019
   Salio M, 2003, INT IMMUNOL, V15, P1265, DOI 10.1093/intimm/dxg123
   Schjetne KW, 2003, J IMMUNOL, V171, P32, DOI 10.4049/jimmunol.171.1.32
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099
   Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029
NR 35
TC 124
Z9 132
U1 3
U2 10
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 2004
VL 114
IS 11
BP 1612
EP 1623
DI 10.1172/JCI200422787
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 876DK
UT WOS:000225475900013
PM 15578093
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Jacobs, MJ
   van Eps, RGS
   de Jong, DS
   Schurink, GWH
   Mochtar, B
AF Jacobs, MJ
   van Eps, RGS
   de Jong, DS
   Schurink, GWH
   Mochtar, B
TI RETRACTED: Prevention of renal failure in patients undergoing
   thoracoabdominal aortic aneurysm repair (Retracted Article. See vol 43,
   pg 429, 2006)
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 58th Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 03-06, 2004
CL Anaheim, CA
SP Soc Vasc Surg
ID PERFUSION; SURGERY; OPERATIONS; BYPASS; BLOOD
AB Objective: Renal failure is a potential complication after thoracoabdominal aortic aneurysm (TAAA) repair and is a significant risk factor for postoperative mortality. We assessed the results of distal aortic perfusion and continuous volume-controlled and pressure-controlled blood perfusion of the kidneys during TAAA repair in patients with preoperative normal and impaired renal function.
   Methods: Surgical repair of TAAA was performed in 279 consecutive patients (type I, n = 90; type II, 117; type III, 42; type IV, 30). In 195 patients preoperative renal function was normal; however, in 84 patients renal insufficiency was diagnosed (serum creatinine concentration [SCr], 1.4-2.0 mg/dL, n = 46; SCr, 2.0-2.5 mg/dL, n = 20; and SCr, > 2.5 mg/dL, n = 18). Renal perfusion was established with catheters connected to the left-sided heart bypass. Volume flow was assessed with ultrasound, and pressure channels in the catheters enabled pressure-controlled perfusion of the kidneys.
   Results. Selective renal artery perfusion was achieved in all patients without technical problems or complications. In each catheter, mean arterial pressure was 69 mm Hg and volume flow was 275 mL/min. During aortic cross-clamping, urine output was uninterrupted, irrespective of clamp time. Most patients demonstrated limited or moderate increase in SCr concentration. In 17 patients (6%) SCr doubled, and peaked above 3 mg/dL, but returned to baseline levels within several days. Three patients (1%) required temporary dialysis but were discharged without further need for dialysis. In general, preoperative renal impairment did not worsen.
   Conclusion: Distal aortic and selective renal blood perfusion is an effective measure to protect renal function during TAAA repair, but only if perfusion is provided with adequate volume and pressure. This technique also averts dialysis in most patients with preoperative renal failure.
C1 Univ Hosp Maastricht, Dept Surg, Maastricht, Netherlands.
   Univ Hosp Maastricht, Dept Cardiothorac Surg, Maastricht, Netherlands.
RP Jacobs, MJ (reprint author), Acad Hosp Maastricht, Dept Vasc Surg, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.jacobs@surgery.azm.nl
CR Anderson RJ, 1999, KIDNEY INT, V55, P1057, DOI 10.1046/j.1523-1755.1999.0550031057.x
   Brasile L, 2001, CLIN TRANSPLANT, V15, P369, DOI 10.1034/j.1399-0012.2001.150601.x
   Cambria RP, 2002, ANN SURG, V236, P471, DOI 10.1097/01.SLA.0000031240.26001.E2
   Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408
   Idu MM, 2004, EUR J VASC ENDOVASC, V27, P138, DOI 10.1016/j.ejvs.2003.11.009
   Jacobs Michael J, 2003, Semin Thorac Cardiovasc Surg, V15, P353, DOI 10.1053/S1043-0679(03)00084-4
   Jacobs MJ, 2002, J VASC SURG, V35, P30, DOI 10.1067/mva.2002.120041
   Jacobs MJHM, 1998, EUR J CARDIO-THORAC, V14, P201, DOI 10.1016/S1010-7940(98)00164-X
   Kashyap VS, 1997, J VASC SURG, V26, P949, DOI 10.1016/S0741-5214(97)70006-5
   Koksoy C, 2002, ANN THORAC SURG, V73, P730, DOI 10.1016/S0003-4975(01)03575-5
   Safi HJ, 1996, J VASC SURG, V24, P338, DOI 10.1016/S0741-5214(96)70189-1
   SVENSSON LG, 1989, J VASC SURG, V10, P230, DOI 10.1067/mva.1989.13947
NR 12
TC 20
Z9 20
U1 3
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD DEC
PY 2004
VL 40
IS 6
BP 1067
EP 1072
DI 10.1016/j.jvs.2004.08.055
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 902XF
UT WOS:000227389300001
PM 15622356
OA Bronze
DA 2018-12-27
ER

PT J
AU Ip, P
   Wong, V
   Ho, M
   Lee, J
   Wong, W
AF Ip, P
   Wong, V
   Ho, M
   Lee, J
   Wong, W
TI RETRACTED: Environmental mercury exposure in children: South China's
   experience (Retracted article. See vol. 50, pg. 606, 2008)
SO PEDIATRICS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE children; Chinese; environmental exposure; fish; mercury
ID METHYLMERCURY EXPOSURE; HUMAN-HAIR; HONG-KONG; FISH; INTOXICATION;
   CORONARY; HEALTH; RISK; DIET
AB Background: Environmental mercury levels significantly increased in the past decades following its increase in industrial applications. In spite of an increasing concern on the potential harmful effects of mercury on children, there is no reported data for the Chinese population. The relationship between dietary habit and environmental mercury exposure in Chinese children was studied.
   Methods: The hair and blood mercury levels of Chinese children aged above 3 years in 2000 March to September, were Studied. Sociodemographic data, dietary habits of the past 6 months, and other risk factors for environmental mercury exposure were collected. Those children with blood mercury levels above the toxic range (i.e. > 45 nmol/L) and their family members were further evaluated and their blood and hair mercury levels were monitored before and after Fishing-Moratorium period (June to August 2000) in South China Sea.
   Results: Altogether, 137 Chinese children (mean age, 7.2 years) were recruited. The mean hair mercury level was 2.2 p.p.rn and the mean blood mercury level was 17.6 nmol/L. There was a strong correlation (r = 0.88) between hair and blood mercury levels in our cohort. Frequency of fish consumption correlated with hair (r = 0.51) and blood (r = 0.54) mercury levels. For those children who consumed fish more than 3 times/week, hair and blood mercury levels were twice as high as those who consurned fish 1 - 3 times/week and threefold of those who never consumed fish. Five children and 12 family members had toxic blood mercury levels. Their blood (P < 0.0001) and hair (P = 0.02) mercury levels dropped significantly after reducing fish consumption during Fishing-Moratorium period.
   Conclusion: Both blood and hair (i.e. Tissue) mercury levels of children in Hong Kong was elevated and correlated with the frequency of fish consumption.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Div Neurodev Paediat, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Div Clin Biochem, Hong Kong, Hong Kong, Peoples R China.
RP Wong, V (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Div Neurodev Paediat, Hong Kong, Hong Kong, Peoples R China.
EM venwong@hkucc.hku.hk
CR AIREY D, 1983, ENVIRON HEALTH PERSP, V52, P303, DOI 10.2307/3429683
   Battigelli M. C., 1983, ENV OCCUPATIONAL MED, P449
   Chapman L, 2000, ENVIRON HEALTH PERSP, V108, P29, DOI 10.2307/3454292
   Chen HP, 1998, ATOM SPECTROSC, V19, P176
   Dickman MD, 1998, CHEMOSPHERE, V37, P991, DOI 10.1016/S0045-6535(98)00006-X
   Dickman MD, 1998, SCI TOTAL ENVIRON, V214, P165, DOI 10.1016/S0048-9697(98)00062-X
   *EUR PLC, 1997, CONS AS
   Foo SC, 1998, SCI TOTAL ENVIRON, V209, P185, DOI 10.1016/S0048-9697(97)00309-4
   Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4
   Grandjean P, 1999, PUBLIC HEALTH REP, V114, P512, DOI 10.1093/phr/114.6.512
   INSKIP MJ, 1985, J APPL TOXICOL, V5, P113, DOI 10.1002/jat.2550050302
   IP P, 2003, IN PRESS J CHILD NEU
   Kaiser J, 2000, SCIENCE, V289, P371, DOI 10.1126/science.289.5487.2031
   KATZ SA, 1992, J APPL TOXICOL, V12, P79, DOI 10.1002/jat.2550120203
   KINSELLA JE, 1987, SEAFOODS FISH OILS H
   Kulig K, 1998, NEW ENGL J MED, V338, P1692, DOI 10.1056/NEJM199806043382311
   MACHLIN LJ, 1980, COMPREHHENSIVE TREAT
   Myers GJ, 2000, ENVIRON RES, V83, P275, DOI 10.1006/enrs.2000.4065
   *NAT RES COUNC, 2000, TOX EFFMETH
   *NIH, 1995, BIBLIOGRAPHY, VA
   OZUAH PO, 2000, CURR PROBL PEDIATR, V3, P91
   Pellizzari ED, 1999, J EXPO ANAL ENV EPID, V9, P393, DOI 10.1038/sj.jea.7500056
   Pless R, 2000, J PEDIATR-US, V136, P571, DOI 10.1067/mpd.2000.106797
   Rissanen T, 2000, CIRCULATION, V102, P2677, DOI 10.1161/01.CIR.102.22.2677
   Safeliu C, 2001, NEUROTOXICOLOGY, V22, P317, DOI 10.1016/S0161-813X(01)00015-8
   SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645
   SHAW B, 1995, THESIS U HONG KONG H
   SIU KWM, 1989, OCCURRENCE DISTRIBUT
   Steuerwald U, 2000, J PEDIATR-US, V136, P599, DOI 10.1067/mpd.2000.102774
   U.S. EPA(U.S. Environmental Protection Agency), 1997, MERC STUD REP C
   Wang L, 2000, Schriftenr Ver Wasser Boden Lufthyg, V105, P413
   WHO World Health Organization, 1990, ENV HLTH CRIT 101
   Wu CH, 1999, ENVIRON HEALTH PERSP, V107, P251, DOI 10.2307/3434590
NR 33
TC 31
Z9 33
U1 4
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1328-8067
EI 1442-200X
J9 PEDIATR INT
JI Pediatr. Int.
PD DEC
PY 2004
VL 46
IS 6
BP 715
EP 721
DI 10.1111/j.1442-200x.2004.01972.x
PG 7
WC Pediatrics
SC Pediatrics
GA 888OQ
UT WOS:000226384500016
PM 15660873
DA 2018-12-27
ER

PT J
AU Singh, D
   Chopra, K
AF Singh, D
   Chopra, K
TI RETRACTED: Effect of trimetazidine on renal ischemia/reperfusion injury
   in rats (Retracted article. See vol 57, pg. 476, 2008)
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article; Retracted Publication
DE ischemia-reperfusion; oxidative stress; trimetazidine
ID ISCHEMIA-REPERFUSION INJURY; SUPEROXIDE-DISMUTASE; GLUTATHIONE; DAMAGE;
   LIVER; ACCUMULATION; MITOCHONDRIA; TRANSITION; CALCIUM; CELLS
AB There is increasing evidence to suggest that toxic oxygen radicals play a role in the pathogenesis of ischemia/reperfusion (I/R) injury in the kidney. This study was designed to investigate the effects of trimetazidine, in I/R induced renal failure in rats. The protective effect of trimetazidine (Tmz) against the damage inflicted by reactive oxygen species (ROS) during renal I/R was investigated in Sprague-Dawley rats using histopathological and biochemical parameters. In one set of experiments animals were unilaterally nephrectomized, and subjected to 45 min of left renal pedicle occlusion and in another set both the renal pedicles were occluded for 45 min followed by 24 h of reperfusion. Trimetazidine Q mg kg(-1), i.p.) was administered 30 min prior to ischemia and repeated 12 h after the first dose. At the end of the reperfusion period, rats were sacrificed. Thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) levels, glutathione reductase (GR) catalase (CAT), and superoxide dismutase (SOD) activities were determined in renal tissue. Serum creatinine and blood urea nitrogen (BUN) concentrations were measured for the evaluation of renal function. Ischemic control animals demonstrated severe deterioration of renal function, renal morphology and a significant renal oxidative stress. Pretreatment of animals with trimetazidine markedly attenuated renal dysfunction, morphological alterations, reduced elevated TBARS levels and restored the depleted renal antioxidant enzymes. The findings imply that ROS play a causal role in I/R induced renal injury and trimetazidine exert renoprotective effects probably by the radical scavenging and antioxidant activities. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Punjabi Univ, Univ Inst Pharmaceut Sci, Div Pharmacol, Chandigarh 160014, India.
RP Chopra, K (reprint author), Punjabi Univ, Univ Inst Pharmaceut Sci, Div Pharmacol, Chandigarh 160014, India.
EM dr_chopra_k@yahoo.com
CR AUBERT A, 1989, EUR J PHARMACOL, V174, P215, DOI 10.1016/0014-2999(89)90314-2
   BAUD L, 1993, BRIT MED BULL, V49, P621, DOI 10.1093/oxfordjournals.bmb.a072635
   BLEBEA J, 1987, Current Surgery, V44, P396
   Bomzon A, 1997, SEMIN NEPHROL, V17, P549
   CARLBERG I, 1975, J BIOL CHEM, V250, P5475
   Claiborne A, 1985, CRC HDB METHODS OXYG, P283
   GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504
   GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523
   GREENE EL, 1994, AM J PHYSIOL, V266, pF13
   HARPEY C, 1989, CARDIOVASC DRUG REV, V6, P292
   HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2
   Hughes AK, 1996, KIDNEY INT, V49, P181, DOI 10.1038/ki.1996.25
   JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485
   JONES DP, 1986, ANNU REV PHYSIOL, V48, P33
   Kantor PF, 2000, CIRC RES, V86, P580, DOI 10.1161/01.RES.86.5.580
   KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4
   Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705
   LABRID C, 1986, PRESSE MED, V15, P1754
   LAVANCHY N, 1987, ARCH INT PHARMACOD T, V286, P97
   Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477
   MARIDONNEAUPARINI I, 1985, BRIT J CLIN PHARMACO, V20, P148, DOI 10.1111/j.1365-2125.1985.tb05047.x
   Mashiach E, 1998, NEPHRON, V80, P458, DOI 10.1159/000045220
   MOHANDAS J, 1984, CANCER RES, V44, P5086
   Morin D, 1998, BRIT J PHARMACOL, V123, P1385, DOI 10.1038/sj.bjp.0701755
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   RENAUD J F, 1988, Cardiovascular Drugs and Therapy, V1, P677, DOI 10.1007/BF02125756
   Salducci MD, 1996, J PHARMACOL EXP THER, V277, P417
   SENGA S, 1990, TRANSPL P, P22
   Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x
   THADHANI R, 1996, NEW ENGL J MED, V360, P1148
   VARLEY H, 1988, PRACTICAL CLIN BIOCH, P236
   VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87
   Weight SC, 1996, BRIT J SURG, V83, P162, DOI 10.1002/bjs.1800830206
   WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58
   WILLIAMS FM, 1993, J CARDIOVASC PHARM, V22, P828, DOI 10.1097/00005344-199312000-00008
   YOUNES M, 1987, RES EXP MED, V187, P9, DOI 10.1007/BF01854963
   ZELENOCK GB, 1997, SURG SCI PRINCIPLES, P1643
   ZIMMERMAN BJ, 1994, LANCET, V344, P934
NR 38
TC 24
Z9 28
U1 3
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD DEC
PY 2004
VL 50
IS 6
BP 623
EP 629
DI 10.1016/j.phrs.2004.06.006
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 868QQ
UT WOS:000224928500012
PM 15501702
DA 2018-12-27
ER

PT J
AU Tian, E
   Ten Hagen, KG
   Shum, L
   Hang, HC
   Imbert, Y
   Young, WW
   Bertozzi, CR
   Tabak, LA
AF Tian, E
   Ten Hagen, KG
   Shum, L
   Hang, HC
   Imbert, Y
   Young, WW
   Bertozzi, CR
   Tabak, LA
TI RETRACTED: An inhibitor of O-glycosylation induces apoptosis in NIH3T3
   cells and developing mouse embryonic mandibular tissues (Retracted
   Article. See vol 283, pg 4460, 2008)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; DROSOPHILA-MELANOGASTER;
   LINKED GLYCOSYLATION; D-GALACTOSAMINE; FAMILY; EXPRESSION; PROTEINS;
   CLONING; ELEGANS; NEURONS
AB The family of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (ppGaNTases) is responsible for initiating mucin-type O-linked glycosylation in higher eukaryotes. To begin to examine the biological role of O-linked glycosylation, mammalian cells were treated with a small molecule inhibitor (designated 1-68A, Ref. 15) of ppGaNTase activity. NIH3T3 cells exposed to the inhibitor were shown to undergo a significant reduction in cell surface O-glycosylation as detected by staining with jacalin and peanut agglutinin lectins after 30 min of treatment; no reduction in staining using antibodies to O-linked N-acetylglucosamine or the lectin concanavalin A was detected. Apoptosis was also observed in treated cells after 45 min of exposure, ostensibly following the O-glycosylation reduction. Overexpression of several different ppGaNTase isoforms restored cell surface O-glycosylation and rescued inhibitor-induced apoptosis. Additionally, mouse embryonic mandibular organ cultures exposed to 1-68A developed abnormally, presumably because of epithelial and mesenchymal apoptosis that followed a reduction in jacalin and peanut agglutinin staining. Our studies suggest that mucin-type O-linked glycosylation may be required for normal development and that ppGaNTases may play a role in the regulation of apoptosis.
C1 NIDDK, NIH, Biol Chem Sect, Bethesda, MD 20892 USA.
   NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA.
   Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Louisville, Sch Dent, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA.
   Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.
   Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
   Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
RP Tabak, LA (reprint author), NIDDK, NIH, Biol Chem Sect, Bldg 31, Rm 2C39,31 Ctr Dr,MSC 2290, Bethesda, MD 20892 USA.
EM tabakl@mail.nih.gov
FU NEI NIH HHS [EY015134]; NIGMS NIH HHS [GM66047]
CR Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132
   Garrido C, 2003, CELL DEATH DIFFER, V10, P619, DOI 10.1038/sj.cdd.4401229
   Hagen F, 2001, TRENDS GLYCOSCI GLYC, V13, P463, DOI 10.4052/tigg.13.463
   Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797
   Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochems.73.011303.074043
   Hang HC, 2004, CHEM BIOL, V11, P337, DOI 10.1016/j.chembiol.2004.02.023
   Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070
   Kim EJ, 2004, J BIOL CHEM, V279, P18342, DOI 10.1074/jbc.M400205200
   Kingsley PD, 2000, GLYCOBIOLOGY, V10, P1317, DOI 10.1093/glycob/10.12.1317
   Lee JC, 2003, IMMUNOL REV, V193, P39, DOI 10.1034/j.1600-065X.2003.00043.x
   McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8
   Moody AM, 2003, J BIOL CHEM, V278, P7240, DOI 10.1074/jbc.M210468200
   Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200
   Pak JH, 2002, J BIOL CHEM, V277, P49927, DOI 10.1074/jbc.M204222200
   Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0
   Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6
   Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200
   SHUM L, 1993, DEVELOPMENT, V118, P903
   Slavkin H, 2000, METH MOL B, V136, P45
   Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114
   Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200
   Ten Hagen KG, 2003, J BIOL CHEM, V278, P35039, DOI 10.1074/jbc.M303836200
   Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007
   Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200
   THEILER K, 1989, HOUSE MOUSE ATLAS EM, P60
   Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358
   Tzima E, 2000, PLATELETS, V11, P245
   Wang H, 2003, BIOCHEM BIOPH RES CO, V300, P738, DOI 10.1016/S0006-291X(02)02908-X
   Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112
   Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev
   Yeh JRJ, 2003, DEV CELL, V5, P11, DOI 10.1016/S1534-5807(03)00200-4
   Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200
   Young WW, 2003, GLYCOBIOLOGY, V13, P549, DOI 10.1093/glycob/cwg062
   Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200
   Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373
   Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200
NR 36
TC 16
Z9 16
U1 2
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 26
PY 2004
VL 279
IS 48
BP 50382
EP 50390
DI 10.1074/jbc.M406397200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 872SU
UT WOS:000225229500103
PM 15342645
DA 2018-12-27
ER

PT J
AU Duffy, AA
   Martin, MM
   Elton, TS
AF Duffy, AA
   Martin, MM
   Elton, TS
TI RETRACTED: Transcriptional regulation of the AT(1) receptor gene in
   immortalized human trophoblast cells (Retracted article. See vol. 1829,
   pg. 980, 2013)
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION
LA English
DT Article; Retracted Publication
DE angiotensin II receptor; transcriptional regulation; ChIP
ID ANGIOTENSIN-II RECEPTOR; PREGNANCY-INDUCED HYPERTENSION;
   PLASMINOGEN-ACTIVATOR; TYPE-1 RECEPTOR; AGONISTIC AUTOANTIBODIES;
   GENOMIC ORGANIZATION; SP3; EXPRESSION; PREECLAMPSIA; DOMAINS
AB Studies investigating the mechanisms that govern the expression of the human angiotensin II (Ang II) type 1 receptor (hAT(1)R) gene have progressed slowly due to the lack of human cell lines that express the AT(1)R. Recently, however, an immortalized human trophoblast cell line (HTR-8/SVNeo) was demonstrated to respond to Ang II. Therefore, we utilized this cell line to characterize the AT(1)R expressed on the cell surface and to investigate the mechanisms by which the hAT(1)R gene is regulated in these cells. HTR-8/SVNeo cells were shown to express functional high affinity AT(1)Rs having a B-max value of 114+/-11 fmol/mg protein and a K-d value of 0.14+/-0.1 nM. Additionally, Ang II-induced IP3 production was mediated via the AT(1)R. Deletional analysis of the hAT(1)R promoter localized a major basal regulatory sequence within the -105 to -79 by region, relative to the transcription start site, in HTR-8/SVNeo cells. Electrophoretic mobility shift assay (EMSA) and Chromatin Immunoprecipitation (ChIP) assay demonstrated that the transcription factors, Sp1 and Sp3, interact with this region of the hAT(1)R promoter in vitro and in vivo. Taken together, our data demonstrate that HTR-8/SVNeo cells express functional AT(1)Rs and that basal level expression of this gene is regulated, in part, by Sp1 and Sp3 in this cell line. (C) 2004 Elsevier B.V. All rights reserved.
C1 Ohio State Univ, Coll Pharm, Div Pharmacol, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
RP Elton, TS (reprint author), Ohio State Univ, Coll Pharm, Div Pharmacol, Davis Heart & Lung Res Inst, DHLRI 515,473 W 12th Ave, Columbus, OH 43210 USA.
EM elton-1@medctr.osu.edu
FU NHLBI NIH HHS [HL48848]
CR Alfonso-Jaume MA, 2004, BIOCHEM J, V380, P735, DOI 10.1042/BJ20031281
   Alhenc-Gelas F, 1986, Adv Nephrol Necker Hosp, V15, P25
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976
   BIRD IM, 1994, ENDOCRINOLOGY, V134, P2468, DOI 10.1210/en.134.6.2468
   Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034
   Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6
   CAMPANILE CP, 1982, J BIOL CHEM, V257, P4951
   COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5
   CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250
   Danser AHJ, 2003, INT J BIOCHEM CELL B, V35, P759
   de Gasparo M, 2000, PHARMACOL REV, V52, P415
   Dechend R, 2003, CIRCULATION, V107, P1632, DOI 10.1161/01.CIR.0000058200.90059.B1
   Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x
   Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573
   Estelles A, 1998, THROMB HAEMOSTASIS, V79, P500
   Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335
   GERRETSEN G, 1981, BRIT J OBSTET GYNAEC, V88, P876, DOI 10.1111/j.1471-0528.1981.tb02222.x
   GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139
   GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207
   Granger JP, 2001, AM J HYPERTENS, V14, p178S, DOI 10.1016/S0895-7061(01)02086-6
   Granger JP, 2001, HYPERTENSION, V38, P718, DOI 10.1161/01.HYP.38.3.718
   Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281
   GUO DF, 1994, BIOCHEM BIOPH RES CO, V200, P313, DOI 10.1006/bbrc.1994.1450
   HAGEMANN A, 1994, EXP CLIN ENDOCRINOL, V102, P252, DOI 10.1055/s-0029-1211289
   Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712
   Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1
   Karteris E, 2003, J CLIN ENDOCR METAB, V88, P363, DOI 10.1210/jc.2002-020375
   Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678
   Leung PS, 2001, MOL CELL ENDOCRINOL, V184, P95, DOI 10.1016/S0303-7207(01)00637-2
   Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021
   Martin MM, 2001, MOL CELL ENDOCRINOL, V183, P81, DOI 10.1016/S0303-7207(01)00595-0
   MARTIN MM, 2003, ENDOCRINOL METAB, V14, P66
   Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x
   PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007
   Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991
   Poisner AM, 1998, FRONT NEUROENDOCRIN, V19, P232, DOI 10.1006/frne.1998.0166
   Roberts JM, 1998, LANCET, V352, P22
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D
   SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SKINNER SL, 1972, CLIN SCI, V42, P479, DOI 10.1042/cs0420479
   Strawn W B, 2000, J Renin Angiotensin Aldosterone Syst, V1, P11, DOI 10.3317/jraas.2000.001
   STRICKLAND S, 1976, J BIOL CHEM, V251, P5694
   STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8
   SU BG, 1994, BIOCHEM BIOPH RES CO, V204, P1039, DOI 10.1006/bbrc.1994.2567
   Su BG, 1996, ADV EXP MED BIOL, V396, P11
   Takeda-Matsubara Y, 2003, AM J HYPERTENS, V16, P993, DOI 10.1016/j.amjhyper.2003.07.020
   Vaughan DE, 2000, CIRCULATION, V101, P1496, DOI 10.1161/01.CIR.101.13.1496
   Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106
   Wallukat G, 2003, CAN J PHYSIOL PHARM, V81, P79, DOI 10.1139/Y02-160
   Xia Y, 2003, J SOC GYNECOL INVEST, V10, P82, DOI 10.1016/S1071-5576(02)00259-9
   Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200
   Xia Y, 2002, BIOL REPROD, V66, P135, DOI 10.1095/biolreprod66.1.135
   Zhao X, 2001, BBA-GENE STRUCT EXPR, V1522, P195, DOI 10.1016/S0167-4781(01)00341-4
   Zhao X, 2000, BBA-GENE STRUCT EXPR, V1494, P181, DOI 10.1016/S0167-4781(00)00228-1
NR 57
TC 12
Z9 12
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4781
J9 BBA-GENE STRUCT EXPR
JI Biochim. Biophys. Acta-Gene Struct. Expression
PD NOV 5
PY 2004
VL 1680
IS 3
BP 158
EP 170
DI 10.1016/j.bbaexp.2004.09.008
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 868UK
UT WOS:000224938300003
PM 15507319
DA 2018-12-27
ER

PT J
AU Fukada, S
   Morimitsu, S
   Shimoozaki, N
   Nishikawa, N
AF Fukada, S
   Morimitsu, S
   Shimoozaki, N
   Nishikawa, N
TI RETRACTED: Profiles of hydrogen molar fraction and temperature in
   ZrV1.9Fe0.1 alloy bed for hydrogen absorption (Retracted article. See
   vol. 495, pg. 292, 2010)
SO JOURNAL OF ALLOYS AND COMPOUNDS
LA English
DT Article; Retracted Publication
DE hydrogen storage materials; gas-solid reactions; heat conduction;
   thermal analysis
ID METAL HYDRIDE BED; MASS-TRANSFER; PARTICLE BED; HEAT-PUMP; DESORPTION
AB Profiles of hydrogen molar fraction and temperature in a long ZrV1.9Fe0.1 alloy particle bed with a small diameter were determined experimentally and analytically as a basic study of chemical heat pumps operated at higher temperature. Since the alloy bed absorbed hydrogen even at 873 K and generated heat, the alloy was considered a suitable material for heat pump or hydrogen storage at higher temperature. Experimental profiles of both hydrogen molar fraction at the bed outlet and temperature inside the bed agreed with analytical solutions to heat and mass-transfer equations. The analytical solutions were obtained under the conditions where constant-pattern approximation could be applied to the temperature and concentration profiles propagating in a bed with the same velocity. Properties relating with heat transfer such as a heat capacity, enthalpy change of hydrogen absorption and a heat-transfer coefficient between a wall and particles were correlated to two dimensionless parameters, alpha and beta. (C) 2004 Elsevier B.V All rights reserved.
C1 Kyushu Univ, Dept Appl Quantrum Phys & Nucl Engn, Higashi Ku, Fukuoka 8128581, Japan.
RP Fukada, S (reprint author), Kyushu Univ, Dept Appl Quantrum Phys & Nucl Engn, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.
EM sfukada@nucl.kyushu-u.ac.jp
CR Aldas K, 2002, INT J HYDROGEN ENERG, V27, P1049, DOI 10.1016/S0360-3199(02)00010-1
   CHOI H, 1990, INT J HEAT MASS TRAN, V33, P1281, DOI 10.1016/0017-9310(90)90257-U
   FUKADA S, 1988, J NUCL SCI TECHNOL, V25, P895, DOI 10.1080/18811248.1988.9735945
   Fukada S, 2004, J ALLOY COMPD, V375, P305, DOI 10.1016/j.jallcom.2003.12.008
   Fukada S, 2004, INT J HYDROGEN ENERG, V29, P619, DOI 10.1016/j.ijhydene.2003.08.002
   FUKADA S, 1991, J CHEM ENG JPN, V24, P609, DOI 10.1252/jcej.24.609
   FUKADA S, 2000, HYDROGEN ISOTOPE SEP
   Isselhorst A, 1995, J ALLOY COMPD, V231, P871, DOI 10.1016/0925-8388(95)01775-5
   Jemni A, 1999, INT J HYDROGEN ENERG, V24, P631, DOI 10.1016/S0360-3199(98)00117-7
   MENDELSOHN MH, 1977, NATURE, V269, P45, DOI 10.1038/269045a0
   MITSUISHI N, 1990, J NUCL MATER, V175, P209, DOI 10.1016/0022-3115(90)90209-6
   MITSUISHI N, 1986, J LESS-COMMON MET, V123, P65, DOI 10.1016/0022-5088(86)90115-3
   Nakagawa T, 2000, INT J HYDROGEN ENERG, V25, P339, DOI 10.1016/S0360-3199(99)00036-1
   NISHIZAKI T, 1983, J LESS-COMMON MET, V89, P559, DOI 10.1016/0022-5088(83)90372-7
   OSUMI Y, 1993, HYDROGEN ABSORBING A
   RON M, 1984, J LESS-COMMON MET, V104, P259, DOI 10.1016/0022-5088(84)90411-9
   Ruthven D. M., 1984, PRINCIPLES ADSORPTIO
   TAMURA H, 1998, HYDROGEN STORAGE ALL
NR 18
TC 2
Z9 2
U1 2
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-8388
EI 1873-4669
J9 J ALLOY COMPD
JI J. Alloy. Compd.
PD NOV 3
PY 2004
VL 381
IS 1-2
BP 258
EP 265
DI 10.1016/j.jallcom.2004.03.099
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering
GA 866GP
UT WOS:000224762300043
DA 2018-12-27
ER

PT J
AU Akan, H
   Aksoz, T
   Belet, U
   Sesen, T
AF Akan, H
   Aksoz, T
   Belet, U
   Sesen, T
TI RETRACTED: Dynamic upper airway soft-tissue and caliber changes in
   healthy subjects and snoring patients (Retracted Article. See vol 28, pg
   1624, 2007)
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article; Retracted Publication
ID OBSTRUCTIVE SLEEP-APNEA; OBESE-PATIENTS; WEIGHT-LOSS; NREM SLEEP; CINE
   CT; PHYSIOLOGY; PRESSURE; PHARYNX; SNORERS; FAT
AB BACKGROUND AND PURPOSE: The oropharyngeal airways are smaller in those who snore than in those who do not. We sought to determine which soft-tissue component surrounding the airways contributes to upper airway narrowing in those who snore.
   METHODS. Ten control subjects and 19 snoring patients underwent CT, with 2-mm-thick axial sections obtained every 0.6 seconds during the respiration cycle at the same oropharyngeal level. We selected two sections with the widest and narrowest parts of the oropharyngeal airway to measure the anteroposterior and lateral dimensions of the airway and the thickness of the bilateral parapharyngeal fat pads, pterygoid muscles, and parapharyngeal walls. Mean values were calculated for each phase. For each subject, differences were calculated by subtracting the values in narrowest phase from those in the widest phase.
   RESULTS: Changes in airway dimension (P < .05) and lateral parapharyngeal wall thickness (P < .01) were significantly different between snorers and control subjects. Changes in parapharyngeal wall thickness and transverse oropharyngeal airway diameter changes were significantly related (P < .01) in those who snored but not in control subjects.
   CONCLUSION. Airway narrowing predominantly occurs in the lateral dimension in people who snore. Changes in the lateral pharyngeal wall are more important than the parapharyngeal fat pads in airway calibration. Narrowing of the upper airway area at the end of the expirium and the beginning of the inspirium is thought to be the cause of snoring and due to augmented muscle mass and prolonged laxity rather than inadequate activation of the pharyngeal dilating muscles.
C1 Ondokuz Mayis Univ, Fac Med, Dept Radiol, TR-55139 Samsun, Turkey.
   Ondokuz Mayis Univ, Fac Med, Dept Otolaryngol, TR-55139 Samsun, Turkey.
RP Akan, H (reprint author), Ondokuz Mayis Univ, Fac Med, Dept Radiol, TR-55139 Samsun, Turkey.
CR Arens R, 2001, AM J RESP CRIT CARE, V164, P698, DOI 10.1164/ajrccm.164.4.2101127
   Ayappa I, 2003, SLEEP MED REV, V7, P9, DOI 10.1053/smrv.2002.0238
   Beck R, 1995, EUR RESPIR J, V8, P2120, DOI 10.1183/09031936.95.08122120
   BLOCK AJ, 1979, NEW ENGL J MED, V300, P513, DOI 10.1056/NEJM197903083001001
   BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105
   ELL SR, 1986, AM J ROENTGENOL, V146, P669
   GALVIN JR, 1989, RADIOLOGY, V171, P775, DOI 10.1148/radiology.171.3.2717750
   GLEDHILL IG, 1991, AM REV RESPIR DIS, V143, P1300
   GREEN DE, 1991, CHEST, V99, P49, DOI 10.1378/chest.99.1.49
   HAPONIK EF, 1983, AM REV RESPIR DIS, V127, P221
   Hoffstein V, 1996, CHEST, V109, P201, DOI 10.1378/chest.109.1.201
   HORNER RL, 1989, EUR RESPIR J, V2, P613
   Huang LX, 1999, J APPL PHYSIOL, V86, P1759
   HUDGEL DW, 1988, AM REV RESPIR DIS, V138, P1542, DOI 10.1164/ajrccm/138.6.1542
   HUDGEL DW, 1992, CHEST, V101, P541, DOI 10.1378/chest.101.2.541
   MAHADEVIA AK, 1983, AM REV RESPIR DIS, V128, P708
   Mortimore IL, 1998, AM J RESP CRIT CARE, V157, P280, DOI 10.1164/ajrccm.157.1.9703018
   PALOMAKI H, 1992, NEUROLOGY, V42, P75
   PHILLIPSON EA, 1977, AM REV RESPIR DIS, V115, P251
   RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355
   SCHWAB RJ, 1995, AM J RESP CRIT CARE, V152, P1673, DOI 10.1164/ajrccm.152.5.7582313
   SCHWAB RJ, 1993, AM REV RESPIR DIS, V148, P1385, DOI 10.1164/ajrccm/148.5.1385
   SCHWAB RJ, 1993, J APPL PHYSIOL, V74, P1504
   SCHWARTZ AR, 1988, J APPL PHYSIOL, V64, P535
   SHELTON KE, 1993, AM REV RESPIR DIS, V148, P462, DOI 10.1164/ajrccm/148.2.462
   SKATRUD JB, 1985, J APPL PHYSIOL, V59, P328
   SMIRNE S, 1991, LANCET, V337, P597
   SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850
   Sovijarvi A. R. A., 2000, EUR RESPIR REV, V10, P591
   STEIN MG, 1987, AM J ROENTGENOL, V148, P1069, DOI 10.2214/ajr.148.6.1069
   STOOHS R, 1991, RESP PHYSIOL, V85, P151, DOI 10.1016/0034-5687(91)90058-Q
   SURATT PM, 1987, CHEST, V92, P631, DOI 10.1378/chest.92.4.631
   Thompson SR, 2001, ADV PHYSIOL EDUC, V25, P29
   Welch KC, 2002, SLEEP, V25, P532, DOI 10.1093/sleep/25.5.530
   WETTER DW, 1994, ARCH INTERN MED, V154, P2219, DOI 10.1001/archinte.154.19.2219
   Zohar Y, 1998, ANN OTO RHINOL LARYN, V107, P170, DOI 10.1177/000348949810700214
NR 36
TC 11
Z9 12
U1 2
U2 6
PU AMER SOC NEURORADIOLOGY
PI OAK BROOK
PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA
SN 0195-6108
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD NOV-DEC
PY 2004
VL 25
IS 10
BP 1846
EP 1850
PG 5
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 874IN
UT WOS:000225344200043
PM 15569762
DA 2018-12-27
ER

PT J
AU Singh, D
   Chander, V
   Chopra, K
AF Singh, D
   Chander, V
   Chopra, K
TI RETRACTED: The effect of Quercetin, a bioflavonoid on
   ischemia/reperfusion induced renal injury in rats (Retracted Article.
   See vol 39, pg 714, 2008)
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE ischernia/reperfusion; oxidative stress; Quercetin
ID ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE;
   SUPEROXIDE-DISMUTASE; ANTIINFLAMMATORY AGENT; GLUTATHIONE-REDUCTASE;
   CHRONIC REJECTION; XANTHINE-OXIDASE; FLAVONOIDS; STRESS; CURCUMIN
AB pathogenesis of ischemia/reperfusion (I/R) injury in the kidney. This study was designed to investigate the effects of quercetin (Qr), a bioflavonoid in ischemia-reperfusion induced renal failure in rats. The effect of quercetin against the damage inflicted by reactive oxygen species (ROS) during renal I/R was investigated in Sprague-Dawley rats using histopathological and biochemical parameters. In one set of experiments, animals were unilaterally nephrectomized and subjected to 45 min of left renal pedicle occlusion, and in another set both renal pedicles were occluded for 45 min followed by 24 h of reperfusion. Quercetin (2 mg/kg, 30 mg/ko, i.p. and 100 mg/kg, p.o.) was administered 2 h prior to ischemia. At the end of the reperfusion period, rats were sacrificed. Thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) levels, glutathione reductase (GR), catalase (CAT), and superoxide dismutase (SOD) activities were determined in renal tissue. Serum creatinine and blood urea nitrogen (BUN) concentrations were measured for the evaluation of renal function. Ischemic control animals demonstrated severe deterioration of renal function, renal morphology and a significant renal oxidative stress. Pretreatment of animals with quercetin (2 mg/kg and 30 mg/kg, i.p.) markedly attenuated renal dysfunction, morphological alterations, reduced elevated TBARS levels and restored the depleted renal antioxidant enzymes, whereas the (100 mg/kg, p.o.) dose of quercetin failed to revert the renal I/R induced changes. The findings imply that ROS play a causal role in I/R induced renal injury and quercetin exerts protective and deleterious effects in the kidney, depending upon the dose. (C) 2004 IMSS. Published by Elsevier Inc.
C1 Panjab Univ, Div Pharmacol, UIPS, Chandigarh 160014, India.
RP Chopra, K (reprint author), Panjab Univ, Div Pharmacol, UIPS, Chandigarh 160014, India.
EM devindercpsingh@yahoo.co.uk
CR ALMOND PS, 1993, TRANSPLANT P, V25, P936
   Babu PS, 1997, MOL CELL BIOCHEM, V166, P169, DOI 10.1023/A:1006819605211
   BAKER GL, 1985, ANN SURG, V202, P628, DOI 10.1097/00000658-198511000-00016
   BARNES JL, 1981, LAB INVEST, V45, P378
   BIRD JE, 1988, J CLIN INVEST, V81, P1630, DOI 10.1172/JCI113498
   BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076
   BULKLEY G B, 1987, British Journal of Cancer, V55, P66
   CARLBERG I, 1975, J BIOL CHEM, V250, P5475
   CARPENTER CB, 1995, KIDNEY INT, V48, pS40
   CHANG WS, 1993, ANTICANCER RES, V13, P2165
   Chatterjee PK, 1999, KIDNEY INT, V56, P973, DOI 10.1046/j.1523-1755.1999.00644.x
   Chatterjee PK, 2000, FASEB J, V14, P641
   Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x
   Chen ZY, 1996, CHEM PHYS LIPIDS, V79, P157, DOI 10.1016/0009-3084(96)02523-6
   CHIESI M, 1995, BIOCHEM PHARMACOL, V49, P495, DOI 10.1016/0006-2952(94)00433-M
   Claiborne A, 1985, CRC HDB METHODS OXYG, P283
   COLE E, 1995, CLIN TRANSPLANT, V9, P282
   DOSLUOGLU HH, 1993, TRANSPLANT INT, V6, P138
   Ferrali M, 1997, FEBS LETT, V416, P123, DOI 10.1016/S0014-5793(97)01182-4
   FINN WF, 1981, J LAB CLIN MED, V98, P21
   Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1
   GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269
   Haenen GRMM, 1997, BIOCHEM BIOPH RES CO, V236, P591, DOI 10.1006/bbrc.1997.7016
   Hiratsuka M, 1998, J HEART LUNG TRANSPL, V17, P1238
   HUANG HC, 1992, EUR J PHARMACOL, V221, P381
   Inal ME, 2000, TOXICOLOGY, V154, P21
   JAESCHKE H, 1990, METHOD ENZYMOL, V186, P752
   JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485
   Kelly KJ, 2001, KIDNEY INT, V59, P1798, DOI 10.1046/j.1523-1755.2001.0590051798.x
   Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478
   KONO Y, 1976, KIDNEY INT S, V6, pS62
   LANGREHR JM, 1993, ANN SURG, V218, P159, DOI 10.1097/00000658-199308000-00007
   Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327
   MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853
   MOHANDAS J, 1984, CANCER RES, V44, P5086
   Morpurgo E, 1996, TRANSPLANTATION, V62, P1221, DOI 10.1097/00007890-199611150-00006
   NAMGOONG SY, 1994, LIFE SCI, V54, P313, DOI 10.1016/0024-3205(94)00787-X
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Pirsch JD, 1996, TRANSPLANTATION, V61, P1581, DOI 10.1097/00007890-199606150-00006
   ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4
   SCHILLER HJ, 1991, KLIN WOCHENSCHR, V69, P1083, DOI 10.1007/BF01645163
   Shoskes DA, 1997, TRANSPLANTATION, V63, P495, DOI 10.1097/00007890-199702270-00002
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   SINGHAL RL, 1995, BIOCHEM BIOPH RES CO, V208, P425, DOI 10.1006/bbrc.1995.1355
   SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x
   Szeto YT, 2002, FREE RADICAL RES, V36, P113, DOI 10.1080/10715760290001227
   TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039
   VARLEY H, 1988, PRACTICAL CLIN BIOCH, P236
   Williams P, 1997, J PHARMACOL TOX MET, V37, P1, DOI 10.1016/S1056-8719(96)00141-4
   Zhang K, 1997, BIOCHEM PHARMACOL, V54, P1047, DOI 10.1016/S0006-2952(97)00315-8
NR 50
TC 45
Z9 49
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD NOV-DEC
PY 2004
VL 35
IS 6
BP 484
EP 494
DI 10.1016/j.arcmed.2004.10.004
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 893HJ
UT WOS:000226709600003
PM 15631872
DA 2018-12-27
ER

PT J
AU Rekers, H
   Affandi, B
AF Rekers, H
   Affandi, B
TI RETRACTED: Letter to the editor (Retracted Article)
SO CONTRACEPTION
LA English
DT Letter; Retracted Publication
C1 NV Organon, NL-5340 BH Oss, Netherlands.
   Univ Indonesia, Fac Med, Div Reprod Hlth, Dept Obstet & Gynecol, Jakarta, Indonesia.
RP Rekers, H (reprint author), NV Organon, POB 20, NL-5340 BH Oss, Netherlands.
EM hans.rekers@organon.com; biran@indo.net.id
NR 0
TC 8
Z9 8
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD NOV
PY 2004
VL 70
IS 5
BP 433
EP 433
DI 10.1016/j.contraception.2004.07.004
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 873ZO
UT WOS:000225320900014
PM 15504385
DA 2018-12-27
ER

PT J
AU Firestone, KA
   Reid, P
   Lawson, R
   Jang, SH
   Dalton, LR
AF Firestone, KA
   Reid, P
   Lawson, R
   Jang, SH
   Dalton, LR
TI RETRACTED: Advances in organic electro-optic materials and processing
   (Retracted article. See vol. 411, pg. 212, 2014)
SO INORGANICA CHIMICA ACTA
LA English
DT Article; Retracted Publication
DE organic electro-optic materials; nanoimprint lithography; density
   functional theory; Hyper-Rayleigh scattering; flexible thin film
   devices; hyperpolarizability
ID NONLINEAR-OPTICAL-MATERIALS; ASSEMBLED CHROMOPHORIC SUPERLATTICES;
   HYPER-RAYLEIGH SCATTERING; X-RAY REFLECTIVITY; POLYMER MODULATORS;
   MICROSTRUCTURAL CHARACTERIZATION; MOLECULAR HYPERPOLARIZABILITIES;
   INFRARED-ABSORPTION; DEVICE-QUALITY; HOST MATERIAL
AB Frequency-agile, femtosecond Hyper-Rayleigh scattering measurements are used to test the utility of density functional theory calculations for suggesting chromophore structures with improved molecular first hyperpolarizability, beta. A tricyanopyrroline acceptor is shown to yield a factor of approximately three improvement over the commonly used tricyanofuran acceptor. The combination of improved chromophores and incorporation of chromophores into novel nanostructured lattices is leading to routine realization of electro-optic coefficients greater than 100 pm/V at telecommunication wavelengths. In this communication, the use of nanoimprint lithography to stamp out active and passive optical circuitry is also demonstrated. The potential for low-cost, mass production of electro-optic devices, including conformal and flexible devices, is suggested. (C) 2004 Published by Elsevier B.V.
C1 Univ Washington, Dept Chem, Seattle, WA 98195 USA.
RP Dalton, LR (reprint author), Univ Washington, Dept Chem, Bagley Hall 202D, Seattle, WA 98195 USA.
EM dalton@chem.washington.edu
CR Albert IDL, 1998, OPT ENGIN, V60, P37
   Albert IDL, 1998, CHEM MATER, V10, P753, DOI 10.1021/cm970478a
   Albert IDL, 1997, J AM CHEM SOC, V119, P3155, DOI 10.1021/ja964389v
   Albert IDL, 1998, J AM CHEM SOC, V120, P11174, DOI 10.1021/ja982073c
   ALBERT IDL, 1997, J AM CHEM SOC, V119, P6582
   An DC, 2000, APPL PHYS LETT, V76, P1972, DOI 10.1063/1.126226
   Bechtel JH, 2000, P SOC PHOTO-OPT INS, V4114, P58, DOI 10.1117/12.408539
   BECKER MW, 1994, CHEM MATER, V6, P104, DOI 10.1021/cm00038a002
   Breitung EM, 2000, J AM CHEM SOC, V122, P1154, DOI 10.1021/ja9930364
   Chang DH, 2000, IEEE PHOTONIC TECH L, V12, P537, DOI 10.1109/68.841278
   Chen AT, 2000, OPT ENG, V39, P1507, DOI 10.1117/1.602523
   Chen DT, 1997, APPL PHYS LETT, V70, P3335, DOI 10.1063/1.119162
   Chen DT, 1999, IEEE PHOTONIC TECH L, V11, P54, DOI 10.1109/68.736388
   Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85
   CLAYS K, 1991, PHYS REV LETT, V66, P2980, DOI 10.1103/PhysRevLett.66.2980
   Dalton L, 1999, IND ENG CHEM RES, V38, P8, DOI 10.1021/ie9705970
   Dalton L, 2002, ADV POLYM SCI, V158, P1
   Dalton LR, 2004, P SOC PHOTO-OPT INS, V5351, P1, DOI 10.1117/12.533167
   Dalton LR, 2004, PURE APPL CHEM, V76, P1421, DOI 10.1351/pac200476071421
   Dalton LR, 2003, OPT MATER, V21, P19, DOI 10.1016/S0925-3467(02)00107-6
   Dalton LR, 2003, J PHYS-CONDENS MAT, V15, pR897, DOI 10.1088/0953-8984/15/20/203
   DALTON LR, 1995, CHEM MATER, V7, P1060, DOI 10.1021/cm00054a006
   DALTON LR, IN PRESS MAT RES SOC
   DeRosa ME, 2004, J PHYS CHEM B, V108, P8725, DOI 10.1021/jp037907e
   Ermer S, 2000, P SOC PHOTO-OPT INS, V3949, P148, DOI 10.1117/12.382892
   Evmenenko G, 2001, J CHEM PHYS, V115, P6722, DOI 10.1063/1.1398576
   Facchetti A, 2003, CHEM MATER, V15, P1064, DOI 10.1021/cm020929d
   FECCHETTI A, 2001, LANGMUIR, V17, P5939
   FECCHETTI A, 2002, CHEM MATER, V14, P4996
   Galvan-Gonzalez A, 2003, J APPL PHYS, V94, P756, DOI 10.1063/1.1578703
   Garner SM, 2004, APPL PHYS LETT, V84, P1049, DOI 10.1063/1.1646754
   Garner SM, 1999, IEEE J QUANTUM ELECT, V35, P1146, DOI 10.1109/3.777214
   Han J, 2003, P SOC PHOTO-OPT INS, V4991, P562, DOI 10.1117/12.479442
   He MQ, 2002, CHEM MATER, V14, P4669, DOI 10.1021/cm0204066
   He MQ, 2002, CHEM MATER, V14, P4662, DOI 10.1021/cm020405d
   Huang YY, 2004, J PHYS CHEM B, V108, P8606, DOI 10.1021/jp049724d
   Jin DL, 2003, P SOC PHOTO-OPT INS, V4991, P610, DOI 10.1117/12.479448
   Kaatz P, 1998, OPT COMMUN, V157, P177, DOI 10.1016/S0030-4018(98)00479-9
   KANIS DR, 1994, CHEM REV, V94, P195, DOI 10.1021/cr00025a007
   Lawson R. A., UNPUB
   LEE M, 2002, SCIENCE, V298, P140
   LI DQ, 1990, J AM CHEM SOC, V112, P7389, DOI 10.1021/ja00176a045
   LIN WB, 1995, ANGEW CHEM INT EDIT, V34, P1497, DOI 10.1002/anie.199514971
   Lin WB, 1997, J AM CHEM SOC, V119, P2205, DOI 10.1021/ja962293v
   Lin WB, 1996, J AM CHEM SOC, V118, P8034, DOI 10.1021/ja960395f
   Liu S, 2003, ADV MATER, V15, P603, DOI 10.1002/adma.200304813
   Lundquist PM, 1997, APPL PHYS LETT, V70, P1941, DOI 10.1063/1.118786
   Luo JD, 2003, P SOC PHOTO-OPT INS, V5224, P104, DOI 10.1117/12.508356
   Luo JD, 2003, P SOC PHOTO-OPT INS, V4991, P520, DOI 10.1117/12.475459
   Malik A, 1997, J CHEM PHYS, V107, P645, DOI 10.1063/1.474425
   Mao SSH, 1998, CHEM MATER, V10, P146, DOI 10.1021/cm9702833
   MARKS TJ, 1995, ANGEW CHEM INT EDIT, V34, P155, DOI 10.1002/anie.199501551
   Maune B, 2003, APPL PHYS LETT, V83, P4689, DOI 10.1063/1.1630370
   Rabiei P, 2002, J LIGHTWAVE TECHNOL, V20, P1968, DOI 10.1109/JLT.2002.803058
   RAIBIEI P, 2002, OSA TRENDS OPTICS PH, V70, P31
   RAIBIEI P, 2002, INT OPT COMMUN, V1, P14
   Robinson BH, 2000, J PHYS CHEM A, V104, P4785, DOI 10.1021/jp993873s
   Shi YQ, 2000, SCIENCE, V288, P119, DOI 10.1126/science.288.5463.119
   Song HC, 2003, APPL PHYS LETT, V82, P4432, DOI 10.1063/1.1586474
   Srinivasan U, 1998, J MICROELECTROMECH S, V7, P252, DOI 10.1109/84.679393
   Sullivan PA, 2004, P SOC PHOTO-OPT INS, V5351, P253, DOI 10.1117/12.527818
   Sun L, 2001, OPT ENG, V40, P1217, DOI 10.1117/1.1385164
   van der Boom ME, 2002, ANGEW CHEM INT EDIT, V41, P3363, DOI 10.1002/1521-3773(20020916)41:18<3363::AID-ANIE3363>3.0.CO;2-V
   van der Boom ME, 2002, LANGMUIR, V18, P3704, DOI 10.1021/la011561m
   van der Boom ME, 2001, ADV FUNCT MATER, V11, P393, DOI 10.1002/1616-3028(200110)11:5<393::AID-ADFM393>3.3.CO;2-J
   van der Boom ME, 2001, CHEM MATER, V13, P15, DOI 10.1021/cm000746w
   WONG G, 2002, APPL PHYS LETT, V81, P2169
   Yacoubian A, 2000, IEEE J SEL TOP QUANT, V6, P810, DOI 10.1109/2944.892622
   Yitzchaik S, 1996, ACCOUNTS CHEM RES, V29, P197, DOI 10.1021/ar9501582
   Zhang C, 2003, P SOC PHOTO-OPT INS, V4991, P537, DOI 10.1117/12.479445
   Zhao YG, 2003, OPT ENG, V42, P298, DOI 10.1117/1.1536183
   Zhao YG, 2001, APPL PHYS LETT, V79, P587, DOI 10.1063/1.1389514
   Zhu PW, 2002, CHEM MATER, V14, P4982, DOI 10.1021/cm020438t
NR 73
TC 35
Z9 37
U1 3
U2 17
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0020-1693
EI 1873-3255
J9 INORG CHIM ACTA
JI Inorg. Chim. Acta
PD NOV 1
PY 2004
VL 357
IS 13
BP 3957
EP 3966
DI 10.1016/j.ica.2004.07.031
PG 10
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 874QW
UT WOS:000225365900020
DA 2018-12-27
ER

PT J
AU Otani, M
   Yoshida, M
   Iwashita, H
   Kawano, Y
   Miyamae, K
   Inadome, A
   Nishi, T
   Ueda, S
AF Otani, M
   Yoshida, M
   Iwashita, H
   Kawano, Y
   Miyamae, K
   Inadome, A
   Nishi, T
   Ueda, S
TI RETRACTED: Electroporation-mediated muscarinic M-3 receptor gene
   transfer into rat urinary bladder (Retracted article. See vol. 17, pg.
   590, 2010)
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE detrusor underactivity; electroporation; gene therapy; muscarinic M-3
   receptor; rat bladder smooth muscle
ID IN-VIVO ELECTROPORATION; THYMIDINE KINASE GENE; SKELETAL-MUSCLE;
   DIELECTRIC-BREAKDOWN; ELECTRIC-FIELDS; PLASMID DNA; EXPRESSION; THERAPY;
   DETRUSOR; CELLS
AB Background: Muscarinic M-3 (M-3) receptor has been recognized as a major muscarinic receptor for smooth muscle contractions of the urinary bladder. Under the hypothesis that overexpression of M-3 receptor in the urinary bladder would enhance urinary bladder contractions, we have transferred the M-3 receptor gene into rat bladders using electroporation (EP) and evaluated the functional expression of the transferred gene.
   Methods: Plasmids expressing luciferase, a green fluorescence protein and M-3 receptor were injected into the rat bladder and square-wave electric pulses were immediately applied. Two days after gene transfer, we analyzed gene expression. Immunohistochemical staining was performed and the contractile responses from isolated bladder strips, which were induced KCl, carbachol and electrical field stimulation (EFS), were evaluated.
   Results: The optimal conditions of electroporation were 8 pulses, 45 voltages, 50 milliseconds/pulses and 1 Hz. Under these conditions, luciferase gene expression was enhanced approximately 300-fold, compared to an injection of DNA only. Regarding immunohistochemistry with an anti-M-3 receptor, an increase in immunoactivity was observed in the M-3 receptor gene transferred rat bladder, compared to the bladder of the control rat. In rats with the transferred M-3 receptor gene, carbachol- and EFS-induced maximum contractile responses of bladder smooth muscle strips significantly increased.
   Conclusions: These findings suggest that an in vivo EP procedure is an useful method for gene transfer into the bladder and that an overexpression of M-3 receptor in the rat bladder enhances bladder contractility. This technique may become a new treatment modality for detrusor underactivity.
C1 Kumamoto Univ, Grad Sch Med Sci, Dept Urol, Kumamoto 8608556, Japan.
   Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto 8608556, Japan.
RP Yoshida, M (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Urol, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM masaki@kaiju.medic.kumamoto-u.ac.jp
CR Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
   Adachi O, 2002, GENE THER, V9, P577, DOI 10.1038/sj.gt.3301691
   Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867
   Braverman AS, 2003, AM J PHYSIOL-REG I, V285, pR701, DOI 10.1152/ajpregu.00009.2003
   Caulfield MP, 1998, PHARMACOL REV, V50, P279
   Chancellor MB, 2001, TRENDS MOL MED, V7, P301, DOI 10.1016/S1471-4914(01)02088-3
   Christ GJ, 2001, AM J PHYSIOL-REG I, V281, pR1699
   Eglen RM, 1996, PHARMACOL REV, V48, P531
   ELBADAWI A, 1993, J UROLOGY, V150, P1657, DOI 10.1016/S0022-5347(17)35867-6
   Fewell JG, 2001, MOL THER, V3, P574, DOI 10.1006/mthe.2001.0295
   FROMM M, 1985, P NATL ACAD SCI USA, V82, P5824, DOI 10.1073/pnas.82.17.5824
   Goins WF, 2001, J UROLOGY, V165, P1748, DOI 10.1016/S0022-5347(05)66407-5
   Goto T, 2000, P NATL ACAD SCI USA, V97, P354, DOI 10.1073/pnas.97.1.354
   HARRISS DR, 1995, J UROLOGY, V154, P1241, DOI 10.1016/S0022-5347(01)67039-3
   Hegde SS, 1999, LIFE SCI, V64, P419, DOI 10.1016/S0024-3205(98)00581-5
   Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X
   KINOSITA K, 1977, NATURE, V268, P438, DOI 10.1038/268438a0
   Lin CR, 2002, GENE THER, V9, P1247, DOI 10.1038/sj.gt.3301790
   MALONELEE J, 1993, BRIT J UROL, V72, P873, DOI 10.1111/j.1464-410X.1993.tb16289.x
   McMenamin MM, 1998, NEUROSCIENCE, V83, P1225, DOI 10.1016/S0306-4522(97)00513-7
   Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262
   Muramatsu T, 1998, INT J MOL MED, V1, P55
   Muramatsu T, 2001, INT J MOL MED, V7, P37
   NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x
   NEUMANN E, 1972, J MEMBRANE BIOL, V10, P279, DOI 10.1007/BF01867861
   Nishi T, 1996, CANCER RES, V56, P1050
   Pagala MK, 2001, J UROLOGY, V166, P721, DOI 10.1016/S0022-5347(05)66050-8
   REISS M, 1986, BIOCHEM BIOPH RES CO, V137, P244, DOI 10.1016/0006-291X(86)91202-7
   TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F
   van der Eb MM, 1998, GENE THER, V5, P451, DOI 10.1038/sj.gt.3300637
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410
   VIENKEN J, 1978, CYTOBIOLOGIE, V17, P182
   WANG P, 1995, J PHARMACOL EXP THER, V273, P959
   Xue F, 2002, GUT, V50, P558, DOI 10.1136/gut.50.4.558
   Yamaguchi O, 1996, J UROLOGY, V156, P1208, DOI 10.1016/S0022-5347(01)65752-5
   Yoshida M, 2001, EXP GERONTOL, V36, P99, DOI 10.1016/S0531-5565(00)00175-3
   Zhang L, 1996, BIOCHEM BIOPH RES CO, V220, P633, DOI 10.1006/bbrc.1996.0455
   ZIMMERMANN U, 1976, BIOCHIM BIOPHYS ACTA, V436, P460, DOI 10.1016/0005-2736(76)90208-X
   ZIMMERMANN U, 1974, BIOPHYS J, V14, P881, DOI 10.1016/S0006-3495(74)85956-4
NR 39
TC 6
Z9 7
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD NOV
PY 2004
VL 11
IS 11
BP 1001
EP 1008
DI 10.1111/j.1442-2042.2004.00924.x
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 865WX
UT WOS:000224736000011
PM 15509205
DA 2018-12-27
ER

PT J
AU Reuben, SS
   Rosenthal, EA
   Steinberg, RB
   Faruqi, S
   Kilaru, PA
AF Reuben, SS
   Rosenthal, EA
   Steinberg, RB
   Faruqi, S
   Kilaru, PA
TI RETRACTED: Surgery on the affected upper extremity of patients with a
   history of complex regional pain syndrome: The use of intravenous
   regional anesthesia with clonidine (Retracted article. See vol. 21, pg.
   235, 2009)
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Annual Meeting of the American-Society-of-Anesthesiologists
CY OCT 12-16, 2002
CL ORLANDO, FL
SP Amer Soc Anesthesiologists
DE anesthesia; intravenous regional; clonidine; complex regional pain
   syndrome; extremity surgery; hand surgery; reflex sympathetic dystrophy
ID REFLEX SYMPATHETIC DYSTROPHY; DOUBLE-BLIND CROSSOVER; MAINTAINED PAIN;
   CLINICAL-TRIALS; GUANETHIDINE; BLOCKADE; LIDOCAINE; MANAGEMENT;
   RESERPINE; ANALGESIA
AB Study Objectives: To evaluate the efficacy of intravenous regional anesthesia (TVRA) with clonidine in patients with a previous history of complex regional pain syndrome (CRPS) who are undergoing upper extremity hand surgery.
   Design: Prospective, randomized, double-blind study.
   Setting: Operating suites and Pain Management Center of a large university-affiliated medical center.
   Patients: 84 patients with a previous history of upper extremity CRPS undergoing surgery on the affected extremity. All signs and symptoms of CRPS had resolved prior to the time.
   Interventions: Patients were randomized to receive IVRA with 0.5 % lidocaine with either 1 mL normal saline (n = 42) or clonidine 1 mug/kg (n = 42) added to the lidocaine solution.
   Measurements: Recurrence of CRPS symptoms at 1 year following surgery were recorded. Main Results: The recurrence rate of CRPS was significantly lower (p < 0.001) in those patients receiving IRVA with lidocaine and clonidine (10%, n = 4) compared with those patients receiving IRVA lidocaine only (74%, n = 31).
   Conclusions: Intraoperative TVRA with lidocaine and clonidine on patients with a history of CRPS can significantly reduce the recurrence rate of this disease process. (C) 2004 by Elsevier Inc.
C1 Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA.
RP Reuben, SS (reprint author), Baystate Med Ctr, Dept Anesthesiol, 759 Chesnut St, Springfield, MA 01199 USA.
EM scott.reuben@bhs.org
CR Abram S. E., 1981, REGION ANESTH PAIN M, V6, P79
   Blanchard J, 1990, J Pain Symptom Manage, V5, P357, DOI 10.1016/0885-3924(90)90030-N
   BOAS RA, 1997, REFLEX SYMPATHETIC D, P79
   Bruehl S, 1999, PAIN, V81, P147, DOI 10.1016/S0304-3959(99)00011-1
   Cousins MJ, 2000, REGION ANESTH PAIN M, V25, P6, DOI 10.1016/S1098-7339(00)80005-X
   Cramer G, 2000, J Foot Ankle Surg, V39, P387
   DAVIS KD, 1991, PAIN, V47, P309, DOI 10.1016/0304-3959(91)90221-I
   GHOSTINE SY, 1984, J NEUROSURG, V60, P1263, DOI 10.3171/jns.1984.60.6.1263
   GLYNN CJ, 1981, BRIT J ANAESTH, V53, P1297
   GLYNN CJ, 1993, PAIN, V53, P39, DOI 10.1016/0304-3959(93)90053-R
   GOLDNER JL, 1980, J HAND SURG-AM, V5, P295, DOI 10.1016/S0363-5023(80)80021-9
   Goris R J, 1987, Free Radic Res Commun, V3, P13, DOI 10.3109/10715768709069764
   Gschwind C, 1995, J HAND SURG-BRIT EUR, V20B, P773, DOI 10.1016/S0266-7681(95)80045-X
   HANNA MH, 1989, PAIN, V38, P145, DOI 10.1016/0304-3959(89)90232-7
   HANNINGTONKIFF JG, 1974, LANCET, V1, P1019
   HOGAN QH, 1994, CLIN J PAIN, V10, P139, DOI 10.1097/00002508-199406000-00008
   HORD AH, 1992, ANESTH ANALG, V74, P818
   JADAD AR, 1995, J PAIN SYMPTOM MANAG, V10, P13, DOI 10.1016/0885-3924(94)00064-R
   JANIG W, 1997, REFLEX SYMPATHETIC D, P79
   Kabeer AA, 1996, REGION ANESTH, V21, P249
   KATZ MM, 1987, J BONE JOINT SURG BR, V69, P797
   KETTLER RE, 1988, ANESTHESIOLOGY, V69, P933, DOI 10.1097/00000542-198812000-00020
   Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3
   KIOWSKI W, 1987, J CARDIOVASC PHAR S6, V7, pS144
   LANKFORD LL, 1988, OPERATIVE HAND SURG, P633
   MCKAIN CW, 1983, J BONE JOINT SURG AM, V65, P808, DOI 10.2106/00004623-198365060-00012
   MOESKER A, THESIS ERASMUS U ROT, P1
   MOORE DC, 1957, REGIONAL BLOCK, P102
   Perez RSGM, 2001, J PAIN SYMPTOM MANAG, V21, P511, DOI 10.1016/S0885-3924(01)00282-2
   Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038
   RAJA SN, 1991, ANESTHESIOLOGY, V74, P691, DOI 10.1097/00000542-199104000-00012
   RAMAMURTHY S, 1995, ANESTH ANALG, V81, P718, DOI 10.1097/00000539-199510000-00011
   RAUCK RL, 1993, ANESTHESIOLOGY, V79, P1163, DOI 10.1097/00000542-199312000-00005
   Reuben SS, 1998, ANESTHESIOLOGY, V89, P527, DOI 10.1097/00000542-199808000-00034
   Reuben SS, 1999, ANESTHESIOLOGY, V91, P654, DOI 10.1097/00000542-199909000-00015
   REUBEN SS, 1994, ANESTHESIOLOGY, V81, P1548, DOI 10.1097/00000542-199412000-00034
   Reuben SS, 2000, J HAND SURG-AM, V25A, P1147
   REUBEN SS, 1995, ANESTH ANALG, V81, P110, DOI 10.1097/00000539-199507000-00022
   REUBEN SS, 2002, REGION ANESTH PAIN M, V26, P18
   Ribbers GM, 2003, ARCH PHYS MED REHAB, V84, P141, DOI 10.1053/apmr.2003.50076
   ROCCO AG, 1989, CLIN J PAIN, V5, P205, DOI 10.1097/00002508-198909000-00002
   ROCCO AG, 1993, ANESTHESIOLOGY, V79, P865, DOI 10.1097/00000542-199310000-00035
   SENNWALD GR, 1990, J HAND SURG-AM, V15A, P755, DOI 10.1016/0363-5023(90)90151-G
   STANTONHICKS M, 1995, PAIN, V63, P127, DOI 10.1016/0304-3959(95)00110-E
   VELDMAN PHJM, 1995, UNFALLCHIRURG, V98, P45
   VELDMAN PHJM, 1993, LANCET, V342, P1012, DOI 10.1016/0140-6736(93)92877-V
   VIEL EJ, 1994, ANESTHESIOLOGY, V81, P265, DOI 10.1097/00000542-199407000-00040
   WALLIN G, 1976, SENSORY FUNCTIONS SK, P489
   WILSON PR, 1997, REFLEX SYMPATHETIC D, P93
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026
   YAKSH TL, 1985, PHARMACOL BIOCHEM BE, V22, P845, DOI 10.1016/0091-3057(85)90537-4
NR 51
TC 16
Z9 17
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD NOV
PY 2004
VL 16
IS 7
BP 517
EP 522
DI 10.1016/j.jclinane.2004.02.001
PG 6
WC Anesthesiology
SC Anesthesiology
GA 880XF
UT WOS:000225822700008
PM 15590255
DA 2018-12-27
ER

PT J
AU Vergnolle, N
   Cellars, L
   Mencarelli, A
   Rizzo, G
   Swaminathan, S
   Beck, P
   Steinhoff, M
   Andrade-Gordon, P
   Bunnett, NW
   Hollenberg, MD
   Wallace, JL
   Cirino, G
   Fiorucci, S
AF Vergnolle, N
   Cellars, L
   Mencarelli, A
   Rizzo, G
   Swaminathan, S
   Beck, P
   Steinhoff, M
   Andrade-Gordon, P
   Bunnett, NW
   Hollenberg, MD
   Wallace, JL
   Cirino, G
   Fiorucci, S
TI RETRACTED: A role for proteinase-activated receptor-1 in inflammatory
   bowel diseases (Retracted article. See vol 116, pg 2056, 2006)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID HAPTEN-INDUCED MODEL; EPITHELIAL-CELLS; ULCERATIVE-COLITIS; RAT COLON;
   INTESTINAL INFLAMMATION; NEUROGENIC MECHANISM; MITE ALLERGENS; PROTEASE;
   THROMBIN; EXPRESSION
AB Proteinase-activated receptor-1 (PAR(1)), a G protein-coupled receptor activated by thrombin, is highly expressed in different cell types of the gastrointestinal tract. The activity of thrombin and of other proteinases is significantly increased in the colon of inflammatory bowel disease (IBD) patients. Since PAR(1) activation in tissues other than the gut provoked inflammation, we hypothesized that PAR(1) activation in the colon is involved in the pathogenesis of IBD. Here, we demonstrate that PAR(1) is overexpressed in the colon of IBD patients. In mice, intracolonic administration of PAR(1) agonists led to an inflammatory reaction characterized by edema and granulocyte infiltration. This PAR(1) activation-induced inflammation was dependent on B and T lymphocytes. Moreover, PAR(1) activation exacerbated and prolonged inflammation in a mouse model of IBD induced by the intracolonic administration of trinitrobenzene sulfonic acid (TNBS), while PAR(1) antagonism significantly decreased the mortality and severity of colonic inflammation induced by TNBS and dextran sodium sulfate. In these 2 models, colitis development was strongly attenuated by PAR(1) deficiency. Taken together, these results imply an important role for PAR(1) in the pathogenesis of experimental colitis supporting the notion that PAR(1) inhibition may be beneficial in the context of IBD and possibly in other chronic intestinal inflammatory disorders.
C1 Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada.
   Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy.
   Univ Calgary, Dept Med, Calgary, AB T2N 4N1, Canada.
   Univ Munster, Dept Dermatol, D-4400 Munster, Germany.
   Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA USA.
   Univ Calif San Francisco, Dept Surg & Physiol, San Francisco, CA 94143 USA.
   Univ Naples Federico II, Dept Expt Pathol, Naples, Italy.
RP Vergnolle, N (reprint author), Univ Calgary, Dept Pharmacol & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM nvergnol@ucalgary.ca
RI Fiorucci, Stefano/I-1251-2012; Vergnolle, Nathalie/C-7677-2018
OI Vergnolle, Nathalie/0000-0003-1825-6015; Cirino,
   Giuseppe/0000-0003-3954-4083
CR AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201
   ASKONANTHAN N, 2002, J IMMUNOL, V168, P3577
   Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572
   Bar-Shavit R, 2002, IMMUNOLOGY, V105, P35, DOI 10.1046/j.0019-2805.2001.01351.x
   Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638
   BURESI MC, 2001, LIVER PHYSL, V281, pG323
   Bustos D, 1998, MEDICINA-BUENOS AIRE, V58, P262
   Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5
   Chin AC, 2003, P NATL ACAD SCI USA, V100, P11104, DOI 10.1073/pnas.1831452100
   Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821
   Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497
   COOPER HS, 1993, LAB INVEST, V69, P238
   Copple BL, 2003, J PHARMACOL EXP THER, V305, P417, DOI 10.1124/jpet.102.046391
   Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x
   Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023
   Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564
   Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6
   de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152
   Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429
   Elson CO, 1996, J IMMUNOL, V157, P2174
   Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913
   Fiorucci S, 2002, IMMUNITY, V17, P769, DOI 10.1016/S1074-7613(02)00476-4
   Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298
   Fiorucci S, 2004, HEPATOLOGY, V39, P365, DOI 10.1002/hep.20054
   HAWKEY CJ, 1983, GUT, V24, P881, DOI 10.1136/gut.24.10.881
   Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203
   Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832
   Kawabata A, 2004, GASTROENTEROLOGY, V126, P208, DOI 10.1053/j.gastro.2003.10.071
   Kjeldsen J, 1998, SCAND J GASTROENTERO, V33, P637, DOI 10.1080/00365529850171927
   Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001
   Macfarlane SR, 2001, PHARMACOL REV, V53, P245
   McCafferty DM, 1999, J LEUKOCYTE BIOL, V66, P67
   MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9
   Mule F, 2002, J PHARMACOL EXP THER, V303, P1265, DOI 10.1124/jpet.102.041301
   Mule F, 2002, BRIT J PHARMACOL, V136, P367, DOI 10.1038/sj.bjp.0704746
   Naldini A, 1998, J CELL PHYSIOL, V177, P76, DOI 10.1002/(SICI)1097-4652(199810)177:1<76::AID-JCP8>3.0.CO;2-B
   Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080
   OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H
   Seymour ML, 2003, AM J PHYSIOL-CELL PH, V284, pC1185, DOI 10.1152/ajpcell.00126.2002
   Steinhoff M, 2000, NAT MED, V6, P151
   Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X
   Suk K, 1999, IMMUNOL LETT, V67, P223, DOI 10.1016/S0165-2478(99)00015-2
   Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014
   VANDERHEIJDEN PJ, 1987, J IMMUNOL METHODS, V103, P161, DOI 10.1016/0022-1759(87)90285-7
   VERGNOLL EN, 2004, BRIT J PHARMACOL, V141, P1264
   Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5
   Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408
   Vergnolle N, 2000, ALIMENT PHARM THERAP, V14, P257
   VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V
   Zhang HC, 2001, J MED CHEM, V44, P1021, DOI 10.1021/jm000506s
NR 50
TC 81
Z9 85
U1 4
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2004
VL 114
IS 10
BP 1444
EP 1456
DI 10.1172/JCI200421689
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 871EU
UT WOS:000225113200014
PM 15545995
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Accili, D
   Valenti, L
AF Accili, D
   Valenti, L
TI RETRACTED: Turning up the heat in the fat cell (Retracted Article. See
   vol 11, pg 691, 2005)
SO NATURE MEDICINE
LA English
DT Editorial Material; Retracted Publication
ID ADIPOSE-TISSUE; PTEN; SUPPRESSION; OBESITY
AB Obesity researchers have inched closer to a long-sought goal: creating a fat cell that burns up calories without causing obesity. The trick is to knock out a protein better known for its role in cancer, the inositol-phosphatase Pten (pages 1208-1215).
C1 Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
RP Accili, D (reprint author), Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
EM da230@columbia.edu
OI Valenti, Luca/0000-0001-8909-0345
CR Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633
   Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4
   Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Fasshauer M, 2003, DIABETOLOGIA, V46, P1594, DOI 10.1007/s00125-003-1228-z
   Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513
   Komazawa N, 2004, NAT MED, V10, P1208, DOI 10.1038/nm1117
   Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X
   Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100
   Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9
   Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI200320514
NR 12
TC 1
Z9 1
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2004
VL 10
IS 11
BP 1168
EP 1169
DI 10.1038/nm1104-1168
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 866PR
UT WOS:000224785900024
PM 15516912
DA 2018-12-27
ER

PT J
AU Komazawa, N
   Matsuda, M
   Kondoh, G
   Mizunoya, W
   Iwaki, M
   Takagi, T
   Sumikawa, Y
   Inoue, K
   Suzuki, A
   Mak, TW
   Nakano, T
   Fushiki, T
   Takeda, J
   Shimomura, I
AF Komazawa, N
   Matsuda, M
   Kondoh, G
   Mizunoya, W
   Iwaki, M
   Takagi, T
   Sumikawa, Y
   Inoue, K
   Suzuki, A
   Mak, TW
   Nakano, T
   Fushiki, T
   Takeda, J
   Shimomura, I
TI RETRACTED: Enhanced insulin sensitivity, energy expenditure and
   thermogenesis in adipose-specific Pten suppression in mice (Retracted
   Article. See vol 11, pg 691, 2005)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION;
   CRE RECOMBINASE; PROTEIN; OBESITY; TISSUE; ADIPONECTIN; METABOLISM
AB Pten is an important phosphatase, suppressing the phosphatidylinositol-3 kinase/Akt pathway. Here, we generated adipose-specific Pten-deficient (AdipoPten-KO) mice, using newly generated Acdc promoter-driven Cre transgenic mice. AdipoPten-KO mice showed lower body and adipose tissue weights despite hyperphagia and enhanced insulin sensitivity with induced phosphorylation of Akt in adipose tissue. AdipoPten-KO mice also showed marked hyperthermia and increased energy expenditure with induced mitochondriagenesis in adipose tissue, associated with marked reduction of p53, inactivation of Rb, phosphorylation of cyclic AMP response element binding protein (CREB) and increased expression of Ppargc1a, the gene that encodes peroxisome proliferative activated receptor gamma coactivator 1 alpha. Physiologically, adipose Pten mRNA decreased with exposure to cold and increased with obesity, which were linked to the mRNA alterations of mitochondriagenesis. Our results suggest that altered expression of adipose Pten could regulate insulin sensitivity and energy expenditure. Suppression of adipose Pten may become a beneficial strategy to treat type 2 diabetes and obesity.
C1 Osaka Univ, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan.
   Osaka Univ, Grad Sch Frontier Biosci, Dept Social & Environm Med, Suita, Osaka 5650871, Japan.
   Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan.
   Osaka Univ, Dept Dermatol, Suita, Osaka 5650871, Japan.
   Akita Univ, Dept Biochem, Akita 0108543, Japan.
   Univ Toronto, Adv Med Discovery Inst, Toronto, ON M5G 2C1, Canada.
   Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan.
   Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan.
   Osaka Univ, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan.
   Japan Sci & Technol Agcy, PREST, Kawaguchi, Saitama 3320012, Japan.
RP Shimomura, I (reprint author), Osaka Univ, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ichi@imed2.med.osaka-u.ac.jp
OI Takagi, Toshiyuki/0000-0003-1283-4320
CR Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543
   Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5
   Boord JB, 2002, CURR OPIN LIPIDOL, V13, P141, DOI 10.1097/00041433-200204000-00005
   Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7
   Fu YC, 2002, ATHEROSCLEROSIS, V165, P259, DOI 10.1016/S0021-9150(02)00305-2
   Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101
   Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5
   Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513
   Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898
   Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655
   Jiang Guoqiang, 2002, Frontiers in Bioscience, V7, pd903, DOI 10.2741/jiang
   KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685
   Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7
   Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392
   Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727
   Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889
   Nishizawa H, 2004, J BIOL CHEM, V279, P19391, DOI 10.1074/jbc.C400066200
   OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173
   Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411
   Rossmeisl M, 2002, EUR J BIOCHEM, V269, P19, DOI 10.1046/j.0014-2956.2002.02627.x
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101
   Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5
   Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100
   Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101
   Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0
   Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5
   Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244
   Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954
NR 39
TC 29
Z9 34
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2004
VL 10
IS 11
BP 1208
EP 1215
DI 10.1038/nm1117
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 866PR
UT WOS:000224785900042
PM 15489860
DA 2018-12-27
ER

PT J
AU Kalpana, C
   Menon, VP
AF Kalpana, C
   Menon, VP
TI RETRACTED: Protective effect of curcumin on circulatory lipid
   peroxidation and antioxidant status during nicotine-induced toxicity
   (Retracted Article. See vol 20, pg 222, 2010)
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article; Retracted Publication
DE antioxidant; curcumin; lipid peroxidation; lung toxicity; nicotine
ID OXIDATIVE STRESS; SERUM FERRITIN; LUNG-CANCER; IN-VITRO; CARCINOGENESIS;
   INHIBITION; CELLS; ACID; PLASMA; TISSUE
AB Nicotine, an active substance present in tobacco has been identified as a major risk factor for lung related diseases. In the present study, we have evaluated the protective effect of curcumin on circulatory lipid peroxidation and antioxidants in nicotine administered Wistar rats. Lung toxicity was induced by subcutaneous injection of nicotine at a dose of 2.5 mg/kg body weight ( 5 days a week, for 22 weeks) and curcumin ( 80 mg/kg body weight) was given simultaneously along with nicotine by intragastric intubation for 22 weeks. Enhanced lipid peroxidation (41.68%) in the circulation of nicotine treated animals was accompanied by a significant decrease in the levels of ascorbic acid, vitamin E, reduced glutathione, glutathione peroxidase, superoxide dismutase and catalase. Further, reduction in the levels of zinc and elevation of copper and ferritin were observed in circulation of nicotine treated rats. Administration of curcumin significantly lowered the concentrations of lipid peroxides (36%) and enhanced the antioxidant status with modulation in the levels of zinc, copper and ferritin. Our data suggest that curcumin exerts its preventive effects by modulating the degree of lipid peroxidation, antioxidant status and trace element levels.
C1 Annamalai Univ, Fac Sci, Dept Biochem, Annamalainagar 608002, Tamil Nadu, India.
RP Menon, VP (reprint author), Annamalai Univ, Fac Sci, Dept Biochem, Annamalainagar 608002, Tamil Nadu, India.
EM cmrana@sify.com
OI Menon, Venugopal Padmanabhan/0000-0002-1283-3822
CR BAKER H, 1980, NUTR REP INT, V21, P531
   Borella P, 1997, J TRACE ELEM MED BIO, V11, P162, DOI 10.1016/S0946-672X(97)80046-6
   CARMELLA S, 1997, CARCINOGENESIS, V18, P101
   Cheng Y, 2003, FOOD CHEM TOXICOL, V41, P1045, DOI 10.1016/S0278-6915(03)00032-2
   Chiarugi P., 2003, ITAL J BIOCHEM, V52, P31
   De Flora S, 2003, MUTAT RES-FUND MOL M, V523, P237, DOI 10.1016/S0027-5107(02)00340-8
   Devasena T, 2002, J Biochem Mol Biol Biophys, V6, P289
   Devasena T, 2002, PHARMACOL RES, V46, P39, DOI 10.1016/S1043-6618(02)00043-9
   Dinkova-Kostova AT, 2002, MINI-REV MED CHEM, V2, P595, DOI 10.2174/1389557023405558
   DONNAN SK, 1950, J BIOL CHEM, V182, P415
   Drabkin DL, 1932, J BIOL CHEM, V98, P719
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   GERSTER H, 1995, EUR J CLIN NUTR, V49, P155
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   HEBBEL RP, 1986, J LAB CLIN MED, V107, P401
   Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y
   Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
   KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130
   Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4
   Lee BM, 2003, MUTAT RES-FUND MOL M, V523, P265, DOI 10.1016/S0027-5107(02)00342-1
   LIPSCHITZ DA, 1974, NEW ENGL J MED, V290, P1213, DOI 10.1056/NEJM197405302902201
   Mahady GB, 2002, ANTICANCER RES, V22, P4179
   Milman N, 2002, ONCOL REP, V9, P193
   Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X
   Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2
   Phan TT, 2001, J TRAUMA, V51, P927, DOI 10.1097/00005373-200111000-00017
   Ray Gibanananda, 2002, Indian Journal of Experimental Biology, V40, P1213
   REDDY ACP, 1994, FOOD CHEM TOXICOL, V32, P279
   Roe JH, 1943, J BIOL CHEM, V147, P399
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Rukkumani R, 2003, PHYTOTHER RES, V17, P925, DOI 10.1002/ptr.1254
   Singletary K, 1998, CARCINOGENESIS, V19, P1039, DOI 10.1093/carcin/19.6.1039
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7
   Smith KR, 2002, FREE RADICAL BIO MED, V33, P1106, DOI 10.1016/S0891-5849(02)01003-1
   Sorenson JRJ, 2002, CURR MED CHEM, V9, P639, DOI 10.2174/0929867023370725
   TAYLOR A, 1981, CLIN CHIM ACTA, V110, P83, DOI 10.1016/0009-8981(81)90304-1
   Thapliyal R, 2001, FOOD CHEM TOXICOL, V39, P541, DOI 10.1016/S0278-6915(00)00165-4
   Velmurugan B, 2002, EUR J CANCER PREV, V11, P19, DOI 10.1097/00008469-200202000-00004
   YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5
   Yildiz D, 1999, ARCH ENVIRON CON TOX, V37, P434, DOI 10.1007/s002449900537
   Zowczak M, 2001, BIOL TRACE ELEM RES, V82, P1, DOI 10.1385/BTER:82:1-3:001
NR 41
TC 24
Z9 24
U1 3
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1537-6516
EI 1537-6524
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD NOV-DEC
PY 2004
VL 14
IS 6
BP 339
EP 343
DI 10.1080/15376520490434692
PG 5
WC Toxicology
SC Toxicology
GA 861ZN
UT WOS:000224457900003
PM 20021100
DA 2018-12-27
ER

PT J
AU Sezen, B
   Sames, D
AF Sezen, B
   Sames, D
TI RETRACTED: Oxidative C-arylation of free (NH)-heterocycles via direct
   (sp(3)) C-H bond functionalization (Retracted Article. See vol 128, pg
   3102, 2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID BETA-HYDROGEN ELIMINATION; ORGANIC-SYNTHESIS; AMIDO COMPLEX; ARYL
   HALIDES; AMINES; IMINES; ORGANOSTANNANES; AMINATION; INSERTION; LIGANDS
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
RI 丹丹, 李/D-2431-2010
CR Andersen NG, 2001, CHEM REV, V101, P997, DOI 10.1021/cr000024o
   Chatani N, 2001, J AM CHEM SOC, V123, P10935, DOI 10.1021/ja011540e
   Davies HML, 2002, J MOL CATAL A-CHEM, V189, P125, DOI 10.1016/S1381-1169(02)00201-7
   DeBoef B, 2004, J AM CHEM SOC, V126, P6556, DOI 10.1021/ja049111e
   DIAMOND SE, 1977, J ORGANOMET CHEM, V142, pC55, DOI 10.1016/S0022-328X(00)88360-6
   Dieter RK, 1997, J ORG CHEM, V62, P7726, DOI 10.1021/jo970985b
   Ferrando-Miguel G, 2002, NEW J CHEM, V26, P687, DOI 10.1039/b200168n
   GIOVANNINI A, 1989, J ORG CHEM, V54, P228, DOI 10.1021/jo00262a048
   Hamann BC, 1998, J AM CHEM SOC, V120, P3694, DOI 10.1021/ja9721881
   Hartwig JF, 1996, J AM CHEM SOC, V118, P3626, DOI 10.1021/ja954121o
   Hartwig JF, 1996, J AM CHEM SOC, V118, P7010, DOI 10.1021/ja961439n
   Hayashi T, 2000, J AM CHEM SOC, V122, P976, DOI 10.1021/ja9927220
   Ishiyama T, 2000, J AM CHEM SOC, V122, P12043, DOI 10.1021/ja003306e
   Krug C, 2004, J AM CHEM SOC, V126, P2694, DOI 10.1021/ja038819a
   Krug C, 2002, J AM CHEM SOC, V124, P1674, DOI 10.1021/ja017401e
   Lewis JC, 2004, ORG LETT, V6, P35, DOI 10.1021/ol035985e
   Murahashi SI, 2003, J AM CHEM SOC, V125, P15312, DOI 10.1021/ja0390303
   MURAHASHI SI, 1983, J AM CHEM SOC, V105, P5002, DOI 10.1021/ja00353a025
   Oi S, 1999, TETRAHEDRON LETT, V40, P9259, DOI 10.1016/S0040-4039(99)01857-2
   Sezen B, 2003, J AM CHEM SOC, V125, P10580, DOI 10.1021/ja036157j
   Sezen B, 2003, J AM CHEM SOC, V125, P5274, DOI 10.1021/ja034848
   STRIETER ER, 2003, J AM CHEM SOC, V125, P13987
   Wagaw S, 1997, J AM CHEM SOC, V119, P8451, DOI 10.1021/ja971583o
NR 23
TC 24
Z9 24
U1 3
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 20
PY 2004
VL 126
IS 41
BP 13244
EP 13246
DI 10.1021/ja045402b
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 862OH
UT WOS:000224500000039
PM 15479077
DA 2018-12-27
ER

PT J
AU Roman-Gomez, J
   Jimenez-Velasco, A
   Castillejo, JA
   Agirre, X
   Barrios, M
   Navarro, G
   Molina, FJ
   Calasanz, MJ
   Prosper, F
   Heiniger, A
   Torres, A
AF Roman-Gomez, J
   Jimenez-Velasco, A
   Castillejo, JA
   Agirre, X
   Barrios, M
   Navarro, G
   Molina, FJ
   Calasanz, MJ
   Prosper, F
   Heiniger, A
   Torres, A
TI RETRACTED: Promoter hypermethylation of cancer-related genes: a strong
   independent prognostic factor in acute lymphoblastic leukemia (Retracted
   article. See vol. 113, pg. 2370, 2009)
SO BLOOD
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR GENE; CELL-CELL ADHESION; DNA METHYLATION; CPG-ISLAND;
   PETHEMA ALL-89; E-CADHERIN; ADULT; CHILDHOOD; CHILDREN; TRIAL
AB Promoter hypermethylation plays an important role in the inactivation of cancer-related genes. This abnormality occurs early in leukemogenesis and seems to be associated with poor prognosis in acute lymphoblastic leukemia (ALL). To determine the extent of hypermethylation in ALL, we analyzed the methylation status of the CDH1, p73, p16, p15, p57, NES-1, DKK-3, CDH13, p14, TMS-1, APAF-1, DAPK, PARKIN, LATS-1, and PTEN genes in 251 consecutive ALL patients. A total of 77.3% of samples had at least 1 gene methylated, whereas 35.9% of cases had 4 or more genes methylated. Clinical features and complete remission rate did not differ among patients without methylated genes, patients with 1 to 3 methylated genes (methylated group A), or patients with more than 3 methylated genes (methylated group B). Estimated disease-free survival (DFS) and overall survival (OS) at 11 years were 75.5% and 66.1%, respectively, for the nonmethylated group; 37.2% and 45.5% for methylated group A; and 9.4% and 7.8% for methylated group B (P < .0001 and P = .0004, respectively). Multivariate analysis demonstrated that the methylation profile was an independent prognostic factor in predicting DFS (P < .0001) and OS (P = .003). Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in ALL. (C) 2004 by The American Society of Hematology.
C1 Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain.
   Carlos Haya Hosp, Dept Hematol, Malaga, Spain.
   Univ Navarra Clin, Sch Med, Fdn Appl Med Res, Dept Hematol,Cellular Therapy Area, E-31080 Pamplona, Spain.
RP Roman-Gomez, J (reprint author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM peperosa@teleline.es
RI Calasanz, MJ/R-5813-2016; Prosper, Felipe/H-6859-2017
OI Calasanz, MJ/0000-0002-0374-3008; Prosper, Felipe/0000-0001-6115-8790
CR Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100
   CIMINO G, 1995, LEUKEMIA, V9, P391
   Conway KE, 2000, CANCER RES, V60, P6236
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Esteller M, 2000, CANCER RES, V60, P129
   Esteller M, 2001, CANCER RES, V61, P3225
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Faderl S, 1998, BLOOD, V91, P3995
   Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147
   Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA
   Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347
   Kawano S, 1999, BLOOD, V94, P1113
   Melki JR, 2000, BLOOD, V95, P3208
   Ortega JJ, 1998, INT J PEDIAT HEM ONC, V5, P163
   Ortega JJ, 2001, HAEMATOLOGICA, V86, P586
   Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907
   Ribera JM, 2002, HAEMATOLOGICA, V87, P154
   Ribera JM, 1998, HAEMATOLOGICA, V83, P222
   Roman J, 2001, BRIT J HAEMATOL, V113, P329, DOI 10.1046/j.1365-2141.2001.02764.x
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   SEHN L, 2003, BLOOD, V101, P4131
   Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18
   TAKEUCHI S, 1995, CANCER RES, V55, P5377
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592
   WADA M, 1993, BLOOD, V82, P3163
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Wong IHN, 2000, BLOOD, V95, P1942
   Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141
   Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4
NR 39
TC 166
Z9 179
U1 4
U2 17
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 15
PY 2004
VL 104
IS 8
BP 2492
EP 2498
DI 10.1182/blood-2004-03-0954
PG 7
WC Hematology
SC Hematology
GA 860XU
UT WOS:000224378300047
PM 15198948
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ozawa, A
   Tada, H
   Sugawara, Y
   Uehara, A
   Sasano, T
   Shimauchi, H
   Takada, H
   Sugawara, S
AF Ozawa, A
   Tada, H
   Sugawara, Y
   Uehara, A
   Sasano, T
   Shimauchi, H
   Takada, H
   Sugawara, S
TI RETRACTED: Endogenous IL-15 sustains recruitment of IL-2R beta and
   common gamma and IL-2-mediated chemokine production in normal and
   inflamed human gingival fibroblasts (Retracted article. See vol 183, pg
   2193, 2009)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; NK CELL-DIFFERENTIATION;
   INTERLEUKIN-2 RECEPTOR; CD34(+) PROGENITORS; INTERFERON-GAMMA; SIGNAL
   PEPTIDES; UP-REGULATION; EXPRESSION; SECRETION; LIPOPOLYSACCHARIDE
AB We recently reported that anti-IL-15 neutralizing mAb has been shown to inhibit production of MCP-1 in response to IL-2 from normal human gingival fibroblasts (HGF), the major constituent of gingival tissue. In the present study, we examined the expression of IL-2R and IL-15R subunits in HGF from normal and inflamed regions and the role of endogenous IL-15 in IL-2-mediated signaling. Normal HGF expressed IL-2Rbeta and common gamma-chain (gamma(c)) but not IL-2Ralpha or IL-15betaalpha, whereas inflamed HGF expressed IL-2Ralpha, IL-15Ralpha, IL-2Rbeta, and gamma(c), as assessed by RT-PCR and flow cytometry. Exogenous IL-2 and IL-15 induced production of MCP-1 but not IL-8 in normal HGF, and induced the production of both chemokines in inflamed HGF. Both HGF constitutively transcribed the 48 aa-IL-15 isoform, and the isoform was not actively secreted but rather existed as a membrane-bound form. Pretreatment with anti-IL-15 neutralizing mAb for 24 h completely inhibited the production of MCP-1 induced by IL-2 and IL-15 and IL-2-induced phosphorylation of Jak 1 and 3 in HGF. The pretreatment and RNA interference targeted to IL-15 mRNA resulted in total inhibition of the IL-2Rbeta and gamma(c) expression at mRNA and protein levels. Furthermore, excess amounts of IL-2 restored the inhibitory effect of anti-IL-15, inhibition of NF-kappaB abrogated the expression of IL-2Rbeta and gamma(c), and IL-2-induced-nuclear translocation of NF-kappaB was completely inhibited by the RNA interference in HGF. These results suggest that endogenous membrane-bound IL-15 sustains recruitment of IL-2Rbeta and gamma(c) through activation of NF-kappaB in HGF.
C1 Tohoku Univ, Grad Sch Dent, Div Oral Immunol, Dept Oral Biol,Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Grad Sch Dent, Div Oral Microbiol, Sendai, Miyagi, Japan.
   Tohoku Univ, Grad Sch Dent, Div Periodont & Endodontol, Dept Oral Biol, Sendai, Miyagi, Japan.
   Tohoku Univ, Grad Sch Dent, Div Oral Diagnosis, Dept Oral Med & Surg, Sendai, Miyagi, Japan.
RP Sugawara, S (reprint author), Tohoku Univ, Grad Sch Dent, Div Oral Immunol, Dept Oral Biol,Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.
EM sugawars@mail.tains.tohoku.ac.jp
CR Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   BOSCO MC, 1994, BLOOD, V83, P3462
   Briard D, 2002, J IMMUNOL, V168, P4326, DOI 10.4049/jimmunol.168.9.4326
   Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4
   Carayol G, 2000, ONCOGENE, V19, P2758, DOI 10.1038/sj.onc.1203584
   Corrigall VM, 2001, J IMMUNOL, V166, P4141, DOI 10.4049/jimmunol.166.6.4141
   DongariBagtzoglou AI, 1997, INT IMMUNOL, V9, P1233, DOI 10.1093/intimm/9.9.1233
   Doucet C, 2000, ONCOGENE, V19, P5898, DOI 10.1038/sj.onc.1203933
   Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6
   Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.3.CO;2-M
   Giron-Michel J, 2003, BLOOD, V102, P109, DOI 10.1182/blood-2002-09-2760
   Gruss HJ, 1996, J IMMUNOL, V157, P851
   Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097
   Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713
   Johnson E W, 1995, J Back Musculoskelet Rehabil, V5, P3, DOI 10.3233/BMR-1995-5103
   Kaplan D, 1996, IMMUNOL TODAY, V17, P303, DOI 10.1016/0167-5699(96)30017-0
   Lekic PC, 1997, CRIT REV ORAL BIOL M, V8, P253, DOI 10.1177/10454411970080030201
   Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502
   Meazza R, 1996, ONCOGENE, V12, P2187
   Musso T, 1999, BLOOD, V93, P3531
   Musso T, 1998, INFECT IMMUN, V66, P2640
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Neely GG, 2001, J IMMUNOL, V167, P5011, DOI 10.4049/jimmunol.167.9.5011
   Onu A, 1997, J IMMUNOL, V158, P255
   Ozawa A, 2003, J LEUKOCYTE BIOL, V74, P352, DOI 10.1186/jlb.0103044
   PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739
   PLAISANCE S, 1993, INT IMMUNOL, V5, P843
   Rappl G, 2001, J INVEST DERMATOL, V116, P102, DOI 10.1046/j.1523-1747.2001.00239.x
   SAPPINO AP, 1990, LAB INVEST, V63, P144
   Sugawara S, 2000, J IMMUNOL, V165, P411, DOI 10.4049/jimmunol.165.1.411
   Sugawara S, 1998, INFECT IMMUN, V66, P3043
   Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444
   TAKADA H, 1991, INFECT IMMUN, V59, P295
   Tamai R, 2002, INFECT IMMUN, V70, P1272, DOI 10.1128/IAI.70.1272-1278.2002
   TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G
   Taubman MA, 2001, CRIT REV ORAL BIOL M, V12, P125, DOI 10.1177/10454411010120020301
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Watanabe A, 1996, INFECT IMMUN, V64, P4488
   Yamashiro S, 2001, J LEUKOCYTE BIOL, V69, P698
NR 39
TC 15
Z9 15
U1 3
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2004
VL 173
IS 8
BP 5180
EP 5188
DI 10.4049/jimmunol.173.8.5180
PG 9
WC Immunology
SC Immunology
GA 861BX
UT WOS:000224392200049
PM 15470063
OA Bronze
DA 2018-12-27
ER

PT J
AU Sun, YX
   Nie, Y
AF Sun, YX
   Nie, Y
TI RETRACTED: Ammonium 2,6-dicarboxy-4-nitrophenolate (Retracted article.
   See vol. 67, pg. E16, 2011)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID PI INTERACTIONS
AB The title compound, NH4+.C8H4NO7- consists of a 2,6-dicarboxy-4-nitrophenolate anion and an ammonium cation, both of which possess crystallographic twofold rotation symmetry. All the 0 atoms of the anion and the H atoms of the cation contribute to hydrogen bonds, forming a three-dimensional network.
C1 Qufu Normal Univ, Dept Chem, Qufu 273165, Peoples R China.
RP Sun, YX (reprint author), Qufu Normal Univ, Dept Chem, Qufu 273165, Peoples R China.
EM yuxisun@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BENT HA, 1968, CHEM REV, V68, P587, DOI 10.1021/cr60255a003
   Berg J.-A. v. d., 2003, CRYST GROWTH DES, V3, P643
   *BRUK AXS INC, 1998, SMART VERS 5 628 SAI
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016
   Jeffrey G.A., 2003, CRYSTALLOGR REV, V9, P135, DOI DOI 10.1080/08893110310001621754
   Kim D, 2004, J PHYS CHEM A, V108, P1250, DOI 10.1021/jp037631a
   LINDOY LF, 2000, SELF ASSEMBLY SUPRAM
   PRICE SL, 1987, J CHEM PHYS, V86, P2859, DOI 10.1063/1.452037
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M, 1997, SHELXTL VERSION 5 1
NR 13
TC 2
Z9 2
U1 4
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2004
VL 60
BP O1742
EP O1744
DI 10.1107/S1600536804022135
PN 10
PG 3
WC Crystallography
SC Crystallography
GA 858UD
UT WOS:000224216500104
DA 2018-12-27
ER

PT J
AU Urdaneta, F
   Willert, JL
   Beaver, T
   Naik, B
   Kirby, DS
   Lobato, EB
AF Urdaneta, F
   Willert, JL
   Beaver, T
   Naik, B
   Kirby, DS
   Lobato, EB
TI RETRACTED: Effects of a new phosphodiesterase enzyme type V inhibitor
   (UK 343-664) versus Milrinone in a porcine model of acute pulmonary
   hypertension (Retracted article. See vol. 91, pg. 338, 2011)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID INHALED NITRIC-OXIDE; HEART-TRANSPLANTATION; SODIUM-NITROPRUSSIDE;
   VASCULAR-RESISTANCE; SILDENAFIL; PROSTACYCLIN; VASODILATOR;
   NITROGLYCERIN; COMBINATION; THERAPY
AB Background. Perioperative pulmonary hypertension remains a clinical challenge. The phosphodiesterase enzyme type III inhibitor milrinone produces pulmonary vasodilation but lacks selectivity. Sildenafil, a phosphodiesterase enzyme type V inhibitor, can also induce relaxation of the pulmonary vasculature; however, only the oral formulation is presently available. This study evaluated the effects of a new intravenous sildenafil analogue-UK 343-664--compared with milrinone during acute pulmonary hypertension in a porcine model of thromboxane-induced pulmonary hypertension.
   Methods. After acute pulmonary hypertension, 24 adult swine were randomized to 3 groups. Group 1 (n = 9) received an intravenous dose of 500 mug of UK 343-664, group 2 (n = 8) received milrinone 50 mg/kg, and group 3 (n = 7) received 10 mL of normal saline solution. All agents were administered for more than 5 minutes. Data were recorded continuously for 30 minutes.
   Results. Both milrinone and UK 343-664 partially reversed thromboxane-induced pulmonary hypertension, with a notable decrease in mean pulmonary artery pressure and pulmonary vascular resistance and a concomitant increase in cardiac output. In addition, milrinone improved right ventricular contractility but produced marked systemic vasodilatation. In contrast, the administration of UK 343-664 was associated with pulmonary vasodilatation, without appreciable changes in systemic arterial pressure or vascular resistance.
   Conclusions. Milrinone and UK 343-664 were equally effective as pulmonary vasodilators; however, only UK 343-664 exhibited a high degree of pulmonary selectivity. Potential uses for this new phosphodiesterase enzyme type V inhibitor warrant further study. (C) 2004 by The Society of Thoracic Surgeons.
C1 Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Div Thorac & Cardiovasc Surg, Gainesville, FL 32610 USA.
   N Florida S Georgia Vet Hlth Syst, Malcolm B Randall Vet Affairs Med Ctr, Gainesville, FL USA.
RP Lobato, EB (reprint author), Univ Florida, Coll Med, Dept Anesthesiol, Box 100254, Gainesville, FL 32610 USA.
EM elobato@anest.ufl.edu
CR Atz AM, 1999, ANESTHESIOLOGY, V91, P307, DOI 10.1097/00000542-199907000-00041
   Atz AM, 2002, J THORAC CARDIOV SUR, V124, P628, DOI 10.1067/mtc.2002.125265
   Bigatello LM, 2000, ANESTHESIOLOGY, V92, P1827, DOI 10.1097/00000542-200006000-00044
   Bradford KK, 2000, J CARDIOVASC PHARM, V36, P146, DOI 10.1097/00005344-200008000-00002
   Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729
   DENT G, 1994, LUNG, V172, P129
   Fullerton DA, 1996, ANN THORAC SURG, V61, P1856, DOI 10.1016/0003-4975(96)00046-X
   Givertz MM, 1996, J AM COLL CARDIOL, V28, P1775, DOI 10.1016/S0735-1097(96)00399-3
   Hanson KA, 1998, AM J PHYSIOL-LUNG C, V275, pL931, DOI 10.1152/ajplung.1998.275.5.L931
   Ichinose F, 2001, CRIT CARE MED, V29, P1000, DOI 10.1097/00003246-200105000-00024
   KIELERJENSEN N, 1993, J HEART LUNG TRANSPL, V12, P179
   KIELERJENSEN N, 1995, J HEART LUNG TRANSPL, V14, P436
   McMullan DM, 2001, AM J PHYSIOL-HEART C, V280, pH777
   Mychaskiw G, 2001, J CLIN ANESTH, V13, P218, DOI 10.1016/S0952-8180(01)00252-5
   PASCUAL JMS, 1990, J HEART TRANSPLANT, V9, P644
   Rajek A, 2000, ANESTH ANALG, V90, P523, DOI 10.1097/00000539-200003000-00005
   SCHROEDER RA, 1995, ANESTH ANALG, V81, P1052, DOI 10.1097/00000539-199511000-00027
   THUSU KG, 1995, AM J RESP CRIT CARE, V152, P1605, DOI 10.1164/ajrccm.152.5.7582302
   TONZ M, 1994, ANN THORAC SURG, V58, P1031
   VanObbergh LJ, 1996, BRIT J ANAESTH, V77, P227, DOI 10.1093/bja/77.2.227
   Weimann J, 2000, ANESTHESIOLOGY, V92, P1702, DOI 10.1097/00000542-200006000-00030
   Weinberger B, 2001, TOXICOL SCI, V59, P5, DOI 10.1093/toxsci/59.1.5
   Ziegler JW, 1998, AM J RESP CRIT CARE, V158, P1388, DOI 10.1164/ajrccm.158.5.9710117
NR 23
TC 8
Z9 8
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD OCT
PY 2004
VL 78
IS 4
BP 1433
EP 1437
DI 10.1016/j.athoracsur.2004.04.039
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 858VZ
UT WOS:000224221600048
PM 15464509
DA 2018-12-27
ER

PT J
AU Leuschner, RGK
   Baird, F
   Donald, B
   Cox, LJ
AF Leuschner, RGK
   Baird, F
   Donald, B
   Cox, LJ
TI RETRACTED: A medium for the presumptive detection of Enterobacter
   sakazakii in infant formula (Retracted Article. See vol 23, pg 409,
   2006)
SO FOOD MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Enterobacter sakazakii; selective medium; detection; infant formula
ID CLINICAL SPECIMENS; POWDERED MILK; INFECTIONS; IDENTIFICATION
AB A differential-elective medium for the isolation of Enterobacter sakazakii was developed. It is based on the presence of an enzyme alpha-glucosidase in this species that can differentiate this organism from other members of the family Enterobacteriaceae. Nutrient agar (NA) was supplemented with 4-methyl-umbelliferyl alpha-D-glucoside (alpha-MUG). This Substrate was metabolized by the enzyme to yield an UV fluorescent product. E sakakakii formed yellow pigmented UV fluorescent colonies on NA with alpha-MUG. Fifty-six E. sakazakii strains from culture collections were examined and found positive for both characteristics. Fifty-eight formula products from 11 countries were sampled in their entity by using a pre- and selective enrichment method following ISO 8523. The selective enrichment was streaked on NA + alpha-MUG and violet red brilliant green (VRBG) agar. Twenty-one (36%) of products were positive for Enterobacteriaceae. E. sakazakii was isolated from eight out of 58 infant formula products representing 13.8%. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Cent Sci Lab, Dept Environm Food & Rural Affairs, York YO41 1LZ, N Yorkshire, England.
RP Leuschner, RGK (reprint author), Cent Sci Lab, Dept Environm Food & Rural Affairs, York YO41 1LZ, N Yorkshire, England.
EM renata.leuschner@cec.eu.int
CR ALDOVA E, 1983, ZBL BAKT-INT J MED M, V256, P103
   Bar-Oz B, 2001, ACTA PAEDIATR, V90, P356, DOI 10.1080/080352501300067857
   BIERING G, 1989, J CLIN MICROBIOL, V27, P2054
   Block C, 2002, EUR J CLIN MICROBIOL, V21, P613, DOI 10.1007/s10096-002-0774-5
   Breeuwer P, 2003, J APPL MICROBIOL, V95, P967, DOI 10.1046/j.1365-2672.2003.02067.x
   CLARK NC, 1990, DIAGN MICR INFEC DIS, V13, P467, DOI 10.1016/0732-8893(90)90078-A
   Cox L J, 1988, J APPL BACTERIOL S, p237S
   FARMER JJ, 1985, J CLIN MICROBIOL, V21, P46
   FARMER JJ, 1980, INT J SYST BACTERIOL, V30, P569, DOI 10.1099/00207713-30-3-569
   FARMER JJ, 1992, MANUAL CLIN MICROBIO, P360
   GOULLET P, 1986, J GEN MICROBIOL, V132, P3105
   Kuzina LV, 2001, CURR MICROBIOL, V42, P290, DOI 10.1007/s002840010219
   Lai KK, 2001, MEDICINE, V80, P113, DOI 10.1097/00005792-200103000-00004
   Muytjens H. L., 1988, J CLIN MICROBIOL, V26, P367
   MUYTJENS HL, 1984, J CLIN MICROBIOL, V20, P684
   Nazarowec-White M, 1999, J MED MICROBIOL, V48, P559, DOI 10.1099/00222615-48-6-559
   Nazarowec-White M, 1999, FOOD RES INT, V32, P375, DOI 10.1016/S0963-9969(99)00100-3
   NazarowecWhite M, 1997, J FOOD PROTECT, V60, P226, DOI 10.4315/0362-028X-60.3.226
   NazarowecWhite M, 1997, INT J FOOD MICROBIOL, V34, P103, DOI 10.1016/S0168-1605(96)01172-5
   Pagotto FJ, 2003, J FOOD PROTECT, V66, P370, DOI 10.4315/0362-028X-66.3.370
   POSTUPA R, 1984, MICROBIOL IMMUNOL, V28, P435
   SIMMONS BP, 1989, INFECT CONT HOSP EP, V10, P398
   Van Acker J, 2001, J CLIN MICROBIOL, V39, P293, DOI 10.1128/JCM.39.1.293-297.2001
   2003, ISOLATION ENUMERATIO
   2002, MMWR, V51, P298
   1991, 8523 ISO
NR 26
TC 22
Z9 26
U1 4
U2 17
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0740-0020
J9 FOOD MICROBIOL
JI Food Microbiol.
PD OCT
PY 2004
VL 21
IS 5
BP 527
EP 533
DI 10.1016/j.fm.2003.12.002
PG 7
WC Biotechnology & Applied Microbiology; Food Science & Technology;
   Microbiology
SC Biotechnology & Applied Microbiology; Food Science & Technology;
   Microbiology
GA 820NU
UT WOS:000221397300005
DA 2018-12-27
ER

PT J
AU Ito, S
   Takeyama, KI
   Yamamoto, A
   Sawatsubashi, S
   Shirode, Y
   Kouzmenko, A
   Tabata, T
   Kato, S
AF Ito, S
   Takeyama, KI
   Yamamoto, A
   Sawatsubashi, S
   Shirode, Y
   Kouzmenko, A
   Tabata, T
   Kato, S
TI RETRACTED: In vivo potentiation of human oestrogen receptor alpha by
   Cdk7-mediated phosphorylation (Retracted article. See vol. 18, pg. 1144,
   2013)
SO GENES TO CELLS
LA English
DT Article; Retracted Publication
ID NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; HISTONE
   ACETYLTRANSFERASE; COACTIVATOR COMPLEX; GENE-EXPRESSION; DROSOPHILA;
   BINDING; PROTEIN; DOMAINS; KINASE
AB Phosphorylation of the Ser(118) residue in the N-terminal A/B domain of the human oestrogen receptor alpha (hERalpha) by mitogen-activated protein kinase (MAPK), stimulated via growth factor signalling pathways, is known to potentiate ERalpha ligand-induced transactivation function. Besides MAPK, cyclin dependent kinase 7 (Cdk7) in the TFIIH complex has also been found to potentiate hERalpha transactivation in vitro through Ser(118) phosphorylation. To investigate an impact of Cdk7 on hERalpha transactivation in vivo, we assessed activity of hERalpha in a wild-type and cdk7 inactive mutant Drosophila that ectopically expressed hERalpha in the eye disc. Ectopic expression of the wild-type or mutant receptors, together with a green fluorescent protein (GFP) reporter gene, allowed us to demonstrate that hERalpha expressed in the fly tissues was transcriptionally functional and adequately responded to hERalpha ligands in the patterns similar to those observed in mammalian cells. Replacement of Ser(118) with alanine in hERalpha (S118A mutant) significantly reduced the ligand-induced hERalpha transactivation function. Importantly, while in cdk7 inactive mutant Drosophila the wild-type hERalpha exhibited reduced response to the ligand; levels of transactivation by the hERalpha S118A mutant were not affected in these inactive cdk7 mutant flies. Furthermore, phosphorylation of hERalpha at Ser(118) has been observed in vitro by both human and Drosophila Cdk7. Our findings demonstrate that Cdk7 is involved in regulation of the ligand-induced transactivation function of hERalphain vivo via Ser(118) phosphorylation.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
   Japan Sci & Technol, SORST, Kawaguchi, Saitama, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0
   ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x
   Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788
   Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7
   Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x
   BRAND AH, 1993, DEVELOPMENT, V118, P401
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9
   Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4
   Ciana P, 2003, NAT MED, V9, P82, DOI 10.1038/nm809
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000
   Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2
   Glass CK, 2000, GENE DEV, V14, P121
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200
   KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2
   Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749
   LE GP, 1994, J BIOL CHEM, V269, P4458
   MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579
   MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583
   Naar AM, 1999, NATURE, V398, P828
   ONATE SA, 1995, SCIENCE, V270, P1354
   Rachez C, 1999, NATURE, V398, P824
   RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1
   Spencer TE, 1997, NATURE, V389, P194
   Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9
   TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939
NR 46
TC 13
Z9 13
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-9597
EI 1365-2443
J9 GENES CELLS
JI Genes Cells
PD OCT
PY 2004
VL 9
IS 10
BP 983
EP 992
DI 10.1111/j.1365-2443.2004.00777.x
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 858CS
UT WOS:000224168500010
PM 15461668
OA Bronze
DA 2018-12-27
ER

PT J
AU Riener, EK
   Arnold, N
   Kommoss, F
   Lauinger, S
   Pfisterer, J
AF Riener, EK
   Arnold, N
   Kommoss, F
   Lauinger, S
   Pfisterer, J
TI RETRACTED: The prognostic and predictive value of immunohistochemically
   detected HER-2/neu overexpression in 361 patients with ovarian cancer: a
   multicenter study (Retracted Article. See vol 96, pg 1021, 2005)
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article; Retracted Publication
DE ovarian cancer; HER-2/neu; prognosis; immunohistochemistry
ID BREAST-CARCINOMA; EXPRESSION; CHEMOTHERAPY; ONCOGENE; ANTIBODY;
   IDENTIFICATION; AMPLIFICATION; HERCEPTEST; PROTEIN; GROWTH
AB Objective. The prognostic and predictive relevance of HER-2/neu dysregulation in epithelia] ovarian cancer is controversial. The purpose of our study was to document HER-2/neu expression patterns and their correlation with clinicopathologic parameters and survival in a large and biologically homogenous Caucasian patient collective.
   Methods. Expression of HER-2/neu in ovarian cancer tissue was assessed by immunohistochemistry. Immunohistochemical staining was performed according to established protocols.
   Results were correlated to clinical data. Results. HER-2/neu overexpression was detected in 6.9% (25/361) of the tumor samples and was significantly associated with tumor stage (P=0.03), but not with lymph node involvement (P=0.5), tumor grade (P=0.3), histological type (P=0.6), residual tumor (P=0.4), serum CA-125 before therapy (P=0.2), and patient age (P=0.8). We found no significant influence of HER-2/neu overexpression on overall and disease-free survival independent of FIGO stage, tumor grade, and residual tumor mass. In a subset of 73 suboptimally debulked patients, women with response to first-line chemotherapy (complete remission [CR] + partial remission [PR]) and no response to first-line chemotherapy (stable disease [SDI + progressive disease [PD]) showed significantly different rates of HER-2/neu overexpression (0% [0/51] vs. 14% [3/22]; P=0.02).
   Conclusions. Tumor overexpression of HER-2/neu in women with advanced ovarian cancer is rare and provides no prognostic information in addition to that provided by established clinicopathologic parameters. This multicenter study, however, indicates that HER-2/neu overexpression is a predictive factor for the response to first-line chemotherapy in suboptimally debulked patients. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Freiburg, Sch Med, Dept Obstet & Gynecol, D-79098 Freiburg, Germany.
   Univ Kiel, Sch Med, Dept Obstet & Gynecol, Kiel, Germany.
   Univ Heidelberg, Sch Med, Dept Pathol, Heidelberg, Germany.
RP Riener, EK (reprint author), Univ Freiburg, Sch Med, Dept Obstet & Gynecol, D-79098 Freiburg, Germany.
EM riener@frk.ukl.uni-freiburg.de
CR Afify AM, 1999, EXP MOL PATHOL, V66, P163, DOI 10.1006/exmp.1999.2255
   Akamatsu M, 2003, INT J RADIAT ONCOL, V57, P1323, DOI 10.1016/S0360-3016(03)00782-X
   Baselga J, 2002, ONCOLOGY-BASEL, V63, P6, DOI 10.1159/000066198
   BERCHUCK A, 1990, CANCER RES, V50, P4087
   BEREK JS, 1994, PRACTICAL GYNECOLOGI, P327
   Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104
   Camilleri-Broet S, 2004, ANN ONCOL, V15, P104, DOI 10.1093/annonc/mdh021
   DEPOTTER CR, 1989, INT J CANCER, V44, P969, DOI 10.1002/ijc.2910440604
   Ferrandina G, 2002, GYNECOL ONCOL, V85, P305, DOI 10.1006/gyno.2002.6620
   Hogdall EVS, 2003, CANCER-AM CANCER SOC, V98, P66, DOI 10.1002/cncr.11476
   Hsu C, 2002, CANCER, V94, P415, DOI 10.1002/cncr.10180
   Iwamoto H, 2003, INT J GYNECOL CANCER, V13, P28, DOI 10.1046/j.1525-1438.2003.13028.x
   Koka V, 2002, ANTICANCER RES, V22, P1593
   Lassus H, 2004, GYNECOL ONCOL, V92, P31, DOI 10.1016/j.ygyno.2003.10.010
   Meden H, 1998, INT J GYNECOL PATHOL, V17, P61, DOI 10.1097/00004347-199801000-00011
   METTLER L, 1996, ZENTRALBL GYNAEKOL, V118, P374
   NAISH SJ, 1989, HDB IMMUNOCHEMICAL S
   Peethambaram PP, 2003, GYNECOL ONCOL, V89, P99, DOI 10.1016/S0090-8258(03)00065-9
   Potti A, 2002, LEUKEMIA LYMPHOMA, V43, P2427, DOI 10.1080/1042819021000040198
   REMMELE W, 1987, PATHOLOGE, V8, P138
   RUBIN SC, 1993, AM J OBSTET GYNECOL, V168, P162, DOI 10.1016/S0002-9378(12)90907-2
   RUBIN SC, 1994, CANCER, V73, P1456, DOI 10.1002/1097-0142(19940301)73:5<1456::AID-CNCR2820730522>3.0.CO;2-L
   Santin AD, 2002, CLIN CANCER RES, V8, P1271
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Tsuda H, 2002, PATHOL INT, V52, P126, DOI 10.1046/j.1440-1827.2002.01327.x
   Varshney D, 2004, AM J CLIN PATHOL, V121, P70, DOI 10.1309/FUQH92B039025LHG
   Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625
NR 28
TC 15
Z9 18
U1 2
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD OCT
PY 2004
VL 95
IS 1
BP 89
EP 94
DI 10.1016/j.ygyno.2004.06.048
PG 6
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 860FU
UT WOS:000224328700013
PM 15385115
DA 2018-12-27
ER

PT J
AU Kawabata, T
   Matsuyama, W
   Higashimoto, I
   Koreeda, Y
   Eiraku, N
   Kawabata, M
   Osame, M
AF Kawabata, T
   Matsuyama, W
   Higashimoto, I
   Koreeda, Y
   Eiraku, N
   Kawabata, M
   Osame, M
TI RETRACTED: Pleural cryptococcosis with idiopathic CD4 positive
   T-lymphocytopenia (Retracted Article. See vol 47, pg 1765, 2008)
SO INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
DE CD4 lymphocytes; Cryptococcus neoformans; CD95 (Fas/Apo-1)
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CELL-SURFACE ANTIGEN; BLOOD
   STEM-CELLS; FAS ANTIGEN; BONE-MARROW; PATIENT; TRANSPLANTATION;
   TUBERCULOSIS; APOPTOSIS; CDNA
AB A 19-year-old man was admitted to our hospital because of chest pain. He was diagnosed as having pleural cryptococcosis by pleural biopsy. His CD4 positive T-lymphocyte count was low (<300 mul) and there was no evidence of human immunodeficiency virus infection. He was successfully treated with fluconazole. However, his CD4 positive lymphocyte counts remained low after the recovery and he was diagnosed as idiopathic CD4 positive T-lymphocytopenia. Pleural cryptococcosis is rare and its predisposing condition is still controversial. To our knowledge, this is the first case of pleural cryptococcosis associated with idiopathic CD4 positive T lymphocytopenia.
C1 Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ, Fac Med, Dept Internal Med 3, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
CR Ageitos AG, 1999, BONE MARROW TRANSPL, V23, P63, DOI 10.1038/sj.bmt.1701524
   BAKER RD, 1955, AM J CLIN PATHOL, V25, P14
   BUSCH MP, 1994, TRANSFUSION, V34, P192, DOI 10.1046/j.1537-2995.1994.34394196614.x
   Fleck M, 1998, J IMMUNOL, V160, P3766
   FRIEDMAN EP, 1995, CLIN RADIOL, V50, P756, DOI 10.1016/S0009-9260(05)83214-3
   Hirasaki S, 2000, J GASTROENTEROL, V35, P47, DOI 10.1007/PL00009975
   Ho CL, 1998, RESP MED, V92, P120, DOI 10.1016/S0954-6111(98)90043-9
   Ino K, 1997, J LEUKOCYTE BIOL, V61, P583
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   KHOURY MB, 1984, AM J ROENTGENOL, V142, P893, DOI 10.2214/ajr.142.5.893
   KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533
   Laurence J, 1996, J CLIN INVEST, V97, P672, DOI 10.1172/JCI118464
   Matsuyama W, 1998, INTERNAL MED, V37, P891, DOI 10.2169/internalmedicine.37.891
   Mielcarek M, 1997, BLOOD, V89, P1629
   Mills KC, 1996, BONE MARROW TRANSPL, V18, P53
   Mohanty SK, 2003, HISTOPATHOLOGY, V42, P96, DOI 10.1046/j.1365-2559.2003.01513_4.x
   NEWMAN TG, 1987, CHEST, V91, P459, DOI 10.1378/chest.91.3.459
   OEHM A, 1992, J BIOL CHEM, V267, P10709
   Roger PM, 1999, CLIN INFECT DIS, V28, P1012, DOI 10.1086/514739
   Sider L, 1994, J Thorac Imaging, V9, P78, DOI 10.1097/00005382-199421000-00004
   SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601
   SORIANO V, 1992, LANCET, V340, P607, DOI 10.1016/0140-6736(92)92140-B
   SUSTER B, 1986, RADIOLOGY, V161, P87, DOI 10.1148/radiology.161.1.3489955
   Suzuki Y, 1998, RESP MED, V92, P977, DOI 10.1016/S0954-6111(98)90203-7
   TAGUCHI H, 1992, ACTA MED OKAYAMA, V46, P45
   Talmadge JE, 1996, BONE MARROW TRANSPL, V17, P101
   Talmadge JE, 1997, BONE MARROW TRANSPL, V19, P161, DOI 10.1038/sj.bmt.1700626
   Tanaka J, 1998, BLOOD, V91, P347
   TINDALL B, 1993, AIDS, V7, P1272
   Watanabe H, 2000, Rinsho Shinkeigaku, V40, P249
   WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274
   YOUNG EJ, 1980, AM REV RESPIR DIS, V121, P743
   1992, MMWR RECOMM REP, V41, P541
NR 33
TC 6
Z9 8
U1 3
U2 8
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PD OCT
PY 2004
VL 43
IS 10
BP 977
EP 981
DI 10.2169/internalmedicine.43.977
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 870CH
UT WOS:000225031100021
PM 15575251
OA Bronze
DA 2018-12-27
ER

PT J
AU Srivastava, HB
AF Srivastava, HB
TI RETRACTED: Finite strain and deformation from a refolded region of the
   Dudatoli-Almora Crystalline, Kumaun Lesser Himalaya (Retracted article.
   See vol. 81, pg. 153, 2014)
SO JOURNAL OF ASIAN EARTH SCIENCES
LA English
DT Article; Retracted Publication
DE finite strain; Dudatoli-Almora crystalline; grains
ID SINGLE-LAYER; RHEOLOGY; ROCKS; FOLDS
AB The outcrop of the southern extension of Dudatoli Almora-Crystalline Group around Tamadhun in the Kumaun Lesser Himalaya exhibits a map-scale refolded structure. The major lithological units are phyllites, schists and gneisses. The gneisses exhibit deformed feldspar porphyroblasts on mesoscopic and microscopic scales. Deformed feldspar porphyroblasts, were used under the microscope to estimate finite strain in the rocks. Different analytical methods have been compared, of which the R-f/1phi method is found to be reliable and sensitive to minor changes in strain pattern.
   The rocks of the area have undergone three phases of deformation D1, D2 and D3, synchronous to three phases of folding F1, F2 and F3. The early isoclinal folds (F1) of similar type (class 2), appear to have developed by a buckling process. The second (F2) open concentric (class 1B type) folds developed on the limbs of the F1 folds. The presence of rotated feldspar grains and S-C structures on the limbs of F2 folds reveals a flexural-slip mechanism for their development. F3 chevron folds are restricted to the phyllites of the area.
   The deformation of feldspar grains in the gneisses involves modification of the fabric from low strain (E-s = 0.34) to high strain (E, = 1.10). The strain variations can be related to the general fold geometry and suggest a competency contrast between the matrix and feldspar grains which increase with increased strain intensity and magnitude. This study reveals that the present day strain pattern in the gneissic rocks originated by flexural-slip mechanisms, which took place during the second phase of folding and modified the strain patterns developed during earlier isoclinal folding. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Banaras Hindu Univ, Dept Geol, Varanasi 221005, Uttar Pradesh, India.
RP Srivastava, HB (reprint author), Banaras Hindu Univ, Dept Geol, Varanasi 221005, Uttar Pradesh, India.
EM harivandana@sify.com
CR AGARWAL NC, 1973, KUMAUN HIMALAYA HIMA, V3, P1
   Auden J. B., 1937, REC GEOL SURV INDIA, V71, P407
   DAVIDSON DM, 1983, J STRUCT GEOL, V5, P181, DOI 10.1016/0191-8141(83)90043-3
   DEPOAR DG, 1979, TECTONPHYSICS, V64, pT29
   DUNNET D, 1969, TECTONOPHYSICS, V7, P117, DOI 10.1016/0040-1951(69)90002-X
   FLETCHER RC, 1974, AM J SCI, V274, P1029, DOI 10.2475/ajs.274.9.1029
   FLINN D, 1956, J GEOL, V64, P480, DOI 10.1086/626380
   FRY N, 1979, TECTONOPHYSICS, V60, P89, DOI 10.1016/0040-1951(79)90135-5
   FUCHS G, 1978, JB GEOL B A, V121, P219
   Gansser A., 1964, GEOLOGY HIMALAYAS, P1
   GROSHONG RH, 1975, GEOL SOC AM BULL, V86, P1363, DOI 10.1130/0016-7606(1975)86<1363:SFAPSI>2.0.CO;2
   Heim A., 1939, MEM SOC HELV SCI NAT, V73, P1
   Hippertt J, 2002, J STRUCT GEOL, V24, P1087, DOI 10.1016/S0191-8141(01)00093-1
   HOLST TB, 1987, J STRUCT GEOL, V9, P915, DOI 10.1016/0191-8141(87)90001-0
   HOSSACK JR, 1968, TECTONOPHYSICS, V5, P315, DOI 10.1016/0040-1951(68)90035-8
   Hsu TC, 1966, J STRAIN ANAL, V1, P216, DOI DOI 10.1243/03093247V013216
   HUDLESTON PJ, 1984, TECTONOPHYSICS, V106, P321, DOI 10.1016/0040-1951(84)90183-5
   Jain A. K., 1971, HIMAL GEOL, V1, P25
   KUMAR G, 1974, HIMAL GEOL, V4, P321
   KUMAR G, 1975, HIMAL GEOL, V5, P29
   Lisle R. J., 1977, GEOL MIJNBOUW, V56, P140
   LISLE RJ, 1985, GEOLOGICAL STRAIN AN, P1
   Mehdi S. M. W., 1972, HIMAL GEOL, V2, P481
   NADAI A, 1963, ENG SCI MONOGRAPHS
   PFIFFNER OA, 1980, TECTONOPHYSICS, V61, P337, DOI 10.1016/0040-1951(80)90239-5
   RAINA BN, 1978, TECTONIC GEOLOGY HIM, P79
   Ramsay J. G., 1967, FOLDING FRACTURING R, P1
   Ramsay J.G., 1987, TECHNIQUES MODERN ST, V2, P309
   RAMSAY JG, 1983, TECHNIQUES MODERN ST, V1, P307
   RUPKE J, 1974, SEDIMENT GEOL, V11, P81, DOI 10.1016/0037-0738(74)90027-X
   SCHWAN W, 1980, CURRENT TRENDS GEOLO, P1
   SCHWERDTNER WM, 1977, TECTONOPHYSICS, V39, P515, DOI 10.1016/0040-1951(77)90151-2
   SPANG JH, 1980, TECTONOPHYSICS, V66, P253, DOI 10.1016/0040-1951(80)90049-9
   SRIVASTAVA HB, 1999, B INDIAN GEOLOGISTS, V32, P1
   Srivastava HB, 1995, ANN TECTONICAE, V9, P3
   Valdiya KS, 1980, GEOLOGY KUMAUN LESSE
NR 36
TC 3
Z9 3
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1367-9120
EI 1878-5786
J9 J ASIAN EARTH SCI
JI J. Asian Earth Sci.
PD OCT
PY 2004
VL 24
IS 1
BP 115
EP 125
DI 10.1016/j.jseaes.2003.09.006
PG 11
WC Geosciences, Multidisciplinary
SC Geology
GA 878SN
UT WOS:000225667200010
DA 2018-12-27
ER

PT J
AU Budagian, V
   Bulanova, E
   Orinska, Z
   Pohl, T
   Borden, EC
   Silverman, R
   Bulfone-Paus, S
AF Budagian, V
   Bulanova, E
   Orinska, Z
   Pohl, T
   Borden, EC
   Silverman, R
   Bulfone-Paus, S
TI RETRACTED: Reverse signaling through membrane-bound interleukin-15
   (Retracted Article. See vol 286, pg 8708, 2011)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; 2 IL-15 ISOFORMS; INTRACELLULAR TRAFFICKING;
   PROTEIN-KINASE; CELL PROLIFERATION; CYTOPLASMIC DOMAIN; HUMAN MONOCYTES;
   NATURAL-KILLER; GROWTH-FACTOR; FAS LIGAND
AB The results from this study implicate membrane-anchored interleukin (IL)-15 constitutively expressed on the cell surface of PC-3 human prostate carcinoma cells and interferon-gamma-activated human monocytes in reverse signaling upon stimulation with soluble IL-15 receptor-alpha or anti-IL-15 antibodies, mediating the outside-to-inside signal transduction that involves the activation of members of the MAPK family (ERK and p38) and focal adhesion kinase. The presence of membrane-bound IL-15 was not dependent on the expression of the trimeric IL-15 receptor complex by these cells and resisted treatment with acidic buffer or trypsin. Reverse signaling through membrane-bound IL-15 considerably increased the production of several pro-inflammatory cytokines by monocytes, such as IL-6, IL-8, and tumor necrosis factor-alpha, thereby indicating the relevance of this process to the complex immunomodulatory function of these cells. Furthermore, stimulation of transmembrane IL-15 also enhanced the transcription of IL-6 and IL-8 in the PC-3 cell line and promoted migration of PC-3 cells as well as LNCaP human prostate carcinoma cells stably expressing IL-15 on the cell surface. Thus, IL-15 can exist as a biologically active transmembrane molecule that possesses dual ligand-receptor qualities with a potential to induce bidirectional signaling. This fact highlights a new level of complexity in the biology of IL-15 and offers novel important insights into our understanding of the cellular responses modulated by this pleiotropic cytokine.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Taussig Canc Ctr, Ctr Canc Drug Discovery & Dev, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA.
   WITA GmbH, D-14513 Teltov, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
CR ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
   Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   Budagian V, 2004, J BIOL CHEM, V279, P40368, DOI 10.1074/jbc.M404125200
   Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546
   Domonkos A, 2001, EUR CYTOKINE NETW, V12, P411
   Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6
   Eissner G, 2000, J IMMUNOL, V164, P6193, DOI 10.4049/jimmunol.164.12.6193
   Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255
   Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.3.CO;2-M
   GIRI JG, 1995, EMBO J, V14, P3464
   GOLD MR, 1993, CELL GROWTH DIFFER, V4, P647
   Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130
   Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200
   Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0
   KEEL BA, 1995, ENDOCRINOLOGY, V136, P1197, DOI 10.1210/en.136.3.1197
   Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771
   Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200
   Langstein J, 1998, J IMMUNOL, V160, P2488
   Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0
   McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189
   Miyashita T, 1997, J IMMUNOL, V158, P4620
   Musso T, 1999, BLOOD, V93, P3531
   Nabi IR, 1999, J CELL SCI, V112, P1803
   Neely GG, 2001, J IMMUNOL, V167, P5011, DOI 10.4049/jimmunol.167.9.5011
   Newell MK, 1999, APOPTOSIS, V4, P311, DOI 10.1023/A:1009670802382
   Onu A, 1997, J IMMUNOL, V158, P255
   OWENS LV, 1995, CANCER RES, V55, P2752
   Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873
   Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624
   Rappl G, 2001, J INVEST DERMATOL, V116, P102, DOI 10.1046/j.1523-1747.2001.00239.x
   Ruchatz H, 1998, J IMMUNOL, V160, P5654
   Ruckert R, 2000, J IMMUNOL, V165, P2240, DOI 10.4049/jimmunol.165.4.2240
   Shinozaki M, 2002, J CLIN INVEST, V109, P951, DOI 10.1172/JCI14574
   Sieg DJ, 1999, J CELL SCI, V112, P2677
   Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i
   STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4
   Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123
   Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(09)00091-0
   Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119
   Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903
   Wiley SR, 1996, J IMMUNOL, V157, P3635
   WINSTON BW, 1995, J IMMUNOL, V155, P1525
   Zheng DQ, 1999, CANCER RES, V59, P1655
   ZHOU GX, 1993, BIOCHEM BIOPH RES CO, V197, P578, DOI 10.1006/bbrc.1993.2518
NR 50
TC 51
Z9 55
U1 3
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 1
PY 2004
VL 279
IS 40
BP 42192
EP 42201
DI 10.1074/jbc.M403182200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 856WG
UT WOS:000224075500111
PM 15284244
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Haarer, BK
   Amberg, DC
AF Haarer, BK
   Amberg, DC
TI RETRACTED: Old yellow enzyme protects the actin cytoskeleton from
   oxidative stress (Retracted article. See vol. 21, pg. 842, 2010)
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article; Retracted Publication
ID IRREVERSIBLY SICKLED CELLS; POLYMERASE-CHAIN-REACTION;
   SACCHAROMYCES-CEREVISIAE; BETA-ACTIN; IN-VIVO; YEAST; BINDING; ANEMIA;
   GENE
AB Old Yellow Enzyme (OYE) has long served as a paradigm for the study of flavin-containing NADPH oxido-reductases and yet its physiological role has remained a mystery. A two-hybrid interaction between Oye2p and actin led us to investigate a possible function in the actin cytoskeleton. We found that oye deletion strains have an overly elaborate actin cytoskeleton that cannot be attributed to changes in actin concentration but likely reflect stabilization of actin filaments, resulting in excessive actin assembly. Cells expressing the actin mutant act1-123p, which has a weakened interaction with Oye2p, show comparable defects in actin organization to the oye deletion strain that can be suppressed by overexpression of Oye2p. Similarly, mutation of either conserved cysteine of the potential disulfide pair Cys285-Cys374 in actin completely suppresses the actin organization defect of the oyeDelta phenotype. Strains lacking Oye function are also sensitive to oxidative stress as induced by H2O2, menadione, and diamide treatment. Mutation of either Cys285 or Cys374 of actin suppresses the sensitivity of oyeDelta strains to oxidative stress and in fact confers super-resistance to oxidative stress in otherwise wild-type strains. These results suggest that oxidative damage to actin, like that which has been observed in irreversibly sickled red blood cells, may be a general phenomenon and that OYE functions to control the redox state of actin thereby maintaining the proper plasticity of the actin cytoskeleton. In addition to uncovering a long sought biological function for Old Yellow Enzyme, these results establish that cellular sensitivity to oxidative stress can in part be directly attributed to a specific form (C285-C374 disulfide bond formation) of oxidative damage to actin.
C1 SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.
RP Amberg, DC (reprint author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.
EM ambergd@upstate.edu
FU NIGMS NIH HHS [R01 GM056189, GM-56189]
CR AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28
   AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307
   Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399
   Belmont LD, 1999, J CELL SCI, V112, P1325
   Bencsath FA, 1996, BIOCHEMISTRY-US, V35, P4403, DOI 10.1021/bi960063n
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555
   FABRY ME, 1992, BLOOD, V79, P1602
   FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1
   Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241
   Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jazwinski SM, 2002, ANNU REV MICROBIOL, V56, P769, DOI 10.1146/annurev.micro.56.012302.160830
   KAUL DK, 1983, J CLIN INVEST, V72, P22, DOI 10.1172/JCI110960
   Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644
   KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4
   Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x
   LUX SE, 1976, J CLIN INVEST, V58, P955, DOI 10.1172/JCI108549
   NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983
   PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357
   ROSE MD, 1989, METHODS YEAST GENETI
   SCHOPFER LM, 1991, STUDY ENZYMES, V2, P247
   SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0
   SHARTAVA A, 1995, J CELL BIOL, V128, P805, DOI 10.1083/jcb.128.5.805
   STOTT K, 1993, J BIOL CHEM, V268, P6097
   THOR H, 1982, J BIOL CHEM, V257, P2419
   Warburg O, 1933, BIOCHEM Z, V266, P377
   WERTMAN KF, 1992, GENETICS, V132, P337
   WETTERSTROEM N, 1984, J LAB CLIN MED, V103, P589
   Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x
NR 31
TC 47
Z9 48
U1 4
U2 16
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD OCT
PY 2004
VL 15
IS 10
BP 4522
EP 4531
DI 10.1091/mbc.E04-06-0445
PG 10
WC Cell Biology
SC Cell Biology
GA 858AJ
UT WOS:000224162200016
PM 15304519
OA Green Published
DA 2018-12-27
ER

PT J
AU Yoo, TH
   Park, CJ
   Ham, BK
   Kim, KJ
   Paek, KH
AF Yoo, TH
   Park, CJ
   Ham, BK
   Kim, KJ
   Paek, KH
TI RETRACTED: Ornithine decarboxylase gene (CaODC1) is specifically induced
   during TMV-mediated but salicylate-independent resistant response in hot
   pepper (Retracted article. See vol. 54, pg. 1569, 2013)
SO PLANT AND CELL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE differential screening; hot pepper (Capsicum annuum L.); hypersensitive
   response; ornithine decarboxylase cDNA clone; subcelluar localization;
   tobacco mosaic virus
ID TOBACCO-MOSAIC-VIRUS; SYSTEMIC ACQUIRED-RESISTANCE; PATHOGENESIS-RELATED
   PROTEINS; PROGRAMMED CELL-DEATH; DISEASE RESISTANCE; HYPERSENSITIVE
   RESPONSE; DEFENSE RESPONSES; NICOTIANA-TABACUM; PLANT DEFENSE; ACID
AB A gene encoding putative ornithine decarboxylase (ODC) has been isolated by differential screening of a cDNA library from the resistant hot pepper (Capsicum annuum L.) inoculated with avirulent tobacco mosaic virus (TMV) pathotype P-0. In hot pepper plants, transcripts of the CaODC1 (C. annuum ODC1) gene started to accumulate at 24 h post-inoculation of TMV-P-0 and the signal was spread systemically. The transcript level of CaODC1 was increased rapidly in a hot pepper resistant to Xanthomonas campestris pv. vesicatoria (Xcv) but not in a susceptible hot pepper after inoculation. These results suggest possible role(s) for CaODC1 in plant defense against a broad range of pathogens including viruses and bacteria.
C1 Korea Univ, Sch Life Sci & Biotehcnol, Sungbuk Gu, Seoul 136701, South Korea.
RP Paek, KH (reprint author), Korea Univ, Sch Life Sci & Biotehcnol, Sungbuk Gu, 1,5-Ga, Seoul 136701, South Korea.
EM khpaek95@korea.ac.kr
CR Alabadi D, 1998, PLANT PHYSIOL, V118, P323, DOI 10.1104/pp.118.1.323
   Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0
   Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2
   Flores HE, 1991, BIOCH PHYSL POLYAMIN, P213
   Fodor J, 1997, PLANT PHYSIOL, V114, P1443, DOI 10.1104/pp.114.4.1443
   FORSTER SA, 1992, J PLANT PHYSL, V140, P134
   HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773
   Iturbe-Ormaetxe I, 1998, PLANT PHYSIOL, V116, P173, DOI 10.1104/pp.116.1.173
   Kuriyama H, 2002, CURR OPIN PLANT BIOL, V5, P568, DOI 10.1016/S1369-5266(02)00305-9
   Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184
   Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251
   Lee GJ, 2001, MOL CELLS, V12, P250
   MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553
   Michael AJ, 1996, BIOCHEM J, V314, P241, DOI 10.1042/bj3140241
   NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2747, DOI 10.1016/0031-9422(84)83008-3
   Overmyer K, 2003, TRENDS PLANT SCI, V8, P335, DOI 10.1016/S1360-1385(03)00135-3
   Park CJ, 2001, MOL CELLS, V11, P122
   Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309
   Pieterse CMJ, 1998, PLANT CELL, V10, P1571, DOI 10.1105/tpc.10.9.1571
   Schipper RG, 2002, J HISTOCHEM CYTOCHEM, V50, P1143, DOI 10.1177/002215540205000901
   Shin R, 2001, PLANT SCI, V161, P727, DOI 10.1016/S0168-9452(01)00465-4
   Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235
   Tai TH, 1999, P NATL ACAD SCI USA, V96, P14153, DOI 10.1073/pnas.96.24.14153
   UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692
   Walden R, 1997, PLANT PHYSIOL, V113, P1009, DOI 10.1104/pp.113.4.1009
   Walters DR, 2000, PHYSIOL MOL PLANT P, V57, P137, DOI 10.1006/pmpp.2000.0286
   Wang JM, 2000, PLANT SCI, V158, P19, DOI 10.1016/S0168-9452(00)00293-4
   Willmann MR, 2002, TRENDS PLANT SCI, V7, P8, DOI 10.1016/S1360-1385(01)02218-X
   Yamakawa H, 1998, PLANT PHYSIOL, V118, P1213, DOI 10.1104/pp.118.4.1213
   Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621
   Yoda H, 2003, PLANT PHYSIOL, V132, P1973, DOI 10.1104/pp.103.024737
   Yoo TH, 2002, MOL CELLS, V14, P75
NR 32
TC 13
Z9 17
U1 3
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0032-0781
EI 1471-9053
J9 PLANT CELL PHYSIOL
JI Plant Cell Physiol.
PD OCT
PY 2004
VL 45
IS 10
BP 1537
EP 1542
DI 10.1093/pcp/pch176
PG 6
WC Plant Sciences; Cell Biology
SC Plant Sciences; Cell Biology
GA 870VF
UT WOS:000225086100020
PM 15564537
OA Bronze
DA 2018-12-27
ER

PT J
AU Baer, C
   Bilkei, G
AF Baer, C
   Bilkei, G
TI RETRACTED: The effect of intravaginal applied GnRH-agonist on the time
   of ovulation and subsequent reproductive performance of weaned
   multiparous sows (Retracted article. See vol. 45, pg. 564, 2010)
SO REPRODUCTION IN DOMESTIC ANIMALS
LA English
DT Article; Retracted Publication
ID TO-ESTRUS INTERVAL; FERTILIZATION
AB In order to prove the effect of 'fixed time insemination' and insemination at standing oestrus after post-weaning application of GnRH, in a Croatian large breeding unit, 502 sows were assigned to three groups and were artificially inseminated (AI) at their first post-weaning oestrus as many times as they stand, in 24-h intervals. The groups were treated as follows: group 1 (control, n = 160) were AI during their standing reflex; group 2 ['GnRH-fixed time insemination' (GnRH-FT-AI), n = 175] were AI, independent of detection of oestrus and following administration of GnRH-agonist at 96 h post-weaning; group 3 [GnRH insemination at standing oestrus (GnRH-OE-AI), n = 167] the animals were GnRH-agonist treated as group 2 and were AI at their standing reflex. Pre-trial daily average lactational feed intake, average daily feed intake from weaning to oestrus, oestrus within 6 days post-weaning (%), ovulation within 6 days post-weaning (%), weaning-to-oestrus interval (h), duration of oestrus (h), follicle size (mm), interval from oestrus to ovulation (h), subsequent day 24 pregnancy rate (%), farrowing rate (%) and total pigs born were evaluated. Pre-trial average daily lactational voluntary feed intake was 7.1 +/- 0.08 kg in group 1, 7.0 +/- 0.07 kg in group 2 and 7.1 +/- 0.17 kg in group 3 (p > 0.05). Average voluntary daily feed intake from weaning to oestrus was 5.1 +/- 0.3 kg in group 1, 5.2 +/- 0.5 kg in group 2 and 5.2 +/- 0.19 kg in group 3 (p > 0.05). Oestrus was detected within 6 days post-weaning in 134 (83.8%) in control, 164 (93.7%) in GnRH-FT-AI and 155 (92.8%) animals in GnRH-OE-AI groups (p = 0.05). Follicle size did not differ (p > 0.05) among the groups. In control 82.8%, in GnRH-FT-AI 91.5% and in GnRH-OE-AI 91.0% of the sows ovulated within 6 days post-weaning (p = 0.04), and had 80.6, 90.9 and 89.7% 24-day pregnancy rates (p = 0.16), respectively. In GnRH-FT-AI group 90.2%, in GnRH-OE-AI sows 89.7%, in control animals 79.9% farrowing rates were recorded (p = 0.17). Weaning to oestrus interval was 113.1 h in control, 114.1 h in GnRH-FT-AI and 112.6 h GnRH-OE-AI (p > 0.05). Duration of oestrus was significantly shorter in GnRH-FT-AI (44.9 h) and GnRH-OE-AI (48.1 h) animals, compared with the control (62.9 h) sows (p = 0.001). Similarly, the interval from oestrus to ovulation revealed significant (p = 0.004) differences between the groups (control 44.1 h, GnRH-OE-AI 34.1 h and GnRH-FT-AI 32.9 h). GnRH-FT-AI (12.5) and GnRH-OE-AI (12.6) sows had significantly higher (p = 0.01) number of total pigs born (n = 10.4) compared with control sows. GnRH-agonist-gel treatment to the sow shortens duration of oestrus, the interval from oestrus to ovulation, and may eliminate the need for oestrus detection in the hands of skilled personnel.
C1 Bilkei Consulting, DVM, CH-8600 Dubendorf, Switzerland.
   BC Osijek, Osijek, Croatia.
RP Bilkei, G (reprint author), Bilkei Consulting, DVM, Raubbuhlstr 4, CH-8600 Dubendorf, Switzerland.
CR BILKEI G, 1996, P EAAP 47 ANN M LILL
   Bilkei G. 1995, 1995, HUNG VET J, V10, P766
   Hoffmann CK, 2003, VET REC, V152, P261, DOI 10.1136/vr.152.9.261
   Horvat G, 2003, THERIOGENOLOGY, V59, P1479, DOI 10.1016/S0093-691X(02)01187-1
   HUHN U, 1995, 46 ANN M EUR ASS AN, P17
   HUHN U, 1999, PRAKTISCHE TIERARZT, V76, P35
   Kanitz W, 1999, TIERARZTL UMSCHAU, V54, P208
   Kemp B, 1996, J ANIM SCI, V74, P944
   KNOX RV, 1998, J ANIM SCI S1, V76, P73
   Molnar GB, 2003, REPROD DOMEST ANIM, V38, P236, DOI 10.1046/j.1439-0531.2003.00420.x
   *SAS STAT I INC, 2002, US GUID SAS STAT
   SOEDE NM, 1995, J REPROD FERTIL, V104, P99
   SZABO I, 1991, ACTA VET HUNG, V39, P3
   VESSEUR PC, 1994, J ANIM PHYSIOL AN N, V72, P225, DOI 10.1111/j.1439-0396.1994.tb00391.x
   Wahner M, 1996, REPROD DOMEST ANIM, V31, P477
   WAHNER M, 1995, 46 ANN M EUR ASS AN, P11
   WAHNER M, 1989, THESIS LEIPZIG
   Waller CM, 2002, REPROD DOMEST ANIM, V37, P116, DOI 10.1046/j.1439-0531.2002.00334.x
   Wilson M. R., 1993, Swine Health and Production, V1, P10
   XUE JL, 1994, J AM VET MED ASSOC, V204, P1486
   Zak LJ, 1997, J ANIM SCI, V75, P208
NR 21
TC 14
Z9 15
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0936-6768
EI 1439-0531
J9 REPROD DOMEST ANIM
JI Reprod. Domest. Anim.
PD OCT
PY 2004
VL 39
IS 5
BP 293
EP 297
DI 10.1111/j.1439-0531.2004.00500.x
PG 5
WC Agriculture, Dairy & Animal Science; Reproductive Biology; Veterinary
   Sciences
SC Agriculture; Reproductive Biology; Veterinary Sciences
GA 853XF
UT WOS:000223863200001
PM 15367259
DA 2018-12-27
ER

PT J
AU Budagian, V
   Bulanova, E
   Orinska, Z
   Ludwig, A
   Rose-John, S
   Saftig, P
   Borden, EC
   Bulfone-Paus, S
AF Budagian, V
   Bulanova, E
   Orinska, Z
   Ludwig, A
   Rose-John, S
   Saftig, P
   Borden, EC
   Bulfone-Paus, S
TI RETRACTED: Natural soluble Interleukin-15R alpha is generated by
   cleavage that involves the tumor necrosis factor-alpha-converting enzyme
   (TACE/ADAM17) (Retracted Article. See vol 286, pg 9894, 2011)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID IL-15 RECEPTOR-ALPHA; HORMONE-BINDING-PROTEIN; TNF-ALPHA; GROWTH-FACTOR;
   IN-VITRO; METALLOPROTEASE-DISINTEGRINS; CYTOKINE RECEPTORS;
   CELL-ADHESION; CHAIN; TACE
AB This study shows that the high affinity alpha-chain of the interleukin (IL)-15 receptor exists not only in membrane-anchored but also in soluble form. Soluble IL-15Ralpha (sIL-15Ralpha) can be detected in mouse sera and cell-conditioned media by enzyme-linked immunosorbent assay and by immunoprecipitation and Western blotting. This protein has a molecular mass of about 30 kDa because of the presence of a single N-glycosylation site, which is reduced to 26 kDa after N-glycosidase treatment. Transmembrane IL-15Ralpha is constitutively converted into its soluble form by proteolytic cleavage that involves tumor necrosis factor-alpha-converting enzyme ( TACE), and this process is further enhanced by phorbol 12-myristate 13-acetate (PMA) stimulation. The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective. Overexpression of TACE but not ADAM10 in COS-7 cells enhanced the constitutive and PMA-inducible cleavage of IL-15Ralpha. Moreover, murine fibroblasts deficient in TACE but not ADAM10 expression exhibited a significant reduction in the spontaneous and inducible IL-15Ralpha shedding, whereas a reconstitution of TACE in these cells restored the release of sIL-15Ralpha, thereby suggesting that TACE-mediated proteolysis may represent a major mechanism for sIL-15Ralpha generation in mice. The existence of natural sIL-15Ralpha offers novel insights into the complex biology of IL-15 and envisages a new level for therapeutic intervention.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Canc Drug Discovery & Dev, Cleveland, OH 44195 USA.
   Univ Kiel, Inst Biochem, D-24118 Kiel, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Pk Allee 22, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
RI Saftig, Paul/A-7966-2010; Rose-John, Stefan/A-7998-2010
OI Rose-John, Stefan/0000-0002-7519-3279
CR Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362
   Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x
   ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
   ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433
   Baumann G, 2002, Minerva Endocrinol, V27, P265
   BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199
   Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8
   Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X
   Blum H, 1996, J IMMUNOL, V157, P1846
   BUDAGIAN V, 2004, IN PRESS J BIOL CHEM, V279
   Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   CHILTON PM, 1993, J IMMUNOL, V151, P5907
   Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200
   Cui XZ, 2003, J HEPATOL, V39, P731, DOI 10.1016/S0168-8278(03)00216-2
   Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165
   Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978
   Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6
   Fernandez-Botran R, 2000, EXPERT OPIN INV DRUG, V9, P497, DOI 10.1517/13543784.9.3.497
   GIRI JG, 1995, EMBO J, V14, P3464
   GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C
   Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703
   Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615
   Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100
   Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135
   Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265
   Humphreys DT, 1999, CYTOKINE, V11, P773, DOI 10.1006/cyto.1998.0492
   Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775
   HWANG CD, 1993, J IMMUNOL, V151, P5631
   Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1
   Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200
   McInnes IB, 2003, ANN RHEUM DIS, V62, P51
   Mohan MJ, 2003, BIOCHEMISTRY-US, V42, P11092, DOI 10.1021/bi033012g
   Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27
   Musso T, 1999, BLOOD, V93, P3531
   Neely GG, 2004, J IMMUNOL, V172, P4225, DOI 10.4049/jimmunol.172.7.4225
   Onu A, 1997, J IMMUNOL, V158, P255
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624
   Rose-John S, 2003, ACTA BIOCHIM POL, V50, P603
   Ruchatz H, 1998, J IMMUNOL, V160, P5654
   Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9
   Schlondorff J, 1999, J CELL SCI, V112, P3603
   Shinozaki M, 2002, J CLIN INVEST, V109, P951, DOI 10.1172/JCI14574
   Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100
   Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787
   Smith XG, 2000, J IMMUNOL, V165, P3444, DOI 10.4049/jimmunol.165.6.3444
   Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200
   TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041
   Vincent B, 2001, J BIOL CHEM, V276, P37743
   Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200
   Wei XQ, 2001, J IMMUNOL, V167, P277, DOI 10.4049/jimmunol.167.1.277
   Westphal G, 2002, CLIN EXP MED, V2, P45, DOI 10.1007/s102380200006
   Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342
NR 57
TC 68
Z9 71
U1 4
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 24
PY 2004
VL 279
IS 39
BP 40368
EP 40375
DI 10.1074/jbc.M404125200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 854PW
UT WOS:000223916800020
PM 15215246
OA Bronze
DA 2018-12-27
ER

PT J
AU Kawasaki, H
   Taira, K
AF Kawasaki, H
   Taira, K
TI RETRACTED: Induction of DNA methylation and gene silencing by short
   interfering RNAs in human cells (Retracted article. See vol 441, pg
   1176, 2006)
SO NATURE
LA English
DT Article; Retracted Publication
ID DOUBLE-STRANDED-RNA; CPG ISLAND METHYLATION; HUMAN CANCER-CELLS;
   EXPRESSION; DROSOPHILA; CYTOPLASM; PLANTS; DNMT1
AB Double-stranded RNAs (dsRNAs) induce post-transcriptional gene silencing in several species of animal and plant(1-2). In plants, dsRNAs targeted to CpG islands within a promoter can also induce RNA-directed DNA methylation(3-8); however, it remains unclear whether gene silencing mediated by DNA methylation can be induced by dsRNAs in mammalian cells. Here, we demonstrate that short interfering RNAs (siRNAs; 21-25-nucleotide RNA molecules) induce DNA methylation and histone H3 methylation in human cells. Synthetic siRNAs targeted to CpG islands of an E-cadherin promoter induced significant DNA methylation and histone H3 lysine 9 methylation in both MCF-7 and normal mammary epithelial cells. As a result, these siRNAs repressed expression of the E-cadherin gene at the transcriptional level. In addition, disrupting the expression of either one of two DNA methyltransferases (DNMT1 or DNMT3B) by specific siRNAs abolished the siRNA-mediated methylation of DNA. Moreover, vector-based siRNAs targeted to the erbB2 (also known as HER2) promoter also induced DNA methylation in MCF-7 cells. Thus, siRNAs targeted to CpG islands within the promoter of a specific gene can induce transcriptional gene silencing by means of DNA-methyltransferase-dependent methylation of DNA in human cells, and might have potential as a new type of gene therapeutic agent.
C1 Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba 3058562, Japan.
RP Kawasaki, H (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM kawasaki@chembio.t.u-tokyo.ac.jp
CR Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663
   Beclin C, 2002, CURR BIOL, V12, P684, DOI 10.1016/S0960-9822(02)00792-3
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464
   Hammond SM, 2000, NATURE, V404, P293
   Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3
   Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg/158
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194
   Morel JB, 2000, CURR BIOL, V10, P1591, DOI 10.1016/S0960-9822(00)00862-9
   Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653
   Pelissier T, 2000, RNA, V6, P55, DOI 10.1017/S135583820099201X
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071
   Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695
NR 30
TC 311
Z9 354
U1 4
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 9
PY 2004
VL 431
IS 7005
BP 211
EP 217
DI 10.1038/nature02889
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 852HI
UT WOS:000223746000050
PM 15311210
DA 2018-12-27
ER

PT J
AU Fechner, J
   Ihmsen, H
   Hatterscheid, D
   Jeleazcov, C
   Schiessl, C
   Vornov, JJ
   Schwilden, H
   Schuttler, J
AF Fechner, J
   Ihmsen, H
   Hatterscheid, D
   Jeleazcov, C
   Schiessl, C
   Vornov, JJ
   Schwilden, H
   Schuttler, J
TI RETRACTED: Comparative pharmacokinetics and pharmacodynamics of the new
   propofol prodrug GPI 15715 and propofol emulsion (Retracted article. See
   vol. 112, pg. 1058, 2010)
SO ANESTHESIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Euroanaesthesia 2002 Meeting
CY APR 06-09, 2002
CL Nice, FRANCE
ID EEG; RATS; VOLUNTEERS; MIDAZOLAM; INFUSION; SEDATION; CONSCIOUSNESS;
   ANESTHESIA; KINETICS
AB Background: GPI 15715 is a new water-soluble prodrug that is hydrolyzed to release propofol. The objectives of this crossover study in volunteers were to investigate the pharmacokinetics and pharmacodynamics of GPI 15715 in comparison with propofol emulsion.
   Methods: In two separate sessions, nine healthy male volunteers (19-35 yr, 70-86 kg) received GPI 15715 and propofol emulsion as a target controlled infusion over 60 min. In the first 20 min, the propofol target concentration increased linearly to 5 mug/ml. Subsequently, the targets were reduced to 3 mug/ml and 1.5 mug/ml for 20 min each. The plasma concentrations of GPI 15715 and propofol were measured from arterial and venous blood samples up to 24 h and pharmacokinetics were analyzed. The pharmacodynamic effect was measured by the median frequency of the power spectrum of the electroencephalogram, and a sigmoid model with effect compartment was fitted to the data.
   Results: Compared with propofol emulsion, propofol from GPI 15715 showed a different disposition function and especially larger volumes of distribution. The propofol effect site concentration for half maximum effect was 2.0 +/- 0.5 mug/ml for GPI 15715 and 3.0 +/- 0.7 mug/ml for propofol emulsion (P < 0.05). Propofol from GPI 15715 did not show a hysteresis between plasma concentration and effect.
   Conclusions: Compared with propofol emulsion, propofol from GPI 15715 showed different pharmacokinetics and pharmacodynamics, particularly a higher potency with respect to concentration. These differences may indicate an influence of the formulation.
C1 Univ Erlangen Nurnberg, Anasthesiol Klin, D-91054 Erlangen, Germany.
   Guildford Pharmaceut, Baltimore, MD USA.
RP Fechner, J (reprint author), Univ Erlangen Nurnberg, Anasthesiol Klin, Krankenhausstr 12, D-91054 Erlangen, Germany.
EM Joerg.Fechner@kfa.imed.uni-erlangen.de
OI Vornov, James/0000-0003-1965-5456
CR Albrecht S, 1999, ANAESTHESIST, V48, P794, DOI 10.1007/s001010050787
   Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8
   CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244
   Dingemanse J, 1997, BRIT J ANAESTH, V79, P567
   Doursout MF, 2002, BRIT J ANAESTH, V89, P492, DOI 10.1093/bja/aef205
   Dutta S, 1998, J PHARM PHARMACOL, V50, P37, DOI 10.1111/j.2042-7158.1998.tb03302.x
   Dutta S, 1998, ANESTHESIOLOGY, V89, P678, DOI 10.1097/00000542-199809000-00018
   Egan TD, 2003, ANESTH ANALG, V97, P72, DOI 10.1213/01.ANE.0000066019.42467.7A
   Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012
   FORREST FC, 1994, BRIT J ANAESTH, V72, P35, DOI 10.1093/bja/72.1.35
   GEPTS E, 1987, ANESTH ANALG, V66, P1256
   Hering WJ, 1996, ANESTHESIOLOGY, V85, P1290, DOI 10.1097/00000542-199612000-00010
   HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1
   HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003
   Janzen PRM, 2000, ANAESTHESIA, V55, P666, DOI 10.1046/j.1365-2044.2000.01534.x
   Kelbel I, 1999, ACTA ANAESTH SCAND, V43, P71, DOI 10.1034/j.1399-6576.1999.430115.x
   Kuizenga K, 2001, BRIT J ANAESTH, V86, P354, DOI 10.1093/bja/86.3.354
   Luer MS, 1998, NEUROL RES, V20, P178
   Nakane M, 1999, BRIT J ANAESTH, V83, P397
   PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8
   Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023
   Ririe DG, 2001, J CARDIOTHOR VASC AN, V15, P745, DOI 10.1053/jcan.2001.28321
   Russell D, 1998, ANAESTHESIA, V53, P42, DOI 10.1111/j.1365-2044.1998.53s113.x
   Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003
   SCHUTTLER J, 1985, POSTGRAD MED J, V61, P53
   Schuttler J, 1985, Eur J Anaesthesiol, V2, P133
   Schwilden H, 1985, Eur J Anaesthesiol, V2, P121
   Schywalsky M, 2003, EUR J ANAESTH, V20, P182, DOI 10.1097/00003643-200303000-00002
NR 28
TC 48
Z9 53
U1 3
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD SEP
PY 2004
VL 101
IS 3
BP 626
EP 639
DI 10.1097/00000542-200409000-00011
PG 14
WC Anesthesiology
SC Anesthesiology
GA 850IS
UT WOS:000223605100009
PM 15329587
DA 2018-12-27
ER

PT J
AU Fiorucci, S
   Antonelli, E
   Distrutti, E
   Mencarelli, A
   Farneti, S
   Del Soldato, P
   Morelli, A
AF Fiorucci, S
   Antonelli, E
   Distrutti, E
   Mencarelli, A
   Farneti, S
   Del Soldato, P
   Morelli, A
TI RETRACTED: Liver delivery of NO by NCX-1000 protects against acute liver
   failure and mitochondrial dysfunction induced by APAP in mice (Retracted
   article. See vol. 156, pg. 868, 2009)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE APAP; nitric oxide; mitochondrial membrane potential; hepatocytes
ID ACETAMINOPHEN-INDUCED HEPATOTOXICITY; NITRIC-OXIDE SYNTHASE;
   CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; URSODEOXYCHOLIC ACID;
   ENDOTHELIAL-CELLS; MOUSE-LIVER; APOPTOSIS; RESPIRATION; TOXICITY
AB 1 NCX-1000, (3alpha, 5beta, 7beta)- 3,7- dihydroxycholan-24oic acid[2-methoxy-4-[3-[4-(nitroxy) butoxy]-3-oxo-1propenyl] phenyl ester, is a nitric oxide ( NO)- derivative of ursodeoxyxholic acid ( UDCA) that selectively release NO in the liver.
   2 Here, we demonstrated that administering mice with 40 mumol kg(-1) NCX-1000, but not UDCA, improves liver histopathology and reduces mortality caused by 330 mumol kg(-1) APAP from 60 to 25% (P<0.01). Administration of NCX-1000, in a therapeutic manner, that is, 2 h after acetaminophen ( APAP) intoxication reduced mortality, improved liver histopathology and prevented liver IFN-gamma, TNF-alpha, Fas/Fas ligand and inducible nitric oxide synthase ( iNOS) mRNA accumulation caused by APAP.
   3 In vitro exposure of primary cultures of mouse hepatocytes to APAP, 6.6 mM, resulted in apoptosis followed by necrosis. Loss of cell viability correlates with early mitochondrial membrane potential (Delta psi(m)) hyperpolarization followed by depolarization and cytochrome c translocation from mitochondria to cytosol. APAP-induced apoptosis associated with procaspase-3 and - 9 cleavage, appearance of truncated Bid and activation of poly( ADP-ribose) polymerase ( PARP).
   4 Treating primary culture of hepatocytes with 5 mM cyclosporine and 10 mM trifluoperazine for eight resulted in significant reduction of apoptosis induced by APAP suggesting that loss of Delta psi m was mechanistically involved in apoptosis induced by APAP in vitro.
   5 NCX-1000, but not UDCA, concentration-dependently (ED50 = 16 mM) protected against Delta psi(m) depolarization and reduced transition from apoptosis to necrosis caused by 6.6 mM APAP.
   6 Treating primary cultures of hepatocytes with the NO-donor DETA- NO, 100 mu M, reduced apoptosis induced by APAP and prevented caspase activation.
   7 In conclusion, NCX-1000 is effective in protecting against APAP-induced hepatotoxicity when administered in a therapeutic manner. This protection may involve the inhibition of apoptosis and the maintenance of mitochondrial integrity.
C1 Univ Perugia, Dipartimento Med Clin & Sperimentale, Clin Gastroenterol & Epatol, I-06100 Perugia, Italy.
   Nicox SA, Sophia Antipolis, France.
RP Fiorucci, S (reprint author), Monteluce Policlin, Clin Gastroenterol & Endoscopia Digest, I-06100 Perugia, Italy.
EM fiorucci@unipg.it
RI Fiorucci, Stefano/I-1251-2012
CR ADAMSON GM, 1993, BIOCHEM PHARMACOL, V45, P2289, DOI 10.1016/0006-2952(93)90201-7
   Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602
   BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125
   Boess F, 1998, HEPATOLOGY, V27, P1021, DOI 10.1002/hep.510270418
   Bordenave E, 2002, OPT EXPRESS, V10, P35, DOI 10.1364/OE.10.000035
   Bridger S, 1998, BRIT MED J, V316, P1724, DOI 10.1136/bmj.316.7146.1724
   Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200
   Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0
   Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631
   DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327
   Fiorucci S, 2002, FASEB J, V16, P1645, DOI 10.1096/fj.02-0297fje
   Fiorucci S, 2002, BRIT J PHARMACOL, V135, P589, DOI 10.1038/sj.bjp.0704500
   Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P2652, DOI 10.1073/pnas.041603898
   Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P8897, DOI 10.1073/pnas.151136298
   Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316
   Gardner CR, 2002, TOXICOL APPL PHARM, V184, P27, DOI 10.1006/taap.2002.9474
   Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315
   Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156
   Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814
   HINSON JA, 1995, DRUG METAB REV, V27, P73, DOI 10.3109/03602539509029816
   Hinson JA, 2002, NITRIC OXIDE-BIOL CH, V6, P160, DOI 10.1006/niox.2001.0404
   Horbach M, 1997, TOXICOLOGY, V121, P117, DOI 10.1016/S0300-483X(97)00061-9
   Ishida Y, 2002, FASEB J, V16, DOI 10.1096/fj.02-0046com
   KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913
   Knight TR, 2001, TOXICOL SCI, V62, P212, DOI 10.1093/toxsci/62.2.212
   Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409
   Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589
   LASKIN DL, 1995, HEPATOLOGY, V21, P1045, DOI 10.1016/0270-9139(95)90253-8
   Lawson JA, 1999, TOXICOL APPL PHARM, V156, P179, DOI 10.1006/taap.1999.8635
   Liu J, 2003, HEPATOLOGY, V37, P324, DOI 10.1053/jhep.2003.50063
   Liu J, 2002, J PHARMACOL EXP THER, V300, P18, DOI 10.1124/jpet.300.1.18
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   MEYERS LL, 1988, TOXICOL APPL PHARM, V93, P378, DOI 10.1016/0041-008X(88)90040-3
   Michael SL, 2001, NITRIC OXIDE-BIOL CH, V5, P432, DOI 10.1006/niox.2001.0385
   Michael SL, 1999, HEPATOLOGY, V30, P186, DOI 10.1002/hep.510300104
   Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Nieminen AL, 1996, NEUROSCIENCE, V75, P993
   Ruepp SU, 2002, TOXICOL SCI, V65, P135, DOI 10.1093/toxsci/65.1.135
   Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602
   Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898
   SIMKO V, 1994, ALIMENT PHARM THERAP, V8, P315
   Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533
   Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3
   Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475
NR 46
TC 23
Z9 28
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD SEP
PY 2004
VL 143
IS 1
BP 33
EP 42
DI 10.1038/sj.bjp.0705780
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 855HW
UT WOS:000223965100006
PM 15345658
OA Green Published
DA 2018-12-27
ER

PT J
AU Chen, JZ
   Zhang, FR
   Tao, QM
   Wang, XX
   Zhu, JH
   Zhu, JH
AF Chen, JZ
   Zhang, FR
   Tao, QM
   Wang, XX
   Zhu, JH
   Zhu, JH
TI RETRACTED: Number and activity of endothelial progenitor cells from
   peripheral blood in patients with hypercholesterolaemia (Retracted
   Article. See vol 119, pg 545, 2010)
SO CLINICAL SCIENCE
LA English
DT Article; Retracted Publication
DE coronary artery disease; endothelial progenitor cell;
   hypercholesterolaema; peripheral blood; vasculogenesis
ID BONE-MARROW; POSTNATAL NEOVASCULARIZATION; TRANSPLANTATION;
   MOBILIZATION; PRECURSORS; ORIGIN; RISK; VIVO
AB Hypercholesterolaemia contributes to atherosclerosis and coronary artery diseases by inducing endothelial cell injury and dysfunction. Recent studies have provided increasing evidence that EPCs (endothelial progenitor cells) participate in ongoing endothelial repair and postnatal neovascularization. However, the changes in EPCs in patients with hypercholesterolaemia have not been elucidated to date. Therefore we investigated the number and functional activity of EPCs in patients with hypercholesterolemia. Total MNCs (mononuclear cells) were isolated from 20 patients with hype rcholesterolaemia and 20 matched control subjects. EPCs were characterized as adherent cells double-positive for Dil-LDL (1,1'-dioctaclecyl-3,3,3,3'-tetramethylindocarbocyanide percholate-labelled low-density lipoprotein) uptake and lectin binding by direct fluorescent staining under a laser scanning confocal microscope, and were characterized further by demonstrating the expression of KDR (kinase insert domain-containing receptor), CD34 and AC133 by flow cytometry. Proliferation, migration and in vitro vasculogenesis activity of EPCs were assayed using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay, modified Boyden chamber assay and an in vitro vasculogenesis kit respectively. EPC adhesion assay was performed by replating cells on fibronectin-coated dishes and then counting the adherent cells. As a result, the number of EPCs was significantly reduced in patients with hypercholesterolaemia compared with that in control subjects (41.8 +/- 8.7 compared with 64.5 +/- 16.6 EPCs/ x 200 field respectively; P < 0.05). The number of EPCs was inversely correlated with total cholesterol (r = -0.659, P < 0.001) and LDL-cholesterol (r = -0.611, P < 0.001) levels. In addition, the functional activities of isolated EPCs, such as proliferative, migratory, adhesive and in vitro vasculogenesis capacity, were also impaired. In conclusion, the results of the present study may state a novel pathophysiological mechanism of hypercholesterolaemia: the reduction of EPCs with decreased functional activity.
C1 Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Cardiovasc, Hangzhou 310003, Peoples R China.
RP Wang, XX (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Cardiovasc, Hangzhou 310003, Peoples R China.
EM wangxx19730312@yahoo.com.cn
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Chen JZ, 2004, J MOL CELL CARDIOL, V36, P233, DOI 10.1016/j.yjmcc.2003.10.005
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Ito H, 1999, CANCER RES, V59, P5875
   Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568
   Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6
   Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296
   National Cholesterol Education Program (NCEP), 2002, CIRCULATION, V106, P3143, DOI DOI 10.2215/CJN.04131206
   Peichev M, 2000, BLOOD, V95, P952
   Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774
   Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   Strehlow K, 2003, CIRCULATION, V107, P3059, DOI 10.1161/01.CIR.0000077911.81151.30
   Suzuki T, 2003, CARDIOVASC RES, V58, P487, DOI 10.1016/S0008-6363(02)00780-0
   Takahashi T, 1999, NAT MED, V5, P434
   Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55
NR 23
TC 176
Z9 191
U1 5
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD SEP
PY 2004
VL 107
IS 3
BP 273
EP 280
DI 10.1042/CS20030389
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 855RT
UT WOS:000223992100006
PM 15099190
DA 2018-12-27
ER

PT J
AU Karakaya, S
AF Karakaya, S
TI RETRACTED: A comparative study: English and Turkish teachers'
   conceptions of their professional responsibility (Retracted article. See
   vol. 38, pg. 122, 2012)
SO EDUCATIONAL STUDIES
LA English
DT Article; Retracted Publication
DE teacher; professional responsibility; teachers' concepts; comparison
ID EDUCATION
AB This paper discusses some of the findings pertaining to how teachers see their work, produced by a comparative study of 120 English and 120 Turkish primary school teachers. The sample was drawn from schools in four different types of matched catchment areas-rural, inner city, suburban and affluent suburban-in Leicestershire. England, and in Erzurum, Turkey. Four major dimensions of difference between the two national contexts are identified in terms of the range of professional activities undertaken, the ambiguity of relative importance to teachers of the process as against the products of learning. Against a background of contemporary policy changes which seem likely to effect different teaching and learning activities in the two countries, the paper argues that attempts to change teachers' practice without due regard to those conceptions of professional responsibility which are deeply rooted in particular national traditions, as well as more general classroom realities, will result in a lowering of morale and decreased effectiveness.
C1 Ataturk Univ, Erzurum, Turkey.
RP Karakaya, S (reprint author), Ataturk Univ, Erzurum, Turkey.
EM kseref@atauni.edu.tr
CR ACKERS S, 1987, PRIMARY SCH TEACHER
   Alexander R. J., 1984, PRIMARY TEACHING
   BERESFORDHILL P, 1993, OXFORD REV EDUC, V19, P79, DOI 10.1080/0305498930190106
   Berlak A., 1981, DILEMMAS SCH TEACHIN
   Bernstein B., 1977, CLASS CODES CONTROL, V3
   BOLTON E, 1988, INOGOV C BIRM
   BONO TR, 1990, TEACHER ED EUROPE CH
   BROADFOOT P, 1988, BRIT J SOCIOLOGY ED, V9
   BROADFOOT P, 1987, TIMES ED SUPPLE 0703
   BROADFOOT P, 1987, COMP EDUC, V23, P26
   BROADFOOT PM, 1981, CONSTANTS CONTEXTS E
   Brown S., 1988, SCOTTISH ED REV
   BUCHMANN M, 1987, J EDUC RES, V31, P1
   CALDERHEAD J, 1989, TEACH TEACH EDUC, V5, P43, DOI 10.1016/0742-051X(89)90018-8
   Calderhead J., 1987, EXPLORING TEACHERS T
   CARLGREN I, 1991, TEACH TEACH EDUC, V7, P507, DOI 10.1016/0742-051X(91)90045-Q
   CLARK C, 1985, ISATT C TILB NETH
   ERICKSON G, 1987, ANN M AM ED RES ASS
   FOGELMAN K, 1999, CITIZENSHIP SCH
   GALTON M, 1994, HDB TEACHERS TRAININ
   GALTON M, 1990, INSIDE PRIMARY CLASS
   Galton M, 1980, PROGR PERFORMANCE PR
   Grace G., 1978, TEACHERS IDEOLOGY CO
   HOYLE E, 1980, WORLD YB ED 1980, P42
   ISAMBERTJAMATI V, 1984, CULTURE TECHNIQUE CR
   Jackson P. W., 1968, LIFE IN CLASSROOMS
   JOHNSTON K, 1988, TEACHERS PROFESSIONA
   KAGAN DM, J TEACHER ED, V42, P281
   Kazamias A., 1966, ED QUEST MODERNITY T
   KOHN ML, 1987, ANN M AM SOC ASS CHI
   KREMER L, 1991, J TEACH EDUC, V4, P79
   MITTER W, 1991, BRIT J EDUC STUD, V39, P138, DOI 10.2307/3120916
   NIAS J, 1986, BERA C BRIST
   OSBORN M, 1992, OXFORD REV EDUC, V18, P3, DOI 10.1080/0305498920180101
   POLLARD A, 1986, SOCIAL WORLD PRIMARY
   POLLARD A, 1988, FIRST CARR C ST LUC
   POPPLETON P, 1992, COMP EDUC, V28, P215, DOI 10.1080/0305006920280208
   POPPLETON P, 1986, BERA C BRIST
   Sharp R., 1975, ED SOCIAL CONTROL
   THOMAS N, 1985, IMPROVING PRIMARY SC
   ZEICHNER KM, 1987, EXPLORING TEACHERS T
NR 41
TC 16
Z9 16
U1 2
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0305-5698
EI 1465-3400
J9 EDUC STUD-UK
JI Educ. Stud.
PD SEP
PY 2004
VL 30
IS 3
BP 195
EP 216
DI 10.1080/0305569042000224170
PG 22
WC Education & Educational Research
SC Education & Educational Research
GA 827AR
UT WOS:000221871100001
DA 2018-12-27
ER

PT J
AU Bulut, S
AF Bulut, S
TI RETRACTED: Factor structure of posttraumatic stress disorder in children
   experienced natural disaster (Retracted article. See vol. 48, pg. 354,
   2005)
SO PSYCHOLOGIA
LA English
DT Article; Retracted Publication
DE post traumatic stress disorder; child survivors of natural disaster;
   Sefa Bulut child-post traumatic stress disorder inventory for children
ID HURRICANE-ANDREW; PSYCHIC TRAUMA; SYMPTOM STRUCTURE; PTSD; SCHOOL;
   EARTHQUAKE; INTRUSION; TORNADO; AROUSAL
AB Because Oklahoma has more tornadoes per square mile than any region in the world, children in Oklahoma and other disaster prone areas are at risk for developing posttraumatic stress disorder (PTSD) due to exposure to and threat of tornadoes. Given the gaps in the literature and the risk to children living in Oklahoma, the present study was undertaken to factor analyze items representing underlying dimensions of PTSD. This factor analysis of the responses of children who experienced a tornado indicate that it may be more useful to re align the DSM-IV symptoms into five underlying dimensions. These dimensions appears to be: (1) blocking/vigilance, (2) affective/adjustment difficulties, (3) re-experiencing/ intrusion, (4) somatic/attachment and (5) sense of foreshortened future. Items of avoidance stimuli, loaded across factors, with avoiding places associated with vigilance, avoiding people associated with adjustment problems, and television stimuli associated with re-experiencing. Psychologists should consider these results when developing interventions.
C1 AIBU, Egitim Fak, PDR Bolumu Golkoy, Bolu, Turkey.
RP Bulut, S (reprint author), AIBU, Egitim Fak, PDR Bolumu Golkoy, Bolu, Turkey.
EM sefabulut22@yahoo.com
CR American Psychiatric Association, 1987, DIAGN STAT MAN MENT
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Basoglu M, 2002, J TRAUMA STRESS, V15, P269, DOI 10.1023/A:1016241826589
   BRADBURN IS, 1991, ADV BEHAV RES THER, V13, P173, DOI 10.1016/0146-6402(91)90005-U
   Buckley TC, 1998, BEHAV RES THER, V36, P1091, DOI 10.1016/S0005-7967(98)00076-X
   CHINNICI R, 1985, PASTORAL PSYCHOL, V33, P245
   Cordova MJ, 2000, J TRAUMA STRESS, V13, P301, DOI 10.1023/A:1007762812848
   CRAWFORD FR, 1957, THESIS U TEXAS
   Fletcher K. E., 1996, 12 ANN M INT SOC TRA
   Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286
   Foa E.B., 1993, AM PSYCHIAT PRESS RE, V12, P273
   FOA EB, 1995, AM J PSYCHIAT, V152, P116
   FREDERICKS CJ, 1985, POSTTRAUMATIC STRESS
   GALANTE R, 1986, J AM ACAD CHILD PSY, V25, P357, DOI 10.1016/S0002-7138(09)60257-0
   GARRISON CZ, 1995, J AM ACAD CHILD PSY, V34, P1193, DOI 10.1097/00004583-199509000-00017
   GARRISON CZ, 1993, AM J EPIDEMIOL, V138, P522, DOI 10.1093/oxfordjournals.aje.a116886
   HAMADA R, IN PRESS KAUAI RECOV
   HURST JL, 1981, THESIS PURDUE U
   KEANE MT, 1993, POSTTRAUMATIC STRESS, P99
   LaGreca AM, 1996, J CONSULT CLIN PSYCH, V64, P712, DOI 10.1037/0022-006X.64.4.712
   LONIGAN CJ, 1994, J AM ACAD CHILD PSY, V33, P94, DOI 10.1097/00004583-199401000-00013
   Lonigan CJ, 1998, J CLIN CHILD PSYCHOL, V27, P255, DOI 10.1207/s15374424jccp2703_3
   MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008
   McMillen JC, 2000, J TRAUMA STRESS, V13, P57, DOI 10.1023/A:1007768830246
   McNally R. J., 1991, PSYCHOL ASSESSMENT, V3, P531, DOI [10.1037/1040-3590.3.4.531, DOI 10.1037/1040-3590.3.4.531]
   MOORE HE, 1958, MENT HYG, V42, P45
   Mulilis JP, 1997, J APPL SOC PSYCHOL, V27, P1750, DOI 10.1111/j.1559-1816.1997.tb01623.x
   NADER K, 1990, AM J PSYCHIAT, V147, P1526
   Penick E C, 1976, J Community Psychol, V4, P64, DOI 10.1002/1520-6629(197601)4:1<64::AID-JCOP2290040103>3.0.CO;2-0
   PERRY SE, 1956, CHILD HIS FAMILY DIA
   PERRY SH, 1959, SCHOOLHOUSE DISASTER
   PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057
   PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239
   Sack WH, 1997, J AM ACAD CHILD PSY, V36, P49, DOI 10.1097/00004583-199701000-00017
   SAIGH PA, 1989, INT J SPECIAL ED, V4, P75
   Sauter J, 1998, RES SOCIAL WORK PRAC, V8, P251, DOI 10.1177/104973159800800301
   SHANNON MP, 1994, J AM ACAD CHILD ADOL, V32, P117
   Shavelson R., 1996, STAT REASONING BEHAV
   Taylor S, 1998, J ABNORM PSYCHOL, V107, P154, DOI 10.1037//0021-843X.107.1.154
   Terr L., 1991, CHILD ADOLESCENT PSY, P755
   Terr L C, 1979, Psychoanal Study Child, V34, P547
   TERR LC, 1983, AM J PSYCHIAT, V140, P1543
   TERR LC, 1981, AM J PSYCHIAT, V138, P14
   Vernberg EM, 1996, J ABNORM PSYCHOL, V105, P237, DOI 10.1037//0021-843X.105.2.237
   WEBB NB, 1991, PLAY THERAPY CHILDRE
   WEINREB J, 1954, J NERV MENT DIS, V120, P397
   ZARLE TH, 1974, J COMMUNITY PSYCHOL, V2, P311
   1999, DAILY OKLAHOMAN 0514
NR 49
TC 3
Z9 3
U1 2
U2 13
PU PSYCHOLOGIA SOC
PI KYOTO
PA DEPT EDUC PSYCHOL FAC EDUC KYOTO UNIV, KYOTO, 606, JAPAN
SN 0033-2852
EI 1347-5916
J9 PSYCHOLOGIA
JI Psychologia
PD SEP
PY 2004
VL 47
IS 3
BP 158
EP 168
DI 10.2117/psysoc.2004.158
PG 11
WC Psychology, Multidisciplinary
SC Psychology
GA 861DH
UT WOS:000224395800002
DA 2018-12-27
ER

PT J
AU Suvardhan, K
   Kumar, KS
   Krishnaiah, L
   Rao, SP
   Chiranjeevi, P
AF Suvardhan, K
   Kumar, KS
   Krishnaiah, L
   Rao, SP
   Chiranjeevi, P
TI RETRACTED: The determination of nickel(II) after on-line sorbent
   preconcentration by inductively coupled plasma atomic emission
   spectrometry using Borassus Flabellifer inflorescence loaded with
   coniine dithiocarbamate (Retracted article. See vol 152, pg. 450, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE nickel(II); preconcentration; coniine dithiocarbamate (CDC); inductively
   coupled plasma atomic emission spectrometry (ICP-AES); Borassus
   Flabellifer inflorescence (BFI); water samples
ID ABSORPTION-SPECTROMETRY; SAMPLES; WATER; FLAME
AB A procedure was developed for the determination of nickel(II) in water samples by inductively coupled plasma atomic emission spectrometry (ICP-AES) after preconcentration on coniine dithiocarbamate (CDC) supported by Borassus Flabellifer inflorescence. The sorbed element was subsequently eluted with 0.4 M nitric acid and the acid eluates are analysed by ICP-AES. The influence of various parameters such as pH, flow rate of sample, eluent concentration, volume of the sample and volume eluent were investigated. Under the optimal conditions, nickel in aqueous sample was concentrated about 100-fold. Nickel recovery was obtained by the proposed method in range of 98.9-99.9%. This method is also applied for the analysis of spiked and natural water samples. The results provide strong evidence to support the hypothesis of an adsorption mechanism. (C) 2004 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR Ali A, 1999, MICROCHEM J, V63, P365, DOI 10.1006/mchj.1999.1799
   Arpadjan S, 1997, ANALYST, V122, P243, DOI 10.1039/a606917g
   Atanasova D, 1998, TALANTA, V45, P857, DOI 10.1016/S0039-9140(97)00175-6
   Bagheri H, 2000, ANALYST, V125, P1649, DOI 10.1039/b001454k
   BAKSTROM K, 1984, ANAL CHIM ACTA, V109, P323
   BIURRUN MCY, 1995, ANAL CHIM ACTA, V303, P341
   CARTHY M, 1991, ANAL CHEM, V63, pR301
   Christensen JM, 1999, TOXICOL LETT, V108, P185, DOI 10.1016/S0378-4274(99)00088-0
   ENSAFI AA, 1994, IRAN J CHEM CHEM ENG, V13, P97
   ENSAFI AA, 2003, J CHEM ENV, V7, P48
   FANG ZL, 1984, ANAL CHIM ACTA, V164, P41
   Kristiansen J, 2000, ANAL CHIM ACTA, V403, P265, DOI 10.1016/S0003-2670(99)00568-1
   Kristiansen J, 1997, SCI TOTAL ENVIRON, V204, P147, DOI 10.1016/S0048-9697(97)00155-1
   LICHTE FE, 1980, ANAL CHEM, V52, P120, DOI 10.1021/ac50051a029
   Nielsen GD, 1999, TOXICOL APPL PHARM, V154, P67, DOI 10.1006/taap.1998.8577
   OLESIK JW, 1990, ANAL CHEM, V62, P840, DOI 10.1021/ac00207a014
   Scansetti G, 1998, INT ARCH OCC ENV HEA, V71, P60, DOI 10.1007/s004200050251
   TEMPLETON D, 1990, BIOL MONITORING CHEM
   WELZ B, 1992, MICROCHEM J, V45, P163, DOI 10.1016/0026-265X(92)90007-P
   WELZ B, 1991, APPL SPECTROSC, P45
   ZHUANG ZX, 1994, J ANAL ATOM SPECTROM, V9, P779, DOI 10.1039/ja9940900779
NR 21
TC 21
Z9 23
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD AUG 30
PY 2004
VL 112
IS 3
BP 233
EP 238
DI 10.1016/j.jhazmat.2004.05.003
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 849YD
UT WOS:000223576700008
PM 15302444
DA 2018-12-27
ER

PT J
AU Sharma, AK
   Rohrer, B
AF Sharma, AK
   Rohrer, B
TI RETRACTED: Calcium-induced calpain mediates apoptosis via caspase-3 in a
   mouse photoreceptor cell line (Retracted article. See vol. 292, pg.
   13186, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID DOMINANT RETINITIS-PIGMENTOSA; RETINAL DEGENERATION; CYTOCHROME-C;
   DEATH; RD; MEMBRANE; MICE; PHOSPHODIESTERASE; RHODOPSIN; MUTATION
AB The rd mouse, an accepted animal model for photoreceptor degeneration in retinitis pigmentosa, has a recessive mutation for the gene encoding the beta-subunit of the cGMP phosphodiesterase. This mutation results in high levels of cGMP, which leaves an increased number of the cGMP-gated channels in the open state, thus allowing intracellular calcium (Ca2+) to rise to toxic levels, and rapid photoreceptor degeneration follows. To delineate the events in rd photoreceptor degeneration, we demonstrated an increase in calpain and caspase-3 activity, hypothesizing that Ca2+-mediated apoptosis in photoreceptors is mediated by calpain, involving mitochondrial depolarization and caspase-3 activation. To examine this hypothesis further, a murine photoreceptor-derived cell line (661W) was treated with the Ca2+ ionophore A23187, cGMP-gated channel agonist 8-bromoc-GMP, or phosphodiesterase inhibitor isobutylmethylxanthine to mimic the increased Ca2+ influx seen in the rd photoreceptors. Ca2+-induced cell death in 661W cells was found to be mediated by calpain and caspase-3 and could be completely inhibited by the calpain inhibitor SJA6017, implicating both calpain and caspases in the apoptotic process. The apoptotic events correlated in an SJA6017-inhibitable manner with bid cleavage, mitochondrial depolarization, cytochrome c release, and caspase-3 and -9 activation. We concluded that Ca2+ influx in the rd model of photoreceptor degeneration leads to the activation of the cysteine protease calpain, which executes apoptosis via modulation of caspase-3 activity.
C1 Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, Charleston, SC 29425 USA.
   Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU NEI NIH HHS [EY13520, EY014793]
CR BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   BLANKS JC, 1974, J COMP NEUROL, V156, P95, DOI 10.1002/cne.901560108
   CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   CROSSON CE, 1990, J OCUL PHARMACOL, V6, P293, DOI 10.1089/jop.1990.6.293
   Doonan F, 2003, J NEUROSCI, V23, P5723
   EDWARD DP, 1991, ARCH OPHTHALMOL-CHIC, V109, P554, DOI 10.1001/archopht.1991.01080040122042
   FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5
   FARRAR GJ, 1990, GENOMICS, V8, P35
   FARRAR GJ, 1992, GENOMICS, V14, P805
   Fox DA, 1999, ANN NY ACAD SCI, V893, P282, DOI 10.1111/j.1749-6632.1999.tb07837.x
   Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200
   He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Jomary C, 2001, MOL CELL NEUROSCI, V18, P335, DOI 10.1006/mcne.2001.1036
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   MOLINARI M, 1994, J BIOL CHEM, V269, P27992
   Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6
   Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053
   Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   THIRKILL CE, 1987, ARCH OPHTHALMOL-CHIC, V105, P372
   Wei MC, 2000, GENE DEV, V14, P2060
NR 26
TC 119
Z9 123
U1 4
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 20
PY 2004
VL 279
IS 34
BP 35564
EP 35572
DI 10.1074/jbc.M401037200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 846GJ
UT WOS:000223303400052
PM 15208318
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Owens, RM
   Pritchard, G
   Skipp, P
   Hodey, M
   Connell, SR
   Nierhaus, KH
   O'Connor, CD
AF Owens, RM
   Pritchard, G
   Skipp, P
   Hodey, M
   Connell, SR
   Nierhaus, KH
   O'Connor, CD
TI RETRACTED: A dedicated translation factor controls the synthesis of the
   global regulator Fis (Retracted Article. See vol 26, pg 4607, 2007)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE Fis; GTPase; regulation; ribosome; translation
ID ENTEROPATHOGENIC ESCHERICHIA-COLI; INTEGRATION HOST FACTOR;
   ELONGATION-FACTOR-G; SALMONELLA-TYPHIMURIUM; STRINGENT CONTROL; GTPASE
   ACTIVITY; DNA INVERSION; PROTEIN FIS; RNA; EXPRESSION
AB BipA is a highly conserved protein with global regulatory properties in Escherichia coli. We show here that it functions as a translation factor that is required specifically for the expression of the transcriptional modulator Fis. BipA binds to ribosomes at a site that coincides with that of elongation factor G and has a GTPase activity that is sensitive to high GDP:GTP ratios and stimulated by 70S ribosomes programmed with mRNA and aminoacylated tRNAs. The growth rate-dependent induction of BipA allows the efficient expression of Fis, thereby modulating a range of downstream processes, including DNA metabolism and type III secretion. We propose a model in which BipA destabilizes unusually strong interactions between the 50 untranslated region of fis mRNA and the ribosome. Since BipA spans phylogenetic domains, transcript-selective translational control for the 'fast-track' expression of specific mRNAs may have wider significance.
C1 Univ Southampton, Ctr Proteom Res, Southampton SO16 7PX, Hants, England.
   Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England.
   Max Planck Inst Mol Genet, Berlin, Germany.
RP O'Connor, CD (reprint author), Univ Southampton, Ctr Proteom Res, Southampton SO16 7PX, Hants, England.
EM doc1@soton.ac.uk
RI Connell, Sean/K-6725-2013
OI Connell, Sean/0000-0001-7807-7049
CR Adams P, 1999, ELECTROPHORESIS, V20, P2241, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2241::AID-ELPS2241>3.0.CO;2-S
   Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851
   Azam TA, 1999, J BACTERIOL, V181, P6361
   BALL CA, 1992, J BACTERIOL, V174, P8043
   Barker HC, 2000, MOL MICROBIOL, V35, P1518, DOI 10.1046/j.1365-2958.2000.01820.x
   Blaha G, 2000, METHOD ENZYMOL, V317, P292
   Brandi A, 1999, EMBO J, V18, P1653, DOI 10.1093/emboj/18.6.1653
   Bremer H, 1996, ESCHERICHIA COLI SAL, V2, P1553
   Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8
   Connell SR, 2003, EMBO J, V22, P945, DOI 10.1093/emboj/cdg093
   Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072
   Farris M, 1998, MOL MICROBIOL, V28, P265, DOI 10.1046/j.1365-2958.1998.00793.x
   FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992
   FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x
   Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597
   Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100
   GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167
   Goldberg MD, 2001, MOL MICROBIOL, V41, P549, DOI 10.1046/j.1365-2958.2001.02526.x
   GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x
   Grant AJ, 2003, MOL MICROBIOL, V48, P507, DOI 10.1046/j.1365-2958.2003.t01-1-03447.x
   Grant AJ, 2001, GENE, V280, P145, DOI 10.1016/S0378-1119(01)00769-7
   GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001
   GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022
   KOCH C, 1988, P NATL ACAD SCI USA, V85, P4237, DOI 10.1073/pnas.85.12.4237
   Mallik P, 2004, J BACTERIOL, V186, P122, DOI 10.1128/JB.186.1.122-135.2004
   Mawn MV, 2002, J BACTERIOL, V184, P494, DOI 10.1128/JB.184.2.494-502.2002
   Nasser W, 2002, EMBO J, V21, P715, DOI 10.1093/emboj/21.4.715
   Nasser W, 2001, J BIOL CHEM, V276, P17878, DOI 10.1074/jbc.M100632200
   NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x
   NILSSON L, 1992, FEMS MICROBIOL LETT, V99, P85
   NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x
   OSUNA R, 1995, J BACTERIOL, V177, P2021, DOI 10.1128/jb.177.8.2021-2032.1995
   Owens RM, 2001, PROTEIN EXPRES PURIF, V21, P352, DOI 10.1006/prep.2000.1384
   Pfennig PL, 2001, MOL GENET GENOMICS, V266, P313, DOI 10.1007/s004380100559
   Pratt TS, 1997, J BACTERIOL, V179, P6367, DOI 10.1128/jb.179.20.6367-6377.1997
   QI SY, 1995, MOL MICROBIOL, V17, P523, DOI 10.1111/j.1365-2958.1995.mmi_17030523.x
   ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x
   Rowe S, 2000, J BACTERIOL, V182, P2741, DOI 10.1128/JB.182.10.2741-2745.2000
   Savelsbergh A, 2000, J BIOL CHEM, V275, P890, DOI 10.1074/jbc.275.2.890
   Schneider R, 1997, MOL MICROBIOL, V26, P519, DOI 10.1046/j.1365-2958.1997.5951971.x
   Schneider R, 2001, NUCLEIC ACIDS RES, V29, P5107, DOI 10.1093/nar/29.24.5107
   Schneider R, 2000, MOL MICROBIOL, V38, P167, DOI 10.1046/j.1365-2958.2000.02129.x
   Shultzaberger RK, 2001, J MOL BIOL, V313, P215, DOI 10.1006/jmbi.2001.5040
   SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3
   Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044
   Walker KA, 2002, J BACTERIOL, V184, P4783, DOI 10.1128/JB.184.17.4782.4791.2002
   Weinstein-Fischer D, 2000, MOL MICROBIOL, V35, P1413, DOI 10.1046/j.1365-2958.2000.01805.x
   Wendrich TM, 2002, MOL CELL, V10, P779, DOI 10.1016/S1097-2765(02)00656-1
   Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X
   XU JM, 1995, J BACTERIOL, V177, P5222, DOI 10.1128/jb.177.18.5222-5231.1995
   Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1
   Zhang XY, 1996, J MOL BIOL, V259, P27, DOI 10.1006/jmbi.1996.0299
NR 52
TC 47
Z9 48
U1 4
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD AUG 18
PY 2004
VL 23
IS 16
BP 3375
EP 3385
DI 10.1038/sj.emboj.7600343
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 852CK
UT WOS:000223732600019
PM 15297874
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bardin, A
   Hoffmann, P
   Boulle, N
   Katsaros, D
   Vignon, F
   Pujol, P
   Lazennec, G
AF Bardin, A
   Hoffmann, P
   Boulle, N
   Katsaros, D
   Vignon, F
   Pujol, P
   Lazennec, G
TI RETRACTED: Involvement of estrogen receptor beta in ovarian
   carcinogenesis (Retracted article. See vol 65, pg 5480, 2005)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID HUMAN-BREAST-CANCER; ER-BETA; CELL-LINE; CYCLIN D1; DIFFERENTIAL
   EXPRESSION; PROGESTERONE-RECEPTORS; REPLACEMENT THERAPY;
   GENE-EXPRESSION; MESSENGER-RNAS; ALPHA
AB Knockout and expression studies suggest that estrogen receptor beta (ERbeta) plays a prominent role in ovarian function and pathology. Moreover, ovarian cancers are characterized by high morbidity and low responsiveness to anti-estrogens. Here we demonstrate, using quantitative PCR to measure ERalpha and ERbeta levels in 58 ovarian cancer patients, that ERbeta expression decreased in cysts and ovarian carcinomas as compared with normal ovaries and that this decrease is attributable only to a selective loss in ERbeta expression during cancer progression. To address the question of a possible involvement of ERbeta in ovarian cancers, we restored ERalpha and ERbeta expression in two human ovarian cancer cell lines PEO14 (ERalpha-negative) and BG1 (ERalpha-positive) using adenoviral delivery. ERalpha, but not ERbeta, could induce progesterone receptor and fibulin-IC. Moreover, ERalpha and ERbeta had opposite actions on cyclin D1 gene regulation, because ERbeta down-regulated cyclin D1 gene expression, whereas ERalpha increased cyclin D1 levels. Interestingly, ERbeta expression strongly inhibited PEO14 and BG1 cell proliferation and cell motility in a ligand-independent manner, whereas ERalpha had no marked effect. Induction of apoptosis by ERbeta also contributed to the decreased proliferation of ovarian cancer cells, as shown by Annexin V staining. This study shows that ERbeta is an important regulator of proliferation and motility of ovarian cancer and provides the first evidence for a proapoptotic role of ERbeta. The loss of ERbeta expression may thus be an important event leading to the development of ovarian cancer.
C1 INSERM, U540, F-34090 Montpellier, France.
   Hop Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, Montpellier, France.
   Univ Turin, Dept Obstet & Gynecol, I-10124 Turin, Italy.
RP Bardin, A (reprint author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.
EM lazennec@montp.inserm.fr
CR Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739
   Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917
   Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025
   CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965
   Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025
   Copois V, 2003, LAB INVEST, V83, P599, DOI 10.1097/01.LAB.0000062853.92828.20
   Courjal F, 1996, INT J CANCER, V69, P247
   Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328
   Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929
   Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2
   DAY TG, 1975, NATL CANCER I MONOGR, P15
   de Cremoux P, 2002, BIOCHEM PHARMACOL, V64, P507, DOI 10.1016/S0006-2952(02)01187-5
   Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171
   Foley EF, 2000, CANCER RES, V60, P245
   Fuqua SAW, 2003, CANCER RES, V63, P2434
   GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497
   GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N
   Ghahremani M, 1999, MED HYPOTHESES, V52, P23, DOI 10.1054/mehy.1997.0620
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Harris HA, 2001, ENDOCRINOLOGY, V142, P645, DOI 10.1210/en.142.2.645
   HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O
   Havrilesky LJ, 2001, J SOC GYNECOL INVEST, V8, P104, DOI 10.1016/S1071-5576(01)00093-4
   Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677
   Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   LANGDON SP, 1994, J STEROID BIOCHEM, V50, P131, DOI 10.1016/0960-0760(94)90019-1
   Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120
   Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206
   Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787
   Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619
   Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446
   Pujol P, 1998, CANCER RES, V58, P5367
   RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14
   Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460
   Roger P, 2001, CANCER RES, V61, P2537
   Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0
   Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337
   Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4
   SCAMBIA G, 1995, BRIT J CANCER, V72, P361, DOI 10.1038/bjc.1995.339
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682
   Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898
   Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569
   WYSOCKI SJ, 1990, CANCER RES, V50, P1800
   Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936
NR 48
TC 79
Z9 90
U1 6
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2004
VL 64
IS 16
BP 5861
EP 5869
DI 10.1158/0008-5472.CAN-04-0552
PG 9
WC Oncology
SC Oncology
GA 846NH
UT WOS:000223321900046
PM 15313930
OA Bronze
DA 2018-12-27
ER

PT J
AU Jeong, SM
   Koo, WH
   Choi, SH
   Jo, SJ
   Baik, HK
   Lee, SJ
   Song, KM
AF Jeong, SM
   Koo, WH
   Choi, SH
   Jo, SJ
   Baik, HK
   Lee, SJ
   Song, KM
TI RETRACTED: Effects of aluminum cathodes prepared by ion-beam-assisted
   deposition in organic light-emitting devices (Retracted Article. See vol
   88, art. no. 179901, 2006)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID ELECTROLUMINESCENT DEVICES; DIODES; DEGRADATION
AB We have fabricated highly stable organic electroluminescent devices based on spin-coated soluble phenyl-substituted poly-p-phenylene-vinylene (Ph-PPVs) thin films. The electrical properties of aluminum cathode, prepared by ion-beam-assisted deposition, on Ph-PPV have been investigated and compared to those prepared by thermal evaporation. Although energetic particles of Al assisted by Ar+ ion may damage the organic material, I-V-L characteristics are improved by evaporating a thin Al buffer layer prior to ion-beam-assisted deposition. In addition, a dense Al cathode inhibits the permeation of H2O and O-2 into Ph-PPV film by suppressing pinhole defects, and thus retards dark spot growth. This may be deduced from highly packed structure of Al cathode with smaller contact resistance between Al and Ph-PPV. The lifetime of an organic light-emitting device has been extended by dense Al film through an ion-beam-assisted deposition process. (C) 2004 American Institute of Physics.
C1 Yonsei Univ, Dept Engn Met, Seoul 120749, South Korea.
   Kyungsung Univ, Dept Mat Engn, Pusan 608736, South Korea.
   Konkuk Univ, Dept Appl Phys, Chungju 380701, South Korea.
RP Baik, HK (reprint author), Yonsei Univ, Dept Engn Met, Seoul 120749, South Korea.
EM thinfilm@yonsei.ac.kr
CR ANTONIADIS H, 1994, APPL PHYS LETT, V65, P2030, DOI 10.1063/1.112784
   Aziz H, 1997, J PHYS CHEM B, V101, P4009, DOI 10.1021/jp9700488
   BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0
   Do LM, 1996, THIN SOLID FILMS, V273, P209, DOI 10.1016/0040-6090(95)06781-7
   Gu G, 1996, APPL PHYS LETT, V68, P2606, DOI 10.1063/1.116196
   Hung LS, 1999, J APPL PHYS, V86, P4607, DOI 10.1063/1.371410
   Liao LS, 1999, APPL PHYS LETT, V75, P1619, DOI 10.1063/1.124773
   Meier M, 1997, J APPL PHYS, V82, P1961, DOI 10.1063/1.366003
   Papadimitrakopoulos F, 1996, CHEM MATER, V8, P1363, DOI 10.1021/cm960152m
   Parthasarathy G, 2000, APPL PHYS LETT, V76, P2128, DOI 10.1063/1.126275
   Parthasarathy G, 1998, APPL PHYS LETT, V72, P2138, DOI 10.1063/1.121301
   Rothberg LJ, 1996, J MATER RES, V11, P3174, DOI 10.1557/JMR.1996.0403
   Savvateev VN, 1997, APPL PHYS LETT, V71, P3344, DOI 10.1063/1.120332
   Suzuki H, 1996, APPL PHYS LETT, V68, P2276, DOI 10.1063/1.115883
   TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799
NR 15
TC 12
Z9 12
U1 3
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD AUG 9
PY 2004
VL 85
IS 6
BP 1051
EP 1053
DI 10.1063/1.1779348
PG 3
WC Physics, Applied
SC Physics
GA 843TM
UT WOS:000223109500067
DA 2018-12-27
ER

PT J
AU Wada, O
   Oishi, H
   Takada, I
   Yanagisawa, J
   Yano, T
   Kato, S
AF Wada, O
   Oishi, H
   Takada, I
   Yanagisawa, J
   Yano, T
   Kato, S
TI RETRACTED: BRCA1 function mediates a TRAP/DRIP complex through direct
   interaction with TRAP220 (Retracted article. See vol. 33, pg. 804, 2014)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE BRCA1; TRAP220; breast cancer
ID ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; BREAST-CANCER; DNA-REPAIR;
   TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; PROTEIN; GENE;
   SUSCEPTIBILITY; COACTIVATOR
AB Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene mutated in a high percentage of hereditary breast and ovarian cancers. The multifunctional BRCA1 protein acts on cell cycle control, exerting several highly specialized DNA repair processes through diverse domains. Gene regulation through its C-terminal domain (BRCT) is indispensable for BRCA1-mediated tumor suppression, suggesting the possibility that the BRCT domain interacts with co-regulator complexes. Using a biochemical approach with HeLa S3 nuclear extracts, we isolated BRCT-associated complexes and identified one of the purified components as TRAP220. We then performed interaction studies in vivo (co-immunoprecipitation) and in vitro (glutathione S-transferase pull-down assays) and showed that BRCT directly interacted with TRAP220. This in vitro interaction was completely abolished by BRCT point mutations typical of those found in patients with BRCA1 that lack transactivation function. BRCA1 transactivation function was dependent on TRAP220 expression level in a transient expression assay. Moreover, a cell survival assay showed that antisense TRAP220 expression to disrupt endogenous TRAP220 expression significantly reduced the survival rate potentiated by BRCA1 after DNA damage. These results suggested that a TRAP220 complex play an important role as putative co-activator complexes in BRCA1-mediated tumor suppression.
C1 Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Tokyo 1130034, Japan.
   Univ Tokyo, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138655, Japan.
   Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan.
RP Yano, T (reprint author), Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130034, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Anderson SE, 1998, NAT GENET, V19, P254
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9
   Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X
   Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0
   Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354
   Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329
   Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Greenman J, 1998, GENE CHROMOSOME CANC, V21, P244, DOI 10.1002/(SICI)1098-2264(199803)21:3<244::AID-GCC9>3.0.CO;2-#
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820
   Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3
   Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200
   Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595
   Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6
   Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606
   Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020
   Rachez C, 1999, NATURE, V398, P824
   Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388
   Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932
   Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298
   Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747
   Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848
NR 34
TC 31
Z9 31
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 5
PY 2004
VL 23
IS 35
BP 6000
EP 6005
DI 10.1038/sj.onc.1207786
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 841OV
UT WOS:000222941100015
PM 15208681
OA Bronze
DA 2018-12-27
ER

PT J
AU Kato, T
   Hashikabe, H
   Iwata, C
   Akimoto, K
   Hattori, Y
AF Kato, T
   Hashikabe, H
   Iwata, C
   Akimoto, K
   Hattori, Y
TI RETRACTED: Statin blocks Rho/Rho-kinase signalling and disrupts the
   actin cytoskeleton: relationship to enhancement of LPS-mediated nitric
   oxide synthesis in vascular smooth muscle cells (Retracted article. See
   vol. 1812, pg. 1200, 2011)
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article; Retracted Publication
DE statin; nitric oxide; Rho/Rho-kinase; actin cytoskeleton; vascular
   smooth muscle
ID RHO GTPASE; SYNTHASE; INHIBITION; CERIVASTATIN; SUPPRESSES; EXPRESSION;
   INDUCTION
AB We previously demonstrated statins to enhance cytokine-mediated nitric oxide (NO) synthesis in vascular smooth muscle cells (VSMC). To clarify the mechanism by which this occurs, we evaluated the effects of fluvastatin in lipopolysaccharide (LPS)-stimulated VSMC. NO production induced by LPS was dose-dependently enhanced by fluvastatin, as were iNOS mRNA levels and iNOS protein expression. Exogenous mevalonate and geranylgeranylpyrophosphate (GGPP) dampened the stimulatory effect of fluvastatin. A pull-down assay demonstrated fluvastatin to decrease levels of GTP-bound Rho A. Moreover, a Rho-kinase inhibitor, Y-27632, was observed to enhance LPS-induced NO production. We recently demonstrated that disrupting F-actin formation dramatically potentiates the ability of LPS to induce iNOS mRNA and protein expression. In the present study, staining of F-actin with nitrobenzoxadiazole (NBD)-phallacidin demonstrated that fluvastatin significantly impairs F-actin stress fiber formation. In light of these results, the ability of statins to increase NO production is due, at least in part, to their ability to block the biosynthesis of mevalonate, thereby preventing isoprenoid biosynthesis. This inhibits Rho/Rho-kinase signalling and, in turn, disrupts the actin cytoskeleton. Further analysis of the signalling pathway by which the actin cytoskeleton affects iNOS expression might yield new insight into mechanisms of regulation of NO production. (C) 2004 Elsevier B.V. All rights reserved.
C1 Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
   Dokkyo Univ, Sch Med, Mol & Cellular Biol Lab, Mibu, Tochigi 3210293, Japan.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
CR Aji W, 1997, CIRCULATION, V95, P430
   BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036
   Behr D, 1999, ATHEROSCLEROSIS, V142, P335, DOI 10.1016/S0021-9150(98)00254-8
   BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T
   CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512
   CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1
   Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265
   DURANTE W, 1991, AM J PHYSIOL, V261, pH2024
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   GROSS SS, 1992, J BIOL CHEM, V267, P25722
   Hattori Y, 2004, J CARDIOVASC PHARM, V43, P209, DOI 10.1097/00005344-200402000-00007
   Hattori Y, 2002, CARDIOVASC RES, V54, P649, DOI 10.1016/S0008-6363(02)00266-3
   Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459
   Kibbe M, 1999, CARDIOVASC RES, V43, P650, DOI 10.1016/S0008-6363(99)00130-3
   KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827
   Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926
   Muck W, 1999, J INT MED RES, V27, P107
   Rupin A, 1996, BRIT J PHARMACOL, V119, P1233, DOI 10.1111/j.1476-5381.1996.tb16027.x
   Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459
   *SCAND SIMV SURV S, 1994, LANCET, V344, P1383, DOI DOI 10.1016/S0140-6736(94)90566-5
   Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Takeuchi S, 2000, BIOCHEM BIOPH RES CO, V269, P97, DOI 10.1006/bbrc.2000.2238
   THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B
   TSE FLS, 1992, J CLIN PHARMACOL, V32, P630, DOI 10.1002/j.1552-4604.1992.tb05773.x
NR 25
TC 37
Z9 44
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD AUG 4
PY 2004
VL 1689
IS 3
BP 267
EP 272
DI 10.1016/j.bbadis.2004.04.006
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 845ZM
UT WOS:000223284200013
PM 15276654
OA Bronze
DA 2018-12-27
ER

PT J
AU Saitoh, Y
   Hattori, H
   Sanbe, N
   Nakajima, H
   Akatu, M
   Murakawa, M
AF Saitoh, Y
   Hattori, H
   Sanbe, N
   Nakajima, H
   Akatu, M
   Murakawa, M
TI RETRACTED: Reversal of vecuronium with neostigmine in patients with
   diabetes mellitus (Retracted article. See vol. 73, pg. 527, 2018)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE neuromuscular blocking agents, vecuronium; anticholinesterase drugs,
   neostigmine; monitoring, intra-operative; diabetes mellitus
ID INDUCED NEUROMUSCULAR BLOCK; NERVE CONDUCTION VELOCITY; POSTTETANIC
   TWITCH; ATRACURIUM; ANTAGONISM; NEUROPATHY; ISOFLURANE; ANESTHESIA;
   RECOVERY; ROCURONIUM
AB Reversal of vecuronium-induced neuromuscular blockade with neostigmine was compared in two groups of 16 subjects: patients with Type 2 diabetes mellitus and normal controls. When the first twitch of the train-of-four had returned to 25% of the control value, neostigmine 40 mug.kg(-1) and atropine 20 mug.kg(-1) were given to reverse the neuromuscular blockade. The train-of-four ratio was lower at 3 min, 6 min, 9 min, 12 min and 15 min after reversal in the diabetic group than in the control group but the differences did not reach statistical significance. Fifteen minutes after reversal, the number of patients in whom recovery from neuromuscular blockade was judged insufficient to guarantee good respiratory function (train-of-four ratio < 0.74) did not differ between the groups. However, 15 min after reversal, the number of patients with a train-of-four ratio < 0.9 was significantly higher in the Diabetic Group than in the Control Group (15 vs. 10, p = 0.033).
C1 Saitama Med Sch, Dept Anaesthesiol, Saitama, Japan.
   Fukushima Med Univ, Sch Med, Dept Anaesthesiol, Fukushima, Japan.
RP Saitoh, Y (reprint author), Saitama Med Sch, Dept Anaesthesiol, Saitama, Japan.
EM ysys@r5.dion.ne.jp
CR ABUSHAKRA SR, 1991, MUSCLE NERVE, V14, P858, DOI 10.1002/mus.880140910
   ALI HH, 1973, ANESTH ANALG, V52, P740
   BAKER T, 1986, ANESTHESIOLOGY, V65, P480, DOI 10.1097/00000542-198611000-00005
   BAURAIN MJ, 1991, ANESTHESIOLOGY, V74, P474, DOI 10.1097/00000542-199103000-00014
   Baurain MJ, 1996, BRIT J ANAESTH, V77, P496, DOI 10.1093/bja/77.4.496
   Baurain MJ, 1996, ACTA ANAESTH SCAND, V40, P574, DOI 10.1111/j.1399-6576.1996.tb04490.x
   Bennett P.H., 1994, JOSLINS DIABETES MEL, P193
   Bevan JC, 1999, ANESTH ANALG, V89, P333, DOI 10.1097/00000539-199908000-00016
   Boulbou Mary S, 2003, Can Respir J, V10, P259
   DERNOVOI B, 1987, ANESTHESIOLOGY, V66, P698, DOI 10.1097/00000542-198705000-00022
   DONATI F, 1988, Canadian Journal of Anaesthesia, V35, pS52
   Eady J L, 1997, J South Orthop Assoc, V6, P250
   GOLDHILL DR, 1991, ANAESTHESIA, V46, P496, DOI 10.1111/j.1365-2044.1991.tb11696.x
   HORTON JN, 1994, ANAESTHESIA, P1077
   Kirkegaard-Nielsen H, 1999, ACTA ANAESTH SCAND, V43, P834, DOI 10.1034/j.1399-6576.1999.430809.x
   KirkegaardNielsen H, 1995, J CLIN ANESTH, V7, P635, DOI 10.1016/0952-8180(95)00088-7
   Kopman AF, 1997, ANESTHESIOLOGY, V86, P765, DOI 10.1097/00000542-199704000-00005
   KOPMAN AF, 1985, ANESTHESIOLOGY, V63, P208, DOI 10.1097/00000542-198508000-00020
   LAMONTAGNE A, 1970, J NEUROL NEUROSUR PS, V33, P442, DOI 10.1136/jnnp.33.4.442
   LAWRENCE DG, 1961, ARCH NEUROL-CHICAGO, V5, P483, DOI 10.1001/archneur.1961.00450170021003
   LEVINE HJ, 1987, NEW ENGL J MED, V316, P1394
   MORITA T, 1995, ANESTH ANALG, V80, P1175, DOI 10.1097/00000539-199506000-00019
   NESTO RV, 1994, JOSLINS DIABETES MEL, P844
   ROCCA PV, 1993, SEMIN ARTHRITIS RHEU, V22, P280, DOI 10.1016/0049-0172(93)80076-R
   SAITOH Y, 1994, BRIT J ANAESTH, V72, P688, DOI 10.1093/bja/72.6.688
   SAITOH Y, 1993, BRIT J ANAESTH, V71, P443, DOI 10.1093/bja/71.3.443
   Saitoh Y, 2003, BRIT J ANAESTH, V90, P480, DOI 10.1093/bja/aeg089
   SAITOH Y, 1993, BRIT J ANAESTH, V70, P402, DOI 10.1093/bja/70.4.402
   SKILLMAN TG, 1961, DIABETES, V10, P46, DOI 10.2337/diab.10.1.46
   SLYKE MAV, 1995, MAGN RESON IMAGING, V13, P325
   VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x
   WOOLF AL, 1957, J PATHOL BACTERIOL, V73, P316
NR 32
TC 8
Z9 9
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD AUG
PY 2004
VL 59
IS 8
BP 750
EP 754
DI 10.1111/j.1365-2044.2004.03833.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 839RE
UT WOS:000222801500004
PM 15270964
DA 2018-12-27
ER

PT J
AU Simon, LS
AF Simon, LS
TI RETRACTED: The treatment of rheumatoid arthritis (Retracted Article. See
   vol 22, pg AR3, 2008)
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Review; Retracted Publication
DE disease modifying anti-rheumatic drugs; methotrexate; leflunomide;
   sulfasalazine; biological response modifiers; etanercept; infliximab;
   anakinra; adalimumab
ID NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
   PLACEBO-CONTROLLED TRIAL; CHIMERIC MONOCLONAL-ANTIBODY; FC FUSION
   PROTEIN; DOUBLE-BLIND; METHOTREXATE THERAPY; RADIOLOGICAL PROGRESSION;
   PULSE METHOTREXATE; CLINICAL-TRIAL
AB The treatment of rheumatoid arthritis has changed dramatically in the last 10 years and in parallel the definition and expectations of patients and clinicians of the effects of disease-modifying antirheumatic agents has changed as well. Current expectations of efficacy now include improvement of signs and symptoms of disease activity as well as slowing, if not complete inhibition, of disease progression as measured by X-ray progression along with significant improvement in patient physical function. In addition, clinicians assess the safety profile of these agents more critically in an attempt to improve the risk:benefit profile. Drugs, such as methotrexate, sulfasalazine and leflunomide have provided patients with substantial relief of symptoms and improvement in terms of X-ray progression, but they have been hampered by the occurrence of significant adverse events along with the inability to maintain benefit for prolonged periods of time. With the increased understanding of the basic biological mechanisms of the disease process, there has been the introduction of four biological disease modifying therapies and other drugs into clinical practice, which have altered aspects of the risk:benefit ratio for patients with various rheumatic diseases.
C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Simon, LS (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 110 Francis St Suite 48, Boston, MA 02215 USA.
EM lsimon@bidmc.harvard.edu
CR ALARCON GS, 1999, RHEUM ARTHRITIS IDX, V1, P4
   *AM COLL RHEUM SUB, 2002, ARTHRITIS RHEUM, V46, P328, DOI DOI 10.1002/ART.10148
   ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489
   *AUSTR MULT CLIN T, 1992, J RHEUMATOL, V19, P1672
   Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180
   BANNWARTH B, 1995, REV RHUM, V62, P471
   Barrett EM, 2000, RHEUMATOLOGY, V39, P1403, DOI 10.1093/rheumatology/39.12.1403
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   BATHON JM, 2002, ANN RHEUMATIC DIS, V61
   BAX DE, 1985, ANN RHEUM DIS, V44, P194, DOI 10.1136/ard.44.3.194
   Bloom BJ, 2000, ARTHRITIS RHEUM, V43, P2606, DOI 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X
   BOERBOOMS AMT, 1988, CLIN RHEUMATOL, V7, P249, DOI 10.1007/BF02204463
   Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7
   BORIGINI MJ, 2001, RHEUMATOID ARTHRITIS
   Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2
   Brion PH, 1999, ANN INTERN MED, V131, P634, DOI 10.7326/0003-4819-131-8-199910190-00031
   BROOKS P, 1997, PRIMER RHEUMATIC DIS
   Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679
   BURMEISTER GR, 2002, ARTHRITIS RHEUMATISM, V46
   Butler DM, 1995, EUR CYTOKINE NETW, V6, P225
   CANNON GW, 2002, ARTHRITIS RHEUMATISM, V46
   Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D
   CHIN JE, 1990, ARTHRITIS RHEUM, V33, P1776, DOI 10.1002/art.1780331204
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141
   DINARELLO CA, 2001, PROINFLAMMATORY ANTI
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   DROSOS AA, 1990, CLIN RHEUMATOL, V9, P342, DOI 10.1007/BF02114394
   Ellerin T, 2003, ARTHRITIS RHEUM, V48, P3013, DOI 10.1002/art.11301
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9
   ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362
   EMERY P, 1999, ANN RHEUM DIS, V59, pS133
   *FDA, 2001, KIN AN FDA BRIEF INF
   FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003
   FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602
   FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001
   Fleischmann R, 2002, DRUG SAFETY, V25, P173, DOI 10.2165/00002018-200225030-00004
   FLEISCHMANN R, 2003, IN PRESS ARTHRITIS R
   FLEISCHMANN R, 2002, CLIN EXPT RHEUMATO S, V27, pS35
   FLEISCHMANN R, 2002, ARTHRITIS RHEUMATISM, V46
   Fleischmann RM, 2002, J RHEUMATOL, V29, P27
   FLEISCHMANN RM, 2003, IN PRESS J RHEUMATOL
   FLEISCHMANN RM, 2001, ANN RHEUM DIS, V60, P172
   FURST D, 2002, ARTHRITIS RHEUMATISM, V46
   Gabriel S, 1998, ARTHRITIS RHEUM, V41, pS132
   Galaria NA, 2000, J RHEUMATOL, V27, P2041
   GalindoRodriguez G, 1997, J RHEUMATOL, V24, P633
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130
   GISPEN JG, 1987, J RHEUMATOL, V14, P74
   GORDON DA, 2001, KELLEYS TXB RHEUMATO
   HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104
   HANRAHAN PS, 1989, BRIT J RHEUMATOL, V28, P147
   HOCHBERG MC, 1990, EPIDEMIOL REV, V12, P247, DOI 10.1093/oxfordjournals.epirev.a036058
   HOLMAN J, 2002, ANN RHEUM DIS S1, V61, P167
   JEURISSEN MEC, 1991, ANN INTERN MED, V114, P999, DOI 10.7326/0003-4819-114-12-999
   Jiang YB, 2000, ARTHRITIS RHEUM, V43, P1001, DOI 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P
   Jones M, 1996, BRIT J RHEUMATOL, V35, P738
   KAVANAUGH A, 2002, ANN RHEUMATIC DIS, V61
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   KEYSTONE E, 2002, ARTHRITIS RHEUMATISM, V46
   KEYSTONE E, 2002, EUR LEAG RHEUM EULAR
   KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L
   KOOPMAN WJ, 2001, ARTHRITIS ALLIED CON
   KREMER J, 2002, ARTHRITIS RHEUMATISM, V46
   Kremer JM, 2002, ANN INTERN MED, V137, P726, DOI 10.7326/0003-4819-137-9-200211050-00007
   Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075
   KREMER JM, 1988, ARTHRITIS RHEUM-US, V31, P577, DOI 10.1002/art.1780310501
   KUZELL WILLIAM C, 1950, CALIFORNIA MED, V73, P476
   LARSEN A, 1999, ANN RHEUM DIS, V59, pS209
   LAWRENCE RC, 1989, J RHEUMATOL, V16, P427
   Lipsky P, 2000, ARTHRITIS RHEUM, V43, pS269
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   LOPEZMENDEZ A, 1993, ARTHRITIS RHEUM, V36, P1364
   Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103
   Lovell DJ, 2003, ARTHRITIS RHEUM, V48, P218, DOI 10.1002/art.10710
   Luukkainen R, 1980, Scand J Rheumatol Suppl, V34, P1
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0
   Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207
   Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
   MANADAN AN, 2002, ARTHRITIS RHEUMATI S, V46
   MCCONKEY B, 1978, AGENTS ACTIONS, V8, P438, DOI 10.1007/BF01968673
   MCCONKEY B, 1980, BRIT MED J, V280, P442, DOI 10.1136/bmj.280.6212.442
   Mellemkjaer L, 1996, EUR J CANCER, V32A, P1753, DOI 10.1016/0959-8049(96)00210-9
   MLADENOVIC V, 1995, ARTHRITIS RHEUM, V38, P1595, DOI 10.1002/art.1780381111
   Mohan N, 2001, ARTHRITIS RHEUM, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Moreland LW, 1996, J RHEUMATOL, V23, P1849
   Moreland LW, 1998, ARTHRITIS RHEUM, V41, pS59
   MORELAND LW, 2002, ANN RHEUMATIC DIS, V61
   MORELAND LW, 2002, ARTHRITIS RHEUMATISM, V46
   NAM MH, 1996, CLIN RES, V41, pA249
   NEUMANN VC, 1983, BRIT MED J, V287, P1099, DOI 10.1136/bmj.287.6399.1099
   NORDSTROM DM, 1987, ANN INTERN MED, V107, P797, DOI 10.7326/0003-4819-107-6-797
   Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578
   ODell JR, 1997, RHEUM DIS CLIN N AM, V23, P779, DOI 10.1016/S0889-857X(05)70360-4
   PETERSON JR, 2002, ANN RHEUMATIC DIS, V61
   PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749
   PINALS RS, 1987, ARTHRITIS RHEUM-US, V30, P473, DOI 10.1002/art.1780300421
   PINALS RS, 1986, ARTHRITIS RHEUM, V29, P1427, DOI 10.1002/art.1780291202
   PINCUS T, 1992, J RHEUMATOL, V19, P1885
   PULLAR T, 1983, BRIT MED J, V287, P1102, DOI 10.1136/bmj.287.6399.1102
   QUINN M, 2002, ARTHRITIS RHEUMATISM, V46
   QUINN MA, 2002, AM COLL RHEUM OCT
   RAU R, 1991, ARTHRITIS RHEUM, V34, P1236, DOI 10.1002/art.1780341006
   RAU R, 1999, 14 EUR LEAG RHEUM EU
   REYKDAL S, 1989, SCAND J RHEUMATOL, V18, P221, DOI 10.3109/03009748909099932
   RICHTER JA, 1980, J RHEUMATOL, V7, P153
   RIES LAG, 2002, SEER CANC STAT REV 1
   RUDERMAN EM, 2003, IN PRESS ANN RHEUMAT
   Russell E, 2000, ARTHRITIS RHEUM, V43, P944, DOI 10.1002/1529-0131(200004)43:4<944::AID-ANR29>3.0.CO;2-Y
   SABATH DF, 2002, ARTHRITIS RHEUMATI S, V46
   SABATH DF, 2002, ANN RHEUM DIS S1, V61, P38
   SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0
   Salfield J, 1998, ARTHRITIS RHEUM, V41, pS57
   Sandoval DM, 1995, BRIT J RHEUMATOL, V34, P49
   Sangha O, 2000, RHEUMATOLOGY, V39, P3, DOI 10.1093/rheumatology/39.suppl_2.3
   SCHIFF M, 2002, ANN RHEUMATIC DIS, V61
   Scott DL, 2001, ANN RHEUM DIS, V60, P913, DOI 10.1136/ard.60.10.913
   Sharp JT, 2000, ARTHRITIS RHEUM, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U
   SHARP JT, 1971, ARTHRITIS RHEUM-US, V14, P706, DOI 10.1002/art.1780140605
   SHERGY WJ, 2002, AM COLL RHEUM OCT
   SHINGU M, 1993, CLIN EXP IMMUNOL, V94, P145
   SIEGEL SA, 1995, CYTOKINE, V7, P15, DOI 10.1006/cyto.1995.1003
   SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21
   SIMLANER S, 2000, 14 EUR LEAG RHEUM EU
   SINCLAIR RJG, 1949, ANN RHEUM DIS, V8, P226, DOI 10.1136/ard.8.3.226
   Slifman NR, 2003, ARTHRITIS RHEUM, V48, P319, DOI 10.1002/art.10758
   Smolen J. S., 1999, Arthritis and Rheumatism, V42, pS82
   Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3
   SPECTOR TD, 1988, CLIN RHEUMATOL, V7, P315, DOI 10.1007/BF02239187
   Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542
   SVARTZ N, 1948, RHEUMATISM, V56, P1
   TAFFET SL, 1983, DIGEST DIS SCI, V28, P833, DOI 10.1007/BF01296907
   THOMPSON RN, 1984, J RHEUMATOL, V11, P760
   TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358
   VANDEPULTE LB, 2002, ARTHRITIS RHEUMATISM, V46
   VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26
   WAGNER CL, 2002, ARTHRITIS RHEUMATI S, V46
   WALLIS WJ, 2002, ARTHRITIS RHEUMATISM, V46
   WEINBLATT ME, 1993, ARTHRITIS RHEUM-US, V36, P613, DOI 10.1002/art.1780360507
   Weinblatt ME, 1999, ARTHRITIS RHEUM, V42, P1322, DOI 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P
   WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697
   WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702
   WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602
   WILLKENS RF, 1990, SEMIN ARTHRITIS RHEU, V20, P76, DOI 10.1016/0049-0172(90)90020-G
   WOLFE F, 1995, BAILLIERE CLIN RHEUM, V9, P619, DOI 10.1016/S1521-6942(05)80012-9
   WOLFE F, 2002, ARTHRITIS RHEUMATISM, V46
   Wooten M D, 2000, Del Med J, V72, P517
   YOCUM DE, 2002, CENT S AM COLL RHEUM
   2002, PACKAGE INSERT ENBRE
   2001, IMPORTANT WARNING
   2002, PACKAGE INSERT REMIC
   2003, PACKAGE INSERT HUMIR
NR 157
TC 10
Z9 11
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6942
EI 1521-1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD AUG
PY 2004
VL 18
IS 4
BP 507
EP 538
DI 10.1016/j.berh.2004.04.005
PG 32
WC Rheumatology
SC Rheumatology
GA 852VW
UT WOS:000223785900005
PM 15301984
DA 2018-12-27
ER

PT J
AU Yang, ZF
   Poon, RT
   To, J
   Ho, DW
   Fan, ST
AF Yang, ZF
   Poon, RT
   To, J
   Ho, DW
   Fan, ST
TI RETRACTED: The potential role of hypoxia inducible factor 1 alpha in
   tumor progression after hypoxia and chemotherapy in hepatocellular
   carcinoma (Retracted article. See vol. 78, pg. 3399, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID HEPATIC STELLATE CELLS; EXPERIMENTAL MELANOMA METASTASIS; ENDOTHELIAL
   GROWTH-FACTOR; IN-VITRO; EFFICACY; GENE; CHEMOEMBOLIZATION; ACTIVATION;
   CISPLATIN; HIF-1-ALPHA
AB This study investigates the possible molecular basis leading to failure in a treatment that is composed of hypoxia and chemotherapy in a rat orthotopic hepatoma model. Hypoxia was induced by hepatic artery ligation, whereas chemotherapeutic effect was achieved by intraportal injection of cisplatin. High-dose sodium salicylate was administered to achieve transcriptional blockade. Significant prolongation of animal survival was observed in the groups receiving hepatic artery ligation with cisplatin or sodium salicylate. Massive tumor cell necrosis and apoptosis were found in the ligation and all of the combined treatment groups. Up-regulation of hypoxia inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) at both mRNA and protein levels were detected in the groups receiving ligation and ligation with cisplatin, whereas a decreased level of von Hippel-Lindau tumor suppressor protein was identified in the group receiving ligation with cisplatin. Sodium salicylate enhanced expression of von Hippel-Lindau tumor suppressor protein but down-regulated HIF-1alpha and VEGF levels after ligation with or without cisplatin. An increased number of activated hepatic stellate cells in the tumors were observed in the ligation and ligation with cisplatin groups, whereas they were greatly reduced by sodium salicylate. In vitro study revealed that under hypoxic condition, both cisplatin and sodium salicylate could remarkably augment P53 and caspase 3 levels. Cisplatin stimulated HIF-1alpha up-regulation, whereas sodium salicylate suppressed HIF-1alpha expression. In conclusion, tumor progression after hypoxia and chemotherapy might be related to up-regulation of HIF-1alpha and subsequent VEGF production, and transcriptional blockade by sodium salicylate could enhance the therapeutic efficacy of hypoxia and chemotherapy.
C1 Univ Hong Kong, Ctr Study Liver Dis, Pokfulam, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China.
RP Poon, RT (reprint author), Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM poontp@hkucc.hku.hk
RI Poon, Ronnie/C-4383-2009; Fan, Sheung Tat/C-4138-2009
CR Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434
   ACKERMAN NB, 1969, SURGERY, V66, P1067
   Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9
   Ando E, 2002, CANCER, V95, P588, DOI 10.1002/cncr.10694
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Cieslik K, 2002, J BIOL CHEM, V277, P49304, DOI 10.1074/jbc.M205030200
   Comerford KM, 2002, CANCER RES, V62, P3387
   Faouzi S, 1999, LAB INVEST, V79, P485
   Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200
   Jelkmann W, 2001, ADV EXP MED BIOL, V502, P169
   Jones MK, 2001, FASEB J, V15, P264, DOI 10.1096/fj.01-0589fje
   Koch S, 2003, BRIT J CANCER, V89, P2133, DOI 10.1038/sj.bjc.6601375
   Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129
   Leung TWT, 2003, J CLIN ONCOL, V21, P652, DOI 10.1200/JCO.2003.04.152
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746
   Liu MY, 2003, CANCER RES, V63, P2675
   Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047
   Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9
   NAGASUE N, 1976, CANCER, V38, P2593, DOI 10.1002/1097-0142(197612)38:6<2593::AID-CNCR2820380654>3.0.CO;2-6
   O'Suilleabhain CB, 2003, BRIT J SURG, V90, P325, DOI 10.1002/bjs.4045
   Olaso E, 1997, HEPATOLOGY, V26, P634, DOI 10.1002/hep.510260315
   Olaso E, 2003, HEPATOLOGY, V37, P674, DOI 10.1053/jhep.2003.50068
   Olive PL, 2000, BRIT J CANCER, V83, P1525, DOI 10.1054/bjoc.2000.1489
   Sangro B, 2002, ONCOLOGY-BASEL, V62, P293, DOI 10.1159/000065059
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Sun X, 2001, GENE THER, V8, P638, DOI 10.1038/sj.gt.3301388
   Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385
   von Pawel J, 2000, J CLIN ONCOL, V18, P1351, DOI 10.1200/JCO.2000.18.6.1351
   Vordermark D, 2003, INT J RADIAT ONCOL, V56, P1184, DOI 10.1016/S0360-3016(03)00289-X
NR 36
TC 47
Z9 56
U1 3
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2004
VL 64
IS 15
BP 5496
EP 5503
DI 10.1158/0008-5472.CAN-03-3311
PG 8
WC Oncology
SC Oncology
GA 842XO
UT WOS:000223038200063
PM 15289360
DA 2018-12-27
ER

PT J
AU Komazawa, N
   Suzuki, A
   Sano, S
   Horie, K
   Matsuura, N
   Mak, TW
   Nakano, T
   Takeda, J
   Kondoh, G
AF Komazawa, N
   Suzuki, A
   Sano, S
   Horie, K
   Matsuura, N
   Mak, TW
   Nakano, T
   Takeda, J
   Kondoh, G
TI RETRACTED: Tumorigenesis facilitated by Pten deficiency in the skin:
   Evidence of p53-Pten complex formation on the initiation phase
   (Retracted Article. See vol 96, pg 377, 2005)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR; MOUSE SKIN; GERMLINE MUTATIONS; TRANSGENIC MICE;
   DNA-DAMAGE; GENE; CANCER; P53; CARCINOGENESIS; EXPRESSION
AB Pten, a tumor suppressor gene, is mutated in various human cancers and in hereditary cancer syndromes, such as Cowden disease. We have previously developed a knockout mouse in which Pten is specifically disrupted in the skin, resulting in hyperproliferation and spontaneous tumorigenesis of the skin keratinocytes. In this study, we further clarified the effects of Pten deficiency in tumorigenesis, by using a two-step model in intact skin of Pten knockout mouse. Although the conventional protocol requires serial exposures to DMBA and TPA, mice deficient for Pten developed skin papilloma within 6 weeks after a single exposure to DMBA, indicating that loss of Pten has a tumor-promoting effect. Serial exposure to DMBA-TPA ointments produced 10-fold more papillomas in the skin of knockout mice than in the wild-type counterpart, suggesting an increased rate of initiation. Therefore, we precisely examined the effect of DMBA. This treatment was highly apoptotic in wild-type mice, whereas the number of apoptotic cells was diminished in Pten-deficient skin. Moreover, primary keratinocytes isolated from Pten-deficient mice were also resistant to the apoptotic effect of DMBA. The status of p53, Pten proteins and downstream targets of p53, such as p21, 14-3-3sigma, and Reprimo, were also examined, and we found that accumulation of p53 protein and up-regulation of p53 targets were delayed in Pten-knockout skin. These observations suggest that Pten is involved in rapid recruitment of p53 in the tumor initiation phase.
C1 Osaka Univ, Dept Social & Environm Med, Suita, Osaka 5650871, Japan.
   Osaka Univ, Dept Dermatol, Grad Sch Med, Suita, Osaka 5650871, Japan.
   Osaka Univ, Dept Pathol, Sch Allied Hlth Sci, Suita, Osaka 5650871, Japan.
   Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan.
   Osaka Univ, Collaborat Res Ctr Adv Sci & Technol, Suita, Osaka 5650871, Japan.
   Akita Univ, Sch Med, Dept Biochem, Akita 0108543, Japan.
   Univ Toronto, Adv Med Discovery Inst, Toronto, ON M5G 2C1, Canada.
RP Kondoh, G (reprint author), Osaka Univ, Dept Social & Environm Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM kondohg@mr-envi.med.osaka-u.ac.jp
CR Ali IU, 2000, JNCI-J NATL CANCER I, V92, P861, DOI 10.1093/jnci/92.11.861
   Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991
   DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z
   DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7
   Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600
   Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973
   Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   MANOHARAN K, 1987, CANCER BIOCHEM BIOPH, V9, P127
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7
   Paez Juan, 2003, Cancer Treat Res, V115, P145
   Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9
   Suzuki A, 2003, CANCER RES, V63, P674
   Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0
   Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5
   Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400
   Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com
   Yamasaki Lili, 2003, Cancer Treat Res, V115, P209
NR 24
TC 8
Z9 9
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2004
VL 95
IS 8
BP 639
EP 643
DI 10.1111/j.1349-7006.2004.tb03322.x
PG 5
WC Oncology
SC Oncology
GA 848RK
UT WOS:000223484600004
PM 15298725
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, G
   Dombkowski, A
   Chuang, L
   Xu, XXS
AF Wang, G
   Dombkowski, A
   Chuang, L
   Xu, XXS
TI RETRACTED: The involvement of XPC protein in the cisplatin DNA damaging
   treatment-mediated cellular response (Retracted Article. See vol 15, pg
   558, 2005)
SO CELL RESEARCH
LA English
DT Article; Retracted Publication
DE XPC; cisplatin DNA-damaging treatment; microarray analysis
ID NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-C; CYCLOBUTANE PYRIMIDINE
   DIMERS; TRANSCRIPTION FACTOR IIH; IN-VIVO; COMPLEX; RECOGNITION; P53;
   RAD23; CELLS
AB Recognition of DNA damage is a critical step for DNA damage-mediated cellular response. XPC is an important DNA damage recognition protein involved in nucleotide excision repair (NER). We have studied the XPC protein in cisplatin DNA damaging treatment-mediated cellular response. Comparison of the microarray data from both normal and XPC-defective human fibroblasts identified 861 XPC-responsive genes in the cisplatin treatment (with minimum fold changegreater than or equal to1.5). The cell cycle and cell proliferation-related genes are the most affected genes by the XPC defect in the treatment. Many other cellular function genes, especially the DNA repair and signal transduction-related genes, were also affected by the XPC defect in the treatment. To validate the microarray data, the transcription levels of some microarray-identified genes were also determined by an RT-PCR based real time PCR assay. The real time PCR results are consistent with the microarray data for most of the tested genes, indicating the reliability of the microarray data. To further validate the microarray data, the cisplatin treatment-mediated caspase-3 activation was also determined. The Western blot hybridization results indicate that the XPC defect greatly attenuates the cisplatin treatment-mediated Caspase-3 activation. We elucidated the role of p53 protein in the XPC protein DNA damage recognition-mediated signaling process. The XPC defect reduces the cisplatin treatment-mediated p53 response. These results suggest that the XPC protein plays an important role in the cisplatin treatment-mediated cellular response. it may also suggest a possible mechanism of cancer cell drug resistance.
C1 Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA.
RP Wang, G (reprint author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave, Detroit, MI 48201 USA.
EM g.wang@wayne.edu
FU NIEHS NIH HHS [P30 ES06639, R01ES09699]
CR Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857
   Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8
   Chang Yih-Hsin, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1030
   Chen ZW, 2003, CARCINOGENESIS, V24, P1111, DOI 10.1093/carcin/bgg051
   Cheo DL, 1999, CANCER RES, V59, P771
   Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697
   Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200
   Friedberg E C, 1999, Prog Exp Tumor Res, V35, P37
   FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779
   Janicijevic A, 2003, DNA REPAIR, V2, P325, DOI 10.1016/S1568-7864(02)00222-7
   Kaufmann WK, 1996, FASEB J, V10, P238
   Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220
   LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0
   Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x
   Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5
   Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923
   Masson C, 2003, P NATL ACAD SCI USA, V100, P616, DOI 10.1073/pnas.023616100
   MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x
   Miyashita H, 2001, ONCOL REP, V8, P1133
   Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166
   Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468
   Sugasawa K, 1996, MOL CELL BIOL, V16, P4852
   Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301
   Takebayashi Y, 2001, CANCER LETT, V174, P115, DOI 10.1016/S0304-3835(01)00690-5
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9
   vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551
   Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7
   Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759
   Wang AJ, 2003, CARCINOGENESIS, V24, P225, DOI 10.1093/carcin/24.2.225
   Wang G, 2001, NUCLEIC ACIDS RES, V29, P1801, DOI 10.1093/nar/29.8.1801
   Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8
   Wijnhoven SWP, 2001, CARCINOGENESIS, V22, P1099, DOI 10.1093/carcin/22.7.1099
   Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4
   Zhou NY, 2003, J MOL BIOL, V332, P337, DOI 10.1016/S0022-2836(03)00793-9
   Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430
NR 40
TC 30
Z9 37
U1 4
U2 14
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD AUG
PY 2004
VL 14
IS 4
BP 303
EP 314
DI 10.1038/sj.cr.7290375
PG 12
WC Cell Biology
SC Cell Biology
GA 853PJ
UT WOS:000223839200005
PM 15353127
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Numazaki, M
AF Fujii, Y
   Numazaki, M
TI RETRACTED: Randomized, double-blind comparison of subhypnotic- dose
   propofol alone and combined with dexamethasone for emesis in parturients
   undergoing cesarean delivery (Retracted article. See vol. 40, pg. 1048,
   2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE vomiting; antiemetic; propofol; dexamethasone; cesarean delivery
ID SPINAL-ANESTHESIA; POSTOPERATIVE NAUSEA; PREVENTION; SECTION;
   METOCLOPRAMIDE; PROPHYLAXIS; DROPERIDOL; CISPLATIN
AB Background: Nausea, retching, and vomiting are common in parturients undergoing cesarean delivery performed under regional anesthesia. Subhypnotic-dose propofol 1.0 mg/kg per hour has been used to reduce the incidence of these emetic symptoms. Dexamethasone has been shown to reduce chemotherapy-induced emesis when added to an antiemetic regimen.
   Objective: The aim of this study was to examine the difference in efficacy and tolerability between subhypnotic-dose propofol 1.0 mg/kg per hour alone and combined with dexamethasone 8 mg for reducing postdelivery emetic episodes in parturients undergoing cesarean delivery.
   Methods: In a randomized, double-blind trial, parturients received IV placebo (saline) or dexamethasone 8 mg followed by a continuous infusion of propofol at subhypnotic dose (1.0 mg/kg per hour) immediately after clamping of the umbilical cord. Intraoperative, postdelivery emetic episodes and safety assessments were performed by an investigator.
   Results: One hundred twenty parturients (mean [SD] age, 29 [5] years; age range, 21-38 years; mean [SD] height, 158 [7] cm; height range, 145-172 cm; mean [SD] body weight, 72 [8] kg; weight range, 54-90 kg) were enrolled in the study, 60 in each treatment group. The treatment groups were comparable with respect to maternal demographics and operative management. The rate of emetic symptoms (nausea, retching, and vomiting) in an intraoperative, postdelivery period was lower in patients who received the combination regimen than in those who received subhypnotic-dose propofol 1.0 mg/kg per hour alone (5% [3/60] vs 20% [12/60], respectively; P = 0.012). No clinically important adverse events attributable to the study drug were observed in either group.
   Conclusion: In the parturients undergoing cesarean delivery performed under spinal anesthesia in this study, the combination of subhypnotic-dose propofol 1.0 mg/kg per hour and dexamethasone 8 mg was more effective than propofol alone for reducing the incidence of postdelivery emetic symptoms. (Clin Ther. 2004;26:1286-1291) Copyright (C) 2004 Excerpta Medica, Inc.
C1 Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AAPRO MS, 1981, NEW ENGL J MED, V305, P520
   BORGEAT A, 1992, ANESTH ANALG, V74, P539
   Cechetto DF, 2001, ANESTH ANALG, V92, P934
   DATTA S, 1982, ANESTHESIOLOGY, V56, P68, DOI 10.1097/00000542-198201000-00019
   FLEISHER LA, 1996, CLIN ANESTH, P443
   Fujii Y, 2001, OTOLARYNG HEAD NECK, V124, P266, DOI 10.1067/mhn.2001.113140
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   Loewen PS, 2000, CAN J ANAESTH, V47, P1008, DOI 10.1007/BF03024875
   LUSSOS SA, 1992, REGION ANESTH, V17, P126
   McCormick C., 2002, ASA NEWSL, V66, P19
   Numazaki M, 2000, ANAESTH INTENS CARE, V28, P262
   Numazaki M, 2003, J CLIN ANESTH, V15, P423, DOI 10.1016/S0952-8180(03)00086-2
   RATRA CK, 1972, BRIT J ANAESTH, V44, P1208, DOI 10.1093/bja/44.11.1208
   SANTOS A, 1984, ANESTH ANALG, V63, P85
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   Shi J J, 1994, Acta Anaesthesiol Sin, V32, P95
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 19
TC 11
Z9 12
U1 1
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD AUG
PY 2004
VL 26
IS 8
BP 1286
EP 1291
DI 10.1016/S0149-2918(04)80129-2
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 853MX
UT WOS:000223832800009
PM 15476909
DA 2018-12-27
ER

PT J
AU Tian, H
   Tenzen, T
   McMahon, AR
AF Tian, H
   Tenzen, T
   McMahon, AR
TI RETRACTED: Dose dependency of Disp1 and genetic interaction between
   Disp1 and other hedgehog signaling components in the mouse (Retracted
   Article. See vol 132, pg 5615, 2005)
SO DEVELOPMENT
LA English
DT Article; Retracted Publication
DE dispatched; sonic hedgehog; patched; hypomorph; mouse; morphogenesis
ID VENTRAL NEURAL-TUBE; TERMINAL CLEAVAGE PRODUCT; PROGENITOR-CELL
   IDENTITY; FLOOR PLATE INDUCTION; HUMAN SONIC HEDGEHOG; INDIAN-HEDGEHOG;
   LONG-RANGE; SPINAL-CORD; CARTILAGE DIFFERENTIATION; CHOLESTEROL
   MODIFICATION
AB Genetic analyses in Drosophila have demonstrated that a transmembrane protein Dispatched (Disp) is required for the release of lipid-modified Hedgehog (Hh) protein from Hh secreting cells. Analysis of Disp1 null mutant embryos has demonstrated that Disp1 plays a key role in hedgehog signaling in the early mouse embryo. Here we have used a hypomorphic allele in Disp1(Disp1(Delta2)), to extend our knowledge of Displ function in Hh-mediated patterning of the mammalian embryo. Through genetic combinations with null afleles of patched 1 (Ptch1), sonic hedgehog (Shh) and Indian hedgehog (Ihh), we demonstrate that Disp1 genetically interacts with Hh signaling components. As Disp1 activity is decreased we see a progressive increase in the severity of hedgehog-dependent phenotypes, which is further enhanced by reducing hedgehog ligand levels. Analysis of neural tube patterning demonstrates a progressive loss of ventral cell identities that most likely reflects decreased Shh signaling as Disp1 levels are attenuated. Conversely, increasing available Shh ligand by decreasing Ptch1 dosage leads to the restoration of ventral cell types in Disp1(Delta2/Delta2) mutants. Together, these studies suggest that Disp1 actively regulates the levels of hedgehog ligand that are available to the hedgehog target field. Further, they provide additional support for the dose-dependent action of Shh signaling in patterning the embryo. Finally, in-vitro studies on Disp1 null mutant fibroblasts indicate that Disp1 is not essential for membrane targeting or release of lipid-modified Shh ligand.
C1 Harvard Univ, Dept Mol & Cellular Biol, The Biolabs, Cambridge, MA 02138 USA.
RP McMahon, AR (reprint author), Harvard Univ, Dept Mol & Cellular Biol, The Biolabs, 16 Divin Ave, Cambridge, MA 02138 USA.
EM amcmahon@mcb.harvard.edu
FU NINDS NIH HHS [NS 33642]
CR ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011
   Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353
   Briscoe J, 2001, CURR OPIN NEUROBIOL, V11, P43, DOI 10.1016/S0959-4388(00)00172-0
   Briscoe J, 1999, NATURE, V398, P622
   Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3
   BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294
   Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3
   Cai J, 2000, GENESIS, V27, P6, DOI 10.1002/1526-968X(200005)27:1<6::AID-GENE20>3.3.CO;2-F
   Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8
   Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437
   Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611
   Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8
   Ding Q, 1998, DEVELOPMENT, V125, P2533
   Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2
   Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0
   Ericson J, 1997, COLD SPRING HARB SYM, V62, P451
   FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4
   Gallet A, 2003, DEV CELL, V4, P191, DOI 10.1016/S1534-5807(03)00031-5
   Gao B, 2001, NAT GENET, V28, P386, DOI 10.1038/ng577
   Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301
   Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647
   Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467
   Hu D, 1999, DEVELOPMENT, V126, P4873
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541
   Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178
   Kume T, 2000, MOL CELL BIOL, V20, P1419, DOI 10.1128/MCB.20.4.1419-1425.2000
   Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7
   MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0
   MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645
   Matise MP, 1998, DEVELOPMENT, V125, P2759
   McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045
   McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2
   Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403
   Muenke M, 2000, CURR OPIN GENET DEV, V10, P262, DOI 10.1016/S0959-437X(00)00084-8
   Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9
   Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479
   Pabst O, 2000, DEV GENES EVOL, V210, P47, DOI 10.1007/PL00008188
   Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181
   Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037
   PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443
   Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4
   Rallu M, 2002, DEVELOPMENT, V129, P4963
   ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6
   SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823
   St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9
   St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Takebayashi H, 2000, MECH DEVELOP, V99, P143, DOI 10.1016/S0925-4773(00)00466-4
   Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wallis DE, 1999, MOL GENET METAB, V68, P126, DOI 10.1006/mgme.1999.2895
   Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702
   WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75
   YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V
   Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648
   Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898
   Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3
NR 63
TC 22
Z9 22
U1 3
U2 12
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD AUG
PY 2004
VL 131
IS 16
BP 4021
EP 4033
DI 10.1242/dev.01257
PG 13
WC Developmental Biology
SC Developmental Biology
GA 851OL
UT WOS:000223694300019
PM 15269168
OA Bronze
DA 2018-12-27
ER

PT J
AU De Monte, VE
   Geffen, GM
   May, CR
   McFarland, K
AF De Monte, VE
   Geffen, GM
   May, CR
   McFarland, K
TI RETRACTED: Double cross-validation and improved sensitivity of the rapid
   screen of mild traumatic brain injury (Retracted Article. See vol 29, pg
   904, 2007)
SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY
LA English
DT Article; Retracted Publication
ID MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; STANDARDIZED ASSESSMENT;
   POSTTRAUMATIC AMNESIA; AUSTRALIAN RULES; FOOTBALL PLAYERS; CONCUSSION;
   RECOVERY
AB This study aimed to replicate and cross-validate the Rapid Screen of Concussion (RSC) for diagnosing mild TBI (mTBI). One hundred (81 male, 19 female) cases of mTBI and 35 (23 male and 12 female) cases of orthopaedic injuries were tested within 24 hr of injury. Double cross-validation was used to examine whether total RSC scores obtained in the cur-rent sample, generalised to one previously reported. In the new sample, mTBI patients answered fewer orientation questions, recalled fewer words on the learning trial and after a delay, judged fewer sentences in 2 min, and completed fewer symbols in the Digit Symbol Substitution Test than orthopaedic controls. The formulae and cut-offs developed on the original and new samples produced similar sensitivity and overall correct classification rates. Inclusion of the Digit Symbol Substitution Test performance of the new sample improved the sensitivity (80.2%) and specificity (82.6%) in males. It did not improve the correct classification rate in females, which was 89.5% sensitivity and 91.7% specificity before the inclusion of the Digit Symbol Substitution Test. Taken together, these results indicate that a combined score on this 12-min screen yields a measure of level of brain impairment up to 24 hr after mTBI.
C1 Univ Queensland, Cognit Psychophysiol Lab, St Lucia, Qld 4067, Australia.
   Royal Brisbane Hosp, Dept Emergency Med, Brisbane, Qld 4029, Australia.
   Univ Queensland, Sch Psychol, Brisbane, Qld, Australia.
RP De Monte, VE (reprint author), Sch Med, Cognit Psychophysiol Lab, Edith Cavell Bldg,Herston Rd, Brisbane, Qld 4006, Australia.
EM comerf@psy.uq.edu.au
CR ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912
   Baddeley A. D, 1992, SPEED CAPACITY LANGU
   BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008
   Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964
   Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044
   FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969
   FORRESTER G, 1995, J FARR SERVICES POST
   GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367
   Hillier SL, 1997, BRAIN INJURY, V11, P649
   Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945
   HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857
   KAY T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010
   KRAUS JF, 1989, MILD HEAD INJURY, P8
   LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234
   Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584
   MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439
   McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586
   McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005
   McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171
   Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066
   SHORES EA, 1986, MED J AUSTRALIA, V144, P569
   Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x
   Trenerry M.R., 1989, STROOP NEUROPSYCHOLO
   Wechsler D, 1981, WECHSLER ADULT INTEL
   WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774
NR 25
TC 17
Z9 17
U1 5
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1380-3395
EI 1744-411X
J9 J CLIN EXP NEUROPSYC
JI J. Clin. Exp. Neuropsychol.
PD AUG
PY 2004
VL 26
IS 5
BP 628
EP 644
DI 10.1080/13803390490504443
PG 17
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA 862HE
UT WOS:000224480800005
PM 15370385
DA 2018-12-27
ER

PT J
AU Melendez, AJ
   Ibrahim, FBM
AF Melendez, AJ
   Ibrahim, FBM
TI RETRACTED: Antisense knockdown of sphingosine kinase 1 in human
   macrophages inhibits C-5a receptor-dependent signal transduction, Ca2+
   signals, enzyme release, cytokine production, and chemotaxis (Retracted
   article. See vol. 190, pg. 3005, 2013)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; FC-GAMMA-RI; HUMAN MAST-CELLS;
   FUNCTIONAL-CHARACTERIZATION; CALCIUM MOBILIZATION; C5A ANAPHYLATOXIN;
   MOLECULAR-CLONING; T-LYMPHOCYTES; C3A RECEPTOR; HL-60 CELLS
AB The anaphylatoxin C5a is produced following the activation of the complement system and is associated with a variety of pathologies, including septic shock and adult respiratory distress syndrome, and with immune complex-dependent diseases such as rheumatoid arthritis. C5a has been shown to regulate inflammatory functions by interacting with its receptor, C5aR, which belong to the rhodopsin family of seven-transmembrane GPCRs. However, the intracellular signaling pathways triggered by C5aR on immune-effector cells are not well understood. In this report we present data showing that, in human monocyte-derived macrophages, C5aR uses the intracellular signaling molecule sphingosine kinase (SPHK)1 to trigger various physiological responses. Our data show that C5a rapidly stimulates the generation of sphingosine-1-phosphate, SPHK activity, and membrane translocation of SPHK1. Using an antisense oligonucleotide against SPHK1, we show that knockdown of SPHK1 abolishes the C5a-triggered intracellular Ca2+ signals, degranulation, cytokine generation, and chemotaxis. Our study shows for the first time that SPHK1 not only plays a key role in the generation and release of proinflammatory mediators triggered by anaphylatoxins from human macrophages but is also involved in the process of immune cell motility, thus pointing out SPHK1 as a potential therapeutic target for the treatment of inflammatory and autoimmune diseases.
C1 Natl Univ Singapore, Dept Physiol, Singapore 117597, Singapore.
RP Melendez, AJ (reprint author), Natl Univ Singapore, Dept Physiol, 2 Med Dr,MD9 Room 01-05, Singapore 117597, Singapore.
EM phsmraj@nus.edu.sg
CR Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994
   AREND WP, 1989, J IMMUNOL, V142, P173
   Bless NM, 1998, AM J PATHOL, V153, P1113, DOI 10.1016/S0002-9440(10)65655-6
   BOMFELDT KE, 1995, J CELL BIOL, V130, P193
   BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002
   CAVAILLON JM, 1990, EUR J IMMUNOL, V20, P253, DOI 10.1002/eji.1830200204
   CHENOWETH DE, 1982, J EXP MED, V156, P68, DOI 10.1084/jem.156.1.68
   Choi OH, 1996, NATURE, V380, P634
   COOPER NR, 1999, INFLAMMATION BASIC P, P281
   Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512
   Devaraj S, 2001, J LIPID RES, V42, P521
   DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165
   DiScipio RG, 1999, J IMMUNOL, V162, P1127
   Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594
   GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0
   HANNUN YA, 1994, J BIOL CHEM, V269, P3125
   HARKIN DG, 1994, CELL BIOL INT, V18, P177, DOI 10.1006/cbir.1994.1059
   Hartmann K, 1997, BLOOD, V89, P2863
   HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5
   Heller T, 1999, J IMMUNOL, V163, P985
   Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896
   KELLER HU, 1983, CELL MOTIL CYTOSKEL, V3, P47, DOI 10.1002/cm.970030105
   Kirchhoff K, 2001, IMMUNOLOGY, V103, P210, DOI 10.1046/j.1365-2567.2001.01197.x
   KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3
   Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200
   MacKinnon AC, 2002, J IMMUNOL, V169, P6394, DOI 10.4049/jimmunol.169.11.6394
   MARDER SR, 1985, J IMMUNOL, V134, P3325
   Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199
   Matsumoto K, 1999, CLIN EXP IMMUNOL, V117, P361, DOI 10.1046/j.1365-2249.1999.00975.x
   Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5
   Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393
   Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5
   Melendez AJ, 1999, IMMUNOLOGY, V96, P457
   Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200
   Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3
   Mohr M, 1998, EUR J CLIN INVEST, V28, P227
   Nataf S, 1999, J IMMUNOL, V162, P4018
   Niwa M, 2000, LIFE SCI, V66, P245
   OKUSAWA S, 1987, J IMMUNOL, V139, P2635
   OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443
   OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589
   Pellas TC, 1998, J IMMUNOL, V160, P5616
   Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1
   Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338
   SMEDEGARD G, 1989, AM J PATHOL, V135, P489
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506
   WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955
   Werfel T, 2000, J IMMUNOL, V165, P6599, DOI 10.4049/jimmunol.165.11.6599
   Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651
   Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196
   Yang D, 2000, J IMMUNOL, V165, P2694, DOI 10.4049/jimmunol.165.5.2694
   Zhang XQ, 2004, J LEUKOCYTE BIOL, V75, P358, DOI 10.1189/jlb.0903412
   ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34
   ZWIMER J, 1999, IMMUNOLOGY, V97, P166
NR 57
TC 80
Z9 85
U1 3
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 1
PY 2004
VL 173
IS 3
BP 1596
EP 1603
DI 10.4049/jimmunol.173.3.1596
PG 8
WC Immunology
SC Immunology
GA 839TF
UT WOS:000222807100014
PM 15265887
OA Bronze
DA 2018-12-27
ER

PT J
AU Carlson, MA
   Longaker, MT
   Thompson, JS
AF Carlson, MA
   Longaker, MT
   Thompson, JS
TI RETRACTED: Modulation of FAK, Akt, and p53 by stress release of the
   fibroblast-populated collagen matrix (Retracted Article. See vol 121, pg
   151, 2004)
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 2001 Surgical Forum
CY 2001
CL New Orleans, LA
DE fibroblast populated collagen matrix; focal adhesion kinase; protein
   kinase B; Akt; p53; mdm2; p21
ID FOCAL ADHESION KINASE; JUN NH2-TERMINAL KINASE; EXTRACELLULAR-MATRIX;
   DERMAL FIBROBLASTS; GRANULATION-TISSUE; TRIGGERS APOPTOSIS; SURVIVAL
   SIGNALS; CONTRACTION; QUIESCENCE; CELLS
AB Background. Fibroblast survival in a three-dimensional collagen matrix is dependent in part upon the rigid anchorage of the matrix to tissue culture plastic. We hypothesized that focal adhesion kinase (FAK) and protein kinase B (Akt) would be activated and that the p53 level would be low in the rigidly anchored (attached) collagen matrix; loss of anchorage (detachment) was hypothesized to have the opposite effects.
   Materials and methods. Human foreskin fibroblasts were cultured in attached bovine collagen matrices for 48 h before detachment as free-floating matrices. At various time points postrelease, matrix lysates were blotted for the proteins of interest, and the terminal deoxynucleotidyltransferase-mediated dUTP nick-end label assay was performed on both whole matrices and cytospin preparations. Irradiated monolayer fibroblasts were used as positive controls for the amount of p53 protein.
   Results. Terminal deoxynucleotidyltransferase-mediated dUTP nick-end label positivity in attached versus detached matrices (at 24 h post detachment) was 0.7 +/- 03 versus 5.3 +/- 1.7% (P < 0.05, unpaired t test). FAK and Akt were phosphorylated (activated) in the attached matrix; there was a near complete of loss of both activated forms within 4 h of matrix detachment. Irradiated monolayer fibroblasts had increased levels of p53, mdm2, and p21. In contrast, the p53, mdm2, and p21 levels were just at the level of detection in the attached matrix, but were induced 5- to 10-fold within 2-4 h after matrix detachment.
   Conclusions. FAK and Akt are activated in the attached fibroblast-populated collagen matrix whereas the p53 level is relatively low; matrix detachment downregulates FAK and Akt activity and induces p53. The state of mechanical anchorage of the collagen matrix regulates the survival of embedded fibroblasts through a mechanism which may involve FAK. (C) 2004 Elsevier Inc. All rights reserved.
C1 VA Med Ctr, Omaha, NE 68105 USA.
   Univ Nebraska, Dept Surg, Ctr Med, Omaha, NE 68182 USA.
   Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
RP Carlson, MA (reprint author), VA Med Ctr, Surg 112,4104 Woolworth Ave, Omaha, NE 68105 USA.
EM macarlso@unmc.edu
FU NIGMS NIH HHS [K08 GM 00703]
CR Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741
   BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x
   BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366
   Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2
   Carlson MA, 2001, ANN PLAS SURG, V46, P36, DOI 10.1097/00000637-200101000-00007
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   Clark R. A. F., 1996, MOL CELLULAR BIOL WO
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   DELVOYE P, 1991, J INVEST DERMATOL, V97, P898, DOI 10.1111/1523-1747.ep12491651
   DESMOULIERE A, 1995, AM J PATHOL, V146, P56
   DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4
   Eastwood M, 1996, J CELL PHYSIOL, V166, P33, DOI 10.1002/(SICI)1097-4652(199601)166:1<33::AID-JCP4>3.0.CO;2-H
   Ehrlich HP, 2003, METH MOLEC MED, V78, P277
   Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x
   Fringer J, 2003, J BIOL CHEM, V278, P20612, DOI 10.1074/jbc.M212365200
   Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200
   Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440
   GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401
   Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6
   Ilic D, 1998, J CELL BIOL, V143, P547
   Komarova EA, 1997, CANCER RES, V57, P5217
   Linke SP, 1997, CANCER RES, V57, P1171
   MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026
   McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901
   MEREDITH JE, 1993, MOL BIOL CELL, V4, P953
   NAKAGAWA S, 1989, J INVEST DERMATOL, V93, P792, DOI 10.1111/1523-1747.ep12284425
   Niland S, 2001, J INVEST DERMATOL, V116, P686, DOI 10.1046/j.1523-1747.2001.01342.x
   Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088
   Sambrook J., 2001, MOL CLONING LAB MANU
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2
   Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200
   Varedi M, 2000, BIOCHEM CELL BIOL, V78, P427, DOI 10.1139/bcb-78-4-427
   Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9
   Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050
NR 36
TC 20
Z9 20
U1 3
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2004
VL 120
IS 2
BP 171
EP 177
DI 10.1016/j.jss.2003.12.002
PG 7
WC Surgery
SC Surgery
GA 835RX
UT WOS:000222504300002
PM 15234210
DA 2018-12-27
ER

PT J
AU Ohkusu-Tsukada, K
   Tominaga, N
   Udono, H
   Yui, K
AF Ohkusu-Tsukada, K
   Tominaga, N
   Udono, H
   Yui, K
TI RETRACTED: Regulation of the maintenance of peripheral T-cell anergy by
   TAB1-mediated p38 alpha-activation (Retracted Article. See vol 25, pg
   8763, 2005)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID PROTEIN-KINASE ACTIVATION; P38 MAP KINASE; IN-VIVO; SIGNAL-TRANSDUCTION;
   CLONAL ANERGY; TYROSINE PHOSPHORYLATION; GENE-TRANSCRIPTION; IL-10
   PRODUCTION; TAK1 MAPKKK; RECEPTOR
AB In anergic T cells, T-cell receptor (TCR)-mediated responses are functionally inactivated by negative regulatory signals whose mechanisms are poorly understood. Here, we show that CD4(+) T cells anergized in vivo by superantigen Mls-1(a) express a scaffolding protein, transforming growth factor beta-activated protein kinase 1-binding protein 1 (TAB1), that negatively regulates TCR signaling through the activation of mitogen-activated protein kinase p38alpha. TAB1 was not expressed in naive and activated CD4(+) T cells. Inhibition of p38 activity in anergic T cells by a chemical inhibitor resulted in the recovery of interleukin 2 (IL-2) and the inhibition of IL-10 secretion. T-cell hybridoma 2B4 cells transduced with TAB1-containing retrovirus (TAB1-2B4 cells) showed activated p38alpha, inhibited extracellular signal-regulated kinase (ERK) activity, culminating in reduced IL-2 levels and increased IL-10 production. The use of a p38 inhibitor or cotransfection of a dominant-negative form of p38 in TAB1-2B4 cells resulted in the recovery of ERK activity and IL-2 production. These results imply that TAB1-mediated activation of p38alpha in anergic T cells regulates the maintenance of T-cell unresponsiveness both by inhibiting IL-2 production and by promoting IL-10 production.
C1 Nagasaki Univ, Div Immunol, Dept Translat Med Sci, Grad Sch Biomed Sci, Nagasaki 8528523, Japan.
   Nagasaki Univ, Div Med Virol, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan.
   Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528523, Japan.
   RIKEN, Res Ctr Allergy & Immunol, Lab Immunochaperones, Yokohama, Kanagawa 2300045, Japan.
RP Yui, K (reprint author), Nagasaki Univ, Div Immunol, Dept Translat Med Sci, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM katsu@net.nagasaki-u.ac.jp
CR Akdis CA, 2000, FASEB J, V14, P1666
   Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0
   Attinger A, 2000, J IMMUNOL, V165, P1171, DOI 10.4049/jimmunol.165.3.1171
   BHANDOOLA A, 1993, J IMMUNOL, V151, P2355
   Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144
   Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124
   Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940
   Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177
   Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552
   DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017
   Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276
   Foey AD, 1998, J IMMUNOL, V160, P920
   Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289
   Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200
   Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19
   Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603
   KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134
   Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448
   Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4
   Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5
   MIGITA K, 1995, J IMMUNOL, V155, P5083
   Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53
   MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603
   Munder M, 2002, J EXP MED, V196, P1151, DOI 10.1084/jem.20020390
   Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077
   Okamoto N, 2003, BIOCHEM BIOPH RES CO, V310, P691, DOI 10.1016/j.bbrc.2003.09.065
   Powell JD, 1999, J IMMUNOL, V163, P6631
   RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420
   RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0
   SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972
   Sano I, 2001, J HEART LUNG TRANSPL, V20, P583, DOI 10.1016/S1053-2498(00)00324-7
   Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110
   Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179
   Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593
   SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9
   Sundstedt A, 1997, J IMMUNOL, V158, P180
   Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979
   Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0
   Tanchot C, 2001, J IMMUNOL, V167, P2030, DOI 10.4049/jimmunol.167.4.2030
   Telander DG, 1999, J IMMUNOL, V162, P1460
   Tominaga N, 2003, INT IMMUNOL, V15, P1, DOI 10.1093/intimm/dxg001
   Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730
   Udono H, 2001, INT IMMUNOL, V13, P1233, DOI 10.1093/intimm/13.10.1233
   Utting O, 2000, J IMMUNOL, V164, P2881, DOI 10.4049/jimmunol.164.6.2881
   Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001
   YUI K, 1993, J IMMUNOL, V151, P6062
   YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135
   Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200
NR 49
TC 38
Z9 39
U1 4
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2004
VL 24
IS 16
BP 6957
EP 6966
DI 10.1128/MCB.24.16.6957-6966.2004
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 843AF
UT WOS:000223045600007
PM 15282297
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Eskandar, MA
   Sobande, AA
   Damole, IO
   Bahar, AM
AF Eskandar, MA
   Sobande, AA
   Damole, IO
   Bahar, AM
TI RETRACTED: Emergency cervical cerclage - Does the gestational age make a
   difference? (Retracted article)
SO SAUDI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
ID INCOMPETENT CERVIX
AB Objective: To investigate the effectiveness of emergency cervical cerclage in prolongation of pregnancy and its effect on pregnancy outcome in patients with cervical incompetence.
   Methods: A retrospective review of patients who had an emergency cervical cerclage performed for cervical incompetence during the period from July 1995 to June 2002 was carried out in Abha General Hospital, Abha, Kingdom of Saudi Arabia. Twenty patients between 1 6 and 26 weeks of gestation with 1) cervical effacement, 2) cervical dilatation of less than or equal to3 cm, 3) herniation of intact fetal membranes through the cervical os, 4) absence of established labor, and 5) absence of clinical evidence of infection were studied. The duration of cerclage in situ, gestation at delivery and birth weight were analyzed.
   Results: The mean duration of cerclage in situ was 68.5 days. The mean gestation at delivery was 30.5 weeks and the mean birth weight was 1844 grams. The duration of cerclage in situ was significantly longer when the procedure was performed at or before 22 weeks of gestation with a P value of <0.02 (Mann-Whitney U test), but the difference in the gestation at delivery and birth weight was not significant. There was also a significant negative correlation between the gestation at cerclage and the duration of cerclage in situ (Spearman's correlation coefficient r(s) = -0.56, p<0.05).
   Conclusion: Emergency cervical cerclage in early second trimester effectively prolonged pregnancy compared to emergency cerclage performed in late second trimester.
C1 King Khalid Univ, Coll Med, Dept Obstet & Gynecol & Reprod Med, Abha, Saudi Arabia.
   Abha Gen Hosp, Dept Obstet & Gynecol, Abha, Saudi Arabia.
RP Eskandar, MA (reprint author), King Khalid Univ, Coll Med, Dept Obstet & Gynecol & Reprod Med, POB 641, Abha, Saudi Arabia.
EM mamdoheskandar@hotmail.com
CR Aarts J M, 1995, Obstet Gynecol Surv, V50, P459, DOI 10.1097/00006254-199506000-00022
   Althuisius SM, 2000, AM J OBSTET GYNECOL, V183, P823, DOI 10.1067/mob.2000.108874
   Forster F M, 1967, Med J Aust, V2, P807
   GOODLIN RC, 1987, SURG GYNECOL OBSTET, V165, P410
   HEFNER JD, 1961, OBSTET GYNECOL, V18, P616
   Kurup M, 1999, AM J OBSTET GYNECOL, V181, P240, DOI 10.1016/S0002-9378(99)70542-9
   Lefebvre F, 1996, AM J OBSTET GYNECOL, V174, P833, DOI 10.1016/S0002-9378(96)70309-5
   MACDOUGALL J, 1991, BRIT J OBSTET GYNAEC, V98, P1234, DOI 10.1111/j.1471-0528.1991.tb15395.x
   MCDONALD IA, 1957, J OBSTET GYNAECOL, V64, P346
   *MRC RCOG WORK PAR, 1993, FR J OBSTET GYNAECOL, V100, P516
   RATNAVALE M, 1997, OBSTET GYNECOL, V17, P49
   ROMERO R, 1992, AM J OBSTET GYNECOL, V167, P1086, DOI 10.1016/S0002-9378(12)80043-3
   Shirodkar V, 1955, ANTISEPTIC, V52, P299
   THOMASON JL, 1982, J REPROD MED, V27, P187
   WARD RM, 1994, CLIN PERINATOL, V21, P523
NR 15
TC 3
Z9 3
U1 0
U2 7
PU SAUDI MED J
PI RIYADH
PA ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA
SN 0379-5284
J9 SAUDI MED J
JI Saudi Med. J.
PD AUG
PY 2004
VL 25
IS 8
BP 1028
EP 1031
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 851RN
UT WOS:000223702800011
PM 15322593
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Tao, YG
   Tan, YN
   Liu, YP
   Song, X
   Zeng, L
   Gu, HH
   Tang, M
   Li, W
   Yi, W
   Cao, Y
AF Tao, YG
   Tan, YN
   Liu, YP
   Song, X
   Zeng, L
   Gu, HH
   Tang, M
   Li, W
   Yi, W
   Cao, Y
TI RETRACTED: Nuclear factor kappa B (NF kappa B) dependent modulation of
   Epstein-Barr virus latent membrane protein 1 (LMP1) in epidermal growth
   factor receptor (EGFR) promoter activity (Retracted Article. See vol
   106, pg 83, 2004)
SO VIRUS RESEARCH
LA English
DT Article; Retracted Publication
DE latent membrane protein 1; epidermal growth factor receptor; promoter;
   nuclear factor kappa B; nasopharyngeal carcinoma; Epstein-Barr virus;
   inhibitory kappa B alpha; C-terminal activation region-1; (CTAR1);
   CTAR2; tetracycline
ID TERMINAL CYTOPLASMIC DOMAIN; CARCINOMA-CELL LINE; NASOPHARYNGEAL
   CARCINOMA; TRANSFORMING PROTEIN; ACTIVATION; EXPRESSION; GENE;
   TRANSCRIPTION; KINASE; PATHWAY
AB The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) oncoprotein may cause multiple cellular changes, including the induction of epidermal growth factor receptor (EGFR) expression and the activation of the nuclear factor kappa B (NFkappaB) transcription factor. LMP1 p increases the levels of both EGFR protein and mRNA but does not stabilize EGFR mRNA. Thus the effects of LMP1 are likely to be mediated by direct activation of the EGFR promoter. In this study, induction of LMP1 increased the EGFR in both protein and promoter levels in a dose dependent manner using tetracycline-regulated LMP1 expression in nasopharyngeal carcinoma (NPC) cell line. Mutational analysis of the LMP1 protein indicated that the C-terminal activation region-1 (CTAR1) domain was mainly involved in the EGFR promoter induction, while CTAR2 was necessary but not sufficient to induce EGFR promoter. Inhibition of LMP1 mediated NFkappaB activation by constitutive repressive inhibitory kappa B alpha (IkappaBalpha) marginally decreased EGFR promoter activity using transiently transfected IkappaBalpha dominant negative mutant. Promoter mutagenesis analysis demonstrated that two putative NFkappaB binding sites of EGFR promoter were very necessary for the transcriptional activity of EGFR induced by LMP1, the proximal NFkappaB binding site was more important than the distal NFkappaB binding site. Taken together, Epstein-Barr virus latent membrane protein I modulated the EGFR promoter activity in a NFkappaB dependent manner. (C) 2004 Elsevier B.V. All rights reserved.
C1 Cent S Univ, Inst Canc Res, Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China.
RP Cao, Y (reprint author), Cent S Univ, Inst Canc Res, Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China.
EM ycao98@public.cs.hn.cn
RI Cao, Ya/C-6801-2008
CR Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2
   Baselga J, 2002, ONCOLOGIST, V7, P2
   Blake SMS, 2001, VIROLOGY, V282, P278, DOI 10.1006/viro.2001.0828
   Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0
   Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497
   CARLOS LA, 2002, ONCOLOGIST S, V7, P31
   Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344
   Deng L, 2003, CELL RES, V13, P187, DOI 10.1038/sj.cr.7290163
   Devergne O, 1996, MOL CELL BIOL, V16, P7098
   Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410
   Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X
   Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694
   ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x
   Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064
   Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva
   He ZM, 2000, CANCER RES, V60, P1845
   HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207
   HUEN DS, 1995, ONCOGENE, V10, P549
   ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920
   IZUMI KM, 1994, J VIROL, V68, P4369
   Izumi KM, 1999, MOL CELL BIOL, V19, P5759
   Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447
   Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592
   JOHNSON AC, 1988, J BIOL CHEM, V263, P5693
   JOHNSON AC, 1992, J BIOL CHEM, V267, P1689
   Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931
   Johnson AC, 1996, J BIOL CHEM, V271, P3033
   KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016
   KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525
   KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508
   Kaye KM, 1999, J VIROL, V73, P10525
   Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085
   Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478
   Li JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102
   Liao W, 1999, ACTA BIOCH BIOPH SIN, V31, P309
   LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009
   Magne N, 2001, EUR J CANCER, V37, P2169, DOI 10.1016/S0959-8049(01)00280-5
   Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4
   MILLER WE, 1995, J VIROL, V69, P4390
   Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835
   Miller WE, 1997, J VIROL, V71, P586
   MITCHELL T, 1995, J VIROL, V69, P2968
   Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845
   Newby JC, 1997, CLIN CANCER RES, V3, P1643
   Nicholson RI, 2001, EUR J CANCER, V37, pS9
   Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200
   Nishi H, 2003, INT J MOL MED, V11, P49
   Nishi H, 2002, CANCER RES, V62, P827
   Rickinson AB, 1998, NEW ENGL J MED, V338, P1461, DOI 10.1056/NEJM199805143382011
   Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106
   Thornburg NJ, 2003, CANCER RES, V63, P8293
   Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044-579X(02)00090-1
   Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768
   Wu BY, 1997, J VIROL, V71, P3161
   XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0
   Yin LQ, 2001, CHINESE MED J-PEKING, V114, P718
NR 57
TC 3
Z9 4
U1 3
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD AUG
PY 2004
VL 104
IS 1
BP 61
EP 70
DI 10.1016/j.virusres.2004.03.003
PG 10
WC Virology
SC Virology
GA 830ZH
UT WOS:000222162200008
PM 15177893
DA 2018-12-27
ER

PT J
AU Nitz, N
   Gomes, C
   Rosa, AD
   D'Souza-Ault, MR
   Moreno, F
   Lauria-Pires, L
   Nascimento, RJ
   Teixeira, ARL
AF Nitz, N
   Gomes, C
   Rosa, AD
   D'Souza-Ault, MR
   Moreno, F
   Lauria-Pires, L
   Nascimento, RJ
   Teixeira, ARL
TI RETRACTED: Heritable integration of kDNA minicircle sequences from
   Trypanosoma cruzi into the avian genome: Insights into human Chagas
   disease (Retracted article. See vol 122, pg 969, 2005)
SO CELL
LA English
DT Article; Retracted Publication
ID DNA; RABBITS; AMPLIFICATION; RETROTRANSPOSITION; CLASSIFICATION;
   AUTOIMMUNITY; DIAGNOSIS; CELLS
AB We demonstrate the genetic transfer of DNA between eukaryotes from different kingdoms. The mitochondrial kinetoplast DNA (kDNA) of the intracellular parasite Trypanosoma cruzi is transferred to human patients with Chagas disease. This transfer was reproduced experimentally in rabbits and chickens. The kDNA is integrated into the host genome. In the human chromosomes, five loci were identified as integration sites, and the beta-globin locus and LINE-1 retrotransposons were frequently targeted. Short repeated sequences in the parasite and the target host DNAs favor kDNA integration by homologous recombination. Introduced kDNA was present in offspring of chronically infected rabbits and in chickens hatched from T. cruzi-inoculated eggs. kDNA incorporated into the chicken germline was inherited through the F2 generation in the absence of persistent infection. kDNA integration represents a potential cause for the autoimmune response that develops in a percentage of chronic Chagas patients, which can now be approached experimentally.
C1 Univ Brasilia, Fac Med, Chagas Dis Multidisciplinary Res Lab, Brasilia, DF, Brazil.
RP Teixeira, ARL (reprint author), Univ Brasilia, Fac Med, Chagas Dis Multidisciplinary Res Lab, Brasilia, DF, Brazil.
EM ateixeir@unb.br
CR Buckner FS, 1999, INFECT IMMUN, V67, P403
   Campbell DA, 2003, MICROBES INFECT, V5, P1231, DOI 10.1016/j.micinf.2003.09.005
   Chagas C., 1909, Memorias do Instituto Oswaldo Cruz, V1
   Chagas Carlos, 1911, Memorias do Instituto Oswaldo Cruz, V3
   DARWIN C, 1932, BEAGLE, P328
   Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0
   Evans D.A., 1985, Parasitology Today, V1, P172, DOI 10.1016/0169-4758(85)90176-0
   Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2
   Ginsburg M, 1997, POULTRY SCI, V76, P91, DOI 10.1093/ps/76.1.91
   Girones N, 2003, TRENDS PARASITOL, V19, P19, DOI 10.1016/S1471-4922(02)00006-5
   HANNAERT V, 2003, P NATL ACAD SCI USA, V100, P765
   Kagami H, 1997, MOL REPROD DEV, V48, P501, DOI 10.1002/(SICI)1098-2795(199712)48:4<501::AID-MRD11>3.0.CO;2-W
   Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19
   KLEIN J, 2002, WHERE DO WE COME FRO, P67
   Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LAURIAPIRES L, 2000, AM J TROP MED HYG, V63, P43
   Leon JS, 2003, FRONT BIOSCI, V8, pE315, DOI 10.2741/1023
   Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002
   Margulis L, 2002, ACQUIRING GENOMES TH, P25
   Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045
   MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477
   MURTHY VK, 1992, MOL CELL PROBE, V6, P237, DOI 10.1016/0890-8508(92)90022-P
   Penfold LM, 2001, REPRODUCTION, V121, P267, DOI 10.1530/rep.0.1210267
   PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T
   Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2
   PRICE DK, 1992, GENOMICS, V14, P320, DOI 10.1016/S0888-7543(05)80222-8
   REQUENA JM, 1992, MOL BIOCHEM PARASIT, V51, P271, DOI 10.1016/0166-6851(92)90077-W
   Rudi K, 1999, BIOTECHNIQUES, V27, P1170, DOI 10.2144/99276st03
   Sambrook J., 2001, MOL CLONING LAB MANU, P7
   Schenone Hugo, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P231, DOI 10.1590/S0036-46652001000400011
   STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0
   Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5
   Teixeira AR, 1996, MICROORGANISMS AUTOI, P233
   TEIXEIRA ARL, 1978, J CLIN INVEST, V62, P1132, DOI 10.1172/JCI109232
   TEIXEIRA ARL, 1986, AM J PATHOL, V124, P363
   TEIXEIRA ARL, 1983, AM J TROP MED HYG, V32, P258, DOI 10.4269/ajtmh.1983.32.258
   TEIXEIRA ARL, 1990, AM J TROP MED HYG, V43, P146, DOI 10.4269/ajtmh.1990.43.146
   TEIXEIRA ARL, 1994, MUTAT RES, V305, P197, DOI 10.1016/0027-5107(94)90240-2
   Teixeira ARL., 1987, IMMUNE RESPONSES PAR, P125
   TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520
   Vianna Gaspar, 1911, Memorias do Instituto Oswaldo Cruz, V3
NR 42
TC 36
Z9 41
U1 2
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUL 23
PY 2004
VL 118
IS 2
BP 175
EP 186
DI 10.1016/j.cell.2004.07.001
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 841XQ
UT WOS:000222966000007
PM 15260988
OA Bronze
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Nguyen, LT
   Ciric, B
   Flies, D
   Van Keulen, VP
   Tamada, K
   Chen, LP
   Rodriguez, M
   Pease, LR
AF Radhakrishnan, S
   Nguyen, LT
   Ciric, B
   Flies, D
   Van Keulen, VP
   Tamada, K
   Chen, LP
   Rodriguez, M
   Pease, LR
TI RETRACTED: Immunotherapeutic potential of B7-DC (PD-L2) cross-linking
   antibody in conferring antitumor immunity (Retracted article. See vol.
   70, pg. 9528, 2010)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID COLONY-STIMULATING FACTOR; HUMAN DENDRITIC CELLS; T-CELLS; IN-VIVO;
   IFN-GAMMA; TUMOR REJECTION; CUTTING EDGE; MELANOMA; ANTIGEN; ACTIVATION
AB A naturally occurring human antibody potentiates dendritic cell function on cross-linking B7-DC (PD-L2), supporting robust T-cell responses in vitro. Moreover, treatment of dendritic cells with B7-DC cross-linking antibody resulted in secretion of interieukin-12, suggesting a TH1 polarization of this response. Here we show an in vivo immunotherapeutic effect of this B7-DC cross-linking antibody using a poorly immunogenic B16 melanoma tumor model. Treatment of mice systemically with antibody at the time of tumor cell engraftment prevented tumor growth in a CD4 and CD8 T-cell-dependent manner. The protective effect of B7-DC crosslinking antibody treatment was independent of endogenous antibody responses. Tumor-specific CTL precursors could be isolated from lymph nodes draining the tumor site in animals treated with B7-DC cross-linking antibody, but not from those treated with isotype control antibodies. The elicited antitumor responses in vivo were specific and long-lasting. More strikingly, treatment of mice with B7-DC cross-linking antibody after the tumors were established in the lungs resulted in protection in a CD8-, perforin-, and granzyme B-dependent fashion. Depletion of natural killer cells did not block the effects of treatment with B7-DC cross-linking antibody. Together, these findings demonstrate that cross-linking B7-DC with the human IgM antibody sHIgM12 can induce a protective immune response against a weakly antigenic experimental tumor and therefore has potential as a novel immunotherapeutic approach for treating cancer.
C1 Coll Med, Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.
   Coll Med, Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Coll Med, Mayo Clin, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Rodriguez, Moses/0000-0001-6328-6497
CR Agadjanyan MG, 1999, J IMMUNOL, V162, P3417
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119
   Bohm W, 1998, J IMMUNOL, V161, P897
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747
   Chiang EY, 2003, J IMMUNOL, V170, P4515, DOI 10.4049/jimmunol.170.9.4515
   Dobrzanski MJ, 2000, J IMMUNOL, V164, P916, DOI 10.4049/jimmunol.164.2.916
   Hayakawa Y, 2002, J IMMUNOL, V169, P5377, DOI 10.4049/jimmunol.169.10.5377
   Hess SD, 2003, J IMMUNOL, V170, P400, DOI 10.4049/jimmunol.170.1.400
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Kelly JM, 2002, J IMMUNOL, V168, P4472, DOI 10.4049/jimmunol.168.9.4472
   Kim JJ, 1997, NAT BIOTECHNOL, V15, P641
   KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0
   Koopman LA, 2000, J EXP MED, V191, P961, DOI 10.1084/jem.191.6.961
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Liu XL, 2003, J EXP MED, V197, P1721, DOI 10.1084/jem.20022089
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Pardo J, 2002, EUR J IMMUNOL, V32, P2881, DOI 10.1002/1521-4141(2002010)32:10<2881::AID-IMMU2881>3.0.CO;2-K
   Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Shin T, 2003, J EXP MED, V198, P31, DOI 10.1084/jem.200030242
   Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2
   Smyth MJ, 2003, J IMMUNOL, V171, P515, DOI 10.4049/jimmunol.171.2.515
   Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297
   Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823
   Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040
   VanBelle P, 1996, AM J PATHOL, V148, P1887
   vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
   Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820
   Xu DP, 2004, INT J CANCER, V109, P499, DOI 10.1002/ijc.11696
   Yajima T, 2002, INT J CANCER, V99, P573, DOI 10.1002/ijc.10395
   Yamazaki T, 2002, J IMMUNOL, V169, P5538, DOI 10.4049/jimmunol.169.10.5538
NR 37
TC 48
Z9 50
U1 2
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2004
VL 64
IS 14
BP 4965
EP 4972
DI 10.1158/0008-5472.CAN-03-3025
PG 8
WC Oncology
SC Oncology
GA 837XM
UT WOS:000222674700040
PM 15256470
OA Bronze
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Iijima, K
   Kobayashi, T
   Rodriguez, M
   Kita, H
   Pease, LR
AF Radhakrishnan, S
   Iijima, K
   Kobayashi, T
   Rodriguez, M
   Kita, H
   Pease, LR
TI RETRACTED: Blockade of allergic airway inflammation following systemic
   treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody
   (Retracted article. See vol. 184, pg. 6553, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID DENDRITIC CELLS; T-CELLS; MURINE MODEL; IFN-GAMMA; TH2 CELLS; RESPONSES;
   ASTHMA; B7-DC; ACTIVATION; MICE
AB We present a novel immunotherapeutic strategy using a human B7-DC cross-linking Ab that prevents lung inflammation, airway obstruction, and hyperreactivity to allergen in a mouse model of allergic inflammatory airway disease. Dendritic cells (DC) have the ability to skew the immune response toward a Th1 or Th2 polarity. The sHIgM12 Ab functions in vitro by cross-linking the costimulatory family molecule B7-DC (PD-L2) on DC up-regulating IL-12 production, homing to lymph nodes, and T cell-activating potential of these APCs. Using chicken OVA as a model Ag, the administration of sHIgM12 Ab to BALB/c mice blocked lung inflammation, airway pathology, and responsiveness to methacholine, even after animals were presensitized and a Th2-polarized immune response was established. This therapeutic strategy was ineffective in STAT4-deficient animals, indicating that IL-12 production is critical in this system. Moreover, the polarity of the immune response upon in vitro restimulation with Ag is changed in wild-type mice, with a resulting decrease in Th2 cytokines IL-4 and H-5 and an increase in the immunoregulatory cytokine IL-10. These studies demonstrate that the immune response of hypersensitized responders can be modulated using B7-DC cross-linking Abs, preventing allergic airway disease upon re-exposure to allergen.
C1 Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Div Allerg Dis & Internal Med, Dept Internal Med, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Rodriguez, Moses/0000-0001-6328-6497
CR Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439, DOI 10.1289/ehp.99107s3439
   Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561
   Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195
   Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027
   Gajewska Beata U., 2003, Current Drug Targets - Inflammation and Allergy, V2, P279, DOI 10.2174/1568010033484052
   HOLT PG, 1987, IMMUNOLOGY, V62, P349
   Hurez V, 1997, BLOOD, V90, P4004
   JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755
   Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0
   KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Liu XL, 2003, J EXP MED, V197, P1721, DOI 10.1084/jem.20022089
   Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Machida I, 2004, J IMMUNOL, V172, P1833, DOI 10.4049/jimmunol.172.3.1833
   Matsumoto K, 2004, J IMMUNOL, V172, P2530, DOI 10.4049/jimmunol.172.4.2530
   NGUYEN LT, 2002, J EXP MED, V196, P393
   *NIH, 1999, NAT HEART LUNG BLOOD
   Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204
   SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436
   Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415
   Strachan DP, 2000, THORAX S1, V55, pS2
   Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019
   Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942
   Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
   Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255
   Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1081/jem.20030422
   Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210
NR 33
TC 28
Z9 28
U1 3
U2 8
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2004
VL 173
IS 2
BP 1360
EP 1365
DI 10.4049/jimmunol.173.2.1360
PG 6
WC Immunology
SC Immunology
GA 837IA
UT WOS:000222621000077
PM 15240731
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, YM
   Xu, WP
   Qiang, JB
   Wong, CH
   Shek, CH
   Dong, C
AF Wang, YM
   Xu, WP
   Qiang, JB
   Wong, CH
   Shek, CH
   Dong, C
TI RETRACTED: The e/a criterion of Zr-based bulk metallic glasses
   (Retracted article. See vol. 589, pg. 310, 2014)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 11th International Conference on Rapidly Quenched and Metastable
   Materials
CY AUG 25-30, 2002
CL Univ Oxford, Dept Mat, Oxford, ENGLAND
HO Univ Oxford, Dept Mat
DE metallic glasses; quasicrystals; conduction electron; Zr-based alloys
ID ICOSAHEDRAL QUASI-CRYSTAL; TRANSITION-METALS; ALLOYS; NI; PHASES; CU
AB Bulk metallic glasses (BMGs) have been found in many Zr-based multi-component alloys. After discussions on the diffraction characteristics corresponding to the Fermi surfaces-Brillouin zone interaction effect in the Zr-based BMG-related phases, we point out that the 2k(f)approximate tok(p) rule is satisfied when the conduction electron concentration of Zr is 1.5. These BMG- and quasicrystal-related phases, sharing nearly the same conduction electron concentrations per atom (e/a), are e/a-constant phases in a given alloy system. Such an e/a-based criterion is then applied to the Zr-Al-Ni system and a series of BMGs with constant e/a ratio, equal to 1.5, are obtained by suction casting. (C) 2003 Elsevier B.V. All rights reserved.
C1 Dalian Univ Technol, Dept Mat Engn, State Key Lab Mat Modificat, Dalian 116024, Peoples R China.
   City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon, Hong Kong, Peoples R China.
RP Dong, C (reprint author), Dalian Univ Technol, Dept Mat Engn, State Key Lab Mat Modificat, Dalian 116024, Peoples R China.
EM dong@dlut.edu.cn
RI SHEK, Chan Hung/J-3857-2015
OI SHEK, Chan Hung/0000-0002-6870-523X
CR DONG C, 1995, SCRIPTA METALL MATER, V33, P239, DOI 10.1016/0956-716X(95)00149-P
   DONG C, 1986, SCRIPTA METALL MATER, V20, P1155, DOI 10.1016/0036-9748(86)90194-8
   FRIEDEL J, 1988, HELV PHYS ACTA, V61, P538
   INOUE A, 1990, MATER T JIM, V31, P177, DOI 10.2320/matertrans1989.31.177
   Kelton KF, 1997, APPL PHYS LETT, V70, P3230, DOI 10.1063/1.119133
   Kim WJ, 1998, PHILOS MAG A, V78, P1111, DOI 10.1080/01418619808239978
   Koster U, 1996, MATER SCI FORUM, V225, P311
   Koster U, 1996, APPL PHYS LETT, V69, P179, DOI 10.1063/1.117364
   MIEDEMA AR, 1973, J LESS-COMMON MET, V32, P117, DOI 10.1016/0022-5088(73)90078-7
   MIZUTANI U, IN PRESS PROG MAT SC
   MORUZZI VL, 1983, PHYS REV B, V27, P2049, DOI 10.1103/PhysRevB.27.2049
   NAGEL SR, 1975, PHYS REV LETT, V35, P380, DOI 10.1103/PhysRevLett.35.380
   PETTIFOR DG, 1977, J PHYS F MET PHYS, V7, P613, DOI 10.1088/0305-4608/7/4/013
   Saida J, 2001, J MATER RES, V16, P28, DOI 10.1557/JMR.2001.0008
   Shek CH, 2000, MAT SCI ENG A-STRUCT, V291, P78, DOI 10.1016/S0921-5093(00)00979-5
   TAYLOR WH, 1954, ACTA METALL MATER, V2, P684, DOI 10.1016/0001-6160(54)90116-9
   ZHANG T, 1991, MATER T JIM, V32, P1005, DOI 10.2320/matertrans1989.32.1005
NR 17
TC 20
Z9 25
U1 3
U2 12
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD JUL 15
PY 2004
VL 375
SI SI
BP 411
EP 416
DI 10.1016/j.msea.2003.10.215
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA 846QC
UT WOS:000223329700072
DA 2018-12-27
ER

PT J
AU Zhang, JH
   Zhao, YS
AF Zhang, JH
   Zhao, YS
TI RETRACTED: Formation of zirconium metallic glass (Retracted Article. See
   vol 437, pg 1057, 2005)
SO NATURE
LA English
DT Article; Retracted Publication
ID PRESSURE-INDUCED AMORPHIZATION; BCC PHASE-TRANSITION; AMORPHOUS-ALLOYS;
   DECOMPOSITION; ZR; CRYSTALLIZATION; PHONONS; LIQUIDS; MODEL
AB Bulk metallic glasses are commonly produced by the rapid cooling of liquid alloys(1). They have emerged over the past decade as a novel class of materials, with attractive properties and technological promise(1,2). The bulk metallic glasses so far produced contain three or more component elements(3,4). These complex compositions are necessary to frustrate the crystallization of the liquid melt on cooling, but can also lead to phase separation, which is detrimental to the thermal and mechanical properties of metallic glasses(5-8). Here we report, using X-ray diffraction measurements, the formation of a bulk metallic glass from elemental zirconium at high static pressures and low temperatures ( relative to its melting temperature at atmospheric pressure). Amorphous zirconium can be recovered at ambient conditions and demonstrates a superior thermal stability compared to amorphous alloys(3,9), which could lead to new high-temperature applications of amorphous metals.
C1 Los Alamos Natl Lab, LANSCE Div, Los Alamos, NM 87545 USA.
RP Zhang, JH (reprint author), Los Alamos Natl Lab, LANSCE Div, POB 1663, Los Alamos, NM 87545 USA.
EM jzhang@lanl.gov
RI Zhao, Yusheng/B-9448-2018; Lujan Center, LANL/G-4896-2012
OI Zhao, Yusheng/0000-0003-1640-5216; 
CR ASHBY MF, 1986, ENG MAT, V2
   BUSCH R, 1995, APPL PHYS LETT, V67, P1544, DOI 10.1063/1.114487
   Busch R, 1998, MATER SCI FORUM, V269-2, P547, DOI 10.4028/www.scientific.net/MSF.269-272.547
   Busch R, 2000, JOM-J MIN MET MAT S, V52, P39, DOI 10.1007/s11837-000-0160-7
   DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714
   Eckert J, 1998, MATER T JIM, V39, P623, DOI 10.2320/matertrans1989.39.623
   HEIMING A, 1991, PHYS REV B, V43, P10948, DOI 10.1103/PhysRevB.43.10948
   HEMLEY RJ, 1988, NATURE, V334, P52, DOI 10.1038/334052a0
   HIGHMORE RJ, 1989, NATURE, V339, P363, DOI 10.1038/339363a0
   Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6
   JAYARAMAN A, 1963, PHYS REV, V131, P644, DOI 10.1103/PhysRev.131.644
   Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252
   Jona F, 2003, J PHYS-CONDENS MAT, V15, P5009, DOI 10.1088/0953-8984/15/29/312
   Kundig AA, 2001, SCRIPTA MATER, V44, P1269, DOI 10.1016/S1359-6462(01)00691-1
   Loffler JF, 2000, APPL PHYS LETT, V76, P3394, DOI 10.1063/1.126657
   Loffler JF, 2003, INTERMETALLICS, V11, P529, DOI 10.1016/S0966-9795(03)00046-3
   Miller MK, 1998, MAT SCI ENG A-STRUCT, V250, P133, DOI 10.1016/S0921-5093(98)00549-8
   MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0
   Olijnyk H, 1997, PHYS REV B, V56, P10751, DOI 10.1103/PhysRevB.56.10751
   Ostanin SA, 1998, PHYS REV B, V57, P13485, DOI 10.1103/PhysRevB.57.13485
   Pinsook U, 1999, PHYS REV B, V59, P13642, DOI 10.1103/PhysRevB.59.13642
   Richet P, 1997, EUR J MINERAL, V9, P907
   VAUGHAN MT, 1998, REV HIGH PRESSURE SC, V7, P1520
   Wang WH, 2002, INTERMETALLICS, V10, P1249, DOI 10.1016/S0966-9795(02)00140-1
   Weidner D. J., 1992, GEOPHYS MONOGR SER, P13
   XIA H, 1990, PHYS REV LETT, V64, P204, DOI 10.1103/PhysRevLett.64.204
   XIA H, 1991, PHYS REV B, V44, P10374, DOI 10.1103/PhysRevB.44.10374
   Zhao YS, 1999, HIGH PRESSURE RES, V16, P161, DOI 10.1080/08957959908200289
NR 28
TC 36
Z9 38
U1 8
U2 57
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUL 15
PY 2004
VL 430
IS 6997
BP 332
EP 335
DI 10.1038/nature02715
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 837LG
UT WOS:000222631200036
PM 15254533
DA 2018-12-27
ER

PT J
AU Holweg, C
   Nick, P
AF Holweg, C
   Nick, P
TI RETRACTED: Arabidopsis myosin XI mutant is defective in organelle
   movement and polar auxin transport (Retracted Article. See vol 105, pg
   3658, 2008)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE cell elongation; cytoplasmic streaming; plant myosin; trichome
   branching; auxin trafficking
ID UNCONVENTIONAL MYOSINS; TRICHOME MORPHOGENESIS; ENDOPLASMIC-RETICULUM;
   HIGHER-PLANT; HEAVY-CHAIN; HAIR-CELLS; LOCALIZATION; ACTIN;
   MICROFILAMENTS; PROTEIN
AB Myosins are eukaryotic molecular motors moving along actin filaments. Only a small set of myosin classes is present in plants, in which myosins have been found to play a role in cytoplasmic streaming and chloroplast movement. Whereas most studies have been done on green algae, more recent data suggest a role of higher plant myosin at the postcytokinetic cell wall. Here we characterize a loss-of-function mutation for a myosin of plant-specific class X1 and demonstrate myosin functions during plant development in Arabidopsis. T-DNA insertion in MYA2 caused pleiotropic effects, including flower sterility and dwarf growth. Elongation of epidermal cells, such as in hypocotyls and anther filaments, was reduced by up to 50% of normal length. This effect on anther filaments is responsible for flower sterility. In the meristems of root tips, it was evident that cell division was delayed and that cell plates were mislocated. Like zwichel, a kinesin-related mutation causing two-branched trichomes, the mya2 knockout causes branching defects, but here the trichomes remained unbranched. Growth was also impaired in pollen tubes and root hairs, cells that are highly dependent on vesicle transport. A failure in vesicle flow could be directly confirmed, because cytoplasmic streaming of vesicles and, more so, of large endoplasmic reticulumbased organelles was slowed. The defect in vesicle trafficking was accompanied by failures in basipetal auxin transport, measured in stem segments of inflorescences. This result strongly suggests a causal link between auxin-dependent processes and the distribution of vesicles and membrane-bound molecules by plant myosin.
C1 Univ Karlsruhe, Inst Bot 1, D-76128 Karlsruhe, Germany.
RP Holweg, C (reprint author), Univ Karlsruhe, Inst Bot 1, Kaiserstr 2, D-76128 Karlsruhe, Germany.
EM carola.holweg@biologie.uni-freiburg.de
CR ARAROW AS, 1990, ARAB INF SERV, V27, P9
   Baluska F, 2003, TRENDS CELL BIOL, V13, P282, DOI 10.1016/S0962-8924(03)00084-9
   Bezanilla M, 2003, J MOL EVOL, V57, P229, DOI 10.1007/s00239-003-2469-7
   BRADLEY MO, 1973, J CELL SCI, V12, P327
   Chaffey N, 2002, PLANTA, V214, P526, DOI 10.1007/s004250100652
   Fehrenbacher KL, 2003, TRENDS CELL BIOL, V13, P472, DOI 10.1016/S0962-8924(03)00174-0
   Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369-5266(02)00003-1
   Friml J, 2002, PLANT MOL BIOL, V49, P273, DOI 10.1023/A:1015248926412
   Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x
   Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571
   Godbole R, 2000, PLANT BIOLOGY, V2, P176, DOI 10.1055/s-2000-9154
   Hawes C, 2001, TRENDS PLANT SCI, V6, P245, DOI 10.1016/S1360-1385(01)01980-X
   Hodge T, 2000, J CELL SCI, V113, P3353
   HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X
   KINKEMA M, 1994, J MOL BIOL, V239, P591, DOI 10.1006/jmbi.1994.1400
   KINKEMA M, 1994, PLANT MOL BIOL, V26, P1139, DOI 10.1007/BF00040695
   Kwok EY, 2003, PLANT J, V35, P16, DOI 10.1046/j.1365-313X.2003.01777.x
   LIEBE S, 1994, PHYSIOL PLANTARUM, V90, P114, DOI 10.1111/j.1399-3054.1994.tb02200.x
   Liebe S, 1995, BIOL CELL, V85, P207, DOI 10.1016/0248-4900(96)85282-8
   Liu LY, 2001, CELL MOTIL CYTOSKEL, V48, P130, DOI 10.1002/1097-0169(200102)48:2<130::AID-CM1004>3.3.CO;2-P
   MAI GUNTER, 1934, JAHRB WISS BOT, V79, P681
   Mathur J, 1999, DEVELOPMENT, V126, P5559
   Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527
   Molchan TM, 2002, PLANTA, V214, P683, DOI 10.1007/s004250100672
   Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cb.11.110195.003221
   Morimatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P147, DOI 10.1006/bbrc.2000.2391
   NAGAI R, 1979, PLANT PHYSIOL, V10, P45
   Nebenfuhr A, 1999, PLANT PHYSIOL, V121, P1127, DOI 10.1104/pp.121.4.1127
   Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261
   Radford JE, 1998, PLANT J, V14, P743, DOI 10.1046/j.1365-313x.1998.00162.x
   Reddy ASN, 2001, GENOME BIOL, V2
   Reddy ASN, 2000, TRENDS PLANT SCI, V5, P503, DOI 10.1016/S1360-1385(00)01792-1
   Reed RC, 1998, PLANT PHYSIOL, V118, P1369, DOI 10.1104/pp.118.4.1369
   Reichelt S, 1999, PLANT J, V19, P555, DOI 10.1046/j.1365-313X.1999.00553.x
   Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4
   Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601
   Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7
   Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630
   Shimmen T, 2000, PROTOPLASMA, V214, P1, DOI 10.1007/BF02524256
   TANG XJ, 1989, J CELL SCI, V92, P569
   Thimann KV, 1933, P NATL ACAD SCI USA, V19, P714, DOI 10.1073/pnas.19.7.714
   Thompson MV, 2003, J THEOR BIOL, V220, P419, DOI 10.1006/jtbi.2003.3115
   Tominaga M, 2003, EMBO J, V22, P1263, DOI 10.1093/emboj/cdg130
   Waller F, 2002, PROTOPLASMA, V219, P72, DOI 10.1007/s007090200007
   Wang ZY, 2004, CELL MOTIL CYTOSKEL, V57, P218, DOI 10.1002/cm.10168
   Yokota E, 1999, PLANT PHYSIOL, V121, P525, DOI 10.1104/pp.121.2.525
   Yokota E, 2003, PROTOPLASMA, V221, P217, DOI 10.1007/s00709-002-0055-2
   YOKOTA E, 1995, PROTOPLASMA, V185, P178, DOI 10.1007/BF01272858
NR 48
TC 57
Z9 65
U1 5
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 13
PY 2004
VL 101
IS 28
BP 10488
EP 10493
DI 10.1016/pnas.0403155101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 837TR
UT WOS:000222664200044
PM 15240891
DA 2018-12-27
ER

PT J
AU Case, RB
   Chang, YP
   Smith, SB
   Gore, J
   Cozzarelli, NR
   Bustamante, C
AF Case, RB
   Chang, YP
   Smith, SB
   Gore, J
   Cozzarelli, NR
   Bustamante, C
TI RETRACTED: The bacterial condensin MukBEF compacts DNA into a
   repetitive, stable structure (Retracted Article. See vol 307, pg 1409,
   2005)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID MITOTIC CHROMOSOME CONDENSATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS;
   13S CONDENSIN; COMPLEX; PROTEIN; SMC; YEAST; ARCHITECTURE; SEGREGATION
AB Condensins are conserved proteins containing SMC ( structural maintenance of chromosomes) moieties that organize and compact chromosomes in an unknown mechanism essential for faithful chromosome partitioning. We show that MukBEF, the condensin in Escherichia coli, cooperatively compacts a single DNA molecule into a. lament with an ordered, repetitive structure in an adenosine triphosphate (ATP) binding-dependent manner. When stretched to a tension of similar to17 pico-newtons, the. lament extended in a series of repetitive transitions in a broad distribution centered on 45 nanometers. A. lament so extended and held at a lower force recondensed in steps of 35 nanometers or its multiples; this cycle was repeatable even in the absence of ATP and free MukBEF. Remarkably, the pattern of transitions displayed by a given. lament during the initial extension was identical in every subsequent extension. Hence, after being deformed micrometers in length, each. lament returned to its original compact structure without the addition of energy. Incubation with topoisomerase I increased the rate of recondensation and allowed the structure to extend and reform almost reversibly, indicating that supercoiled DNA is trapped in the condensed structure. We suggest a new model for how MukBEF organizes the bacterial chromosome in vivo.
C1 Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
RP Cozzarelli, NR (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
EM ncozzare@socrates.berkeley.edu; carlos@alice.berkeley.edu
OI Bustamante, Carlos/0000-0002-2970-0073
FU NIGMS NIH HHS [GM32543, GM31655]
CR Anderson JD, 2002, MOL CELL BIOL, V22, P7147, DOI 10.1128/MCB.22.20.7147-7157.2002
   Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4
   Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254
   Brower-Toland BD, 2002, P NATL ACAD SCI USA, V99, P1960, DOI 10.1073/pnas.022638399
   BUSTAMANTE C, IN PRESS ANN REV BIO
   Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127
   Graumann PL, 2001, J BACTERIOL, V183, P4052, DOI 10.1128/JB.183.13.4052-4060.2001
   Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4
   GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517
   Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4
   Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302
   Hardy CD, 2004, PHILOS T R SOC B, V359, P39, DOI 10.1098/rstb.2003.1363
   Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0
   HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2
   Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9
   HOWARD J, 2001, MECH MOTOR PROTEINS, P61
   Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996
   Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1
   Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3
   Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200
   Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305
   Lindow JC, 2002, J BACTERIOL, V184, P5317, DOI 10.1128/JB.184.19.5317-5322.2002
   Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498
   Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595
   NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x
   Ohsumi K, 2001, MOL MICROBIOL, V40, P835, DOI 10.1046/j.1365-2958.2001.02447.x
   Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595
   Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397
   Sherratt DJ, 2003, SCIENCE, V301, P780, DOI 10.1126/science.1084780
   Smith SB, 2003, METHOD ENZYMOL, V361, P134
   Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795
   SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819
   Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200
   STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587
   Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271
   Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5
   Trun NJ, 1998, ASM NEWS, V64, P276
   van den Ent F, 1999, STRUCT FOLD DES, V7, P1181, DOI 10.1016/S0969-2126(00)80052-0
   Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x
   Weitao T, 2000, EMBO REP, V1, P494
   Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873
NR 41
TC 32
Z9 34
U1 1
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUL 9
PY 2004
VL 305
IS 5681
BP 222
EP 227
DI 10.1126/science.1098225
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 835QQ
UT WOS:000222501000046
PM 15178751
DA 2018-12-27
ER

PT J
AU de Tayrac, R
   Chevalier, N
   Chauveaud-Lambing, A
   Gervaise, A
   Fernandez, H
AF de Tayrac, R
   Chevalier, N
   Chauveaud-Lambing, A
   Gervaise, A
   Fernandez, H
TI RETRACTED: Risk of urge and stress urinary incontinence at long-term
   follow-up after vaginal hysterectomy (Retracted Article. See vol 192, pg
   3A, 2005)
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Retracted Publication
DE vaginal hysterectomy; urinary incontinence
ID ABDOMINAL HYSTERECTOMY; SYMPTOMS; BLADDER; MENOPAUSE; WOMEN
AB Objective: The purpose of this study was to evaluate the prevalence of urinary symptoms at long-term follow-up after vaginal hysterectomy.
   Study design: One hundred seventeen patients who had a vaginal hysterectomy for menorrhagia from January 1991 to December 2001 answered a self-report questionnaire about de novo urinary symptoms. The control group was a population of 116 patients who had a conservative treatment for dysfunctional uterine bleeding by endometrial thermocoagulation from January 1994 to December 2001.
   Results: Patient characteristics (mean age, mean parity, menopausal status, smoking status, drink habits) were similar in the 2 groups. Mean follow-up was 4.6 +/- 2.2 years (range, 1.5-11 years) after vaginal hysterectomy and 4 +/- 1.8 years (range, 1.5-7 years) after conservative treatment. The prevalence of urinary symptoms, which included urge and stress incontinence, was statistically similar in the 2 groups.
   Conclusion: This study reveals no risk of urge or stress urinary incontinence at long-term follow-up after vaginal hysterectomy, compared with conservative treatment. (C) 2004 Elsevier Inc. All rights reserved.
C1 Hop Antoine Beclere, Serv Gynecol Obstet, Dept Obstet & Gynecol, F-92141 Clamart, France.
RP de Tayrac, R (reprint author), Hop Antoine Beclere, Serv Gynecol Obstet, Dept Obstet & Gynecol, 157 Rue Porte Trivaux, F-92141 Clamart, France.
EM renaud.detayrac@abc.ap-hop-paris.fr
CR Benassi L, 2002, AM J OBSTET GYNECOL, V187, P1561, DOI 10.1067/mob.2002.127596
   Bhattacharya S, 1996, BRIT J OBSTET GYNAEC, V103, P898, DOI 10.1111/j.1471-0528.1996.tb09909.x
   Brown JS, 2000, LANCET, V356, P535, DOI 10.1016/S0140-6736(00)02577-0
   Brown JS, 1996, OBSTET GYNECOL, V87, P715, DOI 10.1016/0029-7844(96)00013-0
   CARLSON KJ, 1994, OBSTET GYNECOL, V83, P556, DOI 10.1097/00006250-199404000-00012
   Cosson M, 2001, EUR J OBSTET GYN R B, V94, P239, DOI 10.1016/S0301-2115(00)00339-0
   DARGENT D, 1980, J GYNECOL OBST BIO R, V9, P895
   GRIFFITHJONES MD, 1991, BRIT J UROL, V67, P295, DOI 10.1111/j.1464-410X.1991.tb15138.x
   Hanley H G, 1969, Br J Urol, V41, P682, DOI 10.1111/j.1464-410X.1969.tb09977.x
   HASSON HM, 1993, J REPROD MED, V38, P781
   Hwang JL, 2002, ACTA OBSTET GYN SCAN, V81, P1132, DOI 10.1034/j.1600-0412.2002.811206.x
   Kovac SR, 2002, AM J OBSTET GYNECOL, V187, P1521, DOI 10.1067/mob.2002.129165
   MILSOM I, 1993, J UROLOGY, V149, P1459, DOI 10.1016/S0022-5347(17)36415-7
   Miskry T, 2003, ACTA OBSTET GYN SCAN, V82, P351, DOI 10.1034/j.1600-0412.2003.00115.x
   PARYS BT, 1990, EUR UROL, V17, P129
   PARYS BT, 1989, BRIT J UROL, V64, P594, DOI 10.1111/j.1464-410X.1989.tb05316.x
   REKERS H, 1992, MATURITAS, V15, P101, DOI 10.1016/0378-5122(92)90244-X
   TAYLOR T, 1990, INT J COLORECTAL DIS, V5, P228, DOI 10.1007/BF00303282
   van der Vaart CH, 2002, BJOG-INT J OBSTET GY, V109, P149, DOI 10.1016/S1470-0328(02)01332-0
   VIRTANEN H, 1993, BRIT J UROL, V72, P868, DOI 10.1111/j.1464-410X.1993.tb16288.x
NR 20
TC 13
Z9 13
U1 4
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUL
PY 2004
VL 191
IS 1
BP 90
EP 94
DI 10.1016/j.ajog.2004.01.031
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 844EB
UT WOS:000223139100013
PM 15295347
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: The recovery profile of reduced diaphragmatic contractility
   induced by propofol in dogs (Retracted article. See vol. 116, pg. 747,
   2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID MUSCLE FATIGUE; HALOTHANE; VOLUNTARY
AB Propofol decreases contractility of the diaphragm, but no data are available for its effects on recovery. We studied the recovery profile of reduced diaphragmatic contractility induced by propofol in dogs. Animals were divided into 4 groups of 7 each. Group I, without fatigue, received only maintenance fluid; Group II, without fatigue, was infused with propofol; Group III, with fatigue, received no study drug; Group IV, with fatigue, was infused propofol. Propofol at an anesthetic dose (0.1 mg/kg initial dose plus 6.0 mg (.) kg(-1) (.) h(-1)) was administered for 60 min. In Groups III and IV, diaphragmatic fatigue was induced by intermittent supra-maximal bilateral electrophrenic stimulation at 20-Hz for 30 min. We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). In group II, Pdi at low-frequency (20-Hz) stimulation decreased to less than baseline (P < 0.05), whereas there was no change in Pdi at high-frequency (100-Hz) stimulation. At 10 min after the end of propofol administration, Pdi at 20-Hz stimulation returned to baseline. When fatigue was established, in Groups III and TV, Pdi at 20-Hz stimulation decreased to less than baseline (P < 0.05), whereas Pdi at 100-Hz stimulation did not change. After administering propofol in Group IV, Pdi at 20-Hz stimulation decreased from fatigued values (P < 0.05). At 20 min after the end of propofol administration, Pdi at 20-Hz stimulation returned to fatigued values. We conclude that reduced contractility in nonfatigued and fatigued canine diaphragm induced by propofol recovers within 20 min after the cessation of administration.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1,Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   DUREUIL B, 1987, J APPL PHYSIOL, V63, P1757
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   Fujii Y, 1999, ANESTH ANALG, V89, P1557, DOI 10.1097/00000539-199912000-00046
   Fujii Y, 2001, ANESTH ANALG, V93, P1194, DOI 10.1097/00000539-200111000-00029
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Moxham J, 1981, Ciba Found Symp, V82, P197
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 14
TC 8
Z9 8
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUL
PY 2004
VL 99
IS 1
BP 113
EP 116
DI 10.1213/01.ANE.0000116927.80080.1E
PG 4
WC Anesthesiology
SC Anesthesiology
GA 832GW
UT WOS:000222256400023
PM 15281514
DA 2018-12-27
ER

PT J
AU Zuo, L
   Ushio-Fukai, M
   Hilenski, LL
   Alexander, RW
AF Zuo, L
   Ushio-Fukai, M
   Hilenski, LL
   Alexander, RW
TI RETRACTED: Microtubules regulate angiotensin II type 1 receptor and Rac1
   localization in caveolae/lipid rafts - Role in redox signaling
   (Retracted article. See vol. 31, pg. E10, 2011)
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE microtubules; angiotensin II; reactive oxygen species; caveolae;
   vascular smooth muscle
ID SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE;
   NAD(P)H OXIDASE; PLASMA-MEMBRANE; RHO GTPASES; TRANSACTIVATION;
   TRANSDUCTION; GLUT4; TRANSLOCATION
AB Objective - Microtubules are important in signal transduction temporal - spatial organization. Full expression of angiotensin II (Ang II) signaling in vascular smooth muscle cells (VSMCs) is dependent on the reactive oxygen species (ROS) derived from nicotinamide-adenine dinucleotide phosphate (NAD(P)H) oxidase and the dynamic association of the Ang II type 1 receptor (AT(1)R) with caveolae/lipid rafts. Translocation of the small GTPase Rac1 to the plasma membrane is an essential step for activation of NAD(P)H oxidase; however, its precise localization in the plasma membrane after agonist stimulation and how it is targeted are unknown. We hypothesized that microtubules are involved in regulating multiphasic Ang II signaling events in VSMC.
   Methods and Results - We show that Ang II promotes Rac1 and AT1R trafficking into caveolae/lipid rafts, which is blocked by disruption of microtubules with nocodazole. As a consequence, nocodazole significantly inhibits Ang II - stimulated H2O2 production, its downstream ROS-dependent epidermal growth factor receptor transactivation, Akt phosphorylation, and vascular hypertrophy without affecting Rac1 activation or ROS-independent extracellular signal-regulated kinase 1/2 phosphorylation.
   Conclusions - These results suggest that proper Rac1 and AT(1)R trafficking into caveolae/lipid rafts requires the integrity of microtubules and provide insight into the essential role of microtubules for the spatial - temporal organization of ROS-dependent and caveolae/lipid rafts-dependent AT(1)R signaling linked to vascular hypertrophy.
C1 Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA.
RP Ushio-Fukai, M (reprint author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,Room 319, Atlanta, GA 30322 USA.
EM mfukai@emory.edu
FU NHLBI NIH HHS [HL60728]
CR Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277
   Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200
   CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421
   Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890
   Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251
   Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901
   Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6
   Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c
   Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132
   Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459
   Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200
   Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200
   Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430
   Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117
   Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419
   Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002
   QUINN MT, 1993, J BIOL CHEM, V268, P20983
   Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954
   Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237
   Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200
   Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489
   Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699
   Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022
   Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081
   Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509
NR 32
TC 37
Z9 41
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUL
PY 2004
VL 24
IS 7
BP 1223
EP 1228
DI 10.1161/01.ATV.0000132400.25045.2a
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 834WR
UT WOS:000222442100015
PM 15142861
OA Bronze
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Yamamoto, M
   Higashimoto, I
   Oonakahara, K
   Watanabe, M
   Machida, K
   Yoshimura, T
   Eiraku, N
   Kawabata, M
   Osame, M
   Arimura, K
AF Matsuyama, W
   Yamamoto, M
   Higashimoto, I
   Oonakahara, K
   Watanabe, M
   Machida, K
   Yoshimura, T
   Eiraku, N
   Kawabata, M
   Osame, M
   Arimura, K
TI RETRACTED: TNF-related apoptosis-inducing ligand is involved in
   neutropenia of systemic lupus erythematosus (Retracted article. See vol.
   112, pg. 3529, 2008)
SO BLOOD
LA English
DT Article; Retracted Publication
ID TRAIL-INDUCED APOPTOSIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES;
   COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; PROGRAMMED
   CELL-DEATH; HUMAN NEUTROPHILS; FAS LIGAND; IFN-GAMMA; INTRACELLULAR
   REGULATION; RHEUMATOID-ARTHRITIS
AB Neutropenia is a common laboratory finding in systemic lupus erythematosus (SLE). However, the molecular mechanism of SLE neutropenia has not been fully explained. In this study, we examined whether TNF-related apopiosis-inducing ligand (TRAIL) is involved in the pathogenesis of SLE neutropenia using samples from SLE patients. Serum TRAIL levels in SLE patients. With neutropenia were significantly higher than those of SLE patients without neutropenia and healthy volunteers. Serum TRAIL levels showed a significant negative correlation with neutrophil counts in SLE patients. The expression of TRAIL receptor 3 was significantly lower 16 SLE patients with neutropenia than in patients without neutropenia or in healthy volunteers. Treatment with glucocorticoids negated the decrease of TRAIL receptor 3 expression on neutrophils of SLE patients. TRAIL may accelerate neutrophil apoptosis of neutrophils from SLE patients, and autologous T cells of SLE patients, which express TRAIL on surface, may kill autologous neutrophils. Interferon gamma and glucocorticoid modulated the expression of TRAIL on T cells of SLE patients and also modulated the expression of cellular Fas-associating protein with death domain-like interleukin-1beta-converting enzyme (FLICE)-inhibitory protein (cFLIP), an inhibitor-of death receptor signaling, in neutrophils. Thus, our results provide a novel insight into the molecular pathogenesis of SLE neutropenia.
C1 Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 8908520, Japan.
   Natl Minami Kyushu Hosp, Dept Resp Med, Kagoshima, Japan.
   Natl Canc Inst, Mol Immunoregulat Lab, Frederick, MD USA.
RP Matsuyama, W (reprint author), Kagoshima Univ, Fac Med, Dept Internal Med 3, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM ega@xa2.so-net.ne.jp
CR ALJANADI M, 1993, J CLIN IMMUNOL, V13, P58, DOI 10.1007/BF00920636
   BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220
   Chatham WW, 2001, LUPUS, V10, P140, DOI 10.1191/096120301675075008
   COLOTTA F, 1992, BLOOD, V80, P2012
   Cox G, 1997, J LEUKOCYTE BIOL, V61, P224
   Csiszar A, 2000, CLIN EXP IMMUNOL, V122, P464, DOI 10.1046/j.1365-2249.2000.01369.x
   DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165
   GINZLER E, 1978, ARTHRITIS RHEUM, V21, P37, DOI 10.1002/art.1780210107
   Griffith TS, 1998, J IMMUNOL, V161, P2833
   HADLEY AG, 1987, BRIT J HAEMATOL, V65, P61, DOI 10.1111/j.1365-2141.1987.tb06136.x
   Hao CH, 2001, CANCER RES, V61, P1162
   Harper L, 2000, AM J PATHOL, V157, P211, DOI 10.1016/S0002-9440(10)64532-4
   HARVEY AM, 1954, MEDICINE, V33, P291, DOI 10.1097/00005792-195412000-00001
   HASLETT C, 1992, CLIN SCI, V83, P639, DOI 10.1042/cs0830639
   Hellmich B, 2002, AM J MED, V113, P134, DOI 10.1016/S0002-9343(02)01161-0
   Hellmich B, 2002, ARTHRITIS RHEUM, V46, P2384, DOI 10.1002/art.10497
   Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314
   Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
   Hsieh SC, 2003, CLIN EXP IMMUNOL, V131, P506, DOI 10.1046/j.1365-2249.2003.02084.x
   Kaplan MJ, 2002, J IMMUNOL, V169, P6020, DOI 10.4049/jimmunol.169.10.6020
   Koene HR, 1998, BLOOD, V91, P3962
   Koene HR, 1996, BRIT J HAEMATOL, V93, P235, DOI 10.1046/j.1365-2141.1996.4971038.x
   Kurien BT, 2000, CLIN EXP IMMUNOL, V120, P209, DOI 10.1046/j.1365-2249.2000.01195.x
   LANDRY M, 1977, ARCH DERMATOL, V113, P147, DOI 10.1001/archderm.113.2.147
   LEE A, 1993, J LEUKOCYTE BIOL, V54, P283
   LEE P, 1977, Q J MED, V46, P1
   Leverkus M, 2000, CANCER RES, V60, P553
   Li JH, 2002, AM J PATHOL, V161, P1485, DOI 10.1016/S0002-9440(10)64424-0
   LILES WC, 1995, BLOOD, V86, P3181
   Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429
   LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M
   Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2
   Matsumura R, 2002, Clin Exp Rheumatol, V20, P791
   Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795
   Mitsiades CS, 2003, J ENDOCRINOL, V178, P205, DOI 10.1677/joe.0.1780205
   Mitsiades N, 2001, TRENDS ENDOCRIN MET, V12, P384, DOI 10.1016/S1043-2760(01)00441-6
   Murray J, 1997, BLOOD, V90, P2772
   NOSSENT JC, 1991, Q J MED, V80, P605
   Palmblad J, 2001, J INTERN MED, V250, P476, DOI 10.1046/j.1365-2796.2001.00915.x
   Palmblad JEW, 2002, SEMIN HEMATOL, V39, P113, DOI 10.1053/shem.2002.31919
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P233, DOI 10.1006/bbrc.2002.6452
   Rauova L, 2002, CLIN IMMUNOL, V103, P69, DOI 10.1006/clim.2002.5194
   Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027
   Ruiz LM, 2002, INFLAMMATION, V26, P215, DOI 10.1023/A:1019714618068
   SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970
   Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200
   STAPLES PJ, 1974, ARTHRITIS RHEUM, V17, P1, DOI 10.1002/art.1780170102
   Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wang SX, 2003, J IMMUNOL, V171, P2789, DOI 10.4049/jimmunol.171.6.2789
   WENGER ME, 1973, J LAB CLIN MED, V82, P513
   WHYTE MKB, 1993, J IMMUNOL, V150, P5124
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   YU CL, 1989, SCAND J RHEUMATOL, V18, P97, DOI 10.3109/03009748909099924
   ZURIER RB, 1976, ARTHRITIS RHEUM, V19, P73, DOI 10.1002/art.1780190112
NR 62
TC 50
Z9 59
U1 2
U2 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUL 1
PY 2004
VL 104
IS 1
BP 184
EP 191
DI 10.1182/blood-2003-12-4274
PG 8
WC Hematology
SC Hematology
GA 832ZZ
UT WOS:000222307500036
PM 15001474
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kawasaki, T
AF Fujii, Y
   Tanaka, H
   Kawasaki, T
TI RETRACTED: Effects of granisetron in the treatment of nausea and
   vomiting after laparoscopic cholecystectomy: A dose-ranging study
   (Retracted article. See vol. 40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE nausea; vomiting; antiemetic; granisetron; laparoscopic cholecystectomy
ID RECEPTOR ANTAGONIST
AB Background: Patients undergoing general anesthesia for laparoscopic cholecystectomy are at high risk for postoperative emetic symptoms (nausea, vomiting, and retching). Antihistamines, butyrophenones, dopamine receptor antagonists, and selective serotonin receptor antagonists (SSRAs) have been investigated for the prevention and treatment of emetic symptoms. However, these drugs are associated with undesirable adverse effects (AEs), such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations, and extrapyramidal signs. Granisetron hydrochloride is a newer SSRA developed for the prevention and treatment of cytotoxic drug-induced emetic symptoms, but its effects in postoperative laparoscopic cholecystectomy have not been studied.
   Objective: The aims of this study were to assess the efficacy and tolerability of 4 doses of granisetron, and to determine the minimum effective dose, for the control of established emetic symptoms in patients undergoing general anesthesia for laparoscopic cholecystectomy
   Methods: This prospective, randomized, double-blind, placebo-controlled, dose-ranging study was conducted in the Departments of Anesthesiology and Surgery, Toride Kyodo General Hospital (Toride, Japan). Male and female patients aged 23 to 68 years with American Society of Anesthesiologists physical status 1 (no organic, physiologic, biochemical, or psychiatric disturbance) who were experiencing nausea lasting >10 minutes or retching or vomiting within 3 hours after recovery from general anesthesia for laparoscopic cholecystectomy were enrolled. Patients were randomized to receive a single IV dose of placebo or granisetron at 1 of 4 doses (10, 20, 40, or 80 mug/kg). Patients were monitored for 24 hours after study drug administration.
   Results: One hundred patients (60 women, 40 men; mean [SD] age, 48 [10] years [range, 23-68 years]; mean [SD] height, 158 [7] cm [range, 145-177 cm]; mean [SD] body weight, 56 [8] kg [range, 43-75 kg]) were enrolled. No significant differences in baseline demographic or clinical characteristics were found between the study groups. The proportions of patients who were free of emetic symptoms were significantly higher with granisetron 20, 40, and 80 mug/kg than with placebo (P = 0.02, 0.007, and 0.007, respectively). The difference between the granisetron 10-mug/kg group and the placebo group was not significant. No clinically significant AEs were reported in any group.
   Conclusions: Granisetron 20 pg/kg was the minimum effective dose for the treatment of established postoperative emetic symptoms in patients undergoing laparoscopic cholecystectomy. Increasing the dose to 80 pg/kg provided no further benefit. Copyright (C) 2004 Excerpta Medica, Inc.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Surg, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   CASSIDY J, 1988, BRIT J CANCER, V58, P651, DOI 10.1038/bjc.1988.278
   FLEISHER LA, 1996, CLIN ANESTH, P443
   Fujii Y, 2000, BRIT J SURG, V87, P285, DOI 10.1046/j.1365-2168.2000.01393.x
   Iitomi T, 1995, Masui, V44, P1627
   McCormick C., 2002, ASA NEWSL, V66, P19
   SANTON JM, 1991, ANAESTHESIA, V46, P317
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 10
TC 4
Z9 7
U1 1
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD JUL
PY 2004
VL 26
IS 7
BP 1055
EP 1060
DI 10.1016/S0149-2918(04)90177-4
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 842VL
UT WOS:000223032400008
PM 15336470
DA 2018-12-27
ER

PT J
AU Bagheri-Yarmand, R
   Talukder, AH
   Wang, RA
   Vadlamudi, RK
   Kumar, R
AF Bagheri-Yarmand, R
   Talukder, AH
   Wang, RA
   Vadlamudi, RK
   Kumar, R
TI RETRACTED: Metastasis-associated protein 1 deregulation causes
   inappropriate mammary gland development and tumorigenesis (Retracted
   article. See vol. 142, pg. 1388, 2015)
SO DEVELOPMENT
LA English
DT Article; Retracted Publication
DE mammary gland development; transgenic mice; MTA1; progesterone
   receptors; cyclin D1; Bcl-X-L; Bcl211
ID BCL-X-L; PROGESTERONE-RECEPTOR-A; PROGRAMMED CELL-DEATH; HUMAN
   BREAST-CANCER; ESTROGEN-RECEPTOR; TRANSGENIC MICE; TRANSACTIVATION
   FUNCTIONS; EPITHELIAL-CELLS; GENE-EXPRESSION; CYCLIN D1
AB Emerging data suggest that metastasis-associated protein 1 (MTA1) represses ligand-dependent transactivation functions of estrogen receptor-alpha in cultured breast cancer cells and that MTA1 is upregulated in human breast tumors. However, the role of MTA1 in tumorigenesis in a physiologically relevant animal system remains unknown. To reveal the role of MTA1 in mammary gland development, transgenic mice expressing MTA1 under the control of the mouse mammary tumor virus promoter long terminal repeat were generated. Unexpectedly, we found that mammary glands of these virgin transgenic mice exhibited extensive side branching and precocious differentiation because of increased proliferation of ductal and alveolar epithelial cells. Mammary glands of virgin transgenic mice resemble those from wild-type mice in mid-pregnancy and inappropriately express beta-casein, cyclin D1 and beta-catenin protein. Increased ductal growth was also observed in the glands of ovariectomized female mice, as well as of transgenic male mice. MTA1 dysregulation in mammary epithelium and cancer cells triggered downregulation of the progesterone receptor-B isoform and upregulation of the progesterone receptor-A isoform, resulting in an imbalance in the native ratio of progesterone receptor A and B isoforms. MTA1 transgene also increased the expression of progesterone receptor-A target genes Bcl-X-L (Bcl2l1) and cyclin D1 in mammary gland of virgin mice, and, subsequently, produced a delayed involution. Remarkably, 30% of MTA1 transgenic females developed focal hyperplastic nodules, and about 7% exhibited mammary tumors within 18 months. These studies establish, for the first time, a potential role of MTA1 in mammary gland development and tumorigenesis. The underlying mechanism involves the upregulation of progesterone receptor A and its targets, Bcl-X-L and cyclin D1.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
RP Kumar, R (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA.
EM rkumar@mdanderson.org
FU NCI NIH HHS [CA 098823, CA90970, CA16672]
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Bagheri-Yarmand R, 2003, J BIOL CHEM, V278, P17421, DOI 10.1074/jbc.M300761200
   BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x
   Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982
   Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076
   Chou YC, 2003, CARCINOGENESIS, V24, P403, DOI 10.1093/carcin/24.3.403
   CLARKE CL, 1987, ENDOCRINOLOGY, V121, P1123, DOI 10.1210/endo-121-3-1123
   Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8
   Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329
   Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   GRAHAM JD, 1995, CANCER RES, V55, P5063
   Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4
   Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8
   HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6
   Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555
   Klockel BJ, 2002, CELL DEATH DIFFER, V9, P1063, DOI 10.1038/sj.cdd.4401067
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162
   LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266
   Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003
   MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30
   Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299
   Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200
   Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738
   Mote PA, 2001, J CLIN PATHOL, V54, P624, DOI 10.1136/jcp.54.8.624
   Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100
   Olopade OI, 1997, CANCER J SCI AM, V3, P230
   Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3
   Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200
   Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37
   SCHNEIDER W, 1991, J STEROID BIOCHEM, V38, P285, DOI 10.1016/0960-0760(91)90099-Q
   Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359
   Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044
   Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696
   Sivaraman L, 2001, J ENDOCRINOL, V171, P75, DOI 10.1677/joe.0.1710075
   Sjostrom J, 2002, CLIN CANCER RES, V8, P811
   Soyal S, 2002, BREAST CANCER RES, V4, P191, DOI 10.1186/bcr451
   STRASSER A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151
   Talukder AH, 2003, J BIOL CHEM, V278, P11676, DOI 10.1074/jbc.M209570200
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   Tonner E, 2002, DEVELOPMENT, V129, P4547
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Vilenchik M, 2002, CANCER RES, V62, P2175
   WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0
   Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488
NR 49
TC 79
Z9 86
U1 4
U2 6
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD JUL
PY 2004
VL 131
IS 14
BP 3469
EP 3479
DI 10.1242/dev.01213
PG 11
WC Developmental Biology
SC Developmental Biology
GA 844BR
UT WOS:000223132600021
PM 15226262
OA Bronze
DA 2018-12-27
ER

PT J
AU Barreiro, C
   Gonzalez-Lavado, E
   Patek, M
   Martin, JF
AF Barreiro, C
   Gonzalez-Lavado, E
   Patek, M
   Martin, JF
TI RETRACTED: Transcriptional analysis of the groES-groEL1, groEL2, and
   dnaK genes in Corynebacterium glutamicum: Characterization of heat
   shock-induced promoters (Retracted article. See vol. 195, pg. 2706,
   2013)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID GRAM-POSITIVE BACTERIA; STREPTOMYCES-ALBUS G;
   MYCOBACTERIUM-TUBERCULOSIS; BACILLUS-SUBTILIS; SEQUENCE-ANALYSIS;
   OPERON; GENOME; IDENTIFICATION; EXPRESSION; LIVIDANS
AB The appropriate conditions to switch on the heat shock promoters in Corynebacterium glutamicum were defined by Northern blot analysis. Transcriptional patterns were characterized for the groEL2 gene and the groES-groEL1 and dnaK operons. Transcriptional start points of these genes were determined by primer extension analysis, allowing the identification of CIRCE and HAIR boxes close to the -10 and -35 regions of the promoters. The presence of both CIRCE and HAIR sequences within a single promoter (P-groEL2) in bacteria is described for the first time. In addition, the dnaK promoter showed - 10 and - 35 sequences similar to those recognized by SigH of Mycobacterium and SigR of Streptomyces close to a second transcription start region with -10 and -35 boxes typical of promoters for housekeeping genes.
C1 INBIOTEC, Leon 24006, Spain.
   Univ Leon, Area Microbiol, Fac Biol & Environm Sci, E-24071 Leon, Spain.
   Acad Sci Czech Republic, Inst Microbiol, CR-14220 Prague 4, Czech Republic.
RP Martin, JF (reprint author), INBIOTEC, Sci Pk Leon,Av Real 1, Leon 24006, Spain.
EM degjmm@unileon.es
RI Patek, Miroslav/H-8629-2014
CR Ahmad S, 2000, INT J SYST EVOL MICR, V50, P1761, DOI 10.1099/00207713-50-5-1761
   Barrington K J, 2001, BMC Pediatr, V1, P1, DOI 10.1186/1471-2431-1-1
   CADENAS RF, 1991, GENE, V98, P117, DOI 10.1016/0378-1119(91)90113-P
   Chastanet A, 2003, MOL MICROBIOL, V47, P1061, DOI 10.1046/j.1365-2958.2003.03355.x
   Grandvalet C, 1997, MOL MICROBIOL, V23, P77, DOI 10.1046/j.1365-2958.1997.1811563.x
   Grandvalet C, 1999, MOL MICROBIOL, V31, P521, DOI 10.1046/j.1365-2958.1999.01193.x
   Herrmann T, 2003, J BIOTECHNOL, V104, P155
   Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1
   Karlin S, 2000, P NATL ACAD SCI USA, V97, P11348, DOI 10.1073/pnas.97.21.11348
   Kirchner O, 2003, J BIOTECHNOL, V104, P287, DOI 10.1016/S0168-1656(03)00148-2
   Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x
   MARTIN JF, 1989, SYMP SOC GEN MICROBI, V44, P25
   MARTIN JF, 1999, MANUAL IND MICROBIOL, P379
   Muffler A, 2002, J BIOTECHNOL, V98, P255, DOI 10.1016/S0168-1656(02)00136-0
   Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603
   Paget MSB, 2001, MOL MICROBIOL, V42, P1007, DOI 10.1046/j.1365-2958.2001.02675.x
   Patek M, 1996, MICROBIOL-SGM, V142, P1297, DOI 10.1099/13500872-142-5-1297
   Patek M, 2003, J BIOTECHNOL, V104, P311, DOI 10.1016/S0168-1656(03)00155-X
   Patek M, 2003, J BIOTECHNOL, V104, P325, DOI 10.1016/S0168-1656(03)00159-7
   Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001
   Roberts RC, 1996, J BACTERIOL, V178, P1829, DOI 10.1128/jb.178.7.1829-1841.1996
   Rosen R, 2002, MASS SPECTROM REV, V21, P244, DOI 10.1002/mas.10031
   Servant P, 2001, ARCH MICROBIOL, V176, P237, DOI 10.1007/s002030100321
   Simic P, 2001, J BACTERIOL, V183, P5317, DOI 10.1128/JB.183.18.5317-5324.2001
   van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567
   Vasicova P, 1998, BIOTECHNOL TECH, V12, P743, DOI 10.1023/A:1008827609914
   Viala J, 2000, MOL MICROBIOL, V38, P602, DOI 10.1046/j.1365-2958.2000.02155.x
   ZUBER U, 1994, J BACTERIOL, V176, P1359, DOI 10.1128/jb.176.5.1359-1363.1994
NR 28
TC 37
Z9 40
U1 4
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD JUL
PY 2004
VL 186
IS 14
BP 4813
EP 4817
DI 10.1128/JB.186.14.4813-4817.2004
PG 5
WC Microbiology
SC Microbiology
GA 838QM
UT WOS:000222728100042
PM 15231814
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Beer, M
   Kong, YH
   Seviour, RJ
AF Beer, M
   Kong, YH
   Seviour, RJ
TI RETRACTED: Are some putative glycogen accumulating organisms (GAO) in
   anaerobic: aerobic activated sludge systems members of the
   alpha-Proteobacteria? (Retracted article. See vol 155, pg 2460, 2009)
SO MICROBIOLOGY-SGM
LA English
DT Article; Retracted Publication
ID BIOLOGICAL PHOSPHORUS REMOVAL; TARGETED OLIGONUCLEOTIDE PROBES; IN-SITU
   IDENTIFICATION; MICROBIAL COMMUNITY STRUCTURE; PHOSPHATE-REMOVAL;
   AMARICOCCUS-KAPLICENSIS; PHYLOGENETIC ANALYSIS; FUNCTIONAL-ANALYSIS;
   LABORATORY-SCALE; BACTERIA
AB Activated sludge plants designed to remove phosphorus microbiologically often perform unreliably. One suggestion is that the polyphosphate-accumulating organisms (PAO) are out-competed for substrates by another group of bacteria, the glycogen-accumulating organisms (GAO) in the anaerobic zones of these processes. This study used fluorescence in situ hybridization (FISH) and denaturing gradient gel electrophoresis (DGGE) to analyse the communities from laboratory-scale anaerobic: aerobic sequencing batch reactors. Members of the genus Sphingomonas in the alpha-Proteobacteria were present in large numbers in communities with poor phosphorus removal capacity where the biomass had a high glycogen content. Their ability to store poly-beta-hydroxyalkanoates anaerobically, but not aerobically, and not accumulate polyphosphate aerobically is consistent with these organisms behaving as GAO there. No evidence was found to support an important role for the gamma-Proteobacteria as possible GAO in these communities, although these bacterial populations have been considered in other studies to act as possible competitors for the PAO.
C1 La Trobe Univ, Biotechnol Res Ctr, Bendigo, Vic 3552, Australia.
RP Seviour, RJ (reprint author), La Trobe Univ, Biotechnol Res Ctr, Bendigo, Vic 3552, Australia.
EM r.seviour@latrobe.edu.au
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   AMANN RI, 1995, MICROBIOL REV, V59, P143
   Bond PL, 1999, APPL ENVIRON MICROB, V65, P4077
   Bouchez T, 2000, ENVIRON MICROBIOL, V2, P179
   CECH JS, 1993, WATER RES, V27, P1219, DOI 10.1016/0043-1354(93)90014-9
   Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039
   Crocetti GR, 2000, APPL ENVIRON MICROB, V66, P1175, DOI 10.1128/AEM.66.3.1175-1182.2000
   Crocetti GR, 2002, MICROBIOL-SGM, V148, P3353, DOI 10.1099/00221287-148-11-3353
   Dabert P, 2001, APPL MICROBIOL BIOT, V55, P500, DOI 10.1007/s002530000529
   Daims H, 1999, SYST APPL MICROBIOL, V22, P434, DOI 10.1016/S0723-2020(99)80053-8
   Eschenhagen M, 2003, WATER RES, V37, P3224, DOI 10.1016/S0043-1354(03)00136-2
   Falvo A, 2001, J APPL MICROBIOL, V91, P299, DOI 10.1046/j.1365-2672.2001.01384.x
   Felsenstein J, 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Felske A, 1997, MICROBIOL-UK, V143, P2983, DOI 10.1099/00221287-143-9-2983
   Filipe CDM, 2001, WATER ENVIRON RES, V73, P213, DOI 10.2175/106143001X139191
   Hesselmann RPX, 1999, SYST APPL MICROBIOL, V22, P454, DOI 10.1016/S0723-2020(99)80055-1
   Heuer H, 2001, ENVIRONMENTAL MOLECULAR MICROBIOLOGY : PROTOCOLS AND APPLICATIONS, P177
   KITAMURA S, 1994, BIOTECHNOL TECH, V8, P345, DOI 10.1007/BF02428979
   Kong YH, 2002, MICROBIOL-SGM, V148, P2299, DOI 10.1099/00221287-148-8-2299
   Kong YH, 2001, SYST APPL MICROBIOL, V24, P597, DOI 10.1078/0723-2020-00075
   KONG YH, 2002, ENVIRON MICROBIOL, V4, P826
   Levantesi C, 2002, ENVIRON MICROBIOL, V4, P559, DOI 10.1046/j.1462-2920.2002.00339.x
   Liu WT, 2001, ENVIRON MICROBIOL, V3, P110, DOI 10.1046/j.1462-2920.2001.00164.x
   Liu WT, 1997, WATER RES, V31, P1430, DOI 10.1016/S0043-1354(96)00352-1
   Liu WT, 2000, MICROBIOL-UK, V146, P1099, DOI 10.1099/00221287-146-5-1099
   Loy A, 2003, NUCLEIC ACIDS RES, V31, P514, DOI 10.1093/nar/gkg015
   MANZ W, 1992, SYST APPL MICROBIOL, V15, P593, DOI 10.1016/S0723-2020(11)80121-9
   Maszenan AM, 1997, INT J SYST BACTERIOL, V47, P727, DOI 10.1099/00207713-47-3-727
   MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131
   Neef A, 1999, J IND MICROBIOL BIOT, V23, P261, DOI 10.1038/sj.jim.2900768
   NIELSEN AT, 1999, APL ENV MICROBIOL, V58, P2717
   Schonborn C, 2001, WATER RES, V35, P3190, DOI 10.1016/S0043-1354(01)00025-2
   Serafim LS, 2002, J MICROBIOL METH, V51, P1, DOI 10.1016/S0167-7012(02)00056-8
   Seviour RJ, 2003, FEMS MICROBIOL REV, V27, P99, DOI 10.1016/S0168-6445(03)00021-4
   Seviour RJ, 2000, ENVIRON MICROBIOL, V2, P581, DOI 10.1046/j.1462-2920.2000.00153.x
   Shintani T, 2000, INT J SYST EVOL MICR, V50, P201, DOI 10.1099/00207713-50-1-201
   Snaidr J, 1997, APPL ENVIRON MICROB, V63, P2884
   Tsai CS, 2002, WATER SCI TECHNOL, V46, P179
   Wagner M, 2002, CURR OPIN BIOTECH, V13, P218, DOI 10.1016/S0958-1669(02)00315-4
   Weller R, 2000, SYST APPL MICROBIOL, V23, P107, DOI 10.1016/S0723-2020(00)80051-X
   Whang LM, 2002, WATER SCI TECHNOL, V46, P191
   Yeates C, 2003, MICROBIOL-SGM, V149, P1239, DOI 10.1099/mic.0.26112-0
   Zilles JL, 2002, APPL ENVIRON MICROB, V68, P2763, DOI 10.1128/AEM.68.6.2763-2769.2002
NR 43
TC 51
Z9 54
U1 3
U2 11
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD JUL
PY 2004
VL 150
BP 2267
EP 2275
DI 10.1099/mic.0.26825-0
PN 7
PG 9
WC Microbiology
SC Microbiology
GA 840KQ
UT WOS:000222857900027
PM 15256569
OA Bronze
DA 2018-12-27
ER

PT J
AU Yin, MB
   Li, ZR
   Cao, SS
   Durrani, FA
   Azrak, RG
   Frank, C
   Rustum, YM
AF Yin, MB
   Li, ZR
   Cao, SS
   Durrani, FA
   Azrak, RG
   Frank, C
   Rustum, YM
TI RETRACTED: Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by
   methylselenocysteine is associated with Chk2 phosphorylation at
   threonine-68 and down-regulation of Cdc6 expression (Retracted Article.
   See vol 69, pg 1074, 2006)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID CELL-CYCLE ARREST; REPLICATION PROTEIN CDC6; I INHIBITOR BNP1350;
   DAMAGE-INDUCED S; DNA-DAMAGE; SELENIUM-COMPOUNDS; CANCER
   CHEMOPREVENTION; A253 CELLS; CHECKPOINT; APOPTOSIS
AB Methylselenocysteine ( MSC) is an organic selenium compound in preventative clinical trials involving prostate, lung, and colon carcinoma. We found that methioninase-activated MSC potentiates 7-ethyl-10-hydroxycamptothecin (SN-38)-induced cell lethality in vitro in the p53-defective human head and neck carcinoma A253 cells. Activated MSC increases chk2 phosphorylation at threonine-68 induced by SN-38, with no significant effect on chk1 phosphorylation. Cell cycle arrest induced by SN-38, however, was not abrogated or potentiated by MSC. These results suggest that the enhanced cellular lethality of SN-38 by MSC was not associated with cell cycle regulation pathways. Because chk2, in addition to its role in cell cycle arrest, can induce apoptosis by phosphorylation/activation, we examined whether increased chk2 phosphorylation could induce preapoptotic DNA fragmentation. DNA damage analysis showed that megabase DNA fragmentation is decreased, accompanied by the increased 30 to 300 kilobase pairs of DNA fragmentation after exposure to SN-38 with MSC, compared with SN-38 alone. No significant changes in the amount of DNA fragments were observed in cells treated with SN-38 or MSC alone. Moreover, proteolytic destruction of DNA replication-associated proteins cdc6, MCM2, and cdc25A may induce a DNA damage checkpoint response. The observed down-regulation of DNA replication proteins cdc6, MCM2, and cdc25A after exposure to SN-38 with MSC further indicates a relationship between drug response and DNA damage. Exposure to SN-38 with MSC resulted in a significant increase of poly(ADP-ribose) polymerasecleavage and caspase 3 activation. All together, the data support the hypothesis that enhanced lethality of this combination is associated with increased chk2 phosphorylation at Thr68 and down-regulation of specific DNA replication-associated proteins, which result in poly(ADP-ribose) polymerase cleavage, caspase 3 activation, and the induction of 30 to 300 kilobase pairs of DNA fragmentation.
C1 Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA.
RP Rustum, YM (reprint author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.
EM youcef.rustum@roswellpark.org
FU NCI NIH HHS [CA16056, CA65761]
CR Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6
   BELL DW, 1999, SCIENCE, V286, P2433
   BHUYAN BK, 1992, CANCER RES, V52, P5687
   Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010
   Burhans W, 2002, CELL DEATH DIFFER, V9, P870, DOI 10.1038/sj.cdd.4401086
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702
   Eastman A, 2002, MOL CANCER THER, V1, P1067
   Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124
   Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657
   Hapke G, 2002, INT J ONCOL, V21, P1059
   Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.18.6521-6532.2002
   Hirose Y, 2001, CANCER RES, V61, P5843
   IP C, 1994, CARCINOGENESIS, V15, P187, DOI 10.1093/carcin/15.2.187
   Kohn EA, 2003, CANCER RES, V63, P31
   Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425
   MEDINA D, 1988, PATHOL IMMUNOPATH R, V7, P187, DOI 10.1159/000157115
   OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x
   Patterson BH, 1997, CANCER EPIDEM BIOMAR, V6, P63
   Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161
   Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285
   Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758
   Sinha R, 1996, CANCER LETT, V107, P277, DOI 10.1016/0304-3835(96)04373-X
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378
   SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8
   Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748
   Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6
   Tannock I.F., 1998, BASIC SCI ONCOLOGY
   Wang ZG, 1998, NAT GENET, V20, P266
   Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200
   Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200
   Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9
   Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869
   Yin MB, 2000, MOL PHARMACOL, V57, P453
   Yin MB, 2002, BIOCHEM BIOPH RES CO, V295, P435, DOI 10.1016/S0006-291X(02)00683-6
   Yin MB, 2001, ONCOGENE, V20, P5249, DOI 10.1038/sj.onc.1204686
   Yu Q, 2002, CANCER RES, V62, P5743
   Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9
NR 39
TC 12
Z9 13
U1 3
U2 12
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD JUL
PY 2004
VL 66
IS 1
BP 153
EP 160
DI 10.1124/mol.66.1.153
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 831FJ
UT WOS:000222179000019
PM 15213307
OA Bronze
DA 2018-12-27
ER

PT J
AU Seo, SH
   Hoffmann, E
   Webster, RG
AF Seo, SH
   Hoffmann, E
   Webster, RG
TI RETRACTED: The NS1 gene of H5N1 influenza viruses circumvents the host
   anti-viral cytokine responses (Retracted Article. See vol 149, pg 133,
   2010)
SO VIRUS RESEARCH
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 1st European Influenza Conference
CY OCT, 2002
CL ST JULIANS, MALTA
DE H5N1; influenza; cytokines; virulence
ID NECROSIS-FACTOR-ALPHA; A-VIRUS; HONG-KONG; INTERFERON-PRODUCTION;
   WILD-TYPE; INFECTION; PROTEIN; HUMANS; PATHOGENESIS; INDUCTION
AB The H5N1 influenza viruses transmitted to humans in 1997 were highly virulent, but the mechanism of their virulence in humans is largely unknown. Here we show that lethal H5N1 influenza viruses, unlike other human, avian, and swine influenza viruses, are resistant to the anti-viral effects of interferons and tumor necrosis factor alpha The nonstructural (NS) gene of H5N1 viruses is associated with this resistance. Pigs infected with recombinant human H1N1 influenza virus that carried the H5N1 NS gene experienced significantly greater and more prolonged viremia, fever, and weight loss than did pigs infected with wild-type human H1N1 influenza virus. These effects required the presence of glutamic acid at position 92 of the NS1 molecule. These findings may explain the mechanism of the high virulence of H5N1 influenza viruses in humans and provide insight into the virulence of 1918 Spanish influenza. (C) 2004 Elsevier B.V. All rights reserved.
C1 St Jude Childrens Res Hosp, Div Virol, Dept Infect Dis, Memphis, TN 38105 USA.
   Chungnam Natl Univ, Dept Microbiol, Coll Vet Med, Taejon 305764, South Korea.
   MedImmune Vaccines Inc, Mountain View, CA 94043 USA.
RP Webster, RG (reprint author), St Jude Childrens Res Hosp, Div Virol, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM robert.webster@stjude.org
FU NCI NIH HHS [CA-21765]; NIAID NIH HHS [AI-95357, AI-29860]
CR Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198
   Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0
   deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218
   ENNIS FA, 1981, LANCET, V2, P891
   Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938
   Gao P, 1999, J VIROL, V73, P3184
   Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508
   GREEN JA, 1982, J INFECT DIS, V145, P837, DOI 10.1093/infdis/145.6.837
   Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363
   Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882
   HILL DA, 1972, J AMER MED ASSOC, V219, P1179, DOI 10.1001/jama.219.9.1179
   Hoffmann E, 2000, J VIROL, V74, P6309, DOI 10.1128/JVI.74.14.6309-6315.2000
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Jameson J, 1999, J IMMUNOL, V162, P7578
   Lin G, 2000, J MICROELECTROMECH S, V9, P9, DOI 10.1109/84.825771
   LINDENMANN J, 1957, BRIT J EXP PATHOL, V38, P551
   Lu XH, 1999, J VIROL, V73, P5903
   LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937
   MURPHY BR, 1973, J INFECT DIS, V128, P488, DOI 10.1093/infdis/128.4.488
   Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000
   Qian XY, 1995, RNA, V1, P948
   RICHMAN DD, 1976, J CLIN MICROBIOL, V3, P223
   Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001
   Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002
   Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757
   Seo SH, 2001, J VIROL, V75, P9517, DOI 10.1128/JVI.75.19.9517-9525.2001
   Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488
   STAEHELI P, 1988, MOL CELL BIOL, V8, P4518, DOI 10.1128/MCB.8.10.4518
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000
   To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3<242::AID-JMV1007>3.0.CO;2-N
   Van Reeth K, 1998, J INFECT DIS, V177, P1076, DOI 10.1086/517398
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002
NR 34
TC 119
Z9 162
U1 7
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD JUL
PY 2004
VL 103
IS 1-2
SI SI
BP 107
EP 113
DI 10.1016/j.virusres.2004.02.022
PG 7
WC Virology
SC Virology
GA 829QR
UT WOS:000222065200019
PM 15163498
DA 2018-12-27
ER

PT J
AU Finfer, S
   Norton, R
   Bellomo, R
   Boyce, N
   French, J
   Myburgh, J
AF Finfer, S
   Norton, R
   Bellomo, R
   Boyce, N
   French, J
   Myburgh, J
CA SAFE Study Investigators
TI RETRACTED: The SAFE study: saline vs. albumin for fluid resuscitation in
   the critically ill (Retracted Article. See vol 87, pg 142, 2004)
SO VOX SANGUINIS
LA English
DT Article; Retracted Publication
ID CLINICAL-TRIALS; DEFINITIONS
C1 Australian Red Cross Blood Serv, ANZICS Clin Trials Grp, S Melbourne, Vic 3205, Australia.
RP Boyce, N (reprint author), Australian Red Cross Blood Serv, ANZICS Clin Trials Grp, POB 354, S Melbourne, Vic 3205, Australia.
EM nboyce@arcbs.redcross.org.au
CR BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Boldt J, 2003, ANESTH ANALG, V97, P1595, DOI 10.1213/01.ANE.0000089961.15975.78
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   BUNN F, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001319
   Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053
   *COCHR INJ GROUP A, 1998, BMJ-BRIT MED J, V317, P235
   Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5
   Cook D, 2001, ANN INTERN MED, V135, P205, DOI 10.7326/0003-4819-135-3-200108070-00013
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037
   TEASDALE G, 1974, LANCET, V2, P81
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007
   Woodward M., 1999, EPIDEMIOLOGY STUDY D
   2001, ANN INTERN MED, V135, pS25
NR 15
TC 18
Z9 19
U1 4
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2004
VL 87
SU 2
BP 123
EP 131
DI 10.1111/j.1741-6892.2004.00468.x
PG 9
WC Hematology
SC Hematology
GA 831RD
UT WOS:000222212900033
PM 15209896
DA 2018-12-27
ER

PT J
AU Jobb, G
   von Haeseler, A
   Strimmer, K
AF Jobb, G
   von Haeseler, A
   Strimmer, K
TI RETRACTED: TREEFINDER: a powerful graphical analysis environment for
   molecular phylogenetics - art. no. 18 (Retracted article. See vol. 15,
   243, 2015)
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article; Retracted Publication
ID MAXIMUM-LIKELIHOOD APPROACH; DNA-SEQUENCES; STATISTICAL TESTS;
   MITOCHONDRIAL-DNA; TREES; SUBSTITUTION; INFERENCE; EVOLUTION; MODELS;
   RATES
AB Background: Most analysis programs for inferring molecular phylogenies are difficult to use, in particular for researchers with little programming experience.
   Results: TREEFINDER is an easy-to-use integrative platform-independent analysis environment for molecular phylogenetics. In this paper the main features of TREEFINDER ( version of April 2004) are described. TREEFINDER is written in ANSI C and Java and implements powerful statistical approaches for inferring gene tree and related analyzes. In addition, it provides a user-friendly graphical interface and a phylogenetic programming language.
   Conclusions: TREEFINDER is a versatile framework for analyzing phylogenetic data across different platforms that is suited both for exploratory as well as advanced studies.
C1 Univ Munich, Dept Stat, D-80539 Munich, Germany.
   Univ Dusseldorf, Dept Comp Sci, D-40225 Dusseldorf, Germany.
   Forschungszentrum Julich, John Von Neumann Inst Comp, D-52425 Julich, Germany.
RP Jobb, G (reprint author), Univ Munich, Dept Stat, Ludwigstr 33, D-80539 Munich, Germany.
EM gangolf@treefinder.de; haeseler@cs.uni-duesseldorf.de;
   strimmer@stat.uni-muenchen.de
OI Strimmer, Korbinian/0000-0001-7917-2056
CR Dayhoff M.O., 1978, ATLAS PROTEIN SEQ S3, V5, P345
   FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Felsenstein J, 2004, INFERRING PHYLOGENIE
   Felsenstein J, 1993, PHYLIP PHYLOGENETIC
   GOLDMAN N, 1993, J MOL EVOL, V36, P182, DOI 10.1007/BF00166252
   GOLDMAN N, 1993, J MOL EVOL, V37, P650
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   LANAVE C, 1984, J MOL EVOL, V20, P86, DOI 10.1007/BF02101990
   Lewis PO, 1998, MOL BIOL EVOL, V15, P277, DOI 10.1093/oxfordjournals.molbev.a025924
   MOSHIER SLB, 1989, METHODS PROGRAMS MAT
   Nordborg M., 2001, HDB STAT GENETICS, P179
   OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41
   Page R. D. M., 1998, MOL EVOLUTION PHYLOG
   Rambaut A, 1997, COMPUT APPL BIOSCI, V13, P235
   ROBINSON DF, 1981, MATH BIOSCI, V53, P131, DOI 10.1016/0025-5564(81)90043-2
   Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Simon AL, 2002, P NATL ACAD SCI USA, V99, P2912, DOI 10.1073/pnas.042692299
   Swofford D. L., 1998, PAUP PHYLOGENETIC AN
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512
   Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851
   Wilkinson M, 1996, MOL BIOL EVOL, V13, P437, DOI 10.1093/oxfordjournals.molbev.a025604
   YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
NR 24
TC 872
Z9 893
U1 8
U2 42
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD JUN 28
PY 2004
VL 4
AR 18
DI 10.1186/1471-2148-4-18
PG 9
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA 837UE
UT WOS:000222665600001
PM 15222900
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Dwyer, MA
   Looger, LL
   Hellinga, HW
AF Dwyer, MA
   Looger, LL
   Hellinga, HW
TI RETRACTED: Computational design of a biologically active enzyme
   (Retracted article. See vol 319, pg 569, 2008)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID TRIOSEPHOSPHATE ISOMERASE; RANDOM MUTAGENESIS; PROTON-TRANSFER;
   HYDROGEN-BOND; CATALYSIS; RESOLUTION; PROTEINS; RECEPTOR;
   2-PHOSPHOGLYCOLATE; CONSTRUCTION
AB Rational design of enzymes is a stringent test of our understanding of protein chemistry and has numerous potential applications. Here, we present and experimentally validate the computational design of enzyme activity in proteins of known structure. We have predicted mutations that introduce triose phosphate isomerase activity into ribose-binding protein, a receptor that normally lacks enzyme activity. The resulting designs contain 18 to 22 mutations, exhibit 10(5)- to 10(6)-fold rate enhancements over the uncatalyzed reaction, and are biologically active, in that they support the growth of Escherichia coli under gluconeogenic conditions. The inherent generality of the design method suggests that many enzymes can be designed by this approach.
C1 Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
RP Hellinga, HW (reprint author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
EM hwh@biochem.duke.edu
CR Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515
   Bolon DN, 2002, CURR OPIN CHEM BIOL, V6, P125, DOI 10.1016/S1367-5931(02)00303-4
   Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529
   De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860
   Dwyer MA, 2003, P NATL ACAD SCI USA, V100, P11255, DOI 10.1073/pnas.2032284100
   Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635
   FERSHT A. R, 1999, STRUCTURE MECH PROTE
   FRAENKEL DG, 1986, ANNU REV BIOCHEM, V55, P317, DOI 10.1146/annurev.biochem.55.1.317
   Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172
   HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032
   Harris TK, 1997, BIOCHEMISTRY-US, V36, P14661, DOI 10.1021/bi972039v
   HELLINGA HW, 1991, J MOL BIOL, V222, P763, DOI 10.1016/0022-2836(91)90510-D
   HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0
   Hilvert D, 2000, ANNU REV BIOCHEM, V69, P751, DOI 10.1146/annurev.biochem.69.1.751
   Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100
   KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0
   Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427
   Kursula I, 2003, J BIOL CHEM, V278, P9544, DOI 10.1074/jbc.M211389200
   LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010
   Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556
   MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L
   RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057
   RICHARD JP, 1985, BIOCHEMISTRY-US, V24, P949, DOI 10.1021/bi00325a021
   Richard JP, 2001, CURR OPIN CHEM BIOL, V5, P626, DOI 10.1016/S1367-5931(01)00258-7
   SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015
   SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P230
   Segel IH, 1975, ENZYME KINETICS
   Wisz MS, 2003, PROTEINS, V51, P360, DOI 10.1002/prot.10332
   Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i
   Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049
NR 30
TC 232
Z9 241
U1 2
U2 47
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUN 25
PY 2004
VL 304
IS 5679
BP 1967
EP 1971
DI 10.1126/science.1098432
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 832BG
UT WOS:000222241600046
PM 15218149
DA 2018-12-27
ER

PT J
AU Ganesh, VK
   Smith, SA
   Kotwal, GJ
   Murthy, KHM
AF Ganesh, VK
   Smith, SA
   Kotwal, GJ
   Murthy, KHM
TI RETRACTED: Structure of vaccinia complement protein in complex with
   heparin and potential implications for complement regulation (Retracted
   article. See vol. 115, pg. E6965, 2018)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID HEMOLYTIC-UREMIC SYNDROME; FIBROBLAST-GROWTH-FACTOR; FACTOR-H;
   CRYSTAL-STRUCTURE; BINDING-SITES; ALTERNATIVE PATHWAY; FACTOR-I; X-RAY;
   VIRUS; DOMAIN
AB Vaccinia virus complement control protein (VCP), a homolog of the regulators of the complement activation family of proteins, inhibits complement activation through mechanisms similar to human fluid-phase complement regulators factor H and CO-binding protein. VCP has a heparin-binding activity that assists vaccinia in host interactions. Interaction with cell-surface polyanions like heparin is centrally important in the functioning of fluid-phase complement regulators and is the basis of host-target discrimination by the alternative pathway. We report the structure of VCP in complex with a heparin decasaccharide, which reveals changes in VCP that might be pertinent to complement regulation. Properties that VCP shares with fluid-phase complement regulators suggest that such conformational changes may be of relevance in the functioning of other complement regulators. Additionally, comparison of VCP-heparin interactions with potentially similar interactions in factor H might enable understanding of the structural basis of familial hemolytic uremic syndrome, attributed to mutational disruption of heparin and C3b binding by factor H.
C1 Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
   Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40202 USA.
   Univ Cape Town, HSC, Div Med Virol, ZA-7925 Cape Town, South Africa.
   Univ Cape Town, HSC, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
RP Murthy, KHM (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
EM murthy@cbse.uab.edu
FU Wellcome Trust; NIAID NIH HHS [AI51615, R01 AI051615]
CR Al-Mohanna F, 2001, TRANSPLANTATION, V71, P796, DOI 10.1097/00007890-200103270-00019
   [Anonymous], 1981, ARCH BIOCHEM BIOPHYS, V207, P469
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237
   Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911
   CCP4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   COOPER NR, 1991, IMMUNOL TODAY, V12, P327, DOI 10.1016/0167-5699(91)90010-Q
   Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5
   DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461
   DISCIPPIO RG, 1993, CELL, V149, P2592
   Dunlop LR, 2003, MICROBES INFECT, V5, P1049, DOI 10.1016/S1286-4579(03)00194-1
   Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N
   Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935
   Henderson CE, 2001, J MOL BIOL, V307, P323
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x
   Kotwal GJ, 2000, IMMUNOL TODAY, V21, P242, DOI 10.1016/S0167-5699(00)01606-6
   KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0
   KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434
   Krushkal J, 2000, MOL BIOL EVOL, V17, P1718, DOI 10.1093/oxfordjournals.molbev.a026270
   Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623
   Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8
   Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Raman R, 2003, P NATL ACAD SCI USA, V100, P2357, DOI 10.1073/pnas.0437842100
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Richards A, 2002, CURR OPIN NEPHROL HY, V11, P431, DOI 10.1097/00041552-200207000-00010
   Rosengard AM, 1999, MOL IMMUNOL, V36, P685, DOI 10.1016/S0161-5890(99)00081-4
   Rosengard AM, 1999, IMMUNOPHARMACOLOGY, V42, P99, DOI 10.1016/S0162-3109(99)00012-0
   Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499
   Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4
   Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000
   Smith SA, 2003, BBA-PROTEINS PROTEOM, V1650, P30, DOI 10.1016/S1570-9639(03)00189-4
   Smith SA, 2002, BBA-PROTEINS PROTEOM, V1598, P55, DOI 10.1016/S0167-4838(02)00339-4
   Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118
   Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.073084410
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241
   Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3
NR 61
TC 49
Z9 49
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 15
PY 2004
VL 101
IS 24
BP 8924
EP 8929
DI 10.1073/pnas.0400744101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 830EQ
UT WOS:000222104900018
PM 15178763
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Piper, SN
   Rohm, KD
   Suttner, SW
   Maleck, WH
   Kranke, P
   Boldt, J
AF Piper, SN
   Rohm, KD
   Suttner, SW
   Maleck, WH
   Kranke, P
   Boldt, J
TI RETRACTED: A comparison of nefopam and clonidine for the prevention of
   postanaesthetic shivering: A comparative, double-blind and
   placebo-controlled dose-ranging study (Retracted article. See vol. 66,
   pg. 646, 2011)
SO ANAESTHESIA
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th World Congress of Anaesthesiologists
CY APR 17-23, 2004
CL Paris, FRANCE
DE post operative complications, shivering; nefopam; clonidine
ID ANESTHESIA; PATHOPHYSIOLOGY; ISOFLURANE; RECOVERY; URAPIDIL; SCORE
AB Postanaesthetic shivering is a frequent complication following general anaesthesia. The aim of this study was to compare the effectiveness of three doses of nefopam with clonidine and placebo in the prevention of postanaesthetic shivering. We studied 371 patients undergoing abdominal or orthopaedic surgery. Patients were allocated to one of five groups: Group A (n = 73) received 0.2 mg.kg(-1) nefopam, Group B (n = 75) 0.1 mg.kg(-1) nefopam, Group C (n = 76) 0.05 mg.kg(-1) nefopam, Group D (n = 73) 1.5 mug.kg(-1) clonidine, and Group E (n = 74) saline 0.9% as placebo. We found a significant reduction in the incidence of shivering in Group A compared to Group C and clonidine as well as to the placebo group. All active treatments reduced the incidence and the severity of shivering compared to placebo. At 5 min postoperatively clonidine-treated patients showed a significant decrease in MAP and a significantly lower Aldrete score compared to all other groups. No haemodynamic or sedative adverse events were observed in the nefopam-treated patients. The results of our study indicate that nefopam (0.2 mg.kg(-1)) is superior to clonidine (1.5 mug.kg(-1)) in the prophylaxis of postanaesthetic shivering and not accompanied by sedative or haemodynamic side-effects.
C1 Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Ludwigshafen, Germany.
   Univ Wurzburg, Dept Anaesthesiology & Intens Care Med, D-97070 Wurzburg, Germany.
RP Piper, SN (reprint author), Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Ludwigshafen, Germany.
EM swen.n.piper@t-online.de
CR ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924
   Alfonsi P, 2001, DRUGS, V61, P2193, DOI 10.2165/00003495-200161150-00004
   Alfonsi P, 2002, ANESTHESIOLOGY, V96, pA257
   Apfel CC, 1998, ACTA ANAESTH SCAND, V42, P502, DOI 10.1111/j.1399-6576.1998.tb05158.x
   Bilotta F, 2002, REGION ANESTH PAIN M, V27, P380, DOI 10.1053/rapm.2002.33563
   Bilotta F, 2002, ANESTH ANALG, V95, P1125, DOI 10.1213/01.ANE.0000022677.46533.B9
   Bilotta F, 2001, ANAESTHESIA, V56, P514, DOI 10.1046/j.1365-2044.2001.02057.x
   Buggy D, 1997, CAN J ANAESTH, V44, P263, DOI 10.1007/BF03015363
   CIOFOLO MJ, 1989, ANESTHESIOLOGY, V70, P737
   De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036
   HEEL RC, 1980, DRUGS, V19, P249, DOI 10.2165/00003495-198019040-00001
   Horn E P, 1999, Curr Opin Anaesthesiol, V12, P449, DOI 10.1097/00001503-199908000-00010
   Horn EP, 1998, ANESTHESIOLOGY, V89, P878, DOI 10.1097/00000542-199810000-00012
   Horn EP, 1997, ANESTH ANALG, V84, P613, DOI 10.1097/00000539-199703000-00028
   Horn EP, 2002, ANASTH INTENSIV NOTF, V37, P409, DOI 10.1055/s-2002-32703
   JORIS J, 1993, ANESTHESIOLOGY, V79, P532, DOI 10.1097/00000542-199309000-00017
   Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043
   Kranke Peter, 2003, Paediatr Drugs, V5, P373, DOI 10.2165/00128072-200305060-00003
   Launo C, 1991, Minerva Anestesiol, V57, P427
   Piper SN, 1999, ANAESTHESIA, V54, P695, DOI 10.1046/j.1365-2044.1999.00849.x
   Piper SN, 2000, ANESTH ANALG, V90, P954, DOI 10.1213/00000539-200004000-00033
   Piper SN, 2002, ANESTH ANALG, V94, P106, DOI 10.1097/00000539-200201000-00020
   Piper SN, 2001, CAN J ANAESTH, V48, P742, DOI 10.1007/BF03016688
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x
   ROSLAND JH, 1990, J PHARM PHARMACOL, V42, P437, DOI 10.1111/j.2042-7158.1990.tb06587.x
   Schafer M, 2002, ANAESTHESIST, V51, P768, DOI 10.1007/s00101-002-0381-y
   Vanderstappen I, 1996, ANAESTHESIA, V51, P351, DOI 10.1111/j.1365-2044.1996.tb07747.x
   Vecchia P., 1993, Acta Anaesthesiologica Italica, V44, P225
   Wrench IJ, 1997, BRIT J ANAESTH, V79, P541, DOI 10.1093/bja/79.4.541
   Zhang Y, 1999, Acta Anaesthesiol Sin, V37, P115
NR 31
TC 26
Z9 32
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0003-2409
J9 ANAESTHESIA
JI Anaesthesia
PD JUN
PY 2004
VL 59
IS 6
BP 559
EP 564
DI 10.1111/j.1365-2044.2004.03734.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 820PJ
UT WOS:000221401500006
PM 15144295
OA Bronze
DA 2018-12-27
ER

PT J
AU Vayalil, PK
   Mittal, A
   Katiyar, SK
AF Vayalil, PK
   Mittal, A
   Katiyar, SK
TI RETRACTED: Proanthocyanidins from grape seeds inhibit expression of
   matrix metalloproteinases in human prostate carcinoma cells, which is
   associated with the inhibition of activation of MAPK and NF kappa B
   (Retracted article. See vol. 33, pg. 1121, 2012)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID DU145 CELLS; TRIMERIC PROCYANIDINS; ANDROGEN RECEPTOR; CANCER
   STATISTICS; EPITHELIAL-CELLS; LINE LNCAP; GROWTH; METASTASIS; INVASION;
   EXTRACT
AB Prostate cancer (PCA) is the second most frequently diagnosed and leading cause of cancer-related deaths in men in the USA. The recognition that matrix metalloproteinases (MMPs) facilitate tumor cell invasion and metastasis of PCA has led to the development of MMP inhibitors as cancer therapeutic agents. As part of our efforts to develop newer and effective chemopreventive agents for PCA, we evaluated the effect of proanthocyanidins from grape seeds (GSP) on metastasis-specific MMP-2 and -9 in human prostate carcinoma DU145 cells by employing western blot and gelatinolytic zymography. Treatment of GSP dose-dependently inhibited cell proliferation (15-100% by 5-80 mug/ml of GSP), viability (30-80% by 20-80 mug/ml of GSP) and fibroblast conditioned medium (FCM)-induced expression of MMP-2 and -9 in DU145 cells. Since the signaling cascade of mitogen-activated protein kinases (MAPK) have been shown to regulate the expression of MMPs in tumor cells, we found that the treatment of DU145 cells with GSP (20-80 mug/ml) resulted in marked inhibition of FCM-induced phosphorylation of extracellular signal regulated kinase (ERK)1/2 and p38 but had little effect on c-Jun N-terminal kinase under similar experimental conditions. GSP treatment (20-80 mug/ml) to DU145 cells also dose-dependently inhibited FCM-induced activation of NFkappaB concomitantly with inhibition of MMP-2 and -9 expression in the same system. Additionally, the treatment of inhibitors of MEK (PD98059) and p38 (SB203580) to DU145 cells resulted in the reduction of FCM-induced phosphorylation of ERK1/2 and p38 concomitantly marked reduction in MMP-2 and -9 expressions. In further studies, treatment of androgen-sensitive LNCaP cells with a synthetic androgen R1881, resulted in an increase of MMP-2 and -9, which were completely abrogated in the presence of GSP (20-60 mug/ml). These data suggest that inhibition of metastasis-specific MMPs in tumor cells by GSP is associated with the inhibition of activation of MAPK and NFkappaB pathways, and thus provides the molecular basis for the development of GSP as a novel chemopreventive agent for both androgen-sensitive and -insensitive prostate cancer therapies.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Environm Hlth Sci Ctr, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
CR Agarwal C, 2000, MOL CARCINOGEN, V28, P129, DOI 10.1002/1098-2744(200007)28:3<129::AID-MC1>3.0.CO;2-0
   Agarwal C, 2002, CARCINOGENESIS, V23, P1869, DOI 10.1093/carcin/23.11.1869
   *AM CANC SOC INC, 1982, CANC FACTS FIG 2002
   Bagchi D, 2002, ANN NY ACAD SCI, V957, P260, DOI 10.1111/j.1749-6632.2002.tb02922.x
   Brawley OW, 2001, ANN NY ACAD SCI, V952, P145, DOI 10.1111/j.1749-6632.2001.tb02735.x
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Denmeade SR, 1996, PROSTATE, V28, P251
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Forget Marie-Annick, 1999, Canadian Journal of Physiology and Pharmacology, V77, P465, DOI 10.1139/cjpp-77-7-465
   Gabetta B, 2000, FITOTERAPIA, V71, P162, DOI 10.1016/S0367-326X(99)00161-6
   GALI HU, 1994, PLANTA MED, V60, P235, DOI 10.1055/s-2006-959466
   Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4
   Harris KA, 2001, DRUGS, V61, P2177, DOI 10.2165/00003495-200161150-00003
   Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Joshi S. S., 2001, Current Pharmaceutical Biotechnology, V2, P187, DOI 10.2174/1389201013378725
   Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276
   Klein RD, 1999, PROSTATE, V41, P215, DOI 10.1002/(SICI)1097-0045(19991201)41:4<215::AID-PROS1>3.0.CO;2-V
   KLEINER DE, 1999, CANCER CHEMOTH PHARM, V43, P42
   Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170
   Liao XB, 2003, ENDOCRINOLOGY, V144, P1656, DOI 10.1021/en.2002-0157
   Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x
   Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200
   Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095
   Miyagi N, 1998, INT J ONCOL, V12, P1085
   Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545
   Sun BS, 1999, J CHROMATOGR A, V841, P115, DOI 10.1016/S0021-9673(99)00281-2
   Tyagi A, 2003, ONCOGENE, V22, P1302, DOI 10.1038/sj.onc.1206265
   Upadhyay J, 1999, CLIN CANCER RES, V5, P4105
   VANSTEENBRUGGE GJ, 1991, J STEROID BIOCHEM, V40, P207, DOI 10.1016/0960-0760(91)90184-7
   Vayalil PK, 2004, PROSTATE, V59, P33, DOI 10.1002/pros.10352
   Westermarck J, 1999, FASEB J, V13, P781
   Wilson MJ, 2002, J CELL PHYSIOL, V191, P208, DOI 10.1002/jcp.10092
   Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006
   Zhao J, 1999, CARCINOGENESIS, V20, P1737, DOI 10.1093/carcin/20.9.1737
NR 44
TC 85
Z9 93
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUN
PY 2004
VL 25
IS 6
BP 987
EP 995
DI 10.1093/carcin/bgh095
PG 9
WC Oncology
SC Oncology
GA 825IQ
UT WOS:000221750400017
PM 14742313
OA Bronze
DA 2018-12-27
ER

PT J
AU Getso, R
AF Getso, R
TI RETRACTED: The institutional model of US supreme Court decision-making
   (Retracted article. See vol. 37, pg. 64, 2009)
SO INTERNATIONAL JOURNAL OF THE SOCIOLOGY OF LAW
LA English
DT Article; Retracted Publication
ID ERROR-CORRECTION; COINTEGRATION
C1 Univ Appl Sci, D-50858 Cologne, Germany.
RP Getso, R (reprint author), Univ Appl Sci, Benfleestr 10, D-50858 Cologne, Germany.
EM rmgesto@yahoo.com
CR Abraham H., 1992, JUSTICES PRESIDENTS
   Barrow Deborah J., 1996, FEDERAL JUDICIARY I
   Baum L, 1997, PUZZLE JUDICIAL BEHA
   Berry W. D., 1987, UNDERSTANDING US GOV
   BISKUPIC J, 1997, C Q GUIDE US SUPREME
   Brigham J., 1987, CULT COURT
   CALDEIRA GA, 1982, SUPREME COURT ACTIVI
   CANON DT, 1989, LEGIS STUD QUART, V14, P415, DOI 10.2307/439887
   CASPER JD, 1976, AM POLIT SCI REV, V70, P50, DOI 10.2307/1960323
   COOK BB, 1993, J POLIT, V55, P1127, DOI 10.2307/2131953
   Cox G. W., 1993, LEGISLATIVE LEVIATHA
   DAHL RA, 1957, J PUBLIC LAW, V6, P279
   Durr Robert H., 1992, POLIT ANAL, V4, P185, DOI 10.1093/pan/4.1.185
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   Feldman S, 1985, MULTIPLE REGRESSION
   FREEMAN JR, 1983, AM J POLIT SCI, V27, P327, DOI 10.2307/2111021
   GADBOIS GH, 1987, COMP JUDICIAL SYSTEM
   Gillman Howard, 1999, SUPREME COURT DECISI
   GRANINGER W, 1994, J CHEMOTHERAPY, V6, P23
   HAINES CG, 1959, AM DOCTRINE JUDICIAL
   HEDLUND RD, 1985, HDB LEGISLATIVE RES
   HIBBING JR, 1988, AM J POLIT SCI, V32, P681, DOI 10.2307/2111242
   Huntington S., 1968, POLITICAL ORDER CHAN
   KING G, 1988, AM J POLIT SCI, V32, P838, DOI 10.2307/2111248
   MARCH JG, 1984, AM POLIT SCI REV, V78, P734, DOI 10.2307/1961840
   MAYHEW D, 1974, C ELECTORAL CONNE
   MCINTOSH WV, 1991, AM COURTS CRITICAL A
   McIver JP, 1981, UNIDIMENSIONAL SCALI
   MISHLER W, 1973, LEGISLATURES COMP PE
   MOE TM, 1985, NEW DIRECTIONS AM PO
   MURRAY MP, 1994, AM STAT, V48, P37, DOI 10.2307/2685084
   North D. C., 1990, I I CHANGE EC PERFOR
   O'Brien David, 2000, STORM CTR SUPREME CO
   Perry H. W., 1991, DECIDING DECIDE AGEN
   POLSBY NW, 1968, AM POLIT SCI REV, V62, P144, DOI 10.2307/1953331
   PRICE S, 1998, RES STRATEGIES SOCIA
   Ragsdale L, 1997, AM J POLIT SCI, V41, P1280, DOI 10.2307/2960490
   ROHDE DW, 1972, MIDWEST J POLIT SCI, V16, P652, DOI 10.2307/2110381
   SARAT A, 1975, AM POLIT SCI REV, V69, P1200, DOI 10.2307/1955281
   SCHMIDHAUSER JR, 1959, MIDWEST J POLIT SCI, V3, P1, DOI 10.2307/2109285
   SCHMIDHAUSER JR, 1979, JUDGES JUSTICES FEDE
   SCHMIDHAUSER JR, 1973, LEGISLATURES COMP PE
   Schwartz B., 1993, HIST SUPREME COURT
   Segal Jeffrey A, 1993, SUPREME COURT ATTITU
   Selznick P., 1957, LEADERSHIP ADM SOCIO
   SHEPSLE KA, 1986, POLITICAL SCI SCI PO
   SLOTNICK EE, 1979, AM J POLIT SCI, V23, P60, DOI 10.2307/2110771
   SMITH RM, 1988, AM POLIT SCI REV, V82, P89, DOI 10.2307/1958060
   SPAETH HJ, 1999, MAJORITY RULE MINORI
   STARR KW, 2002, 1 EQUALS SUPREME COU
   Stinchcombe A. L., 1968, CONSTRUCTING SOCIAL
   WARREN C, 1937, SUPREME COURT US HIS
   WHITE GE, 1991, MARSHALL COURT CULTU
   Young James Sterling, 1966, WASHINGTON COMMUNITY
   Zorn CJW, 2001, AM J POLIT SCI, V45, P470, DOI 10.2307/2669353
NR 55
TC 1
Z9 1
U1 2
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0194-6595
J9 INT J SOCIOL LAW
JI Int. J. Sociol. Law
PD JUN
PY 2004
VL 32
IS 2
BP 119
EP 141
DI 10.1016/j.ijsl.2004.06.001
PG 23
WC Law; Sociology
SC Government & Law; Sociology
GA 856FW
UT WOS:000224032100002
DA 2018-12-27
ER

PT J
AU Pogrel, MA
   Jordan, RCK
AF Pogrel, MA
   Jordan, RCK
TI RETRACTED: Marsupialization as a definitive treatment for the
   odontogenic keratocyst (Retracted Article. See vol 65, pg 362, 2007)
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article; Retracted Publication
ID BENIGN CYSTIC NEOPLASM; TERM-FOLLOW-UP; AGGRESSIVE NATURE; MANAGEMENT;
   DECOMPRESSION; ENUCLEATION; DIFFERENTIATION; PROLIFERATION; CRYOTHERAPY;
   EXPRESSION
AB Purpose: We sought to show that marsupialization can be a definitive treatment for the odontogenic keratocyst (OKC).
   Materials and Methods: Ten patients (10 males and 4 females) between the ages of 11 and 64 with biopsy-proven OKC (8 mandibular and 2 maxillary) measuring between 2 and 8 cm were treated by marsupialization consisting of excision of the overlying mucosa and the opening of a 1-cm window into the cystic cavity and, where possible, suturing of the cyst lining to the oral mucosa. Immunohistologic determination of bcl-2 was done for all samples of cyst lining. The cavities were kept open either by vigorous use of a home syringe by the patient or by suturing into place the flange and short length of a nasopharyngeal airway. Once the cyst had largely filled in, histologic material was taken from the base of the residual depression and studied by light microscopy and bcl-2 expression.
   Results: In the 10 patients, the OKCs completely resolved both clinically and radiographically. The time taken for resolution varied from 7 to 19 months. In all cases, the histologic material obtained after marsupialization showed normal epithelium only, with no signs of cystic remnants, daughter cysts, or budding of the basal layer of the epithelium. At initial biopsy, bcl-2 was expressed in the keratocyst lining, but not in the histologic material obtained after marsupialization. Follow-up time ranged from a minimum of 1.8 years to a maximum of 4.8 years. Teeth at the periphery of the cysts were observed to upright and erupt.
   Conclusions: All 10 OKCs resolved completely after marsupialization. Teeth within the cyst were found to be upright and erupt. Marsupialization requires a cooperative patient who will irrigate the cavity and keep it open. It appears that the cyst lining is replaced by normal epithelium during this treatment. (C) 2004 American Association of Oral and Maxillofacial Surgeons.
C1 Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Stomatol, Div Oral Pathol, San Francisco, CA 94143 USA.
RP Pogrel, MA (reprint author), Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.
EM map@itsa.ucsf.edu
CR AHLFORS E, 1984, J ORAL MAXIL SURG, V42, P10, DOI 10.1016/0278-2391(84)90390-2
   August M, 2000, J ORAL MAXIL SURG, V58, P935, DOI 10.1053/joms.2000.8731
   Bataineh AB, 1998, ORAL SURG ORAL MED O, V86, P42, DOI 10.1016/S1079-2104(98)90148-2
   BRAMLEY P, 1974, INT J ORAL MAXILLOF, V3, P337, DOI 10.1016/S0300-9785(74)80074-8
   BRONDUM N, 1991, ORAL SURG ORAL MED O, V72, P265, DOI 10.1016/0030-4220(91)90211-T
   Cranin A N, 1994, N Y State Dent J, V60, P41
   Dowsett EB, 1932, P ROY SOC MED, V25, P47
   EYRE J, 1985, BRIT J ORAL MAX SURG, V23, P195, DOI 10.1016/0266-4356(85)90090-7
   FICKLING BW, 1965, P ROY SOC MED, V58, P847
   HOPPER FE, 1982, BRIT DENT J, V153, P306, DOI 10.1038/sj.bdj.4804925
   IRVINE GH, 1985, BRIT J ORAL MAX SURG, V23, P204, DOI 10.1016/0266-4356(85)90091-9
   JENSEN J, 1988, J CRANIO MAXILL SURG, V16, P362, DOI 10.1016/S1010-5182(88)80080-5
   Marker P, 1996, ORAL SURG ORAL MED O, V82, P122, DOI 10.1016/S1079-2104(96)80214-9
   Ninomiya T, 2002, J ORAL PATHOL MED, V31, P526, DOI 10.1034/j.1600-0714.2002.00029.x
   PARTRIDGE M, 1987, BRIT J ORAL MAX SURG, V25, P271, DOI 10.1016/0266-4356(87)90065-9
   Partsch C, 1892, DTSCH MSCHR ZAHNHEIL, V10, P271
   Partsch C, 1910, DTSCH MSCHR ZAHNHEIL, V28, P252
   Phillipsen HP, 1956, TANDLAEGEBLADET, V60, P963
   Piattelli A, 1998, ORAL ONCOL, V34, P404, DOI 10.1016/S1368-8375(98)00026-8
   PINDBORG JJ, 1963, ACTA PATHOL MIC SC, V58, P283
   RUD J, 1969, J ORAL SURG, V27, P323
   Schmidt BL, 2001, J ORAL MAXIL SURG, V59, P720, DOI 10.1053/joms.2001.24278
   Schoelch ML, 1999, ORAL ONCOL, V35, P77, DOI 10.1016/S1368-8375(98)00065-7
   Shear M, 2002, ORAL ONCOL, V38, P407, DOI 10.1016/S1368-8375(01)00067-7
   Shear M, 2002, ORAL ONCOL, V38, P323, DOI 10.1016/S1368-8375(01)00066-5
   Shear M, 2002, ORAL ONCOL, V38, P219, DOI 10.1016/S1368-8375(01)00065-3
   SHEAR M, 1960, J DENT ASSOC S AFR, V15, P211
   Stoelinga PJW, 2001, INT J ORAL MAX SURG, V30, P14, DOI 10.1054/ijom.2000.0027
   TUCKER WM, 1972, J ORAL SURG, V30, P669
   VOORSMIT RACA, 1981, J MAXILLOFAC SURG, V9, P228, DOI 10.1016/S0301-0503(81)80049-5
NR 30
TC 106
Z9 118
U1 5
U2 20
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
EI 1531-5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD JUN
PY 2004
VL 62
IS 6
BP 651
EP 655
DI 10.1016/j.joms.2003.08.029
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 825HC
UT WOS:000221745800002
PM 15170272
DA 2018-12-27
ER

PT J
AU Thangadurai, D
   Viswanathan, MB
   Ramesh, N
AF Thangadurai, D
   Viswanathan, MB
   Ramesh, N
TI RETRACTED: Characterization of a new decahydropyridoquinoline from
   Indigofera longeracemosa Boiv. Ex Baill (Fabaceae) (Retracted Article)
SO NATURAL PRODUCT RESEARCH
LA English
DT Correction; Retracted Publication
CR THANGADURAI D, 1995, NAT PROD RES, V48, P955
NR 1
TC 1
Z9 1
U1 2
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD JUN
PY 2004
VL 18
IS 3
BP 287
EP 287
DI 10.1080/14786410410001709223
PG 1
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 818JS
UT WOS:000221242000015
OA Bronze
DA 2018-12-27
ER

PT J
AU Hayakawa, Y
   Berzins, SP
   Crowe, NY
   Godfrey, DI
   Smyth, MJ
AF Hayakawa, Y
   Berzins, SP
   Crowe, NY
   Godfrey, DI
   Smyth, MJ
TI RETRACTED: Antigen-induced tolerance by intrathymic modulation of
   self-recognizing inhibitory receptors (Retracted article. See vol 7, pg
   890, 2006)
SO NATURE IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID NK T-CELLS; ALPHA-GALACTOSYLCERAMIDE; SELECTIVE REDUCTION; CYTOKINE
   PRODUCTION; NEGATIVE SELECTION; BONE-MARROW; MICE; LYMPHOCYTES;
   CYTOTOXICITY; RECOGNITION
AB CD1d-restricted invariant natural killer T cell (iNKT cells) have a limited T cell receptor (TCR) repertoire and share characteristics common to T cells and natural killer cells. While intrathymic selection facilitates the production of T cells carrying self major histocompatibility complex-restricted TCRs, natural killer cells carry an appropriate repertoire of self major histocompatibility complex-recognizing receptors to avoid self-reactivity. Here we show that chronic exposure to specific glycolipid antigen resulted in iNKT cell disappearance and thymus-dependent repopulation of iNKT cells with increased expression of inhibitory Ly-49 molecules that resulted in impaired responsiveness. Thymic selection of peripheral Ly-49-expressing iNKT cell repertoire inhibited cytokine production and other functions in vivo. These observations emphasize the acquisition of self-recognizing inhibitory receptors on NKT cells as a previously unknown mechanism of thymic tolerance after chronic antigen exposure.
C1 Peter MacCallum Canc Ctr, Trescowthick Labs, Canc Immunol Program, Melbourne, Vic 3002, Australia.
   Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.
RP Hayakawa, Y (reprint author), Peter MacCallum Canc Ctr, Trescowthick Labs, Canc Immunol Program, St Andrews Pl, Melbourne, Vic 3002, Australia.
EM yoshihiro.hayakawa@petermac.org
OI Godfrey, Dale/0000-0002-3009-5472; Smyth, Mark/0000-0001-7098-7240
CR Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535
   BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697
   Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017
   Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G
   Chun T, 2003, J EXP MED, V197, P907, DOI 10.1084/jem.20021366
   Coles MC, 2000, EUR J IMMUNOL, V30, P236, DOI 10.1002/1521-4141(200001)30:1<236::AID-IMMU236>3.0.CO;2-X
   Crowe NY, 2003, J IMMUNOL, V171, P4020, DOI 10.4049/jimmunol.171.8.4020
   Crowe NY, 2002, J EXP MED, V196, P119, DOI 10.1084/jem.20020092
   DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0
   Dhodapkar MV, 2003, J EXP MED, V197, P1667, DOI 10.1084/jem.20021650
   Eberl G, 2000, EUR J IMMUNOL, V30, P985, DOI 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E
   Eberl G, 1998, IMMUNITY, V9, P345, DOI 10.1016/S1074-7613(00)80617-2
   Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827
   Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710
   Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369
   Giaccone G, 2002, CLIN CANCER RES, V8, P3702
   Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7
   Huard B, 2000, EUR J IMMUNOL, V30, P1665, DOI 10.1002/1521-4141(200006)30:6<1665::AID-IMMU1665>3.0.CO;2-2
   Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105
   Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626
   Kojo S, 2001, ARTHRITIS RHEUM, V44, P1127, DOI 10.1002/1529-0131(200105)44:5<1127::AID-ANR194>3.0.CO;2-W
   Korner H, 2000, J EXP MED, V191, P89, DOI 10.1084/jem.191.1.89
   Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854
   MacDonald HR, 1998, J EXP MED, V187, P2109, DOI 10.1084/jem.187.12.2109
   MacDonald HR, 2002, SCIENCE, V296, P481, DOI 10.1126/science.1071492
   Mieza MA, 1996, J IMMUNOL, V156, P4035
   Moser JM, 2002, NAT IMMUNOL, V3, P189, DOI 10.1038/ni757
   Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155
   Ortaldo JR, 1998, J IMMUNOL, V160, P1158
   Pellicci DG, 2003, EUR J IMMUNOL, V33, P1816, DOI 10.1002/eji.200323894
   Pellicci DG, 2002, J EXP MED, V195, P835, DOI 10.1084/jem.20011544
   PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542
   Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829
   Sidobre S, 2002, J IMMUNOL, V169, P1340, DOI 10.4049/jimmunol.169.3.1340
   Singh N, 1999, J IMMUNOL, V163, P2373
   Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661
   Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3
   Speiser DE, 1999, J EXP MED, V190, P775, DOI 10.1084/jem.190.6.775
   Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601 .141107
   SUMIDA T, 1995, J EXP MED, V182, P1163, DOI 10.1084/jem.182.4.1163
   TAHIR M, 2001, J IMMUNOL, V167, P4046
   TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155
   VANKAER L, 1992, CELL, V71, P1205
   Voyle RB, 2003, J EXP MED, V197, P919, DOI 10.1084/jem.20021615
   Wilson MT, 2003, P NATL ACAD SCI USA, V100, P10913, DOI 10.1073/pnas.1833166100
   Wilson SB, 1998, NATURE, V391, P177
   Yanagisawa K, 2002, J IMMUNOL, V168, P6494, DOI 10.4049/jimmunol.168.12.6494
   Yang JQ, 2003, J IMMUNOL, V171, P4439, DOI 10.4049/jimmunol.171.8.4439
   Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055
NR 49
TC 36
Z9 37
U1 4
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2004
VL 5
IS 6
BP 590
EP 596
DI 10.1038/ni1069
PG 7
WC Immunology
SC Immunology
GA 824DH
UT WOS:000221664000017
PM 15122252
DA 2018-12-27
ER

PT J
AU Wen, FR
   Yuan, BZ
AF Wen, FR
   Yuan, BZ
TI RETRACTED: Least-squares fitting for deformable superquadric model based
   on orthogonal distance (Retracted Article. See vol 26, pg 685, 2005)
SO PATTERN RECOGNITION LETTERS
LA English
DT Article; Retracted Publication
DE fitting; superquadric; algebraic distance; geometric distance
ID CONIC SECTIONS; SCATTERED DATA; RANGE DATA; 3D DATA; SEGMENTATION;
   SURFACES; FORM
AB The least-squares fitting minimizes the squares sum of error-of-fit in predefined measures. By the geometric fitting, the error distances are defined as the orthogonal, or shortest distances from the given points to the geometric model to be fitted. Then the nonlinear optimization algorithm can be used to obtain the optimum solution. In this paper, we propose a geometric fitting algorithm for the deformable superquadric model, which is the computation of a measure of vector from each given point to orthogonal contacting point on the superquadric model, and estimates the optimum parameters of the model to minimize the squares sum of error distances. The estimated parameters by the proposed algorithm are invariant to coordinate transformation and we can easily find a physical interpretation of the fitting parameters. (C) 2004 Elsevier B.V. All rights reserved.
C1 No Jiaotong Univ, Inst Informat Sci, Beijing 100044, Peoples R China.
RP Wen, FR (reprint author), No Jiaotong Univ, Inst Informat Sci, Beijing 100044, Peoples R China.
EM frwen@163.net
CR Andrew F, 1999, IEEE T PATTERN ANAL, V21, P476
   Bajcsy R., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3), P231
   Bardinet E, 1998, COMPUT VIS IMAGE UND, V71, P39, DOI 10.1006/cviu.1997.0595
   Barr A. H., 1984, Computers & Graphics, V18, P21
   Barr A. H., 1981, IEEE COMPUT GRAPH, V1, P1, DOI [10.1109/MCG.1981.1673788, DOI 10.1109/MCG.1981.1673788]
   BOOKSTEIN FL, 1979, COMPUT VISION GRAPH, V9, P56, DOI 10.1016/0146-664X(79)90082-0
   CAO X, 1995, P 5 INT C IM PROC IT, P345
   CAO XP, 1994, PATTERN RECOGN LETT, V15, P781, DOI 10.1016/0167-8655(94)90006-X
   GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027
   Liu WB, 2001, CHINESE J ELECTRON, V10, P100
   Marshall D, 2001, IEEE T PATTERN ANAL, V23, P304, DOI 10.1109/34.910883
   PENTLAND AP, 1986, ARTIF INTELL, V28, P293, DOI 10.1016/0004-3702(86)90052-4
   SAMPSON PD, 1982, COMPUT VISION GRAPH, V18, P97, DOI 10.1016/0146-664X(82)90101-0
   SOLINA F, 1990, IEEE T PATTERN ANAL, V12, P131, DOI 10.1109/34.44401
   SUNG JA, 2001, PATTERN RECOGN, V34, P2283
   TAUBIN G, 1991, IEEE T PATTERN ANAL, V13, P1115, DOI 10.1109/34.103273
NR 16
TC 1
Z9 2
U1 4
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8655
EI 1872-7344
J9 PATTERN RECOGN LETT
JI Pattern Recognit. Lett.
PD JUN
PY 2004
VL 25
IS 8
BP 933
EP 941
DI 10.1016/j.patrec.2004.02.009
PG 9
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 823YN
UT WOS:000221650400011
DA 2018-12-27
ER

PT J
AU Tor, M
   Brown, D
   Cooper, A
   Woods-Tor, A
   Sjolander, K
   Jones, JDG
   Holub, EB
AF Tor, M
   Brown, D
   Cooper, A
   Woods-Tor, A
   Sjolander, K
   Jones, JDG
   Holub, EB
TI RETRACTED: Arabidopsis downy mildew resistance gene RPP27 encodes a
   receptor-like protein similar to CLAVATA2 and tomato Cf-9 (Retracted
   Article. See vol 143, pg 1079, 2007)
SO PLANT PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID PATHOGEN CLADOSPORIUM-FULVUM; DISEASE RESISTANCE;
   PERONOSPORA-PARASITICA; AVIRULENCE DETERMINANTS; BINDING-SITE; KINASE;
   LOCUS; THALIANA; RACE; AVR9
AB The Arabidopsis Ler-RPP27 gene confers AtSgt1b-independent resistance to downy mildew (Peronospora parasitica) isolate Hiks1. The RPP27 locus was mapped to a four-bacterial artificial chromosome interval on chromosome 1 from genetic analysis of a cross between the enhanced susceptibility mutant Col-edm1 (Col-sgt1) and Landsberg erecta (Ler-0). A Cf-like candidate gene in this interval was PCR amplified from Ler-0 and transformed into mutant Col-rpp7.1 plants. Homozygous transgenic lines conferred resistance to Hiks1 and at least four Ler-0 avirulent/Columbia-0 (Col-0) virulent isolates of downy mildew pathogen. A full-length RPP27 cDNA was isolated, and analysis of the deduced amino acid sequences showed that the gene encodes a receptor-like protein (RLP) with a distinct domain structure, composed of a signal peptide followed by extracellular Leu-rich repeats, a membrane spanning region, and a short cytoplasmic carboxyl domain. RPP27 is the first RLP-encoding gene to be implicated in disease resistance in Arabidopsis, enabling the deployment of Arabidopsis techniques to investigate the mechanisms of RLP function. Homology searches of the Arabidopsis genome, using the RPP27, Cf-9, and Cf-2 protein sequences as a starting point, identify 59 RLPs, including the already known CLAVATA2 and TOO MANY MOUTHS genes. A combination of sequence and phylogenetic analysis of these predicted RLPs reveals conserved structural features of the family.
C1 Hort Res Int, Warwick CV35 9EF, England.
   Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
   Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.
RP Tor, M (reprint author), Hort Res Int, Warwick CV35 9EF, England.
EM mahmur.tor@hri.ac.uk
RI tor, mahmut/C-1132-2009; Jones, Jonathan/J-5129-2012
OI Jones, Jonathan/0000-0002-4953-261X; Tor, Mahmut/0000-0002-4416-5048
FU Biotechnology and Biological Sciences Research Council [D16978]
CR ADACHI J, 1996, COMPUTER MONOGRAPHS, V28
   Belfanti E, 2004, P NATL ACAD SCI USA, V101, P886, DOI 10.1073/pnas.0304808101
   Bittner-Eddy PD, 2000, PLANT J, V21, P177, DOI 10.1046/j.1365-313x.2000.00664.x
   Botella MA, 1998, PLANT CELL, V10, P1847
   Bryan GT, 2000, PLANT CELL, V12, P2033, DOI 10.1105/tpc.12.11.2033
   Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502
   Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x
   Cooley MB, 2000, PLANT CELL, V12, P663, DOI 10.1105/tpc.12.5.663
   Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161
   DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9
   Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8
   Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963
   Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911
   GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602
   Gunn ND, 2002, ADVANCES IN DOWNY MILDEW RESEARCH, P185, DOI 10.1007/0-306-47914-1_9
   Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1
   HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575
   HOLUB EB, 1994, MOL PLANT MICROBE IN, V7, P223, DOI 10.1094/MPMI-7-0223
   Holub EB, 2001, NAT REV GENET, V2, P516, DOI 10.1038/35080508
   Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925
   JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631
   Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kawchuk LM, 2001, P NATL ACAD SCI USA, V98, P6511, DOI 10.1073/pnas.091114198
   KOCH E, 1990, PLANT CELL, V2, P437
   KoomanGersmann M, 1996, PLANT CELL, V8, P929
   KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288
   LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195
   Luderer R, 2001, MOL PLANT MICROBE IN, V14, P867, DOI 10.1094/MPMI.2001.14.7.867
   Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X
   Manners JM, 1983, BIOCH PLANT PATHOLOG, P163
   MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614
   McDowell JM, 1998, PLANT CELL, V10, P1861, DOI 10.1105/tpc.10.11.1861
   McDowell JM, 2000, PLANT J, V22, P523, DOI 10.1046/j.1365-313x.2000.00771.x
   Meyers BC, 2003, PLANT CELL, V15, P809, DOI [10.1105/tpc.009308, 10.1102/tpc.009308]
   MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8
   Nadeau JA, 2002, SCIENCE, V296, P1697, DOI 10.1126/science.1069596
   Parker JE, 1996, PLANT CELL, V8, P2033
   Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879
   Piedras P, 1998, MOL PLANT MICROBE IN, V11, P1155, DOI 10.1094/MPMI.1998.11.12.1155
   Rehmany AP, 2003, FUNGAL GENET BIOL, V38, P33, DOI 10.1016/S1087-1845(02)00515-7
   Rethage J, 2000, PHYSIOL MOL PLANT P, V56, P179, DOI 10.1006/pmpp.2000.0261
   Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]
   Romeis T, 2000, PLANT CELL, V12, P803, DOI 10.1105/tpc.12.5.803
   Romeis T, 1999, PLANT CELL, V11, P273
   Shiu SH, 2003, PLANT PHYSIOL, V132, P530, DOI 10.1104/pp.103.021964
   SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804
   Stein JC, 1996, PLANT CELL, V8, P429
   STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816
   Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217
   ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x
   Tor M, 2003, MOL PLANT PATHOL, V4, P287, DOI [10.1046/j.1364-3703.2003.00169.x, 10.1046/J.1364-3703.2003.00169.X]
   Tor M, 2002, PLANT CELL, V14, P993, DOI 10.1105/tpc.001123
   VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1046/j.1365-313X.1992.t01-34-00999.x
   VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052
   Wang GL, 1998, PLANT CELL, V10, P765, DOI 10.1105/tpc.10.5.765
   WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6
NR 60
TC 36
Z9 42
U1 2
U2 14
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
EI 1532-2548
J9 PLANT PHYSIOL
JI Plant Physiol.
PD JUN
PY 2004
VL 135
IS 2
BP 1100
EP 1112
DI 10.1104/pp.103.037770
PG 13
WC Plant Sciences
SC Plant Sciences
GA 831AM
UT WOS:000222165300051
PM 15155873
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Tabata, Y
AF Hosseinkhani, H
   Tabata, Y
TI RETRACTED: PEGylation enhances tumor targeting of plasmid DNA by an
   artificial cationized protein with repeated RGD sequences,
   Pronectin((R)) (Retracted article. See vol. 232, pg. 270, 2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE tumor targeting; enhanced gene expression; pronectin; cationization;
   PEGylation
ID C-DEXTRAN CONJUGATE; VIVO GENE-TRANSFER; IN-VIVO; MITOMYCIN-C;
   DISPOSITION CHARACTERISTICS; LIPOSOME COMPLEXES; INTEGRIN
   ALPHA(V)BETA(3); INTRAVENOUS-INJECTION; POLYMERIC PRODRUG; CIRCULATION
   TIME
AB The objective of this study is to investigate feasibility of a non-viral gene carrier with repeated RGD sequences (Pronectin F+) in tumor targeting for gene expression. The Pronectin F+ was cationized by introducing spermine (Sm) to the hydroxyl groups to allow to polyionically complex with plasmid DNA. The cationized Pronectin F+ prepared was additionally modified with poly(ethylene glycol) (PEG) molecules which have active ester and methoxy groups at the terminal, to form various PEG-introduced cationized Pronectin F+. The cationized Pronectin F+ with or without PEGylation at different extents was mixed with a plasmid DNA of LacZ to form respective cationized Pronectin F+-plasmid DNA complexes. The plasmid DNA was electrophoretically complexed with cationized Pronectin F+ and PEG-introduced cationized Pronectin F+, irrespective of the PEGylation extent, although the higher N/P ratio of complexes was needed for complexation with the latter Pronectin F+. The molecular size and zeta potential measurements revealed that the plasmid DNA was reduced in size to about 250 nm and the charge was changed to be positive by the complexation with cationized Pronectin F+. For the complexation with PEG-introduced cationized Pronectin F+, the charge of complex became neutral being almost 0 mV with the increasing PEGylation extents, while the molecular size was similar to that of cationized Pronectin F+. When cationized Pronectin F+-plasmid DNA complexes with or without PEGylation were intravenously injected to mice carrying a subcutaneous Meth-AR-1 fibrosarcoma mass, the PEG-introduced cationized Pronectin F+-plasmid DNA complex specifically enhanced the level of gene expression in the tumor, to a significantly high extent compared with the cationized Pronectin F+-plasmid DNA complexes and free plasmid DNA. The enhanced level of gene expression depended on the percentage of PEG introduced, the N/P ratio, and the plasmid DNA dose. A fluorescent microscopic study revealed that the localization of plasmid DNA in the tumor tissue was observed only for the PEG-introduced cationized Pronectin F+-plasmid DNA complex injected. We conclude that the PEGylation of cationized Pronectin F+ is a promising way to enable the plasmid DNA to target to the tumor for gene expression. (C) 2004 Elsevier B.V. All rights reserved.
C1 Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, Kyoto 6068507, Japan.
RP Tabata, Y (reprint author), Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, 53 Kawara-Cho, Kyoto 6068507, Japan.
EM yasuhiko@frontier.kyoto-u.ac.jp
CR Aplin AE, 1998, PHARMACOL REV, V50, P197
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   ATSUMI R, 1987, CANCER RES, V47, P5546
   BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002
   Boulikas T, 1996, INT J ONCOL, V9, P941
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8
   Budker V, 2000, J GENE MED, V2, P76, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<76::AID-JGM97>3.0.CO;2-4
   Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663
   CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39
   Cappello J., 1990, POLYM PREPRINTS, V31, P193
   CAPPELLO J, 1994, PLASTICS MICROBES, P35
   Coll JL, 1999, HUM GENE THER, V10, P1659, DOI 10.1089/10430349950017662
   Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063
   Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y
   DUNCAN R, 1992, ANTI-CANCER DRUG, V3, P175, DOI 10.1097/00001813-199206000-00001
   Egilmez NK, 1996, BIOCHEM BIOPH RES CO, V221, P169, DOI 10.1006/bbrc.1996.0564
   Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869
   Eng C, 2001, ANN ONCOL, V12, P1743, DOI 10.1023/A:1013574328938
   Fang J, 2002, CANCER RES, V62, P3138
   FERRARI FA, 1986, Patent No. 8803533
   FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Griffioen AW, 2000, PHARMACOL REV, V52, P237
   Gutheil JC, 2000, CLIN CANCER RES, V6, P3056
   HERMANSON GT, 1992, IMMOBILIZED AFFINITY, P51
   Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040
   Hosseinkhani H, 2003, J CONTROL RELEASE, V86, P169, DOI 10.1016/S0168-3659(02)00412-1
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   IMOTO H, 1992, CANCER RES, V52, P4396
   KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002
   Kaul G, 2002, PHARM RES-DORDR, V19, P1061, DOI 10.1023/A:1016486910719
   KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505
   Kircheis R, 1999, J GENE MED, V1, P111
   Kircheis R, 2001, J CONTROL RELEASE, V72, P165, DOI 10.1016/S0168-3659(01)00272-3
   Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   KISHIDA A, 1992, BIOMATERIALS, V13, P113, DOI 10.1016/0142-9612(92)90006-A
   Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273
   Kopecek J, 2001, J CONTROL RELEASE, V74, P147, DOI 10.1016/S0168-3659(01)00330-3
   KOSMAS C, 1989, DRUGS, V38, P645, DOI 10.2165/00003495-198938050-00001
   LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553
   Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482
   Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1
   Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167
   Luo Y, 2002, CURR CANCER DRUG TAR, V2, P209, DOI 10.2174/1568009023333836
   Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1
   Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083
   Molineux G, 2002, CANCER TREAT REV, V28, P13, DOI 10.1016/S0305-7372(02)80004-4
   MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   Nomura T, 1998, J CONTROL RELEASE, V52, P239, DOI 10.1016/S0168-3659(97)00185-5
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   PARK JW, 2002, BREAST CANCER RES, V4, P495
   Pehamberger H, 2002, RECENT RESULTS CANC, V160, P158
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   Sato N, 2001, CLIN CANCER RES, V7, P3606
   Schraa Astrid J, 2002, Biotechnol Annu Rev, V8, P133, DOI 10.1016/S1387-2656(02)08007-9
   Schraaa AJ, 2002, J CONTROL RELEASE, V83, P241, DOI 10.1016/S0168-3659(02)00206-7
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   Skubitz KM, 2002, INVEST NEW DRUG, V20, P101, DOI 10.1023/A:1014428720551
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267
   Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756
   Tabata T, 1998, J CONTROL RELEASE, V50, P123, DOI 10.1016/S0168-3659(97)00129-6
   Tabata Y, 1997, DRUG DELIV, V4, P213, DOI 10.3109/10717549709051895
   TAKAKURA Y, 1987, INT J PHARM, V37, P145, DOI 10.1016/0378-5173(87)90019-6
   TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753
   TAKAKURA Y, 1987, INT J PHARM, V37, P135, DOI 10.1016/0378-5173(87)90018-4
   Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647
   THORPE PE, 1997, J CONTROL RELEASE, V129, P57
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P181, DOI 10.1016/0005-2736(94)90025-6
   WAGNER E, 1994, ADV DRUG DELIVER REV, V14, P113, DOI 10.1016/0169-409X(94)90008-6
   WAWRZYNCZAK EJ, 1990, CLIN EXP IMMUNOL, V82, P189
   WILLIAMS JA, 1992, PATHOL BIOL, V40, P813
   WOODLE MC, 1994, BIOCONJUGATE CHEM, V5, P493, DOI 10.1021/bc00030a001
   Yu L, 2001, PHARMACEUT RES, V18, P1277, DOI 10.1023/A:1013081710135
   ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073
NR 80
TC 35
Z9 36
U1 3
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 31
PY 2004
VL 97
IS 1
BP 157
EP 171
DI 10.1016/j.jconrel.2004.02.025
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 827JZ
UT WOS:000221897000014
PM 15147813
DA 2018-12-27
ER

PT J
AU Khalil, S
   Wassel, AA
   Belal, FF
AF Khalil, S
   Wassel, AA
   Belal, FF
TI RETRACTED: Coated graphite-epoxy ion-selective electrode for the
   determination of chromium(III) in oxalic medium (Retracted Article. See
   vol 75, pg 1150, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE chromium(III) ion-selective electrode; coated raphite-epoxy conductor
   electrode potentiometry; PVC
ID ATOMIC-ABSORPTION-SPECTROMETRY; FLOW-INJECTION; LIQUID; EXCHANGER
AB A coated graphite-epoxy chromium(111) ion-selective electrode, based on the ion-pair between [Cr(oxalate)(3)](3-) anion and tricaprylmethylammonium cation (Aliquat 336) in a poly(vinylchloride) (PVC) matrix is constructed. A thin membrane film of this ion-pair, dibutylphthalate (DBP) in PVC was deposited directly onto a Perspex(R) tube containing a graphite-epoxy conductor substrate attached to the end of a glass tube. The effect of membrane composition (ion-pair, DBP and PVC), oxalate concentration, pH and some cations and anions upon the electrode response is investigated. The electrode shows a linear anionic response to E vs. log [Cr(3+)](i) in the chromium(III) concentration range from 2.9 x 10(-6) to 10(-2) mol l(-1), and a slope of -18.7 +/- 0.5 mV dec(-1), at pH working range of 2-8 and 0.3 mol l(-1) oxalate concentration. Variation in the potential of about 2 mV was observed during a working day of 7-8 h. The response time was less than 5 s and the life time of this electrode was superior to I year (over 1500 determinations by each polymeric membrane), with a practical detection limit of 2.1 x 10(-6) mol l(-1). Application of this electrode for chromium(III) determination in some food materials and various types of plants is described. (C) 2003 Elsevier B.V. All rights reserved.
C1 Cairo Univ, Fac Sci, Dept Chem, Fayoum Branch, Al Fayyum 63514, Egypt.
   Natl Org Drug Control & Res, Cairo, Egypt.
   King Saud Univ, Fac Pharm, Riyadh, Saudi Arabia.
RP Khalil, S (reprint author), Teachers Coll, Dept Chem, POB 4341, Riyadh 11491, Saudi Arabia.
EM s_khalil_99@yahoo.co.uk
CR Abbaspour A, 2001, TALANTA, V53, P1009, DOI 10.1016/S0039-9140(00)00593-2
   AGRAWAL C, 1989, INT J ENVIRON AN CH, V36, P95
   Arancibia V, 2003, J CHROMATOGR B, V785, P303, DOI 10.1016/S1570-0232(02)00924-8
   ARNOLD MA, 1986, ANAL CHEM, V58, pR84
   BARRAIS P, 1989, ANALUSIS, V17, P87
   CATTRALL RW, 1971, ANAL CHEM, V43, P1905, DOI 10.1021/ac60307a032
   COX JA, 1982, ANAL CHEM, V54, P787, DOI 10.1021/ac00241a042
   Cubadda F, 2003, FOOD CHEM, V81, P463, DOI 10.1016/S0308-8146(03)00002-5
   Davies R J, 1997, Sleep Med Rev, V1, P87, DOI 10.1016/S1087-0792(97)90011-3
   DONGHNI L, 1989, PHYS TEST CHEM ANAL, V25, P221
   ECKERT JM, 1990, ANAL CHIM ACTA, V236, P357, DOI 10.1016/S0003-2670(00)83334-6
   ECKERT JM, 1991, ANAL CHIM ACTA, V255, P31, DOI 10.1016/0003-2670(91)85083-5
   Eiras SD, 2003, TALANTA, V59, P621, DOI 10.1016/S0039-9140(02)00577-5
   ELBIETA S, 2003, ANAL CHIM ACTA, V479, P191
   ESTELLES L, 2001, FRESEN J ANAL CHEM, V371, P358
   FENG D, 1983, HUAXUE XUEBAO, V41, P371
   GABRERA A, 1986, QUIM ANAL, V5, P443
   GHOLIAN MB, 2003, TALANTA, V6, P707
   GONZALEZ M, 1989, TALANTA, V36, P945
   GUREV IA, 1985, ZH ANAL KHIM, V40, P2270
   JACOB MB, 1951, CHEM ANAL FOODS FOOD, P182
   JAFFAR M, 1990, PAKISTAN J SCI IND R, V33, P465
   JIANZHANG F, 1991, ACTA SCI NATUR U PEK, V22, P135
   Kaneko M, 2002, ANAL CHIM ACTA, V474, P167, DOI 10.1016/S0003-2670(02)01005-X
   kiewicz D. B., 2001, ANAL CHIM ACTA, V437, P11
   LIMA JLFC, 1986, ANALYST, V111, P799, DOI 10.1039/an9861100799
   MININ A, 1974, UCH ZAP PERMSK U, V324, P194
   Monteiro MIC, 2001, ANAL CHIM ACTA, V428, P265, DOI 10.1016/S0003-2670(00)01249-6
   MOODY GJ, 1970, ANALYST, V95, P910, DOI 10.1039/an9709500910
   MOODY GJ, 1971, ION SELECTIVE ELECTR, P15
   Revanasiddappa HD, 2003, TALANTA, V60, P1, DOI 10.1016/S0039-9140(02)00567-2
   ROSS JW, 1967, SCIENCE, V156, P1378, DOI 10.1126/science.156.3780.1378
   SHAFSTAHL J, 1989, MIKROCHIM ACTA, V2, P67
   Singh AK, 1999, ANALYST, V124, P521, DOI 10.1039/a901162e
   TEIXEIRA MFS, 1994, QUIM NOVA, V17, P124
   VAZHENIN G, 1974, METHODS DETERMINATIO
   Wuilloud GM, 2003, J PHARMACEUT BIOMED, V31, P117, DOI 10.1016/S0731-7085(02)00604-0
NR 37
TC 19
Z9 21
U1 4
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD MAY 28
PY 2004
VL 63
IS 2
BP 303
EP 307
DI 10.1016/j.talanta.2003.10.046
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 821BK
UT WOS:000221434300013
PM 18969432
DA 2018-12-27
ER

PT J
AU Asato, J
   Kanaya, F
AF Asato, J
   Kanaya, F
TI RETRACTED: Fatal infection of the hand due to Photobacterium damsela: A
   case report (Retracted article. See vol. 39, pg. 152, 2004)
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article; Retracted Publication
ID VIBRIO-DAMSELA; NECROTIZING FASCIITIS; SEPTICEMIA
AB We report a case of fatal acute renal failure due to Photobacterium damsela infection of the hand. Although the patient received intensive medical care and surgical treatment, he died 8 h after arrival at the hospital. This is the first case of P. damsela sepsis proven by blood culture in Japan.
C1 Nakagami Hosp, Dept Orthoped, Okinawa 9042195, Japan.
   Univ Ryukyus, Sch Med, Dept Orthoped Surg, Okinawa, Japan.
RP Asato, J (reprint author), Nakagami Hosp, Dept Orthoped, Okinawa 9042195, Japan.
EM asato@nakagami.or.jp
CR CLARRIDGE JE, 1985, J CLIN MICROBIOL, V21, P302
   COFFEY JA, 1986, J INFECT DIS, V153, P800, DOI 10.1093/infdis/153.4.800-a
   CUTTER DL, 1990, INFECT IMMUN, V58, P266
   DRYDEN M, 1989, MED J AUSTRALIA, V151, P540
   Fraser SL, 1997, CLIN INFECT DIS, V25, P935, DOI 10.1086/597647
   KREGER AS, 1984, INFECT IMMUN, V44, P326
   Lehane L, 2000, MED J AUSTRALIA, V173, P256
   LEVINE WC, 1993, J INFECT DIS, V167, P479, DOI 10.1093/infdis/167.2.479
   LOVE M, 1981, SCIENCE, V214, P1139, DOI 10.1126/science.214.4525.1139
   MORRIS JG, 1982, LANCET, V1, P1294
   PEREZTIRSE J, 1993, ARCH INTERN MED, V153, P1838, DOI 10.1001/archinte.153.15.1838
   Shin JH, 1996, CLIN INFECT DIS, V22, P856, DOI 10.1093/clinids/22.5.856
   SMITH SK, 1991, INT J SYST BACTERIOL, V41, P529, DOI 10.1099/00207713-41-4-529
   Tang WM, 1999, ORTHOPEDICS, V22, P443
   YUEN KY, 1993, SCAND J INFECT DIS, V25, P659, DOI 10.3109/00365549309008557
NR 15
TC 8
Z9 8
U1 3
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2004
VL 38
IS 10
BP E100
EP E101
DI 10.1086/383468
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 817JH
UT WOS:000221173300036
PM 15156501
OA Bronze
DA 2018-12-27
ER

PT J
AU Chen, CB
   Li, QS
AF Chen, CB
   Li, QS
TI RETRACTED: A strict solution for the optimal superimposition of protein
   structures (Retracted Article. See vol A60, Pg 640, Nov 2004)
SO ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES
LA English
DT Article; Retracted Publication
ID RELATE 2 SETS; METRIC PROPERTIES; VECTOR SETS; SUPERPOSITION; ROTATION
AB Existing methods for the optimal superimposition of one vector set on another in the comparison of parts or the whole of related protein molecules are based on the precondition that the centroids of the two sets are coincident. As a result, the translation components of the transformation are artificially removed from the superimposition process. This is obviously not strict in the mathematical sense. The theorem presented in this paper is a strict solution for the optimal superimposition of two vector sets, which is in fact the problem of the weighted optimal rigid superimposition of two vector sets. Examples show its advantages compared with the method of simply coinciding the centroids of the two vector sets for the translation transformation.
C1 Huazhong Univ Sci & Technol, Coll Comp Sci & Technol, Wuhan 430074, Peoples R China.
RP Li, QS (reprint author), Huazhong Univ Sci & Technol, Coll Comp Sci & Technol, Wuhan 430074, Peoples R China.
EM li_qishen@yahoo.com
CR DIAMOND R, 1988, ACTA CRYSTALLOGR A, V44, P211, DOI 10.1107/S0108767387010535
   DIAMOND R, 1976, ACTA CRYSTALLOGR A, V32, P1, DOI 10.1107/S0567739476000016
   FERRO DR, 1977, ACTA CRYSTALLOGR A, V33, P345, DOI 10.1107/S0567739477000862
   KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873
   KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680
   Kaindl K, 1997, ACTA CRYSTALLOGR A, V53, P809, DOI 10.1107/S0108767397010325
   LESK AM, 1986, ACTA CRYSTALLOGR A, V42, P110, DOI 10.1107/S0108767386099786
   MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5
   MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806
   MCLACHLAN AD, 1972, ACTA CRYSTALLOGR A, VA 28, P656, DOI 10.1107/S0567739472001627
   Steipe B, 2002, ACTA CRYSTALLOGR A, V58, P506, DOI 10.1107/S0108767302011637
   UMEYAMA S, 1991, IEEE T PATTERN ANAL, V13, P376, DOI 10.1109/34.88573
NR 12
TC 1
Z9 1
U1 1
U2 1
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2053-2733
J9 ACTA CRYSTALLOGR A
JI Acta Crystallogr. Sect. A
PD MAY
PY 2004
VL 60
BP 201
EP 203
DI 10.1107/S0108767304003654
PN 3
PG 3
WC Chemistry, Multidisciplinary; Crystallography
SC Chemistry; Crystallography
GA 814KX
UT WOS:000220974700001
PM 15103161
DA 2018-12-27
ER

PT J
AU Oonakahara, K
   Matsuyama, W
   Higashimoto, I
   Kawabata, M
   Arimura, K
   Osame, M
AF Oonakahara, K
   Matsuyama, W
   Higashimoto, I
   Kawabata, M
   Arimura, K
   Osame, M
TI RETRACTED: Stromal-derived factor-1 alpha/CXCL12-CXCR 4 axis is involved
   in the dissemination of NSCLC cells into pleural space (Retracted
   article. See vol 39, pg. 380, 2008)
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID CHEMOKINE RECEPTOR CXCR4; LUNG-CANCER; SIGNAL-TRANSDUCTION; LYMPHOCYTE
   CHEMOATTRACTANT; PHOSPHOINOSITIDE 3-KINASE; ALPHA-CHEMOKINE; FACTOR-1
   SDF-1; EFFUSION; EXPRESSION; MIGRATION
AB Malignant pleural effusion (PE) is one of the poor prognostic factors in non-small cell lung cancer (NSCLC), and the detailed mechanism of the malignant PE formation is not fully elucidated. Recently, CXCR4, a receptor for chemokine stromal-derived factor-la (SDF-1alpha) that can induce chemotaxis of cells, was reported to be expressed on NSCLC. In this study, we hypothesized that the SDF-1alpha/CXCR4 axis may be involved in the dissemination of malignant cells into pleural space, and investigated its expression, function, and signaling pathway using NSCLC cell lines and clinical samples from 43 patients with NSCLC with malignant PE. We found functional expression of CXCR4 on NSCLC cell lines, and also found that SDF-1alpha could induce migration via phosphaticlylinositol 3 (Pl-3) kinase- and p44/42 mitogen-activated protein kinase-dependent manner. The SDF-1alpha levels in malignant PE were significantly higher than those in transudate PE and showed a significant positive correlation with PE volumes. The sensitivity and specificity for prediction of recurrence of malignant PE was 61.5% and 83.3%, respectively (cutoff SDF-1alpha = 2,500 ng/ml), and better than those using pH of PE. Cancer cells in malignant PE expressed CXCR4, and mesothelial cells of the pleura stained positive for SDF-1alpha. The SDF-1alpha/CXCR4 axis is involved in the dissemination of NSCLC cells into pleural space.
C1 Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 8908520, Japan.
   Natl Minami Kyushu Hosp, Dept Resp Med, Kagoshima, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ, Fac Med, Dept Internal Med 3, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   Arenberg DA, 2001, CANCER IMMUNOL IMMUN, V50, P533, DOI 10.1007/s00262-001-023109
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Burrows CM, 2000, CHEST, V117, P73, DOI 10.1378/chest.117.1.73
   Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3
   Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585
   DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/0022-1759(80)90211-2
   Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   HAUSHEER FH, 1987, CANCER METAST REV, V6, P23, DOI 10.1007/BF00047607
   HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54
   Heffner JE, 2000, CHEST, V117, P87, DOI 10.1378/chest.117.1.87
   Heffner JE, 2000, CHEST, V117, P79, DOI 10.1378/chest.117.1.79
   Jourdan P, 1998, J IMMUNOL, V160, P4153
   Kijima T, 2002, CANCER RES, V62, P6304
   Light RW, 1997, LUNG, V175, P213, DOI 10.1007/PL00007568
   Luciani MG, 1998, J CLIN PATHOL-MOL PA, V51, P273
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   Mohle R, 1998, BLOOD, V91, P4523
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Naito T, 1997, ANTICANCER RES, V17, P4743
   Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   Popik W, 1998, J VIROL, V72, P6406
   REED CE, 1996, LUNG CANC PRINCIPLES, P643
   Rodriguez-Panadero F, 2003, TXB PLEURAL DIS, P297
   Rollins BJ, 1997, BLOOD, V90, P909
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   RUSCH VW, 1991, CHEST, V100, P1483, DOI 10.1378/chest.100.6.1483
   SAHN SA, 1993, CLIN CHEST MED, V14, P189
   Sanchez X, 1997, J BIOL CHEM, V272, P27529, DOI 10.1074/jbc.272.44.27529
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Sotsios Y, 1999, J IMMUNOL, V163, P5954
   Sozzani S, 1997, J IMMUNOL, V159, P1993
   Sugiura S, 1997, CLIN CANCER RES, V3, P47
   Taichman RS, 2002, CANCER RES, V62, P1832
   Vicari AP, 2000, J IMMUNOL, V165, P1992, DOI 10.4049/jimmunol.165.4.1992
   Wang JF, 1998, BLOOD, V92, P756
   WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 47
TC 64
Z9 67
U1 3
U2 6
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2004
VL 30
IS 5
BP 671
EP 677
DI 10.1165/rcmb.2003-0340OC
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 818YM
UT WOS:000221280400010
PM 14672915
DA 2018-12-27
ER

PT J
AU Kulkarni, MR
AF Kulkarni, MR
TI RETRACTED: Critical radius for radial heat conduction: a necessary
   criterion but not always sufficient (Retracted article. See vol. 130,
   pg. 1619, 2018)
SO APPLIED THERMAL ENGINEERING
LA English
DT Article; Retracted Publication
AB Use of the critical radius for radial heat conduction in thermal insulation systems has been widely reported in the literature. When it is desirable to increase heat dissipation in these systems, the critical radius can be used in a definitive manner to maximize the heat dissipation. However, if it is desirable to decrease heat gain or heat loss, the critical radius only serves as a necessary condition, but it is not sufficient. To address design issues of such thermal systems, the crossover radius is utilized. The crossover radius is defined as a radius greater than the critical radius such that the heat transfer with the corresponding amount of insulating material is equal to that of the bare thermal system. Both cylindrical and spherical systems are considered.
   Justification: It will be pointed out later in this paper that the concept of the crossover insulation radius is applicable when the Biot number is less than I in a cylindrical system or when it is less than 2 for the spherical system. Once the Biot number is larger than these respective values, the heat transfer reduction is immediate with application of any amount of insulation. However, the Justification for the present work is threefold. First, all the available heat transfer textbooks discuss only the concept of the critical insulation radius and the subsequent increase in the relative heat transfer as compared to the bare radial system. The present work extends the discussion beyond the critical insulation radius along with he impact on the relative heat transfer and thus completing the discussion. Secondly, even today there are smaller, cylindrical thermal systems that are employed in the refrigeration and cryogenics industry which have rather small value of the Biot numbers. Third, with the current trends in the compact heat exchangers, as thermal systems get smaller and smaller, it is natural that the smaller values of Biot number will be encountered more frequently where the concept of the crossover insulation radius is applicable. At times such systems are improperly insulated resulting actually in an energy penalty due to increased heat transfer. With adequate knowledge about the crossover insulation radius, these systems can be properly insulated while improving their energy effectiveness. Such present-day smaller thermal systems are discussed next.
   In this work the Biot number is defined as the ratio of convective heat transfer coefficient times the inner radius of the insulation divided by the thermal conductivity of the insulating material. Thus all the three parameters will be addressed first before discussing the smaller Biot numbers. As reported in one cryogenic heat transfer study, the convective heat transfer coefficient varies almost linearly with the prevailing temperature difference [Adv. Cryog. Eng. 6 (1960) 499]. The value varies from 8.1 to 11.6 W/m(2)K over the temperature difference of 100-300 K. According to the most recent developments, the smallest pipe or tubing diameter that is employed in the industry is 2/16 in. for aluminum and 3/16 in. for copper [TRANE Reciprocating Refrigeration Manual, North American Commercial Group, The Trane Company, 3600 Pammel Creek Road, Las Crosse, WI, 2000; Insulation Products, Armstrong World Industries, Inc., P.O. Box 3001, Lancaster, PA, 1996; Johnstones Supply Company, http://wwwjohnstonesupply.com/main/]. The capillary tubing is available even in smaller sizes. The thermal conductivity values of foam insulation at cryogenic temperatures range from 0.033 to 0.055 W/m K [R.H. Kropschot, Low-Temperature Insulation, Applied Cryogenic Engineering, John Wiley, 1962, pp. 152-1691. The interstitial gas contained in the cells plus internal radiation and a contribution due to solid conduction determines the thermal conductivity of foam. Evacuation of foam provides the initial apparent low thermal conductivity. But many Freon-blown types of foam will be penetrated by air over a period of time, which may increase their conductivity by as much as 30%. Based on the available data for refrigeration tube diameters (2/16 in. for aluminum and 3/16 in. for copper) and the insulation thermal conductivity values, the current range of smaller Biot numbers for the refrigeration systems turns out to be 0.23-0.84, which makes the present work relevant. It should be noted that as the thermal conductivity increases with age, the Biot number will become even smaller. Further, with the current trends in miniaturization, it is expected that the smaller Biot numbers will be encountered more frequently in the future. Representative energy penalties are analyzed next. (C) 2003 Elsevier Ltd. All rights reserved.
C1 So Illinois Univ, Dept Mech Engn & Energy Proc, Carbondale, IL 62901 USA.
RP Kulkarni, MR (reprint author), So Illinois Univ, Dept Mech Engn & Energy Proc, Carbondale, IL 62901 USA.
EM kulkarni@siu.edu
CR *ARMSTR WORLD IND, 1996, INS PROD
   BEJAN A, 1993, HEAT TRANSFER, P42
   Holman J. P., 1997, HEAT TRANSFER, P38
   HOLTEN DC, 1960, ADV CRYOGEN ENG, V6, P499
   Incropera F. P., 1996, INTRO HEAT TRANSFER, P93
   KLEIN SA, 1995, ENG EQUATION SOLVER
   KROPSCHOT RH, 1962, APPLIED CRYOGENIC EN, P152
   KUKAC S, 1993, HEART CONDUCTION, P62
   KULKARNI MR, COMMUNICATION VARIET
   SIMMONS LD, 1976, J HEAT TRANS-T ASME, V98, P150, DOI 10.1115/1.3450462
   SPARROW EM, 1970, AICHE J, V16, P149, DOI 10.1002/aic.690160130
   SUKHATME SP, 1983, HEAT TRASFER, P27
   *TRAN CO, 2000, TRANE REC REFR MAN
   WITTE LC, 1988, IND ENERGY MANAGEMEN, P387
NR 14
TC 8
Z9 8
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-4311
J9 APPL THERM ENG
JI Appl. Therm. Eng.
PD MAY
PY 2004
VL 24
IS 7
BP 967
EP 979
DI 10.1016/j.applthermaleng.2003.08.017
PG 13
WC Thermodynamics; Energy & Fuels; Engineering, Mechanical; Mechanics
SC Thermodynamics; Energy & Fuels; Engineering; Mechanics
GA 806BS
UT WOS:000220410000002
DA 2018-12-27
ER

PT J
AU Takahashi, T
   Shivapurkar, N
   Reddy, J
   Shigematsu, H
   Miyajima, K
   Suzuki, M
   Toyooka, S
   Zochbauer-Muller, S
   Drach, J
   Parikh, G
   Zheng, YY
   Feng, ZD
   Kroft, SH
   Timmons, C
   McKenna, RW
   Gazdar, AF
AF Takahashi, T
   Shivapurkar, N
   Reddy, J
   Shigematsu, H
   Miyajima, K
   Suzuki, M
   Toyooka, S
   Zochbauer-Muller, S
   Drach, J
   Parikh, G
   Zheng, YY
   Feng, ZD
   Kroft, SH
   Timmons, C
   McKenna, RW
   Gazdar, AF
TI RETRACTED: DNA methylation profiles of lymphoid and hematopoietic
   malignancies (Retracted article. See vol. 19, pg. 307, 2013)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CPG-ISLAND METHYLATION; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS-LYMPHOMAS;
   HYPERMETHYLATION-ASSOCIATED INACTIVATION; ABERRANT PROMOTER METHYLATION;
   MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; MULTIPLE-MYELOMA;
   EPIGENETIC INACTIVATION; PROGNOSTIC-SIGNIFICANCE
AB Purpose: Aberrant methylation of the 5' gene promoter regions is an epigenetic phenomenon that is the major mechanism for silencing of tumor suppressor genes in many cancer types. The aims of our study were (a) to compare the methylation profiles of the major forms of hematological malignancies and (b) to determine the methylation profile of monoclonal gammopathy of undetermined significance (MGUS) and compare it with that of multiple myeloma (MM).
   Experimental Design: We compared the aberrant promoter methylation profile of 14 known or suspected tumor suppressor genes in leukemias (n = 48), lymphomas (n = 42), and MMs (n = 40). We also examined the methylation profile of MGUS (n = 20), a premalignant plasma cell dyscrasia. The genes studied represent five of the six "hall-marks of cancer."
   Results: Peripheral blood lymphocytes (n = 14) from healthy volunteers were negative for methylation of all genes, and methylation percentages in 41 nonmalignant tissues (peripheral blood mononuclear cells, bone marrows, and lymph nodes) from hematological patients were low (0-9%) for all 14 genes, confirming that methylation was tumor specific. Ten of the genes were methylated at frequencies of 29-68% in one or more tumor types, and the methylation indices (an indicator of overall methylation) varied from 0.25 to 0.34. With two exceptions, the methylation patterns of leukemias and lymphomas were similar. However, the pattern of MMs varied from the other tumor types for six genes. In general, the methylation pattern of MGUS was similar to that of MM, although the methylation frequencies were lower (the methylation index of MGUS was 0.15, and that of MM was 0.3). However, the methylation frequencies of six genes were significantly higher in MGUS than in control tissues. The relatively high frequencies of methylation in MGUS are consistent with it being a premalignant condition.
   Conclusions: The three major forms of lymphoid/hematopoietic malignancies show overlapping but individual patterns of methylation.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therpeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   Univ Hosp Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria.
RP Gazdar, AF (reprint author), Univ Texas, SW Med Ctr, Hamon Ctr Therpeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Adi.Gazdar@UTSouthwestern.edu
RI Zochbauer-Muller, Sabine/B-8399-2012
OI Zochbauer-Muller, Sabine/0000-0002-6777-1729
FU NCI NIH HHS [5U01 CA 8497102]
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Aggerholm A, 1999, CANCER RES, V59, P436
   Bachman KE, 1999, CANCER RES, V59, P798
   Baldini L, 1996, BLOOD, V87, P912
   Baur AS, 1999, BLOOD, V94, P1773
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chim CS, 2003, BRIT J HAEMATOL, V122, P571, DOI 10.1046/j.1365-2141.2003.04462.x
   Chim CS, 2001, CANCER, V91, P2222, DOI 10.1002/1097-0142(20010615)91:12<2222::AID-CNCR1252>3.3.CO;2-I
   Corn PG, 1999, CANCER RES, V59, P3352
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2000, NAT GENET, V25, P315
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2002, CANCER RES, V62, P5902
   Garcia MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7
   Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Guillerm G, 2001, BLOOD, V98, P244, DOI 10.1182/blood.V98.1.244
   Hallek M, 1998, BLOOD, V91, P3
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1997, CANCER RES, V57, P837
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 2000, ANN NY ACAD SCI, V910, P140
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347
   Kramer AK, 2002, LEUKEMIA, V16, P1844, DOI 10.1038/sj.leu.2402609
   Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202
   KYLE RA, 1984, JAMA-J AM MED ASSOC, V251, P1849, DOI 10.1001/jama.251.14.1849
   Kyle RA, 1995, BAILLIERE CLIN HAEM, V8, P761, DOI 10.1016/S0950-3536(05)80258-6
   Martinez-Delgado B, 2002, INT J CANCER, V102, P15, DOI 10.1002/ijc.10618
   Martinez-Delgado B, 1998, LEUKEMIA, V12, P937, DOI 10.1038/sj.leu.2401009
   MartinezDelgado B, 1997, LEUKEMIA, V11, P425, DOI 10.1038/sj.leu.2400579
   Maruyama R, 2001, CANCER RES, V61, P8659
   Melki JR, 2000, BLOOD, V95, P3208
   Melki JR, 1999, CANCER RES, V59, P3730
   Ng MHL, 2001, CLIN CANCER RES, V7, P1724
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Siu LLP, 2003, BRIT J HAEMATOL, V122, P70, DOI 10.1046/j.1365-2141.2003.04396.x
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
   van Noesel MM, 2002, CANCER RES, V62, P2157
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Virmani AK, 2001, CLIN CANCER RES, V7, P584
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong IHN, 2000, BLOOD, V95, P1942
   Zochbauer-Muller S, 2001, CANCER RES, V61, P249
NR 55
TC 55
Z9 57
U1 3
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2004
VL 10
IS 9
BP 2928
EP 2935
DI 10.1158/1078-0432.CCR-03-0716
PG 8
WC Oncology
SC Oncology
GA 818UN
UT WOS:000221270100005
PM 15131027
OA Bronze
DA 2018-12-27
ER

PT J
AU Rachmani, R
   Slavachevsky, I
   Amit, M
   Levi, Z
   Kedar, Y
   Berla, M
   Ravid, M
AF Rachmani, R
   Slavachevsky, I
   Amit, M
   Levi, Z
   Kedar, Y
   Berla, M
   Ravid, M
TI RETRACTED: The effect of spironolactone, cilazapril and their
   combination on albuminuria in patients with hypertension and diabetic
   nephropathy is independent of blood pressure reduction: a randomized
   controlled study (Retracted article see vol 23, pg 818, 2006)
SO DIABETIC MEDICINE
LA English
DT Article; Retracted Publication
DE albuminuria; cilazapril; diabetic nephropathy; hypertension;
   spironolactone
ID SEVERE HEART-FAILURE; ALDOSTERONE BLOCKADE; RENAL-FUNCTION; MELLITUS;
   MORBIDITY; MORTALITY; LOSARTAN; TRIAL
AB Objective The effect of spironolactone, cilazapril and their combination on albuminuria was examined in a randomized prospective study in female patients with diabetes and hypertension.
   Patients and methods Sixty female diabetic patients aged 45-70 years with blood pressure (BP) 140-180/90-110 mmHg, serum creatinine (sCr) less than or equal to 160 mumol/l, HbA(1c) less than or equal to 10%, and albuminuria were treated by atenolol 12.5-75 mg/d and hydrochlorothiazide 6.25-25 mg/d. Titration-to-target helped to reach BP values less than or equal to 135185 mmHg in 46 patients after 12 weeks. These patients were randomized to spironolactone 100 mg/d or cilazapril 5 mg/d for 24 weeks. Then both groups received spironolactone 50 mg/d and cilazapril 2.5 mg/d for 24 weeks. BP was stabilized by tapering the dose of the initial agents. Urinary albumin/creatinine ratio (ACR), BP, K+. sCr and HbA(1c) were assessed at baseline and at weeks 12, 16, 36 and 60.
   Results The average BP at week 12 was 128 +/- 4/81 +/- 3 mmHg and remained constant, in both groups, throughout the study. ACR declined on spironolactone from a median value (range) of 452 (124-1571) to 216 (64-875) mg/g (P = 0.001), and on cilazapril to 302 (90-975) mg/g (P = 0.001). The difference between spironolactone and cilazapril was significant (P = 0.002). Combined treatment resulted in a further modest decline in ACR. Serum creatinine was unaltered by spironolactone and rose slightly (121 to 126 mumol/l, P = 0.02) on cilazapril.
   Conclusion At the doses tested, spironolactone was superior to cilazapril in reducing albuminuria. Combined administration was more effective than either drug alone. These effects were independent of BP values. Hyperkalaemia was the main side-effect.
C1 Meir Hosp, Dept Med, IL-44281 Kefar Sava, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
RP Ravid, M (reprint author), Meir Hosp, Dept Med, IL-44281 Kefar Sava, Israel.
EM motirv@clalit.org.il
OI Levi, Zohar/0000-0003-2456-8891
CR Alzamora R, 2003, ENDOCRINOLOGY, V144, P1266, DOI 10.1210/en.2002-220950
   BARTELS H, 1972, CLIN CHIM ACTA, V37, P193, DOI 10.1016/0009-8981(72)90432-9
   Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   Chun TY, 2003, ENDOCRINOLOGY, V144, P1712, DOI 10.1210/en.2002-220956
   Cicoira M, 2002, J AM COLL CARDIOL, V40, P304, DOI 10.1016/S0735-1097(02)01965-4
   Epstein M, 2002, AM J HYPERTENS, V15, p82S, DOI 10.1016/S0895-7061(02)02948-5
   Feria I, 2003, KIDNEY INT, V63, P43, DOI 10.1046/j.1523-1755.2003.00707.x
   Gerstein HC, 2000, LANCET, V355, P253
   Glick HA, 2002, CARDIOVASC DRUG THER, V16, P53, DOI 10.1023/A:1015371616135
   Griffin KA, 2003, HYPERTENSION, V41, P201, DOI 10.1161/01.HYP.0000049881.25304.73
   Jiang GR, 2003, HYPERTENSION, V41, P1131, DOI 10.1161/01.HYP.0000066128.04083.CA
   Koppel H, 2003, J CLIN ENDOCR METAB, V88, P1297, DOI 10.1210/jc.2002-020248
   Krum H, 2002, HYPERTENSION, V40, P117, DOI 10.1161/01.HYP.0000025146.19104.FE
   Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X
   Mogensen CE, 1999, DIABETOLOGIA, V42, P263, DOI 10.1007/s001250051151
   Neves MF, 2003, J HYPERTENS, V21, P189, DOI 10.1097/01.hjh.0000045515.82010.5a
   Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489
   Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001
   Puavilai G, 1999, DIABETES RES CLIN PR, V44, P21, DOI 10.1016/S0168-8227(99)00008-X
   Rachmani R, 1998, NEPHRON, V80, P175, DOI 10.1159/000045163
   Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004
   SATHIANATHAN P, 1986, CLIN CHEM, V32, P202
   Sato A, 2003, HYPERTENSION, V41, P64, DOI 10.1161/01.HYP.0000044937.95080.E9
   Stier Charles T Jr, 2002, Cardiol Rev, V10, P97
   Struthers AD, 2002, AM HEART J, V144, pS2, DOI 10.1067/mhj.2002.129969
   Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018
   Weber MA, 2002, AM HEART J, V144, pS12, DOI 10.1067/mhj.2002.129970
   Weinberger M., 2002, American Journal of Hypertension, V15, p24A, DOI 10.1016/S0895-7061(02)02334-8
NR 28
TC 103
Z9 108
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD MAY
PY 2004
VL 21
IS 5
BP 471
EP 475
DI 10.1111/j.1464-5491.2004.01194.x
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 818KJ
UT WOS:000221243700011
PM 15089793
DA 2018-12-27
ER

PT J
AU Cone, EJ
   Fant, RV
   Rohay, JM
   Caplan, YH
   Ballina, M
   Reder, RF
   Haddox, JD
AF Cone, EJ
   Fant, RV
   Rohay, JM
   Caplan, YH
   Ballina, M
   Reder, RF
   Haddox, JD
TI RETRACTED: Oxycodone involvement in drug abuse deaths. II. Evidence for
   toxic multiple drug-drug interactions (Retracted Article. See vol 28, pg
   616, 2004)
SO JOURNAL OF ANALYTICAL TOXICOLOGY
LA English
DT Article; Retracted Publication
ID HEROIN-RELATED DEATHS; NEW-SOUTH-WALES; CIRCUMSTANCES; COMBINATION;
   MIDAZOLAM; AUSTRALIA; LETHALITY; OVERDOSE; ETHANOL; USERS
C1 Purdue Pharma LP, Hlth Policy, Stamford, CT 06901 USA.
   Pinney Associates, Bethesda, MD USA.
   Pinney Associates, Pittsburgh, PA USA.
   Natl Sci Serv, Baltimore, MD USA.
RP Haddox, JD (reprint author), Purdue Pharma LP, Hlth Policy, 1 Stamford Forum, Stamford, CT 06901 USA.
EM dr.j.david.haddox@pharma.com
OI Haddox, James/0000-0001-5922-2108
CR Burt MJ, 2001, J FORENSIC SCI, V46, P1138
   Clayton R R, 1986, Recent Dev Alcohol, V4, P7
   Cone EJ, 2003, J ANAL TOXICOL, V27, P57, DOI 10.1093/jat/27.2.57
   Darke S, 1997, DRUG ALCOHOL DEPEN, V47, P45, DOI 10.1016/S0376-8716(97)00070-7
   Darke S, 2000, DRUG ALCOHOL DEPEN, V60, P141, DOI 10.1016/S0376-8716(99)00147-7
   DARKE S, 1995, DRUG ALCOHOL DEPEN, V39, P231, DOI 10.1016/0376-8716(95)01171-9
   Darke S, 1996, ADDICTION, V91, P1765, DOI 10.1111/j.1360-0443.1996.tb03800.x
   DRUMMER OH, 1994, J FORENSIC SCI, V39, P1069
   GARTY M, 1985, J PHARMACOL EXP THER, V234, P391
   Gossop M, 2002, ADDICTION, V97, P39, DOI 10.1046/j.1360-0443.2002.00079.x
   Gueye PN, 2002, TOXICOL SCI, V65, P107, DOI 10.1093/toxsci/65.1.107
   HABERMAN PW, 1995, J STUD ALCOHOL, V56, P344, DOI 10.15288/jsa.1995.56.344
   HENDERSON GL, 1991, J FORENSIC SCI, V36, P422
   ISENSCHMID DS, 1988, J FORENSIC SCI, V33, P1421
   Jones G. R, 1998, DRUG ABUSE HDB, P970
   LEANDER JD, 1977, RES COMMUN CHEM PATH, V17, P255
   LEVINE B, 1995, J FORENSIC SCI, V40, P808
   MOALLEM SA, 2003, HDB FORENSIC DRUG IN
   PENNING R, 1993, FORENSIC SCI INT, V62, P135, DOI 10.1016/0379-0738(93)90058-I
   POLING A, 1985, PHARMACOL BIOCHEM BE, V22, P333, DOI 10.1016/0091-3057(85)90399-5
   Poulin C, 1998, Chronic Dis Can, V19, P177
   PUSCHEL K, 1993, FORENSIC SCI INT, V62, P121, DOI 10.1016/0379-0738(93)90056-G
   RATTAN AK, 1994, PHARMACOL BIOCHEM BE, V48, P357, DOI 10.1016/0091-3057(94)90538-X
   Reisine T, 1996, GOODMAN GILMANS PHAR, P521
   Richards R G, 1976, J Forensic Sci, V21, P467
   RUTTENBER AJ, 1990, J FORENSIC SCI, V35, P891
   *SUBS AB MENT HLTH, 2002, DAWN SER, V23
   White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x
   Zador D, 1996, MED J AUSTRALIA, V164, P204
NR 29
TC 31
Z9 32
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0146-4760
EI 1945-2403
J9 J ANAL TOXICOL
JI J. Anal. Toxicol.
PD MAY-JUN
PY 2004
VL 28
IS 4
BP 217
EP 225
DI 10.1093/jat/28.4.217
PG 9
WC Chemistry, Analytical; Toxicology
SC Chemistry; Toxicology
GA 818XK
UT WOS:000221277600001
PM 15189671
OA Bronze
DA 2018-12-27
ER

PT J
AU Nekora-Azak, A
AF Nekora-Azak, A
TI RETRACTED: Temporomandibular disorders in relation to female
   reproductive hormones: A literature review (Retracted Article. See vol
   94, pg 305, 2005)
SO JOURNAL OF PROSTHETIC DENTISTRY
LA English
DT Review; Retracted Publication
ID STRESS-INDUCED ANALGESIA; ESTROGEN REPLACEMENT; STEROID-HORMONES;
   ELASTIC FIBERS; JOINT DISEASE; EPIDEMIOLOGY; RECEPTORS; PREGNANCY;
   SYMPTOMS; PAIN
AB Temporomandibular disorders (TMD) are common pain conditions that have the highest prevalence among women of reproductive age. The pattern of onset after puberty and lowered prevalence rates in the postmenopausal years suggest that female reproductive hormones may play an etiologic role in temporomandibular disorders. The purpose of this article is to review the role of female reproductive hormones in TMD. English-language peer-reviewed articles between 1975 and 2002 were identified using Medline as well as a hand search and were reviewed.
C1 Istanbul Univ, Fac Dent, Istanbul, Turkey.
RP Nekora-Azak, A (reprint author), Innere Altachen 21, CH-4800 Zofingen, Sweden.
EM aysenazak@hotmail.com
CR ABUBAKER AO, 1993, J ORAL MAXIL SURG, V51, P1096
   Abubaker AO, 1996, J ORAL MAXIL SURG, V54, P721, DOI 10.1016/S0278-2391(96)90690-4
   AKAISHI T, 1988, NEUROSCI LETT, V84, P57, DOI 10.1016/0304-3940(88)90337-0
   AUFDEMORTE TB, 1986, ORAL SURG ORAL MED O, V61, P307, DOI 10.1016/0030-4220(86)90407-X
   BODNAR RJ, 1988, BRAIN RES BULL, V21, P947, DOI 10.1016/0361-9230(88)90032-9
   CALGUNERI M, 1982, ANN RHEUM DIS, V41, P126, DOI 10.1136/ard.41.2.126
   CAMPBELL JH, 1993, J ORAL MAXIL SURG, V51, P1101, DOI 10.1016/S0278-2391(10)80449-5
   CARLSSON GE, 1995, PROG PAIN RES MANAG, V4, P211
   CHAMBERLAIN G, 1998, CLIN PHYSL OBSTETRIC, P99
   CORVOL M, 1992, J STEROID BIOCHEM, V43, P415, DOI 10.1016/0960-0760(92)90078-W
   Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301
   DWORKIN SF, 1990, J AM DENT ASSOC, V120, P273, DOI 10.14219/jada.archive.1990.0043
   GELB H, 1983, J PROSTHET DENT, V49, P234, DOI 10.1016/0022-3913(83)90509-7
   Glock J L, 1995, Early Pregnancy, V1, P206
   GOLDSMITH NF, 1975, J BONE JOINT SURG AM, V57, P657, DOI 10.2106/00004623-197557050-00014
   HASKIN CL, 1995, CRIT REV ORAL BIOL M, V6, P248, DOI 10.1177/10454411950060030601
   Kapila S, 1998, LAB INVEST, V78, P925
   Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002
   KUTTEH WH, 1994, J SOC GYNECOL INVEST, V1, P256, DOI 10.1177/107155769400100403
   Leonardi R, 2001, J ORAL MAXIL SURG, V59, P1186, DOI 10.1053/joms.2001.26723
   LeResche L, 1997, CRIT REV ORAL BIOL M, V8, P291, DOI 10.1177/10454411970080030401
   LeResche L, 1997, PAIN, V69, P153, DOI 10.1016/S0304-3959(96)03230-7
   LOCKER D, 1988, COMMUNITY DENT ORAL, V16, P310, DOI 10.1111/j.1600-0528.1988.tb01783.x
   MARBACH JJ, 1988, PAIN, V34, P139, DOI 10.1016/0304-3959(88)90159-5
   MILAM SB, 1987, ORAL SURG ORAL MED O, V64, P527, DOI 10.1016/0030-4220(87)90025-9
   MILAM SB, 1995, PROG PAIN RES MANAG, V4, P89
   MOGIL JS, 1993, PAIN, V53, P17, DOI 10.1016/0304-3959(93)90050-Y
   Mushayandebvu TI, 1998, OBSTET GYNECOL, V92, P17, DOI 10.1016/S0029-7844(98)00091-X
   ODELL NL, 1990, ARCH ORAL BIOL, V35, P807, DOI 10.1016/0003-9969(90)90005-U
   RIEDER CE, 1983, J PROSTHET DENT, V50, P81, DOI 10.1016/0022-3913(83)90171-3
   SPECTOR TD, 1991, J RHEUMATOL, V18, P1877
   Sternberg WF, 1995, PAIN, V63, P321, DOI 10.1016/0304-3959(95)00059-3
   VONKORFF M, 1988, PAIN, V32, P173, DOI 10.1016/0304-3959(88)90066-8
   Westling L, 1992, Swed Dent J Suppl, V81, P1
   Yasuoka T, 2000, J ORAL MAXIL SURG, V58, P189, DOI 10.1016/S0278-2391(00)90337-9
NR 35
TC 15
Z9 16
U1 3
U2 13
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3913
EI 1097-6841
J9 J PROSTHET DENT
JI J. Prosthet. Dent.
PD MAY
PY 2004
VL 91
IS 5
BP 491
EP 493
DI 10.1016/j.prosdent.2004.03.002
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 822IC
UT WOS:000221531500015
PM 15153858
DA 2018-12-27
ER

PT J
AU Kato, S
   Fujiki, R
   Kitagawa, H
AF Kato, S
   Fujiki, R
   Kitagawa, H
TI RETRACTED: Vitamin D receptor (VDR) promoter targeting through a novel
   chromatin remodeling complex (Retracted article. See vol. 126, pg. 55,
   2011)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE vitamin D receptor; WINAC; histone acetyltransferase; chromatin
   remodeling
ID TRANSCRIPTION; GENE; ISWI; SELECTIVITY; CONTAINS; REQUIRES
AB We have purified nuclear complexes for Vitamin D receptor (VDR), and identified one of them as a novel ATP-dependent chromatine remodeling containing Williams syndrome transcription factor (WSTF), that is supposed to be responsible for Williams syndrome. This complex (WSTF including nucleosome assembly complex (WINAC)) exhibited an ATP-dependent chromatin remodeling activity in vitro. Transient expression assays revealed that WINAC potentiates ligand-induced function of VDR in gene activation and repression. Thus, this study describes a molecular basis of the VDR function on chromosomal DNA through chromatine remodeling. sigma 2004 Elsevier Ltd. All rights reserved.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Japan Sci & Technol, SOREST, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214
   Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7
   Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9
   Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a
   LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900
   Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Peoples RJ, 1998, CYTOGENET CELL GENET, V82, P238, DOI 10.1159/000015110
   Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377
   Rachez C, 1999, NATURE, V398, P824
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X
   VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
NR 22
TC 23
Z9 23
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAY
PY 2004
VL 89-90
IS 1-5
SI SI
BP 173
EP 178
DI 10.1016/j.jsbmb.2004.03.100
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 840IS
UT WOS:000222852500032
PM 15225768
DA 2018-12-27
ER

PT J
AU Mori, N
   Matsuda, T
   Tadano, M
   Kinjo, T
   Yamada, Y
   Tsukasaki, K
   Ikeda, S
   Yamasaki, Y
   Tanaka, Y
   Ohta, T
   Iwamasa, T
   Tomonaga, M
   Yamamoto, N
AF Mori, N
   Matsuda, T
   Tadano, M
   Kinjo, T
   Yamada, Y
   Tsukasaki, K
   Ikeda, S
   Yamasaki, Y
   Tanaka, Y
   Ohta, T
   Iwamasa, T
   Tomonaga, M
   Yamamoto, N
TI RETRACTED: Apoptosis induced by the histone deacetylase inhibitor
   FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and
   primary adult T-cell leukemia cells (Retracted Article. See vol 85, pg
   1415, 2011)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; I TAX PROTEIN; HTLV-I; CONSTITUTIVE ACTIVATION; DEPSIPEPTIDE
   FR901228; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; INFECTED-CELLS; CYCLIN
   D2; TRANSCRIPTION
AB Inhibition of histone deacetylase (HDAC) activity induces growth arrest, differentiation, and, in certain cell types, apoptosis. FR901228, FK228, or depsipeptide, is an HDAC inhibitor effective in T-cell lymphomas. Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1) and remains incurable. We examined whether FR901228 is effective for treatment of ATL by assessing its ability to induce apoptosis of HTLV-1-infected T-cell lines and primary leukemic cells from ATL patients. FR901228 induced apoptosis of Tax-expressing and -unexpressing HTLV-1-infected T-cell lines and selective apoptosis of primary ATL cells, especially those of patients with acute ATL. FR901228 also efficiently reduced the DNA binding of NF-kappaB and AP-1 in HTLV-1-infected T-cell lines and primary ATL cells and down-regulated the expression of Bcl-x(L) and cyclin D2, regulated by NF-kappaB. Although the viral protein Tax is an activator of NF-kappaB and AP-1, FR901228-induced apoptosis was not associated with reduced expression of Tax. In vivo use of FR901228 partly inhibited the growth of tumors of HTLV-1-infected T cells transplanted subcutaneously in SCID mice. Our results indicated that FR901228 could induce apoptosis of these cells and suppress the expression of NF-kappaB and AP-1 and suggest that FR901228 could be therapeutically effective in ATL.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welfare, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Pathol & Cell Biol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
   Nagasaki Univ, Grad Sch Biomed Sci, Div Lab Med, Nagasaki 8528501, Japan.
   Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol,Mol Med Unit, Nagasaki 8528523, Japan.
   Sasebo City Gen Hosp, Dept Hematol, Sasebo 8578511, Japan.
   Kokura Mem Hosp, Dept Internal Med, Kitakyushu, Fukuoka 8028555, Japan.
   Tokyo Med & Dent Univ, Grad Sch, Dept Mol Virol, Tokyo 1138519, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR AKAGI T, 1995, BLOOD, V86, P4243
   Akagi T, 1996, ONCOGENE, V12, P1645
   ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265
   Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452
   BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985
   Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849
   Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509
   Byrd JC, 1999, BLOOD, V94, P1401
   Cereseto A, 1996, BLOOD, V88, P1551
   COLOTTA F, 1992, J BIOL CHEM, V267, P18278
   De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000
   DIXIT VM, 1989, J BIOL CHEM, V264, P16905
   DUYAO MP, 1992, J BIOL CHEM, V267, P16288
   FUJII M, 1991, ONCOGENE, V6, P1023
   Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987
   FURUKAWA Y, 1995, BLOOD, V85, P1865
   Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198
   ISHIYAMA M, 1993, CHEM PHARM BULL, V41, P1118
   Iwanaga Y, 1999, J VIROL, V73, P1271
   Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Koyama Y, 2000, BLOOD, V96, P1490
   Mariner JM, 2001, J IMMUNOL, V166, P2602, DOI 10.4049/jimmunol.166.4.2602
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388
   Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Mulloy JC, 1998, J VIROL, V72, P8852
   Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620
   Nicot C, 2000, BLOOD, V96, P275
   Okazaki S, 2001, VIRUS GENES, V23, P123, DOI 10.1023/A:1011840918149
   Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865
   Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519
   Qin JZ, 1999, BLOOD, V93, P260
   Sakaki Y, 2002, EXP HEMATOL, V30, P340, DOI 10.1016/S0301-472X(02)00775-0
   Sander LW, 2000, INF MENTAL HLTH J, V21, P5, DOI 10.1002/(SICI)1097-0355(200001/04)21:1/2<5::AID-IMHJ2>3.0.CO;2-S
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Seth A, 1997, AIDS, V11, P1059
   SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389
   Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760
   Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Tsukahara T, 1999, J VIROL, V73, P7981
   UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Zhang CH, 1996, J IMMUNOL, V157, P3980
NR 59
TC 48
Z9 51
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2004
VL 78
IS 9
BP 4582
EP 4590
DI 10.1128/JVI.78.9.4582-4590.2004
PG 9
WC Virology
SC Virology
GA 813AO
UT WOS:000220880200022
PM 15078940
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Dunoyer, P
   Lecellier, CH
   Parizotto, EA
   Himber, C
   Voinnet, O
AF Dunoyer, P
   Lecellier, CH
   Parizotto, EA
   Himber, C
   Voinnet, O
TI RETRACTED: Probing the microRNA and small interfering RNA pathways with
   virus-encoded suppressors of RNA silencing (Retracted article. See vol.
   27, pg. 1815, 2015)
SO PLANT CELL
LA English
DT Article; Retracted Publication
ID TURNIP CRINKLE VIRUS; VIRAL SUPPRESSOR; NICOTIANA-BENTHAMIANA;
   CAENORHABDITIS-ELEGANS; ENZYME COMPLEX; C-ELEGANS; GENE; ARABIDOPSIS;
   PROTEIN; PLANTS
AB In plants, small interfering RNAs (siRNAs) and microRNAs (miRNAs) are effectors of RNA silencing, a process involved in defense through RNA interference (RNAi) and in development. Plant viruses are natural targets of RNA silencing, and as a counterdefensive strategy, they have evolved highly diverse silencing suppressor proteins. Although viral suppressors are usually thought to act at distinct steps of the silencing machinery, there had been no consensus system so far that allowed a strict side-by-side analysis of those factors. We have set up such a system in Arabidopsis thaliana and used it to compare the effects of five unrelated viral silencing suppressors on the siRNA and miRNA pathways. Although all the suppressors inhibited RNAi, only three of them induced developmental defects, indicating that the two pathways are only partially overlapping. These developmental defects were remarkably similar, and their penetrance correlated with inhibition of miRNA-guided cleavage of endogenous transcripts and not with altered miRNA accumulation per se. Among the suppressors investigated, the tombusviral P19 protein coimmunoprecipitated with siRNA duplexes and miRNA duplexes corresponding to the primary cleavage products of miRNA precursors. Thus, it is likely that P19 prevents RNA silencing by sequestering both classes of small RNAs. Moreover, the finding here that P19 binds siRNAs and suppresses RNAi in Hela cells also suggests that this factor may be useful to dissect the RNA silencing pathways in animals. Finally, the differential effects of the silencing suppressors tested here upon other types of Arabidopsis silencing-related small RNAs revealed a surprising variety of biosynthetic and, presumably, functional pathways for those molecules. Therefore, silencing suppressors are valuable probes of the complexity of RNA silencing.
C1 CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France.
RP Voinnet, O (reprint author), CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France.
EM olivier.voinnet@ibmp-ulp.u-strasbg.fr
CR Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2
   Anandalakshmi R, 2000, SCIENCE, V290, P142, DOI 10.1126/science.290.5489.142
   Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   BERTEL B, 2003, PLANT PHYSIOL, V132, P709
   Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739
   Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102
   Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060
   Dernburg AF, 2002, CELL, V111, P159, DOI 10.1016/S0092-8674(02)01039-5
   Dunoyer P, 2002, PLANT J, V29, P555, DOI 10.1046/j.0960-7412.2001.01242.x
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Finnegan EJ, 2003, CURR BIOL, V13, P236, DOI 10.1016/S0960-9822(03)00010-1
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Foster TM, 2002, PLANT CELL, V14, P1497, DOI 10.1105/tpc.001685
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Hammond SM, 2000, NATURE, V404, P293
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Jacobsen SE, 1999, DEVELOPMENT, V126, P5231
   Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X
   Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
   Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210
   Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311
   Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999
   Mette MF, 2001, CURR BIOL, V11, P1119, DOI 10.1016/S0960-9822(01)00315-3
   Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358
   Moss EG, 2002, CURR BIOL, V12, pR138, DOI 10.1016/S0960-9822(02)00708-X
   Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523
   Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980
   Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402
   Ren T, 2000, PLANT CELL, V12, P1917, DOI 10.1105/tpc.12.10.1917
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Silhavy D, 2002, EMBO J, V21, P3070, DOI 10.1093/emboj/cdf312
   Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103
   Thomas CL, 2003, VIROLOGY, V306, P33, DOI 10.1016/S0042-6822(02)00018-1
   Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X
   Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147
   Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8
   Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7
   Xie ZX, 2003, CURR BIOL, V13, P784, DOI 10.1016/S0960-9822(03)00281-1
   Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213
   Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695
NR 45
TC 346
Z9 365
U1 58
U2 108
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD MAY
PY 2004
VL 16
IS 5
BP 1235
EP 1250
DI 10.1105/tpc.020719
PG 16
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 821LF
UT WOS:000221461400013
PM 15084715
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Rommens, CM
   Humara, JM
   Ye, JS
   Yan, H
   Richael, C
   Zhang, L
   Perry, R
   Swords, K
AF Rommens, CM
   Humara, JM
   Ye, JS
   Yan, H
   Richael, C
   Zhang, L
   Perry, R
   Swords, K
TI RETRACTED: Crop improvement through modification of the plant's own
   genome (Retracted article. See vol. 161, pg. 2182, 2013)
SO PLANT PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID GENETICALLY-MODIFIED FOODS; TOMATO POLYPHENOL OXIDASE; SOLANUM-TUBEROSUM
   L.; T-DNA TRANSFER; AGROBACTERIUM-TUMEFACIENS; TRANSGENIC PLANTS;
   POTATO-TUBERS; ARABIDOPSIS-THALIANA; CYTOSINE DEAMINASE; SELECTABLE
   MARKER
AB Plant genetic engineering has, until now, relied on the incorporation of foreign DNA into plant genomes. Public concern about the extent to which transgenic crops differ from their traditionally bred counterparts has resulted in molecular strategies and gene choices that limit, but not eliminate, the introduction of foreign DNA. Here, we demonstrate that a plant-derived (P-) DNA fragment can be used to replace the universally employed Agrobacterium transfer (T-) DNA. Marker-free P-DNAs are transferred to plant cell nuclei together with conventional T-DNAs carrying a selectable marker gene. By subsequently linking a positive selection for temporary marker gene expression to a negative selection against marker gene integration, 29% of derived regeneration events contain P-DNA insertions but lack any copies of the T-DNA. Further refinements are accomplished by employing Q-mutated virD2 and isopentenyl transferase cytokinin genes to impair T-DNA integration and select against backbone integration, respectively. The presented methods are used to produce hundreds of marker-free and backbone-free potato (Solanum tuberosum) plants displaying reduced expression of a tuber-specific polyphenol oxidase gene in potato. The modified plants represent the first example of genetically engineered plants that only contain native DNA.
C1 JR Simplot Co, Simplot Plant Sci, Boise, ID 83706 USA.
RP Rommens, CM (reprint author), JR Simplot Co, Simplot Plant Sci, Boise, ID 83706 USA.
EM crommens@simplot.com
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   BACHEM CWB, 1994, BIO-TECHNOL, V12, P1101, DOI 10.1038/nbt1194-1101
   Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48
   Banno H, 2001, PLANT CELL, V13, P2609, DOI 10.1105/tpc.13.12.2609
   Coetzer C, 2001, J AGR FOOD CHEM, V49, P652, DOI 10.1021/jf001217f
   Daniell H, 2001, CURR GENET, V39, P109, DOI 10.1007/s002940100185
   De Buck S, 2000, MOL PLANT MICROBE IN, V13, P658, DOI 10.1094/MPMI.2000.13.6.658
   de Vetten N, 2003, NAT BIOTECHNOL, V21, P439, DOI 10.1038/nbt801
   DEPICKER A, 2001, Patent No. 0144482
   GARBARINO JE, 1992, PLANT MOL BIOL, V20, P235, DOI 10.1007/BF00014491
   GARBARINO JE, 1994, PLANT MOL BIOL, V24, P119, DOI 10.1007/BF00040579
   Gaskell G, 1999, SCIENCE, V285, P384, DOI 10.1126/science.285.5426.384
   Gleave AP, 1999, PLANT MOL BIOL, V40, P223, DOI 10.1023/A:1006184221051
   Hanson B, 1999, PLANT J, V19, P727, DOI 10.1046/j.1365-313x.1999.00564.x
   Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982
   Kim SR, 2003, PLANT MOL BIOL, V52, P761, DOI 10.1023/A:1025093101021
   Komari T, 1996, PLANT J, V10, P165, DOI 10.1046/j.1365-313X.1996.10010165.x
   Konig A, 2003, NAT BIOTECHNOL, V21, P1274, DOI 10.1038/nbt1103-1274
   Kononov ME, 1997, PLANT J, V11, P945, DOI 10.1046/j.1365-313X.1997.11050945.x
   Koprek T, 1999, PLANT J, V19, P719, DOI [10.1046/j.1365-313x.1999.00557.x, 10.1046/j.1365-313X.1999.00557.x]
   Krall L, 2002, FEBS LETT, V527, P315, DOI 10.1016/S0014-5793(02)03258-1
   Lusk JL, 2002, FOOD TECHNOL-CHICAGO, V56, P32
   Meissner R, 2000, PLANT J, V22, P265, DOI 10.1046/j.1365-313x.2000.00735.x
   Mysore KS, 1998, MOL PLANT MICROBE IN, V11, P668, DOI 10.1094/MPMI.1998.11.7.668
   Naested H, 1999, PLANT J, V18, P571, DOI 10.1046/j.1365-313X.1999.00477.x
   Nielsen KM, 2003, NAT BIOTECHNOL, V21, P227, DOI 10.1038/nbt0303-227
   PADGETTE SR, 1987, ARCH BIOCHEM BIOPHYS, V258, P564, DOI 10.1016/0003-9861(87)90378-X
   Pereira A, 2000, TRANSGENIC RES, V9, P245, DOI 10.1023/A:1008967916498
   PERERA RJ, 1993, PLANT MOL BIOL, V23, P793, DOI 10.1007/BF00021534
   ROHDE W, 1990, Journal of Genetics and Breeding, V44, P311
   ROMMENS CM, 2003, Patent No. 221213
   ROMMENS CMT, 1992, PLANT MOL BIOL, V20, P61, DOI 10.1007/BF00029149
   SANGER M, 1990, PLANT MOL BIOL, V14, P433, DOI 10.1007/BF00028779
   SHAH DM, 1995, TRENDS BIOTECHNOL, V13, P362, DOI 10.1016/S0167-7799(00)88982-9
   Shi HZ, 2003, NAT BIOTECHNOL, V21, P81, DOI 10.1038/nbt766
   SHURVINTON CE, 1992, P NATL ACAD SCI USA, V89, P11837, DOI 10.1073/pnas.89.24.11837
   Stevens LH, 1997, J AGR FOOD CHEM, V45, P4221, DOI 10.1021/jf9608837
   Sun JQ, 2003, PLANT PHYSIOL, V131, P167, DOI 10.1104/pp.011494
   Tai TH, 1999, P NATL ACAD SCI USA, V96, P14153, DOI 10.1073/pnas.96.24.14153
   Thipyapong P, 1997, PLANT PHYSIOL, V115, P409, DOI 10.1104/pp.115.2.409
   Thirkettle-Watts D, 2003, PLANT PHYSIOL, V133, P1158, DOI 10.1104/pp.103.028183
   Tiraby M, 1998, FEMS MICROBIOL LETT, V167, P41, DOI 10.1111/j.1574-6968.1998.tb13205.x
   Trindade LM, 2003, GENE, V303, P77, DOI 10.1016/S0378-1119(02)01147-2
   VANHAAREN MJJ, 1989, PLANT MOL BIOL, V13, P523, DOI 10.1007/BF00027312
   Verhoog H, 2003, TRENDS BIOTECHNOL, V21, P294, DOI 10.1016/S0167-779(03)00142-2
   WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456
   Wolfenbarger LL, 2000, SCIENCE, V290, P2088, DOI 10.1126/science.290.5499.2088
   Xin ZG, 2003, BIOTECHNIQUES, V34, P820, DOI 10.2144/03344rr04
   Zuo JR, 2001, NAT BIOTECHNOL, V19, P157, DOI 10.1038/84428
NR 49
TC 94
Z9 104
U1 4
U2 25
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
J9 PLANT PHYSIOL
JI Plant Physiol.
PD MAY
PY 2004
VL 135
IS 1
BP 421
EP 431
DI 10.1104/pp.104.040949
PG 11
WC Plant Sciences
SC Plant Sciences
GA 820WQ
UT WOS:000221420800043
PM 15133156
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Petersen, CCH
   Brecht, M
   Hahn, TTG
   Sakmann, B
AF Petersen, CCH
   Brecht, M
   Hahn, TTG
   Sakmann, B
TI RETRACTED: Synaptic changes in layer 2/3 underlying map plasticity of
   developing barrel cortex (Retracted article. See vol 306, pg. 54, 2004)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID EXPERIENCE-DEPENDENT PLASTICITY; CAT STRIATE CORTEX; VISUAL-CORTEX;
   IN-VIVO; HORIZONTAL CONNECTIONS; SENSORY DEPRIVATION; CORTICAL
   PLASTICITY; DENDRITIC SPINES; RESPONSES; SYNAPSES
AB The functional and anatomical rearrangements of cortical sensory maps accompanying changes in experience are not well understood. We examined in vivo and in vitro how the sensory map and underlying synaptic connectivity of the developing rat barrel cortex are altered when the sensory input to the cortex is partially deprived. In the nondeprived cortex, both the sensory responses and synaptic connectivity between columns were strengthened through an increase in the synaptic connection probability between L2/3 pyramids in adjacent columns. This was accompanied by a selective growth of L2/3 pyramid axonal arbors between spared columns. In contrast, deprived and nondeprived cortical columns became weakly connected in their L2/3 pyramid connections.
C1 Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany.
   Ecole Polytech Fed Lausanne, Lab Sensory Proc Brain & Mind Inst, CH-1015 Lausanne, Switzerland.
RP Petersen, CCH (reprint author), Max Planck Inst Med Res, Dept Cell Physiol, Jahnstr 29, D-69120 Heidelberg, Germany.
EM carl.petersen@epfl.ch
CR Allen CB, 2003, NAT NEUROSCI, V6, P291, DOI 10.1038/nn1012
   Brecht M, 2003, J PHYSIOL-LONDON, V553, P243, DOI 10.1113/jphysiol.2003.044222
   Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149
   CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745
   DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0
   Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878
   DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215
   Finnerty GT, 1999, NATURE, V400, P367
   GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0
   Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714
   Haydon D., UNPUB
   Heynen AJ, 2003, NAT NEUROSCI, V6, P854, DOI 10.1038/nn1100
   HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041
   Keller A, 1999, J COMP NEUROL, V412, P83, DOI 10.1002/(SICI)1096-9861(19990913)412:1<83::AID-CNE6>3.0.CO;2-7
   Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3
   Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107
   LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754
   Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100
   Petersen CCH, 2001, J NEUROSCI, V21, P8435
   Petersen CCH, 2000, J NEUROSCI, V20, P7579
   Petersen CCH, 2003, J NEUROSCI, V23, P1298
   Polley DB, 1999, NEURON, V24, P623, DOI 10.1016/S0896-6273(00)81117-4
   Schierloh A, 2003, NEUROREPORT, V14, P1787, DOI 10.1097/01.wnr.0000093288.85057.92
   Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1
   SIMONS DJ, 1987, NATURE, V326, P694, DOI 10.1038/326694a0
   Stern EA, 2001, NEURON, V31, P305, DOI 10.1016/S0896-6273(01)00360-9
   Trachtenberg JT, 2001, J NEUROSCI, V21, P3476, DOI 10.1523/JNEUROSCI.21-10-03476.2001
   WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003
   WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X
NR 29
TC 10
Z9 12
U1 2
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD APR 30
PY 2004
VL 304
IS 5671
BP 739
EP 742
DI 10.1126/science.1096750
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 816JD
UT WOS:000221105300047
PM 15118164
DA 2018-12-27
ER

PT J
AU Guarrera, JV
   Polyak, M
   Arrington, BO
   Kapur, S
   Stubenbord, WT
   Kinkhabwala, M
AF Guarrera, JV
   Polyak, M
   Arrington, BO
   Kapur, S
   Stubenbord, WT
   Kinkhabwala, M
TI RETRACTED: Pulsatile machine perfusion with vasosol solution improves
   early graft function after cadaveric renal transplantation (Retracted
   Article. See vol 79, pg 1774, 2005)
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 19th International Congress of the Transplantation-Society
CY AUG 25-30, 2002
CL MIAMI, FL
SP Transplantat Soc
ID CRITERIA DONOR KIDNEYS; COLD-STORAGE; PRESERVATION CHARACTERISTICS;
   REPERFUSION INJURY; ALLOGRAFT FUNCTION; LUNG PRESERVATION; CELSIOR
   SOLUTION; PROTECTIVE ROLE; LIVER; HYPOXIA/REOXYGENATION
AB Background. Cold storage is the most common method of preservation in renal transplantation, but pulsatile machine perfusion (MP) is increasingly used for purposes of ex vivo assessment and resuscitation of high risk allografts. Vasosol (VSL) MP solution (MPS) (Pike Laboratories Inc, Eagle, PA) is a novel perfusate with enhanced vasodilatory and antioxidant capacity. We report our experience with VSL in machine preservation of renal allografts.
   Methods. Locally procured cadaver kidney pairs undergoing MP were randomized to VSL or control solution (Belzer MPS; Trans-Med, Elk River, MN). En bloc perfusion was performed according to standard MP procedures. Transplantation was performed at 1 of 12 local transplant centers. Donor and recipient data were collected prospectively. Results. Data from 162 transplanted kidneys were analyzed. A total of 82 renal grafts were perfused with VSL, and 80 were perfused with control solution. No organs were lost secondary to the technique of MP. There was no difference in donor or recipient age between groups. Kidneys perfused with VSL exhibited significantly higher rates of immediate function and significantly less delayed graft function (12.2% vs. 21.2%). Discharge creatinine and length of stay were also significantly improved in the VSL group. One-year graft and patient survivals were equivalent (95%) in both groups.
   Conclusions. VSL improved early graft function and shortened the length of stay compared with Belzer MPS. Further improvement in preservation solutions in conjunction with pulsatile perfusion shows promise in improving early outcomes after renal transplantation, especially for extended criteria donor kidneys.
C1 New York Presbyterian Hosp, Organ Preservat Unit, New York, NY 10021 USA.
   Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10027 USA.
   Cornell Univ, Weill Med Coll, Dept Surg, New York, NY USA.
RP Guarrera, JV (reprint author), New York Presbyterian Hosp, Organ Preservat Unit, 525 E 68th St,M507,Box 20, New York, NY 10021 USA.
EM jjg46@columbia.edu
CR ALIJANI MR, 1985, TRANSPLANTATION, V40, P659, DOI 10.1097/00007890-198512000-00017
   BARBER WH, 1988, TRANSPLANT P, V20, P865
   Baxter K, 2001, TRANSPLANTATION, V71, P1380, DOI 10.1097/00007890-200105270-00004
   Bhabra MS, 1996, ANN THORAC SURG, V62, P1494, DOI 10.1016/0003-4975(96)00498-5
   BOUDJEMA K, 1991, TRANSPLANT P, V23, P2341
   Burdick JF, 1997, TRANSPLANTATION, V64, P1730, DOI 10.1097/00007890-199712270-00018
   COLE E, 1995, CLIN TRANSPLANT, V9, P282
   Erkasap S, 2000, NEPHROL DIAL TRANSPL, V15, P1224, DOI 10.1093/ndt/15.8.1224
   Faenza A, 2001, TRANSPLANTATION, V72, P1274, DOI 10.1097/00007890-200110150-00016
   FANTONE JC, 1983, BIOCHEM BIOPH RES CO, V113, P506, DOI 10.1016/0006-291X(83)91754-0
   FUKUZAWA K, 1995, TRANSPLANTATION, V59, P6, DOI 10.1097/00007890-199501150-00002
   Geller DA, 2001, JPEN-PARENTER ENTER, V25, P142, DOI 10.1177/0148607101025003142
   Groenewoud A F, 1994, Transpl Int, V7 Suppl 1, pS479
   HENRY ML, 1990, TRANSPLANT P, V22, P388
   Kjellman UW, 1997, ANN THORAC SURG, V63, P1625, DOI 10.1016/S0003-4975(97)00213-0
   OAKES DD, 1978, ARCH SURG-CHICAGO, V113, P654
   OLTOFF KM, 1991, J SURG RES, V50, P595
   PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086
   Polyak M, 1997, TRANSPLANT P, V29, P3582, DOI 10.1016/S0041-1345(97)01145-7
   Polyak MMR, 1999, J SURG RES, V85, P17, DOI 10.1006/jsre.1999.5652
   Polyak MMR, 1999, TRANSPLANT INT, V12, P378, DOI 10.1111/j.1432-2277.1999.tb00625.x
   Polyak MMR, 2000, TRANSPLANTATION, V69, P249, DOI 10.1097/00007890-200001270-00010
   ROSENTHAL JT, 1991, TRANSPLANTATION, V51, P1115
   SCHLONDORFF D, 1978, AM J PHYSIOL, V235, pF458
   Sellers MT, 2000, CLIN TRANSPLANT, V14, P543, DOI 10.1034/j.1399-0012.2000.140605.x
   Southard JH, 1997, TRANSPL P, V29, P3510, DOI 10.1016/S0041-1345(97)00999-8
   St Peter SD, 2002, LANCET, V359, P604, DOI 10.1016/S0140-6736(02)07749-8
   TESI RJ, 1994, CLIN TRANSPLANT, V8, P134
   TROPPMANN C, 1995, TRANSPLANTATION, V59, P962, DOI 10.1097/00007890-199504150-00007
   Vairetti M, 2001, FREE RADICAL BIO MED, V31, P954, DOI 10.1016/S0891-5849(01)00670-0
   Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826
   Weinberg JM, 2001, AM J PATHOL, V158, P2153, DOI 10.1016/S0002-9440(10)64687-1
   Weinbroum AA, 2001, TRANSPLANTATION, V71, P300, DOI 10.1097/00007890-200101270-00023
   Wight J, 2003, Health Technol Assess, V7, P1
NR 34
TC 17
Z9 19
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 27
PY 2004
VL 77
IS 8
BP 1264
EP 1268
DI 10.1097/01.TP.0000122221.28546.61
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 816SZ
UT WOS:000221130900024
PM 15114096
DA 2018-12-27
ER

PT J
AU Grand, CL
   Powell, TJ
   Nagle, RB
   Bearss, DJ
   Tye, D
   Gleason-Guzman, M
   Hurley, LH
AF Grand, CL
   Powell, TJ
   Nagle, RB
   Bearss, DJ
   Tye, D
   Gleason-Guzman, M
   Hurley, LH
TI RETRACTED: Mutations in the G-quadruplex silencer element and their
   relationship to c-MYC overexpression, NM23 repression, and therapeutic
   rescue (Retracted Article. See vol 102, pg 516, 2005)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID MOLECULAR CYTOGENETIC CHARACTERIZATION; NUCLEASE-HYPERSENSITIVE ELEMENT;
   ZINC-FINGER PROTEIN; DIPHOSPHATE KINASE; BURKITT-LYMPHOMA; PROMOTER
   REGION; GENE-EXPRESSION; BINDING-PROTEIN; DNA; TRANSCRIPTION
AB We have demonstrated that a parallel G-quadruplex structure in the c-MYC promoter functions as a transcriptional repressor element. Furthermore, a specific G-to-A mutation in this element results in destabilization of the G-quadruplex repressor element and an increase in basal transcriptional activity. To validate this model in an in vivo context, we have examined the sequence of this region in human colorectal tumors and the surrounding normal tissue. We have found that approximate to30% of tumors contain one of two specific G-to-A mutations, not present in the surrounding normal tissue, that destabilize the parallel G-quadruplex, which would be expected to give rise to abnormally high expression of c-MYC in these cells. in contrast, G-quadruplex-disruptive mutations were absent in 20 colon adenomas, suggesting that these mutations occur late in tumorigenesis. We have also demonstrated that these same mutations are found in established colorectal cell lines. NM23-H2 levels are lower in cancer tissues and cell lines that harbor these mutations. In cells with repressed levels of NM23-H2, the mutated and destabilized G-quadruplex silencer element can be reinstated by the addition of G-cluadruplex-stabilizing compounds, providing an opportunity for therapeutic intervention for patients carrying these mutations.
C1 Arizona Canc Ctr, Tucson, AZ 85724 USA.
   Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.
   Univ Arizona, Dept Chem, Tucson, AZ 85721 USA.
RP Hurley, LH (reprint author), Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM hurley@pharmacy.arizona.edu
OI Bearss, David/0000-0002-4280-5670
FU NCI NIH HHS [P50 CA095060, CA88310, R01 CA094166, CA95060, CA94166, R01
   CA088310]
CR BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006
   BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452
   COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213
   DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824
   DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111
   Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681
   ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969
   Freier K, 2003, CANCER RES, V63, P1179
   Grand CL, 2002, MOL CANCER THER, V1, P565
   Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Jackson-Cook C, 2003, CANCER GENET CYTOGEN, V141, P56, DOI 10.1016/S0165-4608(02)00665-9
   Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489
   JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312
   Levens D, 1997, CURR TOP MICROBIOL, V224, P33
   Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4
   MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113
   MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494
   Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029
   Postel EH, 2003, J BIOENERG BIOMEMBR, V35, P31, DOI 10.1023/A:1023485505621
   Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821
   ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0
   Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322
   Schlotter CM, 2003, BREAST CANCER RES, V5, pR30, DOI 10.1186/bcr568
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4
   Simonsson T, 2000, BIOCHEM BIOPH RES CO, V278, P158, DOI 10.1006/bbrc.2000.3783
   Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167
   SPENCER CA, 1991, ADV CANCER RES, V56, P1
   STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200
   TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837
   Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830
   Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200
NR 35
TC 45
Z9 47
U1 4
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2004
VL 101
IS 16
BP 6140
EP 6145
DI 10.1073/pnas.0400460101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 814ME
UT WOS:000220978000083
PM 15079086
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Majumder, S
   Varadharaj, S
   Ghoshal, K
   Monani, U
   Burghes, AHM
   Jacob, ST
AF Majumder, S
   Varadharaj, S
   Ghoshal, K
   Monani, U
   Burghes, AHM
   Jacob, ST
TI RETRACTED: Identification of a novel cyclic AMP-response element
   (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the
   survival motor neuron (SMN) gene (Retracted article. See vol. 293, pg.
   12946, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SPINAL MUSCULAR-ATROPHY; TRANSCRIPTION FACTOR; MESSENGER-RNA; SPLICING
   ENHANCER; SINGLE NUCLEOTIDE; SOMATOSTATIN GENE; COPY NUMBER; IN-VIVO;
   PROTEIN; MOUSE
AB Spinal muscular atrophy, an autosomal recessive disorder, is caused by loss of the SMN1 (survival motor neuron) gene while retaining the SMN2 gene. SMN1 produces a majority of full-length SMN transcript, whereas SMN2 generates mostly an isoform lacking exon 7. Here, we demonstrate a novel cAMP-response element, CRE-II, in the SMN promoter that interacts with the cAMP-response element-binding (CREB) family of proteins. In vitro DNase I protection analysis and in vivo genomic foot-printing of the SMN promoter using the brain and liver nuclei from SMN2 transgenic mice revealed footprinting at the CRE-II site. Site-directed mutation of the CRE-II element caused a marked reduction in the SMN promoter activity revealed by transient transfection assay. Activation of the cAMP pathway by dibutyryl cAMP (0.5 mM) alone or in combination with forskolin (20 muM) caused a 2-5-fold increase in the SMN promoter activity but had no effect on the CRE-II mutated promoter. Electrophoretic mobility shift assay and a UV-induced DNA-protein cross-linking experiment confirmed that CREB1 binds specifically to the CRE-II site. Transient overexpression of CREB1 protein resulted in a 4-fold increase of the SMN promoter activity. Intraperitoneal injection of epinephrine in mice expressing two copies of the human SMN2 gene resulted in a 2-fold increase in full-length SMN transcript in the liver. Combined treatment with dibutyryl cAMP and forskolin significantly increased the level of both the full-length and exon 7-deleted SMN (exonDelta7SMN) transcript in primary hepatocytes from mice expressing two copies of human SMN2 gene. Similar treatments of type I spinal muscular atrophy mouse and human fibroblasts as well as HeLa cells resulted in an augmented level of SMN transcript. These findings suggest that the CRE-II site in SMN promoter positively regulates the expression of the SMN gene, and treatment with cAMP-elevating agents increases expression of both the full-length and exonDelta7SMN transcript.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   Ohio State Univ, Coll Med, Dept Neurol, Columbus, OH 43210 USA.
RP Jacob, ST (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.
EM jacob.42@osu.edu
OI Burghes, Arthur/0000-0001-9031-1555
FU NINDS NIH HHS [R01 NS041649, NS 41649]
CR AIYAR A, 1993, BIOTECHNIQUES, V14, P366
   Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841
   Andreassi C, 2002, NEUROGENETICS, V4, P29, DOI 10.1007/s10048-001-0128-y
   Baron-Delage S, 2000, MOL MED, V6, P957, DOI 10.1007/BF03401830
   Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351
   Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913
   BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335
   Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887
   Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854
   Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205
   Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x
   Echaniz-Laguna A, 2002, J NEUROL, V249, P290, DOI 10.1007/s004150200007
   Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2
   Germain-Desprez D, 2001, GENE, V279, P109, DOI 10.1016/S0378-1119(01)00758-2
   Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539
   Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001
   GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5
   GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2
   HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927
   HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083
   Hsieh-Li HM, 2000, NAT GENET, V24, P66
   HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601
   Le TT, 2000, NEUROGENETICS, V3, P7, DOI 10.1007/s100480000090
   Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3
   LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758
   Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200
   Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0
   Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x
   LIU ZJ, 1994, J BIOL CHEM, V269, P16618
   Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307
   Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259
   Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588
   Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301
   McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465
   Monani UR, 2000, HUM MOL GENET, V9, P2451, DOI 10.1093/hmg/9.16.2451
   Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177
   Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333
   Monani UR, 1999, BBA-GENE STRUCT EXPR, V1445, P330, DOI 10.1016/S0167-4781(99)00060-3
   Monti B, 2002, EUR J NEUROSCI, V16, P1490, DOI 10.1046/j.1460-9568.2002.02232.x
   Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807
   MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0
   MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500
   MUNSAT TL, 1992, NEUROMUSCULAR DISORD, V2, P423, DOI 10.1016/S0960-8966(06)80015-5
   NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101
   Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727
   Parsons DW, 1998, AM J HUM GENET, V63, P1712, DOI 10.1086/302160
   PEARN J, 1978, J MED GENET, V15, P414, DOI 10.1136/jmg.15.6.414
   Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3
   ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33
   Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93
   SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002
   Sambrook J., 1989, MOL CLONING LAB MANU, V2
   Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127
   Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100
   Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497
   Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6
   Wirth B, 1999, AM J HUM GENET, V64, P1340, DOI 10.1086/302369
   Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858
   Zhang ML, 2001, GENE THER, V8, P1532, DOI 10.1038/sj.gt.3301550
NR 66
TC 42
Z9 42
U1 1
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 9
PY 2004
VL 279
IS 15
BP 14803
EP 14811
DI 10.1074/jbc.M308225200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 808UT
UT WOS:000220594700040
PM 14742439
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Geremia, JM
   Stockton, JK
   Mabuchi, H
AF Geremia, JM
   Stockton, JK
   Mabuchi, H
TI RETRACTED: Real-time quantum feedback control of atomic spin-squeezing
   (Retracted Article. See vol 321, pg 489, 2008)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID NONDEMOLITION MEASUREMENT; STATES; ENTANGLEMENT; SPECTROSCOPY;
   GENERATION
AB Real-time feedback performed during a quantum nondemolition measurement of atomic spin-angular momentum allowed us to influence the quantum statistics of the measurement outcome. We showed that it is possible to harness measurement backaction as a form of actuation in quantum control, and thus we describe a valuable tool for quantum information science. Our feedback-mediated procedure generates spin-squeezing, for which the reduction in quantum uncertainty and resulting atomic entanglement are not conditioned on the measurement outcome.
C1 CALTECH, Pasadena, CA 91125 USA.
RP Geremia, JM (reprint author), CALTECH, Pasadena, CA 91125 USA.
EM jgeremia@caltech.edu
CR BRUNE M, 1990, PHYS REV LETT, V65, P976, DOI 10.1103/PhysRevLett.65.976
   Geremia JM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.250801
   Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319
   Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524
   KITAGAWA M, 1993, PHYS REV A, V47, P5138, DOI 10.1103/PhysRevA.47.5138
   Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594
   Silberfarb A, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.013817
   Smith GA, 2003, J OPT B-QUANTUM S O, V5, P323, DOI 10.1088/1464-4266/5/4/301
   Sorensen AS, 2001, PHYS REV LETT, V86, P4431, DOI 10.1103/PhysRevLett.86.4431
   Thomsen LK, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.061801
   WINELAND DJ, 1994, PHYS REV A, V50, P67, DOI 10.1103/PhysRevA.50.67
   WISEMAN HM, 1994, PHYS REV A, V49, P2133, DOI 10.1103/PhysRevA.49.2133
   WU LA, 1986, PHYS REV LETT, V57, P2520, DOI 10.1103/PhysRevLett.57.2520
NR 13
TC 204
Z9 205
U1 5
U2 27
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 9
PY 2004
VL 304
IS 5668
BP 270
EP 273
DI 10.1126/science.1095374
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 810QS
UT WOS:000220719400040
PM 15073372
DA 2018-12-27
ER

PT J
AU Murayama, A
   Kim, MS
   Yanagisawa, J
   Takeyama, K
   Kato, S
AF Murayama, A
   Kim, MS
   Yanagisawa, J
   Takeyama, K
   Kato, S
TI RETRACTED: Transrepression by a liganded nuclear receptor via a bHLH
   activator through co-regulator switching (Retracted article. See vol.
   33, pg. 2880, 2014)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE bHLH-type activator; co-regulator; nuclear receptor; transrepression;
   vitamin D
ID VITAMIN-D-RECEPTOR; D-3 1-ALPHA-HYDROXYLASE GENE; LOOP-HELIX PROTEINS;
   PARATHYROID-HORMONE; DNA-BINDING; TRANSCRIPTIONAL REPRESSION;
   ESTROGEN-RECEPTOR; COMPLEX; COACTIVATOR; 1-ALPHA,25(OH)(2)D-3
AB Vitamin D receptor (VDR) is essential for ligand-induced gene repression of 25(OH)D-3 1alpha-hydroxylase (1alpha(OH)ase) in mammalian kidney, while this gene expression is activated by protein kinase A (PKA) signaling downstream of the parathyroid hormone action. The mapped negative vitamin D response element (1alphanVDRE) in the human 1alpha(OH)ase gene promoter (around 530 bp) was distinct from those of the reported DR3-like nVDREs, composed of two E-box-like motifs. Unlike the reported nVDREs, no direct binding of VDR/RXR heterodimer to 1alphanVDRE was detected. A bHLH-type factor, designated VDIR, was identified as a direct sequence-specific activator of 1alphanVDRE. The transactivation function of VDIR was further potentiated by activated-PKA signaling through phosphorylation of serine residues in the transactivation domains, with the recruitment of a p300 histone acetyltransferase co-activator. The ligand-dependent association of VDR/RXR heterodimer with VDIR bound to 1alphanVDRE caused the dissociation of p300 co-activators from VDIR, and the association of HDAC co-repressor complex components resulting in ligand-induced transrepression. Thus, the present study deciphers a novel mechanism of ligand-induced transrepression by nuclear receptor via co-regulator switching.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
   Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan.
   Japan Sci & Technol, SORST, Kawaguchi, Saitama, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387
   Chambon P, 1996, FASEB J, V10, P940
   CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0
   CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0
   DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V
   DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097
   Ebihara K, 1996, MOL CELL BIOL, V16, P3393
   Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672
   Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329
   Glass CK, 2000, GENE DEV, V14, P121
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   HENRY HL, 1985, ENDOCRINOLOGY, V116, P503, DOI 10.1210/endo-116-2-503
   Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200
   Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kitanaka S, 1999, J CLIN ENDOCR METAB, V84, P4111, DOI 10.1210/jc.84.11.4111
   Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352
   LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9
   Murayama A, 1999, ENDOCRINOLOGY, V140, P2224, DOI 10.1210/en.140.5.2224
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X
   MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0
   Ohkido I, 2003, PFLUG ARCH EUR J PHY, V446, P106, DOI 10.1007/s00424-003-1010-6
   ONATE SA, 1995, SCIENCE, V270, P1354
   Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498
   Rachez C, 1999, NATURE, V398, P824
   SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1
   Spencer TE, 1997, NATURE, V389, P194
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   VIERRA CA, 1995, MOL ENDOCRINOL, V9, P64, DOI 10.1210/me.9.1.64
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 48
TC 121
Z9 126
U1 4
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD APR 7
PY 2004
VL 23
IS 7
BP 1598
EP 1608
DI 10.1038/sj.emboj.7600157
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 819QC
UT WOS:000221328700019
PM 15934135
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Jin, WH
   Wu, HS
AF Jin, WH
   Wu, HS
TI RETRACTED: Studies on structures and photoelectron spectroscopy of
   GamPn, and GamPn- clusters (Retracted article. See vol. 112, pg. 1233,
   2012)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE GamPn and Gam P-n(-) clusters; density functional theory; photoelectron
   spectroscopy
ID ELECTRONIC STATES; GALLIUM-PHOSPHIDE; SPECTRA; GAP2; GA2P3
AB Using density functional theory associated with the B3LYP method with 6-31 G* basis set, we have carried out the optimizing calculations of the geometry, electronic state and vibrational frequency for GamPn- (m + n less than or equal to 5) clusters, moreover, discussed the vertical detachment energy of GamPn- and the adiabatic electron affinities of GamPn. The results show that the structures with singlet have higher symmetry, while the one with doublet has lower symmetry.
C1 Shanxi Normal Univ, Sch Chem & Mat Sci, Linfen 041004, Peoples R China.
RP Jin, WH (reprint author), Shanxi Normal Univ, Sch Chem & Mat Sci, Linfen 041004, Peoples R China.
CR ANDREONI W, 1992, PHYS REV B, V45, P4203, DOI 10.1103/PhysRevB.45.4203
   Archibong EF, 2000, CHEM PHYS LETT, V316, P151, DOI 10.1016/S0009-2614(99)01285-3
   Archibong EF, 2000, CHEM PHYS LETT, V330, P199, DOI 10.1016/S0009-2614(00)01014-9
   Archibong EF, 2002, CHEM PHYS LETT, V361, P411, DOI 10.1016/S0009-2614(02)00902-8
   Costales A, 2002, J PHYS CHEM B, V106, P1940, DOI 10.1021/jp013906f
   Feng PY, 1996, CHEM PHYS LETT, V258, P387, DOI 10.1016/0009-2614(96)00685-9
   Feng PY, 1998, CHEM PHYS LETT, V283, P167, DOI 10.1016/S0009-2614(97)01362-6
   Feng PY, 1997, CHEM PHYS LETT, V265, P41, DOI 10.1016/S0009-2614(96)01418-2
   Feng PY, 1997, CHEM PHYS LETT, V265, P547, DOI 10.1016/S0009-2614(96)01469-8
   He CL, 2003, ACTA PHYS SIN-CH ED, V52, P1911
   He J, 2002, ACTA PHYS SIN-CH ED, V51, P2580
   LI S, 1993, J PHYS CHEM-US, V97, P11393, DOI 10.1021/j100146a009
   Liu Q, 2002, ACTA PHYS SIN-CH ED, V51, P2756
   MICIC OI, 1995, J PHYS CHEM-US, V99, P7754, DOI 10.1021/j100019a063
   Taylor TR, 1999, EUR PHYS J D, V9, P317, DOI 10.1007/s100530050447
   Taylor TR, 1998, CHEM PHYS LETT, V297, P133, DOI 10.1016/S0009-2614(98)01104-X
   Taylor TR, 2001, J CHEM PHYS, V115, P4620, DOI 10.1063/1.1391267
   Tozzini V, 2000, PHYS REV LETT, V85, P4554, DOI 10.1103/PhysRevLett.85.4554
   Wang F, 2003, CHINESE PHYS, V12, P164, DOI 10.1088/1009-1963/12/2/308
NR 19
TC 1
Z9 1
U1 1
U2 4
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD APR
PY 2004
VL 53
IS 4
BP 1056
EP 1062
PG 7
WC Physics, Multidisciplinary
SC Physics
GA 807XL
UT WOS:000220534100017
DA 2018-12-27
ER

PT J
AU Yurusoy, M
AF Yurusoy, M
TI RETRACTED: Similarity solutions for creeping flow and heat transfer in
   second grade fluid (Retracted article. See vol. 32, pg. 1489, 2011)
SO APPLIED MATHEMATICS AND MECHANICS-ENGLISH EDITION
LA English
DT Article; Retracted Publication
DE creeping flow; heat transfer; Lie group
ID 2ND-ORDER FLUID; UNIQUENESS; MOTION
AB The two dimensional equations of motions for the slowly flowing and heat transfer in second grade fluid are written in Cartesian coordinates neglecting the inertial terms. When the inertia terms are simply omitted from the equations of motions the resulting solutions are valid approximately for Re much less than 1. This fact can also be deduced from the dimensionless form of the momentum and energy equations. By employing Lie group analysis, the symmetries of the equations are calculated. The Lie algebra consists of four finite parameter and one infinite parameter Lie group transformations, one being the scaling symmetry and the others being translations. Two different types of solutions are found using the symmetries. Using translations in x and y coordinates, an exponential type of exact solution is presented. For the scaling symmetry, the outcoming ordinary differential equations are more involved and only a series type of approximate solution is presented. Finally, some boundary value problems are discussed.
C1 Afyon Kocatepe Univ, Fac Tech Educ, Dept Mech Educ, TR-03200 Afyon, Turkey.
RP Yurusoy, M (reprint author), Afyon Kocatepe Univ, Fac Tech Educ, Dept Mech Educ, TR-03200 Afyon, Turkey.
EM yurusoy@aku.edu.tr
CR Bluman G., 1989, SYMMETRICS DIFFERENT
   BOURGIN P, 1989, INT J NONLINEAR MECH, V24, P561, DOI 10.1016/0020-7462(89)90020-6
   DUNN JE, 1995, INT J ENG SCI, V33, P689, DOI 10.1016/0020-7225(94)00078-X
   DUNN JE, 1974, ARCH RATION MECH AN, V56, P191, DOI 10.1007/BF00280970
   FOSDICK RL, 1978, INT J NONLINEAR MECH, V13, P131, DOI 10.1016/0020-7462(78)90001-X
   Galdi GP, 1997, INT J ENG SCI, V35, P33, DOI 10.1016/S0020-7225(96)00064-X
   HUILGOL RR, 1973, SIAM J APPL MATH, V24, P226, DOI 10.1137/0124023
   RAJAGOPAL KR, 1984, J NON-NEWTON FLUID, V15, P239, DOI 10.1016/0377-0257(84)80008-7
   RAJAGOPAL KR, 1994, NAVIERSTOKES EQUATIO
   TANNER RI, 1966, PHYS FLUIDS, V9, P1246, DOI 10.1063/1.1761827
NR 10
TC 3
Z9 3
U1 3
U2 10
PU SHANGHAI UNIV
PI SHANGHAI
PA 149 YANCHANG RD, SHANGHAI 200072, PEOPLES R CHINA
SN 0253-4827
EI 1573-2754
J9 APPL MATH MECH-ENGL
JI Appl. Math. Mech.-Engl. Ed.
PD APR
PY 2004
VL 25
IS 4
BP 467
EP 474
DI 10.1007/BF02437531
PG 8
WC Mathematics, Applied; Mechanics
SC Mathematics; Mechanics
GA 816UJ
UT WOS:000221134500013
DA 2018-12-27
ER

PT J
AU Vuthaluru, HB
AF Vuthaluru, HB
TI RETRACTED: Investigations into the pyrolytic behaviour of coal/biomass
   blends using thermogravimetric analysis (Retracted article. See vol.
   243, pg. 1263, 2017)
SO BIORESOURCE TECHNOLOGY
LA English
DT Article; Retracted Publication
DE coal; biomass; thermal degradation; co-pyrolysis co-firing
ID BIOMASS; COAL; KINETICS; COMBUSTION; STRAW
AB Investigations into the pyrolytic behaviour during co-pyrolysis of coal, biomass materials and coal/biomass blends prepared at different ratios (10:90, 20:80, 30:70 and 50:50) have been conducted using a thermogravimetric analysis (TGA) apparatus. The coal sample selected was Collie sub-bituminous coal from Western Australia, while wood waste (WW) and wheat straw (WS) were used as biomass samples. Three thermal events were identified during the pyrolysis. The first two were dominated by the biomass pyrolysis, while the third was linked to the coal pyrolysis, which occurred at much higher temperatures. No interactions were seen between the coal and biomass during co-pyrolysis. The pyrolytic characteristics of the blends followed those of the parent fuels in an additive manner. Among the tested blends, 20:80 blends showed the lowest activation energies of 90.9 and 78.7 U mol(-1) for coal/ WW and coal/WS blends respectively. The optimum blend ratio for pyrolysis of coal/WS was 50:50 with a high degradation rate in all the thermal events and a higher mass loss over the course of the co-pyrolysis compared to coal/WW blends examined. The reaction orders in these experiments were in the range of 0.21-1.60, thus having a significant effect on the overall reaction rate. Besides the pyrolysis of coal alone, the 50:50 coal/biomass blends had the highest reaction rate, ranging 1 x 10(9)-2 x 10(9) min(-1). The experimental results may provide useful data for power generation industries for the development of co-firing options with biomass. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Curtin Univ Technol, Dept Chem Engn, Perth, WA 6845, Australia.
RP Vuthaluru, HB (reprint author), Curtin Univ Technol, Dept Chem Engn, GPO Box 1987, Perth, WA 6845, Australia.
EM h.vuthaluru@exchange.curtin.edu.au
CR ABBAS T, 1990, 26 S INT COMB US, P3041
   AHMED S, 1988, RES THERMOCHEMICAL B, P295
   Blazej A, 1993, PHYTOMASS
   Caballero JA, 1997, J ANAL APPL PYROL, V44, P75, DOI 10.1016/S0165-2370(97)00068-5
   Hatakeyama T., 1999, THERMAL ANAL FUNDAME
   Heinzel T, 1998, FUEL PROCESS TECHNOL, V54, P109, DOI 10.1016/S0378-3820(97)00063-5
   Helsen L, 2000, J ANAL APPL PYROL, V53, P51, DOI 10.1016/S0165-2370(99)00050-9
   Kastanaki E, 2002, FUEL PROCESS TECHNOL, V77, P159, DOI 10.1016/S0378-3820(02)00049-8
   Mansaray KG, 1999, ENERG SOURCE, V21, P773, DOI 10.1080/00908319950014335
   Meesri C, 2002, BIOMASS BIOENERG, V23, P55, DOI 10.1016/S0961-9534(02)00034-X
   Nassar MM, 1999, ENERG SOURCE, V21, P131, DOI 10.1080/00908319950015000
   NETSCH, 2001, WITTELSBACHERSTRASSE, P42
   Pan YG, 1996, FUEL, V75, P412, DOI 10.1016/0016-2361(95)00275-8
   Pedersen LS, 1996, FUEL, V75, P1584, DOI 10.1016/0016-2361(96)82642-1
   RAMIAH MV, 1970, J APPL POLYM SCI, V14, P1323, DOI 10.1002/app.1970.070140518
   RUDIGER H, 1994, APAS CLEAN COAL TECH, pC4
   Sami M, 2001, PROG ENERG COMBUST, V27, P171, DOI 10.1016/S0360-1285(00)00020-4
   Smith L., 1994, STRUCTURE REACTION P
   SWANEKAMP R, 1995, POWER, V139, P51
   Wendlandt WW, 1974, THERMAL METHODS ANAL
   Werther J, 2000, PROG ENERG COMBUST, V26, P1, DOI 10.1016/S0360-1285(99)00005-2
   Williams A, 2001, PROG ENERG COMBUST, V27, P587, DOI 10.1016/S0360-1285(01)00004-1
NR 22
TC 87
Z9 101
U1 3
U2 56
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD APR
PY 2004
VL 92
IS 2
BP 187
EP 195
DI 10.1016/j.biortech.2003.08.008
PG 9
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 801VG
UT WOS:000220122800010
PM 14693452
DA 2018-12-27
ER

PT J
AU Baig, MK
   Wexner, SD
AF Baig, MK
   Wexner, SD
TI RETRACTED: Postoperative ileus: A review (Retracted Article - See vol
   48, pg 1983, 2005)
SO DISEASES OF THE COLON & RECTUM
LA English
DT Review; Retracted Publication
DE ileus; bowel motility; postoperative; colorectal surgery
ID PROSPECTIVE RANDOMIZED-TRIAL; PLACEBO-CONTROLLED TRIAL; GASTRIC-EMPTYING
   RATE; GENE-RELATED PEPTIDE; EPIDURAL ANALGESIA; PARALYTIC ILEUS;
   COLORECTAL SURGERY; ABDOMINAL-SURGERY; GASTROINTESTINAL MOTILITY;
   LAPAROSCOPIC COLECTOMY
AB PURPOSE: Postoperatively, some patients experience a prolonged inhibition of coordinated bowel activity, which causes accumulation of secretions and gas, resulting in nausea, vomiting, abdominal distension, and pain. This prolonged inhibition can take days or weeks to resolve and often is referred to as postoperative paralytic ileus lasting more than three days after surgery. This article reviews the etiology, pathophysiology, and treatment options of postoperative ileus. METHODS: The relevant literature from 1965 to 2003 was identified and reviewed using MEDLINE database of the U.S. Medical Library of Medicine. Both retrospective and prospective studies were included in this review. RESULTS: The pathophysiology of postoperative ileus is multifactorial. The duration of postoperative ileus correlates with the degree of surgical trauma and is most extensive after colonic surgery. However, postoperative ileus can develop after all types of surgery including extraperitoneal surgery. A variety of treatment options have been used to decrease the duration of postoperative ileus. However, it is difficult to compare these studies because of small sample sizes and differences in operations performed, anesthesia protocols provided both intraoperatively and postoperatively, patient comorbidities, and in the measured end points, such as the time to the presence of bowel sounds, flatus, or bowel movements, tolerance of solid food, or discharge from the hospital. However, despite these drawbacks, some conclusions can be made. CONCLUSIONS: Paralytic postoperative Hens continues to be a significant problem after abdominal and other types of surgery. The etiology is multifactorial and is best treated with a combination of different approaches. Currently, the important factors that could effect the duration and recovery from postoperative ileus include limitation of narcotic use by substituting alternative medications such as nonsteroidals and placing a thoracic epidural with local anesthetic when possible. The selective use of nasogastric decompression and. correction of electrolyte imbalances also are important factors to consider.
C1 Cleveland Clin Florida, Dept Colorectal Surg, Weston, FL 33331 USA.
RP Wexner, SD (reprint author), Cleveland Clin Florida, Dept Colorectal Surg, 2950 Cleveland Clin Blvd, Weston, FL 33331 USA.
EM mcderme@ccf.org
CR AHN H, 1988, BRIT J SURG, V75, P1176, DOI 10.1002/bjs.1800751210
   ASANTILA R, 1991, ACTA ANAESTH SCAND, V35, P513, DOI 10.1111/j.1399-6576.1991.tb03339.x
   Asao T, 2002, J AM COLL SURGEONS, V195, P30, DOI 10.1016/S1072-7515(02)01179-1
   BARQUIST E, 1992, AM J PHYSIOL, V262, pG616
   Basse L, 2000, ANN SURG, V232, P51, DOI 10.1097/00000658-200007000-00008
   Basse L, 2001, BRIT J SURG, V88, P1498, DOI 10.1046/j.0007-1323.2001.01916.x
   Bayliss W M, 1899, J Physiol, V24, P99
   Bederman SS, 2001, J ARTHROPLASTY, V16, P1066, DOI 10.1054/arth.2001.27675
   BENSON MJ, 1994, GASTROENTEROLOGY, V106, P924, DOI 10.1016/0016-5085(94)90751-X
   BINDEROW SR, 1994, DIS COLON RECTUM, V37, P584, DOI 10.1007/BF02050994
   BOGHAERT A, 1987, Acta Anaesthesiologica Belgica, V38, P195
   BOHM B, 1995, ARCH SURG-CHICAGO, V130, P415
   BONACINI M, 1993, AM J GASTROENTEROL, V88, P208
   BREDTMANN RD, 1990, BRIT J SURG, V77, P638, DOI 10.1002/bjs.1800770615
   Brown TA, 1999, AM J SURG, V177, P399, DOI 10.1016/S0002-9610(99)00071-9
   BURKS TF, 1994, PHYSL GASTROINTESTIN, V1
   Cali RL, 2000, DIS COLON RECTUM, V43, P163, DOI 10.1007/BF02236975
   CHEAPE JD, 1991, DIS COLON RECTUM, V34, P437, DOI 10.1007/BF02049925
   CHEATHAM ML, 1995, ANN SURG, V221, P469, DOI 10.1097/00000658-199505000-00004
   CULLEN JJ, 1993, AM J SURG, V165, P113, DOI 10.1016/S0002-9610(05)80413-1
   CULLEN JJ, 1994, DIGEST DIS SCI, V39, P1179, DOI 10.1007/BF02093781
   DAVIDSON ED, 1979, ANN SURG, V190, P27, DOI 10.1097/00000658-197907000-00006
   Davies W, 1997, SURGERY, V121, P550, DOI 10.1016/S0039-6060(97)90110-0
   De Winter BY, 1998, BRIT J PHARMACOL, V124, P1181, DOI 10.1038/sj.bjp.0701954
   Di Fronzo LA, 1999, ARCH SURG-CHICAGO, V134, P941, DOI 10.1001/archsurg.134.9.941
   DISBROW EA, 1993, WESTERN J MED, V158, P488
   Donat SM, 1999, J UROLOGY, V162, P1599, DOI 10.1016/S0022-5347(05)68175-X
   DUBOIS A, 1975, GASTROENTEROLOGY, V68, P466
   ESPAT NJ, 1995, J SURG RES, V58, P719, DOI 10.1006/jsre.1995.1113
   Fanning J, 1999, GYNECOL ONCOL, V73, P412, DOI 10.1006/gyno.1999.5401
   FERRAZ AAB, 1995, AM SURGEON, V61, P1079
   FURNESS JB, 1974, MED BIOL, V52, P82
   GUYTON AC, 1986, TXB MED PHYSL, P754
   HALLERBACK B, 1991, ALIMENT PHARM THERAP, V5, P503
   HEIMBACH DM, 1971, SURGERY, V69, P582
   Heslin MJ, 1997, ANN SURG, V226, P567, DOI 10.1097/00000658-199710000-00016
   HJORTSO NC, 1985, ACTA ANAESTH SCAND, V29, P790, DOI 10.1111/j.1399-6576.1985.tb02302.x
   Holte K, 2000, BRIT J SURG, V87, P1480, DOI 10.1046/j.1365-2168.2000.01595.x
   Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514
   Huge A, 1998, J SURG RES, V74, P112, DOI 10.1006/jsre.1997.5245
   JEPSEN S, 1986, BRIT J SURG, V73, P290, DOI 10.1002/bjs.1800730414
   Johnson LR, 1994, PHYSL GASTROINTESTIN
   Jorgensen H, 2001, BRIT J ANAESTH, V87, P577, DOI 10.1093/bja/87.4.577
   Kalff JC, 1999, GASTROENTEROLOGY, V117, P378, DOI 10.1053/gast.1999.0029900378
   Kalff JC, 1998, ANN SURG, V228, P652, DOI 10.1097/00000658-199811000-00004
   Kalff JC, 1999, SURGERY, V126, P498, DOI 10.1067/msy.2099.99575
   Kalff JC, 2000, GASTROENTEROLOGY, V118, P316, DOI 10.1016/S0016-5085(00)70214-9
   KATSCHINSKI M, 1992, GASTROENTEROLOGY, V103, P383, DOI 10.1016/0016-5085(92)90825-J
   KAUFMAN PN, 1988, GASTROENTEROLOGY, V94, P1351, DOI 10.1016/0016-5085(88)90673-7
   KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129
   KLEINFEL.G, 1973, JAMA-J AM MED ASSOC, V223, P922, DOI 10.1001/jama.1973.03220080052022
   Kreis ME, 2001, SURGERY, V130, P449, DOI 10.1067/msy.2001.116451
   LACY AM, 1995, SURG ENDOSC-ULTRAS, V9, P1101
   Lander A, 1997, ARCH DIS CHILD, V77, pF119, DOI 10.1136/fn.77.2.F119
   Leung KL, 2000, ANN SURG, V231, P506, DOI 10.1097/00000658-200004000-00008
   LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015
   LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233
   Lobo DN, 2002, LANCET, V359, P1812, DOI 10.1016/S0140-6736(02)08711-1
   LONGO WE, 1993, DIS COLON RECTUM, V36, P696, DOI 10.1007/BF02238599
   Macmillan SLM, 2000, OBSTET GYNECOL, V96, P604, DOI 10.1016/S0029-7844(00)00957-1
   MADSEN PV, 1983, DIS COLON RECTUM, V26, P159, DOI 10.1007/BF02560160
   MOSS G, 1986, SURGERY, V99, P206
   NEELY J, 1971, BRIT J SURG, V58, P21, DOI 10.1002/bjs.1800580104
   Neudecker J, 1999, BRIT J SURG, V86, P1292, DOI 10.1046/j.1365-2168.1999.01242.x
   OGILVY AJ, 1995, EUR J ANAESTH, V12, P35
   Prasad M, 1999, GASTROENTEROLOGY, V117, P489, DOI 10.1053/gast.1999.0029900489
   Rao SSC, 1999, AM J PHYSIOL-GASTR L, V276, pG1221
   RASHID MU, 1990, BRIT J CLIN PHARMACO, V30, P25, DOI 10.1111/j.1365-2125.1990.tb03739.x
   REISSMAN P, 1995, ANN SURG, V222, P73, DOI 10.1097/00000658-199507000-00012
   RIVIERE PJM, 1993, GASTROENTEROLOGY, V104, P724, DOI 10.1016/0016-5085(93)91007-5
   ROBERTS JP, 1995, DIS COLON RECTUM, V38, P139, DOI 10.1007/BF02052441
   SADEK S A, 1988, Alimentary Pharmacology and Therapeutics, V2, P47
   SAGAR PM, 1992, BRIT J SURG, V79, P1127, DOI 10.1002/bjs.1800791105
   Sargrada A, 1987, GUT, V28, P955
   SCHEININ B, 1987, ACTA ANAESTH SCAND, V31, P161, DOI 10.1111/j.1399-6576.1987.tb02541.x
   SCHIPPERS E, 1991, DIGEST DIS SCI, V36, P621, DOI 10.1007/BF01297029
   Schmidt WK, 2001, AM J SURG, V182, p27S, DOI 10.1016/S0002-9610(01)00784-X
   SCHURIZEK BA, 1989, EUR J ANAESTH, V6, P265
   SCHURIZEK BA, 1989, BRIT J ANAESTH, V62, P129, DOI 10.1093/bja/62.2.129
   Schwarz NT, 2002, ANN SURG, V235, P31, DOI 10.1097/00000658-200201000-00005
   Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605
   Schwenk W, 1998, LANGENBECK ARCH SURG, V383, P49, DOI 10.1007/s004230050091
   SENAGORE AJ, 1993, AM SURGEON, V59, P549
   Shibata Y, 1998, SURG TODAY, V28, P787, DOI 10.1007/s005950050227
   Smith AJ, 2000, DIS COLON RECTUM, V43, P333, DOI 10.1007/BF02258298
   SOFFER EE, 1992, DIGEST DIS SCI, V37, P1009, DOI 10.1007/BF01300279
   Steinbrook RA, 1998, ANESTH ANALG, V86, P837, DOI 10.1097/00000539-199804000-00029
   Stewart BT, 1998, AUST NZ J SURG, V68, P125, DOI 10.1111/j.1445-2197.1998.tb04721.x
   Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564
   THOREN T, 1989, ACTA ANAESTH SCAND, V33, P181, DOI 10.1111/j.1399-6576.1989.tb02886.x
   TOLLESSON PO, 1991, SCAND J GASTROENTERO, V26, P477, DOI 10.3109/00365529108998569
   VERLINDEN M, 1987, BRIT J SURG, V74, P614, DOI 10.1002/bjs.1800740727
   VONRITTER C, 1987, S AFR J SURG, V25, P19
   WALDHAUSEN JHT, 1990, ANN SURG, V212, P671, DOI 10.1097/00000658-199012000-00004
   WALLIN G, 1986, ANESTHESIOLOGY, V65, P292
   Watters JM, 1997, ANN SURG, V226, P369, DOI 10.1097/00000658-199709000-00016
   WATTWIL M, 1989, ANESTH ANALG, V68, P353
   Yuan CS, 2000, JAMA-J AM MED ASSOC, V284, P1383, DOI 10.1001/jama.284.11.1383
   Yuan CS, 2000, CLIN PHARMACOL THER, V67, P398, DOI 10.1067/mcp.2000.105037
   Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367
   Zittel TT, 1998, SURGERY, V123, P518, DOI 10.1067/msy.1998.88090
   ZITTEL TT, 1994, ANN SURG, V219, P79, DOI 10.1097/00000658-199401000-00013
NR 102
TC 85
Z9 94
U1 5
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0012-3706
EI 1530-0358
J9 DIS COLON RECTUM
JI Dis. Colon Rectum
PD APR
PY 2004
VL 47
IS 4
BP 516
EP 526
DI 10.1007/s10350-003-0067-9
PG 11
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 808MZ
UT WOS:000220574500019
PM 14978625
DA 2018-12-27
ER

PT J
AU Shin, JJ
   Bryksin, AV
   Godfrey, HP
   Cabello, FC
AF Shin, JJ
   Bryksin, AV
   Godfrey, HP
   Cabello, FC
TI RETRACTED: Localization of BmpA on the exposed outer membrane of
   Borrelia burgdorferi by monospecific anti-recombinant BmpA rabbit
   antibodies (Retracted Article. See vol 76, pg 4792, 2008)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID LYME-DISEASE SPIROCHETE; TREPONEMA-PALLIDUM; MONOCLONAL-ANTIBODIES;
   SURFACE EXPOSURE; TRITON X-114; GENE FAMILY; PROTEIN; EXPRESSION;
   LIPOPROTEINS; SEQUENCE
AB BmpA (P39) is an immunodominant chromosomally encoded Borrelia burgdorferi protein. The potential strong cross-reactivity of anti-BmpA antibodies with the other members of this paralogous protein family and the previous use of antibodies whose reactivity to the other Bmp proteins was uncharacterized have resulted in continued controversy over its localization in B. burgdorferi. In an effort to provide a definitive demonstration of the localization of BmpA, rabbit antibodies raised to recombinant BmpA (rBmpA) were rendered mono-specific by absorption with rBmpB. This reagent did not react with rBmpB, rBmpC, or rBmpD in dot immunobinding, detected only a single 39-kDa band and a single 39-kDa, pI 5.0 spot on one- and two-dimensional immunoblots of B. burgdorferi lysates, respectively, and immunoprecipitated a single 39-kDa protein from these lysates. It detected BmpA in the Triton X-114-soluble and -insoluble fractions of B. burgdorferi, suggesting association with both inner and outer bacterial cell membranes. Treatment of intact B. burgdorferi with proteinase K partially digested BmpA, consistent with a limited surface exposure on the outer bacterial membrane, a suggestion confirmed by immunofluorescence of unfixed B. burgdorferi cultured in vitro and in vivo. Anti-rBmpA antibody was bacteriostatic for B. burgdorferi B31 in culture, again suggesting localization of BmpA on the exposed spirochetal outer surface. Surface localization of BmpA, growth inhibition by anti-rBmpA antibodies, and the previously reported conservation of bmpA in different B. burgdorferi sensu lato strains may indicate that BmpA plays an essential role in B. burgdorferi biology.
C1 New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
   New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA.
RP Cabello, FC (reprint author), New York Med Coll, Dept Microbiol & Immunol, Basic Sci Bldg, Valhalla, NY 10595 USA.
EM cabello@nymc.edu
OI Godfrey, Henry/0000-0002-7195-6363
FU NIAID NIH HHS [R01 AI048856, R01 AI48856]
CR Akins DR, 1998, J CLIN INVEST, V101, P2240, DOI 10.1172/JCI2325
   ARON L, 1994, FEMS MICROBIOL LETT, V123, P75, DOI 10.1016/0378-1097(94)90277-1
   BARBOUR AG, 1986, MICROBIOL REV, V50, P381
   BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182
   Bugrysheva J, 2002, INFECT IMMUN, V70, P3061, DOI 10.1128/IAI.70.6.3061-3067.2002
   Bunikis J, 1999, INFECT IMMUN, V67, P2874
   Casjens S, 2000, J MOL MICROB BIOTECH, V2, P401
   COLEMAN JL, 1992, INFECT IMMUN, V60, P3098
   COX DL, 1995, MOL MICROBIOL, V15, P1151, DOI 10.1111/j.1365-2958.1995.tb02288.x
   Cox DL, 2001, MICROBIOL-SGM, V147, P1161, DOI 10.1099/00221287-147-5-1161
   Cox DL, 1996, P NATL ACAD SCI USA, V93, P7973, DOI 10.1073/pnas.93.15.7973
   Crother TR, 2003, INFECT IMMUN, V71, P3419, DOI 10.1128/IAI.71.6.3419-3428.2003
   CULLEN PA, 2003, IN PRES FEMS MICROBI
   CUNNINGHAM TM, 1988, J BACTERIOL, V170, P5789, DOI 10.1128/jb.170.12.5789-5796.1988
   Dobrikova EY, 2001, MOL MICROBIOL, V39, P370, DOI 10.1046/j.1365-2958.2001.02220.x
   El-Hage N, 2001, MICROBIOL-SGM, V147, P821, DOI 10.1099/00221287-147-4-821
   Escudero R, 1997, INFECT IMMUN, V65, P1908
   Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551
   Gilmore RD, 1996, INFECT IMMUN, V64, P2234
   Gorbacheva VY, 2000, J BACTERIOL, V182, P2037, DOI 10.1128/JB.182.7.2037-2042.2000
   Harlow E, 1988, ANTIBODIES LAB MANUA
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Hengge UR, 2003, LANCET INFECT DIS, V3, P489, DOI 10.1016/S1473-3099(03)00722-9
   Hirschfeld M, 1999, J IMMUNOL, V163, P2382
   Hubner A, 2001, P NATL ACAD SCI USA, V98, P12724, DOI 10.1073/pnas.231442498
   JOHNSON RC, 2002, MANUAL CLIN LAB IMMU, P494
   KOVARIK A, 1987, FOLIA BIOL-PRAGUE, V33, P253
   Landowski CP, 2001, J CLIN MICROBIOL, V39, P2418, DOI 10.1128/JCM.39.7.2418-2424.2001
   Liang FT, 2002, J EXP MED, V196, P275, DOI 10.1084/jem.20020770
   MA JN, 1995, INFECT IMMUN, V63, P2221
   Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261
   Motaleb MA, 2000, P NATL ACAD SCI USA, V97, P10899, DOI 10.1073/pnas.200221797
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Pal U, 2001, J IMMUNOL, V166, P7398, DOI 10.4049/jimmunol.166.12.7398
   PAVIA CS, 1991, J INFECT DIS, V163, P656, DOI 10.1093/infdis/163.3.656
   RADOLF JD, 1988, INFECT IMMUN, V56, P490
   Ramamoorthy R, 1996, INFECT IMMUN, V64, P1259
   Roberts DM, 2000, J BACTERIOL, V182, P4222, DOI 10.1128/JB.182.15.4222-4226.2000
   SADZIENE A, 1993, J INFECT DIS, V167, P165, DOI 10.1093/infdis/167.1.165
   SADZIENE A, 1994, INFECT IMMUN, V62, P2037
   Sambrook J., 2001, MOL CLONING
   SCRIBA M, 1993, INFECT IMMUN, V61, P4523
   SIMPSON WJ, 1994, FEMS MICROBIOL LETT, V119, P381, DOI 10.1016/0378-1097(94)90444-8
   SIMPSON WJ, 1990, J CLIN MICROBIOL, V28, P1329
   SULLIVAN TJ, 1994, J CLIN MICROBIOL, V32, P423
   Yang XFF, 2003, INFECT IMMUN, V71, P5012, DOI 10.1128/IAI.71.9.5012-5020.2003
NR 46
TC 13
Z9 14
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2004
VL 72
IS 4
BP 2280
EP 2287
DI 10.1128/IAI.72.4.2280-2287.2004
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 807DG
UT WOS:000220481600051
PM 15039353
OA Bronze
DA 2018-12-27
ER

PT J
AU Kossykh, VG
   Lloyd, RS
AF Kossykh, VG
   Lloyd, RS
TI RETRACTED: A DNA adenine methyltransferase of Escherichia coli that is
   cell cycle regulated and essential for viability (Retracted Article. See
   vol 186, pg 6340, 2004)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID DEPENDENT METHYLATION; DAM METHYLTRANSFERASE; GENE-EXPRESSION; PHASE
   VARIATION; VECTORS; FRACTIONATION; RESTRICTION; REPLICATION; REPRESSION;
   MECHANISM
AB DNA sequence analysis revealed that the putative yhdJ DNA methyltransferase gene of Escherichia coli is 55% identical to the Nostoc sp. strain PCC7120 gene encoding DNA methyltransferase AvaIII, which methylates adenine in the recognition sequence, ATGCAT. The yhdJ gene was cloned, and the enzyme was overexpressed and purified. Methylation and restriction analysis showed that the DNA methyl transferase methylates the first adenine in the sequence ATGCAT. This DNA methylation was found to be regulated during the cell cycle, and the DNA adenine methyltransferase was designated M.EcoKCcrM (for "cell cycle-regulated methyltransferase"). The CcrM DNA adenine methyltransferase is required for viability in E. coli, as a strain lacking a functional genomic copy of ccrM can be isolated only in the presence of an additional copy of ccrM supplied in trans. The cells of such a knockout strain stopped growing when expression of the inducible plasmid ccrM gene was shut off. Overexpression of M.EcoKCcrM slowed bacterial growth, and the ATGCAT sites became fully methylated throughout the cell cycle; a high proportion of cells with an anomalous size distribution and DNA content was found in this population. Thus, the temporal control of this methyltransferase may contribute to accurate cell cycle control of cell division and cellular morphology. Homologs of M.EcoKCcrM are present in other bacteria belonging to the gamma subdivision of the class Proteobacteria, suggesting that methylation at ATGCAT sites may have similar functions in other members of this group.
C1 Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.
   Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.
RP Kossykh, VG (reprint author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.
EM vakossyk@utmb.edu
FU NIEHS NIH HHS [P30 ES 06676, P30 ES006676]
CR AU KG, 1992, J BIOL CHEM, V267, P12142
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BICKLE TA, 1993, MICROBIOL REV, V57, P434
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x
   BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G
   CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F
   Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784
   Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7
   GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995
   Haagmans W, 2000, MOL MICROBIOL, V35, P877, DOI 10.1046/j.1365-2958.2000.01762.x
   Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967
   Julio SM, 2001, INFECT IMMUN, V69, P7610, DOI 10.1128/IAI.69.12.7610-7615.2001
   Low DA, 2001, INFECT IMMUN, V69, P7197, DOI 10.1128/IAI.69.12.7197-7204.2001
   Makinoshima H, 2002, MOL MICROBIOL, V43, P269, DOI 10.1046/j.1365-2958.2002.02746.x
   MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577
   MARINUS MG, 1996, ESCHERICHIA COLI SAL, P782
   Minko I, 2001, NUCLEIC ACIDS RES, V29, P1484, DOI 10.1093/nar/29.7.1484
   Nicholson B, 2000, MOL MICROBIOL, V35, P728, DOI 10.1046/j.1365-2958.2000.01743.x
   Pertoft H, 2000, J BIOCHEM BIOPH METH, V44, P1, DOI 10.1016/S0165-022X(00)00066-X
   PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3
   REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207
   Reisenauer A, 1999, J BACTERIOL, V181, P5135
   Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P418, DOI 10.1093/nar/gkg069
   Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9
NR 26
TC 12
Z9 14
U1 3
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD APR
PY 2004
VL 186
IS 7
BP 2061
EP 2067
DI 10.1128/JB.186.7.2061-2067.2004
PG 7
WC Microbiology
SC Microbiology
GA 805JS
UT WOS:000220363200017
PM 15028690
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Moshonov, J
   Peretz, B
   Brown, T
   Rotstein, I
AF Moshonov, J
   Peretz, B
   Brown, T
   Rotstein, I
TI RETRACTED: Cleaning of the root canal using Nd : YAP laser and its
   effect on the mineral content of the dentin (Retracted article. See vol.
   33, pg. 576, 2015)
SO JOURNAL OF CLINICAL LASER MEDICINE & SURGERY
LA English
DT Article; Retracted Publication
ID IN-VITRO; IRRADIATION
AB Objective: To compare the efficacy of root canal cleanliness with and without Nd:YAP laser and to assess the effect of the laser on the mineral content of the dentin. Background Data: A high degree of cleanliness of the canal when using Nd:YAG laser has been shown while the laser had been in contact with the canal wall. A new Nd:YAP laser has been studied recently, which is considered to be superior to Nd:YAG with regard to anti-bactericidal ability due to its 1.34-mu wavelength, which is in the infra red range. This wavelength is absorbed better in water that of Nd:YAG. Materials and Methods: Fourteen extracted single rooted premplars were divided into two groups. In group 1, canals were cleaned, instrumented and shaped with K files. In group 2, initial preparation was done using K files and completed with a Nd:YAP laser. Teeth were then split longitudinally and submitted to SEM. Results: The cleanliness of the laser treated teeth was significantly greater than teeth treated with K files alone (p < 0.05). No difference in Ca and P content was detected when the use of K files was compared to the use of laser. Conclusions: It appears that Nd:YAP laser improves the cleanliness of the root canal. However, since Nd:YAP laser serves as an addition to K riles, its clinical value for replacing conventional root canal instrumentation remains to be determined.
C1 Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Endodont, IL-91120 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Pediat Dent, IL-91120 Jerusalem, Israel.
RP Moshonov, J (reprint author), Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Endodont, POB 12272, IL-91120 Jerusalem, Israel.
EM moshon@cc.huji.ac.il
CR Blum JY, 1997, J ENDODONT, V23, P669, DOI 10.1016/S0099-2399(97)80398-6
   Blum JY, 1997, J ENDODONT, V23, P583, DOI 10.1016/S0099-2399(06)81127-1
   CALAS P, 1998, USE ND YAP LASER ROO
   Dankner E, 1997, ENDOD DENT TRAUMATOL, V13, P234
   Farge P, 1998, J ENDODONT, V24, P359, DOI 10.1016/S0099-2399(98)80135-0
   FEGAN SE, 1995, J ENDODONT, V21, P415, DOI 10.1016/S0099-2399(06)80827-7
   GOODIS HE, 1993, SCANNING MICROSCOPY, V7, P979
   KOORT HJ, 1995, LASERS DENT, P55
   LEVY G, 1992, J ENDODONT, V18, P123, DOI 10.1016/S0099-2399(06)81312-9
   MACHIDA T, 1995, J ENDODONT, V21, P88, DOI 10.1016/S0099-2399(06)81102-7
   MISERENDINO LJ, 1995, J ENDODONT, V21, P83, DOI 10.1016/S0099-2399(06)81101-5
   MISERENDINO LJ, 1995, LASERS DENT, P62
   MISERENDINO LJ, 1995, LASERS DENT, P17
   MOSHONOV J, 1995, ENDOD DENT TRAUMATOL, V11, P220
   MOSHONOV J, 1995, ORAL SURG ORAL MED O, V79, P221, DOI 10.1016/S1079-2104(05)80287-2
   SAUNDERS WP, 1995, INT ENDOD J, V28, P213, DOI 10.1111/j.1365-2591.1995.tb00302.x
NR 16
TC 7
Z9 8
U1 4
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5471
J9 J CLIN LASER MED SUR
JI J. Clin. Laser Med. Sur.
PD APR
PY 2004
VL 22
IS 2
BP 87
EP 89
DI 10.1089/104454704774076127
PG 3
WC Engineering, Biomedical; Surgery
SC Engineering; Surgery
GA 821TY
UT WOS:000221486800002
PM 15165381
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Lippman, SM
   Lee, JJ
   Mao, L
   Kildal, W
   Sudbo, A
   Sagen, S
   Bryne, M
   El-Naggar, A
   Risberg, B
   Evensen, JF
   Reith, A
AF Sudbo, J
   Lippman, SM
   Lee, JJ
   Mao, L
   Kildal, W
   Sudbo, A
   Sagen, S
   Bryne, M
   El-Naggar, A
   Risberg, B
   Evensen, JF
   Reith, A
TI RETRACTED: The influence of resection and aneuploidy on mortality in
   oral leukoplakia (Retracted article. See vol 355 pg 1927, 2006)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID SQUAMOUS-CELL CARCINOMA; NECK-CANCER; FIELD CANCERIZATION;
   CLINICAL-IMPLICATIONS; GENETIC PROGRESSION; MEDICAL PROGRESS; HEAD;
   RISK; LESIONS; RECOMMENDATIONS
AB BACKGROUND:
   Although the standard treatment of oral leukoplakia ranges from watchful waiting to complete resection, the value of these approaches is unknown.
   METHODS:
   We studied the relations among resection, ploidy status, and death from cancer in 103 patients with diploid dysplastic oral leukoplakia, 20 patients with tetraploid lesions, and 27 patients with aneuploid lesions. Data on cancer-specific mortality and treatment were obtained from the Cancer Registry of Norway, Statistics Norway, and chart reviews.
   RESULTS:
   Primary oral carcinoma developed in 47 of the 150 patients with leukoplakia (31 percent) -- 5 with diploid, 16 with tetraploid, and 26 with aneuploid leukoplakia -- during a mean follow-up of 80 months (range, 4 to 237). The margin status of the initial leukoplakia resection had no relation to the development of oral cancer (P=0.95). Twenty-six of the 47 patients in whom cancer developed (4 with prior tetraploid and 22 with prior aneuploid lesions) had recurrences (55 percent); the recurrences were more frequently multiple and distant (within the oral cavity) among patients with aneuploid lesions than among those with tetraploid or diploid lesions. All 47 patients underwent a standard regimen of surgery and radiation, followed by chemotherapy in the 26 with recurrent cancer. Only patients with aneuploid leukoplakia died of oral cancer; the five-year rate of death from cancer was 72 percent. Aneuploidy-related first carcinomas were diagnosed at a more advanced stage than were carcinomas originating from diploid or tetraploid leukoplakia (P=0.03) and were more likely to be lethal regardless of the stage.
   CONCLUSIONS:
   Complete resection of aneuploid leukoplakia does not reduce the high risk of aggressive carcinoma and death from oral cancer.
C1 Univ Oslo, Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Div Digital Pathol, N-0310 Oslo, Norway.
   Univ Oslo, Norwegian Radium Hosp, Dept Pathol, Div Cytol, N-0310 Oslo, Norway.
   Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol & Head & Neck Surg, Houston, TX 77030 USA.
   Norwegian Univ Sci & Technol, Dept Phys, N-7034 Trondheim, Norway.
   Univ Oslo, Dept Oral Biol, Oslo, Norway.
RP Sudbo, A (reprint author), Univ Oslo, Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Div Digital Pathol, Ullernchausseen 70, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
RI Mao, Li/C-7570-2011
OI Mao, Li/0000-0001-7263-3358
FU NCI NIH HHS [CA16672]
CR Bedi GC, 1996, CANCER RES, V56, P2484
   Bouquot J E, 1995, Pract Periodontics Aesthet Dent, V7, P59
   Braakhuis BJM, 2002, HEAD NECK-J SCI SPEC, V24, P198, DOI 10.1002/hed.10042
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704
   Califano J, 1996, CANCER RES, V56, P2488
   Califano J, 2000, CLIN CANCER RES, V6, P347
   CHIESA F, 1993, ORAL ONCOL, V29B, P23, DOI 10.1016/0964-1955(93)90006-Z
   COTE RA, 1979, SYSTEMATIZED NOMENCL, V1, P61
   DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905
   Fleming ID, 1997, AJCC CANC STAGING MA, P29
   Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375
   FORASTIERE A, 2002, NEW ENGL J MED, V346, P788
   Jang SJ, 2001, ONCOGENE, V20, P2235, DOI 10.1038/sj.onc.1204311
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Lee JJ, 2000, AM STAT, V54, P63, DOI 10.2307/2685614
   Lee JJ, 2000, CLIN CANCER RES, V6, P1702
   Lippman SM, 2002, CANCER RES, V62, P5119
   Lippman SM, 2001, NEW ENGL J MED, V344, P1323, DOI 10.1056/NEJM200104263441710
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   MORK J, 1995, APMIS, V103, P375, DOI 10.1111/j.1699-0463.1995.tb01121.x
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   Partridge M, 2000, CANCER RES, V60, P3893
   PINDBORG JJ, 1997, HISTOLOGICAL TYPING, P21
   Reibel J, 2003, MED PRIN PRACT, V12, P22, DOI 10.1159/000069845
   Scully C, 2000, BRIT MED J, V321, P225, DOI 10.1136/bmj.321.7255.225
   SHAFER WG, 1975, CANCER-AM CANCER SOC, V36, P1021, DOI 10.1002/1097-0142(197509)36:3<1021::AID-CNCR2820360327>3.0.CO;2-W
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Sudbo J, 2002, J CLIN ONCOL, V20, P456, DOI 10.1200/JCO.20.2.456
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Sudbo Jon, 2003, Tidsskr Nor Laegeforen, V123, P1518
   Tradati N, 1997, ORAL ONCOL, V33, P317, DOI 10.1016/S1368-8375(97)00016-X
   Tralongo V, 1999, ANTICANCER RES, V19, P3503
   VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306
   Zhang L, 2001, ORAL ONCOL, V37, P505, DOI 10.1016/S1368-8375(00)00140-8
NR 35
TC 78
Z9 80
U1 3
U2 11
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 1
PY 2004
VL 350
IS 14
BP 1405
EP 1413
DI 10.1056/NEJMoa033374
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 808IJ
UT WOS:000220562500007
PM 15070790
DA 2018-12-27
ER

PT J
AU First, SM
   Pins, JJ
   Shamliyan, T
   Keenan, JC
   Keenan, JM
AF First, SM
   Pins, JJ
   Shamliyan, T
   Keenan, JC
   Keenan, JM
TI RETRACTED: An interim analysis of the lipid-altering effects of the
   dietary supplement pantethine (Retracted article. See vol. 23, pg. 1616,
   2009)
SO FASEB JOURNAL
LA English
DT Meeting Abstract; Retracted Publication
CT Experimental Biology 2004 Annual Meeting
CY APR 17-21, 2004
CL Washington, DC
C1 Univ Minnesota, Dept Family Practice & Community Hlth, Minneapolis, MN 55455 USA.
NR 0
TC 1
Z9 1
U1 1
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAR 24
PY 2004
VL 18
IS 5
SU S
BP A910
EP A910
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 806ZB
UT WOS:000220470700726
DA 2018-12-27
ER

PT J
AU Miyagi, Y
   Kimura, H
   Carpenter, RC
   Parent, AD
   Zhang, J
AF Miyagi, Y
   Kimura, H
   Carpenter, RC
   Parent, AD
   Zhang, J
TI RETRACTED: alpha,beta-MeATP augments the UTP contraction of rabbit
   basilar artery (Retracted Article. See vol 497, pg 245, 2004)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE uridine 5'-triphosphate; alpha,beta-methyleneadenosine 5'-triphosphate;
   P2Y(4) receptor; basilar artery; ectonucleotidase; smooth muscle
ID VASCULAR SMOOTH-MUSCLE; NUCLEOTIDE RECEPTORS; ENDOTHELIAL-CELLS; P-2
   PURINOCEPTOR; MESSENGER-RNAS; P2X RECEPTORS; ECTO-ATPASE; GAMMA-S;
   RT-PCR; VASOCONSTRICTION
AB The mechanism underlying the interaction between alpha, beta-methyleneadenosine 5'-triphosphate (alpha,beta-MeATP) and uridine 5'-triphosphate (UTP) was investigated using the basilar artery of a rabbit. UTP induced a concentration-dependent contraction, whereas P2X receptor agonists, such as alpha,beta-MeATP and 2-methylthioadenosine 5'-triphosphate (2-MeSATP), did not induce any contraction up to 100 muM. alpha,beta-MeATP augmented the UTP contraction two-fold, immediately and reversibly. This effect was observed with ectonucleotidase inhibition with 1 mM Ni2+, the removal of extracellular Ca2+ or Evans blue. The contractile response to adenosine 5'-O-(3-triphosphate) (ATPgammaS), a selective agonist for P2Y(4), was augmented by pretreatment with alpha,beta-MeATP also. ATPgammaS had no additional effect on the UTP contraction fully activated with alpha,beta-MeATP, UTP (100 muM) did not induce an increase in cytosolic Ca2+ in a rabbit basilar arterial strip; however, in the presence of 1 mM alpha,beta-MeATP, UTP induced a significant increase in cytosolic Ca2+. These results suggest that alpha,beta-MeATP facilitates the activation by UTP of the P2Y receptor (P2y(4)) of the rabbit basilar artery through mechanisms other than nucleotidase inhibition, and that it does not do so via a P2X receptor. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA.
RP Miyagi, Y (reprint author), Kaizuka Hosp, Dept Stereotact & Funct Neurosurg, 7-7-27 Hakozaki, Fukuoka 8120053, Japan.
EM suitecello2003@yahoo.co.jp
OI Miyagi, Yasushi/0000-0002-1241-0838
CR Broad LM, 1999, BIOCHEM J, V342, P199, DOI 10.1042/0264-6021:3420199
   Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x
   BULTMANN R, 1995, N-S ARCH PHARMACOL, V351, P555
   BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1
   Burnstock G, 1996, CIBA F SYMP, V198, P1
   Carpenter RC, 2001, STROKE, V32, P516, DOI 10.1161/01.STR.32.2.516
   CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152
   Chen BC, 1997, BIOCHEM BIOPH RES CO, V233, P442, DOI 10.1006/bbrc.1997.6478
   Chen X, 1997, J CEREBR BLOOD F MET, V17, P236, DOI 10.1097/00004647-199702000-00015
   CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x
   Erlinge D, 1998, BIOCHEM BIOPH RES CO, V248, P864, DOI 10.1006/bbrc.1998.9083
   Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437
   Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895
   KREUTZBERG GW, 1978, BRAIN RES, V158, P247, DOI 10.1016/0006-8993(78)90672-8
   Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257
   Lee H, 1997, J BIOL CHEM, V272, P21831, DOI 10.1074/jbc.272.35.21831
   Lopez C, 1998, EUR J PHARMACOL, V349, P225, DOI 10.1016/S0014-2999(98)00186-1
   Malmsjo M, 2000, BRIT J PHARMACOL, V131, P51, DOI 10.1038/sj.bjp.0703536
   McLaren GJ, 1998, EUR J PHARMACOL, V351, P139, DOI 10.1016/S0014-2999(98)00294-5
   McMillan MR, 1999, BRIT J PHARMACOL, V128, P549, DOI 10.1038/sj.bjp.0702814
   MIYAGI Y, 1995, J PHYSIOL-LONDON, V484, P123, DOI 10.1113/jphysiol.1995.sp020652
   Miyagi Y, 1996, BRIT J PHARMACOL, V118, P847, DOI 10.1111/j.1476-5381.1996.tb15477.x
   Nicholas RA, 1996, MOL PHARMACOL, V50, P224
   Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582
   North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563
   Otsuguro KI, 1996, EUR J PHARMACOL, V317, P97, DOI 10.1016/S0014-2999(96)00694-2
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x
   STROMEK SM, 1998, MOL PHARM, V54, P485
   VONKUGELGEN I, 1987, N-S ARCH PHARMACOL, V336, P556, DOI 10.1007/BF00169313
   VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V341, P538, DOI 10.1007/BF00171734
   WELFORD LA, 1987, EUR J PHARMACOL, V141, P123, DOI 10.1016/0014-2999(87)90418-3
   WILKINSON GF, 1994, MOL PHARMACOL, V45, P731
NR 33
TC 2
Z9 2
U1 5
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 19
PY 2004
VL 488
IS 1-3
BP 117
EP 125
DI 10.1016/j.ejphar.2004.02.002
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 810GE
UT WOS:000220692000015
PM 15044043
DA 2018-12-27
ER

PT J
AU Sasaki, M
   Tanaka, Y
   Okino, ST
   Nomoto, M
   Yonezawa, S
   Nakagawa, M
   Fujimoto, S
   Sakuragi, N
   Dahiya, R
AF Sasaki, M
   Tanaka, Y
   Okino, ST
   Nomoto, M
   Yonezawa, S
   Nakagawa, M
   Fujimoto, S
   Sakuragi, N
   Dahiya, R
TI RETRACTED: Polymorphisms of the CYP1B1 gene as risk factors for human
   renal cell cancer(Retracted article. See vol.23, pg.5321, 2017)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID PRIMARY CONGENITAL GLAUCOMA; CYTOCHROME P4501B1; AROMATIC-HYDROCARBONS;
   METABOLIZING ENZYMES; ENDOMETRIAL CANCER; CARCINOMA; SUSCEPTIBILITY;
   ASSOCIATION; MUTATIONS; INDUCTION
AB Purpose: CYP1B1 activates various environmental carcinogens in human tissues, including renal tissues. We hypothesize that certain polymorphisms of the CYP1B1 gene are risk factors for renal cell cancer. The rationale for this hypothesis is that chemical procarcinogenic compounds require metabolic activation by oxidative enzymes such as CYP1B1 to be transformed into potentially carcinogenic forms. To test this hypothesis, we investigated the genotypic distributions of six different loci on the CYP1B1 gene and their association with renal cell cancer.
   Experimental Design: DNA from 211 cases of human renal cell cancer and 200 healthy controls was analyzed by sequence-specific PCR and direct DNA sequencing to determine the genotypic frequencies of six different pollymorphic loci on the CYP1B1 gene.
   Results: The results of this study demonstrate that the frequencies of genotype 119T/T and genotype 432G/G were significantly higher in renal cell cancer patients compared with healthy normal controls. The relative risks were calculated as 3.01 and 2.17 for genotypes 119T/T and 432G/G, respectively, in renal cell carcinoma patients. These genotypic distributions were also significantly different between male and female patients. The relative risks of genotype 119T/T were calculated as 3.95 in males and 1.92 in females, and the relative risks of genotype 432G/G were calculated as 2.81 in males and 1.35 in females.
   Conclusions: The present study demonstrates for the first time that the polymorphisms at codons 119 and 432 may be risk factors for renal cancer, especially in the male population.
C1 Univ Calif San Francisco, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA.
   Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Kita Ku, Sapporo, Hokkaido, Japan.
   Tenshi Hosp, Dept Clin Genet, Kita Ku, Sapporo, Hokkaido, Japan.
   Kagoshima Univ, Fac Med, Dept Pathol 2, Kagoshima 890, Japan.
   Kagoshima Univ, Fac Med, Dept Urol, Kagoshima 890, Japan.
   Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
RP Dahiya, R (reprint author), Univ Calif San Francisco, Urol Res Ctr 112F, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM Urologylab@aol.com
RI Sakuragi, Noriaki/D-6507-2012
FU NIA NIH HHS [R01AG21418, R01AG016870]
CR Autrup H, 2000, MUTAT RES-GEN TOX EN, V464, P65, DOI 10.1016/S1383-5718(99)00167-9
   Bailey LR, 1998, CANCER RES, V58, P5038
   Bejjani BA, 1998, AM J HUM GENET, V62, P325, DOI 10.1086/301725
   Godley Paul A., 1998, Current Opinion in Oncology, V10, P261, DOI 10.1097/00001622-199805000-00014
   Gonzalez FJ, 1997, REPROD TOXICOL, V11, P397, DOI 10.1016/S0890-6238(96)00154-2
   Hanna IH, 2000, CANCER RES, V60, P3440
   Iwanari M, 2002, ARCH TOXICOL, V76, P287, DOI 10.1007/s00204-002-0340-z
   Longuemaux S, 1999, CANCER RES, V59, P2903
   MEYER UA, 1986, XENOBIOTICA, V16, P449, DOI 10.3109/00498258609050251
   Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207
   Rintala S, 1998, UROL RES, V26, P117, DOI 10.1007/s002400050033
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2002, BIOCHEM BIOPH RES CO, V297, P558, DOI 10.1016/S0006-291X(02)02248-9
   Shimada T, 1999, CARCINOGENESIS, V20, P1607, DOI 10.1093/carcin/20.8.1607
   Shimada T, 2002, CARCINOGENESIS, V23, P1199, DOI 10.1093/carcin/23.7.1199
   Soll-Johanning H, 1998, OCCUP ENVIRON MED, V55, P594, DOI 10.1136/oem.55.9.594
   Stoilov I, 1998, AM J HUM GENET, V62, P573, DOI 10.1086/301764
   SUTTER TR, 1994, J BIOL CHEM, V269, P13092
   WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333
   Yuan JM, 1998, CANCER EPIDEM BIOMAR, V7, P429
NR 20
TC 35
Z9 37
U1 3
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2004
VL 10
IS 6
BP 2015
EP 2019
DI 10.1158/1078-0432.CCR-03-0166
PG 5
WC Oncology
SC Oncology
GA 804ZW
UT WOS:000220337600021
PM 15041720
OA Bronze
DA 2018-12-27
ER

PT J
AU Razem, FA
   Luo, M
   Liu, JH
   Abrams, SR
   Hill, RD
AF Razem, FA
   Luo, M
   Liu, JH
   Abrams, SR
   Hill, RD
TI RETRACTED: Purification and characterization of a barley aleurone
   abscisic acid-binding protein (Retracted Article. See vol 285, pg 4264,
   2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID THALIANA SUSPENSION CELLS; ABA SIGNAL-TRANSDUCTION; EM GENE-EXPRESSION;
   ARABIDOPSIS-THALIANA; GUARD-CELLS; BIOLOGICAL-ACTIVITY; PLASMA-MEMBRANE;
   PHOSPHATASE 2C; SH3 DOMAINS; VICIA-FABA
AB A protein designated ABAP1 and encoded by a novel gene (GenBank(TM) accession number AF127388) was purified and shown to specifically bind abscisic acid (ABA). ABAP1 protein is a 472-amino acid polypeptide containing a WW protein interaction domain and is induced by ABA in barley aleurone layers. Polyclonal anti-idiotypic antibodies (AB2) cross-reacted with purified ABAP1 and with a corresponding 52-kDa protein associated with membrane fractions of ABA-treated barley aleurones. ABAP1 genes were detected in diverse monocot and dicot species, including wheat, tobacco, alfalfa, garden pea, and oilseed rape. The recombinant ABAP1 protein optimally bound H-3-(+)-ABA at neutral pH. Denatured ABAP1 protein did not bind H-3-(+)-ABA, nor did bovine serum albumin. The maximum specific binding as shown by Scatchard plot analysis was 0.8 mol of ABA mol(-1) protein with a linear function of r(2) = 0.94, an indication of one ABA-binding site with a dissociation constant (K-d) of 28 x 10(-9) M. ABA binding in aleurone plasma membranes showed a maximum binding capacity of 330 nmol of ABA g(-1) protein with a K-d of 26.5 x 10(-9) M. The similarities in the dissociation constants for ABA binding of the recombinant protein and that of the plasma membranes suggest that the protein within the plasma membrane fraction is the native form of ABAP1. The stereospecificity of ABAP1 was established by the incapability of ABA analogs and metabolites, including (-)-ABA, trans-ABA, phaseic acid, dihydrophaseic acid, and (+)-abscisic acid-glucose ester, to displace H-3-(+)ABA bound to ABAP1. However, two ABA precursors, (+)-ABA aldehyde and (+)-ABA alcohol, were able to displace H-3-(+)-ABA, an indication that the structural requirement of ABAP1 at the C-1 position is not strict. Our data show that ABAP1 exerts high binding affinity for ABA. The interaction is reversible, follows saturation kinetics, and has stereospecificity, thus meeting the criteria for an ABA-binding protein.
C1 Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
   Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada.
RP Hill, RD (reprint author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
EM rob_hill@umanitoba.ca
CR ALDASORO JJ, 1981, PHYSIOL PLANTARUM, V53, P139, DOI 10.1111/j.1399-3054.1981.tb04123.x
   ANDERSON BE, 1994, PLANT PHYSIOL, V104, P1177, DOI 10.1104/pp.104.4.1177
   Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602
   Bleecker AB, 1999, TRENDS PLANT SCI, V4, P269, DOI 10.1016/S1360-1385(99)01427-2
   Bonetta D, 1998, TRENDS PLANT SCI, V3, P231, DOI 10.1016/S1360-1385(98)01241-2
   BOSTOCK RM, 1992, PLANT PHYSIOL, V98, P1356, DOI 10.1104/pp.98.4.1356
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x
   Churchill GC, 1998, PLANT GROWTH REGUL, V25, P35, DOI 10.1023/A:1005982216957
   EISENBERG AJ, 1985, PLANTA, V166, P505, DOI 10.1007/BF00391275
   FARID NR, 1989, METHOD ENZYMOL, V178, P191
   Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441
   FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x
   GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.immunol.4.1.253
   Ghelis T, 2000, FEBS LETT, V474, P43, DOI 10.1016/S0014-5793(00)01574-X
   Gilroy S, 1996, PLANT CELL, V8, P2193
   GILROY S, 1994, PLANT PHYSIOL, V104, P1185, DOI 10.1104/pp.104.4.1185
   GUSTA LV, 1992, CAN J BOT, V70, P1550, DOI 10.1139/b92-195
   HARTUNG W, 1983, PLANT CELL ENVIRON, V6, P427, DOI 10.1111/j.1365-3040.1983.tb01276.x
   Hays DB, 1996, J PLANT GROWTH REGUL, V15, P5, DOI 10.1007/BF00213128
   Heyl A, 2003, CURR OPIN PLANT BIOL, V6, P480, DOI 10.1016/S1369-5266(03)00087-6
   HIGGINS T J V, 1982, Plant Molecular Biology, V1, P191, DOI 10.1007/BF00021032
   Hill R. D., 1992, Seed Science Research, V2, P207
   HILL RD, 1995, PLANT PHYSIOL, V108, P573, DOI 10.1104/pp.108.2.573
   HOCKING TJ, 1978, PLANTA, V138, P303, DOI 10.1007/BF00386826
   Hodges T K, 1974, Methods Enzymol, V32, P392
   HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0
   Jaradat ZW, 2001, FOOD AGR IMMUNOL, V13, P241, DOI 10.1080/09540100120094500
   Jeannette E, 1999, PLANT J, V18, P13, DOI 10.1046/j.1365-313X.1999.00423.x
   JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305
   KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x
   Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277
   LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981
   Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199
   Liu JH, 1999, J EXP BOT, V50, P727, DOI 10.1093/jexbot/50.334.727
   Lovegrove A, 2000, TRENDS PLANT SCI, V5, P102, DOI 10.1016/S1360-1385(00)01571-5
   Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325
   LUO M, 1992, J BIOL CHEM, V267, P15367
   LUO M, 1992, PLANT RESPONSES ENV, P147
   Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1
   Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1
   Meinhard M, 2001, FEBS LETT, V508, P443, DOI 10.1016/S0014-5793(01)03106-4
   MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457
   MOHAPATRA SS, 1987, PLANT PHYSIOL, V84, P1172, DOI 10.1104/pp.84.4.1172
   Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3
   Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955
   Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x
   PATERSON NW, 1988, PLANT CELL ENVIRON, V11, P83, DOI 10.1111/j.1365-3040.1988.tb01122.x
   Pedron J, 1998, EUR J BIOCHEM, V252, P385, DOI 10.1046/j.1432-1327.1998.2520385.x
   Razem FA, 2003, J EXP BOT, V54, P935, DOI 10.1093/jxb/erg094
   Razem FA, 2002, ENVIRON EXP BOT, V48, P247, DOI 10.1016/S0098-8472(02)00039-4
   Ritchie SM, 2002, PHYSIOL PLANTARUM, V115, P342, DOI 10.1034/j.1399-3054.2002.1150303.x
   Rotin D, 1998, CURR TOP MICROBIOL, V228, P115
   Sambrook J, 1989, MOL CLONING LAB MANU
   Sandelius A. S., 1990, The plant plasma membrane., P44
   Sauter A, 2002, PLANT CELL ENVIRON, V25, P223, DOI 10.1046/j.1365-3040.2002.00747.x
   Sauter A, 2002, J PLANT GROWTH REGUL, V21, P50, DOI 10.1007/s003440010040
   Schultz TF, 1997, PLANT SCI, V130, P63, DOI 10.1016/S0168-9452(97)00204-5
   SCHWARTZ A, 1994, P NATL ACAD SCI USA, V91, P4019, DOI 10.1073/pnas.91.9.4019
   SLOVIK S, 1992, PLANTA, V187, P37, DOI 10.1007/BF00201621
   SUDOL M, 1994, ONCOGENE, V9, P2145
   Villaverde A, 2003, BIOTECHNOL LETT, V25, P1385, DOI 10.1023/A:1025024104862
   Von Jagow G., 1994, PRACTICAL GUIDE MEMB, P3
   WALKERSIMMONS M, 1987, PLANT PHYSIOL, V84, P61, DOI 10.1104/pp.84.1.61
   WALKERSIMMONS MK, 1991, PLANT PHYSIOL, V95, P46, DOI 10.1104/pp.95.1.46
   Wu Y, 2003, PLANT J, V34, P307, DOI 10.1046/j.1365-313X.2003.01721.x
   Yamazaki D, 2003, PLANT J, V35, P129, DOI 10.1046/j.1365-313X.2003.01782.x
   Zhang DP, 2002, PLANT PHYSIOL, V128, P714, DOI 10.1104/pp.010531
   Zhang DP, 2001, J EXP BOT, V52, P2097, DOI 10.1093/jexbot/52.364.2097
NR 69
TC 43
Z9 50
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 12
PY 2004
VL 279
IS 11
BP 9922
EP 9929
DI 10.1074/jbc.M311064200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 800TK
UT WOS:000220050400033
PM 14699092
OA Bronze
DA 2018-12-27
ER

PT J
AU Aoki, N
   Ueno, S
   Mano, H
   Yamasaki, S
   Shiota, M
   Miyazaki, H
   Yamaguchi-Aoki, Y
   Matsuda, T
   Ullrich, A
AF Aoki, N
   Ueno, S
   Mano, H
   Yamasaki, S
   Shiota, M
   Miyazaki, H
   Yamaguchi-Aoki, Y
   Matsuda, T
   Ullrich, A
TI RETRACTED: Mutual regulation of protein-tyrosine phosphatase 20 and
   protein-tyrosine kinase Tec activities by tyrosine phosphorylation and
   dephosphorylation (Retracted Article. See vol 285, pg 32678, 2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID X-LINKED AGAMMAGLOBULINEMIA; COLONY-STIMULATING FACTOR; GROWTH-FACTOR
   RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; POSITIVE
   REGULATOR; SIGNALING PATHWAY; ACTIVATION; FAMILY; EXPRESSION
AB PTP20, also known as HSCF/protein-tyrosine phosphatase K1/fetal liver phosphatase 1/brain-derived phosphatase 1, is a cytosolic protein-tyrosine phosphatase with currently unknown biological relevance. We have identified that the nonreceptor protein-tyrosine kinase Tec-phosphorylated PTP20 on tyrosines and coimmunoprecipitated with the phosphatase in a phosphotyrosine-dependent manner. The interaction between the two proteins involved the Tec SH2 domain and the C-terminal tyrosine residues Tyr-281, Tyr-303, Tyr-354, and Tyr-381 of PTP20, which were also necessary for tyrosine phosphorylation/dephosphorylation. Association between endogenous PTP20 and Tec was also tyrosine phosphorylation-dependent in the immature B cell line Ramos. Finally, the Tyr-281 residue of PTP20 was shown to be critical for deactivating Tec in Ramos cells upon B cell receptor ligation as well as dephosphorylation and deactivation of Tec and PTP20 itself in transfected COS7 cells. Taken together, PTP20 appears to play a negative role in Tec-mediated signaling, and Tec-PTP20 interaction might represent a negative feedback mechanism.
C1 Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.
   Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan.
   Jichi Med Sch, Div Cardiol, Minami Kawachi, Tochigi 3290498, Japan.
   Jichi Med Sch, Div Hematol, Minami Kawachi, Tochigi 3290498, Japan.
   Chiba Univ, Grad Sch Med, Chiba 2608670, Japan.
   Univ Tsukuba, Ctr Gene Res, Tsukuba, Ibaraki 3058572, Japan.
   Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.
RP Aoki, N (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.
EM naoki@agr.nagoya-u.ac.jp
CR Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x
   Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001
   Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422
   BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335
   BOULTON TG, 1994, J BIOL CHEM, V269, P11648
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   Cheng J, 1996, BLOOD, V88, P1156
   Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6
   Dosil M, 1996, BLOOD, V88, P4510
   FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088
   Gadina M, 1998, J IMMUNOL, V160, P4657
   GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x
   GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635
   HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659
   HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669
   HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928
   Huang K, 1996, ONCOGENE, V13, P1567
   Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200
   Kim YW, 1996, ONCOGENE, V13, P2275
   Kitanaka A, 1998, BLOOD, V91, P940
   Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139
   MACHIDE M, 1995, ONCOGENE, V11, P619
   MANO H, 1990, ONCOGENE, V5, P1781
   MANO H, 1995, BLOOD, V85, P343
   MANO H, 1993, ONCOGENE, V8, P417
   Mano H, 1996, FASEB J, V10, P637
   Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638
   MATSUDA T, 1995, BLOOD, V85, P627
   MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1
   Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135
   Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976
   Shiota M, 2003, MOL ENDOCRINOL, V17, P534, DOI 10.1210/me.2002-0187
   SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194
   Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845
   Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8
   TAMAGNONE L, 1994, ONCOGENE, V9, P3683
   TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432
   Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200
   TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631
   Tauchi T, 1996, BLOOD, V87, P4495
   Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4
   TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F
   VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0
   VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217
   Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001
   WELHAM MJ, 1994, J BIOL CHEM, V269, P23764
   Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487
   YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404
   Yamashita Y, 1998, BLOOD, V91, P1496
   Yamashita Y, 1997, EXP HEMATOL, V25, P211
   Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199
NR 51
TC 15
Z9 17
U1 2
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 12
PY 2004
VL 279
IS 11
BP 10765
EP 10775
DI 10.1074/jbc.M310401200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 800TK
UT WOS:000220050400132
PM 14679216
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hwang, WS
   Ryu, YJ
   Park, JH
   Park, ES
   Lee, EG
   Koo, JM
   Jeon, HY
   Lee, BC
   Kang, SK
   Kim, SJ
   Ahn, C
   Hwang, JH
   Park, KY
   Cibelli, JB
   Moon, SY
AF Hwang, WS
   Ryu, YJ
   Park, JH
   Park, ES
   Lee, EG
   Koo, JM
   Jeon, HY
   Lee, BC
   Kang, SK
   Kim, SJ
   Ahn, C
   Hwang, JH
   Park, KY
   Cibelli, JB
   Moon, SY
TI RETRACTED: Evidence of a pluripotent human embryonic stem cell line
   derived from a cloned blastocyst (Retracted Article. See vol 311, pg
   335, 2006)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID NUCLEAR TRANSFER; CULTURE-MEDIUM; IN-VITRO; MOUSE; DIFFERENTIATION;
   CLONING; FETAL
AB Somatic cell nuclear transfer (SCNT) technology has recently been used to generate animals with a common genetic composition. In this study, we report the derivation of a pluripotent embryonic stem (ES) cell line (SCNT-hES-1) from a cloned human blastocyst. The SCNT-hES-1 cells displayed typical ES cell morphology and cell surface markers and were capable of differentiating into embryoid bodies in vitro and of forming teratomas in vivo containing cell derivatives from all three embryonic germ layers in severe combined immunodeficient mice. After continuous proliferation for more than 70 passages, SCNT-hES-1 cells maintained normal karyotypes and were genetically identical to the somatic nuclear donor cells. Although we cannot completely exclude the possibility that the cells had a parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.
C1 Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.
   Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea.
   MizMedi Hosp, Med Res Ctr, Seoul, South Korea.
   Gachon Med Sch, Inchon 417840, South Korea.
   Seoul Natl Univ, Coll Med, Seoul 110744, South Korea.
   Hanyang Univ, Sch Med, Seoul 471701, South Korea.
   Sunchon Natl Univ, Coll Nat Sci, Sunchon 540742, South Korea.
   Michigan State Univ, Dept Anim Sci Physiol, E Lansing, MI 48824 USA.
RP Hwang, WS (reprint author), Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.
EM hwangws@snu.ac.kr; shmoon@plaza.snu.ac.kr
RI Ahn, Curie/J-5527-2012
CR Barnett DK, 1996, MOL REPROD DEV, V43, P105
   Choi YH, 2002, THERIOGENOLOGY, V58, P1187, DOI 10.1016/S0093-691X(02)00946-9
   Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642
   CIBELLI JB, 2001, J REGEN MED, V2, P25, DOI DOI 10.1089/152489001753262168
   Gardner DK, 2002, J REPROD IMMUNOL, V55, P85, DOI 10.1016/S0165-0378(01)00136-X
   Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399
   Hyun S, 2003, BIOL REPROD, V69, P1060, DOI 10.1095/biolreprod.102.014886
   JOHN SR, 2002, TRENDS BIOTECHNOL, V20, P417
   KAUFMAN MH, 1973, NATURE, V242, P475, DOI 10.1038/242475a0
   Kawase E, 2000, GENESIS, V28, P156, DOI 10.1002/1526-968X(200011/12)28:3/4<156::AID-GENE100>3.0.CO;2-T
   KUHHOLZER B, 2004, BIOL REPROD, V64, P1635
   Kwun J, 2003, MOL REPROD DEV, V65, P167, DOI 10.1002/mrd.10309
   LANGENDONCKT A, 2001, FERTIL STERIL, V76, P1023
   Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404
   Lanzendorf SE, 2001, FERTIL STERIL, V76, P132, DOI 10.1016/S0015-0282(01)01825-8
   Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536
   MITELMAN F, 1995, INT SYSTEM HUMAN CYT
   Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5
   Nakagawa K, 2001, ZYGOTE, V9, P83, DOI 10.1017/S0967199401001083
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   Shu YM, 2002, FERTIL STERIL, V78, pS286, DOI 10.1016/S0015-0282(02)03934-1
   Simerly C, 2003, SCIENCE, V300, P297, DOI 10.1126/science.1082091
   Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066
   THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vrana KE, 2003, P NATL ACAD SCI USA, V100, P11911, DOI 10.1073/pnas.2034195100
   Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
NR 28
TC 443
Z9 487
U1 4
U2 112
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAR 12
PY 2004
VL 303
IS 5664
BP 1669
EP 1674
DI 10.1126/science.1094515
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 802GG
UT WOS:000220151400044
PM 14963337
OA Bronze
DA 2018-12-27
ER

PT J
AU Smart, EJ
   De Rose, RA
   Farber, SA
AF Smart, EJ
   De Rose, RA
   Farber, SA
TI RETRACTED: Annexin 2-caveolin 1 complex is a target of ezetimibe and
   regulates intestinal cholesterol transport (Retracted article. See vol.
   110, pg. 797, 2013)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID ABSORPTION INHIBITOR; CHAPERONE COMPLEX; ZEBRAFISH; GENE; CAVEOLIN;
   PROTEIN; MEMBRANE; BINDING; MICE; HYPERCHOLESTEROLEMIA
AB Modulation of cholesterol absorption in the intestine, the primary site of dietary cholesterol uptake in humans, can have profound clinical implications. We have undertaken a reverse genetic approach by disrupting putative cholesterol processing genes in zebrafish larvae by using morpholino (MO) antisense oligonucleoticles. By using targeted MO injections and immunoprecipitation (IP) experiments coupled with mass spectrometry, we determined that annexin (ANX)2 complexes with caveolin (CAV)1 in the zebrafish and mouse intestine. The complex is heat stable and unaffected by SDS or reducing conditions. MO targeting of anx2b or cav1, which are both strongly expressed in the larval and adult zebrafish intestinal epithelium, prevents formation of the protein heterocomplex. Furthermore, anx2b MO injection prevents processing of a fluorescent cholesterol reporter and results in reduced sterol mass. Pharmacological treatment of mice with ezetimibe disrupts the heterocomplex in only hypercholesterolemic animals. These data suggest that ANX2 and CAV1 are components of an intestinal sterol transport complex.
C1 Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
RP Farber, SA (reprint author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
EM steven.farber@mail.tju.edu
FU NHLBI NIH HHS [R01 HL064056, R01 HL058475, HL62844, HL64056, HL58475];
   NIGMS NIH HHS [R56 GM063904, GM63904, R01 GM063904, R01 GM063904-01];
   NIDDK NIH HHS [DK60369, R01 DK060369]
CR Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418
   Farber SA, 2003, GENOME RES, V13, P1082, DOI 10.1101/gr.479603
   Feng B, 2002, EXP CELL RES, V279, P14, DOI 10.1006/excr.2002.5579
   Field FJ, 2001, J LIPID RES, V42, P1687
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565
   Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745
   ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003
   Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9
   Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194
   Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951
   Ober EA, 2003, MECH DEVELOP, V120, P5, DOI 10.1016/S0925-4773(02)00327-1
   Raynor CM, 1999, BIOCHEMISTRY-US, V38, P5089, DOI 10.1021/bi982095b
   Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200
   Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200
   Rosenblum SB, 1998, J MED CHEM, V41, P973, DOI 10.1021/jm970701f
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z
   SEATON BA, 1996, ANNEXINS MOL STRUCTU
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427
   THISSE C, 1993, DEVELOPMENT, V119, P1203
   Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200
   Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200
   Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525
   van Heek M, 2001, EUR J PHARMACOL, V415, P79, DOI 10.1016/S0014-2999(01)00825-1
   VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157
   Wallace KN, 2003, DEV BIOL, V255, P12, DOI 10.1016/S0012-1606(02)00034-9
   WESTERFIELD M, 1995, ZEBRAFISH BOOK
NR 31
TC 105
Z9 111
U1 3
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 9
PY 2004
VL 101
IS 10
BP 3450
EP 3455
DI 10.1073/pnas.0400441101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 802LA
UT WOS:000220163800024
PM 14985510
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ma, C
   Chang, G
AF Ma, C
   Chang, G
TI RETRACTED: Structure of the multidrug resistance efflux transporter EmrE
   from Escherichia coli (Retracted Article. See vol 104, pg 3668, 2007)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID DEPENDENT K+ CHANNEL; COMMON BINDING-SITE; LIGHT-DRIVEN PUMP;
   X-RAY-STRUCTURE; SUBSTRATE-BINDING; ANTIMICROBIAL RESISTANCE;
   ANTIBIOTIC-RESISTANCE; PROTON TRANSLOCATION; CRYSTAL-STRUCTURE;
   MEMBRANE-PROTEIN
AB Multidrug resistance efflux transporters threaten to reverse the progress treating infectious disease by extruding a wide range of drug and other cytotoxic compounds. One such drug transporter, EmrE, from the small multidrug resistance family, utilizes proton gradients as an energy source to drive substrate translocation. In an effort to understand the molecular structural basis of this transport mechanism, we have determined the structure of EmrE from Escherichia coli to 3.8 Angstrom. EmrE is a tetramer comprised of two conformational heterodimers related by a pseudo two-fold symmetry axis perpendicular to the cell membrane. Based on the structure and biochemical evidence, we propose a mechanism by which EmrE accomplishes multidrug efflux by coupling conformational changes between two heterodimers with proton gradient. Because of its simplicity and compact size, the structure of EmrE can serve as an ideal model for understanding the general structural basis of proton:drug antiport for other drug efflux systems.
C1 Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Chang, G (reprint author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,CB-105, La Jolla, CA 92037 USA.
EM gchang@scripps.edu
FU NIGMS NIH HHS [GM067644, R01 GM067644]
CR Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196
   Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i
   BRUNGER AT, 1992, XPLOR VERSION 3 1 SY
   Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793
   Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4
   Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220
   Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517
   Chung Y J, 2001, Curr Opin Drug Discov Devel, V4, P237
   Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a
   Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y
   GRINIUS LL, 1994, J BIOL CHEM, V269, P29998
   Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200
   Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000
   Jack DL, 2001, EUR J BIOCHEM, V268, P3620, DOI 10.1046/j.1432-1327.2001.02265.x
   Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581
   Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867
   LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6
   Lanyi JK, 1999, FEBS LETT, V464, P103, DOI 10.1016/S0014-5793(99)01685-3
   Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193
   Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46
   LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695
   Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142
   Masaoka Y, 2000, J BACTERIOL, V182, P2307, DOI 10.1128/JB.182.8.2307-2310.2000
   MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2
   MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900
   MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191
   Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748
   Moellering RC, 1998, CLIN INFECT DIS, V26, P1177
   Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480
   Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050
   Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064
   Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200
   Ostermeier C, 1997, CURR OPIN STRUC BIOL, V7, P697, DOI 10.1016/S0959-440X(97)80080-2
   PADDOCK ML, 1994, BIOCHEMISTRY-US, V33, P734, DOI 10.1021/bi00169a015
   Paulsen IT, 1996, MICROBIOL REV, V60, P575
   Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x
   Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224
   SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4
   Schuldiner S, 1997, J EXP BIOL, V200, P335
   Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130
   Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899
   Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7
   Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611
   Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7
   Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i
   Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X
   Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264
   YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856
   Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200
   Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044
   Yu EW, 2003, SCIENCE, V300, P976, DOI 10.1126/science.1083137
   Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990
NR 61
TC 77
Z9 80
U1 4
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 2
PY 2004
VL 101
IS 9
BP 2852
EP 2857
DI 10.1073/pnas.0400137101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 800ZD
UT WOS:000220065300039
PM 14970332
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU deTayrac, R
   Deffieux, X
   Droupy, S
   Chauveaud-Lambling, A
   Calvanese-Benamour, L
   Fernandez, H
AF deTayrac, R
   Deffieux, X
   Droupy, S
   Chauveaud-Lambling, A
   Calvanese-Benamour, L
   Fernandez, H
TI RETRACTED: A prospective randomized trial comparing tension-free vaginal
   tape and transobturator suburethral tape for surgical treatment of
   stress urinary incontinence (Retracted Article. See vol 192, pg 3A,
   2005)
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Retracted Publication
DE urinary incontinence; vaginal surgery; tension-free vaginal tape
ID PROSPECTIVE MULTICENTER; WOMEN; TVT; QUESTIONNAIRE; COMPLICATIONS
AB Objective: The purpose of this study was to prospectively and randomly compare tension-free vaginal tape (TVT) with transobturator suburethral tape (T.O.T.) for the surgical treatment of stress urinary incontinence (SUI) in women.
   Study design: Sixty-one women with SUI were randomly assigned,to either TVT (n = 31) or T.O.T. (n = 30). The preoperative evaluation included a quality-of-life questionnaire and a comprehensive urodynamic examination. The 1-year outcome included a detrusor pressure-uroflow study to compare bladder outlet obstruction.
   Results: Patient characteristics, preoperative quality of life, and urodynamic evaluation were similar in the 2 groups. Mean operative time was significantly shorter in the T.O.T. group (15 min +/- 4 vs 27 min +/- 8, P<.001). No bladder injury occurred in the T.O.T. group versus 9.7% (n = 3) in the TVT group (P>.05). The rate of postoperative urinary retention was 25.8% (n = 8) in the TVT group versus 13.3% (n = 4) in the T.O.T. group (P>.05). The rates of cure (83.9% vs 90%), improvement (9.7% vs 3.3%), and failure (6.5% vs 6.7%) were similar for the TVT and T.O.T. groups, respectively. The 1-year outcome data were collected in 29 women of the TVT group and 27 women of the T.O.T. group. No vaginal erosion occurred in either of the groups. In terms of bladder outlet obstruction, no differences' were found after TVT and T.O.T.
   Conclusion: T.O.T. appears to be equally efficient as TVT for surgical treatment of stress urinary incontinence in women, with no reduction of bladder outlet obstruction at 1-year follow-up. (C) 2004 Elsevier Inc. All rights reserved.
C1 Hop Antoine Beclere, Serv Gynecol Obstet, Dept Obstet & Gynecol, F-92141 Clamart, France.
   Kremlin Bicetre Hosp, Dept Urol, Le Kremlin Bicetre, France.
RP deTayrac, R (reprint author), Hop Antoine Beclere, Serv Gynecol Obstet, Dept Obstet & Gynecol, 157 Rue Porte Trivaux, F-92141 Clamart, France.
EM renaud.detayrac@abc.ap-hop-paris.fr
CR Amarenco G, 2003, EUR UROL, V43, P391, DOI 10.1016/S0302-2838(03)00054-X
   Arunkalaivanan AS, 2003, INT UROGYNECOL J, V14, P17, DOI 10.1007/s00192-002-1000-9
   Azam U, 2001, J UROLOGY, V166, P554, DOI 10.1016/S0022-5347(05)65983-6
   Blaivas JG, 2000, NEUROUROL URODYNAM, V19, P553, DOI 10.1002/1520-6777(2000)19:5<553::AID-NAU2>3.0.CO;2-B
   Boustead GB, 2002, BJU INT, V89, P687, DOI 10.1046/j.1464-410X.2002.02659.x
   Dargent D, 2002, Gynecol Obstet Fertil, V30, P576, DOI 10.1016/S1297-9589(02)00389-2
   Debodinance P, 2002, EUR J OBSTET GYN R B, V105, P49, DOI 10.1016/S0301-2115(02)00107-0
   Delorme E, 2001, PROG UROL, V11, P1306
   Hermieu JF, 2003, PROG UROL, V13, P115
   Ingelman-Sundberg A, 1983, Contrib Gynecol Obstet, V10, P51
   IOSIF CS, 1988, INT J GYNECOL OBSTET, V26, P255, DOI 10.1016/0020-7292(88)90270-6
   Jacquetin B, 2000, J Gynecol Obstet Biol Reprod (Paris), V29, P242
   Karram MM, 2003, OBSTET GYNECOL, V101, P929, DOI 10.1016/S0029-7844(03)00122-4
   Klutke C, 2001, UROLOGY, V58, P697, DOI 10.1016/S0090-4295(01)01366-8
   Meschia M, 2001, INT UROGYNECOL J, V12, pS24, DOI 10.1007/s001920170008
   Nilsson CG, 2001, BRIT J OBSTET GYNAEC, V108, P414, DOI 10.1111/j.1471-0528.2001.00092.x
   Rardin CR, 2002, OBSTET GYNECOL, V100, P898, DOI 10.1016/S0029-7844(02)02279-2
   Soulie M, 2001, EUR UROL, V39, P709, DOI 10.1159/000052531
   Ulmsten U, 1999, BRIT J OBSTET GYNAEC, V106, P345, DOI 10.1111/j.1471-0528.1999.tb08272.x
   Ulmsten U, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P210, DOI 10.1007/BF01901606
   Ulmsten U, 2001, UROLOGE A, V40, P269, DOI 10.1007/s001200170035
   Ulmsten U, 1996, Int Urogynecol J Pelvic Floor Dysfunct, V7, P81, DOI 10.1007/BF01902378
   Ward K, 2002, BMJ-BRIT MED J, V325, P67, DOI 10.1136/bmj.325.7355.67
NR 23
TC 171
Z9 185
U1 3
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2004
VL 190
IS 3
BP 602
EP 608
DI 10.1016/j.ajog.2003.09.070
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 808OH
UT WOS:000220577900004
PM 15041987
DA 2018-12-27
ER

PT J
AU Piper, SN
   Triem, JG
   Rohm, KD
   Maleck, WH
   Schollhorn, TAH
   Boldt, J
AF Piper, SN
   Triem, JG
   Rohm, KD
   Maleck, WH
   Schollhorn, TAH
   Boldt, J
TI RETRACTED: ProSeal (TM)-laryngeal mask versus endotracheal intubation in
   patients undergoing gynaecologic laparoscopy (Retracted article. See
   vol. 46, pg. 490, 2011)
SO ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE
LA German
DT Article; Retracted Publication
DE laryngeal mask airway; endotracheal intubation; ProSeal-LMA;
   laparoscopy; gastric tube
ID PROSEAL LARYNGEAL MASK; TRACHEAL INTUBATION; AIRWAY; ASPIRATION;
   CHOLECYSTECTOMY; LMA; LMA-PROSEAL(TM); VENTILATION; STANDARD; TUBE
AB Background: The aim of this study was to assess the practicalness of the ProSeal(TM) laryngeal mask (PS-LMA) airway during laparoscopic surgery with capnoperitoneum compared to endotracheal intubation (ET). Methods: Prospective, randomized study. 104 patients undergoing gynaecologic, laparoscopic surgery were allocated randomly to two groups: 1. ET-group (n = 50). 2. PS-LMA-group (n = 54). Total intravenous anaesthesia was performed by the same anaesthesiologist. Measurements: Mean arterial pressure, heart rate, at 4 and circuit pressure at 2 measurement points, and the incidences of coughing and sore throat. Insertion of the ET and the PS-LMA was scored by using a four-point scale. Ease of placing the gastric tube was judged by measuring the number of attempts at insertion and the insertion times. A p-value of < 0.05 was considered as significant. Results: There were no differences between PS-LMA and ET concerning circuit pressure at any measurement point. At the end of anaesthesia, mean arterial pressure (92 +/- 13 vs. 100 +/- 14 mmHg; p < 0.01) and heart rate (66 +/- 13 vs. 76 +/- 14 beats/min; p < 0.01) were lower in the PS-LMA-group compared to the ET-group. At the end of anaesthesia 25 patients of the ET-group coughed but nobody in the PS-LMA-group (p < 0.00001). There was no difference with regard to postoperative sore throat. The insertion of the PS-LMA was easier compared to ET (p < 0,05), but we found no significant difference concerning insertion times. Fewer attempts at insertion of the gastric tube were necessary in the PS-LMA-group than in the ET-group (p < 0,01), whereas insertion times did not differ. Conclusion: The PS-LMA is a convenient and practicable approach for anaesthesia in patients undergoing laparoscopic surgery.
C1 Klinikum Stadt Ludwigshafen, Klin Anasthesiol & Operat Intensivmedizin, Ludwigshafen, Germany.
   Spital Grenchen, Abt Anasthesie, Grenchen, Switzerland.
RP Piper, SN (reprint author), Klinikum Stadt Ludwigshafen, Klin Anasthesiol & Operat Intensivmedizin, Bremserstr 7967063, Ludwigshafen, Germany.
EM swen.n.piper@t-online.de
CR ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924
   Brain AIJ, 2000, BRIT J ANAESTH, V84, P650, DOI 10.1093/bja/84.5.650
   Braun U, 2002, ANASTH INTENSIV NOTF, V37, P727, DOI 10.1055/s-2002-35911
   Brimacombe J, 2002, ANESTHESIOLOGY, V96, P289, DOI 10.1097/00000542-200202000-00011
   Brimacombe J, 2003, ANESTH ANALG, V97, P1192, DOI 10.1213/01.ANE.0000078818.64971.44
   Cook TM, 2002, BRIT J ANAESTH, V88, P527, DOI 10.1093/bja/88.4.527
   CUNNINGHAM AJ, 1993, ANESTH ANALG, V76, P1120
   Evans NR, 2002, BRIT J ANAESTH, V88, P584, DOI 10.1093/bja/88.4.584
   Evans NR, 2002, CAN J ANAESTH, V49, P413, DOI 10.1007/BF03017332
   Fullekrug B, 2001, ANASTH INTENSIV NOTF, V36, P213, DOI 10.1055/s-2001-12750
   HOLDEN R, 1991, ANAESTHESIA, V46, P922, DOI 10.1111/j.1365-2044.1991.tb09847.x
   Joshi GP, 1997, ANESTH ANALG, V85, P573, DOI 10.1097/00000539-199709000-00016
   Koay CK, 2003, ANAESTH INTENS CARE, V31, P123
   Krier C, 2001, ANASTH INTENSIV NOTF, V36, P193, DOI 10.1055/s-2001-12753
   Langer A, 1993, Anasthesiol Intensivmed Notfallmed Schmerzther, V28, P156, DOI 10.1055/s-2007-998898
   LARSEN R, 1999, ANASTHESIE, V6, P445
   Lu PP, 2002, BRIT J ANAESTH, V88, P824, DOI 10.1093/bja/88.6.824
   MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357
   Maltby JR, 2000, CAN J ANAESTH, V47, P622, DOI 10.1007/BF03018993
   Maltby JR, 2003, CAN J ANAESTH, V50, P71, DOI 10.1007/BF03020191
   Maltby JR, 2002, CAN J ANAESTH, V49, P857, DOI 10.1007/BF03017420
   Mark DA, 2003, CAN J ANAESTH, V50, P78, DOI 10.1007/BF03020192
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   Todd DW, 2002, J ORAL MAXIL SURG, V60, P2, DOI 10.1053/joms.2002.29047
   Van Damme E, 1994, Anasthesiol Intensivmed Notfallmed Schmerzther, V29, P284, DOI 10.1055/s-2007-996738
NR 25
TC 22
Z9 22
U1 2
U2 11
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-2661
J9 ANASTH INTENSIV NOTF
JI Anasthesiol. Intensivmed. NotfMed. Schmerzther.
PD MAR
PY 2004
VL 39
IS 3
BP 132
EP 137
DI 10.1055/s-2004-814331
PG 6
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA 804VW
UT WOS:000220327200003
PM 15042502
DA 2018-12-27
ER

PT J
AU Ghatnekar, GS
   Barnes, JA
   Dow, JL
   Smoak, IW
AF Ghatnekar, GS
   Barnes, JA
   Dow, JL
   Smoak, IW
TI RETRACTED: Hypoglycemia-induced changes in cell death and cell
   proliferation in the organogenesis-stage embryonic mouse heart
   (Retracted article. See vol 76, pg 278, 2006)
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article; Retracted Publication
DE embryonic heart; hypoglycemia; apoptosis; cell proliferation; flow
   cytometry; caspase-3; p53; PCNA
ID HYPOXIA-INDUCED APOPTOSIS; RAT CARDIAC MYOCYTES; IN-VITRO; GLUCOSE
   DEPRIVATION; DNA FRAGMENTATION; P53; PROTEIN; METABOLISM; EXPRESSION;
   EXPOSURE
AB BACKGROUND: Hypoglycemia is a side effect of diabetes therapy and causes abnormal heart development. Embryonic heart cells are largely resistant to teratogen-induced apoptosis. METHODS: Hypoglycemia was tested for effects on cell death and cell proliferation in embryonic heart cells by exposing mouse embryos on embryonic day (E) 9.5 (plug = E0.5) to hypoglycemia (30-50 mg/dl glucose) in vivo or in vitro for 24 hr. Long-term effects of in vivo exposure on conceptus viability were evaluated at E18.5. Cell death was evaluated on E10.5 by: 1) two TUNEL assays in sectioned embryos to demonstrate DNA fragmentation; 2) confocal microscopy in whole embryos stained with Lysotracker; 3) flow cytometry in dispersed heart cells stained for TUNEL and myosin heavy chain (MHC) to quantify and characterize cell type susceptibility; and 4) immunohistochemistry (IHC) and Western analysis in sectioned embryos to evaluate potential involvement of caspase-3 active subunit and p53. Effects on cell proliferation were evaluated by IHC and Western analysis of proliferating cell nuclear antigen (PCNA). RESULTS: In vivo hypoglycemic exposure on E9.5 reduced viability in conceptuses examined on E18.5. Hearts examined on E10.5 demonstrated increased TUNEL and Lysotracker staining. In hearts of embryos exposed to hypoglycemia, flow cytometry demonstrated increased TUNEL-positive cells and cells dual-labeled for TUNEL and MHC. Protein expression of caspase-3 active subunit and p53 was increased and PCNA was markedly reduced in hearts of embryos exposed to hypoglycemia. CONCLUSIONS: Hypoglycemia reduces embryonic viability, induces significant cell death, and reduces cell proliferation in the E9.5 mouse heart, and these processes may involve active caspase-3 and p53. (C) 2004 Wiley-Liss, Inc.
C1 N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA.
   N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC 27606 USA.
RP Ghatnekar, GS (reprint author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.
EM gsghatne@unity.ncsu.edu
FU NHLBI NIH HHS [HL 60752]
CR Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403
   BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUCHANAN TA, 1986, J CLIN INVEST, V78, P643, DOI 10.1172/JCI112622
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727
   Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200
   CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0
   COX SJ, 1972, J EMBRYOL EXP MORPH, V28, P591
   COX SJ, 1972, J EMBRYOL EXP MORPH, V28, P235
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Dugyala RR, 2002, TOXICOL SCI, V69, P183, DOI 10.1093/toxsci/69.1.183
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271
   FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464
   Fisher SA, 2000, CIRC RES, V87, P856, DOI 10.1161/01.RES.87.10.856
   GAO X, 1994, TERATOLOGY, V49, P1, DOI 10.1002/tera.1420490103
   Gittenberger-de Groot AC, 1998, CIRC RES, V82, P1043, DOI 10.1161/01.RES.82.10.1043
   Grosse F, 1993, Methods Mol Biol, V16, P95, DOI 10.1385/0-89603-234-5:95
   KASTAN MB, 1991, CANCER RES, V51, P6304
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Keyes WM, 1999, J MOL CELL CARDIOL, V31, P1015, DOI 10.1006/jmcc.1999.0946
   Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580
   KOHLER E, 1970, N-S ARCH PHARMAKOL, V266, P371
   Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294
   Krinka D, 2001, ANAT EMBRYOL, V204, P207, DOI 10.1007/s004290100195
   Lee KKH, 1999, DEV BIOL, V207, P14
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lichnovsky V, 1998, J CLIN PATHOL-MOL PA, V51, P131, DOI 10.1136/mp.51.3.131
   Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452
   LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0
   MAJNO G, 1995, AM J PATHOL, V146, P3
   Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567
   MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0
   Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068
   MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292
   Miosge N, 1997, ANAT EMBRYOL, V195, P345, DOI 10.1007/s004290050054
   Mirkes PE, 1998, CELL DEATH DIFFER, V5, P592, DOI 10.1038/sj.cdd.4400390
   Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332
   Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834
   NEW DAT, 1978, BIOL REV, V53, P81, DOI 10.1111/j.1469-185X.1978.tb00993.x
   NILSSON A, 1988, ACTA MED SCAND, V224, P257
   PEETERS MPFMV, 1995, ANAT EMBRYOL, V191, P503
   Poelmann RE, 2000, CELL TISSUE RES, V301, P43, DOI 10.1007/s004410000227
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Rees WD, 1999, J NUTR, V129, P1532
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Saraste A, 1999, EUR J CLIN INVEST, V29, P380
   SENIOR B, 1989, ACTA PAEDIATR SC   S, V352, P2
   Sherr CJ, 2000, CANCER RES, V60, P3689
   Smoak IW, 1997, REPROD TOXICOL, V11, P495, DOI 10.1016/S0890-6238(97)00016-6
   SMOAK IW, 1990, AM J OBSTET GYNECOL, V163, P619, DOI 10.1016/0002-9378(90)91213-V
   Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451
   TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3
   Umpierre CC, 2001, TERATOLOGY, V63, P134, DOI 10.1002/tera.1024
   Veinot JP, 1997, HUM PATHOL, V28, P485, DOI 10.1016/S0046-8177(97)90039-3
   Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9
   Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047
   Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0
   Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819
   Zucker RM, 1999, METHODS, V18, P473, DOI 10.1006/meth.1999.0815
NR 61
TC 7
Z9 7
U1 65
U2 72
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAR
PY 2004
VL 70
IS 3
BP 121
EP 131
DI 10.1002/bdra.20000
PG 11
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 808PG
UT WOS:000220580400004
PM 15039926
DA 2018-12-27
ER

PT J
AU Rohm, KD
   Schollhorn, TAH
   Gwosdek, MJ
   Piper, SN
   Maleck, WH
   Boldt, J
AF Rohm, KD
   Schollhorn, TAH
   Gwosdek, MJ
   Piper, SN
   Maleck, WH
   Boldt, J
TI RETRACTED: Do we necessarily need local anaesthetics for venous
   cannulation? A comparison of different cannula sizes (Retracted article.
   See vol. 28, pg. 469, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE anaesthetics, local, mepivacaine; veins, venepuncture, cannulation
ID LIGNOCAINE-PRILOCAINE CREAM; INTRADERMAL ANESTHESIA; INFILTRATION; EMLA;
   PAIN; CHILDREN
AB Background and objective: This randomized, prospective study was performed to evaluate the efficacy of a subcutaneous local anaesthetic infiltration prior to venepuncture using different cannula sizes.
   Methods: Three-hundred-and-one patients were included in the study, 150 received mepivacaine 1% (0.25 mL) subcutaneously, 151 were cannulated without local analgesia. Patients were further allocated to one of five cannula size groups (standard wire gauge (G)): 20-, 18-, 17-, 16- and 14-G. They were asked to quantify the pain experienced using a four-point rating scale.
   Results: In the group without local anaesthetics, 28.8% complained about pain compared to 12% receiving local analgesia. The incidence of pain for 14-G (10%) and 16-G (12.9%) cannulae was significantly reduced in the local analgesia group (P<0.01) compared to no local analgesia (77.4% and 45.1%). Other cannula sizes showed no difference in pain whether using local analgesia or not.
   Conclusions: Patients profit from a subcutaneous infiltration with mepivacaine 1% prior to intravenous cathetherization only when cannulae of size >= 16-G are inserted.
C1 Klinikum Ludwigshafen, Dept Anaesthesiol, D-67063 Ludwigshafen, Germany.
   Spital Grenchen, Dept Anaesthesiol, Grenchen, Switzerland.
RP Rohm, KD (reprint author), Klinikum Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM k.d.roehm@t-online.de
CR GERSHON RY, 1991, ANESTH ANALG, V73, P469
   HALLEN B, 1984, ANAESTHESIA, V39, P969, DOI 10.1111/j.1365-2044.1984.tb08884.x
   HARRISON N, 1992, ANAESTHESIA, V47, P210, DOI 10.1111/j.1365-2044.1992.tb02120.x
   Holdgate A, 1999, ANAESTH INTENS CARE, V27, P257
   HOPKINS CS, 1988, ANAESTHESIA, V43, P198
   KEEP PJ, 1978, ANAESTHESIA, V33, P830, DOI 10.1111/j.1365-2044.1978.tb08502.x
   LANGHAM BT, 1993, BRIT J ANAESTH, V70, P519, DOI 10.1093/bja/70.5.519
   LANGHAM BT, 1992, ANAESTHESIA, V47, P890, DOI 10.1111/j.1365-2044.1992.tb03157.x
   OCONNOR PJ, 1995, ANAESTHESIA, V50, P1005, DOI 10.1111/j.1365-2044.1995.tb05901.x
   PRIEN T, 1994, ACTA ANAESTH SCAND, V38, P805, DOI 10.1111/j.1399-6576.1994.tb04008.x
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   SELBY IR, 1995, J ROY SOC MED, V88, P264
   SMITH M, 1990, BRIT J ANAESTH, V65, P240, DOI 10.1093/bja/65.2.240
   SOLIMAN IE, 1988, ANESTHESIOLOGY, V68, P804, DOI 10.1097/00000542-198805000-00025
   VANWIJK MGF, 1990, ANAESTHESIA, V45, P679
NR 15
TC 9
Z9 9
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD MAR
PY 2004
VL 21
IS 3
BP 214
EP 216
DI 10.1017/S0265021504003096
PG 3
WC Anesthesiology
SC Anesthesiology
GA 805EG
UT WOS:000220349000009
PM 15055895
DA 2018-12-27
ER

PT J
AU Mathangi, DC
   Namasivayam, A
AF Mathangi, DC
   Namasivayam, A
TI RETRACTED: Calcium ions: its role in cyanide neurotoxicity (Retracted
   Article. See vol 43, pg 185, 2005)
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article; Retracted Publication
DE cyanide; diltiazem; dopamine; serotine
ID BRAIN; CELLS; NEURONS; RATS
AB Cyanide is a well-established poison known for its rapid lethal action and toxicity. The central nervous system is one of the main target sites for cyanide toxicity. Cyanide also alters the brain biogenic amine levels. In the present study the role of calcium ions in cyanide toxicity was evaluated using the calcium channel blocker diltaizem (DIL) in Wistar strain albino rats. This study showed that DIL pretreatment prevented cyanide induced changes in the dopaminergic and serotonergic system in the corpus striatum. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Madras, Post Grad Inst Basic Med Sci, DR ALM, Dept Physiol, Madras 600113, Tamil Nadu, India.
RP Mathangi, DC (reprint author), Univ Madras, Post Grad Inst Basic Med Sci, DR ALM, Dept Physiol, Madras 600113, Tamil Nadu, India.
EM mathangidc@hotmail.com
OI Damal Chandrasekar, Mathangi/0000-0002-3148-3792
CR Ballantyne B., 1984, P 4 ANN CHEM DEF BIO
   Cebers G, 1998, BRAIN RES, V779, P194, DOI 10.1016/S0006-8993(97)01123-2
   GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x
   HENKART M, 1980, FED PROC, V39, P2776
   JOHNSON C, 1987, MATH COMPUT, V49, P25, DOI 10.2307/2008248
   JOHNSON JD, 1986, TOXICOL APPL PHARM, V84, P464, DOI 10.1016/0041-008X(86)90251-6
   JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X
   KANTHASAMY AG, 1994, TOXICOL APPL PHARM, V126, P156, DOI 10.1006/taap.1994.1102
   MADUH EU, 1990, TOXICOL APPL PHARM, V103, P214, DOI 10.1016/0041-008X(90)90224-I
   Mathangi DC, 2000, J OCCUP HEALTH, V42, P88, DOI 10.1539/joh.42.88
   Mathangi DC, 2000, FOOD CHEM TOXICOL, V38, P51, DOI 10.1016/S0278-6915(99)00118-0
   PATEL MN, 1991, NEUROSCI LETT, V131, P42, DOI 10.1016/0304-3940(91)90332-N
   Shou Y, 2000, TOXICOL APPL PHARM, V164, P196, DOI 10.1006/taap.2000.8900
   SPEDDING M, 1984, LIFE SCI, V35, P575, DOI 10.1016/0024-3205(84)90252-2
   WAGNER J, 1982, J NEUROCHEM, V38, P1241, DOI 10.1111/j.1471-4159.1982.tb07897.x
NR 15
TC 3
Z9 3
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD MAR
PY 2004
VL 42
IS 3
BP 359
EP 361
DI 10.1016/j.fct.2003.09.009
PG 3
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA 802LK
UT WOS:000220164800003
PM 14871577
DA 2018-12-27
ER

PT J
AU Boldt, J
   Ducke, M
   Kumle, B
   Papsdorf, M
   Zurmeyer, EL
AF Boldt, J
   Ducke, M
   Kumle, B
   Papsdorf, M
   Zurmeyer, EL
TI RETRACTED: Influence of different volume replacement strategies on
   inflammation and endothelial activation in the elderly undergoing major
   abdominal surgery (Retracted article. See vol. 37, pg. 1231, 2011)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE abdominal surgery; volume replacement; crystalloids; hydroxyethyl
   starch; endothelium; adhesion molecules
ID HYDROXYETHYL STARCH; RESUSCITATION FLUIDS; NEUTROPHIL ACTIVATION;
   PLASMA-CONCENTRATIONS; HEMORRHAGIC-SHOCK; IMMUNE-RESPONSES; ADHESION;
   CRYSTALLOIDS; PREDICTION; MORTALITY
AB Objective: Adequate restoration of intravascular volume remains an important maneuver in the management of the surgical patient. Influence of different volume replacement regimens on inflammation/endothelial activation in elderly surgical patients was assessed. Design: Prospective, randomized study. Setting: Surgical intensive care unit of a university-affiliated hospital. Patients: Sixty-six patients >65 years undergoing major abdominal surgery. Interventions: Ringer's lactate (RL; n=22), normal saline solution (NS; n=22) or a low-molecular HES (mean molecular weight 130 kD) with a low degree of substitution (0.4; HES 130/0.4; n=22) were administered after induction of anesthesia until the 1st postoperative day (POD) to keep central venous pressure between 8-12 mmHg. Measurements and results: C-reactive protein, interleukins (IL-6, IL-8), adhesion molecules [endothelial leukocyte adhesion molecule-1 (ELAM-1) and intercellular adhesion molecule-1 (ICAM-1)] were measured prior to volume therapy at the end of surgery, 5 h after surgery and at the morning of the 1st POD. RL patients received 10,150+/-1,660 ml of RL, NS patients 10,220+/-1,770 ml of NS and the HES-treated group 2,850+/-300 ml of HES 130/0.4 and 2,810+/-350 ml of RL. Hemodynamics were similar in all groups. CRP, IL-6 and IL-8 plasma levels increased significantly higher in both crystalloid groups (IL-6 in the NS group: increase to 407+/-33 pg/ml; RL: increase to 377+/-35 pg/dl) than in the HES-130 treated group (IL-6: increase to 197+/-20 pg/dl). Plasma levels of ELAM-1 and ICAM remained almost unchanged in the HES 130-, but significantly increased in the RL- and NS-treated patients. Conclusions: In elderly patients, markers of inflammation and endothelial injury and activation were significantly higher after crystalloid-than after HES 130/0.4-based volume replacement regimens.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Dept Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM boldtj@gmx.net
CR COLLIS RE, 1994, INTENS CARE MED, V20, P37, DOI 10.1007/BF02425053
   Cook TM, 1998, BRIT J ANAESTH, V80, P776, DOI 10.1093/bja/80.6.776
   COWLEY HC, 1994, CRIT CARE MED, V22, P651, DOI 10.1097/00003246-199404000-00022
   CUSSAK RJ, 2002, INTENSIVMED, V39, P571
   EASTLUND DT, 1992, TRANSFUSION, V32, P855, DOI 10.1046/j.1537-2995.1992.32993110760.x
   Esmon CT, 2000, BLOOD, V95, P1113
   Frumento RJ B-GE, 2003, PERIOPERATIVE ORGAN, P1
   Geppert A, 2003, CRIT CARE MED, V31, P805, DOI 10.1097/01.CCM.0000054861.69462.B5
   Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011
   Hinder F, 2003, CRIT CARE MED, V31, P903, DOI 10.1097/01.CCM.0000050289.15988.67
   Jaeger K, 2000, INFUS THER TRANSFUS, V27, P256
   JUSTICZ AG, 1991, AM HEART J, V122, P671, DOI 10.1016/0002-8703(91)90510-O
   Khandelwal P, 2002, CRIT CARE, V6, P286
   Lang K, 2001, ANESTH ANALG, V93, P405, DOI 10.1097/00000539-200108000-00034
   Meisner M, 1998, INTENS CARE MED, V24, P680, DOI 10.1007/s001340050644
   MORISAKI H, 1994, J APPL PHYSIOL, V77, P1507
   MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423
   ONEILL PJ, 1994, SHOCK, V1, P381, DOI 10.1097/00024382-199405000-00012
   Perret C, 2000, B ACAD NAT MED PARIS, V184, P1621
   Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012
   Rhee P, 1998, J TRAUMA, V44, P313, DOI 10.1097/00005373-199802000-00014
   Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X
   Ruttmann TG, 1998, BRIT J ANAESTH, V80, P612
   SCHMAND JF, 1994, CRIT CARE MED, V22, P1076, DOI 10.1097/00003246-199407000-00005
   Sillett HK, 1998, BRIT J ANAESTH, V81, P242
   Sillett HK, 1997, TRANSFUSION, V37, P953, DOI 10.1046/j.1537-2995.1997.37997454024.x
   Sinclair S, 1997, BRIT MED J, V315, P909
   SUFFREDINI AF, 1994, CRIT CARE MED, V22, pS12
   Suttner SW, 2001, INTENS CARE MED, V27, P1762, DOI 10.1007/s00134-001-1126-0
   Tortorella C, 2001, MICROBIOS, V106, P129
   VANDERHEIDE RS, 1997, J MOL CELL CARDIOL, V19, P619
   Webb AR, 1999, CRIT CARE, V3, pR25, DOI 10.1186/cc346
   Welters ID, 2000, ANAESTHESIST, V49, P196, DOI 10.1007/s001010050814
   Wilson MA, 1996, J TRAUMA, V41, P622, DOI 10.1097/00005373-199610000-00005
   Wolf SE, 1997, ANN SURG, V225, P554, DOI 10.1097/00000658-199705000-00012
NR 35
TC 69
Z9 84
U1 4
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAR
PY 2004
VL 30
IS 3
BP 416
EP 422
DI 10.1007/s00134-003-2110-7
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 780GQ
UT WOS:000189364300010
PM 14712346
DA 2018-12-27
ER

PT J
AU Ahn, MH
   Kim, GI
AF Ahn, MH
   Kim, GI
TI RETRACTED: Characterization of Pythagorean curves and Pythagoreanization
   using a rational transform - (Retracted article. See vol 41, pg 122,
   2006)
SO JOURNAL OF SYMBOLIC COMPUTATION
LA English
DT Article; Retracted Publication
ID OFFSETS; APPROXIMATION; SURFACES
AB In this paper, for Pythagorean hodograph (for short, PH) curves defined as polynomial/rational ones with a polynomial/rational speed function, we consider the following question: "can we reparametrize a plane polynomial curve so that the reparametrized curve is PH?" Our answer is as follows: "the reparametrized curve is PH only when the hodograph of the original curve is the product of a Pythagorean curve and a primary non-Pythagorean curve of degree I under the complex representation for plane curves". (C) 2003 Elsevier Ltd. All rights reserved.
C1 Pohang Univ Sci & Technol, Dept Math, CVLab, Pohang 790784, South Korea.
   GyeongSang Natl Univ, Dept Math & RINS, Chinju 660701, South Korea.
RP Ahn, MH (reprint author), Digital Aria Co Ltd, Korea Design Ctr, Visual Informat Lab, 344-1 Yatop 1 Dong,Bundang 405, Seongnam 463828, Kyonggi Do, South Korea.
EM mhahn@postech.ac.kr; gikim@nongae.gsnu.ac.kr
CR Arrondo E, 1997, J SYMB COMPUT, V23, P267, DOI 10.1006/jsco.1996.0088
   Farouki R. T., 1990, Computer-Aided Geometric Design, V7, P101, DOI 10.1016/0167-8396(90)90024-L
   Farouki R. T., 1990, Computer-Aided Geometric Design, V7, P83, DOI 10.1016/0167-8396(90)90023-K
   FAROUKI RT, 1994, COMPUT AIDED GEOM D, V11, P363, DOI 10.1016/0167-8396(94)90204-6
   HOSCHEK J, 1994, COMPUT AIDED DESIGN, V26, P189
   Lee IK, 1998, GRAPH MODEL IM PROC, V60, P136, DOI 10.1006/gmip.1998.0464
   Lee IK, 1996, COMPUT AIDED DESIGN, V28, P617, DOI 10.1016/0010-4485(95)00078-X
   PHAM B, 1992, COMPUT AIDED DESIGN, V24, P223, DOI 10.1016/0010-4485(92)90059-J
   Pottmann H, 1996, GRAPH MODEL IM PROC, V58, P544, DOI 10.1006/gmip.1996.0045
   Seiler A, 1997, INT J MACH TOOL MANU, V37, P717, DOI 10.1016/S0890-6955(96)00005-3
   TILLER W, 1984, IEEE COMPUT GRAPH, V4, P36, DOI 10.1109/MCG.1984.275995
NR 11
TC 2
Z9 2
U1 3
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0747-7171
J9 J SYMB COMPUT
JI J. Symb. Comput.
PD MAR
PY 2004
VL 37
IS 3
BP 377
EP 389
DI 10.1016/j.jsc.2003.06.002
PG 13
WC Computer Science, Theory & Methods; Mathematics, Applied
SC Computer Science; Mathematics
GA 779WK
UT WOS:000189324700006
OA Bronze
DA 2018-12-27
ER

PT J
AU Ahluwalia, J
   Tinker, A
   Clapp, LH
   Duchen, MR
   Abramov, AY
   Pope, S
   Nobles, M
   Segal, AW
AF Ahluwalia, J
   Tinker, A
   Clapp, LH
   Duchen, MR
   Abramov, AY
   Pope, S
   Nobles, M
   Segal, AW
TI RETRACTED: The large-conductance Ca2+-activated K+ channel is essential
   for innate immunity (Retracted article. See vol. 468, 2010)
SO NATURE
LA English
DT Article; Retracted Publication
ID ACTIVATED POTASSIUM CHANNEL; NADPH OXIDASE; HUMAN-NEUTROPHILS; ELECTRON
   CURRENTS; RESPIRATORY BURST; HUMAN EOSINOPHILS; PHORBOL ESTER; PH
   CHANGES; CALCIUM; PHAGOCYTES
AB Neutrophil leukocytes have a pivotal function in innate immunity. Dogma dictates that the lethal blow is delivered to microbes by reactive oxygen species (ROS) and halogens(1,2), products of the NADPH oxidase, whose impairment causes immunodeficiency. However, recent evidence indicates that the microbes might be killed by proteases, activated by the oxidase through the generation of a hypertonic, K+-rich and alkaline environment in the phagocytic vacuole(3). Here we show that K+ crosses the membrane through large-conductance Ca2+-activated K+ (BKCa) channels. Specific inhibitors of these channels, iberiotoxin and paxilline, blocked oxidase-induced Rb-86(+) fluxes and alkalinization of the phagocytic vacuole, whereas NS1619, a BKCa channel opener, enhanced both. Characteristic outwardly rectifying K+ currents, reversibly inhibited by iberiotoxin, were demonstrated in neutrophils and eosinophils and the expression of the alpha-subunit of the BK channel was confirmed by western blotting. The channels were opened by the combination of membrane depolarization and elevated Ca2+ concentration, both consequences of oxidase activity. Remarkably, microbial killing and digestion were abolished when the BKCa channel was blocked, revealing an essential and unexpected function for this K+ channel in the microbicidal process.
C1 UCL, Dept Med, London WC1E 6BT, England.
   UCL, Dept Physiol, London WC1E 6BT, England.
RP Segal, AW (reprint author), UCL, Dept Med, Gower St, London WC1E 6BT, England.
EM t.segal@ucl.ac.uk
RI duchen, michael/A-2116-2009; Abramov, Andrey/H-9053-2012; Clapp,
   Lucie/B-1088-2008
OI duchen, michael/0000-0003-2548-4294; Abramov,
   Andrey/0000-0002-7646-7235; Clapp, Lucie/0000-0001-7802-4481; Pope,
   Simon/0000-0002-2991-3722; Segal, Anthony/0000-0001-7602-9043
FU Wellcome Trust [067287]
CR Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2
   Cherny VV, 2001, J PHYSIOL-LONDON, V535, P783, DOI 10.1111/j.1469-7793.2001.00783.x
   Clapp LH, 1998, CURR OPIN NEPHROL HY, V7, P91
   Da Silva-Santos JE, 2002, J PHARMACOL EXP THER, V300, P946, DOI 10.1124/jpet.300.3.946
   DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523
   DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595
   Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell,00245.2002
   GALVEZ A, 1990, J BIOL CHEM, V265, P11083
   GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814
   GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55
   HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325
   HENDERSON LM, 1988, BIOCHEM J, V255, P285
   HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563
   Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098
   Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699
   KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117
   Lawson K, 2000, KIDNEY INT, V57, P838, DOI 10.1046/j.1523-1755.2000.00923.x
   Mahomed AG, 2000, INFLAMMATION, V24, P559, DOI 10.1023/A:1007029524141
   Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47
   PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283
   PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3
   Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a
   Salvemini D, 2002, NAT REV DRUG DISCOV, V1, P367, DOI 10.1038/nrd796
   Sanchez M, 1996, NEUROPHARMACOLOGY, V35, P963, DOI 10.1016/0028-3908(96)00137-2
   Schrenzel J, 1998, NATURE, V392, P734
   SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0
   THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7
   TSIEN RY, 1989, METHOD CELL BIOL, V30, P127
   Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x
   Willoughby D, 2001, J PHYSIOL-LONDON, V530, P405, DOI 10.1111/j.1469-7793.2001.0405k.x
NR 30
TC 149
Z9 159
U1 4
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD FEB 26
PY 2004
VL 427
IS 6977
BP 853
EP 858
DI 10.1038/nature02356
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 777WU
UT WOS:000189207500043
PM 14985765
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Chiang, AS
   Blum, A
   Barditch, J
   Chen, YH
   Chiu, SL
   Regulski, M
   Armstrong, JD
   Tully, T
   Dubnau, J
AF Chiang, AS
   Blum, A
   Barditch, J
   Chen, YH
   Chiu, SL
   Regulski, M
   Armstrong, JD
   Tully, T
   Dubnau, J
TI RETRACTED: radish encodes a phospholipase-A2 and defines a neural
   circuit involved in anesthesia-resistant memory (Retracted Article. See
   vol 17, pg 1720, 2007)
SO CURRENT BIOLOGY
LA English
DT Article; Retracted Publication
ID DROSOPHILA MUSHROOM BODY; LONG-TERM-MEMORY; PROTEIN-KINASE-C; INDUCED
   RETROGRADE-AMNESIA; PASSIVE-AVOIDANCE TASK; ARACHIDONIC-ACID; OLFACTORY
   MEMORY; CONSOLIDATED MEMORY; PRODUCE AMNESIA; LIMAX-FLAVUS
AB Background: In both vertebrate and invertebrate animals, anesthetic agents cause retrograde amnesia for recently experienced events. In contrast, older memories are resistant to the same treatments. In Drosophila, anesthesia-resistant memory (ARM) and long-term memory (LTM) are genetically distinct forms of long-lasting memory that exist in parallel for at least a day after training. ARM is disrupted in radish mutants but is normal in transgenic flies overexpressing a CREB repressor transgene. In contrast, LTM is normal in radish mutants but is disrupted in CREB repressor transgenic flies. To date, nothing is known about the molecular, genetic, or cell biological pathways underlying ARM.
   Results: Here, we report the molecular identification of radish as a phospholipase-A2, providing the first clue about signaling pathways underlying ARM in any animal. An enhancer-trap allele of radish (Cl 33) reveals expression in a novel anatomical pathway. Transgenic expression of PLA2 under control of C133 restores normal levels of ARM to radish mutants, whereas transient disruption of neural activity in C133 neurons inhibits memory retention. Notably, expression of C133 is not in mushroom bodies, the primary anatomical focus of olfactory memory research in Drosophila.
   Conclusions: Identification of radish as a phospholipase-A2 and the neural expression pattern of an enhancer-trap allele significantly broaden our understanding of the biochemistry and anatomy underlying olfactory memory in Drosophila.
C1 Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA.
   Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30043, Taiwan.
   Univ Edinburgh, Div Informat, Inst Adapt & Neural Computat, Edinburgh EH1 2QL, Midlothian, Scotland.
   Univ Syst Taiwan, Brain Res Ctr, Hsinchu 30043, Taiwan.
RP Dubnau, J (reprint author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.
EM dubnau@cshi.edu
OI Chiu, Shu-Ling/0000-0003-4429-7830
CR Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185
   ALLWEIS C, 1991, NEURAL BEHAV PLASTIC, P370
   Baddeley A. D, 1976, PSYCHOL MEMORY
   BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0
   Budd DC, 1998, NEUROSCI LETT, V244, P133, DOI 10.1016/S0304-3940(98)00157-8
   BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47
   CALIGNANO A, 1991, MOL BRAIN RES, V9, P347, DOI 10.1016/0169-328X(91)90083-A
   Chiang AS, 2001, J COMP NEUROL, V440, P1, DOI 10.1002/cne.1365
   Clements MP, 1996, J NEUROCHEM, V67, P1317
   Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104
   DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T
   DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280
   DeZazzo J, 1999, J NEUROSCI, V19, P8740, DOI 10.1523/JNEUROSCI.19-20-08740.1999
   DeZazzo J, 2000, NEURON, V27, P145, DOI 10.1016/S0896-6273(00)00016-7
   Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820
   Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077
   Dubnau J, 2003, CURR BIOL, V13, P286, DOI 10.1016/S0960-9822(03)00064-2
   Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407
   ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258
   FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370
   FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123
   Fujita S, 2000, JPN J PHARMACOL, V83, P277, DOI 10.1254/jjp.83.277
   GALLUSCIO EH, 1971, J COMP PHYSIOL PSYCH, V75, P136, DOI 10.1037/h0030680
   Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85
   Grunbaum L, 1998, J NEUROSCI, V18, P4384
   HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A
   HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140
   Holscher C, 1995, EUR J PHARMACOL, V294, P253, DOI 10.1016/0014-2999(95)00541-2
   HOLSCHER C, 1994, BEHAV NEURAL BIOL, V61, P225, DOI 10.1016/S0163-1047(05)80005-6
   HOLSCHER C, 1995, NEUROREPORT, V6, P730
   HOLSCHER C, 1995, EUR J NEUROSCI, V7, P1360, DOI 10.1111/j.1460-9568.1995.tb01127.x
   James W, 1890, PRINCIPLES PSYCHOL
   Joiner MLA, 1999, LEARN MEMORY, V6, P177
   KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442
   Kane NS, 1997, NEURON, V18, P307, DOI 10.1016/S0896-6273(00)80270-6
   Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018
   MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638
   Massicotte G, 2000, CELL MOL LIFE SCI, V57, P1542, DOI 10.1007/PL00000639
   McGaugh J.L., 1972, MEMORY CONSOLIDATION
   McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622
   Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801
   MENZEL R, 1990, MEMORY STAGES HONEY
   Micheau J, 1999, CELL MOL LIFE SCI, V55, P534, DOI 10.1007/s000180050312
   Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2
   Muzzio IA, 2001, J NEUROPHYSIOL, V85, P1639
   Nishizaki T, 1999, MOL BRAIN RES, V69, P263, DOI 10.1016/S0169-328X(99)00117-5
   Pascual A, 2001, SCIENCE, V294, P1115, DOI 10.1126/science.1064200
   QUINN WG, 1976, NATURE, V262, P576, DOI 10.1038/262576a0
   QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0
   Schwaerzel M, 2002, NEURON, V35, P951, DOI 10.1016/S0896-6273(02)00832-2
   SEKIGUCHI T, 1994, NEUROSCI RES, V18, P267, DOI 10.1016/0168-0102(94)90162-7
   Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127
   Squire L. R., 1987, MEMORY BRAIN
   Stocker RF, 1997, J NEUROBIOL, V32, P443, DOI 10.1002/(SICI)1097-4695(199705)32:5<443::AID-NEU1>3.0.CO;2-5
   Strausfeld N.J., 1976, ATLAS INSECT BRAIN
   Talk AC, 1997, BRAIN RES, V751, P196, DOI 10.1016/S0006-8993(96)01397-2
   TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0
   TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033
   Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5
   Waddell S, 2001, ANNU REV NEUROSCI, V24, P1283, DOI 10.1146/annurev.neuro.24.1.1283
   Wang YL, 2003, CURR BIOL, V13, P1900, DOI 10.1016/j.cub.2003.10.003
   Weissman A, 1967, Int Rev Neurobiol, V10, P167, DOI 10.1016/S0074-7742(08)60153-1
   Wong AM, 2002, CELL, V109, P229, DOI 10.1016/S0092-8674(02)00707-9
   Xia SZ, 1997, PHARMACOL BIOCHEM BE, V58, P727, DOI 10.1016/S0091-3057(97)00045-2
   Xia SZ, 1999, PHYSIOL BEHAV, V65, P617
   YAMADA A, 1992, J NEUROSCI, V12, P729
   YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5
   YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9
   YU Y, 1997, J NEUROGENET, V11, P212
   Zars T, 2000, SCIENCE, V288, P672, DOI 10.1126/science.288.5466.672
NR 70
TC 22
Z9 24
U1 3
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD FEB 17
PY 2004
VL 14
IS 4
BP 263
EP 272
DI 10.1016/j.cub.2004.02.003
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 776UK
UT WOS:000189136600016
PM 14972677
OA Bronze
DA 2018-12-27
ER

PT J
AU Van Le, TS
   Myers, J
   Konety, BR
   Barder, T
   Getzenberg, RH
AF Van Le, TS
   Myers, J
   Konety, BR
   Barder, T
   Getzenberg, RH
TI RETRACTED: Functional characterization of the bladder cancer marker,
   BLCA-4 (Retracted article. See vol. 19, pg. 3327, 2013)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID METHYL-N-NITROSOUREA; ETS FAMILY; PROTEINS
AB Introduction: Bladder cancer is a common disease of the genitourinary tract for which the development of a noninvasive detection technique would have a significant impact on disease management. One of our previously identified bladder cancer-specific proteins, BLCA-4, appears to be associated with a "field effect" of the disease, and in clinical trials is able to separate individuals with bladder cancer from those without the disease with high sensitivity and specificity. The potential clinical utility of this marker has led to the analysis of its function in bladder cancer pathobiology.
   Experimental Design: To additionally analyze the specificity of this marker, the expression in the urine of a variety of benign urologic conditions was analyzed. After cloning the gene encoding BLCA-4, functional aspects of the protein were analyzed by overexpressing it in cell systems, as well as its interaction with other transcription factors and in gel mobility shift assays. Finally, to determine the timing of expression in relation to the observance of bladder cancer, an animal model of the disease was examined.
   Results: Expression of BLCA-4, the cDNA of which reveals that it is a novel member of the ETS transcription factor family, is not found in benign urologic conditions. Overexpression leads to increased growth rates of cells, and the protein interacts with other transcription factors. In vivo studies reveal that BLCA-4 expression occurs significantly before the observance of grossly visible tumors in an animal model of the disease.
   Conclusions: BLCA-4 is a bladder cancer marker that is highly specific and occurs early in the development of the disease. It appears to be a transcription factor that may play a role in the regulation of the gene expression in bladder cancer. BLCA-4 is a marker with significant clinical utility that may have an active role in the disease.
C1 Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Res Labs, Pittsburgh, PA 15232 USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   Univ Iowa, Dept Urol, Iowa City, IA 52242 USA.
   Eprogen Inc, Darien, IL USA.
RP Getzenberg, RH (reprint author), Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Res Labs, Suite G40,5200 Ctr Ave, Pittsburgh, PA 15232 USA.
EM getzenbergrh@msx.upmc.edu
FU NCI NIH HHS [CA82522]
CR *AM CANC SOC, 2003, CANC FACTS FIG 2003
   Getzenberg RH, 1996, CANCER RES, V56, P1690
   HICKS RM, 1972, CHEM-BIOL INTERACT, V5, P139, DOI 10.1016/0009-2797(72)90040-3
   HICKS RM, 1976, CANCER RES, V36, P2502
   Konety BR, 2000, CLIN CANCER RES, V6, P2618
   KONETY BR, 2000, J UROL S, V163
   LOWER GM, 1982, CANCER-AM CANCER SOC, V49, P1056, DOI 10.1002/1097-0142(19820301)49:5<1056::AID-CNCR2820490535>3.0.CO;2-I
   Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045
   MOSTOFI FK, 1988, DIAGNOSIS MANAGEMENT, P83
   MURPHY WM, 1982, J UROLOGY, V127, P849, DOI 10.1016/S0022-5347(17)54105-1
   RAGHAVAN D, 1986, PROG CLIN BIOL RES, V171, P208
   RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641
   Soloway MS, 1996, J UROLOGY, V156, P363, DOI 10.1016/S0022-5347(01)65851-8
   STEINBERG GD, 1990, CANCER RES, V50, P6668
   WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x
NR 15
TC 51
Z9 52
U1 4
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2004
VL 10
IS 4
BP 1384
EP 1391
DI 10.1158/1078-0432.CCR-0455-03
PG 8
WC Oncology
SC Oncology
GA 776JE
UT WOS:000189112200027
PM 14977841
OA Bronze
DA 2018-12-27
ER

PT J
AU Reck-Peterson, SL
   Vale, RD
AF Reck-Peterson, SL
   Vale, RD
TI RETRACTED: Molecular dissection of the roles of nucleotide binding and
   hydrolysis in dynein's AAA domains in Saccharomyces cerevisiae
   (Retracted Article. See vol 101, pg 14395, 2004)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID REPLICATION FACTOR-C; CYTOPLASMIC DYNEIN; HEAVY-CHAIN;
   MICROTUBULE-BINDING; ATP HYDROLYSIS; MOTOR DOMAIN; ATPASES; PROTEIN;
   MEMBRANE; COMPLEX
AB The motor protein cytoplasmic dynein is responsible for most of the minus-end-directed microtubule traffic within cells. Dynein contains four evolutionarily conserved AAA (ATPase associated with various cellular activities) domains that are thought to bind nucleotide; the role of nucleotide binding and hydrolysis in each of these four AAA domains has constituted an important and unresolved question in understanding dynein's mechanism. Using Saccharomyces cerevisiae cytoplasmic dynein as a model system, we mutagenized residues involved in nucleotide binding or hydrolysis in the four AAA domains and examined the ability of the mutant dyneins to mediate nuclear segregation in vivo and to bind microtubules in vitro. Our analysis shows that an AAA1 hydrolysis mutant blocks dynein function, whereas a triple AAA2/3/4 hydrolysis mutant does not, suggesting that nucleotide binding is required at only one site. We also show that nucleotide binding at AAA3, but not hydrolysis, is essential for motor activity in vivo and ATIP-induced dissociation of dynein from microtubules, suggesting that this domain acts as a critical allosteric site. In contrast, mutations in AAA2 cause subtle defects in dynein function, whereas mutation in AAA4 produce no obvious defects. These results show that the four conserved dynein AAA domains have distinct functions in dynein's mechanochemical cycle.
C1 Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA.
   Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA.
RP Vale, RD (reprint author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94107 USA.
EM vale@cmp.ucsf.edu
FU NIAMS NIH HHS [P01 AR 42895-10, P01 AR042895]; NIGMS NIH HHS [F32
   GM067403, GM 67403-01, R01 GM038499]
CR Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4
   Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5
   Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982
   Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377
   Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607
   Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949
   ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172
   Gee MA, 1997, NATURE, V390, P636
   Gheber L, 1999, J BIOL CHEM, V274, P9564, DOI 10.1074/jbc.274.14.9564
   GIBBONS IR, 1987, J BIOL CHEM, V262, P2780
   GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0
   Hartman JJ, 1999, SCIENCE, V286, P782, DOI 10.1126/science.286.5440.782
   Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200
   JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.biophys.14.1.161
   KINOSHITA S, 1995, CELL MOTIL CYTOSKEL, V32, P46, DOI 10.1002/cm.970320106
   KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108
   LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096
   Menendez J, 1998, YEAST, V14, P647
   Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8
   Mocz G, 1996, BIOCHEMISTRY-US, V35, P9204, DOI 10.1021/bi960662u
   Neuwald AF, 1999, GENOME RES, V9, P27
   Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x
   Polyak SW, 2001, J BIOL CHEM, V276, P3037, DOI 10.1074/jbc.M003968200
   REID RJD, 2002, METHOD ENZYMOL B, V350, P258, DOI DOI 10.1016/S0076-6879(02)50968-X
   Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909
   Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584
   Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200
   Sheeman B, 2003, CURR BIOL, V13, P364, DOI 10.1016/S0960-9822(03)00013-7
   Shiroguchi K, 2001, CELL MOTIL CYTOSKEL, V49, P189, DOI 10.1002/cm.1032
   SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001
   Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675
   Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9
   VALE RD, 2000, J CELL BIOL, V150, P13
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
   WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945
   Yagi T, 2000, CELL STRUCT FUNCT, V25, P263, DOI 10.1247/csf.25.263
NR 36
TC 76
Z9 76
U1 4
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 10
PY 2004
VL 101
IS 6
BP 1491
EP 1495
DI 10.1073/pnas.2637011100
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 773JT
UT WOS:000188921200014
PM 14755060
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Badawi, AF
   Eldeen, MB
   Liu, YY
   Ross, EA
   Badr, MZ
AF Badawi, AF
   Eldeen, MB
   Liu, YY
   Ross, EA
   Badr, MZ
TI RETRACTED: Inhibition of rat mammary gland carcinogenesis by
   simultaneous targeting of cyclooxygenase-2 and peroxisome
   proliferator-activated receptor gamma (Retracted article. See vol. 65,
   pg. 8057, 2005)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID HUMAN BREAST-CANCER; PROGRAMMED CELL-DEATH; KINASE-C-ALPHA;
   EPITHELIAL-CELLS; GENE-EXPRESSION; MESSENGER-RNA; TUMOR-CELLS;
   PPAR-GAMMA; PROGNOSTIC-SIGNIFICANCE; BAX EXPRESSION
AB We examined the effect of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and N-(9-fluorenyl-methyloxycarbonyl)-L-leucine(F-L-Leu), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, separately and combined, on the development of methylnitrosourea (MNU)-induced rat mammary gland carcinogenesis. Celecoxib and F-L-Leu significantly reduced tumor incidence and multiplicity (P < 0.05). Combining both agents exerted higher (synergistic) cancer inhibition than separate treatments (P < 0.05). The effects of the test drugs on COX-2 and PPARgamma expression and on the synthesis of prostaglandin E-2 (PGE(2)) and 15-deoxy-Delta(12,14) -PGJ(2) (15d-PGJ(2)) were examined in rat mammary normal (MNU-untreated), uninvolved, and tumor (MNU-treated) tissues. Celecoxib and F-L-Leu, separately, inhibited COX-2 and up-regulated PPARgamma expression. These effects were paralleled by inhibition of PGE2 synthesis and up-regulation of 15d-PGJ(2). Combined treatment resulted in higher alterations in COX-2 and PPARy transcripts and PG synthesis compared with separate administrations. The effect of the test agents on Bcl(2), BAX, and protein kinase Calpha expression levels were examined in the rat mammary gland and the pro-(BAX:Bcl(2)) and anti-[PKCalpha*(Bcl(2)/BAX)] apoptotic ratios were evaluated. Each drug increased the proapoptotic ratio by 2- to 7-fold and reduced the antiapoptotic ratio by 2- to >8-fold in all tissues. Combined treatment, however, resulted in >9- to 14-fold up-regulation in the proapoptotic processes and 15- to >30-fold down-regulation in the antiapoptotic ones. Analyses were also carried out on the drug-induced modulation of cell cycle regulators and proliferation markers (cyclin-dependent kinase 1 and proliferating cell nuclear antigen). F-L-Leu and celecoxib each reduced the cyclin-dependent kinase 1 and proliferating cell nuclear antigen expression in the tumor. Higher down-regulation was attained in all tissues by combined treatment where cyclin-dependent kinase 1 and proliferating cell nuclear antigen almost retained the expression levels observed in the normal glands. In conclusion, simultaneous targeting of COX-2 and PPARy may inhibit mammary cancer development more effectively than targeting each molecule alone. COX-2 inhibitors and PPARgamma agonists coordinately mediate their anticancer effect via both COX-dependent (inhibition of COX-2, activation of PPARy, and modulation PG synthesis) and COX-independent (induction of proapoptotic factors and inhibition of cell proliferation) pathways.
C1 Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA.
   Univ Missouri, Sch Pharm, Kansas City, MO USA.
RP Badawi, AF (reprint author), Fox Chase Canc Ctr, Div Populat Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
EM af_badawi@fccc.edu
FU NCI NIH HHS [CA-97473, CA06927, CA57708]
CR Abou-Issa HM, 2001, ANTICANCER RES, V21, P3425
   Badawi AF, 1998, PROSTAG OTH LIPID M, V56, P167, DOI 10.1016/S0090-6980(98)00049-5
   Badawi AF, 2003, INT J CANCER, V103, P84, DOI 10.1002/ijc.10770
   Badawi AF, 1998, CARCINOGENESIS, V19, P905, DOI 10.1093/carcin/19.5.905
   Badawi AF, 2002, INT J ONCOL, V20, P1109
   BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622
   Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CELIS JE, 1984, LEUKEMIA RES, V8, P143, DOI 10.1016/0145-2126(84)90135-8
   Cheng JD, 2002, INT J CANCER, V99, P755, DOI 10.1002/ijc.10409
   Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n
   Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905
   Davis CD, 2002, J NUTR, V132, P1018
   Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951
   El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264
   ELSNER E, 1998, P NATL ACAD SCI USA, V95, P8806
   Fournier DB, 2001, GYNECOL ONCOL, V81, P366, DOI 10.1006/gyno.2001.6164
   Frey RS, 2001, BIOCHEM PHARMACOL, V61, P979, DOI 10.1016/S0006-2952(01)00572-X
   Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345
   Gimble JM, 1998, BIOCHEM BIOPH RES CO, V253, P813, DOI 10.1006/bbrc.1998.9858
   Harris RE, 2000, CANCER RES, V60, P2101
   Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4
   HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059
   Hiroyasu S, 1999, J SURG RES, V84, P204, DOI 10.1006/jsre.1999.5644
   Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302
   Kapranos N, 1997, ANTICANCER RES, V17, P2499
   Kohno H, 2002, JPN J CANCER RES, V93, P133, DOI 10.1111/j.1349-7006.2002.tb01251.x
   Konturek PC, 1998, ALIMENT PHARM THERAP, V12, P767
   Kornblau SM, 2000, CLIN CANCER RES, V6, P1401
   Krajewski S, 1997, CLIN CANCER RES, V3, P199
   Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257
   Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406
   LIU YC, 1989, BIOCHEM BIOPH RES CO, V161, P873, DOI 10.1016/0006-291X(89)92681-8
   Lu SY, 2002, CANCER LETT, V184, P7, DOI 10.1016/S0304-3835(02)00201-X
   Mao YR, 2002, CANCER INVEST, V20, P922, DOI 10.1081/CNV-120005905
   Martinez-Arribas F, 2003, ANTICANCER RES, V23, P565
   MAY WS, 1994, J BIOL CHEM, V269, P26865
   Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418
   Michael MS, 2003, INT J MOL MED, V11, P733
   NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0
   Okumura M, 2002, BBA-MOL CELL RES, V1592, P107, DOI 10.1016/S0167-4889(02)00276-8
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203
   Parrett ML, 1997, INT J ONCOL, V10, P503
   Pighetti GM, 2001, ANTICANCER RES, V21, P825
   Reinacher-Schick A, 2000, ENDOSCOPY, V32, P245, DOI 10.1055/s-2000-135
   Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17
   Ristimaki A, 2002, CANCER RES, V62, P632
   Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7
   Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143
   Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436
   Shilkaitis A, 2000, CELL GROWTH DIFFER, V11, P437
   SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441
   Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525
   Srivastava P, 1997, CARCINOGENESIS, V18, P1799, DOI 10.1093/carcin/18.9.1799
   Strobel T, 1998, CANCER RES, V58, P4776
   Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200
   Suh N, 1999, CANCER RES, V59, P5671
   Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   THOMPSON HJ, 1995, CARCINOGENESIS, V16, P2407, DOI 10.1093/carcin/16.10.2407
   Toyoda M, 2002, GUT, V50, P563, DOI 10.1136/gut.50.4.563
   TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Veronese S, 1998, INT J CANCER, V79, P13, DOI 10.1002/(SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z
   Vogiagis D, 2000, AM J PHYSIOL-GASTR L, V278, pG820
   Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200
   Yang E, 1996, BLOOD, V88, P386
   Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379
NR 75
TC 49
Z9 55
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2004
VL 64
IS 3
BP 1181
EP 1189
DI 10.1158/0008-5472.CAN-03-2556
PG 9
WC Oncology
SC Oncology
GA 771VF
UT WOS:000188806200057
PM 14871855
OA Bronze
DA 2018-12-27
ER

PT J
AU Hattori, Y
   Kasai, K
AF Hattori, Y
   Kasai, K
TI RETRACTED: Disruption of the actin cytoskeleton up-regulates iNOS
   expression in vascular smooth muscle cells (Retracted article. See vol.
   58, pg. 336, 2011)
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE actin; iNOS; latrunculin B; vascular smooth muscle
ID NITRIC-OXIDE SYNTHASE; ACTIVATION; BARRIER; PROTEIN; RNA
AB Cytokines and bacterial lipopolysaccharide (LPS) induce the expression of inducible nitric oxide synthase (iNOS), resulting in the release of nitric oxide (NO) from vascular smooth muscle cells. We here demonstrated that disruption of F-actin formation by sequestration of G-actin with the toxin latrunculin B (Lat B) dramatically potentiated LPS-induced iNOS mRNA and protein expression. We also showed that Lat B enhanced interleukin-1beta- and TNFalpha-induced NO production. Lat B by itself had little or no effect on iNOS expression. Cytochalasin D also enhanced LPS-induced NO production. Lat B dose-dependently enhanced LPS-induced iNOS promoter activity but had no effect on the stability of iNOS mRNA. Staining of F-actin with nitrobenzoxadiazole (NBD)-phallacidin demonstrated that Lat B significantly impaired F-actin stress fiber formation. These data indicate that disruption of the actin cytoskeleton up-regulates cytokine-induced iNOS expression via transcriptional regulation. Further analysis of the signaling pathway from the actin cytoskeleton to iNOS expression may yield new insight into the mechanism of iNOS regulation.
C1 Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
CR Banan A, 2002, AM J PHYSIOL-GASTR L, V283, pG909, DOI 10.1152/ajpgi.00143.2002
   Banan A, 2001, AM J PHYSIOL-GASTR L, V280, pG1234
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8
   Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V278, pC942
   GROSS SS, 1992, J BIOL CHEM, V267, P25722
   Hattori Y, 2003, CARDIOVASC RES, V58, P186, DOI 10.1016/S0008-6363(02)00855-6
   HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062
   Hattori Y, 1999, BIOCHEM BIOPH RES CO, V259, P128, DOI 10.1006/bbrc.1999.0736
   Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   NATHAN C, 1992, FASEB J, V6, P3051
   Smith J, 1996, PORTL PR P, V10, P8
   Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712
   Zeng CB, 2001, AM J PHYSIOL-CELL PH, V281, pC932
   Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465
NR 18
TC 11
Z9 11
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD FEB
PY 2004
VL 43
IS 2
BP 209
EP 213
DI 10.1097/00005344-200402000-00007
PG 5
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 767EX
UT WOS:000188428200007
PM 14716207
OA Bronze
DA 2018-12-27
ER

PT J
AU Reuben, SS
   Makari-Judson, G
   Lurie, SD
AF Reuben, SS
   Makari-Judson, G
   Lurie, SD
TI RETRACTED: Evaluation of efficacy of the perioperative administration of
   venlafaxine XR in the prevention of postmastectomy pain syndrome
   (Retracted article. See vol. 37, pg 41, 2009)
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 27th Annual Meeting of the American-Society-for-Regional-Anesthesia
CY APR 25-28, 2002
CL CHICAGO, IL
SP Amer Soc Reg Anesthesia
DE pain; postmastectomy pain syndrome; mastectomy; breast surgery;
   neuropathic pain; venlafaxine; preemptive analgesia
ID PERIPHERAL DIABETIC-NEUROPATHY; PHANTOM BREAST SYNDROME;
   INTERCOSTOBRACHIAL NERVE; CLINICAL CHARACTERISTICS; PREEMPTIVE
   ANALGESIA; POSTOPERATIVE PAIN; LIMB PAIN; CANCER; SURGERY; MASTECTOMY
AB Postmastectomy pain syndrome (PMPS) is a neuropathic pain syndrome that may develop following breast surgery. Venlafaxine has been shown to be efficacious in the management of PMPS. The preemptive administration of venlafaxine has been shown to be efficacious in reducing the incidence of neuropathic pain in the rat model. We examined the efficacy of administering either venlafaxine or placebo for two weeks starting the night before surgery to 100 patients scheduled for either partial or radical mastectomy with axillary dissection. Patients were administered PCA morphine for the first 24 hours following surgery and then acetaminophen/oxycodone tablets. Pain scores were recorded at rest and movement on day 1, at 1 month, and at 6 months after surgery. At 6 months postoperatively, the presence of pain in the chest, arm, and axilla, edema; decreased sensation in the operative area; and phantom breast pain were recorded. There was no difference in postoperative opioid use. Pain scores with movement were lower in the venlafaxine group at 6 months. Pain scores at all other time intervals were similar. There was a significant decrease in the incidence of chest wall pain (55% vs. 19%, P = 0.0002), arm pain (45% vs. 17%, P = 0.003), and axilla pain (51% vs. 19%, P = 0.0009) between the control group and the venlafaxine group, respectively. No significant differences were noted between the two groups with regard to edema, phantom pain, or sensory changes. We conclude that the perioperative administration of venlafaxine beginning the night prior to surgery significantly reduces the incidence of PAWS following breast cancer surgery. j Pain Symptom Manage 2004;27:133-139. (C) 2004 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA.
   Tufts Univ, Sch Med, Boston, MA 02111 USA.
   Caritas Norwood Hosp, Norwood, MA USA.
RP Reuben, SS (reprint author), Baystate Med Ctr, Dept Anesthesiol, 759 Chestnut St, Springfield, MA 01199 USA.
CR ASSA J, 1974, J SURG ONCOL, V6, P123, DOI 10.1002/jso.2930060206
   BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6
   Cousins MJ, 2000, REGION ANESTH PAIN M, V25, P6, DOI 10.1016/S1098-7339(00)80005-X
   Davis JL, 1999, DIABETES CARE, V22, P1909, DOI 10.2337/diacare.22.11.1909
   EGBUNIKE IG, 1990, PHARMACOTHERAPY, V10, P262
   Enggaard TP, 2001, CLIN PHARMACOL THER, V69, P245, DOI 10.1067/mcp.2001.114873
   Fassoulaki A, 2000, REGION ANESTH PAIN M, V25, P350, DOI 10.1053/rapm.2000.7812
   Fassoulaki A, 2001, REGION ANESTH PAIN M, V26, P223, DOI 10.1053/rapm.2001.23205
   Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1213/01.ANE.0000024206.70089.15
   FOLEY KM, 1987, MED CLIN N AM, V71, P169, DOI 10.1016/S0025-7125(16)30864-1
   Galer BS, 1995, NEUROLOGY, V45, pS17, DOI 10.1212/WNL.45.12_Suppl_9.S17
   HADDOX DJ, 1992, PRACTICAL MANAGEMENT, V2, P636
   Hayes C, 1997, INT ANESTHESIOL CLIN, V35, P67, DOI 10.1097/00004311-199703520-00006
   HOLLIDAY SM, 1995, DRUGS, V49, P280, DOI 10.2165/00003495-199549020-00010
   JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9
   Jensen TS, 1996, PAIN 1996 UPDATED RE, P77
   JUHLIN L, 1989, ACTA DERM-VENEREOL, V69, P18
   Kalso E, 1995, PAIN, V64, P293
   KARYDAS I, 1986, BREAST CANC RES TREA, V21, P139
   Kiayias JA, 2000, DIABETES CARE, V23, P699, DOI 10.2337/diacare.23.5.699b
   Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3
   KRONER K, 1992, CLIN J PAIN, V8, P346, DOI 10.1097/00002508-199212000-00009
   KRONER K, 1989, PAIN, V36, P327, DOI 10.1016/0304-3959(89)90092-4
   Kwekkeboom K, 1996, CANCER NURS, V19, P37, DOI 10.1097/00002820-199602000-00005
   Lakdja F, 1997, B CANCER, V84, P259
   Lang E, 1996, PAIN, V68, P151, DOI 10.1016/S0304-3959(96)03223-X
   Low PA, 1998, JAMA-J AM MED ASSOC, V280, P1863, DOI 10.1001/jama.280.21.1863
   MUTH EA, 1986, BIOCHEM PHARMACOL, V35, P4493, DOI 10.1016/0006-2952(86)90769-0
   Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038
   Pernia A, 2000, J PAIN SYMPTOM MANAG, V19, P408, DOI 10.1016/S0885-3924(00)00151-2
   Reuben SS, 2000, J HAND SURG-AM, V25A, P1147
   Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021
   Schreiber S, 1999, NEUROSCI LETT, V273, P85, DOI 10.1016/S0304-3940(99)00627-8
   Senturk M, 2002, ANESTH ANALG, V94, P11
   STEVENS PE, 1995, PAIN, V61, P61, DOI 10.1016/0304-3959(94)00162-8
   Sumpton JE, 2001, ANN PHARMACOTHER, V35, P557
   Tasmuth T, 1996, PAIN, V68, P343, DOI 10.1016/S0304-3959(96)03219-8
   Tasmuth T, 1996, BRIT J CANCER, V74, P2024, DOI 10.1038/bjc.1996.671
   Tasmuth T, 2002, EUR J PAIN-LONDON, V6, P17, DOI 10.1053/eujp.2001.0266
   VECHT CJ, 1989, PAIN, V38, P171, DOI 10.1016/0304-3959(89)90235-2
   Warmuth MA, 1998, CANCER, V83, P1362, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1362::AID-CNCR13>3.0.CO;2-2
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026
NR 42
TC 65
Z9 68
U1 3
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2004
VL 27
IS 2
BP 133
EP 139
DI 10.1016/j.jpainsymman.2003.06.004
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA 778YR
UT WOS:000189269400008
PM 15157037
DA 2018-12-27
ER

PT J
AU Sun, XY
   Fischer, DR
   Yang, MY
   Tian, TX
AF Sun, XY
   Fischer, DR
   Yang, MY
   Tian, TX
TI RETRACTED: Effect of burn injury on glucocorticoid receptor binding
   activity in rat muscle (Retracted Article. See vol 122, pg 143, 2004)
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article; Retracted Publication
DE thermal-injury; steroid hormones receptor; skeletal muscle
ID SKELETAL-MUSCLE; GENE-EXPRESSION; IMMOBILIZATION STRESS;
   PROTEIN-DEGRADATION; HORMONE-BINDING; DISUSE ATROPHY; SEPTIC RATS;
   UBIQUITIN; METABOLISM; SEPSIS
AB Burn injury is associated with increased muscle proteolysis and up-regulated gene expression in the proteolytic pathway. Glucocorticoids (GCs) are the most important mediator of burn injury induced muscle cachexia. However, the understanding of the mechanisms of GCs action in response to burn injury remains elusive. It is well known that GC acts by binding its own receptor. Therefore, in the present study, we examined the influence of burn injury on the hormone binding activity of the glucocorticoid receptor (GR) in skeletal muscle. Burn injury resulted in increased hormone binding activity in extensor digitorum longus (EDL) and soleus muscles. Scatchard plots revealed that the increased GR hormone binding activity reflected increased numbers of hormone binding sites, whereas receptor affinity for GCs was unchanged. Western blot analysis showed that dissociation of GR/heat shock protein 90 heterocomplex or increase in GR protein may account for the effect of burn injury. The GR antagonist RU 38486 blocked the burn injury-induced increase in GR hormone binding activity, implicating a positive regulatory effect of GCs on GR binding activity under the present experimental conditions. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA.
   Shriners Hosp Children, Cincinnati, OH USA.
   Univ Cincinnati, Dept Med, Cincinnati, OH USA.
   Univ Cincinnati, Dept Mol & Cellular Physiol, Cincinnati, OH USA.
RP Sun, XY (reprint author), Univ Cincinnati, Dept Surg, 231 Albert Sabin Way,Mail Locat 0558, Cincinnati, OH 45267 USA.
EM sunxn@email.uc.edu
CR ABCOUWER SF, 1995, J SURG RES, V59, P59, DOI 10.1006/jsre.1995.1132
   Al-Mohaisen M, 2000, STEROIDS, V65, P8, DOI 10.1016/S0039-128X(99)00076-8
   ALI M, 1991, LIFE SCI, V48, P603, DOI 10.1016/0024-3205(91)90534-I
   ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984
   ARDAWI MSM, 1991, METABOLISM, V40, P155
   BAXTER JD, 1972, P NATL ACAD SCI USA, V69, P1892, DOI 10.1073/pnas.69.7.1892
   BEATO M, 1972, BIOCHEM BIOPH RES CO, V47, P1464, DOI 10.1016/0006-291X(72)90237-9
   DUBOIS DC, 1980, ENDOCRINOLOGY, V107, P1649, DOI 10.1210/endo-107-5-1649
   DUBOIS DC, 1981, MUSCLE NERVE, V4, P370, DOI 10.1002/mus.880040504
   FANG CH, 1995, J AM COLL SURGEONS, V180, P33
   Fang CH, 2000, ENDOCRINOLOGY, V141, P2743, DOI 10.1210/en.141.8.2743
   Fang CH, 2000, J BURN CARE REHABIL, V21, P528, DOI 10.1067/mbc.2000.110611
   Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002
   Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003
   Hasselgren PO, 1999, J AM COLL SURGEONS, V188, P98, DOI 10.1016/S1072-7515(98)00297-X
   Horst K, 1930, J NUTR, V3, P177
   KITAYAMA I, 1989, J NEURAL TRANSM, V77, P93, DOI 10.1007/BF01248925
   LLovera M, 1998, INT J MOL MED, V2, P69
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MEALY K, 1990, ARCH SURG-CHICAGO, V125, P42
   MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208
   NICHOLSON WF, 1984, PFLUG ARCH EUR J PHY, V401, P321, DOI 10.1007/BF00584330
   Rich MM, 1999, NEUROBIOL DIS, V6, P515, DOI 10.1006/nbdi.1999.0257
   Santoro JC, 2001, ANAL BIOCHEM, V289, P18, DOI 10.1006/abio.2000.4911
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SCHMIDT TJ, 1982, PHYSIOL REV, V62, P1131
   SILVA CM, 1989, J BIOL CHEM, V264, P6638
   SIMONS SS, 1995, METHOD ENZYMOL, V251, P406
   SMITH KL, 1993, BRIT J CANCER, V67, P680, DOI 10.1038/bjc.1993.126
   Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831
   STEFFEN JM, 1987, AVIAT SPACE ENVIR MD, V58, P996
   STITH RD, 1986, CIRC SHOCK, V18, P301
   Sun XY, 2002, AM J PHYSIOL-REG I, V282, pR509, DOI 10.1152/ajpregu.00509.2001
   SVEC F, 1989, BIOCHEM MED METAB B, V41, P224, DOI 10.1016/0885-4505(89)90030-3
   SVEC F, 1981, J BIOL CHEM, V256, P5984
   Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421
   VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68
   Williams A, 1999, SURGERY, V126, P744, DOI 10.1016/S0039-6060(99)70131-5
   Williams AB, 1999, FASEB J, V13, P1435
   WING SS, 1993, AM J PHYSIOL, V264, pE668
   ZAMIR O, 1993, METABOLISM, V42, P1190, DOI 10.1016/0026-0495(93)90279-W
NR 41
TC 2
Z9 3
U1 3
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD FEB
PY 2004
VL 116
IS 2
BP 234
EP 241
DI 10.1016/S0022-4804(03)00285-3
PG 8
WC Surgery
SC Surgery
GA 774WC
UT WOS:000189008300007
PM 15013361
DA 2018-12-27
ER

PT J
AU Tolentino, MJ
   Brucker, AJ
   Fosnot, J
   Ying, GS
   Wu, IH
   Malik, G
   Wan, SH
   Reich, SJ
AF Tolentino, MJ
   Brucker, AJ
   Fosnot, J
   Ying, GS
   Wu, IH
   Malik, G
   Wan, SH
   Reich, SJ
TI RETRACTED: Intravitreal injection of vascular endothelial growth factor
   small interfering RNA inhibits growth and leakage in a nonhuman primate,
   laser-induced model of choroidal neovascularization (Retracted Article.
   See vol 24, pg 660, 2004)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article; Retracted Publication
ID MACULAR DEGENERATION; THERAPY; VEGF
AB Purpose: To determine the safety and efficacy of small interfering RNA (siRNA) directed against vascular endothelial growth factor (VEGF) in a nonhuman primate model of laser-induced choroidal neovascularization (CNV).
   Methods: Each animal received laser rupture of Bruch's membrane to induce CNV in both eyes. Each animal was then randomized to receive 0.05 mL of either vehicle alone or VEGF siRNA at 70 mug, 150 mug, or 350 mug in both eyes by intravitreal injection. Eyes were monitored weekly by ophthalmic examination, color photography, and fluorescein angiography for 36 days after laser injury. Electroretinograms were measured at baseline and at 5 weeks after laser. CNV on fluorescein angiograms were measured for area and graded for clinically significant leakage in a standardized, randomized, and double-masked fashion on days 15, 22, 29, and 36 after laser.
   Results: VEGF siRNA did not cause any change in electroretinographic, hemorrhage, inflammation, or clinical signs of toxicity. A single administration of VEGF siRNA significantly inhibited growth of CNV and attenuated angiographic leakage in a dose-dependent manner.
   Conclusion: Intravitreal injection of VEGF siRNA is capable of inhibiting the growth and vascular permeability of laser-induced CNV in a nonhuman primate in a dose-dependent manner. This study demonstrates preclinical proof of a principle that supports proceeding to clinical studies of VEGF siRNA in patients with exudative age-related macular degeneration.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Acuity Pharmaceut, Philadelphia, PA USA.
RP Tolentino, MJ (reprint author), Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
FU NEI NIH HHS [EY 13410-01]
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   *AM AC OPHTH, 1995, BAS CLIN SCI COMPL C
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Eyetech-Study-Group, 2002, RETINA, V22, P143
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Reich S, 2003, MOL VIS, V9, P210
   SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 16
TC 105
Z9 119
U1 2
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2004
VL 24
IS 1
BP 132
EP 138
DI 10.1097/00006982-200402000-00018
PG 7
WC Ophthalmology
SC Ophthalmology
GA 778HU
UT WOS:000189234200018
PM 15076954
DA 2018-12-27
ER

PT J
AU Lei, SA
AF Lei, SA
TI RETRACTED: Soil compaction from human trampling, biking, and off-road
   motor vehicle activity in a blackbrush (Coleogyne ramosissima) shrubland
   (Retracted article. See vol. 71, pg. 139, 2011)
SO WESTERN NORTH AMERICAN NATURALIST
LA English
DT Article; Retracted Publication
DE trampling; hiking; biking; motorcycle; vehicle; soil compaction;
   disturbance; blackbrush; Coleogyne ramosissima; Kyle Canyon; Spring
   Mountains; southern Nevada
ID MOJAVE-DESERT; RECOVERY; USA
AB Soil compaction from human trampling, biking, and off-road motor vehicle traffic was quantitatively investigated in a blackbrush (Coleogyne ramosissima) shrubland in Kyle Canyon of the Spring Mountains in southern Nevada. A significant difference was detected in soil compaction, bulk density, and percent pore space at a particular frequency of visits in each of 4 disturbance types. On average a single vehicle pass was equivalent to 10 human footprints. Ten and 100 footprints were equivalent to 1 motorcycle pass and 10 vehicle passes, respectively. Soil compaction is a product of increased bulk density and decreased pore space. The degree of soil compaction is a function of disturbance type and visit frequency when examining these 2 factors independently. However, interactive effects of disturbance type and visit frequency on soil bulk density, compaction, and percent pore space were not significantly different. The greatest effects occurred during the first few passes, with changes per pass decreasing as the number of passes increased in all 4 trails. Results of this study suggest that the effects of hiking and biking slowly increase over time relative to the effects of motor vehicle traffic in the Coleogyne shrubland of Kyle Canyon in southern Nevada.
C1 Community Coll So Nevada, WDB, Dept Biol, Las Vegas, NV 89146 USA.
RP Lei, SA (reprint author), Community Coll So Nevada, WDB, Dept Biol, 6375 W Charleston Blvd, Las Vegas, NV 89146 USA.
CR *AN SOFTW, 1994, STAT 4 1 INT STAT PR
   BOUYOUCOS GJ, 1951, AGRON J, V43, P434, DOI 10.2134/agronj1951.00021962004300090005x
   Brittingham S, 2000, WEST N AM NATURALIST, V60, P374
   DAVIDSON E D, 1974, Madrono, V22, P381
   Gill W R, 1967, AGR HDB, V316
   HAUSEBUILLER RL, 1972, SOIL SCI
   MARBLE JR, 1985, TECHNIQUES REVEGETAT
   SMITH SD, 1995, J ARID ENVIRON, V29, P339, DOI 10.1016/S0140-1963(05)80113-2
   VOLLMER AT, 1976, ENVIRON MANAGE, V1, P1
   WEAVER T, 1978, J APPL ECOL, V15, P451, DOI 10.2307/2402604
   Webb R. H., 1983, Environmental effects of off-road vehicles. Impacts and management in arid regions, P51
   WEBB RH, 1980, J ARID ENVIRON, V3, P291, DOI 10.1016/S0140-1963(18)31634-3
   WEBB RH, 1982, ENVIRON CONSERV, V9, P197, DOI 10.1017/S0376892900020403
   Webb RH, 2002, ARID LAND RES MANAG, V16, P291, DOI [10.1080/153249802760284829, 10.1080/15324980290000403]
   WEBB RH, 1986, SOIL SCI SOC AM J, V50, P1341, DOI 10.2136/sssaj1986.03615995005000050051x
   Wilshire H. G., 1976, CALIFORNIA GEOLOGY, V29, P123
NR 16
TC 18
Z9 20
U1 1
U2 24
PU BRIGHAM YOUNG UNIV
PI PROVO
PA 290 LIFE SCIENCE MUSEUM, PROVO, UT 84602 USA
SN 1527-0904
EI 1944-8341
J9 WEST N AM NATURALIST
JI West. North Am. Naturalist
PD FEB
PY 2004
VL 64
IS 1
BP 125
EP 130
PG 6
WC Biodiversity Conservation; Ecology
SC Biodiversity & Conservation; Environmental Sciences & Ecology
GA 778XW
UT WOS:000189267500015
DA 2018-12-27
ER

PT J
AU Zhang, LQ
   Lopez, P
   He, T
   Yu, WJ
   Ho, DD
AF Zhang, LQ
   Lopez, P
   He, T
   Yu, WJ
   Ho, DD
TI RETRACTED: Retraction of an interpretation (Retracted Article)
SO SCIENCE
LA English
DT Correction; Retracted Publication
ID BETA-CHEMOKINES; HIV-1 REPLICATION; TYPE-1 INFECTION; ANTIVIRAL FACTOR;
   CD8(+) CELLS; T-CELLS; VIRUS; ALPHA-DEFENSIN-1; SUPPRESSION; LYMPHOCYTES
C1 Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.
RP Zhang, LQ (reprint author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.
CR CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Chang TLY, 2003, J VIROL, V77, P6777, DOI 10.1128/JVI.77.12.6777-6784.2003
   Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253
   Geiben-Lynn R, 2001, J VIROL, V75, P8306, DOI 10.1128/JVI.75.17.8306-8316.2001
   Le Borgne S, 2000, J VIROL, V74, P4456, DOI 10.1128/JVI.74.10.4456-4464.2000
   Mackewicz CE, 2003, AIDS, V17, pF23, DOI 10.1097/01.aids.0000088209.77946.21
   Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341
   Mosoian A, 2000, VIRAL IMMUNOL, V13, P481, DOI 10.1089/vim.2000.13.481
   Tomaras GD, 2000, P NATL ACAD SCI USA, V97, P3503, DOI 10.1073/pnas.070521097
   TOSO JF, 1995, J INFECT DIS, V172, P964, DOI 10.1093/infdis/172.4.964
   WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484
   Yang OO, 1997, J VIROL, V71, P3120
   Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185
NR 13
TC 26
Z9 27
U1 0
U2 39
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 23
PY 2004
VL 303
IS 5657
BP 467
EP 467
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 765XM
UT WOS:000188316400016
PM 14739439
DA 2018-12-27
ER

PT J
AU Zhao, CS
   Ishizaka, Y
AF Zhao, CS
   Ishizaka, Y
TI RETRACTED: Modeling marine stratocumulus with a detailed microphysical
   scheme (Retracted article. See vol. 21, pg. 382, 2004)
SO ADVANCES IN ATMOSPHERIC SCIENCES
LA English
DT Article; Retracted Publication
DE cloud condensation nuclei; aerosol; cloud; marine stratocumulus;
   modeling
ID PLANETARY BOUNDARY-LAYER; LARGE-EDDY SIMULATION; NUMERICAL-MODEL;
   SPECTRAL MICROPHYSICS; AIRCRAFT OBSERVATIONS; TURBULENT STRUCTURE;
   STRATIFORM CLOUDS; MIXED-LAYER; STRATUS; RADIATION
AB A one-dimensional 3rd-order turbulence closure model with size-resolved microphysics and radiative transfer has been developed for investigating aerosol and cloud interactions of the stratocumulus-topped marine boundary layer. A new method is presented for coupling between the dynamical model and the microphysical model. This scheme allows the liquid water related correlations to be directly calculated rather than parameterized. On 21 April 2001, a marine stratocumulus was observed by the Caesar aircraft over the west Pacific Rim south of Japan during the 2001 APEX/ACE-Asia field measurements. This cloud is simulated by the model we present here. The model results show that the general features of the stratocumulus-topped marine boundary layer predicted by the model are in agreement with the measurements. A new onboard cloud condensation nuclei (CCN) counter provides not only total CCN number concentration (as the traditional CCN counters do at a certain supersaturation) but also the CCN size distribution information. Using these CCN data, model responses to different CCN initial concentrations are examined. The model results are consistent with both observations and expectations. The numerical results show that the cloud microphysical properties are changed fundamentally by different initial CCN concentrations but the cloud liquid water content does not differ significantly. Different initial CCN loadings have large impacts on the evolution of cloud microstructure and radiation transfer while they have a modest effect on thermodynamics. Increased CCN concentration leads to significant decrease of cloud effective radius.
C1 Peking Univ, Sch Phys, Dept Atmospher Sci, Beijing 100871, Peoples R China.
   Nagoya Univ, HyARC, Nagoya, Aichi, Japan.
RP Zhao, CS (reprint author), Peking Univ, Sch Phys, Dept Atmospher Sci, Beijing 100871, Peoples R China.
EM zcs@pku.edu.cn
RI AAS, AAS/C-2949-2014; Zhao, Chunsheng/D-1176-2011
OI Zhao, Chunsheng/0000-0003-1951-379X
CR ACKERMAN AS, 1995, J ATMOS SCI, V52, P1204, DOI 10.1175/1520-0469(1995)052<1204:AMFPMT>2.0.CO;2
   BARKSTROM BR, 1978, J ATMOS SCI, V35, P665, DOI 10.1175/1520-0469(1978)035<0665:SEORET>2.0.CO;2
   Bechtold P, 1996, B AM METEOROL SOC, V77, P2033
   Bott A, 1996, Q J ROY METEOR SOC, V122, P635
   Bott A, 1998, ECOL MODEL, V113, P13, DOI 10.1016/S0304-3800(98)00131-8
   Bott A, 1997, Q J ROY METEOR SOC, V123, P1785, DOI 10.1002/qj.49712354219
   Bott A, 1999, ATMOS ENVIRON, V33, P1921, DOI 10.1016/S1352-2310(98)00151-4
   BOUGEAULT P, 1981, J ATMOS SCI, V38, P2429, DOI 10.1175/1520-0469(1981)038<2429:MTTWCB>2.0.CO;2
   BOUGEAULT P, 1981, J ATMOS SCI, V38, P2414, DOI 10.1175/1520-0469(1981)038<2414:MTTWCB>2.0.CO;2
   BOUGEAULT P, 1985, J ATMOS SCI, V42, P2826, DOI 10.1175/1520-0469(1985)042<2826:TDCOTM>2.0.CO;2
   Brown R, 1997, Q J ROY METEOR SOC, V123, P1783, DOI 10.1002/qj.49712354218
   BUCK AL, 1981, J APPL METEOROL, V20, P1527, DOI 10.1175/1520-0450(1981)020<1527:NEFCVP>2.0.CO;2
   CHEN C, 1987, J ATMOS SCI, V44, P2951, DOI 10.1175/1520-0469(1987)044<2951:TPOTMS>2.0.CO;2
   DING SG, 2001, THESIS PEKING U
   DUYNKERKE PG, 1988, J ATMOS SCI, V45, P2343, DOI 10.1175/1520-0469(1988)045<2343:TSOASD>2.0.CO;2
   DUYNKERKE PG, 1987, J ATMOS SCI, V44, P43, DOI 10.1175/1520-0469(1987)044<0043:AMFTTS>2.0.CO;2
   Feingold G, 1996, J ATMOS SCI, V53, P1108, DOI 10.1175/1520-0469(1996)053<1108:TRBDIC>2.0.CO;2
   Feingold G, 1998, ATMOS RES, V48, P505, DOI 10.1016/S0169-8095(98)00058-1
   HALL WD, 1980, J ATMOS SCI, V37, P2486, DOI 10.1175/1520-0469(1980)037<2486:ADMMWA>2.0.CO;2
   LILLY DK, 1968, Q J ROY METEOR SOC, V94, P292, DOI 10.1002/qj.49709440106
   Liou K.-N., 1992, RAD CLOUD PROCESSES
   LIOU KN, 1988, J ATMOS SCI, V45, P1940, DOI 10.1175/1520-0469(1988)045<1940:ASFOTD>2.0.CO;2
   MELLOR GL, 1977, J ATMOS SCI, V34, P356, DOI 10.1175/1520-0469(1977)034<0356:TGCMR>2.0.CO;2
   Moeng CH, 1996, B AM METEOROL SOC, V77, P261, DOI 10.1175/1520-0477(1996)077<0261:SOASTP>2.0.CO;2
   MOENG CH, 1986, J ATMOS SCI, V43, P2886, DOI 10.1175/1520-0469(1986)043<2886:LESOAS>2.0.CO;2
   NICHOLLS S, 1984, Q J ROY METEOR SOC, V110, P783, DOI 10.1002/qj.49711046603
   NOAA NASA and USAF, 1976, US STAND ATM
   Pruppacher H., 1997, MICROPHYSICS CLOUDS
   RANDALL DA, 1984, B AM METEOROL SOC, V65, P1290, DOI 10.1175/1520-0477(1984)065<1290:OFROSM>2.0.CO;2
   Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY
   SLINGO A, 1982, Q J ROY METEOR SOC, V108, P833, DOI 10.1256/smsqj.45806
   SOMMERIA G, 1977, J ATMOS SCI, V34, P344, DOI 10.1175/1520-0469(1977)034<0344:SSCIMO>2.0.CO;2
   Stevens B, 1998, ATMOS RES, V48, P529, DOI 10.1016/S0169-8095(98)00059-3
   Taylor JP, 1999, Q J ROY METEOR SOC, V125, P2643, DOI 10.1002/qj.49712555915
   TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3
   TWOMEY S, 1976, J ATMOS SCI, V33, P720, DOI 10.1175/1520-0469(1976)033<0720:TEOFIL>2.0.CO;2
   Twomey S., 1977, ATMOSPHERIC AEROSOLS
   TWOMEY SA, 1984, TELLUS B, V36, P356, DOI 10.1111/j.1600-0889.1984.tb00254.x
   WANG SP, 1994, J ATMOS SCI, V51, P1559, DOI 10.1175/1520-0469(1994)051<1559:RODIAO>2.0.CO;2
   ZHAO C, 1998, PROGR NATURAL SCI, V8, P440
   ZHAO CS, 1996, THESIS PEKING U
NR 41
TC 2
Z9 4
U1 3
U2 8
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 0256-1530
EI 1861-9533
J9 ADV ATMOS SCI
JI Adv. Atmos. Sci.
PD JAN
PY 2004
VL 21
IS 1
BP 61
EP 74
DI 10.1007/BF03342546
PG 14
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 767KH
UT WOS:000188438400007
DA 2018-12-27
ER

PT J
AU Correia, HR
   Balseiro, SC
   Correia, ER
   Mota, PG
   de Areia, ML
AF Correia, HR
   Balseiro, SC
   Correia, ER
   Mota, PG
   de Areia, ML
TI RETRACTED: Why are human newborns so fat? Relationship between fatness
   and brain size at birth (Retracted Article. See vol 16, pg 111, 2004)
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Article; Retracted Publication
ID BODY-MASS INDEX; HEAD SIZE; ADIPOSE-TISSUE; AGE; WEIGHT; CHILDREN;
   GROWTH; INTELLIGENCE; METABOLISM; CHILDHOOD
AB The plumpness of the human newborn has long been recognized as a trait in need of explanation among researchers. Using a linear regression analysis, we find that head circumference is significantly and positively associated with BMI at birth, after gestational age and birthlength were controlled for, in a sample of 1,069 healthy liveborn routinely delivered at the University Hospital of Coimbra (partial correlation r = 0.409, P < 0.0001). This significant association is consistent with the idea that newborn fatness is related to the higher need of lipids in newborn humans as an energetic and plastic substrate during its accelerated brain growth period. As birthweight and birth head size are associated with head size and cognitive abilities in childhood and adult life, it could be postulated that these cognitive abilities could have acted as selective pressure responsible for the newborn fatness increase in our lineage. (C) 2003 Wiley-Liss, Inc.
C1 Univ Coimbra, Dept Anthropol, P-3000056 Coimbra, Portugal.
   Univ Aveiro, Dept Biol, P-3810 Aveiro, Portugal.
RP Correia, HR (reprint author), Rua Dr Paulo Quintela 329,Lote 7,3o A, P-3030393 Coimbra, Portugal.
EM hamilton.correia@clix.pt
CR ADOLPH EF, 1971, GROWTH, V35, P55
   Aiello LC, 2002, AM J HUM BIOL, V14, P551, DOI 10.1002/ajhb.10069
   AIELLO LC, 1998, SCI ARCHAEOLOGY AGEN, P25
   ARMSTRONG E, 1983, SCIENCE, V220, P1302, DOI 10.1126/science.6407108
   BILLEWICZ WZ, 1962, BRIT J PREV SOC MED, V16, P183
   Bogin B, 1997, YEARB PHYS ANTHROPOL, V40, P63
   Bouchard C., 1994, GENETICS OBESITY, P1
   COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9
   CUZNER ML, 1968, BIOCHEM J, V106, P29, DOI 10.1042/bj1060029
   DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410
   Dufour DL, 2002, AM J HUM BIOL, V14, P584, DOI 10.1002/ajhb.10071
   Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2
   EPSTEIN HT, 1978, AM J PHYS ANTHROPOL, V48, P471, DOI 10.1002/ajpa.1330480405
   Eveleth P., 1976, WORLDWIDE VARIATION
   FLINT MM, 1977, HUM BIOL, V49, P559
   FOLEY RA, 1991, PHILOS T ROY SOC B, V334, P223, DOI 10.1098/rstb.1991.0111
   FORBES GB, 1987, HUMAN BODY COMPOSITI
   FROST GT, 1987, HUM EVOL, V2, P193
   GARN SM, 1975, PEDIATRICS, V56, P306
   GIRARD J, 1992, PHYSIOL REV, V72, P507
   HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403
   HADDERSALGRA M, 1988, EUR J PEDIATR, V147, P460, DOI 10.1007/BF00441967
   Hardy A., 1960, NEW SCI, P642
   He Q, 2000, ACTA PAEDIATR, V89, P582, DOI 10.1080/080352500750027907
   JELLIFFE DB, 1969, J PEDIATR, V75, P334, DOI 10.1016/S0022-3476(69)80409-9
   Jensen A. R., 1993, BIOL APPROACHES STUD, P139
   JOHNSTON FE, 1985, J HUM EVOL, V14, P341, DOI 10.1016/S0047-2484(85)80040-3
   KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S
   Kuzawa CW, 1998, YEARB PHYS ANTHROPOL, V41, P177
   LEONARD WR, 1994, AM J HUM BIOL, V6, P77, DOI 10.1002/ajhb.1310060111
   LEWIS DS, 1983, J NUTR, V113, P2253
   LLOYD RD, 1987, HUM BIOL, V59, P7
   Loesch DZ, 1999, AM J HUM BIOL, V11, P772, DOI 10.1002/(SICI)1520-6300(199911/12)11:6<772::AID-AJHB7>3.3.CO;2-8
   LYNCH G, 1983, J HUM EVOL, V12, P519, DOI 10.1016/S0047-2484(83)80031-1
   LYNN R, 1990, BEHAV GENET, V20, P545, DOI 10.1007/BF01067719
   MacDonald K, 1997, HUM NATURE-INT BIOS, V8, P327, DOI 10.1007/BF02913038
   MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0
   Martyn CN, 1996, BRIT MED J, V312, P1393
   Matte TD, 2001, BRIT MED J, V323, P310, DOI 10.1136/bmj.323.7308.310
   McFarland Robin, 1997, P163
   MICOZZI MS, 1986, AM J CLIN NUTR, V44, P725
   MILLER EM, 1994, PERS INDIV DIFFER, V17, P803, DOI 10.1016/0191-8869(94)90049-3
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9
   NELSON KB, 1970, DEV MED CHILD NEUROL, V12, P487
   Norgan NG, 1997, INT J OBESITY, V21, P738, DOI 10.1038/sj.ijo.0800473
   OFTEDAL OT, 1989, BIOL NEONATE, V56, P283
   PALTI H, 1975, HUM BIOL, V47, P523
   Pawlowski Buguslaw, 1998, Human Evolution, V13, P65, DOI 10.1007/BF02439370
   POND C, 1997, EVOLVING FEMALE LIFE, P147
   POSKITT EME, 1995, ACTA PAEDIATR, V84, P961, DOI 10.1111/j.1651-2227.1995.tb13806.x
   Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763
   ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178
   Schroeder DG, 1999, AM J CLIN NUTR, V70, p137S, DOI 10.1093/ajcn/70.1.137s
   Schultz A. H., 1969, THE LIFE OF PRIMATES
   SMART JL, 1977, GENETICS ENV INTELLI, P215
   Smith S, 1975, Adv Lipid Res, V13, P195
   Tramo MJ, 1998, NEUROLOGY, V50, P1246, DOI 10.1212/WNL.50.5.1246
   VOIGT J, 1983, ACTA ANAT, V116, P290
   WATTS ES, 1990, MG PRIMATOL, V14, P89
   Wells JCK, 2002, J THEOR BIOL, V214, P413, DOI 10.1006/jtbi.2001.2465
   WINICK M, 1966, J NUTR, V89, P300
   Winick M., 1972, Lipids, malnutrition and the developing brain. A Ciba Foundation Symposium jointly with the Nestle Foundation in memory of Sir Norman Wright., P199
NR 63
TC 7
Z9 7
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD JAN-FEB
PY 2004
VL 16
IS 1
BP 24
EP 30
DI 10.1002/ajhb.10233
PG 7
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 758WU
UT WOS:000187675200003
PM 14689513
DA 2018-12-27
ER

PT J
AU Nakao, N
   Seno, H
   Kasuga, H
   Toriyama, T
   Kawahara, H
   Fukagawa, M
AF Nakao, N
   Seno, H
   Kasuga, H
   Toriyama, T
   Kawahara, H
   Fukagawa, M
TI RETRACTED: Effects of combination treatment with losartan and
   trandolapril on office and ambulatory blood pressures in non-diabetic
   renal disease: A COOPERATE-ABP substudy (Retracted article. See vol. 30,
   pg. 563, 2009)
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article; Retracted Publication
DE blood pressure monitoring, ambulatory; chronic renal failure;
   combination treatment, clinical trials; combination treatment, losartan
   and trandolapril; losartan; office blood pressure; renin-angiotensin
   system blockade; trandolapril
ID RENIN-ANGIOTENSIN SYSTEM; II RECEPTOR BLOCKADE; DIABETIC-NEPHROPATHY;
   DUAL BLOCKADE; ACE-INHIBITION; TRIAL
AB Background: In the COOPERATE trial, the combination treatment of the angiotensin-II receptor blocker losartan and the angiotensin-converting-enzyme inhibitor trandolapril significantly retarded progression of non-diabetic kidney disease compared with each monotherapy. The benefit could be greatly attributable to the potent reduction of proteinuria, because the three treatment groups showed the same reductions of office blood pressure (OBP). Ambulatory blood pressure (ABP) is reported to be better than OBP in predicting progression of kidney disease. Methods: Ninety-two patients enrolled in the COOPERATE trial underwent 24-hour ABP monitoring at randomization and at month 6, year 1, year 2 and year 3 on randomized treatment. Results: Both OBP and ABP were similarly reduced among the three groups at all measurement points ( p = NS) and throughout the whole study period ( p = NS). No significant correlation between the change in 24-hour ABP and the change in proteinuria was seen ( p = NS). A Cox-multivariable analysis showed that covariates affecting the renal outcomes ( a doubling serum-Cr level and/or end-stage renal failure) were the change in proteinuria ( hazard ratio 0.49, 95% CI 0.34-0.78, p = 0.01) and treatments (0.58, 0.45 - 0.99, 0.03), but not 24-hour ABP (0.98, 0.89 - 2.01, 0.17). Conclusion: The better renoprotective effect of the combination treatment is attributed to BP-independent mechanisms by more complete renin-angiotensin system blockade. Copyright (C) 2004 S. Karger AG, Basel.
C1 Nagaya Kyoritsu Hosp, Div Nephrol, Kaikou Kai Cent Clin, Nakagawa Ku, Nagoya, Aichi 4540932, Japan.
   Kobe Univ, Sch Med, Div Nephrol, Kobe, Hyogo 650, Japan.
   Kobe Univ, Sch Med, Dialysis Ctr, Kobe, Hyogo 650, Japan.
RP Nakao, N (reprint author), Nagaya Kyoritsu Hosp, Div Nephrol, Kaikou Kai Cent Clin, Nakagawa Ku, Nakajima Shinmachi 3-2518, Nagoya, Aichi 4540932, Japan.
EM lancetjp@paw.hi-ho.ne.jp
CR Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   Covic A, 1999, J NEPHROL, V12, P220
   Covic A, 2002, NEPHROL DIAL TRANSPL, V17, P1737, DOI 10.1093/ndt/17.10.1737
   Ferrari P, 2002, J HYPERTENS, V20, P125, DOI 10.1097/00004872-200201000-00018
   Hansen HP, 1996, KIDNEY INT, V50, P579, DOI 10.1038/ki.1996.352
   Jacobsen P, 2003, J AM SOC NEPHROL, V14, P992, DOI 10.1097/01.ASN.000054495.96193.BF
   Jacobsen P, 2002, NEPHROL DIAL TRANSPL, V17, P1019, DOI 10.1093/ndt/17.6.1019
   Nakao N, 2003, LANCET, V361, P117, DOI 10.1016/S0140-6736(03)12229-5
   Rossing K, 2002, DIABETES CARE, V25, P95, DOI 10.2337/diacare.25.1.95
   Ruggenenti P, 1997, LANCET, V349, P1857
   Rutkowski P, 2004, AM J KIDNEY DIS, V43, P260, DOI 10.1053/j.ajkd.2003.10.032
   Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421
NR 12
TC 28
Z9 31
U1 3
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2004
VL 24
IS 5
BP 543
EP 548
DI 10.1159/000081953
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 873DL
UT WOS:000225259500011
PM 15528874
DA 2018-12-27
ER

PT J
AU O'Malley, CMN
   Frumento, RJ
   Mets, B
   Naka, Y
   Bennett-Guerrero, E
AF O'Malley, CMN
   Frumento, RJ
   Mets, B
   Naka, Y
   Bennett-Guerrero, E
TI RETRACTED: Endotoxaemia during left ventricular assist device insertion:
   relationship between risk factors and outcome (Retracted article. See
   vol. 119, pg.554, 2017)
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article; Retracted Publication
DE complications, endotoxaemia; heart, left ventricular assist device;
   measurement techniques, gastrictonometry; surgery, cardiac
ID SURGERY
AB Background. Endotoxaemia, caused by splanchnic ischaemia during surgery, is believed to trigger systemic inflammation and cause postoperative organ dysfunction. A relationship between the plasma concentration of endotoxin during surgery and known risk factors for postoperative morbidity and mortality (e.g. age, abnormal gastric tonometric variables) and adverse outcome after surgery has not been demonstrated.
   Methods. In a prospective study, the plasma concentration of endotoxin was measured in 12 patients undergoing implantation of a left ventricular assist device. Automated air gastric tonometry was performed in all patients. The relationship between plasma endotoxin concentration, risk factors, and postoperative outcome was explored.
   Results. Carbon dioxide gap increased from 0.7 (0.3) to 3.6 (1.6) kPa at the end of surgery. Endotoxin was detected in one of 12 patients at baseline and in nine of 12 patients at the end of surgery (P=0.003). A high plasma concentration of endotoxin at the end of surgery was associated with a higher carbon dioxide gap (r=0.59, P<0.05), and a higher postoperative multiple organ dysfunction score (r=0.7, P=0.01).
   Conclusions. The finding of an association between high intraoperative plasma concentrations of endotoxin, abnormal gastric tonometric variables and adverse outcome supports the view that endotoxaemia is caused by gut hypoperfusion during surgery and is associated with postoperative organ dysfunction.
C1 Columbia Univ Coll Phys & Surg, Dept Anaesthesia, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA.
RP O'Malley, CMN (reprint author), Columbia Univ Coll Phys & Surg, Dept Anaesthesia, 630 W 168th St, New York, NY 10032 USA.
EM cathomalley@hotmail.com
CR [Anonymous], 1998, CARDIAC ANESTHESIA, P297
   Bennett-Guerrero E, 2000, ANESTHESIOLOGY, V92, P38, DOI 10.1097/00000542-200001000-00012
   Chapman M V, 2000, Intensive Care Med, V26, P613, DOI 10.1007/s001340051212
   MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007
   Mets B, 2002, J CARDIOTHOR VASC AN, V16, P727, DOI 10.1053/jcan.2002.128411
   Mets B, 2000, J CARDIOTHOR VASC AN, V14, P316
   Oz MC, 1997, CIRCULATION, V95, P1844
   Theodoropoulos G, 2001, AM SURGEON, V67, P303
   Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338
NR 9
TC 5
Z9 5
U1 2
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JAN
PY 2004
VL 92
IS 1
BP 131
EP 133
DI 10.1093/bja/aeh010
PG 3
WC Anesthesiology
SC Anesthesiology
GA 753ED
UT WOS:000187218400022
PM 14665564
DA 2018-12-27
ER

PT J
AU Doldi, SB
   Micheletto, G
   Perrini, MN
   Rapetti, R
AF Doldi, SB
   Micheletto, G
   Perrini, MN
   Rapetti, R
TI RETRACTED: Intragastric balloon: Another option for treatment of obesity
   and morbid obesity (Retracted article. See vol. 59, pg. 2683, 2012)
SO HEPATO-GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
DE intragastric balloon; obesity; morbid obesity
ID GASTRIC-BALLOON; SURGERY; EXPERIENCE
AB Background/Aims: The BioEnterics Intragrastric Balloon (BIB(R), BioEnterics, Santa Barbara, CA) in association with restricted diet has been used for the treatment of obesity and morbid obesity.
   Methodology: Since March 1998, 349 BIBO were placed in 303 obese and morbidly obese patients; 95 patients were male and 208 female; mean age was 41.5 years (19-70); mean weight was 118.8Kg (67-229); mean BMI was 42Kg/m(2), % excess weight was 62.3% (4.6-216.3). The balloon was inserted and removed endoscopically under general anesthesia. Patients were given a balanced diet of 1000Kcal/day. Results: After 4 months of balloon treatment, the mean weight loss was 13.9Kg and the mean reduction in BMI was 4.8Kg/m(2). Weight loss was greater in male patients. Weight loss was accompanied by an improvement of the diseases associated with obesity, in particular diabetes.
   Conclusions: The best indications for BIB were: morbidly obese (BMI >40) and super-obese patients (BMI >50) in preparation for bariatric operations; obese patients with BMI 35-40 with co-morbidity in preparation for bariatric surgery; obese patients with BMI 30-35 with a chronic disease otherwise unresolved; patients with BMI <30 only in a multidisciplinary approach.
C1 Ist Clin St Ambrogio, Unita Operat Chirurg Gen, I-20149 Milan, Italy.
   Univ Milan, Ctr Farmacoterapia Malattie Nutriz & Metab E Geno, Div Chirurg Gen, Dipartimento Sci Chirurg, I-20122 Milan, Italy.
RP Doldi, SB (reprint author), Ist Clin St Ambrogio, Unita Operat Chirurg Gen, Via Faravelli 16, I-20149 Milan, Italy.
EM santo.bressani@unimi.it
CR De Waele B, 2001, OBES SURG, V11, P223, DOI 10.1381/096089201321577938
   Doldi SB, 1998, ANN CHIR, V52, P125
   Doldi SB, 2000, OBES SURG, V10, P578, DOI 10.1381/096089200321594200
   Galloro G, 1999, OBES SURG, V9, P68, DOI 10.1381/096089299765553827
   Kuhlmann HW, 2000, OBES SURG, V10, P549, DOI 10.1381/096089200321594156
   Loffredo A, 2001, OBES SURG, V11, P330, DOI 10.1381/096089201321336700
   MCFARLAND RJ, 1987, BRIT J SURG, V74, P137, DOI 10.1002/bjs.1800740222
   PASULKA PS, 1986, ANN INTERN MED, V104, P540, DOI 10.7326/0003-4819-104-4-540
   SCHAPIRO M, 1987, GASTROINTEST ENDOSC, V33, P323, DOI 10.1016/S0016-5107(87)71611-3
   SIARDI C, 1990, GIORN ITAL END DIG, V13, P105
   Totte E, 2001, OBES SURG, V11, P519
   Wahlen CH, 2001, OBES SURG, V11, P524, DOI 10.1381/096089201321209468
   Weiner R, 1999, OBES SURG, V9, P261, DOI 10.1381/096089299765553133
NR 13
TC 47
Z9 50
U1 0
U2 9
PU H G E UPDATE MEDICAL PUBLISHING S A
PI ATHENS
PA PO BOX 17257, ATHENS GR-10024, GREECE
SN 0172-6390
J9 HEPATO-GASTROENTEROL
JI Hepato-Gastroenterol.
PD JAN-FEB
PY 2004
VL 51
IS 55
BP 294
EP 297
PG 4
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 779XN
UT WOS:000189327600073
PM 15025034
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Somekawa, Y
AF Fujii, Y
   Tanaka, H
   Somekawa, Y
TI RETRACTED: A randomized, double-blind, placebo-controlled trial of
   ramosetron for preventing nausea and vomiting during termination of
   pregnancy (Retracted article. See vol. 22, pg. 86, 2013)
SO INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
LA English
DT Article; Retracted Publication
ID NITROUS-OXIDE; GRANISETRON; THYROIDECTOMY; DROPERIDOL; CHILDREN;
   SURGERY; EMESIS
AB Women undergoing general anesthesia for dilatation and curettage have a high risk for postoperative nausea and vomiting. We therefore evaluated the efficacy and safety of ramosetron, a new compound having serotonin receptor antagonist activity, for preventing nausea and vomiting in termination of pregnancy. Eighty women scheduled for dilatation and curettage received, in a randomized, double-blind manner, an intravenous placebo or ramosetron at three different doses (0.15 mg, 0.3 mg, 0.6 mg) at the end of surgery (n = 20 per group). Emetic episodes and safety were assessed. The percentage of patients who were emesis-free (no nausea, no retching, no vomiting) during 0-24 h after anesthesia was 55% with ramosetron 0.15 mg (P = 0.5), 85% with ramosetron 0.3 mg (P = 0.02), and 90% with ramosetron 0.6 mg (P = 0.007), compared with 50% in the placebo group. No clinically serious adverse events due to the study drugs were observed in any group. Our results suggest that ramosetron 0.3 mg is an effective antiemetic for prophylaxis against emetic symptoms after dilatation and curettage. Increasing the dose to 0.6 mg provides no further benefit. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Obstet & Gynecol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Dept Anesthesiol, Inst Clin Med, 2-1-1,Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR Fisher DM, 1996, ANESTH ANALG, V83, P4, DOI 10.1097/00000539-199607000-00002
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 2002, EUR J SURG, V168, P583, DOI 10.1080/11024150201680002
   Fujii Y, 2002, CLIN THER, V24, P1148, DOI 10.1016/S0149-2918(02)80025-X
   Fujii Y, 2002, CLIN THER, V24, P766, DOI 10.1016/S0149-2918(02)85150-5
   Fujii Y, 2001, BRIT J OPHTHALMOL, V85, P670, DOI 10.1136/bjo.85.6.670
   Fujii Y, 2001, LARYNGOSCOPE, V111, P255, DOI 10.1097/00005537-200102000-00013
   Hartung J, 1996, ANESTH ANALG, V83, P114, DOI 10.1097/00000539-199607000-00020
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   LEESER J, 1991, ANESTH ANALG, V72, P751
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   McCormick C., 2002, ASA NEWSL, V66, P19
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   Tramer M, 1996, BRIT J ANAESTH, V76, P186
   Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 17
TC 12
Z9 12
U1 3
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-289X
EI 1532-3374
J9 INT J OBSTET ANESTH
JI Int. J. Obstet. Anesth.
PD JAN
PY 2004
VL 13
IS 1
BP 15
EP 18
DI 10.1016/S0959-289X(03)00101-8
PG 4
WC Anesthesiology; Obstetrics & Gynecology
SC Anesthesiology; Obstetrics & Gynecology
GA 764WG
UT WOS:000188228500004
PM 15321434
DA 2018-12-27
ER

PT J
AU Jia, YL
   Guo, ZY
AF Jia, YL
   Guo, ZY
TI RETRACTED: Effect of low-power He-Ne laser irradiation on rabbit
   articular chondrocytes in vitro (Retracted Article. See vol 37, pg 330,
   2005)
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article; Retracted Publication
DE low-power laser (LPL); articular chondrocyte; biostimulation; XTT
   colorimetric method; metachromasia; immunocytochemistry
ID CENTRAL-NERVOUS-SYSTEM; THERAPY; RATS
AB Background and Objectives: In the orthopaedic field, the repair of articular cartilage is still a difficult problem, because of the physiological characters of cartilaginous tissues and chondrocytes. To find an effective method of stimulating their regeneration, this in vitro study focuses on the biostimulation of rabbit articular chondrocytes by low-power He-Ne laser.
   Study Design/Materials and Methods: The articular chondrocytes isolated from the cartilage of the medial condyle of the femur of the rabbit were incubated in DMEM/ HamF(12) medium. The second passage culture were spread on 24 petri dishes and were irradiated with laser at power output of 2-12 mW for 6.5 minutes, corresponding to the energy density of 1-6 J/cm(2). Laser treatment was performed three times at a 24-hour interval. After lasering, incubation was continued for 24 hours. Non-irradiated cells were kept under the same conditions as the irradiated ones. The cell proliferation activity was evaluated with a XTT colorimetric method and the cell secretion activity was analyzed by metachromasia and immunocytochemistry.
   Results: Irradiation of 4-6 J/cm(2) increased the cell numbers and revealed a considerably higher cell proliferation activity comparing to control cultures. Thereinto, the energy density of 4 and 5 J/cm(2) remarkably increased cell growth, with positive effect on synthesis and secretion of extracellular matrix.
   Conclusions: The present study showed that a particular laser irradiation stimulates articular chondrocytes proliferation and secretion. These findings might be clinically relevant, indicating that low-power laser irradiation treatment is likely to achieve the repair of articular cartilage in clinic. (C) 2004 Wiley-Liss, Inc.
C1 S China Normal Univ, Inst Laser Life Sci, Guangzhou 510631, GD, Peoples R China.
RP Guo, ZY (reprint author), S China Normal Univ, Inst Laser Life Sci, Guangzhou 510631, GD, Peoples R China.
EM ann@scnu.edu.cn
CR ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7
   BOBIC V, 1998, 1 ANN C TISS REP REP
   DEWITH A, 1995, J PHOTOCH PHOTOBIO B, V30, P71, DOI 10.1016/1011-1344(95)07151-Q
   HALL G, 1994, SWED DENT J, V18, P29
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096-9101(1998)22:2<97::AID-LSM5>3.3.CO;2-E
   Matic Milan, 2003, Med Pregl, V56, P137
   Medrado ARAP, 2003, LASER SURG MED, V32, P239, DOI 10.1002/lsm.10126
   MESTER A, 1992, P 3 WORLD C INT SOC, P33
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   Morrone G, 1998, LASER MED SCI, V13, P293, DOI 10.1007/s101030050011
   Nara Y, 1991, SURG MED LASERS, V4, P17
   ROCHKIND S, 1989, LASER SURG MED, V9, P174, DOI 10.1002/lsm.1900090214
   ROCHKIND S, 1992, Neurological Research, V14, P2
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889-5406(97)70152-5
   Schindl M, 1999, PHOTODERMATOL PHOTO, V15, P18, DOI 10.1111/j.1600-0781.1999.tb00047.x
   Shen Y, 2002, PROG BIOCHEM BIOPHYS, V29, P659
   Steinlechner Colin W. B., 1993, Laser Therapy, V5, P65
   Tullberg M, 2003, PAIN, V105, P89, DOI 10.1016/S0304-3959(03)00166-0
   VACCA RA, 1994, BIOCHEM BIOPH RES CO, V203, P991, DOI 10.1006/bbrc.1994.2280
   Walsh LJ, 1997, AUST DENT J, V42, P247, DOI 10.1111/j.1834-7819.1997.tb00129.x
   WILLIAM T, 1971, CLIN ORTHOP RELAT R, V75, P248
   WOLFF DA, 1992, J ORTHOPAED RES, V10, P49, DOI 10.1002/jor.1100100106
NR 23
TC 32
Z9 35
U1 5
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 2004
VL 34
IS 4
BP 323
EP 328
DI 10.1002/lsm.20017
PG 6
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 813MF
UT WOS:000220910500006
PM 15083493
DA 2018-12-27
ER

PT J
AU Schroeder, C
AF Schroeder, C
TI RETRACTED: First person account: My dream life, a normal life (Retracted
   article. See vol. 35, pg. 658, 2009)
SO SCHIZOPHRENIA BULLETIN
LA English
DT Editorial Material; Retracted Publication
RP Schroeder, C (reprint author), 11024 Calloway View Dr, Knoxville, TN 37922 USA.
NR 0
TC 1
Z9 1
U1 3
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PY 2004
VL 30
IS 4
BP 1063
EP 1065
DI 10.1093/schbul/30-4-1063
PG 3
WC Psychiatry
SC Psychiatry
GA 910FN
UT WOS:000227916000034
PM 15954208
OA Bronze
DA 2018-12-27
ER

PT J
AU Kim, SJ
   Park, JH
   Lee, JE
   Kim, JM
   Lee, JB
   Moon, SY
   Il Roh, S
   Kim, CG
   Yoon, HS
AF Kim, SJ
   Park, JH
   Lee, JE
   Kim, JM
   Lee, JB
   Moon, SY
   Il Roh, S
   Kim, CG
   Yoon, HS
TI RETRACTED: Effects of type IV collagen and laminin on the
   cryopreservation of human embryonic stem cells (Retracted Article. See
   vol 24, pg 804, 2006)
SO STEM CELLS
LA English
DT Article; Retracted Publication
ID SULFATE PROTEOGLYCAN; HUMAN BLASTOCYSTS; GROWTH; DIFFERENTIATION;
   SURVIVAL; INTEGRIN; SUPPORT; CULTURE; LINE; BODY
AB Previous reports have indicated that extracellular matrices (ECMs) affect the developmental fate of human embryonic stem cells (hESCs). Specially, type IV collagen and laminin, which belong to a group of macromolecular proteins with a substantial proportion of ECMs, are known to influence the proliferation and differentiation of hES cells. In this study, we evaluated the effects of type IV collagen and laminin in freezing medium on the survival and differentiation rates of hES cells after slow freezing and rapid thawing. The addition of type IV collagen (1 mug/ml) to the freezing medium significantly increased the survival rate of hES cells after thawing compared with that of a control group. The spontaneous differentiation rates of groups treated with type IV collagen (1 mug/ml) or laminin (1 mug/ml) were significantly lower than those of the control group. Frozen-thawed hES cells have currently been cultured for more than 70 passages and retain key properties of hES cells such as morphological characteristics, normal karyotype, marker expression (alkaline phosphatase, SSEA-1, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, Rex-1, and Oct-4), basement membrane-related gene expression, and the potential to differentiate into derivatives of all three germ layers. This new slow freezing method by ECM treatment is a reliable and effective cryopreservation method for pluripotent hES cells.
C1 MizMedi Hosp, Med Res Ctr, Div Stem Cell Biol, Kangseo Ku, Seoul 157280, South Korea.
   Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul, South Korea.
   Stem Cell Res Ctr, Seoul, South Korea.
RP Yoon, HS (reprint author), MizMedi Hosp, Med Res Ctr, Div Stem Cell Biol, Kangseo Ku, 701-4 Naebalsan Dong, Seoul 157280, South Korea.
EM yoon@mizmedi.net
CR ANDREWS PW, 1987, TERATOCARCINOMAS EMB, P207
   BONGSO A, 1994, HUM REPROD, V9, P2110, DOI 10.1093/oxfordjournals.humrep.a138401
   Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8
   Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431
   Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726
   COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843
   COOPER S, 1992, BIOCHEM J, V286, P959, DOI 10.1042/bj2860959
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331
   Frederickx V, 2004, HUM REPROD, V19, P948, DOI 10.1093/humrep/deh154
   FRESHNEY RI, 1994, MANUAL BASIC TECHNIQ, P255
   Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061
   Hawkins AE, 1996, J VIROL METHODS, V60, P81, DOI 10.1016/0166-0934(96)02048-4
   JAROSLAW C, 2001, DIFFERENTIATION, V68, P167
   KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025
   Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073
   Li XF, 2001, J CELL BIOL, V153, P811, DOI 10.1083/jcb.153.4.811
   Lim JWE, 2002, PROTEOMICS, V2, P1187, DOI 10.1002/1615-9861(200209)2:9<1187::AID-PROT1187>3.0.CO;2-T
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Park JH, 2003, BIOL REPROD, V69, P2007, DOI 10.1095/biolreprod.103.017467
   Reubinoff BE, 2001, HUM REPROD, V16, P2187, DOI 10.1093/humrep/16.10.2187
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726
   Srebrow A, 1998, J CELL BIOCHEM, V69, P377, DOI 10.1002/(SICI)1097-4644(19980615)69:4<377::AID-JCB1>3.0.CO;2-K
   TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Woods EJ, 2003, J HEMATOTH STEM CELL, V12, P341, DOI 10.1089/152581603322023070
   XLAOFENG L, 2001, P NATL ACAD SCI USA, V98, P14416
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   ZHU XY, 1995, MOL BIOL CELL, V6, P273
NR 31
TC 20
Z9 23
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PY 2004
VL 22
IS 6
BP 950
EP 961
DI 10.1634/stemcells.22-6-950
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 870XX
UT WOS:000225093300009
PM 15536186
OA Bronze
DA 2018-12-27
ER

PT J
AU Wansink, B
   Westgren, R
AF Wansink, B
   Westgren, R
TI RETRACTED: Profiling taste-motivated segments (Retracted article. See
   vol. 125, pg. 566, 2018)
SO APPETITE
LA English
DT Article; Retracted Publication
DE soy taste profiles; taste-motivated; segmentation; soy consumption;
   yogurt; wine; fruits and vegetables; soy foods
AB Early adopters of unfamiliar, but nutritious foods can do so because of a combination of taste-motivations and health-motivations. Yet because taste can provide an enduring motivation for dietary change, profiling the taste-motivated segment of a particular food might prove useful in identifying and stimulating adoption among similar predisposed segments. This manuscript describes a basic qualitative and quantitative procedure-in the context of soy consumption-that can be used to begin profiling taste-motivated segments of a particular food. A survey of 606 North Americans indicates that when contrasted to health-motivated consumers of soy, taste-motivated consumers were more likely to claim they are opinion-leaders who live with (or who are) great cooks, and they were more likely to exhibit other behaviors associated with food appreciation, such as dining out and wine consumption. In light of these findings, instead of encouraging people to eat soy solely for health reasons, a more productive method may be to target those who are more likely to prefer it for taste-motivated reasons. This same method has potential for more effectively promoting the consumption of fruits and vegetables or the consumption of genetically enhanced foods among predisposed taste-motivated segments. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Illinois, Champaign, IL 61801 USA.
RP Wansink, B (reprint author), Univ Illinois, 350 Wohlers Hall, Champaign, IL 61801 USA.
EM wansink@uiuc.edu
RI Wansink, Brian/G-4284-2010
CR Barnes S, 1998, P SOC EXP BIOL MED, V217, P386
   Christensen L, 2001, APPETITE, V36, P137, DOI 10.1006/appe.2001.0390
   Coletta F. A., 1999, Nutrition Today, V34, P166, DOI 10.1097/00017285-199907000-00008
   DECKER KJ, 2001, FOOD PRODUCT DES APR
   GLADSTON I, 1941, J AM DIET ASSOC, V25, P745
   KEPNER KW, 1978, YOGURT FROZEN YOGURT
   SHORK D, 2000, MARKETING MACLEAN HU, V105, P14
   Sudman Seymour, 2002, CONSUMER PANELS
   SWEENY M., 1942, Journal of Home Economics, V34, P457
   Wansink B, 2002, J SENS STUD, V17, P483, DOI 10.1111/j.1745-459X.2002.tb00360.x
   Wansink B., 2002, Pakistan Journal of Nutrition, V1, P276
   Wansink B, 2003, FOOD QUAL PREFER, V14, P289, DOI 10.1016/S0950-3293(02)00088-5
   Wansink B, 2002, J PUBLIC POLICY MARK, V21, P90, DOI 10.1509/jppm.21.1.90.17614
   WANSINK B, 2000, MARK RES         SUM, P28
   WANSINK B, 2003, IN PRESS J FOOD SCI, V75, P3
   WANSINK B, 2004, MARKETING NUTR SOY F
   WANSINK B, 2001, J MED FOOD, V4, P147
NR 17
TC 8
Z9 8
U1 1
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0195-6663
EI 1095-8304
J9 APPETITE
JI Appetite
PD DEC
PY 2003
VL 41
IS 3
BP 323
EP 327
DI 10.1016/S0195-6663(03)00120-X
PG 5
WC Behavioral Sciences; Nutrition & Dietetics
SC Behavioral Sciences; Nutrition & Dietetics
GA 753LN
UT WOS:000187233000012
PM 14637331
DA 2018-12-27
ER

PT J
AU Hoeldtke, RD
AF Hoeldtke, RD
TI RETRACTED: Nitrosative stress in early type 1 diabetes David H. P
   Streeten Memorial Lecture (Retracted Article. See vol 17, pg 197, 2007)
SO CLINICAL AUTONOMIC RESEARCH
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th International Symposium of the American-Autonomic-Society
CY OCT 27, 2002
CL Hilton Head Isl, SC
SP Amer Auton Soc
DE nitrosative stress; sudomotor function; diabetes
ID NITRIC-OXIDE SYNTHASE; PANCREATIC BETA-CELLS; PERIPHERAL-NERVE FUNCTION;
   OXIDATIVE STRESS; URIC-ACID; GLUCOSE TOXICITY; IN-VIVO; ACUTE
   HYPERGLYCEMIA; LIPID-PEROXIDATION; SMOOTH-MUSCLE
AB Although hyperglycemia has been shown to cause peripheral nerve dysfunction in patients with diabetes, the biochemical mechanisms for this effect are poorly understood. The excessive production of reactive oxygen species and reactive nitrogen species has been proven to be detrimental in experimental diabetes, but there is little evidence that these metabolic events take place clinically and are physiologically important in man. To assess this we measured nitrite and nitrate (indices of nitric oxide production), nitrotyrosine (an index of peroxynitrite), 8-isoprostaglandin F-2 alpha, an isoprostane reflective of oxidative stress and lipid peroxidation, and uric acid, an index of antioxidant defense in patients with recently diagnosed Type 1 diabetes and aged-matched controls. The diabetic patients were followed for three years. We documented the overproduction of nitric oxide and increased lipid peroxidation in early diabetes and showed these changes had detectable adverse effects on peripheral nerve function especially sympathetic sudomotor nerves. We documented the suppression of uric acid and showed this was associated with multiple abnormalities in autonomic function. In addition, we present indirect evidence that overproduction of reactive oxygen species and reactive nitrogen species have adverse effects on beta cell function and blood pressure.
C1 W Virginia Univ, Dept Med, Sch Med, Morgantown, WV 26506 USA.
RP Hoeldtke, RD (reprint author), W Virginia Univ, Dept Med, Sch Med, POB 9159, Morgantown, WV 26506 USA.
EM rhoeldtke@hsc.wvu.edu
CR AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045
   AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858
   Bagi Z, 2002, ARTERIOSCL THROM VAS, V22, P28, DOI 10.1161/hq0102.101127
   BANK N, 1993, KIDNEY INT, V43, P1306, DOI 10.1038/ki.1993.183
   Banks BA, 1998, PEDIATRICS, V101, P870, DOI 10.1542/peds.101.5.870
   Bardell AL, 2001, J PHARMACOL EXP THER, V296, P252
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Benkusky NA, 1999, EUR J PHARMACOL, V364, P151, DOI 10.1016/S0014-2999(98)00791-2
   Bojunga J, 2001, DIABETES, V50, pA148
   Bottino R, 2002, DIABETES, V51, P2561, DOI 10.2337/diabetes.51.8.2561
   Chaudhuri Ajay, 2002, Curr Diab Rep, V2, P305, DOI 10.1007/s11892-002-0018-1
   Chiarelli F, 2000, DIABETES, V49, P1258, DOI 10.2337/diabetes.49.7.1258
   Coppey LJ, 2001, DIABETES, V50, P1927, DOI 10.2337/diabetes.50.8.1927
   COWIE CC, 2001, DIABETES CONTROL COM
   Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6
   Davi G, 1999, CIRCULATION, V99, P224
   DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601
   Diabet Control Complications Trial Res Grp, 1998, ANN INTERN MED, V128, P517, DOI 10.7326/0003-4819-128-7-199804010-00001
   Eizirik DL, 1996, DIABETOLOGIA, V39, P875
   EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491
   Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JC1200317863
   Flodstrom M, 1999, DIABETES, V48, P706, DOI 10.2337/diabetes.48.4.706
   Garcia SB, 1999, EXP PARASITOL, V93, P191, DOI 10.1006/expr.1999.4451
   Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239
   Hensley K, 1998, J NEUROSCI, V18, P8126
   HOELDTKE RD, 1984, J CLIN ENDOCR METAB, V59, P246, DOI 10.1210/jcem-59-2-246
   Hoeldtke RD, 2003, AM J HYPERTENS, V16, P761, DOI 10.1016/S0895-7061(03)00976-2
   Hoeldtke RD, 2003, J CLIN ENDOCR METAB, V88, P1624, DOI 10.1210/jc.2002-021525
   Hoeldtke RD, 2000, J CLIN ENDOCR METAB, V85, P585, DOI 10.1210/jc.85.2.585
   Hoeldtke RD, 2002, DIABETES, V51, P2817, DOI 10.2337/diabetes.51.9.2817
   Hoeldtke RD, 2001, DIABETES, V50, P436, DOI 10.2337/diabetes.50.2.436
   Hoeldtke RD, 2000, J CLIN ENDOCR METAB, V85, P3297, DOI 10.1210/jc.85.9.3297
   Ihara Y, 2000, FEBS LETT, V473, P24, DOI 10.1016/S0014-5793(00)01489-7
   Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927
   JAMAL GA, 1987, MUSCLE NERVE, V10, P537, DOI 10.1002/mus.880100608
   KAGEYAMA N, 1971, CLIN CHIM ACTA, V31, P421, DOI 10.1016/0009-8981(71)90413-X
   Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398
   Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855
   KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364
   Klandorf H, 2001, COMP BIOCHEM PHYS C, V129, P93, DOI 10.1016/S1532-0456(01)00186-7
   Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413
   LOW PA, 1983, ANN NEUROL, V14, P573, DOI 10.1002/ana.410140513
   MARFELLA R, 1995, AM J PHYSIOL-ENDOC M, V268, pE1167
   Marfella R, 2001, J CLIN INVEST, V108, P635, DOI 10.1172/JCI0113727A
   MARNER B, 1985, DIABETOLOGIA, V28, P875, DOI 10.1007/BF00703129
   Marnett LJ, 2000, J BIOL CHEM, V275, P13427, DOI 10.1074/jbc.275.18.13427
   Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126
   MINGCHIA H, 2003, J LAB CLIN MED, V151, P200
   O'Byrne S, 2000, DIABETES, V49, P857, DOI 10.2337/diabetes.49.5.857
   Peuchant E, 1997, DIABETES CARE, V20, P202, DOI 10.2337/diacare.20.2.202
   Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983
   Pitre DA, 2001, NEUROSCI LETT, V303, P67, DOI 10.1016/S0304-3940(01)01696-2
   RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435
   Rassaf T, 2002, CIRC RES, V91, P470, DOI 10.1161/01.RES.0000035038.41739.CB
   Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491
   Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165
   SNEDECOR GW, 1967, STATISTICAL METHODS, P172
   Sodum RS, 2000, ANAL BIOCHEM, V280, P278, DOI 10.1006/abio.2000.4528
   SUTO T, 1995, KIDNEY INT, V48, P1272, DOI 10.1038/ki.1995.411
   Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493
   Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857
   Vinik AI, 2001, DIABETES CARE, V24, P1468, DOI 10.2337/diacare.24.8.1468
   Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804
   YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415
NR 65
TC 24
Z9 24
U1 3
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0959-9851
EI 1619-1560
J9 CLIN AUTON RES
JI Clin. Auton. Res.
PD DEC
PY 2003
VL 13
IS 6
BP 406
EP 421
DI 10.1007/s10286-003-0139-x
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 765PA
UT WOS:000188291300008
PM 14673690
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Randomized, double-blind, placebo-controlled, dose-finding
   study of the antiemetic effects and tolerability of ramosetron in adults
   undergoing middle ear surgery (Retracted article. See vol. 40, pg. 1048,
   2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE middle ear; nausea; retching; vomiting; antiemetics; ramosetron;
   selective serotonin receptor antagonist
ID POSTOPERATIVE NAUSEA; GENERAL-ANESTHESIA; PREVENTION; GRANISETRON
AB Background: Ramosetron is a selective serotonin receptor antagonist (SSRA) that is approved for the treatment of emetic symptoms induced by cytotoxic drugs in Japan. We have reported that ramosetron 0.3 mg had comparable efficacy to granisetron 3 mg, another SSRA, in preventing emetic symptoms in adults in the first 48 hours after the start of anesthesia for middle ear surgery. Although it has been shown that a high dose of ramosetron can cause adverse effects (AEs), such as severe headache, the minimal effective dose of ramosetron is unknown.
   Objective: The aim of this study was to determine the minimum effective and tolerable dose of ramosetron needed to prevent postoperative emetic symptoms in adult patients undergoing middle ear surgery.
   Methods: This randomized, double-blind, placebo-controlled, dose-finding study was conducted at the Department of Anesthesiology, Toride Kyodo General Hospital (Toride, Japan). Patients aged greater than or equal to20 years scheduled for middle ear surgery were randomized to receive either placebo or ramosetron at 1 of 3 doses (0.15, 0.3, or 0.6 mg), regardless of body weight, IV immediately before anesthesia induction. Emetic symptoms (nausea, retching, or vomiting) occurring from 0 to <24 and 24 to 48 hours after the start of anesthesia were recorded. Other AEs also were assessed.
   Results: A total of 100 patients (55 women, 45 men; mean [SDI age, 44 [12] years; mean [SDI body weight, 56 [8] kg; mean [SD] height, 159 [8] cm) were enrolled. Each treatment group comprised 25 patients. The treatment groups were comparable with regard to demographic characteristics and type of surgery After the second 24-hour postanesthesia period, significantly more patients in the ramosetron 0.3-mg and 0.6-mg groups were emesis free than in the placebo group (both P < 0.001). The number of emesis-free patients in the ramosetron 0.15-mg group and the placebo group were similar after both study periods. No significant difference in aritiemetic efficacy was found between the ramosetron 0.3-mg and 0.6-mg groups. No relationship between body weight and the efficacy of ramosetron was observed. The incidence of AEs was similar in all 4 groups.
   Conclusions: Ramosetron 0.3 mg, regardless of body weight, was more effective than either ramosetron 0.15 mg or placebo and as effective as ramosetron 0.6 mg for the prevention of emetic symptoms in the first 48 hours after the start of anesthesia in this selected population of adult patients who underwent middle ear surger. Copyright (C) 2003 Excerpta Medica, Inc.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR FLEISHER LA, 1996, CLIN ANESTH, P443
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1998, BRIT J ANAESTH, V80, P764, DOI 10.1093/bja/80.6.764
   Fujii Y, 1997, BRIT J ANAESTH, V79, P539
   Fujii Y, 1999, LARYNGOSCOPE, V109, P1988, DOI 10.1097/00005537-199912000-00017
   HONKAVAARA P, 1994, BRIT J ANAESTH, V73, P763, DOI 10.1093/bja/73.6.763
   Honkavaara P, 1996, BRIT J ANAESTH, V76, P316
   McCormick C., 2002, ASA NEWSL, V66, P19
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   REINHART DJ, 1994, ANESTH ANALG, V79, P281
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 11
TC 9
Z9 9
U1 1
U2 2
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD DEC
PY 2003
VL 25
IS 12
BP 3100
EP 3108
DI 10.1016/S0149-2918(03)90094-4
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 763MK
UT WOS:000188089600006
PM 14749148
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Results of a prospective, randomized, double-blind,
   placebo-controlled, dose-ranging trial to determine the effective dose
   of ramosetron for the prevention of vomiting after tonsillectomy in
   children (Retracted article. See vol. 40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE children; tonsillectomy; vomiting; antiemetics; ramosetron
ID GRANISETRON; ONDANSETRON; EMESIS
AB Background: Postoperative vomiting (POV) is an important adverse effect of anesthesia and surgery, and children undergoing tonsillectomy may be particularly at risk.
   Objective: The aim of this study was to determine the effective dose of ramosetron, a 5-hydroxytryptamine type 3 receptor antagonist, for prophylaxis of severe POV ( greater than or equal to2 episodes) in children undergoing general anesthesia for tonsillectomy.
   Methods: Standard general anesthetic technique and postoperative analgesia were used in this prospective, randomized, double-blind, placebo-controlled, dose-ranging trial of pediatric patients. Patients who had experienced POV, had taken an antiemetic medication within 24 hours before surgery, or had a history of motion sickness were excluded. Only patients aged 4 to 10 years were included, because of their ability to answer questions. Patients received a single administration of either IV placebo or IV ramosetron at 3, 6, or 12 mug/kg immediately after the end of surgery During the first 48 hours after anesthesia, episodes of retching, vomiting, and adverse events were recorded by nursing staff blinded to treatment assignment.
   Results: Eighty children (20 in each group)-42 girls and 38 boys-were enrolled. There were no differences in patient demographic characteristics among the treatment groups. The rates of complete response (no vomiting, retching, or need for another antiemetic medication) from 0 to 24 hours after anesthesia were 35% (7/20) with ramosetron 3 mug/kg, 90% (18/20) with ramosetron 6 mug/kg, and 90% (18/20) with ramosetron 12 mug/kg compared with placebo (30% [6/20]; P = NS, P = 0.001, and P = 0.001 vs placebo, respectively); the corresponding rates from 24 to 48 hours after anesthesia were 35% (7/20), 90% (18/20), and 95% (19/20) compared with placebo (35% [7/20]; P = NS, P = 0.001, and P = 0.001 vs; placebo, respectively). No difference in antiemetic efficacy was observed between ramosetron 6 and 12 mug/kg. No clinically serious adverse events attributable to the study drug were observed in any group.
   Conclusions: In the pediatric population studied, ramosetron 6 mug/kg was effective for the prevention of vomiting after tonsillectomy from 0 to 48 hours after anesthesia. Increasing the dose to 12 mug/kg did not appear to provide further benefit. Copyright (C) 2003 Excerpta Medica, Inc.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 2001, LARYNGOSCOPE, V111, P255, DOI 10.1097/00005537-200102000-00013
   ITO H, 1995, NEUROPHARMACOLOGY, V34, P631, DOI 10.1016/0028-3908(95)00033-3
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   McCormick C., 2002, ASA NEWSL, V66, P19
   VANWIJNGAARDEN I, 1990, EUR J PHARM-MOLEC PH, V188, P301, DOI 10.1016/0922-4106(90)90190-9
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 8
TC 5
Z9 5
U1 1
U2 2
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD DEC
PY 2003
VL 25
IS 12
BP 3135
EP 3142
DI 10.1016/S0149-2918(03)90097-X
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 763MK
UT WOS:000188089600009
PM 14749151
DA 2018-12-27
ER

PT J
AU Boltze, C
   Lehnert, H
   Schneider-Stock, R
   Peters, B
   Hoang-Vu, C
   Roessner, A
AF Boltze, C
   Lehnert, H
   Schneider-Stock, R
   Peters, B
   Hoang-Vu, C
   Roessner, A
TI RETRACTED: HSP90 is a key for telomerase activation and malignant
   transition in pheochromocytoma (Retracted Article. See vol 23, pg 229,
   2004)
SO ENDOCRINE
LA English
DT Article; Retracted Publication
DE HSP90; telomerase; pheochromocytoma; hTERT
ID REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; RNA COMPONENT; EXPRESSION;
   TUMORS; CARCINOMAS; DIAGNOSIS; FEATURES; PROTEIN; LESIONS
AB Recent studies on a limited number of pheochromocytomas (PCs) revealed a potential role of telomerase in the malignant transition of these tumors. Telomerase is a ribonucleoprotein complex that includes the telomerase RNA component (M), the telomerase-associated protein (TP1), the telomerase catalytic subunit (hTERT), and the heat-shock protein 90 (HSP90). The interactions between these subunits and the activation machinery of telomerase are still unclear. To test whether the expression and regulation of telomerase subunits are reflected in the malignant transition of PCs, we determined their mRNA and/or protein expression in 28 benign and 9 malignant PCs and compared the results with telomerase activity. Reverse transcriptase polymerase chain reaction analysis revealed that TP1 was ubiquitously expressed. hTR was found in all malignant (100%) and in 13/28 (46%) benign PCs. By contrast, hTERT was clearly associated with aggressive biologic behavior. All the malignant (100%) but only 2/28 benign (7%) PCs expressed hTERT. HSP90 was increased in malignant PCs but was also expressed at a lower level in benign tumors. High telomerase activity was measurable in only hTERT-positive tissues. Our data indicate that hTERT, HSP90, and telomerase activity are upregulated in malignant cells of the adrenal medulla. Overexpression of HSP90 is an important factor in the activation of telomerase via hTERT. The common expression of hTERT and telomerase activity thus represents an additional prognostic marker that may identify more aggressive tumors.
C1 Univ Magdeburg, Dept Pathol, D-39120 Magdeburg, Germany.
   Univ Magdeburg, Dept Endocrinol & Metab, D-39120 Magdeburg, Germany.
   Univ Magdeburg, Dept Biometr, D-39120 Magdeburg, Germany.
   Univ Halle Wittenberg, Clin Gen Surg, Halle An Der Saale, Germany.
RP Boltze, C (reprint author), Univ Magdeburg, Dept Pathol, Leipziger Str 44, D-39120 Magdeburg, Germany.
EM carsten.boltze@medizin.uni-magdeburg.de
RI Schneider-Stock, Regine/H-8863-2012
CR Aogi K, 1998, CLIN CANCER RES, V4, P1965
   Avilion AA, 1996, CANCER RES, V56, P645
   Bamberger CM, 1999, EXP CLIN ENDOCR DIAB, V107, P272, DOI 10.1055/s-0029-1212111
   Chang JTC, 2002, EUR J BIOCHEM, V269, P3442, DOI 10.1046/j.1432-1033.2002.03025.x
   Clarke MR, 1998, HUM PATHOL, V29, P522, DOI 10.1016/S0046-8177(98)90070-3
   FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491
   Goldstein RE, 1999, ANN SURG, V229, P755, DOI 10.1097/00000658-199906000-00001
   HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7
   Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973
   Hoang-Vu C, 2002, INT J ONCOL, V21, P265
   Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817
   HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841
   John H, 1999, UROLOGY, V53, P679, DOI 10.1016/S0090-4295(98)00612-8
   Katayama S, 1999, J CANCER RES CLIN, V125, P405, DOI 10.1007/s004320050294
   Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595
   Kinoshita H, 1998, UROL RES, V26, P29, DOI 10.1007/s002400050019
   Kubota Y, 1998, CANCER, V82, P176, DOI 10.1002/(SICI)1097-0142(19980101)82:1<176::AID-CNCR22>3.3.CO;2-N
   LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3
   LINNOILA RI, 1990, HUM PATHOL, V21, P1168
   Lundblad V, 1998, P NATL ACAD SCI USA, V95, P8415, DOI 10.1073/pnas.95.15.8415
   Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200
   Mundschenk J, 1998, EXP CLIN ENDOCR DIAB, V106, P373, DOI 10.1055/s-0029-1212001
   Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955
   Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65
   Okayasu I, 1998, J CANCER RES CLIN, V124, P444, DOI 10.1007/s004320050197
   Poremba C, 1998, INT J ONCOL, V12, P641
   Ramakrishnan S, 1998, CANCER RES, V58, P622
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   Saji M, 1999, CLIN CANCER RES, V5, P1483
   Schneider-Stock R, 2003, J PATHOL, V199, P517, DOI 10.1002/path.1315
   Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091
NR 31
TC 13
Z9 15
U1 3
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD DEC
PY 2003
VL 22
IS 3
BP 193
EP 201
DI 10.1385/ENDO:22:3:193
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766YW
UT WOS:000188412200002
PM 14709792
DA 2018-12-27
ER

PT J
AU Kofidis, T
   Lenz, A
   Boublik, J
   Akhyari, P
   Wachsmann, B
   Stahl, KM
   Haverich, A
   Leyh, RG
AF Kofidis, T
   Lenz, A
   Boublik, J
   Akhyari, P
   Wachsmann, B
   Stahl, KM
   Haverich, A
   Leyh, RG
TI RETRACTED: Bioartiticial grafts for transmural myocardial restoration: a
   new cardiovascular tissue culture concept (Retracted article. See vol.
   40, pg. 1555, 2011)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article; Retracted Publication
DE myocardial grafts; tissue engineering; cardiomyocytes
ID ENGINEERED CARTILAGE; PULSATILE BIOREACTOR; HEART-VALVES; DESIGN; MUSCLE
AB Objective: Survival of bioartificial grafts that are destined to restore cardiac function stands and falls with their nutrient supply. Engineering of myocardial tissue is limited because of lack of vascularization. We introduce a new concept to obtain bioartificial myocardial grafts in which perfusion by a macroscopic core vessel is simulated. Methods: We have designed an experimental reactor with multiple chambers for the production of bioartificial tissue or tissue precursors. By introduction of in- and output lines of distinct diameter and insertion of a core vessel into each chamber, we established pulsatile, continuous flow through the embodied three-dimensional tissue culture. In the present study, collagen components served as the ground matrix wherein neonatal rat cardiomyocytes were inoculated. For the assessment of cellular viability and distribution in comparison to static, non-perfused culture, fluor-desoxy-glucose-positron-emission-tomography and life/dead assays were employed. Results: We obtained 3D constructs of 8-mm thickness, which display high viability and metabolism (6.0 +/- 1.3(e-03) in the perfused vs. 4.0 +/- 0.3(e-03) in the unperfused chambers). The core vessel has the size of a human coronary and remained patent during the entire culture process. We observed centripetal migration of the embedded cardiomyocytes to the site of the core vessel. Cardiomyocytes partially resumed a spindle like form without additional stretch. Conclusions: The present dynamic tissue culture concept is highly effective in manufacturing thick, viable grafts for cardiac muscle restoration, which could be surgically anastomosable. The bioreactor may accommodate multiple types of cells and tissues for innumerable in vitro and in vivo applications. (C) 2003 Elsevier B.V. All rights reserved.
C1 Hannover Med Sch, Dept Thorac & Cardiovasc Surg, D-3000 Hannover, Germany.
   ARTISS GmbH, Hannover, Germany.
   Leibnez Labs Biotechnol & Artificial Organs, Hannover, Germany.
RP Kofidis, T (reprint author), Stanford Univ, Sch Med, Cardiothorac Surg Falk Res Ctr, 2 Fl,300 Pasteur Dr, Stanford, CA 94305 USA.
EM tkofidis@stanford.edu
RI Kofidis, Theodoros/B-9283-2011; Kofidis, Theodoros/B-9283-2011
OI Kofidis, Theodoros/0000-0002-9623-6450; Akhyari,
   Payam/0000-0002-6452-8678; Kofidis, Theodoros/0000-0002-8938-819X
CR Akhyari P, 2002, CIRCULATION, V106, pI137, DOI 10.1161/01.cir.0000032893.55215.fc
   Akins RE, 1999, TISSUE ENG, V5, P103, DOI 10.1089/ten.1999.5.103
   ASSOULINE M, 1992, INVEST OPHTH VIS SCI, V33, P1742
   Baek CH, 2002, LARYNGOSCOPE, V112, P1050, DOI 10.1097/00005537-200206000-00021
   BELL RS, 1988, J ORTHOPAED RES, V6, P467, DOI 10.1002/jor.1100060402
   Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X
   Davisson T, 2002, J ORTHOPAED RES, V20, P842, DOI 10.1016/S0736-0266(01)00160-7
   Dumont K, 2002, ARTIF ORGANS, V26, P710, DOI 10.1046/j.1525-1594.2002.06931_3.x
   Hoerstrup SP, 2000, TISSUE ENG, V6, P75, DOI 10.1089/107632700320919
   Hutmacher DW, 2001, J BIOMAT SCI-POLYM E, V12, P107, DOI 10.1163/156856201744489
   Hutmacher DW, 2001, ANN ACAD MED SINGAP, V30, P183
   Kim Julian A, 2003, Methods Mol Med, V75, P697
   Kofidis T, 2002, J THORAC CARDIOV SUR, V124, P63, DOI 10.1067/mtc.2002.121971
   Korossis SA, 2002, J HEART VALVE DIS, V11, P463
   Lwigale PY, 2000, CELLS TISSUES ORGANS, V167, P171, DOI 10.1159/000016780
   Naughton GK, 2002, ANN NY ACAD SCI, V961, P372, DOI 10.1111/j.1749-6632.2002.tb03127.x
   Ozawa T, 2002, CIRCULATION, V106, pI176, DOI 10.1161/01.cir.0000032901.55215.cc
   Papadaki M, 2001, AM J PHYSIOL-HEART C, V280, pH168
   Vailhe B, 1997, IN VITRO CELL DEV-AN, V33, P763
   van Luyn MJA, 2002, BIOMATERIALS, V23, P4793, DOI 10.1016/S0142-9612(02)00230-2
   WILTING J, 1993, CELL TISSUE RES, V274, P163, DOI 10.1007/BF00327997
NR 21
TC 24
Z9 27
U1 5
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD DEC
PY 2003
VL 24
IS 6
BP 906
EP 911
DI 10.1016/S1010-7940(03)00577-3
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 754ZH
UT WOS:000187363000008
PM 14643807
OA Bronze
DA 2018-12-27
ER

PT J
AU Pai, SA
   Kini, D
   Shetty, K
   Rao, UV
AF Pai, SA
   Kini, D
   Shetty, K
   Rao, UV
TI RETRACTED: Psammomatous carcinoid of the rectum (Retracted Article. See
   vol 58, pg 672, 2005)
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Correction; Retracted Publication
C1 Manipal Hosp, Bangalore 560017, Karnataka, India.
RP Pai, SA (reprint author), Manipal Hosp, Airport Rd, Bangalore 560017, Karnataka, India.
EM s_pai@vsnl.com
CR BURKE AP, 1990, CANCER, V65, P1591, DOI 10.1002/1097-0142(19900401)65:7<1591::AID-CNCR2820650723>3.0.CO;2-N
   COOPER HS, 1999, DIAGNOSTIC SURG PATH, P1446
   DAYAL Y, 1983, AM J SURG PATHOL, V7, P653, DOI 10.1097/00000478-198310000-00006
   Green BT, 2001, J CLIN GASTROENTEROL, V33, P415, DOI 10.1097/00004836-200111000-00015
   MURAYAMA H, 1979, CANCER, V43, P1411, DOI 10.1002/1097-0142(197904)43:4<1411::AID-CNCR2820430430>3.0.CO;2-B
NR 5
TC 1
Z9 1
U1 4
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD DEC 1
PY 2003
VL 56
IS 12
BP 978
EP 978
DI 10.1136/jcp.56.12.978
PG 1
WC Pathology
SC Pathology
GA 747HX
UT WOS:000186800100023
PM 14645365
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Izumi, Y
   Ami, Y
   Matsuo, K
   Someya, K
   Sata, T
   Yamamoto, N
   Honda, M
AF Izumi, Y
   Ami, Y
   Matsuo, K
   Someya, K
   Sata, T
   Yamamoto, N
   Honda, M
TI RETRACTED: Intravenous inoculation of replication-deficient recombinant
   vaccinia virus DIs expressing simian immunodeficiency virus gag controls
   highly pathogenic simian-human immunodeficiency virus in monkeys
   (Retracted Article. See vol 79, pg 3229, 2005)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID CYTOTOXIC T-LYMPHOCYTES; CLASS-I MOLECULE; RHESUS-MONKEYS; ATTENUATED
   STRAIN; MUCOSAL CHALLENGE; IMMUNE-RESPONSES; HIV-INFECTION; ANKARA MVA;
   MACAQUES; VIREMIA
AB To be effective, a vaccine against human immunodeficiency virus type 1 (HIV-1) must induce virus-specific T-cell responses and it must be safe for use in humans. To address these issues, we developed a recombinant vaccinia virus DIs vaccine (rDIsSIVGag), which is nonreplicative in mammalian cells and expresses the full-length gag gene of simian immunodeficiency virus (SIV). Intravenous inoculation of 10(6) PFU of rDIsSIVGag in cynomologus macaques induced significant levels of gamma interferon (IFN-gamma) spot-forming cells (SFC) specific for SIV Gag. Antigen-specific lymphocyte proliferative responses were also induced and were temporally associated with the peak of IFN-gamma SFC activity in each macaque. In contrast, macaques immunized with a vector control (rDIsLacZ) showed no significant induction of antigen-specific immune responses. After challenge with a highly pathogenic simian-human immunodeficiency virus (SHIV), CD4(+) T lymphocytes were maintained in the peripheral blood and lymphoid tissues of the immunized macaques. The viral set point in plasma was also reduced in these animals, which may be related to the enhancement of virus-specific intracellular IFN-gamma(+) CD8(+) cell numbers and increased antibody titers after SHIV challenge. These results demonstrate that recombinant DIs has potential for use as an HIV/AIDS vaccine.
C1 Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan.
   Natl Inst Infect Dis, Div Expt Anim Res, Shinjuku Ku, Tokyo 1628640, Japan.
   Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 1628640, Japan.
   Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan.
RP Honda, M (reprint author), Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan.
EM mhonda@nih.go.jp
CR Allen TM, 1998, J IMMUNOL, V160, P6062
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Barouch DH, 2001, J VIROL, V75, P5151, DOI 10.1128/JVI.75.11.5151-5158.2001
   Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845
   Carroll MW, 1997, VACCINE, V15, P387, DOI 10.1016/S0264-410X(96)00195-8
   Egan MA, 2000, J VIROL, V74, P7485, DOI 10.1128/JVI.74.16.7485-7495.2000
   Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224
   FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678
   Gauduin MC, 1999, J MED PRIMATOL, V28, P233, DOI 10.1111/j.1600-0684.1999.tb00274.x
   Hanke T, 1999, J VIROL, V73, P7524
   Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803
   Hel Z, 2000, NAT MED, V6, P1140
   Ishii K, 2002, VIROLOGY, V302, P433, DOI 10.1006/viro.2002.1622
   Kawahara M, 2002, INFECT IMMUN, V70, P6614, DOI 10.1128/IAI.70.12.6614-6620.2002
   KITAMURA T, 1967, NATURE, V215, P1187, DOI 10.1038/2151187a0
   Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767
   Lehner T, 2002, SCIENCE, V297, P1276
   Lu YC, 1996, J ACQ IMMUN DEF SYND, V12, P99, DOI 10.1097/00042560-199606010-00001
   MATSUO K, 1992, J GEN VIROL, V73, P2445, DOI 10.1099/0022-1317-73-9-2445
   McMichael AJ, 2000, PHILOS T ROY SOC B, V355, P1007, DOI 10.1098/rstb.2000.0637
   MORITA CHIHARU, 1967, JAP J VET SCI, V29, P171
   MORITA M, 1987, VACCINE, V5, P65, DOI 10.1016/0264-410X(87)90012-0
   MORITA M, 1977, MICROBIOL IMMUNOL, V21, P417, DOI 10.1111/j.1348-0421.1977.tb00306.x
   MORITA M, 1977, ARCH VIROL, V53, P197, DOI 10.1007/BF01314664
   MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.immunol.5.1.305
   Mothe BR, 2002, J VIROL, V76, P875, DOI 10.1128/JVI.76.2.875-884.2002
   Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500
   Ourmanov I, 2000, J VIROL, V74, P2740, DOI 10.1128/JVI.74.6.2740-2751.2000
   Reimann KA, 1996, J VIROL, V70, P3198
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Rosenberg ES, 1999, IMMUNOL LETT, V66, P89, DOI 10.1016/S0165-2478(98)00165-5
   Sasaki Y, 2000, CLIN EXP IMMUNOL, V122, P381, DOI 10.1046/j.1365-2249.2000.01327.x
   Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000
   Seth A, 1998, P NATL ACAD SCI USA, V95, P10112, DOI 10.1073/pnas.95.17.10112
   Shinohara K, 1999, J GEN VIROL, V80, P1231
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   STAHLHENNIG C, 1993, AIDS, V7, P787, DOI 10.1097/00002030-199306000-00005
   STIEKL H, 1973, MUNCHEN MED WOCHEN, V115, P1471
   TAGAYA I, 1961, NATURE, V192, P381, DOI 10.1038/192381a0
   TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B
   Walker BD, 2000, NATURE, V407, P313, DOI 10.1038/35030283
   Walker BD, 2000, NAT MED, V6, P1094, DOI 10.1038/80415
   Walker BD, 1998, ADV EXP MED BIOL, V452, P159
   Yoshino N, 2000, BIOCHEM BIOPH RES CO, V268, P868, DOI 10.1006/bbrc.2000.2163
   Yoshino N, 2000, MICROBIOL IMMUNOL, V44, P363, DOI 10.1111/j.1348-0421.2000.tb02507.x
   Zhou DJ, 1999, J IMMUNOL, V162, P2204
NR 48
TC 6
Z9 6
U1 3
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2003
VL 77
IS 24
BP 13248
EP 13256
DI 10.1128/JVI.77.24.13248-13256.2003
PG 9
WC Virology
SC Virology
GA 750YF
UT WOS:000187025500033
PM 14645581
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zeytun, A
   Jeromin, A
   Scalettar, BA
   Waldo, GS
   Bradbury, ARM
AF Zeytun, A
   Jeromin, A
   Scalettar, BA
   Waldo, GS
   Bradbury, ARM
TI RETRACTED: Fluorobodies combine GFP fluorescence with the binding
   characteristics of antibodies (Retracted Article. See vol 22, pg 601,
   2004)
SO NATURE BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
ID SINGLE-CHAIN ANTIBODIES; MAMMALIAN-CELLS; PROTEIN SCAFFOLD;
   FLOW-CYTOMETRY; PHAGE; EXPRESSION; LIBRARIES; DISPLAY; LIGANDS; SURFACE
AB The difficulty of deriving binding ligands to targets identified by genomic sequencing has led to a bottleneck in genomic research. By inserting diverse antibody binding loops into four of the exposed loops at one end of green fluorescent protein (GFP), we have mimicked the natural antibody binding footprint to create robust binding ligands that combine the advantages of antibodies (high affinity and specificity) with those of GFP (intrinsic fluorescence, high stability, expression and solubility). These `fluorobodies' have been used effectively in enzyme- linked immunosorbent assays (ELISAs), flow cytometry, immunofluorescence, arrays and gel shift assays, and show affinities as high as antibodies. Furthermore, the intrinsic fluorescence of fluorobodies correlates with binding activity, allowing the rapid determination of functionality, concentration and affinity. These properties render them especially suitable for the high- throughput genomic scale selections required in proteomics, as well as in diagnostics, target validation and drug development.
C1 Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA.
   Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.
   Lewis & Clark Coll, Dept Phys, Portland, OR 97219 USA.
RP Bradbury, ARM (reprint author), Los Alamos Natl Lab, Biosci Div, HRL-1 TA-43 MS M888, Los Alamos, NM 87545 USA.
EM waldo@telomere.lanl.gov; amb@lanl.gov
FU NCRR NIH HHS [RR01315]; NIGMS NIH HHS [GM061539]
CR Abedi MR, 1998, NUCLEIC ACIDS RES, V26, P623, DOI 10.1093/nar/26.2.623
   Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241
   Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173
   CUBBIT AB, 1999, METHOD CELL BIOL, V58, P19
   Davies J, 1996, PROTEIN ENG, V9, P531, DOI 10.1093/protein/9.6.531
   DEANE M, 1991, BRIT J HAEMATOL, V77, P274, DOI 10.1111/j.1365-2141.1991.tb08570.x
   Doi N, 1999, FEBS LETT, V453, P305, DOI 10.1016/S0014-5793(99)00732-2
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   GOSLIN K, 1997, CULTURING NERVE CELL, P252
   GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x
   Hink MA, 2000, J BIOL CHEM, V275, P17556, DOI 10.1074/jbc.M001348200
   Hufton SE, 2000, FEBS LETT, V475, P225, DOI 10.1016/S0014-5793(00)01701-4
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752
   KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9
   Lochner JE, 1998, MOL BIOL CELL, V9, P2463, DOI 10.1091/mbc.9.9.2463
   Lou JL, 2001, J IMMUNOL METHODS, V253, P233, DOI 10.1016/S0022-1759(01)00385-4
   MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U
   Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840
   Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190
   Nolan JP, 1999, DRUG DISCOV TODAY, V4, P173, DOI 10.1016/S1359-6446(99)01320-3
   Nolan JP, 1998, NAT BIOTECHNOL, V16, P633, DOI 10.1038/nbt0798-633
   Peelle B, 2001, CHEM BIOL, V8, P521, DOI 10.1016/S1074-5521(01)00031-X
   Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w
   Sblattero D, 2001, J Biotechnol, V74, P303, DOI 10.1016/S1389-0352(01)00022-8
   Sblattero D, 2000, NAT BIOTECHNOL, V18, P75
   Scalettar BA, 2002, J CELL SCI, V115, P2399
   Scalettar BA, 1996, J MICROSC-OXFORD, V182, P50, DOI 10.1046/j.1365-2818.1996.122402.x
   SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028
   Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157
   Shi HD, 2001, ENZYME MICROB TECH, V28, P25, DOI 10.1016/S0141-0229(00)00281-7
   Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1
   Siegel RW, 2000, J MOL BIOL, V302, P285, DOI 10.1006/jmbi.2000.4070
   Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509
   van den Beucken T, 2001, J MOL BIOL, V310, P591, DOI 10.1006/jmbi.2001.4703
   Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309
   Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2001.5392
NR 41
TC 26
Z9 26
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD DEC
PY 2003
VL 21
IS 12
BP 1473
EP 1479
DI 10.1038/nbt911
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 748CT
UT WOS:000186845200025
PM 14608366
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Bryne, IM
   Mao, L
   Lotan, R
   Reith, A
   Kildal, W
   Davidson, B
   Soland, TM
   Lippman, SM
AF Sudbo, J
   Bryne, IM
   Mao, L
   Lotan, R
   Reith, A
   Kildal, W
   Davidson, B
   Soland, TM
   Lippman, SM
TI RETRACTED: Molecular based treatment of oral cancer (Retracted article.
   See vol 43, pg 421, 2007)
SO ORAL ONCOLOGY
LA English
DT Review; Retracted Publication
DE chemoprevention; molecular targeting; COX-2; EGFR; combinatorial therary
ID SQUAMOUS-CELL CARCINOMA; EPIDERMAL-GROWTH-FACTOR; CAUSES
   DOWN-REGULATION; FACTOR RECEPTOR; COLORECTAL-CANCER; NECK-CANCER;
   CYCLOOXYGENASE-2 EXPRESSION; PREMALIGNANT LESIONS; SOCIETY GUIDELINES;
   RISK ASSESSMENT
AB Given the increase in the age distribution of the population, an increase in cancer incidence rates are to be expected. Oral cancer is a disfiguring disease that continues to increase in incidence, particularly in the young, and to an extent that cannot be fully explained by increased exposure to known risk factors. Despite extensive research on treatment modalities towards oral cancer, the 5-year survival rate of this disease has not been improved over the last 4-5 decades. These facts strongly favour chemoprevention-systemic medication to revert, stop, or delay the carcinogenic process-as an approach to treating oral cancer. A chemopreventive approach to oral cancer most likely should encompass a combination of drugs targeting metabolic pathways relevant to oral carcinogenesis. Candidate drugs are retinoids and selective inhibitors of cyclooxygenase-2, epidermal growth factor receptor (EGFR), and peroxisome proliferator activated receptors (PPARs). Chernopreventive trials so far have used surrogate intermediate biomarkers as measurement of treatment effect. However, the efficiency of any drug for chemopreventive use should be assessed through a prospective randomized trial and evaluated by the only definitive end point for prevention of cancer, the incidence rates of new carcinomas. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
   Univ Oslo, Dept Oral Biol, N-0316 Oslo, Norway.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA.
   Norwegian Radium Hosp, Dept Pathol, Oslo, Norway.
   Univ Texas, MD Anderson Canc Ctr, Div Canc Prevent, Dept Clin Canc Prevent, Houston, TX USA.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
RI Mao, Li/C-7570-2011
OI Mao, Li/0000-0001-7263-3358
CR Annertz K, 2002, INT J CANCER, V101, P95, DOI 10.1002/ijc.10577
   [Anonymous], 2002, Mayo Clin Health Lett, V20, P7
   Appleton DR, 2002, CELL PROLIFERAT, V35, P68, DOI 10.1046/j.1365-2184.35.s1.7.x
   Araki Y, 2003, CANCER RES, V63, P728
   Axell T, 1996, J ORAL PATHOL MED, V25, P49, DOI 10.1111/j.1600-0714.1996.tb00191.x
   Banerjee AG, 2002, MOL CANCER THER, V1, P1265
   Bei R, 2001, J PATHOL, V195, P343, DOI 10.1002/path.965
   Blasco MA, 2002, EUR J CANCER, V38, P2222, DOI 10.1016/S0959-8049(02)00450-1
   Boardman LA, 2002, GASTROENTEROL CLIN N, V31, P1107, DOI 10.1016/S0889-8553(02)00049-3
   Boschelli Diane H., 2002, Current Topics in Medicinal Chemistry, V2, P1051, DOI 10.2174/1568026023393354
   Brunin F, 1999, HEAD NECK-J SCI SPEC, V21, P751, DOI 10.1002/(SICI)1097-0347(199912)21:8<751::AID-HED11>3.3.CO;2-W
   Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201
   Cohen EEW, 2002, J CLIN ONCOL, V20, P359, DOI 10.1200/JCO.2002.20.2.359
   Courtneidge SA, 1998, CURR OPIN BIOTECH, V9, P632, DOI 10.1016/S0958-1669(98)80142-0
   Dajani E Z, 2000, J Assoc Acad Minor Phys, V11, P28
   Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0
   Dannenberg AJ, 2001, ANN NY ACAD SCI, V952, P109, DOI 10.1111/j.1749-6632.2001.tb02731.x
   Di Gennaro E, 2003, J CELL PHYSIOL, V195, P139, DOI 10.1002/jcp.10239
   Dubois RN, 1998, FASEB J, V12, P1063
   Giercksky KE, 2001, BEST PRACT RES CL GA, V15, P821, DOI 10.1053/bega.2001.0237
   Gordon KE, 2003, CANCER RES, V63, P458
   Grandis JR, 1998, CLIN CANCER RES, V4, P13
   Grandis JR, 1998, J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824
   Gupta RA, 2002, AM J PHYSIOL-GASTR L, V283, pG266, DOI 10.1152/ajpgi.00486.2001
   Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642
   Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370
   HONG WK, 1987, AM J CLIN ONCOL-CANC, V10, P182, DOI 10.1097/00000421-198704000-00056
   Hsu S, 2002, CELL PROLIFERAT, V35, P183, DOI 10.1046/j.1365-2184.2002.00237.x
   Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200
   Jaeckel EC, 2001, ARCH OTOLARYNGOL, V127, P1253, DOI 10.1001/archotol.127.10.1253
   Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606
   Johnson S C, 2000, Adv Intern Med, V45, P1
   Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t
   Kleinman D V, 1993, Adv Dent Res, V7, P32
   Krause W F, 2001, Clin Colorectal Cancer, V1, P47, DOI 10.3816/CCC.2001.n.005
   Li SQ, 2002, ACTA CYTOL, V46, P1069, DOI 10.1159/000327109
   LIND PO, 1987, SCAND J DENT RES, V95, P449
   Lippman SM, 2002, CLIN CANCER RES, V8, P305
   Lippman SM, 2002, CANCER RES, V62, P5119
   Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514
   Longchampt E, 2003, BJU INT, V91, P567, DOI 10.1046/j.1464-410X.2003.04117.x
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Luo XY, 2003, INT J CANCER, V104, P716, DOI 10.1002/ijc.11007
   MACFARLANE GJ, 1994, CANCER CAUSE CONTROL, V5, P259, DOI 10.1007/BF01830246
   MACFARLANE GJ, 1994, CANCER CAUSE CONTROL, V5, P255, DOI 10.1007/BF01830245
   MACFARLANE GJ, 1987, LANCET, V2, P912
   Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509
   Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   Mao L, 2000, CLIN CANCER RES, V6, P321
   Milas I, 2003, CLIN CANCER RES, V9, P1070
   Mitchell A, 2002, NAT REV MOL CELL BIO, V3, P150, DOI 10.1038/nrm764
   Mork J, 1998, ANTICANCER RES, V18, P3705
   MORK J, 1995, APMIS, V103, P375, DOI 10.1111/j.1699-0463.1995.tb01121.x
   Nagler RM, 2002, CANCER LETT, V186, P137, DOI 10.1016/S0304-3835(02)00265-3
   Nam NH, 2003, CURR DRUG TARGETS, V4, P159, DOI 10.2174/1389450033346966
   NEURMANN AA, 2002, NAT REV CANCER, V2, P879
   NEWMAN AN, 1983, ARCH OTOLARYNGOL, V109, P302
   Nikitakis NG, 2002, INT J CANCER, V98, P817, DOI 10.1002/ijc.10278
   Nikitakis NG, 2002, CANCER RES, V62, P1004
   Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618
   Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Piiper A, 2003, BIOCHEM BIOPH RES CO, V301, P848, DOI 10.1016/S0006-291X(03)00055-X
   Pindborg J J, 1994, Recent Results Cancer Res, V134, P9
   Pindborg JJ, 1997, HISTOLOGICAL TYPING
   Reith A, 2002, INT J CANCER, V101, P205, DOI 10.1002/ijc.10569
   Rosin MP, 2002, CANCER RES, V62, P6447
   Ruffini PA, 2002, BIOMED PHARMACOTHER, V56, P129, DOI 10.1016/S0753-3322(02)00169-5
   Saldanha SN, 2003, EUR J BIOCHEM, V270, P389, DOI 10.1046/j.1432-1033.2003.03410.x
   Schwartz GJ, 2000, HEAD NECK-J SCI SPEC, V22, P34, DOI 10.1002/(SICI)1097-0347(200001)22:1<34::AID-HED6>3.0.CO;2-3
   Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8
   Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38
   Song JI, 2001, CANCER RES, V61, P5919
   Soria JC, 2001, J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257
   Sporn MB, 1997, ANN NY ACAD SCI, V833, P137, DOI 10.1111/j.1749-6632.1997.tb48599.x
   Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844
   Suarez P, 1998, Adv Anat Pathol, V5, P137, DOI 10.1097/00125480-199805000-00001
   Sudbo J, 2002, J CLIN ONCOL, V20, P456, DOI 10.1200/JCO.20.2.456
   Sudbo J, 2001, ORAL ONCOL, V37, P558, DOI 10.1016/S1368-8375(00)00126-3
   Sudbo J, 2001, J PATHOL, V194, P303, DOI 10.1002/1096-9896(200107)194:3<303::AID-PATH879>3.0.CO;2-Q
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Sumitani H, 2001, J ORAL PATHOL MED, V30, P41, DOI 10.1034/j.1600-0714.2001.300107.x
   Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1
   Torrance CJ, 2000, NAT MED, V6, P1024
   Treon SP, 2000, SEMIN ONCOL, V27, P598
   Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952
   WALDRON CA, 1975, CANCER-AM CANCER SOC, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
   Wamakulasuriya S, 2001, J PATHOL, V194, P294, DOI 10.1002/1096-9896(200107)194:3<294::AID-PATH911>3.0.CO;2-Q
   Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c
   Wissner A, 2002, BIOORG MED CHEM LETT, V12, P2893, DOI 10.1016/S0960-894X(02)00598-X
   Xi S, 2003, J DENT RES, V82, P11, DOI 10.1177/154405910308200104
   Zhang L, 2001, J ORAL PATHOL MED, V30, P513, DOI 10.1034/j.1600-0714.2001.300901.x
NR 97
TC 17
Z9 18
U1 3
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD DEC
PY 2003
VL 39
IS 8
BP 749
EP 758
DI 10.1016/S1368-8375(03)00098-8
PG 10
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 745GG
UT WOS:000186680500001
PM 13679198
DA 2018-12-27
ER

PT J
AU Yun, TH
   Baglia, FA
   Myles, T
   Navaneetham, D
   Lopez, JA
   Walsh, PN
   Leung, LLK
AF Yun, TH
   Baglia, FA
   Myles, T
   Navaneetham, D
   Lopez, JA
   Walsh, PN
   Leung, LLK
TI RETRACTED: Thrombin activation of factor XI on activated platelets
   requires the interaction of factor XI and platelet glycoprotein Ib alpha
   with thrombin anion-binding exosites I and II, respectively (Retracted
   Article. See vol 282, pg 29067, 2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID COAGULATION-FACTOR-XI; PRO-ARG CHLOROMETHYLKETONE; MOLECULAR-WEIGHT
   KININOGEN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; V COMPLEX;
   ANTITHROMBIN-III; HIGH-AFFINITY; FACTOR-VIII; FACTOR IXA
AB Activation of factor XI (FXI) by thrombin on stimulated platelets plays a physiological role in hemostasis, providing additional thrombin generation required in cases of severe hemostatic challenge. Using a collection of 53 thrombin mutants, we identified 16 mutants with < 50% of the wild-type thrombin FXI-activating activity in the presence of dextran sulfate. These mutants mapped to anion-binding exosite (ABE) I, ABE-II, the Na+-binding site, and the 50-insertion loop. Only the ABE-II mutants showed reduced binding to dextran sulfate-linked agarose. Selected thrombin mutants in ABE-I (R68A, R70A, and R73A), ABE-II (R98A, R245A, and K248A), the 50-insertion loop (W50A), and the Na+-binding site ( E229A and R233A) with < 10% of the wildtype activity also showed a markedly reduced ability to activate FXI in the presence of stimulated platelets. The ABE-I, 50-insertion loop, and Na+-binding site mutants had impaired binding to FXI, but normal binding to glycocalicin, the soluble form of glycoprotein Ibalpha (GPIbalpha). In contrast, the ABE-II mutants were defective in binding to glycocalicin, but displayed normal binding to FXI. Our data support a quaternary complex model of thrombin activation of FXI on stimulated platelets. Thrombin bound to one GPIbalpha molecule, via ABE-II on its posterior surface, is properly oriented for its activation of FXI bound to a neighboring GPIalpha molecule, via ABE-I on its anterior surface. GPIbalpha plays a critical role in the co-localization of thrombin and FXI and the resultant efficient activation of FXI.
C1 Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA.
   Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
   Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA.
   Houston Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Leung, LLK (reprint author), Stanford Univ, Sch Med, Dept Med, Div Hematol, 269 Campus Dr, Stanford, CA 94305 USA.
EM lawrence.leung@stanford.edu
FU NHLBI NIH HHS [HL46213, HL57530, HL70683, HL69493]; PHS HHS [P5065967]
CR AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006
   AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024
   Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200
   Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200
   BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   Baglia FA, 1996, J BIOL CHEM, V271, P3652
   Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+
   BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038
   BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x
   BODE W, 1992, PROTEIN SCI, V1, P426
   BOUMA BN, 1977, J BIOL CHEM, V252, P6432
   DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977
   De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887
   De Cristofaro R, 2003, BIOCHEM J, V373, P593, DOI 10.1042/BJ20030167
   De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f
   DECRISTOFARO R, 1998, BIOCHEM J, V332, P6403
   DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089
   EDSON JR, 1967, THROMB DIATH HAEMOST, V18, P342, DOI 10.1055/s-0038-1655041
   FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018
   Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117
   GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0
   GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510
   Hall SW, 2001, THROMB HAEMOSTASIS, V86, P1466
   HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013
   Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200
   Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q
   HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049
   Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2
   KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590
   Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487
   Leung LLK, 2000, TRENDS CARDIOVAS MED, V10, P89, DOI 10.1016/S1050-1738(00)00047-5
   Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200
   LIU LW, 1991, J BIOL CHEM, V266, P16977
   MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008
   Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843
   Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200
   NAITO K, 1991, J BIOL CHEM, V266, P7353
   RAGNI MV, 1985, BLOOD, V65, P719
   Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823
   Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650
   Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803
   ROSENTHAL RL, 1955, BLOOD, V10, P120
   RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926
   SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715
   SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639
   SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361
   STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004
   SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331
   THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898
   TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854
   Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108
   van Zanten GH, 1998, BLOOD, V91, P2353
NR 56
TC 62
Z9 65
U1 3
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 28
PY 2003
VL 278
IS 48
BP 48112
EP 48119
DI 10.1074/jbc.M306925200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 746DM
UT WOS:000186731400092
PM 12968031
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, Q
   Yang, F
   Zhang, JH
   Chen, YJ
AF Li, Q
   Yang, F
   Zhang, JH
   Chen, YJ
TI RETRACTED: Proteomic analysis of proteins that binds specifically to the
   homologous repeat regions of white spot syndrome virus (Retracted
   Article. See vol 27, pg 598, 2004)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE white spot syndrome virus (WSSV); homologous repeat region; DNA-binding
   protein; proteomics; interaction
ID NUCLEAR POLYHEDROSIS-VIRUS; GENOME SEQUENCE; SHRIMP; DNA; GENES;
   IDENTIFICATION
AB White spot syndrome virus (WSSV) is a major pathogen in the cultivated shrimp. Nine homologous repeat regions (hrrs) have been reported interspersed throughout the WSSV genome. In this investigation, the protein fraction that specifically bound to the hrrs was isolated by using DNA-affinity chromatography. A total of 9 (SI to S9) and 5 (C1 to C5) proteins separated from the WSSV infected shrimp and the healthy shrimp, respectively, were detected by using two-dimensional polyacrylamide gel electrophoresis, and 6 proteins changed with WSSV infection were analyzed by mass spectrometry (MS). One (S4) of the 6 proteins examined was identified as WSSV ORF59 protein, and another (S3) was a shrimp arginine kinase. No homologous proteins were found with the remaining 4 proteins by searching in the WSSV ORF database and NCBI database. The specific binding site of the 6 proteins was then determined by gel mobility shift assay (GMSA). Temporal analysis revealed that ORF59 gene was transcribed at the early stage of the infection. The results we obtained provide important information to understand WSSV replication. The combination of DNA-affinity chromatography, 2D-PAGE and MS approaches should have general application to the identification of gene regulating proteins of WSSV. The results represent the first isolation of a set of proteins that bind to the hrrs, and, furthermore, lead us a new research direction for the prevention and the therapy of WSSV.
C1 Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Dept Biochem & Mol Biol, Shenyang 110016, Peoples R China.
   Third Inst Oceanog, Xiamen 361005, Peoples R China.
RP Li, Q (reprint author), Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Dept Biochem & Mol Biol, Wenhua Rd 103, Shenyang 110016, Peoples R China.
EM lq751111@163.com
CR GUARINO LA, 1986, J VIROL, V60, P224
   Hayakawa T, 2000, VIROLOGY, V278, P1, DOI 10.1006/viro.2000.0668
   Huang CH, 2002, MOL CELL PROTEOMICS, V1, P223, DOI 10.1074/mcp.M100035-MCP200
   KOOL M, 1993, VIROLOGY, V192, P94, DOI 10.1006/viro.1993.1011
   KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229
   Kurtz S, 1999, BIOINFORMATICS, V15, P426, DOI 10.1093/bioinformatics/15.5.426
   Mann M, 2001, TRENDS BIOCHEM SCI, V26, P54, DOI 10.1016/S0968-0004(00)01726-6
   Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Rohrmann G., 1997, BACULOVIRUSES
   SENZO M, 1984, BIOCHEMISTRY-US, V23, P6491
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Tsai MF, 2000, VIROLOGY, V277, P100, DOI 10.1006/viro.2000.0597
   van Hulten MCW, 2000, J GEN VIROL, V81, P307, DOI 10.1099/0022-1317-81-2-307
   van Hulten MCW, 2001, VIROLOGY, V286, P7, DOI 10.1006/viro.2001.1002
   van Hulten MCW, 2000, VIROLOGY, V266, P227, DOI 10.1006/viro.1999.0088
   VLAK JM, 2002, 12 INT C VIR PAR
   Yang F, 2001, J VIROL, V75, P11811, DOI 10.1128/JVI.75.23.11811-11820.2001
   Yang F, 1997, J VIROL METHODS, V67, P1, DOI 10.1016/S0166-0934(97)00060-8
   YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417
NR 20
TC 4
Z9 5
U1 4
U2 20
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD NOV
PY 2003
VL 26
IS 11
BP 1517
EP 1522
DI 10.1248/bpb.26.1517
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 738YP
UT WOS:000186315700002
PM 14600393
OA Bronze
DA 2018-12-27
ER

PT J
AU Baykal, C
   Demirtas, E
   Al, A
   Ayhan, A
   Yuce, K
   Tulunay, G
   Kose, MF
   Ayhan, A
AF Baykal, C
   Demirtas, E
   Al, A
   Ayhan, A
   Yuce, K
   Tulunay, G
   Kose, MF
   Ayhan, A
TI RETRACTED: Comparison of HGF (hepatocyte growth factor) levels of
   epithelial ovarian cancer cyst fluids with benign ovarian cysts
   (Retracted Article. See vol 16, pg 953, 2006)
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article; Retracted Publication
DE c-met; hepatocyte growth factor; ovarian cancer; ovarian cysts
ID C-MET; CARCINOMA CELLS; SCATTER FACTOR; RECEPTOR; OVEREXPRESSION;
   COEXPRESSION; MODULATION; EXPRESSION; TUMORS
AB Hepatocyte growth factor (HGF) is known to take a role in oncogenesis and tumoral behavior of the tumors of the organs that contain both mesenchymal and epithelial cells. This study compares HGF levels in cyst fluids of epithelial ovarian cancer and benign ovarian cysts to look for the role of HGF in ovarian carcinogenesis. Twenty-four consecutive patients with ovarian cancer and 34 with benign ovarian cysts were recruited prospectively at the Gynecologic Oncology Departments of SSK Ankara Maternity Hospital and Hacettepe University School of Medicine between 2001 and 2002. Cyst fluids were collected during primary staging in cancer patients and during laparatomy for benign patients. HGF levels were measured by ELISA method. Median HGF levels of the benign ovarian cysts and epithelial ovarian tumoral fluids were found to be 3822 pg/ml (85-15,253 pg/ml) and 12,962 pg/ml (4136-16,025 pg/ml), respectively. Malignant cyst fluids have higher HGF levels when compared with benign ovarian cysts (P < 0.01). This finding suggests that HGF may take a paracrine role in oncogenic differentiation and tumoral development of epithelial ovarian cancers. Mechanisms that take a role in HGF secretion and the responses of neighboring epithelial cells to HGF during tumoral development need to be investigated.
C1 Univ Hacettepe, Sch Med, SSK Ankara Matern & Womens Hlth Teaching Hosp, Dept Gynecol Oncol, TR-06100 Ankara, Turkey.
   Univ Hacettepe, Sch Med, Dept Obstet & Gynaecol, TR-06100 Ankara, Turkey.
   Univ Hacettepe, Sch Med, Dept Pathol, TR-06100 Ankara, Turkey.
RP Baykal, C (reprint author), Cem Baykal, Paris Cad 37-9, Ankara, Turkey.
EM cem.baykal@ttnet.net.tr
RI al, ragip/A-1177-2012; AYHAN, Ayse/H-3331-2012
OI al, ragip/0000-0003-2921-1891; AYHAN, Ayse/0000-0003-0136-4271
CR Baykal C, 2003, GYNECOL ONCOL, V88, P123, DOI 10.1016/S0090-8258(02)00073-2
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   CHRISTENSEN BG, 1949, ACTA MED SCAND     S, V234, P103
   COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131
   Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I
   DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507
   GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0
   Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9
   LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1
   LYON M, 1994, J BIOL CHEM, V269, P11216
   Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591
   MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966
   MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4
   MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1
   MOGHUL A, 1994, ONCOGENE, V9, P2045
   NEGAMI AI, 1995, HORM RES, V44, P42, DOI 10.1159/000184660
   ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783
   SHIBAMOTO S, 1992, CELL STRUCT FUNCT, V1, P185
   SONNENBERG E, 1993, HEPATOCYTE GROWTH FA, P381
   Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.3.CO;2-M
   STRAIN AJ, 1982, IN VITRO CELL DEV B, V18, P108
   Tuck AB, 1996, AM J PATHOL, V148, P225
   WILSON AP, 1991, BRIT J CANCER, V63, P102, DOI 10.1038/bjc.1991.21
   WOLF HK, 1991, HEPATOLOGY, V14, P488, DOI 10.1016/0270-9139(91)90188-2
   Wong AST, 2001, ONCOGENE, V20, P1318, DOI 10.1038/sj.onc.1204253
NR 25
TC 14
Z9 16
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD NOV-DEC
PY 2003
VL 13
IS 6
BP 771
EP 775
DI 10.1111/j.1525-1438.2003.13326.x
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 752UD
UT WOS:000187184800007
PM 14675313
DA 2018-12-27
ER

PT J
AU Gonzalez, S
   Prives, C
   Cordon-Cardo, C
AF Gonzalez, S
   Prives, C
   Cordon-Cardo, C
TI RETRACTED: p73 alpha regulation by Chk1 in response to DNA damage
   (Retracted article. See vol. 37, 2017)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID KINASE C-ABL; CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS;
   PROTEIN-KINASE; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; INDUCE
   APOPTOSIS; TARGET GENES; S-PHASE
AB The checkpoint kinase 1 (Chk1) is an essential component of the DNA damage checkpoint. Previous studies have demonstrated an indispensable role for the p53-related transcription factor p73alpha in DNA damage-induced apoptosis. Here, we provide evidence that p73alpha is a target of Chk1. We found that endogenous p73alpha is serine phosphorylated by endogenous Chk1 upon DNA damage, which is a mechanism required for the apoptotic-inducing function of p73alpha. Consistent with this, we discovered that endogenous p73 interacts with Chk1 and is phosphorylated by Chk1 at serine 47 in vitro and in vivo. In contrast, Chk2 does not phosphorylate p73alpha in vitro. Moreover, mutation of serine 47 abolishes both Chk1-dependent phosphorylation of p73alpha upon DNA damage in vivo and the ability of Chk1 to upregulate the transactivation capacity of p73alpha. Our data indicate a novel biochemical pathway through which the p73a proapoptotic function requires DNA damage-triggered p73alpha phosphorylation by Chk1.
C1 Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA.
   Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.
RP Cordon-Cardo, C (reprint author), Mem Sloan Kettering Canc Ctr, Div Mol Pathol, 1275 York Ave, New York, NY 10021 USA.
EM cordon-c@mskcc.org
RI Gonzalez, Susana/I-3154-2015
OI Gonzalez, Susana/0000-0002-7443-6195
FU NCI NIH HHS [P01 CA 87497, P01 CA087497]
CR Agami R, 1999, NATURE, V399, P809
   Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4
   Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925
   Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2
   Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149
   Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8
   Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
   Di Como CJ, 1998, ONCOGENE, V16, P2527
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099
   Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a
   Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001
   Gong JG, 1999, NATURE, V399, P806
   Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600
   Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824
   Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9
   Jayaraman L, 1997, METHOD ENZYMOL, V283, P245
   Jost CA, 1997, NATURE, V389, P191
   Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955
   Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218
   Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793
   Levrero M, 2000, J CELL SCI, V113, P1661
   Liu QH, 2000, GENE DEV, V14, P1448
   Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X
   Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893
   Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8
   Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200
   MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0
   Ozaki T, 1999, CANCER RES, V59, P5902
   Prives C, 1999, J PATHOL, V187, P112
   Rhind N, 2000, J CELL SCI, V113, P3889
   Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497
   Shieh SY, 2000, GENE DEV, V14, P289
   Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj/cdd/4400995
   WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0
   Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450
   Yuan ZM, 1999, NATURE, V399, P814
   Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200
   Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.18557299
   Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001
   Zhu JH, 1998, CANCER RES, V58, P5061
NR 41
TC 65
Z9 65
U1 3
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2003
VL 23
IS 22
BP 8161
EP 8171
DI 10.1128/MCB.23.22.8161-8171.2003
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 739PC
UT WOS:000186354800021
PM 14585975
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Savastano, HI
   Arcediano, F
   Stout, SC
   Miller, RR
AF Savastano, HI
   Arcediano, F
   Stout, SC
   Miller, RR
TI RETRACTED: Interaction between preexposure and overshadowing: Further
   analysis of the extended comparator hypothesis (Retracted Article. See
   vol 59, pg 2207, 2006)
SO QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY SECTION B-COMPARATIVE AND
   PHYSIOLOGICAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID RELATIVE STIMULUS VALIDITY; WITHIN-COMPOUND ASSOCIATIONS; HUMAN CAUSAL
   JUDGMENT; LATENT INHIBITION; RETROSPECTIVE REVALUATION; BIOLOGICAL
   SIGNIFICANCE; BACKWARD BLOCKING; CUE COMPETITION; RECOVERY; EXTINCTION
AB Three experiments with rats used conditioned suppression of barpress to test predictions of the extended comparator hypothesis, which assumes that the effectiveness of (first-order) comparator stimuli in modulating responding to a target conditioned stimulus (CS) is itself modulated by other (second-order) comparator stimuli. Experiment 1 demonstrated that both pretraining exposure to the target CS alone (i.e., CS-preexposure effect, also known as latent inhibition) and pretraining exposure to a compound of the target CS and nontarget CS (i.e., compound-CS-preexposure effect) counteract overshadowing, and that posttraining deflation (i.e., extinction) of the overshadowing stimulus attenuates responding to the target CS when overshadowing is preceded by a CS-preexposure treatment (i.e., yields a CS-preexposure effect), but not when overshadowing is preceded by a compound-CS-preexposure treatment. Experiment 2 examined the consequences of posttraining associative inflation of the overshadowing stimulus or the preexposure companion stimulus following conjoint compound-CS-preexposure and overshadowing treatment. Experiment 3 examined the consequences of posttraining inflation of the overshadowing stimulus or the context following conjoint CS-alone preexposure and overshadowing treatment. The results support the expression-focused comparator view in contrast to recent acquisition-focused models of retrospective revaluation.
C1 SUNY Binghamton, Dept Psychol, Binghamton, NY 13902 USA.
RP Miller, RR (reprint author), SUNY Binghamton, Dept Psychol, Binghamton, NY 13902 USA.
EM miller@binghamton.edu
FU NIMH NIH HHS [MH33881]
CR Arcediano F, 2001, ANIM LEARN BEHAV, V29, P354, DOI 10.3758/BF03192901
   Blaisdell AP, 1999, ANIM LEARN BEHAV, V27, P63, DOI 10.3758/BF03199432
   Blaisdell AP, 2001, J EXP PSYCHOL-ANIM B, V27, P48, DOI 10.1037//0097-7403.27.1.48
   Blaisdell AP, 1998, J EXP PSYCHOL ANIM B, V24, P335, DOI 10.1037//0097-7403.24.3.335
   Brogden WJ, 1939, J EXP PSYCHOL, V25, P323, DOI 10.1037/h0058944
   Cole RP, 1997, LEARN MOTIV, V28, P1, DOI 10.1006/lmot.1997.0949
   Cole RP, 1996, ANIM LEARN BEHAV, V24, P256, DOI 10.3758/BF03198974
   De Houwer J, 2002, Q J EXP PSYCHOL-B, V55, P137, DOI 10.1080/02724990143000216
   De Houwer J, 2002, EXP PSYCHOL, V49, P27, DOI 10.1027//1618-3169.49.1.27
   Denniston JC, 1996, PSYCHOL SCI, V7, P325, DOI 10.1111/j.1467-9280.1996.tb00383.x
   Denniston JC, 2001, HANDBOOK OF CONTEMPORARY LEARNING THEORIES, P65
   Dickinson A, 1996, Q J EXP PSYCHOL-B, V49, P60, DOI 10.1080/713932614
   GRAHAME NJ, 1992, ANIM LEARN BEHAV, V20, P329, DOI 10.3758/BF03197956
   Holland PC, 1999, Q J EXP PSYCHOL-B, V52, P307, DOI 10.1080/027249999393022
   Kamin L. J, 1968, MIAM S PRED BEH AV S, P9
   KASPROW WJ, 1982, LEARN MOTIV, V13, P155, DOI 10.1016/0023-9690(82)90018-2
   KAUFMAN MA, 1981, B PSYCHONOMIC SOC, V18, P318
   KRAEMER PJ, 1988, ANIM LEARN BEHAV, V16, P164, DOI 10.3758/BF03209060
   Larkin MJW, 1998, J EXP PSYCHOL LEARN, V24, P1331, DOI 10.1037/0278-7393.24.6.1331
   Lashley KS, 1942, J GEN PSYCHOL, V26, P241, DOI 10.1080/00221309.1942.10545168
   LOY I, 2001, 13 ANN M SOC ESP PSI
   LUBOW RE, 1959, J COMP PHYSIOL PSYCH, V52, P415, DOI 10.1037/h0046700
   LUBOW RE, 1976, J EXP PSYCHOL ANIM B, V2, P163, DOI 10.1037/0097-7403.2.2.163
   LUBOW RE, 1973, PSYCHOL BULL, V79, P398, DOI 10.1037/h0034425
   LUBOW RE, 1982, ANIM LEARN BEHAV, V10, P483, DOI 10.3758/BF03212288
   MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778
   MATZEL LD, 1985, LEARN MOTIV, V16, P398, DOI 10.1016/0023-9690(85)90023-2
   Miller R.R., 1985, INFORMATION PROCESSI, P51
   Miller RR, 1996, J EXP PSYCHOL GEN, V125, P370, DOI 10.1037/0096-3445.125.4.370
   Millett R., 1988, Proceedings of the 1988 DCLASS Conference, P51, DOI 10.1016/S0079-7421(08)60038-9
   Oberling P, 2000, ANIM LEARN BEHAV, V28, P172, DOI 10.3758/BF03200252
   Pavlov I. P, 1927, CONDITIONED REFLEXES
   PEARCE JM, 1980, PSYCHOL REV, V87, P532, DOI 10.1037/0033-295X.87.6.532
   Rauhut AS, 2000, ANIM LEARN BEHAV, V28, P92, DOI 10.3758/BF03199775
   Rescorla R. A, 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1037/A0030892
   RUDY JW, 1976, J EXP PSYCHOL ANIM B, V2, P235, DOI 10.1037/0097-7403.2.3.235
   VANHAMME LJ, 1994, LEARN MOTIV, V25, P127, DOI 10.1006/lmot.1994.1008
   Wagner A.R., 1981, P5
   WAGNER AR, 1968, J EXP PSYCHOL, V76, P171, DOI 10.1037/h0025414
   Wasserman EA, 1998, Q J EXP PSYCHOL-B, V51, P121
NR 40
TC 12
Z9 12
U1 2
U2 9
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 0272-4995
J9 Q J EXP PSYCHOL-B
JI Q. J. Exp. Psychol. Sect. B-Comp. Physiol. Psychol.
PD NOV
PY 2003
VL 56
IS 4
BP 371
EP 395
DI 10.1080/02724990344000006
PG 25
WC Psychology, Biological; Physiology; Psychology; Psychology, Experimental
SC Psychology; Physiology
GA 733PT
UT WOS:000186010400004
PM 14578081
OA Bronze
DA 2018-12-27
ER

PT J
AU Lee, M
   Hwang, JT
   Lee, HJ
   Jung, SN
   Kang, IS
   Chi, SG
   Kim, SS
   Ha, JH
AF Lee, M
   Hwang, JT
   Lee, HJ
   Jung, SN
   Kang, IS
   Chi, SG
   Kim, SS
   Ha, JH
TI RETRACTED: AMP-activated protein kinase activity is critical for
   hypoxia-inducible factor-1 transcriptional activity and its target gene
   expression under hypoxic conditions in DU145 cells (Retracted article.
   See vol. 293, pg. 18013, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACETYL-COA CARBOXYLASE; FACTOR 1-ALPHA HIF-1-ALPHA; GLUCOSE-TRANSPORT;
   O-2 HOMEOSTASIS; NITRIC-OXIDE; FATTY-ACID; HIF-ALPHA; PHOSPHORYLATION;
   PATHWAY; STABILIZATION
AB AMP-activated protein kinase ( AMPK) functions as an energy sensor to provide metabolic adaptations under the ATP-deprived conditions such as hypoxia. In the present study, we considered a role of AMPK in the adaptive response to hypoxia by examining whether AMPK is involved in the regulation of hypoxia-inducible factor-1 (HIF-1), a heterodimeric transcription factor that is critical for hypoxic induction of physiologically important genes. We demonstrate that hypoxia or CoCl2 rapidly activated AMPK in DU145 human prostate cancer cells, and its activation preceded the induction of HIF-1alpha expression. Under these conditions, blockade of AMPK activity by a pharmacological or molecular approach significantly attenuated hypoxia-induced responses such as HIF-1 target gene expression, secretion of vascular endothelial growth factor, glucose uptake, and HIF-1-dependent reporter gene expression, indicating that AMPK is critical for the HIF-1 transcriptional activity and its target gene expression. Its functional requirement for HIF-1 activity was also demonstrated in several different cancer cell lines, but AMPK activation alone was not sufficient to stimulate the HIF-1 transcriptional activity. We further present data showing that AMPK transmits a positive signal for HIF-1 activity via a signaling pathway that is independent of phosphatidylinositol 3-kinase/AKT and several mitogen-activated protein kinases. Taken together, our results suggest that AMPK is a novel and critical component of HIF-1 regulation, implying its new roles in oxygen-regulated cellular phenomena.
C1 Kyung Hee Univ, Coll Med, Dept Mol Biol, Seoul 130701, South Korea.
   Kyung Hee Univ, Coll Med, Dept Biochem, Seoul 130701, South Korea.
   Kyung Hee Univ, Coll Med, Dept Pathol, Med Res Ctr Bioreact React Oxygen Species, Seoul 130701, South Korea.
   Dong A Univ, Dept Pharmacol, Med Res Ctr Canc Mol Therapy, Pusan 602103, South Korea.
RP Ha, JH (reprint author), Kyung Hee Univ, Coll Med, Dept Mol Biol, Hoegi Dong 1, Seoul 130701, South Korea.
EM hajh@khu.ac.kr
CR Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200
   Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200
   Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938
   Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002
   Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0
   Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544
   CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1
   Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798
   Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519
   HA J, 1994, J BIOL CHEM, V269, P22162
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186
   Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879
   Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369
   HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076
   Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253
   Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Kemp BE, 2003, BIOCHEM SOC T, V31, P162
   Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200
   Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852
   KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001
   Leff T, 2003, BIOCHEM SOC T, V31, P224
   Lopez JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053
   Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9
   Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200
   Mazure NM, 2003, CURR PHARM DESIGN, V9, P531, DOI 10.2174/1381612033391469
   MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9
   Palmer LA, 2000, MOL PHARMACOL, V58, P1197
   Peralta C, 2001, HEPATOLOGY, V34, P1164, DOI 10.1053/jhep.2001.29197
   Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631
   Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533
   Sambandam N, 2003, PROG LIPID RES, V42, P238, DOI 10.1016/S0163-7827(02)00065-6
   Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1
   Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299
   Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000
   Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200
   Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516
   Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085
   Zhong H, 2000, CANCER RES, V60, P1541
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200
NR 59
TC 191
Z9 201
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 10
PY 2003
VL 278
IS 41
BP 39653
EP 39661
DI 10.1074/jbc.M306104200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 728JJ
UT WOS:000185713800050
PM 12900407
OA Bronze
DA 2018-12-27
ER

PT J
AU Patil, NM
   Kelkar, AA
   Nabi, Z
   Chaudhari, RV
AF Patil, NM
   Kelkar, AA
   Nabi, Z
   Chaudhari, RV
TI RETRACTED: Novel CuI/tributyl phosphine catalyst system for amination of
   aryl chlorides (Retracted Article. See pg 2368, 2004)
SO CHEMICAL COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID NITROGEN; HALIDES; TRIARYLAMINES; COMPLEXES
AB A simple and efficient methodology for the synthesis of triarylamines from aryl chlorides in a single step has been demonstrated using a novel CuI/tributyl phosphine catalyst system with high activity and selectivity (80-87% yield).
C1 Natl Chem Lab, Homogeneous Catalysis Div, Pune 411008, Maharashtra, India.
RP Chaudhari, RV (reprint author), Natl Chem Lab, Homogeneous Catalysis Div, Pune 411008, Maharashtra, India.
EM rvc@ems.ncl.res.in
CR Beller M, 2001, J ORG CHEM, V66, P1403, DOI 10.1021/jo001544m
   Driver MS, 1997, J AM CHEM SOC, V119, P8232, DOI 10.1021/ja971057x
   Fagan PJ, 2000, J AM CHEM SOC, V122, P5043, DOI 10.1021/ja000094c
   Goodbrand HB, 1999, J ORG CHEM, V64, P670, DOI 10.1021/jo981804o
   GRUSHIN VV, 1994, CHEM REV, V94, P1047, DOI 10.1021/cr00028a008
   Gujadhur R, 2001, TETRAHEDRON LETT, V42, P4791, DOI 10.1016/S0040-4039(01)00888-7
   Gujadhur RK, 2001, ORG LETT, V3, P4315, DOI 10.1021/ol0170105
   GUJADHUR RK, 2001, SYNTHETIC COMMUN, V31, P139
   Hartwig JF, 1998, ANGEW CHEM INT EDIT, V37, P2046, DOI 10.1002/(SICI)1521-3773(19980817)37:15<2046::AID-ANIE2046>3.0.CO;2-L
   Hong YP, 1998, TETRAHEDRON LETT, V39, P3121, DOI 10.1016/S0040-4039(98)00517-6
   Kelkar AA, 2002, TETRAHEDRON LETT, V43, P7143, DOI 10.1016/S0040-4039(02)01708-2
   Kiyomori A, 1999, TETRAHEDRON LETT, V40, P2657, DOI 10.1016/S0040-4039(99)00291-9
   LEWIN AH, 1967, J CHEM SOC CHEM COMM, V80
   LINDLEY J, 1984, TETRAHEDRON, V40, P1433, DOI 10.1016/S0040-4020(01)91791-0
   Littke AF, 2002, ANGEW CHEM INT EDIT, V41, P4176, DOI 10.1002/1521-3773(20021115)41:22<4176::AID-ANIE4176>3.0.CO;2-U
   Wolfe JP, 1998, ACCOUNTS CHEM RES, V31, P805, DOI 10.1021/ar9600650
   Wolfe JP, 2000, J ORG CHEM, V65, P1158, DOI 10.1021/jo991699y
   Wolter M, 2001, ORG LETT, V3, P3803, DOI 10.1021/ol0168216
   Yang BH, 1999, J ORGANOMET CHEM, V576, P125, DOI 10.1016/S0022-328X(98)01054-7
NR 19
TC 22
Z9 22
U1 4
U2 28
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PD OCT 7
PY 2003
IS 19
BP 2460
EP 2461
DI 10.1039/b308034j
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 733YY
UT WOS:000186029500033
PM 14587731
DA 2018-12-27
ER

PT J
AU Sezen, B
   Sames, D
AF Sezen, B
   Sames, D
TI RETRACTED: Cobalt-catalyzed arylation of azole heteroarenes via direct
   C-H bond functionalization (Retracted Article. See vol 8, pg 2899, 2006)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID CROSS-COUPLING REACTIONS; ORGANOMAGNESIUM REAGENTS; ALKYL-HALIDES;
   COPPER IODIDE; ARYL; DERIVATIVES; ALKENYLATION; CYCLIZATIONS;
   HETEROCYCLES; COMPLEXES
AB We herein report a new cobalt-catalyzed method for arylation of azole heteroarenes, including thiazole, oxazole, imidazole, benzothiazole, benzoxazole, and benzimidazole. The direct arylation of thiazole and oxazole was achieved both with iodo- and bromoarenes as the aryl donors in the presence of cobalt catalyst [Co(OAc)(2)/IMes] and cesium carbonate, while imidazole required the use of zinc oxide as the base. A complete reversal of arylation from C-5 to C-2 was accomplished using the bimetallic Co/Cu/IMes system. A direct comparison of the new cobalt method and the previously developed palladium protocol revealed significant differences, in terms of both chemical yield and selectivity.
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sezen, B (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
CR Anderson BA, 1996, SYNTHESIS-STUTTGART, P583
   Arduengo A., 1991, WO, Patent No. [91/14678, 9114678]
   Arduengo A.J, 1992, [No title captured], Patent No. [5,077,414, 5077414]
   Avedissian H, 1998, TETRAHEDRON LETT, V39, P6163, DOI 10.1016/S0040-4039(98)01267-2
   BHANDAL H, 1990, J CHEM SOC PERK T 1, P2691, DOI 10.1039/p19900002691
   Cahiez G, 1998, TETRAHEDRON LETT, V39, P6159, DOI 10.1016/S0040-4039(98)01266-0
   CLARK AJ, 1989, TETRAHEDRON LETT, V40, P5485
   GRIMMETT MR, 1984, COMPREHENSIVE HETERO, V5, P418
   Grundemann S, 2002, J AM CHEM SOC, V124, P10473, DOI 10.1021/ja026735g
   Harrowven DC, 2000, TETRAHEDRON LETT, V41, P6681, DOI 10.1016/S0040-4039(00)01119-9
   Herrmann WA, 2002, ANGEW CHEM INT EDIT, V41, P1290, DOI 10.1002/1521-3773(20020415)41:8<1290::AID-ANIE1290>3.0.CO;2-Y
   Hillier AC, 2002, J ORGANOMET CHEM, V653, P69, DOI 10.1016/S0022-328X(02)01154-3
   IYER S, 1995, J ORGANOMET CHEM, V490, pC27, DOI 10.1016/0022-328X(94)05363-G
   Kneisel FF, 2002, TETRAHEDRON LETT, V43, P4875, DOI 10.1016/S0040-4039(02)00839-0
   Kondo Y, 2000, ORG LETT, V2, P3111, DOI 10.1021/ol000183u
   LAMPEKA JD, 1988, Z CHEM, V28, P70
   LIEBESKIND LS, 1990, J ORG CHEM, V55, P5359, DOI 10.1021/jo00306a012
   METZGER JV, 1984, COMPREHENSIVE HETERO, V6, P263
   Miura M, 2002, TOP CURR CHEM, V219, P211
   Mori A, 2003, J AM CHEM SOC, V125, P1700, DOI 10.1021/ja0269189
   OKURO K, 1993, J ORG CHEM, V58, P4716, DOI 10.1021/jo00069a040
   Pivsa-Art S, 1998, B CHEM SOC JPN, V71, P467, DOI 10.1246/bcsj.71.467
   Sezen B, 2003, J AM CHEM SOC, V125, P10580, DOI 10.1021/ja036157j
   Sezen B, 2003, J AM CHEM SOC, V125, P5274, DOI 10.1021/ja034848
   Tan KL, 2002, J AM CHEM SOC, V124, P3202, DOI 10.1021/ja017351d
   TSUJI J, 1997, PALLADIUM REAGENTS C
   Tsuji T, 2002, ANGEW CHEM INT EDIT, V41, P4137, DOI 10.1002/1521-3773(20021104)41:21<4137::AID-ANIE4137>3.0.CO;2-0
   Wakabayashi K, 2001, J AM CHEM SOC, V123, P5374, DOI 10.1021/ja0100423
NR 28
TC 90
Z9 92
U1 6
U2 51
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD OCT 2
PY 2003
VL 5
IS 20
BP 3607
EP 3610
DI 10.1021/ol035313o
PG 4
WC Chemistry, Organic
SC Chemistry
GA 725WN
UT WOS:000185565500016
PM 14507184
DA 2018-12-27
ER

PT J
AU Bremner, JD
   Vythilingam, M
   Anderson, G
   Vermetten, E
   McGlashan, T
   Heninger, G
   Rasmusson, A
   Southwick, SM
   Charney, DS
AF Bremner, JD
   Vythilingam, M
   Anderson, G
   Vermetten, E
   McGlashan, T
   Heninger, G
   Rasmusson, A
   Southwick, SM
   Charney, DS
TI RETRACTED: Assessment of the hypothalamic-pituitary-adrenal axis over a
   24-hour diurnal period and in response to neuroendocrine challenges in
   women with and without childhood sexual abuse and posttraumatic stress
   disorder (Retracted Article. See vol 55, pg 1202, 2004)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article; Retracted Publication
DE HPA axis; posttraumatic stress disorder; childhood abuse; cortisol; ACTH
ID CORTICOTROPIN-RELEASING-FACTOR; URINARY CORTISOL EXCRETION;
   MATERNAL-DEPRIVATION; COMBAT VETERANS; ADRENOCORTICAL AXIS; PROLONGED
   STRESS; PLASMA-CORTISOL; PRENATAL STRESS; MESSENGER-RNA; PTSD SCALE
AB Background: Preclinical studies showed that early stress results in long-term alterations in the hypothalamic-pituitary-adrenal (HPA) axis. We performed a comprehensive assessment of the HPA axis in women with and without a history of early childhood sexual abuse and posttraumatic stress disorder (PTSD).
   Methods: Fifty-two women with and without a history of early childhood sexual abuse and PTSD underwent a comprehensive assessment of the HPA axis, including measurement of cortisol in plasma every 15 min over a 24-hour period and cortisol and corticotropin (ACTH) following corticotropin-releasing factor (CRF) and ACTH challenge.
   Results: Abused women with PTSD had lower levels of cortisol during the afternoon hours (12:00-8:00 Pm) of a 24-hour period compared with non-PTSD women. Their ACTH response to a CRF challenge was blunted compared with nonabused non-PTSD (but not abused non-PTSD) women. There were no differences in cortisol response to CRF and ACTH challenges between the groups. Increased PTSD symptom levels were associated with low afternoon cortisol levels.
   Conclusions: These findings suggest that early abuse is associated with increased CRF drive as evidenced by decreased pituitary sensitivity to CRF, whereas in abuse with PTSD there is a specific hypocortisolemia that is most pronounced in the afternoon hours. (C) 2003 Society of Biological Psychiatry.
C1 Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30306 USA.
   Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30306 USA.
   Emory Univ, Sch Med, Emory Ctr Positron Emiss Tomog, Atlanta, GA 30306 USA.
   Atlanta VAMC, Decatur, GA USA.
   NIMH, Program Mood & Anxiety Disorders, Bethesda, MD 20892 USA.
   Yale Univ, Child Study Ctr, Sch Med, New Haven, CT USA.
   Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
RP Bremner, JD (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, 1256 Briarcliff Rd, Atlanta, GA 30306 USA.
RI Bremner, James/B-1632-2013
OI Vermetten, Eric/0000-0003-0579-4404
FU NIMH NIH HHS [1R01 MH56120-02]
CR Baker DG, 1999, AM J PSYCHIAT, V156, P585
   BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106
   Bremner JD, 2000, DEPRESS ANXIETY, V12, P1, DOI 10.1002/1520-6394(2000)12:1<1::AID-DA1>3.0.CO;2-W
   Bremner JD, 1998, J TRAUMA STRESS, V11, P125, DOI 10.1023/A:1024465317902
   Bremner JD, 1997, AM J PSYCHIAT, V154, P624
   BREMNER JD, IN PRESS PSYCHONEURO
   BREMNER JD, 2002, DOES STRESS DAMAGE B
   CHAPPELL PB, 1986, J NEUROSCI, V6, P2908
   Cicchetti D, 2001, DEV PSYCHOPATHOL, V13, P783
   Coplan JD, 1996, P NATL ACAD SCI USA, V93, P1619, DOI 10.1073/pnas.93.4.1619
   DALLMAN MF, 1973, ENDOCRINOLOGY, V92, P1367, DOI 10.1210/endo-92-5-1367
   De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1259, DOI 10.1016/S0006-3223(99)00044-X
   DEBELLIS MD, 1994, J CLIN ENDOCR METAB, V78, P249, DOI 10.1210/jc.78.2.249
   ELZINGA BM, IN PRESS NEUROPSYCHO
   FRIDE E, 1986, PHYSIOL BEHAV, V37, P681, DOI 10.1016/0031-9384(86)90172-1
   Friedman Matthew J., 1995, P429
   Gunnar MR, 2001, DEV PSYCHOPATHOL, V13, P611, DOI 10.1017/S095457940100311X
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Hart J, 1996, DEV PSYCHOPATHOL, V8, P201, DOI 10.1017/S0954579400007045
   Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592
   Heim C, 2001, AM J PSYCHIAT, V158, P575, DOI 10.1176/appi.ajp.158.4.575
   HERMAN JP, 1989, J NEUROSCI, V9, P3072
   JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118
   KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1
   Kaufman J, 1997, BIOL PSYCHIAT, V42, P669, DOI 10.1016/S0006-3223(96)00470-2
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   KUDLER H, 1987, AM J PSYCHIAT, V144, P1068
   Ladd CO, 1996, ENDOCRINOLOGY, V137, P1212, DOI 10.1210/en.137.4.1212
   LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002
   LEVINE S, 1993, PSYCHONEUROENDOCRINO, V18, P297, DOI 10.1016/0306-4530(93)90026-H
   MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131
   MAKINO S, 1995, ENDOCRINOLOGY, V136, P3299, DOI 10.1210/en.136.8.3299
   MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003
   Mason JW, 2002, PSYCHOSOM MED, V64, P238, DOI 10.1097/00006842-200203000-00006
   McCauley J, 1997, JAMA-J AM MED ASSOC, V277, P1362, DOI 10.1001/jama.277.17.1362
   OTTENWELLER JE, 1989, BIOL PSYCHIAT, V26, P829, DOI 10.1016/0006-3223(89)90123-6
   OWENS MJ, 1991, PHARMACOL REV, V43, P425
   PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K
   PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V
   Rasmusson AM, 2001, BIOL PSYCHIAT, V50, P965, DOI 10.1016/S0006-3223(01)01264-1
   RIVIER C, 1987, ENDOCRINOLOGY, V121, P1320, DOI 10.1210/endo-121-4-1320
   SAIGH PA, 1999, POSTTRAUMATIC STRESS
   Sapolsky RM, 1997, ARCH GEN PSYCHIAT, V54, P1137
   Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749
   Smith MA, 1997, ENDOCRINOLOGY, V138, P4622, DOI 10.1210/en.138.11.4622
   SMITH MA, 1989, BIOL PSYCHIAT, V26, P349, DOI 10.1016/0006-3223(89)90050-4
   Spitzer RL, 1987, STRUCTURED CLIN INTE
   STANTON ME, 1988, BEHAV NEUROSCI, V102, P692, DOI 10.1037//0735-7044.102.5.692
   Stein MB, 1997, BIOL PSYCHIAT, V42, P680, DOI 10.1016/S0006-3223(96)00489-1
   Takahashi LK, 1998, PSYCHONEUROENDOCRINO, V23, P571
   VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409
   YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004
   YEHUDA R, 1991, AM J PSYCHIAT, V148, P499
   YEHUDA R, 1994, ANN NY ACAD SCI, V746, P378
   Yehuda R, 1996, PSYCHONEUROENDOCRINO, V21, P1, DOI 10.1016/0306-4530(95)00055-0
   YEHUDA R, 1995, AM J PSYCHIAT, V152, P982
   YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583
   YEHUDA R, 1993, AM J PSYCHIAT, V150, P83
   YEHUDA R, 1995, NEUROBIOLOGICAL CLIN, P367
   YOUNG EA, 1985, ENDOCRINOLOGY, V117, P23, DOI 10.1210/endo-117-1-23
NR 60
TC 69
Z9 71
U1 4
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD OCT 1
PY 2003
VL 54
IS 7
BP 710
EP 718
DI 10.1016/S0006-3223(03)01912-1
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 724RL
UT WOS:000185500500007
PM 14512211
DA 2018-12-27
ER

PT J
AU Yu, ZS
   Zhang, HX
AF Yu, ZS
   Zhang, HX
TI RETRACTED: Ethanol fermentation of acid-hydrolyzed cellulosic pyrolysate
   with Saccharomyces cerevisiae (Retracted Article. See vol 100, pg 4539,
   2009)
SO BIORESOURCE TECHNOLOGY
LA English
DT Article; Retracted Publication
DE acid-hydrolysis; cellulosic pyrolysate; ethanol; fermentation; S.
   cerevisiae
ID WOOD; LEVOGLUCOSAN; IMPROVEMENT; INHIBITION; XYLITOL
AB The acid hydrolysis of cellulosic pyrolysate to glucose and its fermentation to ethanol were investigated. The maximum glucose yield (17.4%) was obtained by the hydrolysis with 0.2 mol sulfuric acid per liter pyrolysate using autoclaving at 121 degreesC for 20 min. The fermentation by Saccharomyces cerevisiae of a hydrolysate medium containing 31.6 g/l glucose gave 14.2 g/l ethanol in 24 h, whereas the fermentation of the medium containing 31.6 g/l pure glucose gave 13.7 g/l ethanol in 18 h. The results showed that the acid-hydrolyzed pyrolysate could be used for ethanol production. Different nitrogen sources were evaluated and the best ethanol concentration (15.1 g/l) was achieved by single urea. S. cerevisiae (R) was obtained by adaptation of S. cerevisiae to the hydrolysate medium for 12 times, and 40.2 g/l ethanol was produced by S. cerevisiae (R) in the fermentation with the hydrolysate medium containing 95.8 g/l glucose, which was about 47% increase in ethanol production compared to its parent strain. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Chinese Acad Sci, Lab Environm Biotechnol, Ecoenvironm Sci Res Ctr, Beijing 100085, Peoples R China.
RP Zhang, HX (reprint author), Chinese Acad Sci, Lab Environm Biotechnol, Ecoenvironm Sci Res Ctr, POB 2871, Beijing 100085, Peoples R China.
EM hxzhang@mail.rcees.ac.cn
CR Bafrncova P, 1999, BIOTECHNOL LETT, V21, P337, DOI 10.1023/A:1005436816047
   BONN G, 1985, J CARBOHYD CHEM, V4, P405, DOI 10.1080/07328308508070190
   BROWN RC, 2001, ACS SYM SER, V784, P123
   Kumakura M, 1997, PROCESS BIOCHEM, V32, P555, DOI 10.1016/S0032-9592(97)00011-3
   Mamma D, 1996, PROCESS BIOCHEM, V31, P377, DOI 10.1016/0032-9592(95)00075-5
   NAKAGAWA M, 1984, J FERMENT TECHNOL, V62, P201
   OOSHIMA H, 1985, BIOTECHNOL BIOENG, V27, P389, DOI 10.1002/bit.260270402
   Palmqvist E, 2000, BIORESOURCE TECHNOL, V74, P17, DOI 10.1016/S0960-8524(99)00160-1
   PAREKH SR, 1986, APPL MICROBIOL BIOT, V25, P300, DOI 10.1007/BF00253667
   PISKORZ J, 1989, J ANAL APPL PYROL, V16, P127, DOI 10.1016/0165-2370(89)85012-0
   PROSEN EM, 1993, BIOTECHNOL BIOENG, V42, P538, DOI 10.1002/bit.260420419
   RADLEIN D, 1991, J ANAL APPL PYROL, V19, P41, DOI 10.1016/0165-2370(91)80034-6
   Roberto ICC, 1996, APPL BIOCHEM BIOTECH, V57-8, P339, DOI 10.1007/BF02941712
   SHAFIZADEH F, 1982, J APPL POLYM SCI, V27, P4577, DOI 10.1002/app.1982.070271205
   Silva CJSM, 2001, LETT APPL MICROBIOL, V32, P248, DOI 10.1046/j.1472-765X.2001.00899.x
   Wu Z, 1997, BIOTECHNOL LETT, V19, P977, DOI 10.1023/A:1018487015129
   Zhuang XL, 2001, BIORESOURCE TECHNOL, V79, P63, DOI 10.1016/S0960-8524(01)00023-2
NR 17
TC 26
Z9 27
U1 2
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD OCT
PY 2003
VL 90
IS 1
BP 95
EP 100
DI 10.1016/S0960-8524(03)00093-2
PG 6
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 709XN
UT WOS:000184652000015
PM 12835064
DA 2018-12-27
ER

PT J
AU Siegers, K
   Bolter, B
   Schwarz, JP
   Bottcher, UMK
   Guha, S
   Hartl, FU
AF Siegers, K
   Bolter, B
   Schwarz, JP
   Bottcher, UMK
   Guha, S
   Hartl, FU
TI RETRACTED: TRiC/CCT cooperates with different upstream chaperones in the
   folding of distinct protein classes (Retracted Article. See vol 27, pg
   301, 2008)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE chaperonin-assisted folding; GimC; Ssb-type Hsp70; TRiC; WD40 proteins
ID POLYPEPTIDE-ASSOCIATED COMPLEX; NEWLY SYNTHESIZED PROTEINS;
   TUMOR-SUPPRESSOR COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; CYTOSOLIC
   CHAPERONIN; MOLECULAR CHAPERONES; NASCENT CHAIN; UNFOLDED PROTEINS;
   TRIGGER FACTOR
AB The role in protein folding of the eukaryotic chaperonin TRiC/CCT is only partially understood. Here, we show that a group of WD40 beta-propeller proteins in the yeast cytosol interact transiently with TRiC upon synthesis and require the chaperonin to reach their native state. TRiC cooperates in the folding of these proteins with the ribosome-associated heat shock protein (Hsp)70 chaperones Ssb1/2p. In contrast, newly synthesized actin and tubulins, the major known client proteins of TRiC, are independent of Ssb1/2p and instead use the co-chaperone GimC/prefoldin for efficient transfer to the chaperonin. GimC can replace Ssb1/2p in the folding of WD40 substrates such as Cdc55p, but combined deletion of SSB and GIM genes results in loss of viability. These findings expand the substrate range of the eukaryotic chaperonin by a structurally defined class of proteins and demonstrate an essential role for upstream chaperones in TRiC-assisted folding.
C1 Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.
RP Siegers, K (reprint author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.
EM siegers@biochem.mpg.de
CR ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729
   [Anonymous], 1991, Methods Enzymol, V194, P1
   BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360
   Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9
   Delneri D, 2000, GENE, V252, P127, DOI 10.1016/S0378-1119(00)00217-1
   Deuerling E, 1999, NATURE, V400, P693
   Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7
   Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0
   Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6
   FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0
   Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603
   Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289
   Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198
   Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599
   Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952
   George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296
   Goasduff T, 2000, ARCH BIOCHEM BIOPHYS, V379, P321, DOI 10.1006/abbi.2000.1870
   Guenther MG, 2002, GENE DEV, V16, P3130, DOI 10.1101/gad.1037502
   Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767
   Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a
   Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W
   Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294
   Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640
   McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591
   Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003
   Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6
   Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7
   NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0
   NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I
   Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382
   Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981
   Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L
   Ruepp A, 2001, J STRUCT BIOL, V135, P126, DOI 10.1006/jsbi.2001.4402
   Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75
   Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5
   Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0
   Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4
   Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85
   Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4
   Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0
   Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K
   WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310
   Wiedmann B, 1999, FEBS LETT, V458, P51, DOI 10.1016/S0014-5793(99)01118-7
   WIEDMANN M, 1988, EMBO J, V7, P1763, DOI 10.1002/j.1460-2075.1988.tb03006.x
   Yang HF, 2000, MOL CELL BIOL, V20, P8143, DOI 10.1128/MCB.20.21.8143-8156.2000
NR 50
TC 79
Z9 80
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD OCT 1
PY 2003
VL 22
IS 19
BP 5230
EP 5240
DI 10.1093/emboj/cdg483
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 728RZ
UT WOS:000185731300033
PM 14517260
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Wenderoth, DF
   Ferslev, B
   Macarri, G
   Molinari, G
   Lunsdorf, H
   Timmis, KN
AF Wenderoth, DF
   Ferslev, B
   Macarri, G
   Molinari, G
   Lunsdorf, H
   Timmis, KN
TI RETRACTED: Leitbakteria of microbial biofilm communities causing
   occlusion of biliary stents (Retracted Article. See vol 5, pg 452, 2005)
SO ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID PSEUDOMONAS-AERUGINOSA; HYBRIDIZATION; PREVENTION
AB Biliary stents inserted to relieve obstructive jaundice caused by biliary or pancreatic malignancies inevitably become occluded by microbial growth in the form of diverse microbial community biofilms. The scarce information available on these communities is based on cultivation methods, but such methods usually provide distorted overviews of community composition, so commonalities and differences in biliary stent communities are uncertain. We extracted DNA and RNA from the microbial communities of 11 biliary stents explanted from nine patients in hospitals from two different countries, amplified 16S rRNA and rDNA sequences, analysed the amplicons by the singlestrand conformation polymorphism (SSCP) method, and sequenced and deduced phylogenetic assignments of the major amplicons representing the major biofilm community members. We used a Modified Robbins Device (MRD) to study de novo development of a stent biofilm from a patient stent microbial community. Single-strand conformation polymorphism fingerprinting revealed the same six abundant bacterial species, here designated Leitbakteria, namely Klebsiella pneumoniae, Enterococcus faecalis, Pseudomonas aeruginose, Enterobacter aerogenes; and two unculturable bacteria distantly related to E. coli and Shigella sonnei, in all of the stent biofilm communities. In the experimental biliary stent system, a sequential colonization of the stent surface was observed, with P. aeruginosa being the pioneer colonizer, followed by K. pneumoniae and one of the unculturable Leitbakteria, followed by the remainder of the community. The overview of microbial biofilm communities of biliary stents gained by the use of culture-independent methods revealed new unculturable bacteria as major members of biliary stent biofilms, and the diversity of the abundant members of the stent biofilms is considerably lower than suggested from earlier studies based on cultivation methods, and that communities from different stents from different patients in different countries are remarkably similar and have similar major members, the stent Leitbakteria.
C1 GBF German Res Ctr Biotechnol, Div Microbiol, D-38124 Braunschweig, Germany.
   Braunschweig Gen Hosp, Surg Clin, D-38126 Braunschweig, Germany.
   Univ Ancona, Dept Gastroenterol, I-60100 Ancona, Italy.
RP Wenderoth, DF (reprint author), GBF German Res Ctr Biotechnol, Div Microbiol, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
EM dfw@gbf.de
OI Molinari, Gabriella/0000-0002-6781-1292
CR Di Rosa Roberta, 1999, Microbial Ecology in Health and Disease, V11, P84
   DORING G, 1989, EPIDEMIOL INFECT, V103, P555
   GOVAN JRW, 1975, J MED MICROBIOL, V8, P513, DOI 10.1099/00222615-8-4-513
   Haeussler Susanne, 1999, Clinical Infectious Diseases, V29, P621
   KESSNER DM, 1967, AM J EPIDEMIOL, V85, P45, DOI 10.1093/oxfordjournals.aje.a120674
   Kiewitz C, 2000, J BACTERIOL, V182, P3125, DOI 10.1128/JB.182.11.3125-3135.2000
   Libby ED, 1997, AM J GASTROENTEROL, V92, P543
   Libby ED, 1996, AM J GASTROENTEROL, V91, P1301
   LINDE K, 1963, ARCH HYG, V146, P126
   Lunsdorf H, 2001, METHODS ENZYMOL, V336, P317
   MCCOY WF, 1981, CAN J MICROBIOL, V27, P910, DOI 10.1139/m81-143
   Molinari G, 1996, EUR J CLIN MICROBIOL, V15, P88, DOI 10.1007/BF01586194
   Moore E, 1999, MOL MICROBIAL ECOLOG, V1, P1
   Nielsen JL, 2002, APPL ENVIRON MICROB, V68, P4629, DOI 10.1128/AEM.68.9.4629-4636.2002
   Pelz O, 2001, FEMS MICROBIOL ECOL, V38, P123
   Sambrook J., 1989, MOL CLONING LAB MANU
   Schwieger F, 1998, APPL ENVIRON MICROB, V64, P4870
   SUNG J Y, 1990, Microbial Ecology in Health and Disease, V3, P199
   VASIL ML, 1986, J PEDIATR-US, V108, P800, DOI 10.1016/S0022-3476(86)80748-X
   Ward BB, 2002, P NATL ACAD SCI USA, V99, P10234, DOI 10.1073/pnas.162359199
NR 20
TC 11
Z9 13
U1 3
U2 14
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1462-2912
J9 ENVIRON MICROBIOL
JI Environ. Microbiol.
PD OCT
PY 2003
VL 5
IS 10
BP 859
EP 866
DI 10.1046/j.1462-2920.2003.00513.x
PG 8
WC Microbiology
SC Microbiology
GA 728YG
UT WOS:000185743500005
PM 14510839
DA 2018-12-27
ER

PT J
AU Densmore, CL
AF Densmore, CL
TI RETRACTED: Polyethyleneimine-based gene therapy by inhalation (Retracted
   article. See vol. 12, pg. 135, 2012)
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review; Retracted Publication
DE aerosol; cancer; gene therapy; inhalation; non-viral delivery;
   polyethyleneimine; toxicity
ID OSTEOSARCOMA LUNG METASTASES; DNA/TRANSFERRIN-PEI COMPLEXES; LIPID-DNA
   COMPLEXES; CELLS IN-VITRO; AEROSOL DELIVERY; LINEAR POLYETHYLENIMINE;
   CATIONIC LIPIDS; MOUSE LUNG; GUANIDINIUM-CHOLESTEROL; TRANSGENE
   EXPRESSION
AB The delivery of genes by inhalation holds promise for the treatment of a wide range of pulmonary and non-pulmonary disorders and offers numerous advantages over more invasive modes of delivery. Subsequent to the cloning of the cystic fibrosis gene, there was great interest in the delivery of genes directly to the lung surfaces by aerosol, and most early efforts focused on the use of non-viral vectors, particularly cationic lipids. Unfortunately, nebulisation shear forces, inefficient penetration of mucous barriers and inhibitory effects of surfactant and other lung-specific features have generally resulted in a lack of therapeutic effect, and much of this work has diminished in recent years as a consequence. Polyethyleneimine (PEI)-based formulations have proven stable during nebulisation and result in nearly 100% efficient transfection throughout the airways, as well as significant although lower, levels of transfection throughout the lung parenchyma. Most importantly, therapeutic responses have been obtained in several animal lung tumour models when PEI-based complexes of p53 and IL-12 genes were delivered by aerosol. This approach may also prove useful as a means of localised genetic immunisation. In addition, this mode of delivery seems to be associated with surprisingly low toxicity, and results in little or no CpG immunostimulatory response, which has presented a challenge to repeated gene therapy via other modes of delivery.
C1 Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.
RP Densmore, CL (reprint author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.
EM charlesd@bcm.tmc.edu
CR ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135
   BIKALIS M, 1985, ENCY POLYM SCI ENG, V1
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Boussif O, 1996, GENE THER, V3, P1074
   Bramson JL, 1996, HUM GENE THER, V7, P1995, DOI 10.1089/hum.1996.7.16-1995
   BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223
   CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378
   Chadwick SL, 1997, GENE THER, V4, P937, DOI 10.1038/sj.gt.3300481
   Chen L, 1997, J IMMUNOL, V159, P351
   Chollet P, 2002, J GENE MED, V4, P84, DOI 10.1002/jgm.237
   COHEN J, 1995, SCIENCE, V270, P908
   Coll JL, 1999, HUM GENE THER, V10, P1659, DOI 10.1089/10430349950017662
   DEFFIE A, 1995, MOL CELL BIOL, V15, P3926
   Densmore CL, 2000, MOL THER, V1, P180, DOI 10.1006/mthe.1999.0021
   Densmore CL, 1999, J GENE MED, V1, P251
   Densmore CL, 2001, CANCER GENE THER, V8, P619, DOI 10.1038/sj.cgt.7700343
   DENSMORE CL, 2002, RESP DRUG DELIV, V8, P1
   Duncan JE, 1997, HUM GENE THER, V8, P431, DOI 10.1089/hum.1997.8.4-431
   Eastman SJ, 1998, HUM GENE THER, V9, P43, DOI 10.1089/hum.1998.9.1-43
   Eastman SJ, 1997, HUM GENE THER, V8, P313, DOI 10.1089/hum.1997.8.3-313
   Eastman SJ, 1997, HUM GENE THER, V8, P765, DOI 10.1089/hum.1997.8.6-765
   Erbacher P, 1999, J GENE MED, V1, P210
   Fan JG, 1999, MOL PHARMACOL, V56, P966
   Gately M K, 1994, Ther Immunol, V1, P187
   GATELY MK, 1992, CELL IMMUNOL, V143, P127, DOI 10.1016/0008-8749(92)90011-D
   Gautam A, 2000, MOL THER, V2, P63, DOI 10.1006/mthe.2000.0087
   Gautam A, 2000, MOL THER, V2, P318, DOI 10.1006/mthe.2000.0138
   Gautam A, 2002, GENE THER, V9, P353, DOI 10.1038/sj/gt/3301662
   Gautam A, 2002, CANCER GENE THER, V9, P28, DOI 10.1038/sj/cgt/7700405
   Gautam A, 2001, MOL THER, V3, P551, DOI 10.1006/mthe.2001.0300
   Gautam A, 2001, GENE THER, V8, P254, DOI 10.1038/sj.gt.3301369
   GAUTAM A, 2002, METHODS MOL MED LUNG, V2, P607
   Gautam Ajay, 2002, Am J Respir Med, V1, P35
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Guillaume CR, 2001, BIOCHEM BIOPH RES CO, V286, P464, DOI 10.1006/bbrc.2001.5418
   HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338
   Hunter AC, 2002, DRUG DISCOV TODAY, V7, P998, DOI 10.1016/S1359-6446(02)02444-3
   Jia SF, 2003, CLIN CANCER RES, V9, P3462
   Jia SF, 2002, CANCER GENE THER, V9, P260, DOI 10.1038/sj/cgt/7700432
   Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465
   Kayaga J, 1999, GENE THER, V6, P1475, DOI 10.1038/sj.gt.3300961
   Kichler A, 2001, J GENE MED, V3, P135, DOI 10.1002/jgm.173
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   Knight V, 1999, CANCER CHEMOTH PHARM, V44, P177, DOI 10.1007/s002800050965
   KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827
   Koshkina NV, 2003, MOL THER, V8, P249, DOI 10.1016/S1525-0016(03)00177-1
   Koshkina NV, 2000, CLIN CANCER RES, V6, P2876
   Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701
   LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635
   MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   MISSOL E, 1995, CANCER LETT, V97, P189, DOI 10.1016/0304-3835(95)03961-U
   Missol-Kolka E, 1998, NEOPLASMA, V45, P305
   NASTALA CL, 1994, J IMMUNOL, V153, P1697
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Okaichi K, 1998, J RADIAT RES, V39, P111, DOI 10.1269/jrr.39.111
   Orson FM, 2002, GENE THER, V9, P463, DOI 10.1038/sj/gt/3301666
   Oudrhiri N, 1997, P NATL ACAD SCI USA, V94, P1651, DOI 10.1073/pnas.94.5.1651
   Pitard B, 2001, J GENE MED, V3, P478, DOI 10.1002/jgm.211
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Qin HX, 1996, HUM GENE THER, V7, P1853, DOI 10.1089/hum.1996.7.15-1853
   SAITO M, 1995, CLIN EXP METASTAS, V13, P249, DOI 10.1007/BF00133480
   SARMIENTO UM, 1994, LAB INVEST, V71, P862
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689
   Schwarz LA, 1996, HUM GENE THER, V7, P731, DOI 10.1089/hum.1996.7.6-731
   STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277
   Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149
   Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454
   Tsan MF, 1997, HUM GENE THER, V8, P817, DOI 10.1089/hum.1997.8.7-817
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Worth LL, 2000, CLIN CANCER RES, V6, P3713
   WU GY, 1988, BIOCHEMISTRY-US, V27, P887, DOI 10.1021/bi00403a008
   Zhang LL, 2000, CANCER RES, V60, P3655
   Zou SM, 2000, J GENE MED, V2, P128, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W
NR 77
TC 20
Z9 21
U1 4
U2 24
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD OCT
PY 2003
VL 3
IS 7
BP 1083
EP 1092
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 734EP
UT WOS:000186042500007
PM 14519073
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Faure, M
   Yoshimura, T
AF Matsuyama, W
   Faure, M
   Yoshimura, T
TI RETRACTED: Activation of discoidin domain receptor 1 facilitates the
   maturation of human monocyte-derived dendritic cells through the TNF
   receptor associated factor 6 TGF-beta-activated protein kinase 1 binding
   protein 1 beta/p38 alpha mitogen-activated protein kinase signaling
   cascade (Retracted article. See vol. 185, pg. 1984, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; COSTIMULATORY
   MOLECULES; HUMAN BLOOD; COLLAGEN; LIPOPOLYSACCHARIDE; EXPRESSION;
   CYTOKINES; ANTIGEN; TRANSDUCTION
AB Maturation of dendritic cells (DCs) is critical for their ability to stimulate resting naive T cells in primary immune responses. Previous studies demonstrated that collagen, such as type I collagen, could facilitate DC maturation; however, the basis of collagen-mediated DC maturation remains unclear. Discoidin domain receptor 1 (DDR1) is a nonintegrin collagen receptor constitutively expressed in a variety of epithelial cells, including tumor cells, and is inducible in leukocytes. In this study, we evaluated the role of DDR1 in DC maturation using human monocyte-derived DCs. Two DDRI isoforms, DDR1a and DDR1b, were expressed in both immature and mature DCs. Activation of DDR1 on immature DCs resulted in their partial maturation; however, DDR1 activation markedly amplified TNF-alpha- and LPS-induced phenotypic and functional maturation of I)Cs through activation of p38 mitogen-activated protein kinase (MAPK), suggesting the involvement of DDR1b in this process. Activation of DDR1b on differentiated DDR1b-overexpressing THP-1 cells or DDR1 on mature DCs induced the formation of TNFR associated factor 6 (TRAF6)/TGF-beta-activated kinase 1 binding protein 1beta/p38alpha MAPK complex and p38alpha autophosphorylation. Transfection of differentiated DDR1b-overexpressing THP-1 cells with dominant negative TRAF6 completely abrogated DDR1b-mediated p38 MAPK phosphorylation, indicating a critical role of TRAF6 in DDR1b-mediated p38 MAPK activation. Taken together, our data suggest that DDR1b-collagen interaction augments the maturation of DCs in a tissue microenvironment through a unique TRAF6/TGF-beta-activated kinase 1 binding protein lbeta/p38alpha MAPK signaling cascade and contributes to the development of adaptive immune responses.
C1 NCI, Lab Mol Immunoregulat, Frederick, MD 21702 USA.
   SUGEN Inc, San Francisco, CA 94080 USA.
RP Yoshimura, T (reprint author), NCI, Lab Mol Immunoregulat, Bldg 559,Room 9, Frederick, MD 21702 USA.
EM yoshimur@mail.ncifcrf.gov
CR AIBA S, 1993, J INVEST DERMATOL, V100, P143, DOI 10.1111/1523-1747.ep12462783
   Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141
   Akagawa KS, 1996, BLOOD, V88, P4029
   Alves F, 2001, FASEB J, V15, P1321
   Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x
   Ardeshna KM, 2000, BLOOD, V96, P1039
   Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837
   Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bradley J R, 2001, ONCOGENE, V20, P6842
   Brand U, 1998, EUR J IMMUNOL, V28, P1673, DOI 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821
   Chung JY, 2002, J CELL SCI, V115, P679
   DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/0022-1759(80)90211-2
   Foehr ED, 2000, FASEB J, V14, P973
   Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8
   Fukao Taro, 2002, Trends in Immunology, V23, P231, DOI 10.1016/S1471-4906(02)02198-1
   Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289
   Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230
   INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359
   LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532
   LU L, 1994, J EXP MED, V179, P1823, DOI 10.1084/jem.179.6.1823
   Mahnke K, 1996, J LEUKOCYTE BIOL, V60, P465
   Marra F, 1997, FEBS LETT, V414, P221, DOI 10.1016/S0014-5793(97)01004-1
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Puig-Kroger A, 2001, BLOOD, V98, P2175, DOI 10.1182/blood.V98.7.2175
   ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237
   Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0
   Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6
   Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x
   Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   Sozzani S, 1998, J IMMUNOL, V161, P1083
   Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9
   Verhasselt V, 1997, J IMMUNOL, V158, P2919
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931
   Yanagihara S, 1998, J IMMUNOL, V161, P3096
NR 50
TC 41
Z9 44
U1 5
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2003
VL 171
IS 7
BP 3520
EP 3532
DI 10.4049/jimmunol.171.7.3520
PG 13
WC Immunology
SC Immunology
GA 725MY
UT WOS:000185548000027
PM 14500648
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, ZR
   Wende, H
   Scherz, A
   Ceballos, G
   Baberschke, K
AF Li, ZR
   Wende, H
   Scherz, A
   Ceballos, G
   Baberschke, K
TI RETRACTED: Spin fluctuation in single-crystalline terbium probed by
   temperature-dependent magnetic EXAFS - art. no. 134406 (Retracted
   Article. See vol 72, art. no. 029901(E), 2005)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID ABSORPTION FINE-STRUCTURE; CIRCULAR-DICHROISM; L-EDGES; SCATTERING; GD
AB Magnetic extended x-ray absorption fine structure (MEXAFS) is a helicity-dependent counterpart of the well-established EXAFS technique. By means of MEXAFS it is possible not only to analyze the local magnetic structure but also to learn about magnetic fluctuations. Here temperature-dependent MEXAFS was employed to study the spin fluctuation of a terbium single crystal in a wide temperature range from 10 to 250 K covering two magnetic transitions. As compared with EXAFS, the MEXAFS signal intensity decreases more dramatically with increasing temperature, especially when spin orientation changes from ferromagnetic order to helical structure and paramagnetic order. The strong temperature dependence of MEXAFS is related to the atomic thermal vibrations (probed by EXAFS) and to the reduction of the magnetization at increasing temperatures. To analyze the individual scattering contributions to the MEXAFS and the EXAFS, ab initio calculations have been performed. The strongly enhanced magnetic multiple scattering was observed at low temperature and interpreted on the basis of the exchange interaction model.
C1 Univ Sci & Technol China, Natl Synchrotron Radiat Lab, Hefei 230029, Peoples R China.
   Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany.
RP Li, ZR (reprint author), Univ Sci & Technol China, Natl Synchrotron Radiat Lab, Hefei 230029, Peoples R China.
EM zrli@uga.edu
CR Ahlers D, 1998, PHYS REV B, V57, P3466, DOI 10.1103/PhysRevB.57.3466
   ANKUDINOV A, 1995, PHYS REV B, V52, P10214, DOI 10.1103/PhysRevB.52.10214
   Ankudinov AL, 1997, PHYS REV B, V56, pR1712, DOI 10.1103/PhysRevB.56.R1712
   Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565
   Brouder C, 1996, PHYS REV B, V54, P7334, DOI 10.1103/PhysRevB.54.7334
   CHABOY J, 1994, PHYS REV B, V49, P11652, DOI 10.1103/PhysRevB.49.11652
   Chakarian V, 1996, J APPL PHYS, V79, P6493, DOI 10.1063/1.361980
   Coqblin B., 1977, ELECT STRUCTURE RARE
   DARTYGE E, 1992, PHYS REV B, V46, P3155, DOI 10.1103/PhysRevB.46.3155
   DARTYGE E, 1995, PHYSICA B, V208, P751, DOI 10.1016/0921-4526(94)00897-5
   Ebert H, 1999, PHYS REV B, V60, P7156, DOI 10.1103/PhysRevB.60.7156
   GAUTHIER C, 1995, PHYSICA B, V208, P232, DOI 10.1016/0921-4526(94)01028-Y
   Hanham ML, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.180101
   HEGLAND DE, 1963, PHYS REV, V131, P158, DOI 10.1103/PhysRev.131.158
   KNULLE M, 1995, SOLID STATE COMMUN, V94, P267, DOI 10.1016/0038-1098(95)00056-9
   Rogalev A, 1998, J SYNCHROTRON RADIAT, V5, P989, DOI 10.1107/S0909049597014702
   SCHUETZ G, 1996, LECT NOTES PHYSICS, V466
   SCHUTZ G, 1989, PHYS REV LETT, V62, P2620, DOI 10.1103/PhysRevLett.62.2620
   Srivastava P, 1998, J APPL PHYS, V83, P7025, DOI 10.1063/1.367840
   TROGER L, 1992, PHYS REV B, V46, P3283, DOI 10.1103/PhysRevB.46.3283
   Wende H, 2001, J SYNCHROTRON RADIAT, V8, P419, DOI 10.1107/S0909049500016915
   Wende H, 1999, J SYNCHROTRON RADIAT, V6, P696, DOI 10.1107/S0909049598017488
   Wende H, 1998, J APPL PHYS, V83, P7028, DOI 10.1063/1.367841
NR 23
TC 2
Z9 2
U1 5
U2 15
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD OCT 1
PY 2003
VL 68
IS 13
AR 134406
DI 10.1103/PhysRevB.68.134406
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 740VN
UT WOS:000186422400060
DA 2018-12-27
ER

PT J
AU Sama, MT
   Homeida, M
   Ngang, P
   Liese, BH
   Amazigo, U
   Seketeli, A
AF Sama, MT
   Homeida, M
   Ngang, P
   Liese, BH
   Amazigo, U
   Seketeli, A
TI RETRACTED: A multi-centre study of community-directed ivermectin
   distributors' (CDDs') involvement in other healthcare and development
   programme activities in Cameroon, Togo, Sudan, Nigeria and Uganda
   (Retracted Article. See vol 34, pg 93, 2004)
SO TROPICAL DOCTOR
LA English
DT Article; Retracted Publication
ID ONCHOCERCIASIS
AB A multi-centre study to determine whether community-directed distributors (CDDs) are capable of carrying out additional healthcare and developmental activities in their communities was carried out in Cameroon, Nigeria, Sudan, Uganda and Togo to ascertain the potential effects of their involvement on the implementation of community-directed treatment with ivermectin (CDTI).
   Both quantitative and qualitative methods were used to collect data from households, community-directed distributors, community leaders, and health workers. The results showed no major decrease in the CDDs' performance in CDTI: on the contrary, the involvement of CDDs in other health and development activities motivated them to perform their CDTI functions better. However, the results did not show any significant increase in therapeutic coverage of ivermectin distribution.
   The expansion of the CDDs' experience to include additional healthcare and development related activities would be of interest to onchocerciasis control programmes - it will strengthen CDTI sustainability through greater integration.
C1 Inst Met Res & Med Plants, Yaounde, Cameroon.
   Natl Onchocerciasis Task Force, Khartoum, Sudan.
   TEYEN Res Fdn, Yaounde, Cameroon.
   World Bank, Human Dev African Reg, Washington, DC USA.
   African Programme Onchocerciasis Control, Ouagadougou, Burkina Faso.
RP Sama, MT (reprint author), Inst Met Res & Med Plants, BP 4424, Yaounde, Cameroon.
EM msama@camnet.cm
CR AKPALA C, 1993, ANN TROP MED PARASIT, V87, P399, DOI 10.1080/00034983.1993.11812784
   Amazigo U, 1998, ANN TROP MED PARASIT, V92, pS23, DOI 10.1080/00034983.1998.11813362
   Katabarwa NM, 2000, ANN TROP MED PARASIT, V94, P343, DOI 10.1080/00034980050034590
   Ngoumou P, 1996, World Health Forum, V17, P25
   *WHO, 1992, 852 WHO
   *WHO, 1996, WHO TECHNICAL REPORT, V852
   1996, INTEGRATING IVERMECT
NR 7
TC 6
Z9 6
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0049-4755
EI 1758-1133
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2003
VL 33
IS 4
BP 237
EP 241
DI 10.1177/004947550303300417
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 734BC
UT WOS:000186034500016
PM 14620432
DA 2018-12-27
ER

PT J
AU Song, C
   Jiang, S
   Singh, G
AF Song, C
   Jiang, S
   Singh, G
TI RETRACTED: Synthesis of (6S)-6-fluoroshikimic acid (Retracted Article.
   See vol 16, pg. 2832, 2005)
SO TETRAHEDRON-ASYMMETRY
LA English
DT Article; Retracted Publication
ID SHIKIMATE PATHWAY; APICOMPLEXAN PARASITES; QUINIC ACID; ENANTIOSPECIFIC
   SYNTHESIS; ESCHERICHIA-COLI; BIOSYNTHESIS; ANALOGS
AB (6S)-6-Fluoroshikimic acid 2 and (6R)-6-hydroxyshikimic acid 16 have been synthesised via an OsO4-catalysed dihydroxylation of diene 8, which was derived from (-)-shikimic acid 1. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Sunderland, Dept Chem, Sunderland SR1 3SD, Tyne & Wear, England.
RP Singh, G (reprint author), Univ Sunderland, Dept Chem, Sunderland SR1 3SD, Tyne & Wear, England.
EM gurdial.singh@sunderland.ac.uk
RI Jiang, Shende/K-1671-2015
CR ABELL C, 1999, ENZYMOLOGY MOL BIOL, V1, P573
   Adams H, 1996, TETRAHEDRON, V52, P8565, DOI 10.1016/0040-4020(96)00398-5
   BLACKER AJ, 1995, J CHEM SOC PERK T 1, P2861, DOI 10.1039/p19950002861
   Brettle R, 1996, TETRAHEDRON, V52, P10547, DOI 10.1016/0040-4020(96)00574-1
   Carless HAJ, 1996, TETRAHEDRON-ASYMMETR, V7, P649, DOI 10.1016/0957-4166(96)00055-9
   CHAHOUA L, 1992, J ORG CHEM, V57, P5798, DOI 10.1021/jo00047a049
   DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403
   Draths KM, 1999, J AM CHEM SOC, V121, P1603, DOI 10.1021/ja9830243
   DUGGAN PJ, 1995, BIOORG MED CHEM LETT, V5, P2347, DOI 10.1016/0960-894X(95)00405-I
   EWART CDC, 1995, ANTIMICROB AGENTS CH, V39, P87, DOI 10.1128/AAC.39.1.87
   FLEET GWJ, 1984, J CHEM SOC PERK T 1, P905, DOI 10.1039/p19840000905
   Franke D, 2001, ANGEW CHEM INT EDIT, V40, P555, DOI 10.1002/1521-3773(20010202)40:3<555::AID-ANIE555>3.0.CO;2-0
   Franz J. E, 1997, GLYPHOSATE UNIQUE GL
   GREWE R, 1953, CHEM BER-RECL, V86, P928, DOI 10.1002/cber.19530860717
   Haslam E, 1993, SHIKIMIC ACID METABO
   Huntley CFM, 2000, TETRAHEDRON LETT, V41, P2031, DOI 10.1016/S0040-4039(00)00103-9
   Jiang S, 1999, TETRAHEDRON-ASYMMETR, V10, P4087, DOI 10.1016/S0957-4166(99)00447-4
   Jiang SD, 1998, TETRAHEDRON, V54, P4697, DOI 10.1016/S0040-4020(98)00016-7
   Jude DA, 1996, BBA-BIOMEMBRANES, V1279, P125, DOI 10.1016/0005-2736(95)00295-2
   Karpf M, 2001, J ORG CHEM, V66, P2044, DOI 10.1021/jo0057021
   Keeling PJ, 1999, NATURE, V397, P219, DOI 10.1038/16618
   KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211
   MEIER RM, 1991, HELV CHIM ACTA, V74, P807, DOI 10.1002/hlca.19910740415
   Roberts CW, 1999, NATURE, V397, P220
   Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723
   Song CJ, 2001, TETRAHEDRON LETT, V42, P9069, DOI 10.1016/S0040-4039(01)01976-1
   SUTHERLAND JK, 1989, J CHEM SOC CHEM COMM, P1386, DOI 10.1039/c39890001386
   SUTHERLAND JK, 1993, J CHEM SOC CHEM COMM, P464, DOI 10.1039/c39930000464
   Tran CH, 1996, TETRAHEDRON-ASYMMETR, V7, P691
NR 29
TC 2
Z9 2
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4166
J9 TETRAHEDRON-ASYMMETR
JI Tetrahedron-Asymmetry
PD SEP 19
PY 2003
VL 14
IS 18
BP 2833
EP 2838
DI 10.1016/S0957-4166(03)00584-6
PG 6
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic; Chemistry, Physical
SC Chemistry
GA 724UU
UT WOS:000185505700023
DA 2018-12-27
ER

PT J
AU Sezen, B
   Sames, D
AF Sezen, B
   Sames, D
TI RETRACTED: Diversity synthesis via C-H bond functionalization:
   Concept-guided development of new C-arylation methods for imidazoles
   (Retracted Article. See vol 128, pg 8364, 2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID N-ARYLATION; AROMATIC IMINES; ARYL HALIDES; ARYLBORONIC ACID; ORGANIC
   HALIDES; ACTIVATION; NITROGEN; COMPLEX; 2-ARYLPYRIDINES; ALKENYLATION
AB Herein, we have formulated the concept of systematic derivatization of a structural motif via C-H bond functionalization. This concept may not only serve as a blueprint for new strategies in diversity synthesis but also provide systematic guidance for the identification of unsolved and important synthetic challenges. To illustrate this point, 2-phenylimiclazole was selected as the core motif for this study, a choice inspired by numerous azole-based synthetics, including pharmaceuticals (compound SB 202190), and also fluorescent and chemiluminescent probes. We were able to show that systematic and comprehensive arylation of the 2-phenylimidazole core was feasible, and in the context of this study new arylation methods were developed. The direct 4-arylation of free 2-phenylimidazole was achieved with iodoarenes as the aryl donors in the presence of palladium catalyst (Pd/Ph3P) and magnesium oxide as the base. A complete switch from C-4 to C-2' arylation was accomplished using a ruthenium catalyst [CpRu(Ph3P)(2)C1] and Cs2CO3. The corresponding transformations for (N,2)-diphenylimidazole (C-5 and C-2' arylation) were accomplished via the palladium-based method [Pd(OAc)(2)/Ph3P/Cs2CO3] and a rhodium-catalyzed procedure [Rh(acac)(CO)(2)/ Cs2CO3], respectively. All of the arylation methods described herein demonstrated broad synthetic scope, high efficiency, and exclusive selectivity. Furthermore, these new methods proved to be orthogonal to one another and applicable to sequential arylation schemes. With these methods in hand, arrays of arylated imidazoles may now be accessed in a direct manner from 2-phenylimidazole. This strategy stands in sharp contrast to a traditional approach, wherein a distinct and multistep synthesis would be required for each analogue.
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
FU NIGMS NIH HHS [R01 GM 60326]
CR BARTON DH, 1961, J AM CHEM SOC, V83, P4083, DOI 10.1021/ja01480a031
   BRESLOW R, 1973, J AM CHEM SOC, V95, P3251, DOI 10.1021/ja00791a031
   Cho JY, 2002, SCIENCE, V295, P305, DOI 10.1126/science.1067074
   Collman JP, 2000, ORG LETT, V2, P1233, DOI 10.1021/ol000033j
   COREY EJ, 1965, J AM CHEM SOC, V87, P2518, DOI 10.1021/ja01089a055
   Dangel BD, 2002, J AM CHEM SOC, V124, P11856, DOI 10.1021/ja027311p
   Dangel BD, 2001, J AM CHEM SOC, V123, P8149, DOI 10.1021/ja016280f
   Davies HML, 2003, J AM CHEM SOC, V125, P6462, DOI 10.1021/ja0290072
   Grasa GA, 2001, J ORG CHEM, V66, P7729, DOI 10.1021/jo010613+
   Hartwig JF, 1999, J ORG CHEM, V64, P5575, DOI 10.1021/jo990408i
   Ishiyama T, 2002, J AM CHEM SOC, V124, P390, DOI 10.1021/ja0173019
   Jackson Paul F., 2002, Current Topics in Medicinal Chemistry, V2, P1011, DOI 10.2174/1568026023393372
   Johnson JA, 2002, J AM CHEM SOC, V124, P6900, DOI 10.1021/ja026130k
   Jun CH, 2000, ANGEW CHEM INT EDIT, V39, P3440, DOI 10.1002/1521-3773(20001002)39:19<3440::AID-ANIE3440>3.0.CO;2-1
   Kakiuchi F, 2003, J AM CHEM SOC, V125, P1698, DOI 10.1021/ja029273f
   Kakiuchi F., 1999, ACTIVATION UNREACTIV, P47
   Klapars A, 2001, J AM CHEM SOC, V123, P7727, DOI 10.1021/ja016226z
   Lam PYS, 2000, J AM CHEM SOC, V122, P7600, DOI 10.1021/ja001305g
   Lam PYS, 2001, TETRAHEDRON LETT, V42, P3415, DOI 10.1016/S0040-4039(01)00510-X
   Lam PYS, 1998, TETRAHEDRON LETT, V39, P2941, DOI 10.1016/S0040-4039(98)00504-8
   Loffler K, 1909, BER DTSCH CHEM GES, V42, P3431, DOI 10.1002/cber.19090420378
   Mann G, 1998, J AM CHEM SOC, V120, P827, DOI 10.1021/ja973524g
   Miura M, 2002, TOP CURR CHEM, V219, P211
   Mori A, 2003, J AM CHEM SOC, V125, P1700, DOI 10.1021/ja0269189
   MORITANI I, 1967, TETRAHEDRON LETT, P1119
   Nakashima K, 1998, DYES PIGMENTS, V38, P127, DOI 10.1016/S0143-7208(98)80002-8
   Oi S, 2002, ORG LETT, V4, P1783, DOI 10.1021/ol025851l
   Oi S, 2001, ORG LETT, V3, P2579, DOI 10.1021/ol016257z
   Oi S, 1998, CHEM COMMUN, P2439, DOI 10.1039/a806790b
   Old DW, 2000, ORG LETT, V2, P1403, DOI 10.1021/ol005728z
   Pivsa-Art S, 1998, B CHEM SOC JPN, V71, P467, DOI 10.1246/bcsj.71.467
   Sezen B, 2003, J AM CHEM SOC, V125, P5274, DOI 10.1021/ja034848
   Taber DF, 1998, CHEM-EUR J, V4, P990, DOI 10.1002/(SICI)1521-3765(19980615)4:6<990::AID-CHEM990>3.0.CO;2-U
   Takagi J, 2002, TETRAHEDRON LETT, V43, P5649, DOI 10.1016/S0040-4039(02)01135-8
   Thalji RK, 2001, J AM CHEM SOC, V123, P9692, DOI 10.1021/ja016642j
NR 35
TC 91
Z9 91
U1 4
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 3
PY 2003
VL 125
IS 35
BP 10580
EP 10585
DI 10.1021/ja036157j
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 716DD
UT WOS:000185012800034
PM 12940740
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: Midazolam-Induced muscle dysfunction and its recovery in
   fatigued diaphragm in dogs (Retracted article. See vol. 116, pg. 747,
   2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID BLOOD-FLOW; CONTRACTILITY; VOLUNTARY
AB Midazolam, widely used for sedation and anesthesia, decreases contractility in nonfatigued diaphragm; however, its effects on contractility in fatigued diaphragm that are implicated as a cause of respiratory failure have not been established. We therefore studied the effects of midazolam on diaphragm muscle function and recovery in fatigued diaphragm. Dogs were divided into three groups of eight each. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20-Hz stimulation for 30 min. When fatigue was established, Group I received no study drug; Group II was infused with a sedative dose (0.1 mg . kg(-1) . h(-1)) of midazolam; and Group III was infused with an anesthetic dose (0.5 mg . kg(-1) . h(-1)) of midazolam. We assessed diaphragm muscle function (contractility and electrical activity) by transdiaphragmatic pressure (Pdi) and integrated electrical activity of the diaphragm (Edi). In the presence of fatigue, Pdi at low-frequency (20-Hz) stimulation decreased from baseline values (P < 0.05), Pdi at high-frequency (100Hz) stimulation did not change, and Edi to each stimulus did not change. With an infusion of midazolam, in Groups II and III, Pdi at both stimuli and Edi at 100-Hz stimulation decreased from fatigued values (P < 0.05). The decrease in Pdi and Edi was more in Group III than in Group II (P < 0.05). At 60 min after the cessation of midazolam administration, in Group II, Pdi and Edi recovered from midazolam-induced values (P < 0.05) and returned to fatigued values. In Group III, Pdi and Edi did not change from midazolam-induced values. We conclude that midazolam causes, in a dose-related manner, diaphragm muscle dysfunction in fatigued canine diaphragm and that at a sedative dose, but not at an anesthetic dose, midazolam does not delay its recovery.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   BION JF, 1988, HOSPITAL UPDATE, V14, P1272
   BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513
   COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   Fujii Y, 1999, ANESTH ANALG, V89, P781, DOI 10.1097/00000539-199909000-00048
   Fujii Y, 2001, ANESTH ANALG, V92, P1590
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   MALACRIDA R, 1992, CRIT CARE MED, V20, P1123, DOI 10.1097/00003246-199208000-00010
   Moxham J, 1981, Ciba Found Symp, V82, P197
   REID MB, 1983, J APPL PHYSIOL, V54, P763
   REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
NR 17
TC 4
Z9 4
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2003
VL 97
IS 3
BP 755
EP 758
DI 10.1213/01.ANE.0000076142.42255.BF
PG 4
WC Anesthesiology
SC Anesthesiology
GA 714AN
UT WOS:000184890300028
PM 12933396
DA 2018-12-27
ER

PT J
AU Sun, XY
   Mammen, JMV
   Tian, XT
AF Sun, XY
   Mammen, JMV
   Tian, XT
TI RETRACTED: Sepsis induces the transcription of the glucocorticoid
   receptor in skeletal muscle cells (Retracted Article. See vol 107, pg
   633, 2004)
SO CLINICAL SCIENCE
LA English
DT Article; Retracted Publication
DE dexamethasone; glucocorticoid receptor; L6 myotubes; sera from septic
   rats
ID STEROID-HORMONE RECEPTORS; NF-KAPPA-B; DEPENDENT MECHANISM; PROTEIN
   BREAKDOWN; BINDING-ACTIVITY; GENE-EXPRESSION; SEPTIC MUSCLE;
   PROTEOLYSIS; PROTEASOME; ACTIVATION
AB Evidence from a recent study indicates that glucocorticoids (GCs) mediate skeletal muscle proteolysis during sepsis via the GC receptor (GR) pathway. Attempts to identify the mechanisms regulating GR gene expression in skeletal muscle during sepsis have been hampered by the lack of an appropriate in vitro model system that can mimic in vivo septic conditions. In the present study, we report that GR gene transcription in LIS myocytes in vitro is up-regulated by treatment with sera from septic rats in a manner similar to that measured in septic rats in vivo. Sera from septic rats were collected from animals in which sepsis was induced by caecal ligation and puncture and from control rats that were sham-operated. Finally, by treating L6 myotubes with the GR antagonist RU 38486, thereby preventing sepsis-induced GR transcription, we confirmed that the possible septic effect on the GR was due to increased GCs. L6 myocytes treated with sera from septic rats might therefore be useful as an experimental model for identifying the molecular mechanisms by which the GR regulates muscle cachexia during sepsis. Furthermore, RU 38486 inhibited the sepsis-induced increase in total and myofibrillar energy-dependent protein breakdown rates in incubated extensor digitorum longus muscles from septic and sham-operated rats, as measured by release of tyrosine and 3-methylhistidine respectively. Our results demonstrate for the first time that sepsis induces GR transcription in skeletal muscle, and supports the hypothesis that the GC-induced proteolysis under sepsis is partially a consequence of GR activation.
C1 Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA.
   Shriners Hosp Children, Cincinnati, OH 45229 USA.
   Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA.
RP Sun, XY (reprint author), Univ Cincinnati, Dept Surg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
EM sunxn@email.uc.edu
CR Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283
   ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984
   BAULIEU EE, 1990, ENDOCRINOLOGY, V127, P2043
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   BOMSZTYK K, 1991, CELL REGUL, V2, P329
   CHAUDRY IH, 1979, SURGERY, V85, P205
   De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269
   DIBATTISTA JA, 1991, J RHEUMATOL, V18, P102
   EISEN LP, 1988, J BIOL CHEM, V263, P12044
   EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W
   Fischer D, 2000, BIOCHEM BIOPH RES CO, V267, P504, DOI 10.1006/bbrc.1999.1987
   GONCI M, 1990, CANCER RES, V50, P1873
   HALLANGERAS M, 1991, SURGERY, V109, P468
   Hasselgren PO, 2002, BIOCHEM BIOPH RES CO, V290, P1, DOI 10.1006/bbrc.2001.5849
   HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5
   HASSELGREN PO, 1990, ARCH SURG-CHICAGO, V125, P510
   HASSELGREN PO, 1993, PROTEIN METABOLISM S
   HASSELGREN PO, 1999, CURR OPIN CLIN NUTR, V3, P201
   Hobler SC, 1999, AM J PHYSIOL-REG I, V277, pR434, DOI 10.1152/ajpregu.1999.277.2.R434
   HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6
   KAM JC, 1993, J IMMUNOL, V151, P3460
   KONAGAYA M, 1988, J STEROID BIOCHEM, V29, P685
   Luo GJ, 2000, AM J PHYSIOL-REG I, V278, pR749
   Macdonald J, 2003, BRIT J ANAESTH, V90, P221, DOI 10.1093/bja/aeg034
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8
   Penner CG, 2001, BIOCHEM BIOPH RES CO, V281, P1331, DOI 10.1006/bbrc.2001.4497
   Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001
   Periti P, 2000, Expert Opin Pharmacother, V1, P1203, DOI 10.1517/14656566.1.6.1203
   RAKASZ E, 1993, SCAND J IMMUNOL, V37, P684, DOI 10.1111/j.1365-3083.1993.tb01684.x
   Remick DG, 2003, CURR PHARM DESIGN, V9, P75, DOI 10.2174/1381612033392567
   RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H
   SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283
   SCHMID W, 1995, J STEROID BIOCHEM, V53, P33, DOI 10.1016/0960-0760(95)00038-2
   SHERIFF S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P219, DOI 10.1016/0167-4889(92)90260-I
   Sun XY, 2002, AM J PHYSIOL-REG I, V282, pR509, DOI 10.1152/ajpregu.00509.2001
   TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588
   Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421
   TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459
   Wang Q, 1997, ARCH SURG-CHICAGO, V132, P82
   WEISS LG, 1995, ASSESSMENT FOCUS, V1, P6
   Williams A, 1998, AM J PHYSIOL-REG I, V275, pR1983
   Williams AB, 1999, FASEB J, V13, P1435
   WILMORE DW, 1991, NEW ENGL J MED, V325, P695
   YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477
   ZAMIR O, 1993, METABOLISM, V42, P1190, DOI 10.1016/0026-0495(93)90279-W
   Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/01.CCM.0000042465.21096.B5
NR 47
TC 7
Z9 8
U1 3
U2 10
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD SEP
PY 2003
VL 105
IS 3
BP 383
EP 391
DI 10.1042/CS20030087
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 721BF
UT WOS:000185296600017
PM 12797863
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kawasaki, T
AF Fujii, Y
   Tanaka, H
   Kawasaki, T
TI RETRACTED: A randomized, double-blind comparison of granisetron alone
   and combined with dexamethasone for post-laparoscopic cholecystectomy
   emetic symptoms (Retracted article. See vol. 88, pg. 54, 2018)
SO CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
LA English
DT Article; Retracted Publication
DE nausea; vomiting; emesis; antiemetics; granisetron; dexamethasone;
   laparoscopic cholecystectomy
ID HIGH-DOSE DEXAMETHASONE; POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST;
   METOCLOPRAMIDE; PREVENTION; CISPLATIN
AB Background. Granisetron hydrochloride, a selective serotonin receptor antagonist, has been used to treat established postoperative nausea and vomiting (PONV). Dexamethasone has been shown to reduce the incidence of chemotherapy-induced emesis when added to an antiemetic regimen.
   Objective: The aim of this study was to examine the differences in efficacy and tolerability between the combination of granisetron plus dexamethasone and granisetron alone for the treatment of PONV.
   Methods: This study was a randomized, double-blind trial conducted at Toride Kyodo General Hospital (Toride, Ibaraki, Japan). Men and women aged 25 to 65 years and experiencing emetic symptoms after laparoscopic cholecystectomy were eligible for the study. Patients received IV therapy with either granisetron 40 mug/kg alone or with dexamethasone 8 mg. Patients were observed for 24 hours. Emetic episodes and the need for a rescue antiemetic were recorded by nursing staff, who were blinded to treatment assignment.
   Results: One hundred patients (63 women, 37 men; mean [SD] age, 47 [10] years; range, 25-65 years) were enrolled; 50 patients were randomized to each treatment group. No significant differences in baseline demographic or clinical characteristics were observed between the groups. Complete control of established PONV, defined as no emetic symptoms and no need for another rescue antiemetic medication, occurred in significantly more patients who received the combination (49/50 [98%]) than in those who received granisetron alone (41/50 [82%]) (P = 0.008). No clinically important adverse effects due to the study drugs were observed in either group.
   Conclusion: In this study population of patients experiencing post-cholecystectomy emesis, the combination of granisetron plus dexamethasone was more efficacious than granisetron alone for the treatment of PONV. Tolerability between the 2 treatments was similar.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Surg, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AAPRO MS, 1981, NEW ENGL J MED, V305, P520
   AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FLEISHER LA, 1996, CLIN ANESTH, P443
   Fujii Y, 2000, BRIT J SURG, V87, P285, DOI 10.1046/j.1365-2168.2000.01393.x
   Fujii Y, 1997, CAN J ANAESTH, V44, P396, DOI 10.1007/BF03014460
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   Iitomi T, 1995, Masui, V44, P1627
   McCormick C., 2002, ASA NEWSL, V66, P19
   SANTON JM, 1991, ANAESTHESIA, V46, P317
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   Sekine I, 1997, BRIT J CANCER, V76, P90, DOI 10.1038/bjc.1997.341
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 14
TC 2
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-393X
EI 1879-0313
J9 CURR THER RES CLIN E
JI Curr. Ther. Res.-Clin. Exp.
PD SEP-OCT
PY 2003
VL 64
IS 8
BP 514
EP 521
DI 10.1016/S0011-393X(03)00159-0
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 745JD
UT WOS:000186684800002
PM 24944401
DA 2018-12-27
ER

PT J
AU Schaller, B
   Ruegg, SJ
AF Schaller, B
   Ruegg, SJ
TI RETRACTED: Brain tumor and seizures: Pathophysiology and its
   implications for treatment revisited (Retracted Article. vol 44, pg
   1463, 2003)
SO EPILEPSIA
LA English
DT Review; Retracted Publication
DE brain tumor; seizures; pathophysiology; treatment; antiepileptic drugs
ID TEMPORAL-LOBE EPILEPSY; CA1 PYRAMIDAL NEURONS; HUMAN GLIOMA-CELLS;
   ANTIEPILEPTIC DRUGS; MULTIDRUG-RESISTANCE; DENTATE GYRUS; GLIAL-CELLS;
   IN-VIVO; ELECTROPHYSIOLOGICAL PROPERTIES; SYNAPTIC TRANSMISSION
AB Seizures affect similar to50% of patients with primary and metastatic brain tumors. Partial Seizures have the highest incidence, followed by secondarily generalized, depending on histologic subtype, location, and tumor extent. The underlying pathophysiologic mechanisms of tumor-associated seizures are poorly understood and include theories of altered peritumoral amino acids, regional metabolism, pH, neuronal or glial enzyme and protein expression, as well as immunologic activity. An involvement of changed distribution and function of N-methyl-D-aspartate subclass of glutamate receptors also has been suggested. The often unpredictable responses to seizures after surgical tumor removal add substantial evidence that multiple factors are involved. The therapy Of tumor-related seizures is far from perfect. Several factors contribute to these treatment difficulties, such as tumor growth and drug interactions; however, one of the main reasons for poor seizure control may result from the insufficient or even absent influence of the currently available antiepileptic drugs (AEDs) on most of the pathophysiologic mechanisms of tumor-related seizures. Studies are needed to elucidate more clearly the pathophysiologic mechanisms of tumor-related seizures and to identify and develop the optimal AEDs.
C1 Max Planck Inst Neurol Res, Cologne, Germany.
   Univ Penn, Dept Neurol, Comprehens Epilepsy Ctr, Philadelphia, PA USA.
RP Schaller, B (reprint author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, S-17177 Stockholm, Sweden.
EM bernhard.schaller@pet.mpin-koeln.mpg.de
CR ALGER JR, 1990, RADIOLOGY, V177, P633, DOI 10.1148/radiology.177.3.2243962
   Amzica F, 2002, J PHYSIOL-PARIS, V96, P209, DOI 10.1016/S0928-4257(02)00008-6
   Aronica E, 2001, ACTA NEUROPATHOL, V101, P449
   Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x
   AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412
   AWAD IA, 1991, EPILEPSIA, V32, P179, DOI 10.1111/j.1528-1157.1991.tb05242.x
   BATEMAN D E, 1988, Neurological Research, V10, P112
   Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499
   Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017
   Bordey A, 1998, J NEUROPHYSIOL, V79, P2782
   CADOUXHUDSON TAD, 1989, BRIT J CANCER, V60, P430, DOI 10.1038/bjc.1989.300
   CHAO CC, 1993, J IMMUNOL, V151, P1473
   CHURCH J, 1989, J PHYSIOL-LONDON, V415, P85, DOI 10.1113/jphysiol.1989.sp017713
   Clusmann H, 2002, J NEUROSURG, V97, P1131, DOI 10.3171/jns.2002.97.5.1131
   COHEN N, 1988, J CLIN ONCOL, V6, P1621, DOI 10.1200/JCO.1988.6.10.1621
   CONTINHO V, 2002, NEUROSCIENTIST, V8, P551
   CRAWFORD N, 2000, J PHARM TOXICOL METH, V42, P121
   Dichter M A, 1998, Adv Neurol, V76, P1
   Dietrich D, 2002, NEUROPHARMACOLOGY, V42, P297, DOI 10.1016/S0028-3908(01)00193-9
   Dutuit M, 2000, GLIA, V32, P15, DOI 10.1002/1098-1136(200010)32:1<15::AID-GLIA20>3.0.CO;2-#
   ENGLE JA, 1997, EPILEPSY COMPREHENSI
   Ernestus RI, 2001, J NEUROL NEUROSUR PS, V71, P88, DOI 10.1136/jnnp.71.1.88
   Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633
   Fonseca CG, 2002, BRAIN RES, V929, P105, DOI 10.1016/S0006-8993(01)03289-9
   FRANCESCHETTI S, 1990, ACTA NEUROCHIR, V103, P47, DOI 10.1007/BF01420191
   Gerweck LE, 1996, CANCER RES, V56, P1194
   Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886
   Goldman B, 2003, J NATL CANCER I, V95, P255, DOI 10.1093/jnci/95.4.255
   Goldring S, 1986, Clin Neurosurg, V33, P15
   GOLDSTEIN DS, 1988, J NEUROCHEM, V50, P225, DOI 10.1111/j.1471-4159.1988.tb13253.x
   Guye M, 2002, EPILEPSIA, V43, P1197, DOI 10.1046/j.1528-1157.2002.05102.x
   HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209
   HAMBERGER A, 1991, EPILEPSY RES, V9, P32, DOI 10.1016/0920-1211(91)90044-G
   HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215
   HOSSAIN MZ, 1994, BRAIN RES, V652, P311, DOI 10.1016/0006-8993(94)90242-9
   Jabs R, 1997, NEUROSCIENCE, V81, P847, DOI 10.1016/S0306-4522(97)00207-8
   JENNEMANN R, 1990, CANCER RES, V50, P7444
   Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132
   KIM JH, 1990, ACTA NEUROPATHOL, V80, P41, DOI 10.1007/BF00294220
   Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7
   Kohling R, 2002, SCIENCE, V298, P1350
   Kohling R, 2000, J NEUROSCI, V20, P6820
   LASCHET J, 1992, EPILEPSY RES, V12, P151, DOI 10.1016/0920-1211(92)90035-R
   Li XH, 2002, J AFFECT DISORDERS, V69, P1, DOI 10.1016/S0165-0327(00)00361-X
   Liigant A, 2001, EUR NEUROL, V45, P46, DOI 10.1159/000052089
   Loscher W, 2002, J PHARMACOL EXP THER, V301, P7, DOI 10.1124/jpet.301.1.7
   Louw DF, 1997, NEUROSURGERY, V41, P1146, DOI 10.1097/00006123-199711000-00025
   Lynch M, 2000, J NEUROPHYSIOL, V84, P2868
   MANGOURA D, 1989, NEUROCHEM RES, V14, P941, DOI 10.1007/BF00965927
   Martin ED, 2001, J NEUROPHYSIOL, V86, P2878
   MCBAIN CJ, 1998, J PHYSIOL-LONDON, V511, P311
   McIntyre DC, 2002, J NEUROSCI, V22, P9922
   McNamara J. O., 1999, NATURE, V399, P15
   MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0
   MURAKAMI M, 1990, J NEUROSURG, V73, P760, DOI 10.3171/jns.1990.73.5.0760
   NEUMAN RS, 1989, EPILEPSIA, V30, P207
   NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672
   OLSON JM, 1992, J NEURO-ONCOL, V13, P35
   PASTERNACK M, 1992, NEUROSCIENCE, V47, P921, DOI 10.1016/0306-4522(92)90040-9
   PASTERNACK M, 1992, J COMP PHYSIOL A, V170, P521
   Powell EM, 2003, J NEUROSCI, V23, P622
   RAMACHANDRAN V, 2003, EPILEPSIA S1, V44, pS33
   RANSOM BR, 1992, PROG BRAIN RES, V94, P37
   Rogawski MA, 2002, EPILEPSY BEHAV, V3, P493, DOI 10.1016/S1525-5050(02)00557-7
   Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0
   RUTECKI PA, 2002, EPILIPSIA, V43, pS179
   SESSA A, 1994, CANCER LETT, V76, P121, DOI 10.1016/0304-3835(94)90387-5
   SHAW MDM, 1990, ACT NEUR S, V50, P55
   SHERWIN A, 1988, NEUROLOGY, V38, P920, DOI 10.1212/WNL.38.6.920
   Siddiqui A, 2003, NEW ENGL J MED, V348, P1442, DOI 10.1056/NEJMoa021986
   Singh S M, 1990, Am J Dent, V3, P15
   Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002
   SOLIVEN B, 1992, J NEUROCHEM, V58, P1073, DOI 10.1111/j.1471-4159.1992.tb09364.x
   Steriade M, 1999, J NEUROPHYSIOL, V82, P3108
   STRANGE RC, 1992, BIOCHIM BIOPHYS ACTA, V1139, P222, DOI 10.1016/0925-4439(92)90138-D
   Striano S, 2002, EPILEPSY RES, V49, P81, DOI 10.1016/S0920-1211(02)00005-0
   SUBRAMANIAM S, 1994, EXP NEUROL, V130, P323, DOI 10.1006/exnr.1994.1210
   Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011
   TIZZANO JP, 1995, NEUROPHARMACOLOGY, V34, P1063, DOI 10.1016/0028-3908(95)00083-I
   VANDENPOL AN, 1992, J NEUROSCI, V12, P2648
   Vezzani A, 2002, EPILEPSIA, V43, P30, DOI 10.1046/j.1528-1157.43.s.5.14.x
   Wen PY, 2002, CURR OPIN ONCOL, V14, P299, DOI 10.1097/00001622-200205000-00008
   WHITTLE IR, 1995, ACTA NEUROCHIR, V135, P19, DOI 10.1007/BF02307409
   Wolf HK, 1996, ACTA NEUROPATHOL, V91, P376, DOI 10.1007/s004010050439
   Wrensch M, 2002, NEURO-ONCOLOGY, V4, P278, DOI 10.1093/neuonc/4.4.278
   YAN QS, 1993, EPILEPSY RES, V14, P229, DOI 10.1016/0920-1211(93)90047-B
NR 86
TC 75
Z9 79
U1 5
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2003
VL 44
IS 9
BP 1223
EP 1232
DI 10.1046/j.1528-1157.2003.05203.x
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 721PJ
UT WOS:000185324500013
PM 12919395
OA Bronze
DA 2018-12-27
ER

PT J
AU Penkowa, M
   Keller, C
   Keller, P
   Jauffred, S
   Pedersen, BK
AF Penkowa, M
   Keller, C
   Keller, P
   Jauffred, S
   Pedersen, BK
TI RETRACTED: Immunohistochemical detection of interleukin-6 in human
   skeletal muscle fibers following exercise (Retracted article. See vol.
   28, pg. 1526, 2014)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE cytokine staining; physical training; health
ID IL-6; ACTIVATION; INCREASE; RELEASE; PATTERN; CELLS
AB Interleukin-6 (IL-6) is produced by many different cell types. Human skeletal muscles produce and release high amounts of IL-6 during exercise; however, the cell source of origin in the muscle is not known. Therefore, we studied the protein expression of IL-6 by immunohistochemistry in human muscle tissue from biopsies obtained at time points 0, 3, 4.5, 6, 9, and 24 h in relation to 3 h of bicycle exercise performed by healthy young males (n=12) and in resting controls (n=6). The IL-6 expression was clearly increased after exercise and remained high even by 24 h, relative to preexercise or resting individuals. The IL-6 immunostainings of skeletal muscle cells were homogeneous and without difference between muscle fiber types. The IL-6 mRNA peaked immediately after the exercise, and, in accordance, the IL-6 protein expression within muscle cells was most pronounced around 3 h post-exercise. However, the finding that plasma IL-6 concentration peaked in the end of exercise indicates a high turnover of muscle-derived IL-6. In conclusion, the finding of marked IL-6 protein expression exclusively within skeletal muscle fibers following exercise demonstrates that skeletal muscle fibers of all types are the dominant cell source of exercise-induced release of IL-6 from working muscle.
C1 Univ Copenhagen, Rigshosp, Dept Infect Dis 7641, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
   Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen O, Denmark.
RP Pedersen, BK (reprint author), Univ Copenhagen, Rigshosp, Dept Infect Dis 7641, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
CR Abbate F, 2002, AM J PHYSIOL-CELL PH, V283, pC42, DOI 10.1152/ajpcell.00416.2001
   BARTOCCIONI E, 1994, IMMUNOL LETT, V42, P135, DOI 10.1016/0165-2478(94)90076-0
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x
   BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670
   De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329
   Dolmetsch RE, 1998, NATURE, V392, P933
   Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev
   GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515
   GOLLNICK PD, 1974, J PHYSIOL-LONDON, V241, P45, DOI 10.1113/jphysiol.1974.sp010639
   Helge JW, 2003, J PHYSIOL-LONDON, V546, P299, DOI 10.1113/jphysiol.2002.030437
   Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086
   Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje
   KELLER C, 2002, J PHYSL, pP539
   Klouche M, 1999, J IMMUNOL, V163, P4583
   Langberg H, 2002, J PHYSIOL-LONDON, V542, P985, DOI 10.1113/jphysiol.2002.019141
   Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285
   Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T
   Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x
   Pedersen BK, 2000, PHYSIOL REV, V80, P1055
   Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   RD L, 1965, HISTOPATHOLOGIC TECH
   SOGAARD K, 1995, MUSCLE NERVE, V18, P292, DOI 10.1002/mus.880180305
   Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje
   Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x
   Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769
   Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x
   Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x
   van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687
   YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463
NR 31
TC 102
Z9 114
U1 4
U2 17
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2003
VL 17
IS 12
DI 10.1096/fj.03-0311fje
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 732DG
UT WOS:000185925100016
PM 12958150
DA 2018-12-27
ER

PT J
AU Matsumoto, T
   Honda, S
   Harada, N
AF Matsumoto, T
   Honda, S
   Harada, N
TI RETRACTED: Neurological effects of aromatase deficiency in the mouse
   (Retracted article. See vol. 128, pg. 87, 2012)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 6th International Aromatase Conference
CY OCT 26-30, 2002
CL KYOTO, JAPAN
DE estrogen; brain; sexual differentiation; cytochrome p450; knockout mouse
ID ESTROGEN-RECEPTOR-ALPHA; CASTRATED MALE-RATS; SEXUAL-BEHAVIOR; MICE
   LACKING; CYP19 GENE; IMMUNOREACTIVE CELLS; TARGETED DISRUPTION; KNOCKOUT
   MICE; FEMALE MICE; BETA-ERKO
AB In the brain, the conversion from androgen into estrogen is an important process for the differentiation of the brain function in male rodents. The aromatase is expressed in some nucleus of the brain. To assess the functional significance of the aromatase gene in development and activation of sex-specific behavior, we analyzed behavioral phenotypes of the aromatase knockout (ArKO) male mice. ArKO males obviously decreased their fertility and showed deficits in male sexual behavior including mount, intromission and ejaculation. Noncontact penile erection was not significantly affected by defect of the aromatase gene. A reduction of aggressive behavior against male intruders was also observed in ArKO males, while they tend to exhibit aggression toward estrous females during male copulatory tests. Moreover, the infanticide toward the pups was observed in the ArKO males, whereas characteristic parental behavior, but not infanticide was observed in wild-type males. These results indicate that aromatase gene expression is a critical step not only for motivational and consummatory aspects of male sexual behavior, but also for aggressive and parental behaviors in male mice. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Fujita Hlth Univ, Sch Med, Dept Biochem, Aichi, Japan.
RP Honda, S (reprint author), Fujita Hlth Univ, Sch Med, Dept Biochem, Aichi, Japan.
EM shonda@fujita-hu.ac.jp
CR Bakker J, 2002, HORM BEHAV, V42, P158, DOI 10.1006/hbeh.2002.1805
   Bakker J, 2002, J NEUROSCI, V22, P9104
   BALTHAZART J, 1991, CELL TISSUE RES, V263, P71, DOI 10.1007/BF00318401
   BEACH FA, 1981, HORM BEHAV, V15, P325, DOI 10.1016/0018-506X(81)90001-5
   BERKOVITZ GD, 1984, J CLIN ENDOCR METAB, V59, P665, DOI 10.1210/jcem-59-4-665
   BRADSHAW WG, 1981, ENDOCRINOLOGY, V109, P1047, DOI 10.1210/endo-109-4-1047
   Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204
   Carani C, 1999, CLIN ENDOCRINOL, V51, P517, DOI 10.1046/j.1365-2265.1999.00849.x
   CHRISTENSEN LW, 1974, ENDOCRINOLOGY, V95, P984, DOI 10.1210/endo-95-4-984
   CHRISTENSEN LW, 1975, ENDOCRINOLOGY, V97, P1545, DOI 10.1210/endo-97-6-1545
   DAVIDSON JM, 1966, ANIM BEHAV, V14, P266, DOI 10.1016/S0003-3472(66)80082-9
   Deladoey J, 1999, J CLIN ENDOCR METAB, V84, P4050, DOI 10.1210/jc.84.11.4050
   Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965
   FOIDART A, 1995, CELL TISSUE RES, V280, P561, DOI 10.1007/s004410050385
   GRAY GD, 1980, PHYSIOL BEHAV, V24, P463, DOI 10.1016/0031-9384(80)90237-1
   GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207
   Harada N, 1999, CIRC RES, V84, P1285, DOI 10.1161/01.RES.84.11.1285
   HARADA N, 1992, J BIOL CHEM, V267, P4781
   HART BL, 1979, PHYSIOL BEHAV, V23, P107, DOI 10.1016/0031-9384(79)90129-X
   Honda S, 1998, BIOCHEM BIOPH RES CO, V252, P445, DOI 10.1006/bbrc.1998.9672
   ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673
   Kristensen VN, 2000, ONCOGENE, V19, P1329, DOI 10.1038/sj.onc.1203425
   LAUBER ME, 1994, ENDOCRINOLOGY, V135, P1661, DOI 10.1210/en.135.4.1661
   Lephart ED, 1996, BRAIN RES REV, V22, P1
   MCNATTY KP, 1976, J ENDOCRINOL, V71, P77, DOI 10.1677/joe.0.0710077
   MEISEL RL, 1984, HORM BEHAV, V18, P56, DOI 10.1016/0018-506X(84)90050-3
   MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689
   NAFTOLIN F, 1994, J REPROD MED, V39, P257
   Naftolin F, 1975, Adv Biosci, V15, P105
   NAFTOLIN F, 1972, ENDOCRINOLOGY, V90, P295, DOI 10.1210/endo-90-1-295
   Ogawa S, 1999, P NATL ACAD SCI USA, V96, P12887, DOI 10.1073/pnas.96.22.12887
   Ogawa S, 1998, ENDOCRINOLOGY, V139, P5058, DOI 10.1210/en.139.12.5058
   Ogawa S, 1997, P NATL ACAD SCI USA, V94, P1476, DOI 10.1073/pnas.94.4.1476
   Ogawa S, 2000, P NATL ACAD SCI USA, V97, P14737, DOI 10.1073/pnas.250473597
   Rissman EF, 1997, HORM BEHAV, V31, P232, DOI 10.1006/hbeh.1997.1390
   Robertson KM, 2001, J ANDROL, V22, P825
   Rochira V, 2001, MOL CELL ENDOCRINOL, V178, P107, DOI 10.1016/S0303-7207(01)00432-4
   RYAN KJ, 1959, J BIOL CHEM, V234, P268
   Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416
   SHINODA K, 1994, J COMP NEUROL, V343, P113, DOI 10.1002/cne.903430109
   Simpson ER, 2000, P NATL ACAD SCI USA, V97, P14038, DOI 10.1073/pnas.011526097
   Toda K, 2001, J ENDOCRINOL, V168, P455, DOI 10.1677/joe.0.1680455
   Toda K, 2001, J ENDOCRINOL, V168, P217, DOI 10.1677/joe.0.1680217
   Toda K, 2001, J ENDOCRINOL, V170, P99, DOI 10.1677/joe.0.1700099
   VALLADARES LE, 1979, P NATL ACAD SCI USA, V76, P4460, DOI 10.1073/pnas.76.9.4460
   Wersinger SR, 1997, HORM BEHAV, V32, P176, DOI 10.1006/hbeh.1997.1419
NR 46
TC 27
Z9 27
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD SEP
PY 2003
VL 86
IS 3-5
BP 357
EP 365
DI 10.1016/S0960-0760(03)00345-5
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 749GX
UT WOS:000186912500020
PM 14623532
DA 2018-12-27
ER

PT J
AU Kester, RR
   Mooppan, UMM
   Gousse, AE
   Alver, JE
   Gintautas, J
   Gulmi, FA
   Abadir, AR
   Kim, H
AF Kester, RR
   Mooppan, UMM
   Gousse, AE
   Alver, JE
   Gintautas, J
   Gulmi, FA
   Abadir, AR
   Kim, H
TI RETRACTED: Pharmacological characterization of isolated human prostate
   (Retracted Article. See vol 170, pg 2394, 2003)
SO JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE prostate; prostatic hyperplasia; muscle; smooth; muscle contraction;
   receptors; sensory
ID DOUBLE-BLIND; HYPERPLASIA; SEROTONIN; TERAZOSIN; RECEPTOR; MULTICENTER;
   OBSTRUCTION; ANTAGONIST; KETANSERIN; DOXAZOSIN
AB Purpose: Human prostate contains alpha-1 adrenergic, cholinergic and nonadrenergic noncholinergic neuroreceptors. Using agonistic and antagonistic agents at these neuroreceptors we studied the resultant contractile responses in isolated human prostate.
   Materials and Methods: Human prostate tissue was obtained at prostatectomy for benign prostatic hyperplasia in 37 adult male patients. Tissues were suspended in tissue bath chambers connected to force displacement transducers. Specimens were subjected to agonist induced the first always being norepinephrine (NE). Specimens were pretreated with antagonist (adrenergic, cholinergic, nonadrenergic noncholinergic or none if control), followed by contraction with a second agonist (NE or other). Contractile tensions were recorded on a polygraph and then statistically analyzed.
   Results: The order of highest to lowest agonist induced tensile forces was NE, dopamine, acetylcholine, bethanechol, histamine and serotonin. Excitatory concentration EC50 values were determined for each agonist tested. Significant differences were found between specific a-1 Adrenergic receptor blockers (terazosin, prazosin and the experimental drug LY253352). In addition, many other agents antagonized the a-1 adrenergic receptor. Inhibitory concentration IC50 values were obtained and the order of a-1 adrenergic antagonistic strengths from strongest weakest was LY253352, prazosin, terazosin, ketanserin, SCH23390, diphenhydramine, DO,710, dopamine, serotonin and histamine.
   Conclusions: Human prostate neuroreceptors were determined to be alpha-1 adrenergic, dopaminergic, muscarinic cholinergic, 2A serotonergic and H1 histaminergic. Dopamine, serotonin, histamine and their antagonists blocked the adrenergic response, indicating possible receptor-receptor interaction. Further study of the pharmacology of human prostate would likely identify new drugs for treating patients with bladder outlet obstruction due to benign prostatic hyperplasia.
C1 Univ Miami, Sch Med, Dept Urol, Miami, FL 33101 USA.
   Brookdale Univ, Med Ctr, Dept Urol, Brooklyn, NY USA.
   Brookdale Univ, Med Ctr, Dept Anesthesiol, Brooklyn, NY USA.
RP Gousse, AE (reprint author), Univ Miami, Sch Med, Dept Urol, POB 016960,M814, Miami, FL 33101 USA.
EM agousse@med.miami.edu
CR ABRAHAMSSON PA, 1986, PATHOL RES PRACT, V181, P675, DOI 10.1016/S0344-0338(86)80043-7
   Akduman B, 2001, UROLOGY, V58, P49, DOI 10.1016/S0090-4295(01)01302-4
   Boston LN, 1928, MED TIMES NY, V56, P94
   CAINE M, 1978, BRIT J UROL, V50, P551, DOI 10.1111/j.1464-410X.1978.tb06210.x
   DAVIS NS, 1987, PROSTATE, V11, P353, DOI 10.1002/pros.2990110407
   DELAERE KPJ, 1987, UROLOGY, V29, P669, DOI 10.1016/0090-4295(87)90121-X
   DISANTAGNESE PA, 1984, HUM PATHOL, V15, P1034
   EPSTEIN JI, 1984, HUM PATHOL, V15, P818, DOI 10.1016/S0046-8177(84)80142-2
   FURUYA S, 1982, J UROLOGY, V128, P836, DOI 10.1016/S0022-5347(17)53216-4
   GILLENWATER JY, 1995, J UROLOGY, V154, P110, DOI 10.1016/S0022-5347(01)67243-4
   Hassin-Baer S, 2001, J NEURAL TRANSM, V108, P1299, DOI 10.1007/s007020100006
   HEDLUND H, 1985, J UROLOGY, V134, P1291, DOI 10.1016/S0022-5347(17)47714-7
   HORBYPETERSEN J, 1985, J UROLOGY, V133, P1095, DOI 10.1016/S0022-5347(17)49388-8
   Khanna O P, 1977, Urology, V10, P375, DOI 10.1016/0090-4295(77)90171-6
   KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x
   LEPOR H, 1988, UROLOGY, V32, P21
   LEPOR H, 1984, J UROLOGY, V132, P397, DOI 10.1016/S0022-5347(17)49636-4
   LEPOR H, 1988, J UROLOGY, V140, P664, DOI 10.1016/S0022-5347(17)41751-4
   LEPOR H, 1988, J UROLOGY, V140, P668, DOI 10.1016/S0022-5347(17)41752-6
   LEPOR H, 1984, J UROLOGY, V132, P1226, DOI 10.1016/S0022-5347(17)50110-X
   LEPOR H, 1993, J UROLOGY, V149, P640, DOI 10.1016/S0022-5347(17)36170-0
   Macht DI, 1922, J UROLOGY, V7, P409
   Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6
   NICKERSON M, 1947, J PHARMACOL EXP THER, V89, P167
   VAALASTI A, 1980, INVEST UROL, V17, P293
   Waddell JA, 1916, J PHARMACOL EXP THER, V9, P179
NR 26
TC 21
Z9 23
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2003
VL 170
IS 3
BP 1032
EP 1038
DI 10.1097/01.ju.0000080440.74266.b1
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 712TN
UT WOS:000184813400096
PM 12913765
DA 2018-12-27
ER

PT J
AU Stermitz, FR
   Bais, HP
   Foderaro, TA
   Vivanco, JM
AF Stermitz, FR
   Bais, HP
   Foderaro, TA
   Vivanco, JM
TI RETRACTED: 7,8-Benzoflavone: a phytotoxin from root exudates of invasive
   Russian knapweed (Retracted article. See vol. 70, pg. 156, 2009)
SO PHYTOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Acroptilon repens; Asteraceae; Centaurea repens; Compositae; Russian
   knapweed; 7,8-benzoflavone; alpha-napthoflavone; flavone; phytotoxin;
   allelochemical
ID CENTAUREA-REPENS; FALL ARMYWORM; CELLS
AB Root exudates from Acroptilon repens (Russian knapweed) were found to be phytotoxic and the phytotoxin in the exudate was identified as 7,8-benzoflavone (alpha-naphthoflavone), (1), not previously known as a natural product. In tests on growing seedlings both 1 and its isomer 5,6-benzoflavone (2) were phytotoxic. Flavone, a structural analog of 1 and a known granular leaf and stern exudate of other plant species, was also phytotoxic and more potent than 1 or 2. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
   Colorado State Univ, Grad Degree Program Ecol, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
   Roche Colorado Corp, Boulder, CO 80301 USA.
RP Stermitz, FR (reprint author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
EM frslab@lamar.colostate.edu; jvivanco@lamar.colostate.edu
RI Rechsteiner, Cynthia/C-5894-2011
CR BAIRD WM, 1976, CHEM-BIOL INTERACT, V13, P67, DOI 10.1016/0009-2797(76)90014-4
   Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019
   FREEMAN PW, 1981, AUST J CHEM, V34, P1779, DOI 10.1071/CH9811779
   GARCIAJACAS N, 2001, ANN BOT, V87, P405
   Goslee SC, 2001, ECOL MODEL, V139, P31, DOI 10.1016/S0304-3800(01)00231-9
   HARBORNE JB, 1971, PHYTOCHEMISTRY, V10, P472, DOI 10.1016/S0031-9422(00)94084-6
   HEGNAUER R, 1969, CHEMOTAXONOMIE PFLAN, V5, P394
   Ji XD, 1996, J MED CHEM, V39, P781, DOI 10.1021/jm950661k
   Lee CA, 1997, DRUG METAB DISPOS, V25, P1150
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   STEVENS KL, 1986, J CHEM ECOL, V12, P1205, DOI 10.1007/BF01012342
   STEVENS KL, 1982, PHYTOCHEMISTRY, V21, P1093, DOI 10.1016/S0031-9422(00)82423-1
   WELLER LE, 1953, ANTIBIOT CHEMOTHER, V3, P603
   WHITSON T. D., 1992, WEEDS W
   Wu CH, 2001, J AGR FOOD CHEM, V49, P2579, DOI 10.1021/jf001341z
   YU SJ, 1995, ARCH INSECT BIOCHEM, V28, P365, DOI 10.1002/arch.940280406
   Yu SJ, 2000, ZOOL STUD, V39, P243
NR 17
TC 42
Z9 48
U1 4
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9422
J9 PHYTOCHEMISTRY
JI Phytochemistry
PD SEP
PY 2003
VL 64
IS 2
BP 493
EP 497
DI 10.1016/S0031-9422(03)00276-0
PG 5
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 723FM
UT WOS:000185421800017
PM 12943767
DA 2018-12-27
ER

PT J
AU Kraus, S
   Benard, O
   Naor, Z
   Seger, R
AF Kraus, S
   Benard, O
   Naor, Z
   Seger, R
TI RETRACTED: c-Src is activated by the epidermal growth factor receptor in
   a pathway that mediates JNK and ERK activation by gonadotropin-releasing
   hormone in COS7 cells (Retracted article. See vol. 292, pg. 8851, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID PROTEIN-COUPLED RECEPTORS; G-BETA-GAMMA; SIGNAL-REGULATED KINASE;
   N-TERMINAL KINASE; TYROSINE KINASE; EGF RECEPTOR; BETA(2)-ADRENERGIC
   RECEPTOR; STIMULATED ACTIVITY; SUBUNIT PROMOTER; 3-KINASE GAMMA
AB Key participants in G protein-coupled receptor (GPCR) signaling are the mitogen-activated protein kinase (MAPK) signaling cascades. The mechanisms involved in the activation of the above cascades by GPCRs are not fully elucidated. A prototypic GPCR that has been widely used to study these signaling mechanisms is the receptor for gonadotropin-releasing hormone (GnRHR), which serves as a key regulator of the reproductive system. Here we expressed GnRHR in COS7 cells and found that GnRHR transmits its signals to MAPKs mainly via Galpha(i), EGF receptor without the involvement of Hb-EGF, and c-Src, but independently of PKCs. The main pathway that leads to JNK activation downstream of the EGF receptor involves a sequential activation of c-Src and phosphatidylinositol 3-kinase (PI3K). ERK activation by GnRHR is mediated by the EGF receptor, which activates Ras either directly or via c-Src. Besides the main pathway, the dissociated Gbetagamma and beta-arrestin may initiate additional, albeit minor, pathways that lead to MAPK activation in the transfected COS7 cells. The pathways detected are significantly different from those in other cell lines bearing GnRHR, indicating that GnRH can utilize various signaling mechanisms for the activation of MAPK cascades. The unique pathway elucidated here in which c-Src and PI3K are sequentially activated downstream of the EGF receptor may serve as a prototype of signaling mechanisms by GnRHR and by additional GPCRs in various cell types.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
   Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM rony.seger@weizmann.ac.il
CR Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185
   AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309
   Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982
   Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200
   Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7
   CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131
   Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0
   Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685
   Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0
   Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032
   Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657
   Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5
   de Rooij J, 1998, NATURE, V396, P474
   DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267
   Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X
   FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0
   Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251
   Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839
   Han XB, 1999, ENDOCRINOLOGY, V140, P2241, DOI 10.1210/en.140.5.2241
   Harris D, 2002, ENDOCRINOLOGY, V143, P1018, DOI 10.1210/en.143.3.1018
   Harris D, 2003, ENDOCRINOLOGY, V144, P612, DOI 10.1210/en.2002-220690
   HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135
   Ho MKC, 2001, ONCOGENE, V20, P1615, DOI 10.1038/sj.onc.1204190
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   Jiang Y, 1998, NATURE, V395, P808
   Kimura A, 1999, CANCER RES, V59, P5133
   KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0
   Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677
   Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024
   Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200
   Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505
   LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394
   Lu WY, 1999, NAT NEUROSCI, V2, P331
   Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4
   Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637
   LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495
   Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443
   Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898
   Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655
   Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6
   Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572
   McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574
   Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312
   Mochizuki N, 1999, NATURE, V400, P891
   Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796
   Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182
   Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080
   Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5
   Naor Z, 1995, CELL MOL NEUROBIOL, V15, P527, DOI 10.1007/BF02071315
   Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678
   NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184
   Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908
   Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200
   Prenzel N, 1999, NATURE, V402, P884
   Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673
   Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0
   SEGER R, 1995, FASEB J, V9, P726
   Shacham S, 1999, ANN ENDOCRINOL-PARIS, V60, P79
   Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200
   SHAH BH, 2003, J BIOL CHEM, V17, P17
   Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7
   STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Troskie B, 1998, GEN COMP ENDOCR, V112, P296, DOI 10.1006/gcen.1998.7156
   Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X
   Vasilyev VV, 2002, ENDOCRINOLOGY, V143, P3414, DOI 10.1210/en.2001-211215
   Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199
NR 73
TC 67
Z9 67
U1 2
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 29
PY 2003
VL 278
IS 35
BP 32618
EP 32630
DI 10.1074/jbc.M303886200
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 714FN
UT WOS:000184901800019
PM 12750372
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Schramke, V
   Allshire, R
AF Schramke, V
   Allshire, R
TI RETRACTED: Hairpin RNAs and retrotransposon LTRs effect RNAi and
   chromatin-based gene silencing (Retracted Article. See vol 301, pg 1069,
   2003)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID DISRUPT CHROMOSOME SEGREGATION; H3 LYSINE-9 METHYLATION; FISSION YEAST;
   HISTONE H3; SEQUENCE-ANALYSIS; DNA METHYLATION; CENTROMERE IDENTITY;
   HETEROCHROMATIN; INTERFERENCE; ARABIDOPSIS
AB The expression of short hairpin RNAs in several organisms silences gene expression by targeted mRNA degradation. This RNA interference (RNAi) pathway can also affect the genome, as DNA methylation arises at loci homologous to the target RNA in plants. We demonstrate in fission yeast that expression of a synthetic hairpin RNA is sufficient to silence the homologous locus in trans and causes the assembly of a patch of silent Swi6 chromatin with cohesin. This requires components of the RNAi machinery and Clr4 histone methyltransferase for small interfering RNA generation. A similar process represses several meiotic genes through nearby retrotransposon long terminal repeats (LTRs). These analyses directly implicate interspersed LTRs in regulating gene expression during cellular differentiation.
C1 Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland.
RP Allshire, R (reprint author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.
EM robin.allshire@ed.ac.uk
CR ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Baulcombe D, 2002, SCIENCE, V297, P2002, DOI 10.1126/science.1077906
   Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027
   BOWEN NJ, IN PRESS GENOME RES
   BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349
   Comfort NC, 2001, TRENDS GENET, V17, P475, DOI 10.1016/S0168-9525(01)02383-6
   Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468
   Dawe RK, 2003, PLANT CELL, V15, P297, DOI 10.1105/tpc.150230
   Dernburg AF, 2002, CELL, V111, P159, DOI 10.1016/S0092-8674(02)01039-5
   Ekwall K, 1999, GENETICS, V153, P1153
   Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877
   Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655
   Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950
   Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024
   Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099
   Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466
   Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714
   Jones L, 1999, PLANT CELL, V11, P2291, DOI 10.1105/tpc.11.12.2291
   Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5
   Kashkush K, 2003, NAT GENET, V33, P102, DOI 10.1038/ng1063
   Kidner CA, 2003, TRENDS GENET, V19, P13, DOI 10.1016/S0168-9525(02)00011-2
   Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951
   Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194
   Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612
   Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739
   Partridge JF, 2000, GENE DEV, V14, P783
   Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6
   Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183
   SCHRAMKE V, UNPUB
   Sleutels F, 2002, NATURE, V415, P810
   Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001
   Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512
   Sun XP, 2003, GENOME RES, V13, P182, DOI 10.1101/gr.681703
   TUFARELLI C, 2003, NATURE GENET
   Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X
   WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8
   Watanabe T, 2001, NUCLEIC ACIDS RES, V29, P2327, DOI 10.1093/nar/29.11.2327
   WEAVER DC, 1993, GENE, V131, P135, DOI 10.1016/0378-1119(93)90682-S
   Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1
   Zhong CX, 2002, PLANT CELL, V14, P2825, DOI 10.1105/tpc.006106
   Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695
NR 53
TC 240
Z9 252
U1 40
U2 49
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD AUG 22
PY 2003
VL 301
IS 5636
BP 1069
EP 1074
DI 10.1126/science.1086870
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 713RP
UT WOS:000184872400032
PM 12869699
DA 2018-12-27
ER

PT J
AU Narayanan, BA
   Condon, MS
   Bosland, MC
   Narayanan, NK
   Reddy, BS
AF Narayanan, BA
   Condon, MS
   Bosland, MC
   Narayanan, NK
   Reddy, BS
TI RETRACTED: Suppression of N-methyl-N-nitrosourea/testosterone-induced
   rat prostate cancer growth by celecoxib: Effects on cyclooxygenase-2,
   cell cycle regulation, and apoptosis mechanism(s) (Retracted article.
   See vol. 22, pg. 270, 2016)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AUTOCHTHONOUS INTESTINAL TUMORS;
   COLON-CANCER; IN-VIVO; RETINOBLASTOMA PROTEIN; INHIBITOR CELECOXIB;
   OVER-EXPRESSION; MOUSE EPIDERMIS; CARCINOMA-CELLS; MESSENGER-RNA
AB Purpose: This study was aimed at examining the mechanisms underlying the chemopreventive effect of celecoxib against prostate cancer. We focused our attention on events at the cellular level to show the ability of celecoxib to inhibit prostate cancer growth, by inducing cell cycle arrest and apoptosis. Moreover, we attempted to demonstrate the expression of genes involved in the downstream events related to cyclooxygenase-2 (COX-2) regulation and apoptosis.
   Experimental Design: To determine the level of COX-2 expression, we used paraffin-embedded tumor tissue sections and cancer cells (1-26) derived from N-methyl-N-nitro-so-urea/testosterone-induced rat dorsolateral prostate, and we used immunofluorescence detection and Western blot analyses with anti-COX-2 monoclonal antibodies. We conducted clonogenic cell survival assays to demonstrate cell growth inhibition at very low doses of celecoxib. Flow cytometric analysis demonstrated the effects on the cell cycle. Reverse transcription-PCR and Western blot analyses were performed to show the effect of celecoxib on the downstream events of COX-2 and apoptosis- related targets.
   Results: The summary of our findings indicates that (a) these cells from chemically induced rat prostate tumors express COX-2 at both the mRNA and the protein level; (b)celecoxib significantly reduces COX-2 expression in these cancer cells; and (c) celecoxib induces cell cycle arrest at the G(1)-S phase transition point and modifies cell cycle regulatory proteins such as cyclin D1, retinoblastoma (Rb), and phosphorylated Rb, cyclin E, p27(KIP1), and p21 (WAF1/CIP1). Furthermore, celecoxib inhibits DNA synthesis and induces apoptosis. Most importantly, celecoxib-induced apoptosis was associated with down-regulation of COX-2, nuclear factor KBp65, and with activation of peroxisome proliferator activated receptor gamma, apoptosis activating factor-1, and caspase-3.
   Conclusion: Results from the present study clearly indicate that celecoxib exerts its anticancer effect partly through COX-2-independent mechanisms in addition to the known primary function of COX-2 inhibition.
C1 Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Div Nutr Carcinogenesis, Valhalla, NY 10595 USA.
   Amer Hlth Fdn, Microarray Unit Mol Pathol & Bioinformat, Valhalla, NY 10595 USA.
   SUNY, Dutchess Community Coll, Dept Allied Hlth & Biol Sci, Poughkeepsie, NY 12601 USA.
   NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
RP Narayanan, BA (reprint author), Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Div Nutr Carcinogenesis, 1 Dana Rd, Valhalla, NY 10595 USA.
EM bnarayan@ifcp.us
FU PHS HHS [01A015]; NCI NIH HHS [CA-17613]
CR Aaltomaa S, 1999, PROSTATE, V38, P175
   Anderson WF, 2002, CURR PHARM DESIGN, V8, P1035, DOI 10.2174/1381612023394935
   Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0
   Bosland M C, 1996, Urol Oncol, V2, P103, DOI 10.1016/S1078-1439(97)82840-2
   Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681
   CHAUDRY A, 1991, BRIT J CANCER, V64, P1157, DOI 10.1038/bjc.1991.481
   CHAUDRY AA, 1994, INT J CANCER, V57, P176, DOI 10.1002/ijc.2910570208
   Condon MS, 1999, MOL CARCINOGEN, V25, P179, DOI 10.1002/(SICI)1098-2744(199907)25:3<179::AID-MC4>3.3.CO;2-J
   CONDON MS, 1995, IN VITRO CELL DEV, V31, P32
   Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0
   Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1
   Dubois RN, 1998, FASEB J, V12, P1063
   Esmat AY, 2002, TUMORI, V88, P513
   Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286
   FURSTENBERGER G, 1980, BIOCHEM BIOPH RES CO, V92, P749, DOI 10.1016/0006-291X(80)90767-6
   Furuya Y, 1997, ANTICANCER RES, V17, P4589
   GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Guinan P, 1998, METHOD FIND EXP CLIN, V20, P739
   Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
   Han EKH, 1998, BREAST CANCER RES TR, V48, P195, DOI 10.1023/A:1005924730450
   Hawk ET, 2002, J NATL CANCER I, V94, P545
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Itoh N, 1997, JPN J CANCER RES, V88, P229, DOI 10.1111/j.1349-7006.1997.tb00371.x
   Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23
   Johnson AJ, 2001, ADV ENZYME REGUL, V41, P221, DOI 10.1016/S0065-2571(00)00015-7
   Katayose Y, 1997, CANCER RES, V57, P5441
   KATO J, 1993, GENE DEV, V7, P331
   Kawamori T, 1998, CANCER RES, V58, P409
   Kirschenbaum A, 2001, UROLOGY, V58, P127, DOI 10.1016/S0090-4295(01)01255-9
   Leahy KM, 2002, CANCER RES, V62, P625
   Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2
   Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1
   Madaan S, 2000, BJU INT, V86, P736, DOI 10.1046/j.1464-410x.2000.00867.x
   Masferrer JL, 2000, CANCER RES, V60, P1306
   McCormick DL, 1999, CANCER RES, V59, P521
   McCormick DL, 1998, CANCER RES, V58, P3282
   McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095
   Milanesa DM, 2000, EUR UROL, V37, P728, DOI 10.1159/000020226
   Narayanan BA, 2003, CANCER RES, V63, P972
   Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1
   Narayanan BA, 2001, ANTICANCER RES, V21, P359
   Perry JE, 1998, PROSTATE, V35, P117
   Piazza GA, 1997, CANCER RES, V57, P2452
   POLLARD M, 1986, J NATL CANCER I, V77, P583
   POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4
   POLLARD M, 1983, J NATL CANCER I, V70, P1103
   POLLARD M, 1984, CANCER LETT, V25, P117, DOI 10.1016/S0304-3835(84)80035-X
   POLLARD M, 1986, PROSTATE, V8, P81, DOI 10.1002/pros.2990080110
   Rao KVN, 1999, CANCER RES, V59, P3084
   Reddy BS, 2000, DRUG AGING, V16, P329, DOI 10.2165/00002512-200016050-00002
   Reddy BS, 2000, CANCER RES, V60, P293
   REDDY BS, 1987, CANCER RES, V47, P5340
   ROBERTS RO, 2001, P AM ASSOC CANC RES, V42, P767
   Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049
   Seibert K, 1997, ADV EXP MED BIOL, V400, P167
   Shappell SB, 2001, NEOPLASIA, V3, P287, DOI 10.1038/sj.neo.7900166
   Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400
   Singh G, 1999, J CELL PHYSIOL, V180, P431, DOI 10.1002/(SICI)1097-4652(199909)180:3<431::AID-JCP14>3.0.CO;2-O
   Song XQ, 2002, J NATL CANCER I, V94, P585
   Subbarayan V, 2001, CANCER RES, V61, P2720
   SUKUMAR S, 1991, MOL CARCINOGEN, V4, P362, DOI 10.1002/mc.2940040507
   Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192
   Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369
   TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2
   Uotila P, 2001, Urol Res, V29, P23
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Williams CS, 2000, CANCER RES, V60, P6045
   YAMAMOTO S, 1992, CARCINOGENESIS, V13, P905, DOI 10.1093/carcin/13.5.905
   Yoshimura R, 2000, CANCER, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C
   Zha S, 2001, CANCER RES, V61, P8617
NR 74
TC 73
Z9 76
U1 2
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2003
VL 9
IS 9
BP 3503
EP 3513
PG 11
WC Oncology
SC Oncology
GA 718XW
UT WOS:000185172600038
PM 12960143
DA 2018-12-27
ER

PT J
AU Sato, Y
   Metoki, N
   Iwamoto, J
   Satoh, K
AF Sato, Y
   Metoki, N
   Iwamoto, J
   Satoh, K
TI RETRACTED: Amelioration of osteoporosis and hypovitaminosis D by
   sunlight exposure in stroke patients(Retracted article.See
   vol.87,pg.239,2016)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID VITAMIN-D DEFICIENCY; BONE MASS; HIP-FRACTURES; OSTEOPENIA;
   IMMOBILIZATION; OSTEOMALACIA; WOMEN; SUPPLEMENTATION; METACARPAL;
   CALCIUM
AB Background: The authors' previous investigations have disclosed low serum 25-hydroxyvitamin D (25-OHD) concentrations in 45 patients during long-term hospitalization following stroke (mean 5.9 ng/mL). This 25-OHD deficiency resulted from sunlight deprivation. Objective: To evaluate the efficacy of sunlight exposure in increasing serum 25-OHD, in reducing the severity of osteoporosis in bone mineral density (BMD), and in decreasing the risk of hip fractures in chronically hospitalized, disabled stroke patients. Methods: In a 12-month randomized and prospective study of stroke patients, 129 received regular sunlight exposure for 12 months, and the remaining 129 (sunlight-deprived) did not. Results: At baseline, patients of both groups showed vitamin D deficiency. BMD increased by 3.1% in the sunlight-exposed group and decreased by 3.3% in the sunlight-deprived group (p = 0.0001). 25-OHD level increased by fourfold in the sunlight-exposed group. Six patients sustained hip fractures on the hemiplegic side in the sunlight-deprived group, and one hip fracture occurred among the sunlight-exposed group (p = 0421; odds ratio = 6.1). Conclusion: Sunlight exposure can increase the BMD of vitamin D-deficient bone by increasing 25-OHD concentration.
C1 Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Inst Brain Sci, Hirosaki, Aomori 036, Japan.
   Futase Social Insurance Hosp, Dept Neurol, Iizuka, Fukuoka, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR BEADLE PC, 1977, BRIT J DERMATOL, V97, P585
   CAMPBELL GA, 1984, LANCET, V2, P386
   Chalmers J, 1967, J Bone Joint Surg Br, V49, P403
   CHIU KY, 1992, INJURY, V23, P297, DOI 10.1016/0020-1383(92)90171-N
   CORLESS D, 1975, LANCET, V1, P1404
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   EASTWOOD JB, 1979, LANCET, V1, P1377
   FRAME B, 1978, ANN INTERN MED, V89, P966, DOI 10.7326/0003-4819-89-6-966
   Francis RM, 1997, BAILLIERE CLIN ENDOC, V11, P145, DOI 10.1016/S0950-351X(97)80569-1
   GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   LESTER E, 1980, SCAND J CLIN LAB INV, V40, P145, DOI 10.3109/00365518009093017
   MAHONEY F I, 1965, Md State Med J, V14, P61
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   MCKENNA MJ, 1985, AM J CLIN NUTR, V41, P101
   National Institute of Neurological Disorders and Stroke Ad Hoc Comittee. Special report from the National Institute of Neurological Disorders and Stroke, 1990, STROKE, V21, P637
   NIEVES J, 1994, NEUROLOGY, V44, P1687, DOI 10.1212/WNL.44.9.1687
   PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Sato Y, 1998, J NEUROL SCI, V156, P205, DOI 10.1016/S0022-510X(98)00041-0
   Sato Y, 2001, STROKE, V32, P1673, DOI 10.1161/01.STR.32.7.1673
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 1999, AGE AGEING, V28, P265, DOI 10.1093/ageing/28.3.265
   Sato Y, 1996, EUR NEUROL, V36, P278, DOI 10.1159/000117272
   Sato Y, 1999, AM J PHYS MED REHAB, V78, P457, DOI 10.1097/00002060-199909000-00008
   Sato Y, 1997, STROKE, V28, P736, DOI 10.1161/01.STR.28.4.736
   Sato Y, 1999, BONE, V24, P271, DOI 10.1016/S8756-3282(98)00185-9
   Sato Y, 1996, STROKE, V27, P2183, DOI 10.1161/01.STR.27.12.2183
   SHAHAR E, 1995, STROKE, V26, P1
NR 30
TC 37
Z9 39
U1 4
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 12
PY 2003
VL 61
IS 3
BP 338
EP 342
DI 10.1212/01.WNL.0000078892.24356.90
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 710ZL
UT WOS:000184712600012
PM 12913194
DA 2018-12-27
ER

PT J
AU Cremonini, F
   Di Caro, S
   Delgado-Aros, S
   Sepulveda, A
   Gasbarrini, G
   Gasbarrini, A
   Camilleri, M
AF Cremonini, F
   Di Caro, S
   Delgado-Aros, S
   Sepulveda, A
   Gasbarrini, G
   Gasbarrini, A
   Camilleri, M
TI RETRACTED: Meta-analysis: the relationship between Helicobacter pylori
   infection and gastro-oesophageal reflux disease (Retracted Article. See
   vol 19, p 145, 2004)
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Retracted Publication
ID RANDOMIZED CONTROLLED-TRIAL; DUODENAL-ULCER; SYMPTOMATIC BENEFIT;
   ERADICATION THERAPY; NONULCER DYSPEPSIA; CORPUS GASTRITIS; HIGH
   PREVALENCE; PEPTIC-ULCER; ESOPHAGITIS; ACID
AB Background: The relationship between Helicobacter pylori infection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial.
   Aims: To establish if H. pylori infection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD.
   Methods: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials.
   Results: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15-1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy - GERD was 2.54 (95% CI 1.92-3.37). The OR for de novo GERD was 3.25 (95% CI 2.09-5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75-3.34). Associations were higher among Asian studies than among North American and European studies.
   Conclusions: This meta-analysis shows significant association between absence of H. pylori infection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.
C1 Mayo Clin & Mayo Fdn, Clin Enter Neurosci Translat & Epidemiol Res Prog, Rochester, MN 55902 USA.
   Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
   Gemelli Hosp, Rome, Italy.
RP Cremonini, F (reprint author), Mayo Clin & Mayo Fdn, Clin Enter Neurosci Translat & Epidemiol Res Prog, Charlton Bldg 08 8-118, Rochester, MN 55902 USA.
EM Cremonini.Filippo@mayo.edu
FU NIDDK NIH HHS [R01 DK54681, K24 DK02638]; NCRR NIH HHS [RR00585]
CR Adamek RJ, 2001, EUR J GASTROEN HEPAT, V13, P811, DOI 10.1097/00042737-200107000-00009
   Befrits R, 2000, HELICOBACTER, V5, P202, DOI 10.1046/j.1523-5378.2000.00031.x
   Boixeda D, 1995, MED CLIN-BARCELONA, V105, P774
   Calam J, 1997, GASTROENTEROLOGY, V113, pS43, DOI 10.1016/S0016-5085(97)80010-8
   CHENG EH, 1989, ARCH INTERN MED, V149, P1373, DOI 10.1001/archinte.149.6.1373
   Csendes A, 1997, Dis Esophagus, V10, P38
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Serag HB, 1998, GUT, V43, P327, DOI 10.1136/gut.43.3.327
   El-Serag HB, 1999, GUT, V45, P181, DOI 10.1136/gut.45.2.181
   ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1
   Fallone CA, 2000, AM J GASTROENTEROL, V95, P914
   Feldman M, 1998, AM J PHYSIOL-GASTR L, V274, pG1011
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   GOGGIN PM, 1992, GASTROENTEROLOGY, V103, P1486, DOI 10.1016/0016-5085(92)91168-4
   Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1
   GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P643
   Hamada H, 2000, ALIMENT PHARM THER, V14, P729
   Haruma K, 2000, HELICOBACTER, V5, P24, DOI 10.1046/j.1523-5378.2000.00003.x
   HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903
   Holtmann G, 1999, GASTROENTEROLOGY, V117, P11, DOI 10.1016/S0016-5085(99)70544-5
   Hurenkamp GJB, 2001, ALIMENT PHARM THERAP, V15, P1047, DOI 10.1046/j.1365-2036.2001.01017.x
   Kiltz U, 2002, EUR J GASTROEN HEPAT, V14, P979, DOI 10.1097/00042737-200209000-00008
   Koike T, 2001, GUT, V49, P330, DOI 10.1136/gut.49.3.330
   Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603
   Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6
   Liston R, 1996, POSTGRAD MED J, V72, P221, DOI 10.1136/pgmj.72.846.221
   Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x
   Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P1431, DOI 10.1046/j.1365-2036.2002.01285.x
   Manes G, 2001, DIGEST LIVER DIS, V33, P665, DOI 10.1016/S1590-8658(01)80042-6
   McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601
   McColl KEL, 2000, AM J GASTROENTEROL, V95, P101
   Miyaji H, 1999, ALIMENT PHARM THERAP, V13, P1473
   Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4
   Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332
   MOAYYEDI P, 2003, COCHRANE DB SYST REV, V1, P2096
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Newton M, 1997, GUT, V40, P9, DOI 10.1136/gut.40.1.9
   Oberg S, 1999, ARCH SURG-CHICAGO, V134, P722, DOI 10.1001/archsurg.134.7.722
   Schwizer W, 2001, LANCET, V357, P1738, DOI 10.1016/S0140-6736(00)04894-7
   Sonnenberg A, 1999, YALE J BIOL MED, V72, P81
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tefera S, 2002, SCAND J GASTROENTERO, V37, P877, DOI 10.1080/003655202760230810
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999
   Vakil N, 2000, ALIMENT PHARM THER, V14, P45
   Werdmuller BFM, 1997, DIGEST DIS SCI, V42, P103, DOI 10.1023/A:1018841222856
   Wu JCY, 2002, GASTROINTEST ENDOSC, V55, P461, DOI 10.1067/mge.2002.122617
   Wu JCY, 1999, AM J GASTROENTEROL, V94, P1790
   Wu JCY, 2002, ALIMENT PHARM THER, V16, P545, DOI 10.1046/j.1365-2036.2002.01189.x
   Wu JCY, 2001, ALIMENT PHARM THERAP, V15, P1913, DOI 10.1046/j.1365-2036.2001.01132.x
   Wu JCY, 2000, ALIMENT PHARM THER, V14, P427, DOI 10.1046/j.1365-2036.2000.00714.x
   Yerra L N, 1999, Trop Gastroenterol, V20, P175
NR 52
TC 65
Z9 73
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD AUG 1
PY 2003
VL 18
IS 3
BP 279
EP 289
DI 10.1046/j.1365-2036.2003.01665.x
PG 11
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 707PX
UT WOS:000184520000003
PM 12895212
OA Bronze
DA 2018-12-27
ER

PT J
AU Fechner, J
   Ihmsen, H
   Hatterscheid, D
   Schiessl, C
   Vornov, JJ
   Burak, E
   Schwilden, H
   Schuttler, JR
AF Fechner, J
   Ihmsen, H
   Hatterscheid, D
   Schiessl, C
   Vornov, JJ
   Burak, E
   Schwilden, H
   Schuttler, JR
TI RETRACTED: Pharmacokinetics and clinical pharmacodynamics of the new
   propofol prodrug GPI 15715 in volunteers (Retracted article. See vol.
   112, pg. 1058, 2010)
SO ANESTHESIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Annual Meeting of the American-Society-of-Anesthesiologists
CY OCT 10-20, 2001
CL NEW ORLEANS, LA
SP Amer Soc Anesthesiologists
ID BISPECTRAL INDEX; CONSCIOUSNESS; RATS; EEG; ANESTHESIA; INFUSIONS;
   SEDATION; DIPRIVAN; BLOOD
AB Background: GPI 15715 (AQUAVAN injection) is a new water-soluble prodrug which is hydrolyzed to release propofol. The objectives of this first study in humans were to investigate the safety, tolerability, pharmacokinetics, and clinical pharmacodynamics of GPI 15715.
   Methods: Three groups of three healthy mate volunteers (aged 19-35 y, 67-102 kg) received 290, 580, and 1,160 mg GPI 15715 as a constant rate infusion over 10 min. The plasma concentrations of GPI 15715 and propofol were measured from arterial and venous blood samples up to 24 h. Pharmacokinetics were analyzed with compartment models. Pharmacodynamics were assessed by clinical signs.
   Results: GPI 15715 was well tolerated without pain on injection. Two subjects reported a transient unpleasant sensation of burning or tingling at start of infusion. Loss of consciousness was achieved in none with 290 mg and in one subject with 580 mg. After 1,160 mg, all subjects experienced loss of consciousness at propofol concentrations of 2.1 +/- 0.6 mug/ml. A two-compartment model for GPI 15715 (central volume of distribution, 0.07 l/kg; clearance, 7 ml . kg(-1) min(-1); terminal half-life, 46 min) and a three-compartment model for propofol (half-lives: 2.2, 20, 477 min) best described the data. The maximum decrease of blood pressure was 25%; the heart rate increased by approximately 35%. There were no significant laboratory abnormalities.
   Conclusions: Compared with propofol lipid emulsion, the potency seemed to be higher with respect to plasma concentration but was apparently less with respect to dose. Pharmacokinetic simulations showed a longer time to peak propofol concentration after a bolus dose and a longer context-sensitive half-time.
C1 Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany.
   Guilford Pharmaceut Inc, Baltimore, MD USA.
RP Fechner, J (reprint author), Univ Erlangen Nurnberg, Dept Anesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.
EM joerg.fechner@kfa.imed.uni-erlangen.de
OI Vornov, James/0000-0003-1965-5456
CR Albrecht S, 1999, ANAESTHESIST, V48, P794, DOI 10.1007/s001010050787
   BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008
   CHEMIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244
   Doursout MF, 2002, BRIT J ANAESTH, V89, P492, DOI 10.1093/bja/aef205
   Dutta S, 1998, J PHARM PHARMACOL, V50, P37, DOI 10.1111/j.2042-7158.1998.tb03302.x
   Dutta S, 1998, ANESTHESIOLOGY, V89, P678, DOI 10.1097/00000542-199809000-00018
   FORREST FC, 1994, BRIT J ANAESTH, V72, P35, DOI 10.1093/bja/72.1.35
   GEPTS E, 1987, ANESTH ANALG, V66, P1256
   HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003
   Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004
   Kelbel I, 1999, ACTA ANAESTH SCAND, V43, P71, DOI 10.1034/j.1399-6576.1999.430115.x
   KIRKPATRICK T, 1988, BRIT J ANAESTH, V60, P146, DOI 10.1093/bja/60.2.146
   Lindholm M, 1992, Minerva Anestesiol, V58, P875
   Nakane M, 1999, BRIT J ANAESTH, V83, P397
   PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8
   Ririe DG, 2001, J CARDIOTHOR VASC AN, V15, P745, DOI 10.1053/jcan.2001.28321
   Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006
   Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017
   SCHUTTLER J, 1985, POSTGRAD MED J, V61, P53
   SCHUTTLER J, 1990, PHARM DYNAMIK INTRAV
   SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011
   SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008
   Struys MMRF, 2001, ANESTHESIOLOGY, V95, P6, DOI 10.1097/00000542-200107000-00007
   TACKLEY RM, 1989, BRIT J ANAESTH, V62, P46, DOI 10.1093/bja/62.1.46
   Wakeling HG, 1999, ANESTHESIOLOGY, V90, P92, DOI 10.1097/00000542-199901000-00014
NR 25
TC 55
Z9 60
U1 2
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD AUG
PY 2003
VL 99
IS 2
BP 303
EP 313
DI 10.1097/00000542-200308000-00012
PG 11
WC Anesthesiology
SC Anesthesiology
GA 704QY
UT WOS:000184352400011
PM 12883403
DA 2018-12-27
ER

PT J
AU Roovers, K
   Klein, EA
   Castagnino, P
   Assoian, RK
AF Roovers, K
   Klein, EA
   Castagnino, P
   Assoian, RK
TI RETRACTED: Nuclear translocation of LIM kinase mediates Rho-Rho kinase
   regulation of cyclin D1 expression (Retracted Article. See vol 10, pg
   681, 2006)
SO DEVELOPMENTAL CELL
LA English
DT Article; Retracted Publication
ID SERUM RESPONSE FACTOR; CROSS-CASCADE ACTIVATION; ACTIN STRESS FIBERS;
   PROTEIN-KINASE; DEPENDENT KINASES; GENE-EXPRESSION; FOCAL ADHESIONS; CDK
   INHIBITORS; G(1) PHASE; PHOSPHORYLATION
AB We previously reported that the Rho-Rho kinase pathway controls cyclin D1 expression by preventing its early G1 phase induction in response to Rac and/or Cdc42, thus increasing its dependence on ERK signaling and actin stress fiber formation. We now show that the Rho kinase effector LIM kinase is responsible for this effect. Surprisingly, inhibition of Rac-dependent cyclin D1 expression by LIM kinase is independent of both cofilin phosphorylation and actin polymerization. Instead, specific mutation of its nuclear localization and export sequences showed that LIM kinase acts in the nucleus to suppress Rac/Cdc42-dependent cyclin D1 expression. Our results therefore describe an unexpected role for LIM kinase that requires nuclear translocation. The effect of nuclear LIM kinase on cyclin D1 expression ultimately regulates the duration of G1 phase and the degree to which G1 phase progression depends on actin stress fiber formation and imposition of cellular tension.
C1 Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
RP Assoian, RK (reprint author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
EM rka@pharm.med.upenn.edu
FU NCI NIH HHS [CA72639]; NIGMS NIH HHS [GM51878]
CR Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962
   AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582
   Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308
   Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149
   Arber S, 1998, NATURE, V393, P805
   Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551
   Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647
   Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185
   Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571
   Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj/onc/1205302
   Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092
   Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008
   Edwards DC, 1999, NAT CELL BIOL, V1, P253
   Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426
   Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126
   Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200
   Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1
   Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7
   Ishizaki T, 2000, MOL PHARMACOL, V57, P976
   Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245
   King AJ, 1998, NATURE, V396, P180
   Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9
   Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200
   Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129
   Murai K, 2002, MOL CELL BIOL, V22, P7083, DOI 10.1128/MCB.22.20.7083-7092.2002
   Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481
   Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577
   Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321
   Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425
   Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847
   Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065
   Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001
   Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197
   Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003
   Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755
   SAITOH M, 1987, J BIOL CHEM, V262, P7796
   Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009
   Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9
   Sumi T, 2001, J BIOL CHEM, V276, P23092, DOI 10.1074/jbc.C100196200
   Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200
   Sumida J, 1998, VICTORIAN STUD, V42, P147, DOI 10.2979/VIC.1998.42.1.147
   Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454
   Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8
   Watanabe N, 1999, NAT CELL BIOL, V1, P136
   Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061
   Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966
   Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950
   Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324
   Yang N, 1998, NATURE, V393, P809
   Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793
   Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200
NR 57
TC 45
Z9 46
U1 3
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD AUG
PY 2003
VL 5
IS 2
BP 273
EP 284
DI 10.1016/S1534-5807(03)00206-5
PG 12
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 713UR
UT WOS:000184876800012
PM 12919678
OA Bronze
DA 2018-12-27
ER

PT J
AU Dzhura, I
   Wu, YJ
   Zhang, R
   Colbran, RJ
   Hamilton, SL
   Anderson, ME
AF Dzhura, I
   Wu, YJ
   Zhang, R
   Colbran, RJ
   Hamilton, SL
   Anderson, ME
TI RETRACTED: C terminus L-type Ca2+ channel calmodulin-binding domains are
   'auto-agonist' ligands in rabbit ventricular myocytes (Retracted
   article. See vol. 593, pg. 2245, 2015)
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article; Retracted Publication
ID CA2+-CALMODULIN-DEPENDENT PROTEIN-KINASE; VOLTAGE-DEPENDENT
   FACILITATION; ALPHA(1C) CA(V)1.2 SUBUNIT; CALCIUM-CHANNELS;
   CA2+-DEPENDENT INACTIVATION; IQ DOMAIN; CELLS; MECHANISM; ENHANCEMENT;
   ARRHYTHMIAS
AB L-type Ca2+ channel C terminus calmodulin (CaM)-binding domains are molecular determinants for Ca2+-CaM-dependent increases in L-type Ca2+ current (I-Ca), and a CaM-binding IQ domain mimetic peptide (IQmp) increases L-type Ca2+ channel current by promoting a gating mode with prolonged openings (mode 2), suggesting the intriguing possibility that CaM-binding domains are (auto-agonist' signalling molecules. In order to test the breadth of this concept, we studied the effect of a second C terminus CaM-binding domain (CB) mp (CBmp), in conjunction with IQmp, on single L-type Ca2+ channel currents in excised cell membrane patches from rabbit ventricular myocytes. Here we show that both CBmp and IQmp are agonist ligands that non-additively increase L-type Ca2+ channel opening probability (P-0) by inducing mode 2 gating. CBmp and IQmp agonist effects were lost under conditions favouring calcification of CaM (Ca2+-CaM, 150 nm free Ca2+ and 10-20 mum CaM), but persisted in the presence of CaM (0-20 muM) under conditions adverse to Ca2+-CaM (20 mm BAPTA), indicating that CaM-binding domains increase L-type Ca2+ channel P. by a low Ca2+-CaM activity mechanism. Increasing Ca2+-CaM in the bath (cytosol) reduced the efficacy of CBmp and IQmp signals with Ba2+ as charge carrier, suggesting that CaM binding motifs target a site outside of the pore region. We measured the combined effects of CBmp and Ca2+-CaM-dependent protein kinase II (CaMKII) on L-type Ca2+ channels by using an engineered Ca2+-CaM-independent form of CaMKII that remains active under low Ca2+-CaM conditions, permissive for CBmp signalling. CBmp and CaMKII increased L-type Ca2+ channel P. in a non-additive manner, suggesting that low and high Ca2+-CaM-dependent L-type Ca2+ channel facilitation pathways converge upon a common signalling mechanism.
C1 Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Internal Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.
RP Anderson, ME (reprint author), Vanderbilt Univ, Dept Med, 221 Kirkland Hall, Nashville, TN 37232 USA.
EM mark.anderson@vanderbilt.edu
OI Colbran, Roger/0000-0001-7401-8244
FU NIAMS NIH HHS [AR44864, R01 AR044864]; NHLBI NIH HHS [HL03727, R01
   HL062494, HL62494]
CR AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435
   ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854
   Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200
   BERS DM, 1994, METHOD CELL BIOL, V40, P3
   BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221
   BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944
   Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851
   Dzhura I, 2002, J PHYSIOL-LONDON, V545, P399, DOI 10.1113/jphysiol.2002.021881
   Dzhura I, 2000, NAT CELL BIOL, V2, P173
   Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X
   Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200
   Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200
   GUPTA RC, 1989, BIOCHEMISTRY-US, V28, P5909, DOI 10.1021/bi00440a030
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0
   Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228
   HUDMON A, 2002, BIOPHYS J, V82, P32
   Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126
   Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x
   MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321
   MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0
   Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200
   Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6
   PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0
   Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200
   PLANT TD, 1983, J PHYSIOL-LONDON, V334, P189, DOI 10.1113/jphysiol.1983.sp014489
   PRIORI SG, 1990, AM J PHYSIOL, V258, pH1796
   Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435
   Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649
   VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X
   Wu YJ, 2002, CIRCULATION, V106, P1288, DOI 10.1161/01.CIR.0000027583.73268.E7
   Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198
   Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x
   Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168
   XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659
   YUAN WL, 1994, AM J PHYSIOL, V267, pH982
   YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753
   Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200
   Zuhlke RD, 1999, NATURE, V399, P159
NR 39
TC 17
Z9 19
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD AUG 1
PY 2003
VL 550
IS 3
BP 731
EP 738
DI 10.1113/jphysiol.2003.043778
PG 8
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 715ZV
UT WOS:000185005100007
PM 12807986
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Boubaker, A
   Prior, JO
   Meyrat, B
   Delaloye, AB
AF Boubaker, A
   Prior, JO
   Meyrat, B
   Delaloye, AB
TI RETRACTED: Unilateral ureteropelvic junction obstruction in children:
   Long-term followup after unilateral pyeloplasty (Retracted Article. See
   vol 170, pg 2394, 2003)
SO JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE kidney; ureter; hydronephrosis; constriction; pathologic; radionuclide
   imaging
ID RENAL-FUNCTION; HISTOLOGICAL-CHANGES; INFANTS; UROPATHY; IMPROVE; RATS
AB Purpose: The benefit of surgery on renal function in unilateral ureteropelvic junction stenosis (UPJS) is still debated. We evaluated renal function outcome after unilateral pyeloplasty in 53 children.
   Material and Methods: We retrospectively reviewed I-123-hippuran renography performed at diagnosis and 5 to 15 years (mean +/- SD 7 +/- 3 years) after successful pyeloplasty. UPJS was prenatally detected in 26 children because of urinary tract infection in 17 and miscellaneous reasons in 10. Relative function (RF) and absolute function were measured on background corrected renograms. Absolute function of the affected and contralateral kidneys was determined by an accumulation index (AI), representing the percent injected dose extracted by each kidney 30 to 90 seconds after the heart peak.
   Results: Preoperatively 33 of the 53 UPJS kidneys had a decreased AT but only 8 had a RF of less than 40%, which was improved in 7 at followup. In addition, the AT improved in 29 kidneys, of which 19 (36%) normalized. Of the UPJS kidneys 14 had an initially decreased AT that remained abnormal at followup. In these kidneys preoperative RF was less than 40% in all. At followup RF was greater than 40% in 4 children, in whom the AT of the UPJS kidney did not improve but the AI of the contralateral one decreased from supranormal to normal. Seven contralateral kidneys had a supranormal AI, whereas the AT remained normal in 3, of which the RF in the UPJS kidney remained at less than 40%. The AT and RF were normal in 20 UPJS kidneys and remained normal.
   Conclusions: When normal, the AI and RF reflected renal function outcome similarly. The AT added relevant information in UPJS kidneys with impaired function, showing compensation of the contralateral kidney.
C1 Univ Lausanne Hosp, Dept Nucl Med, Lausanne, Switzerland.
   Univ Lausanne Hosp, Dept Pediat Surg, Lausanne, Switzerland.
RP Boubaker, A (reprint author), CHU Vaudois, Nucl Med Serv, BH-07,Bugnon 46, CH-1011 Lausanne, Switzerland.
RI PRIOR, John/I-5364-2017
OI PRIOR, John/0000-0003-1429-1374
CR Boubaker A, 2001, J NUCL MED, V42, P1780
   BOUBAKER A, 2002, IMAG FONCT METABOL, V25, P526
   Chandrasekharam VVSS, 2001, PEDIATR SURG INT, V17, P524, DOI 10.1007/s003830100604
   Chertin B, 1999, J UROLOGY, V162, P1037, DOI 10.1016/S0022-5347(01)68058-3
   Chertin B, 2002, BJU INT, V90, P72, DOI 10.1046/j.1464-410X.2002.02829.x
   Chevalier RL, 2000, KIDNEY INT, V58, P1987, DOI 10.1111/j.1523-1755.2000.00371.x
   DELALOYEBISCHOF A, 1980, RADIONUCLIDES NEPHRO, P40
   Dissing TH, 2001, J UROLOGY, V166, P2354, DOI 10.1016/S0022-5347(05)65588-7
   ELDER JS, 1995, J UROLOGY, V154, P719, DOI 10.1016/S0022-5347(01)67143-X
   Eskild-Jensen A, 2002, J UROLOGY, V167, P1435, DOI 10.1016/S0022-5347(05)65338-4
   Han SW, 1998, J UROLOGY, V160, P984, DOI 10.1016/S0022-5347(01)62676-4
   Houben CH, 2000, PEDIATR SURG INT, V16, P189, DOI 10.1007/s003830050720
   LYTHGOE MF, 1994, EUR J NUCL MED, V21, P1333, DOI 10.1007/BF02426698
   McAleer IM, 1999, J UROLOGY, V162, P1041, DOI 10.1016/S0022-5347(01)68059-5
   Pascual L, 1998, J UROLOGY, V160, P976, DOI 10.1016/S0022-5347(01)62674-0
   Produit S, 1987, Contrib Nephrol, V56, P243
   Seseke F, 2001, J UROLOGY, V165, P2289, DOI 10.1016/S0022-5347(05)66186-1
   Sfakianakis GN, 2001, UROLOGY, V57, P1167, DOI 10.1016/S0090-4295(01)01009-3
   STOCK JA, 1995, J UROLOGY, V154, P716, DOI 10.1016/S0022-5347(01)67142-8
   Wen JG, 1999, UROL RES, V27, P29, DOI 10.1007/s002400050086
NR 20
TC 13
Z9 13
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD AUG
PY 2003
VL 170
IS 2
BP 575
EP 579
DI 10.1097/01.ju.0000071480.83890.36
PN 1
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 700WL
UT WOS:000184134100069
PM 12853834
DA 2018-12-27
ER

PT J
AU Quattrocchi, CC
   Huang, C
   Niu, S
   Sheldon, M
   Benhayon, D
   Cartwright, J
   Mosier, DR
   Keller, F
   D'Arcangelo, G
AF Quattrocchi, CC
   Huang, C
   Niu, S
   Sheldon, M
   Benhayon, D
   Cartwright, J
   Mosier, DR
   Keller, F
   D'Arcangelo, G
TI RETRACTED: Reelin promotes peripheral synapse elimination and maturation
   (Retracted Article. See vol 303, pg 1974, 2004)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID APOE RECEPTOR 2; NEUROMUSCULAR-JUNCTIONS; EXTRACELLULAR-MATRIX; VLDL
   RECEPTOR; MOUSE; BRAIN; MICE; DISABLED-1; EXPRESSION; SCRAMBLER
AB Reelin is an extracellular protein that is crucial for layer formation in the embryonic brain. Here, we demonstrate that Reelin functions postnatally to regulate the development of the neuromuscular junction. Reelin is required for motor end-plate maturation and proper nerve-muscle connectivity, and it directly promotes synapse elimination. Unlike layer formation, neuromuscular junction development requires a function of Reelin that is not mediated by Disabled1 or very-low-density lipoprotein receptors and apolipoprotein E receptor 2 receptors but by a distinct mechanism involving its protease activity.
C1 Cain Fdn Labs, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
   Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.
   Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.
   Univ Brescia, Program Neurosci, I-25123 Brescia, Italy.
   Div Hematol Oncol, Houston, TX 77030 USA.
   Texas Childrens Canc Ctr, Houston, TX 77030 USA.
   Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
   Vet Adm Med Ctr, Houston, TX 77030 USA.
   Lab Dev Neurosci & Neural Plast, I-00155 Rome, Italy.
RP D'Arcangelo, G (reprint author), Cain Fdn Labs, Houston, TX 77030 USA.
EM gangelo@bcm.tmc.edu
OI D'Arcangelo, Gabriella/0000-0003-1575-1010; Quattrocchi, Carlo
   Cosimo/0000-0001-6823-7707
CR Borrell V, 1999, J NEUROSCI, V19, P1345
   D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0
   DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0
   DArcangelo G, 1997, J NEUROSCI, V17, P23
   deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6
   Derer P, 2001, J COMP NEUROL, V440, P136, DOI 10.1002/cne.1375
   Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2
   Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246
   Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607
   Impagnatiello F, 1998, P NATL ACAD SCI USA, V95, P15718, DOI 10.1073/pnas.95.26.15718
   Liu WS, 2001, P NATL ACAD SCI USA, V98, P3477, DOI 10.1073/pnas.051614698
   LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300
   MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121
   Marques MJ, 2000, J NEUROSCI, V20, P3663
   Martinez-Cerdeno V, 2002, CEREB CORTEX, V12, P1298, DOI 10.1093/cercor/12.12.1298
   Misgeld T, 2002, NEURON, V36, P635, DOI 10.1016/S0896-6273(02)01020-6
   PERSICO AM, 2001, MOL PSYCHIATR, V6, P129
   Quattrocchi CC, 2002, J BIOL CHEM, V277, P303, DOI 10.1074/jbc.M106996200
   Rafuse VF, 2000, J NEUROSCI, V20, P6529, DOI 10.1523/JNEUROSCI.20-17-06529.2000
   Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005
   Rice DS, 2001, NEURON, V31, P929, DOI 10.1016/S0896-6273(01)00436-6
   Ross ME, 2002, NATURE, V418, P376, DOI 10.1038/418376a
   Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389
   Schiffmann SN, 1997, EUR J NEUROSCI, V9, P1055, DOI 10.1111/j.1460-9568.1997.tb01456.x
   Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601
   Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5
   Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8
   Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200
   Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274
NR 29
TC 25
Z9 26
U1 2
U2 17
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD AUG 1
PY 2003
VL 301
IS 5633
BP 649
EP 653
DI 10.1126/science.1082690
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 706UN
UT WOS:000184473600041
PM 12893944
DA 2018-12-27
ER

PT J
AU Sasaki, M
   Tanaka, Y
   Kaneuchi, M
   Sakuragi, N
   Dahiya, R
AF Sasaki, M
   Tanaka, Y
   Kaneuchi, M
   Sakuragi, N
   Dahiya, R
TI RETRACTED: CYP1B1 gene polymorphisms have higher risk for endometrial
   cancer, and positive correlations with estrogen receptor alpha and
   estrogen receptor beta expressions (Retracted article. See vol. 77, pg.
   5211, 2017)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID PRIMARY CONGENITAL GLAUCOMA; CYTOCHROME P4501B1; BREAST-CANCER; 1B1;
   CATECHOLESTROGENS; ASSOCIATION; MUTATIONS; INDUCTION; SEQUENCE
AB The estradiol metabolites by CYP1B1 received particular attention because of their causative role in malignant transformation of endometrium. We hypothesize that polymorphisms of CYP1B1 gene can predict higher incidence of endometrial cancer. To test this hypothesis, the genetic distributions of six different CYP1B1 gene polymorphisms were investigated, by sequence-specific PCR and direct DNA sequencing, in 113 Japanese endometrial cancer patients and 202 healthy controls. We also investigated whether the expression of estrogen receptors (ERalpha and ERbeta), progesterone receptor, and androgen receptor genes are influenced by the CYP1B1 genotypes in endometrial cancer. The results of our study demonstrated that the distributions of CYP1B1 genotypes at codons 119 and 432 were significantly different between endometrial cancer patients and healthy normal controls. The relative risks of 119T/T and 432G/G in endometrial cancer were calculated as 3.32 and 2.49 compared with wild-types. The 119T/T showed significant correlation for positivities of ERalpha and ERbeta. The 432G/G also showed weak correlations for ERalpha positivity. Other loci, intron 1, codon 48, and codon 449 were not different between endometrial cancer patients and healthy normal control.
   This is the first report that demonstrates that the rare polymorphisms at codons 119 and 432 of CYP1B1 gene have higher risk for endometrial cancer, and positive correlations with ERalpha and ERbeta expressions in endometrial cancer.
C1 Univ Calif San Francisco, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA.
   Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
   Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 060, Japan.
RP Dahiya, R (reprint author), Univ Calif San Francisco, Urol Res Ctr 112F, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM Urologylab@aol.com
RI Sakuragi, Noriaki/D-6507-2012
CR Bailey LR, 1998, CANCER RES, V58, P5038
   Bejjani BA, 1998, AM J HUM GENET, V62, P325, DOI 10.1086/301725
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   HAN XL, 1994, CARCINOGENESIS, V15, P997, DOI 10.1093/carcin/15.5.997
   Hanna IH, 2000, CANCER RES, V60, P3440
   Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776
   Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95
   KAWAJIRI K, 1995, PHARMACOGENETICS, V5, pS70, DOI 10.1097/00008571-199512001-00004
   Lee KM, 2003, BRIT J CANCER, V88, P675, DOI 10.1038/sj.bjc.6600761
   Liehr J G, 1998, Adv Pharmacol, V42, P824
   LIEHR JG, 1990, MUTAT RES, V238, P269, DOI 10.1016/0165-1110(90)90018-7
   MEYER UA, 1986, XENOBIOTICA, V16, P449, DOI 10.3109/00498258609050251
   Newbold RR, 2000, CANCER RES, V60, P235
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2001, CANCER RES, V61, P3262
   SCHUTZE N, 1993, J STEROID BIOCHEM, V46, P781, DOI 10.1016/0960-0760(93)90319-R
   Shimada T, 1996, CANCER RES, V56, P2979
   Stoilov I, 1998, AM J HUM GENET, V62, P573, DOI 10.1086/301764
   SUTTER TR, 1994, J BIOL CHEM, V269, P13092
NR 20
TC 68
Z9 80
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2003
VL 63
IS 14
BP 3913
EP 3918
PG 6
WC Oncology
SC Oncology
GA 705DE
UT WOS:000184379800014
PM 12873984
DA 2018-12-27
ER

PT J
AU Chang, G
AF Chang, G
TI RETRACTED: Structure of MsbA from Vibrio cholera: A multidrug resistance
   ABC transporter homolog in a closed conformation (Retracted Article. See
   vol 369, pg 596, 2007)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE multidrug resistance; integral membrane proteins; X-ray crystallography
ID ESCHERICHIA-COLI MSBA; BINDING CASSETTE TRANSPORTER; ATP-BINDING;
   CRYSTAL-STRUCTURES; DRUG-BINDING; TRANSMEMBRANE DOMAINS;
   MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; GLYCOPROTEIN; HYDROLYSIS
AB The spread of multidrug resistance (MDR) is a world health crisis that presents a significant challenge to the treatment of cancer and infection. MDR can be caused by a group of ABC (MDR-ABC) transporters that move hydrophobic drug molecules and lipids across the cell membrane. To gain insight into the conformational changes these transporters undergo when flipping hydrophobic substrates across the lipid bilayer, we have determined the structure of the lipid flippase MsbA from Vibrio cholera (VC-MsbA) to 3.8 Angstrom. Structural comparison of VC-MsbA to MsbA from Escherichia coli reveals that the transporters share a structurally conserved core of transmembrane a-helices, but differ in the relative orientations of their nucleotide-binding domains (NBD). The transmembrane domain of VC-MsbA is captured in a closed conformation and the structure supports a "power stroke" model of transporter dynamics where opposing NBDs associate upon ATP binding. The separation of the a and 0 domains of the NBD suggests the possibility that their association could make them competent to bind ATP and gives further insight into the structural basis for catalytic regulation. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Chang, G (reprint author), Scripps Res Inst, Dept Mol Biol, CB-105, La Jolla, CA 92037 USA.
EM gchang@scripps.edu
FU NIGMS NIH HHS [GM61905-02]
CR Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361
   AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760
   BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458
   Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309
   Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793
   Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220
   Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5
   Dean M, 2001, J LIPID RES, V42, P1007
   Diez J, 2001, J MOL BIOL, V305, P905, DOI 10.1006/jmbi.2000.4203
   Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200
   Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200
   ESNOUF RM, 1997, J MOL GRAPH MODEL, V15, P112
   Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2
   Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964
   Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188
   GROS P, 1987, SCIENCE, V235, P1149
   HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A
   Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993
   Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9
   HUGHES AL, 1994, MOL BIOL EVOL, V11, P899
   HUNG LW, 1998, NATURE, V396, P623
   KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x
   Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407
   Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142
   Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759
   Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253
   Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200
   Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b
   McDonald MK, 1997, J BACTERIOL, V179, P7638, DOI 10.1128/jb.179.24.7638-7643.1997
   MERRITT EA, 1997, METHOD ENZYMOL, P277
   Pellegrini M, 1997, PROTEINS, V29, P426, DOI 10.1002/(SICI)1097-0134(199712)29:4<426::AID-PROT3>3.0.CO;2-6
   Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h
   Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615
   Ruth A, 2001, BIOCHEMISTRY-US, V40, P4332, DOI 10.1021/bi001373f
   SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4
   SARKADI B, 1992, J BIOL CHEM, V267, P4854
   Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200
   Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442
   Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2
   Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tomii K, 1998, GENOME RES, V8, P1048, DOI 10.1101/gr.8.10.1048
   van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503
   Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8
   Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466
NR 48
TC 243
Z9 248
U1 5
U2 23
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUL 4
PY 2003
VL 330
IS 2
BP 419
EP 430
DI 10.1016/S0022-2836(03)00587-4
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 695HK
UT WOS:000183824900021
PM 12823979
DA 2018-12-27
ER

PT J
AU Mannila, H
   Koivisto, M
   Perola, M
   Varilo, T
   Hennah, W
   Ekelund, J
   Lukk, M
   Peltonen, L
   Ukkonen, E
AF Mannila, H
   Koivisto, M
   Perola, M
   Varilo, T
   Hennah, W
   Ekelund, J
   Lukk, M
   Peltonen, L
   Ukkonen, E
TI RETRACTED: Minimum description length block finder, a method to identify
   haplotype blocks and to compare the strength of block boundaries
   (Retracted Article. See vol 73, pg 444, 2003)
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article; Retracted Publication
ID LINKAGE DISEQUILIBRIUM; HUMAN GENOME; CHROMOSOMES; DIVERSITY; PRINCIPLE;
   LOCI
AB We describe a new probabilistic method for finding haplotype blocks that is based on the use of the minimum description length (MDL) principle. We give a rigorous definition of the quality of a segmentation of a genomic region into blocks and describe a dynamic programming algorithm for finding the optimal segmentation with respect to this measure. We also describe a method for finding the probability of a block boundary for each pair of adjacent markers: this gives a tool for evaluating the significance of each block boundary. We have applied the method to the published data of Daly and colleagues. The results expose some problems that exist in the current methods for the evaluation of the significance of predicted block boundaries. Our method, MDL block finder, can be used to compare block borders in different sample sets, and we demonstrate this by applying the MDL-based method to define the block structure in chromosomes from population isolates.
C1 Natl Publ Hlth Inst, Dept Mol Med, FIN-00251 Helsinki, Finland.
   Univ Helsinki, Dept Comp Sci, SF-00510 Helsinki, Finland.
   Univ Helsinki, Helsinki Inst Informat Technol, Basic Res Unit, Helsinki, Finland.
   Univ Helsinki, Dept Med Genet, Helsinki, Finland.
RP Peltonen, L (reprint author), Natl Publ Hlth Inst, Dept Mol Med, POB 104,Haartmaninkatu 8, FIN-00251 Helsinki, Finland.
EM leena.peltonen@ktl.fi
RI Ekelund, Jesper/D-6655-2013
OI Lukk, Margus/0000-0002-0701-5358
CR Cardon LR, 2003, TRENDS GENET, V19, P135, DOI 10.1016/S0168-9525(03)00022-2
   Couzin J, 2002, SCIENCE, V296, P1391, DOI 10.1126/science.296.5572.1391
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   DOMINGOS P, 1999, DATA MIN KNOWL DISC, V3, P1
   Durbin R., 1998, BIOL SEQUENCE ANAL P
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hansen MH, 2001, J AM STAT ASSOC, V96, P746, DOI 10.1198/016214501753168398
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   KILPELAINEN P, 1995, P 2 EUR C EUR, P252
   Li M., 1997, INTRO KOLMOGOROV COM
   Li WT, 2001, PHYS REV LETT, V86, P5815, DOI 10.1103/PhysRevLett.86.5815
   Liu JS, 1999, BIOINFORMATICS, V15, P38, DOI 10.1093/bioinformatics/15.1.38
   Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573
   Paunio T, 2001, HUM MOL GENET, V10, P3037, DOI 10.1093/hmg/10.26.3037
   Peltonen L, 2000, NAT REV GENET, V1, P182, DOI 10.1038/35042049
   QUINLAN JR, 1989, INFORM COMPUT, V80, P227
   RISSANEN J, 1978, AUTOMATICA, V14, P465, DOI 10.1016/0005-1098(78)90005-5
   RISSANEN J, 1987, J ROY STAT SOC B MET, V49, P223
   Stumpf MPH, 2002, TRENDS GENET, V18, P226, DOI 10.1016/S0168-9525(02)02641-0
   Varilo T, 2003, HUM MOL GENET, V12, P51, DOI 10.1093/hmg/ddg005
   Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398
   Zhang K, 2002, AM J HUM GENET, V71, P1386, DOI 10.1086/344780
   Zhang K, 2002, P NATL ACAD SCI USA, V99, P7335, DOI 10.1073/pnas.102186799
NR 23
TC 15
Z9 15
U1 3
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUL
PY 2003
VL 73
IS 1
BP 86
EP 94
DI 10.1086/376438
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 696UA
UT WOS:000183904900008
PM 12761696
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Leong, ST
   Laortanakul, P
AF Leong, ST
   Laortanakul, P
TI RETRACTED: Indicators of benzene emissions and exposure in Bangkok
   street (Retracted Article. See vol 95, pg 116, 2004)
SO ENVIRONMENTAL RESEARCH
LA English
DT Article; Retracted Publication
DE blood benzene; meteorological parameters; population exposure; traffic
   density; trans, trans-muconic acid
ID VOLATILE ORGANIC-COMPOUNDS; THAILAND; AIR
AB Ambient benzene measurements were conducted for the first time at four air monitoring sites in the Bangkok metropolitan region (BMR), from January to December 2001. Analytical results show that the mean benzene concentrations range from 42.4 mug/m(3) at the Din Daeng urban site to 15.1 mug/m(3) at the Chaeng Wattana suburban site. The monitoring results show that at a larger distance from the roadside or a higher level from the street surface, the level of benzene decreases. Analysis of the ambient benzene concentrations was carried out with reference to meteorological influences and traffic density. In traffic analysis, the combined effects of street topography and traffic flows established high impact on the overall benzene concentration in Bangkok. Statistical analysis shows good correlations of blood benzene levels and trans, trans-muconic acid with ambient benzene and demonstrated substantial exposure from traffic. (C) 2003 Elsevier Science (USA). All rights reserved.
C1 Asian Inst Technol, Urban Environm Engn & Management Program, Sch Environm Resource & Dev, Pathum Thani 12120, Thailand.
RP Leong, ST (reprint author), Asian Inst Technol, Urban Environm Engn & Management Program, Sch Environm Resource & Dev, GPO Box 4, Pathum Thani 12120, Thailand.
EM tet@ait.ac.th
CR Brown VM, 1998, ENVIRON MONIT ASSESS, V52, P43, DOI 10.1023/A:1005830532238
   CAREY PM, 1987, EPAAATSSPA865 OFF MO
   Issaragrisil S, 1999, AM J HEMATOL, V61, P164, DOI 10.1002/(SICI)1096-8652(199907)61:3<164::AID-AJH2>3.3.CO;2-I
   *JAP AUT MAN ASS I, 1990, MOT EM REG CONTR TEC
   Jo WK, 1996, J AIR WASTE MANAGE, V46, P749, DOI 10.1080/10473289.1996.10467509
   Jones SG, 2000, ENVIRON MONIT ASSESS, V64, P531, DOI 10.1023/A:1006316713924
   Keary J, 1998, ENVIRON MONIT ASSESS, V52, P3, DOI 10.1023/A:1005935411345
   Kok PW, 1997, ENVIRON MONIT ASSESS, V44, P425, DOI 10.1023/A:1005745130712
   *LAND TRANSP DEP, 2000, ANN REP STAT NUMB RE
   Leong ST, 2002, ATMOS ENVIRON, V36, P3495, DOI 10.1016/S1352-2310(02)00288-1
   Muttamara S, 2000, ENVIRON MONIT ASSESS, V60, P163, DOI 10.1023/A:1006122006933
   NIOSH, 1977, NIOSH MANUAL ANAL ME
   *US EPA, 1993, 420D99002A EPA
   *US EPA, 1988, EPA450484007Q OFF AI
   *US EPA, 2000, INT RISK INF SYST
   WANGWONGWATANA S, 1999, THAILANDS AUTOMOTIVE
   *WHO, 1996, EURO REP WHO M WHO R
NR 17
TC 9
Z9 11
U1 3
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD JUL
PY 2003
VL 92
IS 3
BP 173
EP 181
DI 10.1016/S0013-9351(02)00084-1
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 693WG
UT WOS:000183740900001
PM 12804513
DA 2018-12-27
ER

PT J
AU Lindsay, JO
   Ciesielski, CJ
   Scheinin, T
   Brennan, FM
   Hodgson, HJ
AF Lindsay, JO
   Ciesielski, CJ
   Scheinin, T
   Brennan, FM
   Hodgson, HJ
TI RETRACTED: Local delivery of adenoviral vectors encoding murine
   interleukin 10 induces colonic interleukin 10 production and is
   therapeutic for murine colitis (Retracted Article. See vol 53, pg 774,
   2004)
SO GUT
LA English
DT Article; Retracted Publication
ID INFLAMMATORY-BOWEL-DISEASE; RECOMBINANT HUMAN INTERLEUKIN-10; ACTIVE
   CROHNS-DISEASE; IMMUNE-RESPONSES; GENE-THERAPY; SCID MICE; CELLS;
   RECEPTOR; ENTEROCOLITIS; TOLERANCE
AB Introduction: Interleukin 10 knockout (IL-10-/-) mice spontaneously develop a Th1 T cell mediated colitis with many similarities to Crohn's disease. Daily injections of IL-10 are unable to induce remission in mice with established disease. In contrast, we have shown previously that intravenous administration of adenoviral vectors encoding IL-10 ( AdvmuIL-10) induces hepatic IL-10 release and leads to long term disease suppression with profound systemic immunoregulatory changes.
   Aims: To determine whether rectal delivery of AdvmuIL-10 induces localised colonic IL-10 expression without systemic immune suppression, and assess its therapeutic efficacy in IL-10-/- mice with established colitis.
   Results: A single rectal infusion of 5 x 10(8) PFU AdvmuIL-10 to 10 week IL-10-/- mice resulted in a median level of 27.3 pg/mg IL-10 in colonic homogenates harvested one week later. IL-10-/- mice with established colitis treated with an enema of 5 x 108 PFU AdvmuIL-10 entered clinical and histological remission whereas empty cassette adenovirus ( Adv0) or phosphate buffered saline ( PBS) treated mice developed progressive disease. After four weeks, the histological score of AdvmuIL-10 treated mice ( 4.4 (1.5)) was significantly lower than that of Adv0 (11.1 (1.1); p< 0.001) and PBS ( 10.9 (1.0); p< 0.01) treated controls. In addition, the stool concentration of IL-1 over the four week experiment was significantly higher in mice treated with saline or Adv0 than in those treated with AdvmuIL-10 ( p< 0.01).
   Conclusion: Local AdvmuIL-10 therapy reverses colitis in IL-10-/- mice without the systemic effects seen after intravenous administration. Gene therapy strategies using adenoviral vectors encoding immunoregulatory cytokines may prove to be a potent approach to the treatment of chronic inflammatory diseases such as Crohn's disease.
C1 Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England.
   Univ Helsinki, Dept Surg 4, Cent Hosp, FIN-00130 Helsinki, Finland.
   UCL Royal Free & Univ Coll Med Sch, Dept Hepatol, London, England.
RP Lindsay, JO (reprint author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.
EM j.lindsay@doctors.org.uk
CR Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861
   BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290
   Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320
   David A, 1998, HUM GENE THER, V9, P1755, DOI 10.1089/hum.1998.9.12-1755
   De Winter H, 2002, GASTROENTEROLOGY, V122, P1829, DOI 10.1053/gast.2002.33655
   Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448
   During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625
   Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229
   Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6
   Foreman PK, 1998, HUM GENE THER, V9, P1313, DOI 10.1089/hum.1998.9.9-1313
   GORDON JI, 1992, FASEB J, V6, P3039
   GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331
   Groux H, 1997, NATURE, V389, P737
   Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Lindsay JO, 2001, J IMMUNOL, V166, P7625, DOI 10.4049/jimmunol.166.12.7625
   Miagkov AV, 2002, J CLIN INVEST, V109, P1223, DOI 10.1172/JCI200214536
   MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   PALLONE F, 1987, GUT, V28, P745, DOI 10.1136/gut.28.6.745
   POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0
   Schreiber S, 2000, GASTROENTEROLOGY, V119, P1461, DOI 10.1053/gast.2000.20196
   SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4
   Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571
   Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352
   Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352
   Tomoyose M, 1998, SCAND J GASTROENTERO, V33, P435
   Whalen JD, 1999, J IMMUNOL, V162, P3625
   Wirtz S, 2002, J IMMUNOL, V168, P411, DOI 10.4049/jimmunol.168.1.411
   Wirtz S, 1999, GUT, V44, P800, DOI 10.1136/gut.44.6.800
   YANG YP, 1995, J VIROL, V69, P2004
NR 31
TC 28
Z9 35
U1 3
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUL
PY 2003
VL 52
IS 7
BP 981
EP 987
DI 10.1136/gut.52.7.981
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 688PB
UT WOS:000183443500014
PM 12801955
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Mori, N
   Krens, AM
   Geleziunas, R
   Wada, A
   Hirayama, T
   Sasakawa, C
   Yamamoto, N
AF Mori, N
   Krens, AM
   Geleziunas, R
   Wada, A
   Hirayama, T
   Sasakawa, C
   Yamamoto, N
TI RETRACTED: Helicobacter pylori induces RANTES through activation of
   NF-kappa B (Retracted article. See vol. 79, pg. 544, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID MESSENGER-RNA EXPRESSION; GASTRIC EPITHELIAL-CELLS; LEUKEMIA-VIRUS
   TYPE-1; CAG PATHOGENICITY ISLAND; T-LYMPHOCYTES; KINASE-ALPHA; IN-VIVO;
   MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL REGULATION; SIGNALING
   PATHWAY
AB Helicobacter pylori-infected gastric mucosa displays a conspicuous infiltration of mononuclear cells and neutrophils. RANTES (short for "regulated upon activation, normal T cell expressed and secreted") is a chemoattractant cytokine (chemokine) important in the infiltration of T lymphocytes and monocytes. RANTES may therefore contribute to the cellular infiltrate in the H. pylori-infected gastric mucosa. The aim of this study was to analyze the molecular mechanism responsible for H. pylori-mediated RANTES expression. We observed that gastric epithelial cells produced RANTES upon coculture with H. pylori. In addition, H. pylori induced RANTES mRNA expression and an increase in luciferase activity in cells which were transfected with a luciferase reporter construct derived from the RANTES promoter, in gastric epithelial cells, indicating that the induction of RANTES production occurred at the transcriptional level. Induction of RANTES was dependent on an intact cag pathogenicity island. Activation of the RANTES promoter by H. pylori occurred through the action of NF-KB. Transfection of kinase-deficient mutants of IKB kinase (IKK) and NF-KB-inducing kinase (NIK) inhibited H. pylori-mediated RANTES activation. In contrast, tumor necrosis factor alpha- or interleukin-1/Toll-like receptor signaling molecules-such as mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1, MyD88, and interleukin-1 receptor-associated kinase-did not play a role in RANTES activation by H. pylori. Collectively, H. pylori induced NF-KB activation through an intracellular signaling pathway that involved IKK and NIK, leading to RANTES gene transcription. RANTES induction by H. pylori may play an important role in gastric inflammation.
C1 Univ Ryukyus, Fac Med, Dept Virol, Nishihara, Okinawa 9030215, Japan.
   Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki, Japan.
   Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Tokyo, Japan.
   Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo, Japan.
   Stanford Univ, Sch Med, Dept Pediat, Stanford, CA USA.
   Merck & Co Inc, Merck Res Labs, West Point, PA USA.
RP Mori, N (reprint author), Univ Ryukyus, Fac Med, Dept Virol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-tyukyu.ac.jp
CR Aihara M, 1997, INFECT IMMUN, V65, P3218
   Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.0.CO;2-C
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   BLASER MJ, 1995, CANCER RES, V55, P2111
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   Cottet S, 2002, J BIOL CHEM, V277, P33978, DOI [10.1074/jbc.M201726200, 10.1074/mcp.M201726200]
   COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791
   CRABTREE JE, 1994, J CLIN PATHOL, V47, P945, DOI 10.1136/jcp.47.10.945
   CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7
   Debreceni A, 2001, J PHYSIOLOGY-PARIS, V95, P461, DOI 10.1016/S0928-4257(01)00064-X
   DIXON MF, 1995, BAILLIERE CLIN GASTR, V9, P467, DOI 10.1016/0950-3528(95)90043-8
   FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kikuchi T, 2000, J PATHOL, V192, P243, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH688>3.0.CO;2-D
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   Li SDD, 1999, INFECT IMMUN, V67, P3893
   Lin RT, 1999, MOL CELL BIOL, V19, P959
   Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 1999, BLOOD, V93, P2360
   Moriuchi H, 1997, J IMMUNOL, V158, P3483
   Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097
   Nelson PJ, 1998, CURR OPIN IMMUNOL, V10, P265, DOI 10.1016/S0952-7915(98)80164-7
   NELSON PJ, 1993, J IMMUNOL, V151, P2601
   NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604
   Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497
   Ortiz BD, 1996, MOL CELL BIOL, V16, P202
   PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603
   Peek RM, 1995, LAB INVEST, V73, P760
   PHADNIS SH, 1994, INFECT IMMUN, V62, P1557
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   Schluger NW, 1997, CURR OPIN IMMUNOL, V9, P504, DOI 10.1016/S0952-7915(97)80102-1
   Shimoyama T, 1998, J CLIN PATHOL, V51, P765, DOI 10.1136/jcp.51.10.765
   Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x
   Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2
   Swanson BJ, 2002, IMMUNITY, V17, P605, DOI 10.1016/S1074-7613(02)00456-9
   Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113
   Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x
   Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.1994.03520010077036
   Yamaoka Y, 1998, GUT, V42, P609, DOI 10.1136/gut.42.5.609
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
   Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611
NR 51
TC 22
Z9 22
U1 2
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUL
PY 2003
VL 71
IS 7
BP 3748
EP 3756
DI 10.1128/IAI.71.7.3748-3756.2003
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 694WB
UT WOS:000183797200010
PM 12819056
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Ninis, VN
   Kylync, MO
   Kandemir, M
   Dadly, E
   Tolun, A
AF Ninis, VN
   Kylync, MO
   Kandemir, M
   Dadly, E
   Tolun, A
TI RETRACTED: High frequency of T9 and CFTR mutations in children with
   idiopathic bronchiectasis (Retracted Article. See vol 41, pg 813, 2004)
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article; Retracted Publication
ID CYSTIC-FIBROSIS GENE; CONGENITAL BILATERAL ABSENCE; VAS-DEFERENS;
   PULMONARY-DISEASE; 5T ALLELE; DELTA-F508 MUTATION; CODING REGIONS;
   REGULATOR GENE; SPLICE-SITE; IDENTIFICATION
C1 Bogazici Univ, Dept Mol Biol & Genet, TR-34342 Istanbul, Turkey.
   Marmara Univ Hosp, Dept Paediat, Istanbul, Turkey.
RP Tolun, A (reprint author), Bogazici Univ, Dept Mol Biol & Genet, TR-34342 Istanbul, Turkey.
EM tolun@boun.edu.tr
CR Amaral MD, 2001, J MED GENET, V38, P777, DOI 10.1136/jmg.38.11.777
   Andrieux J, 2002, CLIN GENET, V62, P60, DOI 10.1034/j.1399-0004.2002.620108.x
   Beck S, 1999, HUM MUTAT, V14, P133, DOI 10.1002/(SICI)1098-1004(1999)14:2<133::AID-HUMU5>3.0.CO;2-T
   Bombieri C, 2000, HUM GENET, V106, P172, DOI 10.1007/s004390051025
   Bombieri C, 1998, HUM GENET, V103, P718, DOI 10.1007/s004390050897
   Castellani C, 2001, GENET TEST, V5, P249, DOI 10.1089/10906570152742317
   CHEHAB FF, 1991, AM J HUM GENET, V48, P223
   CHILLON M, 1995, AM J HUM GENET, V56, P623
   CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204
   Cohn JA, 2002, J INVEST MED, V50, p247S, DOI 10.1136/jim-50-suppl5-01
   Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002
   COSTES B, 1993, HUM MUTAT, V2, P185, DOI 10.1002/humu.1380020306
   COSTES B, 1995, EUR J HUM GENET, V3, P285
   Costes B, 2000, CLIN CHEM, V46, P1417
   CULARD JF, 1994, HUM GENET, V93, P467
   Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639
   Dork T, 2000, HUM GENET, V106, P259, DOI 10.1007/s004390000246
   Estivill X, 1996, NAT GENET, V12, P348, DOI 10.1038/ng0496-348
   FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I
   Friedman KJ, 1997, HUM MUTAT, V10, P108, DOI 10.1002/(SICI)1098-1004(1997)10:2<108::AID-HUMU3>3.0.CO;2-G
   Girodon E, 1997, EUR J HUM GENET, V5, P149
   HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503
   KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447
   Kilinc MO, 2002, AM J MED GENET, V113, P250, DOI 10.1002/ajmg.10721
   MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183
   MERCIER B, 1995, AM J HUM GENET, V56, P272
   Miller PW, 1996, AM J HUM GENET, V59, P45
   MORRAL N, 1991, GENOMICS, V10, P692, DOI 10.1016/0888-7543(91)90454-M
   Noone PG, 2000, AM J RESP CRIT CARE, V162, P1919, DOI 10.1164/ajrccm.162.5.2003160
   OSBORNE L, 1992, HUM GENET, V89, P653, DOI 10.1007/BF00221957
   Pignatti PF, 1996, AM J HUM GENET, V58, P889
   PIGNATTI PF, 1995, HUM MOL GENET, V4, P635, DOI 10.1093/hmg/4.4.635
   Romey MC, 1999, J MED GENET, V36, P263
   SCHROEDER SA, 1995, NAT MED, V1, P703, DOI 10.1038/nm0795-703
   Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001
   SOKAL RR, 1995, BIOMETRY, P736
   Tucker Stephen J., 1992, Human Molecular Genetics, V1, P77, DOI 10.1093/hmg/1.2.77
   Tzetis M, 2001, HUM GENET, V108, P216, DOI 10.1007/s004390100467
   ZIELENSKI J, 1991, AM J HUM GENET, V49, P1256
NR 39
TC 7
Z9 7
U1 3
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD JUL
PY 2003
VL 40
IS 7
BP 530
EP 535
DI 10.1136/jmg.40.7.530
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 697JP
UT WOS:000183939400018
PM 12843327
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Saleh, FH
   Crotty, KA
   Hersey, P
   Menzies, SW
   Rahman, W
AF Saleh, FH
   Crotty, KA
   Hersey, P
   Menzies, SW
   Rahman, W
TI RETRACTED: Autonomous histopathological regression of primary tumours
   associated with specific immune responses to cancer antigens (Retracted
   Article. See vol 210, pg 383, 2006)
SO JOURNAL OF PATHOLOGY
LA English
DT Article; Retracted Publication
DE histopathological regression; immunological surveillance; melanoma;
   cancer antigens
ID INFILTRATING LYMPHOCYTES; MALIGNANT-MELANOMA; METASTATIC MELANOMA;
   T-CELLS; ADOPTIVE IMMUNOTHERAPY; IN-VIVO; INTERLEUKIN-2; PEPTIDE;
   IMMUNOSELECTION; EXPRESSION
AB Spontaneous histopathological regression of cancer has been reported. The involvement of the immune system in such regression has been advocated, leading to the theory of immunological surveillance against cancer. A prediction of this theory is that common tumour antigens can be recognized upon repeated exposure by cell-mediated immunity, which leads to tumour regression and the subsequent appearance of tumour antigen-loss variants. However, no direct evidence has been provided in non-viral-induced experimental animal models of primary malignancy or in human primary cancer. This study examined two groups of melanoma patients where histopathological regression of the primary tumour was observed. Many of the 23 patients with multiple ( :3) primary melanomas showed significant regression of their last melanoma (median 33%, mean 40) compared with matched melanomas from patients with a single primary melanoma (median 0%, mean 12) (p = 0.0080), or compared with their first primary melanoma (P = 0.0013). Regression was consistent with an 'immunization effect' seen in murine tumour transplantation studies, where inoculation with ?:3 asynchronous tumours induces transplantation rejection on subsequent challenge. A significant decrease in the expression of the melanoma common tumour antigen MART-1 in the last primary tumour from multiple melanoma patients (median 8%, mean 24) versus matched single melanoma patients (median 79%, mean 68) (p = 0.0041) and in the last versus first tumour in multiple primary patients was found (p = 0.0083). Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (median 51%, mean 50) (p = 0.0013). MART-1 antigen-loss variants observed in the multiple primary and occult primary patients correlated with the presence of peripheral blood MART-1-specific cytotoxic T lymphocytes (CTLs) (p = 0.03). No similar effects were observed with two other melanoma antigens, gp100 and CD63. Thus, in two groups of human melanoma patients, evidence is provided for histopathological tumour regression associated with cancer immune surveillance. Copyright (C) 2003 John Wiley Sons, Ltd.
C1 Amer Univ Beirut, Fac Med, Dept Human Morphol, Beirut, Lebanon.
   Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
   Univ Sydney, Royal Prince Alfred Hosp, Dept Surg,Sydney Melanoma Unit, Melanoma & Skin Canc Res Inst, Camperdown, NSW 2050, Australia.
   Univ Newcastle, Oncol & Immunol Unit, Newcastle, NSW 2300, Australia.
   Westmead Hosp, Dept Pathol, Sydney, NSW, Australia.
RP Saleh, FH (reprint author), Amer Univ Beirut, Fac Med, Dept Human Morphol, POB 11-0236, Beirut, Lebanon.
EM FaridSlh@netscape.net
CR Barrio MM, 1998, HYBRIDOMA, V17, P355, DOI 10.1089/hyb.1998.17.355
   BURLINGHAM WJ, 1995, TRANSPLANTATION, V59, P1147, DOI 10.1097/00007890-199504270-00013
   BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1
   Dudley ME, 1996, J EXP MED, V184, P441, DOI 10.1084/jem.184.2.441
   EVERSON TC, 1966, SPONTANEOUS REGRESSI, P164
   Fujiwara T, 2001, ANN HEMATOL, V80, P561, DOI 10.1007/s002770100335
   GARFINKEL L, 1980, CANC STAT, V24, P23
   Hamid Y, 1998, J CLIN PATHOL, V51, P334, DOI 10.1136/jcp.51.4.334
   Ijiri R, 2000, AM J SURG PATHOL, V24, P807, DOI 10.1097/00000478-200006000-00005
   Jager E, 1996, INT J CANCER, V66, P470, DOI 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C
   Jungbluth AA, 1998, AM J SURG PATHOL, V22, P595, DOI 10.1097/00000478-199805000-00011
   KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458
   Lee PP, 1999, NAT MED, V5, P677
   Markowska J, 1998, Ginekol Pol, V69, P39
   Menzies SW, 1997, ARCH SURG-CHICAGO, V132, P553
   Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328
   Papac RJ, 1998, IN VIVO, V12, P571
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705
   POCKAJ BA, 1994, CANCER, V73, P1731, DOI 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
   Printz C, 2001, J NATL CANCER I, V93, P1047, DOI 10.1093/jnci/93.14.1047
   Riker A, 1999, SURGERY, V126, P112, DOI 10.1016/S0039-6060(99)70143-1
   ROBERTS L, 1986, EXPT CLIN PHOTOIMMUN, P77
   ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159
   ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527
   ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291
   Salgaller ML, 1996, CANCER RES, V56, P4749
   SHAW HM, 1989, HISTOPATHOLOGY, V15, P257, DOI 10.1111/j.1365-2559.1989.tb03076.x
   SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067
   TEFANY FJ, 1991, J INVEST DERMATOL, V97, P197, DOI 10.1111/1523-1747.ep12479662
   TRAU H, 1983, J AM ACAD DERMATOL, V8, P363, DOI 10.1016/S0190-9622(83)70040-X
   TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276
   UTZ U, 1992, J IMMUNOL, V149, P214
   UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040
   Valmori D, 1998, J IMMUNOL, V160, P1750
   VONWASIELEWSKI R, 1994, HISTOCHEMISTRY, V102, P165, DOI 10.1007/BF00268892
   Wagner SN, 1997, CANCER IMMUNOL IMMUN, V44, P239, DOI 10.1007/s002620050379
NR 37
TC 34
Z9 34
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2003
VL 200
IS 3
BP 383
EP 395
DI 10.1002/path.1369
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA 697FJ
UT WOS:000183931300014
PM 12845635
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Ristimaki, A
   Sondresen, JE
   Kildal, W
   Boysen, M
   Koppang, HS
   Reith, A
   Risberg, B
   Nesland, JM
   Bryne, M
AF Sudbo, J
   Ristimaki, A
   Sondresen, JE
   Kildal, W
   Boysen, M
   Koppang, HS
   Reith, A
   Risberg, B
   Nesland, JM
   Bryne, M
TI RETRACTED: Cyclooxygenase-2 (COX-2) expression in high-risk premalignant
   oral lesions (Retracted Article. See vol 43, pg 420, 2007)
SO ORAL ONCOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer
   Therapeutics
CY NOV 19-22, 2002
CL FRANKFURT, GERMANY
DE oral precancer; premalignancy; oral carcinoma; risk markers;
   cyclooxygenase-2; chemoprevention; coxibs; DNA content; aneuploidy
ID SQUAMOUS-CELL CARCINOMA; CANCER CHEMOPREVENTION; OXIDATIVE STRESS;
   DNA-ADDUCTS; NECK-CANCER; HEAD; MARKERS; HEALTH; LEUKOPLAKIA;
   ABERRATIONS
AB Emerging data indicate a link between genetic instability and up-regulation of cyclooxygenase-2 (COX-2). To see if individuals at high risk of oral cancer are candidates for treatment with selective COX-2 inhibitors (coxibs), levels of COX-2 expression in healthy, premalignant and cancerous oral mucosa were compared with the occurrence of DNA ploidy status as a genetic risk marker of oral cancer. COX-2 gene product was evaluated immunohistochemically in 30 healthy persons, in 22 patients with dysplastic lesions without previous or concomitant carcinomas, and in 29 patients with oral carcinomas. The immunohistochemical findings were verified by western blotting. COX-2 expression was correlated to DNA content as a genetic risk marker of oral cancer. COX-2 was up-regulated from healthy to premalignant to cancerous oral mucosa. Thus, COX-2 expression was found in 1 case of healthy oral mucosa (3%). All specimens from healthy mucosa had a normal DNA content. In patients with premalignancies. In 29 patients with oral carcinomas, cyclooxygenase-2 expression was observed in 26 (88%), and aneuploidy was observed in 25 cases (94%, P=0.04). Notably, of 22 patients with dysplastic lesions, COX-2 was exclusively expressed in a subgroup of nine patients (41%) identified to be at high risk of cancer by the aberrant DNA content of their lesions. Seven of these patients were followed for 5 years or more. An oral carcinoma developed in six of them (85%; P=0.02). These findings emphasize the need to determine whether coxibs can reduce the risk of oral cancer in patients with high-risk precancerous lesions. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
   Univ Helsinki, Dept Pathol, Helsinki Univ Cent Hosp, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Mol & Canc Biol Res Program, FIN-00014 Helsinki, Finland.
   Dept Oral Biol, Oslo, Norway.
   Norwegian Radium Hosp, Dept Pathol, Oslo, Norway.
   Univ Oslo, Natl Hosp, Dept Otorhinolaryngol, Oslo, Norway.
   Univ Oslo, Dept Clin Dent, Oslo, Norway.
   Univ Oslo, Dept Pathol & Forens Odontol, Oslo, Norway.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
CR Bartsch H, 2001, ADV EXP MED BIOL, V500, P675
   Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3
   BARTSCH H, 2000, MUTAT RES, V462, P25579
   BOYSEN M, 1993, ACTA ONCOL, V32, P283, DOI 10.3109/02841869309093596
   CALLERY CD, 1984, AM J SURG, V148, P449, DOI 10.1016/0002-9610(84)90368-4
   Chan G, 1999, CANCER RES, V59, P991
   Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225
   DEVRIES N, 1992, ORAL ONCOL, V28B, P153, DOI 10.1016/0964-1955(92)90045-3
   Dubois RN, 1998, FASEB J, V12, P1063
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Gupta RA, 2000, NAT MED, V6, P974, DOI 10.1038/79664
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   HEDLEY DW, 1994, METHOD CELL BIOL, V41, P231
   Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8
   INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965
   KARABULUT A, 1995, J ORAL PATHOL MED, V24, P198, DOI 10.1111/j.1600-0714.1995.tb01166.x
   Kelloff GJ, 1999, ANN NY ACAD SCI, V889, P1, DOI 10.1111/j.1749-6632.1999.tb08718.x
   Kelloff GJ, 1999, EUR J CANCER, V35, P1755, DOI 10.1016/S0959-8049(99)00164-1
   KELLOFF GJ, 1993, J CELL BIOCHEM, P2
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Lee JJ, 2000, CLIN CANCER RES, V6, P1702
   Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322
   Lippman Scott M., 1995, Current Opinion in Oncology, V7, P234, DOI 10.1097/00001622-199505000-00008
   LIPPMAN SM, 1989, INT J RADIAT ONCOL, V17, P691, DOI 10.1016/0360-3016(89)90126-0
   LIPPMAN SM, 1995, J CELL BIOCHEM, P1
   Lippman SM, 2001, NEW ENGL J MED, V344, P1323, DOI 10.1056/NEJM200104263441710
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   MACFARLANE GJ, 1994, CANCER CAUSE CONTROL, V5, P259, DOI 10.1007/BF01830246
   Mestre JR, 1997, CANCER RES, V57, P2890
   Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1
   Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2
   Pindborg JJ, 1997, HISTOLOGICAL TYPING
   Schantz SP, 1997, P SOC EXP BIOL MED, V216, P275
   Schmezer P, 2000, TOXICOLOGY, V144, P149, DOI 10.1016/S0300-483X(99)00201-2
   Scully C, 2000, BRIT MED J, V321, P225, DOI 10.1136/bmj.321.7255.225
   Scully C, 2000, BRIT MED J, V321, P97, DOI 10.1136/bmj.321.7253.97
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628
   SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Sudbo J, 2002, J PATHOL, V196, P244, DOI 10.1002/path.1022
   Sudbo J, 2002, J CLIN ONCOL, V20, P456, DOI 10.1200/JCO.20.2.456
   Sudbo J, 2001, ORAL ONCOL, V37, P558, DOI 10.1016/S1368-8375(00)00126-3
   Sudbo J, 2001, J PATHOL, V194, P303, DOI 10.1002/1096-9896(200107)194:3<303::AID-PATH879>3.0.CO;2-Q
   Sudbo J, 2000, LAB INVEST, V80, P1881, DOI 10.1038/labinvest.3780198
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Taketo MM, 1998, J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609
   Torrance CJ, 2000, NAT MED, V6, P1024
   Vainio H, 2001, INT J CANCER, V94, P613, DOI 10.1002/ijc.1518
   Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0
NR 51
TC 47
Z9 61
U1 3
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JUL
PY 2003
VL 39
IS 5
BP 497
EP 505
DI 10.1016/S1368-8375(03)00012-5
PG 9
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 682QC
UT WOS:000183102200010
PM 12747975
DA 2018-12-27
ER

PT J
AU Hutchings, A
   Wu, JG
   Asiedu, C
   Hubbard, W
   Eckhoff, D
   Contreras, J
   Thomas, FT
   Neville, D
   Thomas, JM
AF Hutchings, A
   Wu, JG
   Asiedu, C
   Hubbard, W
   Eckhoff, D
   Contreras, J
   Thomas, FT
   Neville, D
   Thomas, JM
TI RETRACTED: The immune decision toward allograft tolerance in non-human
   primates requires early inhibition of innate immunity and induction of
   immune regulation (Retracted article. See vol. 21, pg. 56, 2009)
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE primate; tolerance; deoxyspergualin; innate immunity; heat shock
   protein; NF-kappa B
ID CHRONIC REJECTION EVENTS; DONOR BONE-MARROW; T-CELL RESPONSES; DENDRITIC
   CELLS; REPERFUSION INJURY; IN-VIVO; TRANSPLANTATION TOLERANCE;
   RHESUS-MONKEYS; IMMUNOSUPPRESSANT 15-DEOXYSPERGUALIN; ANTI-CD3
   IMMUNOTOXIN
AB Brief treatment of rhesus macaques with immunotoxin plus 15-deoxyspergualin has yielded exceptional numbers (54%) of stable tolerant kidney allograft recipients, surviving over 6 years without rejection or immunosuppression. An early increase in IL-10 and reduction in IFNgamma distinguished recipients that subsequently became tolerant. Furthermore, analysis suggested that this immune switch was programmed within hours of transplantation. Administering deoxyspergualin within 5 h of surgery gave a higher incidence of tolerance (76%) compared to administration > 5 h before or after surgery ( 11%, P < 0.01). Deoxyspergualin inhibits nuclear translocation of activated NF-kappaB through heat shock proteins. Lymph node biopsies from tolerant recipients showed significant reductions in cytoplasmic expression of Hsp70 and RelB and almost complete inhibition of nuclear translocation of both. The early timing effect of deoxyspergualin suggests a crucial limitation to induction of stable tolerance is activation of Hsp-dependent innate responses to damage by ischemia-reperfusion. This was supported by studies in murine kidney reperfusion injury, where deoxyspergualin given 5 h before reperfusion protected renal function and reduced levels of IL-6 and IL-12. The narrow timing window for initiating deoxyspergualin treatment suggests the innate immune system is poised to defeat allograft tolerance induction, so effective blockade of NF-kappaB-mediated innate immunity must be in place early, to enable development of a tolerogenic environment. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Alabama, Dept Surg Transplant Immunobiol, Birmingham, AL 35294 USA.
   NIH, Mol Biol Lab, Bethesda, MD USA.
RP Thomas, JM (reprint author), Univ Alabama, Dept Surg Transplant Immunobiol, 1808 7th Ave S,BDB 563, Birmingham, AL 35294 USA.
EM jthomas@uab.edu
FU NIDDK NIH HHS [U19DK57958]
CR Asea A, 2000, NAT MED, V6, P435
   Asiedu C, 2002, IMMUNOL RES, V26, P297, DOI 10.1385/IR:26:1-3:297
   BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493
   Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539
   Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177
   Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749
   Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Daemen MARC, 2002, TRANSPLANTATION, V73, P1693
   Davies JD, 1996, J IMMUNOL, V157, P529
   Dong C, 2001, CURR OPIN HEMATOL, V8, P47, DOI 10.1097/00062752-200101000-00009
   Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200
   Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6
   Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558
   Groux H, 1997, NATURE, V389, P737
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   Hoffmann SC, 2002, TRANSPLANTATION, V74, P916, DOI 10.1097/01.TP.0000031932.83993.E9
   Hubbard WJ, 2001, HUM IMMUNOL, V62, P479, DOI 10.1016/S0198-8859(01)00235-X
   Hutchings A, 2002, IMMUNOL RES, V26, P143, DOI 10.1385/IR:26:1-3:143
   Kishimoto K, 2000, J CLIN INVEST, V106, P63, DOI 10.1172/JCI9586
   Konieczny BT, 1998, J IMMUNOL, V160, P2059
   LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010
   Land W, 2002, EUR SURG RES, V34, P160, DOI 10.1159/000048904
   LAND W, 1994, TRANSPLANT P, V26, P3169
   Lobashevsky A, 1999, TISSUE ANTIGENS, V54, P254, DOI 10.1034/j.1399-0039.1999.540306.x
   Lobashevsky AL, 2000, HUM IMMUNOL, V61, P1013, DOI 10.1016/S0198-8859(00)00177-4
   MAEDA K, 1993, ANN NY ACAD SCI, V685, P123, DOI 10.1111/j.1749-6632.1993.tb35859.x
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026
   Nadler SG, 1998, BIOCHEM BIOPH RES CO, V253, P176, DOI 10.1006/bbrc.1998.9775
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   STEIGER J, 1995, J IMMUNOL, V155, P489
   Thomas F, 2001, SURGERY, V130, P333, DOI 10.1067/msy.2001.116413
   THOMAS J, 1987, TRANSPLANTATION, V43, P332, DOI 10.1097/00007890-198703000-00002
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   Thomas JM, 2001, IMMUNOL REV, V183, P223, DOI 10.1034/j.1600-065x.2001.1830118.x
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   Thomas JM, 2001, DIABETES, V50, P1227, DOI 10.2337/diabetes.50.6.1227
   THOMAS JM, 1979, TRANSPLANTATION, V27, P163, DOI 10.1097/00007890-197903000-00005
   Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007
   THOMAS JM, 2002, AM J TRANSPLANT S3, V2, P144
   Waaga AM, 2001, J CLIN INVEST, V107, P909, DOI 10.1172/JCI11427
   Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4
NR 45
TC 25
Z9 25
U1 3
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD JUL-SEP
PY 2003
VL 11
IS 3-4
BP 335
EP 344
DI 10.1016/S0966-3274(03)00054-6
PG 10
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 724UD
UT WOS:000185504300011
PM 12967786
DA 2018-12-27
ER

PT J
AU Lei, SA
AF Lei, SA
TI RETRACTED: Environmental attributes correlating with density of
   blackbrush (Coleogyne ramosissima) shrubs in the Spring Mountains of
   Southern Nevada (Retracted article. See vol. 71, pg. 139, 2011)
SO WESTERN NORTH AMERICAN NATURALIST
LA English
DT Article; Retracted Publication
DE edaphic; soil attributes; soil surface variables; upper Coleogyne
   ecotone; Spring Mountains; southern Nevada
ID COMMUNITIES
AB Discovery of distinct mid-elevational bands of blackbrush (Coleogyne ramosissima Torr.) shrublands on desert mountain slopes in the Mojave Desert caused an investigation of the relationships between environmental factors and Coleogyne distribution. Environmental factors were quantitatively examined to determine which were significant predictors of Coleogyne density at upper-elevational limits (ecotones) in the Spring Mountains of southern Nevada. Path analysis revealed significant, direct causal effects of air temperature, soil moisture, soil depth, and percent litter cover on the distribution of Coleogyne. Specifically, air temperature was a significant positive predictor, while soil moisture, soil depth, and percent litter cover were significant negative predictors of Coleogyne density, with the effects of other environmental variables parceled out. Path analysis also indicated that indirect effects of soil pH, bulk density, compaction, percent pore space, organic matter, soil temperature, salinity, cryptogam, and percent bare soil and rock cover on Coleogyne density were substantially more potent than their direct causal effects. Environmental attributes associated with elevational changes correlate with and may determine the density of Coleogyne shrubs at upper ecotones in southern Nevada.
C1 Community Coll So Nevada, WDB, Dept Biol, Las Vegas, NV 89146 USA.
RP Lei, SA (reprint author), Community Coll So Nevada, WDB, Dept Biol, 6375 W Charleston Blvd, Las Vegas, NV 89146 USA.
CR *AN SOFTW, 1994, STAT 4 1 INT STAT PR
   Barbour MG, 1999, TERRESTRIAL PLANT EC
   BATANOUNY K H, 1973, Acta Botanica Academiae Scientiarum Hungaricae, V19, P13
   BEATLEY JC, 1969, OIKOS, V20, P261, DOI 10.2307/3543193
   Bowns J.E., 1976, 27 UT STAT U UT AGR
   Bowns JE, 1973, THESIS UTAH STATE U
   Brady N. C., 1974, NATURE PROPERTIES SO
   CALLISON J, 1985, GREAT BASIN NAT, V45, P321
   DAVIDSON E D, 1974, Madrono, V22, P381
   HAUSENBUILLER RL, 1972, SOIL SCI
   JEFFREY D. W., 1987, SOIL PLANT RELATIONS
   KORTHUIS SL, 1988, FIRE SERVICE INTERMO
   Lei S., 1995, THESIS U NEVADA LAS
   Lei SA, 1997, GREAT BASIN NAT, V57, P155
   Lei SA, 1997, GREAT BASIN NAT, V57, P163
   Lei SA, 1997, GREAT BASIN NAT, V57, P172
   NELSON DL, 1983, INT314 USDA FOR SERV
   SMITH SD, 1995, J ARID ENVIRON, V29, P339, DOI 10.1016/S0140-1963(05)80113-2
   SMITH SD, 1995, P WILDL SHRUB AR LAN
   West N. E., 1983, TEMPERATE DESERTS SE, P399
   Wright H. A., 1979, INT58 USDA FOR SERV
NR 21
TC 2
Z9 2
U1 1
U2 5
PU BRIGHAM YOUNG UNIV
PI PROVO
PA 290 LIFE SCIENCE MUSEUM, PROVO, UT 84602 USA
SN 1527-0904
EI 1944-8341
J9 WEST N AM NATURALIST
JI West. North Am. Naturalist
PD JUL
PY 2003
VL 63
IS 3
BP 391
EP 399
PG 9
WC Biodiversity Conservation; Ecology
SC Biodiversity & Conservation; Environmental Sciences & Ecology
GA 712HG
UT WOS:000184791800014
DA 2018-12-27
ER

PT J
AU Kitagawa, H
   Fujiki, R
   Yoshimura, K
   Mezaki, Y
   Uematsu, Y
   Matsui, D
   Ogawa, S
   Unno, K
   Okubo, M
   Tokita, A
   Nakagawa, T
   Ito, T
   Ishimi, Y
   Nagasawa, H
   Matsumoto, T
   Yanagisawa, J
   Kato, S
AF Kitagawa, H
   Fujiki, R
   Yoshimura, K
   Mezaki, Y
   Uematsu, Y
   Matsui, D
   Ogawa, S
   Unno, K
   Okubo, M
   Tokita, A
   Nakagawa, T
   Ito, T
   Ishimi, Y
   Nagasawa, H
   Matsumoto, T
   Yanagisawa, J
   Kato, S
TI RETRACTED: The chromatin-remodeling complex WINAC targets a nuclear
   receptor to promoters and is impaired in Williams syndrome (Retracted
   article. See vol. 149, pg. 245, 2012)
SO CELL
LA English
DT Article; Retracted Publication
ID ESTROGEN-RECEPTOR; DNA-REPLICATION; TRANSCRIPTION; GENE; ISWI;
   ACTIVATION; IDENTIFICATION; ACETYLATION; SUPERFAMILY; REQUIREMENT
AB We identified a human multiprotein complex (WINAC) that directly interacts with the vitamin D receptor (VDR) through the Williams syndrome transcription factor (WSTF), WINAC has ATP-dependent chromatin-remodeling activity and contains both SWI/SNF components and DNA replication-related factors. The latter might explain a WINAC requirement for normal S phase progression. WINAC mediates the recruitment of unliganded VDR to VDR target sites in promoters, while subsequent binding of coregulators requires ligand binding. This recruitment order exemplifies that an interaction of a sequence-specific regulator with a chromatin-remodeling complex can organize nucleosomal arrays at specific local sites in order to make promoters accessible for coregulators. Furthermore, overexpression of WSTF could restore the impaired recruitment of VDR to vitamin D regulated promoters in fibroblasts from Williams syndrome patients. This suggests that WINAC dysfunction contributes to Williams syndrome, which could therefore be considered, at least in part, a chromatin-remodeling factor disease.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 7708503, Japan.
   Juntendo Univ, Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138431, Japan.
   Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan.
   Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan.
   Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Dept Appl Biol Chem, Tokyo 1130032, Japan.
   SORST, Japan Sci & Technol, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T
   CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815
   DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7
   Fujita M, 1996, J BIOL CHEM, V271, P4349
   Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002
   Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0
   GARABEDIAN M, 1985, NEW ENGL J MED, V312, P948, DOI 10.1056/NEJM198504113121503
   Glass CK, 2000, GENE DEV, V14, P121
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Hoogenraad CC, 2002, NAT GENET, V32, P116, DOI 10.1038/ng954
   Ito T, 2000, GENE DEV, V14, P1899
   Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9
   Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001
   Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002
   Lazzaro MA, 2001, J NEUROCHEM, V77, P1145, DOI 10.1046/j.1471-4159.2001.00324.x
   Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a
   LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900
   Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X
   Loyola A, 2001, GENE DEV, V15, P2837
   Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Ohba R, 1996, MOL CELL BIOL, V16, P5754
   ONATE SA, 1995, SCIENCE, V270, P1354
   Peoples RJ, 1998, CYTOGENET CELL GENET, V82, P238, DOI 10.1159/000015110
   Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9
   SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X
   Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356
   TAYLOR AB, 1982, NEW ENGL J MED, V306, P972, DOI 10.1056/NEJM198204223061607
   VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 47
TC 192
Z9 202
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUN 27
PY 2003
VL 113
IS 7
BP 905
EP 917
DI 10.1016/S0092-8674(03)00436-7
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 695EJ
UT WOS:000183817900014
PM 12837248
OA Bronze
DA 2018-12-27
ER

PT J
AU Kawasaki, H
   Taira, K
AF Kawasaki, H
   Taira, K
TI RETRACTED: Hes1 is a target of microRNA-23 during retinoic-acid-induced
   neuronal differentiation of NT2 cells (Retracted Article. See 426, pg
   100, 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; C-ELEGANS; REGULATORY RNA;
   INTERFERENCE; GENES; EXPRESSION; ROLES; IDENTIFICATION; TRANSLATION
AB MicroRNAs (miRNAs) are phylogenetically widespread small RNAs of 18-25 nucleotides in length, and are found in animals and plants. These small RNAs can regulate gene expression at a translational level through interactions with their target messenger RNAs, and they have a role in the development of Caenorhabditis elegans and plants. Although more than two hundred miRNAs have been found in mammals, their mRNA targets remain to be identified. Here, we demonstrate that the expression of Hes1, basic helix-loop-helix transcriptional repressor, is regulated by miRNA-23 (miR-23) in NT2 cells. miR-23 is almost complementary to part of the coding region, just upstream of the termination codon, of Hes1 mRNA. Reduction in the level of miR-23 by small interfering RNAs resulted in the accumulation of Hes1, and hindered the retinoic-acid-induced neuronal differentiation of NT2 cells. Thus, our results indicate that miR-23 regulates the expression of Hes1 at the post-transcriptional level, and participates in retinoic-acid-induced neuronal differentiation of NT2 cells.
C1 Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   AIST, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan.
RP Kawasaki, H (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM kawasaki@chembio.t.u-tokyo.ac.jp; taria@chembio.t.u-tokyo.ac.jp
CR Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Cheung WMW, 2000, J NEUROCHEM, V75, P34, DOI 10.1046/j.1471-4159.2000.0750034.x
   Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503
   Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0
   Kawasaki H, 1998, NATURE, V393, P284
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   KURIE JM, 1993, DIFFERENTIATION, V54, P115
   Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311
   Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702
   Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200
   Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196
   Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523
   Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556
   PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603
   Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2
   Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563
   Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2
   Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103
   Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503
   Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5
NR 40
TC 70
Z9 82
U1 4
U2 60
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 19
PY 2003
VL 423
IS 6942
BP 838
EP 842
DI 10.1038/nature01730
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 691BQ
UT WOS:000183585300036
PM 12808467
DA 2018-12-27
ER

PT J
AU Baglia, FA
   Shrimpton, CN
   Lopez, JA
   Walsh, PN
AF Baglia, FA
   Shrimpton, CN
   Lopez, JA
   Walsh, PN
TI RETRACTED: The glycoprotein Ib-IX-V complex mediates localization of
   factor XI to lipid rafts on the platelet membrane (Retracted Article.
   See vol 282, pg 29067, 2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; PLASMA-MEMBRANE;
   RESTING PLATELETS; CELL-SURFACE; BINDING-SITE; ACTIVATION; THROMBIN;
   DOMAIN; RECEPTOR
AB Factor XI binds to activated platelets where it is efficiently activated by thrombin. The factor XI receptor is the platelet membrane glycoprotein ( GP) Ib- IX- V complex ( Baglia, F. A., Badellino, K. O., Li, C. Q., Lopez, J. A., and Walsh, P. N. ( 2002) J. Biol. Chem. 277, 1662 - 1668), a significant fraction of which exists within lipid rafts on stimulated platelets ( Shrimpton, C. N., Borthakur, G., Larrucea, S., Cruz, M. A., Dong, J. F., and Lopez, J. A. ( 2002) J. Exp. Med. 196, 1057 - 1066). Lipid rafts are membrane microdomains enriched in cholesterol and sphingolipids implicated in localizing membrane ligands and in cellular signaling. We now show that factor XI was localized to lipid rafts in activated platelets ( similar to 8% of total bound) but not in resting platelets. Optimal binding of factor XI to membrane rafts required prothrombin ( and Ca2+ ) or high molecular weight kininogen ( and Zn2+), which are required for factor XI binding to platelets. An antibody to GPIb ( SZ- 2) that disrupts factor XI binding to the GPIb- IX- V complex also disrupted factor XI- raft association. The isolated recombinant Apple 3 domain of factor XI, which mediates factor XI binding to platelets, also completely displaces factor XI from membrane rafts. To investigate the physiological relevance of the factor XI- raft association, the structural integrity of lipid rafts was disrupted by cholesterol depletion utilizing methyl-beta-cyclodextrin. Cholesterol depletion completely prevented FXI binding to lipid rafts, and initial rates of factor XI activation by thrombin on activated platelets were inhibited > 85%. We conclude that factor XI is localized to GPIb in membrane rafts and that this association is important for promoting the activation of factor XI by thrombin on the platelet surface.
C1 Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
   Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA.
   Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Walsh, PN (reprint author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.
EM pnw@temple.edu
FU NHLBI NIH HHS [HL 46213, HL 54218, HL 56914, HL 64796, HL 64943]
CR Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200
   Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200
   Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200
   BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+
   BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200
   BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J
   BRUNNEE T, 1993, BLOOD, V81, P580
   DEMARCO L, 1991, J BIOL CHEM, V266, P23776
   Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067
   Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373
   DU XP, 1987, BLOOD, V69, P1524
   Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276
   Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291
   Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929
   Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200
   Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q
   Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x
   Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200
   LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97
   MODDERMAN PW, 1992, J BIOL CHEM, V267, P364
   Roper K, 2000, NAT CELL BIOL, V2, P582
   SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901
   SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017
   SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353
   Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862
   van Zanten GH, 1998, BLOOD, V91, P2353
   WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x
   Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8
NR 37
TC 30
Z9 30
U1 3
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 13
PY 2003
VL 278
IS 24
BP 21744
EP 21750
DI 10.1074/jbc.M212991200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 687AT
UT WOS:000183354200055
PM 12517745
DA 2018-12-27
ER

PT J
AU Brinkmeier, H
   Weber, F
   Aulkemeyer, P
   Wollinsky, KH
   Rudel, R
AF Brinkmeier, H
   Weber, F
   Aulkemeyer, P
   Wollinsky, KH
   Rudel, R
TI RETRACTED: The pentapeptide QYNAD does not block voltage-gated sodium
   channels (Retracted Article. See vol 66, pg 456, 2006)
SO NEUROLOGY
LA English
DT Letter; Retracted Publication
CR Brinkmeier H, 2000, NAT MED, V6, P808
   Brinkmeier H, 2003, NEUROLOGY, V60, P1871, DOI 10.1212/WNL.60.11.1871-a
   Cummins TR, 2003, NEUROLOGY, V60, P224, DOI 10.1212/01.WNL.0000042423.36650.BD
   Weber F, 2002, NEUROSCI LETT, V317, P33, DOI 10.1016/S0304-3940(01)02420-X
NR 4
TC 3
Z9 3
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 10
PY 2003
VL 60
IS 11
BP 1871
EP 1871
DI 10.1212/WNL.60.11.1871-a
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 688DT
UT WOS:000183418400049
PM 12796562
DA 2018-12-27
ER

PT J
AU Stucki, G
   Ewert, T
   Cieza, A
AF Stucki, G
   Ewert, T
   Cieza, A
TI RETRACTED: Value and application of the ICF in rehabilitation medicine
   (Retracted article. See vol. 31, pg. 425, 2009)
SO DISABILITY AND REHABILITATION
LA English
DT Article; Retracted Publication
ID HEALTH; CLASSIFICATION; DISABILITY
AB Rehabilitation medicine may be defined as the multi- and interdisciplinary management of a person's functioning and health. Rehabilitation medicine defines itself with respect to concepts of functioning, disability and health. Assessment and intervention management rely on this concept.
   The Current framework of disability-the WHO International Classification of Functioning, Disability and Health (ICF)providing a coherent view of health from a biological, individual and social perspective.
   However, ICF success will depend on its compatibility with measures used in rehabilitation and on the improvement of its practicability. Thus, it is expected to see the development of the ICF based on versions of currently used instruments and on the development of ICF Core Sets.
   The new language ICF is an exciting landmark event for rehabilitation. It may lead to a stronger position of rehabilitation within the medical community, change multi-professional communication and improve communication between patients and rehabilitation professionals.
C1 Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany.
RP Stucki, G (reprint author), Univ Munich, Dept Phys Med & Rehabil, Marchioninistr 15, D-81377 Munich, Germany.
EM gerold.stucki@phys.med.uni-muenchen.de
CR Boers M, 1998, J RHEUMATOL, V25, P198
   Keith R A, 1987, Adv Clin Rehabil, V1, P6
   NAGI SZ, 1964, AM J PUBLIC HEALTH N, V54, P1568, DOI 10.2105/AJPH.54.9.1568
   POPE A, 1991, DISABILITY AM NATL A
   Ruof J, 1999, J RHEUMATOL, V26, P1959
   Stucki G, 2000, PHYS MED REHAB KUROR, V10, P78, DOI 10.1055/s-2008-1057763
   Stucki G, 2002, DISABIL REHABIL, V24, P281, DOI 10.1080/09638280110105222
   STUCKI G, 1997, RHEUMATOLOGY
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   *WHO, 1980, ICIDH INT CLASS IMP
   World Health Organization, 2001, INT CLASS FUNCT DIS
NR 11
TC 149
Z9 154
U1 8
U2 23
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0963-8288
J9 DISABIL REHABIL
JI Disabil. Rehabil.
PD JUN 3
PY 2003
VL 25
IS 11-2
BP 628
EP 634
DI 10.1080/09638280110070221
PG 7
WC Rehabilitation
SC Rehabilitation
GA 694JZ
UT WOS:000183772600010
PM 12959337
DA 2018-12-27
ER

PT J
AU Niederhofer, H
   Staffen, W
AF Niederhofer, H
   Staffen, W
TI RETRACTED: Acamprosate and its efficacy in treating alcohol dependent
   adolescents (Retracted article. See vol. 21, pg. 713, 2012)
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Article; Retracted Publication
DE acramposate; alcohol; adolescents
ID PLACEBO-CONTROLLED TRIAL; CA-ACETYL-HOMOTAURINATE; DOUBLE-BLIND; RELAPSE
   PREVENTION; RATS; FLUOXETINE; NALTREXONE; RECEPTORS; THERAPY; ABUSE
AB Background About 50% of adult alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that acamprosate may help to prevent such relapse. The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence of adolescents. Methods In this, double-blind, placebo-controlled study, we recruited 26 patients, aged 16-19 years, with chronic or episodic alcohol dependence. Patients were randomly allocated treatment with acamprosate (1332 mg daily) or placebo for 90 days. Patients were assessed on the day treatment started and on days 30, and 90 by interview, self report, questionnaire, and laboratory screening. Findings 13 acamprosate-treated and 13 placebo-treated patients completed the treatment phase: of those withdrawn, 11 (1 vs 6) relapsed, 5 (3 vs 2) refused to continue treatment, 3 (1 vs 2) had concurrent illness, and 2 (1 vs 1) had adverse side-effects. At the end of treatment, 7 acamprosate treated and 2 placebo-treated patients had been continuously abstinent (p = 0.0076). Mean cumulative abstinence duration was significantly greater in the acamprosate group than in the placebo group (79.8 [SD 37.5] vs 32.8 [19.0] days; p = 0.012). Interpretation Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial treatment programmes.
C1 Christian Doppler Klin, A-5020 Salzburg, Austria.
RP Niederhofer, H (reprint author), Christian Doppler Klin, A-5020 Salzburg, Austria.
EM helmut.niederhofer@uibk.ac.at
CR BOISMARE F, 1984, PHARMACOL BIOCHEM BE, V21, P787, DOI 10.1016/S0091-3057(84)80020-9
   BORG V, 1983, ACTA PSYCHIAT SCAND, V68, P100, DOI 10.1111/j.1600-0447.1983.tb06987.x
   BURKE TR, 1988, PUBLIC HEALTH REP, V103, P564
   Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P176, DOI 10.1093/alcalc/35.2.176
   CROFTON J, 1987, ALCOHOL ALCOHOLISM, V22, P321
   DAOUST M, 1992, PHARMACOL BIOCHEM BE, V41, P669, DOI 10.1016/0091-3057(92)90210-7
   EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905
   FAWCETT J, 1987, ARCH GEN PSYCHIAT, V44, P248
   GALLIMBERTI L, 1992, ALCOHOL CLIN EXP RES, V16, P673, DOI 10.1111/j.1530-0277.1992.tb00658.x
   GERRA G, 1992, CURR THER RES CLIN E, V52, P291, DOI 10.1016/S0011-393X(05)80480-1
   GRANT KA, 1989, PHARMACOL BIOCHEM BE, V32, P607, DOI 10.1016/0091-3057(89)90005-1
   GREB J, 1995, NCDEU ORL FLOR
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391
   Lehert P, 1993, Alcohol Alcohol Suppl, V2, P157
   LEMAGNEN J, 1987, ALCOHOL, V4, P97, DOI 10.1016/0741-8329(87)90005-X
   LHUINTRE J, 1985, LANCT, V1, P101
   LHUINTRE JP, 1990, ALCOHOL ALCOHOLISM, V25, P613, DOI 10.1093/oxfordjournals.alcalc.a045057
   MAAON BJ, 1994, ALCOHOL CLINN EXP RE, V18, P1162
   MILLER WR, 1986, TREATING ADDICTIVE B, P121
   NARANJO CA, 1991, ALCOHOL ALCOHOLISM, P523
   OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881
   PAILLE FM, 1995, ALCOHOL ALCOHOLISM, V30, P239
   Poldrugo F, 1997, ADDICTION, V92, P1537
   RASSNICK S, 1992, ANN NY ACAD SCI, V654, P502
   SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x
   SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653
   SHAW GK, 1994, BRIT J PSYCHIAT, V165, P515, DOI 10.1192/bjp.165.4.515
   Tempesta E, 2000, ALCOHOL ALCOHOLISM, V35, P202, DOI 10.1093/alcalc/35.2.202
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   ZEISE ML, 1993, EUR J PHARMACOL, V231, P47, DOI 10.1016/0014-2999(93)90682-8
NR 31
TC 34
Z9 37
U1 5
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
PD JUN
PY 2003
VL 12
IS 3
BP 144
EP 148
DI 10.1007/s00787-003-0327-1
PG 5
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 691AL
UT WOS:000183582600005
PM 12768462
DA 2018-12-27
ER

PT J
AU Hui, EKW
   Barman, S
   Yang, TY
   Nayak, DP
AF Hui, EKW
   Barman, S
   Yang, TY
   Nayak, DP
TI RETRACTED: Basic residues of the helix six domain of influenza virus M1
   involved in nuclear translocation of M1 can be replaced by PTAP and YPDL
   late assembly domain motifs (Retracted article. See vol. 80, pg. 10289,
   2006)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID MATRIX PROTEIN M1; ROUS-SARCOMA-VIRUS; BASOLATERAL LOCALIZATION SIGNAL;
   RNA-BINDING DOMAINS; A VIRUS; CYTOPLASMIC TAIL; TERMINAL DOMAIN; COAT
   PROTEIN; MDCK CELLS; YXXL MOTIF
AB Influenza type A virus matrix (M1) protein possesses multiple functional motifs in the helix 6 (116) domain (amino acids 91 to 105), including nuclear localization signal (NLS) (101-RKLKR-105) involved in translocating M1 from the cytoplasm into the nucleus. To determine the role of the NLS motif in the influenza virus life cycle, we mutated these and the neighboring sequences by site-directed mutagenesis, and influenza virus mutants were generated by reverse genetics. Our results show that infectious viruses were rescued by reverse genetics from all single alanine mutations of amino acids in the H6 domain and the neighboring region except in three positions (K104A and R105A within the NLS motif and E106A in loop 6 outside the NLS motif). Among the rescued mutant viruses, R101A and R105K exhibited reduced growth and small-plaque morphology, and all other mutant viruses showed the wild-type phenotype. On the other hand, three single mutations (KI04A, K105A, and E106A) and three double mutations (R101A/K102A, K104A/K105A, and K102A/R105A) failed to generate infectious virus. Deletion (DeltaYRKL) or mutation (4A) of YRKL also abolished generation of infectious virus. However, replacement of the YRKL motif with PTAP or YPDL as well as insertion of PTAP after 4A mutation yielded infectious viruses with the wild-type phenotype. Furthermore, mutant M1 proteins (R101A/K102A, DeltaYRKL, 4A, PTAP, 4A+PTAP, and YPDL) when expressed alone from cloned cDNAs were only cytoplasmic, whereas the wild-type M1 expressed alone was both nuclear and cytoplasmic as expected. These results show that the nuclear translocation function provided by the positively charged residues within the NLS motif does not play a critical role in influenza virus replication. Furthermore, these sequences of H6 domain can be replaced by late (L) domain motifs and therefore may provide a function similar to that of the L domains of other negative.-strand RNA and retroviruses.
C1 Univ Calif Los Angeles, Sch Med, Inst Mol Biol,Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
RP Nayak, DP (reprint author), Univ Calif Los Angeles, Sch Med, Inst Mol Biol,Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, 650 Charles E Young Dr So, Los Angeles, CA 90095 USA.
EM dnayak@ucla.edu
FU NIAID NIH HHS [AI 16348, R01 AI041681, R01 AI016348, AI 41681]
CR Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000
   ALLEN H, 1980, VIROLOGY, V107, P548, DOI 10.1016/0042-6822(80)90324-4
   Arzt S, 2001, VIROLOGY, V279, P439, DOI 10.1006/viro.2000.0727
   Barman S, 2003, VIROLOGY, V305, P138, DOI 10.1006/viro.2002.1731
   BAUDIN F, 1994, EMBO J, V13, P3158, DOI 10.1002/j.1460-2075.1994.tb06614.x
   Baudin F, 2001, VIROLOGY, V281, P102, DOI 10.1006/viro.2000.0804
   BUCHER DJ, 1980, J VIROL, V36, P586
   Choi YG, 2000, VIROLOGY, V270, P377, DOI 10.1006/viro.2000.0312
   Cimarelli A, 2002, CELL MOL LIFE SCI, V59, P1166, DOI 10.1007/s00018-002-8495-6
   Craven RC, 1999, J VIROL, V73, P3359
   Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002
   Elster C, 1997, J GEN VIROL, V78, P1589, DOI 10.1099/0022-1317-78-7-1589
   Favoreel HW, 2002, J VIROL, V76, P6845, DOI 10.1128/JVI.76.13.6845-6851.2002
   Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2
   Gomez-Puertas P, 2000, J VIROL, V74, P11538, DOI 10.1128/JVI.74.24.11538-11547.2000
   GREGORIADES A, 1981, J VIROL, V40, P323
   GREGORIADES A, 1980, J VIROL, V36, P470
   GUJULUVA CN, 1994, VIROLOGY, V204, P491, DOI 10.1006/viro.1994.1563
   Harris A, 1999, J GEN VIROL, V80, P863, DOI 10.1099/0022-1317-80-4-863
   Harris A, 2001, VIROLOGY, V289, P34, DOI 10.1006/viro.2001.1119
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Huang XY, 2001, VIROLOGY, V287, P405, DOI 10.1006/viro.2001.1067
   Hui EKW, 2002, J GEN VIROL, V83, P3055, DOI 10.1099/0022-1317-83-12-3055
   Hui EKW, 2001, VIROLOGY, V290, P329, DOI 10.1006/viro.2001.1181
   Hui EKW, 1999, J GEN VIROL, V80, P2661, DOI 10.1099/0022-1317-80-10-2661
   Kuribayashi H, 2000, BIOORG MED CHEM LETT, V10, P2227, DOI 10.1016/S0960-894X(00)00448-0
   LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647
   Lamb R. A., 2001, Fundamental virology, P725
   Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001
   Le Blanc I, 2002, J VIROL, V76, P10024, DOI 10.1128/JVI.76.19.10024-10029.2002
   Lee M, 2001, SCAND J METALL, V30, P286, DOI 10.1034/j.1600-0692.2001.300502.x
   Liu T, 2002, VIROLOGY, V304, P89, DOI 10.1006/viro.2002.1669
   Liu T, 2002, J VIROL, V76, P13055, DOI 10.1128/JVI.76.24.13055-13061.2002
   LOPEZTURISO JA, 1990, VIRUS RES, V16, P325, DOI 10.1016/0168-1702(90)90056-H
   Luban J, 2001, NAT MED, V7, P1278, DOI 10.1038/nm1201-1278
   Mora R, 2002, J VIROL, V76, P3544, DOI 10.1128/JVI.76.7.3544-3553.2002
   Morrison KL, 2001, CURR OPIN CHEM BIOL, V5, P302, DOI 10.1016/S1367-5931(00)00206-4
   NASSAL M, 1992, J VIROL, V66, P4107
   NAYAK DP, 2000, VIRAL ECOLOGY, P64
   NAYAK DP, 2002, RRD VIROLOGY, V4, P35
   Olson JK, 1997, J VIROL, V71, P4042
   PARENT LJ, 1995, J VIROL, V69, P5455
   Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002
   Perez DR, 1998, VIROLOGY, V249, P52, DOI 10.1006/viro.1998.9318
   Perez OD, 2001, IMMUNITY, V15, P687, DOI 10.1016/S1074-7613(01)00238-2
   Portela A, 2002, J GEN VIROL, V83, P723, DOI 10.1099/vir.0.18133-0.
   Puffer BA, 1998, J VIROL, V72, P10218
   Puffer BA, 1997, J VIROL, V71, P6541
   REES PJ, 1982, J GEN VIROL, V59, P403, DOI 10.1099/0022-1317-59-2-403
   Reinhardt J, 2000, VET MICROBIOL, V74, P87, DOI 10.1016/S0378-1135(00)00169-3
   REY O, 1992, J VIROL, V66, P5815
   Roberts PC, 1998, P NATL ACAD SCI USA, V95, P5746, DOI 10.1073/pnas.95.10.5746
   Roberts PC, 1998, VIROLOGY, V240, P127, DOI 10.1006/viro.1997.8916
   RUIGROK RWH, 1995, J GEN VIROL, V76, P1009, DOI 10.1099/0022-1317-76-4-1009
   Ruigrok RWH, 2000, VIROLOGY, V267, P289, DOI 10.1006/viro.1999.0134
   Schmitz I, 1998, VIROLOGY, V248, P323, DOI 10.1006/viro.1998.9257
   SCHULZE IT, 1972, VIROLOGY, V47, P181, DOI 10.1016/0042-6822(72)90251-6
   Sha BD, 1997, NAT STRUCT BIOL, V4, P239, DOI 10.1038/nsb0397-239
   Shishkov AV, 1999, P NATL ACAD SCI USA, V96, P7827, DOI 10.1073/pnas.96.14.7827
   TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282
   Tirabassi RS, 1999, J VIROL, V73, P2717
   VANDERGRAAF M, 1992, BIOCHEMISTRY-US, V31, P9177, DOI 10.1021/bi00153a009
   WAKEFIELD L, 1989, NUCLEIC ACIDS RES, V17, P8569, DOI 10.1093/nar/17.21.8569
   Watanabe K, 1996, J VIROL, V70, P241
   WHITTAKER G, 1995, J VIROL, V69, P439
   Xiang Y, 1996, J VIROL, V70, P5695
   YASUDA J, 1993, VIROLOGY, V196, P249, DOI 10.1006/viro.1993.1473
   Ye ZP, 1999, J VIROL, V73, P7467
   YE ZP, 1989, J VIROL, V63, P3586
   YE ZP, 1987, J VIROL, V61, P239
   YE ZP, 1995, J VIROL, V69, P1964
   Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000
   Zhao HX, 1998, J GEN VIROL, V79, P2435, DOI 10.1099/0022-1317-79-10-2435
   Zhirnov OP, 1997, VIROLOGY, V235, P302, DOI 10.1006/viro.1997.8700
   Zimmer G, 2002, J VIROL, V76, P4103, DOI 10.1128/JVI.76.8.4103-4107.2002
NR 76
TC 36
Z9 38
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2003
VL 77
IS 12
BP 7078
EP 7092
DI 10.1128/JVI.77.12.7078-7092.2003
PG 15
WC Virology
SC Virology
GA 684LT
UT WOS:000183209400049
PM 12768027
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Roovers, K
   Assoian, RK
AF Roovers, K
   Assoian, RK
TI RETRACTED: Effects of Rho kinase and actin stress fibers on sustained
   extracellular signal-regulated kinase activity and activation of G(1)
   phase cyclin-dependent kinases (Retracted Article. See vol 26, pg 5203,
   2006)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID FOCAL ADHESION KINASE; CROSS-CASCADE ACTIVATION; GROWTH-FACTOR
   ACTIVATION; ADAPTER PROTEIN SHC; CELL-CYCLE; MAP KINASE;
   ENDOTHELIAL-CELLS; LIM-KINASE; TYROSINE PHOSPHORYLATION; SMOOTH-MUSCLE
AB We recently reported that Rho kinase is required for sustained ERK signaling and the consequent mid-G, phase induction of cyclin D1 in fibroblasts. The results presented here indicate that these Rho kinase effects are mediated by the formation of stress fibers and the consequent clustering of alpha5beta1 integrin. Mechanistically, alpha5beta1 signaling and stress fiber formation allowed for the sustained activation of MEK, and this effect was mediated upstream of Ras-GTP loading. Interestingly, disruption of stress fibers with ML-7 led to G(1) phase arrest while comparable disruption of stress fibers with Y27632 (an inhibitor of Rho kinase) or dominant-negative Rho kinase led to a more rapid progression through G(1) phase. Inhibition of either MLCK or Rho kinase blocked sustained ERK signaling, but only Rho kinase inhibition allowed for the induction of cyclin D1 and activation of cdk4 via Rae/Cdc42. The levels of cyclin E, cdk2, and their major inhibitors, p21(cip1) and p27(kip1), were not affected by inhibition of MLCK or Rho kinase. Overall, our results indicate that Rho kinase-dependent stress fiber formation is required for sustained activation of the MEK/ERK pathway and the mid-G(1) phase induction of cyclin D1, but not for other aspects of cdk4 or cdk2 activation. They also emphasize that G(1) phase cell cycle progression in fibroblasts does not require stress fibers if Rac/Cdc42 signaling is allowed to induce cyclin D1.
C1 Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
RP Assoian, RK (reprint author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk,167 Johnson Pavil, Philadelphia, PA 19104 USA.
EM rka@pharm.med.upenn.edu
FU NIGMS NIH HHS [GM51878, R01 GM051878]; NCI NIH HHS [CA72639, R01
   CA072639]
CR Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962
   AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582
   Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308
   Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246
   Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223
   Arber S, 1998, NATURE, V393, P805
   Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551
   Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200
   Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456
   Bohmer RM, 1996, MOL BIOL CELL, V7, P101
   Bottazzi ME, 2001, MOL CELL BIOL, V21, P7607, DOI 10.1128/MCB.21.22.7607-7616.2001
   Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463
   CHAN PY, 1994, J BIOL CHEM, V269, P20567
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571
   ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403
   Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573
   Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj/onc/1205302
   Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200
   Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426
   Gilmore AP, 1996, MOL BIOL CELL, V7, P1209
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hansen LK, 1999, J CELL SCI, V112, P2971
   HERMAN IM, 1982, ANN NY ACAD SCI, V401, P50, DOI 10.1111/j.1749-6632.1982.tb25706.x
   Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065
   Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536
   Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396
   Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504
   Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179
   INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579
   Ishizaki T, 2000, MOL PHARMACOL, V57, P976
   Iwamoto H, 2000, J HEPATOL, V32, P762, DOI 10.1016/S0168-8278(00)80245-7
   IWIG M, 1981, EXP CELL RES, V131, P47, DOI 10.1016/0014-4827(81)90404-3
   Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459
   Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023
   King AJ, 1998, NATURE, V396, P180
   Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926
   Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200
   Lin TH, 1997, J BIOL CHEM, V272, P8849
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4
   Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633
   MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531
   Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622
   Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200
   Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425
   Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200
   Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302
   QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611
   Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592
   RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669
   Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906
   Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197
   Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y
   Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088
   Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755
   Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0
   SAITOH M, 1987, J BIOL CHEM, V262, P7796
   Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030
   Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200
   Tang D, 1999, AM J PHYSIOL-CELL PH, V276, pC250, DOI 10.1152/ajpcell.1999.276.1.C250
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797
   VAN AL, 1997, GENE DEV, V11, P2295
   Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9
   Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6
   Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966
   Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950
   WHITE GE, 1983, J CELL BIOL, V97, P416, DOI 10.1083/jcb.97.2.416
   WONG AJ, 1983, SCIENCE, V219, P867, DOI 10.1126/science.6681677
   Yang N, 1998, NATURE, V393, P809
   Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635
   Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200
   Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066
   Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997
   Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391
NR 85
TC 85
Z9 89
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2003
VL 23
IS 12
BP 4283
EP 4294
DI 10.1128/MCB.23.12.4283-4294.2003
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 686HP
UT WOS:000183315600022
PM 12773570
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Kofidis, T
   Akhyari, P
   Wachsmann, B
   Mueller-Stahl, K
   Boublik, J
   Ruhparwar, A
   Mertsching, H
   Balsam, L
   Robbins, R
   Haverich, A
AF Kofidis, T
   Akhyari, P
   Wachsmann, B
   Mueller-Stahl, K
   Boublik, J
   Ruhparwar, A
   Mertsching, H
   Balsam, L
   Robbins, R
   Haverich, A
TI RETRACTED: Clinically established hemostatic scaffold (tissue fleece) as
   biomatrix in tissue- and organ-engineering research (Retracted article.
   See vol. 18, pg. 1529, 2012)
SO TISSUE ENGINEERING
LA English
DT Article; Retracted Publication
ID MARROW STROMAL CELLS; IN-VITRO; CARDIOMYOCYTES; MATRIX; MODEL
AB Various types of three-dimensional matrices have been used as basic scaffolds in myocardial tissue engineering. Many of those are limited by insufficient mechanical function, availability, or biocompatibility. We present a clinically established collagen scaffold for the development of bioartificial myocardial tissue. Neonatal rat cardiomyocytes were seeded into Tissue Fleece (Baxter Deutschland, Heidelberg, Germany). Histological and ultrastructural examinations were performed by DAPI and DiOC(18) staining and electron microscopy, respectively. Force measurements from the spontaneously beating construct were obtained. The constructs were stimulated with agents such as adrenalin and calcium, and by stretching. Passive stretch curves were obtained. Spontaneous contractions of solid bioartificial myocardial tissue (BMT), 20 X 15 X 2 mm, resulted. Contractions continued to week 12 (40% of BMTs) in culture. Histology revealed intercellular and also cell-fibril junctions. Elasticity was similar to that of native rat myocardium. Contractile force increased after topical administration of Ca2+ and adrenaline. Stretch led to the highest levels of contractile force. In summary, bioartificial myocardial tissue with significant in vitro longevity, spontaneous contractility, and homogeneous cell distribution was produced using Tissue Fleece. Tissue Fleece constitutes an effective scaffold to engineer solid organ structures, which could be used for repair of congenital defects or replacement of diseased tissue.
C1 Stanford Univ, Sch Med, Falk Res Ctr, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
   Hannover Med Sch, Div Thorac & Cardiovasc Surg, D-3000 Hannover, Germany.
   Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, D-3000 Hannover, Germany.
RP Kofidis, T (reprint author), Stanford Univ, Sch Med, Falk Res Ctr, Dept Cardiothorac Surg, 2nd Floor,300 Pasteur Dr, Stanford, CA 94305 USA.
EM tkofidis@stanford.edu
RI Kofidis, Theodoros/B-9283-2011; Kofidis, Theodoros/B-9283-2011
OI Kofidis, Theodoros/0000-0002-9623-6450; Akhyari,
   Payam/0000-0002-6452-8678; Kofidis, Theodoros/0000-0002-8938-819X
CR Bursac N, 1999, AM J PHYSIOL-HEART C, V277, pH433
   Eschenhagen T, 1997, FASEB J, V11, P683
   Fink C, 2000, FASEB J, V14, P669
   Hay ED, 1999, FASEB J, V13, pS281
   HOFFMAN RM, 1993, STEM CELLS, V11, P105, DOI 10.1002/stem.5530110205
   Kraft T, 1999, BIOPHYS J, V76, P1494, DOI 10.1016/S0006-3495(99)77309-1
   Li RK, 2000, J THORAC CARDIOV SUR, V119, P368, DOI 10.1016/S0022-5223(00)70193-0
   Li RK, 1999, CIRCULATION, V100, P63
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Medeiros Argelia, 2000, Archivos del Instituto de Cardiologia de Mexico, V70, P46
   MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SIMPSON DG, 1994, J CELL PHYSIOL, V161, P89, DOI 10.1002/jcp.1041610112
   Tomita S, 1999, CIRCULATION, V100, P247
   Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250
   2000, TIS SEEL FIBRIN GLUE
NR 16
TC 26
Z9 30
U1 2
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4947
J9 TISSUE ENG
JI Tissue Eng.
PD JUN
PY 2003
VL 9
IS 3
BP 517
EP 523
DI 10.1089/107632703322066697
PG 7
WC Cell & Tissue Engineering
SC Cell Biology
GA 692VP
UT WOS:000183681200013
PM 12857419
DA 2018-12-27
ER

PT J
AU Chandok, MR
   Ytterberg, AJ
   van Wijk, KJ
   Klessig, DF
AF Chandok, MR
   Ytterberg, AJ
   van Wijk, KJ
   Klessig, DF
TI RETRACTED: The pathogen-inducible nitric oxide synthase (iNOS) in plants
   is a variant of the P protein of the glycine decarboxylase complex
   (Retracted Article. See vol 119, pg 445, 2004)
SO CELL
LA English
DT Article; Retracted Publication
ID SALICYLIC-ACID; DISEASE RESISTANCE; NITRATE REDUCTASE; PHYTOALEXIN
   ACCUMULATION; ARABIDOPSIS-THALIANA; POLYACRYLAMIDE-GELS;
   MASS-SPECTROMETRY; MOLECULAR-CLONING; BINDING-PROTEIN; REACTIVE OXYGEN
AB A growing body of evidence indicates that nitric oxide (NO) plays important signaling roles in plants. However, the enzyme(s) responsible for its synthesis after infection was unknown. Here, we demonstrate that the pathogen-induced, NO-synthesizing enzyme is a variant form of the P protein of glycine decarboxylase (GDC). Inhibitors of the P protein of GDC block its NO synthase (NOS)-like activity, and variant P produced in E. coli or insect cells displays NOS activity. The plant enzyme shares many biochemical and kinetic properties with animal NOSs. However, only a few of the critical motifs associated with NO production in animals can be recognized in the variant P sequence, suggesting that it uses very different chemistry for NO synthesis. Since nitrate reductase is likely responsible for NO production in uninfected or nonelicited plants, our results suggest that plants, like animals, use multiple enzymes for the synthesis of this critical hormone.
C1 Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA.
   Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.
RP Klessig, DF (reprint author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.
EM dfk8@cornell.edu
CR Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Barroso JB, 1999, J BIOL CHEM, V274, P36729, DOI 10.1074/jbc.274.51.36729
   Barroso JB, 2000, AM J PHYSIOL-REG I, V279, pR650
   Beligni MV, 2001, PLANT CELL ENVIRON, V24, P267, DOI 10.1046/j.1365-3040.2001.00672.x
   Biswas TK, 2002, J BIOL CHEM, V277, P45704, DOI 10.1074/jbc.M202565200
   Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030
   Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452
   Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670
   CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143
   Cueto M, 1996, FEBS LETT, V398, P159, DOI 10.1016/S0014-5793(96)01232-X
   Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087
   DEMPSEY DA, 1993, PHYTOPATHOLOGY, V83, P1021, DOI 10.1094/Phyto-83-1021
   Dempsey DA, 1999, CRIT REV PLANT SCI, V18, P547, DOI 10.1080/07352689991309397
   Desikan R, 2002, P NATL ACAD SCI USA, V99, P16314, DOI 10.1073/pnas.252461999
   Dong XN, 2001, CURR OPIN PLANT BIOL, V4, P309, DOI 10.1016/S1369-5266(00)00178-3
   Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1
   Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328
   Durner J, 1999, CURR OPIN PLANT BIOL, V2, P369, DOI 10.1016/S1369-5266(99)00007-2
   Foissner I, 2000, PLANT J, V23, P817, DOI 10.1046/j.1365-313X.2000.00835.x
   FUJIWARA K, 1987, BIOCHEM BIOPH RES CO, V149, P621, DOI 10.1016/0006-291X(87)90413-X
   Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594
   GARVEY EP, 1996, METHOD ENZYMOL, V269, P339
   GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491
   Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   HEVEL JM, 1994, METHOD ENZYMOL, V233, P250
   Kaiser WM, 2002, J EXP BOT, V53, P875, DOI 10.1093/jexbot/53.370.875
   Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Li JS, 1999, J BIOL CHEM, V274, P27658, DOI 10.1074/jbc.274.39.27658
   Mackerness SAH, 2001, FEBS LETT, V489, P237, DOI 10.1016/S0014-5793(01)02103-2
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   MALAMY J, 1992, PLANT CELL, V4, P359
   MATA CG, 2002, PLANT PHYSIOL, V128, P790
   Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X
   McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7
   Modolo LV, 2002, PLANT PHYSIOL, V130, P1288, DOI 10.1104/pp.005850
   MURPHY ME, 1994, METHOD ENZYMOL, V233, P240
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841
   Navarre DA, 1999, PLANT CELL, V11, P237
   NAVARRE DA, 1995, PLANT CELL, V7, P463
   Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.128.1.13
   Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908
   Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304
   REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356
   Ribeiro EA, 1999, FEBS LETT, V445, P283, DOI 10.1016/S0014-5793(99)00138-6
   Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103
   SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x
   Shah J, 1999, PLANT CELL, V11, P191
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Shirato M, 1998, BIOCHEM J, V333, P795, DOI 10.1042/bj3330795
   Stuehr D. J., 1992, ADV ENZYMOL RELAT AR, V65, P287
   STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773
   Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324
   Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill
   Tun NN, 2001, FEBS LETT, V509, P174, DOI 10.1016/S0014-5793(01)03164-7
   Van Camp W, 1998, TRENDS PLANT SCI, V3, P330, DOI 10.1016/S1360-1385(98)01297-7
   Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3
   Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0
   WOLPERT TJ, 1994, PLANT CELL, V6, P1145
   Yamasaki H, 1999, TRENDS PLANT SCI, V4, P128, DOI 10.1016/S1360-1385(99)01393-X
   Yao N, 2002, PLANT J, V30, P567, DOI 10.1046/j.1365-313X.2002.01314.x
NR 65
TC 127
Z9 173
U1 5
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 16
PY 2003
VL 113
IS 4
BP 469
EP 482
DI 10.1016/S0092-8674(03)00350-7
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 680MG
UT WOS:000182981500009
PM 12757708
OA Bronze
DA 2018-12-27
ER

PT J
AU Bulanova, E
   Budagian, V
   Orinska, Z
   Krause, H
   Paus, R
   Bulfone-Paus, S
AF Bulanova, E
   Budagian, V
   Orinska, Z
   Krause, H
   Paus, R
   Bulfone-Paus, S
TI RETRACTED: Mast cells express novel functional IL-15 receptor alpha
   isoforms (Retracted article. See vol. 186, pg. 2682, 2011)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID GAMMA-CHAIN; BETA-CHAIN; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION;
   NATURAL-KILLER; GROWTH-FACTOR; HOST-DEFENSE; CYTOKINE; PROLIFERATION;
   APOPTOSIS
AB Mast cells previously have been reported to be regulated by IL-15 and to express a distinct IL-15R, termed IL-15RX. To further examine IL-15 binding and signaling in mast cells, we have studied the nature of the IL-15R and some of its biological activities in these cells. In this study, we report the existence of three novel isoforms of the IL-15Ralpha chain in murine bone marrow-derived mast cells as a result of an alternative exon-splicing mechanism within the IL-15Ra gene. These correspond to new mRNA transcripts lacking exon 4; exons 3 and 4; or exons 3, 4, and 5 (IL-15RDelta4, IL-15RalphaDelta3,4, IL-15RalphaDelta3,4,5). After transient transfection in COS-7 cells, all IL-15Ralpha isoforms associate with the Golgi apparatus, the endoplasmic reticulum, the perinuclear space, and the cell membrane. Analysis of glycosylation pattern demonstrates the usage of a single N-glycosylation site, while no O-glycosylation is observed. Importantly, IL-15 binds with high affinity to, and promotes the survival of, murine BA/F3 cells stably transfected with the IL-15Ralpha isoforms. Furthermore, we report that signaling mediated by IL-15 binding to the newly identified IL-15Ralpha isoforms involves the phosphorylation of STAT3, STAT5, STAT6, Janus kinase 2, and Syk kinase. Taken together, our data indicate that murine mast cells express novel, fully functional IL-15Ralpha isoforms, which can explain the selective regulatory effects of IL-15 on these cells.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Urol, D-1000 Berlin, Germany.
   Univ Hamburg, Univ Hosp Hamburg Eppendorf, Dept Dermatol, Hamburg, Germany.
RP Bulfone-Paus, S (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM sbulfone@fz-borstel.de
CR ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
   ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
   Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Deutsch HHJ, 1998, CYTOKINE, V10, P331, DOI 10.1006/cyto.1997.0293
   Doherty TM, 1996, J IMMUNOL, V156, P735
   Dooms H, 1998, J IMMUNOL, V161, P2141
   Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978
   Galli SJ, 2002, INT J HEMATOL, V75, P363, DOI 10.1007/BF02982125
   GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x
   GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x
   GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155
   HABIB TS, 2000, BIOCHEMISTRY-US, V41, P8725
   Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x
   HUFF TF, 1997, IMMUNOLOGY METHODS, P1793
   Johnson E W, 1995, J Back Musculoskelet Rehabil, V5, P3, DOI 10.3233/BMR-1995-5103
   Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771
   LANTZ CS, 1995, J IMMUNOL, V155, P4024
   Lehours P, 2000, EUR CYTOKINE NETW, V11, P207
   LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x
   Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0
   LOWENTHAL JW, 1997, CURRENT PROTOCOLS IM
   Malaviya R, 2000, J PHARMACOL EXP THER, V295, P912
   Malaviya R, 1999, J BIOL CHEM, V274, P27028, DOI 10.1074/jbc.274.38.27028
   Masuda A, 2000, J BIOL CHEM, V275, P29331, DOI 10.1074/jbc.M910290199
   Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200
   Musso T, 1999, BLOOD, V93, P3531
   NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0
   Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873
   QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669
   Ruckert R, 2000, J IMMUNOL, V165, P2240, DOI 10.4049/jimmunol.165.4.2240
   Rueckert Rene, 1998, European Journal of Immunology, V28, P3312
   Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6918
   Sherman MA, 1999, J IMMUNOL, V162, P2703
   Smit TH, 2000, J BONE MINER RES, V15, P798
   STANLEY P, 1998, BIOCHEMISTRY-US, P402
   Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179
   SUZUKI K, 2000, BLOOD, V96, P2171
   Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x
   Trentin L, 1997, LEUKEMIA LYMPHOMA, V27, P35, DOI 10.3109/10428199709068269
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0
   WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255
   Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71
NR 50
TC 41
Z9 43
U1 4
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2003
VL 170
IS 10
BP 5045
EP 5055
DI 10.4049/jimmunol.170.10.5045
PG 11
WC Immunology
SC Immunology
GA 676NJ
UT WOS:000182758200021
PM 12734349
OA Bronze
DA 2018-12-27
ER

PT J
AU Sezen, B
   Sames, D
AF Sezen, B
   Sames, D
TI RETRACTED: Selective C-arylation of free (NH)-heteroarenes via catalytic
   C-H bond functionalization (Retracted Article. See vol 128, pg 8364,
   2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID CROSS-COUPLING REACTIONS; ARYL HALIDES; N-ARYLATION;
   NITROGEN-HETEROCYCLES; ARYLBORONIC ACID; COPPER IODIDE; AMINATION;
   CLEAVAGE; INDOLES; COMPLEX
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
RI 丹丹, 李/D-2431-2010
FU NIGMS NIH HHS [R01 GM60326]
CR AKITA Y, 1989, CHEM PHARM BULL, V37, P1477
   Collman JP, 2000, ORG LETT, V2, P1233, DOI 10.1021/ol000033j
   Glover B, 2003, ORG LETT, V5, P301, DOI 10.1021/ol027266q
   Grasa GA, 2001, J ORG CHEM, V66, P7729, DOI 10.1021/jo010613+
   Hartwig JF, 1999, J ORG CHEM, V64, P5575, DOI 10.1021/jo990408i
   Hughes CC, 2002, ANGEW CHEM INT EDIT, V41, P1569, DOI 10.1002/1521-3773(20020503)41:9<1569::AID-ANIE1569>3.0.CO;2-8
   JONES WD, 1995, ORGANOMETALLICS, V14, P855, DOI 10.1021/om00002a037
   Klapars A, 2001, J AM CHEM SOC, V123, P7727, DOI 10.1021/ja016226z
   Kondo Y, 2000, ORG LETT, V2, P3111, DOI 10.1021/ol000183u
   Lam PYS, 2001, TETRAHEDRON LETT, V42, P3415, DOI 10.1016/S0040-4039(01)00510-X
   Lam PYS, 1998, TETRAHEDRON LETT, V39, P2941, DOI 10.1016/S0040-4039(98)00504-8
   LIEBESKIND LS, 1990, J ORG CHEM, V55, P5359, DOI 10.1021/jo00306a012
   Mann G, 1998, J AM CHEM SOC, V120, P827, DOI 10.1021/ja973524g
   Miura M, 2002, TOP CURR CHEM, V219, P211
   Mori A, 2003, J AM CHEM SOC, V125, P1700, DOI 10.1021/ja0269189
   OKURO K, 1993, J ORG CHEM, V58, P4716, DOI 10.1021/jo00069a040
   Old DW, 2000, ORG LETT, V2, P1403, DOI 10.1021/ol005728z
   Pivsa-Art S, 1998, B CHEM SOC JPN, V71, P467, DOI 10.1246/bcsj.71.467
   Sezen B, 2002, J AM CHEM SOC, V124, P13372, DOI 10.1021/ja027891q
   UNDBERG R, 1996, J INDOLES, P105
NR 20
TC 150
Z9 152
U1 6
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 7
PY 2003
VL 125
IS 18
BP 5274
EP 5275
DI 10.1021/ja034848
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 675FL
UT WOS:000182682700014
PM 12720429
DA 2018-12-27
ER

PT J
AU Kennedy, D
AF Kennedy, D
TI RETRACTED: Editorial retraction (I) (Retracted Article)
SO SCIENCE
LA English
DT Correction; Retracted Publication
ID SEE
CR Schon JH, 2003, NATURE, V422, P92, DOI [10.1038/nature01464, 10.1038/nature01463, 10.1038/nature01462]
   Schon JH, 2001, SCIENCE, V294, P2138, DOI 10.1126/science.1066171
   Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520
   SCHON JH, 2002, SCIENCE, V298, P961
   SCHON JH, 2002, SCIENCE         0418, DOI DOI 10.1126/SC2ENCE.1070563
NR 5
TC 0
Z9 0
U1 2
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 2
PY 2003
VL 300
IS 5620
BP 737
EP 737
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 673KH
UT WOS:000182579800016
DA 2018-12-27
ER

PT J
AU Kennedy, D
AF Kennedy, D
TI RETRACTED: Editorial retraction (II) (Retracted Article)
SO SCIENCE
LA English
DT Letter; Retracted Publication
ID PG 93 2003; SEE; SUPERCONDUCTIVITY
CR Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, NATURE, V406, P702, DOI 10.1038/35021011
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2002, SCIENCE, V298, P961, DOI 10.1126/science.298.5595.961b
   Schon JH, 2003, NATURE, V422, P93, DOI [10.1038/nature01467, 10.1038/nature01468]
   Schon JH, 2003, NATURE, V422, P92, DOI [10.1038/nature01464, 10.1038/nature01463, 10.1038/nature01462]
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   Schon JH, 2001, SCIENCE, V293, P2430, DOI 10.1126/science.1064204
NR 8
TC 0
Z9 0
U1 2
U2 21
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 2
PY 2003
VL 300
IS 5620
BP 737
EP 737
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 673KH
UT WOS:000182579800017
DA 2018-12-27
ER

PT J
AU Kumle, B
   Boldt, J
   Suttner, SW
   Piper, SN
   Lehmann, A
   Blome, M
AF Kumle, B
   Boldt, J
   Suttner, SW
   Piper, SN
   Lehmann, A
   Blome, M
TI RETRACTED: Influence of prolonged cardiopulmonary bypass times on
   splanchnic perfusion and markers of splanchnic organ function (Retracted
   article. See vol. 92, pg. 412, 2011)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID PANCREATITIS-ASSOCIATED PROTEIN; GASTRIC INTRAMUCOSAL PH;
   CARDIAC-SURGERY; GASTROINTESTINAL COMPLICATIONS; LIVER-FUNCTION;
   BLOOD-FLOW; ISCHEMIA; NECROSIS
AB Background. Cardiopulmonary bypass (CPB) is known to have considerable negative impact on perfusion and organ function. The effects of the duration of CPB on markers of splanchnic organ function was studied.
   Methods. Consecutive patients undergoing elective aorto-coronary bypass grafting with CPB times (CPBT) of either less than 70 minutes (n = 15) or more than 80 minutes (n = 15) were prospectively studied. Splanchnic perfusion was assessed by measuring arterial and gastric mucosal Pco(2)and calculating Pco(2)gap. Hepatic function was evaluated by monoethylglycinexylidide (MEGX) test and by measuring alpha-glutathione S-transferase (alpha-GST). Concentration of pancreatitis-associated protein was measured to assess pancreatic integrity. Measurements were performed after induction of anesthesia, at the end of surgery, 4 hours after arrival in the intensive care unit, and on postoperative day 1.
   Results. The mean (+/- standard deviation) CPBT were 54 +/- 12 minutes and 99 +/- 16 minutes, respectively. Pco(2)gap increased significantly more in the group with CPBT of more than 80 minutes than in that with CPBT of less than 70 minutes, at +15 +/- 4 mm Hg versus +8 +/- 3 mm Hg, respectively, indicating reduction in splanchnic perfusion by longer CPBTs. Postoperative MEGX concentrations were significantly lower and postoperative alpha-GST concentrations were significantly higher in the group with CPBT of more than 80 minutes than in that with CPBT of less than 70 minutes. Plasma levels of pancreatitis-associated protein remained similar in both groups throughout the study period.
   Conclusions. In our patients with CPBT of more than 80 minutes, splanchnic perfusion and hepatocelluar integrity were moderately affected, whereas pancreatic function remained almost unchanged. Studies including a larger patient population are necessary to assess whether protective approaches would be helpful in patients undergoing complex cardiac surgery with very long CPBT. (C) 2003 by The Society of Thoracic Surgeons.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Dept Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM boldtj@gmx.net
CR ALLEN KB, 1992, J VASC SURG, V16, P391, DOI 10.1016/0741-5214(92)90372-F
   ANDERSEN LW, 1993, CRIT CARE MED, V21, P210, DOI 10.1097/00003246-199302000-00011
   BECKETT GJ, 1993, ADV CLIN CHEM, V30, P281, DOI 10.1016/S0065-2423(08)60198-5
   FERNANDEZDELCASTILLO C, 1991, NEW ENGL J MED, V325, P382
   FIDDIANGREEN RG, 1995, BRIT J ANAESTH, V74, P591, DOI 10.1093/bja/74.5.591
   GAER JAR, 1994, ANN THORAC SURG, V57, P371, DOI 10.1016/0003-4975(94)90999-7
   Groeneveld ABJ, 1999, INTENS CARE MED, V25, P249, DOI 10.1007/s001340050830
   Hall RI, 1997, ANESTH ANALG, V85, P766, DOI 10.1097/00000539-199710000-00011
   IOVANNA JL, 1994, GASTROENTEROLOGY, V106, P728, DOI 10.1016/0016-5085(94)90708-0
   KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5
   KRASNA MJ, 1988, SURGERY, V104, P773
   Levy B, 1997, CRIT CARE MED, V25, P1649, DOI 10.1097/00003246-199710000-00013
   MATHIE RT, 1993, CRIT CARE MED, V21, pS72, DOI 10.1097/00003246-199302001-00013
   MONETA GL, 1985, AM J SURG, V149, P648, DOI 10.1016/S0002-9610(85)80148-3
   OELLERICH M, 1987, J CLIN CHEM CLIN BIO, V25, P845
   OHRI SK, 1993, ANN THORAC SURG, V55, P1080, DOI 10.1016/0003-4975(93)90011-6
   OLDHAM HN, 1984, COMPLICATIONS SURGER, P370
   ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115
   OTT MJ, 1995, ANN THORAC SURG, V59, P1210, DOI 10.1016/0003-4975(95)00133-6
   REDICK JA, 1982, J BIOL CHEM, V257, P5200
   Schlichtig R, 1996, J CRIT CARE, V11, P51, DOI 10.1016/S0883-9441(96)90020-9
   SHIMANUKI K, 1993, SURG TODAY, V23, P315, DOI 10.1007/BF00309048
   Takala J, 1996, BRIT J ANAESTH, V77, P50
   VALENTINE BA, 1990, J VET INTERN MED, V4, P140, DOI 10.1111/j.1939-1676.1990.tb00886.x
   Whitten CW, 1998, ANESTH ANALG, V86, P28, DOI 10.1097/00000539-199801000-00006
   Yilmaz AT, 1996, EUR J CARDIO-THORAC, V10, P763, DOI 10.1016/S1010-7940(96)80337-X
NR 26
TC 31
Z9 32
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2003
VL 75
IS 5
BP 1558
EP 1564
AR PII S0003-4975(02)04903-2
DI 10.1016/S0003-4975(02)04903-2
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 671YP
UT WOS:000182493400039
PM 12735579
DA 2018-12-27
ER

PT J
AU Jauregui-Renaud, K
   Hermosillo, AG
   Gomez, A
   Marquez, MF
   Cardenas, M
   Bronstein, AM
AF Jauregui-Renaud, K
   Hermosillo, AG
   Gomez, A
   Marquez, MF
   Cardenas, M
   Bronstein, AM
TI RETRACTED: Autonomic function interferes in cardiovascular reflexes
   (Retracted Article. See vol 34, pg 444, 2003)
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE vestibular neuritis; autonomic function; heart rate variability;
   vertigo; cardiovascular reflex tests
ID HEART-RATE-VARIABILITY; HUMANS; COLD; RESPONSES; SYNCOPE; TIME; TILT
AB Background. Experimental work indicates that the vestibular system participates in autonomic reflexes during body movement and postural changes. However, there are no studies of cardiovascular reflexes during vertigo due to human acute vestibular lesions.
   Methods. We assessed the response to active change of posture and hand immersion in cold water in seven patients with unilateral peripheral vestibular failure (vestibular neuritis) and seven age/sex-matched healthy subjects in acute phase (72 h from vertigo onset) and at 2 weeks of follow-up.
   Results. During acute phase, patients showed decreased blood pressure response during cold hand test (p <0.05). Upright stance induced deficient decrease of the respiratory component of heart rate variability (p <0.05) with lack of increase in low frequency/high frequency (LF/HF) ratio. At 2 weeks of follow-up, these abnormalities improved.
   Conclusions. Results suggest that acute vestibular lesions can interfere with cardiovascular autonomic responses in humans. This may reflect disruption of normal vestibulo-autonomic reflexes. (C) 2003 IMSS. Published by Elsevier Science Inc.
C1 IMSS, UIM, HG, CMN Raza, Mexico City 02990, DF, Mexico.
   INC, Dept Electrofisiol, SSA, Mexico City, DF, Mexico.
   IMSS, Gen Hosp, Dept Audiol & Otoneurol, CMN Raza, Mexico City, DF, Mexico.
   Univ London Imperial Coll Sci Technol & Med, Acad Dept Neurootol, Div Neurosci, Charing Cross Hosp, London, England.
RP Jauregui-Renaud, K (reprint author), IMSS, UIM, HG, CMN Raza, Av Vallejo & Jacarandas, Mexico City 02990, DF, Mexico.
EM kjauren@data.net.mx
OI Gonzalez-Hermosillo, Jesus Antonio/0000-0002-3563-3081; Marquez,
   Manlio/0000-0001-7294-7330
FU Medical Research Council [MC_U950770497]
CR Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Cooke WH, 1999, J PHYSIOL-LONDON, V517, P617, DOI 10.1111/j.1469-7793.1999.0617t.x
   DOBA N, 1974, CIRC RES, V34, P9, DOI 10.1161/01.RES.34.1.9
   GOLDSTEIN DS, 2002, ATONOMIC NERVOUS SYS, P345
   HAYANO J, 1991, AM J CARDIOL, V67, P199, DOI 10.1016/0002-9149(91)90445-Q
   Jauregui-Renaud K, 2001, ARCH MED RES, V32, P21, DOI 10.1016/S0188-4409(00)00255-1
   Kaufmann H, 2002, EXP BRAIN RES, V143, P463, DOI 10.1007/s00221-002-1002-3
   Kouakam C, 1999, HEART, V82, P312, DOI 10.1136/hrt.82.3.312
   LEBLANC J, 1975, J APPL PHYSIOL, V39, P181
   Levine BD, 1997, CIRCULATION, V96, P517
   MORILLO CA, 1994, AM J CARDIOL, V74, P1258, DOI 10.1016/0002-9149(94)90559-2
   Pitzalis MV, 1996, CARDIOVASC RES, V32, P226, DOI 10.1016/0008-6363(96)00086-7
   Radtke A, 2000, LANCET, V356, P736, DOI 10.1016/S0140-6736(00)02635-0
   Ray CA, 2002, CLIN EXP PHARMACOL P, V29, P98, DOI 10.1046/j.1440-1681.2002.03614.x
   Sarno AJ, 2000, BIOMED SCI INSTRUM, V395, P251
   SAYINALP S, 1994, DIABETES RES CLIN PR, V26, P21, DOI 10.1016/0168-8227(94)90135-X
   Silvoniemi P, 1988, Acta Otolaryngol Suppl, V453, P1
   Singh P I, 1991, J Indian Med Assoc, V89, P229
   Stancak A, 1996, CLIN AUTON RES, V6, P83, DOI 10.1007/BF02291228
   Strupp M, 1999, ADV OTO-RHINO-LARYNG, V55, P111
   TAKENAKA K, 1994, ACTA PHYSIOL SCAND, V150, P59
   Woodring SF, 1997, EXP BRAIN RES, V113, P165
   Yates BJ, 1999, EXP BRAIN RES, V125, P476, DOI 10.1007/s002210050705
NR 24
TC 25
Z9 25
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD MAY-JUN
PY 2003
VL 34
IS 3
BP 200
EP 204
DI 10.1016/S0188-4409(03)00023-7
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 703VF
UT WOS:000184301700007
PM 14567399
DA 2018-12-27
ER

PT J
AU Cui, DX
   Gao, HJ
AF Cui, DX
   Gao, HJ
TI RETRACTED: Advance and prospect of bionanomaterials (Retracted Article.
   See vol 21, pg 650, 2005)
SO BIOTECHNOLOGY PROGRESS
LA English
DT Review; Retracted Publication
ID GENE-EXPRESSION; SUPERCOILED DNA; MOLECULE; PROTEIN; FORCES; PREDICTION;
   MECHANICS; NETWORKS; TOPOLOGY; SYSTEM
AB Over the past few years, bionanomaterial science has emerged as a new exciting field in which theoretical and experimental studies of structure and function of bionanomaterials have become a focus, and the importance of DNA, RNA, and peptides as bionanomaterials to the fundamental development in biology and nanomaterials has begun to be recognized. In particular, biochemistry, biophysics, biomechanics, thermodynamics, and electronic properties of DNA, RNA, and peptides, as well as intelligent composite biological materials, have become a new interdisciplinary frontier in life science and material science. There is an increasing need for a more systematic study of the basic issues involved in bionanomaterials and a more active participation of researchers in the application domain of such novel materials. Great advances have been and are being made in nanobiochip materials, nanoscale biomimetic materials, nanomotors, nanocomposite materials, interface biomaterials, and nanobiosensor and nano drug delivery systems, with enormous prospect in industrial, defense, and clinical medicine applications. Here we review some of the main advances in this field over the past few years, explore the application prospects, and discuss the concepts, issues, approaches, and challenges, with the aim of stimulating a broader interest in developing bionanomaterials technology.
C1 Max Planck Inst Met Res, Bionano Engn Ctr, D-70569 Stuttgart, Germany.
RP Gao, HJ (reprint author), Max Planck Inst Met Res, Bionano Engn Ctr, D-70569 Stuttgart, Germany.
EM hjgao@mf.mpg.de
RI Sanguansri, Luz/B-6630-2011
OI Sanguansri, Luz/0000-0003-1908-7604
CR Ahlquist P, 2002, SCIENCE, V296, P1270, DOI 10.1126/science.1069132
   Arzt E, 1998, ACTA MATER, V46, P5611, DOI 10.1016/S1359-6454(98)00231-6
   BAO G, 2000, MECH BIOL, V242, P25
   Batalia MA, 2002, NANO LETT, V2, P269, DOI 10.1021/nl015672h
   BOUCHIE A, 2001, NATURE, V411, P107
   Bustamante C, 2000, CURR OPIN STRUC BIOL, V10, P279, DOI 10.1016/S0959-440X(00)00085-3
   CAROLE C, 2002, 2002 MRS SPRING M AB, P287
   Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2
   Chicurel ME, 1998, NATURE, V392, P730
   Choy JH, 2000, ANGEW CHEM INT EDIT, V39, P4042
   CUI D, 2002, IFMBE P, V3, P770
   DAVID B, 1999, MRS BULL, V24, P27
   Desai TA, 1999, J MEMBRANE SCI, V159, P221, DOI 10.1016/S0376-7388(99)00062-9
   Doyle PS, 2002, SCIENCE, V295, P2237, DOI 10.1126/science.1068420
   DREXLER K, 1992, NANOSYSTEMS MOL MACH, P253
   Echlin P, 2001, MICROSC MICROANAL, V7, P211
   Elston T, 1998, NATURE, V391, P510
   FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0
   FRANTISEK F, 2002, 2 EUR C EM TECHN BER, pP34
   FRITZ M, 2002, INT WORKSH SOFT SOL
   GANG B, 2002, J APPL PHYS, V92, P2959
   GAO H, 2002, INT WORKSH SOFT SOL
   Garrido MA, 2002, POLYMER, V43, P4495, DOI 10.1016/S0032-3861(02)00254-9
   GEWIRTH A, 1995, NANOSCALE PROBES SOL, P317
   GOLUB A, 2002, E MRS SPRING M
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gorb S, 2000, P ROY SOC B-BIOL SCI, V267, P1239, DOI 10.1098/rspb.2000.1133
   GORB S, 1994, J INSECT PHYSL, V76, P1563
   Gorb SN, 1997, J MORPHOL, V234, P1, DOI 10.1002/(SICI)1097-4687(199710)234:1<1::AID-JMOR1>3.0.CO;2-I
   Haseley SR, 2002, ANAL CHIM ACTA, V457, P39, DOI 10.1016/S0003-2670(01)01329-0
   HIDETOSHI K, 1999, PROTEIN-STRUCT FUNCT, V35, P114
   Horton M, 2002, J RECEPT SIGNAL TR R, V22, P169, DOI 10.1081/RRS-120014594
   Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247
   HOWARD J, 2001, MECH MOTOR PROTEINS, P215
   Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156
   Ikkala O, 2002, SCIENCE, V295, P2407, DOI 10.1126/science.1067794
   Kalamkarov AL, 2002, SMART MATER STRUCT, V11, P423, DOI 10.1088/0964-1726/11/3/313
   Kamionkowski M, 2002, SCIENCE, V296, P267, DOI 10.1126/science.1070877
   KASEMO B, 2002, E MRS SPRING M
   Kast CE, 2002, J CONTROL RELEASE, V81, P347, DOI 10.1016/S0168-3659(02)00077-9
   Khan S, 1997, ANNU REV BIOCHEM, V66, P785, DOI 10.1146/annurev.biochem.66.1.785
   Laine RM, 2001, ADV MATER, V13, P800, DOI 10.1002/1521-4095(200106)13:11<800::AID-ADMA800>3.0.CO;2-G
   LANZA RP, 1995, SCI AM SCI MED, V2, P16
   LAURA JV, 2002, NATURE, V415, P530
   Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172
   Li Jianwei J., 2002, NANO LETT, V2, P315
   Ma L, 2002, MACROMOLECULES, V35, P6178, DOI 10.1021/ma020283a
   Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a
   Mao CD, 1999, NATURE, V397, P144
   Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103
   MASSIMILIANO C, 2002, E MRS SPRING M
   Matsunaga T, 2000, J BIOSCI BIOENG, V90, P1
   MELDRUM FC, 2002, INT WORKSH SOFT SOL
   MODZELEWSKI F, 2002, P SHANGH INT NAN COO, P57
   NAOTO S, 2001, NAT TECHNOL, V19, P332
   Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0
   ORIORDAN A, 2002, EMRS SPRING M
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858
   Rossmann R, 1997, FEBS LETT, V406, P249, DOI 10.1016/S0014-5793(97)00270-6
   Sanchez-Brambila GY, 2002, J FOOD SCI, V67, P1559, DOI 10.1111/j.1365-2621.2002.tb10322.x
   Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111
   SELLERGREN B, 2001, MOL IMPRINTED POLYM, P101
   Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j
   STARK H, 2002, 2 EUR C BERL, P30
   Strick TR, 1998, BIOPHYS J, V74, P2016, DOI 10.1016/S0006-3495(98)77908-1
   Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835
   Tirrell M, 2002, SURF SCI, V500, P61, DOI 10.1016/S0039-6028(01)01548-5
   TORRES C, 2002, E MRS SPRING M
   Vinuesa CG, 2002, NATURE, V416, P595, DOI 10.1038/416595a
   Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0
   Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a
   Yao Y, 1999, NANOSTRUCT MATER, V12, P661, DOI 10.1016/S0965-9773(99)00211-1
   2002, EMBO REP, V3, P307
NR 75
TC 90
Z9 93
U1 8
U2 62
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD MAY-JUN
PY 2003
VL 19
IS 3
BP 683
EP 692
DI 10.1021/bp025791i
PG 10
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 740QN
UT WOS:000186413200001
PM 12790626
DA 2018-12-27
ER

PT J
AU Vayalil, PK
   Elmets, CA
   Katiyar, SK
AF Vayalil, PK
   Elmets, CA
   Katiyar, SK
TI RETRACTED: Treatment of green tea polyphenols in hydrophilic cream
   prevents UVB-induced oxidation of lipids and proteins, depletion of
   antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1
   hairless mouse skin (Retracted article. See vol. 39, pg. 738, 2018)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID KINASE SIGNALING PATHWAYS; ULTRAVIOLET-B RADIATION; EPIDERMAL
   GROWTH-FACTOR; (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT;
   GENE-EXPRESSION; TUMOR PROMOTION; CELL-SURVIVAL; AP-1 ACTIVITY; IN-VIVO;
   CANCER
AB The use of botanical supplements has received immense interest in recent years to protect human skin from adverse biological effects of solar ultraviolet (UV) radiation. The polyphenols from green tea are one of them and have been shown to prevent photocarcinogenesis in animal models but their mechanism of photoprotection is not well understood. To determine the mechanism of photoprotection in in vivo mouse model, topical treatment of polyphenols from green tea (GTP) or its most chemopreventive constituent (-)-epigallocatechin-3-gallate (EGCG) (1 mg/cm(2) skin area) in hydrophilic ointment USP before single (180 mJ/cm(2)) or multiple UVB exposures (180 mJ/cm(2), daily for 10 days) resulted in significant prevention of UVB-induced depletion of antioxidant enzymes such as glutathione peroxidase (78-100%, P < 0.005-0.001), catalase (51-92%, P < 0.001) and glutathione level (87-100%, P < 0.005). Treatment of EGCG or GTP also inhibited UVB-induced oxidative stress when measured in terms of lipid peroxidation (76-95%, P < 0.001), and protein oxidation (67-75%, P > 0.001). Further, to delineate the inhibition of UVB-induced oxidative stress with cell signaling pathways, treatment of EGCG to mouse skin resulted in marked inhibition of a single UVB irradiation-induced phosphorylation of ERK1/2 (16-95%), JNK (46-100%) and p38 (100%) proteins of MAPK family in a time-dependent manner. Identical photoprotective effects of EGCG or GTP were also observed against multiple UVB irradiation-induced phosphorylation of the proteins of MAPK family in vivo mouse skin. Photoprotective efficacy of GTP given in drinking water (d.w.) (0.2%, w/v) was also determined and compared with that of topical treatment of EGCG and GTP. Treatment of GTP in d.w. also significantly prevented single or multiple UVB irradiation-induced depletion of antioxidant enzymes (44-61%, P < 0.01-0.001), oxidative stress (33-71%, P < 0.01) and phosphorylation of ERK1/2, JNK and p38 proteins of MAPK family but the photoprotective efficacy was comparatively less than that of topical treatments of EGCG and GTP. Lesser photoprotective efficacy of GTP in d.w. in comparison with topical application may be due to its less bioavailability in skin target cells. Together, for the first time a cream based formulation of green tea polyphenols was tested in this study to explore the possibility of its use for the humans, and the data obtained from this in vivo study further suggest that GTP could be useful in attenuation of solar UVB light-induced oxidative stress-mediated and MAPK-caused skin disorders in humans.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU NCI NIH HHS [CA94593]; NIEHS NIH HHS [ES11421]
CR AGARWAL R, 1993, PHOTOCHEM PHOTOBIOL, V58, P695, DOI 10.1111/j.1751-1097.1993.tb04954.x
   Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742
   Akerboom T P, 1981, Methods Enzymol, V77, P373
   ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x
   Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595
   Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201
   Bus JS, 1979, REV BIOCHEM TOXICOL, V1, P125
   CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E
   COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843
   DANNO K, 1984, J INVEST DERMATOL, V83, P166, DOI 10.1111/1523-1747.ep12263506
   Dragsted L O, 1998, Arch Toxicol Suppl, V20, P209
   Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3
   Dvorakova K, 1999, CANCER CHEMOTH PHARM, V43, P331, DOI 10.1007/s002800050903
   Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   GIROTTI AW, 1990, PHOTOCHEM PHOTOBIOL, V51, P497, DOI 10.1111/j.1751-1097.1990.tb01744.x
   Guyton KZ, 1996, CANCER RES, V56, P3480
   Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604
   Hong JT, 2001, MOL CARCINOGEN, V31, P152, DOI 10.1002/mc.1050
   Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9
   Johnson TM, 1998, J AM ACAD DERMATOL, V38, P681, DOI 10.1016/S0190-9622(98)70196-3
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276
   Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117
   Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287
   Katiyar SK, 1996, INT J ONCOL, V8, P221
   Katiyar SK, 2001, INT J ONCOL, V18, P1307
   KATIYAR SK, 1994, CANCER LETT, V79, P61, DOI 10.1016/0304-3835(94)90063-9
   Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719
   KATIYAR SK, 1992, CANCER RES, V52, P6890
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807
   Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708
   Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7
   Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899
   McCarty MF, 1998, MED HYPOTHESES, V50, P511, DOI 10.1016/S0306-9877(98)90273-0
   MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5
   Mitchell DL, 1999, CANCER RES, V59, P2875
   Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x
   NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x
   Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2
   PUNNONEN K, 1991, BRIT J DERMATOL, V125, P18, DOI 10.1111/j.1365-2133.1991.tb06032.x
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Sander CS, 2002, J INVEST DERMATOL, V118, P618, DOI 10.1046/j.1523-1747.2002.01708.x
   SEGER R, 1995, FASEB J, V9, P726
   Setlow RB, 1999, J INVEST DERM SYMP P, V4, P46, DOI 10.1038/sj.jidsp.5640180
   SHINDO Y, 1993, J INVEST DERMATOL, V100, P260, DOI 10.1111/1523-1747.ep12469048
   SHINDO Y, 1994, J INVEST DERMATOL, V102, P122, DOI 10.1111/1523-1747.ep12371744
   SOTER NA, 1990, SEMIN DERMATOL, V9, P11
   Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525
   Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22
   SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D
   URBACH F, 1991, DERMATOL CLIN, V9, P751
   WANG BK, 1994, MICROW OPT TECHN LET, V7, P12, DOI 10.1002/mop.4650070106
   Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291
   WANG ZY, 1992, CANCER RES, V52, P1162
   Wargovich M J, 1999, Curr Opin Clin Nutr Metab Care, V2, P421, DOI 10.1097/00075197-199909000-00011
   Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S
   Yu R, 1997, CARCINOGENESIS, V18, P451, DOI 10.1093/carcin/18.2.451
NR 63
TC 168
Z9 184
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAY
PY 2003
VL 24
IS 5
BP 927
EP 936
DI 10.1093/carcin/bgg025
PG 10
WC Oncology
SC Oncology
GA 684YX
UT WOS:000183235000017
PM 12771038
OA Bronze
DA 2018-12-27
ER

PT J
AU Oberle, S
   Abate, A
   Grosser, N
   Hemmerle, A
   Vreman, HJ
   Dennery, PA
   Schneider, HT
   Stalleicken, D
   Schroder, H
AF Oberle, S
   Abate, A
   Grosser, N
   Hemmerle, A
   Vreman, HJ
   Dennery, PA
   Schneider, HT
   Stalleicken, D
   Schroder, H
TI RETRACTED: Endothelial protection by pentaerithrityl trinitrate:
   Bilirubin and carbon monoxide as possible mediators (Retracted Article.
   See vol 232, pg 1119, 2007)
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE cell proliferation; oxidative stress; nitric oxide; atherosclerosis
ID CORONARY-ARTERY DISEASE; CYCLIC-GMP ACCUMULATION; RAT LUNG FIBROBLASTS;
   NITRIC-OXIDE; PENTAERYTHRITOL TETRANITRATE; NITRATE TOLERANCE; OXIDATIVE
   STRESS; HEME OXYGENASE-1; GUANYLATE-CYCLASE; SERUM BILIRUBIN
AB Pentaerithrityl tetranitrate (PETN) is a long-acting donor of nitric oxide (NO) and has recently been characterized as an anti-anginal agent that, in contrast with other nitric acid esters, does not induce oxidative stress and is therefore free of tolerance. Moreover, animal experiments have revealed that PETN actively reduces oxygen radical formation in vivo and specifically prevents atherogenesis and endothelial dysfunction. Because heme oxygenase-1 (HO-1) has been described as an antiatherogenic and cytoprotective gene in the endothelium, our aim was to investigate the effect of the active PETN metabolite penta-erithrityl trinitrate (PETriN) on HO-1 expression and catalytic activity in endothelial cells. Endothelial cells derived from human umbilical vein were incubated with PETriN (0.01-1 mM) for 8 hr. PETriN increased HO-1 mRNA and protein levels in a concentration-dependent fashion up to 3-fold over basal levels. Elevation of HO-1 protein was accompanied by a marked increase in catalytic activity of the enzyme as reflected by enhanced formation of both carbon monoxide and the endogenous antioxidant, bilirubin. Pretreatment of endothelial cells with PETriN or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity. HO-1 induction and endothelial protection by PETriN were not mimicked by isosorbide dinitrate, another long-acting nitrate. The present study demonstrates that the active PETN metabolite, PETriN, stimulates mRNA and protein expression as well as enzymatic activity of the antioxidant defense protein, HO-1, in endothelial cells. Increased HO-1 expression and ensuing formation of bilirubin and carbon monoxide may contribute to and explain the specific antioxidant and antiatherogenic actions of PETN.
C1 Univ Halle Wittenberg, Sch Pharm, Dept Pharmacol & Toxicol, D-06120 Halle An Der Saale, Germany.
   Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
   Univ Appl Sci, Div Pharmacol, D-72488 Sigmaringen, Germany.
RP Schroder, H (reprint author), Univ Halle Wittenberg, Sch Pharm, Dept Pharmacol & Toxicol, Wolfgang Langenbeck Str 4, D-06120 Halle An Der Saale, Germany.
EM schroeder@pharmazie.uni-halle.de
CR Abate A, 2000, FREE RADICAL BIO MED, V29, P1135, DOI 10.1016/S0891-5849(00)00425-1
   ABRAMS J, 1995, ARCH INTERN MED, V155, P357, DOI 10.1001/archinte.155.4.357
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   BOGAERT MG, 1968, ARCH INT PHARMACOD T, V171, P221
   Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015
   Coceani F, 2000, CIRC RES, V86, P1184, DOI 10.1161/01.RES.86.12.1184
   Crandall LA, 1931, J PHARMACOL EXP THER, V41, P103
   CREW MC, 1971, BIOCHEM PHARMACOL, V20, P3077, DOI 10.1016/0006-2952(71)90112-2
   Dikalov S, 1998, J PHARMACOL EXP THER, V286, P938
   Feelisch M., 1996, METHODS NITRIC OXIDE, P71
   Fink B, 1997, J CARDIOVASC PHARM, V30, P831, DOI 10.1097/00005344-199712000-00020
   FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9
   Hacker A, 2001, BRIT J PHARMACOL, V132, P1707, DOI 10.1038/sj.bjp.0704021
   HARRISON DG, 1993, CIRCULATION, V87, P1461, DOI 10.1161/01.CIR.87.5.1461
   Hinz B, 1998, BIOCHEM BIOPH RES CO, V253, P658, DOI 10.1006/bbrc.1998.9845
   Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250
   Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3
   Jurt U, 2001, J AM COLL CARDIOL, V38, P854, DOI 10.1016/S0735-1097(01)01414-0
   KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99
   Kojda G, 1998, EUR J PHARMACOL, V355, P23, DOI 10.1016/S0014-2999(98)00460-9
   KOJDA G, 1995, J CARDIOVASC PHARM, V25, P763, DOI 10.1097/00005344-199505000-00012
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Mayer M, 2000, CLIN CHEM, V46, P1723
   Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107
   Munzel T, 1997, J MOL MED-JMM, V75, P891, DOI 10.1007/s001090050181
   MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637
   Oberle S, 1998, CIRC RES, V82, P1016, DOI 10.1161/01.RES.82.9.1016
   Oberle S, 1999, BIOCHEM BIOPH RES CO, V261, P28, DOI 10.1006/bbrc.1999.0941
   Oberle S, 1997, NITRIC OXIDE-BIOL CH, V1, P308, DOI 10.1006/niox.1997.0132
   Otterbein LE, 2000, NAT MED, V6, P422
   Polte T, 2000, ARTERIOSCL THROM VAS, V20, P1209, DOI 10.1161/01.ATV.20.5.1209
   Polte T, 2002, FREE RADICAL BIO MED, V32, P56, DOI 10.1016/S0891-5849(01)00761-4
   SCHRODER H, 1988, J PHARMACOL EXP THER, V245, P413
   SCHRODER H, 1987, J APPL CARDIOL, V2, P301
   STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
   Suda K, 2001, IN VITRO CELL DEV-AN, V37, P505
   Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443
   VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1
   WEBER AA, 1993, EUR J PHARM-MOLEC PH, V247, P29, DOI 10.1016/0922-4106(93)90134-U
   WEBER W, 1995, ARZNEIMITTEL-FORSCH, V45, P781
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127
   Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815
NR 43
TC 45
Z9 45
U1 4
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD MAY
PY 2003
VL 228
IS 5
BP 529
EP 534
DI 10.1177/15353702-0322805-21
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 833ER
UT WOS:000222319700017
PM 12709581
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Kamohara, H
   Galligan, C
   Faure, M
   Yoshimura, T
AF Matsuyama, W
   Kamohara, H
   Galligan, C
   Faure, M
   Yoshimura, T
TI RETRACTED: Interaction of discoidin domain receptor 1 isoform b (DDR1b)
   with collagen activates p38 mitogen-activated protein kinase and
   promotes differentiation of macrophages (Retracted article. See vol. 23,
   pg. 3251, 2009)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE inflammation; receptor tyrosine kinase; dendritic cells; extracellular
   matrix
ID RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION PATHWAY; HUMAN DENDRITIC
   CELLS; CLASS-II GENES; COSTIMULATORY MOLECULES; EXPRESSION; MATURATION;
   LIPOPOLYSACCHARIDE; CYTOKINES; TRANSCRIPTION
AB Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by collagen. DDR1 is constitutively expressed in a variety of normal and transformed epithelial cells and plays a role in cell migration and differentiation through as yet unidentified signaling pathways. We previously reported inducible expression of DDR1 in human leukocytes and suggested a role for the DDR1a isoform in leukocyte migration through extracellular matrix. Here, we evaluated the contribution of DDR1 in the differentiation of the human monocytic THP-1 cells overexpressing these isoforms and of primary macrophages. Interestingly, collagen activation of DDR1b, but not DDR1a, further promoted phorbol ester-induced differentiation of THP-1 cells as determined by reduced cell proliferation and up-regulated expression of HLA-DR, CD11c, CD14, and CD40. Collagen activation of DDR1b also induced the recruitment and phosphorylation of Shc and subsequent phosphorylation of p38 mitogen-activated protein (MAP) kinase and its substrate ATF2. A p38 MAP kinase inhibitor, SB203580, completely inhibited DDR1b-mediated HLA-DR expression. Activation of DDR1 endogenously expressed on macrophages also up-regulated their HLA-DR expression in a p38 MAP kinase-dependent manner. Thus, DDR1b in response to collagen transduces signals that promote maturation/differentiation of HLA-DR-positive antigen-presenting cells and contributes to the development of adaptive immunity in a tissue microenvironment.
C1 NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA.
   SUGEN Inc, San Francisco, CA 94080 USA.
RP Yoshimura, T (reprint author), NCI, Mol Immunoregulat Lab, Bldg 559,Rm 9, Frederick, MD 21702 USA.
EM yoshimur@mail.ncifcrf.gov
OI Yoshimura, Teizo/0000-0002-3853-2075
CR Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141
   ALVES F, 1995, ONCOGENE, V10, P609
   Alves F, 2001, FASEB J, V15, P1321
   Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837
   ASSEFFA A, 1993, ONCOL RES, V5, P11
   Ayala JM, 2000, J LEUKOCYTE BIOL, V67, P869
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681
   Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810
   Berton G, 1999, CELL SIGNAL, V11, P621, DOI 10.1016/S0898-6568(99)00003-0
   Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600
   Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5
   Brand U, 1998, EUR J IMMUNOL, V28, P1673, DOI 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J
   Carter AB, 2001, J BIOL CHEM, V276, P33826, DOI 10.1074/jbc.M100209200
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821
   DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413
   Foehr ED, 2000, FASEB J, V14, P973
   Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289
   GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.immunol.10.1.13
   Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230
   Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Jacob SS, 2001, BBA-MOL CELL RES, V1540, P50, DOI 10.1016/S0167-4889(01)00116-1
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   L'hote CGML, 2001, FASEB J, V15, P234, DOI 10.1096/fj.01-0414fje
   Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094
   LU L, 1994, J EXP MED, V179, P1823, DOI 10.1084/jem.179.6.1823
   Mahnke K, 1996, J LEUKOCYTE BIOL, V60, P465
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620
   Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776
   Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331
   ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8
   SCHWARTZ RB, 1996, NEUROSURG FOCUS, V1, P1
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9
   TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Verhasselt V, 1997, J IMMUNOL, V158, P2919
   Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vogel W, 1999, FASEB J, V13, pS77
   Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001
   XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931
   YOSHIMURA T, 1993, J IMMUNOL, V150, P5025
NR 49
TC 36
Z9 40
U1 2
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2003
VL 17
IS 8
BP 1286
EP +
DI 10.1096/fj.02-0320fje
PG 29
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 683TE
UT WOS:000183165000041
PM 12738814
DA 2018-12-27
ER

PT J
AU Boldt, J
   Brenner, T
   Lehmann, A
   Lang, J
   Kumle, B
   Werling, C
AF Boldt, J
   Brenner, T
   Lehmann, A
   Lang, J
   Kumle, B
   Werling, C
TI RETRACTED: Influence of two different volume replacement regimens on
   renal function in elderly patients undergoing cardiac surgery:
   comparison of a new starch preparation with gelatin (Retracted article.
   See vol. 37, pg. 1230, 2011)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE cardiac surgery; volume replacement; kidney function; hydroxyethyl
   starch; gelatin; kidney-specific proteins
ID HYDROXYETHYL STARCH; CARDIOPULMONARY BYPASS; URINARY-EXCRETION;
   RISK-FACTORS; REVASCULARIZATION; DYSFUNCTION; OUTCOMES; INJURY; PI
AB Objective: There is continuing concern on the influence of hydroxethyl starch (HES) on renal function. Design: Prospective, randomized study. Setting: University-affiliated medical center. Patients: Forty consecutive patients aged >70 years undergoing cardiac surgery using cardiopulmonary bypass. Interventions: Either low-molecular HES (mean molecular weight: 130 kD) with low degree of substitution (0.4) (6% HES 130/0.4) (n=20) or gelatin (n=20) was given after induction of anesthesia until the 2nd postoperative day (POD) to keep central venous pressure between 12-14 mmHg. Measurements and results: Creatinine clearance (CC) and fractional sodium clearance (FSC) were measured. N-acetyl-beta-D-glucosamidase, alpha-1-microglobulin, glutathione transferase-pi, and glutathione transferase-alpha were measured from urine specimens. Measurements were made after induction of anesthesia, at the end of surgery, and at the first and the second POD. More gelatin (total: 4150+/-490 ml) than HES 130/0.4 (total: 3450+/-450 ml) was infused within the study. CC and FSC were without differences between the two groups. All measured kidney-specific proteins were almost within normal range at baseline. They increased significantly after surgery, however, without significant group differences. At the 2nd POD, kidney-specific proteins had returned almost to normal values. None of the patients developed acute renal failure. Conclusions: Sensitive markers of kidney dysfunction increased in our elderly patients indicating moderate alterations in kidney integrity during cardiac surgery. The two volume replacement regimens did not differ with regard to kidney integrity in elderly patients undergoing cardiac surgery.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Clin Cardiac Surg, D-6700 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR Ascione R, 1999, ANN THORAC SURG, V68, P493, DOI 10.1016/S0003-4975(99)00566-4
   Branten AJW, 2000, NEPHRON, V85, P120, DOI 10.1159/000045644
   Chertow GM, 1997, CIRCULATION, V95, P878
   Chew STH, 2000, ANESTHESIOLOGY, V93, P325, DOI 10.1097/00000542-200008000-00008
   CHINITZ JL, 1971, J LAB CLIN MED, V77, P76
   Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5
   Costa P, 1990, J Cardiothorac Anesth, V4, P469, DOI 10.1016/0888-6296(90)90293-O
   De Labarthe A, 2001, AM J MED, V111, P417, DOI 10.1016/S0002-9343(01)00873-7
   DUKE GJ, 1994, CRIT CARE MED, V22, P1919
   IAINA A, 1994, NEPHRON, V68, P413, DOI 10.1159/000188316
   JORRES A, 1994, ARTIF ORGANS, V18, P565, DOI 10.1111/j.1525-1594.1994.tb03380.x
   Jungheinrich C, 2002, ANESTH ANALG, V95, P544, DOI 10.1213/01.ANE.0000023340.61499.72
   Kulka PJ, 1996, CRIT CARE MED, V24, P947, DOI 10.1097/00003246-199606000-00012
   LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T
   LINDEMAN RD, 1992, DRUG AGING, V2, P423, DOI 10.2165/00002512-199202050-00006
   Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005
   MANGOS GJ, 1995, AUST NZ J MED, V25, P284, DOI 10.1111/j.1445-5994.1995.tb01891.x
   Mantur M, 2000, CLIN NEPHROL, V53, P283
   Marik PE, 1997, J CRIT CARE, V12, P51, DOI 10.1016/S0883-9441(97)90001-0
   MORAN M, 1987, NEW ENGL J MED, V317, P150, DOI 10.1056/NEJM198707163170306
   Morgera S, 2002, CRIT CARE MED, V30, P107, DOI 10.1097/00003246-200201000-00017
   MYTHEN MG, 1994, INTENS CARE MED, V20, P203, DOI 10.1007/BF01704701
   Peron S, 2001, CLIN NEPHROL, V55, P408
   RAHN KH, 1991, CHEST, V100, pS197
   Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2
   SUNDBERG AGM, 1994, NEPHRON, V66, P162, DOI 10.1159/000187795
   Traylor RJ, 1996, ANESTH ANALG, V83, P209, DOI 10.1097/00000539-199608000-00001
   Warren BB, 1997, ANESTH ANALG, V84, P206, DOI 10.1097/00000539-199701000-00037
   WESTHUYZEN J, 1994, CLIN CHIM ACTA, V228, P123, DOI 10.1016/0009-8981(94)90283-6
NR 29
TC 79
Z9 91
U1 2
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAY
PY 2003
VL 29
IS 5
BP 763
EP 769
DI 10.1007/s00134-003-1702-6
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 687EF
UT WOS:000183362600016
PM 12665995
DA 2018-12-27
ER

PT J
AU Shang, E
   Geiger, N
   Sturm, JW
   Post, S
AF Shang, E
   Geiger, N
   Sturm, JW
   Post, S
TI RETRACTED: Pump-assisted versus gravity-controlled enteral nutrition in
   long-term percutaneous endoscopic gastrostomy patients: A prospective
   controlled trial (Retracted article. See vol. 36, pg. 485, 2012)
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article; Retracted Publication
ID CANCER-PATIENTS; FOLLOW-UP; COMPLICATIONS; TUBES
AB Background: Vomiting, aspiration, flatulence, and diarrhea are well-known negative side effects of enteral nutrition through percutaneous endoscopic gastrostomy (PEG). However, it is not yet clarified if pump-assisted (PA) or gravity-controlled (GC) application is the more comfortable and safe choice for long-term nutrition through PEG. Methods: This was a prospective, randomized, crossover study. Fifty long-term PEG patients were fed by PA nutrition (G1) and 50 patients were fed by GC nutrition (G2). Six weeks of observation (O1) was followed by a switch of method of nutritional application in both groups and an additional 6 weeks of observation (O2). Daily determination of comfort and safety was done with a standardized questionnaire. Evaluation of blood glucose levels on days 1, 21, and 42 during O1 and O2. Results: The patients in both groups had the same medical conditions and were of the same age and sex. Far less flatulence (p < .0006) and epigastric fullness (p < .0003) was discovered in G1 during O1. Also, significantly less regurgitation (p < .0002) and vomiting of feeding diet (p < .0001) in G1 versus G2 could be observed. The rate of diarrhea (p < .0003) in G2 was higher than in G1. The daily profile of blood glucose was significantly better (p < .0008) in G1 than in G2. After the nutritional application was changed in O2, the PA group (G2) again showed a significantly better rate of flatulence, epigastric fullness, regurgitation, vomiting, diarrhea, and daily profile of blood glucose. Ninety-six percent of the patients in G2 preferred further nutrition by PA after finishing this study. All patients in G1 continued their accustomed nutrition by PA. Conclusion: Nutrition through PA showed not only a higher comfort rate but also increased safety, which was expressed through a low rate of regurgitation and vomiting. PA presented better glucose metabolization manifested in improved blood glucose levels. As a result of this prospective study, PA is preferable to GC and preferred by patients with long-term PEG nutrition.
C1 Univ Hosp Mannheim, Dept Surg, D-68135 Mannheim, Germany.
RP Shang, E (reprint author), Univ Hosp Mannheim, Dept Surg, Theodore Kutzer Ufer 1-3, D-68135 Mannheim, Germany.
EM Edward.shang@urz.uni-heidelberg.de
CR Chowdhury MA, 1996, J GASTROEN HEPATOL, V11, P835, DOI 10.1111/j.1440-1746.1996.tb00089.x
   CIOCON JO, 1992, JPEN-PARENTER ENTER, V16, P525, DOI 10.1177/0148607192016006525
   FAY DE, 1991, AM J GASTROENTEROL, V86, P1604
   Fietkau R, 1998, STRAHLENTHER ONKOL, V174, P47
   Finocchiaro C, 1997, NUTRITION, V13, P520, DOI 10.1016/S0899-9007(97)00030-0
   HEITKEMPER ME, 1981, JPEN-PARENTER ENTER, V5, P125, DOI 10.1177/0148607181005002125
   HULL MA, 1993, LANCET, V341, P869, DOI 10.1016/0140-6736(93)93072-9
   James A, 1998, AGE AGEING, V27, P671, DOI 10.1093/ageing/27.6.671
   JONES BJM, 1980, LANCET, V1, P1057
   Jordan A, 1999, Z GERONTOL GERIATR, V32, P69
   Mathus-Vliegen LMH, 1999, GASTROINTEST ENDOSC, V50, P746, DOI 10.1016/S0016-5107(99)70153-7
   Moller P, 1999, SCAND J GASTROENTERO, V34, P1050
   Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270
   SARTORI S, 1994, SUPPORT CARE CANCER, V2, P188, DOI 10.1007/BF00417479
   SENFT M, 1993, SUPPORT CARE CANCER, V1, P272, DOI 10.1007/BF00366049
NR 15
TC 9
Z9 10
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD MAY-JUN
PY 2003
VL 27
IS 3
BP 216
EP 219
DI 10.1177/0148607103027003216
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 849WE
UT WOS:000223571300014
PM 12757116
DA 2018-12-27
ER

PT J
AU Stoica, GE
   Franke, TF
   Wellstein, A
   Czubayko, F
   List, HJ
   Reiter, R
   Morgan, E
   Martin, MB
   Stoica, A
AF Stoica, GE
   Franke, TF
   Wellstein, A
   Czubayko, F
   List, HJ
   Reiter, R
   Morgan, E
   Martin, MB
   Stoica, A
TI RETRACTED: Estradiol rapidly activates Akt via the ErbB2 signaling
   pathway (Retracted Article. See vol 18, pg 2096, 2004)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID ESTROGEN-RECEPTOR-ALPHA; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER-CELLS;
   INDEPENDENT PROSTATE-CANCER; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE
   SYNTHASE; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE;
   BINDING-SITES; MCF-7 CELLS
AB Previously, we have demonstrated that the two mitogenic growth factors epidermal growth factor and IGF-I can activate Akt and estrogen receptor-a (ERalpha) in the hormone-dependent breast cancer cell line, MCF-7. In this report we now show that estradiol can also rapidly activate phosphatidylinositol 3-kinase (PI 3-K)/Akt and that this effect is mediated by the ErbB2 signaling pathway. Treatment of cells with estradiol resulted in phosphorylation of Akt and a 9-fold increase in Akt activity in 10 min. Akt activation was blocked by wortmannin and LY 294,002, two inhibitors of PI 3-K; by genistein, a protein tyrosine kinase inhibitor and an ER agonist; by AG825, a selective ErbB2 inhibitor; and by the antiestrogens ICI 182,780 and 4-hydroxy-tamoxifen; but not by rapamycin, an inhibitor of the ribosomal protein kinase p70(S6K); nor by AG30, a selective epidermal growth factor receptor inhibitor. Akt activation by estradiol was abrogated by an arginine-to-cysteine mutation in the pleckstrin homology domain of Akt (R25C). Growth factors also activated Akt in the ER-negative variant of MCF-7, MCF-7/ADR, but estradiol did not induce Akt activity in these cells. Transient transfection of ERalpha into these cells restored Akt activation by estradiol, suggesting that estradiol activation of Akt requires the ERalpha. Estradiol did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. In vitro kinase assays using immunoprecipitation and anti-Akt1, -Akt2, and -Akt3-specific antibodies demonstrated that Akt1 is activated by estradiol in MCF-7 cells whereas Akt3 is the activated isoform in ER-negative MDA-MB231 cells, implying that selective activation of Akt subtypes plays a role in the actions of estradiol. Taken together, our data suggest that estradiol, bound to membrane ERalpha, interacts with and activates an ErbB dimer containing ErbB2, inducing activation of PI 3-K/Akt.
C1 Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA.
   Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.
   Univ Marburg, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany.
   Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20007 USA.
RP Stoica, A (reprint author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.
EM stoicaa@georgetown.edu
OI Wellstein, Anton/0000-0002-0570-4950
CR AHMED NN, 1993, ONCOGENE, V8, P1957
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   ALIMANDI M, 1995, ONCOGENE, V10, P1813
   Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2
   Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699
   ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517
   BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496
   Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111
   Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746
   FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0
   GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896
   Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660
   Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677
   Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200
   Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K
   Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686
   JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171
   Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482
   Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253
   Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0
   KIM HH, 1994, J BIOL CHEM, V269, P24747
   Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257
   KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0
   LAGRANGE AH, 1995, ENDOCRINOLOGY, V136, P2341, DOI 10.1210/en.136.5.2341
   Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144
   Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99
   Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729
   Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503
   MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803
   MCLESKEY SW, 1993, CANCER RES, V53, P2168
   Mermelstein PG, 1996, J NEUROSCI, V16, P595
   METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565
   Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492
   Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419
   PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x
   PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x
   Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011
   RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901
   Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434
   Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307
   Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5
   Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738
   Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930
   SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157
   SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128
   SeppLorenzino L, 1996, ONCOGENE, V12, P1679
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455
   Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T
   Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545
   Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371
   Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8
   Tsai EM, 2001, CANCER RES, V61, P8390
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451
   VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251
   Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348
   Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x
   Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030
   Wen Y, 2000, CANCER RES, V60, P6841
   Wosikowski K, 1997, CLIN CANCER RES, V3, P2405
   Zhang K, 1996, J BIOL CHEM, V271, P3884
NR 76
TC 89
Z9 93
U1 3
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAY
PY 2003
VL 17
IS 5
BP 818
EP 830
DI 10.1210/me.2002.0330
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 671CK
UT WOS:000182447500004
PM 12554767
DA 2018-12-27
ER

PT J
AU Walker, TS
   Bais, HP
   Halligan, KM
   Stermitz, FR
   Vivanco, JM
AF Walker, TS
   Bais, HP
   Halligan, KM
   Stermitz, FR
   Vivanco, JM
TI RETRACTED: Metabolic profiling of root exudates of Arabidopsis thaliana
   (Retracted Article. See vol 57, pg 9346, 2009)
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE Arabidopsis thaliana; Brassicaceae; butanoic acid; trans-cinnamic acid;
   o-coumaric acid; p-coumaric acid; ferulic acid; p-hydroxybenzamide;
   methyl p-hydroxybenzoate; 3-indolepropanoic acid; syringic acid;
   vanillic acid; elicitation
ID TRITICUM-AESTIVUM L.; ANTIMICROBIAL ACTIVITY; PHENYLPROPANOID PATHWAY;
   FUNCTIONAL GENOMICS; PHENOLIC-ACIDS; PLANT-ROOTS; GROWTH;
   ALLELOCHEMICALS; IDENTIFICATION; PRESERVATIVES
AB In addition to accumulating biologically active chemicals, plant roots continuously produce and secrete compounds into their immediate rhizosphere. However, the mechanisms that drive and regulate root secretion of secondary metabolites are not fully understood. To enlighten two neglected areas of root biology, root secretion and secondary metabolism, an in vitro system implementing root-specific elicitation over a 48-day time course was developed. After roots of Arabidopsis thaliana had been elicited with salicylic acid, jasmonic acid, chitosan, and two fungal cell wall elicitors, the secondary metabolites subsequently secreted were profiled. High-performance liquid chromatography was used to metabolically profile compounds in the root exudates, and 289 possible secondary metabolites were quantified. The chemical structures of 10 compounds were further characterized by (1)H and (13)C NMR: butanoic acid, trans-cinnamic acid, o-coumaric acid, p-coumaric acid, ferulic acid, P-hydroxybenzamide, methyl p-hydroxybenzoate, 3-indolepropanoic acid, syringic acid, and vanillic acid. Several of these compounds exhibited a wide range of antimicrobial activity against both soil-borne bacteria and fungi at the concentration detected in the root exudates.
C1 Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
RP Vivanco, JM (reprint author), Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
EM jvivanco@lamar.colostate.edu
RI Rechsteiner, Cynthia/C-5894-2011
CR Aguade M, 2001, MOL BIOL EVOL, V18, P1
   Andow DA, 2001, J ENTOMOL SCI, V36, P285, DOI 10.18474/0749-8004-36.3.285
   Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019
   Bais HP, 2001, IN VITRO CELL DEV-PL, V37, P730
   Bais HP, 2002, PLANT PHYSIOL BIOCH, V40, P983, DOI 10.1016/S0981-9428(02)01460-2
   BARBER DA, 1976, NEW PHYTOL, V76, P69, DOI 10.1111/j.1469-8137.1976.tb01439.x
   Chaves N, 2001, J CHEM ECOL, V27, P611, DOI 10.1023/A:1010336921853
   Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178
   Duez P, 1996, CLIN CHEM, V42, P1609
   El Modafar C, 2001, BIOL PLANTARUM, V44, P125, DOI 10.1023/A:1017942927058
   Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137
   Glassbrook N, 2000, NAT BIOTECHNOL, V18, P1142, DOI 10.1038/81116
   Gleba D, 1999, P NATL ACAD SCI USA, V96, P5973, DOI 10.1073/pnas.96.11.5973
   Hagemeier J, 2001, P NATL ACAD SCI USA, V98, P753, DOI 10.1073/pnas.021551098
   Hudson EA, 2000, CANCER EPIDEM BIOMAR, V9, P1163
   Kneer R, 1999, J EXP BOT, V50, P1553, DOI 10.1093/jexbot/50.339.1553
   Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200
   Lin HJ, 1999, J FOOD DRUG ANAL, V7, P291
   Mandavia MK, 2000, ALLELOPATHY J, V7, P85
   Marschner H., 1995, MINERAL NUTR HIGHER
   MATSUDA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1766, DOI 10.1271/bbb.57.1766
   Matsumoto I, 1996, MASS SPECTROM REV, V15, P43, DOI 10.1002/(SICI)1098-2787(1996)15:1<43::AID-MAS3>3.0.CO;2-B
   MCKINLEY TC, 1993, PLANT PHYSIOL BIOCH, V31, P835
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Ning C, 1996, ACTA PAEDIATR JAPON, V38, P661
   PASTER N, 1988, J APPL BACTERIOL, V64, P293, DOI 10.1111/j.1365-2672.1988.tb01874.x
   Paz-Ares J, 2002, COMPAR FUNCT GENOM, V3, P102, DOI 10.1002/cfg.146
   POUCHERT CJ, 1993, ALDRICH LIB 13C 1H F, V1
   Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11
   Roshchina V.V., 1993, EXCRETORY FUNCTIONS
   Ryan PR, 2001, ANNU REV PLANT PHYS, V52, P527, DOI 10.1146/annurev.arplant.52.1.527
   Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200
   Schultz DJ, 1996, P NATL ACAD SCI USA, V93, P8771, DOI 10.1073/pnas.93.16.8771
   Trethewey RN, 2001, CURR OPIN BIOTECH, V12, P135, DOI 10.1016/S0958-1669(00)00187-7
   van der Watt E, 2001, J ETHNOPHARMACOL, V76, P87, DOI 10.1016/S0378-8741(01)00197-0
   VANETTEN HD, 1994, PLANT CELL, V6, P1191
   Vivanco J. M., 2002, Plant roots: the hidden half, P1045
   WINK M, 1999, FUNCTIONS PLANT SECO, P17
   Wu HW, 2001, J CHEM ECOL, V27, P125, DOI 10.1023/A:1005676218582
   Wu HW, 2000, J AGR FOOD CHEM, V48, P5321, DOI 10.1021/jf0006473
   2000, NATURE, V408, P796
NR 41
TC 95
Z9 102
U1 5
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD APR 23
PY 2003
VL 51
IS 9
BP 2548
EP 2554
DI 10.1021/jf021166h
PG 7
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 669CW
UT WOS:000182335200019
PM 12696935
DA 2018-12-27
ER

PT J
AU Levy, Y
   Ronen, D
   Bershadsky, AD
   Zick, Y
AF Levy, Y
   Ronen, D
   Bershadsky, AD
   Zick, Y
TI RETRACTED: Sustained induction of ERK, protein kinase B, and p70 S6
   kinase regulates cell spreading and formation of F-actin microspikes
   upon ligation of integrins by galectin-8, a mammalian lectin (Retracted
   article. See vol. 293, pg. 7265, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SIGNAL-TRANSDUCTION; SOLUBLE FIBRONECTIN; ADHESION RECEPTORS; FASCIN
   SPIKES; RHO GTPASES; T-CELLS; ACTIVATION; MIGRATION; FAMILY; BINDING
AB Galectin-8, a member of the galectin family of mammalian lectins, is a secreted protein that promotes cell adhesion and migration upon binding to a subset of integrins through sugar-protein interactions. Ligation of integrins by galectin-8 triggers a distinct pattern of cytoskeletal organization, including formation of F-actin-containing microspikes. This is associated with activation of integrin-mediated signaling cascades (ERK and phosphatidylinositol 3 kinase (PI3K)) that are much more robust and are of longer duration than those induced upon cell adhesion to fibronectin. Indeed, formation of microspikes is enhanced 40% in cells that overexpress protein kinase B, the downstream effector of PI3K. Inhibition of PI3K activity induced by wortmannin partially inhibits cell adhesion and spreading while largely inhibiting microspike formation in cells adherent to galectin-8. Furthermore, the inhibitory effects of wortmannin are markedly accentuated in cells overexpressing PKB or p70S6K (CHOPKB and CHOp70S6K cells), whose adhesion and spreading on galectin-8 (but not on fibronectin) is inhibited similar to25-35% in the presence of wortmannin. The above results suggest that galectin-8 is an extracellular matrix protein that triggers a unique repertoire of integrin-mediated signals, which leads to a distinctive cytoskeletal organization and microspike formation. They further suggest that downstream effectors of PI3K, including PKB and p70 S6 kinase, in part mediate cell adhesion, spreading, and microspike formation induced by galectin-8.
C1 Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
RP Zick, Y (reprint author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
EM yehiel.zick@weizmann.ac.il
CR Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807
   ADAMS JC, 1995, J CELL SCI, V108, P1977
   ADLER R, 1985, DEV BIOL, V112, P100, DOI 10.1016/0012-1606(85)90124-1
   ALBRECHTBUEHLER G, 1976, J CELL BIOL, V71, P370, DOI 10.1083/jcb.71.2.370
   Aplin AE, 1998, PHARMACOL REV, V50, P197
   Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X
   BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7
   Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X
   CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4
   Camby I, 2001, BRAIN PATHOL, V11, P12
   CHIQUETEHRISMANN R, 1995, CURR OPIN CELL BIOL, V7, P715, DOI 10.1016/0955-0674(95)80114-6
   Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X
   Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881
   Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137
   deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005
   Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0
   FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155
   Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9
   Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Guvakova MA, 2002, J CELL SCI, V115, P4149, DOI 10.1242/jcs.00104
   Guvakova MA, 2002, INT J BIOCHEM CELL B, V34, P685, DOI 10.1016/S1357-2725(01)00160-1
   Hadari YR, 2000, J CELL SCI, V113, P2385
   Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103
   HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447
   Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4
   Hughes RC, 2001, BIOCHIMIE, V83, P667
   Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0968-0004(99)01479-6
   IZZARD CS, 1980, J CELL SCI, V42, P81
   Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133
   Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083
   King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406
   Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200
   Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200
   Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785
   MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0
   Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83
   Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392
   PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0
   Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863
   QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A
   Rabinovich GA, 2002, J LEUKOCYTE BIOL, V71, P741
   REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052
   Ridley AJ, 2001, J CELL SCI, V114, P2713
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5
   Sambrook J, 1989, MOL CLONING LABORATO, P16
   Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65
   Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3
   Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252
   TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265
   Vestweber D, 1999, PHYSIOL REV, V79, P181
   WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237
   Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.0.CO;2-B
   YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29
NR 57
TC 66
Z9 69
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 18
PY 2003
VL 278
IS 16
BP 14533
EP 14542
DI 10.1074/jbc.M207380200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 670JV
UT WOS:000182405000121
PM 12569102
OA Bronze
DA 2018-12-27
ER

PT J
AU Mizutani, A
   Okajima, K
   Uchiba, M
   Isobe, H
   Harada, N
   Mizutani, S
   Noguchi, T
AF Mizutani, A
   Okajima, K
   Uchiba, M
   Isobe, H
   Harada, N
   Mizutani, S
   Noguchi, T
TI RETRACTED: Antithrombin reduces ischemia/reperfusion-induced renal
   injury in rats by inhibiting leukocyte activation through promotion of
   prostacyclin production (Retracted article. See vol. 122, pg. 302, 2013)
SO BLOOD
LA English
DT Article; Retracted Publication
ID KAPPA-B ACTIVATION; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS;
   AFFINITY-CHROMATOGRAPHY; III SUPPLEMENTATION; BLOOD-COAGULATION; SEVERE
   SEPSIS; CYCLIC-AMP; MICE; PROSTAGLANDINS
AB Antithrombin (AT) supplementation in patients with severe sepsis has been shown to improve organ failures in which activated leukocytes are critically involved. However, the precise mechanism(s). for the therapeutic effects of AT is not well understood. We examined in rats whether AT reduces ischemia/reperfusion (VR)-induced renal injury by inhibiting leukocyte activation. AT markedly reduced the I/R-induced renal dysfunction and histologic changes, whereas neither dansyl glutamylglycylarginyl chloromethyl ke-tone-treated factor Xa (DEGR-F.-Xa), a selective inhibitor of thrombin generation, nor Trp49-modified AT, which lacks affinity for heparin, had any effect. Renal tissue levels of 6-keto-PGF(1alpha), a stable metabolite of prostacyclin (PGI(2)), increased after renal I/R. AT enhanced the I/R-induced increases. in renal tissue levels of 6-keto-PGF(1alpha),, Whereas neither DEGR-F.Xa nor Trp49-modified AT had any effect. AT significantly inhibited I/R-induced decrease in renal tissue blood flow and the increase in the vascular permeability. Ischemia/reperfusion-induced increases in renal tissue levels of tumor necrosis factor-alpha, cytokine-induced neutrophil chemoattractant, and myeloperoxidase Were significantly inhibited in.,animals given AT. Pretreatment of animals with indomethacin reversed the effects induced by AT. lloprost, an analog, of PGI(2), produced effects similar to those induced by AT. These observations strongly suggest that AT reduces the I/R-induced renal injury by inhibiting leukocyte activation. The therapeutic effects of AT might be mainly mediated by PGI(2) released from endothelial cells through interaction of AT with cell surface glycosaminoglycans. (C) 2003 by The American Society of Hematology.
C1 Kumamoto Univ, Sch Med, Dept Lab Med, Kumamoto 8600811, Japan.
   Oita Med Univ, Intens Care Unit, Oita, Japan.
   Fukuoka Univ, Sch Med, Dept Pharmacol, Fukuoka 81401, Japan.
   Oita Med Univ, Dept Maternal Pediat Nursing, Oita, Japan.
RP Okajima, K (reprint author), Kumamoto Univ, Sch Med, Dept Lab Med, Honjo 1-1-1, Kumamoto 8600811, Japan.
EM whynot@kaiju.medic.kumamoto-u.ac.jp
CR Altavilla D, 2001, FREE RADICAL BIO MED, V30, P1055, DOI 10.1016/S0891-5849(01)00492-0
   BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531
   Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272
   D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0
   Druid H, 1998, INT J EXP PATHOL, V79, P55, DOI 10.1046/j.1365-2613.1998.00055.x
   Dunzendorfer S, 2001, BLOOD, V97, P1079, DOI 10.1182/blood.V97.4.1079
   EMERSON TE, 1989, AM J MED S3B, V87, P27
   Harada N, 2002, J LAB CLIN MED, V139, P218, DOI 10.1067/mlc.2002.121856
   HARADA N, 2001, BLOOD, V98, pA1084
   Heger A, 2002, THROMB RES, V106, P157, DOI 10.1016/S0049-3848(02)00097-X
   Inthorn D, 1997, SHOCK, V8, P328, DOI 10.1097/00024382-199711000-00003
   Inthorn D, 1998, SHOCK, V10, P90, DOI 10.1097/00024382-199808000-00002
   Isobe H, 2002, BLOOD, V99, P1638, DOI 10.1182/blood.V99.5.1638
   IVANYI B, 1983, AM J PATHOL, V113, P300
   KARP GI, 1984, ARCH BIOCHEM BIOPHYS, V233, P712, DOI 10.1016/0003-9861(84)90498-3
   KAWABATA K, 1991, BIOCHEM BIOPH RES CO, V177, P814, DOI 10.1016/0006-291X(91)91862-7
   Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498
   Lane DA, 1997, THROMB HAEMOSTASIS, V77, P197
   MANN KG, 1984, PROG HEMOST THROMB, V7, P1
   MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2
   Mizutani A, 2000, BLOOD, V95, P3781
   MONCADA S, 1978, PHARMACOL REV, V30, P293
   MORITA T, 1986, J BIOL CHEM, V261, P4008
   NESHEIM ME, 1981, J BIOL CHEM, V256, P6537
   Oelschlager C, 2002, BLOOD, V99, P4015, DOI 10.1182/blood.V99.11.4015
   Ohishi S, 1996, EUR J PHARMACOL, V300, P255, DOI 10.1016/0014-2999(96)00005-2
   Okajima K, 2001, IMMUNOL REV, V184, P258, DOI 10.1034/j.1600-065x.2001.1840123.x
   OKAJIMA K, 1993, BLOOD, V81, P1300
   Okano J, 1997, HEPATOLOGY, V26, P1241
   Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828
   RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779
   RAMOS E, 1994, TRANSPLANTATION, V58, P140, DOI 10.1097/00007890-199405820-00003
   ROSENZWEIG SM, 1989, COMMENTARY, V87, P2
   Singbartl K, 2001, FASEB J, V15, P2337, DOI 10.1096/fj.01-0199com
   Souter PJ, 2001, CRIT CARE MED, V29, P134, DOI 10.1097/00003246-200101000-00027
   Taoka Y, 1998, J NEUROSCI, V18, P1393
   UCHIBA M, 1995, THROMB RES, V80, P201, DOI 10.1016/0049-3848(95)00168-Q
   Uchiba M, 2001, THROMB HAEMOSTASIS, V86, P722
   Uchiba M, 1998, THROMB RES, V89, P233, DOI 10.1016/S0049-3848(98)00012-7
   UCHIBA M, 1996, AM J PHYSIOL, V270, P921
   WATANABE K, 1992, EXP MOL PATHOL, V56, P60, DOI 10.1016/0014-4800(92)90023-5
NR 41
TC 89
Z9 95
U1 2
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 15
PY 2003
VL 101
IS 8
BP 3029
EP 3036
DI 10.1182/blood-2002-08-2406
PG 8
WC Hematology
SC Hematology
GA 665CE
UT WOS:000182101400025
PM 12480701
OA Bronze
DA 2018-12-27
ER

PT J
AU Stoica, GE
   Franke, TF
   Wellstein, A
   Morgan, E
   Czubayko, F
   List, HJ
   Reiter, R
   Martin, MB
   Stoica, A
AF Stoica, GE
   Franke, TF
   Wellstein, A
   Morgan, E
   Czubayko, F
   List, HJ
   Reiter, R
   Martin, MB
   Stoica, A
TI RETRACTED: Heregulin-beta 1 regulates the estrogen receptor-alpha gene
   expression and activity via the ErbB2/PI 3-K/Akt pathway (Retracted
   Article. See vol 24, pg 1964, 2005)
SO ONCOGENE
LA English
DT Review; Retracted Publication
DE estrogen receptor; HRG-beta 1; ErbB2; Akt
ID BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B;
   SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER-RIBONUCLEIC-ACID;
   STEROID-HORMONE RECEPTORS; MAMMARY-TUMOR CELLS; ATHYMIC NUDE-MICE;
   PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITES
AB This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-alpha (ER-alpha) pathways. Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-beta1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-beta1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-alpha into these cells restored Akt phosphorylation by HRG-beta1, suggesting the requirement of ER-alpha. HRG-beta1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-beta1 on ER-alpha expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-beta1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on ER-alpha expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-a regulation. Taken together, our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-alpha phosphorylation, thereby altering its expression and transcriptional activity.
C1 Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA.
   Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.
   Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20007 USA.
   Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany.
RP Stoica, A (reprint author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.
EM stoicaa@georgetown.edu
OI Wellstein, Anton/0000-0002-0570-4950
FU NCI NIH HHS [P30-CA-51008, P50-CA-58185]
CR Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993
   AHMED NN, 1993, ONCOGENE, V8, P1957
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4
   Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515
   Angus WGR, 2000, MOL CELL ENDOCRINOL, V170, P1, DOI 10.1016/S0303-7207(00)00337-3
   ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0
   Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368
   BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412
   BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6
   BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I
   BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x
   BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4
   Brockhoff G, 2001, CYTOMETRY, V44, P338, DOI 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111
   CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9
   Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731
   CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267
   Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121
   Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614
   Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144
   DAUVOIS S, 1993, J CELL SCI, V106, P1377
   DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112
   DOUGALL WC, 1994, ONCOGENE, V9, P2109
   DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0
   ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928
   ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9
   FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0
   GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896
   GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417
   GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6
   GULLICK WJ, 1991, HUM EXP TOXICOL, V10, P398, DOI 10.1177/096032719101000604
   GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049
   HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706
   Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534
   HODA K, 2000, J NEUROSCI RES, V60, P321
   HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205
   Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196
   HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4
   IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658
   IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992
   Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686
   Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482
   Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472
   Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200
   KIM HH, 1994, J BIOL CHEM, V269, P24747
   Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257
   KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x
   Klippel A, 1996, MOL CELL BIOL, V16, P4117
   KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654
   KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193
   Kurokawa H, 2000, CANCER RES, V60, P5887
   Lichtner RB, 1999, J STEROID BIOCHEM, V71, P181, DOI 10.1016/S0960-0760(99)00136-3
   Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144
   LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783
   LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018
   Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784
   LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195
   Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729
   Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503
   MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803
   MCLESKEY SW, 1993, CANCER RES, V53, P2168
   Menard S, 2000, J NATL CANCER I, V92, P943
   Mermelstein PG, 1996, J NEUROSCI, V16, P595
   METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579
   MIMNAUGH EG, 1991, BIOCHEM PHARMACOL, V42, P391, DOI 10.1016/0006-2952(91)90727-M
   Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1
   NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981
   ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105
   PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103
   PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U
   PIERCE JH, 1991, ONCOGENE, V6, P1189
   PIETRAS RJ, 1995, ONCOGENE, V10, P2435
   PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746
   PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x
   Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533
   QUENEL N, 1995, BREAST CANCER RES TR, V35, P283, DOI 10.1007/BF00665980
   RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901
   Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307
   READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295
   READ LD, 1990, CANCER RES, V50, P3947
   Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738
   RUSSELL KS, 1992, CANCER RES, V52, P6624
   SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157
   Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322
   SeppLorenzino L, 1996, ONCOGENE, V12, P1679
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661
   SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550
   Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455
   Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T
   Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371
   Stoica A, 1997, ENDOCRINOLOGY, V138, P1498, DOI 10.1210/en.138.4.1498
   STOICA GE, 2003, UNPUB ONCOGENE
   STOICA GE, 2003, IN PRESS MOL ENDOCRI
   Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200
   Tan M, 1999, CANCER RES, V59, P1620
   Tang CK, 1996, CANCER RES, V56, P3350
   TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471
   TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411
   Tsutsui S, 2002, J SURG ONCOL, V79, P216, DOI 10.1002/jso.10079
   TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25
   ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0
   Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030
   Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657
   Wosikowski K, 1997, CLIN CANCER RES, V3, P2405
   WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54
   Yamamoto T, 1986, Princess Takamatsu Symp, V17, P203
   Yoo JY, 1998, BREAST CANCER RES TR, V51, P71, DOI 10.1023/A:1006035603635
   Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027
NR 118
TC 38
Z9 38
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR 10
PY 2003
VL 22
IS 14
BP 2073
EP 2087
DI 10.1038/sj.onc.1206311
PG 15
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 664NJ
UT WOS:000182066900002
PM 12687010
OA Bronze
DA 2018-12-27
ER

PT J
AU Manjubhashini, AB
   Raman, GK
   Kumar, AS
   Chiranjeevi, P
AF Manjubhashini, AB
   Raman, GK
   Kumar, AS
   Chiranjeevi, P
TI RETRACTED: A simple spectrophotometric technique for the determination
   of carbaryl pesticides in various environments (Retracted Article. See
   vol 75, pg 1147, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE carbaryl; pesticides; spectrophotometric
ID FORMULATIONS; PROPOXUR; WATER
AB A simple, convenient, sensitive and rapid spectrophotometric technique is reported for the analysis of the pesticide carbaryl in its formulations, water and food grains. New coupling/complexing agents namely 2-amino, 4-nitrophenol and 2,4-dimethoxy aniline were employed. The formation of colour with these coupling agents are instantaneous and stable for 24 and 10 h, respectively. The lambda max observed for these coloured complexes were at 520 and 510 nm, respectively. (C) 2003 Elsevier Science B.V. All rights reserved.
C1 Sri Venkateswara Univ, USIC, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Chem, Tirupati 517502, Andhra Pradesh, India.
   Pondicherry Engn Coll, Dept Chem, Pondicherry 605104, India.
RP Kumar, AS (reprint author), Sri Venkateswara Univ, USIC, Tirupati 517502, Andhra Pradesh, India.
EM askumar_usic@hotmail.com
CR AGRAWAL V, 1992, J INDIAN CHEM SOC, V69, P574
   FREIXA A, 1982, PERGAMAN SER ENV SCI, V17, P297
   JOSHI NP, 1976, J INDIAN ACAD FORENS, V15, P44
   KHALAF KD, 1993, ANAL CHIM ACTA, V280, P231, DOI 10.1016/0003-2670(93)85126-5
   MATHEW L, 1995, ANALYST, V120, P1799, DOI 10.1039/an9952001799
   RAMASAMY M, 1974, PESTIC SCI, V5, P383, DOI 10.1002/ps.2780050403
   SASTRY CSP, 1987, TALANTA, V34, P372, DOI 10.1016/0039-9140(87)80051-6
   SASTRY CSP, 1987, ANALYST, V112, P75, DOI 10.1039/an9871200075
   SASTRY CSP, 1986, FOOD CHEM, V20, P157, DOI 10.1016/0308-8146(86)90152-4
NR 9
TC 10
Z9 10
U1 4
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD APR 10
PY 2003
VL 59
IS 5
BP 1015
EP 1019
DI 10.1016/S0039-9140(03)00007-9
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 671ZA
UT WOS:000182494500020
PM 18968992
DA 2018-12-27
ER

PT J
AU Yamaguchi, R
   Newport, J
AF Yamaguchi, R
   Newport, J
TI RETRACTED: A role for Ran-GTP and Crm1 in blocking re-replication
   (Retracted Article. See vol 119, pg 145, 2004)
SO CELL
LA English
DT Article; Retracted Publication
ID ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; CELL-CYCLE; XENOPUS-LAEVIS;
   NUCLEAR EXPORT; EGG EXTRACTS; S-PHASE; CHROMATIN ASSOCIATION; MULTIPLE
   MECHANISMS; KINASE-ACTIVITY
AB All eukaryotic cells have regulatory mechanisms that limit genomic replication to a single round each cell cycle. These systems function by blocking formation of prereplication complexes. The regulatory mechanisms in the yeast S. cerevisiae have been identified, but these do not appear to be conserved in metazoans. Using Xenopus egg extracts, we have identified a metazoan-specific regulatory system that limits replication to a single round. We show that during S phase, soluble MCM helicase, an essential initiation factor, is inactivated when it associates with exportin-1/Crm1. Formation of this complex is dependent on both high Ran-GTP and cdk2 kinase activity. Lowering Ran-GTP within nuclei or nuclear extracts allows MCM to reassociate with chromatin during S phase and induces re-replication. Importantly, prevention of re-replication requires MCM-Crm1 complex formation, but it does not require export of MCM from the nucleus. Therefore, in metazoans, Crm1 functions in both nuclear export and blocking of re-replication.
C1 Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.
RP Newport, J (reprint author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM jnewport@ucsd.edu
OI Yamaguchi, Ryuji/0000-0002-1706-7063
FU NIGMS NIH HHS [R01GM33523]
CR Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425
   BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x
   BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0
   Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2
   Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7
   DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G
   Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200
   Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x
   Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3
   Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9
   Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183
   Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271
   Hughes M, 1998, J CELL SCI, V111, P3017
   Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193
   Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798
   Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645
   Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2
   Labib K, 1999, NAT CELL BIOL, V1, P415
   Lee SH, 2002, J BIOL CHEM, V277, P23358, DOI 10.1074/jbc.M111559200
   Lei M, 2001, J CELL SCI, V114, P1447
   Lounsbury KM, 1997, J BIOL CHEM, V272, P551
   Maiorano D, 2000, NATURE, V404, P622
   McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199
   McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X
   Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000
   Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600
   Nilsson J, 2001, J MOL BIOL, V305, P231, DOI 10.1006/jmbi.2000.4313
   Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x
   Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200
   Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263
   Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300
   Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X
   POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9
   Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201
   SMYTHE C, 1991, METHOD CELL BIOL, V35, P449
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0
   Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309
   Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200
   Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648
NR 41
TC 35
Z9 38
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 4
PY 2003
VL 113
IS 1
BP 115
EP 125
DI 10.1016/S0092-8674(03)00200-9
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 668GX
UT WOS:000182282900011
PM 12679039
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: The effect of inhaled colforsin daropate on contractility of
   fatigued diaphragm in dogs (Retracted article. See vol. 116, pg. 747,
   2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID MUSCLE FATIGUE
AB We studied the effect of inhaled colforsin daropate, a water-soluble forskolin derivative, on the contractility of fatigued diaphragm in dogs. Animals were divided into 3 groups of 8. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20-Hz stimulation applied for 30 min. Immediately after the end of the fatigue-producing period, Group 1 received inhaled vehicle, Group 2 received inhaled colforsin daropate 0.1 mg/mL, and Group 3 received inhaled colforsin daropate 0.2 mg/mL. We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). After fatigue was produced, in each group, Pdi at low-frequency (20-Hz) stimulation decreased from baseline values (P < 0.05), and there was no change in Pdi at high-frequency (100-Hz) stimulation. In Groups 2 and 3, during colforsin daropate inhalation, Pdi at both stimuli increased from fatigued values (P < 0.05). The increase in Pdi was significantly larger in Group 3 than in Group 2. The integrated electrical activity of the diaphragm did not change in any group. We conclude that inhaled colforsin daropate causes an increase in contractility of fatigued canine diaphragm in a dose-related fashion.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   Fujii Y, 2001, ANESTH ANALG, V92, P762, DOI 10.1213/00000539-200103000-00039
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Uemura A, 2002, BRIT J ANAESTH, V88, P408, DOI 10.1093/bja/88.3.408
   Wajima Z, 2002, CRIT CARE MED, V30, P820, DOI 10.1097/00003246-200204000-00017
NR 6
TC 1
Z9 1
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD APR
PY 2003
VL 96
IS 4
BP 1032
EP 1034
DI 10.1213/01.ANE.0000052512.46939.2E
PG 3
WC Anesthesiology
SC Anesthesiology
GA 659ZB
UT WOS:000181808300022
PM 12651654
DA 2018-12-27
ER

PT J
AU Meier, S
   Brauer, AU
   Heimrich, B
   Schwab, ME
   Nitsch, R
   Savaskan, NE
AF Meier, S
   Brauer, AU
   Heimrich, B
   Schwab, ME
   Nitsch, R
   Savaskan, NE
TI RETRACTED: Molecular analysis of Nogo expression in the hippocampus
   during development and following lesion and seizure (Retracted article.
   See vol. 25, pg. 2853, 2011)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE axonal growth inhibitors; entorhinal cortex lesion; reticulons; kainic
   acid-induced seizure; axonal plasticity
ID NEURITE GROWTH-INHIBITORS; CHONDROITIN SULFATE PROTEOGLYCAN; ENTORHINAL
   CORTEX LESION; MYELIN-ASSOCIATED GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM;
   SPINAL-CORD-INJURY; DENTATE GYRUS; ADULT-RAT; AXONAL REGENERATION;
   MESSENGER-RNA
AB The Nogo gene encodes an integral membrane protein mainly responsible for the neurite inhibition properties of myelin. Here, we analyzed the expression pattern of Nogo-A, Nogo-B, and Nogo-C and Nogo-66 receptor (Ng66R) mRNA during hippocampal development and lesion-induced axonal sprouting. Nogo-A and Nogo-B and Ng66R transcripts preceded the progress of myelination and were highly expressed at postnatal day zero (P0) in all principal hippocampal cell layers, with the exception of dentate granule cells. Only a slight Nogo-C expression was found at P0 in the principal cell layers of the hippocampus. During adulthood, all Nogo splice variants and their receptor were expressed in the neuronal cell layers of the hippocampus, in contrast to the myelin basic protein mRNA expression pattern, which revealed a neuronal source of Nogo gene expression in addition to oligodendrocytes. After hippocampal denervation, the Nogo genes showed an isoform-specific temporal regulation. All Nogo genes were strongly regulated in the hippocampal cell layers, whereas the Ng66R transcripts showed a significant increase in the contralateral cortex. These data could be confirmed on protein levels. Furthermore, Nogo-A expression was up-regulated after kainate-induced seizures. Our data show that neurons express Nogo genes with a clearly distinguishable pattern during development. This expression is further dynamically and isoform-specifically altered after lesioning during the early phase of structural rearrengements. Thus, our results indicate a role for Nogo-A, -B, and -C during development and during the stabilization phase of hippocampal reorganization. Taken together with these data, the finding that neurons in a highly plastic brain region express Nogo genes supports the hypothesis that Nogo may function beyond its known neuronal growth inhibition activity in shaping neuronal circuits.
C1 Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany.
   Univ Zurich, Dept Neuromorphol, Brain Res Inst, Zurich, Switzerland.
   Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland.
RP Savaskan, NE (reprint author), Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, Oskar Hertwig House,Philippstr 12, D-10098 Berlin, Germany.
EM nicolai.savaskan@charite.de
RI Schwab, Martin/B-6818-2016; Braeuer, Anja/K-8339-2013
OI Savaskan, Nicolai/0000-0003-1348-094X
CR Alcantara S, 2000, DEVELOPMENT, V127, P1359
   Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022
   BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3
   BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W
   Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x
   BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305
   Bovolenta P, 1997, EUR J NEUROSCI, V9, P977, DOI 10.1111/j.1460-9568.1997.tb01448.x
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Brauer AU, 2001, FASEB J, V15, P2689, DOI 10.1096/fj.01-0235com
   BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0
   Brittis PA, 2001, NEURON, V30, P11, DOI 10.1016/S0896-6273(01)00258-6
   Brosamle C, 2000, J NEUROSCI, V20, P8061
   Buffo A, 2000, J NEUROSCI, V20, P2275
   CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M
   CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7
   CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281
   Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219
   COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x
   DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034
   DELLER T, 1995, J NEUROSCI, V15, P6868
   Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0
   DOU CL, 1994, J NEUROSCI, V14, P7616
   Forster E, 2001, DEVELOPMENT, V128, P3029
   Fournier AE, 2002, PROG BRAIN RES, V137, P361
   Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072
   Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1
   FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400
   GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306
   Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073
   GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226
   Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507
   GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a
   Haas CA, 1999, J NEUROSCI, V19, P9953
   Hens J, 1998, CELL TISSUE RES, V292, P229, DOI 10.1007/s004410051054
   Holder N, 1999, DEVELOPMENT, V126, P2033
   Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559
   Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x
   Huber AB, 2002, J NEUROSCI, V22, P3553
   HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172
   Josephson A, 2001, EXP NEUROL, V169, P319, DOI 10.1006/exnr.2001.7659
   KOVACS A, 2001, SOC NEUR ABSTR, V27, P253
   LIU BP, 2002, SCIENCE         0627
   MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9
   MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2
   MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X
   MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6
   Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999
   OERTLE T, 2000, SOC NEUR ABSTR, V26, P573
   PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3
   Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287
   Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570
   RUST RS, 1991, NEUROCHEM RES, V16, P991, DOI 10.1007/BF00965842
   Savaskan NE, 2002, J NEUROCHEM, V83, P1196, DOI 10.1046/j.1471-4159.2002.01233.x
   Savaskan NE, 2001, REV NEUROSCIENCE, V12, P195
   Savaskan NE, 1999, EUR J NEUROSCI, V11, P316, DOI 10.1046/j.1460-9568.1999.00430.x
   Savaskan NE, 2000, EUR J NEUROSCI, V12, P1024, DOI 10.1046/j.1460-9568.2000.00998.x
   SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0
   SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0
   Schwab ME, 1996, PHYSIOL REV, V76, P319
   Skaper SD, 2001, PROG NEUROBIOL, V65, P593, DOI 10.1016/S0301-0082(01)00017-X
   Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3
   Skutella T, 1999, DEV BIOL, V211, P277, DOI 10.1006/dbio.1999.9295
   SNYDER DC, 1991, J NEUROBIOL, V22, P897, DOI 10.1002/neu.480220903
   Stein E, 1999, J NEUROSCI, V19, P8885, DOI 10.1523/JNEUROSCI.19-20-08885.1999
   Steup A, 1999, EUR J NEUROSCI, V11, P729, DOI 10.1046/j.1460-9568.1999.00517.x
   Steup A, 2000, MOL CELL NEUROSCI, V15, P141, DOI 10.1006/mcne.1999.0818
   STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187
   STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024
   SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108
   SUZUKI M, 1994, GLIA, V12, P294, DOI 10.1002/glia.440120406
   Tessier-Lavigne M, 2000, SCIENCE, V287, P813, DOI 10.1126/science.287.5454.813
   TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123
   Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x
   VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403
   Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176
   Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867
   Wang XX, 2002, J NEUROSCI, V22, P5505
   WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X
   WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9
   Wu W, 1999, NATURE, V400, P331
   Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744
   Zagrebelsky M, 1998, J NEUROSCI, V18, P7912
NR 82
TC 54
Z9 63
U1 5
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2003
VL 17
IS 6
BP 1153
EP +
DI 10.1096/fj.02-0453fje
PG 35
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 673KL
UT WOS:000182580100048
PM 12692091
DA 2018-12-27
ER

PT J
AU Tsay, SL
   Rong, JR
   Lin, PF
AF Tsay, SL
   Rong, JR
   Lin, PF
TI RETRACTED: Acupoints massage in improving the quality of sleep and
   quality of life in patients with end-stage renal disease (Retracted
   article. See vol. 67, pg. 923, 2011)
SO JOURNAL OF ADVANCED NURSING
LA English
DT Article; Retracted Publication
DE end-stage renal disease; acupoints massage; acupressure; sleep
   disturbance; quality of life
ID HEMODIALYSIS; COMPLAINTS; FAILURE
AB Background. Traditional Chinese acupressure is a noninvasive technique that employs pressure and massage to acupoints in order to stimulate the balance of life energy that promotes health and comfort. Sleep disturbance is common in patients with end-stage renal disease but no intervention studies have addressed this problem.
   Aim. The purpose of the present study was to test the effectiveness of acupoints massage for patients with end-stage renal disease and experiencing sleep disturbances and diminished quality of life.
   Methods. The study was a randomized control trial. A total of 98 end-stage renal disease patients with sleep disturbances were randomly assigned into an acupressure group, a sham acupressure group, and a control group. Acupressure and sham acupressure group patients received acupoints or no acupoints massage three times a week during haemodialysis treatment for a total of 4 weeks. The measures included the Pittsburgh Sleep Quality Index, Sleep Log, and the Medical Outcome Study - Short Form 36.
   Findings. The results indicated significant differences between the acupressure group and the control group in Pittsburgh Sleep Quality Index subscale scores of subjective sleep quality, sleep duration, habitual sleep efficiency, sleep sufficiency, and global Pittsburgh Sleep Quality Index scores. Sleep log data revealed that the acupressure group significantly decreased wake time and experienced an improved quality of sleep at night over the control group. Medical Outcome Study - Short Form 36 data also documented that acupressure group patients experienced significantly improved quality of life.
   Conclusion. This study supports the effectiveness of acupoints massage in improving the quality of sleep and life quality of end-stage renal disease patients, and offers a noninvasive therapy for sleep-disturbed patients.
C1 Natl Taipei Coll Nursing, Grad Inst Nursing, Taipei 112, Taiwan.
RP Tsay, SL (reprint author), Natl Taipei Coll Nursing, Grad Inst Nursing, 365 Ming Te Rd, Taipei 112, Taiwan.
EM sltsay@ntcn.edu.tw
CR BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   CHANG YS, 1995, ACUPRESSURE MASSAGIN
   CHEN A, 1993, AM J ACUPUNCTURE, V21, P305
   Chen ML, 1999, J GERONTOL A-BIOL, V54, pM389, DOI 10.1093/gerona/54.8.M389
   Dale RA, 1997, ALTERNATIVE COMPLEME, V3, P125
   DANDIFER J, 1997, ACUPRESSURE HLTH VIT
   Dibble S L, 2000, Oncol Nurs Forum, V27, P41
   FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425
   FREEMAN LW, 2001, MOSBYS COMPLEMENTARY
   GOATS GC, 1994, BRIT J SPORT MED, V28, P153, DOI 10.1136/bjsm.28.3.153
   GUDEX CM, 1995, QUAL LIFE RES, V4, P359, DOI 10.1007/BF01593889
   GUILLAUME J, 1995, NEPHRON, V71, P138
   Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204
   HOLLEY JL, 1992, AM J KIDNEY DIS, V19, P156, DOI 10.1016/S0272-6386(12)70125-7
   Huang ST, 1991, ILLUSTRATED SPECIAL
   Lindqvist R, 1998, J ADV NURS, V27, P312, DOI 10.1046/j.1365-2648.1998.00523.x
   Lok P, 1996, J ADV NURS, V23, P873, DOI 10.1046/j.1365-2648.1996.00893.x
   National Institutes of Health (NIH), 1997, NIH CONSENSUS STATE, V15, P1
   PARKER K, 1996, ANNA J, V23, P201
   PRESSMAN MR, 1993, KIDNEY INT, V43, P1134, DOI 10.1038/ki.1993.159
   ROGERS AE, 1993, NURS RES, V42, P368
   Scharf M B, 1994, Ear Nose Throat J, V73, P395
   Silverberg DS, 1997, NEPHROL DIAL TRANSPL, V12, P680, DOI 10.1093/ndt/12.4.680
   Tsay SL, 2002, INT J NURS STUD, V39, P245, DOI 10.1016/S0020-7489(01)00030-X
   WALKER S, 1995, AM J KIDNEY DIS, V26, P751, DOI 10.1016/0272-6386(95)90438-7
   WANG YW, 1997, THESIS  CASE W RESER
   WARE JE, 1994, PHYSICAL MENTAL HLTH
NR 27
TC 50
Z9 57
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-2402
EI 1365-2648
J9 J ADV NURS
JI J. Adv. Nurs.
PD APR
PY 2003
VL 42
IS 2
BP 134
EP 142
DI 10.1046/j.1365-2648.2003.02596.x
PG 9
WC Nursing
SC Nursing
GA 662UP
UT WOS:000181967500004
PM 12670382
DA 2018-12-27
ER

PT J
AU Andonegui, G
   Bonder, CS
   Green, F
   Mullaly, SC
   Zbytnuik, L
   Raharjo, E
   Kubes, P
AF Andonegui, G
   Bonder, CS
   Green, F
   Mullaly, SC
   Zbytnuik, L
   Raharjo, E
   Kubes, P
TI RETRACTED: Endothelium-derived toll-like receptor-4 is the key molecule
   in LPS-induced neutrophil sequestration into lungs (Retracted Article.
   See vol 112, pg 1264, 2003)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; BACTERIAL LIPOPOLYSACCHARIDE; LEUKOCYTE RECRUITMENT; CUTTING
   EDGE; MICE; ENDOTOXIN; CELLS; EXPRESSION; SELECTINS; RABBIT
AB The rapid and selective accumulation of neutrophils into the lungs is thought to underlie the pulmonary failure that leads to sepsis-related death. In this study we investigated whether neutrophil TLR4 is important in LPS-induced pulmonary neutrophil recruitment by creating chimeric mice (transferring bone marrow between TLR4(+/+) and TLR4(-/-) mice). In TLR4(+/+) mice receiving TLR4(-/-) bone marrow, 6 weeks after transplant TLR4 was absent in all circulating leukocytes as well as in resident macrophages (these mice were termed Leukocyte TLR4(-/-)), and these cells were completely nonresponsive to LPS. In TLR4(-/-) mice receiving TLR4(+/+) bone marrow, endothelial cells but not leukocytes were deficient in TLR4 (EndotheliumTLR4(-/-)). Surprisingly, systemic LPS (0.5 mg/kg) induced a dramatic increase in neutrophil sequestration into the lungs of LeukocyteTLR4(-/-) mice over the first 4 hours. Concomitantly, numbers of circulating leukocytes decreased by 90%. By contrast, Endothefum TLR4(-/-) mice showed very little increase in neutrophil sequestration in the lungs, suggesting that endothelium rather than leukocyte TLR4 was important. Intravital microscopy of peripheral microcirculation in the cremaster muscle revealed about 30-fold more leukocyte-endothelial cell interactions in LPS-treated Endothelium TLR4(-/-) mice than in LPS-treated LeukocyteTLR4(-/-) mice. This is consistent with less sequestration of leukocytes into the lungs of EndothefumTLR4(-/-) mice. In conclusion, our data challenge the view that LPS directly activates neutrophils to trap in lungs and suggest a far more important role than previously appreciated for the endothelial cells.
C1 Univ Calgary, Dept Physiol & Biophys, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
   Univ Calgary, Fac Med, Dept Pathol & Lab Med, Resp Res Grp, Calgary, AB T2N 4N1, Canada.
RP Kubes, P (reprint author), Univ Calgary, Dept Physiol & Biophys, Immunol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM pkubes@ucalgary.ca
CR Andonegui G, 2002, J IMMUNOL, V169, P2111, DOI 10.4049/jimmunol.169.4.2111
   BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560
   ERZURUM SC, 1992, J IMMUNOL, V149, P154
   Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058
   Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018
   Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863
   HASLETT C, 1987, AM REV RESPIR DIS, V136, P9, DOI 10.1164/ajrccm/136.1.9
   Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X
   Hickey MJ, 1999, J IMMUNOL, V162, P1137
   Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje
   Hickey MJ, 1997, FASEB J, V11, P955
   Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Johnston B, 1998, AM J PATHOL, V152, P555
   Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091
   KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344
   Kubo H, 1999, AM J RESP CRIT CARE, V159, P267, DOI 10.1164/ajrccm.159.1.9709011
   Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x
   Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Sheridan BC, 1997, J TRAUMA, V42, P391, DOI 10.1097/00005373-199703000-00005
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tanaka H, 2002, MICROVASC RES, V63, P81, DOI 10.1006/mvre.2001.2368
   VANFURTH R, 1992, INFLAMMATION BASIC P, P325
   WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006
   Wong J, 1997, J CLIN INVEST, V99, P2782, DOI 10.1172/JCI119468
   YANG CS, 1999, CURR PRACT MED, V2, P163
   Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200
   Yang RB, 1998, NATURE, V395, P284
   Yipp BG, 2002, J IMMUNOL, V168, P4650, DOI 10.4049/jimmunol.168.9.4650
   Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611
   Zhao BT, 2001, AM J PHYSIOL-CELL PH, V281, pC1587
   1993, MON VITAL STAT REP, V41, P5
NR 37
TC 286
Z9 292
U1 8
U2 23
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2003
VL 111
IS 7
BP 1011
EP 1020
DI 10.1172/JCI200316510
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 662VY
UT WOS:000181970600012
PM 12671050
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Sawada, M
   Sun, WY
   Hayes, P
   Leskov, K
   Boothman, DA
   Matsuyama, S
AF Sawada, M
   Sun, WY
   Hayes, P
   Leskov, K
   Boothman, DA
   Matsuyama, S
TI RETRACTED: Ku70 suppresses the apoptotic translocation of Bax to
   mitochondria (Retracted article. See vol 9, pg 480, 2007)
SO NATURE CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID CANCER-CELL-LINES; CYTOCHROME-C; INTRACELLULAR-LOCALIZATION; BCL-2
   FAMILY; MAMMALIAN-CELLS; PROTEIN; DEATH; RELEASE; DNA; EXPRESSION
AB Bax induces mitochondrial-dependent cell death signals in mammalian cells. However, the mechanism of how Bax is kept inactive has remained unclear. Yeast-based functional screening of Bax inhibitors from mammalian cDNA libraries identified Ku70 as a new Bax suppressor. Bax-mediated apoptosis was suppressed by overexpression of Ku70 in mammalian cells, but enhanced by downregulation of Ku70. We found that Ku70 interacts with Bax, and that the carboxyl terminus of Ku70 and the amino terminus of Bax are required for this interaction. Bax is known to translocate from the cytosol to mitochondria when cells receive apoptotic stimuli. We found that Ku70 blocks the mitochondrial translocation of Bax. These results suggest that in addition to its previously recognized DNA repair activity in the nucleus, Ku70 has a cytoprotective function in the cytosol that controls the localization of Bax.
C1 Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
   Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   Univ Hosp Cleveland, Cleveland, OH 44106 USA.
RP Sawada, M (reprint author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 8727 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM smatsuyama@bcsew.edu
FU NCI NIH HHS [CA78530]
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5
   Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7
   Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901
   Fewell JW, 1996, J CELL SCI, V109, P1937
   Goldstein JC, 2000, NAT CELL BIOL, V2, P156
   Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207
   Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664
   Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777
   Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879
   Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   Kim GW, 2001, STROKE, V32, P1401, DOI 10.1161/01.STR.32.6.1401
   Kim SH, 1999, CANCER RES, V59, P4012
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783
   Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020
   Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995
   Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7
   Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330
   Nishita M, 1998, EXP CELL RES, V244, P357, DOI 10.1006/excr.1998.4203
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867
   Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X
   Saito M, 2000, NAT CELL BIOL, V2, P553
   Salah-eldin A, 2000, JPN J CANCER RES, V91, P1269, DOI 10.1111/j.1349-7006.2000.tb00914.x
   Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7
   Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000
   Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5
   Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wilson CR, 2000, BRIT J CANCER, V83, P1702, DOI 10.1054/bjoc.2000.1510
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Xu QL, 2000, METHOD ENZYMOL, V322, P283
   Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9
   Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Zhao HJ, 2000, CLIN CANCER RES, V6, P1073
   Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2
NR 43
TC 272
Z9 281
U1 4
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD APR
PY 2003
VL 5
IS 4
BP 320
EP 329
DI 10.1038/ncb950
PG 10
WC Cell Biology
SC Cell Biology
GA 664UR
UT WOS:000182080700015
PM 12652308
DA 2018-12-27
ER

PT J
AU Sawada, M
   Hayes, P
   Matsuyama, S
AF Sawada, M
   Hayes, P
   Matsuyama, S
TI RETRACTED: Cytoprotective membrane-permeable peptides designed from the
   Bax-binding domain of Ku70 (Retracted article. See vol 9, pg 480, 2007)
SO NATURE CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID CELL-DEATH; MITOCHONDRIA; APOPTOSIS; FAMILY; DNA
AB Bax is a pro-apoptotic member of Bcl-2 family proteins and is central to mitochondria-dependent apoptosis(1-3). Bax resides in the cytosol as a quiescent protein and translocates into mitochondria after apoptotic stimuli(4). Ku70 is a 70K subunit of the Ku complex, which has an important role in DNA double-strand break (DSB) repair in the nucleus(5). In another article in this issue, we reported that Ku70 interacts with pro-apoptotic protein Bax in the cytosol and prevents its mitochondrial translocation(6), suggesting that Ku70 suppresses Bax-mediated apoptosis. Here, we describe the development of a new membrane-permeable peptide, Bax-inhibiting peptide (BIP) that inhibits Bax-mediated apoptosis, on the basis of the previous finding that showed an interaction between Ku70 and Bax. BIP is comprised of five amino acids designed from the Bax-binding domain of Ku70, and suppresses the mitochondrial translocation of Bax. BIP inhibited Bax-mediated apoptosis induced by staurosporine, UVC irradiation and anti-cancer drugs in several types of cells. BIP may provide valuable information in the development of therapeutics that control apoptosis-related diseases.
C1 Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
RP Sawada, M (reprint author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 8727 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM smatsuyama@bcsew.edu
CR Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777
   Korsmeyer SJ, 1999, CANCER RES, V59, p1693S
   Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995
   Matsuyama S, 2000, NAT CELL BIOL, V2, P318
   Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330
   Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950
   Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271
   Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7
   Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998
   Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Zhang ZM, 2001, J BIOL CHEM, V276, P38231
NR 16
TC 125
Z9 127
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD APR
PY 2003
VL 5
IS 4
BP 352
EP 357
DI 10.1038/ncb955
PG 6
WC Cell Biology
SC Cell Biology
GA 664UR
UT WOS:000182080700020
PM 12652309
DA 2018-12-27
ER

PT J
AU Haug, K
   Warnstedt, M
   Alekov, AK
   Sander, T
   Ramirez, A
   Poser, B
   Maljevic, S
   Hebeisen, S
   Kubisch, C
   Rebstock, J
   Horvath, S
   Hallmann, K
   Dullinger, JS
   Rau, B
   Haverkamp, F
   Beyenburg, S
   Schulz, H
   Janz, D
   Giese, B
   Muller-Newen, G
   Propping, P
   Elger, CE
   Fahlke, C
   Lerche, H
   Heils, A
AF Haug, K
   Warnstedt, M
   Alekov, AK
   Sander, T
   Ramirez, A
   Poser, B
   Maljevic, S
   Hebeisen, S
   Kubisch, C
   Rebstock, J
   Horvath, S
   Hallmann, K
   Dullinger, JS
   Rau, B
   Haverkamp, F
   Beyenburg, S
   Schulz, H
   Janz, D
   Giese, B
   Muller-Newen, G
   Propping, P
   Elger, CE
   Fahlke, C
   Lerche, H
   Heils, A
TI RETRACTED: Mutations in CLCN2 encoding a voltage-gated chloride channel
   are associated with idiopathic generalized epilepsies (Retracted
   article. See vol 41, pg. 1043, 2009)
SO NATURE GENETICS
LA English
DT Article; Retracted Publication
ID POSTSYNAPTIC INHIBITION; ION CHANNELS; NEURONS; GABA; GAMMA-2-SUBUNIT;
   CONDUCTANCE; HIPPOCAMPUS; POTASSIUM; MOUSE; CELLS
AB Idiopathic generalized epilepsy (IGE) is an inherited neurological disorder affecting about 0.4% of the world's population. Mutations in ten genes causing distinct forms of idiopathic epilepsy have been identified so far(1-7), but the genetic basis of many IGE subtypes is still unknown. Here we report a gene associated with the four most common IGE subtypes: childhood and juvenile absence epilepsy (CAE and JAE), juvenile myoclonic epilepsy (JME), and epilepsy with grand mal seizures on awakening (EGMA; ref. 8). We identified three different heterozygous mutations in the chloride-channel gene CLCN2 in three unrelated families with IGE. These mutations result in (i) a premature stop codon (M200fsX231), (ii) an atypical splicing (del74-117) and (iii) a single amino-acid substitution (G715E). All mutations produce functional alterations that provide distinct explanations for their pathogenic phenotypes. M200fsX231 and del74-117 cause a loss of function of ClC-2 channels and are expected to lower the transmembrane chloride gradient essential for GABAergic inhibition. G715E alters voltage-dependent gating, which may cause membrane depolarization and hyperexcitability.
C1 Univ Klinikum Bonn, Inst Humangenet, D-53111 Bonn, Germany.
   Ctr Estudios Cient, Valdivia, Chile.
   Rhein Westfal TH Aachen, Inst Biochem, D-52057 Aachen, Germany.
   Univ Klinikum Bonn, Klinikum Padiatrie, D-59113 Bonn, Germany.
   Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA.
   Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA.
   Univ Klinikum Bonn, Klin Epileptol, D-53105 Bonn, Germany.
   Humboldt Univ, Virchow Klinikum, Klinikum Charite, Arbeitsgrp Epilepsie Genet,Neurol Klin, D-13353 Berlin, Germany.
   Univ Ulm, Abt Angew Physiol & Neurol, D-89069 Ulm, Germany.
   Rhein Westfal TH Aachen, Lehr & Forschungsgebeit Physiol, D-52057 Aachen, Germany.
RP Heils, A (reprint author), Univ Klinikum Bonn, Inst Humangenet, Wilhelmstr 31, D-53111 Bonn, Germany.
EM holger.lerche@medizin.uni-ulm.de; armin.heils@ukb.uni-bonn.de
RI Kubisch, Christian/F-1893-2011; Fahlke, Christoph/G-3635-2013
OI Kubisch, Christian/0000-0003-4220-0978; Fahlke,
   Christoph/0000-0001-8602-9952
CR Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254
   Berkovic SF, 2001, EPILEPSIA, V42, P16, DOI 10.1046/j.1528-1157.2001.0420s5016.x
   Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289
   CID LP, 1995, HUM MOL GENET, V4, P407, DOI 10.1093/hmg/4.3.407
   Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885
   Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647
   Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a
   Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93
   Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391
   Kaila K, 1997, J NEUROSCI, V17, P7662
   Kalachikov S, 2002, NAT GENET, V30, P335, DOI 10.1038/ng832
   Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786, DOI 10.1073/pnas.041582598
   Lerche H, 2001, AM J MED GENET, V106, P146, DOI 10.1002/ajmg.1582
   Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316
   MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140
   MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084
   Mladinic M, 1999, P ROY SOC B-BIOL SCI, V266, P1207, DOI 10.1098/rspb.1999.0764
   Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516
   Rivera C, 1999, NATURE, V397, P251
   Ross SA, 2000, J NEUROSCI, V20, P6431, DOI 10.1523/JNEUROSCI.20-17-06431.2000
   Sander T, 2000, HUM MOL GENET, V9, P1465, DOI 10.1093/hmg/9.10.1465
   Serratosa JM, 1999, EPILEPSIA, V40, P12, DOI 10.1111/j.1528-1157.1999.tb00893.x
   Sik A, 2000, NEUROSCIENCE, V101, P51, DOI 10.1016/S0306-4522(00)00360-2
   STALEY K, 1994, J NEUROPHYSIOL, V72, P273
   Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5
   Steinlein OK, 2000, CURR OPIN GENET DEV, V10, P286, DOI 10.1016/S0959-437X(00)00079-4
   THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0
   THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512
   Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49
   1989, EPILEPSIA, V30, P389
NR 30
TC 249
Z9 264
U1 4
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD APR
PY 2003
VL 33
IS 4
BP 527
EP 532
DI 10.1038/ng1121
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 662CM
UT WOS:000181928600027
PM 12612585
OA Bronze
DA 2018-12-27
ER

PT J
AU Levin, LI
   Munger, KL
   Rubertone, MV
   Peck, CA
   Lennette, ET
   Spiegelman, D
   Ascherio, A
AF Levin, LI
   Munger, KL
   Rubertone, MV
   Peck, CA
   Lennette, ET
   Spiegelman, D
   Ascherio, A
TI RETRACTED: Multiple sclerosis and Epstein-Barr virus (Retracted Article.
   See vol 293, pg 2466, 2005)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article; Retracted Publication
ID NUCLEAR ANTIGEN; ANTIBODY-TITERS; MONONUCLEOSIS; INFECTION; DISEASE;
   EBNA-2
AB Context Infection with Epstein-Barr virus (EBV) has been associated with an increased risk of multiple sclerosis (MS), but the temporal relationship remains unclear.
   Objective To determine whether antibodies to EBV are elevated before the onset of MS.
   Design, Setting, and Population Nested case-control study conducted among more than 3 million US military personnel with blood samples collected between 1988 and 2000 and stored in the Department of Defense Serum Repository. Cases were identified as individuals granted temporary or permanent disability because of MS. For each case (n=83), 2 controls matched by age, sex, race/ethnicity, and dates of blood sample collection were selected.
   Main Outcome Measures Antibodies including IgA against EBV viral capsid antigen (VCA) and IgG against VCA, nuclear antigens (EBNA complex, EBNA-1, and EBNA-2), diffuse and restricted early antigens, and cytomegalovirus.
   Results The average time between blood collection and MS onset was 4 years. The strongest predictors of MS were serum levels of IgG antibodies to VCA or EBNA complex. The risk of MS increased monotonically with these antibody titers; relative risk (RR) in persons in the highest category of VCA (greater than or equal to2560) compared with those in the lowest (less than or equal to160) was 19.7 (95% confidence interval [CI], 2.2-174; P for trend =.004). For EBNA complex titers, the RR for those in the highest category (greater than or equal to1280) was 33.9 (95% CI, 4.1-283; P for trend <.001) vs those in the lowest category (<= 40). Similarly strong positive associations between EBV antibodies and risk of MS were already present in samples collected 5 or more years before MS onset. No association was found between cytomegalovirus antibodies and MS.
   Conclusion These results suggest a relationship between EBV infection and development of MS.
C1 Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Prevent Med, Washington, DC 20307 USA.
   USA, Med Surveillance Act, Ctr Hlth Promot & Prevent Med, Washington, DC 20310 USA.
   USA, Phys Disabil Agcy, Washington, DC 20310 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Virolab Inc, Berkeley, CA USA.
RP Ascherio, A (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM Alberto.Ascherio@channing.harvard.edu
FU NINDS NIH HHS [NS42194]
CR Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083
   Brex PA, 1999, NEUROLOGY, V53, P1184, DOI 10.1212/WNL.53.6.1184
   Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610
   DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0
   DETHE G, 1982, HERPESVIRUSES, V1, P25
   Diggle PJ, 1994, ANAL LONGITUDINAL DA, P253
   HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570
   HENLE W, 1971, J INFECT DIS, V124, P58, DOI 10.1093/infdis/124.1.58
   HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150
   KUSUNOKI Y, 1993, MICROBIOL IMMUNOL, V37, P461, DOI 10.1111/j.1348-0421.1993.tb03237.x
   LARSEN PD, 1985, NEUROLOGY, V35, P435, DOI 10.1212/WNL.35.3.435
   LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U
   LENNETTE ET, 2000, CLIN VIROLOGY MANUAL, P140
   LENNETTE ET, 1999, MANUAL CLIN MICROBIO, P912
   MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103
   POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302
   Rickinson AB, 1996, FIELDS VIROLOGY, P2397
   Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900
   SHIRODARIA PV, 1987, ARCH NEUROL-CHICAGO, V44, P1237, DOI 10.1001/archneur.1987.00520240019006
NR 19
TC 107
Z9 109
U1 5
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 26
PY 2003
VL 289
IS 12
BP 1533
EP 1536
DI 10.1001/jama.289.12.1533
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 659XE
UT WOS:000181803100031
PM 12672770
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, HJ
   Mardahl-Dumesnil, M
   Sweeney, ST
   O'Kane, CJ
   Bernstein, SL
AF Liu, HJ
   Mardahl-Dumesnil, M
   Sweeney, ST
   O'Kane, CJ
   Bernstein, SL
TI RETRACTED: Drosophila paramyosin is important for myoblast fusion and
   essential for myofibril formation (Retracted Article. See vol 167, pg
   783, 2004)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE contractile protein; cytoskeleton; contraction; muscle; thick filament
ID Z-I-BODIES; CAENORHABDITIS-ELEGANS; THICK FILAMENTS; D-TITIN;
   MINIPARAMYOSIN GENE; MUSCLE DEVELOPMENT; PROTEIN; MYOSIN; MELANOGASTER;
   ISOFORM
AB Paramyosin is a major structural protein of thick filaments in invertebrate muscles. Coiled-coil dimers of paramyosin form a paracrystalline core of these filaments, and the motor protein myosin is arranged on the core surface. To investigate the function of paramyosin in myofibril assembly and muscle contraction, we functionally disrupted the Drosophila melanogaster paramyosin gene by mobilizing a P element located in its promoter region. Homozygous paramyosin mutants die at the late embryo stage. Mutants display defects in both myoblast fusion and in myofibril assembly in embryonic body wall muscles. Mutant embryos have an abnormal body wall muscle fiber pattern arising from defects in myoblast fusion. In addition, sarcomeric units do not assemble properly and muscle contractility is impaired. We confirmed that these defects are paramyosin-specific by rescuing the homozygous paramyosin mutant to adulthood with a paramyosin transgene. Antibody analysis of normal embryos demonstrated that paramyosin accumulates as a cytoplasmic protein in early embryo development before assembling into thick filaments. We conclude that paramyosin plays an unexpected role in myoblast fusion and is important for myofibril assembly and muscle contraction.
C1 San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.
   San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA.
   Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England.
RP Bernstein, SL (reprint author), San Diego State Univ, Dept Biol, 5500 Campanile Dr,Life Sci 371, San Diego, CA 92182 USA.
EM sbernst@sunstroke.sdsu.edu
RI O'Kane, Cahir/C-4413-2011
OI Bernstein, Sanford/0000-0001-7094-5390; O'Kane,
   Cahir/0000-0002-3488-2078
FU NIAMS NIH HHS [R01 AR043396, AR43396]
CR Arredondo JJ, 2001, J BIOL CHEM, V276, P8278, DOI 10.1074/jbc.M009302200
   AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973
   Barral JM, 1998, J CELL BIOL, V143, P1215, DOI 10.1083/jcb.143.5.1215
   Barral JM, 1999, BIOESSAYS, V21, P813, DOI 10.1002/(SICI)1521-1878(199910)21:10<813::AID-BIES3>3.0.CO;2-0
   Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648
   BATE M, 1990, DEVELOPMENT, V110, P791
   BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013
   BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941
   BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131
   BECKER KD, 1992, J CELL BIOL, V116, P669, DOI 10.1083/jcb.116.3.669
   Bloor JW, 2001, DEV BIOL, V239, P215, DOI 10.1006/dbio.2001.0452
   Bour BA, 2000, GENE DEV, V14, P1498
   BROADIE KS, 1993, J NEUROSCI, V13, P144
   Campos-Ortega J.A., 1985, EMBRYONIC DEV DROSOP, P9
   Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3
   Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983
   Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493
   Deak P, 1997, GENETICS, V147, P1697
   Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249
   Ehler E, 1999, J CELL SCI, V112, P1529
   EPSTEIN HF, 1995, J STRUCT BIOL, V115, P163, DOI 10.1006/jsbi.1995.1041
   EPSTEIN HF, 1986, J CELL BIOL, V103, P985, DOI 10.1083/jcb.103.3.985
   EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120
   EPSTEIN HF, 1976, P NATL ACAD SCI USA, V73, P3015, DOI 10.1073/pnas.73.9.3015
   Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589
   FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8
   GOLDSTEIN, 2000, J CELL BIOL, V150, pF63
   Hakeda S, 2000, J CELL BIOL, V148, P101, DOI 10.1083/jcb.148.1.101
   Holtzer H, 1997, CELL STRUCT FUNCT, V22, P83, DOI 10.1247/csf.22.83
   HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X
   KAGAWA H, 1989, J MOL BIOL, V207, P311, DOI 10.1016/0022-2836(89)90257-X
   KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517
   Kulke M, 2001, J CELL BIOL, V154, P1045, DOI 10.1083/jcb.200104016
   LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146
   Liu FZ, 1998, J CELL BIOL, V140, P347, DOI 10.1083/jcb.140.2.347
   Liu FZ, 2000, J CELL SCI, V113, P4001
   Machado C, 2000, J CELL BIOL, V151, P639, DOI 10.1083/jcb.151.3.639
   MACKENZIE JM, 1980, CELL, V22, P747, DOI 10.1016/0092-8674(80)90551-6
   MARDAHLDUMESNIL M, 1998, THESIS SAN DIEGO STA
   Maroto M, 1996, J CELL BIOL, V134, P81, DOI 10.1083/jcb.134.1.81
   MAROTO M, 1995, J BIOL CHEM, V270, P4375, DOI 10.1074/jbc.270.9.4375
   MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0
   Menon SD, 2001, DEV CELL, V1, P691, DOI 10.1016/S1534-5807(01)00075-2
   Muller SA, 2001, J MOL BIOL, V305, P1035, DOI 10.1006/jmbi.2000.4363
   Nose A, 1998, DEVELOPMENT, V125, P215
   OBINATA T, 1993, INT REV CYTOL, V143, P153
   ODONNELL PT, 1988, J CELL BIOL, V107, P2601, DOI 10.1083/jcb.107.6.2601
   Ojima K, 1999, J CELL SCI, V112, P4101
   Paululat A, 1999, MECH DEVELOP, V83, P17, DOI 10.1016/S0925-4773(99)00029-5
   Reedy MC, 2000, J CELL BIOL, V151, P1483, DOI 10.1083/jcb.151.7.1483
   ROULIER EM, 1992, J CELL BIOL, V116, P911, DOI 10.1083/jcb.116.4.911
   Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6
   RUSHTON E, 1995, DEVELOPMENT, V121, P1979
   SPARROW J, 1991, J MOL BIOL, V222, P963, DOI 10.1016/0022-2836(91)90588-W
   Standiford DM, 1997, J MOL BIOL, V265, P40, DOI 10.1006/jmbi.1996.0710
   Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1
   VIGOREAUX JO, 1993, J CELL BIOL, V121, P587, DOI 10.1083/jcb.121.3.587
   VINOS J, 1991, J MOL BIOL, V220, P687, DOI 10.1016/0022-2836(91)90110-R
   Zhang Y, 2000, J CELL SCI, V113, P3103
   Ziegler Clemens, 1996, Biophysics (English Translation of Biofizika), V41, P79
NR 60
TC 13
Z9 15
U1 2
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD MAR 17
PY 2003
VL 160
IS 6
BP 899
EP 908
DI 10.1083/jcb.200208180
PG 10
WC Cell Biology
SC Cell Biology
GA 657QH
UT WOS:000181677500010
PM 12642615
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Fogel, RB
   Malhotra, A
   Dalagiorgou, G
   Robinson, MK
   Jakab, M
   Kikinis, R
   Pittman, SD
   White, DP
AF Fogel, RB
   Malhotra, A
   Dalagiorgou, G
   Robinson, MK
   Jakab, M
   Kikinis, R
   Pittman, SD
   White, DP
TI RETRACTED: Anatomic and physiologic predictors of apnea severity in
   morbidly obese subjects (Retracted article. See vol. 32, pg. 445, 2009)
SO SLEEP
LA English
DT Article; Retracted Publication
DE obesity; upper airway; genioglossus; airway vollapse
ID OBSTRUCTIVE SLEEP-APNEA; QUANTITATIVE FOLLOW-UP; UPPER-AIRWAY;
   NEGATIVE-PRESSURE; PELVIC FLOOR; ASSOCIATION; WOMEN; RISK; MEN;
   SCHIZOPHRENIA
AB Study Objectives: While obesity is the most common risk factor for the development of obstructive sleep apnea, the correlation between measures of obesity and apnea severity is only moderate, We thus attempted to identify anatomic and physiologic predictors of apnea severity.
   Design: We combined a careful assessment of upper airway anatomy, upper airway physiology, and ventilatory control in a group of obese individuals to identify predictors of apnea severity.
   Setting: Tertiary care academic medical center.
   Patients: 14 morbidly obese subjects being evaluated for weight-reduction surgery.
   Interventions: N/A
   Measurement and Results: We found no relationship between obesity (weight or body mass index) and apnea severity (respiratory disturbance index, RDI). However, those with severe apnea (RDI > 30) were found to have higher peak genioglossus EMG (GGEMG) (23.5 +/- 1.9 vs. 14.1 +/- 3.7 %max, p = 0.05) and greater airway collapsibility during pulses of negative pressure (7.6 +/- 0.9 vs. 4.4 +/-0.7 cmH(2)O, p =0.02). Airway collapsibility was significantly associated with RDI (r = 0.62, p < 0.01) as was peak GGEMG (r = 0.55, p < 0.05). Of the anatomic variables airway shape (A-P/lateral ratio) and volume change of the pharyngeal airway between total lung capacity and residual volume were different between those with and without severe apnea. Both correlated with RDI (A-P/lateral ratio: r= 0.70, p < 0.01 and volume change: r = 0,77, p < 0.01).
   Conclusions: We believe these findings suggest that specific anatomic and physiologic properties of the airway interact with obesity to predispose to the development of airway collapse during sleep.
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Sleep Med, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pulm Crit Care, Boston, MA 02115 USA.
RP Fogel, RB (reprint author), Div Sleep Med, 221 Longwood Ave,RFB 390, Boston, MA 02115 USA.
EM rfogel@partners.org
FU NHLBI NIH HHS [R01 HL48531, K23 HL04400, 1 P50 HL60292]; NCRR NIH HHS
   [M01 RR02635]
CR [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107
   [Anonymous], 1992, SLEEP, V15, P174
   [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202
   BEGLE RL, 1990, AM REV RESPIR DIS, V141, P854, DOI 10.1164/ajrccm/141.4_Pt_1.854
   BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105
   DEALBERTO MJ, 1994, CHEST, V105, P1753, DOI 10.1378/chest.105.6.1753
   Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401
   Fielding JR, 1998, AM J ROENTGENOL, V171, P1607, DOI 10.2214/ajr.171.6.9843296
   Fielding JR, 2000, AM J ROENTGENOL, V174, P657, DOI 10.2214/ajr.174.3.1740657
   FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337
   Flemons WW, 1997, J ALLERGY CLIN IMMUN, V99, pS750, DOI 10.1016/S0091-6749(97)70123-4
   Flemons WW, 1999, SLEEP, V22, P667
   GRUNSTEIN RR, 1994, BAILLIERE CLIN ENDOC, V8, P601, DOI 10.1016/S0950-351X(05)80288-5
   Guttmann CRG, 1999, JMRI-J MAGN RESON IM, V9, P509, DOI 10.1002/(SICI)1522-2586(199904)9:4<509::AID-JMRI2>3.3.CO;2-J
   HORNER RL, 1991, J PHYSIOL-LONDON, V436, P31, DOI 10.1113/jphysiol.1991.sp018537
   HUDGEL DW, 1984, J APPL PHYSIOL, V57, P1319
   HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G
   Kikinis R, 1999, J MAGN RESON IMAGING, V9, P519
   Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479
   Leiter JC, 1996, AM J RESP CRIT CARE, V153, P894, DOI 10.1164/ajrccm.153.3.8630569
   Malhotra A, 2000, AM J RESP CRIT CARE, V161, P1746, DOI 10.1164/ajrccm.161.5.9907109
   Malhotra A, 2001, CHEST, V120, P156, DOI 10.1378/chest.120.1.156
   MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751
   MILLMAN RP, 1995, CHEST, V107, P362, DOI 10.1378/chest.107.2.362
   Moharir VM, 1998, LARYNGOSCOPE, V108, P1592, DOI 10.1097/00005537-199811000-00002
   Mortimore IL, 1998, AM J RESP CRIT CARE, V157, P280, DOI 10.1164/ajrccm.157.1.9703018
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   PILLAR G, 1994, J SLEEP RES, V3, P241, DOI 10.1111/j.1365-2869.1994.tb00137.x
   RAJALA R, 1991, J INTERN MED, V230, P125, DOI 10.1111/j.1365-2796.1991.tb00419.x
   READ DJC, 1967, AUSTRALAS ANN MED, V16, P20
   Rechtschaffen A, 1968, NIH PUBLICATION, V204
   REMMERS JE, 1978, J APPL PHYSIOL, V44, P931
   ROEHRS T, 1985, AM REV RESPIR DIS, V132, P520
   SCHWAB RJ, 1995, AM J RESP CRIT CARE, V152, P1673, DOI 10.1164/ajrccm.152.5.7582313
   SCHWAB RJ, 1993, AM REV RESPIR DIS, V148, P1385, DOI 10.1164/ajrccm/148.5.1385
   Schwab RJ, 1998, CLIN CHEST MED, V19, P33, DOI 10.1016/S0272-5231(05)70430-5
   Schwab RJ, 1996, SLEEP, V19, pS170
   SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905
   SHEPARD JW, 1990, PROG CLIN BIOL RES, V345, P273
   Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104
   VANDEGRAAFF WB, 1988, J APPL PHYSIOL, V65, P2124
   VANDEGRAAFF WB, 1991, J APPL PHYSIOL, V70, P1328
   VGONTZAS AN, 1994, ARCH INTERN MED, V154, P1705, DOI 10.1001/archinte.154.15.1705
   WHEATLEY JR, 1993, AM REV RESPIR DIS, V148, P597, DOI 10.1164/ajrccm/148.3.597
   WILHOIT SC, 1987, CHEST, V91, P654, DOI 10.1378/chest.91.5.654
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
   Zahajszky J, 2001, SCHIZOPHR RES, V47, P87, DOI 10.1016/S0920-9964(00)00051-7
NR 47
TC 40
Z9 43
U1 3
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1550-9109
J9 SLEEP
JI Sleep
PD MAR 15
PY 2003
VL 26
IS 2
BP 150
EP 155
DI 10.1093/sleep/26.2.150
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 655FU
UT WOS:000181541300005
PM 12683472
OA Bronze
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Aoyama, T
   Ogawa, O
   Tabata, Y
AF Hosseinkhani, H
   Aoyama, T
   Ogawa, O
   Tabata, Y
TI RETRACTED: Tumor targeting of gene expression through metal-coordinated
   conjugation with dextran (Retracted article. See vol. 232, pg. 266,
   2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE plasmid DNA; tumor targeting; enhanced gene expression; dextran
   conjugation; metal coordination
ID DNA LIPOSOME COMPLEXES; CANCER MONOCLONAL-ANTIBODY; IN-VIVO;
   MITOMYCIN-C; DISPOSITION CHARACTERISTICS; ANTITUMOR-ACTIVITY; PLASMID
   DNA; INTRAVENOUS-INJECTION; POLYMERIC PRODRUG; CIRCULATION TIME
AB Tumor targeting of plasmid DNA was achieved through the conjugation of dextran derivatives with chelate residues based on metal coordination. Diethylenetriamine pentaacetic acid (DTPA), spermidine (Sd), and spermine (Sm) were chemically introduced to the hydroxyl groups of dextran to obtain dextran-DTPA, dextran-Sd and dextran-Sm derivatives. Conjugation of the dextran derivative by Zn2+ coordination decreased the apparent size of the plasmid DNA, depending on the derivative type. The negative zeta potential of plasmid DNA became almost 0 mV after Zn2+-coordinated conjugation with dextran-Sm. When the dextran derivative-plasmid DNA conjugates with Zn2+ coordination were intravenously injected subcutaneously into mice bearing Meth-AR-1 fibrosarcoma, the dextran-Sm-plasmid DNA conjugate significantly enhanced the level of gene expression in the tumor, in contrast to the conjugate of other dextran derivatives and free plasmid DNA. The enhanced gene expression produced by the Zn2+-coordinated dextran-Sm-plasmid DNA conjugate was specific to the tumor, whereas a simple mixture of dextran-Sm and plasmid DNA was not effective. The level of gene expression depended on the percentage of chelate residues introduced, the mixing weight ratio of the plasmid DNA/Sm residue used for conjugate preparation, and the plasmid DNA dose. A fluorescent microscopic study revealed that localization of plasmid DNA in the tumor tissue was observed only after injection of the dextran-Sm-plasmid DNA conjugate with Zn2+ coordination. In addition, the gene expression induced by the conjugate lasted for more than 10 days after the injection. We conclude that Zn2+-coordinated dextran-Sm conjugation is a promising way to enable plasmid DNA to target the tumor in gene expression as well as to prolong the duration of gene expression. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Kyoto Univ, Inst Frontier Med Sci, Field Tissue Engn, Dept Biomat,Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan.
RP Tabata, Y (reprint author), Kyoto Univ, Inst Frontier Med Sci, Field Tissue Engn, Dept Biomat,Sakyo Ku, 53 Kawara Cho Shogoin, Kyoto 6068507, Japan.
EM yasuhiko@frontier.kyoto-u.ac.jp
CR ATSUMI R, 1987, CANCER RES, V47, P5546
   Boulikas T, 1996, INT J ONCOL, V9, P941
   BRUNER HD, 1950, FED PROC, V9, P260
   Budker V, 2000, J GENE MED, V2, P76, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<76::AID-JGM97>3.0.CO;2-4
   Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663
   Coll JL, 1999, HUM GENE THER, V10, P1659, DOI 10.1089/10430349950017662
   Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063
   DUNCAN R, 1992, ANTI-CANCER DRUG, V3, P175, DOI 10.1097/00001813-199206000-00001
   Egilmez NK, 1996, BIOCHEM BIOPH RES CO, V221, P169, DOI 10.1006/bbrc.1996.0564
   Eng C, 2001, ANN ONCOL, V12, P1743, DOI 10.1023/A:1013574328938
   Fang J, 2002, CANCER RES, V62, P3138
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   HASHIDA M, 1981, GANN, V72, P226
   Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040
   HOGFELDT E, 1982, IUPAC CHEM DATA SERI, V21
   Hosseinkhani H, 2002, J CONTROL RELEASE, V83, P287, DOI 10.1016/S0168-3659(02)00201-8
   IMOTO H, 1992, CANCER RES, V52, P4396
   JIA X, 1991, BIOPOLYMERS, V31, P23, DOI 10.1002/bip.360310104
   Kaul G, 2002, PHARM RES-DORDR, V19, P1061, DOI 10.1023/A:1016486910719
   KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505
   Kircheis R, 1999, J GENE MED, V1, P111
   Kircheis R, 2001, J CONTROL RELEASE, V72, P165, DOI 10.1016/S0168-3659(01)00272-3
   Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273
   Kopecek J, 2001, J CONTROL RELEASE, V74, P147, DOI 10.1016/S0168-3659(01)00330-3
   KOSMAS C, 1989, DRUGS, V38, P645, DOI 10.2165/00003495-198938050-00001
   LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553
   Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482
   LITZINGER DC, 1995, J IMMUNOL METHODS, V187, P151, DOI 10.1016/0022-1759(95)00179-E
   Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1
   Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167
   Luo Y, 2002, CURR CANCER DRUG TAR, V2, P209, DOI 10.2174/1568009023333836
   Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1
   Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083
   MATSUMOTO S, 1986, CANCER RES, V46, P4463
   Molineux G, 2002, CANCER TREAT REV, V28, P13, DOI 10.1016/S0305-7372(02)80004-4
   MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4
   Muller BG, 1996, PHARMACEUT RES, V13, P32, DOI 10.1023/A:1016064930502
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   NISHIKAWA M, 1992, J PHARM PHARMACOL, V44, P396, DOI 10.1111/j.2042-7158.1992.tb03632.x
   NOGUCHI A, 1991, JPN J CANCER RES, V82, P219, DOI 10.1111/j.1349-7006.1991.tb01832.x
   NOGUCHI A, 1992, BIOCONJUGATE CHEM, V3, P132, DOI 10.1021/bc00014a007
   Nomura T, 1998, J CONTROL RELEASE, V52, P239, DOI 10.1016/S0168-3659(97)00185-5
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   PARK JW, 2002, BREAST CANCER RES, V4, P495
   Pehamberger H, 2002, RECENT RESULTS CANC, V160, P158
   PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x
   Sato N, 2001, CLIN CANCER RES, V7, P3606
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   SEYMOUR LW, 1992, CRIT REV THER DRUG, V9, P135
   Skubitz KM, 2002, INVEST NEW DRUG, V20, P101, DOI 10.1023/A:1014428720551
   Stehle G, 1997, ANTI-CANCER DRUG, V8, P835, DOI 10.1097/00001813-199710000-00004
   Stehle G, 1999, ANTI-CANCER DRUG, V10, P785, DOI 10.1097/00001813-199909000-00012
   STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267
   Tabata T, 1998, J CONTROL RELEASE, V50, P123, DOI 10.1016/S0168-3659(97)00129-6
   Tabata Y, 1999, J CONTROL RELEASE, V59, P187, DOI 10.1016/S0168-3659(98)00190-4
   Tabata Y, 1997, DRUG DELIV, V4, P213, DOI 10.3109/10717549709051895
   TAKAKURA Y, 1987, INT J PHARM, V37, P145, DOI 10.1016/0378-5173(87)90019-6
   TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753
   TAKAKURA Y, 1987, INT J PHARM, V37, P135, DOI 10.1016/0378-5173(87)90018-4
   TAKAKURA Y, 1987, PHARMACEUT RES, V4, P293, DOI 10.1023/A:1016489002393
   Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647
   THORPE PE, 1997, J CONTROL RELEASE, V129, P57
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P181, DOI 10.1016/0005-2736(94)90025-6
   WAGNER E, 1994, ADV DRUG DELIVER REV, V14, P113, DOI 10.1016/0169-409X(94)90008-6
   WAWRZYNCZAK EJ, 1990, CLIN EXP IMMUNOL, V82, P189
   WOODLE MC, 1994, BIOCONJUGATE CHEM, V5, P493, DOI 10.1021/bc00030a001
   Xi KL, 1996, PHARMACEUT RES, V13, P1846, DOI 10.1023/A:1016037225728
   YOSHIHARU K, 2001, J CONTROL RELEASE, V70, P365
   Yu L, 2001, PHARMACEUT RES, V18, P1277, DOI 10.1023/A:1013081710135
   ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073
NR 72
TC 36
Z9 38
U1 3
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 7
PY 2003
VL 88
IS 2
BP 297
EP 312
DI 10.1016/S0168-3659(02)00425-X
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 659XQ
UT WOS:000181804300010
PM 12628336
DA 2018-12-27
ER

PT J
AU Srisilam, K
   Veeresham, C
AF Srisilam, K
   Veeresham, C
TI RETRACTED: Biotransformation of drugs by microbial cultures for
   predicting mammalian drug metabolism (Retracted Article. See vol 22, pg
   619, 2004)
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review; Retracted Publication
DE biotransformation; drugs; metabolism; metabolites
ID NATURAL ANTITUMOR AGENTS; ANTI-TUMOR AGENTS; FUNGUS
   CUNNINGHAMELLA-ELEGANS; CYMENE-RELATED DRUGS; STREPTOMYCES-RIMOSUS;
   BEAUVERIA-BASSIANA; METHYL 5(6)-BUTYL-2-BENZIMIDAZOLECARBAMATE;
   STEREOSELECTIVE METABOLISM; AROMATIC HYDROXYLATION; PENICILLIUM-NOTATUM
AB This review discusses the microbial transformation studies of drugs, correlating them with the corresponding metabolism (biotransformation) in animal systems. Approaches are provided for development of microbial models for mammalian metabolism. Emphasis is placed on the potential of microorganisms to mimic mammalian metabolism and provide ways for structural elucidation and toxicological and pharmacological studies of metabolites. Microorganisms can provide difficult-to-synthesize drugs and assist in identifying metabolic pathways of drugs.. (C) 2003 Elsevier Science Inc. All rights reserved.
C1 Kakatiya Univ, Fac Pharmaceut Sci, Warangal 506009, Andhra Pradesh, India.
RP Veeresham, C (reprint author), Kakatiya Univ, Fac Pharmaceut Sci, Warangal 506009, Andhra Pradesh, India.
EM ciddiveeresham@yahoo.co.in
CR Abourashed EA, 1999, CURR MED CHEM, V6, P359
   ABULHAJJ YJ, 1986, J NAT PROD, V49, P244, DOI 10.1021/np50044a008
   ALTON KB, 1987, J CHROMATOGR, V385, P249, DOI 10.1016/S0021-9673(01)94637-0
   Azerad R, 1999, Adv Biochem Eng Biotechnol, V63, P169
   BAKER JK, 1981, J MED CHEM, V24, P666, DOI 10.1021/jm00138a004
   Banerjee A, 2002, CRIT REV BIOTECHNOL, V22, P245, DOI 10.1080/07388550290789513
   BANERJEE UC, 1993, ENZYME MICROB TECH, V15, P1037, DOI 10.1016/0141-0229(93)90051-3
   BANERJEE UC, 1992, BIOTECHNOL ADV, V10, P577, DOI 10.1016/0734-9750(92)91454-M
   BETTS RE, 1974, J MED CHEM, V17, P599, DOI 10.1021/jm00252a006
   BEUKERS R, 1972, DRUG DESIGN, V3, P1
   BRANNON DR, 1974, J MED CHEM, V17, P653, DOI 10.1021/jm00252a019
   Cannell RJP, 1997, XENOBIOTICA, V27, P147, DOI 10.1080/004982597240659
   CANNELL RJP, 1995, DRUG METAB DISPOS, V23, P724
   CARROLL FI, 1981, J MED CHEM, V24, P1047, DOI 10.1021/jm00141a006
   CERNIGLIA CE, 1988, XENOBIOTICA, V18, P301, DOI 10.3109/00498258809041666
   CHEN TS, 1993, J ANTIBIOT, V46, P131, DOI 10.7164/antibiotics.46.131
   CHEN TS, 1993, J NAT PROD, V56, P755, DOI 10.1021/np50095a013
   CHIEN MM, 1980, APPL ENVIRON MICROB, V40, P741
   CHIEN MM, 1979, DRUG METAB DISPOS, V7, P211
   CHISTI Y, 1999, ENCY BIOPROCESS TECH, V5, P2379
   Chisti Y, 1998, APPL MECH REV, V51, P33
   CLARK AM, 1982, J NAT PROD, V45, P574, DOI 10.1021/np50023a010
   CLARK AM, 1984, APPL ENVIRON MICROB, V47, P537
   CLARK AM, 1981, ANTIMICROB AGENTS CH, V19, P337, DOI 10.1128/AAC.19.2.337
   CLARK AM, 1984, APPL ENVIRON MICROB, V47, P540
   CLARK AM, 1985, MED RES REV, V5, P231, DOI 10.1002/med.2610050203
   CLARK AM, 1991, MED RES REV, V11, P473, DOI 10.1002/med.2610110503
   COUTTS RT, 1981, LIFE SCI, V29, P1951, DOI 10.1016/0024-3205(81)90603-2
   DAVID L, 1985, AGR BIOL CHEM TOKYO, V49, P2693, DOI 10.1080/00021369.1985.10867130
   DAVIS PJ, 1977, LLOYDIA, V40, P239
   DAVIS PJ, 1984, APPL ENVIRON MICROB, V48, P327
   DAVIS PJ, 1976, J ORG CHEM, V41, P2548, DOI 10.1021/jo00877a009
   DAVIS PJ, 1985, XENOBIOTICA, V15, P1001, DOI 10.3109/00498258509049095
   DAVIS PJ, 1979, APPL ENVIRON MICROB, V38, P891
   DAVIS PJ, 1985, XENOBIOTICA, V15, P845, DOI 10.3109/00498258509045036
   Duhart BT, 1999, XENOBIOTICA, V29, P733, DOI 10.1080/004982599238353
   DUNN GL, 1973, J MED CHEM, V16, P996, DOI 10.1021/jm00267a009
   ELMARAKBY SA, 1986, J PHARM SCI, V75, P614, DOI 10.1002/jps.2600750620
   ELSHARKAWY S, 1987, PHARMACEUT RES, V4, P353, DOI 10.1023/A:1016461623775
   ELSHARKAWY S, 1988, XENOBIOTICA, V18, P365, DOI 10.3109/00498258809041672
   ELSHARKAWY S, 1987, J NAT PROD, V50, P520, DOI 10.1021/np50051a038
   ELSHARKAWY SH, 1991, APPL MICROBIOL BIOT, V35, P436
   ELSHARKAWY SH, 1988, J ORG CHEM, V53, P515, DOI 10.1021/jo00238a008
   FABER K, 1992, BIOTRANSFORMATIONS O
   FONKEN GS, 1972, CHEM OXIDATIONS MICR
   FOSTER BC, 1991, CAN J MICROBIOL, V37, P504, DOI 10.1139/m91-085
   FOSTER BC, 1989, XENOBIOTICA, V19, P445, DOI 10.3109/00498258909042285
   FOSTER BC, 1992, XENOBIOTICA, V22, P1221, DOI 10.3109/00498259209053150
   FOSTER BC, 1989, XENOBIOTICA, V19, P539, DOI 10.3109/00498258909042293
   FOSTER BC, 1991, CAN J MICROBIOL, V37, P791, DOI 10.1139/m91-136
   FOSTER BC, 1988, LIFE SCI, V42, P285, DOI 10.1016/0024-3205(88)90637-6
   Freitag DG, 1997, DRUG METAB DISPOS, V25, P685
   GRIFFITHS DA, 1991, APPL MICROBIOL BIOT, V35, P373
   GRIFFITHS DA, 1993, XENOBIOTICA, V23, P1085, DOI 10.3109/00498259309059424
   GRIFFITHS DA, 1992, APPL MICROBIOL BIOT, V37, P169
   Grothe E, 1999, ENZYME MICROB TECH, V25, P132, DOI 10.1016/S0141-0229(99)00023-X
   HANLON GW, 1994, J APPL BACTERIOL, V76, P442, DOI 10.1111/j.1365-2672.1994.tb01100.x
   HANSEN EB, 1995, XENOBIOTICA, V25, P1081, DOI 10.3109/00498259509061908
   HANSEN EB, 1987, DRUG METAB DISPOS, V15, P97
   HANSEN EB, 1988, J PHARM SCI, V77, P259, DOI 10.1002/jps.2600770316
   HEZARI M, 1993, DRUG METAB DISPOS, V21, P259
   HEZARI M, 1992, DRUG METAB DISPOS, V20, P882
   HOLLAND HL, 1981, ALKALOIDS, V18, P323
   HUFFORD CD, 1979, J PHARM SCI, V68, P1239, DOI 10.1002/jps.2600681011
   HUFFORD CD, 1983, J PHARM SCI, V72, P92, DOI 10.1002/jps.2600720124
   HUFFORD CD, 1992, PHARMACEUT RES, V9, P623, DOI 10.1023/A:1015893808830
   HUFFORD CD, 1981, J PHARM SCI, V70, P151, DOI 10.1002/jps.2600700209
   HUFFORD CD, 1981, J PHARM SCI, V70, P155, DOI 10.1002/jps.2600700210
   IBRAHIM ARS, 1996, SAUDI PHARM J, V4, P165
   IIZUKA H, 1981, MICROBIAL CONVERSION
   JONES DF, 1970, J CHEM SOC C, P1725, DOI 10.1039/j39700001725
   KAMIMURA H, 1986, APPL ENVIRON MICROB, V52, P515
   Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4
   KARIM A, 1972, STEROIDS, V20, P41, DOI 10.1016/0039-128X(72)90117-1
   KITTELMANN M, 1993, BIOSCI BIOTECH BIOCH, V57, P1589, DOI 10.1271/bbb.57.1589
   KUNZ DA, 1985, APPL ENVIRON MICROB, V50, P831
   KUO MS, 1989, ANTIMICROB AGENTS CH, V33, P2089, DOI 10.1128/AAC.33.12.2089
   KUO MS, 1991, J ANTIBIOT, V44, P1096, DOI 10.7164/antibiotics.44.1096
   LANCINI GC, 1967, EXPERIENTIA, V23, P899, DOI 10.1007/BF02136207
   MARSHALL VP, 1989, J ANTIBIOT, V42, P132, DOI 10.7164/antibiotics.42.132
   MARSHECK WJ, 1973, APPL MICROBIOL, V25, P647
   Moody JD, 2000, APPL ENVIRON MICROB, V66, P3646, DOI 10.1128/AEM.66.8.3646-3649.2000
   Moody JD, 1999, DRUG METAB DISPOS, V27, P1157
   Moussa C, 1997, DRUG METAB DISPOS, V25, P301
   Moussa C, 1997, DRUG METAB DISPOS, V25, P311
   OTTEN S, 1979, APPL ENVIRON MICROB, V38, P311
   OTTEN S, 1978, APPL ENVIRON MICROB, V35, P554
   OTTEN SL, 1981, J NAT PROD, V44, P562, DOI 10.1021/np50017a009
   OTTEN SL, 1983, J BIOL CHEM, V258, P1610
   POLLIO A, 1994, PHYTOCHEMISTRY, V37, P1269, DOI 10.1016/S0031-9422(00)90396-0
   RAJU MS, 1982, J NAT PROD, V45, P321, DOI 10.1021/np50021a014
   Rao GP, 1997, DRUG METAB DISPOS, V25, P709
   REDDY CSG, 1990, XENOBIOTICA, V20, P1281, DOI 10.3109/00498259009046627
   Rosazza J P, 1979, Adv Appl Microbiol, V25, P169, DOI 10.1016/S0065-2164(08)70150-3
   ROSAZZA JP, 1977, XENOBIOTICA, V7, P133, DOI 10.3109/00498257709036245
   ROSI D, 1965, NATURE, V208, P1005, DOI 10.1038/2081005a0
   ROSI D, 1967, J MED CHEM, V10, P867, DOI 10.1021/jm00317a025
   SCHMITZ H, 1977, J ANTIBIOT, V30, P635, DOI 10.7164/antibiotics.30.635
   Schwartz H, 1996, APPL MICROBIOL BIOT, V44, P731
   SCHWARTZ H, 1993, APPL MICROBIOL BIOT, V40, P382
   SEBEK OK, 1984, J ANTIBIOT, V37, P136, DOI 10.7164/antibiotics.37.136
   SIH CJ, 1984, ANGEW CHEM INT EDIT, V23, P570, DOI 10.1002/anie.198405701
   SMITH RV, 1974, ARCH BIOCHEM BIOPHYS, V161, P551, DOI 10.1016/0003-9861(74)90338-5
   SMITH RV, 1983, J PHARM SCI, V72, P733, DOI 10.1002/jps.2600720704
   SMITH RV, 1983, J NAT PROD, V46, P79, DOI 10.1021/np50025a006
   SMITH RV, 1975, J PHARM SCI-US, V64, P1737, DOI 10.1002/jps.2600641104
   UMEZAWA H, 1973, J ANTIBIOT, V26, P117, DOI 10.7164/antibiotics.26.117
   VALENTA JR, 1974, APPL MICROBIOL, V28, P995
   WONG YWJ, 1991, J PHARM SCI, V80, P305, DOI 10.1002/jps.2600800402
   WONG YWJ, 1989, PHARMACEUT RES, V6, P982, DOI 10.1023/A:1015905832184
   ZEDAN HH, 1983, J GEN MICROBIOL, V129, P1035
   ZEITLER HJ, 1969, H-S Z PHYSIOL CHEM, V350, P366, DOI 10.1515/bchm2.1969.350.1.366
   Zhang DL, 1996, CHEM-BIOL INTERACT, V102, P79, DOI 10.1016/S0009-2797(96)03736-2
   Zhang DL, 1995, DRUG METAB DISPOS, V23, P1417
   Zhang DL, 1996, APPL ENVIRON MICROB, V62, P3477
   Zhang DL, 1997, XENOBIOTICA, V27, P301, DOI 10.1080/004982597240622
NR 116
TC 24
Z9 32
U1 4
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD MAR
PY 2003
VL 21
IS 1
BP 3
EP 39
DI 10.1016/S0734-9750(02)00096-4
PG 37
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 657EJ
UT WOS:000181652200002
PM 14499135
DA 2018-12-27
ER

PT J
AU Schywalsky, M
   Ihmsen, H
   Tzabazis, A
   Fechner, J
   Burak, E
   Vornov, J
   Schwilden, H
AF Schywalsky, M
   Ihmsen, H
   Tzabazis, A
   Fechner, J
   Burak, E
   Vornov, J
   Schwilden, H
TI RETRACTED: Pharmacokinetics and pharmacodynamics of the new propofol
   prodrug GPI 15715 in rats (Retracted article. See vol. 20, pg. 182,
   2003)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE anaesthetics, intravenous, propofol; electroencephalography;
   pharmacodynamics; pharmacokinetics, biotransformation; rat
ID SEDATION
AB Background and objective: We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan(R) injection), a new water-soluble prodrug metabolized to propofol by hydrolysis.
   Methods: Nine adult male Sprague-Dawley rats (398 +/- 31 g) received a bolus dose of 40 mg GPI 15715. The plasma concentrations of GPI 15715 and propofol were determined from arterial blood samples, and the pharmacokinetics of both compounds were investigated using compartment models whereby the elimination from the central compartment of GPI 15715 was used as drug input for the central compartment of propofol. Pharmacodynamics were assessed using the median frequency of the EEG power spectrum.
   Results: A maximum propofol concentration of 7.1 +/- 1.7 mug mL(-1) was reached 3.7 +/- 0.2 min after bolus administration. Pharmacokinetics were best described by two-compartment models. GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 Lkg(-1). For propofol, the half-life was 1.9 +/- 0.1 and 45 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 Lkg(-1). The maximum effect on the electroencephalogram (EEG) - EEG suppression for >4 s-occurred 6.5 +/- 1.2 min after bolus administration and baseline values of the EEG median frequency were regained 30 min later. The EEG effect could be described by a sigmoid E-max model including an effect compartment (EO = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 mug mL(-1), k(e0) = 0.35 +/- 0.04 min(-1)).
   Conclusions: Compared with known propofol formulations, propofol from GPI 15715 showed a longer half-life, an increased volume of distribution, a delayed onset, a sustained duration of action and a greater potency with respect to concentration.
C1 Univ Erlangen Nurnberg, Dept Anaesthesiol, Erlangen, Germany.
   Guilford Pharmaceut, Baltimore, MD USA.
RP Ihmsen, H (reprint author), Anasthesiol Klin, Krankenhausstr 12, D-91054 Erlangen, Germany.
EM Harald.Ihmsen@kfa.imed.uni-erlangen.de
CR Albrecht S, 1999, ANAESTHESIST, V48, P794, DOI 10.1007/s001010050787
   BEAL SL, 1994, NONMEM USERS GUIDE
   BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008
   COCKSHOTT ID, 1992, XENOBIOTICA, V22, P369, DOI 10.3109/00498259209046648
   Cox EH, 1998, PHARMACEUT RES, V15, P442, DOI 10.1023/A:1011980432646
   Dutta S, 1998, J PHARM PHARMACOL, V50, P37, DOI 10.1111/j.2042-7158.1998.tb03302.x
   Dutta S, 1997, J PHARM SCI, V86, P37, DOI 10.1021/js960247n
   Dutta S, 1998, ANESTHESIOLOGY, V89, P678, DOI 10.1097/00000542-199809000-00018
   EBLING WF, 1994, J PHARMACOKINET BIOP, V22, P259, DOI 10.1007/BF02353622
   GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731
   *GPI, 2001, 15715 GPI GUILF PHAR
   Ihmsen H, 2002, EUR J ANAESTH, V19, P177, DOI 10.1017/S0265021502000327
   Lindholm M, 1992, Minerva Anestesiol, V58, P875
   Yang CH, 1995, J PHARMACOL EXP THER, V275, P1568
NR 14
TC 35
Z9 42
U1 4
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD MAR
PY 2003
VL 20
IS 3
BP 182
EP 190
DI 10.1097/00003643-200303000-00002
PG 9
WC Anesthesiology
SC Anesthesiology
GA 657UV
UT WOS:000181685500002
PM 12650488
DA 2018-12-27
ER

PT J
AU Sanna, LJ
   Parks, CD
   Chang, EC
AF Sanna, LJ
   Parks, CD
   Chang, EC
TI RETRACTED: Mixed-motive conflict in social dilemmas: Mood as input to
   competitive and cooperative goals (Retracted article. See vol. 16, pg.
   205, 2012)
SO GROUP DYNAMICS-THEORY RESEARCH AND PRACTICE
LA English
DT Article; Retracted Publication
ID POSITIVE AFFECT; VALUE ORIENTATION; PERFORMANCE; PERSUASION;
   CATEGORIZATION; PRODUCTIVITY; RECIPROCITY; MOTIVATION; MEDIATION
AB Four studies using diverse manipulations demonstrated that moods interacted with competitive and cooperative goals to influence people's behaviors in social dilemmas. This was true whether moods were manipulated by films (Studies 1 and 2) or music (Study 4) or were assessed dispositionally (Study 3); whether specific or global goals were manipulated (Studies 1, 3, and 4) or were assessed dispositionally (Study 2); and whether participants' actions were tested in a resource dilemma (Studies 1, 2, and 4) or prisoner's dilemma game (Study 3). In 3 studies, bad moods led to more competition (less cooperation) with competitive goals in mind but to more cooperation (less competition) with cooperative goals in mind. A 4th study reversed this pattern with goals framed in terms of enjoyment.
C1 Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA.
   Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.
   Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA.
RP Sanna, LJ (reprint author), Univ N Carolina, Dept Psychol, CB 3270,Davie Hall, Chapel Hill, NC 27599 USA.
EM sanna@unc.edu
OI Parks, Craig/0000-0001-5299-093X
CR ALLISON ST, 1985, J PERS SOC PSYCHOL, V49, P943, DOI 10.1037//0022-3514.49.4.943
   AUSTIN JT, 1984, ACAD MANAGEMENT P, P197
   Bargh JA, 2001, J PERS SOC PSYCHOL, V81, P1014, DOI 10.1037//0022-3514.81.6.1014
   Beck A. T, 1967, DEPRESSION CLIN EXPT
   BLESS H, 1990, PERS SOC PSYCHOL B, V16, P331, DOI 10.1177/0146167290162013
   Bodenhausen GV., 1993, AFFECT COGNITION STE, P13
   Bower G. H., 1991, EMOTION SOCIAL JUDGM, P31
   BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4
   CARNEVALE PJD, 1986, ORGAN BEHAV HUM DEC, V37, P1, DOI 10.1016/0749-5978(86)90041-5
   Carver C. S., 1998, SELF REGULATION BEHA
   CARVER CS, 1990, PSYCHOL REV, V97, P19, DOI 10.1037//0033-295X.97.1.19
   CHIDESTER TR, 1984, ACAD MANAGEMENT P, P202
   DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125
   Dykman BM, 1996, COGNITIVE THER RES, V20, P445, DOI 10.1007/BF02227907
   FIEDLER K, 1988, AFFECT COGNITION SOC, P100
   FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037//0033-2909.117.1.39
   HARDIN G, 1968, SCIENCE, V162, P1243
   Hertel G, 2000, COGNITION EMOTION, V14, P441, DOI 10.1080/026999300402754
   HERTEL G, 1999, RESOLVING SOCIAL DIL, P227
   HUNTER JE, 1983, AM PSYCHOL, V38, P473, DOI 10.1037/0003-066X.38.4.473
   ISEN AM, 1984, J PERS SOC PSYCHOL, V47, P1206, DOI 10.1037//0022-3514.47.6.1206
   ISEN AM, 1985, J PERS SOC PSYCHOL, V48, P1413, DOI 10.1037/0022-3514.48.6.1413
   KERR NL, 1994, J PERS SOC PSYCHOL, V66, P513, DOI 10.1037//0022-3514.66.3.513
   KNAPP A, 1991, PERS SOC PSYCHOL B, V17, P678, DOI 10.1177/0146167291176011
   Komorita S.S, 1996, SOCIAL DILEMMAS
   KOMORITA SS, 1995, ANNU REV PSYCHOL, V46, P183, DOI 10.1146/annurev.ps.46.020195.001151
   KOTLIKOFF LJ, 1987, J POLICY ANAL MANAG, V6, P674, DOI 10.2307/3323524
   LICHBACH MI, 1990, J CONFLICT RESOLUT, V34, P29, DOI 10.1177/0022002790034001002
   Locke E. A., 1990, THEORY GOAL SETTING
   LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037//0033-2909.90.1.125
   MACKIE DM, 1989, J PERS SOC PSYCHOL, V57, P27, DOI 10.1037/0022-3514.57.1.27
   Martin LL, 1997, J PERS SOC PSYCHOL, V73, P242
   MARTIN LL, 1993, J PERS SOC PSYCHOL, V64, P317, DOI 10.1037/0022-3514.64.3.317
   Messick D. M., 1983, REV PERSONALITY SOCI, V4, P11
   MURRAY N, 1990, J PERS SOC PSYCHOL, V59, P411, DOI 10.1037/0022-3514.59.3.411
   NAYLOR JC, 1984, RES ORGAN BEHAV, V6, P95
   Parks C. D., 1999, GROUP PERFORMANCE IN
   Parks CD, 2001, PERS SOC PSYCHOL B, V27, P345, DOI 10.1177/0146167201273008
   Parks CD, 2001, PERS SOC PSYCHOL B, V27, P1301, DOI 10.1177/01461672012710006
   Pruitt D. G, 1993, NEGOTIATION SOCIAL C
   Pruyn A, 2001, J ECON PSYCHOL, V22, P43, DOI 10.1016/S0167-4870(00)00036-2
   RAPOPORT A, 1967, J CONFLICT RESOLUT, V11, P100, DOI 10.1177/002200276701100108
   Rosenthal R, 1985, CONTRAST ANAL FOCUSE
   RUTTE CG, 1990, SOC BEHAV, V5, P285
   Sanna LJ, 1996, PERS SOC PSYCHOL B, V22, P323, DOI 10.1177/0146167296224001
   Sanna LJ, 1999, PSYCHOL SCI, V10, P339, DOI 10.1111/1467-9280.00165
   Sanna LJ, 1999, J PERS SOC PSYCHOL, V76, P543, DOI 10.1037//0022-3514.76.4.543
   Sanna LJ, 2001, BRIT J SOC PSYCHOL, V40, P235, DOI 10.1348/014466601164830
   Sanna LJ, 1997, PSYCHOL SCI, V8, P261, DOI 10.1111/j.1467-9280.1997.tb00436.x
   Schelling T. C, 1960, STRATEGY CONFLICT
   Schroeder D. A, 1995, SOCIAL DILEMMAS
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, P433
   Schwarz N., 1990, HDB MOTIVATION COGNI, V2, P527, DOI DOI 10.1016/J.NEUBIOREV.2008.01.001
   SHEPPERD JA, 1993, PSYCHOL BULL, V113, P67, DOI 10.1037/0033-2909.113.1.67
   Shepperd JA, 2001, GROUP DYN-THEOR RES, V5, P304, DOI 10.1037//1089-2699.5.4.304
   SINCLAIR RC, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P165
   SINCLAIR RC, 1995, COGNITION EMOTION, V9, P417, DOI 10.1080/02699939508408974
   Stotland E., 1969, PSYCHOL HOPE
   TUBBS ME, 1986, J APPL PSYCHOL, V71, P474, DOI 10.1037//0021-9010.71.3.474
   VanLange PAM, 1997, J PERS SOC PSYCHOL, V73, P1330
   VanLange PAM, 1997, J PERS SOC PSYCHOL, V73, P733, DOI 10.1037/0022-3514.73.4.733
   VANLANGE PAM, 1994, J PERS SOC PSYCHOL, V67, P126, DOI 10.1037/0022-3514.67.1.126
   WOOD RE, 1987, J APPL PSYCHOL, V72, P416, DOI 10.1037//0021-9010.72.3.416
   WORTH LT, 1987, SOC COGNITION, V5, P76, DOI 10.1521/soco.1987.5.1.76
NR 64
TC 26
Z9 27
U1 2
U2 31
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1089-2699
EI 1930-7802
J9 GROUP DYN-THEOR RES
JI Group Dyn.-Theory Res. Pract.
PD MAR
PY 2003
VL 7
IS 1
BP 26
EP 40
DI 10.1037/1089-2699.7.1.26
PG 15
WC Psychology, Social
SC Psychology
GA 654NF
UT WOS:000181502400003
DA 2018-12-27
ER

PT J
AU Wang, LY
   Xu, YL
AF Wang, LY
   Xu, YL
TI RETRACTED: Wind-rain-induced vibration of cable: an analytical model (1)
   (Retracted article. See vol. 130, pg. 296, 2018)
SO INTERNATIONAL JOURNAL OF SOLIDS AND STRUCTURES
LA English
DT Article; Retracted Publication
DE stayed-cable; cable vibration; wind; rain; moving rivulet; fixed
   rivulet; analytical model; comparison
AB There have been many reports recently on excessive and unanticipated vibration of cables in cable-stayed bridges under the simultaneous occurrence of wind and rain. Correspondingly, many efforts have been made to avoid such large amplitude cable vibrations that often cause fatigue damage and corrosion to strands in surprisingly short periods. However, the mechanism of wind-rain-induced cable vibration is still not clear and the analytical solution is being actively sought for the design of cables against such a vibration. This paper thus presents a preliminary theoretical study aiming to provide an analytical solution to the problem and to explain some phenomena observed from field measurements and wind-rain tunnel tests. The proposed analytical model takes into account the effect of mean wind speed on the position of upper rivulet and the influence of moving upper rivulet on cable vibration. The analytical model-is then verified through the comparison with the simulated wind tunnel tests for cables with moving rivulet or fixed artificial rivulet. It turns out that the analytical model can capture main features of wind-rain-induced cable vibration. The comparative studies also shed light on the mechanism of wind-rain-induced cable vibration. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Hong Kong Polytech Univ, Dept Civil & Struct Engn, Kowloon, Hong Kong, Peoples R China.
RP Wang, LY (reprint author), Hong Kong Polytech Univ, Dept Civil & Struct Engn, Kowloon, Hong Kong, Peoples R China.
EM 98901561r@polyu.edu.hk
RI Xu, You-Lin/B-8895-2015
OI Xu, You-Lin/0000-0002-1460-082X
CR Blevins R, 1977, FLOW INDUCED VIBRATI
   Bosdogianni A, 1996, J WIND ENG IND AEROD, V64, P171, DOI 10.1016/S0167-6105(96)00089-X
   FLAMAND O, 1995, J WIND ENG IND AEROD, V57, P353, DOI 10.1016/0167-6105(94)00113-R
   GEURTS CPW, 1999, P 10 INT C WIND ENG, V2, P885
   GU M, UNPUB J WIND ENG IND
   HIKAMI Y, 1988, J WIND ENG IND AEROD, V29, P409, DOI 10.1016/0167-6105(88)90179-1
   MATSUMOTO M, 1992, J WIND ENG IND AEROD, V43, P2011
   OHSHIMA K, 1987, P US JAP JOINT SEM N, P324
   RUSCHEWEYH HP, 1999, P 10 INT C WIND ENG, V2, P1041
   YAMAGUCHI H, 1990, J WIND ENG IND AEROD, V33, P73, DOI 10.1016/0167-6105(90)90022-5
NR 10
TC 13
Z9 17
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7683
EI 1879-2146
J9 INT J SOLIDS STRUCT
JI Int. J. Solids Struct.
PD MAR
PY 2003
VL 40
IS 5
BP 1265
EP 1280
AR PII S0020-7683(02)00582-6
DI 10.1016/S0020-7683(02)00582-6
PG 16
WC Mechanics
SC Mechanics
GA 650LE
UT WOS:000181264500011
DA 2018-12-27
ER

PT J
AU Nurieva, RI
   Treuting, P
   Duong, J
   Flavell, RA
   Dong, C
AF Nurieva, RI
   Treuting, P
   Duong, J
   Flavell, RA
   Dong, C
TI RETRACTED: Inducible costimulator is essential for collagen-induced
   arthritis (Retracted Article. See vol 112, pg 1597, 2003)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID T-CELL ACTIVATION; RHEUMATOID-ARTHRITIS; CD28-DEFICIENT MICE; JOINT
   DESTRUCTION; MOLECULE ICOS; INTERLEUKIN-17; IL-17; AUTOANTIBODIES;
   AUTOIMMUNITY; RESPONSES
AB CD4(+) helper Th cells play a major role in the pathogenesis of rheumatoid arthritis. Th cell activation, differentiation, and immune function are regulated by costimulatory molecules. Inducible costimulator (ICOS) is a novel costimulatory receptor expressed on activated T cells. We, as well as others, recently demonstrated its importance in Th2 cytokine expression and Ab class switching by B cells. In this study, we examined the role of ICOS in rheumatoid arthritis using a collagen-induced arthritis model. We found that ICOS knockout mice on the DBA/1 background were completely resistant to collagen-induced arthritis and exhibited absence of joint tissue inflammation. These mice, when immunized with collagen, exhibited reduced anti-collagen IgM Ab's in the initial stage and IgG2a Ab's at the effector phase of collagen-induced arthritis. Furthermore, ICOS regulates the in vitro and in vivo expression of IL-17, a proinflammatory cytokine implicated in rheumatoid arthritis. These data indicate that ICOS is essential for collagen-induced arthritis and may suggest novel means for treating patients with rheumatoid arthritis.
C1 Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA.
   Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.
   Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06510 USA.
RP Dong, C (reprint author), Univ Washington, Sch Med, Dept Immunol, Box 357650,H466 Hlth Sci Complex, Seattle, WA 98195 USA.
EM chendong@u.washington.edu
RI dong, chen/B-3181-2009
OI dong, chen/0000-0002-0084-9130
CR Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609
   Buonfiglio D, 2000, EUR J IMMUNOL, V30, P3463, DOI 10.1002/1521-4141(2000012)30:12<3463::AID-IMMU3463>3.0.CO;2-5
   Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E
   Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1
   Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659
   Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5
   Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593
   HOLMDAHL R, 1990, IMMUNOL REV, V118, P193, DOI 10.1111/j.1600-065X.1990.tb00817.x
   HOLMDAHL R, 1990, SCAND J IMMUNOL, V31, P147, DOI 10.1111/j.1365-3083.1990.tb02754.x
   Hutloff A, 1999, NATURE, V397, P263
   Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Lubberts E, 2002, INFLAMM RES, V51, P102, DOI 10.1007/BF02684010
   Lubberts E, 2001, J IMMUNOL, V167, P1004, DOI 10.4049/jimmunol.167.2.1004
   Luross JA, 2001, IMMUNOLOGY, V103, P407, DOI 10.1046/j.1365-2567.2001.01267.x
   McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035
   McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107
   Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3
   Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6
   Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7
   Redoglia V, 1996, EUR J IMMUNOL, V26, P2781, DOI 10.1002/eji.1830261134
   SEKI N, 1988, J IMMUNOL, V140, P1477
   SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139
   Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X
   Tada Y, 1999, J IMMUNOL, V162, P203
   Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113
   Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513
   YOO ZB, 1995, J IMMUNOL, V155, P5483
   Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582
NR 31
TC 85
Z9 90
U1 0
U2 0
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2003
VL 111
IS 5
BP 701
EP 706
DI 10.1172/JCI200317321
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 651XA
UT WOS:000181346600018
PM 12618524
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Niederhofer, H
   Staffen, W
   Mair, A
AF Niederhofer, H
   Staffen, W
   Mair, A
TI RETRACTED: A placebo-controlled study of lofexidine in the treatment of
   children with tic disorders and attention deficit hyperactivity disorder
   (Retracted Article. See vol 18, 2004)
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE attention deficit hyperactivity disorder; lofexidine; tic disorder
ID LA-TOURETTES SYNDROME; SPATIAL WORKING-MEMORY; IRIS-CILIARY BODY;
   STIMULANT-DRUGS; NORMATIVE DATA; RATING-SCALES; BLOOD-FLOW; CLONIDINE;
   METHYLPHENIDATE; EFFICACY
AB This study evaluated the efficacy and safety of Lofexidine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with lofexidine or placebo under double-blind conditions. Follow-up visits occurred every 2 weeks for safety monitoring and dose adjustment. Fourty-four medication-free subjects (41 boys and three girls; mean age of 10.4 years) with ADHD, combined type, and a tic disorder participated. After 8 weeks of treatment, lofexidine was associated with a mean improvement of 41% in the total score on the teacher-rated ADHD Rating Scale compared to 7% improvement for placebo. Eleven of 22 subjects who received lofexidine were blindly rated on the Clinical Global Scale-Improvement as either much improved or very much improved compared to none of 22 subjects who received placebo. The mean score on the parent-rated hyperactivity index improved by 29% in the lofexidine group and 18% in the placebo group, which was not a significant difference. On the Continuous Performance Test, commission errors decreased by 25% and omission errors by 20% in the lofexidine group, compared with increases of 33% in commission errors and of 36% in omission errors in the placebo group. Tic severity decreased by 27% in the lofexidine group, compared to 0% in the placebo group. One lofexidine subject with sedation withdrew at week 4. Lofexidine was associated with insignificant decreases in blood pressure and pulse. Lofexidine appears to be a safe and effective treatment for children with tic disorders and ADHD.
C1 Christian Doppler Klin, Dept Neurol, A-5020 Salzburg, Austria.
RP Niederhofer, H (reprint author), Christian Doppler Klin, Dept Neurol, Ignaz Harrer Str 79, A-5020 Salzburg, Austria.
EM helmut.niederhofer@uibk.ac.at
RI Cognitive Neuroscience, Centre for/C-7888-2011
CR Akhurst JS, 1999, EUR ADDICT RES, V5, P43, DOI 10.1159/000018962
   Avery RA, 2000, NEUROPSYCHOPHARMACOL, V23, P240, DOI 10.1016/S0893-133X(00)00111-1
   BARKLEY RA, 1990, PEDIATRICS, V86, P184
   BARRICKMAN LL, 1995, J AM ACAD CHILD PSY, V34, P649, DOI 10.1097/00004583-199505000-00017
   BERRIDGE CW, 1991, J NEUROSCI, V11, P3135
   BIEDERMAN J, 1984, NEW ENGL J MED, V310, P968, DOI 10.1056/NEJM198404123101507
   BIEDERMAN J, 1989, J AM ACAD CHILD PSY, V28, P777, DOI 10.1097/00004583-198909000-00022
   BORCHERDING BG, 1990, PSYCHIAT RES, V33, P83, DOI 10.1016/0165-1781(90)90151-T
   Brown AS, 1998, J PSYCHOPHARMACOL, V12, P93, DOI 10.1177/026988119801200112
   Buitelaar JK, 1996, J CHILD PSYCHOL PSYC, V37, P587, DOI 10.1111/j.1469-7610.1996.tb01445.x
   BUZSAKI G, 1991, EUR J NEUROSCI, V3, P222, DOI 10.1111/j.1460-9568.1991.tb00083.x
   Carnwath T, 1998, DRUG ALCOHOL DEPEN, V50, P251, DOI 10.1016/S0376-8716(98)00040-4
   Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016
   COHEN DJ, 1979, LANCET, V2, P551
   CONNERS CK, 1985, PSYCHOPHARMACOL BULL, V21, P809
   Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018
   Connor DF, 2000, CLIN PEDIATR, V39, P15, DOI 10.1177/000992280003900102
   Crenshaw TM, 1999, ADV LEARN B, V13, P135
   DuPaul GJ, 1997, PSYCHOL ASSESSMENT, V9, P436
   EGGERS C, 1988, EUR ARCH PSY CLIN N, V237, P223, DOI 10.1007/BF00449911
   ENGBERG G, 1991, N-S ARCH PHARMACOL, V343, P472
   ERENBERG G, 1985, NEUROLOGY, V35, P1346, DOI 10.1212/WNL.35.9.1346
   Feigin A, 1996, NEUROLOGY, V46, P965, DOI 10.1212/WNL.46.4.965
   GADOW KD, 1995, ARCH GEN PSYCHIAT, V52, P444
   Gadow KD, 1999, ARCH GEN PSYCHIAT, V56, P330, DOI 10.1001/archpsyc.56.4.330
   GOETZ CG, 1987, ANN NEUROL, V21, P307, DOI 10.1002/ana.410210313
   GOWING L, 2001, COCHRANE DB SYST REV, V1
   GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127
   Greenhill LL, 1996, J AM ACAD CHILD PSY, V35, P1304, DOI 10.1097/00004583-199610000-00017
   Gutgesell H, 1999, CIRCULATION, V99, P979, DOI 10.1161/01.CIR.99.7.979
   GUY W, 1976, PUBLICATION ADM, P218
   HUNT RD, 1985, J AM ACAD CHILD PSY, V24, P617, DOI 10.1016/S0002-7138(09)60065-0
   JIN Y, 1989, J OCUL PHARMACOL, V5, P189, DOI 10.1089/jop.1989.5.189
   JIN Y, 1992, J OCUL PHARMACOL, V8, P23, DOI 10.1089/jop.1992.8.23
   KATZ NL, 1989, PHARMACOL BIOCHEM BE, V34, P433, DOI 10.1016/0091-3057(89)90339-0
   Law SF, 1999, J AM ACAD CHILD PSY, V38, P944, DOI 10.1097/00004583-199908000-00009
   LECKMAN JF, 1991, ARCH GEN PSYCHIAT, V48, P324
   LECKMAN JF, 1989, J AM ACAD CHILD PSY, V28, P566, DOI 10.1097/00004583-198907000-00015
   LECKMAN JF, 1986, ARCH GEN PSYCHIAT, V43, P1168
   Leckman JF, 1999, TOURETTES SYNDROME T, P285
   LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343
   Li BM, 1999, NEUROPSYCHOPHARMACOL, V21, P601, DOI 10.1016/S0893-133X(99)00070-6
   LIPKIN PH, 1994, ARCH PEDIAT ADOL MED, V148, P859, DOI 10.1001/archpedi.1994.02170080089017
   LOWE TL, 1982, JAMA-J AM MED ASSOC, V247, P1729, DOI 10.1001/jama.247.12.1729
   Nass R, 2002, NEUROLOGY, V58, P513, DOI 10.1212/WNL.58.4.513
   National Heart, 1987, PEDIATRICS, V79, P1
   Power TJ, 1998, J PSYCHOPATHOL BEHAV, V20, P57, DOI 10.1023/A:1023035426642
   RAPPORT MD, 1994, J AM ACAD CHILD PSY, V33, P882, DOI 10.1097/00004583-199407000-00015
   RIDDLE MA, 1995, J CHILD ADOL PSYCHOP, V5, P205, DOI 10.1089/cap.1995.5.205
   RIDDLE MA, 1993, J AM ACAD CHILD PSY, V32, P792, DOI 10.1097/00004583-199307000-00013
   ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220
   Sallee FR, 2000, J AM ACAD CHILD PSY, V39, P292, DOI 10.1097/00004583-200003000-00010
   Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023
   SHAPIRO E, 1989, ARCH GEN PSYCHIAT, V46, P722
   SINGER HS, 1995, PEDIATRICS, V95, P74
   SORKIN EM, 1986, DRUGS, V31, P301, DOI 10.2165/00003495-198631040-00003
   Strang J, 1999, AM J ADDICTION, V8, P337, DOI 10.1080/105504999305749
   Swanson JM, 1998, J AM ACAD CHILD PSY, V37, P519, DOI 10.1097/00004583-199805000-00014
   WILSON MF, 1986, AM J CARDIOL, V57, pE43, DOI 10.1016/0002-9149(86)90723-X
   Zito JM, 2000, JAMA-J AM MED ASSOC, V283, P1025, DOI 10.1001/jama.283.8.1025
NR 60
TC 16
Z9 16
U1 3
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD MAR
PY 2003
VL 17
IS 1
BP 113
EP 119
DI 10.1177/0269881103017001714
PG 7
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 659BA
UT WOS:000181755500016
PM 12680748
DA 2018-12-27
ER

PT J
AU Barboza, M
   Duschak, VG
   Cazzulo, JJ
   de Lederkremer, RM
   Couto, AS
AF Barboza, M
   Duschak, VG
   Cazzulo, JJ
   de Lederkremer, RM
   Couto, AS
TI RETRACTED: Presence of sialic acid in N-linked oligosaccharide chains
   and O-linked N-acetylglucosamine in cruzipain, the major cysteine
   proteinase of Trypanosoma cruzi (Retracted Article. See vol 129, pg 215,
   2003)
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article; Retracted Publication
DE Trypanosoma cruzi; sialic acids; cruzipain; O-N-acetyl-D-glucosamine
ID C-TERMINAL DOMAIN; TRANS-SIALIDASE; INHIBITORS
C1 Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, CIHIDECAR,CONICET, RA-1428 Buenos Aires, DF, Argentina.
   Univ Nacl Gral San Martin, Inst Invest Biotecnol, RA-1650 Buenos Aires, DF, Argentina.
RP Couto, AS (reprint author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, CIHIDECAR,CONICET, RA-1428 Buenos Aires, DF, Argentina.
EM acouto@qo.fcen.uba.ar
OI Duschak, Vilma G/0000-0002-3613-7899
CR Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6
   ACOSTASERRANO A, 1995, J BIOL CHEM, V270, P27244
   Brooks DR, 2000, J CELL SCI, V113, P4035
   Cazzulo J.J., 1995, ACTA CHIM SLOV, V42, P409
   CAZZULO JJ, 1990, MOL BIOCHEM PARASIT, V38, P41, DOI 10.1016/0166-6851(90)90203-X
   CAZZULO JJ, 1992, FEMS MICROBIOL LETT, V100, P411, DOI 10.1016/0378-1097(92)90239-K
   Cazzulo JJ, 2001, CURR PHARM DESIGN, V7, P1143, DOI 10.2174/1381612013397528
   Coombs Graham H., 1997, P177
   DECAZZULO BMF, 1994, FEMS MICROBIOL LETT, V124, P81
   Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7
   HELLMAN U, 1991, MOL BIOCHEM PARASIT, V44, P15, DOI 10.1016/0166-6851(91)90216-S
   Martinez J, 1998, FEMS MICROBIOL LETT, V159, P35, DOI 10.1016/S0378-1097(97)00539-9
   PARODI AJ, 1995, MOL BIOCHEM PARASIT, V69, P247, DOI 10.1016/0166-6851(94)00213-7
   Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982
   Salto ML, 2000, ANAL BIOCHEM, V279, P79, DOI 10.1006/abio.1999.4466
   SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2
   SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O
   STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E
   YU RK, 1969, J BIOL CHEM, V244, P1306
   Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u
NR 20
TC 8
Z9 9
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
EI 1872-9428
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD MAR
PY 2003
VL 127
IS 1
BP 69
EP 72
DI 10.1016/S0166-6851(02)00303-1
PG 4
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA 658TB
UT WOS:000181735600007
PM 12615337
DA 2018-12-27
ER

PT J
AU Voinnet, O
   Rivas, S
   Mestre, P
   Baulcombe, D
AF Voinnet, O
   Rivas, S
   Mestre, P
   Baulcombe, D
TI RETRACTED: An enhanced transient expression system in plants based on
   suppression of gene silencing by the p19 protein of tomato bushy stunt
   virus (Retracted article. See vol. 84, pg. 846, 2015)
SO PLANT JOURNAL
LA English
DT Article; Retracted Publication
DE Agrobacterium-mediated transient expression; RNA silencing; viral
   suppressors; p19 protein; protein purification
ID DOUBLE-STRANDED-RNA; NICOTIANA-BENTHAMIANA; CLADOSPORIUM-FULVUM;
   RESISTANCE; CF-9; DNA; INTERFERENCE; TRANSGENE; POTATO; ARABIDOPSIS
AB Transient gene expression is a fast, flexible and reproducible approach to high-level expression of useful proteins. In plants, recombinant strains of Agrobacterium tumefaciens can be used for transient expression of genes that have been inserted into the T-DNA region of the bacterial Ti plasmid. A bacterial culture is vacuum-infiltrated into leaves, and upon T-DNA transfer, there is ectopic expression of the gene of interest in the plant cells. However, the utility of the system is limited because the ectopic protein expression ceases after 2-3 days. Here, we show that post-transcriptional gene silencing (PTGS) is a major cause for this lack of efficiency. We describe a system based on co-expression of a viral-encoded suppressor of gene silencing, the p19 protein of tomato bushy stunt virus (TBSV), that prevents the onset of PTGS in the infiltrated tissues and allows high level of transient expression. Expression of a range of proteins was enhanced 50-folds or more in the presence of p19 so that protein purification could be achieved from as little as 100 mg of infiltrated leaf material. The effect of p19 was not saturated in cells that had received up to four individual T-DNAs and persisted until leaf senescence. Because of its simplicity and rapidity, we anticipate that the p19-enhanced expression system will have value in industrial production as well as a research tool for isolation and biochemical characterisation of a broad range of proteins without the need for the time-consuming regeneration of stably transformed plants.
C1 John Innes Ctr Plant Sci Res, Sainsbury Lane, Norwich NR4 7UH, Norfolk, England.
RP Baulcombe, D (reprint author), John Innes Ctr Plant Sci Res, Sainsbury Lane, Colney Lane, Norwich NR4 7UH, Norfolk, England.
EM david.baulcombe@sainsbury-laboratory.ac.uk
OI Baulcombe, David/0000-0003-0780-6878
CR Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079
   Bendahmane A, 2000, PLANT J, V21, P73, DOI 10.1046/j.1365-313x.2000.00654.x
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739
   Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fischer R, 1999, BIOTECHNOL APPL BIOC, V30, P113
   Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Hamilton CM, 1996, P NATL ACAD SCI USA, V93, P9975, DOI 10.1073/pnas.93.18.9975
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   Hammond SM, 2000, NATURE, V404, P293
   Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122
   Johansen LK, 2001, PLANT PHYSIOL, V126, P930, DOI 10.1104/pp.126.3.930
   JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631
   Kapila J, 1997, PLANT SCI, V122, P101, DOI 10.1016/S0168-9452(96)04541-4
   Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1
   KAVANAGH T, 1992, VIROLOGY, V189, P609, DOI 10.1016/0042-6822(92)90584-C
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948
   Mallory AC, 2002, NAT BIOTECHNOL, V20, P622, DOI 10.1038/nbt0602-622
   Mestre P, 2000, PLANT J, V23, P653, DOI 10.1046/j.1365-313x.2000.00834.x
   Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6
   Piedras P, 2000, PLANT J, V21, P529, DOI 10.1046/j.1365-313x.2000.00697.x
   Porta C, 1996, INTERVIROLOGY, V39, P79, DOI 10.1159/000150478
   Ratcliff FG, 1999, PLANT CELL, V11, P1207
   Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]
   Ruiz MT, 1998, PLANT CELL, V10, P937
   Thomas CM, 1997, PLANT CELL, V9, P2209, DOI 10.1105/tpc.9.12.2209
   Van der Hoorn RAL, 2000, MOL PLANT MICROBE IN, V13, P439, DOI 10.1094/MPMI.2000.13.4.439
   Vaquero C, 1999, P NATL ACAD SCI USA, V96, P11128, DOI 10.1073/pnas.96.20.11128
   Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147
   Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8
   Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3
   Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7
   Yusibov V, 1999, CURR TOP MICROBIOL, V240, P81
NR 37
TC 1109
Z9 1158
U1 9
U2 225
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7412
EI 1365-313X
J9 PLANT J
JI Plant J.
PD MAR
PY 2003
VL 33
IS 5
BP 949
EP 956
DI 10.1046/j.1365-313X.2003.01676.x
PG 8
WC Plant Sciences
SC Plant Sciences
GA 650WG
UT WOS:000181285900012
PM 12609035
OA Bronze
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Nguyen, LT
   Ciric, B
   Ure, DR
   Zhou, B
   Tamada, K
   Dong, H
   Tseng, SY
   Shin, T
   Pardoll, DM
   Chen, LP
   Kyle, RA
   Rodriguez, M
   Pease, LR
AF Radhakrishnan, S
   Nguyen, LT
   Ciric, B
   Ure, DR
   Zhou, B
   Tamada, K
   Dong, H
   Tseng, SY
   Shin, T
   Pardoll, DM
   Chen, LP
   Kyle, RA
   Rodriguez, M
   Pease, LR
TI RETRACTED: Naturally occurring human IgM antibody that binds B7-DC and
   potentiates T cell stimulation by dendritic cells (Retracted article.
   See vol. 184, pg. 6552, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; FACTOR FAMILY-MEMBER;
   MULTIPLE-SCLEROSIS; DYSGLOBULINEMIC NEUROPATHY; COSTIMULATORY SIGNALS;
   PROMOTE REMYELINATION; CYTOKINE PRODUCTION; SJOGRENS-SYNDROME;
   COUNTER-RECEPTOR
AB A human IgM Ab, serum-derived human IgM 12 (sHIgM12), is identified that binds mouse and human dendritic cells (DC), inducing dramatic immunopotentiation following treatment of the mouse DC in vitro. Competition, transfection, and knockout studies identified the ligand on mouse DC as the costimulatory molecule family member B7-DC. Potent T cell responses are stimulated by Ag-pulsed DC treated with the sHIgM12 Ab in vitro and upon adoptive transfer of Ab-treated Ag-pulsed DC into animals. The multivalent structure of pentameric IgM provides the potential for cross-linking cell surface targets, endowing the soluble Abs with biological potential not normally associated with immune, function. The ability of the sHIgM12 Ab to potentiate the immune response is dependent on the multimeric structure of IgM, as bivalent monomers do not retain this property. Furthermore, pretreatment of DC with IgM monomers blocks subsequent potentiation by intact IgM pentamers, an indication that cross-linking of B7-DC on the cell surface is critical for potentiation of Ag presentation. These findings imply that, in addition to known costimulatory roles, B7-DC can function as a receptor for signals delivered by cells expressing B7-DC ligands.
C1 Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Grad Sch Med, Dept Internal Med, Rochester, MN 55905 USA.
   Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
RP Pease, LR (reprint author), Mayo Clin & Mayo Grad Sch Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Rodriguez, Moses/0000-0001-6328-6497
FU NCI NIH HHS [CA 62242]
CR Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Block MS, 2001, J IMMUNOL, V167, P821, DOI 10.4049/jimmunol.167.2.821
   Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7
   Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030
   CINES DB, 1985, J CLIN INVEST, V75, P1183, DOI 10.1172/JCI111814
   Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0
   Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251
   FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363
   FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5
   GOSSELIN S, 1991, ANN NEUROL, V30, P54, DOI 10.1002/ana.410300111
   GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313
   HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4
   Hurez V, 1997, BLOOD, V90, P4004
   INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Jakob T, 1998, J IMMUNOL, V161, P3042
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Josien R, 1999, J IMMUNOL, V162, P2562
   KELLY JJ, 1981, NEUROLOGY, V31, P1480, DOI 10.1212/WNL.31.11.1480
   KYLE RA, 1992, NEUROL CLIN, V10, P713
   LANIER LL, 1995, J IMMUNOL, V154, P97
   LARSEN CP, 1994, J IMMUNOL, V152, P5208
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   LEHMAN HA, 1987, NEW ENGL J MED, V316, P194, DOI 10.1056/NEJM198701223160406
   Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233
   Luboshitz J, 1999, J INTERN MED, V245, P301, DOI 10.1046/j.1365-2796.1999.00475.x
   MILLER DJ, 1995, J IMMUNOL, V154, P2460
   MILLER DJ, 1994, J NEUROSCI, V14, P6230
   Monks CRF, 1998, NATURE, V395, P82
   MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367
   Nobuoka A, 1999, INT J HEMATOL, V70, P200
   POWELL HC, 1984, ANN NEUROL, V15, P386, DOI 10.1002/ana.410150414
   Robinson CP, 1998, P NATL ACAD SCI USA, V95, P7538, DOI 10.1073/pnas.95.13.7538
   RODRIGUEZ M, 1986, ANN NEUROL, V19, P204, DOI 10.1002/ana.410190221
   RODRIGUEZ M, 1990, ANN NEUROL, V27, P12, DOI 10.1002/ana.410270104
   Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8
   Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x
   Tamura H, 2001, BLOOD, V97, P1809, DOI 10.1182/blood.V97.6.1809
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903
   Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266
   Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200
NR 47
TC 50
Z9 53
U1 2
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2003
VL 170
IS 4
BP 1830
EP 1838
DI 10.4049/jimmunol.170.4.1830
PG 9
WC Immunology
SC Immunology
GA 642ZC
UT WOS:000180836400029
PM 12574348
OA Bronze
DA 2018-12-27
ER

PT J
AU Roehm, KD
   Piper, SN
   Maleck, WH
   Boldt, J
AF Roehm, KD
   Piper, SN
   Maleck, WH
   Boldt, J
TI RETRACTED: Prevention of propofol-induced injection pain by
   remifentanil: a placebo-controlled comparison with lidocaine (Retracted
   article. See vol. 66, pg. 646, 2011)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE injection pain; remifentanil; propofol; TIVA; lidocaine
ID ALFENTANIL; PHARMACOKINETICS; PRETREATMENT; MEPERIDINE; LIGNOCAINE;
   ANESTHESIA; FENTANYL
AB In a randomised, double-blind study we compared the efficacy of continuous remifentanil infusion (0.25 mu g.kg(-1) .min(-1) ) with 40 mg lidocaine and placebo in the prevention of injection pain due to intravenous propofol administration (1.5-2 mg.kg(-1) ) in 155 patients scheduled for elective surgery. Pain severity was evaluated using a four-point scale. The incidence of injection pain was 62% in the placebo group and could be reduced significantly by using remifentanil (30%; p < 0.0015) or lidocaine (33%; p < 0.005). Analysis of the pain scores showed a significant difference between remifentanil and placebo (p < 0.00005) as well as between lidocaine and placebo (p < 0.0002). There was no significant difference between remifentanil and lidocaine. Remifentanil provided effective pain relief, comparable with lidocaine, and is an alternative as part of an intravenous anaesthesia regimen to using another concomitant drug.
C1 Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Roehm, KD (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
CR Ambesh SP, 1999, ANESTH ANALG, V89, P197, DOI 10.1097/00000539-199907000-00035
   BRIGGS LP, 1982, BRIT J ANAESTH, V54, P303, DOI 10.1093/bja/54.3.303
   Doenicke AW, 1996, ANESTH ANALG, V82, P472, DOI 10.1097/00000539-199603000-00007
   FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0
   FLETCHER JE, 1994, BRIT J ANAESTH, V72, P342, DOI 10.1093/bja/72.3.342
   Gajraj NM, 1996, J CLIN ANESTH, V8, P575, DOI 10.1016/S0952-8180(96)00133-X
   GEHAN G, 1991, BRIT J ANAESTH, V66, P324, DOI 10.1093/bja/66.3.324
   Glass PSA, 1999, ANESTH ANALG, V89, pS7
   HELMERS JHJH, 1990, CAN J ANAESTH, V37, P267, DOI 10.1007/BF03005485
   Iwama H, 1998, BRIT J ANAESTH, V81, P963
   JAMES MK, 1991, J PHARMACOL EXP THER, V259, P712
   JOHNSON RA, 1990, ANAESTHESIA, V45, P439, DOI 10.1111/j.1365-2044.1990.tb14328.x
   KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013
   KLEMENT W, 1991, BRIT J ANAESTH, V67, P281, DOI 10.1093/bja/67.3.281
   Larsen B, 2001, ANAESTHESIST, V50, P842, DOI 10.1007/s00101-001-0234-0
   Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x
   Nathanson MH, 1996, ANESTH ANALG, V82, P469, DOI 10.1097/00000539-199603000-00006
   Pang WW, 1998, ANESTH ANALG, V86, P382, DOI 10.1097/00000539-199802000-00031
   Parmar AK, 1998, ANAESTHESIA, V53, P79, DOI 10.1111/j.1365-2044.1998.00248.x
   Picard P, 2000, ANESTH ANALG, V90, P963
   POWER I, 1991, REGION ANESTH, V16, P204
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   Rau J, 2001, ANESTH ANALG, V93, P382, DOI 10.1097/00000539-200108000-00029
   SAARNIVAARA L, 1991, ACTA ANAESTH SCAND, V35, P19, DOI 10.1111/j.1399-6576.1991.tb03235.x
   SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x
   STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202
   Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x
   WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005
   WRENCH IJ, 1996, BRIT J ANAESTH, V82, P469
NR 29
TC 31
Z9 38
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD FEB
PY 2003
VL 58
IS 2
BP 165
EP 170
DI 10.1046/j.1365-2044.2003.02964_2.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 642JN
UT WOS:000180800500011
PM 12625310
OA Bronze
DA 2018-12-27
ER

PT J
AU Zonia, L
   Feijo, JA
AF Zonia, L
   Feijo, JA
TI RETRACTED: State and spectral properties of chloride oscillations in
   pollen (Retracted Article. See vol 85, pg 3425, 2003)
SO BIOPHYSICAL JOURNAL
LA English
DT Article; Retracted Publication
ID CRASSULACEAN ACID METABOLISM; PLANT CIRCADIAN-RHYTHM; EPITHELIAL-CELL
   LINE; TUBE GROWTH; INOSITOL 3,4,5,6-TETRAKISPHOSPHATE; ACTIVATED
   CHLORIDE; ION CHANNELS; PLASMA-MEMBRANE; GUARD-CELLS;
   KALANCHOE-DAIGREMONTIANA
AB Pollen tube growth is a dynamic system expressing a number of oscillating circuits. Our recent work identified a new circuit, oscillatory efflux of Cl- anion from the pollen tube apex. Cl- efflux is the first ion signal found to be coupled in phase with growth oscillations. Functional analyses indicate an active role for Cl- flux in pollen tube growth. In this report the dynamical properties of Cl- efflux are examined. Phase space analysis demonstrates,that the system trajectory converges on a limit cycle. Fourier analysis reveals that two harmonic frequencies characterize normal growth. Cl- efflux is inhibited by the channel blocker DIDS, is stimulated by hypoosmotic treatment, and is antagonized by the signal encoded in inositol 3,4,5,6-tetrakisphosphate. These perturbations induce transitions of the limit cycle to new metastable states or cause system collapse to a static attractor centered near the origin. These perturbations also transform the spectral profile, inducing subharmonic frequencies, transitions to period doubling and tripling, superharmonic resonance, and chaos. These results indicate that Cl- signals in pollen tubes display features that are characteristic of active oscillators that carry frequency-encoded information. A reaction network of the Cl- oscillator coupled to two nonlinear feedback circuits that may drive pollen tube growth oscillations is considered.
C1 Acad Sci Czech Republ, Inst Expt Bot, Prague 16000 6, Czech Republic.
   Gulbenkian Inst Sci, PT-2780156 Oeiras, Portugal.
RP Zonia, L (reprint author), Acad Sci Czech Republ, Inst Expt Bot, Na Pernikarce 15, Prague 16000 6, Czech Republic.
EM zonia@ueb.cas.cz
CR Acheson D., 1997, CALCULUS CHAOS INTRO
   Allen GJ, 2001, NATURE, V411, P1053, DOI 10.1038/35082575
   Allen GJ, 2000, SCIENCE, V289, P2338, DOI 10.1126/science.289.5488.2338
   Bali MZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1588
   Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958
   Bohn A, 2002, BIOL RHYTHM RES, V33, P151, DOI 10.1076/brhm.33.2.151.1318
   Bohn A, 2001, PLANT CELL ENVIRON, V24, P811, DOI 10.1046/j.0016-8025.2001.00732.x
   Brearley CA, 1996, BIOCHEM J, V314, P215, DOI 10.1042/bj3140215
   Brearley CA, 2000, PLANT PHYSIOL, V122, P1209, DOI 10.1104/pp.122.4.1209
   Carew MA, 2000, J BIOL CHEM, V275, P26906
   Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790
   COSGROVE DJ, 1991, PLANTA, V186, P143
   Feijo JA, 1999, J CELL BIOL, V144, P483, DOI 10.1083/jcb.144.3.483
   Feijo JA, 2001, BIOESSAYS, V23, P86, DOI 10.1002/1521-1878(200101)23:1<86::AID-BIES1011>3.3.CO;2-4
   Goddard H, 2000, P NATL ACAD SCI USA, V97, P1932, DOI 10.1073/pnas.020516397
   Hafke JB, 2001, PROTOPLASMA, V216, P164, DOI 10.1007/BF02673868
   HEDRICH R, 1990, EMBO J, V9, P3889, DOI 10.1002/j.1460-2075.1990.tb07608.x
   Hepler PK, 2001, ANNU REV CELL DEV BI, V17, P159, DOI 10.1146/annurev.cellbio.17.1.159
   Higashiyama T, 2000, PLANT PHYSIOL, V122, P11, DOI 10.1104/pp.122.1.11
   Ho MWY, 2001, J BIOL CHEM, V276, P18673, DOI 10.1074/jbc.M101128200
   HO MWY, 2000, BIOL PHOSPHOINOSITID, P298
   HoldawayClarke TL, 1997, PLANT CELL, V9, P1999
   Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015
   Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505
   Kropman MF, 2001, SCIENCE, V291, P2118, DOI 10.1126/science.1058190
   Kropman MF, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.077601
   Leonhardt N, 2001, FEBS LETT, V494, P15, DOI 10.1016/S0014-5793(01)02289-X
   Luttge U, 2000, PLANTA, V211, P761, DOI 10.1007/s004250000408
   Mallat S., 1999, WAVELET TOUR SIGNAL
   MASCARENHAS JP, 1993, PLANT CELL, V5, P1303
   Messerli MA, 1999, J CELL SCI, V112, P1497
   Messerli MA, 2000, DEV BIOL, V222, P84, DOI 10.1006/dbio.2000.9709
   Messerli MA, 1998, PLANT J, V16, P87, DOI 10.1046/j.1365-313x.1998.00266.x
   MURRAY JD, 1993, MATH BIOL, P140
   Nilius B, 1998, PFLUG ARCH EUR J PHY, V435, P637, DOI 10.1007/s004240050564
   Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x
   Oprins JCJ, 2002, GUT, V50, P314, DOI 10.1136/gut.50.3.314
   Oprins JCJ, 2001, AM J PHYSIOL-CELL PH, V280, pC789
   Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060
   PIERSON ES, 1994, PLANT CELL, V6, P1815
   PITTET D, 1989, J BIOL CHEM, V264, P7251
   Rascher U, 1998, PLANTA, V207, P76, DOI 10.1007/s004250050457
   Rascher U, 2001, P NATL ACAD SCI USA, V98, P11801, DOI 10.1073/pnas.191169598
   RESNTROM E, 2002, J BIOL CHEM, V277, P26717
   Roman RM, 2001, AM J PHYSIOL-GASTR L, V280, pG344
   SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0
   Shabala S, 2000, J EXP BOT, V51, P1243, DOI 10.1093/jexbot/51.348.1243
   Shabala S, 1997, AUST J PLANT PHYSIOL, V24, P91, DOI 10.1071/PP96075
   Shears S B, 1996, Subcell Biochem, V26, P187
   Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587
   Taylor A, 1997, J EXP BOT, V48, P579, DOI 10.1093/jxb/48.Special_Issue.579
   Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461
   Teodoro AE, 1998, PHYSIOL PLANTARUM, V102, P29, DOI 10.1034/j.1399-3054.1998.1020105.x
   TYSON JJ, 1973, J CHEM PHYS, V59, P4164, DOI 10.1063/1.1680609
   VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0
   VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210
   van der Wijk T, 2000, CELL PHYSIOL BIOCHEM, V10, P289, DOI 10.1159/000016359
   WARD JM, 1995, PLANT CELL, V7, P833, DOI 10.1105/tpc.7.7.833
   Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x
   Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x
   Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973
   Zonia L, 2002, PLANT CELL, V14, P2233, DOI 10.1105/tpc.003830
   Zonia L, 2001, SEX PLANT REPROD, V14, P111, DOI 10.1007/s004970100093
NR 63
TC 3
Z9 3
U1 2
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD FEB
PY 2003
VL 84
IS 2
BP 1387
EP 1398
DI 10.1016/S0006-3495(03)74953-4
PN 1
PG 12
WC Biophysics
SC Biophysics
GA 682ZV
UT WOS:000183123700062
PM 12547818
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Granisetron versus granisetron/dexamethasone combination for
   the treatment of nausea, retching, and vomiting after major gynecologic
   surgery: A randomized, double-blind study (Retracted article. See vol.
   40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE nausea; vomiting; antiemetics; granisetron; dexamethasone
ID POSTOPERATIVE NAUSEA; PREVENTION; METOCLOPRAMIDE; ONDANSETRON;
   DROPERIDOL
AB Background: Granisetron, a selective 5-hydroxytryptamine(3) antagonist, is effective for the treatment of patients with postoperative nausea and vomiting. Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen.
   Objective: This study compared the efficacy of granisetron alone with granisetron/ dexa
   methasone combination for the treatment of nausea and vomiting after major gynecologic surgery. Methods: In this randomized, double-blind study, patients who were experiencing emetic symptoms during 0 to 3 hours after the end of anesthesia administration received granisetron 40 mug/kg IV either alone or in combination with dexamethasone 8 mg. Patients then were observed for 24 hours after study drug administration, with emetic episodes recorded and tolerability assessments performed by nursing staff blinded to treatment.
   Results: A total of 120 women were enrolled (n = 60 in each treatment groups mean [SD] age in the granisetron group, 44 [91 years [range, 23-63 years]; combination group, 45 [81 years [range, 21-65 years]). No significant differences in patient demographic characteristics were found between the 2 treatment groups. However, the percentage of patients free of emetic symptoms (nausea, retching, vomiting) was higher in the granisetron/dexamethasone combination group than in the granisetron group (95.0% and 80.0%, respectively; P = 0.012). No clinically serious adverse events attributed to the study drugs were observed in either group.
   Conclusion: In this study, the granisetron/dexamethasone combination was more effective than was granisetron alone for the management of nausea and vomiting during 0 to 3 hours after anesthesia in women undergoing major gynecologic surgery. (Clin Ther 2003;25-.507-514) Copyright (C) 2003 Excerpta Medica, Inc.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   FLEISHER LA, 1996, CLIN ANESTH, P443
   Fujii Y, 2000, AM J OBSTET GYNECOL, V182, P13, DOI 10.1016/S0002-9378(00)70484-4
   KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   STOELTING RK, 2000, BASICS ANESTHESIA, P209
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 12
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD FEB
PY 2003
VL 25
IS 2
BP 507
EP 514
DI 10.1016/S0149-2918(03)80092-9
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 653KG
UT WOS:000181433900009
PM 12749510
DA 2018-12-27
ER

PT J
AU Leisman, G
   Koch, P
AF Leisman, G
   Koch, P
TI RETRACTED: Synaptic strengthening and continuum activity-wave growth in
   temporal sequencing during cognitive tasks (Retracted Article. See vol
   119, pg 305, 2009)
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE cell assemblies; cognition; continuum theory; neural networks; wave
   growth
ID STIMULATION; TOMOGRAPHY; MODEL
AB Sequencing, the distinction between "before" and "after," is a basic feature of cognition, and is exemplified most simply by classical or Pavlovian conditioning. It is generally accepted that such learned behavior is connected anatomically to synaptic strengthening, as first postulated by Hebb. However, the original Hebbian formulation has difficulties, Most prominently the assumption that synaptic connections between individual afferent and efferent neurons while apparently modified by learning, has no mechanism that is presently, understood. There is also the problem that there is, in general, a long synaptic path between the cortical areas associated with the conditioned and unconditioned reflexes. Neural continuum theory, which deals with elements containing large numbers of neurons, provides an alternative explanation, namely, that synaptic strengthening occurs on a larger scale, involving the neurons in regions of consistently substantial activity. The neural continuum has the property of amplifying waves of wavelength large compared with synaptic connection ranges, which propagate over distances comparable to the physical separation between the cortical areas associated with the components of a cognitive task. In this example, propagating waves generated by the conditioned and unconditioned reflexes Interfere, producing a standing wave in an intermediate geometric region concave toward the (temporally later) unconditioned reflex. Synaptic strengthening in this region has the effect of a "lens" focusing the activity generated by the conditioning stimulus toward the motor region associated with the conditioned response, producing the Pavlovian reflex.
C1 Rensselaer Polytech Inst, Dept Cognit Sci, Troy, NY 12180 USA.
   New York Inst Technol, Sch Engn, Old Westbury, NY 11568 USA.
RP Leisman, G (reprint author), Rensselaer Polytech Inst, Dept Cognit Sci, 305 Carnegie Hall,110 8th St, Troy, NY 12180 USA.
EM drgersh@yahoo.com
CR BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5
   ECCLES JC, 1992, P NATL ACAD SCI USA, V89, P7320, DOI 10.1073/pnas.89.16.7320
   ECCLES JC, 1987, HDB PHYSL 1, V5, P137
   ELLIOT HC, 1969, TXB NEUROANATOMY
   Engel P, 1993, J Geriatr Psychiatry Neurol, V6, P144
   GELDARD FA, 1965, J ACOUST SOC AM, V37, P797, DOI 10.1121/1.1909443
   GELDARD FA, 1986, SCI AM, V255, P90, DOI 10.1038/scientificamerican0786-90
   Hebb D., 1949, ORG BEHAV
   Hebb D. O., 1980, ESSAY MIND
   Kandel E. R., 1981, PRINCIPLES NEURAL SC
   Koch P, 2000, J INT NEUROPSYCH SOC, V6, P580, DOI 10.1017/S1355617700655078
   Koch P, 2001, INT J NEUROSCI, V108, P127, DOI 10.3109/00207450108986510
   Koch P, 1996, INT J NEUROSCI, V86, P179, DOI 10.3109/00207459608986709
   Koch P, 2001, INT J NEUROSCI, V107, P199, DOI 10.3109/00207450109150686
   KOCH P, 1990, INT J NEUROSCI, V54, P41, DOI 10.3109/00207459008986621
   KOLB B, 2001, BRAIN BEHAV
   KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675
   Leisman G, 2002, BRAIN COGNITION, V48, P425
   LEISMAN G, 1989, J MANIP PHYSIOL THER, V12, P257
   LEISMAN G, 1980, J NEUROSCI, V11, P151
   Paus T, 1997, J NEUROSCI, V17, P3178
   Rolls ET, 1998, J NEUROPHYSIOL, V79, P1797
   TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715
   Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397
   Wildgruber D, 1999, COGNITIVE BRAIN RES, V7, P285, DOI 10.1016/S0926-6410(98)00031-7
   WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.ne.11.030188.002231
   WILSON HR, 1973, KYBERNETIK, V13, P55, DOI 10.1007/BF00288786
NR 27
TC 3
Z9 3
U1 3
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD FEB
PY 2003
VL 113
IS 2
BP 181
EP +
DI 10.1080/00207450390162029
PG 25
WC Neurosciences
SC Neurosciences & Neurology
GA 651DZ
UT WOS:000181306400004
PM 12751431
DA 2018-12-27
ER

PT J
AU Tsujimura, H
   Tamura, T
   Ozato, K
AF Tsujimura, H
   Tamura, T
   Ozato, K
TI RETRACTED: Cutting edge: IFN consensus sequence binding protein/IFN
   regulatory factor 8 drives the development of type IIFN-producing
   plasmacytoid dendritic cells (Retracted Article. See vol 175, pg 8438,
   2005)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID INTERFERON-PRODUCING CELLS; PROGENITOR CELLS; I INTERFERON; LYMPH-NODES;
   HUMAN BLOOD; MOUSE; DISTINCT; ICSBP; INTERLEUKIN-12; MACROPHAGES
AB IFN consensus sequence binding protein (ICSBP/IFN regulatory factor 8) is a hematopoietic cell-specific transcription factor essential for the generation of CD8alpha(+) dendritic cells (DO). We found that ICSBP(-/-) mice lack B220(+)CD11b(-) plasmacytoid DO (pDCs) in addition to CD8a+ DO. Although ICSBP(-/-) mice have B220(-)CD11b(+) myeloid DCs (mDCs), they fail to mature upon Toll-like receptors signaling. Accordingly, ICSBP(-/-) bone marrow progenitor. tor cells were defective in generating pDCs in the fins-like tyrosine kinase 3 ligand-based culture system and mDCs generated in this system were defective in maturation. We demonstrate that introduction of ICSBP rescues the development of pDCs from -/- bone marrow progenitors. ICSBP also restored the ability of both pDcs and mDCs to mature after Toll-like receptor signals. ICSBP restored DCs produced IFN-alpha and IL-12p40 in a DCs subset-selective manner with the amounts comparable to those by +/+ DCs. Together, ICSBP is essential for early pDC development and final maturation of both pDCs, and mDCs.
C1 NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA.
RP Ozato, K (reprint author), NICHHD, Lab Mol Growth Regulat, NIH, Bldg 6,Room 2A01,6 Ctr Dr,MSC 2753, Bethesda, MD 20892 USA.
EM ozatok@nih.gov
CR ALIBERTI J, IN PRESS BLOOD
   Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736
   Cella M, 1999, NAT MED, V5, P919
   Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672
   del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a
   Gilliet M, 2002, J EXP MED, V195, P953, DOI 10.1084/jem.20020045
   Ito T, 2002, J EXP MED, V195, P1507, DOI 10.1084/jem.20020207
   Kadowaki N, 2001, J IMMUNOL, V166, P2291, DOI 10.4049/jimmunol.166.4.2291
   Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688
   Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692
   Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171
   Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4
   Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9
   Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755
   Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327
   Tsujimura H, 2002, J IMMUNOL, V169, P1261, DOI 10.4049/jimmunol.169.3.1261
   Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372
   Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271
NR 21
TC 169
Z9 172
U1 3
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2003
VL 170
IS 3
BP 1131
EP 1135
DI 10.4049/jimmunol.170.3.1131
PG 5
WC Immunology
SC Immunology
GA 639XM
UT WOS:000180655500001
PM 12538667
OA Bronze
DA 2018-12-27
ER

PT J
AU Ogunyemi, D
   Vargas, N
   Fukushima, T
   Hon, E
AF Ogunyemi, D
   Vargas, N
   Fukushima, T
   Hon, E
TI RETRACTED: Non-invasive cutaneous cardiovascular dynamics (CVD) as a
   predictor of preterm delivery: A pilot study (Retracted Article. See vol
   30, pg 162, 2004)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE labor complications; labor premature; pregnancy complications; preterm
   birth; uterine monitoring
AB Aim: To assess the clinical value of cardiovascular dynamics (CVD) pattern of 'positive cycling' in predicting true preterm labor.
   Methods: Patients with a clinical diagnosis of preterm labor had CVD measurement with a non-invasive miniature pressure transducer applied to the fingertip concomitantly with uterine activity monitoring. Based on previous work by our group, the rapid ejection time (RET) reflects arterial compliance; an elevated RET is suggestive of vasoconstriction. Positive cycling is present when the RET shows elevation with uterine contractions and negative cycling is present when there are no changes in the RET with uterine contractions.
   Results: Twenty-seven women had negative CVD cycling and nine had positive CVD cycling. There was no difference between the two groups in initial gestational age, cervical effacement or cervical dilation at testing. However, the mean interval from testing to delivery was 1.56 (SEM +/- 0.29) days for positive cycling and 39 days (+/- 5.25) for negative cycling (P < 0.001).
   Conclusion: Non-invasive cardiovascular patterns of positive cycling appear predictive of preterm delivery.
C1 King Drew Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90059 USA.
   Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
   Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
RP Ogunyemi, D (reprint author), King Drew Med Ctr, Dept Obstet & Gynecol, 12021 S Wilmington Ave, Los Angeles, CA 90059 USA.
EM DOOGUNYE@CDREWU.EDU
CR BORELL U, 1964, AM J OBSTET GYNECOL, V89, P881, DOI 10.1016/0002-9378(64)90057-2
   Fukishima T, 1999, AM J OBSTET GYNECOL, V180, P1584, DOI 10.1016/S0002-9378(99)70055-4
   Fukushima T, 2002, AM J OBSTET GYNECOL, V186, P1207, DOI 10.1067/mob.2002.123744
   Hon E H, 1998, J Matern Fetal Med, V7, P79
   HON EH, 1992, OBSTET GYNECOL, V79, P597
   HON EH, 1991, OBSTET GYNECOL, V78, P152
   HON EH, 1994, PHYSL BASES J MAT FE, V3, P142
   HON EH, 1993, J MATERN FETAL MED, V2, P179
   HON EH, 1993, J MATERN FETAL MED, V2, P97
   HON EH, 1993, J MATERN FETAL MED, V2, P201
   HON EH, 1995, J MATERN FETAL MED, V4, P235
   HON EH, 1995, J MATERN FETAL MED, V4, P71
   Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904
   KEIRSE MJNC, 1995, AM J OBSTET GYNECOL, V173, P618, DOI 10.1016/0002-9378(95)90292-9
   Leitich H, 1999, AM J OBSTET GYNECOL, V180, P1169, DOI 10.1016/S0002-9378(99)70612-5
NR 15
TC 1
Z9 1
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD FEB
PY 2003
VL 29
IS 1
BP 5
EP 11
DI 10.1046/j.1341-8076.2003.00072.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 642QG
UT WOS:000180802400002
PM 12696621
DA 2018-12-27
ER

PT J
AU Hemanth, J
   Rathnakar, KL
   Shashishekar, KS
   Suresh, R
   Umashankar
AF Hemanth, J
   Rathnakar, KL
   Shashishekar, KS
   Suresh, R
   Umashankar
TI RETRACTED: Effect of high rate heat transfer during solidification of
   alloyed cast iron using water-cooled and sub-zero chills on mechanical
   behavior (Retracted article. See vol. 37, pg. 589, 2012)
SO MATERIALS & DESIGN
LA English
DT Article; Retracted Publication
DE sub-zero; water-cooled; chill; solidification
AB Hypoeutectic cast iron specimens cast using chills that are water-cooled and liquid-nitrogen cooled (cryogenic chilling) were compared with specimens of the same chemical composition which were sand cast without any chill. The solidification behavior, number of eutectic cell, grain size and the effects of these on mechanical properties like strength and fracture toughness were recorded and analyzed in this paper. It is revealed from the above investigation that sub-zero and water cool chilled cast irons exhibit severe under-cooling compared to normal sand cast iron. Thus, it is concluded from the investigation that nucleation conditions are completely altered during solidification but growth conditions prevail as usual. Therefore, under-cooling during solidification is considered to be responsible for the variation in eutectic cell size, grain size, microstructure and hence, the mechanical properties of the cast iron. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Siddaganga Inst Technol, Tumkur 572103, Karnataka, India.
EM joelhemanth@hotmail.com
CR Baker T.J., 1978, MAT ENG APPL, V1, P13, DOI [10.1016/0141-5530(78)90003-1, DOI 10.1016/0141-5530(78)90003-1]
   DAWSON JV, 1960, BCIRA J, V8, P221
   DEHOFF RT, 1980, T AM FOUNDRYMANS SOC, V88, P281
   FEDRIKSSON H, 1971, BRIT FOUNDRYMAN  FEB, P54
   GLOVER D, 1982, AFS T, V90, P745
   HEINE RW, 1969, T AFS, V77, P185
   HILL BER, 1974, PHYSICAL METALLURGY, P665
   MORTON DO, 1979, FOUNDRY PRACTICE FOS, V200, P138
   Ruff GF, 1977, T AM FOUNDRYMANS SOC, V85, P179
   SEAH KHW, 1995, J MATER SCI, V30, P4986, DOI 10.1007/BF01154513
   SPIEGEL MO, 1984, INDIAN FOUNDRY J, V35, P15
   STEFUNESCU DM, 1981, GIESSERI, V5, P73
   SUZUKI K, 1982, T AFS, V90, P423
   WIMBER RT, 1980, T AFS, V88, P717
NR 14
TC 4
Z9 4
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-1275
EI 1873-4197
J9 MATER DESIGN
JI Mater. Des.
PD FEB
PY 2003
VL 24
IS 1
BP 37
EP 45
AR PII S0261-3069(02)00086-9
DI 10.1016/S0261-3069(02)00086-9
PG 9
WC Materials Science, Multidisciplinary
SC Materials Science
GA 638HA
UT WOS:000180564500005
DA 2018-12-27
ER

PT J
AU Kawasaki, H
   Suyama, E
   Iyo, M
   Taira, K
AF Kawasaki, H
   Suyama, E
   Iyo, M
   Taira, K
TI RETRACTED: siRNAs generated by recombinant human Dicer induce specific
   and significant but target site-independent gene silencing in human
   cells (Retracted Article. See vol 34, pg 2153, 2006)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID DOUBLE-STRANDED-RNA; CULTURED-MAMMALIAN-CELLS; MESSENGER-RNA;
   CAENORHABDITIS-ELEGANS; DROSOPHILA-CELLS; INTERFERING RNAS;
   RIBONUCLEASE; DEGRADATION; EXPRESSION; CLEAVAGE
AB RNA interference has emerged as a powerful tool for the silencing of gene expression in animals and plants. It was reported recently that 21 nt synthetic small interfering RNAs (siRNAs) specifically suppressed the expression of endogenous genes in several lines of mammalian cells. However, the efficacy of siRNAs is dependent on the presence of a specific target site within the target mRNA and it remains very difficult to predict the best or most effective target site. In this study, we demonstrate that siRNAs that have been generated in vitro by recombinant human Dicer (re-hDicer) significantly suppress not only the exogenous expression of a puromycin-resistance gene but also the endogenous expression of H-ras, c-jun and c-fos. In our system, selection of a target site is not necessary in the design of siRNAs. However, it is important to avoid homologous sequences within a target mRNA in a given protein family. Our diced siRNA system should be a powerful tool for the inactivation of genes in mammalian cells.
C1 Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Natl Inst Adv Ind Sci & Technol, Gene Funct Res Lab, Tsukuba 3058562, Japan.
RP Taira, K (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
EM taira@chembio.t.u-tokyo.ac.jp
CR Adjei AA, 2001, J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062
   Amarasinghe AK, 2001, METHOD ENZYMOL, V342, P143, DOI 10.1016/S0076-6879(01)42542-0
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bernstein E, 2001, RNA, V7, P1509
   Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698
   Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Grishok A, 2002, ADV GENET, V46, P339
   Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   Hammond SM, 2000, NATURE, V404, P293
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Harborth J, 2001, J CELL SCI, V114, P4557
   Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757
   Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3
   Matsuda S, 2000, BBA-GENE STRUCT EXPR, V1490, P163, DOI 10.1016/S0167-4781(99)00221-3
   MIYAGISHI M, 2003, IN PRESS ANTISENSE N
   Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687
   Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399
   Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578
   Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001
   Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191
   Vaucheret H, 2001, J CELL SCI, V114, P3083
   Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582
   ZUKER M, 1999, RNA BIOCH BIOTECHNOL
NR 31
TC 89
Z9 104
U1 42
U2 56
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 1
PY 2003
VL 31
IS 3
BP 981
EP 987
DI 10.1093/nar/gkg184
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 647VJ
UT WOS:000181114500026
PM 12560494
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zamfirescu, M
   Kavokin, A
   Gil, B
   Malpuech, G
AF Zamfirescu, M
   Kavokin, A
   Gil, B
   Malpuech, G
TI RETRACTED: ZnO as a material mostly adapted for realization of
   room-temperature polariton lasers (Retracted article. See vol 201, pg
   3373, 2004)
SO PHYSICA STATUS SOLIDI A-APPLICATIONS AND MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
ID SEMICONDUCTOR MICROCAVITIES; STIMULATED SCATTERING; QUANTUM MICROCAVITY;
   PHOTOLUMINESCENCE; RELAXATION; BOTTLENECK; EXCITONS
AB Wannier-Mott excitons in the wurzite-type semiconductor material ZnO are stable at room temperature, have an extremely large oscillator strength and emit blue light. This makes ZnO an excellent potential candidate for the fabrication of room-temperature lasers where the coherent light amplification is ruled by the fascinating mechanism of the Bose-condensation of the exciton-polaritons. We first report the direct optical measurement of the exciton oscillator strength f in ZnO. The longitudinal transverse splitting of the exciton resonances Gamma(5)(B) and Gamma(1)(C) are found to reach the record values of 5 and 7 meV, respectively, two orders of magnitude larger than in GaAs. We then propose a model of ZnO-based microcavity structure that appears to be the most adapted structure for the observation of the polariton laser effect. We thus can compute the phase diagram of the lasing regimes. A value of the threshold power as large as of 2 mW per device (at power density of 3000 W/cm(2)) at room temperature is predicted for this laser structure.
C1 Univ Clermont Ferrand, LASMEA, UMR 6602 CNRS, F-63177 Aubiere, France.
   Univ Florence, I-50019 Florence, Italy.
   Univ Montpellier 2, GES, CNRS, F-34095 Montpellier 5, France.
RP Zamfirescu, M (reprint author), Univ Clermont Ferrand, LASMEA, UMR 6602 CNRS, F-63177 Aubiere, France.
EM marian.zamfirescu@lasmea.univ-bpclermont.fr
RI KAVOKINE, ALEXIS/C-3601-2016; Kavokin, Alexey/J-8610-2013
OI KAVOKINE, ALEXIS/0000-0003-2713-1062; 
CR Baumberg JJ, 2000, PHYS REV B, V62, P16247, DOI 10.1103/PhysRevB.62.R16247
   Butov LV, 2001, PHYS REV LETT, V86, P5608, DOI 10.1103/PhysRevLett.86.5608
   Chen YF, 2000, APPL PHYS LETT, V76, P559, DOI 10.1063/1.125817
   Dang LS, 1998, PHYS REV LETT, V81, P3920, DOI 10.1103/PhysRevLett.81.3920
   Imamoglu A, 1996, PHYS REV A, V53, P4250, DOI 10.1103/PhysRevA.53.4250
   Kavokin A, 2002, PHYS STATUS SOLIDI A, V190, P389, DOI 10.1002/1521-396X(200204)190:2<389::AID-PSSA389>3.0.CO;2-T
   Kavokin AV, 1998, PHYS REV B, V57, P3757, DOI 10.1103/PhysRevB.57.3757
   Khitrova G, 1999, REV MOD PHYS, V71, P1591, DOI 10.1103/RevModPhys.71.1591
   LITTON C, COMMUNICATION
   Ohtomo A, 1998, APPL PHYS LETT, V72, P2466, DOI 10.1063/1.121384
   Reynolds DC, 1999, PHYS REV B, V60, P2340, DOI 10.1103/PhysRevB.60.2340
   Senellart P, 2000, PHYS REV B, V62, P16263, DOI 10.1103/PhysRevB.62.R16263
   Skolnick MS, 1998, SEMICOND SCI TECH, V13, P645, DOI 10.1088/0268-1242/13/7/003
   Tartakovskii AI, 2000, PHYS REV B, V62, pR2283, DOI 10.1103/PhysRevB.62.R2283
   Tassone F, 1997, PHYS REV B, V56, P7554, DOI 10.1103/PhysRevB.56.7554
   WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314
   Zamfirescu M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.121304
NR 17
TC 8
Z9 8
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1862-6300
J9 PHYS STATUS SOLIDI A
JI Phys. Status Solidi A-Appl. Mat.
PD FEB
PY 2003
VL 195
IS 3
BP 563
EP 567
DI 10.1002/pssa.200306153
PG 5
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 656GA
UT WOS:000181599300017
DA 2018-12-27
ER

PT J
AU Canbaz, S
   Ege, T
   Sunar, H
   Saygin, G
   Duran, E
AF Canbaz, S
   Ege, T
   Sunar, H
   Saygin, G
   Duran, E
TI RETRACTED: Bilateral popliteal artery aneurysms with rupture and
   pseudoaneurysm formation on the left (Retracted article. See vol. 44,
   pg. 159, 2008)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE poplitcal aneurysm; bilateral aneurysms; ruptured aneurysm; popliteal
   pseudoancurysm
ID EXPERIENCE
AB The rupture of a popliteal artery aneurysm is very rare, and can lead to serious complications if untreated. Any reports of a huge pseudoaneurysm, following rupture of the popliteal artery aneurysm could not be found in a review of the literature.
   A pulsatile huge mass leading to a deep venous thrombosis, was observed in a 74 years old male patient who for 2 months had had a progressively swollen and painful left leg. On angiographic evaluation, the mass was found to be a pseudoaneurysm originating from a ruptured true aneurysm of the popliteal artery. There was also a small true aneurysm in the contralateral extremity at the same localization. Both the false, and true aneurysms were resected surgically and arterial continuity was established with a synthetic polytetrafluoroethylene graft.
C1 Trakya Univ, Fac Med, Dept Cardiovasc Surg, TR-22030 Edirne, Turkey.
   Trakya Univ, Fac Med, Dept Cardiovasc Surg, Edirne, Turkey.
RP Canbaz, S (reprint author), Trakya Univ, Fac Med, Dept Cardiovasc Surg, TR-22030 Edirne, Turkey.
EM scanbaz@trakya.edu.tr
CR ANTON GE, 1986, J VASC SURG, V3, P125, DOI 10.1067/mva.1986.avs0030125
   BARROY JP, 1986, J CARDIOVASC SURG, V27, P42
   Davidovic LB, 1998, WORLD J SURG, V22, P812, DOI 10.1007/s002689900475
   DAWSON I, 1991, J VASC SURG, V13, P398, DOI 10.1067/mva.1991.25131
   Dawson I, 1997, BRIT J SURG, V84, P293
   Duffy ST, 1998, EUR J VASC ENDOVASC, V16, P218, DOI 10.1016/S1078-5884(98)80223-2
   Gouny P, 2000, EUR J VASC ENDOVASC, V19, P496, DOI 10.1053/ejvs.1999.1043
   Ihlberg LHM, 2000, J VASC SURG, V31, P794, DOI 10.1067/mva.2000.102329
   LILLY MP, 1988, J VASC SURG, V7, P653, DOI 10.1067/mva.1988.avs0070653
   Noorpuri BSW, 1999, EUR J VASC ENDOVASC, V18, P534, DOI 10.1053/ejvs.1999.0904
   O'Connor JV, 1998, J ARTHROPLASTY, V13, P830, DOI 10.1016/S0883-5403(98)90039-0
   RAMIN EB, 1998, CURRENT SURG THERAPY, P737
   SHORTELL CK, 1991, J VASC SURG, V14, P771, DOI 10.1067/mva.1991.33214
   Sie RB, 1997, EUR J VASC ENDOVASC, V13, P432, DOI 10.1016/S1078-5884(97)80169-4
   WALSH JJ, 1988, J VASC SURG, V8, P465
NR 15
TC 1
Z9 3
U1 3
U2 4
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD FEB
PY 2003
VL 44
IS 1
BP 159
EP 162
DI 10.3349/ymj.2003.44.1.159
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 654FK
UT WOS:000181483400025
PM 12619192
OA Bronze
DA 2018-12-27
ER

PT J
AU Joos, L
   Eryuksel, E
   Brutsche, MH
AF Joos, L
   Eryuksel, E
   Brutsche, MH
TI RETRACTED: Functional genomics and gene microarrays - the use in
   research and clinical medicine (Retracted Article. See vol 133, pg 630,
   2003)
SO SWISS MEDICAL WEEKLY
LA English
DT Review; Retracted Publication
DE genomics; genetics; pharmacogenomics; pharmacogenetics; microarrays
ID HUMAN CELL-CYCLE; CORONARY ATHEROSCLEROSIS; TANGIER-DISEASE; EXPRESSION;
   ASTHMA; CANCER; ARRAY; ATOPY; IDENTIFICATION; POLYMORPHISMS
AB In the year 2000, the Human Genome Project Consortium presented the first complete draft of the human genome together with Celera Genetics. Since then, the so-called "post-genome era" has started. Microarrays are capable of profiling gene expression patterns of tens of thousands of genes in a single experiment and thus allow a systematic analysis of DNA and RNA variation. They seem likely to become a standard tool of both molecular biology research and clinical diagnostics. These prospects have attracted great interest and investment from both the public and private sectors. This review introduces the principle of microarray technology and gives an overview of its current and future potential in clinical medicine.
C1 Univ Basel Hosp, Div Resp Med, CH-4031 Basel, Switzerland.
   Univ Basel Hosp, Pulm Res Lab, CH-4031 Basel, Switzerland.
RP Brutsche, MH (reprint author), Univ Basel Hosp, Div Resp Med, Petersgraben 4, CH-4031 Basel, Switzerland.
EM mbrutsche@uhbs.ch
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Brooks-Wilson A, 1999, NAT GENET, V22, P336
   Brutsche MH, 2002, J ALLERGY CLIN IMMUN, V109, P271, DOI 10.1067/mai.2002.121530
   Brutsche MH, 2001, CLIN EXP IMMUNOL, V123, P181, DOI 10.1046/j.1365-2249.2001.01441.x
   Brutsche MH, 2001, AM J PHYSIOL-LUNG C, V280, pL627
   BRUTSCHE MH, 2002, AM J RESP CRIT CARE, pA768
   Cho RJ, 2001, NAT GENET, V27, P48
   Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106
   DEKNIJFF P, 1994, J CLIN INVEST, V94, P1252, DOI 10.1172/JCI117443
   Doevendans PA, 2001, INT J CARDIOL, V80, P161, DOI 10.1016/S0167-5273(01)00466-1
   Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   ERYUKSEL E, 2002, EUR RESPIR J, pA1414
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gordon GJ, 2002, CANCER RES, V62, P4963
   Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913
   Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778
   Kittler JT, 2000, PHYSIOL GENOMICS, V3, P175
   Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753
   Kuivenhoven JA, 1995, J CLIN INVEST, V96, P2783, DOI 10.1172/JCI118348
   Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Luzina IG, 2002, AM J RESP CELL MOL, V26, P549, DOI 10.1165/ajrcmb.26.5.4683
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576
   Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921
   Rutherford RM, 2001, SWISS MED WKLY, V131, P459
   St Croix B, 2000, SCIENCE, V289, P1197
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Takahashi Y, 2003, ONCOLOGY-BASEL, V64, P54, DOI 10.1159/000066510
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
NR 34
TC 19
Z9 19
U1 0
U2 3
PU E M H SWISS MEDICAL PUBLISHERS LTD
PI MUTTENZ
PA FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND
SN 1424-7860
EI 1424-3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD JAN 25
PY 2003
VL 133
IS 3-4
BP 31
EP 38
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 657NK
UT WOS:000181673100002
PM 12596084
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Budagian, V
   Bulanova, E
   Brovko, L
   Orinska, Z
   Fayad, R
   Paus, R
   Bulfone-Paus, S
AF Budagian, V
   Bulanova, E
   Brovko, L
   Orinska, Z
   Fayad, R
   Paus, R
   Bulfone-Paus, S
TI RETRACTED: Signaling through P2X7 receptor in human T cells involves
   p56(lck), kinases, and transcription factors AP-1 and NF-kappa B
   (Retracted Article. See vol 286, pg 9894, 2011)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; EXTRACELLULAR ATP; TYROSINE KINASE; ANTIGEN
   RECEPTOR; NUCLEOTIDE RECEPTORS; PURINERGIC RECEPTORS; HUMAN-LYMPHOCYTES;
   MICROGLIAL CELLS; TERMINAL KINASE; P-2Z RECEPTOR
AB ATP-gated ion channel P2X receptors are expressed on the surface of most immune cells and can trigger multiple cellular responses, such as membrane permeabilization, cytokine production, and cell proliferation or apoptosis. Despite broad distribution and pleiotropic activities, signaling pathways downstream of these ionotropic receptors are still poorly understood. Here, we describe intracellular signaling events in Jurkat cells treated with millimolar concentrations of extracellular ATP. Within minutes, ATP treatment resulted in the phosphorylation and activation of p56(lck) kinase, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase but not p38 kinase. These effects were wholly dependent upon the presence of extracellular Ca2+ ions in the culture medium. Nevertheless, calmodulin antagonist calmidazolium and CaM kinase inhibitor KN-93 both had no effect on the activation of p56(lck) and ERK, whereas a pretreatment of Jurkat cells with MAP kinase kinase inhibitor P098059 was able to abrogate phosphorylation of ERK Further, expression of c-Jun and e-Fos proteins and activator protein (AP-1) DNA binding activity were enhanced in a time-dependent manner. In contrast, DNA binding activity of NF-kappaB was reduced. ATP failed to stimulate the phosphorylation of ERK and c-Jun N-terminal kinase and activation of AP-1 in the p56(lck)-deficient isogenic T cell line JCaM1, suggesting a critical role for p56(lck) kinase in downstream signaling. Regarding the biological significance of the ATP-induced signaling events we show that although extracellular ATP was able to stimulate proliferation of both Jurkat and JCaM1 cells, an increase in interleukin-2 transcription was observed only in Jurkat cells. The nucleotide selectivity and pharmacological profile data supported the evidence that the ATP-induced effects in Jurkat cells were mediated through the P2X7 receptor. Taken together, these results demonstrate the ability of extracellular ATP to activate multiple downstream signaling events in a human T-lymphoblastoid cell line.
C1 Res Ctr Borstel, Dept Immunol & Cellular Biol, D-23845 Borstel, Germany.
   Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada.
   Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
   Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cellular Biol, Pk Allee 22, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
CR ALBERTINI M, 1998, BIOCHEM BIOPH RES CO, V248, P822
   ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4
   APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x
   Apasov SG, 1997, J IMMUNOL, V158, P5095
   Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2
   Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206
   Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519
   Bulanova EG, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1021
   Burnstock G, 1996, CIBA F SYMP, V198, P1
   BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3
   CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0
   Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X
   FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770
   Fernando KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/abbi.1998.1045
   Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205
   Ferrari D, 1996, J IMMUNOL, V156, P1531
   Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635
   Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139
   Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0
   FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
   Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081
   GREENBERG S, 1988, J BIOL CHEM, V263, P10337
   GRINKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   GUPTA S, 1994, J BIOL CHEM, V269, P17349
   Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429
   Henning RH, 1996, EUR J PHARMACOL, V301, P91, DOI 10.1016/0014-2999(96)00065-9
   Humphreys BD, 2000, J BIOL CHEM, V275, P26792
   Isakov N, 2000, EUR J BIOCHEM, V267, P3413, DOI 10.1046/j.1432-1327.2000.01412.x
   Jung S, 1995, ANN NY ACAD SCI, V766, P245, DOI 10.1111/j.1749-6632.1995.tb26672.x
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kim HS, 2002, J MED CHEM, V45, P208, DOI 10.1021/jm010369c
   King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1
   KIRIAKIS JM, 1994, NATURE, V369, P156
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536
   LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0
   MAJID M, 1992, BIOCHIM BIOPHYS ACTA, V1138, P283
   Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297
   Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156
   May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3
   Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200
   Moller A, 2001, J BIOL CHEM, V276, P20022, DOI 10.1074/jbc.M011139200
   Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485
   MURGIA M, 1993, J BIOL CHEM, V268, P8199
   Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200
   Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6
   Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177
   OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959
   Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615
   Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482
   RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4
   Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382
   Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7
   ROZENGURT E, 1977, J BIOL CHEM, V252, P4584
   Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6919
   Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653
   STEINBERG TH, 1987, J BIOL CHEM, V262, P8883
   STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F
   Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965
   TOKUMITSU Y, 1991, FEBS LETT, V288, P81, DOI 10.1016/0014-5793(91)81007-U
   Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653
   VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0
   Vigne P, 1999, BIOCHEM BIOPH RES CO, V256, P94, DOI 10.1006/bbrc.1999.9558
   Virginio C, 1999, NAT NEUROSCI, V2, P315
   Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev
   WILLEY JS, 1989, BLOOD, V73, P1316
   Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705
   ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279
NR 76
TC 88
Z9 97
U1 3
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 17
PY 2003
VL 278
IS 3
BP 1549
EP 1560
DI 10.1074/jbc.M206383200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 636NK
UT WOS:000180462200025
PM 12424250
OA Bronze
DA 2018-12-27
ER

PT J
AU Nakao, N
   Yoshimura, A
   Morita, H
   Takada, M
   Kayano, T
   Ideura, T
AF Nakao, N
   Yoshimura, A
   Morita, H
   Takada, M
   Kayano, T
   Ideura, T
TI RETRACTED: Combination treatment of angiotensin-II receptor blocker and
   angiotensin-converting-enzyme inhibitor in non-diabetic renal disease
   (COOPERATE): a randomised controlled trial (Retracted article. See vol.
   374, pg. 1226, 2009)
SO LANCET
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 38th
   European-Renal-Association/European-Dialysis-and-Transplant-Association
   Congress
CY JUN 24-27, 2001
CL VIENNA, AUSTRIA
SP European Renal Assoc, European Dialysis & Transplant Assoc
ID GLOMERULAR-FILTRATION-RATE; ACE-INHIBITORS; PROGRESSION; NEPHROPATHY;
   INSUFFICIENCY; METAANALYSIS; HYPERTENSION; PROTEINURIA; BENAZEPRIL;
   EFFICACY
AB Background Present angiotensin-converting-enzyme inhibitor treatment fails to prevent progression of non-diabetic renal disease. We aimed to assess the efficacy and safety of combined treatment of angiotensin-converting-enzyme inhibitor and angiotensin-II receptor blocker, and monotherapy of each drug at its maximum dose, in patients with non-diabetic renal disease.
   Methods 336 patients with non-diabetic renal disease were enrolled from one renal outpatient department in Japan. After screening and an 18-week run-in period, 263 patients were randomly assigned angiotensin-II receptor blocker (losartan, 100 mg daily), angiotensin-converting-enzyme inhibitor (trandolapril, 3 mg daily), or a combination of both drugs at equivalent doses. Survival analysis was done to compare the effects of each regimen on the combined primary endpoint of time to doubling of serum creatinine concentration or endstage renal disease. Analysis was by intention to treat.
   Findings Seven patients discontinued or were otherwise lost to follow-up. Ten (11%) of 85 patients on combination treatment reached the combined primary endpoint compared with 20 (23%) of 85 on trandolapril alone (hazard ratio 0.38, 95% Cl 0.18-0.63, p=0.018) and 20 (23%) of 86 on losartan alone (0.40, 0.17-0.69, p=0.016). Covariates affecting renal survival were combination treatment (hazard ratio 0.38, 95% Cl 0.18-0.63, p=0.011), age (1.30, 1.03-2.29, p=0.009), baseline renal function (1.80, 1.02-2.99, p=0.021), change in daily urinary protein excretion rate (0.58, 0.24-0.88, p=0.022), use of diuretics (0.80, 0.30-0.94, p=0.043), and antiproteinuric response to trandolapril (0.81, 0.21-0.91, p=0.039). Frequency of side-effects with combination treatment was the same as with trandolapril alone.
   Interpretation Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy. However, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive nondiabetic renal disease need to be researched.
C1 Showa Univ, Fujigaoka Hosp, Div Nephrol, Aoba Ku, Yokohama, Kanagawa 2278501, Japan.
   Gen Gen Do Kimitsu Hosp, Div Nephrol, Kimitsu, Japan.
RP Nakao, N (reprint author), Showa Univ, Fujigaoka Hosp, Div Nephrol, Aoba Ku, 1-30 Fujigaoka, Yokohama, Kanagawa 2278501, Japan.
EM nakao@ce.catv.ne.jp
CR Agarwal R, 2001, KIDNEY INT, V59, P2282, DOI 10.1046/j.1523-1755.2001.0590062282.x
   ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528
   COLES GA, 2000, MECH CLIN MANAGMENT, P401
   GARDMAN AH, 1995, HYPERTENSION, V25, P1345
   Gehan E. A., 1975, CANCER THERAPY PROGN, P7
   Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001
   Hemmelder MH, 1999, NEPHROL DIAL TRANSPL, V14, P98, DOI 10.1093/ndt/14.1.98
   HERBERT LA, 1999, AM J NEPHROL, V19, P1
   Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007
   Kshirsagar AV, 2000, AM J KIDNEY DIS, V35, P695, DOI 10.1016/S0272-6386(00)70018-7
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004
   Locatelli F, 1996, NEPHROL DIAL TRANSPL, V11, P461
   LOCATELLI F, 1997, KIDNEY INT S, V63, P63
   Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502
   Maschio G, 1999, J CARDIOVASC PHARM, V33, pS16, DOI 10.1097/00005344-199900001-00004
   Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440
   *PAT REG COMM JAP, 2000, OV REG DIAL TREATM J
   Ruggenenti P, 1997, LANCET, V349, P1857
   Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X
   Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X
   Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0
   Ruilope LM, 2000, J HYPERTENS, V18, P89, DOI 10.1097/00004872-200018010-00013
   Russo D, 1999, AM J KIDNEY DIS, V33, P851, DOI 10.1016/S0272-6386(99)70416-6
   Shiigai T, 2001, AM J KIDNEY DIS, V37, P477, DOI 10.1053/ajkd.2001.22069
   Toto R, 1998, HYPERTENSION, V31, P684, DOI 10.1161/01.HYP.31.2.684
   ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309
NR 27
TC 728
Z9 775
U1 9
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD JAN 11
PY 2003
VL 361
IS 9352
BP 117
EP 124
DI 10.1016/S0140-6736(03)12229-5
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 635YP
UT WOS:000180428000010
PM 12531578
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Tabata, Y
AF Hosseinkhani, H
   Tabata, Y
TI RETRACTED: In vitro gene expression by cationized derivatives of an
   artificial protein with repeated RGD sequences, Pronectin (R) (Retracted
   article. See vol. 232, pg. 268, 2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE pronectin; RGD sequences; cationization; in vitro transfection;
   buffering capacity
ID CELL-GROWTH; THERAPY; DELIVERY; DNA; TRANSFECTION; RECEPTORS; INTEGRINS;
   COMPLEXES; ADHESION
AB The objective of this study is to investigate the efficiency of a non-viral gene carrier with RGD sequences, Pronectin F+ for gene transfection. The Pronectin F+ was cationized by introducing ethylenediamine (Ed), spermidine (Sd), and spermine (Sm) to the hydroxyl groups while the corresponding gelatin derivative was prepared similarly because gelatin also has one RGD sequence per molecule. The zeta potential and molecular size of Pronectin F+ and gelatin derivatives were examined before and after polyion complexation with a plasmid DNA of luciferase. When complexed with the plasmid DNA at the Pronectin F+/plasmid DNA mixing ratio of 50, the complex exhibited a zeta potential of about 10 mV, which is similar to that of the gelatin derivative-plasmid DNA complex. Irrespective of the type of Pronectin F+ and gelatin derivatives, their complexation enabled the apparent molecular size of plasmid DNA to reduce to about 200 nm, the size decreasing with the increased derivative/plasmid DNA weight mixing ratio. The rat gastric mucosal (RGM)-1 cells treated with both complexes exhibited significantly stronger luciferase activities than free plasmid DNA although the enhanced extent was significant for the Sm derivative compared with the corresponding Ed and Sd derivatives. Cell attachment was enhanced by the Pronectin F+ derivative to a significant high extent compared with the gelatin derivative. The amount of plasmid DNA internalized into the cells was enhanced by the complexation with every Pronectin F+ derivative compared with the gelatin derivative. For both of Pronectin F+ and gelatin carriers, the buffering, capacity of Sm derivatives was higher than that of Ed and Sd derivatives and comparable to that of polyethyleneimine. It is likely that the high efficiency of gene transfection for the Sm derivative is due to the superior buffering effect. We conclude that the Sm derivative of Pronectin F+ is promising as a non-viral vector of gene transfection. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, Kyoto 6068507, Japan.
RP Tabata, Y (reprint author), Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, 53 Kawara Cho Shogoin, Kyoto 6068507, Japan.
EM yasuhiko@frontier.kyoto-u.ac.jp
CR Abdallah B, 1995, BIOL CELL, V85, P1, DOI 10.1016/0248-4900(96)89122-2
   BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002
   CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39
   Cappello J., 1990, POLYM PREPRINTS, V31, P193
   CAPPELLO J, 1994, PLASTICS MICROBES, P35
   Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y
   Dubruel P, 2000, J BIOACT COMPAT POL, V15, P191, DOI 10.1106/UCCK-VJ9J-V3DD-EP1D
   FERRARI F, 1996, Patent No. 5514581
   FERRARI FA, 1986, Patent No. 8803533
   Godbey WT, 1999, GENE THER, V6, P1380, DOI 10.1038/sj.gt.3300976
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   HERMANSON GT, 1992, IMMOBILIZED AFFINITY, P51
   Hosseinkhani H, 2002, J DRUG TARGET, V10, P193, DOI 10.1080/10611860290022624
   HOSSEINKHANI H, 2002, PHARM RES, V19, P1469
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002
   KABANOV AV, 1998, SELF ASSEMBLING COMP
   Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8
   Relou IAM, 1998, TISSUE CELL, V30, P525, DOI 10.1016/S0040-8166(98)80032-3
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   Schreier H, 1994, Pharm Acta Helv, V68, P145, DOI 10.1016/0031-6865(94)90037-X
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   Tomlinson E, 1996, J CONTROL RELEASE, V39, P357, DOI 10.1016/0168-3659(95)00166-2
   WILLIAMS JA, 1992, PATHOL BIOL, V40, P813
NR 26
TC 28
Z9 28
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 9
PY 2003
VL 86
IS 1
BP 169
EP 182
AR PII S0168-3659(02)00412-1
DI 10.1016/S0168-3659(02)00412-1
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 636YU
UT WOS:000180485500015
PM 12490382
DA 2018-12-27
ER

PT J
AU Patel, VA
   Logan, A
   Watkinson, JC
   Uz-Zaman, S
   Sheppard, MC
   Ramsden, JD
   Eggo, MC
AF Patel, VA
   Logan, A
   Watkinson, JC
   Uz-Zaman, S
   Sheppard, MC
   Ramsden, JD
   Eggo, MC
TI RETRACTED: Isolation and characterization of human thyroid endothelial
   cells (Retracted Article. See vol 297, pg E562, 2009)
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article; Retracted Publication
DE Tie-2; thyrotropin; vascular endothelial growth factor; fibroblast
   growth factor receptor-1; angiostatin; thrombospondin; plasminogen
   activators
ID FIBROBLAST-GROWTH-FACTOR; LONG-TERM CULTURE; FGF RECEPTOR 1; FOLLICULAR
   CELLS; NITRIC-OXIDE; STIMULATING HORMONE; EXPRESSION; CANCER;
   ANGIOGENESIS; PLASMINOGEN
AB From collagenase digests of human thyroid, endothelial cells were separated from follicular cells by their greater adherence to gelatin-coated plates. Endothelial cells were further purified using fluorescence-activated cell sorting, selecting for cells expressing factor VIII-related antigen. Isolated cells were negative for thyroglobulin and calcitonin when examined by immunostaining. The receptor for the angiopoietins, Tie-2, was expressed by the cells, and expression was increased by agents that elevate cAMP. Nitric oxide synthase (NOS) 3, the endothelial form of NOS, was expressed by the cells and similarly regulated. Cells responded strongly to the mitogen fibroblast growth factor (FGF)-2 in growth assays but only weakly to vascular endothelial growth factor (VEGF). VEGF was, however, able to stimulate nitric oxide release from the cells consistent with their endothelial origin. The FGF receptor (FGFR1) was full length (120 kDa) and immunolocalized to the cytosol and nucleus. Thyrotropin (TSH) did not regulate FGFR1, but its expression was increased by VEGF. Thrombospondin, a product of follicular cells, was a growth inhibitor, but neither TSH nor 3,5,3'-triiodothyronine had direct mitogenic effects. Thyroid follicular cell conditioned medium contained plasminogen activator activity and stimulated the growth of the endothelial cells, but when treated with plasminogen to produce the endothelial-specific inhibitor, angiostatin, growth was inhibited. Human thyroid endothelial cell cultures will be invaluable in determining the cross talk between endothelial and follicular cells during goitrogenesis.
C1 Univ Birmingham, Div Med Sci, Birmingham B15 2TT, W Midlands, England.
RP Eggo, MC (reprint author), Univ Birmingham Sch Med, Birmingham B15 2TT, W Midlands, England.
EM M.C.Eggo@bham.ac.uk
CR AUGUSTINVOSS HG, 1993, J CELL PHYSIOL, V157, P279, DOI 10.1002/jcp.1041570210
   BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U
   Bidey SP, 1999, J ENDOCRINOL, V160, P321, DOI 10.1677/joe.0.1600321
   Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006
   Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0
   CHRISTOFFERSEN CT, 1994, ENDOCRINOLOGY, V135, P472, DOI 10.1210/en.135.1.472
   Colin IM, 1997, EUR J ENDOCRINOL, V136, P649, DOI 10.1530/eje.0.1360649
   COLIN IM, 1995, ENDOCRINOLOGY, V136, P5283, DOI 10.1210/en.136.12.5283
   Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056
   EGGO MC, 1995, J CLIN ENDOCR METAB, V80, P1006, DOI 10.1210/jc.80.3.1006
   EMOTO N, 1991, ENDOCRINOLOGY, V128, P58, DOI 10.1210/endo-128-1-58
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217
   Gargett CE, 2000, HUM REPROD, V15, P293, DOI 10.1093/humrep/15.2.293
   Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193
   Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868
   GOODMAN AL, 1987, ENDOCRINOLOGY, V121, P2131, DOI 10.1210/endo-121-6-2131
   GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311
   Grooby WL, 1997, IMMUNOL CELL BIOL, V75, P21, DOI 10.1038/icb.1997.4
   Iruela-Arispe ML, 1999, MICROCIRCULATION, V6, P127, DOI 10.1038/sj.mn.7300061
   Isner JM, 1999, CIRCULATION, V99, P1653, DOI 10.1161/01.CIR.99.13.1653
   Jones S.E., 1967, International Journal of Non-Linear Mechanics, V2, P257, DOI 10.1016/0020-7462(67)90026-1
   Karsan A, 1997, AM J PATHOL, V151, P1775
   Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   MAK WW, 1985, THYROGLOBULIN PROTHY
   MAK WWN, 1984, BIOCHEM BIOPH RES CO, V123, P633, DOI 10.1016/0006-291X(84)90276-6
   NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321
   Neufeld G, 1999, FASEB J, V13, P9
   OREILLY MS, 1997, REGULATION ANGIOGENE
   Patel VA, 1996, J ENDOCRINOL, V148, P485, DOI 10.1677/joe.0.1480485
   Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707
   Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3
   PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041
   QIAN X, 1994, MOL BIOL CELL, V5, P179
   Ramsden JD, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730475
   Ramsden JD, 2001, J CLIN ENDOCR METAB, V86, P2709, DOI 10.1210/jc.86.6.2709
   SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164
   SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199
   Soh EY, 1996, SURGERY, V120, P944, DOI 10.1016/S0039-6060(96)80038-9
   Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1
   Thompson SD, 1998, J CLIN ENDOCR METAB, V83, P1336, DOI 10.1210/jc.83.4.1336
   Thorin E, 1998, PHARMACOL THERAPEUT, V78, P155, DOI 10.1016/S0163-7258(98)00005-9
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
   Van den Berghe L, 1998, BIOCHEM BIOPH RES CO, V252, P420, DOI 10.1006/bbrc.1998.9668
   Wang JF, 1998, J ENDOCRINOL, V157, P5, DOI 10.1677/joe.0.1570005
   WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306
   Yashima R, 2001, J CELL PHYSIOL, V188, P201, DOI 10.1002/jcp.1107
NR 48
TC 19
Z9 21
U1 3
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JAN
PY 2003
VL 284
IS 1
BP E168
EP E176
DI 10.1152/ajpendo.00096.2002
PG 9
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 626DY
UT WOS:000179858100021
PM 12388152
DA 2018-12-27
ER

PT J
AU Deligny, M
   Carreaux, F
   Carboni, B
   Toupet, L
   Dujardin, G
AF Deligny, M
   Carreaux, F
   Carboni, B
   Toupet, L
   Dujardin, G
TI RETRACTED: A novel diastereoselective route to
   alpha-hydroxyalkyldihydropyrans using a hetero Diels-Alder/allylboration
   sequence (Retracted Article. See pg 3052, 2003)
SO CHEMICAL COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID ALDER REACTIONS; DERIVATIVES; CATALYSIS; TANDEM
AB The development of a new strategy for the synthesis of alpha-hydroxyalkyl dihydropyrans is reported. This approach is based on a tandem hetero[4+2]/allylboration reaction.
C1 CNRS, UMR 6510, Inst Chim, F-35042 Rennes, France.
   Univ Rennes 1, CNRS, GMCM, F-35042 Rennes, France.
   Univ Maine, CNRS, UMR 6011, Organ Synth Lab, F-72085 Le Mans, France.
RP Carreaux, F (reprint author), CNRS, UMR 6510, Inst Chim, Campus Beaulieu, F-35042 Rennes, France.
EM francois.carreaux@univ-rennes1.fr
RI TOUPET, Loic/N-7043-2014
CR Audrain H, 2000, J ORG CHEM, V65, P4487, DOI 10.1021/jo9918596
   Batey RA, 1999, CHEM COMMUN, P475, DOI 10.1039/a809615e
   BOGER DL, 1987, HETERO DIELSALDER ME
   BOGER DL, 1991, COMPREHENSIVE ORGANI, V5, P451
   Burke SD, 2001, ORG LETT, V3, P237, DOI 10.1021/ol0068871
   Burke SD, 1999, ORG LETT, V1, P71, DOI 10.1021/ol9905506
   Carboni B, 1999, TETRAHEDRON LETT, V40, P7979, DOI 10.1016/S0040-4039(99)01649-4
   DANISHEFSKY S, 1984, TETRAHEDRON LETT, V25, P721, DOI 10.1016/S0040-4039(01)80009-5
   Evans DA, 2000, J AM CHEM SOC, V122, P1635, DOI 10.1021/ja992175i
   Faulkner DJ, 1997, NAT PROD REP, V14, P259, DOI 10.1039/np9971400259
   Gaulon C, 2002, SYNLETT, P952
   JEHANNO E, 1995, TETRAHEDRON LETT, V36, P4439, DOI 10.1016/0040-4039(95)00812-Q
   MATTESON DS, 1995, STEREODIRECTED SYNTH, pCH7
   NORCROSS RD, 1995, CHEM REV, V95, P2041, DOI 10.1021/cr00038a012
   Six Y, 1999, TETRAHEDRON LETT, V40, P1295, DOI 10.1016/S0040-4039(98)02608-2
   Tailor J, 2000, ORG LETT, V2, P3715, DOI 10.1021/ol006626b
   Tietze LF, 1997, TOP CURR CHEM, V189, P1
   VAULTIER M, 1987, TETRAHEDRON LETT, V28, P4169, DOI 10.1016/S0040-4039(00)95569-2
   VUILHORGNE M, 1977, J ORG CHEM, V42, P3289, DOI 10.1021/jo00440a019
   Wallace GA, 2000, J ORG CHEM, V65, P4145, DOI 10.1021/jo0002801
NR 20
TC 28
Z9 29
U1 5
U2 20
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2003
IS 2
BP 276
EP 277
DI 10.1039/b208572k
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 632XF
UT WOS:000180249600051
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Prevention of nausea and vomiting with ramosetron after total
   hip replacement (Retracted article. See vol. 34, pg. 367, 2014)
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article; Retracted Publication
ID POSTOPERATIVE NAUSEA; DROPERIDOL; EMESIS
AB Objective: Patients undergoing total joint replacement procedures have a remarkably high incidence of postoperative nausea and vomiting. The purpose of this study was to evaluate the efficacy and safety of ramosetron, a serotonin 5-HT3 receptor antagonist, for the prevention of nausea and vomiting after total hip replacement.
   Design: Prospective, randomised, double-blind, placebo-controlled study.
   Setting: University-affiliated teaching hospital.
   Patients: Eighty patients, aged 35-77 years, 22 male and 58 female, scheduled for total hip replacement.
   Interventions: Patients received in a randomised, double-blind manner intravenously administered placebo or ramosetron in three different doses (0.15, 0.3 or 0.6mg) at the completion of surgery (n = 20 in each group). A standard general anaesthetic technique and postoperative analgesia were used.
   Main outcome measures and results: Emetic episodes were recorded and safety assessments performed over 0 to 24 hours after anaesthesia. The rate of patients experiencing emetic symptoms (nausea, retching, vomiting) over 0 to 24 hours after anaesthesia was 70% with ramosetron 0.15mg (p = 0.5), 25% with ramosetron 0.3mg (p = 0.002) and 20% with ramosetron 0.6mg (p = 0.001), compared with placebo (75%). No clinically important adverse events were observed in any of the groups.
   Conclusion: Prophylactic antiemetic therapy with ramosetron 0.3mg is efficacious against postoperative nausea and vomiting 0 to 24 hours after anaesthesia in patients undergoing total hip replacement. Increasing the dose to 0.6mg provided no further benefit.
C1 Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tskuba.ac.jp
CR FIJIHARA A, 1996, LAB CLIN, V30, P1965
   GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544
   GAN TJ, 1995, ANESTH ANALG, V80, P81, DOI 10.1097/00000539-199501000-00014
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   Kang YK, 2002, J INT MED RES, V30, P220, DOI 10.1177/147323000203000302
   KAUSTE A, 1986, EUR J ANAESTH, V3, P1
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 9
TC 12
Z9 13
U1 3
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-2563
EI 1179-1918
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PY 2003
VL 23
IS 6
BP 405
EP 409
DI 10.2165/00044011-200323060-00004
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 689YH
UT WOS:000183520200004
PM 17535051
DA 2018-12-27
ER

PT J
AU Schultz, WCMW
   Van de Wiel, HBM
AF Schultz, WCMW
   Van de Wiel, HBM
TI RETRACTED: Sexuality, intimacy, and gynecological cancer (Retracted
   article. See vol. 39, pg. 475, 2013)
SO JOURNAL OF SEX & MARITAL THERAPY
LA English
DT Article; Retracted Publication
AB On a psychological level, not all changes in sexual functioning following gynecological cancer treatment automatically lead to sexual problems or dysfunctions. Whether sexual dissatisfaction occurs will also depend on personal factors, social factors, and the context in which these negative changes occur.
C1 Univ Groningen Hosp, Dept Obstet & Gynecol, NL-9700 RB Groningen, Netherlands.
   Univ Groningen Hosp, Dept Med Psychol, NL-9700 RB Groningen, Netherlands.
RP Schultz, WCMW (reprint author), Univ Groningen Hosp, Dept Obstet & Gynecol, Hamzepleim 1,POB 30-001, NL-9700 RB Groningen, Netherlands.
EM w.c.m.weymar.schultz@oprit.rug.nl
CR ANDERSEN BL, 1989, J CONSULT CLIN PSYCH, V57, P683, DOI 10.1037/0022-006X.57.6.683
   KLEBER RJ, 1986, TRAUMATISOBE ERVARIN
   KYLSTRA WA, 1999, INT J GYNECOLOGICAL, V9, P378
   LALOS A, 1995, J PSYCHOSOM OBST GYN, V16, P153, DOI 10.3109/01674829509024464
   Rotter J. B., 1954, SOCIAL LEARNING CLIN
   SCHOVER LR, 1989, CANCER, V63, P204, DOI 10.1002/1097-0142(19890101)63:1<204::AID-CNCR2820630133>3.0.CO;2-U
   Schultz W. C.Weijmar, 1992, ANN REV SEX RES, V3, P151
   SCHULTZ WCMW, 1990, CANCER-AM CANCER SOC, V66, P402, DOI 10.1002/1097-0142(19900715)66:2<402::AID-CNCR2820660234>3.0.CO;2-X
   SCHULTZ WCMW, 1991, INT J GYNECOL CANCER, V1, P37, DOI 10.1111/j.1525-1438.1991.tb00037.x
   SIMON W, 1986, ARCH SEX BEHAV, V15, P97, DOI 10.1007/BF01542219
   Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3
NR 11
TC 36
Z9 37
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0092-623X
EI 1521-0715
J9 J SEX MARITAL THER
JI J. Sex Marital Ther.
PY 2003
VL 29
IS 1
SU 1
BP 121
EP 128
DI 10.1080/00926230390154970
PG 8
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 632KR
UT WOS:000180222900013
PM 12735096
DA 2018-12-27
ER

PT J
AU Kunce, M
   Gerking, S
   Morgan, W
AF Kunce, M
   Gerking, S
   Morgan, W
TI RETRACTED: Effects of environmental and land use regulation in the oil
   and gas industry using the Wyoming Checkerboard as an experimental
   design (Retracted Article. See vol 97, pg 1032, 2007)
SO AMERICAN ECONOMIC REVIEW
LA English
DT Article; Retracted Publication
C1 Univ Wyoming, Dept Econ & Finance, Laramie, WY 82071 USA.
   Univ Cent Florida, Dept Econ, Orlando, FL 32816 USA.
RP Kunce, M (reprint author), Univ Wyoming, Dept Econ & Finance, Laramie, WY 82071 USA.
CR *AM PETR I, JOINT ASS SURV DRILL
   CARLS EG, 1994, J EVN MANAGEMENT, V40, P273
   HARDER B, 1995, 9707 SOC PETR ENG, P167
   Henderson JV, 1996, AM ECON REV, V86, P789
   KUNCE M, 2001, UNPUB ENV LAND USE R
   LARSON TA, 1965, HIST WYOMING
   Sheskin D, 1997, HDB PARAMETRIC NONPA
   *US DEP EN, COST IND DOM OILF EQ
NR 8
TC 8
Z9 8
U1 1
U2 18
PU AMER ECONOMIC ASSOC
PI NASHVILLE
PA 2014 BROADWAY, STE 305, NASHVILLE, TN 37203 USA
SN 0002-8282
EI 1944-7981
J9 AM ECON REV
JI Am. Econ. Rev.
PD DEC
PY 2002
VL 92
IS 5
BP 1588
EP 1593
DI 10.1257/000282802762024656
PG 6
WC Economics
SC Business & Economics
GA 633VX
UT WOS:000180306100016
DA 2018-12-27
ER

PT J
AU Maric, C
   Harris, PJ
   Alcorn, D
AF Maric, C
   Harris, PJ
   Alcorn, D
TI RETRACTED: Changes in mean arterial pressure predict degranulation of
   renomedullary interstitial cells (Retracted Article. See vol 31, pg 657,
   2004)
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE blood pressure; hypertension; renal interstitial cells; vasoactive
   peptides
ID ANGIOTENSIN-II; RENAL MEDULLARY; HYPERTENSION
AB 1. Renomedullary interstitial cells (RMIC) are characterized by numerous intracellular granules thought to contain renal medullary antihypertensive substances. However, the nature of the trigger for RMIC degranulation remains to be elucidated. The present study examines the effects of acute alterations in mean arterial pressure (MAP) and medullary blood flow (MBF) on RMIC granulation.
   2. Basal MAP and MBF in anaesthetized Sprague-Dawley rats (n = 4/group) were altered by intravenous infusions of vasoactive agents, including angiotensin II alone or with a nitric oxide (NO) synthase inhibitor (N (omega) -nitro-l-arginine) or NO donor (sodium nitroprusside), noradrenaline and by carotid artery clamping. Following these treatments, kidneys were examined by electron microscopy and the absolute volume of granules in the renal medulla was calculated using unbiased stereological methods.
   3. Acute increases in MAP, regardless of the treatment causing the increase, were associated with a reduction in the absolute volume of granules in the range of 42-67%. Regression analysis revealed that only increases in MAP, but not MBF, strongly predict RMIC degranulation.
   4. Despite previous reports that changes in MBF activate renomedullary antihypertensive activity, we conclude that the change in MAP is an important determinant of the activity of the blood pressure-lowering mechanism of the renal medulla, with the assumption that the medullary lipids mediate the antihypertensive property of the renal medulla.
C1 Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3052, Australia.
   Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia.
RP Maric, C (reprint author), Georgetown Univ, Med Ctr, Dept Med, Div Nephrol & Hypertens, 396 Bldg D,4000 Reservoir Rd NW, Washington, DC 20007 USA.
EM cm255@georgetown.edu
CR Bergstrom G, 1996, ACTA PHYSIOL SCAND, V156, P27, DOI 10.1046/j.1365-201X.1996.429150000.x
   Bohman S-V, 1980, RENAL PAPILLA HYPERT, P7
   Correia AG, 2000, HYPERTENSION, V35, P965, DOI 10.1161/01.HYP.35.4.965
   COWLEY AW, 1995, HYPERTENSION, V25, P663, DOI 10.1161/01.HYP.25.4.663
   GARCIAPEREZ A, 1990, HYPERTENSION, V16, P595, DOI 10.1161/01.HYP.16.6.595
   GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x
   KOUSHANPOUR E, 1986, RENAL PHYSL, P270
   MUEHRCKE RC, 1970, CIRC RES, V27, pI109
   MUIRHEAD EE, 1985, J HYPERTENS, V3, P1, DOI 10.1097/00004872-198502000-00001
   MUIRHEAD EE, 1989, J HYPERTENS, V7, P361, DOI 10.1097/00004872-198905000-00003
   MUIRHEAD EE, 1991, CLIN EXP PHARMACOL P, V18, P409, DOI 10.1111/j.1440-1681.1991.tb01472.x
   MUIRHEAD EE, 1985, HYPERTENSION, V7, pI127, DOI 10.1161/01.HYP.7.3_Pt_2.I127
   Pitcock J A, 1984, J Hypertens, V2, P419
   PITCOCK JA, 1981, HYPERTENSION, V3, P75, DOI 10.1161/01.HYP.3.6_Pt_2.II-75
   SZOKOL M, 1979, EXP PATHOL-JENA, V17, P143, DOI 10.1016/S0014-4908(79)80021-6
   THOMAS CJ, 1994, HYPERTENSION, V23, P639, DOI 10.1161/01.HYP.23.5.639
   Tobian L, 1968, Trans Assoc Am Physicians, V81, P125
   Walker LL, 1999, J PHYSIOL-LONDON, V519, P273, DOI 10.1111/j.1469-7793.1999.0273o.x
   WEIBEL ER, 1979, PRACTICAL METHODS BI, P26
   ZHUO JL, 1992, KIDNEY INT, V42, P1372, DOI 10.1038/ki.1992.429
   ZUSMAN RM, 1977, J CLIN INVEST, V60, P215, DOI 10.1172/JCI108758
NR 21
TC 2
Z9 2
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD DEC
PY 2002
VL 29
IS 12
BP 1055
EP 1059
DI 10.1046/j.1440-1681.2002.03780.x
PG 5
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 605JM
UT WOS:000178674800002
PM 12390292
DA 2018-12-27
ER

PT J
AU Yatsuki, H
   Joh, K
   Higashimoto, K
   Soejima, H
   Arai, Y
   Wang, YD
   Hatada, I
   Obata, Y
   Morisaki, H
   Zhang, ZM
   Nakagawachi, T
   Satoh, Y
   Mukai, T
AF Yatsuki, H
   Joh, K
   Higashimoto, K
   Soejima, H
   Arai, Y
   Wang, YD
   Hatada, I
   Obata, Y
   Morisaki, H
   Zhang, ZM
   Nakagawachi, T
   Satoh, Y
   Mukai, T
TI RETRACTED: Domain regulation of imprinting cluster in Kip2/Lit1
   subdomain on mouse chromosome 7F4/F5: Large-scale DNA methylation
   analysis reveals that DMR-Lit1 is control region (Retracted Article. See
   vol 14, pg 1820, 2004)
SO GENOME RESEARCH
LA English
DT Article; Retracted Publication
ID BECKWITH-WIEDEMANN-SYNDROME; GROWTH-FACTOR II; GENE-CLUSTER; CHROMATIN
   CONFORMATION; P57(KIP2); EXPRESSION; SEQUENCE; KVLQT1; LOCUS;
   ESTABLISHMENT
AB Mouse chromosome 7F4/F5, where the imprinting domain is located, is syntenic to human 11p15.5, the locus for Beckwith-Wiedemann syndrome. The domain is thought to consist of the two subdomains Kip2 (p57(kip2))/Lit1 and Igf2/H19. Because DNA methylation is believed to be a key factor in genomic imprinting, we performed large-scale DNA methylation analysis to identify the cis-element crucial for the regulation of the Kip2/Lit1 subdomain. Ten CpG islands (CGls) were found, and these were located at the promoter sites, upstream of genes, and within intergenic regions. Bisulphite sequencing revealed that CGls 4, 5, 8, and 10 were differentially methylated regions (DMRs). CGls 4, 5, and 10 were methylated paternally in somatic tissues but not in germ cells. CGI8 was methylated in oocyte and maternally in somatic tissues during development. Parental-specific DNase I hypersensitive sites (HSSs) were found near CGI8. These data indicate that CGI8, called DMR-Lit1, is not only the region for gametic methylation but might also be the imprinting control region (ICR) of the subdomain.
C1 Saga Med Sch, Dept Biochem, Saga 8498501, Japan.
   Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5658565, Japan.
   Gunma Univ, Gene Res Ctr, Maebashi, Gumma 3718511, Japan.
RP Mukai, T (reprint author), Saga Med Sch, Dept Biochem, Saga 8498501, Japan.
EM mukait@post.saga-med.ac.jp
OI Soejima, Hidenobu/0000-0001-5076-6563
CR Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X
   Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848
   Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466
   Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715
   Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597
   Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691
   Feinberg AD, 2000, J CLIN INVEST, V106, P739, DOI 10.1172/JCI10911
   Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020
   Gould TD, 1998, HUM MOL GENET, V7, P483, DOI 10.1093/hmg/7.3.483
   Hanel ML, 2001, MOL CELL BIOL, V21, P2384, DOI 10.1128/MCB.21.7.2384-2392.2001
   Hark AT, 1998, HUM MOL GENET, V7, P1979, DOI 10.1093/hmg/7.12.1979
   Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171
   HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204
   Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075
   Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715
   John RM, 2001, HUM MOL GENET, V10, P1601, DOI 10.1093/hmg/10.15.1601
   Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200
   Lee MP, 1997, AM J HUM GENET, V61, P304, DOI 10.1086/514858
   Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203
   Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340
   Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209
   Morisaki H, 1998, DNA Res, V5, P235, DOI 10.1093/dnares/5.4.235
   OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854
   Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800
   Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009
   Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829
   Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149
   Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021
   RAZIN A, 1991, MICROBIOL REV, V55, P451
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6
   Sambrook J, 2001, MOL CLONING LAB MANU
   Schweizer J, 1999, HUM MOL GENET, V8, P555, DOI 10.1093/hmg/8.4.555
   Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267
   Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371
   Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064
   STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R
   Sun FL, 1997, NATURE, V389, P809
   Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693
   Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0
   TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407
   Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371
   Yatsuki H, 2000, DNA RES, V7, P195, DOI 10.1093/dnares/7.3.195
   YOSHIDA K, 1995, FORENSIC SCI INT, V72, P25, DOI 10.1016/0379-0738(94)01668-U
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
NR 47
TC 55
Z9 56
U1 1
U2 9
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD DEC
PY 2002
VL 12
IS 12
BP 1860
EP 1870
DI 10.1101/gr.110702
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 621PW
UT WOS:000179599400007
PM 12466290
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU He, JK
   Innis, BL
   Shrestha, MP
   Clayson, ET
   Scott, RM
   Linthicum, KJ
   Musser, GG
   Gigliotti, SC
   Binn, LN
   Kuschner, RA
   Vaughn, DW
AF He, JK
   Innis, BL
   Shrestha, MP
   Clayson, ET
   Scott, RM
   Linthicum, KJ
   Musser, GG
   Gigliotti, SC
   Binn, LN
   Kuschner, RA
   Vaughn, DW
TI RETRACTED: Evidence that rodents are a reservoir of hepatitis E virus
   for humans in Nepal (Retracted Article. See vol 44, pg 1208, 2006)
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID SPORADIC ACUTE HEPATITIS; UNITED-STATES; MOLECULAR CHARACTERIZATION;
   PHYLOGENETIC ANALYSIS; CYNOMOLGUS MACAQUES; INDIAN STRAIN; E INFECTION;
   HEV; SEQUENCE; ISOLATE
AB Hepatitis E virus (HEV) is an important cause of enterically transmitted hepatitis in developing countries. Sporadic autochthonous cases of hepatitis E have been reported recently in the United States and other industrialized countries. The source of HEV infection in these cases is unknown; zoonotic transmission has been suggested. Antibodies to HEV have been detected in many animals in areas where HEV is endemic and in domestic swine and rats in the United States. There is evidence supporting HEV transmission between swine and humans. Nevertheless, HEV has not been detected in wild rodents. We tested murid rodents and house shrews trapped in Nepal's Kathmandu Valley, where hepatitis E is hyperendemic, for HEV infection. The most commonly trapped species was Rattus rattus brunneusculus. Serum samples from 675 animals were tested for immunoglobulin G against HEV by enzyme-linked immunosorbent assay; 78 (12%) were positive, indicating acute or past infection. Antibody prevalence was higher among R. rattus brunneusculus and Bandicota bengalensis than in Suncus murinus. Forty-four specimens from 78 antibody-positive animals had sufficient residual volume for detection of HEV RNA (viremia) by reverse transcription-PCR. PCR amplification detected four animals (9%; three were R. rattus brunneusculus and one was B. bengalensis) with viremia. Phylogenetic analysis of the four genome sequences (405 bp in the capsid gene) recovered showed that they were identical, most closely related to two human isolates from Nepal (95 and 96% nucleotide homology, respectively), and distinct from HEV sequences isolated elsewhere. These data prove that certain peridomestic rodents acquire HEV in the wild and suggest that cross-species transmission occurs, with rodents serving as a virus reservoir for humans.
C1 Walter Reed Army Inst Res, Silver Spring, MD USA.
   Armed Forces Res Inst Med Sci, Res Unit, Walter Reed Army Inst Res, Kathmandu, Nepal.
   Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand.
   Amer Museum Nat Hist, New York, NY 10024 USA.
RP Vaughn, DW (reprint author), USA, Med Res & Mat Command, Mil Infect Dis Res Program, 504 Scott St, Ft Detrick, MD 21702 USA.
EM david.vaughn@det.amedd.army.mil
OI Innis, Bruce/0000-0002-1753-7248
CR Arankalle V A, 1994, J Viral Hepat, V1, P125, DOI 10.1111/j.1365-2893.1994.tb00111.x
   ARANKALLE VA, 1994, P NATL ACAD SCI USA, V91, P3428, DOI 10.1073/pnas.91.8.3428
   ARANKALLE VA, 1993, ACTA VIROL, V37, P515
   AYE TT, 1992, NUCLEIC ACIDS RES, V20, P3512, DOI 10.1093/nar/20.13.3512
   BALAYAN MS, 1990, J MED VIROL, V32, P58, DOI 10.1002/jmv.1890320110
   BI SL, 1993, VIRUS RES, V28, P233, DOI 10.1016/0168-1702(93)90024-H
   BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277
   Carleton M.D., 1984, P289
   CLAYSON ET, 1995, AM J TROP MED HYG, V53, P228, DOI 10.4269/ajtmh.1995.53.228
   CLAYSON ET, 1995, J INFECT DIS, V172, P927, DOI 10.1093/infdis/172.4.927
   CLAYSON ET, 1996, ENTERICALLY TRANSMIT, P329
   deGroen PC, 1997, MAYO CLIN PROC, V72, P1197, DOI 10.1016/S0025-6196(11)63687-2
   Erker JC, 1999, J GEN VIROL, V80, P681, DOI 10.1099/0022-1317-80-3-681
   Gouvea V, 1997, VIRUS RES, V52, P87, DOI 10.1016/S0168-1702(97)00112-3
   He J, 1999, VIRUS RES, V62, P59, DOI 10.1016/S0168-1702(99)00047-7
   He JK, 2001, J BIOMED SCI, V8, P223, DOI 10.1159/000054036
   He JK, 2000, J BIOMED SCI, V7, P334, DOI 10.1159/000025468
   Hsieh SY, 1998, J MED VIROL, V55, P300, DOI 10.1002/(SICI)1096-9071(199808)55:4<300::AID-JMV8>3.0.CO;2-4
   HUANG CC, 1992, VIROLOGY, V191, P550, DOI 10.1016/0042-6822(92)90230-M
   Kabrane-Lazizi Y, 1999, AM J TROP MED HYG, V61, P331, DOI 10.4269/ajtmh.1999.61.331
   KARETNYI YV, 1993, J MICROBIOL EPIDEMIO, V41, P52
   Kwo PY, 1997, MAYO CLIN PROC, V72, P1133, DOI 10.4065/72.12.1133
   Maneerat Y, 1996, J MED VIROL, V48, P121
   McCrudden R, 2000, GUT, V46, P732, DOI 10.1136/gut.46.5.732
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   MICHAEL OF, 2000, J INFECT DIS, V181, P449
   PANDA SK, 1995, J CLIN MICROBIOL, V33, P2653
   PURCELL RH, 1996, FIELDS VIROLOGY, V2, P2831
   REYES GR, 1997, VIRAL HEPATITIS, P239
   RIZZETTO M, 1997, VIRAL HEPATITIS LIVE, P313
   Schlauder GG, 1998, J GEN VIROL, V79, P447, DOI 10.1099/0022-1317-79-3-447
   Schlauder GG, 1999, J MED VIROL, V57, P243, DOI 10.1002/(SICI)1096-9071(199903)57:3<243::AID-JMV6>3.0.CO;2-R
   TSAREV SA, 1992, P NATL ACAD SCI USA, V89, P559, DOI 10.1073/pnas.89.2.559
   Tsarev SA, 1999, J MED VIROL, V57, P68, DOI 10.1002/(SICI)1096-9071(199901)57:1<68::AID-JMV10>3.0.CO;2-E
   USMANOV RK, 1994, VOP VIRUSOL+, V39, P165
   vanCuyckGandre H, 1997, J MED VIROL, V53, P340, DOI 10.1002/(SICI)1096-9071(199712)53:4<340::AID-JMV5>3.0.CO;2-7
   Withers MR, 2002, AM J TROP MED HYG, V66, P384, DOI 10.4269/ajtmh.2002.66.384
   YIN SR, 1994, VIRUS GENES, V9, P23, DOI 10.1007/BF01703432
   Zanetti AR, 1999, J MED VIROL, V57, P356, DOI 10.1002/(SICI)1096-9071(199904)57:4<356::AID-JMV5>3.0.CO;2-D
NR 39
TC 34
Z9 40
U1 3
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 2002
VL 40
IS 12
BP 4493
EP 4498
DI 10.1128/JCM.40.12.4493-4498.2002
PG 6
WC Microbiology
SC Microbiology
GA 622DP
UT WOS:000179631500015
PM 12454141
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Dzhura, I
   Wu, YJ
   Colbran, RJ
   Corbin, JD
   Balser, JR
   Anderson, ME
AF Dzhura, I
   Wu, YJ
   Colbran, RJ
   Corbin, JD
   Balser, JR
   Anderson, ME
TI RETRACTED: Cytoskeletal disrupting agents prevent calmodulin kinase, IQ
   domain and voltage-dependent facilitation of L-type Ca2+ channels
   (Retracted article. See vol. 593, pg. 2247, 2015)
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article; Retracted Publication
ID CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; RABBIT VENTRICULAR MYOCYTES;
   D-ASPARTATE RECEPTOR; CALCIUM-CHANNELS; ANCHORING PROTEIN;
   CA2+-DEPENDENT INACTIVATION; C TRANSLOCATION; ACTIN-BINDING; NR2B
   SUBUNIT; PHOSPHORYLATION
AB A calmodulin (CaM) binding 'IQ' domain on the L-type Ca2+ channel (LTCC) C terminus and calmodulin kinase 11 (CaMK) both signal increases in LTCC opening probability (P-o) by shifting LTCCs into a gating mode (mode 2) with long openings through a process called facilitation. However, the mechanism whereby CaMK and the IQ domain are targeted to LTCCs is unknown. Endogenous CaMK is targeted to LTCCs in excised cell membrane patches because LTCC P. increased significantly in CaM-enriched (20 muM) bath solution and this effect was prevented by a specific CaMK inhibitory peptide, but not by an inactive control peptide. Pre-exposure of myocytes to the cytoskeletal disrupting agents nocodazole (microtubule specific) or cytochalasin D (microfilament specific) prevented the effects of CaM-dependent increases in P-o of LTCCs in excised membrane patches. Neither cytochalasin D nor nocodazole altered the distribution of LTCC gating modes under basal conditions in on-cell mode or excised cell membrane patches, but each of these agents occluded the response of LTCCs to exogenous, constitutively active CaMK and to an IQ-mimetic peptide (lQmp). Cytochalasin D and nocodazole pretreatment also prevented LTCC facilitation that followed a cell membrane depolarizing prepulse. In contrast, cytochalasin D and nocodazole did not affect the increase in LTCC P-o or prevent the shift to mode 2 gating in response to protein kinase A, indicating that cytoskeletal disruption specifically prevents prepulse, CaMK and IQ-dependent LTCC facilitation.
C1 Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Anesthesiol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.
RP Anderson, ME (reprint author), Vanderbilt Univ, Med Ctr, Dept Internal Med, 383 Preston Res Bldg, Nashville, TN 37232 USA.
EM mark.anderson@vanderbilt.edu
OI Colbran, Roger/0000-0001-7401-8244
FU NHLBI NIH HHS [R01 HL062494, HL03727, HL62494]
CR ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854
   ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x
   Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598
   Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080
   BERS DM, 1994, METHOD CELL BIOL, V40, P3
   BLOCH RJ, 1989, EXP CELL RES, V182, P583, DOI 10.1016/0014-4827(89)90261-9
   BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221
   BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944
   Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845
   Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798
   Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35
   Dzhura I, 2000, NAT CELL BIOL, V2, P173
   FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209
   Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X
   GLANTZ SB, 1993, J BIOL CHEM, V268, P12796
   GUPTA RC, 1989, BIOCHEMISTRY-US, V28, P5909, DOI 10.1021/bi00440a030
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763
   Janmey PA, 1998, PHYSIOL REV, V78, P763
   Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962
   Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126
   LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904
   Mazur A, 1999, CIRCULATION, V100, P2437, DOI 10.1161/01.CIR.100.24.2437
   MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043
   MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0
   Mikhailov A, 1998, CELL MOTIL CYTOSKEL, V41, P325, DOI 10.1002/(SICI)1097-0169(1998)41:4<325::AID-CM5>3.0.CO;2-D
   Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206
   OHTA Y, 1986, FEBS LETT, V208, P423, DOI 10.1016/0014-5793(86)81061-4
   Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200
   Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075
   PEDROTTI B, 1994, CELL MOTIL CYTOSKEL, V29, P110, DOI 10.1002/cm.970290203
   Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6
   PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0
   Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200
   Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964
   SAHYOUN N, 1986, J BIOL CHEM, V261, P2339
   Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3
   Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200
   Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689
   TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0
   VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X
   WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0
   Wu YJ, 2002, CIRCULATION, V106, P1288, DOI 10.1161/01.CIR.0000027583.73268.E7
   Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198
   Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x
   Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168
   XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659
   YUAN WL, 1994, AM J PHYSIOL, V267, pH982
   YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753
   Zhong JM, 1999, AM J PHYSIOL-CELL PH, V277, pC840, DOI 10.1152/ajpcell.1999.277.4.C840
   Zuhlke RD, 1999, NATURE, V399, P159
NR 51
TC 45
Z9 45
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD DEC 1
PY 2002
VL 545
IS 2
BP 399
EP 406
DI 10.1113/jphysiol.2002.021881
PG 8
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 629WN
UT WOS:000180075200009
PM 12456820
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Reith, A
AF Sudbo, J
   Reith, A
TI RETRACTED: When is an oral leukoplakia premalignant? (Retracted article.
   See vol 43, pg 419, 2007)
SO ORAL ONCOLOGY
LA English
DT Letter; Retracted Publication
ID MOLECULAR MARKERS; LESIONS; CANCER
C1 Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
   Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
CR KARABULUT A, 1995, J ORAL PATHOL MED, V24, P198, DOI 10.1111/j.1600-0714.1995.tb01166.x
   Kuffer R, 2002, ORAL ONCOL, V38, P125, DOI 10.1016/S1368-8375(01)00050-1
   Lee JJ, 2000, CLIN CANCER RES, V6, P1702
   Lippman SM, 2001, NEW ENGL J MED, V344, P1323, DOI 10.1056/NEJM200104263441710
   Sudbo J, 2002, J CLIN ONCOL, V20, P456, DOI 10.1200/JCO.20.2.456
   Sudbo J, 2001, ORAL ONCOL, V37, P558, DOI 10.1016/S1368-8375(00)00126-3
   Sudbo J, 2000, LAB INVEST, V80, P1881, DOI 10.1038/labinvest.3780198
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Warnakulasuriya S, 2000, J PATHOL, V190, P407, DOI 10.1002/(SICI)1096-9896(200003)190:4<407::AID-PATH546>3.0.CO;2-D
   WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306
NR 10
TC 2
Z9 3
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD DEC
PY 2002
VL 38
IS 8
BP 813
EP 814
AR PII S1368-8375(02)00021-0
DI 10.1016/S1368-8375(02)00021-0
PG 2
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 611XX
UT WOS:000179044100016
PM 12570065
DA 2018-12-27
ER

PT J
AU Nguyen, LT
   Radhakrishnan, S
   Ciric, B
   Tamada, K
   Shin, T
   Pardoll, DM
   Chen, LP
   Rodriguez, M
   Pease, LR
AF Nguyen, LT
   Radhakrishnan, S
   Ciric, B
   Tamada, K
   Shin, T
   Pardoll, DM
   Chen, LP
   Rodriguez, M
   Pease, LR
TI RETRACTED: Cross-linking the B7 family molecule B7-DC directly activates
   immune functions of dendritic cells (Retracted Article. See vol 207,
   2010)
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE dendritic cells; costimulation; B7 superfamily; B7-DC; IL-12
ID MONOCLONAL-ANTIBODY; ANTIGEN; TRANSPLANTATION; PROLIFERATION;
   IMMUNOTHERAPY; SUPERFAMILY; MATURATION; INDUCTION; MEMBER; B7-H1
AB B7-DC molecules are known to function as ligands on antigen-presenting cells (APCs), enhancing T cell activation. In this study, cross-linking B7-DC with the monoclonal antibody sHIgM12 directly potentiates dendritic cell (DC) function by enhancing DC presentation of major histocompatibility complex-peptide complexes, promoting DC survival; and increasing secretion of interleukin (IL)-12p70, a key T helper cell type 1 promoting cytokine. Furthermore, ex vivo treatment of DCs or systemic treatment of mice with sHIgM12 increases the number of transplanted DCs that reach draining lymph nodes and increases the ability of lymph node APCs to activate naive T cells. Systemic administration of the antibody has an equivalent effect on DCs transferred at a distant site. These findings implicate B7-DC expressed on DCs in bidirectional communication. In addition to the established costimulatory and inhibitory functions associated with B7-DC, this molecule can also function as a conduit for extracellular signals to DCs modifying DC functions.
C1 Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA.
   Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
   Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin & Mayo Grad Sch Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Rodriguez, Moses/0000-0001-6328-6497
FU NCI NIH HHS [R01 CA097085, R01 CA104996, CA97085]
CR Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2
   Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111
   Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251
   Dong HD, 1999, NAT MED, V5, P1365
   Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913
   Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495
   Gunzer M, 2001, SEMIN IMMUNOL, V13, P291, DOI 10.1006/smim.2001.0325
   Henry J, 1999, IMMUNOL TODAY, V20, P285, DOI 10.1016/S0167-5699(98)01418-2
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Lu L, 2002, TRANSPLANTATION, V73, pS19, DOI 10.1097/00007890-200201151-00008
   Morelli AE, 2001, SEMIN IMMUNOL, V13, P323, DOI 10.1006/smim.2001.0328
   Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774
   Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1
   Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371
   Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727
   Suvas S, 2002, J BIOL CHEM, V277, P7766, DOI 10.1074/jbc.M105902200
   TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Zitvogel L, 2000, ANN ONCOL, V11, P199, DOI 10.1023/A:1011100720721
NR 23
TC 76
Z9 82
U1 4
U2 11
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD NOV 18
PY 2002
VL 196
IS 10
BP 1393
EP 1398
DI 10.1084/jem.20021466
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 618HL
UT WOS:000179412600013
PM 12438431
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Jorge, B
   Zarich, N
   Oliva, JL
   Azanedo, M
   Martinez, N
   de la Cruz, X
   Rojas, JM
AF Jorge, B
   Zarich, N
   Oliva, JL
   Azanedo, M
   Martinez, N
   de la Cruz, X
   Rojas, JM
TI RETRACTED: hSos1 contains a new amino-terminal regulatory motif with
   specific binding affinity for its pleckstrin homology domain (Retracted
   article. See vol. 293, pg. 11650, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID GUANINE-NUCLEOTIDE EXCHANGE; SON-OF-SEVENLESS; GRB2-BINDING DOMAIN;
   CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN-KINASE; N-TERMINUS; PH
   DOMAIN; RAS; DBL
AB The protein hSos1 is a Ras guanine nucleotide exchange factor. In the present study, we investigated the function of the amino-terminal region of the hSos1 protein, corresponding to the first 600 residues, which includes the DbI and pleckstrin homology (DH and PH) domains. We demonstrated, using a series of truncated mutants, that this region is absolutely necessary for hSos1 activity. Our results suggest that the first 200 residues (upstream of DH domain), which we called the HF motif on the basis of their homology with histone H2A, may exert negative control over the functional activity of the whole hSos1 protein. In vitro binding analysis showed that the HF motif is able to interact specifically with the PH domain of hSos1. The amino-terminal region of hSos1 may be associated in vivo with an expressed HF motif. These findings document the existence of the HF motif located upstream of the DH domain in the hSos1 protein. This motif may be responsible for the negative control of hSos1, probably by intramolecular binding with the PH domain.
C1 Inst Salud Carlos III, Unidad Biol Celular, Ctr Nacl Microbiol, Km 2,Carretera Majadahonda Pozuela, Madrid 28220, Spain.
   Univ Barcelona, Dept Bioquim & Biol Mol, Fac Quim, E-08028 Barcelona, Spain.
   ICREA, E-08028 Barcelona, Spain.
RP Rojas, JM (reprint author), Inst Salud Carlos III, Unidad Biol Celular, Ctr Nacl Microbiol, Km 2,Carretera Majadahonda Pozuela, Madrid 28220, Spain.
EM jmrojas@isciii.es
RI Rojas, Jose/D-3718-2018
OI Rojas, Jose/0000-0002-5383-3482; De la Cruz Montserrat, Fco.
   Xavier/0000-0002-9738-8472
FU ICREA
CR Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4
   Anborgh PH, 1999, MOL CELL BIOL, V19, P4611
   ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2
   BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685
   Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001
   BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0
   Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548
   Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511
   Byrne JL, 1996, ONCOGENE, V13, P2055
   CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579
   Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351
   Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880
   deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272
   Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200
   Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112
   KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106
   Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041
   Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001
   LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0
   Luger K, 1997, NATURE, V389, P251
   MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954
   Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560
   Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771
   QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512
   Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059
   Rojas JM, 1996, ONCOGENE, V12, P2291
   Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483
   Roy S, 1999, NAT CELL BIOL, V1, P98
   Scita G, 1999, NATURE, V401, P290
   Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0
   Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224
   Zarich N, 2000, ONCOGENE, V19, P5872, DOI 10.1038/sj.onc.1203955
NR 32
TC 22
Z9 23
U1 2
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 15
PY 2002
VL 277
IS 46
BP 44171
EP 44179
DI 10.1074/jbc.M204423200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 615XE
UT WOS:000179272000083
PM 12223473
OA Bronze
DA 2018-12-27
ER

PT J
AU Sezen, B
   Franz, R
   Sames, D
AF Sezen, B
   Franz, R
   Sames, D
TI RETRACTED: C-C bond formation via C-H bond activation: Catalytic
   arylation and alkenylation of alkane segments (Retracted Article. See
   vol 128, pg 8364, 2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID FUNCTIONALIZATION; STEROIDS; ARENES; C-18
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
RI 丹丹, 李/D-2431-2010
FU NIGMS NIH HHS [R01 GM60326]
CR BARTON DH, 1961, J AM CHEM SOC, V83, P4083, DOI 10.1021/ja01480a031
   BRESLOW R, 1973, J AM CHEM SOC, V95, P3251, DOI 10.1021/ja00791a031
   BUCHSCHACHER P, 1958, J AM CHEM SOC, V80, P2905, DOI 10.1021/ja01544a080
   Chen HY, 2000, SCIENCE, V287, P1995, DOI 10.1126/science.287.5460.1995
   Cho JY, 2002, SCIENCE, V295, P305, DOI 10.1126/science.1067074
   COREY EJ, 1965, J AM CHEM SOC, V87, P2518, DOI 10.1021/ja01089a055
   COREY EJ, 1958, J AM CHEM SOC, V80, P2903, DOI 10.1021/ja01544a078
   Dangel BD, 2002, J AM CHEM SOC, V124, P11856, DOI 10.1021/ja027311p
   Davies HML, 2000, J AM CHEM SOC, V122, P3063, DOI 10.1021/ja994136c
   Denmark SE, 2001, J AM CHEM SOC, V123, P6439, DOI 10.1021/ja016021q
   DIECK HA, 1975, J ORG CHEM, V40, P103
   DYKER G, 1994, ANGEW CHEM INT EDIT, V33, P103, DOI 10.1002/anie.199401031
   Hirabayashi K, 2000, B CHEM SOC JPN, V73, P1409, DOI 10.1246/bcsj.73.1409
   Ishiyama T, 2002, J AM CHEM SOC, V124, P390, DOI 10.1021/ja0173019
   Jia CG, 2001, ACCOUNTS CHEM RES, V34, P633, DOI 10.1021/ar000209h
   Johnson JA, 2002, J AM CHEM SOC, V124, P6900, DOI 10.1021/ja026130k
   Kakiuchi F., 1999, ACTIVATION UNREACTIV, P47
   Laaziri H, 1999, J AM CHEM SOC, V121, P6940, DOI 10.1021/ja9843977
   Miura M, 2002, TOP CURR CHEM, V219, P211
   MorenoManas M, 1996, J ORG CHEM, V61, P2346, DOI 10.1021/jo9514329
   Taber DF, 1998, CHEM-EUR J, V4, P990, DOI 10.1002/(SICI)1521-3765(19980615)4:6<990::AID-CHEM990>3.0.CO;2-U
   Yonehara F, 2001, J AM CHEM SOC, V123, P11310, DOI 10.1021/ja0164172
NR 22
TC 52
Z9 52
U1 4
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 13
PY 2002
VL 124
IS 45
BP 13372
EP 13373
DI 10.1021/ja027891q
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 613FW
UT WOS:000179122900017
PM 12418875
DA 2018-12-27
ER

PT J
AU Wong, CW
   McNally, C
   Nickbarg, E
   Komm, BS
   Cheskis, BJ
AF Wong, CW
   McNally, C
   Nickbarg, E
   Komm, BS
   Cheskis, BJ
TI RETRACTED: Estrogen receptor-interacting protein that modulates its
   nongenomic activity-crosstalk with Src/Erk phosphorylation cascade
   (Retracted article. See vol 106, pg 14180, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID MAP KINASE; ER-ALPHA; PROGESTERONE-RECEPTOR; PATHWAY ACTIVATION;
   MOLECULAR-CLONING; TYROSINE KINASES; NUCLEAR RECEPTOR; MCF-7 CELLS;
   ESTRADIOL; TRANSCRIPTION
AB Numerous studies have demonstrated that estrogens induce rapid and transient activation of the Src/Erk phosphorylation cascade. Activation of this cascade triggers vital cellular functions including cell proliferation and differentiation. However, the details of the molecular mechanism of this process remain to be elucidated. We have identified a previously uncharacterized nuclear receptor-interacting protein designated as modulator of nongenomic activity of estrogen receptor (MNAR). Here we show that MNAR modulates estrogen-receptor (ER) interaction with members of the Src family of tyrosine kinases, which leads to a stimulation of Src enzymatic activity and activation of Erk1 and Erk2 kinases. We also show that MNAR, through activation of the Src/Erk phosphorylation cascade, affects ER transcriptional activity and ultimately ER-mediated gene expression. These data reveal that MNAR mediates the crosstalk between two important classes of signal transducing molecules and suggest that ER "genomic" and "nongenomic" activities are interrelated.
C1 Wyeth Pharmaceut, Womens Hlth Res Inst, Dept Cell Biol, Collegeville, PA 19426 USA.
RP Cheskis, BJ (reprint author), Wyeth Pharmaceut, Womens Hlth Res Inst, Dept Cell Biol, 500 Arcolla Rd, Collegeville, PA 19426 USA.
EM cheskib@wyeth.com
CR ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517
   Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5
   Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x
   CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347
   Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453
   DiDomenico M, 1996, CANCER RES, V56, P4516
   Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1
   Downward J, 1997, CURR BIOL, V7, P258
   Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746
   Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987
   Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kay BK, 2000, FASEB J, V14, P231
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4
   MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307
   MIGLIACCIO A, 1993, ONCOGENE, V8, P2183
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   Oursler MJ, 1998, CRIT REV EUKAR GENE, V8, P125, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.20
   Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307
   Revelli A, 1998, ENDOCR REV, V19, P3, DOI 10.1210/er.19.1.3
   Singer CA, 1999, J NEUROSCI, V19, P2455
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h
NR 34
TC 262
Z9 280
U1 4
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 12
PY 2002
VL 99
IS 23
BP 14783
EP 14788
DI 10.1073/pnas.192569699
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 615AZ
UT WOS:000179224800033
PM 12415108
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Dong, XC
   Ghoshal, K
   Majumder, S
   Yadav, SP
   Jacob, ST
AF Dong, XC
   Ghoshal, K
   Majumder, S
   Yadav, SP
   Jacob, ST
TI RETRACTED: Mitochondrial transcription factor A and its downstream
   targets are up-regulated in a rat hepatoma (Retracted article. See vol.
   293, pg. 12947, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NUCLEAR RESPIRATORY FACTOR-1; CANCER CELL PHYSIOLOGY; GENE-EXPRESSION;
   MAMMALIAN-CELLS; DNA-BINDING; FACTOR-A; FACTOR-I; RNA; PHOSPHORYLATION;
   POLYMERASE
AB Mitochondrial transcription factor A is a key regulator involved in mitochondrial DNA transcription and replication. In a poorly differentiated rat hepatoma, Morris hepatoma 3924A, the mRNA and protein levels of this factor were elevated about 10- and 11-fold, respectively, relative to the host liver. The mRNA levels for the hepatoma cytochrome c oxidase 1, 11, and NADH dehydrogenase 5,6, the downstream targets of Tfam, were augmented 10-, 8-, 5-, and 3-fold, respectively. Interestingly, Tfam was also found in the hepatoma nucleus. The mRNA levels for nuclear respiratory factor 1 and 2 (NRF-1 and -2), the proteins that are known to interact with specific regulatory elements on human TFAM promoter, were 5- and 3-fold higher, respectively, in the hepatoma relative to the host liver. Unlike the human promoter, the rat Tfam promoter did not form a specific complex with the NRF-1 in the liver or hepatoma nuclear extracts, which is consistent with the absence of an NRF-1 consensus sequence in the proximal rat promoter. A single specific complex formed between the rat promoter and the NRF-2 protein was comparable in the two extracts. The DNA binding activity of Sp1 in the hepatoma nuclear extract was 4-fold greater than that in the liver extract. In vivo genomic footprinting showed occupancy of NRF-2 and Sp1 consensus sites on the promoter of rat Tfam gene. Tfam was also up-regulated. in other hepatoma cells. Together, these results show up-regulation of Tfam in some tumors, particularly the liver tumors. Further, the relatively high level of Sp1 binding to the promoter in the hepatoma could play a major role in the up-regulation of Tfam in these tumor cells.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
RP Jacob, ST (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.
EM Jacob.42@osu.edu
FU NCI NIH HHS [R01 CA081024-03, R01 CA081024-04, R01 CA081024-02, CA
   81024, R01 CA081024, R01 CA081024-01A2]; NIEHS NIH HHS [R01 ES010874-04,
   R01 ES010874-05, R01 ES010874, R01 ES010874-01, R01 ES010874-03, R01
   ES010874-02, ES 10874]
CR Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522
   Capuano F, 1997, J BIOENERG BIOMEMBR, V29, P379, DOI 10.1023/A:1022402915431
   Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   COOPER HM, 1997, CURRENT PROTOCOLS MO, V2
   CORRAL M, 1989, EXP CELL RES, V184, P158, DOI 10.1016/0014-4827(89)90374-1
   Dorward A, 1997, J BIOENERG BIOMEMBR, V29, P385, DOI 10.1023/A:1022454932269
   Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613
   EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023
   Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P
   FISHER RP, 1985, J BIOL CHEM, V260, P1330
   FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0
   Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539
   Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732
   Gugneja S, 1996, MOL CELL BIOL, V16, P5708
   HARLOW E, 1999, USING ATIBODIES LAB, P228
   HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159
   Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216
   LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/3033
   Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296
   LU X, 1992, CANCER RES, V52, P3718
   LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x
   Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200
   Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613
   PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Preston TJ, 2001, ADV DRUG DELIVER REV, V49, P45, DOI 10.1016/S0169-409X(01)00127-2
   QUERTERMOUS T, 1996, CURRENT PROTOCOLS MO, V1
   Rantanen A, 2001, MAMM GENOME, V12, P787, DOI 10.1007/s00335-001-2052-8
   RICE JE, 1997, SUBCELLULAR FRACTION, P107
   ROSE KM, 1975, BIOCHEMISTRY-US, V14, P1025, DOI 10.1021/bi00676a022
   Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846
   Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5
   SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203
   SRERE PA, 1961, J BIOL CHEM, V236, P2557
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   TOMINAGA K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P217, DOI 10.1016/0167-4781(92)90082-B
   VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309
NR 39
TC 42
Z9 45
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 8
PY 2002
VL 277
IS 45
BP 43309
EP 43318
DI 10.1074/jbc.M206958200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 612MZ
UT WOS:000179081200114
PM 12198131
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Hauser, MD
   Weiss, D
   Marcus, G
AF Hauser, MD
   Weiss, D
   Marcus, G
TI RETRACTED: Rule learning by cotton-top tamarins (Retracted article. See
   vol. 117, pg. 106, 2010)
SO COGNITION
LA English
DT Article; Retracted Publication
DE language acquisition; algebraic rules; comparative method; monkeys;
   language evolution
ID PLAYBACK EXPERIMENTS; SAGUINUS-OEDIPUS; NONHUMAN PRIMATE; CHIMPANZEES
   KNOW; LONG CALLS; INFANTS; ALGEBRA; CONSPECIFICS; ACQUISITION;
   PERCEPTION
AB Previous work suggests that human infants are capable of rapidly generalizing patterns that have been characterized as abstract algebraic rules (Science 283 (1999) 77), a process that may play a pivotal role in language acquisition. Here we explore whether this capacity is uniquely human and evolved specifically for the computational problems associated with language, or whether this mechanism is shared with other species, and therefore evolved for problems other than language. We used the same materials and methods that were originally employed in tests of human infants to assess whether cotton-top tamarin monkeys can extract abstract algebraic rules. Specifically, we habituated subjects to sequences of consonant-vowel syllables that followed one of two patterns, AAB (e.g. wi wi di) or ABB (le we we). Following habituation, we presented subjects with two novel test items, one with the same pattern as that presented during habituation and one with a different pattern. Like human infants, tamarins were more likely to dishabituate to the test item with a different pattern. We conclude that the capacity to generalize rule-like patterns, at least at the level demonstrated, did not evolve specifically for language acquisition, though it remains possible that infants might use such rules during language acquisition. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
   Harvard Univ, Neurosci Program, Cambridge, MA 02138 USA.
   Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA.
   NYU, Dept Psychol, New York, NY 10003 USA.
RP Hauser, MD (reprint author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.
EM hauser@wjh.harvard.edu
FU NCRR NIH HHS [P51RR00168-37]
CR ALTMANN GTM, 1999, SCIENCE, V284, P875, DOI DOI 10.1126/SCIENCE.284.5416.875A
   Cheney D, 1990, MONKEYS SEE WORLD IN
   Chomsky N, 1957, SYNTACTIC STRUCTURES
   Christiansen MH, 1999, TRENDS COGN SCI, V3, P289, DOI 10.1016/S1364-6613(99)01356-X
   Eimas PD, 1999, SCIENCE, V284, P435
   Ghazanfar AA, 2001, J COMP PHYSIOL A, V187, P27, DOI 10.1007/s003590000173
   Giurfa M, 2001, NATURE, V410, P930, DOI 10.1038/35073582
   Hare B, 2000, ANIM BEHAV, V59, P771, DOI 10.1006/anbe.1999.1377
   Hare B, 2001, ANIM BEHAV, V61, P139, DOI 10.1006/anbe.2000.1518
   Hauser MD, 2001, COGNITION, V78, pB53, DOI 10.1016/S0010-0277(00)00132-3
   Jusczyk P. W, 1997, DISCOVERY SPOKEN LAN
   Marcus G. F., 2001, ALGEBRAIC MIND INTEG
   Marcus GF, 1999, SCIENCE, V283, P77, DOI 10.1126/science.283.5398.77
   Marcus GF, 1999, SCIENCE, V284, P436
   Marcus GF, 1999, TRENDS COGN SCI, V3, P168, DOI 10.1016/S1364-6613(99)01321-2
   Marcus GF, 1999, TRENDS COGN SCI, V3, P290, DOI 10.1016/S1364-6613(99)01358-3
   McClelland JL, 1999, TRENDS COGN SCI, V3, P166, DOI 10.1016/S1364-6613(99)01320-0
   Miller CT, 2001, NAT NEUROSCI, V4, P783, DOI 10.1038/90481
   Negishi M, 1999, SCIENCE, V284, P435
   Pinker S, 1994, LANGUAGE INSTINCT
   POVINELLI DJ, 1996, MONOGRAPHS SOC RES C, V247
   PREMACK D, 1978, BEHAVIORAL BRAIN SCI, V4, P515, DOI DOI 10.1017/S0140525X00076512
   Ramus F, 2000, SCIENCE, V288, P349, DOI 10.1126/science.288.5464.349
   Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926
   SEIDENBERG MS, 1999, SCIENCE, V284, P435
   Shastri L, 1999, SCIENCE, V285, P1673
   Shultz TR, 1999, PROCEEDINGS OF THE TWENTY FIRST ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P665
   TOMASELLO M, 1997, PRIMATE COGNITION
   von Humboldt W., 1836, LINGUISTIC VARIABILI
   Weiss DJ, 2001, J COMP PSYCHOL, V115, P258, DOI 10.1037//0735-7036.115.3.258
NR 30
TC 67
Z9 69
U1 3
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0010-0277
J9 COGNITION
JI Cognition
PD NOV
PY 2002
VL 86
IS 1
BP B15
EP B22
AR PII S0010-0277(02)00139-7
DI 10.1016/S0010-0277(02)00139-7
PG 8
WC Psychology, Experimental
SC Psychology
GA 598HL
UT WOS:000178270100006
PM 12208654
DA 2018-12-27
ER

PT J
AU Stephanou, A
   Scarabelli, TM
   Townsend, PA
   Bell, R
   Yellon, D
   Knight, RA
   Latchman, DS
AF Stephanou, A
   Scarabelli, TM
   Townsend, PA
   Bell, R
   Yellon, D
   Knight, RA
   Latchman, DS
TI RETRACTED: The C-terminal activation domain of the STAT-1 transcription
   enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes
   (Retracted article. See vol. 32, pg. 2315, 2018)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE co-activator; ischemia
ID TARGETED DISRUPTION; REPERFUSION INJURY; GENE-EXPRESSION; ISCHEMIA;
   PATHWAY; SPECIFICITY; INDUCTION; CASPASE; COMPLEX; CELLS
AB We have demonstrated previously that the STAT-1 transcription factor plays a key role in ischemia/reperfusion (I/R)-induced apoptosis in cardiac myocytes. In the present study we assessed which region of the STAT-1 molecule mediates apoptosis in cardiac myocytes. A STAT-1 construct (amino acid 350-750) lacking the N-terminus could enhance I/R-induced apoptosis in cardiac myocytes. However, a STAT-1 construct, which lacks 60 amino acids at the C-terminus (amino acid 691-750), was ineffective in promoting I/R-induced apoptosis in cardiac myocytes. Furthermore, overexpression of a C-terminal STAT-1 construct (amino acid 691-750) containing the transcriptional activation domain, but not the DNA binding domain, strongly enhanced I/R-induced apoptotic cell death. Cardiac myocytes isolated from mice expressing a truncated C-terminal STAT-1 were more sensitive to I/R-induced cell death. Finally, isolated hearts from these animals exposed to I/R injury had larger infarct size and greater number of TUNEL-positive myocytes than control hearts. These studies demonstrate that the C-terminal transactivation domain of STAT-1 is necessary and sufficient for I/R injury-induced apoptosis in cardiac myocytes.
C1 UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England.
   UCL, Hatter Inst, London, England.
   Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England.
RP Stephanou, A (reprint author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.
EM a.stephanou@ich.ucl.ac.uk
CR Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403
   Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111
   Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   de Moissac D, 2000, J MOL CELL CARDIOL, V32, P53, DOI 10.1006/jmcc.1999.1057
   Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1
   Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949
   HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984
   Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1
   Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796
   King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699
   Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91
   Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050
   Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X
   Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697
   RAMMA CV, 2001, P NATL ACAD SCI USA, V98, P6674
   Scarabelli T, 2001, CIRCULATION, V104, P253
   Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3
   Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651
   Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656
   Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200
   Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846
   Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002
   Sumeray MS, 1998, MOL CELL BIOCHEM, V186, P61, DOI 10.1023/A:1006859011722
   Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798
   Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4
   Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092
   Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963
NR 28
TC 45
Z9 49
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2002
VL 16
IS 13
BP 1841
EP +
DI 10.1096/fj.02-0150fje
PN 1
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 649CJ
UT WOS:000181189100003
PM 12223448
DA 2018-12-27
ER

PT J
AU Kamiya, H
   Yamazaki, J
   Harashima, H
AF Kamiya, H
   Yamazaki, J
   Harashima, H
TI RETRACTED: Size and topology of exogenous DNA as determinant factors of
   transgene transcription in mammalian cells (Retracted Article. See vol
   13, pg 932, 2006)
SO GENE THERAPY
LA English
DT Article; Retracted Publication
DE topology; size; linearization; transcription
ID ESCHERICHIA-COLI RNA; C-HA-RAS; GENE DELIVERY; EXCISION-REPAIR;
   IN-VITRO; 8-HYDROXYGUANINE; MUTATIONS; ETHIDIUM; DAMAGE
AB We prepared a series of linearized DNA duplexes of various lengths in order to examine the effects of topology and the size of exogenous, plasmid-derived DNAs on transgene expression. These linearized DNA duplexes were capped at each end with a highly stable loop (5'-GCGAAGC-3') to produce a dumbbell-shaped construct that is refractory to exonuclease digestion in comparison to the analogous uncapped DNA duplexes. Intranuclear microinjection of the DNA dumbbells into simian COS-7 cells allowed the expression of the green fluorescent protein (GFP) gene on the linearized molecules, which was expressed five- to 10-fold more than that on the circular DNA of the same size. In addition, the expression by the dumbbell DNA was higher than that by the circular plasmid for at least 14 days. Interestingly, the size of the dumbbell DNA affected the transgene expression upon their microinjection into cell nuclei. The GFP expression efficiency increased with decreasing DNA size below a DNA size of 5.7 kb. The effects of topology and size on the expression of DNAs transfected with cationic lipids are similar to those of DNAs microinjected into cell nuclei. In contrast, microinjection into the cytosol showed the inverse size dependency over a range of 2.3 to 9.4 kb. Thus, transcription of a transgene in the nucleus, but not endocytosis or nuclear entry, was influenced by the exogenous DNA structure, and this was the primary determinant of transgene expression upon transfection under our conditions. These results indicate that small, linearized DNA duplexes that are end-capped with a highly stable loop (dumbbell-shaped DNA) would be very useful for nonviral gene therapy.
C1 Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan.
RP Kamiya, H (reprint author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.
CR CLAYCAMP HG, 1992, CARCINOGENESIS, V13, P1289, DOI 10.1093/carcin/13.7.1289
   Darquet AM, 1999, GENE THER, V6, P209, DOI 10.1038/sj.gt.3300816
   DENISS IS, 1976, NUCLEIC ACIDS RES, V3, P315, DOI 10.1093/nar/3.2.315
   Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543
   Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a
   Grundemann D, 1996, BIOTECHNIQUES, V21, P898
   Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288
   HIRAO I, 1992, NUCL ACIDS S SER, V27, P127
   KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893
   KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883
   Kamiya H, 1997, BIOCHEMISTRY-US, V36, P11125, DOI 10.1021/bi970871u
   KAMIYA H, 1992, CANCER RES, V52, P3483
   Kreiss P, 1999, NUCLEIC ACIDS RES, V27, P3792, DOI 10.1093/nar/27.19.3792
   KRISHNAMURTHY G, 1990, BIOCHEMISTRY-US, V29, P981, DOI 10.1021/bi00456a021
   Liang E, 1998, BBA-BIOMEMBRANES, V1369, P39, DOI 10.1016/S0005-2736(97)00172-7
   Liu J, 1998, NUCLEIC ACIDS RES, V26, P1707, DOI 10.1093/nar/26.7.1707
   Rolland AP, 1998, CRIT REV THER DRUG, V15, P143, DOI 10.1615/CritRevTherDrugCarrierSyst.v15.i2.20
   Sambrook J, 1989, MOL CLONING LAB MANU
   Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355
   Schakowski F, 2001, MOL THER, V3, P793, DOI 10.1006/mthe.2001.0322
   Schoen P, 1999, GENE THER, V6, P823, DOI 10.1038/sj.gt.3300919
   Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787
   Simoes S, 1998, GENE THER, V5, P955, DOI 10.1038/sj.gt.3300674
   Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276
   Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809
   Yoshizawa S, 1997, BIOCHEMISTRY-US, V36, P4761, DOI 10.1021/bi961738p
   Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91
NR 27
TC 22
Z9 22
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2002
VL 9
IS 22
BP 1500
EP 1507
DI 10.1038/sj.gt.3301831
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 613HX
UT WOS:000179127800003
PM 12407422
OA Bronze
DA 2018-12-27
ER

PT J
AU Baisa, HP
   Park, SW
   Stermitz, FR
   Halligan, KM
   Vivanco, JM
AF Baisa, HP
   Park, SW
   Stermitz, FR
   Halligan, KM
   Vivanco, JM
TI RETRACTED: Exudation of fluorescent beta-carbolines from Oxalis tuberosa
   L. roots (Retracted article. See vol. 71, pg. 123, 2010)
SO PHYTOCHEMISTRY
LA English
DT Article; Retracted Publication
DE harmine; harmaline; Oxalis tuberosa; Oca; Oxalidaceae; beta-carbolines
ID BIOCHEMISTRY; METABOLISM; ALKALOIDS; BIOLOGY
AB Root fluorescence is a phenomenon in which roots of seedlings fluoresce when irradiated with ultraviolet (UV) light. Soybean (Glycine max) and rye grass (Elymus glaucus) are the only plant species that have been reported to exhibit this occurrence in germinating seedling roots. The trait has been useful as a marker in genetic, tissue culture and diversity studies, and has facilitated selection of plants for breeding purposes. However, the biological significance of this occurrence in plants and other organisms is unknown. Here we report that the Andean tuber crop species Oxalis tuberosa, known as oca in the highlands of South America, secretes a fluorescent compound as part of its root exudates. The main fluorescent compounds were characterized as harmine (7-methoxy-1-methyl-beta-carboline) and harmaline (3, 4-dihydroharmine). We also detected endogenous root fluorescence in other plant species, including Arabidopsis thaliana and Phytolacca americana, a possible indication that this phenomenon is widespread within the plant kingdom. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
RP Vivanco, JM (reprint author), Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
EM jvivanco@lamar.colostate.edu
CR ALLEN JRF, 1980, PHYTOCHEMISTRY, V19, P1573, DOI 10.1016/S0031-9422(00)83773-5
   ALSHAMMA A, 1981, J NAT PROD, V44, P745, DOI 10.1021/np50018a025
   Andow DA, 2001, J ENTOMOL SCI, V36, P285, DOI 10.18474/0749-8004-36.3.285
   Arnold KE, 2002, SCIENCE, V295, P92, DOI 10.1126/science.295.5552.92
   Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019
   Bais HP, 2001, IN VITRO CELL DEV-PL, V37, P730
   DEINERT EI, 1994, NATURE, V370, P23, DOI 10.1038/370023a0
   DELANNAY X, 1982, CROP SCI, V22, P278, DOI 10.2135/cropsci1982.0011183X002200020019x
   Flores HE, 1999, TRENDS PLANT SCI, V4, P220, DOI 10.1016/S1360-1385(99)01411-9
   FLORES T, 1999, THESIS PENNSYLVANIA
   HUDSON JB, 1986, PHOTOCHEM PHOTOBIOL, V44, P483, DOI 10.1111/j.1751-1097.1986.tb04696.x
   KING SR, 1987, ECON BOT, V41, P503, DOI 10.1007/BF02908144
   KING SR, 1987, MT RES DEV, V7, P43, DOI 10.2307/3673323
   LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P20
   LARSON RA, 1988, PHOTOCHEM PHOTOBIOL, V48, P665, DOI 10.1111/j.1751-1097.1988.tb02879.x
   MCKENNA DJ, 1981, PHYTOCHEMISTRY, V20, P1001, DOI 10.1016/0031-9422(81)83017-8
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   *NAT RES COUNC, 1989, LOST CROPS INC, P1
   POUCHERT CJ, 1993, ALDRICH LIB 13C 1H F, V1
   Schober L, 2000, J ENVIRON MONITOR, V2, P651, DOI 10.1039/b004127k
   Stachel SJ, 1999, CHEM BIOL, V6, P531, DOI 10.1016/S1074-5521(99)80085-4
   Vivanco J. M., 2002, Plant roots: the hidden half, P1045
   Yu SJ, 2000, ZOOL STUD, V39, P243
NR 23
TC 20
Z9 22
U1 4
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9422
J9 PHYTOCHEMISTRY
JI Phytochemistry
PD NOV
PY 2002
VL 61
IS 5
BP 539
EP 543
AR PII S0031-9422(02)00235-2
DI 10.1016/S0031-9422(02)00235-2
PG 5
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 619KZ
UT WOS:000179476300008
PM 12409020
DA 2018-12-27
ER

PT J
AU Lilly, JW
   Maul, JE
   Stern, DB
AF Lilly, JW
   Maul, JE
   Stern, DB
TI RETRACTED: The Chlamydomonas reinhardtti organellar genomes respond
   transcriptionally and post-transcriptionally to abiotic stimuli
   (Retracted Article. See vol 16, pg 785, 2004)
SO PLANT CELL
LA English
DT Review; Retracted Publication
ID CHLOROPLAST GENE-EXPRESSION; OPEN READING FRAME; ENCODED RNA-POLYMERASE;
   PSBA MESSENGER-RNA; NUCLEAR GENES; PLASTID TRANSCRIPTION;
   PHYSCOMITRELLA-PATENS; MITOCHONDRIAL GENE; SELECTABLE MARKER;
   ESCHERICHIA-COLI
AB The Chlamydomonas reinhardtii plastid and mitochondrial transcriptomes were surveyed for changes in RNA profiles resulting from growth in 12 culture conditions representing 8 abiotic stimuli. Organellar RNA abundance exhibited marked changes during nutrient stress and exposure to UV light, as revealed by both RNA gel blot and DNA microarray analyses. Of particular note were large increases in tufA and clpP transcript abundance during nutrient limitation. Phosphate and sulfur limitation resulted in the most global, yet opposite, effects on organellar RNA abundance, changes that were dissected further using run-on transcription assays. Removal of sulfate from the culture medium, which is known to reduce photosynthesis, resulted in 2-fold to 10-fold decreases in transcription rates, which were reflected in lower RNA abundance. The decrease in transcriptional activity was completely reversible and recovered to twice the control level after sulfate replenishment. Conversely, phosphate limitation resulted in a twofold to threefold increase in RNA abundance that was found to be a post-transcriptional effect, because it could be accounted for by increased RNA stability. This finding is consistent with the known metabolic slowdown under phosphate stress. Additionally, inhibitor studies suggested that unlike those in higher plants, Chlamydomonas chloroplasts lack a nucleus-encoded plastid RNA polymerase. The apparently single type of polymerase could contribute to the rapid and genome-wide transcriptional responses observed within the chloroplast.
C1 Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA.
RP Stern, DB (reprint author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.
EM ds28@cornell.edu
CR ALLEN JF, 1993, PHOTOSYNTH RES, V36, P95, DOI 10.1007/BF00016274
   Allison LA, 2000, BIOCHIMIE, V82, P537, DOI 10.1016/S0300-9084(00)00611-8
   BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H
   Barkan A, 2000, BIOCHIMIE, V82, P559, DOI 10.1016/S0300-9084(00)00602-7
   Barkan A, 1998, METHOD ENZYMOL, V297, P38
   BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x
   BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781
   Binder S, 1996, PLANT MOL BIOL, V32, P303, DOI 10.1007/BF00039387
   BLOWERS AD, 1990, PLANT CELL, V2, P1059
   BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8
   Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366
   Boudreau E, 1997, MOL GEN GENET, V253, P649, DOI 10.1007/s004380050368
   Bowsher CG, 2001, J EXP BOT, V52, P513, DOI 10.1093/jexbot/52.356.513
   Buchanan B, 2000, BIOCH MOL BIOL PLANT
   Davies JP, 1996, EMBO J, V15, P2150, DOI 10.1002/j.1460-2075.1996.tb00568.x
   DEHOSTOS EL, 1989, MOL GEN GENET, V218, P229, DOI 10.1007/BF00331273
   DENG XW, 1989, PLANT CELL, V1, P645
   DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X
   Dent RM, 2001, TRENDS PLANT SCI, V6, P364, DOI 10.1016/S1360-1385(01)02018-0
   Drager RG, 1998, PLANT J, V13, P85, DOI 10.1046/j.1365-313X.1998.00016.x
   DRAGER RG, 1998, MOL BIOL CHLAMYDOMON, P165
   Drapier D, 1998, PLANT PHYSIOL, V117, P629, DOI 10.1104/pp.117.2.629
   DUBELL AN, 1995, PLANT PHYSIOL, V109, P105, DOI 10.1104/pp.109.1.105
   Duby F, 1999, PLANT CELL, V11, P115
   Eberhard S, 2002, PLANT J, V31, P149, DOI 10.1046/j.1365-313X.2002.01340.x
   Felder S, 2001, PLANT CELL, V13, P2127, DOI 10.1105/tpc.13.9.2127
   FINNEGAN PM, 1990, PLANT CELL, V2, P71
   Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179
   FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664
   GAGNE G, 1992, PLANT MOL BIOL, V18, P429, DOI 10.1007/BF00040659
   Giege P, 2000, EMBO REP, V1, P164, DOI 10.1093/embo-reports/kvd024
   GILLHAM NW, 1994, ANNU REV GENET, V28, P71
   GLICK RE, 1986, P NATL ACAD SCI USA, V83, P4287, DOI 10.1073/pnas.83.12.4287
   GoldschmidtClermont M, 1998, INT REV CYTOL, V177, P115
   GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083
   Gray MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1
   Gray MW, 1998, TRENDS MICROBIOL, V6, P1, DOI 10.1016/S0966-842X(97)01182-7
   GREEN PJ, 1994, ANNU REV PLANT PHYS, V45, P421, DOI 10.1146/annurev.pp.45.060194.002225
   Grossman A, 2000, PROTIST, V151, P201, DOI 10.1078/1434-4610-00020
   GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355
   Hajdukiewicz PTJ, 1997, EMBO J, V16, P4041, DOI 10.1093/emboj/16.13.4041
   Harris E., 1989, CHLAMYDOMONAS SOURCE
   Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01
   HERRMANN RG, 1985, MOL FORM FUNCTION PL
   Hwang S, 1996, P NATL ACAD SCI USA, V93, P996, DOI 10.1073/pnas.93.3.996
   Kabeya Y, 2002, PLANT CELL PHYSIOL, V43, P245, DOI 10.1093/pcp/pcf041
   KLEIN U, 1992, P NATL ACAD SCI USA, V89, P3453, DOI 10.1073/pnas.89.8.3453
   Kloppstech K, 1997, PHYSIOL PLANTARUM, V100, P739
   Knoop V, 2002, CRIT REV PLANT SCI, V21, P111, DOI 10.1080/0735-260291044205
   Komine Y, 2000, RNA, V6, P598, DOI 10.1017/S1355838200992252
   Komine Y, 2002, P NATL ACAD SCI USA, V99, P4085, DOI 10.1073/pnas.052327599
   Krab IM, 2002, PROG NUCLEIC ACID RE, V71, P513, DOI 10.1016/S0079-6603(02)71050-7
   Krause K, 2000, MOL GEN GENET, V263, P1022, DOI 10.1007/PL00008690
   KRISTAL BS, 1994, FREE RADICAL BIO MED, V16, P323, DOI 10.1016/0891-5849(94)90033-7
   Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x
   LAM E, 1987, PLANT MOL BIOL, V8, P415, DOI 10.1007/BF00015819
   Legen J, 2002, PLANT J, V31, P171, DOI 10.1046/j.1365-313X.2002.01349.x
   Leon P, 1998, ANNU REV PLANT PHYS, V49, P453, DOI 10.1146/annurev.arplant.49.1.453
   LEU S, 1990, BIOCHIM BIOPHYS ACTA, V1049, P311, DOI 10.1016/0167-4781(90)90103-9
   Leu S, 1998, BBA-BIOENERGETICS, V1365, P541, DOI 10.1016/S0005-2728(98)00107-8
   LEVINGS CS, 1995, SCIENCE, V268, P695, DOI 10.1126/science.268.5211.695
   Liere K, 1999, EMBO J, V18, P249, DOI 10.1093/emboj/18.1.249
   Lisitsky I, 1997, PLANT J, V12, P1173, DOI 10.1046/j.1365-313X.1997.12051173.x
   Majeran W, 2000, PLANT CELL, V12, P137
   Marschner H., 1995, MINERAL NUTR HIGHER
   MATHEWS DE, 1990, J BIOL CHEM, V265, P493
   Maul JE, 2002, PLANT CELL, V14, P2659, DOI 10.1105/tpc.006155
   MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051
   Menassa R, 1999, PLANT J, V17, P491, DOI 10.1046/j.1365-313X.1999.00397.x
   Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4
   MULLET JE, 1993, PLANT PHYSIOL, V103, P309, DOI 10.1104/pp.103.2.309
   MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533
   Nakajima Y, 2001, CURR GENET, V40, P209, DOI 10.1007/s002940100249
   Oikawa K, 1998, GENE, V210, P277, DOI 10.1016/S0378-1119(98)00075-4
   Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624
   Pfannschmidt T, 1997, MOL GEN GENET, V257, P35, DOI 10.1007/s004380050621
   RAPP JC, 1992, J BIOL CHEM, V267, P21404
   Raven JA, 2001, J PHYCOL, V37, P943, DOI 10.1046/j.1529-8817.2001.01079.x
   REMACLE C, 1998, MOL BIOL CHLOROPLAST, P661
   Richter U, 2002, GENE, V290, P95, DOI 10.1016/S0378-1119(02)00583-8
   ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245
   Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389
   Rodermel S, 2001, TRENDS PLANT SCI, V6, P471, DOI 10.1016/S1360-1385(01)02085-4
   Rolland N, 1997, EMBO J, V16, P6713, DOI 10.1093/emboj/16.22.6713
   SAKAMOTO W, 1993, P NATL ACAD SCI USA, V90, P497, DOI 10.1073/pnas.90.2.497
   Salvador ML, 1999, PLANT PHYSIOL, V121, P1367, DOI 10.1104/pp.121.4.1367
   SALVADOR ML, 1993, PLANT J, V3, P213, DOI 10.1046/j.1365-313X.1993.t01-13-00999.x
   Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937
   SCHUSTER G, 1986, FEBS LETT, V198, P56, DOI 10.1016/0014-5793(86)81184-X
   Shimogawara K, 1999, PLANT PHYSIOL, V120, P685, DOI 10.1104/pp.120.3.685
   SILK GW, 1988, CURR GENET, V14, P119, DOI 10.1007/BF00569335
   Singh AK, 2001, PHOTOSYNTHETICA, V39, P353, DOI 10.1023/A:1015122124866
   Surpin M, 1997, ESSAYS BIOCHEM, V32, P113
   Surpin M, 2002, PLANT CELL, V14, pS327, DOI 10.1105/tpc.010446
   SURZYCKI SJ, 1976, P NATL ACAD SCI USA, V73, P3961, DOI 10.1073/pnas.73.11.3961
   THEODOROU ME, 1991, PLANT PHYSIOL, V95, P1089, DOI 10.1104/pp.95.4.1089
   THOMPSON RJ, 1987, CELL, V48, P281, DOI 10.1016/0092-8674(87)90431-4
   TILLER K, 1993, EMBO J, V12, P1745, DOI 10.1002/j.1460-2075.1993.tb05822.x
   Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000
   Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813
   Wykoff DD, 1998, PLANT PHYSIOL, V117, P129, DOI 10.1104/pp.117.1.129
   Wykoff DD, 1999, P NATL ACAD SCI USA, V96, P15336, DOI 10.1073/pnas.96.26.15336
   Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001
   Yildiz FH, 1996, PLANT PHYSIOL, V112, P669, DOI 10.1104/pp.112.2.669
   Yu JP, 2001, PLANT PHYSIOL BIOCH, V39, P345, DOI 10.1016/S0981-9428(01)01254-2
   ZAITLIN D, 1989, P NATL ACAD SCI USA, V86, P876, DOI 10.1073/pnas.86.3.876
   Zhang LP, 2002, PLANTA, V214, P552, DOI 10.1007/s004250100660
NR 107
TC 46
Z9 49
U1 2
U2 23
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD NOV
PY 2002
VL 14
IS 11
BP 2681
EP 2706
DI 10.1105/tpc.005595
PG 26
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 615UF
UT WOS:000179264700005
PM 12417695
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Martelli, PL
   Fariselli, P
   Malaguti, L
   Casadio, R
AF Martelli, PL
   Fariselli, P
   Malaguti, L
   Casadio, R
TI RETRACTED: Prediction of the disulfide-bonding state of cysteines in
   proteins at 88% accuracy (Retracted Article. See vol 12, pg 1578, 2003)
SO PROTEIN SCIENCE
LA English
DT Article; Retracted Publication
DE hidden neural networks; hidden Markov models; neural networks;
   cysteine-bonding state
ID CONNECTIVITY
AB The task of predicting the cysteine-bonding state in proteins starting from the residue chain is addressed by implementing a new hybrid system that combines a neural network and a hidden Markov model (hidden neural network). Training is performed using 4136 cysteine-containing segments extracted from 969 non-homologous proteins of well-resolved three-dimensional structure. After a 20-fold cross-validation procedure, the efficiency of the prediction scores as high as 88% and 84%, when measured on cysteine and protein basis, respectively. These results outperform previously described methods for the same task.
C1 Univ Bologna, Dept Biol, CIRB, Lab Biocomp, I-40126 Bologna, Italy.
RP Casadio, R (reprint author), Univ Bologna, Dept Biol, CIRB, Lab Biocomp, Via Irnerio 42, I-40126 Bologna, Italy.
EM casadio@alma.unibo.it
RI Casadio, Rita/K-3747-2017; Casadio, Rita/K-4814-2015
OI Casadio, Rita/0000-0002-7462-7039; FARISELLI, PIERO/0000-0003-1811-4762
CR Abkevich VI, 2000, J MOL BIOL, V300, P975, DOI 10.1006/jmbi.2000.3893
   Clarke J, 2000, PROTEIN SCI, V9, P2394, DOI 10.1110/ps.9.12.2394
   Durbin R., 1998, BIOL SEQUENCE ANAL P
   Fariselli P, 1999, PROTEINS, V36, P340
   Fariselli P, 2001, BIOINFORMATICS, V17, P957, DOI 10.1093/bioinformatics/17.10.957
   FISER A, 1992, FEBS LETT, V302, P117, DOI 10.1016/0014-5793(92)80419-H
   Fiser A, 2000, BIOINFORMATICS, V16, P251, DOI 10.1093/bioinformatics/16.3.251
   HARRISON PM, 1994, J MOL BIOL, V244, P448, DOI 10.1006/jmbi.1994.1742
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Krogh A, 1999, NEURAL COMPUT, V11, P541, DOI 10.1162/089976699300016764
   Martelli Pier Luigi, 2002, Bioinformatics, V18 Suppl 1, pS46
   Mucchielli-Giorgi MHM, 2002, PROTEINS, V46, P243, DOI 10.1002/prot.10047
   MUSKAL SM, 1990, PROTEIN ENG, V3, P667, DOI 10.1093/protein/3.8.667
   Narayan M, 2000, ACCOUNTS CHEM RES, V33, P805, DOI 10.1021/ar000063m
   Noguchi T, 2001, NUCLEIC ACIDS RES, V29, P219, DOI 10.1093/nar/29.1.219
   Skolnick J, 1997, J MOL BIOL, V265, P217, DOI 10.1006/jmbi.1996.0720
   Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o
   Welker E, 2001, P NATL ACAD SCI USA, V98, P2312, DOI 10.1073/pnas.041615798
NR 18
TC 29
Z9 30
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD NOV
PY 2002
VL 11
IS 11
BP 2735
EP 2739
DI 10.1110/ps.0219602
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 606NG
UT WOS:000178739600020
PM 12381855
OA Green Published
DA 2018-12-27
ER

PT J
AU Boot, BP
   Mechan, AO
   McCann, UD
   Ricaurte, GA
AF Boot, BP
   Mechan, AO
   McCann, UD
   Ricaurte, GA
TI RETRACTED: MDMA- and p-chlorophenylalanine-induced reduction in 5-HT
   concentrations: effects on serotonin transporter densities (Retracted
   Article)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE MDMA; p-chlorophenylalanine; 5-HT; serotonin transporter;
   neuroadaptation
ID MESSENGER-RNA LEVELS; RAT-BRAIN; NEUROTOXICITY; NEURONS; ECSTASY;
   3,4-METHYLENEDIOXYMETHAMPHETAMINE; METHYLENEDIOXYMETHAMPHETAMINE;
   CHLOROAMPHETAMINE; EXPRESSION; TERMINALS
AB Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a "neuroadaptive response". To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured. As expected, both treatments led to serotonin depletion 1, 7 and 14 days later. However, only MDMA reduced SERT density. This observation suggests that MDMA-induced reductions in SERT density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Neurol, Baltimore, MD 21224 USA.
   Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA.
RP Ricaurte, GA (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Neurol, Baltimore, MD 21224 USA.
EM Ricaurte@jhmi.edu
CR BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911
   Bauman AL, 2000, J NEUROSCI, V20, P7571
   BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104
   COLADO MI, 1993, BRIT J PHARMACOL, V108, P583, DOI 10.1111/j.1476-5381.1993.tb12846.x
   COLADO MI, 1995, BRIT J PHARMACOL, V115, P1281, DOI 10.1111/j.1476-5381.1995.tb15037.x
   DEWAR KM, 1992, J NEUROCHEM, V58, P250, DOI 10.1111/j.1471-4159.1992.tb09303.x
   FISCHER C, 1995, J NEUROSCI, V15, P5476
   LINNET K, 1995, BRAIN RES, V697, P251, DOI 10.1016/0006-8993(95)00906-7
   McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3
   OHEARN E, 1988, J NEUROSCI, V8, P2788
   Qian Y, 1997, J NEUROSCI, V17, P45
   Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763
   Rattray M, 1996, J NEUROCHEM, V67, P463
   RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1
   SCANZELLO CR, 1993, J PHARMACOL EXP THER, V264, P1484
   Scheffel U, 1998, SYNAPSE, V29, P183, DOI 10.1002/(SICI)1098-2396(199806)29:2<183::AID-SYN9>3.3.CO;2-M
   SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   YU AQ, 1995, BRAIN RES, V688, P209, DOI 10.1016/0006-8993(95)00539-3
NR 19
TC 9
Z9 9
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 25
PY 2002
VL 453
IS 2-3
BP 239
EP 244
AR PII S0014-2999(02)02420-2
DI 10.1016/S0014-2999(02)02420-2
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 610CG
UT WOS:000178942700013
PM 12398910
DA 2018-12-27
ER

PT J
AU Beisel, C
   Imhof, A
   Greene, J
   Kremmer, E
   Sauer, F
AF Beisel, C
   Imhof, A
   Greene, J
   Kremmer, E
   Sauer, F
TI RETRACTED: Histone methylation by the Drosophila epigenetic
   transcriptional regulator Ash1 (Retracted article. See vol. 521, pg.
   110, 2015)
SO NATURE
LA English
DT Article; Retracted Publication
ID GENETIC-ANALYSIS; LYSINE 9; CHROMATIN; H3; PROTEIN; TRITHORAX; POLYCOMB;
   METHYLTRANSFERASE; INHERITANCE; ACTIVATION
AB The establishment and maintenance of mitotic and meiotic stable (epigenetic) transcription patterns is fundamental for cell determination and function(1). Epigenetic regulation of transcription is mediated by epigenetic activators and repressors, and may require the establishment, 'spreading' and maintenance of epigenetic signals(2). Although these signals remain unclear, it has been proposed that chromatin structure and consequently post-translational modification of histones may have an important role in epigenetic gene expression(3,4). Here we show that the epigenetic activator Ash1 (ref. 5) is a multi-catalytic histone methyl-transferase (HMTase) that methylates lysine residues 4 and 9 in H3 and 20 in H4. Transcriptional activation by Ash1 coincides with methylation of these three lysine residues at the promoter of Ash1 target genes. The methylation pattern placed by Ash1 may serve as a binding surface for a chromatin remodelling complex containing the epigenetic activator Brahma (Brm)(6), an ATPase, and inhibits the interaction of epigenetic repressors with chromatin. Chromatin immunoprecipitation indicates that epigenetic activation of Ultrabithorax transcription in Drosophila coincides with trivalent methylation by Ash1 and recruitment of Brm. Thus, histone methylation by Ash1 may provide a specific signal for the establishment of epigenetic, active transcription patterns.
C1 Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany.
   Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany.
   Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.
   GSF Munich, Forschungszentrum, Inst Mol Immunol, D-81377 Munich, Germany.
RP Sauer, F (reprint author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.
EM f.sauer@mail.zmbh.uni-heidelberg.de
CR Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201
   Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955
   Elfring LK, 1998, GENETICS, V148, P251
   Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
   Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0
   LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0
   Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8
   Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.961202
   ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N
   PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263
   Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Ridgway P, 2000, J CELL SCI, V113, P2647
   RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833
   Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441
   SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0
   SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825
   Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5
   Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325
   Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967
   Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883
   TRIPOULAS NA, 1994, GENETICS, V137, P1027
   Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.3.CO;2-O
   Urnov FD, 2001, J MAMMARY GLAND BIOL, V6, P153, DOI 10.1023/A:1011304606604
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 28
TC 231
Z9 240
U1 4
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 24
PY 2002
VL 419
IS 6909
BP 857
EP 862
DI 10.1038/nature01126
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 607BD
UT WOS:000178769800051
PM 12397363
DA 2018-12-27
ER

PT J
AU Shamim, W
   Yousufuddin, M
   Wang, D
   Henein, M
   Seggewiss, H
   Flather, M
   Coats, AJS
   Sigwart, U
AF Shamim, W
   Yousufuddin, M
   Wang, D
   Henein, M
   Seggewiss, H
   Flather, M
   Coats, AJS
   Sigwart, U
TI RETRACTED: Nonsurgical reduction of the interventricular septum in
   patients with hypertrophic cardiomyopathy (Retracted article. See vol
   348, pg 951, 2003)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR HYPERTROPHY; OBSTRUCTIVE
   CARDIOMYOPATHY; LONG-TERM; MAJOR DETERMINANT; HEART-FAILURE;
   DOUBLE-BLIND; FOLLOW-UP; ABLATION; THERAPY
AB Background: In patients with hypertrophic cardiomyopathy and obstruction of the left ventricular outflow tract, nonsurgical reduction of the septum is a treatment option when medical therapy has failed. We investigated the long-term effects of nonsurgical reduction of the septum on functional capacity and electrocardiographic and echocardiographic characteristics.
   Methods: Sixty-four consecutive patients with hypertrophic cardiomyopathy and a mean (+/-SD) age of 48.5+/-17.2 years underwent nonsurgical reduction of the septum by injection of ethanol into the septal perforator branch of the left anterior descending coronary artery. These patients were assessed by exercise testing, electrocardiography, and resting and dobutamine (stress-induced) echocardiography after a mean period of 3.0+/-1.3 years.
   Results: At follow-up, patients had significant improvements in New York Heart Association class, peak oxygen consumption (from 18.4+/-5.8 to 30.0+/-4.4 ml per kilogram of body weight per minute, P<0.001), and left ventricular outflow tract gradients (resting gradient, from 64+/-36 to 16+/-15 mm Hg; P<0.001; stress-induced gradient, from 132+/-34 to 45+/-19 mm Hg; P<0.001). Procedure-related complications included right bundle-branch block in all patients, complete heart block in 31 patients (48 percent), and significant increases in QRS and corrected QT intervals. Seventeen patients (27 percent) required permanent pacing. R-wave amplitude was significantly decreased (from 32+/-8 to 17+/-7 mV, P<0.001). The dimensions of the left ventricular cavity increased, and the interventricular septal thickness was reduced.
   Conclusions: Nonsurgical septal reduction leads to sustained improvements in both subjective and objective measures of exercise capacity in association with a persistent reduction in resting and stress-induced left ventricular outflow tract gradients. It is also associated with a high incidence of procedure-related complete heart block, however, often requiring permanent pacing.
C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure & Transplantat, Cleveland, OH 44195 USA.
   Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield Hosp, Natl Heart & Lung Inst, London, England.
   London Sch Hyg & Trop Med, London WC1, England.
   Ruhr Univ Bochum, Univ Hosp, Bad Oeynhausen, Germany.
RP Yousufuddin, M (reprint author), Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure & Transplantat, F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.
RI Stewart Coats, Andrew/E-4451-2012
OI Stewart Coats, Andrew/0000-0002-2771-4260
CR ASSMANN I, 1990, ACTA CARDIOL, V45, P501
   BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1
   Brilakis ES, 2002, AM J CARDIOL, V89, P1013, DOI 10.1016/S0002-9149(02)02267-1
   BROCKENBROUGH EC, 1960, AM J CARDIOL, V6, P1062, DOI 10.1016/0002-9149(60)90361-1
   BRUCE R A, 1963, Pediatrics, V32, P742
   CANNON RO, 1989, CIRCULATION, V79, P766, DOI 10.1161/01.CIR.79.4.766
   DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X
   Faber L, 1998, CIRCULATION, V98, P2415, DOI 10.1161/01.CIR.98.22.2415
   FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149
   FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731
   GOODWIN JF, 1960, BRIT HEART J, V22, P403
   HUTCHINS GM, 1978, AM J CARDIOL, V41, P1127, DOI 10.1016/0002-9149(78)90869-X
   JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7
   KATZ AM, 1990, NEW ENGL J MED, V322, P100
   Knight C, 1997, CIRCULATION, V95, P2075, DOI 10.1161/01.CIR.95.8.2075
   Kuhn H, 1999, EUR HEART J, V20, P1808, DOI 10.1053/euhj.1999.1692
   LINDEEDELSTAM C, 1992, PACE, V15, P1467, DOI 10.1111/j.1540-8159.1992.tb02920.x
   Mann C, 1999, PEDIATR CARDIOL, V20, P229, DOI 10.1007/s002469900450
   Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927
   Maron BJ, 2000, LANCET, V355, P425, DOI 10.1016/S0140-6736(00)82005-X
   Mazur W, 2001, CIRCULATION, V103, P1492
   MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584
   MORROW AG, 1959, CIRCULATION, V20, P181, DOI 10.1161/01.CIR.20.2.181
   Nagueh SF, 2001, J AM COLL CARDIOL, V38, P1701, DOI 10.1016/S0735-1097(01)01614-X
   NOLAN SE, 1988, J AM COLL CARDIOL, V12, P1318, DOI 10.1016/0735-1097(88)92616-2
   PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204
   PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455
   Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358
   SCHOENDUBE FA, 1995, CIRCULATION, V92, P122, DOI 10.1161/01.CIR.92.9.122
   Seggewiss H, 1998, J AM COLL CARDIOL, V31, P252, DOI 10.1016/S0735-1097(97)00508-1
   SHERRID M, 1988, AM J CARDIOL, V62, P1085, DOI 10.1016/0002-9149(88)90553-X
   SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3
   Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107
   VOLTERRANI M, 1994, EUR HEART J, V15, P801, DOI 10.1093/oxfordjournals.eurheartj.a060588
   WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44
   WIGLE ED, 1969, AM J CARDIOL, V24, P698, DOI 10.1016/0002-9149(69)90457-3
NR 36
TC 31
Z9 36
U1 3
U2 12
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 24
PY 2002
VL 347
IS 17
BP 1326
EP 1333
DI 10.1056/NEJMoa012710
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 607FK
UT WOS:000178781300004
PM 12397190
OA Green Published
DA 2018-12-27
ER

PT J
AU Chan, SK
   Struhl, G
AF Chan, SK
   Struhl, G
TI RETRACTED: Evidence that Armadillo transduces Wingless by mediating
   nuclear export or cytosolic activation of Pangolin (Retracted Article.
   See vol 116, pg 481, 2004)
SO CELL
LA English
DT Article; Retracted Publication
ID C-ELEGANS EMBRYOS; LONG-RANGE ACTION; BARR-VIRUS EBNA2; BETA-CATENIN;
   CUBITUS-INTERRUPTUS; SIGNALING ACTIVITY; IMPORTIN-ALPHA; CELL-NUCLEUS;
   DROSOPHILA; PROTEIN
AB Secreted proteins of the Wnt family have profound organizing roles during animal development and are transduced via the activities of the Frizzled (Fz) class of transmembrane receptors and the TCF/LEF/Pangolin class of transcription factors. beta-catenins, including Drosophila Armadillo (Arm), link activation of Fz at the cell surface to transcriptional regulation by TCF in the nucleus. The consensus view is that Wnt signaling induces beta-catenin to enter the nucleus and combine with TCF to form a transcription factor complex in which TCF binds DNA and the C-terminal domain of beta-catenin activates transcription. Here, we present findings, which challenge this view and suggest instead that R-catenin may transduce Wnt signals by exporting TCF from the nucleus or activating it in the cytoplasm.
C1 Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA.
RP Struhl, G (reprint author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA.
EM struhi@cuccfa.ccc.columbia.edu
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   ARIAS AM, 1988, DEVELOPMENT, V103, P157
   AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5
   Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0
   Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982
   Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1
   Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1
   Cox RT, 1999, DEVELOPMENT, V126, P1327
   Cox RT, 1999, GENETICS, V153, P319
   Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1
   DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0
   Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721
   Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607
   Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751
   Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309
   HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102
   Hsieh JJD, 1996, MOL CELL BIOL, V16, P952
   Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807
   Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4
   Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269
   Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728
   Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0
   Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151
   Korswagen HC, 1999, COLD SPRING HARB SYM, V64, P141, DOI 10.1101/sqb.1999.64.141
   Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7
   KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491
   Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4
   Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8
   LIN L, 1990, J BIOL CHEM, V265, P12596
   Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4
   LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0
   Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0
   Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550
   Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9
   Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229
   Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9
   Morel V, 2000, GENE DEV, V14, P377
   Nelson RW, 1998, ANN NY ACAD SCI, V857, P86, DOI 10.1111/j.1749-6632.1998.tb10109.x
   Neufeld KL, 2000, EMBO REP, V1, P519
   Neumann CJ, 1997, DEVELOPMENT, V124, P871
   Pai LM, 1997, DEVELOPMENT, V124, P2255
   Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0
   Parker DS, 2002, DEVELOPMENT, V129, P2565
   PEIFER M, 1994, DEVELOPMENT, V120, P369
   PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9
   Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3
   Polakis P, 2000, GENE DEV, V14, P1837
   Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0
   Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989
   Rosin-Arbesfeld R, 2000, NATURE, V406, P1009
   Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1
   Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7
   Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9
   STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X
   Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786
   Tolwinski NS, 2001, DEVELOPMENT, V128, P2107
   vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X
   White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1
NR 62
TC 48
Z9 50
U1 3
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 18
PY 2002
VL 111
IS 2
BP 265
EP 280
DI 10.1016/S0092-8674(02)01037-1
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 606UX
UT WOS:000178753500015
PM 12408870
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: Flumazenil recovers diaphragm muscle dysfunction caused by
   midazolam in dogs (Retracted article. See vol. 116, pg. 746, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID BLOOD-FLOW; RESPIRATORY MUSCLES; CANINE DIAPHRAGM; CONTRACTILITY;
   HALOTHANE; VOLUNTARY; FAILURE; FATIGUE
AB We studied the effects of flumazenil on diaphragm muscle dysfunction caused by midazolam in dogs. Animals were divided into three groups of eight each. In each group, anesthetic doses (0.1 mg/kg initial dose plus 0.5 mg . kg(-1) . h(-1) maintenance dose) of midazolam were administered for 60 min. Immediately after the end of midazolam administration, Group 1 received no study drug; Group 2 was infused small-dose (0.004 mg . kg(-1) . h(-1)) flumazenil; Group 3 was infused with large-dose (0.02 mg . kg(-1) . h(-1)) flumazenil. We assessed diaphragm muscle function (contractility and electrical activity) by transdiaphragmatic pressure (Pdi) and integrated electrical activity of the diaphragm (Edi). After midazolam was administered in each group, Pdi at low-frequency (20-Hz) and high-frequency (100-Hz) stimulation decreased from baseline values (P < 0.05), and values of Edi at 100-Hz stimulation were less than those obtained during baseline (P < 0.05). In Group 1, Pdi and Edi to each stimulus did not change from midazolam-induced values. In Groups 2 and 3, with an infusion of flumazenil, Pdi at both stimuli and Edi at 100-Hz stimulation increased from midazolam-induced values (P < 0.05). The increase in Pdi and Edi was more in Group 3 than in Group 2 (P < 0.05). We conclude that flumazenil recovers the diaphragm muscle dysfunction (reduced contractility and inhibited electrical activity) caused by anesthetic doses of midazolam in dogs.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR BROGDEN RN, 1991, DRUGS, V42, P1061, DOI 10.2165/00003495-199142060-00010
   DUREUIL B, 1987, J APPL PHYSIOL, V63, P1757
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   Fujii Y, 2001, ANESTH ANALG, V92, P1590
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   HOWELL SA, 1989, AM REV RESPIR DIS, V139, P1410
   HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Moxham J, 1981, Ciba Found Symp, V82, P197
   REID MB, 1983, J APPL PHYSIOL, V54, P763
   REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 18
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2002
VL 95
IS 4
BP 944
EP 947
DI 10.1213/01.ANE.0000028848.31892.3A
PG 4
WC Anesthesiology
SC Anesthesiology
GA 598EF
UT WOS:000178261900031
PM 12351273
DA 2018-12-27
ER

PT J
AU Banerjee, A
   Sharma, R
   Banerjee, UC
AF Banerjee, A
   Sharma, R
   Banerjee, UC
TI RETRACTED: The nitrile-degrading enzymes: current status and future
   prospects (Retracted article. See vol. 100, pg. 7359, 2016)
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review; Retracted Publication
ID RHODOCOCCUS-RHODOCHROUS J1; PSEUDOMONAS-CHLORORAPHIS B23;
   ENANTIOMER-SELECTIVE AMIDASE; TUMEFACIENS STRAIN D3; C-N CLEAVAGE;
   ESCHERICHIA-COLI; ENANTIOSELECTIVE HYDROLYSIS; ARABIDOPSIS-THALIANA;
   HERBICIDE BROMOXYNIL; NUCLEOTIDE-SEQUENCE
AB Nitrile-converting enzymes are becoming commonplace in the synthesis of pharmaceuticals and commodity chemicals. These versatile biocatalysts have potential applications in different fields including synthetic biocatalysis and bioremediation. This review attempts to describe in detail the three major classes of nitrile-converting enzymes, namely nitrilases, nitrile hydratases and amidases. Various aspects of these enzymes including their occurrence, mechanism of action, characteristics and applicability in different sectors have been elaborately elucidated. Cloning of genes related to nitrile-converting enzymes is also discussed.
C1 Natl Inst Pharmaceut Educ & Res, Dept Biotechnol, Mohali 160062, Punjab, India.
RP Banerjee, UC (reprint author), Natl Inst Pharmaceut Educ & Res, Dept Biotechnol, Sector 67, Mohali 160062, Punjab, India.
EM ucbanerjee@niper.ac.in
CR Alfani F, 2001, J MOL CATAL B-ENZYM, V11, P687, DOI 10.1016/S1381-1177(00)00160-0
   Almatawah QA, 1999, EXTREMOPHILES, V3, P283, DOI 10.1007/s007920050129
   ASANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1183, DOI 10.1080/00021369.1982.10865240
   ASANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1165, DOI 10.1080/00021369.1982.10865238
   BANDYOPADHYAY AK, 1986, APPL ENVIRON MICROB, V51, P302
   BARTEL B, 1994, P NATL ACAD SCI USA, V91, P6649, DOI 10.1073/pnas.91.14.6649
   Battistel E, 1997, BIOTECHNOL LETT, V19, P131, DOI 10.1023/A:1018352012093
   BAUER R, 1994, APPL MICROBIOL BIOT, V42, P1
   BESTWICK LA, 1993, PHYSIOL PLANTARUM, V89, P611
   BHALLA TC, 1992, APPL MICROBIOL BIOT, V37, P184
   Boger DL, 2000, BIOORG MED CHEM LETT, V10, P2613, DOI 10.1016/S0960-894X(00)00528-X
   Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8
   Cheong TK, 2000, ENZYME MICROB TECH, V26, P152, DOI 10.1016/S0141-0229(99)00150-7
   CISKANIK LM, 1995, APPL ENVIRON MICROB, V61, P998
   COLLINS P, 1983, J GEN MICROBIOL, V129, P248
   CONN EE, 1981, CYANIDE BIOL, P183
   Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0
   Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819
   Dadd MR, 2001, ENZYME MICROB TECH, V29, P20, DOI 10.1016/S0141-0229(01)00337-4
   DORR PK, 1989, FEMS MICROBIOL LETT, V60, P289
   Endo I, 1999, TRENDS BIOTECHNOL, V17, P244, DOI 10.1016/S0167-7799(99)01303-7
   ENDO T, 1989, FEBS LETT, V243, P61, DOI 10.1016/0014-5793(89)81218-9
   Fallon RD, 1997, APPL MICROBIOL BIOT, V47, P156, DOI 10.1007/s002530050905
   Fournand D, 1998, APPL ENVIRON MICROB, V64, P2844
   Freyssinet G, 1996, FIELD CROP RES, V45, P125, DOI 10.1016/0378-4290(95)00065-8
   GODTFREDSEN SE, 1985, BIOCATALYSTS ORGANIC, P3
   GOLDLUST A, 1989, BIOTECHNOL APPL BIOC, V11, P581
   HARPER DB, 1985, INT J BIOCHEM, V17, P677, DOI 10.1016/0020-711X(85)90364-7
   HARPER DB, 1977, BIOCHEM J, V167, P685, DOI 10.1042/bj1670685
   HARPER DB, 1977, BIOCHEM J, V165, P309, DOI 10.1042/bj1650309
   HASHIMOTO Y, 1992, J GEN MICROBIOL, V138, P1003, DOI 10.1099/00221287-138-5-1003
   Hirrlinger B, 1996, J BACTERIOL, V178, P3501, DOI 10.1128/jb.178.12.3501-3507.1996
   Hoyle AJ, 1998, ENZYME MICROB TECH, V23, P475, DOI 10.1016/S0141-0229(98)00076-3
   Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2
   IKEHATA O, 1989, EUR J BIOCHEM, V181, P563, DOI 10.1111/j.1432-1033.1989.tb14761.x
   INGVORSEN K, 1991, APPL ENVIRON MICROB, V57, P1783
   Johnson DV, 2000, CURR OPIN CHEM BIOL, V4, P103, DOI 10.1016/S1367-5931(99)00059-9
   Kato Y, 2000, APPL ENVIRON MICROB, V66, P2290, DOI 10.1128/AEM.66.6.2290-2296.2000
   Kato Y, 1999, EUR J BIOCHEM, V263, P662, DOI 10.1046/j.1432-1327.1999.00535.x
   Kaufmann G, 1999, STEROIDS, V64, P535, DOI 10.1016/S0039-128X(99)00028-8
   KIENYLHOMME MP, 1981, J GEN APPL MICROBIOL, V27, P307, DOI 10.2323/jgam.27.307
   Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9
   KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714
   KOBAYASHI M, 1989, EUR J BIOCHEM, V182, P349, DOI 10.1111/j.1432-1033.1989.tb14837.x
   Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986
   KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1129, P23, DOI 10.1016/0167-4781(91)90208-4
   Kobayashi M, 1999, BIOCHEM BIOPH RES CO, V255, P549, DOI 10.1006/bbrc.1999.0189
   KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247
   KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042
   KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746
   KOBAYASHI M, 1990, J BACTERIOL, V172, P4807, DOI 10.1128/jb.172.9.4807-4815.1990
   Komeda H, 2000, EUR J BIOCHEM, V267, P2028, DOI 10.1046/j.1432-1327.2000.01208.x
   Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796
   Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572
   Kotlova EK, 1999, BIOCHEMISTRY-MOSCOW+, V64, P384
   KUWAHARA M, 1985, AGR BIOL CHEM TOKYO, V49, P125, DOI 10.1080/00021369.1985.10866689
   Layh N, 1998, J MOL CATAL B-ENZYM, V5, P467, DOI 10.1016/S1381-1177(98)00075-7
   LEVYSCHIL S, 1995, GENE, V161, P15, DOI 10.1016/0378-1119(95)00242-X
   Liu Jong-Kaing, 1997, Proceedings of the National Science Council Republic of China Part B Life Sciences, V21, P37
   MAHADEVAN S, 1964, ARCH BIOCHEM BIOPHYS, V107, P62, DOI 10.1016/0003-9861(64)90269-3
   MAIERGREINER UH, 1991, P NATL ACAD SCI USA, V88, P4260, DOI 10.1073/pnas.88.10.4260
   MATHEW CD, 1988, APPL ENVIRON MICROB, V54, P1030
   MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990
   MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991
   Miyanaga A, 2001, BIOCHEM BIOPH RES CO, V288, P1169, DOI 10.1006/bbrc.2001.5897
   MOREAU JL, 1993, CAN J MICROBIOL, V39, P524, DOI 10.1139/m93-074
   Muller D, 1999, FOLIA MICROBIOL, V44, P377, DOI 10.1007/BF02903708
   NAGASAWA T, 1987, EUR J BIOCHEM, V162, P691, DOI 10.1111/j.1432-1033.1987.tb10692.x
   Nagasawa T, 2000, EUR J BIOCHEM, V267, P138, DOI 10.1046/j.1432-1327.2000.00983.x
   NAGASAWA T, 1986, BIOCHEM BIOPH RES CO, V139, P1305, DOI 10.1016/S0006-291X(86)80320-5
   NAGASAWA T, 1991, EUR J BIOCHEM, V196, P581, DOI 10.1111/j.1432-1033.1991.tb15853.x
   NAGASAWA T, 1990, EUR J BIOCHEM, V194, P765, DOI 10.1111/j.1432-1033.1990.tb19467.x
   NAGASAWA T, 1988, ARCH MICROBIOL, V150, P89, DOI 10.1007/BF00409723
   Nawaz MS, 1996, J BACTERIOL, V178, P2397, DOI 10.1128/jb.178.8.2397-2401.1996
   NAWAZ MS, 1994, APPL ENVIRON MICROB, V60, P3343
   NISHISE H, 1987, AGR BIOL CHEM TOKYO, V51, P2613
   NISHIYAMA M, 1991, J BACTERIOL, V173, P2465, DOI 10.1128/jb.173.8.2465-2472.1991
   NOVO C, 1995, FEBS LETT, V367, P275, DOI 10.1016/0014-5793(95)00585-W
   OKADA M, 1997, J AM CHEM SOC, V119, P3785
   Osswald S, 2002, EUR J BIOCHEM, V269, P680, DOI 10.1046/j.0014-2956.2001.02702.x
   Patricelli MP, 2000, J BIOL CHEM, V275, P19177, DOI 10.1074/jbc.M001607200
   Payne MS, 1997, BIOCHEMISTRY-US, V36, P5447, DOI 10.1021/bi962794t
   Pereira RA, 1998, EXTREMOPHILES, V2, P347, DOI 10.1007/s007920050078
   Piotrowski M, 2001, J BIOL CHEM, V276, P2616, DOI 10.1074/jbc.M007890200
   Pollak P., 1985, ULLMANS ENCY IND C A, VA17, P363
   Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f
   Prepachalova I, 2001, APPL MICROBIOL BIOT, V55, P150
   Rezende RP, 2000, J BASIC MICROB, V40, P389, DOI 10.1002/1521-4028(200012)40:5/6<389::AID-JOBM389>3.0.CO;2-J
   SAWYER DT, 1984, P NATL ACAD SCI USA, V81, P8025, DOI 10.1073/pnas.81.24.8025
   Solomonson L., 1981, CYANIDE BIOL, P11
   Soong CL, 2000, APPL ENVIRON MICROB, V66, P1947, DOI 10.1128/AEM.66.5.1947-1952.2000
   STALKER DM, 1988, SCIENCE, V242, P419, DOI 10.1126/science.242.4877.419
   STALKER DM, 1987, J BACTERIOL, V169, P955, DOI 10.1128/jb.169.3.955-960.1987
   STALKER DM, 1988, J BIOL CHEM, V263, P6310
   StelkesRitter U, 1995, APPL MICROBIOL BIOT, V44, P393
   STEVENSON DE, 1992, BIOTECHNOL APPL BIOC, V15, P283
   SUGIURA Y, 1987, J AM CHEM SOC, V109, P5848, DOI 10.1021/ja00253a046
   Tauber MM, 2000, APPL ENVIRON MICROB, V66, P1634, DOI 10.1128/AEM.66.4.1634-1638.2000
   Trott S, 2001, MICROBIOL-SGM, V147, P1815, DOI 10.1099/00221287-147-7-1815
   VOGEL AI, 1989, TXB PRACTICAL ORGANI, P1056
   WANG P, 1992, ARCH BIOCHEM BIOPHYS, V298, P569, DOI 10.1016/0003-9861(92)90451-2
   Wegman MA, 2000, ORG PROCESS RES DEV, V4, P318, DOI 10.1021/op000055l
   WYATT JM, 1995, INT BIODETER BIODEGR, V35, P227, DOI 10.1016/0964-8305(95)00031-Y
   Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391
   YAMADA H, 1994, Patent No. 5334519
   Yamaki T, 1997, J FERMENT BIOENG, V83, P474, DOI 10.1016/S0922-338X(97)83004-8
   YAMAMOTO K, 1992, J FERMENT BIOENG, V73, P125, DOI 10.1016/0922-338X(92)90501-K
   YAMAMOTO K, 1992, J FERMENT BIOENG, V73, P425, DOI 10.1016/0922-338X(92)90131-D
   YAMAMOTO K, 1991, APPL ENVIRON MICROB, V57, P3028
   YAMAMOTO K, 1990, APPL ENVIRON MICROB, V56, P3125
   YAMAMOTO K, 1991, AGR BIOL CHEM TOKYO, V55, P1459, DOI 10.1080/00021369.1991.10870831
   YU F, 1999, Patent No. 5872000
NR 112
TC 307
Z9 327
U1 8
U2 96
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD OCT
PY 2002
VL 60
IS 1-2
BP 33
EP 44
DI 10.1007/s00253-002-1062-0
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 620ZX
UT WOS:000179565000004
PM 12382040
DA 2018-12-27
ER

PT J
AU Boldt, J
   Brosch, C
   Suttner, S
   Piper, SN
   Lehmann, A
   Werling, C
AF Boldt, J
   Brosch, C
   Suttner, S
   Piper, SN
   Lehmann, A
   Werling, C
TI RETRACTED: Prophylactic use of the phospodiesterase III inhibitor
   enoximone in elderly cardiac surgery patients: effect on hemodynamics,
   inflammation, and markers of organfunction (Retracted article. See vol.
   37, pg. 1229, 2011)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE surgery, cardiac; cardiopulmonary bypass; phosphodiesterase inhibitor;
   enoximone inflammation; organ function
ID CARDIOPULMONARY BYPASS; EXTRACORPOREAL-CIRCULATION;
   CARDIOVASCULAR-SURGERY; PROSTAGLANDIN E-1; AMRINONE; RISK; MILRINONE;
   INJURY
AB Objective: Elderly patients appear prone to develop overwhelming post-bypass inflammation and organ dysfunction. We assessed the effect of prophylactic administration of the phosphodiesterase III inhibitor enoximone on inflammation and organ function. Design: Prospective, blinded, randomized, placebo-controlled study. Setting: Clinical investigations on a surgical intensive care unit. Patients: 40 consecutive patients aged over 80 years undergoing first-time coronary artery bypass grafting. Interventions: Enoximone was given to 20 patients after induction of anesthesia (initial bolus 0.5 mg/kg) followed by a continuous infusion of 2.5 mug/kg per minute until the 2nd postoperative day. Control patients (n=20) received saline solution. Measurements and results: Interleukins 6, 8, and 10 and soluble adhesion molecules were measured. Liver function was assessed by the monoethylglycine-xylidide test and by measuring alpha-glutathione S-transferase plasma levels; splanchnic perfusion by continuous gastric tonometry; renal function by measuring creatinine and alpha(1)-microglobulin. Interleukins increased significantly more in controls than in the enoximone-pretreated patients. Soluble adhesion molecules were significantly more increased in controls. Liver function was more altered in controls than in the enoximone-pretreated patients. alpha(1)-Microglobulin increased significantly more in controls than in the enoximone group, indicating less tubular damage in the verum group. Conclusions: Prophylactic use of enoximone in cardiac surgery patients aged over 80 years resulted in less post-bypass inflammation and improvement in markers of organ function than in the placebo group. The exact mechanisms by which enoximone exerts its beneficial effects in these patients remains to be elucidated.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Clin Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremerstr 79, D-67063 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR BECKETT GJ, 1993, ADV CLIN CHEM, V30, P281, DOI 10.1016/S0065-2423(08)60198-5
   Bennett-Guerrero E, 2000, ANESTHESIOLOGY, V92, P38, DOI 10.1097/00000542-200001000-00012
   Blease K, 1998, BRIT J PHARMACOL, V124, P229, DOI 10.1038/sj.bjp.0701833
   Boldt J, 2001, CRIT CARE MED, V29, P952, DOI 10.1097/00003246-200105000-00008
   Boyle EM, 1997, ANN THORAC SURG, V63, P277
   CASEY LC, 1993, ANN THORAC SURG, V56, pS92, DOI 10.1016/0003-4975(93)91143-B
   Christenson JT, 1999, J CARDIOVASC SURG, V40, P333
   DATI F, 1989, JFCC, V1, P68
   Fiddian-Green R G, 1990, Semin Thorac Cardiovasc Surg, V2, P389
   FRERING B, 1994, J THORAC CARDIOV SUR, V108, P636
   Gott JP, 1998, ANN THORAC SURG, V66, P747, DOI 10.1016/S0003-4975(98)00695-X
   Harris J, 1999, HEART, V82, P119, DOI 10.1136/hrt.82.2.119
   Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21
   Hirose H, 2000, CHEST, V117, P1262, DOI 10.1378/chest.117.5.1262
   Ichioka S, 1998, J SURG RES, V75, P42, DOI 10.1006/jsre.1998.5266
   Iribe G, 2000, CRIT CARE MED, V28, P743, DOI 10.1097/00003246-200003000-00023
   LINDEMAN RD, 1992, DRUG AGING, V2, P423, DOI 10.2165/00002512-199202050-00006
   McNicol L, 1999, J CARDIOTHOR VASC AN, V13, P292, DOI 10.1016/S1053-0770(99)90266-5
   Miller BE, 1997, J CARDIOTHOR VASC AN, V11, P355, DOI 10.1016/S1053-0770(97)90106-3
   MYTHEN MG, 1994, INTENS CARE MED, V20, P203, DOI 10.1007/BF01704701
   Nemeth ZH, 1997, SHOCK, V7, P371, DOI 10.1097/00024382-199705000-00010
   OELLERICH M, 1987, J CLIN CHEM CLIN BIO, V25, P845
   Orii R, 2000, BRIT J ANAESTH, V85, P389, DOI 10.1093/bja/85.3.389
   Paret G, 2000, J CARDIOTHOR VASC AN, V14, P433, DOI 10.1053/jcan.2000.7942
   Priebe HJ, 2000, BRIT J ANAESTH, V85, P763, DOI 10.1093/bja/85.5.763
   Roques F, 1999, EUR J CARDIO-THORAC, V15, P816, DOI 10.1016/S1010-7940(99)00106-2
   Royston D, 1997, J CARDIOTHOR VASC AN, V11, P341, DOI 10.1016/S1053-0770(97)90105-1
   TOFT P, 1998, EUR J ANAESTH, V31, P283
   Veering B T, 1999, Curr Opin Anaesthesiol, V12, P333, DOI 10.1097/00001503-199906000-00014
   Verrier ED, 1998, ANN THORAC SURG, V66, pS17, DOI 10.1016/S0003-4975(98)00965-5
   Wick G, 1997, EXP GERONTOL, V32, P401, DOI 10.1016/S0531-5565(96)00152-0
   ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550
NR 32
TC 19
Z9 20
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD OCT
PY 2002
VL 28
IS 10
BP 1462
EP 1469
DI 10.1007/s00134-002-1435-y
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 641PG
UT WOS:000180753500015
PM 12373472
DA 2018-12-27
ER

PT J
AU Eto, K
   Kimura, H
AF Eto, K
   Kimura, H
TI RETRACTED: The production of hydrogen sulfide is regulated by
   testosterone and S-adenosyl-L-methionine in mouse brain (Retracted
   Article. See vol 93, pg 1633, 2005)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE S-adenosyl-L-methionine; age; cystathionine beta-synthase; hydrogen
   sulfide; sex; testosterone
ID LONG-TERM POTENTIATION; NITRIC-OXIDE; ADENOSYLMETHIONINE; TISSUE;
   CHROMATOGRAPHY; PLASTICITY; MESSENGER; SYNTHASE; MEMORY; GAS
AB Hydrogen sulfide (H-2 S) is endogenously produced in the brain from l-cysteine by the enzyme cystathionine beta-synthase (CBS) and functions as a neuromodulator in the brain. H-2 S selectively enhances NMDA receptor-mediated responses and alters hippocampal long-term potentiation (LTP). The production of H-2 S is regulated by Ca2+ /calmodulin-mediated pathways and is enhanced in response to neuronal excitation. In addition to this fast regulation, we describe here a slower form of the regulation of H-2 S production by testosterone and S -adenosyl-l-methionine (SAM), a CBS activator. Endogenous H-2 S in the mouse brain increases after birth, reaches a maximum level at 8 weeks and then decreases. Female brain contains less H-2 S than male brain at each age. A single administration of testosterone to female mice increases the endogenous H-2 S and SAM, which reach levels similar to those of male mice. In contrast, castration of male mice decreases the levels of testosterone, SAM and H-2 S in the brain. Administration of SAM once a day for 3 days increases the brain H-2 S without significantly changing the testosterone level. These observations suggest that testosterone can regulate the brain H-2 S level via changing the level of SAM.
C1 Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878551, Japan.
RP Kimura, H (reprint author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878551, Japan.
EM kimura@ncnp.go.jp
RI Kimura, Hideo/J-6811-2016
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Eto K, 2002, J NEUROSCI, V22, P3386
   FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X
   Foy MR, 2001, NEUROBIOL LEARN MEM, V76, P239, DOI 10.1006/nlme.2001.4018
   Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251
   GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105
   Harley CW, 2000, HIPPOCAMPUS, V10, P693
   Herlitz A, 2002, J CLIN EXP NEUROPSYC, V24, P107, DOI 10.1076/jcen.24.1.107.970
   HOSHIKA Y, 1977, J CHROMATOGR, V134, P423, DOI 10.1016/S0021-9673(00)88541-6
   Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878
   MANTEUFFELCYMBOROWSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1116, P166, DOI 10.1016/0304-4165(92)90113-9
   ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285
   REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545
   Russo C. Dello, 2000, Journal of Neuroendocrinology, V12, P225
   SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2
   Schiavetto A, 2002, NEUROPSYCHOLOGIA, V40, P1428, DOI 10.1016/S0028-3932(01)00206-8
   SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572
   Singh R, 2000, P NATL ACAD SCI USA, V97, P3672, DOI 10.1073/pnas.050583297
   STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267
   WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8
   Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008
NR 21
TC 54
Z9 63
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD OCT
PY 2002
VL 83
IS 1
BP 80
EP 86
DI 10.1046/j.1471-4159.2002.01097.x
PG 7
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 595DB
UT WOS:000178090600009
PM 12358731
OA Bronze
DA 2018-12-27
ER

PT J
AU Huang, WT
AF Huang, WT
TI RETRACTED: Size and P-glycoprotein expression limit Tc-99m-tetrofosmin
   uptake in parathyroid adenomas (Retracted Article. See vol 29, 2008)
SO NUCLEAR MEDICINE COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE P-glycoprotein; Tc-99m-tetrofosmin; parathyroid adenomas
ID LUNG-CANCER; TC-99M MIBI; LOCALIZATION; TECHNETIUM-99M-TETROFOSMIN;
   TECHNETIUM-99M-SESTAMIBI; HYPERPARATHYROIDISM; ACCUMULATION;
   SCINTIGRAPHY
AB The purpose of this study was to retrospectively evaluate Tc-99m-tetrofosmin (Tc-TF) uptake in large parathyroid adenomas and to compare the results with their expression of multidrug resistance (MDR)-mediated, 170 kDa, P-glycoprotein (Pgp). Twenty patients with large parathyroid adenomas (larger than 1.5 g), who had undergone early and delayed (10 min and 2 h) Tc-TF parathyroid imaging before operation, were enrolled in this retrospective study. Immunohistochernical analyses were performed on multiple, non-consecutive sections of the 20 parathyroid adenomas and 40 normal control specimens (20 normal parathyroid glands and 16 normal thyroid specimens) to detect Pgp expression. Tc-TF parathyroid imaging accurately localized 17 large parathyroid adenomas, but not the remaining three. The 17 parathyroid adenomas with significant Tc-TF uptake in delayed (2 h) parathyroid images revealed negative Pgp expression, but the three adenomas without significant Tc-TF uptake, as well as 20 normal parathyroid glands and 20 normal thyroid specimens, revealed positive Pgp expression. Therefore, not only the size, but also the expression of Pgp, limited the sensitivity of Tc-TF parathyroid imaging to localize parathyroid adenomas before operation. ((C) 2002 Lippincott Williams Wilkins).
C1 Yuanpei Inst Sci Technol, Dept Radiol Technol, Hsinchu 306, Taiwan.
RP Huang, WT (reprint author), Yuanpei Inst Sci Technol, Dept Radiol Technol, 306 Yuanpei St, Hsinchu 306, Taiwan.
EM huangwt@pc.ymit.edu.tw
CR AXIOTIS CA, 1995, CALCIFIED TISSUE INT, V56, P170, DOI 10.1007/BF00296351
   Bae K T, 1997, Q J Nucl Med, V41, P101
   BAILLET GY, 1989, J NUCL MED, V30, P38
   COAKLEY AJ, 1995, NUCL MED COMMUN, V16, P522, DOI 10.1097/00006231-199507000-00002
   Crankshaw CL, 1998, J NUCL MED, V39, P77
   Fjeld JG, 1997, J NUCL MED, V38, P831
   GORIS ML, 1991, J NUCL MED, V32, P887
   Greenspan BS, 1998, J NUCL MED, V39, P1111
   Hendrikse NH, 1999, EUR J NUCL MED, V26, P283, DOI 10.1007/s002590050390
   HIGLEY B, 1993, J NUCL MED, V34, P30
   Ishibashi M, 1998, J NUCL MED, V39, P320
   KELLY JD, 1993, J NUCL MED, V34, P222
   Kostakoglu L, 1998, J NUCL MED, V39, P228
   Kreisholt J, 1998, BRIT J CANCER, V77, P1469, DOI 10.1038/bjc.1998.241
   LESLIE WD, 1995, CLIN NUCL MED, V20, P699, DOI 10.1097/00003072-199508000-00008
   MILLER DL, 1987, RADIOLOGY, V162, P133, DOI 10.1148/radiology.162.1.3538145
   Mitchell BK, 1996, SURGERY, V120, P1039, DOI 10.1016/S0039-6060(96)80052-3
   ODOHERTY MJ, 1992, J NUCL MED, V33, P313
   PIWNICAWORMS D, 1993, CANCER RES, V53, P977
   RAO VV, 1994, J NUCL MED, V35, P510
   Rauth JD, 1996, CLIN NUCL MED, V21, P602, DOI 10.1097/00003072-199608000-00002
   Tabuenca M J, 1998, Rev Esp Med Nucl, V17, P427
   Tabuenca MJ, 1998, J NUCL MED, V39, P1830
   TAILLEFER R, 1992, J NUCL MED, V33, P1801
NR 24
TC 8
Z9 8
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0143-3636
EI 1473-5628
J9 NUCL MED COMMUN
JI Nucl. Med. Commun.
PD OCT
PY 2002
VL 23
IS 10
BP 1001
EP 1004
DI 10.1097/00006231-200210000-00010
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 604VM
UT WOS:000178641800010
PM 12352599
DA 2018-12-27
ER

PT J
AU Thangadurai, D
   Viswanathan, MB
   Ramesh, N
AF Thangadurai, D
   Viswanathan, MB
   Ramesh, N
TI RETRACTED: Indigoferabietone, a novel abietane diterpenoid from
   Indigofera longeracemosa with potential antituberculous and
   antibacterial activity (Retracted Article. See vol 59, pg 336, 2004)
SO PHARMAZIE
LA English
DT Article; Retracted Publication
AB From the stems of Indigofera longeracemosa, a novel abietane diterpenoid, indigoferabietone was isolated. The structure was established by spectral techniques. The inhibitory activity of indigoferabietone (1) tested against Mycobacterium tuberculosis and Candida albicans, and the antibacterial activity tested against Staphylococcus aureus, Proteus vulgaris, and Escherichia coli were found to be significant.
C1 Sri Krishnadevaraya Univ, Dept Bot, Anantapur 515003, Andhra Pradesh, India.
   Manonmaniam Sundaranar Univ, Sri Paramakalyani Ctr Environm Sci, Alwarkurichi, Tamil Nadu, India.
RP Thangadurai, D (reprint author), Sri Krishnadevaraya Univ, Dept Bot, Anantapur 515003, Andhra Pradesh, India.
EM dthangadurai@yahoo.com
CR COOKSEY RC, 1993, ANTIMICROB AGENTS CH, V37, P1348, DOI 10.1128/AAC.37.6.1348
   GAMBLE JS, 1987, FLORA PRESIDENCY MAD, P312
   Kavanagh F., 1963, ANAL MICROBIOLOGY, P125
   LORIAN V, 1986, ANTIBIOTICS LAB MED, P189
   Sleigh JD, 1981, NOTES MED BACTERIOLO, P43
   THANGADURAI D, 2000, INDIAN J PHARM SCI, V62, P287
   THANGADURAI D, 1988, THESIS MANONMANIAM S, P7
   WALLACE RJ, 1986, J CLIN MICROBIOL, V24, P976
NR 8
TC 16
Z9 16
U1 0
U2 9
PU GOVI-VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD OCT
PY 2002
VL 57
IS 10
BP 714
EP 715
PG 2
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 609BA
UT WOS:000178881700012
PM 12426956
DA 2018-12-27
ER

PT J
AU Kavurma, MM
   Bobryshev, Y
   Khachigian, LM
AF Kavurma, MM
   Bobryshev, Y
   Khachigian, LM
TI RETRACTED: Ets-1 positively regulates Fas ligand transcription via
   cooperative interactions with Sp1 (Retracted Article. See vol 285, pg
   21902, 2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HUMAN ATHEROSCLEROTIC LESIONS; SMOOTH-MUSCLE-CELLS; T-CELLS; APOPTOSIS;
   ACTIVATION; EXPRESSION; PROMOTER; FAMILY; DEATH; PROTEINS
AB The FasL/Fas system has been implicated in smooth muscle cell apoptosis and atherosclerotic plaque instability, a process that can lead to plaque rupture, precipitating myocardial infarction and sudden death. The transcriptional mechanisms regulating FasL gene expression in vascular smooth muscle cells are poorly understood. We recently described a novel mechanism mediating inducible FasL gene expression in smooth muscle cells involving the zinc finger transcription factor Sp1 (Kavurma, M. M., Santiago, F. S., Bofocco, E., and Khachigian, L. M. (2001) J. Biol. Chem. 276, 4964-4971). We now show that FasL gene expression is governed by cooperative activation between Sp1 and the Ets family of transcription factors. The overexpression. of Ets-1 was sufficient to induce FasL promoter-dependent expression and protein synthesis. Ets-1 activation of the promoter was abrogated either by deletion or mutation of the Sp1 binding site. The overexpression of Ets-1 together with Sp1 produced cooperative activation of the Fas1, promoter. Sp1 induction of the FasL promoter was abrogated by an Ets-1 mutant lacking the activation domain. Conversely, Ets-1 activation of the promoter was blocked by an Sp1 mutant bearing the DNA-binding domain. The mutation of the (-365)GGAA(-362) element in the FasL promoter abolished Ets-1 activation and attenuated Sp1-inducible gene expression. Immunoprecipitation and supershift experiments revealed that endogenous Ets-1 and Sp1 physically interact and co-occupy this site. Thus, FasL gene expression in vascular smooth muscle cells is mediated by cooperativity between Ets-1 and Sp1.
C1 Univ New S Wales, Ctr Thrombosis & Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.
   Univ New S Wales, St Vincents Hosp, Surg Profess Unit, Sydney, NSW 2052, Australia.
RP Khachigian, LM (reprint author), Univ New S Wales, Ctr Thrombosis & Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.
EM L.Khachigian@unsw.edu.au
RI Bobryshev, Yuri/J-2838-2013
OI Khachigian, Levon/0000-0003-3446-0323
CR Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bassuk AG, 1997, J VIROL, V71, P3563
   BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6
   Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6
   Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591
   Block KL, 1996, BLOOD, V88, P2071
   Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1
   Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953
   Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198
   Geng YJ, 1998, CIRCULATION, V98, P48
   Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200
   GITLIN SD, 1993, J VIROL, V67, P7307
   Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6
   Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200
   Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4
   Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200
   Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7
   Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307
   Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035
   Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200
   Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034
   Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
   Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.0.CO;2-B
   Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036
NR 29
TC 50
Z9 53
U1 3
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 27
PY 2002
VL 277
IS 39
BP 36244
EP 36252
DI 10.1074/jbc.M200463200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 598KN
UT WOS:000178275100060
PM 11970950
OA Bronze
DA 2018-12-27
ER

PT J
AU Takai, N
   Miyazaki, T
   Nishida, M
   Nasu, K
   Miyakawa, I
AF Takai, N
   Miyazaki, T
   Nishida, M
   Nasu, K
   Miyakawa, I
TI RETRACTED: Ca2+/calmodulin-dependent protein kinase IV expression in
   epithelial ovarian cancer (Retracted article. See vol. 338, pg. 332,
   2013)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE Ca2+/calmodulin-dependent protein kinase IV; epithelial ovarian cancer;
   clinical stage; histological grade
ID POLO-LIKE KINASE; ENDOMETRIAL CARCINOMA; HISTOLOGICAL GRADE;
   GENE-EXPRESSION; BINDING PROTEIN; TRANSCRIPTION; ACTIVATION; APOPTOSIS;
   CREB; INHIBITOR
AB Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) is a multifunctional protein kinase expressed abundantly in the central nervous system. Because changes in intracellular Ca2+ concentrations affect progression through the mitotic cell cycle, enhanced expression of CaMKIV has been reported in small cell lung carcinoma and hepatocellular carcinoma. To elucidate the involvement of CaMKIV in epithelial ovarian carcinogenesis, we analyzed serial frozen sections for CaMKIV protein expression in 26 patients with ovarian epithelial carcinoma and ten patients with benign cystadenoma of the ovary by fluorescent immunohistochemistry. We analyzed the relationship between the percentages of CaMKIV-stained cells and the patient's characteristics, including histological classification, clinical stage, histological grade, and clinical outcome. In the benign ovarian cystadenoma, CaMKIV was detected in none of the cases examined. Most of the CaMKIV proteins were found in the nucleus of epithelial ovarian cancer tissue. CaMKIV expression was significantly associated with clinical stage (P < 0.01), histological grade (P < 0.01), and clinical outcome (P < 0.01). Survival data were available for all patients, and univariate Cox regression analysis showed that CaMKIV expression was significantly associated with poor prognosis (P < 0.05). Our results demonstrate that CaMKIV expression in epithelial ovarian cancer correlates with the malignant potential of this tumor. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
C1 Oita Med Univ, Dept Obstet & Gynecol, Oita 8795593, Japan.
RP Takai, N (reprint author), Oita Med Univ, Dept Obstet & Gynecol, Oita 8795593, Japan.
EM takai@oita-med.ac.jp
CR Ahn S, 1999, NEURON, V23, P559, DOI 10.1016/S0896-6273(00)80808-9
   Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597
   Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725
   Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4
   ENSLEN H, 1994, J BIOL CHEM, V269, P15520
   FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592
   Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101
   JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P4050, DOI 10.1073/pnas.88.9.4050
   Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2
   KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387
   MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107
   McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993
   MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960
   MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672
   MIYANO O, 1992, J BIOL CHEM, V267, P1198
   OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866
   See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com
   SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483
   Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066
   Takai N, 2000, CANCER, V89, P2059, DOI 10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3
   Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5
   Takai N, 2001, ONCOL REP, V8, P567
   Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5
   Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5
   Tamura N, 2000, CANCER-AM CANCER SOC, V89, P1910, DOI 10.1002/1097-0142(20001101)89:9<1910::AID-CNCR6>3.3.CO;2-M
   TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315
   TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063
   Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258
   Williams CL, 1996, BIOCHEM PHARMACOL, V51, P707, DOI 10.1016/S0006-2952(95)02393-3
   Yoshida H, 2000, BBA-MOL CELL RES, V1497, P155, DOI 10.1016/S0167-4889(00)00051-3
NR 30
TC 14
Z9 17
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 26
PY 2002
VL 183
IS 2
BP 185
EP 193
AR PII S0304-3835(02)00107-6
DI 10.1016/S0304-3835(02)00107-6
PG 9
WC Oncology
SC Oncology
GA 586KT
UT WOS:000177583700010
PM 12065094
DA 2018-12-27
ER

PT J
AU Wilkie, H
   Osei-Lah, A
   Chioza, B
   Nashef, L
   McCormick, D
   Asherson, P
   Makoff, AJ
AF Wilkie, H
   Osei-Lah, A
   Chioza, B
   Nashef, L
   McCormick, D
   Asherson, P
   Makoff, AJ
TI RETRACTED: Association of mu-opioid receptor subunit gene and idiopathic
   generalized epilepsy (Retracted Article. See vol. 64, pg 579, 2005)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID LINKAGE DISEQUILIBRIUM; ALCOHOL DEPENDENCE; ABSENCE EPILEPSY; HUMAN
   GENOME; DISEASE; SUSCEPTIBILITY; SEIZURES; LOCI
AB Objective: To replicate and extend the previously reported association between the opioid receptor mu subunit gene (OPRM1) and idiopathic absence epilepsy (IAE), using a sample of 230 probands with idiopathic generalized epilepsy (IGE). Background: In humans and in animal models, several lines of evidence implicate opioid receptors with seizures. The G118 allele of OPRM1 was associated with IAE (p = 0.019). Methods: Three single nucleotide, polymorphisms (SNP) of OPRM1 were investigated by association studies with IGE using a case/control design. one of which also used a within-family design. Results: Association was found for G118 with IGE (p = 0.00027, odds ratio [OR] - 1.86), replicating the previous association. Within-family tests of linkage and association (haplotype-based haplotype relative risk and transmission disequilibrium test) confirmed this result. Further evidence for involvement of OPRM1 in IGE was provided by an association with G-172T, located in the 5' untranslated region (p = 0.0015, OR = 2.36). Haplotypes of the two SNPs were associated with IGE with a greater level of significance (p = 0.000087) suggesting that both SNPs might be in linkage disequilibrium with a single functional variant. Analysis of the results by subgroups of IGE showed association with all subgroups tested. Conclusions: These results confirm the previous association and support the hypothesis of a role for OPRM1 in IGE, including absence syndromes. However, the authors found no evidence for a specific association between OPRM1 and idiopathic absence epilepsy. The data suggest that the functional variant predisposing to IGE is located within 60kb of exon 1.
C1 Inst Psychiat, Dept Psychol Med, London SE5 8AF, England.
   Inst Psychiat, Social Genet & Dev Psychiat Res Ctr, London SE5 8AF, England.
   Kings Coll Hosp London, Dept Neurosci, London, England.
   Kent & Canterbury Hosp, Dept Neurol, Canterbury, Kent, England.
   Kent & Canterbury Hosp, Dept Paediat, Canterbury, Kent, England.
RP Makoff, AJ (reprint author), Inst Psychiat, Dept Psychol Med, Denmark Hill, London SE5 8AF, England.
EM a.makoff@iop.kcl.ac.uk
OI Chioza, Barry/0000-0002-3546-1726; Asherson, Philip/0000-0003-2667-2254
CR BARTENSTEIN PA, 1993, J NEUROL NEUROSUR PS, V56, P1295, DOI 10.1136/jnnp.56.12.1295
   Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331
   Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405
   BERKOVIC SF, 1994, EPILEPSIES TWINS
   BIANCHI A, 1995, TYPICAL ABSENCES REL, P328
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556
   Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895
   JANZ D, 1992, NEUROLOGY, V42, P48
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   KLITZ W, 1995, AM J HUM GENET, V57, P1436
   LASON W, 1994, NEUROPHARMACOLOGY, V33, P161, DOI 10.1016/0028-3908(94)90003-5
   MEULENBELT I, 1995, AM J HUM GENET, V57, P1252
   Przewlocka B, 1998, EPILEPSY RES, V29, P167, DOI 10.1016/S0920-1211(97)00081-8
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Sander T, 1998, ALCOHOL CLIN EXP RES, V22, P2108, DOI 10.1097/00000374-199812000-00030
   Sander T, 2000, EPILEPSY RES, V39, P57, DOI 10.1016/S0920-1211(99)00109-6
   TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI
   TORTELLA FC, 1988, TRENDS PHARMACOL SCI, V9, P366, DOI 10.1016/0165-6147(88)90256-8
   Vaccarino AL, 1999, PEPTIDES, V20, P1527, DOI 10.1016/S0196-9781(99)00166-7
   WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230
   Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246
   XIE X, 1993, AM J HUM GENET, V53, P1107
NR 25
TC 19
Z9 19
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 10
PY 2002
VL 59
IS 5
BP 724
EP 728
DI 10.1212/WNL.59.5.724
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 591TU
UT WOS:000177897000014
PM 12221164
DA 2018-12-27
ER

PT J
AU Hoeldtke, RD
   Bryner, KD
   McNeill, DR
   Hobbs, GR
   Riggs, JE
   Warehime, SS
   Christie, I
   Ganser, G
   Van Dyke, K
AF Hoeldtke, RD
   Bryner, KD
   McNeill, DR
   Hobbs, GR
   Riggs, JE
   Warehime, SS
   Christie, I
   Ganser, G
   Van Dyke, K
TI RETRACTED: Nitrosative stress, uric acid, and peripheral nerve function
   in early type 1 diabetes (Retracted article. See vol 55, pg 2664, 2006)
SO DIABETES
LA English
DT Article; Retracted Publication
ID NITRIC-OXIDE SYNTHASE; VITAMIN-E SUPPLEMENTATION; OXIDATIVE STRESS;
   AUTONOMIC DYSFUNCTION; LIPID-PEROXIDATION; NEUROPATHY; NEPHROPATHY;
   APOPTOSIS; HYPERFILTRATION; PEROXYNITRITE
AB The present study was performed to determine whether nitric oxide overproduction is associated with deterioration in peripheral nerve function in type I diabetes. We measured peripheral nerve function and biochemical indicators of nitrosative stress annually for 3 years in 37 patients with type I diabetes. Plasma nitrite and nitrate (collectively NOx) were 34.0 +/- 4.9 mumol/l in the control subjects and 52.4 +/- 5.1, 50.0 +/- 5.1, and 49.0 +/- 5.2 in the diabetic patients at the first, second, and third evaluations, respectively (P < 0.01). Nitrotyrosine (NTY) was 13.3 +/- 2.0 mumol/l in the control subjects and 26.8 +/- 4.4, 26.1 +/- 4.3, and 32.7 +/- 4.3 in the diabetic patients (P < 0.01). Uric acid was suppressed by 20% in the diabetic patients (P < 0.001). Composite motor nerve conduction velocity for the median, ulnar, and peroneal nerves was decreased in patients with high versus low NTY (mean Z score -0.522 +/- 0.25 versus 0.273 +/- 0.22; P < 0.025). Patients with high NOx had decreased sweating, and those with suppressed uric acid had decreased autonomic function. In conclusion, nitrosative stress in early diabetes is associated with suppressed uric acid and deterioration in peripheral nerve function.
C1 W Virginia Univ, Sch Med, Dept Med, Morgantown, WV 26506 USA.
   W Virginia Univ, Dept Community Med & Stat, Morgantown, WV 26506 USA.
   W Virginia Univ, Dept Neurol, Morgantown, WV 26506 USA.
   W Virginia Univ, Dept Math, Morgantown, WV 26506 USA.
   W Virginia Univ, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA.
RP Hoeldtke, RD (reprint author), W Virginia Univ, Sch Med, Dept Med, 1 Med Ctr Dr,POB 9159, Morgantown, WV 26506 USA.
CR AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045
   ALEYASSINE H, 1981, CLIN CHEM, V27, P472
   AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858
   BANK N, 1993, KIDNEY INT, V43, P1306, DOI 10.1038/ki.1993.183
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   BEISSWENGER PJ, 2001, DIABETES S2, V50, pA6
   BIAGGIONI I, 1993, J CLIN ENDOCR METAB, V76, P580, DOI 10.1210/jc.76.3.580
   Bojunga J, 2001, DIABETES, V50, pA148
   Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107
   Chiarelli F, 2000, DIABETES, V49, P1258, DOI 10.2337/diabetes.49.7.1258
   Choudhary S, 2002, FREE RADICAL BIO MED, V32, P360, DOI 10.1016/S0891-5849(01)00810-3
   Coppey LJ, 2001, DIABETES, V50, P1927, DOI 10.2337/diabetes.50.8.1927
   Davi G, 1999, CIRCULATION, V99, P224
   *DIAB CONTR COMPL, 1995, ANN NEUROL, V38, P869, DOI DOI 10.1002/ANA.410380607
   Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923
   EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491
   Garcia SB, 1999, EXP PARASITOL, V93, P191, DOI 10.1006/expr.1999.4451
   Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239
   Hensley K, 1998, J NEUROSCI, V18, P8126
   HOELDTKE RD, 1984, J CLIN ENDOCR METAB, V59, P246, DOI 10.1210/jcem-59-2-246
   Hoeldtke RD, 2000, J CLIN ENDOCR METAB, V85, P585, DOI 10.1210/jc.85.2.585
   Hoeldtke RD, 2001, DIABETES, V50, P436, DOI 10.2337/diabetes.50.2.436
   Hoeldtke RD, 2000, J CLIN ENDOCR METAB, V85, P3297, DOI 10.1210/jc.85.9.3297
   JAMAL GA, 1987, MUSCLE NERVE, V10, P537, DOI 10.1002/mus.880100608
   KAGEYAMA N, 1971, CLIN CHIM ACTA, V31, P421, DOI 10.1016/0009-8981(71)90413-X
   Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x
   Klandorf H, 2001, COMP BIOCHEM PHYS C, V129, P93, DOI 10.1016/S1532-0456(01)00186-7
   KOTCHEN TA, 1984, CLIN SCI, V67, P365, DOI 10.1042/cs0670365
   LOW PA, 1983, ANN NEUROL, V14, P573, DOI 10.1002/ana.410140513
   Manzella D, 2001, AM J CLIN NUTR, V73, P1052
   Marnett LJ, 2000, J BIOL CHEM, V275, P13427, DOI 10.1074/jbc.275.18.13427
   MATSUMURA H, 1981, Japanese Journal of Clinical Electron Microscopy, V14, P1
   Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656
   Nickander KK, 1996, FREE RADICAL BIO MED, V21, P631, DOI 10.1016/0891-5849(96)00172-4
   Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x
   O'Byrne S, 2000, DIABETES, V49, P857, DOI 10.2337/diabetes.49.5.857
   OCHOA J, 1978, MUSCLE NERVE, V1, P375, DOI 10.1002/mus.880010506
   Pitre DA, 2001, NEUROSCI LETT, V303, P67, DOI 10.1016/S0304-3940(01)01696-2
   Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491
   SEALEY JE, 1979, HYPERTENSION, V1, P179, DOI 10.1161/01.HYP.1.3.179
   SHICHIRI M, 1990, AM J NEPHROL, V10, P115, DOI 10.1159/000168065
   SNEDECOR GW, 1967, STATISTICAL METHODS, P172
   Sodum RS, 2000, ANAL BIOCHEM, V280, P278, DOI 10.1006/abio.2000.4528
   SUNDKVIST G, 1993, DIABETES CARE, V16, P773, DOI 10.2337/diacare.16.5.773
   SUTO T, 1995, KIDNEY INT, V48, P1272, DOI 10.1038/ki.1995.411
   Thuraisingham RC, 2000, KIDNEY INT, V57, P1968, DOI 10.1046/j.1523-1755.2000.00046.x
   Tutuncu NB, 1998, DIABETES CARE, V21, P1915, DOI 10.2337/diacare.21.11.1915
   WINER BJ, 1979, STAT PRINCIPLES EXPT, P514
   Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804
   ZANDER E, 1989, DIABETES CARE, V12, P259, DOI 10.2337/diacare.12.4.259
NR 50
TC 72
Z9 75
U1 4
U2 10
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD SEP
PY 2002
VL 51
IS 9
BP 2817
EP 2825
DI 10.2337/diabetes.51.9.2817
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 588KX
UT WOS:000177701600020
PM 12196476
OA Bronze
DA 2018-12-27
ER

PT J
AU Yoo, TH
   Park, CJ
   Lee, GJ
   Shin, R
   Yun, JH
   Kim, KJ
   Rhee, KH
   Paek, KH
AF Yoo, TH
   Park, CJ
   Lee, GJ
   Shin, R
   Yun, JH
   Kim, KJ
   Rhee, KH
   Paek, KH
TI RETRACTED: A hot pepper cDNA encoding ascorbate peroxidase is induced
   during the incompatible interaction with virus and bacteria (Retracted
   article. See vol. 35, pg. 175, 2013)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE ascorbate peroxidase cDNA clone; differential screening; hot pepper
   (Capsicum annuum L.); hypersensitive response; tobacco mosaic virus
ID TOBACCO-MOSAIC-VIRUS; SYSTEMIC ACQUIRED-RESISTANCE; PROGRAMMED
   CELL-DEATH; CAMPESTRIS PV. VESICATORIA; SALICYLIC-ACID;
   HYDROGEN-PEROXIDE; PLANT DEFENSE; HYPERSENSITIVE RESPONSE; DISEASE
   RESISTANCE; OXIDATIVE DAMAGE
AB Capsicum annuum L. is infected by a number of viruses, including the tobacco mosaic virus (TMV). To study the defense-related genes that are induced by TMV in hot peppers, the pepper plant, which is susceptible to P-1.2 but resistant to the P-0 pathotype of TMV, was inoculated with TMV-P-0. Differential screening isolated the genes that were specifically up-or down-regulated during the hypersensitive response (1111). The CaAPX1 cDNA clone that putatively encodes a polypeptide of cytosolic ascorbate peroxidase was selected as an up-regulated gene. It was isolated for further study. The full-length cDNA for CaAPX1, which is 972 bp long, contained the open-reading frame of 250-amino acid residues. A genomic Southern blot analysis showed that there were only limited copies of the CaAPX1 gene in the hot pepper genome. In hot pepper cv. Bugang, which is resistant to TMV-P-0 and susceptible to TMV-P-1.2, the CaAPX1 gene transcript was accumulated by TMV-P-0, but not by TMV-P-1.2 inoculation. CaAPX1 transcripts began to accumulate 24 h post-inoculation of TMV-P-0, and increased gradually until 96 h. To investigate whether each transcript is induced by other stimuli, the plants were treated with various chemicals and wounding. A striking induction of the CaAPX1 transcript was observed at 2 h. It subsided 12 h after salicylic acid (SA), ethephon, and methyl jasmonate (MeJA) treatments. The response of the gene upon other pathogen infection was also examined by a bacterial pathogen (Xanthomonas campestris pv. vesicatoria race 3) inoculation. The CaAPX1 gene was induced in a hot pepper (C. annuum cv. ECW 20R) that was resistant to this bacterial pathogen, but not in a susceptible hot pepper (C. annuum cv. ECW). These results suggest the possible role(s) for the CaAPX1 gene in plant defense against viral and bacterial pathogen.
C1 Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
   Kongju Natl Univ, Dept Biol Sci, Kong Ju 314701, South Korea.
RP Paek, KH (reprint author), Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
EM khpaek95@korea.ac.kr
CR Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x
   Ausubel F, 1995, SHORT PROTOCOLS MOL
   BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x
   Bunkelmann JR, 1996, PLANT PHYSIOL, V110, P589, DOI 10.1104/pp.110.2.589
   CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079
   Ciardi JA, 2000, PLANT PHYSIOL, V123, P81, DOI 10.1104/pp.123.1.81
   Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355
   DOKE N, 1988, PHYSIOL MOL PLANT P, V32, P163, DOI 10.1016/S0885-5765(88)80013-4
   Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0
   Draper J, 1997, TRENDS PLANT SCI, V2, P162, DOI 10.1016/S1360-1385(97)01030-3
   DUMER J, 1997, TRENDS PLANT SCI, V2, P266
   FLOR HH, 1955, PHYTOPATHOLOGY, V45, P680
   Fodor J, 1997, PLANT PHYSIOL, V114, P1443, DOI 10.1104/pp.114.4.1443
   Gassmann W, 2000, J BACTERIOL, V182, P7053, DOI 10.1128/JB.182.24.7053-7059.2000
   Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525
   Guo AL, 2000, PLANT J, V21, P409, DOI 10.1046/j.1365-313x.2000.00692.x
   HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773
   Iturbe-Ormaetxe I, 1998, PLANT PHYSIOL, V116, P173, DOI 10.1104/pp.116.1.173
   Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853
   Jiang MY, 2001, PLANT CELL PHYSIOL, V42, P1265, DOI 10.1093/pcp/pce162
   Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627
   Kim YJ, 2000, PHYSIOL PLANTARUM, V108, P51, DOI 10.1034/j.1399-3054.2000.108001051x./
   Kubo A, 1995, PLANT MOL BIOL, V29, P479, DOI 10.1007/BF00020979
   Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251
   Lee GJ, 2001, MOL CELLS, V12, P250
   Lee SC, 1999, MOL CELLS, V9, P166
   LEON J, 1995, PLANT PHYSIOL, V108, P1673, DOI 10.1104/pp.108.4.1673
   Meyer A, 2001, PLANTA, V213, P214, DOI 10.1007/s004250000493
   Mittler R, 1998, PLANT CELL, V10, P461, DOI 10.1105/tpc.10.3.461
   Mittler R, 1999, PLANT MOL BIOL, V39, P1025, DOI 10.1023/A:1006110223774
   MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962
   Mittler R, 1996, PLANT CELL, V8, P1991
   MIYAKE C, 1993, PLANT CELL PHYSIOL, V34, P881
   Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167
   Park CJ, 2002, PLANT MOL BIOL, V48, P243, DOI 10.1023/A:1013383329361
   Park CJ, 2001, MOL CELLS, V11, P122
   Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309
   Pieterse CMJ, 1996, PLANT CELL, V8, P1225
   Pieterse CMJ, 1998, PLANT CELL, V10, P1571, DOI 10.1105/tpc.10.9.1571
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113
   SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0
   Shin R, 2001, PLANT SCI, V161, P727, DOI 10.1016/S0168-9452(01)00465-4
   Shinozaki K, 2000, CURR OPIN PLANT BIOL, V3, P217, DOI 10.1016/S1369-5266(00)00067-4
   Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235
   Strizhov N, 1997, PLANT J, V12, P557, DOI 10.1046/j.1365-313X.1997.00557.x
   UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692
   XU Y, 1994, PLANT CELL, V6, P1077, DOI 10.1105/tpc.6.8.1077
   Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621
NR 51
TC 10
Z9 14
U1 0
U2 6
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD AUG 31
PY 2002
VL 14
IS 1
BP 75
EP 84
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 589QY
UT WOS:000177772900012
PM 12243356
DA 2018-12-27
ER

PT J
AU Carpena, P
   Bernaola-Galvan, P
   Ivanov, PC
   Stanley, HE
AF Carpena, P
   Bernaola-Galvan, P
   Ivanov, PC
   Stanley, HE
TI RETRACTED: Metal-insulator transition in chains with correlated disorder
   (Retracted Article. See vol 421, pg 764, 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID LONG-RANGE CORRELATIONS; 1D ANDERSON MODEL; DNA-MOLECULES;
   ELECTRICAL-CONDUCTION; LOCALIZATION LENGTH; ABSENCE; EXPONENT; SYSTEMS;
   DELOCALIZATION; TRANSPORT
AB According to Bloch's theorem, electronic wavefunctions in perfectly ordered crystals are extended, which implies that the probability of finding an electron is the same over the entire crystal(1). Such extended states can lead to metallic behaviour. But when disorder is introduced in the crystal, electron states can become localized, and the system can undergo a metal-insulator transition (also known as an Anderson transition)(2-4). Here we theoretically investigate the effect on the physical properties of the electron wavefunctions of introducing long-range correlations in the disorder in one-dimensional binary solids, and find a correlation-induced metal-insulator transition. We perform-numerical simulations using a one-dimensional tight-binding model, and find a threshold value for the exponent characterizing the long-range correlations of the system. Above this threshold, and in the thermodynamic limit, the system behaves as a conductor within a broad energy band; below threshold, the system behaves as an insulator. We discuss the possible relevance of this result for electronic transport in DNA, which displays long-range correlations(5,6) and has recently been reported to be a one-dimensional disordered conductor(7-10)
C1 Univ Malaga, ETSI Telecomunicac, Dept Fis Aplicada 2, E-29071 Malaga, Spain.
   Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA.
   Boston Univ, Dept Phys, Boston, MA 02215 USA.
RP Carpena, P (reprint author), Univ Malaga, ETSI Telecomunicac, Dept Fis Aplicada 2, E-29071 Malaga, Spain.
EM pcarpena@ctima.uma.cs
RI Carpena, Pedro/C-6791-2009; Ivanov, Plamen/E-8004-2012
OI Ivanov, Plamen/0000-0001-7629-762X; Carpena Sanchez, Pedro
   Juan/0000-0001-5568-0216; Bernaola Galvan, Pedro
   Angel/0000-0002-2895-3116
CR ABOUCHACRA R, 1973, J PHYS C SOLID STATE, V6, P1734, DOI 10.1088/0022-3719/6/10/009
   ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492
   ASHCROFT NW, 1976, SOLID STATE PHYSICS
   Chen Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041107
   Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465
   DAVIDS PS, 1995, PHYS REV B, V52, P4146, DOI 10.1103/PhysRevB.52.4146
   de Moura FABF, 1998, PHYS REV LETT, V81, P3735, DOI 10.1103/PhysRevLett.81.3735
   de Pablo PJ, 2000, PHYS REV LETT, V85, P4992, DOI 10.1103/PhysRevLett.85.4992
   DUNLAP DH, 1990, PHYS REV LETT, V65, P88, DOI 10.1103/PhysRevLett.65.88
   Fink HW, 1999, NATURE, V398, P407, DOI 10.1038/18855
   Henderson PT, 1999, P NATL ACAD SCI USA, V96, P8353, DOI 10.1073/pnas.96.15.8353
   Hjort M, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.228101
   HOFSTETTER E, 1993, PHYS REV B, V48, P16979, DOI 10.1103/PhysRevB.48.16979
   Holste D, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.041917
   Hu K, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011114
   ISHII K, 1970, PROG THEOR PHYS SUPP, V45, P56
   Janssen M., 1998, Physics Reports, V295, P1, DOI 10.1016/S0370-1573(97)00050-1
   Kantelhardt JW, 2000, PHYS REV LETT, V84, P198, DOI 10.1103/PhysRevLett.84.198
   Kasumov AY, 2001, SCIENCE, V291, P280, DOI 10.1126/science.291.5502.280
   KRAMER B, 1993, REP PROG PHYS, V56, P1469, DOI 10.1088/0034-4885/56/12/001
   KRAVCHENKO SV, 1996, PHYS REV LETT, V77, P4398
   MACKINNON A, 1981, PHYS REV LETT, V47, P1546, DOI 10.1103/PhysRevLett.47.1546
   Makse HA, 1996, PHYS REV E, V53, P5445, DOI 10.1103/PhysRevE.53.5445
   MOTT NF, 1961, ADV PHYS, V10, P107, DOI 10.1080/00018736100101271
   PENG CK, 1992, NATURE, V356, P168, DOI 10.1038/356168a0
   PHILLIPS P, 1991, SCIENCE, V252, P1805, DOI 10.1126/science.252.5014.1805
   Porath D, 2000, NATURE, V403, P635, DOI 10.1038/35001029
   Schweitzer L, 1997, J PHYS-CONDENS MAT, V9, pL441, DOI 10.1088/0953-8984/9/33/001
   Weymer A, 1998, ANN PHYS-BERLIN, V7, P159, DOI 10.1002/andp.2090070303
   Yoo KH, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198102
NR 30
TC 178
Z9 184
U1 6
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD AUG 29
PY 2002
VL 418
IS 6901
BP 955
EP 959
DI 10.1038/nature00948
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 588AP
UT WOS:000177677500039
PM 12198542
DA 2018-12-27
ER

PT J
AU Rioufol, G
   Finet, G
   Ginon, I
   Andre-Fouet, X
   Rossi, R
   Vialle, E
   Desjoyaux, E
   Convert, G
   Huret, JF
   Tabib, A
AF Rioufol, G
   Finet, G
   Ginon, I
   Andre-Fouet, X
   Rossi, R
   Vialle, E
   Desjoyaux, E
   Convert, G
   Huret, JF
   Tabib, A
TI RETRACTED: Multiple atherosclerotic plaque rupture in acute coronary
   syndrome - A three-vessel intravascular ultrasound study (Retracted
   article. See vol. 125, pg. E1019, 2012)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE ultrasonics; atherosclerosis; plaque; coronary disease
ID ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ARTERY-DISEASE; STENOSIS
   PROGRESSION; VULNERABLE PLAQUES; ISCHEMIC DEATH; THROMBOSIS; DISRUPTION;
   MECHANISMS; PECTORIS
AB Background-To test the hypothesis of general atherosclerotic plaque destabilization during acute coronary syndrome (ACS), the present study sought to analyze the 3 coronary arteries by systematic intravascular ultrasound scan (IVUS).
   Methods and Results-Seventy-two arteries were explored in 24 patients referred for percutaneous coronary intervention after a first ACS with troponin I elevation. Fifty plaque ruptures (mean, 2.08 per patient; range, 0 to 6) were diagnosed by the association of a ruptured capsule with intraplaque cavity. Plaque rupture on the culprit lesion was found in 9 patients (37.5%). At least 1 plaque rupture was found somewhere other than on the culprit lesion in 19 patients (79%). These lesions were in a different artery than the culprit artery in 70.8% and were in both other arteries in 12.5% of these 24 patients. Complete IVUS examination of all 3 coronary axes in patients who had experienced a first ACS revealed that multiple atherosclerotic plaque ruptures were detected by IVUS; these multiple ruptures were present simultaneously with the culprit lesion; they were frequent and located (in three quarters of cases) on the 3 principal coronary trunks; and the multiple plaque ruptures in locations other than on the culprit lesion were less severe, nonstenosing, and less calcified.
   Conclusion-Although one single lesion is clinically active at the time of ACS, the syndrome seems nevertheless associated with overall coronary instability.
C1 Cardiovasc Hosp, Dept Hemodynam, F-69394 Lyon 03, France.
   Univ Lyon 1, F-69365 Lyon, France.
   Ctr Hosp Annecy, Dept Cardiol, Annecy, France.
   Ctr Hosp Roanne, Dept Cardiol, Roanne, France.
   Ctr Hosp Valence, Dept Cardiol, Valence, France.
RP Rioufol, G (reprint author), Cardiovasc Hosp, Dept Hemodynam, BP Lyon Monchat, F-69394 Lyon 03, France.
EM gilles.rioufol@univ-lyon1.fr
CR AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2
   Arbustini E, 1999, HEART, V82, P269, DOI 10.1136/hrt.82.3.269
   Asakura M, 2001, J AM COLL CARDIOL, V37, P1284, DOI 10.1016/S0735-1097(01)01135-4
   Burke AP, 2001, CIRCULATION, V103, P934
   CHEN LJ, 1995, CIRCULATION, V91, P2319, DOI 10.1161/01.CIR.91.9.2319
   Chen LJ, 1996, J AM COLL CARDIOL, V28, P597, DOI 10.1016/0735-1097(96)00203-3
   DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467
   Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013
   DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801
   FALK E, 1983, BRIT HEART J, V50, P127
   FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657
   FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701
   FINET G, 1993, ULTRASOUND MED BIOL, V19, P533, DOI 10.1016/0301-5629(93)90077-2
   Fukuda D, 2001, HEART, V85, P402, DOI 10.1136/heart.85.4.402
   Ge J, 1999, HEART, V81, P621, DOI 10.1136/hrt.81.6.621
   Goldstein JA, 2000, NEW ENGL J MED, V343, P915, DOI 10.1056/NEJM200009283431303
   Guazzi MD, 1997, CIRCULATION, V96, P1145, DOI 10.1161/01.CIR.96.4.1145
   Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118
   HAUSMANN D, 1995, CIRCULATION, V91, P623, DOI 10.1161/01.CIR.91.3.623
   Kaski JC, 1996, EUR HEART J, V17, P1488
   Mann J, 1999, HEART, V82, P265, DOI 10.1136/hrt.82.3.265
   Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5
   Nakamura M, 2001, J AM COLL CARDIOL, V37, P63, DOI 10.1016/S0735-1097(00)01097-4
   Nissen SE, 2001, CIRCULATION, V103, P604, DOI 10.1161/01.CIR.103.4.604
   QIAO JH, 1991, J AM COLL CARDIOL, V17, P1138, DOI 10.1016/0735-1097(91)90844-Y
   Schoenhagen P, 2000, CIRCULATION, V101, P598, DOI 10.1161/01.CIR.101.6.598
   Takagi A, 1999, CIRCULATION, V100, P250, DOI 10.1161/01.CIR.100.3.250
   Takano M, 2001, J AM COLL CARDIOL, V38, P99, DOI 10.1016/S0735-1097(01)01315-8
   von Birgelen C, 2001, J AM COLL CARDIOL, V37, P1864, DOI 10.1016/S0735-1097(01)01234-7
   Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186
NR 30
TC 495
Z9 521
U1 7
U2 31
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD AUG 13
PY 2002
VL 106
IS 7
BP 804
EP 808
DI 10.1161/01.CIR.0000025609.13806.31
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 585NK
UT WOS:000177530700021
PM 12176951
OA Bronze
DA 2018-12-27
ER

PT J
AU Lorenz, T
   Hofmann, M
   Gruninger, M
   Freimurth, A
   Uhrig, GS
   Dumm, M
   Dressel, M
AF Lorenz, T
   Hofmann, M
   Gruninger, M
   Freimurth, A
   Uhrig, GS
   Dumm, M
   Dressel, M
TI RETRACTED: Evidence for spin-charge separation in quasi-one-dimensional
   organic conductors (Retracted Article. See vol 440, pg 707, 2006)
SO NATURE
LA English
DT Article; Retracted Publication
ID THERMAL-CONDUCTIVITY; SUPERCONDUCTORS; CHAIN; (TMTSF)2CLO4
AB Interacting conduction electrons are usually described within Fermi-liquid theory(1), which states that, in spite of strong interactions, the low-energy excitations are electron-like quasiparticles with charge and spin. In recent years there has been tremendous interest in conducting systems that are not Fermi liquids, motivated by the observation of highly anomalous metallic states in various materials, most notably the copper oxide superconductors(2,3). Non-Fermi-liquid behaviour is generic to one-dimensional interacting electron systems, which are predicted to be Luttinger liquids(4,5). One of their key properties is spin-charge separation: instead of quasiparticles, collective excitations of charge (with no spin) and spin (with no charge) are formed, which move independently and at different velocities. However, experimental confirmation of spin-charge separation remains a challenge. Here we report experiments probing the charge and heat current in quasi-one-dimensional conductors-the organic Bechgaard salts(6-10). It was found that the charge and spin excitations have distinctly different thermal conductivities, which gives strong evidence for spin-charge separation. The spin excitations have a much larger thermal conductivity than the charge excitations, which indicates that the coupling of the charge excitations to the lattice is important.
C1 Univ Cologne, Inst Phys 2, D-50937 Cologne, Germany.
   Univ Cologne, Inst Theoret Phys, D-50937 Cologne, Germany.
   Univ Stuttgart, Inst Phys 1, D-70550 Stuttgart, Germany.
RP Freimurth, A (reprint author), Univ Cologne, Inst Phys 2, D-50937 Cologne, Germany.
EM freimuth@ph2.uni-koeln.de
RI Dumm, Michael/N-4362-2016; Lorenz, Thomas/J-2955-2017; Dressel,
   Martin/D-3244-2012
OI Dumm, Michael/0000-0002-3502-8615; Lorenz, Thomas/0000-0003-4832-5157;
   Dressel, Martin/0000-0003-1907-052X
CR Berman R., 1976, THERMAL CONDUCTION S
   BOCHRATH M, 1999, NATURE, V397, P598
   Bourbonnais C, 1997, SYNTHETIC MET, V84, P19, DOI 10.1016/S0379-6779(97)80657-1
   Bourbonnais C, 1998, PHYS WORLD, V11, P41
   Bourbonnais C., 1999, ADV SYNTHETIC METALS, P206
   CHOI MY, 1986, PHYS REV B, V34, P7727, DOI 10.1103/PhysRevB.34.7727
   Claessen R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.096402
   COULON C, 1982, J PHYS-PARIS, V43, P1059, DOI 10.1051/jphys:019820043070105900
   DJUREK D, 1982, J PHYS C SOLID STATE, V15, pL669, DOI 10.1088/0022-3719/15/21/005
   Dumm M, 2000, PHYS REV B, V61, P511, DOI 10.1103/PhysRevB.61.511
   ENGELSBERG S, 1964, PHYS REV A-GEN PHYS, V136, P1582
   Gogolin A. O., 1998, BOSONIZATION STRONGL
   HEEGER AJ, 1988, REV MOD PHYS, V60, P781, DOI 10.1103/RevModPhys.60.781
   Hill RW, 2001, NATURE, V414, P711, DOI 10.1038/414711a
   Ishiguro T., 1998, ORGANIC SUPERCONDUCT
   JEROME D, 1982, ADV PHYS, V31, P299, DOI 10.1080/00018738200101398
   Klumper A, 1998, EUR PHYS J B, V5, P677, DOI 10.1007/s100510050491
   Nozieres P, 1966, THEORY QUANTUM LIQUI
   Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468
   Schwartz A, 1998, PHYS REV B, V58, P1261, DOI 10.1103/PhysRevB.58.1261
   SLACK GA, 1979, SOLID STATE PHYS, V34, P1
   Sologubenko AV, 2000, PHYS REV LETT, V84, P2714, DOI 10.1103/PhysRevLett.84.2714
   Sologubenko AV, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.054412
   VOIT J, 1995, REP PROG PHYS, V58, P977, DOI 10.1088/0034-4885/58/9/002
   Yacoby A, 1997, SOLID STATE COMMUN, V101, P77, DOI 10.1016/S0038-1098(96)00377-8
   Zeini B, 2001, EUR PHYS J B, V20, P189, DOI 10.1007/PL00011098
NR 26
TC 91
Z9 93
U1 7
U2 33
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD AUG 8
PY 2002
VL 418
IS 6898
BP 614
EP 617
DI 10.1038/nature00913
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 581RA
UT WOS:000177305600035
PM 12167854
DA 2018-12-27
ER

PT J
AU Haverdings, RFG
   Haas, M
   Navis, G
   van Loenen-Weemaes, AM
   Meijer, DKF
   de Zeeuw, D
   Moolenaar, F
AF Haverdings, RFG
   Haas, M
   Navis, G
   van Loenen-Weemaes, AM
   Meijer, DKF
   de Zeeuw, D
   Moolenaar, F
TI RETRACTED: Renal targeting of captopril selectively enhances the
   intrarenal over the systemic effects of ACE inhibition in rats
   (Retracted Article. See vol 138, pg 531, 2003)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE ACE inhibitor; blood pressure; renal drug targeting; captopril-lysozyme;
   renal haemodynamics; natriuresis; proteinuria; renal ACE inhibition
ID ANGIOTENSIN-CONVERTING ENZYME; SPONTANEOUSLY HYPERTENSIVE RATS;
   GLOMERULAR-FILTRATION RATE; CIRCULATING ANGIOTENSIN; PROXIMAL TUBULE;
   CONSCIOUS DOGS; BLOOD-PRESSURE; II BLOCKADE; LYSOZYME; DELIVERY
AB 1 In previous studies on the renal targeting of the ACE inhibitor captopril, we demonstrated that a 6 fold increased concentration of this drug could be obtained in the kidney after conjugation to the low-molecular-weight protein lysozyme. In this study, we investigated in unrestrained rats whether systemic administration of captopril-lysozyme also 'results in an enhanced effect on renal parameters, relative to the systemic effects.
   2 Renal effects: intravenous infusion of captopril-lysozyme for 6 h resulted in a more pronounced increment of renal blood flow (31 +/- 2% vs 17 +/- 4% at 0.5 mg kg(-1) 6h(-1), P < 0.01) and an approximately 5 fold enhanced natriuresis (167 +/- 17% vs 36 +/- 7% at 1 mg kg(-1) 6 h(-1), P < 0.001) in comparison with equimolar amounts of captopril as a free drug. In correspondence with these findings, renal ACE inhibition was potentiated approximately 5 fold (-50 +/- 4% vs -22 +/- 3% at 1 mg kg(-1) 6 h(-1), P < 0.001).
   3 Systemic effects: conjugated captopril did not affect blood pressure in dosages up to 5 mg kg(-1) 6 h(-1). This effect coincided with a less pronounced inhibition of the pressor response to intravenously administered angiotensin 1 (-12 +/- 3% vs -66 +/- 5% at 1 mg kg(-1) 6 h(-1), P < 0.001), and a markedly attenuated plasma ACE inhibition (- 19 + 2% vs - 37 + 3% at 1 mg kg(-1) 6h(-1) P < 0.001) compared to an equivalent dose of free captopril.
   4 An experiment of continued intravenous administration of captopril-lysozyme for 7 days in nephrotic syndrome demonstrated that the conjugate is also active in renal disease: the antiproteinuric response was substantially augmented (-67 +/- 5% vs - 15 +/- 7% at 4 mg kg(-1) 24 h(-1), P < 0.001) compared to the free drug, in the absence of blood pressure reduction.
   5 These data demonstrate that intravenous administration of a captopril-lysozyme conjugate leads to more selective renal ACE inhibition and enhanced renal effects as well as less systemic effects compared to captopril itself.
C1 Univ Groningen, Dept Pharmacokinet & Drug Delivery, Univ Ctr Pharm, NL-9713 AV Groningen, Netherlands.
   Univ Groningen, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands.
   Univ Groningen Hosp, Dept Internal Med, Div Nephrol, NL-9713 EZ Groningen, Netherlands.
RP Haverdings, RFG (reprint author), Univ Groningen, Dept Pharmacokinet & Drug Delivery, Univ Ctr Pharm, Antonius Deusinglaan 1,POB 187, NL-9713 AV Groningen, Netherlands.
EM R.F.G.Haverdings@farm.rug.nl
RI de Zeeuw, Dick/E-9080-2014
OI de Zeeuw, Dick/0000-0003-3434-7777
CR Anderson S, 1997, KIDNEY INT, pS107
   Bauer J, 1999, AM J PHYSIOL-REG I, V277, pR412, DOI 10.1152/ajpregu.1999.277.2.R412
   Cervenka L, 1999, J AM SOC NEPHROL, V10, pS196
   CHEN K, 1994, J PHARMACOL EXP THER, V270, P491
   Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562
   CHRISTENSEN EI, 1991, SEMIN NEPHROL, V11, P414
   Danser AHJ, 1998, J HYPERTENS, V16, P2051, DOI 10.1097/00004872-199816121-00029
   deVries PAM, 1997, KIDNEY INT, V52, P244, DOI 10.1038/ki.1997.327
   Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461
   Fogo AB, 2001, KIDNEY INT, V59, P804, DOI 10.1046/j.1523-1755.2001.059002804.x
   FOX J, 1992, AM J PHYSIOL, V262, pF902
   FRANSSEN EJF, 1992, INT J PHARM, V80, pR15, DOI 10.1016/0378-5173(92)90293-B
   FRANSSEN EJF, 1993, PHARMACEUT RES, V10, P963, DOI 10.1023/A:1018946219057
   GANSEVOORT RT, 1992, NEPHRON, V60, P246, DOI 10.1159/000186753
   Haas M, 1997, KIDNEY INT, V52, P1693, DOI 10.1038/ki.1997.504
   HAAS M, 1996, YB NEPHROLOGY, P3
   HAAS M, 2001, DRUG TARGETING ORGAN, P121
   HALL JE, 1981, AM J PHYSIOL, V241, pR190
   Haverdings RFG, 2001, POLYM BIOMATERIALS, P1117
   Ito S, 1997, KIDNEY INT, pS128
   KASTNER PR, 1984, AM J PHYSIOL, V246, pF897
   KIMBROUGH HM, 1977, CIRC RES, V40, P174, DOI 10.1161/01.RES.40.2.174
   Kok RJ, 1999, J PHARMACOL EXP THER, V288, P281
   Kok RJ, 1997, J CHROMATOGR B, V693, P181, DOI 10.1016/S0378-4347(97)00002-9
   KOMERS R, 1995, AM J PHYSIOL-RENAL, V268, pF588
   LEVENS NR, 1990, J CARDIOVASC PHARM, V16, pS65, DOI 10.1097/00005344-199016004-00014
   LEVENS NR, 1983, ENDOCRINOLOGY, V112, P43, DOI 10.1210/endo-112-1-43
   LEVENS NR, 1981, ENDOCRINOLOGY, V108, P536, DOI 10.1210/endo-108-2-536
   LEVENS NR, 1981, ENDOCRINOLOGY, V108, P318, DOI 10.1210/endo-108-1-318
   Li JZ, 1999, HYPERTENS RES-CLIN E, V22, P223, DOI 10.1291/hypres.22.223
   LI T, 1987, Journal of Cardiovascular Pharmacology, V10, pS133
   LI TC, 1992, J HYPERTENS, V10, P795
   LU SH, 1994, HYPERTENSION, V23, P337, DOI 10.1161/01.HYP.23.3.337
   Maack T, 1985, KIDNEY PHYSL PATHOPH, P1773
   Metzger R, 1999, KIDNEY INT, V56, P1442, DOI 10.1046/j.1523-1755.1999.00660.x
   Naitoh M, 1997, AM J PHYSIOL-HEART C, V272, pH679
   Navar LG, 1999, J AM SOC NEPHROL, V10, pS189
   Navar LG, 1996, PHYSIOL REV, V76, P425
   NELISSENVRANCKEN HJMG, 1992, J CARDIOVASC PHARM, V19, P163, DOI 10.1097/00005344-199202000-00002
   Palmer BF, 1997, J INVEST MED, V45, P346
   PENG Y, 1995, AM J PHYSIOL-RENAL, V269, pF40
   RASSIER ME, 1986, J CARDIOVASC PHARM, V8, pS106, DOI 10.1097/00005344-198600101-00019
   REMUZZI A, 1994, AM J PHYSIOL-RENAL, V267, pF1034
   Ruiz-Ortega M, 2000, NEPHROL DIAL TRANSPL, V15, P561, DOI 10.1093/ndt/15.5.561
   SIRAGY HM, 1990, AM J PHYSIOL, V258, pF522
   STIER CT, 1991, AM J HYPERTENS, V4, P680, DOI 10.1093/ajh/4.8.680
   Taal MW, 2000, KIDNEY INT, V57, P1803, DOI 10.1046/j.1523-1755.2000.00031.x
   VERBURG KM, 1990, AM J PHYSIOL, V259, pR7
   WEBER MA, 1992, AM HEART J, V123, P1414, DOI 10.1016/0002-8703(92)91063-7
   WEICHSELBAUM T E, 1946, Am J Clin Pathol, V10, P40
   Weir M R, 2000, Curr Hypertens Rep, V2, P497, DOI 10.1007/s11906-996-0030-y
   WELSCH C, 1989, J CARDIOVASC PHARM, V14, pS26, DOI 10.1097/00005344-198900000-00007
   WONG PC, 1980, LIFE SCI, V27, P1291, DOI 10.1016/0024-3205(80)90222-2
   YEUNG JH, 1983, BIOCHEM PHARMACOL, V23, P3619
   ZIMMERMAN BG, 1982, AM J PHYSIOL, V243, pH277
   ZIMMERMAN BG, 1985, J CARDIOVASC PHARM, V7, P715, DOI 10.1097/00005344-198507000-00016
NR 56
TC 9
Z9 9
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD AUG
PY 2002
VL 136
IS 8
BP 1107
EP 1116
DI 10.1038/sj.bjp.0704814
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 584MZ
UT WOS:000177471600007
PM 12163343
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Piper, SN
   Suttner, SW
   Maleck, WH
   Kumle, B
   Haisch, G
   Boldt, J
AF Piper, SN
   Suttner, SW
   Maleck, WH
   Kumle, B
   Haisch, G
   Boldt, J
TI RETRACTED: Effects of sodium nitroprusside-induced controlled
   hypotension on pancreatic function assessed by pancreatitis-associated
   protein in patients undergoing radical prostatectomy (Retracted article.
   See vol. 28, pg. 469, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE anaesthesia and analgesia, hypotension, controlled; pancreatic function
   tests; vasodilator agents, nitroprusside
ID IMMUNOCYTOCHEMICAL LOCALIZATION; SECRETORY PROTEIN; CARDIAC-SURGERY;
   SMALL-INTESTINE; SERUM-LEVELS; HEMODILUTION; ANESTHESIA; INJURY; HUMANS;
   BLOOD
AB Background and objective: Controlled hypotension may alter organ blood flow and tissue oxygenation. The aim of the study was to investigate whether induced hypotension using sodium nitroprusside alters pancreatic function assessed by pancreatitis-associated protein concentrations in the blood.
   Methods: Thirty patients undergoing elective radical prostatectomy were allocated randomly into two groups: (a) hypotension group: sodium nitroprusside was administered to lower mean arterial pressure to approximately 50 mmHg; (b) control group: no hypotension was used, mean arterial pressure was kept >70 mmHg. Pancreatitis-associated protein and lipase were measured in arterial blood samples: after induction of anaesthesia (T1), at the end of surgery (T2), 2 h (T3) and 24 h (T4) postoperatively.
   Results: Pancreatitis-associated protein plasma concentrations increased significantly in patients in the hypotensive group (from 2.8 +/- 1.1 to 5.5 +/- 2.0 mug L-1 at T4) and pancreatitis-associated protein plasma concentrations were significantly higher in comparison with controls (5.5 +/- 2.0 versus 3.5 +/- 2.4 mug L-1) at T4. Lipase concentrations showed a similar course in both groups. None of the patients showed clinical signs of pancreatitis.
   Conclusions: Controlled hypotension during surgery was associated with a small but significant increase in pancreatitis-associated protein compared with controls. The absence of concomitant elevation in lipase concentrations and a lack of clinical evidence of pancreatitis damage suggest that hypotension induces mild pancreatic stress.
C1 Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Piper, SN (reprint author), Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM wolfgang_maleck@hotmail.com
CR ABDULATIF M, 1994, ANAESTH INTENS CARE, V22, P155
   AGARWAL N, 1990, AM J GASTROENTEROL, V85, P356
   BLAU WS, 1992, ANESTH ANALG, V75, P172
   Bodeker H, 1998, DIGESTION, V59, P186, DOI 10.1159/000007487
   Boldt J, 1999, BRIT J ANAESTH, V82, P170, DOI 10.1093/bja/82.2.170
   BROE PJ, 1982, SURGERY, V91, P377
   Carroccio A, 1997, DIGESTION, V58, P98, DOI 10.1159/000201430
   FEINER H, 1976, AM J SURG, V131, P684, DOI 10.1016/0002-9610(76)90178-1
   Fukusaki M, 1996, J CLIN ANESTH, V8, P545, DOI 10.1016/S0952-8180(96)00119-5
   GOLDBERG ME, 1990, ANESTH ANALG, V70, P537
   Gullo L, 1996, GASTROENTEROLOGY, V111, P1033, DOI 10.1016/S0016-5085(96)70072-0
   HAAS GS, 1985, AM J SURG, V149, P508, DOI 10.1016/S0002-9610(85)80048-9
   HEESEN M, 1995, ANAESTHESIST, V44, P328, DOI 10.1007/s001010050160
   Heller A, 1999, ANESTHESIOLOGY, V91, P1408, DOI 10.1097/00000542-199911000-00034
   IOVANNA JL, 1994, GASTROENTEROLOGY, V106, P728, DOI 10.1016/0016-5085(94)90708-0
   KEIM V, 1984, DIGESTION, V29, P242, DOI 10.1159/000199041
   KEIM V, 1992, GASTROENTEROLOGY, V103, P248, DOI 10.1016/0016-5085(92)91120-S
   KEIM V, 1994, PANCREAS, V9, P606, DOI 10.1097/00006676-199409000-00011
   KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5
   Kemppainen EAJ, 1998, ANN MED, V30, P169, DOI 10.3109/07853899808999400
   Lake Carol L., 1995, P395
   LARSEN R, 1995, ANAESTHESIST, V44, P291, DOI 10.1007/s001010050157
   MASCIOTRA L, 1995, DIGEST DIS SCI, V40, P519, DOI 10.1007/BF02064359
   NORDBACK I, 1995, GUT, V36, P117, DOI 10.1136/gut.36.1.117
   Pezzilli R, 1997, AM J GASTROENTEROL, V92, P1887
   Simic O, 1997, ZBL CHIR, V122, P893
   VanderPijl JW, 1997, TRANSPLANTATION, V63, P995, DOI 10.1097/00007890-199704150-00016
   WARSHAW AL, 1978, ANN SURG, V188, P197, DOI 10.1097/00000658-197808000-00012
NR 28
TC 10
Z9 10
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD AUG
PY 2002
VL 19
IS 8
BP 609
EP 613
DI 10.1017/S0265021502000996
PG 5
WC Anesthesiology
SC Anesthesiology
GA 585LL
UT WOS:000177526200012
PM 12200953
DA 2018-12-27
ER

PT J
AU Kofidis, T
   Akhyari, P
   Wachsmann, B
   Boublik, J
   Mueller-Stahl, K
   Leyh, R
   Fischer, S
   Haverich, A
AF Kofidis, T
   Akhyari, P
   Wachsmann, B
   Boublik, J
   Mueller-Stahl, K
   Leyh, R
   Fischer, S
   Haverich, A
TI RETRACTED: A novel bioartificial myocardial tissue and its prospective
   use in cardiac surgery (Retracted article. See vol. 40, pg. 1554, 2011)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article; Retracted Publication
DE tissue engineering; congenital heart surgery; artificial myocardial
   tissue
ID MARROW STROMAL CELLS; IN-VITRO; CARDIOMYOCYTES; MATRIX; MODEL
AB Background: Congenital heart defects such as atrial septal defect, ventricular septal defect, double outlet ventricles and the hypoplastic left heart syndrome as well as ischemic heart disease are associated with aplastic, defective or necrotic myocardial structures. In many of these instances patch closure, reconstruction of the defect or revascularization is required. We have developed a contractile bioartificial myocardial tissue, which offers new perspectives for various reconstructive surgical interventions, including congenital heart surgery. Methods: Neonatal rat cardiomyocytes were seeded in vitro in a commercially available collagen scaffold. Histological examination and ultrastructural evaluation were performed. Protein and mRNA analysis were carried out by two-dimensional electrophoresis and reverse transcription-polymerase chain reaction (RT-PCR). Force measurements of contractions from the spontaneously beating or the pharmacologically stimulated bioartificial myocardial patch were obtained. Results: A solid matrix of 20 x 15 x 2 mm with spontaneous contractions resulted 36 It after cardiomyocyte seeding. Histology showed a tight mesh of collagen fibrils. Two-dimensional electrophoresis and RT-PCR revealed cardiotypical proteins (actin, tropomyosin, creatine kinase, ventricular light chain) and mRNA (myosin heavy chain, Connexin 43). The elasticity curve during passive stretch was similar to that of myocardium. Contractile force increased after topical administration of Ca(2+) and adrenaline. However, stretch led to the highest levels of contractile force. Conclusions: Our novel contractile bioartificial tissue can be engineered in vitro and may open novel avenues for myocardial tissue replacement in congenital and reconstructive heart surgery. From the current standpoint autologous or allogeneic cells would be preferred over xenogeneic sources. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Hannover Med Sch, Div Thorac & Cardiovasc Surg, D-30625 Hannover, Germany.
   Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, LEBAO, D-30625 Hannover, Germany.
RP Kofidis, T (reprint author), Hannover Med Sch, Div Thorac & Cardiovasc Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM kofidis@thg.mh-hannover.de
RI Kofidis, Theodoros/B-9283-2011
OI Kofidis, Theodoros/0000-0002-9623-6450; Akhyari,
   Payam/0000-0002-6452-8678
CR Bursac N, 1999, AM J PHYSIOL-HEART C, V277, pH433
   Eschenhagen T, 1997, FASEB J, V11, P683
   Fink C, 2000, FASEB J, V14, P669
   HAY ED, 1999, FASEB J S, V13, P281
   HOFFMAN RM, 1993, STEM CELLS, V11, P105, DOI 10.1002/stem.5530110205
   Kraft T, 1997, BIOPHYS J, V72, P272, DOI 10.1016/S0006-3495(97)78666-1
   KRAFT T, 1999, BIOPHYS J, V76, P1496
   Li RK, 2000, J THORAC CARDIOV SUR, V119, P368, DOI 10.1016/S0022-5223(00)70193-0
   Li RK, 1999, CIRCULATION, V100, P63
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Medeiros Argelia, 2000, Archivos del Instituto de Cardiologia de Mexico, V70, P46
   MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109
   OKADA K, 1927, ANN THORAC CARDIOVAS, P6
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SIMPSON DG, 1994, J CELL PHYSIOL, V161, P89, DOI 10.1002/jcp.1041610112
   Tomita S, 1999, CIRCULATION, V100, P247
   Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250
NR 17
TC 35
Z9 44
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1010-7940
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD AUG
PY 2002
VL 22
IS 2
BP 238
EP 243
AR PII S1010-7940(02)00256-7
DI 10.1016/S1010-7940(02)00256-7
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 587VM
UT WOS:000177664200012
PM 12142192
DA 2018-12-27
ER

PT J
AU Penkowa, M
   Poulsen, CB
   Carrasco, J
   Hidalgo, J
AF Penkowa, M
   Poulsen, CB
   Carrasco, J
   Hidalgo, J
TI RETRACTED: M-CSF deficiency leads to reduced metallothioneins I and II
   expression and increased tissue damage in the brain stem after
   6-aminonicotinamide treatment (Retracted article. See vol. 247, pg. 755,
   2013)
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article; Retracted Publication
DE toxic degeneration; inflammatory response; metallothionein;
   neuroprotection; oxidative stress; neurodegeneration; apoptosis
ID CENTRAL-NERVOUS-SYSTEM; STIMULATING FACTOR-I; EXPERIMENTAL AUTOIMMUNE
   ENCEPHALOMYELITIS; IMPAIRED INFLAMMATORY RESPONSE; ASTROCYTE-TARGETED
   EXPRESSION; INCREASED OXIDATIVE STRESS; AMYOTROPHIC-LATERAL-SCLEROSIS;
   ACID-INDUCED SEIZURES; TRANSGENIC MICE; NITRIC-OXIDE
AB 6-Aminonicotinamide (6-AN) is a niacin antagonist, which leads to degeneration of gray-matter astrocytes followed by a vigorous inflammatory response. Macrophage colony stimulating factor (M-CSF) is important during inflammation, and in order to further clarify the roles for M-CSF in neurodegeneration and brain cell death, we have examined the effect of 6-AN on osteopetrotic mice with genetic M-CSF deficiency (op/op mice). The 6-AN-induced degeneration of gray-matter areas was comparable in control and op/op mice, but the numbers of reactive astrocytes, macrophages, and lymphocytes in the damaged areas were significantly decreased in op/op mice relative to controls. The levels of oxidative stress (as determined by using immunoreactivity for inducible nitric oxide synthase, nitrotyrosine, and malondialdehyde) and apoptotic cell death (as determined by using TUNEL and immunoreactivity for caspases and cytochrome c) were significantly increased in 6-AN-injected op/op mice relative to controls. From a number of antioxidant factors assayed, only metallothioneins I and II (MT-I+II) were decreased in op/op mice in comparison to controls. Thus, the present results indicate that M-CSF is an important growth factor for coping with 6-AN-induced central nervous system damage and suggest that MT-I+II are likely to have a significant role. (C) 2002 Elsevier Science (USA).
C1 Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark.
   Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark.
   Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, E-08193 Barcelona, Spain.
   Autonomous Univ Barcelona, Fac Sci, Dept Cellular Biol Physiol & Immunol, E-08193 Barcelona, Spain.
RP Penkowa, M (reprint author), Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark.
EM M.Penkowa@mai.ku.dk
RI Carrasco, Javier/C-9732-2011; Hidalgo, Juan/C-9082-2011
OI Carrasco, Javier/0000-0001-6436-0863; Hidalgo, Juan/0000-0003-0921-1122
CR Abdel-Mageed AB, 1998, CANCER RES, V58, P2335
   AbdelMageed AB, 1997, CANCER GENE THER, V4, P199
   ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1
   Aschner M, 1998, NEUROTOXICOLOGY, V19, P653
   Aschner M, 1997, ANN NY ACAD SCI, V825, P334, DOI 10.1111/j.1749-6632.1997.tb48445.x
   Aschner M, 1996, FASEB J, V10, P1129
   BALASINGAM V, 1994, J NEUROSCI, V14, P846
   Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202
   BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7
   Broadwell RD, 1996, EXP NEUROL, V142, P47, DOI 10.1006/exnr.1996.0178
   Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L
   Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870
   Campbell I L, 2001, Prog Brain Res, V132, P481
   Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6
   Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x
   Carrasco J, 2000, EXP NEUROL, V163, P46, DOI 10.1006/exnr.1999.7335
   Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x
   Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0
   CECCHINI MG, 1994, DEVELOPMENT, V120, P1357
   Crowthers KC, 2000, TOXICOL APPL PHARM, V166, P161, DOI 10.1006/taap.2000.8961
   Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107
   Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x
   Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7
   Floyd RA, 1999, LIFE SCI, V65, P1893, DOI 10.1016/S0024-3205(99)00443-9
   GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851
   Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563
   Giralt M, 2001, EXP NEUROL, V168, P334, DOI 10.1006/exnr.2000.7601
   Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480
   Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772
   GIULIAN D, 1988, J NEUROSCI, V8, P4707
   Gong YH, 2000, EXP NEUROL, V162, P27, DOI 10.1006/exnr.2000.7323
   HAGHIGHAT N, 1996, BRAIN DIS, V12, P29
   Haidara K, 1999, TOXICOL SCI, V49, P297, DOI 10.1093/toxsci/49.2.297
   Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101
   Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9
   Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X
   Hidalgo J., 1997, CURR TOPICS NEUROCHE, V1, P1
   HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83
   Hothersall JS, 1998, FEBS LETT, V434, P97, DOI 10.1016/S0014-5793(98)00959-4
   Jasani B, 1997, HISTOPATHOLOGY, V31, P211, DOI 10.1046/j.1365-2559.1997.2140848.x
   Kalla R, 2001, J COMP NEUROL, V436, P182
   Kondo Y, 1997, MOL PHARMACOL, V52, P195
   KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x
   Krinke GJ, 1998, EXP TOXICOL PATHOL, V50, P277, DOI 10.1016/S0940-2993(98)80007-9
   KRUM JM, 1995, MOL CHEM NEUROPATHOL, V26, P79, DOI 10.1007/BF02815007
   KRUM JM, 1994, GLIA, V11, P354, DOI 10.1002/glia.440110408
   LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506
   Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8
   MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657
   Martiney JA, 1998, NEUROCHEM RES, V23, P349, DOI 10.1023/A:1022457500700
   Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1
   MERRILL JE, 1995, FASEB J, V9, P611
   Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3
   Mikkelsen HB, 1999, CELL TISSUE RES, V295, P485, DOI 10.1007/s004410051254
   Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168
   Molinero A, 1998, NEUROCHEM INT, V33, P559, DOI 10.1016/S0197-0186(98)00065-5
   Nagano S, 2001, EUR J NEUROSCI, V13, P1363, DOI 10.1046/j.0953-816x.2001.01512.x
   Pang ZJ, 1999, ATHEROSCLEROSIS, V147, P33, DOI 10.1016/S0021-9150(99)00159-8
   Penkowa M, 2000, EXP NEUROL, V163, P72, DOI 10.1006/exnr.2000.7383
   Penkowa M, 1997, BRAIN RES, V774, P256, DOI 10.1016/S0006-8993(97)81716-7
   Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5
   Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149
   Penkowa M, 1999, GLIA, V25, P343
   Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7
   Penkowa M, 2001, EXP NEUROL, V170, P1, DOI 10.1006/exnr.2001.7675
   Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056
   Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009
   Penkowa M, 1999, J NEUROSCI, V19, P2535
   Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003
   Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5
   Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T
   PENKOWA M, 2002, UNPUB EXP NEUROL
   PENKOWA M, 2002, IN PRESS BIOMEDICAL
   Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S
   Popovich PG, 2000, PROG BRAIN RES, V128, P43
   Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21
   RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x
   Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7
   Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238
   SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452
   STANLEY ER, 1994, STEM CELLS, V12, P15
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V
   Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5
   Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0
   Sun AY, 1998, J BIOMED SCI, V5, P401
   TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013
   THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6
   Viarengo A, 2000, CELL MOL BIOL, V46, P407
   Xiao BG, 1998, J NEUROL SCI, V157, P1, DOI 10.1016/S0022-510X(98)00049-5
   Yao CP, 2000, BRAIN RES, V855, P32, DOI 10.1016/S0006-8993(99)02211-8
   Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029
NR 93
TC 16
Z9 16
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD AUG
PY 2002
VL 176
IS 2
BP 308
EP 321
DI 10.1006/exnr.2002.7968
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 583QA
UT WOS:000177417800004
PM 12359172
DA 2018-12-27
ER

PT J
AU Kenefick, NJ
   Vaizey, CJ
   Malouf, AJ
   Norton, CS
   Marshall, M
   Kamm, MA
AF Kenefick, NJ
   Vaizey, CJ
   Malouf, AJ
   Norton, CS
   Marshall, M
   Kamm, MA
TI RETRACTED: Injectable silicone biomaterial for faecal incontinence due
   to internal anal sphincter dysfunction (Retracted Article. See vol 55,
   pg 1824, 2006)
SO GUT
LA English
DT Article; Retracted Publication
ID AUTOLOGOUS FAT; INJECTION; MICROIMPLANTS; PRESSURE
AB Background: A weak or disrupted internal anal sphincter can cause passive faecal incontinence. Conservative measures may help some patients but there is no simple surgical solution for those who fail conservative treatment. A successful technique using trans-sphincteric injection of a bulking agent to augment the internal anal sphincter was developed in a previous pilot study.
   Aim: To determine the clinical results and underlying physiological effects of biomaterial injection.
   Patients: Six patients (four males, median age 53 years (range 36-65)) with faecal incontinence to solid or liquid stool related to poor internal anal sphincter function, of varied aetiology, were recruited.
   Methods: Silicone based biomaterial injections were performed, under local anaesthesia, with antibiotic cover. Three injections were placed circumferentially, trans-sphincterically, entering away from the anal margin and injecting at or just above the dentate line. Anorectal physiological studies, endoanal ultrasound, a bowel symptom diary, a validated incontinence score, and quality of life questionnaires were completed before treatment and on completion of follow up.
   Results: At a median follow up of 18 months (range 15-19), five of six patients had marked symptom. improvement. Faecal incontinence scores improved from a median of 14/24 (range 11-20) before to 8/24 (6-15) after injection. Short form-36 quality of life physical and social function scores improved from a median of 26/100 (5-33) to 79/100 (25-100) and from 10/100 (5-37) to 100/100 (50100), respectively. There was a corresponding physiological increase in maximum anal resting and squeeze pressures. Ultrasound showed the Bioplastique to be retained in the correct position in the improved patients without migration. There were no complications.
   Conclusion: Trans-sphincteric injection of silicone biomaterial can provide a marked improvement in faecal incontinence related to a weak or disrupted internal anal sphincter. This is associated with improved sphincter function and quality of life.
C1 St Marks Hosp, London EC1V 2PS, England.
RP Kamm, MA (reprint author), St Marks Hosp, Watford Rd, Harrow HA1 3UJ, Middx, England.
EM kamm@ic.ac.uk
CR Baeten GMI, 2000, DIS COLON RECTUM, V43, P743, DOI 10.1007/BF02238008
   BEISANG AA, 1992, AESTHET PLAST SURG, V16, P83, DOI 10.1007/BF00455154
   Bernardi C, 1998, PLAST RECONSTR SURG, V102, P1626, DOI 10.1097/00006534-199810000-00046
   BURNETT SJD, 1991, INT J COLORECTAL DIS, V6, P2, DOI 10.1007/BF00703951
   ENGEL AF, 1995, INT J COLORECTAL DIS, V10, P152, DOI 10.1007/BF00298538
   ENGEL AF, 1994, GUT, V35, P857, DOI 10.1136/gut.35.6.857
   ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P693, DOI 10.1097/00006534-199104000-00014
   FRENCKNER B, 1975, GUT, V16, P482, DOI 10.1136/gut.16.6.482
   GARCIAAGUILAR J, 1999, DIS COLON RECTUM, V42, P687
   GIBBONS CP, 1986, INT J COLORECTAL DIS, V1, P231, DOI 10.1007/BF01648344
   Harriss DR, 1996, BRIT J UROL, V78, P722, DOI 10.1046/j.1464-410X.1996.17510.x
   JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437
   Kumar D, 1998, BRIT J SURG, V85, P978
   LAW PJ, 1989, GASTROINTEST RADIOL, V14, P349, DOI 10.1007/BF01889235
   Lehur PA, 1998, INT J COLORECTAL DIS, V13, P88, DOI 10.1007/s003840050141
   Leroi AM, 1997, INT J COLORECTAL DIS, V12, P243, DOI 10.1007/s003840050098
   LESTAR B, 1992, INT J COLORECTAL DIS, V7, P159, DOI 10.1007/BF00360358
   LESTAR B, 1989, INT J COLORECTAL DIS, V4, P118, DOI 10.1007/BF01646870
   Malouf AJ, 2001, DIS COLON RECTUM, V44, P595, DOI 10.1007/BF02234337
   Malouf AJ, 2000, ANN SURG, V232, P143, DOI 10.1097/00000658-200007000-00020
   Morgan R, 1997, BRIT J SURG, V84, P226, DOI 10.1002/bjs.1800840225
   SAINIO P, 1985, ACTA CHIR SCAND, V151, P695
   SHAFIK A, 1993, INT SURG, V78, P159
   SHAFIK A, 1995, DIS COLON RECTUM, V38, P583, DOI 10.1007/BF02054115
   Vaizey CJ, 1997, LANCET, V349, P612, DOI 10.1016/S0140-6736(96)09188-X
   Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77
NR 26
TC 53
Z9 56
U1 4
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD AUG
PY 2002
VL 51
IS 2
BP 225
EP 228
DI 10.1136/gut.51.2.225
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 577XK
UT WOS:000177088100019
PM 12117884
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU He, J
   Zhang, X
   Wang, YY
   Xi, XM
   Chan, M
   Hu, CM
AF He, J
   Zhang, X
   Wang, YY
   Xi, XM
   Chan, M
   Hu, CM
TI RETRACTED: Normalized mutual integral difference operator: a novel
   experimental method for extracting threshold voltage of MOSFETs
   (Retracted article. See vol. 41, pg. 693, 2010)
SO MICROELECTRONICS JOURNAL
LA English
DT Article; Retracted Publication
DE normalized mutual integral difference operator; MOSFET devices;
   threshold voltages; series resistance effect; parameter extraction
AB Normalized mutual integral difference operator (NMIDO), a novel experimental method for extracting the threshold voltage of MOSFETs, is presented in this paper, The basic principle of this method is to use the extreme spectrum characteristics of the NMIDO to find the threshold voltage. We have demonstrated numerically that this method is applied in the extraction of the threshold voltage of MOSFETs with different effective channel length and different parasitic series resistance cases. It has been shown that this method is sensitive to the channel length variation while insensitive to the parasitic resistance component. The extracted results on the threshold voltage of MOSFETs have also been compared with those obtained by the second-derivative method and the good agreement has been found, showing the advantage of the method presented here. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Peking Univ, Inst Microelect, Beijing 100871, Peoples R China.
   Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.
RP He, J (reprint author), Univ Calif Berkeley, 373 Cory Hall, Berkeley, CA 94720 USA.
EM jinhe@fermi.eecs.berkeley.edu
CR AORRA N, 1993, MOSFET MODELS VLSI C
   He J, 2002, IEEE T ELECTRON DEV, V49, P331, DOI 10.1109/16.981227
   HE J, 2001, IEEE ELECTR DEVICE L, P597
   JAIN S, 1988, IEE PROC-I, V135, P162, DOI 10.1049/ip-i-1.1988.0029
   Liou JJ, 1998, ANAL DESIGN MOSFETS, DOI 978-0-412-14601-5
   OrtizConde A, 1997, IEEE T ELECTRON DEV, V44, P1523, DOI 10.1109/16.622610
   Schroder D.K., 1990, SEMICONDUCTOR MAT DE
   Tsuno M, 1999, IEEE T ELECTRON DEV, V46, P1429, DOI 10.1109/16.772487
   WONG HS, 1987, SOLID STATE ELECTRON, V30, P953, DOI 10.1016/0038-1101(87)90132-8
   YAN ZX, 1991, IEE PROC-G, V138, P351, DOI 10.1049/ip-g-2.1991.0060
NR 10
TC 5
Z9 5
U1 6
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0026-2692
J9 MICROELECTRON J
JI Microelectron. J.
PD AUG
PY 2002
VL 33
IS 8
BP 667
EP 670
AR PII S0026-2692(02)00028-9
DI 10.1016/S0026-2692(02)00028-9
PG 4
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology
SC Engineering; Science & Technology - Other Topics
GA 574RJ
UT WOS:000176903100010
DA 2018-12-27
ER

PT J
AU Curtis, CL
   Rees, SG
   Cramp, J
   Flannery, CR
   Hughes, CE
   Little, CB
   Williams, R
   Wilson, C
   Dent, CM
   Harwood, JL
   Caterson, B
AF Curtis, CL
   Rees, SG
   Cramp, J
   Flannery, CR
   Hughes, CE
   Little, CB
   Williams, R
   Wilson, C
   Dent, CM
   Harwood, JL
   Caterson, B
TI RETRACTED: Effects of n-3 fatty acids on cartilage metabolism (Retracted
   Article. See vol 65, pg 434, 2006)
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Symposium on Mechanisms in Nutrient Regulation of Inflammation
CY DEC 06, 2001
CL HARROGATE, ENGLAND
DE n-3 PUFA; cartilage metabolism; chondrocytes; degenerative diseases
ID RHEUMATOID-ARTHRITIS; INTERGLOBULAR DOMAIN; MATRIX METALLOPROTEINASES;
   ARTICULAR-CARTILAGE; ADAMTS FAMILY; IN-VITRO; CATABOLISM; AGGRECAN;
   DEGRADATION; MECHANISMS
AB Although the clinical benefits of dietary supplementation with n-3 polyunsaturated fatty acids (PUFA) has been recognised for a number of years, the molecular mechanisms by which particular PUFA affect metabolism of cells within the synovial joint tissues are not understood. This study set out to investigate how n-3 PUFA and other classes of fatty acids affect both degradative and inflammatory aspects of metabolism of articular cartilage chondrocytes using an in vitro model of cartilage degradation. Using well-established culture models, cartilage explants from normal bovine and human osteoarthritic cartilage were supplemented with either n-3 or n-6 PUFA, and cultures were subsequently treated with interleukin 1 to initiate catabolic processes that mimic cartilage degradation in arthritis. Results show that supplementation specifically with n-3 PUFA, but not n-6 PUFA, causes a decrease in both degradative and inflammatory aspects of chondrocyte metabolism, whilst having no effect on the normal tissue homeostasis. Collectively, our data provide evidence supporting dietary supplementation of n-3 PUFA, which in turn may have a beneficial effect of slowing and reducing inflammation in the pathogenesis of degenerative joint diseases in man.
C1 Cardiff Univ, Cardiff Business Sch, Cardiff CF10 3US, S Glam, Wales.
   Cardiff Univ, Dept Traumat & Orthopaed Surg, Cardiff CF14 4XW, S Glam, Wales.
RP Caterson, B (reprint author), Cardiff Univ, Cardiff Business Sch, Museum Ave, Cardiff CF10 3US, S Glam, Wales.
EM caterson@cardiff.ac.uk
RI Little, Christopher/A-9280-2015; Harwood, John/A-4308-2010
OI Little, Christopher/0000-0002-0353-7634; Harwood,
   John/0000-0003-2377-2612; Hughes, Clare/0000-0003-4726-5877
CR Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443
   Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114
   Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679
   Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006
   Calder PC, 2001, NUTR RES, V21, P309, DOI 10.1016/S0271-5317(00)00287-6
   Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0
   Caterson B, 1995, ACTA ORTHOP SCAND, V66, P121, DOI 10.3109/17453679509157666
   Cleland LG, 2000, J RHEUMATOL, V27, P2305
   Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721
   CURTIS CL, 2002, IN PRESS ARTHRITIS R
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5
   HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799
   ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L
   Isomaki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474
   LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903
   Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061
   Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5
   Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181
   Reno C, 1997, BIOTECHNIQUES, V22, P1082, DOI 10.2144/97226bm16
   SANDY JD, 1991, J BIOL CHEM, V266, P8683
   SICARD B, 1985, THROMB HAEMOSTASIS, V53, P264
   Takita T, 1996, J CLIN BIOCHEM NUTR, V20, P149
   Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Volker D, 1996, J CLIN BIOCHEM NUTR, V20, P83
NR 25
TC 39
Z9 40
U1 3
U2 18
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD AUG
PY 2002
VL 61
IS 3
BP 381
EP 389
DI 10.1079/PNS2002174
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 590RP
UT WOS:000177836100009
PM 12230798
OA Bronze
DA 2018-12-27
ER

PT J
AU Miggin, SM
   Kinsella, BT
AF Miggin, SM
   Kinsella, BT
TI RETRACTED: Investigation of the mechanisms of G protein: Effector
   coupling by the human and mouse prostacyclin receptors - Identification
   of critical species-dependent differences (Retracted article. See vol.
   293, pg. 12285, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID MULTIPLE SIGNALING PATHWAYS; PROSTANOID IP-RECEPTOR; MU-OPIOID RECEPTOR;
   KINASE-A; ALPHA-ISOFORM; TP-ALPHA; PHOSPHORYLATION; EXPRESSION; CELLS;
   CLONING
AB We recently identified a novel mechanism explaining how the mouse (m) prostacyclin receptor (IP) couples to Galpha(s), Galpha(i), and Galpha(q) (Lawler, O. A., Miggin, S. M., and Kinsella, B. T. (2001) J. Biol Chem. 276, 33596-33607) whereby mIP coupling to Galpha(i) and Galpha(q) is dependent on its initial coupling to Galpha(s) and subsequent phosphorylation by cAMP-dependent protein kinase A (PKA) on Ser(357). In the current study, the generality of that mechanism was investigated by examining the G protein coupling specificity of the human (h) IP. The hIP efficiently coupled to Galpha(s)/adenylyl cyclase and to Galpha(q)/phospholipase C activation but failed to couple to Galpha(i). Coupling of the hIP to Galpha(q), or indeed to Galpha(s) or Galpha(i), was unaffected by the PKA or protein kinase C (PKC) inhibitors H-89 and GF 109203X, respectively. Thus, mIP and hIP exhibit essential differences in their coupling to Gai and in their dependence on PKA in regulating their coupling to Gaq. Analysis of their primary sequences revealed that the critical PKA phosphorylation site within the mIP, at Ser(357), is replaced by a PKC site within the hIP, at Ser(328). Conversion of the PKC site of the hIP to a PKA site generated hIP(QL325,326RP) that efficiently coupled to Galpha(s) and to Galpha(i) and Galpha(q); coupling of hIp(QL325,326RP) to Galpha(i) but not to Galpha(s) or Galpha(q) was inhibited by H-89. Abolition of the PKC site of the hIP generated hIp(S328A) that efficiently coupled to Galpha(s) and Galpha(q) but failed to couple to Gai. Finally, conversion of the PKA site at Ser 357 within the mIP to a PKC site generated MIplIP354,355QL that efficiently coupled to Galpha(s) but not to Galpha(i) or Galpha(q). Collectively, our data highlight critical differences in signaling by the mIP and hIP that are regulated by their differential phosphorylation by PKA and PKC together with contextual sequence differences surrounding those sites.
C1 Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.
RP Kinsella, BT (reprint author), Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Conway Inst Biomol & Biomed Res, Merville House, Dublin 4, Ireland.
EM Therese.Kinsella@UCD.IE
OI Kinsella, B. Therese/0000-0003-3072-941X; Miggin,
   Sinead/0000-0002-3421-3552
CR Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382
   BOIE Y, 1994, J BIOL CHEM, V269, P12173
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CAMPBELL W B, 1990, P600
   CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534
   COLEMAN RA, 1994, PHARMACOL REV, V46, P205
   Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362
   FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75
   FITZGERALD DJ, 1987, CIRCULATION, V75, P956, DOI 10.1161/01.CIR.75.5.956
   Gaibelet G, 1999, EUR J BIOCHEM, V261, P517, DOI 10.1046/j.1432-1327.1999.00301.x
   Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707
   Hebert RL, 1998, AM J PHYSIOL-RENAL, V275, pF904, DOI 10.1152/ajprenal.1998.275.6.F904
   Higgins DG, 1996, METHOD ENZYMOL, V266, P383
   HilalDandan R, 1997, AM J PHYSIOL-HEART C, V272, pH130
   Hoshikawa Y, 2001, AM J RESP CRIT CARE, V164, P314, DOI 10.1164/ajrccm.164.2.2010150
   KAHN NN, 1990, CIRC RES, V66, P932, DOI 10.1161/01.RES.66.4.932
   Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957
   KOCH WJ, 1994, J BIOL CHEM, V269, P6193
   Komhoff M, 1998, KIDNEY INT, V54, P1899, DOI 10.1046/j.1523-1755.1998.00213.x
   Lawler OA, 2001, J BIOL CHEM, V276, P33596, DOI 10.1074/jbc.M104434200
   Lawler OA, 2001, BRIT J PHARMACOL, V132, P1639, DOI 10.1038/sj.bjp.0704033
   Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684
   Miggin SM, 2002, EUR J BIOCHEM, V269, P1714, DOI 10.1046/j.1432-1327.2002.02817.x
   Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780
   MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x
   NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643
   NAMBA T, 1994, J BIOL CHEM, V269, P9986
   Narumiya S, 1999, PHYSIOL REV, V79, P1193
   OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9
   PEREZ DM, 1993, MOL PHARMACOL, V44, P784
   SAKAI A, 1990, LIFE SCI, V47, P711, DOI 10.1016/0024-3205(90)90626-3
   Schubert R, 1997, AM J PHYSIOL-HEART C, V272, pH1147
   Siegel G, 1989, Eicosanoids, V2, P213
   Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698
   Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258
   Ueno A, 2000, LIFE SCI, V66, pPL155, DOI 10.1016/S0024-3205(00)00420-3
   vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830
   VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4
   Walsh MT, 2000, BBA-MOL CELL RES, V1496, P164, DOI 10.1016/S0167-4889(00)00031-8
   Walsh MT, 2000, BRIT J PHARMACOL, V131, P601, DOI 10.1038/sj.bjp.0703624
   WATSON S, 1994, G PROTEIN LINKED REC
   Wise H, 1996, TRENDS PHARMACOL SCI, V17, P17, DOI 10.1016/0165-6147(96)81565-3
   Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058
   Zucker TP, 1998, EUR J PHARMACOL, V345, P213, DOI 10.1016/S0014-2999(98)00022-3
NR 44
TC 45
Z9 45
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 26
PY 2002
VL 277
IS 30
BP 27053
EP 27064
DI 10.1074/jbc.M203353200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 577HR
UT WOS:000177055900047
PM 12016224
OA Bronze
DA 2018-12-27
ER

PT J
AU Croxen, R
   Hatton, C
   Shelley, C
   Brydson, M
   Chauplannaz, G
   Oosterhuis, H
   Vincent, A
   Newsom-Davis, J
   Colquhoun, D
   Beeson, D
AF Croxen, R
   Hatton, C
   Shelley, C
   Brydson, M
   Chauplannaz, G
   Oosterhuis, H
   Vincent, A
   Newsom-Davis, J
   Colquhoun, D
   Beeson, D
TI RETRACTED: Recessive inheritance and variable penetrance of slow-channel
   congenital myasthenic syndromes (Retracted Article. See vol 72, pg 294,
   2009)
SO NEUROLOGY
LA English
DT Review; Retracted Publication
ID RECEPTOR ALPHA-SUBUNIT; AGONIST BINDING-AFFINITY; MUSCLE
   ACETYLCHOLINE-RECEPTOR; EPSILON-SUBUNIT; ION-CHANNEL; NICOTINIC
   RECEPTORS; M2 DOMAIN; MUTATION; CURRENTS; DESENSITIZATION
AB Background: Slow-channel congenital myasthenic syndromes (SCCMS) typically show dominant inheritance. They are caused by missense mutations within the subunits of muscle nicotinic acetylcholine receptors (AChR) that result in prolonged ion channel activations. SCCMS mutations within the AChR a subunit are located in various functional domains, whereas fully described mutations in AChR non-a subunits have, thus far, been located only in the M2 channel-lining domain. The authors identified and characterized two E-subunit mutations, located outside M2, that underlie SCCMS in three kinships. In two of the three kinships, the syndrome showed an atypical inheritance pattern. Methods: These methods included clinical diagnosis, mutation detection, haplotype analysis, and functional expression studies using single-channel recordings of mutant AChR transiently transfected into HEK293 cells. Results: The authors identified two SCCMS mutations in the AChR E Subunit, epsilonL78P and epsilonL221F. Both mutations prolonged ACh-induced ion channel activations. epsilonL78P is present in a consanguineous family and appears to be pathogenic only when present on both alleles, and epsilonL221F shows variable penetrance in one of the two families that were identified harboring this mutation. Conclusion: SCCMS mutations may show a recessive inheritance pattern and variable penetrance. A diagnosis of SCCMS should not be ruled out in cases of CMS with an apparent recessive inheritance pattern.
C1 John Radcliffe Hosp, Weatherall Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England.
   UCL, Dept Pharmacol, London WC1E 6BT, England.
   Hop Neurol, Lyon, France.
   Univ Lyon 1, Lyon, France.
   Acad Hosp, Dept Neurol, Groningen, Netherlands.
RP Beeson, D (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England.
EM dbeeson@hammer.imm.ox.ac.uk
RI Colquhoun, David/C-1664-2008
OI Colquhoun, David/0000-0002-4263-017X
CR AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002
   BEESON D, 1993, EUR J BIOCHEM, V215, P229, DOI 10.1111/j.1432-1033.1993.tb18027.x
   Beeson D, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P85, DOI 10.1016/B978-044450489-0/50006-9
   Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011
   CHAUPLANNAZ G, 1994, REV NEUROL, V150, P142
   Colquhoun D, 1997, PHILOS T R SOC A, V355, P1743, DOI 10.1098/rsta.1997.0090
   Colquhoun David, 1995, P483
   Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431
   Croxen R, 1997, HUM MOL GENET, V6, P767, DOI 10.1093/hmg/6.5.767
   EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P469, DOI 10.1146/annurev.ph.57.030195.002345
   ENGEL AG, 1982, ANN NEUROL, V11, P553, DOI 10.1002/ana.410110603
   Engel AG, 1996, HUM MOL GENET, V5, P1217, DOI 10.1093/hmg/5.9.1217
   ENGEL AG, 1999, MYASTHENIA GRAVIS MY, P251
   Gomez CM, 1996, ANN NEUROL, V39, P712, DOI 10.1002/ana.410390607
   GOMEZ CM, 1995, NEUROLOGY, V45, P982, DOI 10.1212/WNL.45.5.982
   Gomez CM, 2002, ANN NEUROL, V51, P102, DOI 10.1002/ana.10077
   Jahn K, 2001, NEUROSCI LETT, V307, P89, DOI 10.1016/S0304-3940(01)01929-2
   Milone M, 1997, J NEUROSCI, V17, P5651
   Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5
   OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758
   OOSTERHUIS HJGH, 1987, BRAIN, V110, P1061, DOI 10.1093/brain/110.4.1061
   SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2
   Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757
   Wyllie DJA, 1998, J PHYSIOL-LONDON, V510, P1, DOI 10.1111/j.1469-7793.1998.001bz.x
NR 24
TC 43
Z9 44
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL 23
PY 2002
VL 59
IS 2
BP 162
EP 168
DI 10.1212/WNL.59.2.162
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 574EL
UT WOS:000176875400004
PM 12141316
DA 2018-12-27
ER

PT J
AU Kavokin, A
   Zamfirescu, M
   Gil, B
   Malpuech, G
AF Kavokin, A
   Zamfirescu, M
   Gil, B
   Malpuech, G
TI RETRACTED: ZnO as a material mostly adapted for realisation of
   room-temperature polariton lasers (Retracted article. See Vol 201, pg
   3373, 2004)
SO PHYSICA STATUS SOLIDI A-APPLICATIONS AND MATERIALS SCIENCE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th International Symposium on Blue Lasers and Light Emitting Diodes
CY MAR 11-15, 2002
CL CORDOBA, SPAIN
SP Minist Ciencia & Tecnol, Univ Politecn Madrid, ISOM UPM, ONRIFO, AIXTRON AG, Thomas Swan Sci Equipment, Carburos Metalicos SA, VTS Createc GmbH, MECA 2000, Compound Semiconductor Magazine, Ayuntamiento Cordoba, CajaSur, Bodegas Perez Barquero SA, Consejo Regulador DO Priego Cordoba
ID SEMICONDUCTOR MICROCAVITIES; STIMULATED SCATTERING; QUANTUM MICROCAVITY;
   PHOTOLUMINESCENCE; RELAXATION; BOTTLENECK; EXCITONS
AB Wannier-Mott excitons in the wurzite-type semiconductor material ZnO are stable at room temperature, have an extremely large oscillator strength and emit purple light. This makes ZnO an excellent potential candidate for the fabrication of room-temperature lasers where the coherent light amplification is ruled by the fascinating mechanism of the Bose-condensation of the exciton-polaritons. We first report on the direct optical measurement of the exciton oscillator strength f in ZnO. The longitudinal transverse splitting of the exciton resonances Gamma(5)(B) and Gamma(1)(C) are found to achieve record values of 5 and 7 meV, respectively, that is two orders of magnitude larger than that in GaAs. Secondly, we propose a model ZnO-based microcavity structure that is found to be the most adapted structure for the observation of the polariton laser effect. We thus can compute the phase diagram of the lasing regimes. A record value of the threshold power of 2 mW per device (at power density of 3000 W/cm(2)) at room temperature is found for the model laser structure.
C1 Univ Clermont Ferrand, UMR 6602 CNRS, LASMEA, F-63177 Clermont Ferrand, France.
   Univ Montpellier 2, CNRS, GES, F-34095 Montpellier 5, France.
   Univ Southampton, Dept Phys & Astron, Southampton SO17 1BJ, Hants, England.
RP Kavokin, A (reprint author), Univ Clermont Ferrand, UMR 6602 CNRS, LASMEA, F-63177 Clermont Ferrand, France.
EM kavokin@lasmea.univ-bpclermont.fr
RI Kavokin, Alexey/J-8610-2013; KAVOKINE, ALEXIS/C-3601-2016
OI KAVOKINE, ALEXIS/0000-0003-2713-1062
CR Baumberg JJ, 2000, PHYS REV B, V62, P16247, DOI 10.1103/PhysRevB.62.R16247
   BUF R, 2000, PHYS REV B, V652
   Butov LV, 2001, PHYS REV LETT, V86, P5608, DOI 10.1103/PhysRevLett.86.5608
   Chen YF, 2000, APPL PHYS LETT, V76, P559, DOI 10.1063/1.125817
   Dang LS, 1998, PHYS REV LETT, V81, P3920, DOI 10.1103/PhysRevLett.81.3920
   Imamoglu A, 1996, PHYS REV A, V53, P4250, DOI 10.1103/PhysRevA.53.4250
   Kavokin AV, 1998, PHYS REV B, V57, P3757, DOI 10.1103/PhysRevB.57.3757
   KAVOKIN AV, 1982, PHYS STATUS SOLIDI B, V190, P389
   Khitrova G, 1999, REV MOD PHYS, V71, P1591, DOI 10.1103/RevModPhys.71.1591
   LAGOIS J, 1975, PHYS STAT SOL H, V72, P363
   LITTON C, COMMUNICATION
   Ohtomo A, 1998, APPL PHYS LETT, V72, P2466, DOI 10.1063/1.121384
   Reynolds DC, 1999, PHYS REV B, V60, P2340, DOI 10.1103/PhysRevB.60.2340
   Senellart P, 2000, PHYS REV B, V62, P16263, DOI 10.1103/PhysRevB.62.R16263
   Skolnick MS, 1998, SEMICOND SCI TECH, V13, P645, DOI 10.1088/0268-1242/13/7/003
   Stevenson RM, 2000, PHYS REV LETT, V85, P3680, DOI 10.1103/PhysRevLett.85.3680
   Tartakovskii AI, 2000, PHYS REV B, V62, pR2283, DOI 10.1103/PhysRevB.62.R2283
   Tassone F, 1997, PHYS REV B, V56, P7554, DOI 10.1103/PhysRevB.56.7554
   WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314
   Zamfirescu M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.121304
NR 20
TC 4
Z9 4
U1 2
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1862-6300
J9 PHYS STATUS SOLIDI A
JI Phys. Status Solidi A-Appl. Mat.
PD JUL 16
PY 2002
VL 192
IS 1
BP 212
EP 217
DI 10.1002/1521-396X(200207)192:1<212::AID-PSSA212>3.0.CO;2-B
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 579WT
UT WOS:000177202000038
DA 2018-12-27
ER

PT J
AU Poehlman, ET
AF Poehlman, ET
TI RETRACTED: Menopause, energy expenditure, and body composition
   (Retracted Article. See vol 84, pg 1131, 2005)
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Review; Retracted Publication
DE body fat; energy expenditure; menopause; visceral obesity
ID HORMONE-REPLACEMENT THERAPY; CORONARY HEART-DISEASE; GROWTH-FACTOR-I;
   EARLY POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION;
   COMPUTED-TOMOGRAPHY; PHYSICAL-ACTIVITY; RISK-FACTORS; ESTROGEN
   REPLACEMENT
AB Objectives. The effects of menopause transition on metabolic and cardiovascular disease risk in women are unclear. It is unknown whether estrogen deficiency, aging, or a combination of both factors are independent contributors to a worsening health profile in women. We considered the effects of menopause transition and hormone replacement therapy on body composition, regional body fat, energy expenditure, and insulin sensitivity.
   Methods. A brief review of current literature that has considered the role of menopause transition and hormone replacement therapy on body composition, energy expenditure, and insulin sensitivity with an emphasis on longitudinal investigations.
   Results. Preliminary evidence suggests that natural menopause is associated with reduced energy expenditure during rest and physical activity, an accelerated loss of fat-free mass, and increased central adiposity and fasting insulin levels. Hormone replacement therapy has been shown to attenuate these changes. Longitudinal and longer intervention studies are needed to confirm these initial findings.
   Conclusions. Menopause transition may represent a risky period in a woman's life, 'triggering' adverse metabolic and cardiovascular processes that predispose women to a greater incidence of obesity-related comorbidities. Dietary, exercise, and hormonal interventions specifically targeted at premenopausal women may help mitigate the worsening cardiovascular and metabolic risk profile associated with menopause.
C1 Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
RP Poehlman, ET (reprint author), Univ Vermont, Coll Med, Dept Med, Given B-215, Burlington, VT 05405 USA.
EM Epoehlma@uvm.edu
FU NIA NIH HHS [AG-13978]
CR ALOIA JF, 1995, AM J OBSTET GYNECOL, V172, P896, DOI 10.1016/0002-9378(95)90018-7
   ALOIA JF, 1991, AM J CLIN NUTR, V53, P1378
   Barrett-Connor E, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P6
   BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673
   CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396
   CALLESESCANDON J, 1995, J APPL PHYSIOL, V78, P266
   CallesEscandon J, 1997, AGING-CLIN EXP RES, V9, P57, DOI 10.1007/BF03340128
   Carpenter WH, 1998, AM J PHYSIOL-ENDOC M, V274, pE96, DOI 10.1152/ajpendo.1998.274.1.E96
   COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801
   DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095
   DENTONKELAAR I, 1989, INT J OBESITY, V13, P817
   Despres Jean-Pierre, 1993, Nutrition Research Reviews, V6, P137, DOI 10.1079/NRR19930010
   DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497
   ENZI G, 1986, AM J CLIN NUTR, V44, P739
   Espeland MA, 1997, J CLIN ENDOCR METAB, V82, P1549, DOI 10.1210/jc.82.5.1549
   FLATT JP, 1987, AM J CLIN NUTR, V45, P296, DOI 10.1093/ajcn/45.1.296
   FORBES GB, 1987, HUMAN BODY COMPOSITI
   Gambacciani M, 1997, J CLIN ENDOCR METAB, V82, P414, DOI 10.1210/jc.82.2.414
   GODSLAND IF, 1993, METABOLISM, V42, P846, DOI 10.1016/0026-0495(93)90058-V
   GORDON T, 1978, ANN INTERN MED, V89, P57
   GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W
   HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2
   HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228
   KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4
   KAPLAN NM, 1989, ARCH INTERN MED, V149, P14
   Kaseta JR, 1999, J CLIN ENDOCR METAB, V84, P1835, DOI 10.1210/jc.84.6.1835
   KOHIRT WM, 1993, DIABETES, V42, P273
   Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506
   KRITZSILVERSTEI.D, JAMA, P46
   KVIST H, 1986, INT J OBESITY, V10, P53
   Lemieux S, 1996, AM J CLIN NUTR, V64, P685
   LEY W, 1992, AM J CLIN NUTR, V55, P95
   LINDBERG UB, 1990, HORM METAB RES, V22, P1
   LINDHEIM SR, 1993, FERTIL STERIL, V60, P664
   LOBO RA, 1994, FERTIL STERIL, V61, P592
   MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004
   NATHAN DM, 1986, AM J MED, V81, P837, DOI 10.1016/0002-9343(86)90355-4
   NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P1832, DOI 10.1016/S0002-9378(89)80003-1
   NOTELOVITZ M, 1986, PUBLIC HLTH REP S, P114
   OSULLIVAN AJ, 1995, J CLIN ENDOCR METAB, V80, P1783, DOI 10.1210/jc.80.6.1783
   PEIRIS A, 1987, ACTA MED SCAND, V723, P179
   POEHLMAN ET, 1994, J APPL PHYSIOL, V76, P2281
   POEHLMAN ET, 1993, AM J PHYSIOL, V264, pE450
   Poehlman ET, 1998, CORONARY ARTERY DIS, V9, P799, DOI 10.1097/00019501-199809120-00004
   Poehlman ET, 1997, EUR J CLIN INVEST, V27, P322, DOI 10.1046/j.1365-2362.1997.1160662.x
   POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005
   POEHLMAN ET, 1990, J CLIN ENDOCR METAB, V71, P1468, DOI 10.1210/jcem-71-6-1468
   POEHLMAN ET, 1994, METABOLISM, V43, P1401, DOI 10.1016/0026-0495(94)90035-3
   POEHLMAN ET, 1990, ANNU REV NUTR, V10, P255
   POEHLMAN ET, 1991, J GERONTOL, V46, P1354
   PROUDLER AJ, 1992, CLIN SCI, V83, P489, DOI 10.1042/cs0830489
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P457
   REBUFFESCRIVE M, 1986, METABOLISM, V35, P792, DOI 10.1016/0026-0495(86)90217-9
   REBUFFESCRIVE M, 1988, ACTA MED SCAND, V723, P143
   REUBINOFF BE, 1995, FERTIL STERIL, V64, P963, DOI 10.1016/S0015-0282(16)57910-2
   RUDMAN D, 1981, J CLIN INVEST, V67, P1361, DOI 10.1172/JCI110164
   SHIMOKATA H, 1989, INT J OBESITY, V13, P455
   Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617
   Starling RD, 1999, J APPL PHYSIOL, V86, P2090
   Tchernof A, 1998, CORONARY ARTERY DIS, V9, P503, DOI 10.1097/00019501-199809080-00006
   TOMAYSU NJ, 1999, J AM GERIATR SOC, V47, P710
   TONKELAAR I, 1990, INT J OBESITY, V14, P753
   *US BUR CENS, US POP EST AG SEX RA
   VENTURA S, 1994, MON VITAL STAT REP, V43, P11
   WHELAN EA, 1990, AM J EPIDEMIOL, V131, P625, DOI 10.1093/oxfordjournals.aje.a115546
   WICH BK, 1995, ENDOCRIN METAB CLIN, V24, P273, DOI 10.1016/S0889-8529(18)30042-2
   WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97
   Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67
   ZADOR G, 1997, ACTA OBSTET GYNECO S, P19
   ZURLO F, 1990, AM J PHYSIOL, V259, P650
NR 72
TC 83
Z9 85
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6349
EI 1600-0412
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PD JUL
PY 2002
VL 81
IS 7
BP 603
EP 611
DI 10.1034/j.1600-0412.2002.810705.x
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 574TM
UT WOS:000176905700005
PM 12190834
DA 2018-12-27
ER

PT J
AU Ilia, M
   Beasley, C
   Meijer, D
   Kerwin, R
   Cotter, D
   Everall, I
   Price, J
AF Ilia, M
   Beasley, C
   Meijer, D
   Kerwin, R
   Cotter, D
   Everall, I
   Price, J
TI RETRACTED: Expression of Oct-6, a POUIII domain transcription factor, in
   schizophrenia (Retracted Article. See vol 163, pg 1454, 2006)
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article; Retracted Publication
ID SCHWANN-CELL DIFFERENTIATION; CORTICAL DEVELOPMENT; FACTOR SCIP; GENE;
   NEUROPATHOLOGY; DISTURBANCES; TST-1/OCT6; ACTIVATION; ENHANCER; BRAIN
AB Objective: Oct-6, a POU-III domain transcription factor, is expressed in embryonic stem cells and Schwann cells and in neuronal subpopulations during early mammalian development, but its relevance to disorders of cerebral development in humans is untested, This study evaluated the expression of Oct-6 in schizophrenia, a disorder that has been linked with neurodevelopmental abnormalities.
   Method: Immunohistochemistry was used to examine Oct-6 expression in the temporal lobe in postmortem tissue from 10 subjects with schizophrenia and 10 matched comparison subjects. Western blot analysis was used to study Oct-6 expression in the frontal and temporal cortex in tissue from an additional three schizophrenic and three matched comparison subjects and in the frontal lobe only in tissue from an additional 10 schizophrenic and 10 matched comparison subjects.
   Results: Extensive Oct-6 immunoreactivity was present in the temporal lobe in all 10 schizophrenic subjects, while very little or no expression was found in the comparison subjects. in schizophrenic subjects, Oct-6 immunoreactivity was found in a subset of cells in the pyramidal cell layer of the hippocampus and in the granule cell layer of the dentate gyrus. Oct-6 staining was predominantly localized in the cytoplasm. Western blot analysis confirmed the presence of Oct-6 in the frontal and temporal cortex in schizophrenic subjects but not in comparison subjects.
   Conclusions: The presence of Oct-6 expression in the schizophrenic subjects but not in the comparison subjects suggests that Oct-6 may provide a marker for the neuropathology associated with schizophrenia. Further, it may provide a clue to the neurodevelopmental basis of the disease and could be a reliable means to examine the developmental brain abnormalities described in this disorder.
C1 Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England.
   Kings Coll London, Inst Psychiat, Dept Psychol Med & Neuropathol, London SE5 8AF, England.
   Kings Coll London, Inst Psychiat, Dept Clin Neuropharmacol, London SE5 8AF, England.
   Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands.
RP Price, J (reprint author), Kings Coll London, Inst Psychiat, Dept Neurosci, 1 Windsor Walk,Denmark Hill, London SE5 8AF, England.
EM j.price@iop.kcl.ac.uk
RI cotter, david/D-8249-2012
OI Everall, Ian/0000-0003-3957-3861; Price, Jack/0000-0003-2235-9180;
   Beasley, Clare/0000-0001-5919-7838
CR Akbarian S, 1996, ARCH GEN PSYCHIAT, V53, P425
   AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P169
   ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207
   Arnold SE, 1996, ACTA NEUROPATHOL, V92, P217, DOI 10.1007/s004010050512
   Arroyo EJ, 1998, J NEUROSCI, V18, P7891
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Beasley C, 2001, NEUROSCI LETT, V302, P117, DOI 10.1016/S0304-3940(01)01688-3
   Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751
   BHAT KM, 1994, DEVELOPMENT, V120, P1483
   Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024
   Cotter D, 2000, SCHIZOPHR RES, V41, P313, DOI 10.1016/S0920-9964(99)00068-7
   FRANTZ GD, 1994, J NEUROSCI, V14, P472
   Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593
   Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507
   JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090
   LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4
   Liu Q, 1999, J NEUROSCI, V19, P9747
   Mandemakers W, 2000, EMBO J, V19, P2992, DOI 10.1093/emboj/19.12.2992
   MAYADA A, 2000, NEUROPATHOLOGY SCHIZ, P189
   MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357
   MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954
   MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X
   MURRAY RM, 1992, SCHIZOPHRENIA BULL, V18, P319, DOI 10.1093/schbul/18.2.319
   Pearlson GD, 1999, BIOL PSYCHIAT, V46, P627, DOI 10.1016/S0006-3223(99)00071-2
   PEEPER DS, 1995, CELL GROWTH DIFFER, V6, P977
   Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552
   ROBERTS GW, 1987, BIOL PSYCHIAT, V22, P1459, DOI 10.1016/0006-3223(87)90104-1
   RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P
   Sambrook J, 2001, MOL CLONING LAB MANU
   SCHERER SS, 1994, J NEUROSCI, V14, P1930
   Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512
   SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x
   TOBLER A, 1993, NUCLEIC ACIDS RES, V21, P1043, DOI 10.1093/nar/21.4.1043
   Witta SE, 1997, DEVELOPMENT, V124, P1179
   XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0
   YANG XD, 1994, J BIOL CHEM, V269, P10252
   Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052
NR 37
TC 18
Z9 19
U1 2
U2 11
PU AMER PSYCHIATRIC PUBLISHING, INC
PI WASHINGTON
PA 800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD JUL
PY 2002
VL 159
IS 7
BP 1174
EP 1182
DI 10.1176/appi.ajp.159.7.1174
PG 9
WC Psychiatry
SC Psychiatry
GA 570UE
UT WOS:000176676000015
PM 12091196
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: The dose-related efficacy of diltiazem for enhancing
   diaphragmatic fatigability in dogs (Retracted article. See vol. 116, pg.
   746, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID CANINE DIAPHRAGM; MUSCLE FATIGUE; BLOOD-FLOW; CONTRACTILITY; ACIDOSIS
AB Nicardipine, a calcium channel blockade, enhances the production of diaphragmatic fatigue. We studied the dose-related effects of diltiazem, another calcium channel blockade, on diaphragmatic fatigability in dogs. Animals were divided into three groups of eight each. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min. During this fatigue-producing period, Group I received no study drug, Group II was infused with diltiazem 0.1 mg (.) kg(-1) (.) h(-1), and Group III was infused with diltiazem 0.5 mg (.) kg(-1) (.) h(-1). We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). After the fatigue-producing period, in Group 1, Pdi at low-frequency (20-Hz) stimulation decreased from baseline values (P < 0.05), whereas there was no change in Pdi at high-frequency (100-Hz) stimulation. In Groups H and III, with an infusion of diltiazem, Pdi at both stimuli decreased from baseline values (P < 0.05). The decrease in Pdi to each stimulus was more in Group III than in Group II (P < 0.05). We conclude that diltiazem causes a dose-related augmentation of fatigability in the diaphragm of dogs.
C1 Univ Tsukuba, Dept Anesthesiol, Inst Clin Med, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Dept Anesthesiol, Inst Clin Med, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   CLERGUE F, 1986, ANESTHESIOLOGY, V64, P181, DOI 10.1097/00000542-198602000-00009
   COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   FUJII Y, 1994, CAN J ANAESTH, V41, P435, DOI 10.1007/BF03009869
   GRASSINO A, 1987, J APPL PHYSIOL, V44, P829
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   LAWSON NW, 1996, CLIN ANESTH, P243
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Moxham J, 1981, Ciba Found Symp, V82, P197
   REID MB, 1983, J APPL PHYSIOL, V54, P763
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 18
TC 2
Z9 2
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUL
PY 2002
VL 95
IS 1
BP 129
EP 132
AR UNSP 0003-2999/02
DI 10.1213/01.ANE.0000019063.79800.73
PG 4
WC Anesthesiology
SC Anesthesiology
GA 569ZV
UT WOS:000176634100023
PM 12088956
DA 2018-12-27
ER

PT J
AU Sato, Y
   Honda, Y
   Kaji, M
   Asoh, T
   Hosokawa, K
   Kondo, I
   Satoh, K
AF Sato, Y
   Honda, Y
   Kaji, M
   Asoh, T
   Hosokawa, K
   Kondo, I
   Satoh, K
TI RETRACTED: Amelioration of osteoporosis by menatetrenone in elderly
   female Parkinson's disease patients with vitamin D deficiency (Retracted
   article. See vol. 106, pg. 212, 2018)
SO BONE
LA English
DT Article; Retracted Publication
DE fracture; immobilization; menatetrenone (MK-4); osteoporosis;
   Parkinson's disease (PD)
ID BONE-MINERAL DENSITY; CIRCULATING LEVELS; HIP FRACTURE; WOMEN;
   IMMOBILIZATION; MASS; METABOLISM; CALCIUM; STROKE; FALLS
AB Significant reduction in bone mineral density (BMD) occurs in patients with Parkinson's disease (PD), correlating with immobilization and with vitamin D deficiency, and increasing the risk of hip fracture, especially in elderly women. As a biological indicator of compromised vitamin K status, an increased serum concentration of undercarboxylated osteocalcin (Oc) has been associated with reduced BMD in the hip and an increased risk of fracture in otherwise healthy elderly women. We evaluated treatment with vitamin K-2 (menatetrenone; MK-4) in maintaining BMD and reducing the incidence of nonvertebral fractures in elderly female patients with PD. In a random and prospective study of PD patients, 60 received 45 mg of MK-4 daily for 12 months, and the remaining 60 (untreated group) did not. At baseline, patients of both groups showed vitamin D and K, deficiencies, high serum levels of ionized calcium, and glutaminic residue (Glu) Oc, and low levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25-(OH)(2)D], indicating that immobilization-induced hypercalcemia inhibits renal synthesis of 1,25-(OH)(2)D and compensatory PTH secretion. BMD in the second metacarpals increased by 0.9% in the treated group and decreased by 4.3% in the untreated group (p < 0.0001). Vitamin K-2 level increased by 259.8% in the treated group. Correspondingly, significant decreases in Gin Oc and calcium were observed in the treated group, in association with an increase in both PTH and 1,25-(OH)(2)D. Ten patients sustained fractures (eight at the hip and two at other sites) in the untreated group, and one hip fracture occurred among treated patients (p = 0.0082; odds ratio = 11.5). The treatment with MK-4 can increase the BMD of vitamin D- and K-deficient bone by increasing vitamin K concentration, and it can also decrease calcium levels through inhibition of bone resorption, resulting in an increase in 1,25-(OH)(2)D concentration.
C1 Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 0368562, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 0368562, Japan.
   Ohshima Hosp, Dept Neurol, Kita Shigeyasu, Japan.
   Kurume Univ, Med Ctr, Dept Neurol, Kurume, Fukuoka 830, Japan.
   Futase Social Insurance Hosp, Dept Internal Med, Iizuka, Fukuoka, Japan.
RP Sato, Y (reprint author), Hirosaki Univ, Sch Med, Dept Rehabil Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.
EM noukenrs@cc.hirosaki-u.ac.jp
CR AITA JF, 1982, JAMA-J AM MED ASSOC, V247, P515, DOI 10.1001/jama.247.4.515
   BITENSKY L, 1988, J BONE JOINT SURG BR, V70, P663
   CHIU KY, 1992, J TRAUMA, V32, P584, DOI 10.1097/00005373-199205000-00008
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   EVENTOV I, 1983, J TRAUMA, V23, P98, DOI 10.1097/00005373-198302000-00004
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268
   HODGES SJ, 1993, J BONE MINER RES, V8, P1241
   HODGES SJ, 1991, BONE, V12, P387, DOI 10.1016/8756-3282(91)90027-G
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   JOHNELL O, 1992, AGE AGEING, V21, P32, DOI 10.1093/ageing/21.1.32
   KAO CH, 1994, NUCL MED COMMUN, V15, P173, DOI 10.1097/00006231-199403000-00010
   KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P98
   LANGENBERG JP, 1984, J CHROMATOGR, V289, P377, DOI 10.1016/S0021-9673(00)95103-3
   Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003-9993(99)90050-3
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   Mawatari T, 2000, J BONE MINER RES, V15, P1810, DOI 10.1359/jbmr.2000.15.9.1810
   MEYTHALER JM, 1993, ARCH PHYS MED REHAB, V74, P316
   ORIMO H, 1992, J BONE MINER RES, V7, pS122
   Orimo H, 1998, J BONE MINER METAB, V16, P106, DOI 10.1007/s007740050034
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 1997, NEUROLOGY, V49, P1273, DOI 10.1212/WNL.49.5.1273
   Sato Y, 1999, AGE AGEING, V28, P265, DOI 10.1093/ageing/28.3.265
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   SZUIC P, 1993, J CLIN INVEST, V91, P1769
   SZULC P, 1994, J BONE MINER RES, V9, P1591
   TAGGART H, 1995, AGE AGEING, V24, P326, DOI 10.1093/ageing/24.4.326
   Vergnaud P, 1997, J CLIN ENDOCR METAB, V82, P719, DOI 10.1210/jc.82.3.719
   VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1
NR 31
TC 54
Z9 56
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD JUL
PY 2002
VL 31
IS 1
BP 114
EP 118
AR PII S8756-3282(02)00783-4
DI 10.1016/S8756-3282(02)00783-4
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 576ZA
UT WOS:000177036000020
PM 12110423
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Double-blind, placebo-controlled, dose-ranging study of
   ramosetron for the prevention of nausea and vomiting after thyroidectomy
   (Retracted article. See vol. 40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE nausea; vomiting; antiemetics; ramosetron; thyroidectomy
AB Background: Patients receiving general anesthesia during thyroidectomy have a high risk for postoperative nausea and vomiting.
   Objective: This prospective, randomized, double-blind, placebo-controlled, dose-ranging study was undertaken to assess the efficacy and safety of ramosetron, a selective 5-hydroxytryptamine type 3-receptor antagonist, in preventing nausea and vomiting after thyroidectomy.
   Methods: Standard general anesthetic technique and postoperative analgesia were employed. Patients undergoing thyroidectomy were randomized to receive IV ramosetron 0.15, 0.3, or 0.6 mg or placebo at completion of the procedure. During the first 48 hours after anesthesia, episodes of emesis and adverse events were assessed by nursing staff who were blinded to patients' treatment assignment.
   Results: Eighty patients (22 men, 58 women; age range, 28-63 years; weight range, 37-91 kg) were enrolled in the study. There were no differences in demographic characteristics between treatment groups. The numbers of patients who were emesis free (no nausea, retching, or vomiting) 0 to 24 hours after anesthesia were 10 of 20 (50%) with ramosetron 0.15 mg, 17 of 20 (85%) with ramosetron 0.3 mg, 18 of 20 (90%) with ramosetron 0.6 mg, and 8 of 20 (40%) with placebo. The corresponding numbers 24 to 48 hours after anesthesia were 11 of 20 (55%), 18 of 20 (90%), 18 of 20 (90%), and 9 of 20 (45%). At both time points, only the values for ramosetron 0.3 and 0.6 mg were statistically significant versus placebo (P less than or equal to 0.001). No clinically serious adverse events were observed in any group.
   Conclusions: In this population of patients receiving general anesthesia while undergoing thyroidectomy, ramosetron 0.3 mg was effective in preventing postoperative nausea and vomiting 0 to 48 hours after anesthesia. Increasing the dose to 0.6 mg provided no demonstrable benefit.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR DEJONCKHEERE M, 1990, EUR J ANAESTH, V7, P421
   Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463
   FLEISHER LA, 1996, CLIN ANESTH, P443
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1998, BRIT J ANAESTH, V81, P526, DOI 10.1093/bja/81.4.526
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 11
TC 16
Z9 16
U1 1
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD JUL
PY 2002
VL 24
IS 7
BP 1148
EP 1153
DI 10.1016/S0149-2918(02)80025-X
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 581MQ
UT WOS:000177296500010
PM 12182258
DA 2018-12-27
ER

PT J
AU Lund, I
   Yu, LC
   Uvnas-Moberg, K
   Wang, J
   Yu, C
   Kurosawa, M
   Agren, G
   Rosen, A
   Lekman, M
   Lundeberg, T
AF Lund, I
   Yu, LC
   Uvnas-Moberg, K
   Wang, J
   Yu, C
   Kurosawa, M
   Agren, G
   Rosen, A
   Lekman, M
   Lundeberg, T
TI RETRACTED: Repeated massage-like stimulation induces long-term effects
   on nociception: contribution of oxytocinergic mechanisms (Retracted
   article. See vol. 29, pg. 868, 2009)
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE hot-plate; massage; oxytocin; PAG; Randall Selitto; RIA; sensory
   stimulation; stroking; withdrawal latencies
ID INDUCED ANALGESIA; SENSORY STIMULATION; ANESTHETIZED RATS; SPINAL-CORD;
   BRAIN-STEM; PAIN; INCREASES; LATENCY; SYSTEM; ACUPUNCTURE
AB Massage-like stroking induces acute antinociceptive effects that can be reversed by an oxytocin antagonist, indicating activation of oxytocin on endogenous pain controlling systems. We now demonstrate an increase in hindpaw withdrawal latencies (HWLs), in response to thermal and mechanical stimuli, which was present after six treatments of massage-like stroking every other day and which continued to increase through the remaining seven treatments. Repeated massage-like stroking also resulted in increased oxytocin-like immunoreactivity (oxytocin-LI) levels in plasma and periaquaductal grey matter (PAG). Furthermore, increases in HWLs were also present after injections of oxytocin into the PAG (0.1, 0.5 and 1.0 nmol). Intra-PAG oxytocin injection of 1 nmol followed by 1 or 20 nmol of naloxone attenuated the increments in HWL. Also, there was a dose-dependent attenuation of the oxytocin-induced antinociceptive effects following intra-PAG injection of the mu-opioid antagonist beta-funaltrexamine (beta-FNA) and the kappa-opioid antagonist nor-binaltorphimine (nor-BNI) but not the delta-antagonist naltrindole. The long-term antinociceptive effects of massage-like stroking may be attributed, at least partly, to the oxytocinergic system and its interaction with the opioid system, especially the mu- and the kappa-receptors in the PAG.
C1 Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
   Peking Univ, Coll Life Sci, Dept Physiol, Beijing 100871, Peoples R China.
   Peking Univ, Natl Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China.
   Swedish Univ Agr Sci, Dept Anim Physiol, SE-75661 Uppsala, Sweden.
   Int Univ Hlth & Welf, Sch Hlth Sci, Dept Physiol, Otawara, Tochigi 3248501, Japan.
   Karolinska Hosp, Dept Rehabil Med, SE-17176 Stockholm, Sweden.
RP Lund, I (reprint author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
EM irene.lund@fyfa.ki.se
CR AGREN G, 1995, NEUROSCI LETT, V187, P49, DOI 10.1016/0304-3940(95)11335-T
   Agren G, 1997, NEUROREPORT, V8, P3073, DOI 10.1097/00001756-199709290-00013
   AMIR S, 1978, LIFE SCI, V23, P1143, DOI 10.1016/0024-3205(78)90348-X
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   ARLETTI R, 1993, NEUROPEPTIDES, V24, P125, DOI 10.1016/0143-4179(93)90075-L
   BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521
   BEHBEHANI MM, 1995, PROG NEUROBIOL, V46, P575, DOI 10.1016/0301-0082(95)00009-K
   BRODIN E, 1994, NEUROPEPTIDES, V26, P253, DOI 10.1016/0143-4179(94)90079-5
   Bucinskaite V, 1996, EUR J NEUROSCI, V8, P382, DOI 10.1111/j.1460-9568.1996.tb01221.x
   Cawley N, 1997, Eur J Cancer Care (Engl), V6, P23, DOI 10.1111/j.1365-2354.1997.tb00265.x
   DE KONINCK Y, 1992, NEUROSCIENCE, V50, P435
   DeKock M, 1997, PHARMACOL BIOCHEM BE, V58, P109, DOI 10.1016/S0091-3057(96)00462-5
   Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270
   Fields H. L., 1994, TXB PAIN, P243
   Fuchs PN, 1996, EXP NEUROL, V139, P299, DOI 10.1006/exnr.1996.0103
   FURLAN AD, 2001, COCHRANE LIB
   HALDEMAN S, 1999, TXB PAIN, P1251
   HANSSON P, 1999, TXB PAIN, P951
   Harris JA, 1996, J PHYSIOL-PARIS, V90, P15, DOI 10.1016/0928-4257(96)87165-8
   JORGENSEN HA, 1984, PHARMACOL BIOCHEM BE, V20, P289, DOI 10.1016/0091-3057(84)90256-9
   KAMENETZ HL, 1985, MANIPULATION TRACTIO, P211
   KANETAKE C, 1982, JPN J BACTERIOL, V37, P943
   KUROSAWA M, 1995, J AUTONOM NERV SYST, V56, P26, DOI 10.1016/0165-1838(95)00056-7
   Louvel D, 1996, GUT, V39, P741, DOI 10.1136/gut.39.5.741
   LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
   LUNDEBERG T, 1988, SCAND J REHABIL MED, V20, P149
   LUNDEBERG T, 1993, BRAIN RES, V608, P181, DOI 10.1016/0006-8993(93)91456-3
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3
   Paxinos G, 1986, RAT BRAIN STEREOTAXI, V2
   Petersson M, 1996, NEUROSCI LETT, V212, P87, DOI 10.1016/0304-3940(96)12773-7
   Plone MA, 1996, PAIN, V66, P265, DOI 10.1016/0304-3959(96)03048-5
   Sandkuhler J, 2000, PROG PAIN RES MANAG, V16, P359
   SOFRONIEW MV, 1983, TRENDS NEUROSCI, V6, P467, DOI 10.1016/0166-2236(83)90221-7
   STOCK S, 1988, ACTA PHYSIOL SCAND, V132, P29, DOI 10.1111/j.1748-1716.1988.tb08294.x
   UVNASMOBERG K, 1992, ACTA PHYSIOL SCAND, V144, P487, DOI 10.1111/j.1748-1716.1992.tb09327.x
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   Vallbo AB, 1999, J NEUROPHYSIOL, V81, P2753
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yu LC, 1996, NEUROSCIENCE, V71, P523, DOI 10.1016/0306-4522(95)00428-9
   Yu LC, 1996, BRIT J PHARMACOL, V117, P43, DOI 10.1111/j.1476-5381.1996.tb15152.x
NR 43
TC 109
Z9 109
U1 4
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD JUL
PY 2002
VL 16
IS 2
BP 330
EP 338
DI 10.1046/j.1460-9568.2002.02087.x
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 582RB
UT WOS:000177364000014
PM 12169113
DA 2018-12-27
ER

PT J
AU Pfeffer, S
   Dunoyer, P
   Heim, F
   Richards, KE
   Jonard, G
   Ziegler-Graff, V
AF Pfeffer, S
   Dunoyer, P
   Heim, F
   Richards, KE
   Jonard, G
   Ziegler-Graff, V
TI RETRACTED: P0 of beet western yellows virus is a suppressor of
   posttranscriptional gene silencing(Retracted article. See vol. 91,2017)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID POTATO LEAFROLL VIRUS; DOUBLE-STRANDED-RNA; NICOTIANA-BENTHAMIANA; APHID
   TRANSMISSION; VIRAL SUPPRESSOR; SILENCING SIGNAL; CAPSID PROTEIN;
   PLANT-VIRUSES; ANTISENSE RNA; LUTEOVIRUS
AB Higher plants employ a homology-dependent RNA-degradation system known as posttranscriptional gene silencing (PTGS) as a defense against virus infection. Several plant viruses are known to encode proteins that can suppress PTGS. Here we show that P0 of beet western yellows virus (BWYV) displays strong silencing suppressor activity in a transient expression assay based upon its ability to inhibit PTGS of green fluorescent protein (GFP) when expressed in agro-infiltrated leaves of Nicotiana benthamiana containing a GFP transgene. PTGS suppressor activity was also observed for the P0s of two other poleroviruses, cucurbit aphid-borne yellows virus and potato leafroll virus. P0 is encoded by the 5'-proximal gene in BWYV RNA but does not accumulate to detectable levels when expressed from the genome-length RNA during infection. The low accumulation of P0 and the resulting low PTGS suppressor activity are in part a consequence of the suboptimal translation initiation context of the P0 start codon in viral RNA, although other factors, probably related to the viral replication process, also play a role. A mutation to optimize the P0 translation initiation efficiency in BWYV RNA was not stable during virus multiplication in planta. Instead, the P0 initiation codon in the progeny was frequently replaced by a less efficient initiation codon such as ACG, GTG, or ATA, indicating that there is selection against overexpression of P0 from the viral genome.
C1 CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.
   Univ Strasbourg, F-67084 Strasbourg, France.
RP Ziegler-Graff, V (reprint author), CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.
EM veronique.ziegier-graff@ibmp-ulp.u-strasbg.fr
RI Pfeffer, Sebastien/A-6512-2010
OI Pfeffer, Sebastien/0000-0002-8458-348X
CR Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079
   BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x
   Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457
   Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102
   BRAULT V, 1995, EMBO J, V14, P650, DOI 10.1002/j.1460-2075.1995.tb07043.x
   Brault V, 2000, J VIROL, V74, P1140, DOI 10.1128/JVI.74.3.1140-1148.2000
   Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739
   Carrington JC, 2001, VIROLOGY, V281, P1, DOI 10.1006/viro.2000.0812
   Dalmay T, 2000, PLANT CELL, V12, P369, DOI 10.1105/tpc.12.3.369
   GORDON K, 1992, PLANT J, V2, P809
   Guo HS, 2002, EMBO J, V21, P398, DOI 10.1093/emboj/21.3.398
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Johansen LK, 2001, PLANT PHYSIOL, V126, P930, DOI 10.1104/pp.126.3.930
   Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1
   Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LECOQ H, 1992, PLANT PATHOL, V41, P749, DOI 10.1111/j.1365-3059.1992.tb02559.x
   LEISER RM, 1992, P NATL ACAD SCI USA, V89, P9136, DOI 10.1073/pnas.89.19.9136
   Li HW, 1999, EMBO J, V18, P2683, DOI 10.1093/emboj/18.10.2683
   Li WX, 2001, CURR OPIN BIOTECH, V12, P150, DOI 10.1016/S0958-1669(00)00190-7
   Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397
   Mallory AC, 2001, PLANT CELL, V13, P571, DOI 10.1105/tpc.13.3.571
   Mayo M. A., 1999, LUTEOVIRIDAE, P23
   MAYO MA, 1982, J GEN VIROL, V59, P163, DOI 10.1099/0022-1317-59-1-163
   Mayo MA, 1996, ADV VIRUS RES, V46, P413, DOI 10.1016/S0065-3527(08)60077-9
   NIESBACHKLOSGEN U, 1990, VIROLOGY, V178, P52, DOI 10.1016/0042-6822(90)90378-5
   Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738
   PALUKAITIS P, 1983, VIROLOGY, V131, P533, DOI 10.1016/0042-6822(83)90518-4
   PRUFER D, 1995, VIROLOGY, V214, P150, DOI 10.1006/viro.1995.9945
   Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859
   Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777
   Sadowy E, 2001, J GEN VIROL, V82, P1529, DOI 10.1099/0022-1317-82-6-1529
   Sijen T, 2000, BIOESSAYS, V22, P520, DOI 10.1002/(SICI)1521-1878(200006)22:6<520::AID-BIES5>3.0.CO;2-W
   vanderWilk F, 1997, MOL PLANT MICROBE IN, V10, P153, DOI 10.1094/MPMI.1997.10.2.153
   vanderWilk F, 1997, VIROLOGY, V234, P300, DOI 10.1006/viro.1997.8654
   VEIDT I, 1992, VIROLOGY, V186, P192, DOI 10.1016/0042-6822(92)90073-X
   Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147
   Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8
   Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215
   Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3
   Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7
   Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168
   Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   ZieglerGraff V, 1996, MOL PLANT MICROBE IN, V9, P501, DOI 10.1094/MPMI-9-0501
NR 47
TC 152
Z9 165
U1 4
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2002
VL 76
IS 13
BP 6815
EP 6824
DI 10.1128/JVI.76.13.6815-6824.2002
PG 10
WC Virology
SC Virology
GA 564BF
UT WOS:000176293600042
PM 12050394
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU He, J
   Xi, XM
   Chan, MS
   Hu, CM
   Li, YX
   Xing, Z
   Huang, R
AF He, J
   Xi, XM
   Chan, MS
   Hu, CM
   Li, YX
   Xing, Z
   Huang, R
TI RETRACTED: Linearly graded doping drift region: a novel lateral
   voltage-sustaining layer used for improvement of RESURF LDMOS transistor
   performances (Retracted article. See vol. 25, artn. 119801, 2010)
SO SEMICONDUCTOR SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
ID JUNCTION TERMINATION; BREAKDOWN VOLTAGE; DEVICES; OPTIMIZATION;
   EXTENSION; MOSFETS; MODEL
AB A linearly graded doping drift region structure, a novel lateral voltage-sustained layer used for improvement of reduced surface field (RESURF) LDMOS transistor performance has been evaluated theoretically, numerically and experimentally in this paper for the first time. Due to the coupling effect of the two-dimensional (2D) electrical field, it is found from the theory developed here that the linearly graded drift region-doped profile can provide a high breakdown voltage while maintaining a high doping dose in the total drift region for minimizing the on-resistance R(on). The characteristics of such an LDMOS have been demonstrated by the 2D semiconductor device simulator MEDICI and further verified by our experimental results. We have obtained a reduction of the on-resistance of 50% from 10.3 mOmega cm(2) to 5 mOmega cm(2) in the on-state, and an increase of the breakdown voltage by a factor of 2.5 from 90 V to 234 V in the off-state, compared to the values for conventional RESURF devices. The experimental results verify the performance improvement predicted by the simulation and theory.
C1 Peking Univ, Inst Microelect, Beijing 100871, Peoples R China.
   Univ Calif Berkeley, Elect Res Lab Elect Engn, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Comp Sci, Berkeley, CA 94720 USA.
RP He, J (reprint author), Peking Univ, Inst Microelect, Beijing 100871, Peoples R China.
EM jinhe@fermi.eecs.berkeley.edu
CR AKIO N, 1991, IEEE T ELECTRON DEV, V38, P1650
   Apples J, 1979, IEDM, P238
   Chen SS, 1996, IEEE T ELECTRON DEV, V43, P1387, DOI 10.1109/16.535323
   CHEN XB, 1987, IEEE T ELECTRON DEV, V34, P2344, DOI 10.1109/T-ED.1987.23242
   Chen XB, 1996, INT J ELECTRON, V80, P449, DOI 10.1080/002072196137291
   COLAK S, 1981, IEEE T ELECTRON DEV, V28, P1455, DOI 10.1109/T-ED.1981.20630
   FULOP W, 1967, SOLID STATE ELECTRON, V10, P39, DOI 10.1016/0038-1101(67)90111-6
   Lai T. M. L., 1995, Proceedings of the 7th International Symposium on Power Semiconductor Devices and ICs, ISPSD '95 (IEEE Cat. No.95CH35785), P315, DOI 10.1109/ISPSD.1995.515056
   MENA JG, 1986, SOLID STATE ELECT, V29, P645
   Merchant S, 1999, IEEE T ELECTRON DEV, V46, P1264, DOI 10.1109/16.766896
   MERCHANT S, 1991, PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON POWER SEMICONDUCTOR DEVICES AND ICS, P31, DOI 10.1109/ISPSD.1991.146060
   Merchant S., 1993, Proceedings of the 5th International Symposium on Power Semiconductor Devices and ICs ISPSD '93 (Cat. No.93CH3314-2), P124, DOI 10.1109/ISPSD.1993.297121
   Niu GF, 1996, IEEE T ELECTRON DEV, V43, P2034, DOI 10.1109/16.543048
   PARPIA Z, 1990, IEEE T ELECTRON DEV, V37, P789, DOI 10.1109/16.47787
   SCHULZE HJ, 1989, SOLID STATE ELECTRON, V32, P175, DOI 10.1016/0038-1101(89)90186-X
   Stengl R., 1985, International Electron Devices Meeting. Technical Digest (Cat. No. 85CH2252-5), P154
   SZE SM, 1966, SOLID STATE ELECTRON, V9, P831, DOI 10.1016/0038-1101(66)90033-5
   TANTRAPORN W, 1987, IEEE T ELECTRON DEV, V34, P2200, DOI 10.1109/T-ED.1987.23217
   WILDI EJ, 1982, IEDM TECH DIG, P238
   Zhang SD, 1999, IEEE T ELECTRON DEV, V46, P1036, DOI 10.1109/16.760414
NR 20
TC 15
Z9 16
U1 6
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0268-1242
J9 SEMICOND SCI TECH
JI Semicond. Sci. Technol.
PD JUL
PY 2002
VL 17
IS 7
BP 721
EP 728
AR PII S0268-1242(02)33584-3
DI 10.1088/0268-1242/17/7/315
PG 8
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Condensed Matter
SC Engineering; Materials Science; Physics
GA 578AH
UT WOS:000177094900018
DA 2018-12-27
ER

PT J
AU Koutkia, P
   Mylonakis, E
   Levin, RM
AF Koutkia, P
   Mylonakis, E
   Levin, RM
TI RETRACTED: Human immunodeficiency virus infection and the thyroid
   (Retracted Article. See vol 16, pg 99, 2006)
SO THYROID
LA English
DT Review; Retracted Publication
ID PNEUMOCYSTIS-CARINII INFECTION; IMMUNE-DEFICIENCY-SYNDROME;
   FINE-NEEDLE-ASPIRATION; OF-THE-LITERATURE; HIV-INFECTION; HYPOTHYROID
   PATIENT; INTERFERON-ALPHA; KAPOSIS-SARCOMA; SYNDROME AIDS; ENDOCRINE
AB Abnormalities of thyroid function are associated with a number of systemic conditions, including patients infected with human immunodeficiency virus (HIV). Most patients with early HIV infection and a stable body weight have normal thyroid function. Subtle abnormalities of a number of thyroid function tests have been reported during the early asymptomatic phase of HIV disease. These include an inappropriately normal triiodothyronine (T-3) and reduced reverse triiodothyronine (rT(3)), and increased thyroxine-binding globulin (TBG) levels. Opportunistic infections involving the thyroid gland, neoplasms such as lymphoma and Kaposi's sarcoma, and medications can alter the thyroid function in individuals with more advanced HIV infection. If thyroid dysfunction is diagnosed in an HIV-infected patient, it should be treated in the usual manner. However, high index of suspicion and caution in the interpretation of thyroid function tests in patients with HIV disease are needed for optimal diagnosis and treatment.
C1 Boston Univ, Med Ctr, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA.
   Harvard Univ, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA.
RP Levin, RM (reprint author), Boston Univ, Med Ctr, Dept Med, Sect Endocrinol Diabet & Nutr, Dowling 5 N 818 Harrison Ave, Boston, MA 02118 USA.
EM elconnol@bmc.org
CR Basilio-De-Oliveira C A, 2000, Braz J Infect Dis, V4, P67
   BATTAN R, 1991, J CLIN ENDOCR METAB, V72, P724, DOI 10.1210/jcem-72-3-724
   Bourdoux P P, 1991, Thyroid, V1, P147, DOI 10.1089/thy.1991.1.147
   CONTEMPRE B, 1992, CLIN ENDOCRINOL, V36, P579, DOI 10.1111/j.1365-2265.1992.tb02268.x
   Danoff A, 1996, MED CLIN N AM, V80, P1453, DOI 10.1016/S0025-7125(05)70498-3
   DELMONTE P, 1995, HORM RES, V44, P105, DOI 10.1159/000184605
   DERRY DM, 1995, MED HYPOTHESES, V45, P121, DOI 10.1016/0306-9877(95)90058-6
   Dobs AS, 1996, J CLIN ENDOCR METAB, V81, P4108, DOI 10.1210/jc.81.11.4108
   DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1
   DRUCKER DJ, 1990, J CLIN ENDOCR METAB, V71, P1663, DOI 10.1210/jcem-71-6-1663
   ETZEL JV, 1992, CLIN PHARMACY, V11, P705
   FENTIMAN IS, 1985, LANCET, V1, P1166
   FRANK TS, 1987, YALE J BIOL MED, V60, P1
   FRIED JC, 1990, ARCH INTERN MED, V150, P406, DOI 10.1001/archinte.150.2.406
   GALLANT JE, 1988, AM J MED, V84, P303, DOI 10.1016/0002-9343(88)90429-9
   GOCHU J, 1994, J ENDOCRINOL INVEST, V17, P279, DOI 10.1007/BF03348976
   Golshan MM, 1997, SURGERY, V121, P593, DOI 10.1016/S0039-6060(97)90118-5
   GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360
   GRINSPOON SK, 1994, BAILLIERE CLIN ENDOC, V8, P735, DOI 10.1016/S0950-351X(05)80297-6
   GRUNFELD C, 1993, METABOLISM, V42, P1270, DOI 10.1016/0026-0495(93)90124-7
   GUTTLER R, 1993, ARCH INTERN MED, V153, P393, DOI 10.1001/archinte.153.3.393
   HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184
   Hofbauer LC, 1996, MEDICINE, V75, P262, DOI 10.1097/00005792-199609000-00003
   HOMMES MJT, 1993, METABOLISM, V42, P556, DOI 10.1016/0026-0495(93)90212-7
   ISLEY WL, 1987, ANN INTERN MED, V107, P517, DOI 10.7326/0003-4819-107-4-517
   KAW YT, 1994, ACTA CYTOL, V38, P427
   KITCHING NH, 1986, BRIT MED J, V293, P993, DOI 10.1136/bmj.293.6553.993-a
   KRAUTH PH, 1987, CLIN NUCL MED, V12, P848, DOI 10.1097/00003072-198711000-00004
   LAMBERT M, 1994, BAILLIERE CLIN ENDOC, V8, P825, DOI 10.1016/S0950-351X(05)80303-9
   LAMBERT M, 1990, AM J MED, V89, P748, DOI 10.1016/0002-9343(90)90216-Z
   LOPRESTI JS, 1989, ANN INTERN MED, V110, P970, DOI 10.7326/0003-4819-110-12-970
   MACHAC J, 1985, J NUCL MED ALLIED S, V29, P283
   Martin-Davila P, 1998, EUR J CLIN MICROBIOL, V17, P55, DOI 10.1007/BF01584367
   MARTINEZOCANA JC, 1993, CLIN INFECT DIS, V17, P953, DOI 10.1093/clinids/17.5.953
   MCCARTY M, 1992, CLIN RADIOL, V45, P209, DOI 10.1016/S0009-9260(05)80647-6
   MEIER CA, 2000, WERNER INGBARS THYRO, P265
   MERENICH JA, 1990, J CLIN ENDOCR METAB, V70, P566, DOI 10.1210/jcem-70-3-566
   MILLIGAN SA, 1984, AM J MED, V77, P760, DOI 10.1016/0002-9343(84)90381-4
   Mitteldorf CATS, 1999, ACTA CYTOL, V43, P862, DOI 10.1159/000331305
   MOLLISON LC, 1991, REV INFECT DIS, V13, P826
   Mylonakis E, 2001, CLIN INFECT DIS, V33, P857, DOI 10.1086/322695
   PATEL A, 1992, MED J AUSTRALIA, V156, P136
   RAFFI F, 1991, AIDS, V5, P729, DOI 10.1097/00002030-199106000-00013
   RAGNI MV, 1991, AM J CLIN PATHOL, V95, P489, DOI 10.1093/ajcp/95.4.489
   RicartEngel W, 1996, CLIN ENDOCRINOL, V44, P53, DOI 10.1046/j.1365-2265.1996.623445.x
   Roti E, 1996, AM J MED, V101, P482, DOI 10.1016/S0002-9343(96)00259-8
   Samuels MH, 1998, THYROID, V8, P673, DOI 10.1089/thy.1998.8.673
   SATO K, 1990, J CLIN ENDOCR METAB, V70, P1735, DOI 10.1210/jcem-70-6-1735
   Schurmeyer T H, 1997, Eur J Med Res, V2, P220
   Sellmeyer DE, 1996, ENDOCR REV, V17, P518, DOI 10.1210/er.17.5.518
   SPITZER RD, 1991, AM J MED SCI, V302, P98, DOI 10.1097/00000441-199108000-00005
   TANG WW, 1989, WESTERN J MED, V151, P627
   WALTS AE, 1991, DIAGN CYTOPATHOL, V7, P615, DOI 10.1002/dc.2840070613
   Yachnis AT, 1996, AM J CLIN PATHOL, V106, P535
NR 54
TC 9
Z9 8
U1 2
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD JUL
PY 2002
VL 12
IS 7
BP 577
EP 582
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 578YR
UT WOS:000177149100007
PM 12193301
DA 2018-12-27
ER

PT J
AU Kincer, JF
   Uittenbogaard, A
   Dressman, J
   Guerin, TM
   Febbraio, M
   Guo, L
   Smart, EJ
AF Kincer, JF
   Uittenbogaard, A
   Dressman, J
   Guerin, TM
   Febbraio, M
   Guo, L
   Smart, EJ
TI RETRACTED: Hypercholesterolemia promotes a CD36-dependent and
   endothelial nitric-oxide synthase-mediated vascular dysfunction
   (Retracted article. See vol. 288, pg. 6584, 2013)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID INSULIN-RESISTANCE; CHOLESTEROL DEPLETION; SCAVENGER RECEPTOR;
   PLASMA-MEMBRANE; CLASS-B; TYROSINE PHOSPHORYLATION; SPONTANEOUS
   HYPERTENSION; SIGNAL-TRANSDUCTION; ENOS ACTIVATION; GOLGI-COMPLEX
AB Numerous studies have implicated either the presence or absence of CD36 in the development of hypertension. In addition, hypercholesterolemia is associated with the loss of nitric oxide-induced vasodilation and the subsequent increase in blood pressure. In the current study, we tested the hypothesis that diet-induced hypercholesterolemia promotes the disruption of agonist-stimulated nitric oxide generation and vasodilation in a CD36-dependent manner. To test this, C57BL/6, apoE null, CD36 null, and apoE/CD36 null mice were maintained on chow or high fat diets. In contrast to apoE null mice fed a chow diet, apoE null mice fed a high fat diet did not respond to acetylcholine with a decrease in blood pressure. Caveolae isolated from in vivo vessels did not contain endothelial nitric-oxide synthase and were depleted of cholesterol. Age-matched apoE/CD36 null mice fed a chow or high fat diet responded to acetylcholine with a decrease in blood pressure. The mechanism underlying the vascular dysfunction was reversible because vessels isolated from apoE null high fat-fed mice regained responsiveness to acetylcholine when incubated with plasma obtained from chow-fed mice. Further analysis demonstrated that the plasma low density lipoprotein fraction was responsible for depleting caveolae of cholesterol, removing endothelial nitric-oxide synthase from caveolae, and preventing nitric oxide production. In addition, the pharmacological removal of caveola cholesterol with cyclodextrin mimicked the effects caused by the low density lipoprotein fraction. We conclude that the ablation of CD36 prevented the negative impact of hypercholesterolemia on agonist-stimulated nitric oxide-mediated vasodilation in apoE null mice. These studies provide a direct link between CD36 and the early events that underlie hypercholesterolemia-mediated hypertension and mechanistic linkages between CD36 function, nitric-oxide synthase activation, caveolae integrity, and blood pressure regulation.
C1 Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA.
   Anim Med Ctr, Dept Med, Div Hematol Med Oncol, Weill Med Coll, New York, NY 10021 USA.
RP Smart, EJ (reprint author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.
EM ejsmart@uky.edu
FU NHLBI NIH HHS [HL62844]
CR Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013
   Aitman TJ, 2001, LANCET, V357, P651, DOI 10.1016/S0140-6736(00)04149-0
   Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358
   Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512
   BROWN MS, 1980, J BIOL CHEM, V255, P9344
   Collison M, 2000, DIABETES, V49, P2222, DOI 10.2337/diabetes.49.12.2222
   DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740
   Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067
   FAZIO S, 2001, FRONT BIOSCI, V6, P515
   Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055
   Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006
   Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125
   Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010
   Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p
   Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810
   Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o
   FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004
   Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2
   Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099
   GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237
   Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819
   GOVERS R, 2001, AM J PHYSIOL-RENAL, V280, P193
   Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200
   GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173
   Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969
   Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6
   Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417
   Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200
   LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111
   MATVEEV SV, 2002, AM J PHYSIOL-CELL PH, V282, P935
   Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529
   Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144
   Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200
   Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298
   Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691
   Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777
   Pravenec M, 2000, FOLIA BIOL-PRAGUE, V46, P233
   SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128
   SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759
   Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Sowers JR, 2001, HYPERTENSION, V37, P1053, DOI 10.1161/01.HYP.37.4.1053
   STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203
   Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278
   Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200
   Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525
   Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241
NR 53
TC 46
Z9 46
U1 3
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 28
PY 2002
VL 277
IS 26
BP 23525
EP 23533
DI 10.1074/jbc.M202465200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 567FX
UT WOS:000176475700057
PM 11976335
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Senzaki, H
   Masutani, S
   Kobayashi, J
   Kobayashi, T
   Sasaki, N
   Asano, H
   Kyo, S
   Yokote, Y
   Ishizawa, A
AF Senzaki, H
   Masutani, S
   Kobayashi, J
   Kobayashi, T
   Sasaki, N
   Asano, H
   Kyo, S
   Yokote, Y
   Ishizawa, A
TI RETRACTED: Ventricular afterload and ventricular work in Fontan
   circulation - Comparison with normal two-ventricle circulation and
   single-ventricle circulation with Blalock-Taussig shunts (Retracted
   article. See vol. 125, pg. E1020, 2012)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE Fourier analysis; Fontan procedure; heart defects, congenital;
   hemodynamics; patients
ID CONGESTIVE-HEART-FAILURE; EXERCISE CAPACITY; BLOOD-FLOW; IN-VIVO;
   OPERATION; PERFORMANCE; IMPEDANCE; CONNECTION; MORBIDITY; RESPONSES
AB Background-Recent studies have indicated that there are inherent limitations associated with Fontan physiology. However, there have been no quantitative analyses of the effects of right heart bypass on ventricular afterload, hydraulic power, and resultant overall hemodynamics.
   Methods and Results-During routine cardiac catheterization, aortic impedance and ventricular hydraulic power were determined, both at rest and under increased ventricular work induced by dobutamine, in 17 patients with Fontan circulation, 15 patients with a single ventricle whose pulmonary circulation was maintained only by Blalock-Taussig shunts, and 13 patients who had normal 2-ventricle circulation. Both vascular resistance (nonpulsatile load on the ventricle:) and pulsatile components of ventricular afterload (represented by low-frequency impedance) were significantly higher in the Fontan group than in the other groups (P<0.01), and this was associated with decreased cardiac output in the Fontan patients. In addition, hydraulic power cost per unit forward flow was 40% lower in the 2-ventricle circulation than in the single-ventricle circulation, suggesting lower ventricular efficiency in single-ventricle circulation attributable to the lack of a pulmonary ventricle. Furthermore, in the Fontan group, beta-adrenergic reserve was markedly decreased because of a limited preload reserve.
   Conclusions-Fontan physiology is associated with disadvantageous ventricular power and afterload profiles and has limited ventricular reserve capacity. Thus, to improve the long-term prognosis of patients after Fontan surgery, future research should be conducted into medical interventions that can overcome these limitations inherent in Fontan circulation.
C1 Saitama Med Sch Hosp, Saitama Heart Inst, Div Pediat Cardiol, Moroyama, Saitama 3500495, Japan.
   Saitama Med Sch Hosp, Dept Pediat Cardiol & Cardiovasc Surg, Moroyama, Saitama 3500495, Japan.
   Natl Childrens Hosp, Dept Pediat Cardiol, Tokyo 154, Japan.
RP Senzaki, H (reprint author), Saitama Med Sch Hosp, Saitama Heart Inst, Div Pediat Cardiol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.
EM hsenzaki@saitama-med.ac.jp
OI Senzaki, Hideaki/0000-0002-8289-0953
CR AKAGI T, 1992, J AM COLL CARDIOL, V20, P920, DOI 10.1016/0735-1097(92)90194-R
   AKAGI T, 1993, J AM COLL CARDIOL, V22, P1948, DOI 10.1016/0735-1097(93)90784-X
   BENSHACHAR G, 1982, CIRCULATION, V65, P1043, DOI 10.1161/01.CIR.65.6.1043
   Cetta F, 1996, J AM COLL CARDIOL, V28, P480, DOI 10.1016/0735-1097(96)00135-0
   COLUCCI WS, 1990, CIRCULATION, V82, P44
   DRISCOLL DJ, 1986, J AM COLL CARDIOL, V7, P1087, DOI 10.1016/S0735-1097(86)80227-3
   DRISCOLL DJ, 1992, CIRCULATION, V85, P469, DOI 10.1161/01.CIR.85.2.469
   Ensley AE, 1999, ANN THORAC SURG, V68, P1384, DOI 10.1016/S0003-4975(99)00560-3
   FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290
   Gentles TL, 1997, J THORAC CARDIOV SUR, V114, P376, DOI 10.1016/S0022-5223(97)70183-1
   Gentles TL, 1997, J THORAC CARDIOV SUR, V114, P392, DOI 10.1016/S0022-5223(97)70184-3
   GEWILLIG MH, 1990, J AM COLL CARDIOL, V15, P1424, DOI 10.1016/S0735-1097(10)80034-8
   Hiramatsu T, 1998, ANN THORAC SURG, V65, P761, DOI 10.1016/S0003-4975(97)01352-0
   Kouatli AA, 1997, CIRCULATION, V96, P1507, DOI 10.1161/01.CIR.96.5.1507
   KUSSMAUL WG, 1993, CIRCULATION, V88, P1010, DOI 10.1161/01.CIR.88.3.1010
   Lardo AC, 1999, J THORAC CARDIOV SUR, V117, P697, DOI 10.1016/S0022-5223(99)70289-8
   LING SC, 1973, CIRC RES, V33, P198, DOI 10.1161/01.RES.33.2.198
   LIU ZR, 1986, AM J PHYSIOL, V251, pH588
   Mandarino WA, 1998, J AM COLL CARDIOL, V31, P861, DOI 10.1016/S0735-1097(98)00005-9
   MAVROUDIS C, 1992, CIRCULATION, V86, P85
   MILNOR WR, 1969, CIRC RES, V25, P637, DOI 10.1161/01.RES.25.6.637
   MILNOR WR, 1966, CIRC RES, V19, P467, DOI 10.1161/01.RES.19.3.467
   MURGO JP, 1981, CIRCULATION, V63, P122, DOI 10.1161/01.CIR.63.1.122
   NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P283
   PERSCHAU RA, 1979, CIRCULATION, V59, P1312, DOI 10.1161/01.CIR.59.6.1312
   REUBEN S R, 1970, Circulation Research, V27, P995
   Rokicki W, 1997, Wiad Lek, V50, P85
   Scrutinio D, 2000, EUR HEART J, V21, P927, DOI 10.1053/euhj.1999.1937
   Senzaki H, 2001, J THORAC CARDIOV SUR, V122, P535, DOI 10.1067/mtc.2001.115424
   Senzaki H, 2001, FASEB J, V15, P1718, DOI 10.1096/fj.00-0538com
   SENZAKI H, 1994, CIRCULATION, V89, P266, DOI 10.1161/01.CIR.89.1.266
   Senzaki H, 2000, CIRCULATION, V101, P1040, DOI 10.1161/01.CIR.101.9.1040
   SUNAGAWA K, 1987, VENTRICULAR VASCULAR, P42
   VANDENBERG BF, 1992, CIRCULATION, V86, P159, DOI 10.1161/01.CIR.86.1.159
   WILLIAMS DB, 1982, ANN THORAC SURG, V34, P51, DOI 10.1016/S0003-4975(10)60852-1
NR 35
TC 96
Z9 98
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JUN 18
PY 2002
VL 105
IS 24
BP 2885
EP 2892
DI 10.1161/01.CIR.0000018621.96210.72
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 573FH
UT WOS:000176818300018
PM 12070118
OA Bronze
DA 2018-12-27
ER

PT J
AU Curtis, CL
   Rees, SG
   Little, CB
   Flannery, CR
   Hughes, CE
   Wilson, C
   Dent, CM
   Otterness, IG
   Harwood, JL
   Caterson, B
AF Curtis, CL
   Rees, SG
   Little, CB
   Flannery, CR
   Hughes, CE
   Wilson, C
   Dent, CM
   Otterness, IG
   Harwood, JL
   Caterson, B
TI RETRACTED: Pathologic indicators of degradation and inflammation in
   human osteoarthritic cartilage are abrogated by exposure to n-3 fatty
   acids (Retracted Article. See vol 54, pg 2933, 2006)
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article; Retracted Publication
ID ARTICULAR-CARTILAGE; RHEUMATOID-ARTHRITIS; INTERGLOBULAR DOMAIN; MATRIX
   METALLOPROTEINASES; GENE-EXPRESSION; ADAMTS FAMILY; NITRIC-OXIDE; II
   COLLAGEN; IN-VITRO; AGGRECAN
AB Objective. To determine if n-3 polyunsaturated fatty acid (PUFA) supplementation (versus treatment with n-6 polyunsaturated or other fatty acid supplements) affects the metabolism of osteoarthritic (OA) cartilage.
   Methods. The metabolic profile of human OA cartilage was determined at the time of harvest and after 24-hour exposure to n-3 PUFAs or other classes of fatty acids, followed by explant culture for 4 days in the presence or absence of interleukin-1 (IL-1). Parameters measured were glycosaminoglycan release, aggrecanase and matrix metalloproteinase (MNIP) activity, and the levels of expression of messenger RNA (mRNA) for mediators of inflammation, aggrecanases, MMPs, and their natural tissue inhibitors (tissue inhibitors of metalloproteinases [TIMPs]).
   Results. Supplementation with n-3 PUFA (but not other fatty acids) reduced, in a dose-dependent manner, the endogenous and IL-1-induced release of proteoglycan metabolites from articular cartilage explants and specifically abolished endogenous aggrecanase and collagenase proteolytic activity. Similarly, expression of mRNA for ADAMTS-4, MMP-13, and MMP-3 (but not TIMP-1, -2, or -3) was also specifically abolished with n-3 PUFA supplementation. In addition, n-3 PUFA supplementation abolished the expression of mRNA for mediators of inflammation (cyclooxygenase 2, 5-lipoxygenase, 5-lipoxygenase-activating protein, tumor necrosis factor alpha, IL-1alpha, and IL-1beta) without affecting the expression of message for several other proteins involved in normal tissue homeostasis.
   Conclusion. These studies show that the pathologic indicators manifested in human OA cartilage can be significantly altered by exposure of the cartilage to n-3 PUFA, but not to other classes of fatty acids.
C1 Univ Cardiff, Cardiff Sch Biosci, Connect Tissue Biol Labs, Cardiff CF10 3US, S Glam, Wales.
   Univ Wales Coll Cardiff, Coll Med, Cardiff, S Glam, Wales.
RP Caterson, B (reprint author), Univ Cardiff, Cardiff Sch Biosci, Connect Tissue Biol Labs, Museum Ave, Cardiff CF10 3US, S Glam, Wales.
EM caterson@cardiff.ac.uk
RI Little, Christopher/A-9280-2015
OI Little, Christopher/0000-0002-0353-7634; Hughes,
   Clare/0000-0003-4726-5877; Harwood, John/0000-0003-2377-2612
CR Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443
   Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280
   Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114
   Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594
   AYDELOTTE MB, 1992, CONNECT TISSUE RES, V28, P143, DOI 10.3109/03008209209014233
   Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316
   Bluteau G, 2001, BBA-GEN SUBJECTS, V1526, P147, DOI 10.1016/S0304-4165(01)00122-2
   Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X
   Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679
   Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006
   Calder PC, 2001, NUTR RES, V21, P309, DOI 10.1016/S0271-5317(00)00287-6
   Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857
   CATERSON B, 1995, ACTA ORTHOP SCA S266, V66, P12
   Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1
   Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721
   CURTIS CL, 2001, THESIS CARDIFF U
   Dahlberg L, 2000, ARTHRITIS RHEUM, V43, P673, DOI 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8
   Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5
   FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1
   GALLI C, 1992, ESSENTIAL FATTY ACID, P144
   HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073
   HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799
   Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576
   ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L
   Isomaki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474
   Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63
   Kang RY, 1996, BRIT J RHEUMATOL, V35, P711
   Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821
   Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8
   LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903
   Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061
   Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198
   LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589
   Mizui Y, 2000, MOL BIOL REP, V27, P167, DOI 10.1023/A:1007253930568
   MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265
   Ntambi JM, 2001, J MOL NEUROSCI, V16, P273, DOI 10.1385/JMN:16:2-3:273
   Otterness IG, 1999, MATRIX BIOL, V18, P331, DOI 10.1016/S0945-053X(99)00026-8
   RADMARK O, 1995, J LIPID MEDIAT CELL, V12, P171, DOI 10.1016/0929-7855(95)00017-K
   Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181
   Reno C, 1997, BIOTECHNIQUES, V22, P1082, DOI 10.2144/97226bm16
   SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742
   SANDY JD, 1991, J BIOL CHEM, V266, P8683
   Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200
   Sharma Sangeeta, 1997, Indian Journal of Experimental Biology, V35, P1025
   SICARD B, 1985, THROMB HAEMOSTASIS, V53, P264
   Takita T, 1996, J CLIN BIOCHEM NUTR, V20, P149
   Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664
   Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x
   Volker D, 1996, J CLIN BIOCHEM NUTR, V20, P83
   Yamamoto S, 1998, INT J TISSUE REACT, V20, P17
NR 53
TC 122
Z9 131
U1 3
U2 17
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0004-3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD JUN
PY 2002
VL 46
IS 6
BP 1544
EP 1553
DI 10.1002/art.10305
PG 10
WC Rheumatology
SC Rheumatology
GA 562LX
UT WOS:000176199200016
PM 12115185
OA Bronze
DA 2018-12-27
ER

PT J
AU Long, DJ
   Gaikwad, A
   Multani, A
   Pathak, S
   Montgomery, CA
   Gonzalez, FJ
   Jaiswal, AK
AF Long, DJ
   Gaikwad, A
   Multani, A
   Pathak, S
   Montgomery, CA
   Gonzalez, FJ
   Jaiswal, AK
TI RETRACTED: Disruption of the NAD(P)H : quinone oxidoreductase 1 (NQO1)
   gene in mice causes myelogenous hyperplasia (Retracted article. See vol.
   78, pg. 6526, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NAD(P)H-QUINONE OXIDOREDUCTASE-1 NQO1; DT-DIAPHORASE; BENZENE
   METABOLITES; TOXICITY; SUSCEPTIBILITY; POLYMORPHISM; MECHANISM;
   LEUKEMIA; CELLS; RISK
AB NAD(P)H:quinone oxidoreductasel (NQO1) is a cytosolic protein that reduces and detoxifies quinones and their derivatives, thus protecting cells against redox cycling and oxidative stress. Disruption of the NQO1 gene in mice caused myeloid hyperplasia of bone marrow and highly significant increases in blood neutrophils, eosinophils, and basophils. NQO1-null mice also showed a decrease in lymphocytes and WBCs as compared with wild-type mice. Various techniques also demonstrated an increase in megakaryocytes without an increase in blood platelets. Histological analysis of liver, kidney, spleen, and thymus did not demonstrate a difference between wild-type and NQO1-null mice or a sign of infection. Blood cultures and urine analysis also did not demonstrate any sign of infection in NQO1-null and wild-type mice. Additional analysis of the bone marrow from NQO1-null mice revealed that loss of NQO1 alters the intracellular redox status because of accumulation of NAD(P)H, cofactors for NQO1. This causes a reduction in the levels of pyridine nucleotides and tumor suppressor proteins p53 and p73, and a decrease in apoptosis. The decrease in apoptosis causes myelogenous hyperplasia in NQO1-null mice. These results demonstrate that NQO1 acts as an endogenous factor in the protection against myclogenous hyperplasia. This is significant because 2-4% of human individuals without known abnormalities, and >25% of individuals with benzene poisoning and acute myelogenic leukemia are homozygous for a mutant allele (P187S) of NQO1 and lack NQO1 protein/activity.
C1 Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   Lexicon Genet, The Woodlands, TX 77381 USA.
   NCI, Bethesda, MD 20892 USA.
RP Jaiswal, AK (reprint author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ajaiswal@bcm.tmc.edu
FU NIEHS NIH HHS [R01 ES 07943]
CR AKSOY M, 1978, BLOOD, V52, P285
   Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898
   Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201
   Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2
   EASTMOND DA, 1987, TOXICOL APPL PHARM, V91, P85, DOI 10.1016/0041-008X(87)90196-7
   Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200
   INFANTE PF, 1977, LANCET, V2, P868
   Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369
   Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3
   KALF GF, 1987, CRIT REV TOXICOL, V18, P141, DOI 10.3109/10408448709089859
   KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356
   KOOP DR, 1989, TOXICOL APPL PHARM, V98, P278, DOI 10.1016/0041-008X(89)90233-0
   Larson RA, 1999, BLOOD, V94, P803
   LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4
   Meijne EIM, 1996, GENE CHROMOSOME CANC, V16, P230, DOI 10.1002/(SICI)1098-2264(199608)16:4<230::AID-GCC2>3.3.CO;2-B
   Moran JL, 1999, P NATL ACAD SCI USA, V96, P8150, DOI 10.1073/pnas.96.14.8150
   MORIMOTO K, 1983, MUTAT RES, V119, P355, DOI 10.1016/0165-7992(83)90185-9
   PATHAK S, 1976, J REPROD MED, V17, P25
   Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382
   Rauth AM, 1997, ONCOL RES, V9, P339
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   Rothman N, 1997, CANCER RES, V57, P2839
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   SAWYER JR, 1987, CHROMOSOMA, V95, P350, DOI 10.1007/BF00293182
   Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125
   Smith MT, 2001, BLOOD, V97, P1422, DOI 10.1182/blood.V97.5.1422
   SMITH MT, 1989, ENVIRON HEALTH PERSP, V82, P23, DOI 10.2307/3430757
   Smith MT, 1999, P NATL ACAD SCI USA, V96, P7624, DOI 10.1073/pnas.96.14.7624
   Snyder R, 1975, CRC Crit Rev Toxicol, V3, P265, DOI 10.3109/10408447509079860
   TUNEK A, 1982, CHEM-BIOL INTERACT, V39, P129, DOI 10.1016/0009-2797(82)90116-8
   WHITACRE CM, 1995, CANCER RES, V55, P3697
NR 31
TC 103
Z9 106
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2002
VL 62
IS 11
BP 3030
EP 3036
PG 7
WC Oncology
SC Oncology
GA 559RE
UT WOS:000176038500008
PM 12036909
DA 2018-12-27
ER

PT J
AU Hattori, Y
   Nakanishi, N
   Kasai, K
AF Hattori, Y
   Nakanishi, N
   Kasai, K
TI RETRACTED: Statin enhances cytokine-mediated induction of nitric oxide
   synthesis in vascular smooth muscle cells (Retracted article. See vol.
   92, pg. 180, 2011)
SO CARDIOVASCULAR RESEARCH
LA English
DT Article; Retracted Publication
DE statins; cytokines; nitric oxide; smoooth muscle
ID SYNTHASE GENERATES SUPEROXIDE; RHO GTPASE; INHIBITION;
   TETRAHYDROBIOPTERIN; ATHEROSCLEROSIS; CERIVASTATIN; FLUVASTATIN;
   MACROPHAGES; PRAVASTATIN; SUPPRESSES
AB Objective: We investigated the effects of the statins. cerivastatin and fluvastatin, on the induction of nitric oxide (NO) production in vascular smooth muscle cells (VSMC) stimulated by interleukin-1beta (IL-1) or in combination with interferon-gamma (IFN). Methods: We measured NO release, inducible NO synthase (iNOS) mRNA and protein levels. iNOS gone transcription rates. and iNOS mRNA stabilities in cytokine-activated VSMC. We also evaluated nuclear factor (NF)-kappaB activity and tetrahydrobiopterin (BH4) synthesis. Results: NO production induced by cytokines was dose-dependently enhanced by both statins. Incubating VSMC with IL-1/IFN stimulated iNOS mRNA and protein expression. Both statins significantly upregulated IL-1/IFN-stimulated iNOS mRNA and protein expression, and enhanced iNOS gene transcription as shown by nuclear run-on assays. However, they did not alter the Stability of iNOS mRNA. Both statins slightly modulated IL-1/IFN-induced NF-kappaB activation, which was not associated with their effect on NO production. Cytokines induce the de novo synthesis of BH4 in VSMC. This event is essential for the induction of NO synthesis, which requires transcriptional induction of the genes that encode not only iNOS but also guanosine triphosphate cyclohydrolase I (GTPCH), the first and rate-limiting enzyme in de novo BH4 synthesis. The synthesis of BH4 and GTPCH mRNA induced by IL-1/IFN were enhanced by both statins. Exogenous mevalonate significantly prevented and geranylgeranylpyrophosphate reversed the stimulatory effect of both statins. Furthermore, the geranylgeranyltransferase I inhibitor GGTI-298 significantly increased IL-1/IFN-induced NO production. Conclusion: Our data demonstrated that statins enhance immunostimulants-induced NO production by increasing iNOS gene expression at the transcriptional level via an NF-kappaB-independent pathway. The effect of statins on NO production is due at least partly through blocking the biosynthesis of mevalonate, which prevents isoprenoid biosynthesis, In addition to augmenting iNOS expression, statins potentiate GTPCH gene expression and BH4 synthesis. thereby preventing a relative shortage of BH4 which may shift the balance between NOS-catalyzed generation of protective NO and deleterious reactive oxygen species. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
   Meikai Univ, Sch Dent, Dept Biochem, Sakado, Saitama 35002, Japan.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
CR Aji W, 1997, CIRCULATION, V95, P430
   BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036
   Behr D, 1999, ATHEROSCLEROSIS, V142, P335, DOI 10.1016/S0021-9150(98)00254-8
   Boger RH, 1996, ATHEROSCLEROSIS, V127, P1, DOI 10.1016/S0021-9150(96)05953-9
   BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T
   CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512
   CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1
   Chen H, 2000, HYPERTENSION, V36, P923, DOI 10.1161/01.HYP.36.6.923
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265
   Cosentino F, 1999, CARDIOVASC RES, V43, P274, DOI 10.1016/S0008-6363(99)00134-0
   DURANTE W, 1991, AM J PHYSIOL, V261, pH2024
   Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484
   FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   GROSS SS, 1992, J BIOL CHEM, V267, P25722
   GRRENBERG ME, 1994, CURRENT PROTOCOLS MO
   HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062
   Hattori Y, 1999, HYPERTENSION, V33, P943, DOI 10.1161/01.HYP.33.4.943
   Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607
   Kibbe M, 1999, CARDIOVASC RES, V43, P650, DOI 10.1016/S0008-6363(99)00130-3
   KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827
   Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Muck W, 1999, J INT MED RES, V27, P107
   NATHAN C, 1992, FASEB J, V6, P3051
   NATHAN C, 1994, J BIOL CHEM, V269, P13725
   Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Rupin A, 1996, BRIT J PHARMACOL, V119, P1233, DOI 10.1111/j.1476-5381.1996.tb16027.x
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200
   Takeuchi S, 2000, BIOCHEM BIOPH RES CO, V269, P97, DOI 10.1006/bbrc.2000.2238
   THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B
   TSE FLS, 1992, J CLIN PHARMACOL, V32, P630, DOI 10.1002/j.1552-4604.1992.tb05773.x
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736
   Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108
   Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804
   Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705
   Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770
   Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635
   XIE QW, 1994, J BIOL CHEM, V269, P4705
NR 45
TC 59
Z9 64
U1 2
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD JUN
PY 2002
VL 54
IS 3
BP 649
EP 658
AR PII S0008-6363(02)00266-3
DI 10.1016/S0008-6363(02)00266-3
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 563ZY
UT WOS:000176289700020
PM 12031711
OA Bronze
DA 2018-12-27
ER

PT J
AU Ferguson, KH
   McNeil, JJ
   Morey, AF
AF Ferguson, KH
   McNeil, JJ
   Morey, AF
TI RETRACTED: Mechanical and antibiotic bowel preparation for urinary
   diversion surgery (Retracted Article. See vol 170, pg 2394, 2003)
SO JOURNAL OF UROLOGY
LA English
DT Review; Retracted Publication
DE urinary diversion; colon; antibiotics; polyethylene glycol
ID ELECTIVE COLORECTAL SURGERY; COMPARING SODIUM-PHOSPHATE;
   POLYETHYLENE-GLYCOL; CLOSTRIDIUM-DIFFICILE; ANTIMICROBIAL PROPHYLAXIS;
   COLON SURGERY; INTESTINAL COLONIZATION; HYPOCALCEMIC TETANY; RADICAL
   CYSTECTOMY; RANDOMIZED-TRIAL
AB Purpose: We reviewed the existing scientific literature regarding the efficacy of preoperative mechanical and antibiotic bowel preparation for urinary diversion surgery.
   Materials and Methods: We performed MEDLINE searches of the literature from 1966 through 2000 and obtained additional references through a review of the bibliographies of select articles.
   Results: For urinary diversion surgery information regarding appropriate mechanical and antibiotic bowel preparation is scant. The colorectal surgery literature indicates that oral sodium phosphate appears to be better tolerated than polyethylene glycol and is as effective, although the latter is preferred in patients with compromised renal, cardiac or liver function. A combination of oral and parenteral antibiotics should be used for all urinary reconstructive surgeries involving gastrointestinal tract segments. A parenteral second generation cephalosporin antibiotic should be given within 1 hour of skin incision and repeated at an interval of twice the antibiotic serum half-life or when blood loss exceeds 1 l.
   Conclusions: For urinary diversion surgery contemporary methods of mechanical and antibiotic bowel preparation appear to be safe, effective and better tolerated than traditional bowel preparation methods.
C1 Brooke Army Med Ctr, Serv Urol, San Antonio, TX USA.
   Brooke Army Med Ctr, Gen Surg Serv, San Antonio, TX USA.
   Wilford Hall USAF Med Ctr, Dept Urol, San Antonio, TX 78236 USA.
RP Ferguson, KH (reprint author), Brooke Army Med Ctr, Serv Urol, San Antonio, TX USA.
CR ACKERMANN D, 1986, EUR UROL, V12, P289
   Ahmed M, 1996, AM J GASTROENTEROL, V91, P1261
   AMBROSE NS, 1985, J ANTIMICROB CHEMOTH, V15, P319, DOI 10.1093/jac/15.3.319
   BAUM ML, 1981, NEW ENGL J MED, V305, P795, DOI 10.1056/NEJM198110013051404
   BEGGS FD, 1982, BRIT J SURG, V69, P226, DOI 10.1002/bjs.1800690419
   BENET LZ, 1996, GOODMAN GILMANS PHAR, P1725
   BOWDEN TA, 1987, AM SURGEON, V53, P34
   BURKE P, 1994, BRIT J SURG, V81, P907, DOI 10.1002/bjs.1800810639
   Campisi P, 1999, DIS COLON RECTUM, V42, P1499, DOI 10.1007/BF02235055
   CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501
   Cleary RK, 1998, DIS COLON RECTUM, V41, P464, DOI 10.1007/BF02235760
   COHEN SM, 1994, DIS COLON RECTUM, V37, P689, DOI 10.1007/BF02054413
   CONDON RE, 1979, AM J SURG, V137, P68, DOI 10.1016/0002-9610(79)90013-8
   COPPA GF, 1983, AM J SURG, V145, P62, DOI 10.1016/0002-9610(83)90167-8
   DELLINGER EP, 1994, CLIN INFECT DIS, V18, P422, DOI 10.1093/clinids/18.3.422
   Duthie G S, 1990, J R Coll Surg Edinb, V35, P169
   FIGUERASFELIP J, 1984, SURG GYNECOL OBSTET, V158, P359
   Fine A, 1997, AM J KIDNEY DIS, V29, P103, DOI 10.1016/S0272-6386(97)90015-9
   GODET AS, 1993, J UROLOGY, V149, P142, DOI 10.1016/S0022-5347(17)36026-3
   GOLDRING J, 1975, LANCET, V2, P997
   GOLUB RW, 1995, DIS COLON RECTUM, V38, P594, DOI 10.1007/BF02054117
   GORBACH SL, 1992, CLIN INFECT DIS, V15, pS313, DOI 10.1093/clind/15.Supplement_1.S313
   HENDERSON JM, 1995, GASTROINTEST ENDOSC, V42, P238, DOI 10.1016/S0016-5107(95)70098-6
   Heymann TD, 1996, BRIT MED J, V313, P727
   IRVING AD, 1987, BRIT J SURG, V74, P580, DOI 10.1002/bjs.1800740711
   JOBE BA, 1995, AM J SURG, V169, P480, DOI 10.1016/S0002-9610(99)80199-8
   Lee EC, 1996, DIS COLON RECTUM, V39, P369, DOI 10.1007/BF02054048
   LUDWIG KA, 1993, ANNU REV MED, V44, P385
   Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X
   Marschall HU, 1998, GASTROINTEST ENDOSC, V47, P408, DOI 10.1016/S0016-5107(98)70229-9
   NICHOLS RL, 1971, DIS COLON RECTUM, V14, P123, DOI 10.1007/BF02560057
   Nichols RL, 1997, CLIN INFECT DIS, V24, P609, DOI 10.1093/clind/24.4.609
   NICHOLS RL, 1973, ANN SURG, V178, P453, DOI 10.1097/00000658-197310000-00008
   NICHOLS RL, 1972, ANN SURG, V176, P227, DOI 10.1097/00000658-197208000-00019
   OCONNELL JR, 1983, UROLOGY, V21, P245, DOI 10.1016/0090-4295(83)90078-X
   Oliveira L, 1997, DIS COLON RECTUM, V40, P585, DOI 10.1007/BF02055384
   PAGE CP, 1993, ARCH SURG-CHICAGO, V128, P410
   PECK JJ, 1984, AM J SURG, V147, P633, DOI 10.1016/0002-9610(84)90129-6
   Pitcher DE, 1997, GASTROINTEST ENDOSC, V46, P266, DOI 10.1016/S0016-5107(97)70099-3
   Platell C, 1998, DIS COLON RECTUM, V41, P875, DOI 10.1007/BF02235369
   PRIVITERA G, 1991, ANTIMICROB AGENTS CH, V35, P208, DOI 10.1128/AAC.35.1.208
   *PROD INF SECT, 2000, PHYS DESK REF, P810
   ROWEJONES DC, 1990, BRIT MED J, V300, P18, DOI 10.1136/bmj.300.6716.18
   SANTOS JCM, 1994, BRIT J SURG, V81, P1673, DOI 10.1002/bjs.1800811139
   SCHEIN M, 1995, DIS COLON RECTUM, V38, P749, DOI 10.1007/BF02048035
   SCHOETZ DJ, 1990, ANN SURG, V212, P209, DOI 10.1097/00000658-199008000-00016
   Thomson A, 1996, J GASTROEN HEPATOL, V11, P103, DOI 10.1111/j.1440-1746.1996.tb00044.x
   Vukasin P, 1997, DIS COLON RECTUM, V40, P497, DOI 10.1007/BF02258399
   WENZEL RP, 1993, INFECT CONT HOSP EP, V14, P121
   WISHNOW KI, 1988, UROLOGY, V31, P7, DOI 10.1016/0090-4295(88)90561-4
NR 50
TC 15
Z9 15
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2002
VL 167
IS 6
BP 2352
EP 2356
DI 10.1016/S0022-5347(05)64983-X
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 552DD
UT WOS:000175602500004
PM 11992036
DA 2018-12-27
ER

PT J
AU Kitagawa, H
   Yanagisawa, J
   Fuse, H
   Ogawa, S
   Yogiashi, Y
   Okuno, A
   Nagasawa, H
   Nakajima, T
   Matsumoto, T
   Kato, S
AF Kitagawa, H
   Yanagisawa, J
   Fuse, H
   Ogawa, S
   Yogiashi, Y
   Okuno, A
   Nagasawa, H
   Nakajima, T
   Matsumoto, T
   Kato, S
TI RETRACTED: Ligand-selective potentiation of rat mineralocorticoid
   receptor activation function 1 by a CBP-containing histone
   acetyltransferase complex (Retracted article. See vol. 34, pg. 916,
   2014)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID RNA-POLYMERASE-II; HUMAN ESTROGEN-RECEPTOR; VITAMIN-D-RECEPTOR; IN-GEL
   DIGESTION; TRANSCRIPTIONAL COACTIVATORS; ALDOSTERONE ACTION; NUCLEAR
   RECEPTORS; GLUCOCORTICOID-RECEPTOR; DEPENDENT TRANSCRIPTION; SIGNALING
   PATHWAYS
AB The rat mineralocorticoid receptor (MR) has two activation functions in distinct regions of the A/B domain, designated activation function 1a (AF-1a; amino acids I to 169) and AF-1b (amino acids 451 to 600). Since the p160 family protein TIF2, a known component of the AF-2 coactivator complex, potentiates the transactivation function of AF-1b but not that of AF-1a, it is likely that some other, novel protein complex interacts with the AF-1a region. Therefore, we attempted to identify such coactivator complexes from HeLa nuclear extracts by biochemical purification using a glutathione S-transferase-MR AF-1a fusion protein. Purified AF-1a region-interacting proteins were found to contain RNA helicase A (RHA) and CBP. Further analysis showed that RHA interacted with the AF-1a region directly and then recruited a complex with histone acetyltransferase (HAT) activity that contained CBP. For full-length MR, aldosterone, but not hydrocortisone, was found to induce the binding of RHA/CBP complexes to the AF-1a region, as well as to allow the cooperative potentiation of MR transcriptional activity by RHA and CBP. In addition, a chromatin immunoprecipitation assay showed that aldosterone-bound MR, but not hydrocortisone-bound MR, recruited RHA/CBP complexes to native MR target gene promoters. Our results suggested that an altered conformation of the A/B region induced by aldosterone, but not hydrocortisone, might determine the accessibility of MR AF-1a to RHA/CBP complexes.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1130032, Japan.
   Teikoku Hormone Mfg Co Ltd, Dept Pharmacol Res, Tokyo, Japan.
   Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 770, Japan.
   Japan Sci & Technol, CREST, Kawaguchi, Saitama, Japan.
   St Marianna Univ, Inst Med Sci, Miyamae Ku, Kawasaki, Kanagawa, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ccc.u-tokyo.ac.jp
CR AGARWAL MK, 1994, PHARMACOL REV, V46, P67
   Anderson SE, 1998, NAT GENET, V19, P254
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001
   Berger S, 1998, P NATL ACAD SCI USA, V95, P9424, DOI 10.1073/pnas.95.16.9424
   BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317
   Farman N, 1999, CURR OPIN NEPHROL HY, V8, P45, DOI 10.1097/00041552-199901000-00008
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200
   Funder J, 1996, ENDOCRINOLOGY, V137, P5264, DOI 10.1210/en.137.12.5264
   FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584
   Funder JW, 1998, CLIN EXP PHARMACOL P, V25, pS47, DOI 10.1111/j.1440-1681.1998.tb02300.x
   Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889
   Gass P, 2000, EMBO REP, V1, P447, DOI 10.1093/embo-reports/kvd088
   Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048
   Glass CK, 2000, GENE DEV, V14, P121
   GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE482
   GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE649
   Govindan MV, 1998, J BIOL CHEM, V273, P24439, DOI 10.1074/jbc.273.38.24439
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070
   Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380
   JAUSONSLOFFREDA N, 1994, BIOCHEM BIOPH RES CO, V205, P1610, DOI 10.1006/bbrc.1994.2851
   Kobayashi T, 2000, PSYCHIAT CLIN NEUROS, V54, P531, DOI 10.1046/j.1440-1819.2000.00748.x
   Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200
   Kolla V, 1999, BIOCHEM BIOPH RES CO, V266, P5, DOI 10.1006/bbrc.1999.1765
   Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4
   Le Menuet D, 2001, J BIOL CHEM, V276, P38911, DOI 10.1074/jbc.M103984200
   LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477
   Lim-Tio SS, 1998, ENDOCRINOLOGY, V139, P1653, DOI 10.1210/en.139.4.1653
   LOMBES M, 1994, ENDOCRINOLOGY, V135, P834, DOI 10.1210/en.135.3.834
   Mick VE, 2001, MOL ENDOCRINOL, V15, P575, DOI 10.1210/me.15.4.575
   Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   ONATE SA, 1995, SCIENCE, V270, P1354
   Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75
   Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001
   Rachez C, 1999, NATURE, V398, P824
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B
   Shao DL, 1998, NATURE, V396, P377
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652
   TRAPP T, 1995, BIOCHEM BIOPH RES CO, V215, P286, DOI 10.1006/bbrc.1995.2464
   TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7
   Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
   YOUNG M, 1995, STEROIDS, V60, P133, DOI 10.1016/0039-128X(94)00029-C
   Young MJ, 1996, STEROIDS, V61, P233, DOI 10.1016/0039-128X(96)00020-7
   Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915
   Zennaro MC, 2001, MOL ENDOCRINOL, V15, P1586, DOI 10.1210/me.15.9.1586
NR 60
TC 88
Z9 88
U1 2
U2 18
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2002
VL 22
IS 11
BP 3698
EP 3706
DI 10.1128/MCB.22.11.3698-3706.2002
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 551JP
UT WOS:000175557600013
PM 11997506
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Tanaka, K
   Tsumaki, N
   Kozak, CA
   Matsumoto, Y
   Nakatani, F
   Iwamoto, Y
   Yamada, Y
AF Tanaka, K
   Tsumaki, N
   Kozak, CA
   Matsumoto, Y
   Nakatani, F
   Iwamoto, Y
   Yamada, Y
TI RETRACTED: A Kruppel-associated box-zinc finger protein, NT2, represses
   cell-type-specific promoter activity of the alpha 2(XI) collagen gene
   (Retracted Article)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE;
   TRANSCRIPTIONAL REPRESSION; CAMPOMELIC DYSPLASIA; XI COLLAGEN; RAT
   CHONDROSARCOMA; FIBRILLAR COLLAGEN; MOLECULAR-CLONING; DOMAIN
AB Type XI collagen is composed of three chains, alpha1(XI), alpha2(XI), and alpha3(XI), and plays a critical role in the formation of cartilage collagen fibrils and in skeletal morphogenesis. It was previously reported that the -530-bp promoter segment of the alpha2(XI) collagen gene (Col11a2) was sufficient for cartilage-specific expression and that a 24-bp sequence from this segment was able to switch promoter activity from neural tissues to cartilage in transgenic mice when this sequence was placed in the heterologous neurofilament light gene (NFL) promoter. To identify a protein factor that bound to the 24-bp sequence of the Col11a2 promoter, we screened a mouse limb bud cDNA expression library in the yeast one-hybrid screening system and obtained the cDNA clone NT2. Sequence analysis revealed that NT2 is a zinc finger protein consisting of a Kruppel-associated box (KRAB) and is a homologue of human FPM315, which was previously isolated by random cloning and sequencing. The KRAB domain has been found in a number of zinc finger proteins and implicated as a transcriptional repression domain, although few target genes for KRAB-containing zinc finger proteins has been identified. Here, we demonstrate that NT2 functions as a negative regulator of Col11a2. In situ hybridization analysis of developing mouse cartilage showed that NT2 mRNA is highly expressed by hypertrophic chondrocytes but is minimally expressed by resting and proliferating chondrocytes, in an inverse correlation with the expression patterns of Col11a2. Gel shift assays showed that NT2 bound a specific sequence within the 24-bp site of the Col11a2 promoter. We found that Col11a2 promoter activity was inhibited by transfection of the NT2 expression vector in RSC cells, a chondrosarcoma cell line. The expression vector for mutant NT2 lacking the KRAB domain failed to inhibit Col11a2 promoter activity. These results demonstrate that KRAB-zinc finger protein NT2 inhibits transcription of its physiological target gene, suggesting a novel regulatory mechanism of cartilage-specific expression of Col11a2.
C1 NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.
   NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
   Kyushu Univ, Dept Orthopaed Surg, Grad Sch Med Sci, Fukuoka 8128582, Japan.
RP Yamada, Y (reprint author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 405, Bethesda, MD 20892 USA.
EM yoshi.yamada@nih.gov
RI Matsumoto, Yoichiro/M-4093-2014
CR Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998
   ADAMSON MC, 1991, VIROLOGY, V183, P778
   ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432
   BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608
   Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081
   BERNARD M, 1988, J BIOL CHEM, V263, P17159
   Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998
   CHOWDHURY K, 1992, MECH DEVELOP, V39, P129, DOI 10.1016/0925-4773(92)90040-Q
   DAWSON TM, 1995, NEUROSCIENTIST, V1, P1
   de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493
   DENNY P, 1991, GENE, V106, P221, DOI 10.1016/0378-1119(91)90202-M
   DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495
   FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0
   Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067
   FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6
   Gray S, 1996, CURR OPIN CELL BIOL, V8, P358
   Grimes HL, 1996, MOL CELL BIOL, V16, P6263
   HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500
   HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A
   Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200
   JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3
   Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299
   KIMURA T, 1989, J BIOL CHEM, V264, P13910
   KLUG A, 1995, FASEB J, V9, P597
   KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W
   Lee PL, 1997, GENOMICS, V43, P191, DOI 10.1006/geno.1997.4806
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075
   LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1
   Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   MENDELSOHN DA, 1989, WAVE MOTION, V11, P1, DOI 10.1016/0165-2125(89)90009-7
   Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859
   MORRIS NP, 1987, J BIOL CHEM, V262, P11345
   MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711
   Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402
   PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908
   Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015
   PENGUE G, 1993, HUM MOL GENET, V2, P791, DOI 10.1093/hmg/2.6.791
   PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712
   Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457
   Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000
   Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573
   Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861
   TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372
   VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991
   VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X
   VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R
   WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8
   WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0
   WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143
   Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263
   WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514
   WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15
   Yang XW, 1996, DEVELOPMENT, V122, P555
   Yokoyama M, 1997, BBA-GENE STRUCT EXPR, V1353, P13, DOI 10.1016/S0167-4781(97)00074-2
   Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7
   Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200
NR 60
TC 27
Z9 30
U1 3
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2002
VL 22
IS 12
BP 4256
EP 4267
DI 10.1128/MCB.22.12.4256-4267.2002
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 556UB
UT WOS:000175866400028
PM 12024037
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ahmed, S
   James, K
   Owen, CP
AF Ahmed, S
   James, K
   Owen, CP
TI RETRACTED: The design, synthesis, and biochemical evaluation of
   derivatives of biphenyl sulfamate-based compounds as novel inhibitors of
   estrone sulfatase (Retracted Article. See vol 301, pg 1129, 2003)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID STEROID SULFATASE; ESTRONE-3-O-SULFAMATE; ES
AB We report the initial results of our study into the use of a potential transition state (TS) of the reaction catalyzed by the enzyme estrone sulfatase (ES) in the design of a series of simple 4'-O-sulfamoyl-4-biphenyl-based compounds as novel inhibitors of ES. The results of the study show that these compounds are: potent inhibitors, possessing greater inhibitory activity than 4-methylcoumarin-7-O-sulfamate (COUMATE); weaker inhibitors than the tricyclic derivative of COUMATE, namely 667-COUMATE and the steroidal inhibitor estrone-3-O-sulfamate (EMATE), and irreversible inhibitors of ES. (C) 2002 Elsevier Science (USA). All rights reserved.
C1 Kingston Univ, Sch Chem & Pharmaceut Sci, Kingston upon Thames KT1 2EE, Surrey, England.
   Inst Canc Res, Sutton, Surrey, England.
RP Ahmed, S (reprint author), Kingston Univ, Sch Chem & Pharmaceut Sci, Penrhyn Rd, Kingston upon Thames KT1 2EE, Surrey, England.
EM s.ahmed@kingston.ac.uk
CR Ahmed S, 1999, BIOCHEM BIOPH RES CO, V254, P811, DOI 10.1006/bbrc.1998.9934
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P3001, DOI 10.1016/S0960-894X(01)00607-2
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P899, DOI 10.1016/S0960-894X(01)00087-7
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P841, DOI 10.1016/S0960-894X(01)00086-5
   ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001
   Brodie AMH, 2000, STEROIDS, V65, P171, DOI 10.1016/S0039-128X(99)00104-X
   PUROHIT A, 1995, BIOCHEMISTRY-US, V34, P11508, DOI 10.1021/bi00036a025
   Purohit A, 1998, J STEROID BIOCHEM, V64, P269, DOI 10.1016/S0960-0760(97)00196-9
   Purohit A, 1998, CHEM-BIOL INTERACT, V109, P183, DOI 10.1016/S0009-2797(97)00132-4
   Selcer KW, 1996, J STEROID BIOCHEM, V59, P83, DOI 10.1016/S0960-0760(96)00089-1
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   VONBULOW R, 2001, J MOL BIOL, V274, P12284
   Woo LWL, 2000, CHEM BIOL, V7, P773, DOI 10.1016/S1074-5521(00)00023-5
NR 13
TC 10
Z9 10
U1 2
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 31
PY 2002
VL 294
IS 1
BP 180
EP 183
AR PII S0006-291X(02)00444-8
DI 10.1016/S0006-291X(02)00444-8
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 563BU
UT WOS:000176234500030
PM 12054760
DA 2018-12-27
ER

PT J
AU Zhang, JH
   Li, CJ
AF Zhang, JH
   Li, CJ
TI RETRACTED: InCl3-catalyzed domino reaction of aromatic amines with
   cyclic enol ethers in water: A highly efficient synthesis of new
   1,2,3,4-tetrahydroquinoline derivatives (Retracted Article. See vol 74,
   pg 3620, 2009)
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article; Retracted Publication
ID DIELS-ALDER REACTION; QUINOLINE DERIVATIVES; CONVENIENT SYNTHESIS;
   ORGANIC-SYNTHESIS; AQUEOUS-MEDIA; INDIUM METAL; ANALOGS
AB The tetrahydroquinoline moiety is a structural feature of many natural products. By using a domino reaction of aromatic amines and cyclic enol ethers or 2-hydroxy cyclic ether catalyzed by indium chloride in water, various tetrahydroquinoline derivatives were synthesized efficiently. Most cyclization products showed cis selectivity. The use of 2,3-dihydrofuran as the cyclic enol ether provided both higher reactivity and cis selectivity than the use of 3,4-dihydro-2H-pyran. The cis selectivity was tentatively rationalized due to chelation control in water.
C1 Tulane Univ, Dept Chem, New Orleans, LA 70118 USA.
RP Li, CJ (reprint author), Tulane Univ, Dept Chem, New Orleans, LA 70118 USA.
EM cjli@tulane.edu
CR Babu G, 1998, TETRAHEDRON LETT, V39, P3225, DOI 10.1016/S0040-4039(98)00397-9
   BILLER SA, 1994, CHEM PAP, V48, P261
   BOGER DL, 1987, HETERO DIELS ALDER M, pCH2
   Caling R. W., 1992, J MED CHEM, V35, P1942
   CARLING RW, 1993, BIOORG MED CHEM LETT, V3, P65, DOI 10.1016/S0960-894X(00)80093-1
   Chan TH, 1996, PURE APPL CHEM, V68, P919, DOI 10.1351/pac199668040919
   Chauhan KK, 2000, J CHEM SOC PERK T 1, P3015, DOI 10.1039/a906657h
   CINTAS P, 1995, SYNLETT, P1087
   Crousse B, 2000, J ORG CHEM, V65, P5009, DOI 10.1021/jo9918807
   Cuny G. D., 1999, PCT Int. Appl., Patent No. [WO 9967238, 9967238]
   HANADA K, 2001, Patent No. 0127086
   Hashmi ASK, 1998, J PRAK CHEM-CHEM ZTG, V340, P84, DOI 10.1002/prac.19983400113
   JOHNSON JV, 1989, J MED CHEM, V32, P1942, DOI 10.1021/jm00128a042
   KAMETANI T, 1986, J HETEROCYCLIC CHEM, V23, P185, DOI 10.1002/jhet.5570230138
   Katritzky AR, 1996, TETRAHEDRON, V52, P15031, DOI 10.1016/S0040-4020(96)00911-8
   Kobayashi S, 1998, BIOTECHNOL BIOENG, V61, P23, DOI 10.1002/(SICI)1097-0290(199824)61:1<23::AID-BIT7>3.0.CO;2-0
   Kobayashi S, 1996, J AM CHEM SOC, V118, P8977, DOI 10.1021/ja961062l
   Li CJ, 1999, TETRAHEDRON, V55, P11149, DOI 10.1016/S0040-4020(99)00641-9
   Loh TP, 1996, CHEM COMMUN, P2315, DOI 10.1039/cc9960002315
   LUCCHINI V, 1992, J CHEM SOC PERK T 2, P259, DOI 10.1039/p29920000259
   Ma Y, 1999, J ORG CHEM, V64, P6462, DOI 10.1021/jo982220p
   MAKIOKA Y, 1995, SYNTHESIS-STUTTGART, P801
   MENDOZA JS, 1998, Patent No. 9827093
   Paquette L. A., 1998, GREEN CHEM FRONTIERS
   PERRY NB, 1986, J ORG CHEM, V51, P5476, DOI 10.1021/jo00376a096
   Povarov L. S., 1967, RUSS CHEM REV, V36, P656, DOI DOI 10.1070/RC1967V036N09ABEH001680
   RAMESH M, 1984, TETRAHEDRON, V40, P4041, DOI 10.1016/0040-4020(84)85084-X
   Ranu BC, 2000, EUR J ORG CHEM, P2347
   SCHNIEPP LE, 1946, J AM CHEM SOC, V68, P1646, DOI 10.1021/ja01212a085
   Sundararajan G, 2001, ORG LETT, V3, P1973, DOI 10.1021/ol0159221
   WILLIAMSON NM, 1995, TETRAHEDRON LETT, V36, P7721, DOI 10.1016/0040-4039(95)01572-Y
   WITHERUP KM, 1994, Patent No. 5288725
   WOODS GF, 1955, ORG SYNTH, V3, P470
NR 33
TC 107
Z9 109
U1 3
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD MAY 31
PY 2002
VL 67
IS 11
BP 3969
EP 3971
DI 10.1021/jo020131d
PG 3
WC Chemistry, Organic
SC Chemistry
GA 557NQ
UT WOS:000175915000066
PM 12027728
DA 2018-12-27
ER

PT J
AU Majumder, S
   Ghoshal, K
   Datta, J
   Bai, SM
   Dong, XC
   Quan, N
   Plass, C
   Jacob, ST
AF Majumder, S
   Ghoshal, K
   Datta, J
   Bai, SM
   Dong, XC
   Quan, N
   Plass, C
   Jacob, ST
TI RETRACTED: Role of de novo DNA Methyltransferases and methyl CpG-binding
   proteins in gene silencing in a rat hepatoma (Retracted article. See
   vol. 293, pg. 12948, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HUMAN HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLASE COMPLEX;
   MESSENGER-RNA EXPRESSION; ACUTE MYELOID-LEUKEMIA; METALLOTHIONEIN-I;
   SUPPRESSOR ROLE; LARGE SUBUNIT; MOUSE-LIVER; CELL-LINES; TRANSCRIPTION
AB The expression of metallothionein-I (MT-I), a known antioxidant, was suppressed in a transplanted rat hepatoma because of promoter methylation and was induced by heavy metals only after demethylation by 5-azacytidine (5-AzaC). Treatment of the tumor-bearing rats with 5-AzaC resulted in significant regression of the hepatoma. When the inhibitor-treated tumor was allowed to grow in a new host, MT-I promoter was remethylated, which suggested de novo methylation. The activities of both de novo (3-fold) and maintenance DNA methyltransferases (DNMT) (5-fold) were higher in the hepatoma than in the host liver. The mRNA levels of the de novo methyltransferases DNMT3a and DNMT3b were 3- and 6-fold higher, respectively, in the tumor implicating transcriptional up-regulation of these two genes in this tissue. Immunohistochemical analysis showed exclusive localization of DNMT3a in the nuclei of both the liver and hepatoma, whereas DNMT3b was detected in the nuclei as well as the cytoplasm. Immunoblot assay showed that the levels of DNMT1, DNMT3a, and DNMT3b proteins in the hepatoma were 5-, 10-, and 4-fold higher, respectively, than in the liver. The mRNA level of the major methyl CpG-binding protein (MeCP2) was 8-fold higher in the tumor compared with the liver. Immunohistochemical studies showed that MeCP2 is localized exclusively in the nuclei of both tissues. A chromatin immunoprecipitation assay demonstrated that MeCP2 was associated with the MT-I promoter in the hepatoma implicating its involvement in repressing the methylated promoter. Analysis of the DNA isolated from the liver and hepatoma by RLGS-M (restriction landmark genomic scanning with methylation-sensitive enzyme) (NotI) showed that many genes in addition to MT-I were methylated in the hepatoma. These data demonstrate suppression of the MT-I gene and probably other genes in a solid tumor by promoter methylation and have provided potential molecular mechanisms for the altered methylation profile of the genes in this tumor.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   Ohio State Univ, Coll Dent, Sect Oral Biol, Columbus, OH 43210 USA.
   Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Ghoshal, K (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.
EM ghoshal.l@osu.edu; jacob.42@osu.edu
RI Plass, Christoph/H-7192-2014
FU NIEHS NIH HHS [R01 ES010874-04, R01 ES010874-02, R01 ES010874-01, R01
   ES010874-03, R01 ES010874, ES10874, R01 ES010874-05]; NCI NIH HHS [R01
   CA081024-03, R01 CA081024, R01 CA081024-01A2, R01 CA081024-04, CA81024,
   R01 CA081024-02]
CR Akama TO, 1997, CANCER RES, V57, P3294
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Bachman KE, 1999, CANCER RES, V59, P798
   Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597
   Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162
   Deng DX, 1998, HISTOPATHOLOGY, V32, P340
   Esteller M, 1999, CANCER RES, V59, P793
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390
   Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357
   Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563
   Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539
   Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904
   Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001
   GHOSHAL K, 2002, IN PRESS METHODS ENZ, V353
   GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Herman JG, 1996, CANCER RES, V56, P722
   HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   KAGI JHR, 1991, METHOD ENZYMOL, V205, P613
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347
   Kawano S, 1999, BLOOD, V94, P1113
   KOJIMA Y, 1991, METHOD ENZYMOL, V205, P8
   KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lei H, 1996, DEVELOPMENT, V122, P3195
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X
   MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282
   Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584
   Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004
   Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ng HH, 1999, NAT GENET, V23, P58
   Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   OKAZAKI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1922, DOI 10.1006/bbrc.1994.2895
   PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333
   Plantaz D, 1997, AM J PATHOL, V150, P81
   Plass C, 1999, ONCOGENE, V18, P3159, DOI 10.1038/sj.onc.1202651
   Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106
   QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   ROSE KM, 1981, J BIOL CHEM, V256, P7468
   ROSE KM, 1983, PHILOS T ROY SOC B, V302, P135, DOI 10.1098/rstb.1983.0046
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226
   Stenram U, 1999, APMIS, V107, P420, DOI 10.1111/j.1699-0463.1999.tb01575.x
   STETLER DA, 1985, BIOCHEMISTRY-US, V24, P5163, DOI 10.1021/bi00340a031
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Waalkes MP, 1996, J PHARMACOL EXP THER, V277, P1026
   Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340
   Wade PA, 1999, NAT GENET, V23, P62
   WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822
   Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023
   YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3
   ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157
NR 70
TC 45
Z9 49
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2002
VL 277
IS 18
BP 16048
EP 16058
DI 10.1074/jbc.M111662200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 550PA
UT WOS:000175510400111
PM 11844796
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Scroop, R
   Eskridge, J
   Britz, GW
AF Scroop, R
   Eskridge, J
   Britz, GW
TI RETRACTED: Paradoxical cerebral arterial embolization of cement during
   intraoperative vertebroplasty: Case report (Retracted Article. See vol
   25, pg B1, 2004)
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article; Retracted Publication
ID PERCUTANEOUS VERTEBROPLASTY; ARTHROPLASTY
AB Paradoxical cerebral embolism of cement occurred in a 78-year-old woman after cement-assisted transpedicular spinal fixation surgery. Multiple pulmonary emboli of polymethylmethacrylate precipitated pulmonary hypertension and right-to-left shunting into the systemic circulation through a patent foramen ovale. This rare complication occurred because of failure to recognize venous migration of cement during the procedure and the injection of multiple levels in one setting. Although this was an open procedure, the technical aspects were the same as for vertebroplasty and the precautions should be applied to percutaneous vertebroplasty.
C1 Flinders Med Ctr, Dept Neuroradiol, Bedford Pk, SA, Australia.
   Flinders Med Ctr, Dept Neurol Surg, Bedford Pk, SA, Australia.
RP Scroop, R (reprint author), Flinders Med Ctr, Dept Radiol, Flinders Dr, Bedford Pk, SA, Australia.
CR BYRICK RJ, 1996, ANESTHESIOLOGY, V84, P721
   Chiras J, 1997, J NEURORADIOLOGY, V24, P45
   CHRISTIE J, 1994, J BONE JOINT SURG BR, V76B, P409
   Deramont H, 1990, PERCUTANEOUS VERTEBR
   Edmonds CR, 2000, ANESTHESIOLOGY, V93, P315, DOI 10.1097/00000542-200008000-00006
   GANGI A, 1994, AM J NEURORADIOL, V15, P83
   Jensen ME, 1997, AM J NEURORADIOL, V18, P1897
   Padovani B, 1999, AM J NEURORADIOL, V20, P375
   Turchin DC, 1995, T ORTHOP RES SOC, V20, P252
   Weill A, 1996, RADIOLOGY, V199, P241, DOI 10.1148/radiology.199.1.8633152
   Weiss SJ, 1996, ANESTHESIOLOGY, V84, P721, DOI 10.1097/00000542-199603000-00028
NR 11
TC 109
Z9 119
U1 1
U2 8
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD MAY
PY 2002
VL 23
IS 5
BP 868
EP 870
PG 3
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 552BW
UT WOS:000175599300027
PM 12006295
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
AF Fujii, Y
   Tanaka, H
TI RETRACTED: Comparison of granisetron and ramosetron for the prevention
   of nausea and vomiting after thyroidectomy (Retracted article. See vol.
   40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE thyroidectomy; nausea; vomiting; antiemetics; granisetron; ramosetron.
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; THERAPY
AB Background: Postoperative nausea and vomiting (PONV) are common after thyroidectomy. Granisetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, is more effective than the traditional antiemetics droperidol and metoclopramide for the prevention of PONV after thyroidectomy. Ramosetron, another new selective antagonist of 5-HT3 receptor, has been shown to have more potent and longer-acting properties than granisetron against cisplatin-induced emesis in ferrets.
   Objective: This study was undertaken to compare the efficacy and tolerability of granisetron and ramosetron for the prevention of PONV after thyroidectomy.
   Methods: In this randomized, double-blind study, patients received granisetron 3 mg or ramosetron 0.3 mg intravenously at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. Emetic episodes and safety were assessed during the first 24 hours and the second 24 hours after anesthesia.
   Results: Eighty patients (15 men, 65 women) aged 33 to 58 years were included in the study. Each study group consisted of 40 patients. There were no differences between groups with regard to patient demographics. The percentage of patients who were emesis free (no nausea, no retching, no vomiting) 0 to 24 hours after anesthesia was 83% (33 of 40) with granisetron and 88% (35 of 40) with ramosetron; the corresponding rates 24 to 48 hours after anesthesia were 63% (25 of 40) and 90% (36 of 40), respectively (P 0.004). The safety profile of the two 5-HT3 receptor antagonists was comparable, as no clinically serious adverse effects caused by the study drug were observed in either of the groups.
   Conclusions: Prophylactic antiemetic therapy with ramosetron was comparable to therapy with granisetron for the prevention of PONV 0 to 24 hours after anesthesia in patients who underwent thyroidectomy; 24 to 48 hours after anesthesia, ramosetron was more effective than granisetron for prophylaxis against PONV in this population.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   DEJONCKHEERE M, 1990, EUR J ANAESTH, V7, P421
   Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1999, LARYNGOSCOPE, V109, P664, DOI 10.1097/00005537-199904000-00028
   Fujii Y, 1998, BRIT J ANAESTH, V81, P526, DOI 10.1093/bja/81.4.526
   ITO H, 1995, NEUROPHARMACOLOGY, V34, P631, DOI 10.1016/0028-3908(95)00033-3
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   KUMAKURA H, 1990, J CLIN THER MED, V5, P25
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   VANWIJNGAARDEN I, 1990, EUR J PHARM-MOLEC PH, V188, P301, DOI 10.1016/0922-4106(90)90190-9
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 14
TC 19
Z9 19
U1 1
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD MAY
PY 2002
VL 24
IS 5
BP 766
EP 772
DI 10.1016/S0149-2918(02)85150-5
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 560BN
UT WOS:000176061600004
PM 12075944
DA 2018-12-27
ER

PT J
AU Kawasaki, H
   Taira, K
AF Kawasaki, H
   Taira, K
TI RETRACTED: Identification of genes by hybrid ribozymes that couple
   cleavage activity with the unwinding activity of an endogenous RNA
   helicase (Retracted Article. See vol 7, pg 746, 2006)
SO EMBO REPORTS
LA English
DT Article; Retracted Publication
ID FUNCTIONAL GENOMICS APPROACH; HEPATITIS-C VIRUS; BINDING PROTEINS;
   IN-VITRO; TRANSLATION; CATALYSIS; ENHANCEMENT; SPECIFICITY; HOMOLOG;
   LIBRARY
AB Novel ribozymes that couple the cleavage activity of hammerhead ribozymes with the unwinding activity of RNA helicase eIF4AI were constructed. This leads to extremely efficient cleavage of the target mRNA, regardless of the secondary structure of the RNA, and eliminates one of the major problems: many target sites on the RNA were previously inaccessible to cleavage due to secondary and/or tertiary structure formation. Moreover, libraries of hybrid ribozymes with randomized binding arms were introduced into cells. This procedure made it possible to readily identify the relevant genes associated with phenotype. Specifically, four genes known to be in the Fas-mediated apoptosis pathway were identified along with additional genes. This application of a randomized library of hybrid ribozymes represents a simple, powerful method for the identification of genes associated with specific phenotypes in the post-genome era.
C1 Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan.
   Natl Inst Adv Ind Sci & Technol, AIST, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058562, Japan.
   GenoFunct Inc, Tsukuba, Ibaraki 3058562, Japan.
RP Taira, K (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan.
EM taira@chembio.t.u-tokyo.ac.jp
CR Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   Craig AWB, 1998, NATURE, V392, P520
   Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641
   HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0
   HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x
   Hertel KJ, 1996, EMBO J, V15, P3751, DOI 10.1002/j.1460-2075.1996.tb00745.x
   Hsu CC, 1998, BIOCHEM BIOPH RES CO, V253, P594, DOI 10.1006/bbrc.1998.9813
   JAEGER JA, 1990, METHOD ENZYMOL, V183, P281
   Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200
   Kawasaki H, 1998, NATURE, V393, P284
   Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566
   KRUPP G, 2000, RIBOZYME BIOCH BIOTE
   Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4
   Lee N S, 1997, Methods Mol Biol, V74, P275
   Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709
   Li QX, 2000, NUCLEIC ACIDS RES, V28, P2605, DOI 10.1093/nar/28.13.2605
   MADDOX J, 1989, NATURE, V342, P609, DOI 10.1038/342609a0
   PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x
   Rodgers JT, 2000, ANAL BIOCHEM, V277, P254, DOI 10.1006/abio.1999.4394
   Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5
   SCANLON KJ, 1998, THERAPEUTIC APPL RIB
   TAIRA K, 1999, Patent No. 11316133
   TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597
   UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0
   Warashina M, 2001, P NATL ACAD SCI USA, V98, P5572, DOI 10.1073/pnas.091411398
   Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230
   Zhou DM, 1998, CHEM REV, V98, P991, DOI 10.1021/cr9604292
NR 29
TC 37
Z9 38
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD MAY
PY 2002
VL 3
IS 5
BP 443
EP 450
DI 10.1093/embo-reports/kvf098
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 554TP
UT WOS:000175753500014
PM 11964387
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Eto, K
   Ogasawara, M
   Umemura, K
   Nagai, Y
   Kimura, H
AF Eto, K
   Ogasawara, M
   Umemura, K
   Nagai, Y
   Kimura, H
TI RETRACTED: Hydrogen sulfide is produced in response to neuronal
   excitation (Retracted Article. See vol 24, pg 5649, 2004)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE hydrogen sulfide; neuromodulator; calcium ion; calmodulin; neuronal
   excitation; glutamate; LTP
ID LONG-TERM POTENTIATION; CYSTATHIONINE BETA-SYNTHASE; NITRIC-OXIDE;
   INTERCELLULAR MESSENGER; CARBON-MONOXIDE; HEME OXYGENASE; BRAIN-TISSUE;
   CHROMATOGRAPHY; HIPPOCAMPUS; ACTIVATION
AB Although hydrogen sulfide (H2S) is generally thought of in terms of a poisonous gas, it is endogenously produced in the brain. Physiological concentrations of H2S selectively enhance NMDA receptor-mediated responses and alter the induction of hippocampal long-term potentiation (LTP). Here we use cystathionine beta-synthase (CBS) knock-out mice to clearly show that CBS produces endogenous H2S in the brain and that H2S production is greatly enhanced by the excitatory neurotransmitter L-glutamate, as well as by electrical stimulation. This increased CBS activity is regulated by a pathway involving Ca2+/calmodulin. In addition, LTP is altered in CBS knock-out mice. These observations suggest that H2S is produced by CBS in response to neuronal excitation and that it may regulate some aspects of synaptic activity.
C1 Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878551, Japan.
RP Kimura, H (reprint author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878551, Japan.
EM kimura@ncnp.go.jp
RI Kimura, Hideo/J-6811-2016
FU NIGMS NIH HHS [5R21GM57504]
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682
   FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X
   GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0
   GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105
   GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366
   HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O
   HOSHIKA Y, 1977, J CHROMATOGR, V134, P423, DOI 10.1016/S0021-9673(00)88541-6
   Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723
   KERY V, 1994, J BIOL CHEM, V269, P25283
   Kimura H, 2000, BIOCHEM BIOPH RES CO, V267, P129, DOI 10.1006/bbrc.1999.1915
   LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497
   MAINES MD, 1988, FASEB J, V2, P2557
   MUDD SH, 1989, METABOLIC BASIS INHE, P693
   ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285
   PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0
   Parent A, 1998, J NEUROPHYSIOL, V79, P3295
   REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545
   Rhoads AR, 1997, FASEB J, V11, P331
   Russo C. Dello, 2000, Journal of Neuroendocrinology, V12, P225
   SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2
   SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572
   Shan XY, 2001, HUM MOL GENET, V10, P635, DOI 10.1093/hmg/10.6.635
   STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0
   STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267
   SWAROOP M, 1992, J BIOL CHEM, V267, P11455
   VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352
   WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8
   WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585
   ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368
NR 32
TC 139
Z9 176
U1 3
U2 20
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 1
PY 2002
VL 22
IS 9
BP 3386
EP 3391
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 546VN
UT WOS:000175296200016
PM 11978815
DA 2018-12-27
ER

PT J
AU Xu, YD
   Cheng, LF
   Zhang, LT
   Yin, HF
   Yin, XW
AF Xu, YD
   Cheng, LF
   Zhang, LT
   Yin, HF
   Yin, XW
TI RETRACTED: Microstructure and mechanical properties of three-dimensional
   textile Hi-Nicalon SiC/SiC composites by chemical vapor infiltration
   (Retracted article. See vol 89, 3598, 2006)
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article; Retracted Publication
ID CERAMIC-MATRIX COMPOSITES; SILICON-CARBIDE COMPOSITES; SIC COMPOSITES;
   IN-SITU; FIBER; WOVEN; DEPOSITION; BEHAVIOR; DAMAGE
AB Three-dimensional textile Hi-Nicalon SIC-fiber-reinforced SiC composites were fabricated using chemical vapor infiltration. The microstructure and mechanical properties of the composite materials were investigated under bending, shear, and impact loading. The density of the composites was 2.5 g.cm(-3) after the three-dimensional SiC perform was infiltrated for 30 h. The values of flexural strength were 860 MPa at room temperature and 1010 MPa at 1300degreesC under vacuum. Above the infiltration temperature, the failure behavior of the composites became brittle because of the strong interfacial bonding and the mismatch of thermal expansion coefficients between fiber and matrix. The fracture toughness was 30.2 MPa.m(1/2). The obtained value of shear strength was 67.5 MPa. The composites exhibited excellent impact resistance, and the dynamic fracture toughness of 36.0 kJ.m(-2) was measured using Charpy impact tests.
C1 Northwestern Polytech Univ, State Key Lab Solidificat Proc, Xian 710072, Shaanxi, Peoples R China.
RP Xu, YD (reprint author), Northwestern Polytech Univ, State Key Lab Solidificat Proc, Xian 710072, Shaanxi, Peoples R China.
CR BESMANN TM, 1993, HIGH TEMPERATURE CER, P215
   CLEGG WJ, 1990, NATURE, V347, P455, DOI 10.1038/347455a0
   Davies IJ, 1999, COMPOS PART A-APPL S, V30, P587, DOI 10.1016/S1359-835X(98)00154-7
   Davies IJ, 1999, COMPOS SCI TECHNOL, V59, P429, DOI 10.1016/S0266-3538(98)00092-X
   HAIGIS WR, 1993, MATER DESIGN, V14, P130
   INGHELS E, 1991, J MATER SCI, V26, P5403, DOI 10.1007/BF00553638
   Jacques S, 1997, J EUR CERAM SOC, V17, P1083, DOI 10.1016/S0955-2219(96)00216-6
   Jones RH, 1997, J NUCL MATER, V245, P87, DOI 10.1016/S0022-3115(97)00022-6
   KO FK, 1989, AM CERAM SOC BULL, V68, P401
   LACKEY WJ, 1995, J AM CERAM SOC, V78, P1564, DOI 10.1111/j.1151-2916.1995.tb08852.x
   Lipowitz J., 1995, CERAM ENG SCI P, V16, P55
   Naslain R, 1999, COMPOS PART A-APPL S, V30, P537, DOI 10.1016/S1359-835X(98)00147-X
   Pluvinage P, 1996, J MATER SCI, V31, P232, DOI 10.1007/BF00355150
   SAKI M, 1993, INT MATER REV, V38, P53
   Singh D, 1996, J AM CERAM SOC, V79, P591
   Snead LL, 1996, J NUCL MATER, V233, P26, DOI 10.1016/S0022-3115(96)00318-2
   STINTON DP, 1988, AM CERAM SOC BULL, V67, P350
   Wang MD, 1996, J MATER SCI, V31, P2065, DOI 10.1007/BF00356628
   Xu YD, 1998, CARBON, V36, P1051, DOI 10.1016/S0008-6223(98)00076-1
   Xu YD, 1997, J AM CERAM SOC, V80, P1897
   Xu YD, 2001, MAT SCI ENG A-STRUCT, V300, P196, DOI 10.1016/S0921-5093(00)01533-1
   YANG JM, 1994, J MATER SCI, V29, P5491, DOI 10.1007/BF01171567
NR 22
TC 11
Z9 13
U1 4
U2 16
PU AMER CERAMIC SOC
PI WESTERVILLE
PA 735 CERAMIC PLACE, PO BOX 6136, WESTERVILLE, OH 43086-6136 USA
SN 0002-7820
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD MAY
PY 2002
VL 85
IS 5
BP 1217
EP 1221
PG 5
WC Materials Science, Ceramics
SC Materials Science
GA 555HJ
UT WOS:000175788400032
DA 2018-12-27
ER

PT J
AU Budagian, V
   Nanni, P
   Lollini, PL
   Musiani, P
   Di Carlo, E
   Bulanova, E
   Paus, R
   Bulfone-Paus, S
AF Budagian, V
   Nanni, P
   Lollini, PL
   Musiani, P
   Di Carlo, E
   Bulanova, E
   Paus, R
   Bulfone-Paus, S
TI RETRACTED: Enhanced inhibition of tumour growth and metastasis, and
   induction of antitumour immunity by IL-2-IgG(2b) fusion protein
   (Retracted Article. See vol 73, pg 266, 2011)
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MAMMARY ADENOCARCINOMA; GENE-TRANSFER; INFILTRATING LYMPHOCYTES; SECRETE
   INTERLEUKIN-2; PROTECTIVE IMMUNITY; ENDOTHELIAL-CELLS; INTERFERON-GAMMA;
   T-CELLS; VACCINATION; CARCINOMA
AB Cytokine-immunoglobulin (Ig)-fusion proteins have attracted increasing interest as antitumour agents. Here, we have investigated the antimetastatic and antitumour responses elicited in vivo by mammary adenocarcinoma cells (TS/A) engineered to secrete interleukin (IL)-2-IgG fusion proteins. TS/A cells were transfected with DNA coding for IL-2-IgG2b, IgG2b or IL-2, and injected subcutaneously into syngeneic mice. Animals injected with TS/A-IL-2 or TS/A-IL-2-IgG2b both efficiently rejected tumours, whereas treatment with parental cells or TS/A-IgG2b was lethal. Interestingly, only mice vaccinated with IL-2-IgG2b fusion protein-secreting cells showed a long-lasting protective immunity against a later challenge with parental tumour cells. Moreover, the metastatic potential of TS/A-IL-2-IgG2b-transfected cells was dramatically decreased compared with TS/A-IL-2-cells, with a virtual absence of lung metastases after intravenous injection. Adenocarcinomas secreting IL-2-IgG2b exhibited a more prominent, early and persistent infiltration of CD4(+), CD8(+) and natural killer (NK) cells than TS/A-IL-2 cells. Therefore, upon transfection into adenocarcinoma cells, the IgG2b part of IL-2 fusion protein exerts intriguing added antitumour properties over IL-2 alone, thus contributing to a long-lasting tumour immunity, probably by the recruitment of specific immune effector cells. These findings suggest a promising new oncotherapeutic strategy for poorly immunogenic tumours: vaccination with tumour cells engineered to secrete IL-2-IgG2b fusion protein.
C1 Res Ctr, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Univ Bologna, Canc Res Inst, Bologna, Italy.
   GD Annunzio Univ, Dept Oncol, Chieti, Italy.
   GD Annunzio Univ, Dept Neurosci, Chieti, Italy.
   Univ Hamburg, Dept Dermatol, Univ Hosp Hosp Eppenforf, Hamburg, Germany.
RP Bulfone-Paus, S (reprint author), Res Ctr, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
EM sbulfone@fz-borstel.de
RI Lollini, Pier Luigi/A-7644-2008
OI Lollini, Pier Luigi/0000-0003-1702-4108; Nanni,
   Patrizia/0000-0001-5319-0803
CR Adris S, 2000, CANCER RES, V60, P6696
   Ayalon O, 1998, P NATL ACAD SCI USA, V95, P2435, DOI 10.1073/pnas.95.5.2435
   BENDER JR, 1987, J CLIN INVEST, V79, P1679, DOI 10.1172/JCI113007
   BROZNA JP, 1990, SEMIN THROMB HEMOST, V16, P326, DOI 10.1055/s-2007-1002685
   Bulfone-Paus S, 1998, CANCER RES, V58, P2707
   CAVALLO F, 1993, CANCER RES, V53, P5067
   Cavallo F, 1997, J NATL CANCER I, V89, P1049, DOI 10.1093/jnci/89.14.1049
   DAMLE NK, 1987, J IMMUNOL, V138, P1779
   DEGIOVANNI C, 1991, INT J CANCER, V48, P270, DOI 10.1002/ijc.2910480220
   Dela Cruz JS, 2000, J IMMUNOL, V165, P5112, DOI 10.4049/jimmunol.165.9.5112
   DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539
   Dunussi-Joannopoulos K, 1999, BLOOD, V94, P4263
   Fathallah-Shaykh HM, 1998, INT J CANCER, V75, P266, DOI 10.1002/(SICI)1097-0215(19980119)75:2<266::AID-IJC16>3.0.CO;2-B
   Fuji N, 1999, GENE THER, V6, P1120, DOI 10.1038/sj.gt.3300916
   Giezeman-Smits KM, 2000, CANCER RES, V60, P2449
   HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774
   HOCK H, 1993, CANCER RES, V53, P714
   Klein CA, 2000, TRENDS CELL BIOL, V10, P489, DOI 10.1016/S0962-8924(00)01846-8
   Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534
   Lode HN, 1998, PHARMACOL THERAPEUT, V80, P277, DOI 10.1016/S0163-7258(98)00033-3
   Mach N, 2000, CURR OPIN IMMUNOL, V12, P571, DOI 10.1016/S0952-7915(00)00144-8
   Meazza R, 2000, INT J CANCER, V87, P574, DOI 10.1002/1097-0215(20000815)87:4<574::AID-IJC18>3.0.CO;2-T
   Moingeon P, 2001, VACCINE, V19, P1305, DOI 10.1016/S0264-410X(00)00372-8
   NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199
   Osanto S, 2000, HUM GENE THER, V11, P739, DOI 10.1089/10430340050015635
   Oshikawa K, 1999, P NATL ACAD SCI USA, V96, P13351, DOI 10.1073/pnas.96.23.13351
   Peng LS, 1999, J IMMUNOL, V163, P250
   Rakhmilevich AL, 2000, CANCER GENE THER, V7, P826, DOI 10.1038/sj.cgt.7700176
   Rozera C, 1999, AM J PATHOL, V154, P1211, DOI 10.1016/S0002-9440(10)65373-4
   SALMI M, 1995, J IMMUNOL, V154, P6002
   Shtil AA, 1999, BLOOD, V93, P1831
   Takashima I, 1999, ANTICANCER RES, V19, P5299
   Todo T, 2001, CANCER RES, V61, P153
   Yamamoto T, 2000, EUR J CANCER, V36, P2007, DOI 10.1016/S0959-8049(00)00244-6
   Yoong KF, 1998, J IMMUNOL, V160, P3978
   Zeidler R, 1999, J IMMUNOL, V163, P1246
NR 36
TC 6
Z9 7
U1 2
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD MAY
PY 2002
VL 55
IS 5
BP 484
EP 492
DI 10.1046/j.1365-3083.2002.01081.x
PG 9
WC Immunology
SC Immunology
GA 545KN
UT WOS:000175216500008
PM 11975760
DA 2018-12-27
ER

PT J
AU Aoyama, T
   Hosseinkhani, H
   Yamamoto, S
   Ogawa, O
   Tabata, Y
AF Aoyama, T
   Hosseinkhani, H
   Yamamoto, S
   Ogawa, O
   Tabata, Y
TI RETRACTED: Enhanced expression of plasmid DNA-cationized gelatin complex
   by ultrasound in murine muscle (Retracted article. See vol. 232, pg.
   267, 2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE ultrasound irradiation; enhancement; gene expression; cationized
   gelatin; in vivo
ID DIRECT GENE-TRANSFER; CELLS IN-VITRO; MAMMALIAN-CELLS; TRANSFECTION;
   SONICATION; CAVITATION; DELIVERY; VECTOR; VIVO
AB This study is an investigation to experimentally confirm that ultrasound (US) irradiation is effective in enhancing the gene expression of plasmid DNA. A cationized gelatin was prepared by introducing primary amino groups into gelatin. The plasmid of the LacZ gene was complexed with the cationized gelatin and injected into the femoral muscle of normal mice. Following US irradiation at the injected site of muscle, the gene expression of the treated muscle was evaluated to compare with that of the complex injection plus no US irradiation. US irradiation enabled the complex to significantly enhance the gene expression at the injected muscle, in contrast to naked plasmid DNA. although the extent depended on the experimental conditions, such as the injection dose of plasmid DNA, and the time period or timing of US irradiation. The gene-expressed area at the muscle was not changed by the time interval between the complex injection and US irradiation, Fluorescent microscopic observation revealed that the complex was homogeneously distributed in the muscle tissue around the injected site by US irradiation without any dissociation of plasmid DNA. The fluorescent image of plasmid DNA superposed on that of myosin heavy chain indicated intracellular localization of plasmid DNA. We demonstrated that US irradiation is a promising technique to enhance gene expression even in the normal muscle. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Sakyo Ku, Kyoto 6068507, Japan.
   Grad Sch Med, Dept Urol, Kyoto, Japan.
RP Tabata, Y (reprint author), Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.
EM yasuhiko@frontier.kyoto-u.ac.jp
CR Anwer K, 2000, GENE THER, V7, P1833, DOI 10.1038/sj.gt.3301302
   Bao SP, 1997, ULTRASOUND MED BIOL, V23, P953, DOI 10.1016/S0301-5629(97)00025-2
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y
   CRUM LA, 1992, J ACOUST SOC AM, V91, P1113, DOI 10.1121/1.402638
   Danko I, 1997, HUM MOL GENET, V6, P1435, DOI 10.1093/hmg/6.9.1435
   Doh SG, 1997, GENE THER, V4, P648, DOI 10.1038/sj.gt.3300460
   FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463
   HOSSEINKHANI H, IN PRESS J DRUG TARG
   JOERSBO M, 1992, PHYSIOL PLANTARUM, V85, P230, DOI 10.1034/j.1399-3054.1992.850215.x
   JOERSBO M, 1990, PLANT CELL REP, V9, P207, DOI 10.1007/BF00232181
   Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682
   Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339
   Lauer U, 1997, GENE THER, V4, P710, DOI 10.1038/sj.gt.3300462
   Lawrie A, 1999, CIRCULATION, V99, P2617, DOI 10.1161/01.CIR.99.20.2617
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Manome Y, 2000, HUM GENE THER, V11, P1521, DOI 10.1089/10430340050083252
   Romano G, 2000, STEM CELLS, V18, P19, DOI 10.1634/stemcells.18-1-19
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   Unger EC, 1997, INVEST RADIOL, V32, P723, DOI 10.1097/00004424-199712000-00001
   WEBSTER DF, 1980, ULTRASONICS, V18, P33, DOI 10.1016/0041-624X(80)90050-5
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   ZAKORN D, 1969, BIBL HAEMATOL, V33, P30
   ZHANG LJ, 1991, BIO-TECHNOL, V9, P996, DOI 10.1038/nbt1091-996
NR 25
TC 39
Z9 41
U1 5
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 23
PY 2002
VL 80
IS 1-3
BP 345
EP 356
AR PII S0168-3659(02)00029-9
DI 10.1016/S0168-3659(02)00029-9
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 555PR
UT WOS:000175802900028
PM 11943410
DA 2018-12-27
ER

PT J
AU Tomazic, M
   Janez, A
   Sketelj, A
   Kocijancic, A
   Ecke, J
   Sharma, PM
AF Tomazic, M
   Janez, A
   Sketelj, A
   Kocijancic, A
   Ecke, J
   Sharma, PM
TI RETRACTED: Comparison of alterations in insulin signalling pathway in
   adipocytes from Type II diabetic pregnant women and women with
   gestational diabetes mellitus (Retracted Article. See vol 45, pg 1744,
   2002)
SO DIABETOLOGIA
LA English
DT Article; Retracted Publication
DE Gestational diabetes mellitus; Type II diabetes mellitus; insulin
   resistance; membrane glycoprotein PC-1
ID MEMBRANE GLYCOPROTEIN PC-1; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL
   3-KINASE; SKELETAL-MUSCLE; OBESE WOMEN; PHOSPHORYLATION; STIMULATION;
   RESISTANCE; TOLERANCE; OVEREXPRESSION
AB Aims/hypothesis. The cellular mechanisms for the insulin resistance in pregnancy and gestational diabetes mellitus are not known. The membrane protein plasma cell glycoprotein PC-1 has been identified as an inhibitor of insulin receptor tyrosine kinase activity and could have a role in insulin resistance. This study aimed to examine the effects of insulin on glucose transport and changes in insulin receptor tyrosine phosphorylation, IRS-1 and PC-1.
   Methods. Adipocytes were obtained either during elective cesarean section from three groups of subjects (Type II diabetic pregnant women (n=6) women with gestational diabetes mellitus (n=10) and pregnant women with normal glucose tolerance (n=6) as pregnant control subjects) or during elective gynaecological surgery from non-pregnant (n=6) control subjects.
   Results. Insulin stimulated glucose transport was reduced by 50% in women with gestational diabetes mellitus, and 70% in pregnant women with Type II diabetes, compared to the non-pregnant control subjects. After maximal insulin stimulation of adipocytes, IRTK phosphorylation was reduced by 29.5% in women with gestational diabetes mellitus and 44.5% in women with Type II diabetes, compared to the nonpregnant control subjects. We also found that IRS-1 phosphorylation was reduced by 32% and 48%, respectively. On the other hand, PC-I content in adipocytes in women with gestational diabetes mellitus increased by 320% and 668% in Type II diabetic women, compared to the non-pregnant control subjects.
   Conclusions/interpretation. Our results indicate that women with gestational diabetes mellitus and Type II diabetes have increased PC-1 content and suggest that this could contribute to lower phosphorylation levels of IRTK and IRS-1. Furthermore, these postreceptor defects in insulin signalling pathway are greater in both groups compared to the women with normal pregnancy. However, results from women with Type It diabetes show that pre-existing insulin resistance lead to an even greater deterioration of the signalling pathway.
C1 Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Ljubljana 1525, Slovenia.
   Univ Med Ctr, Dept Obstet & Gynaecol, Ljubljana, Slovenia.
   German Diabet Res Inst, Dusseldorf, Germany.
   Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, San Diego, CA 92103 USA.
RP Tomazic, M (reprint author), Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Zaloska 7, Ljubljana 1525, Slovenia.
EM marjeta.tomazic@kelj.si
CR BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x
   BARDEN T P, 1981, Clinical Obstetrics and Gynecology, V24, P3, DOI 10.1097/00003081-198103000-00005
   Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524
   BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W
   CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902
   CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117
   Friedman JE, 1999, DIABETES, V48, P1807, DOI 10.2337/diabetes.48.9.1807
   Frittitta L, 2001, DIABETES, V50, P1952, DOI 10.2337/diabetes.50.8.1952
   GARVEY WT, 1993, DIABETES, V42, P1773, DOI 10.2337/diabetes.42.12.1773
   GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909
   KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586
   KUHL C, 1991, DIABETES, V40, P18, DOI 10.2337/diab.40.2.S18
   Kumakura S, 1998, J CELL BIOCHEM, V68, P366, DOI 10.1002/(SICI)1097-4644(19980301)68:3<366::AID-JCB7>3.0.CO;2-S
   MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0
   Maddux BA, 2000, DIABETES, V49, P13, DOI 10.2337/diabetes.49.1.13
   OKADA T, 1994, J BIOL CHEM, V269, P3568
   OSULLIVAN JB, 1964, DIABETES, V13, P278
   PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502
   Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171
   Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148
   RUDERMAN NB, 1990, P NATL ACAD SCI USA, V91, P9931
   RYAN EA, 1985, DIABETES, V34, P380, DOI 10.2337/diabetes.34.4.380
   Shao JH, 2000, DIABETES, V49, P603, DOI 10.2337/diabetes.49.4.603
   Youngren JF, 1996, DIABETES, V45, P1324, DOI 10.2337/diabetes.45.10.1324
NR 24
TC 12
Z9 15
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD APR
PY 2002
VL 45
IS 4
BP 502
EP 508
DI 10.1007/s00125-002-0791-z
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 557YL
UT WOS:000175936600004
PM 12032625
OA Bronze
DA 2018-12-27
ER

PT J
AU Deschenes, LA
   Vanden Bout, DA
AF Deschenes, LA
   Vanden Bout, DA
TI RETRACTED: Comparison of ensemble and single molecule approaches to
   probing polymer relaxation dynamics near T-g (Retracted Article. See vol
   124, ARTN 169901, 2006)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID ROTATIONAL REORIENTATION DYNAMICS; GLASS-TRANSITION; O-TERPHENYL;
   HETEROGENEOUS DYNAMICS; SUPERCOOLED LIQUIDS; POLYSTYRENE; DIFFUSION;
   FILMS; SPECTROSCOPY; DECADES
AB Single molecule spectroscopy and polarization holeburning (PHB) are used to measure the dynamics of rotation for rhodamine 6G in poly(methylacrylate). It is found that the ensemble average correlation time obtained from the single molecule experiments is the same as that obtained from bulk fluorescence anisotropy decay. Both reflect the same underlying dynamics as the mechanically measured alpha relaxation. Fitting alpha relaxation and PHB data to the Vogel-Tammann-Fulcher (VTF) equation, it is found that the two measurements follow the same temperature dependence, but with absolute times that differ by nearly four orders of magnitude. This difference is discussed in two contexts. In the first the relative ratio of the correlation and alpha-relaxation times depend on probe size, in which case the large difference is not unexpected given the size of the probe. In the second, the difference is attributed to specific probe/polymer interactions. In this case, a modified VTF equation that includes an activation energy term can be used to explain this phenomenon; when all parameters but the activation energy are fixed to the alpha-relaxation values, it is found that an activation energy of 21 KJ/mol could cause the observed slowing of the rhodamine 6G rotational correlation times. (C) 2002 American Institute of Physics.
C1 Univ Texas, Dept Chem & Biochem, Ctr Nano & Mol Mat Sci, Austin, TX 78712 USA.
   Univ Texas, Texas Mat Inst, Austin, TX 78712 USA.
RP Deschenes, LA (reprint author), Univ Texas, Dept Chem & Biochem, Ctr Nano & Mol Mat Sci, Austin, TX 78712 USA.
EM davandenbout@mail.utexas.edu
RI Vanden Bout, David/J-8633-2013
OI Vanden Bout, David/0000-0001-5410-9421
CR Angell CA, 2000, J APPL PHYS, V88, P3113, DOI 10.1063/1.1286035
   Bohmer R, 1998, J NON-CRYST SOLIDS, V235, P1, DOI 10.1016/S0022-3093(98)00581-X
   CICERONE MT, 1995, J CHEM PHYS, V102, P471, DOI 10.1063/1.469425
   CICERONE MT, 1995, J CHEM PHYS, V103, P5684, DOI 10.1063/1.470551
   CICERONE MT, 1993, J PHYS CHEM-US, V97, P10489, DOI 10.1021/j100142a037
   Deschenes LA, 2001, SCIENCE, V292, P255, DOI 10.1126/science.1056430
   Deschenes LA, 2001, J PHYS CHEM B, V105, P11978, DOI 10.1021/jp012238v
   DHINOJWALA A, 1994, J CHEM PHYS, V100, P6046, DOI 10.1063/1.467115
   DHINOJWALA A, 1994, J NON-CRYST SOLIDS, V172, P286, DOI 10.1016/0022-3093(94)90447-2
   Ediger MD, 1996, J PHYS CHEM-US, V100, P13200, DOI 10.1021/jp953538d
   Ediger MD, 2000, ANNU REV PHYS CHEM, V51, P99, DOI 10.1146/annurev.physchem.51.1.99
   EDIGER MD, 1999, J PHYS CHEM-US, V103, P4177
   FOURKAS JT, 1997, SUPERCOOLED LIQUID A, V676
   GREET RJ, 1967, J CHEM PHYS, V46, P1243, DOI 10.1063/1.1840842
   Hall DB, 1998, MACROMOLECULES, V31, P8817, DOI 10.1021/ma9812128
   Hall DB, 1999, MACROMOLECULES, V32, P8052, DOI 10.1021/ma9904159
   Hwang Y, 2000, J POLYM SCI POL PHYS, V38, P68
   INOUE T, 1995, MACROMOLECULES, V28, P3425, DOI 10.1021/ma00113a049
   Kelley AM, 2001, SCIENCE, V292, P1671
   Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670
   PORTER G, 1977, CHEM PHYS LETT, V49, P416, DOI 10.1016/0009-2614(77)87005-X
   Russell EV, 2000, NATURE, V408, P695
   SANCHIS A, 1995, MACROMOLECULES, V28, P2693, DOI 10.1021/ma00112a014
   SCHEIMER B, 1996, SCIENCE, V274, P5288
   Sillescu H, 1999, J NON-CRYST SOLIDS, V243, P81, DOI 10.1016/S0022-3093(98)00831-X
   Wang CY, 2000, J CHEM PHYS, V112, P6933, DOI 10.1063/1.481319
   WEBER G, 1971, J CHEM PHYS, V55, P2399, DOI 10.1063/1.1676423
NR 27
TC 18
Z9 18
U1 3
U2 13
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD APR 1
PY 2002
VL 116
IS 13
BP 5850
EP 5856
DI 10.1063/1.1456034
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 532JH
UT WOS:000174470700062
DA 2018-12-27
ER

PT J
AU Kawasaki, H
   Onuki, R
   Suyama, E
   Taira, K
AF Kawasaki, H
   Onuki, R
   Suyama, E
   Taira, K
TI RETRACTED: Identification of genes that function in the
   TNF-alpha-mediated apoptotic pathway using randomized hybrid ribozyme
   libraries (Retracted Article. See vol 24, pg 1170, 2006)
SO NATURE BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; GENOMICS APPROACH; IN-VITRO; RECEPTOR;
   EXPRESSION; PROTEIN; CLONING; RNA; TRANSLATION; DEATH
AB Now that the sequences of many genomes are available, methods are required for the rapid identification of functional genes. We describe here a simple system for the isolation of genes that function in the tumor necrosis factor-alpha (TNF-alpha)-mediated pathway of apoptosis, using RNA helicase-associated ribozyme libraries with randomized substrate-binding arms. Because target-site accessibility considerably limits the effective use of intracellular ribozymes, the effectiveness of a conventional ribozyme library has been low. To overcome this obstacle, we attached to ribozymes an RNA motif (poly(A)-tail) able to interact with endogenous RNA helicase(s) so that the resulting helicase-attached, hybrid ribozymes can more easily attack target sites regardless of their secondary or tertiary structures. When the phenotype of cells changes upon introduction of a ribozyme library, genes responsible for these changes may be identified by sequencing the active ribozyme clones. In the case of TNF-alpha-mediated apoptosis, when a ribozyme library was introduced into MCF-7 cells, surviving clones were completely or partially resistant to TNF-alpha-induced apoptosis. We identified many proapoptotic genes and partial sequences of previously uncharacterized genes using this method. Our gene discovery system should be generally applicable to the identification of functional genes in various systems.
C1 AIST, Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058562, Japan.
   Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan.
   Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
RP Taira, K (reprint author), AIST, Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.
EM taira@chembio.t.u-tokyo.ac.jp
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Baker SJ, 1998, ONCOGENE, V17, P3261
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0
   Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9
   Cohen GM, 1997, BIOCHEM J, V326, P1
   Craig AWB, 1998, NATURE, V392, P520
   HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0
   HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8
   Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200
   Kawasaki H, 1998, NATURE, V393, P284
   Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566
   KRUPP G, 2000, RIBOZYME BIOCH BIOTE
   Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830
   Li QX, 2000, NUCLEIC ACIDS RES, V28, P2605, DOI 10.1093/nar/28.13.2605
   ROSSI JJ, 1999, INTRACELLULAR RIBOZY
   SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W
   Serebriiskii IG, 2001, BIOTECHNIQUES, V30, P634, DOI 10.2144/01303dd02
   SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731
   Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053
   SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641
   TAIRA K, 1999, Patent No. 11316133
   Tanabe T, 2000, NATURE, V406, P473, DOI 10.1038/35020190
   Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412
   UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0
   van Berkum NL, 2001, CURR OPIN BIOTECH, V12, P48, DOI 10.1016/S0958-1669(00)00173-7
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Warashina M, 2001, P NATL ACAD SCI USA, V98, P5572, DOI 10.1073/pnas.091411398
   WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704
   Wittrup KD, 2001, CURR OPIN BIOTECH, V12, P395, DOI 10.1016/S0958-1669(00)00233-0
   Zhou DM, 1998, CHEM REV, V98, P991, DOI 10.1021/cr9604292
NR 34
TC 63
Z9 64
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD APR
PY 2002
VL 20
IS 4
BP 376
EP 380
DI 10.1038/nbt0402-376
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 536BY
UT WOS:000174681900025
PM 11923844
DA 2018-12-27
ER

PT J
AU Bais, HP
   Walker, TS
   Stermitz, FR
   Hufbauer, RA
   Vivanco, JM
AF Bais, HP
   Walker, TS
   Stermitz, FR
   Hufbauer, RA
   Vivanco, JM
TI RETRACTED: Enantiomeric-dependent phytotoxic and antimicrobial activity
   of (+/-)-catechin. A rhizosecreted racemic mixture from spotted knapweed
   (Retracted article. See vol. 151, pg. 967, 2009)
SO PLANT PHYSIOLOGY
LA English
DT Letter; Retracted Publication
ID BIOLOGY
C1 Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA.
RP Vivanco, JM (reprint author), Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
EM jvivanco@lamar.colostate.edu
CR AGRIOS GN, 1997, PLATN PATHOLOGY
   Bais HP, 2001, IN VITRO CELL DEV-PL, V37, P730
   Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521
   Callaway RM, 1999, ECOLOGY, V80, P1196, DOI 10.1890/0012-9658(1999)080[1196:BCHMIC]2.0.CO;2
   Callaway RM, 2001, ECOL LETT, V4, P429, DOI 10.1046/j.1461-0248.2001.00251.x
   De Moraes CM, 2001, NATURE, V410, P577, DOI 10.1038/35069058
   DECONDOLLE AP, 1832, PHYSIOLAGIAE VEGETAL
   Du QZ, 2001, J CHROMATOGR A, V921, P331, DOI 10.1016/S0021-9673(01)00862-7
   Karimdzhanov A. K., 1997, Chemistry of Natural Compounds, V33, P187, DOI 10.1007/BF02291539
   Kiderlen AE, 2001, Z NATURFORSCH C, V56, P444
   Kim SJ, 1997, BIOSCI BIOTECH BIOCH, V61, P225, DOI 10.1271/bbb.61.225
   MCKINLEY TC, 1993, PLANT PHYSIOL BIOCH, V31, P835
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   NAHRSTEDT A, 1987, PHYTOCHEMISTRY, V26, P1546, DOI 10.1016/S0031-9422(00)81860-9
   Nardi S, 2000, CHEMOSPHERE, V41, P653, DOI 10.1016/S0045-6535(99)00488-9
   ONO K, 1997, Patent No. 09224689
   ROSHINA VV, 1993, EXCRETORY FUNCTIONS
   SCHULTZE M, 1994, INT REV CYTOL, V156, P1, DOI 10.1016/S0074-7696(08)62252-4
   Shulaev V, 1997, NATURE, V386, P738, DOI 10.1038/386738a0
   Steel RGD, 1980, PRINCIPLES PROCEDURE
   Wu HW, 2000, J AGR FOOD CHEM, V48, P5321, DOI 10.1021/jf0006473
NR 21
TC 176
Z9 195
U1 5
U2 61
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
EI 1532-2548
J9 PLANT PHYSIOL
JI Plant Physiol.
PD APR
PY 2002
VL 128
IS 4
BP 1173
EP 1179
DI 10.1104/pp.011019
PG 7
WC Plant Sciences
SC Plant Sciences
GA 545GY
UT WOS:000175209900004
PM 11950966
OA Bronze
DA 2018-12-27
ER

PT J
AU Saitoh, Y
   Kaneda, K
   Murakawa, M
AF Saitoh, Y
   Kaneda, K
   Murakawa, M
TI RETRACTED: The effect of ulinastatin pre-treatment on vecuronium-induced
   neuromuscular block in patients with hepatic cirrhosis (Retracted
   article. See vol. 73, pg. 526, 2018)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE monitoring : neuromuscular function; neuromuscular relaxants :
   vecuronium liver disease : cirrhosis
ID ORG NC 45; RENAL-FAILURE; PHARMACOKINETICS; PANCURONIUM; INHIBITOR
AB The aim of this study was to investigate the effect of ulinastatin, a protease inhibitor, on the neuromuscular block produced by vecuronium in patients with hepatic cirrhosis. Thirty adult patients with hepatic cirrhosis were randomly allocated to receive ulinastatin (cirrhosis/ulinastatin group, n = 15) or saline (cirrhosis/saline group, it = 15). Fifteen healthy adult patients without hepatic cirrhosis comprised a control group. Patients were given a standardised anaesthetic that included nitrous oxide and isoflurane in oxygen, and fentanyl. A bolus dose of ulinastatin 5000 unit.kg(-1) was given to members of the cirrhosis/ulinastatin group. The same volume of normal saline was given to the other two groups. Two minutes later, vecuronium 0.1 mg.kg(-1) was given. The onset of neuromuscular block was significantly slower in the cirrhosis/ulinastatin group than in the cirrhosis/saline and control groups (p < 0.05). Spontaneous recovery of neuromuscular function was significantly quicker in the cirrhosis/ulinastatin and control groups than in the cirrhosis/saline group (1) < 0.05). The time course of recovery in the cirrhosis/ulinastatin and control groups was similar. We conclude that in cirrhotic patients, ulinastatin delays the onset of neuromuscular block produced by vecuronium. After pretreatment with ulinastatin, the speed of recovery from neuromuscular block in patients with cirrhosis becomes similar to that seen in healthy patients.
C1 Fukushima Med Univ, Sch Med, Dept Anaesthesiol, Fukushima 9601295, Japan.
RP Saitoh, Y (reprint author), Fukushima Med Univ, Sch Med, Dept Anaesthesiol, 1 Hikarigaoka, Fukushima 9601295, Japan.
CR AOIKE I, 1989, NEPHRON, V52, P368, DOI 10.1159/000185683
   BELL CF, 1985, BRIT J ANAESTH, V57, P160, DOI 10.1093/bja/57.2.160
   BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782
   DELVIN JC, 1993, BRIT J ANAESTH, V71, P227
   DONATI F, 1988, Canadian Journal of Anaesthesia, V35, pS52
   DUVALDESTIN P, 1980, BRIT J ANAESTH, V52, P789, DOI 10.1093/bja/52.8.789
   DUVALDESTIN P, 1978, BRIT J ANAESTH, V50, P1131, DOI 10.1093/bja/50.11.1131
   FAHEY MR, 1981, BRIT J ANAESTH, V53, P1049, DOI 10.1093/bja/53.10.1049
   HARVEY AL, 1982, BRIT J PHARMACOL, V77, P153, DOI 10.1111/j.1476-5381.1982.tb09281.x
   LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010
   Matsumoto N, 1989, Masui, V38, P531
   MCINTYRE N, 1991, OXFORD TXB CLIN HEPA, P289
   MILLER RD, 1972, ANESTHESIOLOGY, V37, P573, DOI 10.1097/00000542-197212000-00001
   Munoz HR, 1997, ANESTH ANALG, V85, P437, DOI 10.1097/00000539-199708000-00034
   OHNISHI H, 1985, JPN J PHARMACOL, V39, P137, DOI 10.1254/jjp.39.137
   PARFITT K, 1999, MARTINDALE COMPLETE, P1641
   SAITOH Y, 1993, BRIT J ANAESTH, V70, P402, DOI 10.1093/bja/70.4.402
   Saitoh Y, 1999, ANESTH ANALG, V89, P1565, DOI 10.1097/00000539-199912000-00048
   TRAPNELL JE, 1974, BRIT J SURG, V61, P177, DOI 10.1002/bjs.1800610303
   UPTON RA, 1982, ANESTH ANALG, V61, P313
NR 20
TC 4
Z9 6
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD MAR
PY 2002
VL 57
IS 3
BP 218
EP 222
DI 10.1046/j.0003-2409.2001.02468.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 530QB
UT WOS:000174369500003
PM 11879209
OA Bronze
DA 2018-12-27
ER

PT J
AU Marcato, P
   Mulvey, G
   Armstrong, GD
AF Marcato, P
   Mulvey, G
   Armstrong, GD
TI RETRACTED: Cloned Shiga toxin 2 B subunit induces apoptosis in ramos
   Burkitt's lymphoma B cells (Retracted Article. See vol 71, pg 4828,
   2003)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID ESCHERICHIA-COLI O157-H7; BREFELDIN-A; AFFINITY PURIFICATION;
   SHIGELLA-DYSENTERIAE; PEPTIDE ELONGATION; PROTEIN-SYNTHESIS;
   CRYSTAL-STRUCTURE; ACTIVATION; DEATH; INDUCTION
AB The Shiga toxins (Stx1 and Stx2), produced by Shigella dysenteriae type 1 and enterohemorrhagic Escherichia coli, consist of one A subunit and five B subunits. The Stx1 and Stx2 B subunits form a pentameric structure that binds to globotriaosylceramide (Gb3-Cer) receptors on eukaryotic cells and promotes endocytosis. The A subunit then inhibits protein biosynthesis, which triggers apoptosis in the affected cell. In addition to its Gb3-Cer binding activity, the data in the following report demonstrate that the Stx2 B pentamer induces apoptosis in Ramos Burkitt's lymphoma B cells independently of A subunit activity. Apoptosis was not observed in A subunit-free preparations of the Stx1 B pentamer which competitively inhibited Stx2 B pentamer-mediated apoptosis. The pancaspase inhibitor, Z-VAD-fmk, prevented apoptosis in Ramos cells exposed to the Stx2 B subunit, Stx1 or Stx2. Brefeldin A, an inhibitor of the Golgi transport system, also prevented Stx2 B subunit-mediated apoptosis. These observations suggest that the Stx2 B subunit must be internalized, via Gb3-Cer receptors, to induce Ramos cell apoptosis. Moreover, unlike the two holotoxins, Stx2 B subunit-mediated apoptosis does not involve inhibition of protein biosynthesis. This study provides further insight into the pathogenic potential of this family of potent bacterial exotoxins.
C1 Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada.
RP Armstrong, GD (reprint author), Univ Alberta, Dept Med Microbiol & Immunol, 1-21 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.
EM glen.armstrong@ualberta.ca
CR ACHESON DWK, 1993, MICROB PATHOGENESIS, V14, P57, DOI 10.1006/mpat.1993.1006
   Arab S, 1998, J NEURO-ONCOL, V40, P137, DOI 10.1023/A:1006010019064
   BROWN JE, 1980, FEBS LETT, V117, P84, DOI 10.1016/0014-5793(80)80918-5
   CALDERWOOD SB, 1990, INFECT IMMUN, V58, P2977
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   DONOHUEROLFE A, 1989, MOL MICROBIOL, V3, P1231, DOI 10.1111/j.1365-2958.1989.tb00273.x
   DONTA ST, 1995, J INFECT DIS, V171, P721, DOI 10.1093/infdis/171.3.721
   ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x
   FALK MH, 1992, BLOOD, V79, P3300
   FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59
   GESER A, 1983, EUR J CANCER CLIN ON, V19, P1393, DOI 10.1016/0277-5379(93)90009-T
   GIANVITI A, 1994, PEDIATR NEPHROL, V8, P705, DOI 10.1007/BF00869095
   Gordon J, 2000, CELL DEATH DIFFER, V7, P785, DOI 10.1038/sj.cdd.4400710
   GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481
   GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0
   GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321
   HEAD SC, 1991, J BIOL CHEM, V266, P3617
   HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8
   JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391
   KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15
   Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278
   Kiyokawa N, 2001, J CELL BIOCHEM, V81, P128, DOI 10.1002/1097-4644(20010401)81:1<128::AID-JCB1029>3.0.CO;2-G
   KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071
   KLEIN G, 1983, J IMMUNOL, V130, P1985
   Kojima S, 2000, INFECT IMMUN, V68, P2791, DOI 10.1128/IAI.68.5.2791-2796.2000
   Kojio S, 2000, FEMS IMMUNOL MED MIC, V29, P275, DOI 10.1016/S0928-8244(00)00217-0
   LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035
   LINDBERG AA, 1987, J BIOL CHEM, V262, P1779
   Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2
   MANGENEY M, 1993, CANCER RES, V53, P5314
   Marcato P, 2001, J INFECT DIS, V183, P435, DOI 10.1086/318080
   MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424
   Mori T, 2000, EXP HEMATOL, V28, P1260, DOI 10.1016/S0301-472X(00)00538-5
   Mulvey G, 1998, J MICROBIOL METH, V32, P247, DOI 10.1016/S0167-7012(98)00028-1
   Nakagawa I, 1999, MOL MICROBIOL, V33, P1190, DOI 10.1046/j.1365-2958.1999.01564.x
   OBRIG TG, 1987, BIOCHEM J, V244, P287, DOI 10.1042/bj2440287
   ORCI L, 1991, CELL, V64, P1183
   REISBIG R, 1981, J BIOL CHEM, V256, P8739
   SJOGREN R, 1994, GASTROENTEROLOGY, V106, P306, DOI 10.1016/0016-5085(94)90587-8
   Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021
   STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0
   Suzuki A, 2000, GENE DEV, V14, P1734
   Taga S, 1997, BLOOD, V90, P2757
   Takeda T, 1993, Nihon Rinsho, V51, P198
   THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020
   WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3
   Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4
NR 48
TC 25
Z9 27
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2002
VL 70
IS 3
BP 1279
EP 1286
DI 10.1128/IAI.70.3.1279-1286.2002
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 522EQ
UT WOS:000173883100032
PM 11854211
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Cziraki, A
   Horvath, IG
   Papp, L
AF Cziraki, A
   Horvath, IG
   Papp, L
TI RETRACTED: Endothelial function studies in pulmonary vascular disease:
   Determination of angiotensin coinverting enzyme activity in humans
   (Retracted Article. See vol. 10, pg 665, 2002)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE pulmonary vascular disease; angiotensin converting enzyme; pulmonary
   capillary endothelium
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; EUROPEAN CONSENSUS
   CONFERENCE; INHALED NITRIC-OXIDE; CONVERTING ENZYME; ORGAN FAILURE;
   METABOLISM; INVIVO; SERUM; ARDS
AB Angiotensin converting enzyme (ACE, kininase II) is an endothelial luminal ectoenzyme. The majority of ACE has been found on the pulmonary capillary endothelium (PCE). Pulmonary capillary endothelium-bound (PCEB)-ACE has been extensively studied by means of indicator dilution techniques in animals and man. We have recently developed and applied methodologies for assaying pulmonary capillary endothelium-bound (PCEB) angiotensin convertin enzyme (ACE) activity in man. This article provides a summary of our studies in human subjects utilizing similar methodology. Trace amounts of the specific ACE substrate, H-3-benzoyl-Phe-Ala-Pro (H-3-BPAP; 40 muCi or 2 nmol), was injected as a bolus into the subclavian vein of patients and immediately blood was withdrawn from a radial arterial catheter. Plasma concentrations of surviving substrate and product (H-3-benzoyl-Phe) were estimated and BPAP utilization was calculated during a single transpulmonary passage. To investigate the PCE in this manner we tested the hypothesis that PCEB-ACE is depressed in patients diagnosed with acute lung injury and estimated interaction of an ACE inhibitor (enalaprilat) with PCE in human subjects. An inverse correlation was found between the pulmonary endothelium-bound ACE activity (v) and the lung injury score (r=0.379; p<0.01). Similarly, an inverse correlation was found between the pulmonary capillary perfusion index (CPI) and the lung injury score (r=0.284, p<0.05). PCEB-ACE activity in the group of patients with mild lung injury was significantly different from the group of control patients (0.44 +/- 0.048 vs. 1.15 +/- 0.05; p<0.01). Trace amounts (1.5 mu g/kg) of enalaprilat had no significant effect on mean arterial pressure (91+/-6 vs. 84+/-7 vs. 88+/-6 mmHg for T-1, T-2 and T-3, respectively), but significantly decreased PCEB-ACE activities. When normalized to pre-drug (T-1) activity levels, enalaprilat inhibited PCEB and SE ACE activity at T-2 by 74+/-6 and 68+/-6%, respectively. PCEB-ACE measurements can be used in clinical practice for estimating PCE functions and can provide new insight into the physiology of the pulmonary circulation.
C1 Univ Pecs, Fac Med, Inst Heart, H-7624 Pecs, Hungary.
RP Cziraki, A (reprint author), Univ Pecs, Fac Med, Inst Heart, Ifjusag Ut 13,POB 99, H-7624 Pecs, Hungary.
EM acziraki@clinics.pote.hu
CR Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   ASHBAUGH DG, 1967, LANCET, V2, P319
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   CASEY L, 1981, CRIT CARE MED, V9, P651, DOI 10.1097/00003246-198109000-00008
   Catravas J D, 1986, Adv Exp Med Biol, V198 Pt A, P445
   CATRAVAS JD, 1981, J PHARMACOL EXP THER, V217, P263
   CATRAVAS JD, 1990, BRIT J PHARMACOL, V101, P121, DOI 10.1111/j.1476-5381.1990.tb12100.x
   CATRAVAS JD, 1985, RES COMMUN CHEM PATH, V50, P163
   CATRAVAS JD, 1988, TOXICOL APPL PHARM, V94, P342, DOI 10.1016/0041-008X(88)90276-1
   CATRAVAS JD, 1984, J APPL PHYSIOL, V57, P1173
   CZIRAKI A, 1998, DRUG RES, V41, P22
   DARGENT F, 1985, AM REV RESPIR DIS, V131, P242
   Doyle IR, 1997, AM J RESP CRIT CARE, V156, P1217, DOI 10.1164/ajrccm.156.4.9603061
   Effects of enalapril on mortality in severe congestive heart failure, 1987, NEW ENGL J MED, V316, P1429, DOI DOI 10.1056/NEJM198706043162301
   ELING TE, 1984, ENVIRON HEALTH PERSP, V55, P159, DOI 10.2307/3429700
   FAIST E, 1983, J TRAUMA, V23, P775, DOI 10.1097/00005373-198309000-00002
   FALKENHAHN M, 1995, HYPERTENSION, V25, P219, DOI 10.1161/01.HYP.25.2.219
   FEIN AM, 1982, BRIT J ANAESTH, V54, P723, DOI 10.1093/bja/54.7.723
   FERREIRA SH, 1967, BRIT J PHARM CHEMOTH, V30, P417, DOI 10.1111/j.1476-5381.1967.tb02148.x
   GAVRAS H, 1981, LANCET, V2, P543
   GILLIS CN, 1987, ANN BIOMED ENG, V15, P183, DOI 10.1007/BF02364053
   GILLIS CN, 1977, BRIT J PHARMACOL, V59, P585, DOI 10.1111/j.1476-5381.1977.tb07725.x
   GILLIS CN, 1986, AM REV RESPIR DIS, V134, P739
   GILLIS CN, 1986, ANNU REV PHARMACOL, V26, P183
   GILLIS CN, 1973, ANESTHESIOLOGY, V39, P626, DOI 10.1097/00000542-197312000-00015
   HAMMOND GL, 1977, SURGERY, V81, P716
   HECHTMAN HB, 1982, CIRC SHOCK, V9, P457
   HOLLINGER MA, 1980, AM REV RESPIR DIS, V121, P373
   HOLLINGER MA, 1980, AM REV RESPIR DIS, V121, P795
   Horvath IG, 1998, MICROVASC RES, V56, P95, DOI 10.1006/mvre.1998.2092
   IWAI N, 1995, CIRCULATION, V92, P2690, DOI 10.1161/01.CIR.92.9.2690
   JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P1262
   KRIEGER B, 1980, CIRCULATION, V62, P134
   MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485
   MOREL DR, 1985, AM REV RESPIR DIS, V132, P479
   MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720
   Pitt B, 1996, CIRCULATION, V94, P2497
   PUYBASSET L, 1994, INTENS CARE MED, V20, P319, DOI 10.1007/BF01720903
   Ribeiro W, 1996, EUR J CLIN PHARMACOL, V50, P399, DOI 10.1007/s002280050130
   RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504
   ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605
   Ryan J W, 1971, Trans Assoc Am Physicians, V84, P297
   RYAN JW, 1975, BIOCHEM J, V146, P497, DOI 10.1042/bj1460497
   SCHUSTER DP, 1995, CHEST, V107, P1721, DOI 10.1378/chest.107.6.1721
   SHEPHERD K, 1988, CHEST, V98, P45
   STEPHENSON AH, 1988, AM REV RESPIR DIS, V138, P714, DOI 10.1164/ajrccm/138.3.714
   SWANSON BN, 1984, J PHARM SCI, V73, P1655, DOI 10.1002/jps.2600731146
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   VILLAR J, 1991, J CRIT CARE, V6, P75, DOI 10.1016/0883-9441(91)90011-H
   VOELKEL NF, 1989, CLIN CHEST MED, V10, P95
   WEST JB, 1964, J APPL PHYSIOL, V19, P713
   White CM, 1998, PHARMACOTHERAPY, V18, P588
   WILL JA, 1977, CHEST, V71, P287, DOI 10.1378/chest.71.2_Supplement.287-a
   ZAPOL WM, 1977, NEW ENGL J MED, V296, P476, DOI 10.1056/NEJM197703032960903
   Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088
NR 55
TC 6
Z9 8
U1 2
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2002
VL 9
IS 3
BP 317
EP 325
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 523BT
UT WOS:000173932000016
PM 11836639
DA 2018-12-27
ER

PT J
AU Tan, HT
   Libby, R
   Hunton, JE
AF Tan, HT
   Libby, R
   Hunton, JE
TI RETRACTED: Analysts' reactions to earnings preannouncement strategies
   (Retracted article. See vol. 53, pg. 907, 2015)
SO JOURNAL OF ACCOUNTING RESEARCH
LA English
DT Article; Retracted Publication
ID DISCLOSURES; MANAGEMENT; FORECASTS
AB Preannouncements of earnings tend to overstate negative or understate positive news, which decreases the chance of a negative surprise when actual earnings is announced. We conduct an experiment to investigate how experienced sell-side analysts' earnings forecasts are affected by preannouncements that either understate, accurately state, or overstate the magnitude of positive or negative total earnings news, holding total earnings news constant. We find that firms with negative (positive) total news receive the highest post-earnings announcement forecasts of future earnings when the earlier preannouncement overstates (understates) the magnitude of the news. These forecasts are consistent with the analysts' perceptions about the firms' future prospects, but not their perceptions of management. While analysts expect preannouncements to be lower than actual earnings, they do not adjust their forecasts for these beliefs. These insights into analysts' responses have implications both for managers and analysts.
C1 Nanyang Technol Univ, Singapore, Singapore.
   Cornell Univ, Ithaca, NY 14853 USA.
   Univ S Florida, Tampa, FL 33620 USA.
RP Tan, HT (reprint author), Nanyang Technol Univ, Singapore, Singapore.
CR Bamber LS, 1998, J ACCOUNTING RES, V36, P167, DOI 10.2307/2491473
   Barth ME, 1999, J ACCOUNTING RES, V37, P387, DOI 10.2307/2491414
   BARTOV E, 2000, REWARDS M BEATING EA
   BHOJRAJ S, 2000, SUPPLY SIDE ANAL MAN
   BROWN LD, 2001, J ACCOUNTING RES AUT, V39
   BURGSTAHLER D, 1998, MANAGEMENT EARNINGS
   Degeorge F, 1999, J BUS, V72, P1, DOI 10.1086/209601
   FRANCIS J, 1994, J ACCOUNTING RES, V32, P137, DOI 10.2307/2491279
   Healy P. M., 1999, ACCOUNT HORIZ, V13, P365, DOI DOI 10.2308/ACCH.1999.13.4.365
   Hirst DE, 1999, J ACCOUNTING RES, V37, P101, DOI 10.2307/2491347
   HOGARTH RM, 1992, COGNITIVE PSYCHOL, V24, P1, DOI 10.1016/0010-0285(92)90002-J
   IP G, 1997, WALL STREET J   0623
   Kahneman D, 1996, PSYCHOL REV, V103, P582, DOI 10.1037/0033-295X.103.3.582
   KASZNIK R, 1995, ACCOUNT REV, V70, P113
   KASZNIK R, 1999, DOES M EXPECTATIONS
   KILE C, 1998, FREQUENTLY DO MANAGE
   KRISCHE S, 2000, INFORMATION CONTENT
   Libby R, 2000, ACCOUNT REV, V75, P383, DOI 10.2308/accr.2000.75.4.383
   Libby R, 1999, J ACCOUNTING RES, V37, P415, DOI 10.2307/2491415
   Maines LA, 1997, J ACCOUNTING RES, V35, P1, DOI 10.2307/2491450
   McGee S, 1997, WALL STREET J, pC1
   McNichols M, 1997, J ACCOUNTING RES, V35, P167, DOI 10.2307/2491460
   MILLER JP, 1999, WALL STREET J   1015
   SKINNER DJ, 1994, J ACCOUNTING RES, V32, P38, DOI 10.2307/2491386
NR 24
TC 54
Z9 54
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8456
EI 1475-679X
J9 J ACCOUNT RES
JI J. Account. Res.
PD MAR
PY 2002
VL 40
IS 1
BP 223
EP 246
DI 10.1111/1475-679X.00045
PG 24
WC Business, Finance
SC Business & Economics
GA 557HT
UT WOS:000175903600010
OA Bronze
DA 2018-12-27
ER

PT J
AU Yanagisawa, J
   Kitagawa, H
   Yanagida, M
   Wada, O
   Ogawa, S
   Nakagomi, M
   Oishi, H
   Yamamoto, Y
   Nagasawa, H
   McMahon, SB
   Cole, MD
   Tora, L
   Takahashi, N
   Kato, S
AF Yanagisawa, J
   Kitagawa, H
   Yanagida, M
   Wada, O
   Ogawa, S
   Nakagomi, M
   Oishi, H
   Yamamoto, Y
   Nagasawa, H
   McMahon, SB
   Cole, MD
   Tora, L
   Takahashi, N
   Kato, S
TI RETRACTED: Nuclear receptor function requires a TFTC-type histone acetyl
   transferase complex (Retracted article. See vol. 54, pg. 536, 2014)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; RNA-POLYMERASE-II;
   TRANSCRIPTIONAL COACTIVATORS; TAF(II)-CONTAINING COMPLEX; DEPENDENT
   TRANSCRIPTION; ACTIVATION; BINDING; CBP; SUPERFAMILY
AB Nuclear receptors (NRs) regulate transcription in a [ligand-dependent way through two types of coactivator complexes: the p160/CBP histone acetyl transferase (HAT) complex and the DRIP/TRAP/SMCC complex without HAT activity. Here we identified a large human (h) coactivator complex necessary for the estrogen receptor alpha (ERalpha) transactivation. This complex contains the GCN5 HAT, the c-Myc interacting protein TRRAP/PAF400, TAF1130, and other subunits. Similarly to known TFTC (TBP-free TAFII-containing)-type HAT complexes (hTFTC, hPCAF, and hSTAGA), TRRP directly interacted with liganded ERalpha, or other NRs. ERalpha transactivation was enhanced by the purified complex in vitro. Antisense TRRAP RNA inhibited estrogendependent cell growth of breast cancer cells. Thus, the isolated TFTC-type HAT complex acts as a third class of coactivator complex for NR function.
C1 Univ Tokyo, Grad Sch Agr & Life Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Agr & Technol, Dept Appl Biol Sci, Fuchu, Tokyo 1838509, Japan.
   Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA.
   ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France.
   CU Strasbourg, Strasbourg, France.
   Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
RI Tora, Laszlo/E-9999-2018
OI Tora, Laszlo/0000-0001-7398-2250
CR Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151
   Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285
   Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214
   Chambon P, 1996, FASEB J, V10, P940
   CONAWAY JW, 1987, J BIOL CHEM, V262, P8293
   DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   Glass CK, 2000, GENE DEV, V14, P121
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3
   Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6
   JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0
   Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X
   Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781
   McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8
   Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   ONATE SA, 1995, SCIENCE, V270, P1354
   Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101
   Rachez C, 1999, NATURE, V398, P824
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652
   Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9
   Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507
   Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x
   Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Wieczorek E, 1998, NATURE, V393, P187
   Xu JJ, 1998, ELECTROCHEM SOLID ST, V1, P1
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
NR 44
TC 136
Z9 140
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAR
PY 2002
VL 9
IS 3
BP 553
EP 562
DI 10.1016/S1097-2765(02)00478-1
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 537QA
UT WOS:000174769300013
PM 11931763
OA Bronze
DA 2018-12-27
ER

PT J
AU Rivas, S
   Romeis, T
   Jones, JDG
AF Rivas, S
   Romeis, T
   Jones, JDG
TI RETRACTED: The cf-9 disease resistance protein is present in an similar
   to 420-kilodalton heteromultimeric membrane-associated complex at one
   molecule per complex(Retracted article. See vol. 29, pg. 600, 2017)
SO PLANT CELL
LA English
DT Article; Retracted Publication
ID TERMINAL DILYSINE MOTIF; PLANT DEFENSE RESPONSE; RECEPTOR-LIKE KINASE;
   LEUCINE-RICH REPEAT; CLADOSPORIUM-FULVUM; ENDOPLASMIC-RETICULUM; TOMATO
   CF-4; HYPERSENSITIVE RESPONSE; GENE-EXPRESSION; BINDING
AB The tomato Cf-9 gene confers race-specific resistance to the fungal pathogen Cladosporium fulvum expressing the corresponding avirulence gene Avr9. In tobacco, Cf-9 confers a hypersensitive response to the Avr9 peptide. To investigate Cf-9 protein function in initiating defense signaling, we engineered a functional C-terminal fusion of the Cf-9 gene with the TAP (Tandem Affinity Purification) tag. In addition, we established a transient expression assay in Nicotiana benthamiana leaves for the production of functional Cf-9:myc and Cf-9:TAP. Transiently expressed Cf-9:myc and Cf-9:TAP proteins induced an Avr9-dependent hypersensitive response, consistent with previous results with stably transformed tobacco plants and derived cell suspension cultures expressing c-myc-tagged Cf-9. Gel filtration of microsomal fractions solubilized with octylglucoside revealed that the Cf-9 protein, either as c-myc or TAP fusions, migrated at a molecular mass of 350 to 475 kD. By using blue native gel electrophoresis, the molecular size was confirmed to be similar to420 kD. Our results suggest that only one Cf-9 protein molecule is present in the Cf-9 complex and that Cf-9 is part of a membrane complex consisting of an additional glycoprotein partner(s). The high structural similarity between Cf proteins and Clavata2 (CLV2) of Arabidopsis, together with the similarity of molecular mass between Cf-9 and CLV complexes (420 and 450 kD, respectively), led us to investigate whether Cf-9 is integrated into membrane-associated protein complexes like those formed by CLV1 and CLV2. Unlike CLV2, the Cf-9 protein did not form disulfide-linked heterodimers, no ligand (Avr9)-dependent shift in the molecular mass of the Cf-9 complex was detected, and no Rho-GTPase-related proteins were found associated with Cf-9 under the conditions tested. Thus, Cf-9-dependent defense signaling and CLV2-dependent regulation of meristem development seem to be accomplished via distinct mechanisms, despite the structural similarity of their key components Cf-9 and CLV2.
C1 John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich Res Park,Colney Lane, Norwich NR4 7UH, Norfolk, England.
   Max Planck Inst Plant Breeding, Dept Mol Plant Pathol, D-50829 Cologne, Germany.
RP Jones, JDG (reprint author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich Res Park,Colney Lane, Norwich NR4 7UH, Norfolk, England.
EM jonathan.jones@bbsrc.ac.uk
CR Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36
   Benghezal M, 2000, PLANT CELL, V12, P1179, DOI 10.1105/tpc.12.7.1179
   Blatt MR, 1999, PLANT J, V19, P453, DOI 10.1046/j.1365-313X.1999.00534.x
   Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342
   Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1
   Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x
   COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252
   Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161
   Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807
   DROBAK BK, 1995, BIOCHEM BIOPH RES CO, V210, P7, DOI 10.1006/bbrc.1995.1620
   Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963
   Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7
   Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911
   FRISCH DA, 1995, PLANT MOL BIOL, V27, P405, DOI 10.1007/BF00020193
   HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575
   Helenius A, 1979, Methods Enzymol, V56, P734
   JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x
   Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925
   Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004
   Jones DA, 1997, ADV BOT RES, V24, P89
   JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631
   Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170
   Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335
   KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6
   KoomanGersmann M, 1996, PLANT CELL, V8, P929
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Li H, 1998, PLANT PHYSIOL, V118, P407, DOI 10.1104/pp.118.2.407
   Luderer R, 2001, MOL PLANT MICROBE IN, V14, P867, DOI 10.1094/MPMI.2001.14.7.867
   MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2
   MOLLER JV, 1993, J BIOL CHEM, V268, P18659
   Piedras P, 2000, PLANT J, V21, P529, DOI 10.1046/j.1365-313x.2000.00697.x
   Piedras P, 1998, MOL PLANT MICROBE IN, V11, P1155, DOI 10.1094/MPMI.1998.11.12.1155
   Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732
   Rivas S, 2002, PLANT J, V29, P783, DOI 10.1046/j.1365-313X.2002.01254.x
   Romeis T, 2000, PLANT CELL, V12, P803, DOI 10.1105/tpc.12.5.803
   Romeis T, 1999, PLANT CELL, V11, P273
   Romeis T, 2000, MOL PLANT PATHOL, V1, P3, DOI 10.1046/j.1364-3703.2000.00001.x
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063
   SIMONS K, 1973, J MOL BIOL, V80, P119, DOI 10.1016/0022-2836(73)90236-2
   STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374
   Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060
   Thomas CM, 2000, MOL PLANT MICROBE IN, V13, P465, DOI 10.1094/MPMI.2000.13.4.465
   Thomas CM, 1997, PLANT CELL, V9, P2209, DOI 10.1105/tpc.9.12.2209
   Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613
   Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393
   van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089
   Van der Hoorn RAL, 2001, MOL PLANT MICROBE IN, V14, P412, DOI 10.1094/MPMI.2001.14.3.412
   Van der Hoorn RAL, 2001, PLANT CELL, V13, P273, DOI 10.1105/tpc.13.2.273
   Wulff BBH, 2001, PLANT CELL, V13, P255, DOI 10.1105/tpc.13.2.255
NR 50
TC 67
Z9 70
U1 3
U2 9
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD MAR
PY 2002
VL 14
IS 3
BP 689
EP 702
DI 10.1105/tpc.010357
PG 14
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 537ZC
UT WOS:000174788700015
PM 11910014
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Radziminski, C
   Ballantyne, L
   Hodson, J
   Creason, R
   Andrews, RC
   Chauret, C
AF Radziminski, C
   Ballantyne, L
   Hodson, J
   Creason, R
   Andrews, RC
   Chauret, C
TI RETRACTED: Disinfection of Bacillus subtilis spores with chlorine
   dioxide: a bench-scale and pilot-scale study (Retracted Article. See vol
   41, pg 517, 2007)
SO WATER RESEARCH
LA English
DT Article; Retracted Publication
DE bacterial spores; ClO2; disinfection
ID CRYPTOSPORIDIUM-PARVUM OOCYSTS; DRINKING-WATER TREATMENT; BY-PRODUCTS;
   PLANT PERFORMANCE; INACTIVATION; OZONE; MONOCHLORAMINE; INDICATORS;
   COLIPHAGES; BACTERIA
AB Chlorine dioxide (ClO2) inactivation of Bacillus subtilis ATCC 19659 spores was examined at pilot-scale during periods representative of winter and summer temperature extremes at the Britannia Water Treatment Plant in Ottawa, Canada. In addition, bench-scale experiments using the same source water (Ottawa River, Ontario, Canada), as well as buffered and unbuffered laboratory waters were conducted using B. subtilis spores. Bench-scale inactivation of B. subtilis spores by ClO2, was similar to reported values for Cryptosporidium parvum (both organisms being more resistant to ClO2) than Giardia lamblia), suggesting the possibility that these spores may be used as potential indicators for protozoan parasites. Additionally, spore inactivation was observed to be influenced by pH in laboratory (distilled deionised water) water but not in Ottawa River water. At pilot-scale, spore inactivation was influenced by water temperature: a ClO2 dose of 2.5 mg/L resulted in a spore inactivation of approximately 2.0 log(10) and 0.5 log(10) at water temperatures of 23.2degreesC and 5.2degreesC, respectively. Chlorite concentrations remained below both the US EPA maximum contaminant level of 1.0 mg/L and the maximum contaminant level goal of 0.8 mg/L for up to 2.0 log(10) B. subtilis inactivation. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Indiana Univ Kokomo, Biol & Phys Sci Unit, Kokomo, IN 46904 USA.
   Univ Toronto, Dept Civil Engn, Toronto, ON M5S 1A4, Canada.
RP Chauret, C (reprint author), Indiana Univ Kokomo, Biol & Phys Sci Unit, 2300 S Washington St, Kokomo, IN 46904 USA.
EM cchauret@iuk.edu
CR *APHA WPCF AWWA, 1998, STAND METH EX WAT WA
   BALLANTYNE L, 1999, THESIS U TORONTO TOR
   BERMAN D, 1984, APPL ENVIRON MICROB, V48, P317
   BOTZENHART K, 1993, WATER SCI TECHNOL, V27, P363
   Chauret C, 1998, CAN J MICROBIOL, V44, P1154, DOI 10.1139/cjm-44-12-1154
   Chauret CP, 2001, APPL ENVIRON MICROB, V67, P2993, DOI 10.1128/AEM.67.7.2993-3001.2001
   CHEN YSR, 1985, WATER RES, V19, P783, DOI 10.1016/0043-1354(85)90127-7
   CLANCY JL, 1994, J AM WATER WORKS ASS, V86, P89
   COLCLOUGH CA, 1983, ORGANIC REACTION PRO, V4, P219
   DOUGLAS IP, 1993, 1993 ONT WAT WORKS A
   Finch GR, 1999, OZONE-SCI ENG, V21, P477, DOI 10.1080/01919512.1999.10382886
   FINCH GR, 1995, P CHLOR DIOX DRINK W, P23
   Gyurek LL, 1999, J ENVIRON ENG-ASCE, V125, P913
   HARAKEH S, 1988, J APPL BACTERIOL, V64, P459, DOI 10.1111/j.1365-2672.1988.tb05103.x
   Hofmann R, 1998, ENVIRON TECHNOL, V19, P761, DOI 10.1080/09593331908616733
   HOIGNE J, 1994, WATER RES, V28, P45, DOI 10.1016/0043-1354(94)90118-X
   Huang JL, 1997, WATER RES, V31, P455, DOI 10.1016/S0043-1354(96)00276-X
   KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423
   Liyanage LRJ, 1997, OZONE-SCI ENG, V19, P409, DOI 10.1080/01919512.1997.10382868
   LYKINS BW, 1994, J ENVIRON ENG-ASCE, V120, P745, DOI 10.1061/(ASCE)0733-9372(1994)120:4(745)
   MASSCHELEIN WJ, 1989, OZONE-SCI ENG, V11, P209
   MUTTAMARA S, 1995, WATER SUPP, V13, P105
   Nieminski EC, 2000, J AM WATER WORKS ASS, V92, P67
   NOSS CI, 1985, APPL ENVIRON MICROB, V50, P1162
   OEHLER KE, 1986, WATER SUPPLY, V4, P127
   PAYMENT P, 1993, APPL ENVIRON MICROB, V59, P2418
   PEETERS JE, 1989, APPL ENVIRON MICROB, V55, P1519
   Quinn C. M., 1993, Biomedical Letters, V48, P315
   Rice EW, 1996, J AM WATER WORKS ASS, V88, P122
   RICE RG, 1986, ENVIRON HEALTH PERSP, V69, P31, DOI 10.2307/3430368
   RICHARDSON SD, 1994, ENVIRON SCI TECHNOL, V28, P592, DOI 10.1021/es00053a010
   Ruffell KM, 2000, WATER RES, V34, P868, DOI 10.1016/S0043-1354(99)00187-6
   SOBSEY MD, 1989, WATER SCI TECHNOL, V21, P179
   Swertfeger J, 1999, J AM WATER WORKS ASS, V91, P90
   *US EPA, EPA600R93100
   WERDEHOFF KS, 1987, J AM WATER WORKS ASS, V79, P107
   1998, FED REG, V63, P69389
NR 37
TC 29
Z9 35
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0043-1354
J9 WATER RES
JI Water Res.
PD MAR
PY 2002
VL 36
IS 6
BP 1629
EP 1639
AR PII S0043-1354(01)00355-4
DI 10.1016/S0043-1354(01)00355-4
PG 11
WC Engineering, Environmental; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA 536UB
UT WOS:000174719300023
PM 11996351
DA 2018-12-27
ER

PT J
AU Song, B
   Storr, T
   Liu, S
   Orvig, C
AF Song, B
   Storr, T
   Liu, S
   Orvig, C
TI RETRACTED: Synthesis and solution studies of the complexes of trivalent
   lanthanides with the tetraazamacrocycle TETA-(PO)(2) (Retracted article.
   See vol. 56, pg. 10833, 2017)
SO INORGANIC CHEMISTRY
LA English
DT Article; Retracted Publication
ID CRYSTAL-STRUCTURE; DYNAMICS; LIGANDS; ACID; IONS; LUMINESCENCE;
   STABILITIES; DERIVATIVES; DOTA
AB A new potentially multidentate hexaprotic ligand H-6[TETA-(PO)(2)] has been prepared by reaction of ethylenediamine-N,N'-diacetic acid (EDDA), paraformaldehyde, and phosphinic acid; its coordination properties with three lanthanide ions (La3+, Gd3+, and Lu3+) have been explored. The structures of the complexes were studied in aqueous solution by potentiometric pH titrations and by P-31 NMR spectroscopy. Four acidity constants were determined potentiometrically in the range 2.5 < pH < 14. The four measured pK(a) values can be divided into two groups, and within each group the initial deprotonation was found to have little effect on the second. Variable temperature 31P and P-31{H-1} EXSY NMR spectra showed that, for [Lu(TETA-(PO)(2))](3-), the two phosphorus atoms exist in different chemical environments and undergo an exchange process which is very fast on the NMR time scale at room temperature. This result is consistent with one of the phosphinate residues coordinating the metal ion and exchanging with a free analogue. In the case of [La(TETA-(PO)(2))](3-), only one temperature invariant signal is observed in P-31 NMR spectra; it corresponds to both phosphinate residues remaining uncoordinated to La3+. The stability of [Ln-(TETA-(PO)(2))](3-) has an order of La3+ > Gd3+ > Lu3+. The coordination of one phosphinate residue to Lu3+ brings the metal ion closer to the plane of four nitrogens and farther from the four carboxylate arms, resulting in [Lu(TETA-(PO)(2))](3-) having a lower stability than the corresponding La3+ and Gd3+ complexes. A pM-pH distribution diagram showed that introducing two phosphinate groups into TETA renders [Gd(TETA-(PO)(2))](3-) more stable than [Gd(TETA)](-). The selectivity factor of the ligand for Gd3+ vs Ca2+, Zn2+, and Cu2+ has been calculated, and the hydration number for [Dy(TETA-(PO)(2))](3-) has been measured by O-17 NMR spectroscopy to be zero.
C1 Univ British Columbia, Dept Chem, Med Inorgan Chem Grp, Vancouver, BC V6T 1Z1, Canada.
   Dupont Merck Pharmaceut Co, Med Imaging R&D, N Billerica, MA 01862 USA.
RP Orvig, C (reprint author), Univ British Columbia, Dept Chem, Med Inorgan Chem Grp, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.
EM orvig@chem.ubc.ca
RI Orvig, Chris/A-4099-2010
OI Orvig, Chris/0000-0002-2830-5493
CR Aime S, 1996, J CHEM SOC DALTON, P17, DOI 10.1039/dt9960000017
   Aime S, 1997, INORG CHEM, V36, P4287, DOI 10.1021/ic9704501
   AIME S, 1994, INORG CHEM, V33, P4696, DOI 10.1021/ic00099a020
   Aime S, 1996, INORG CHIM ACTA, V246, P423, DOI 10.1016/0020-1693(96)05130-4
   Aime S, 1998, CHEM SOC REV, V27, P19, DOI 10.1039/a827019z
   ALPOIM MC, 1992, J CHEM SOC DALTON, P463, DOI 10.1039/dt9920000463
   ANELLI PL, 1991, GAZZ CHIM ITAL, V121, P359
   Baes C. F. Jr, 1986, HYDROLYSIS CATIONS
   Beeby A, 1999, J CHEM SOC PERK T 2, P493, DOI 10.1039/a808692c
   BRAUN S, 1996, 100 MORE BASIC NMR E, P112
   CACHERIS WP, 1990, MAGN RESON IMAGING, V8, P467, DOI 10.1016/0730-725X(90)90055-7
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   CLARKE ET, 1991, INORG CHIM ACTA, V190, P27, DOI 10.1016/S0020-1693(00)80228-5
   CLARKE ET, 1991, INORG CHIM ACTA, V190, P37, DOI 10.1016/S0020-1693(00)80229-7
   HELM L, 1994, J PHYS-CONDENS MAT, V6, pA137, DOI 10.1088/0953-8984/6/23A/017
   Kumar K, 1995, INORG CHEM, V34, P6472, DOI 10.1021/ic00130a012
   Lowe MP, 1998, INORG CHEM, V37, P1637, DOI 10.1021/ic971488g
   MAIER L, 1980, PHOSPHORUS SULFUR, V8, P67, DOI 10.1080/03086648008078163
   MARTELL AE, 1988, DETERMINATION USE ST, P4
   REUBEN J, 1969, J CHEM PHYS, V51, P4909, DOI 10.1063/1.1671883
   Sherry AD, 1996, INORG CHEM, V35, P4604, DOI 10.1021/ic9600590
   Sherry AD, 1997, J ALLOY COMPD, V249, P153
   Song B, 2000, J CHEM SOC DALTON, P1325, DOI 10.1039/a908384g
   Song B, 2001, CAN J CHEM, V79, P1058, DOI 10.1139/cjc-79-5-6-1058
   SONG PS, 1987, BLUE LIGHT RESPONSES, V2, P3
   SPIRLET MR, 1984, INORG CHEM, V23, P4278, DOI 10.1021/ic00193a035
   Varga TR, 1997, SYNTHETIC COMMUN, V27, P2899, DOI 10.1080/00397919708004996
   WEDEKING P, 1992, MAGN RESON IMAGING, V10, P641, DOI 10.1016/0730-725X(92)90016-S
   Xu L, 2001, INORG CHEM, V40, P3734, DOI 10.1021/ic0014179
NR 29
TC 17
Z9 17
U1 4
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020-1669
EI 1520-510X
J9 INORG CHEM
JI Inorg. Chem.
PD FEB 25
PY 2002
VL 41
IS 4
BP 685
EP 692
DI 10.1021/ic010716a
PG 8
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 524GA
UT WOS:000174003700014
OA Bronze
DA 2018-12-27
ER

PT J
AU Behr, TM
   Liersch, T
   Greiner-Bechert, L
   Griesinger, F
   Behe, M
   Markus, PM
   Gratz, S
   Angerstein, C
   Brittinger, G
   Becker, H
   Goldenberg, DM
   Becker, W
AF Behr, TM
   Liersch, T
   Greiner-Bechert, L
   Griesinger, F
   Behe, M
   Markus, PM
   Gratz, S
   Angerstein, C
   Brittinger, G
   Becker, H
   Goldenberg, DM
   Becker, W
TI RETRACTED: Radioimmunotherapy of small-volume disease of metastatic
   colorectal cancer - Results of a phase II trial with the
   iodine-131-labeled humanized anti-carcinoembryonic antigen antibody
   hMN-14 (Retracted article. See vol. 121, pg. 2290, 2015)
SO CANCER
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 8th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer
CY OCT 12-14, 2001
CL PRINCETON, NJ
DE radioimmunotherapy; colorectal cancer; carcinoembryonic antigen;
   humanized anti-carcinoembryonic antigen antibody; small-volume
   metastatic disease; adjuvant therapy
ID HUMAN COLONIC-CANCER; I-131-LABELED MONOCLONAL-ANTIBODIES;
   CARCINOEMBRYONIC ANTIGEN; PRECLINICAL EVALUATION; ANTI-CD20 ANTIBODY;
   RANDOMIZED-TRIAL; ADJUVANT THERAPY; CHEMOTHERAPY; CARCINOMA;
   FLUOROURACIL
AB BACKGROUND. Whereas radioimmunotherapy (RIT) has shown disappointing results in bulky, solid tumors, preclinical results in small-volume disease and in an adjuvant setting are promising. In a previous Phase I study, the authors had encouraging results with the iodine-131 (I-131)-labeled humanized anti-carcinoembryonic antigen (anti-CEA) antibody (MAb) hMN-14 in small-volume disease of colorectal cancer. The aim of this study was to evaluate, in a subsequent Phase II trial, the therapeutic efficacy of this I-131-labeled humanized anti-CEA antibody in colorectal cancer patients with small-volume disease or in an adjuvant setting.
   METHODS. Thirty colorectal cancer patients, with small-volume metastatic disease (n = 21; all lesions less than or equal to 3.0 cm, and chemorefractory to 5-fluorouracil and folinic acid) or in an adjuvant setting (n = 9), 4-6 weeks after surgical resection of liver metastases with curative intention, were studied. The patients were given a single injection of I-131 -hMN- 14 immunoglobulin G at a 60 mCi/m(2) dose level, which was shown to be the maximum tolerated dose in the previous Phase I study. Follow-up was obtained at 3-month intervals for as long as 36 months.
   RESULTS. At a mean blood-based red marrow dose of 1.8 +/- 0.8 Gy, myelotoxicity was the only toxicity observed, but only 1 of 28 assessable patients developed transient Grade 4 thrombocytopenia. Of the 21 patients with radiologically documented lesions, 19 were assessable. Three experienced partial remission and eight showed minor responses up to 15 months in duration (corresponding to an objective response rate of 16% and an overall response rate of 58%; the mean duration of response was 9 months). At the time this article was written, seven of nine patients in the adjuvant setting had remained free of disease for up to 36 months (one patient relapsed after 6 months and another after 30 months), whereas the relapse rate in a historical control group receiving chemotherapy was 67% over the same time period. Five patients with radiologically documented lesions, having experienced at least disease stabilization as a consequence of RIT, were retreated at the same 60-mCi/m(2) dose level at 8-16 months after the first therapy. No evidence of increased toxicity was observed (no hematologic toxicity was higher than Grade 3). Two of four assessable retreated patients experienced partial remissions; one of these four again experienced disease stabilization as a consequence of the second radioantibody therapy injection.
   CONCLUSIONS. These data suggest that RIT is a safe and effective form of therapy for small-volume colorectal cancer and has potential as treatment for colorectal. cancer in an adjuvant setting. Toxicity is restricted to mild and transient leuko- and thrombocytopenia. Retreatment seems to be a feasible option. A prospective randomized comparison with standard chemotherapy is indicated. Cancer 2002; 94:1373-81. (C) 2002 American Cancer Society.
C1 Univ Marburg, Dept Nucl Med, D-35043 Marburg, Germany.
   Univ Gottingen, Dept Nucl Med, D-3400 Gottingen, Germany.
   Univ Gottingen, Dept Gen Surg, D-3400 Gottingen, Germany.
   Univ Gottingen, Dept Internal Med Hematol Oncol, D-3400 Gottingen, Germany.
   Immunomed Inc, Morris Plains, NJ USA.
   Garden State Canc Ctr, Belleville, NJ USA.
RP Behr, TM (reprint author), Univ Marburg, Dept Nucl Med, Baldingerstr, D-35043 Marburg, Germany.
EM behrt@mailer.uni-marburg.de
RI Behe, Martin/E-2941-2013
CR ARDALAN B, 1991, J CLIN ONCOL, V9, P625, DOI 10.1200/JCO.1991.9.4.625
   Behr TM, 1999, ANTICANCER RES, V19, P2427
   Behr TM, 1997, J NUCL MED, V38, P858
   Behr TM, 1999, CLIN CANCER RES, V5, p3232S
   Behr TM, 1997, J NUCL MED, V38, P409
   Behr TM, 1996, NUCL MED COMMUN, V17, P767, DOI 10.1097/00006231-199609000-00007
   Behr TM, 2000, CLIN CANCER RES, V6, P4900
   Behr TM, 1997, HYBRIDOMA, V16, P101, DOI 10.1089/hyb.1997.16.101
   BEHR TM, 1997, J NUCL MED, V38
   BEHR TM, 1996, P 6 INT RAD DOS S GA, V1, P113
   BLUMENTHAL RD, 1994, CANCER RES, V54, P142
   BLUMENTHAL RD, 1992, CANCER RES, V52, P6036
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101
   Devita VT, 1997, CANC PRINCIPLES PRAC
   HANSEN HJ, 1993, CANCER, V71, P3478, DOI 10.1002/1097-0142(19930601)71:11<3478::AID-CNCR2820711104>3.0.CO;2-A
   KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703
   Khayat D, 2001, ONCOLOGY-NY, V15, P415
   Lorenz M, 1999, LANGENBECK ARCH SURG, V384, P328, DOI 10.1007/s004230050210
   Machover D, 1997, CANCER, V80, P1179, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1179::AID-CNCR1>3.0.CO;2-G
   MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
   PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3
   PRIMUS FJ, 1983, CANCER RES, V43, P686
   RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1
   Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788
   SALEH MN, 1990, CANCER IMMUNOL IMMUN, V32, P185, DOI 10.1007/BF01771455
   SHARKEY RM, 1995, CANCER RES, V55, pS5935
   Stabin MG, 1996, J NUCL MED, V37, P538
   Tschmelitsch J, 1997, CANCER RES, V57, P2181
   Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501
   Vanhoefer U, 2001, Oncology (Williston Park), V15, P79
NR 31
TC 74
Z9 80
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2002
VL 94
IS 4
SU S
BP 1373
EP 1381
DI 10.1002/cncr.10308
PG 9
WC Oncology
SC Oncology
GA 523MP
UT WOS:000173958100025
PM 11877768
DA 2018-12-27
ER

PT J
AU Schon, JH
   Bao, Z
AF Schon, JH
   Bao, Z
TI RETRACTED: Nanoscale organic transistors based on self-assembled
   monolayers (Retracted Article. See vol 82, pg 1313, 2003)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID LOW-VOLTAGE; MOBILITY; CIRCUITS; DEVICES
AB A device structure is reported for the fabrication of nanoscale organic transistors. In this structure, a self-assembled monolayer is used to define the channel length, as well as acting as the semiconducting material. High current modulation and high current output are demonstrated with 4,4'-dithiolbiphenylene. Various dielectric materials, such as SiO2, Al2O3, and a self-assembled silane monolayer, have been shown to result in high-performance transistors. Finally, nanopatterning can also be achieved by using an insulating alkanethiol to define the channel length of a conventional organic field-effect transistor. (C) 2002 American Institute of Physics.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
CR Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834
   Bao ZN, 1999, J MATER CHEM, V9, P1895, DOI 10.1039/a902652e
   Collet J, 2000, APPL PHYS LETT, V76, P1941, DOI 10.1063/1.126219
   Collet J, 2000, APPL PHYS LETT, V76, P1339, DOI 10.1063/1.126027
   Dimitrakopoulos CD, 2001, IBM J RES DEV, V45, P11, DOI 10.1147/rd.451.0011
   Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783
   GARNIER F, 1993, J AM CHEM SOC, V115, P8716, DOI 10.1021/ja00072a026
   Hatzor A, 2001, SCIENCE, V291, P1019
   Horowitz G, 1999, J MATER CHEM, V9, P2021, DOI 10.1039/a902242b
   Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603
   Klauk H, 2000, SOLID STATE TECHNOL, V43, P63
   Meng H, 2001, J AM CHEM SOC, V123, P9214, DOI 10.1021/ja016525o
   Rampi MA, 1998, APPL PHYS LETT, V72, P1781, DOI 10.1063/1.121183
   Rogers JA, 1999, APPL PHYS LETT, V75, P1010, DOI 10.1063/1.124581
   Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   Sze S. M., 1985, SEMICONDUCTOR DEVICE
NR 18
TC 12
Z9 13
U1 1
U2 18
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD FEB 4
PY 2002
VL 80
IS 5
BP 847
EP 849
PG 3
WC Physics, Applied
SC Physics
GA 517NW
UT WOS:000173617700048
DA 2018-12-27
ER

PT J
AU Fiorucci, S
   Antonelli, E
   Mencarelli, A
   Palazzetti, B
   Alvarez-Miller, L
   Muscara, M
   del Soldato, P
   Sanpaolo, L
   Wallace, JL
   Morelli, A
AF Fiorucci, S
   Antonelli, E
   Mencarelli, A
   Palazzetti, B
   Alvarez-Miller, L
   Muscara, M
   del Soldato, P
   Sanpaolo, L
   Wallace, JL
   Morelli, A
TI RETRACTED: A NO-releasing derivative of acetaminophen spares the liver
   by acting at several checkpoints in the Fas pathway (Retracted article.
   See vol. 156, pg. 868, 2009)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE acetaminophen; nitric oxide; cytokines; hepatitis B transgenic mice;
   Fas; Fas ligand
ID B-VIRUS-REPLICATION; NITRIC-OXIDE; INDUCED HEPATOTOXICITY; HEPATOCYTE
   APOPTOSIS; CYSTEINE PROTEASES; TNF-ALPHA; PARACETAMOL; MICE; INJURY;
   ACTIVATION
AB 1 NCX-701 is a nitric oxide (NO)-releasing acetaminophen (APAP) derivative.
   2 In the present study we demonstrated that NCX-701 is as effective as APAP in controlling body temperature in a rat model of endotoxin-induced fever.
   3 Liver toxicity is a major complication of APAP overdosing. To investigate whether NCX-701 is hepatotoxic, BALB/C mice were injected with 100-500 mg kg(-1) APAP or NCX-701 alone or in combination (i.e. 500 mg kg(-1) of both compounds). Our results demonstrated that although APAP caused a dose-dependent liver injury, NCX-701 was completely devoid of liver toxicity. At the dose of 500 mg kg(-1) APAP caused an approximate to40 fold increase of AST plasma levels and extensive centrilobular necrosis.
   4 APAP and NCX-701 share the same metabolic pathway as demonstrated by the time-course of APAP-glucuronide concentrations in plasma and liver.
   5 NCX-701 was safe in mice with pre-existing chronic liver disease. Indeed, while C57BL6 transgenic mice expressing the hepatitis B virus (HBV) at the age of 8 months were significantly more susceptible to liver damage induced by APAP (500 mg kg(-1)) than their congenic littermates, treating HBV-transgenic mice with NCX-701, 500 mg kg(-1), caused no damage.
   6 Co-administration of NCX-701 at the dose 500 mg kg(-1) to mice treated with APAP, 500 mg kg(-1), completely protected against liver damage induced by APAP.
   7 APAP, but not NCX-701, upregulated liver Fas and Fas Ligand mRNA expression in vivo. Incubating mouse hepatocytes with APAP, but not with NCX-701, increased cell surface Fas expression and sensitized hepatocytes to death induced by challenge with a Fas-agonistic antibody.
   8 Collectively, these observations suggest that APAP toxicity is Fas mediated and that NCX-701 spares the liver by acting at several checkpoints in the Fas pathway.
C1 Monteluce Policlin, Clin Gastroenterol & Endoscopia Digest, Dipartimento Med Clin & Sperimentale, I-06122 Perugia, Italy.
   Univ Perugia, Dipartimento Med Clin & Sperimentale, I-06100 Perugia, Italy.
   Univ Calgary, Mucosal Inflammat Res Grp, Calgary, AB, Canada.
   NicOx, Sophia Antipolis, France.
RP Fiorucci, S (reprint author), Monteluce Policlin, Clin Gastroenterol & Endoscopia Digest, Dipartimento Med Clin & Sperimentale, Via E Dal Pozzo, I-06122 Perugia, Italy.
EM fiorucci@unipg.it
RI Fiorucci, Stefano/I-1251-2012; Muscara, Marcelo/F-3250-2012
OI Muscara, Marcelo/0000-0002-8342-5586
CR ADAMSON GM, 1993, BIOCHEM PHARMACOL, V45, P2289, DOI 10.1016/0006-2952(93)90201-7
   al-Swayeh OA, 2000, BRIT J PHARMACOL, V130, P1453, DOI 10.1038/sj.bjp.0703509
   BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125
   Bond GR, 1999, ACAD EMERG MED, V6, P1115, DOI 10.1111/j.1553-2712.1999.tb00113.x
   Boulares HA, 1999, TOXICOL SCI, V48, P264, DOI 10.1093/toxsci/48.2.264
   Bridger S, 1998, BRIT MED J, V316, P1724, DOI 10.1136/bmj.316.7146.1724
   DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327
   Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365
   ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0
   Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417
   Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765
   Fiorucci S, 2000, GASTROENTEROLOGY, V118, P404, DOI 10.1016/S0016-5085(00)70223-X
   Fiorucci S, 1999, ALIMENT PHARM THERAP, V13, P421
   Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0
   Futter LE, 2001, BRIT J PHARMACOL, V132, P10, DOI 10.1038/sj.bjp.0703837
   Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316
   GUIDOTTI LG, 1995, J VIROL, V69, P6158
   Gunnell D, 1997, J EPIDEMIOL COMMUN H, V51, P175, DOI 10.1136/jech.51.2.175
   Hawton K, 1996, BRIT J PSYCHIAT, V168, P43, DOI 10.1192/bjp.168.1.43
   HINSON JA, 1995, DRUG METAB REV, V27, P73, DOI 10.3109/03602539509029816
   Horbach M, 1997, TOXICOLOGY, V121, P117, DOI 10.1016/S0300-483X(97)00061-9
   Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921
   Kim YC, 1998, TOXICOLOGY, V128, P53, DOI 10.1016/S0300-483X(98)00046-8
   Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409
   Kuo PC, 1997, J PHARMACOL EXP THER, V282, P1072
   Lawson JA, 2000, TOXICOL SCI, V54, P509, DOI 10.1093/toxsci/54.2.509
   Lawson JA, 1999, TOXICOL APPL PHARM, V156, P179, DOI 10.1006/taap.1999.8635
   Li JR, 1999, AM J PHYSIOL-GASTR L, V276, pG1069, DOI 10.1152/ajpgi.1999.276.5.G1069
   Lin M C, 1996, J Biochem Toxicol, V11, P11, DOI 10.1002/(SICI)1522-7146(1996)11:1<11::AID-JBT2>3.0.CO;2-Y
   Liu J, 1999, J PHARMACOL EXP THER, V289, P580
   Michael SL, 1999, HEPATOLOGY, V30, P186, DOI 10.1002/hep.510300104
   Mirochnitchenko O, 1999, J BIOL CHEM, V274, P10349, DOI 10.1074/jbc.274.15.10349
   Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276
   Poulin C, 2000, LANCET, V355, P2009, DOI 10.1016/S0140-6736(00)02342-4
   Prince MI, 2000, LANCET, V355, P2047, DOI 10.1016/S0140-6736(00)02354-0
   Routledge P, 1998, BRIT MED J, V317, P1609
   Salminen WF, 1998, J PHARMACOL EXP THER, V286, P519
   Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602
   Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992
   Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074-7613(00)80111-9
   Turvill JL, 2000, LANCET, V355, P2048, DOI 10.1016/S0140-6736(00)02355-2
   Wallace JL, 1995, J CLIN INVEST, V96, P2711, DOI 10.1172/JCI118338
   YOUNGMYEONG K, 1997, J BIOL CHEM, V272, P31138
   Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475
NR 44
TC 33
Z9 37
U1 2
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-1188
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD FEB
PY 2002
VL 135
IS 3
BP 589
EP 599
DI 10.1038/sj.bjp.0704500
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 521YM
UT WOS:000173869000002
PM 11834606
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Lobashevsky, AL
   Jiang, XL
   Thomas, JM
AF Lobashevsky, AL
   Jiang, XL
   Thomas, JM
TI RETRACTED: Allele-specific in situ analysis of microchimerism by
   fluorescence resonance energy transfer (FRET) in nonhuman primate
   tissues (Retracted article. See vol. 69, pg. 893, 2008)
SO HUMAN IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE nonhuman primates; kidney transplantation; microchimerism; FRET;
   hybridization
ID DONOR BONE-MARROW; POLYMERASE-CHAIN-REACTION; PERITRANSPLANT TOLERANCE
   INDUCTION; RENAL-ALLOGRAFT RECIPIENTS; VERSUS-HOST-DISEASE;
   TRANSPLANTATION TOLERANCE; KIDNEY-TRANSPLANTATION;
   ORGAN-TRANSPLANTATION; RHESUS-MONKEYS; GRAFT ACCEPTANCE
AB Rhesus monkeys are relevant models for tolerance induction. Hematopoetic chimerism is believed to be one of these strategies. The purpose of this study was to detect donor class I A locus allele specific mRNA in Rhesus monkey kidney recipient. We report here for the first time the results of frequency resonance energy transfer (FRET) hybridization technology in frozen tissues. Frequency resonance energy transfer hybridization was performed by using two Mamu-A*05 allele specific oligonucleotides: a donor probe labeled with FITC and acceptor probe conjugated to Texas Red. The PCR-SSP microchimerism analysis method produced 0.05% and 0.5% of donor DNA for Namu-DRB1*1002 and Mamu-DRBw301/3 alleles, respectively. The donor cells were detected in mesenteric and/or inguinal lymph nodes, spleen, and liver, where the signal was the strongest. The results of FRET hybridization demonstrated the identical staining pattern in the recipient frozen tissues to that determined by PCR-SSP. Following FRET hybridization, the sections underwent immunohistochemical analysis, which revealed that donor cells had CD8+ phenotype. We demonstrate here for the first time that FRET in situ hybridization technique can be utilized for microchimerism analysis in frozen tissues. We conclude that using two donor mRNA specific oligonucleotide probes, rather than one, produce higher specificity. Human Immunology 63, 108-120 (2002). (C) American Society For Histocompatibility and Immunogenetics, 2002. Published by Elsevier Science Inc.
C1 Univ Alabama, Dept Surg, Transplantat Immunobiol Div, Birmingham, AL 35294 USA.
RP Thomas, JM (reprint author), Univ Alabama, Dept Surg, Transplantat Immunobiol Div, 1808 7th Ave S,BDB R559, Birmingham, AL 35294 USA.
EM jthomas@ccc.uab.edu
CR ALARD P, 1995, TRANSPLANTATION, V60, P1125, DOI 10.1097/00007890-199511270-00012
   BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011
   Bensinger WI, 1996, BLOOD, V88, P4132
   BOHNAM CA, 1997, CURR OPIN ORGAN TRAN, V2, P23
   BUSHELL A, 1995, TRANSPLANTATION, V59, P1367, DOI 10.1097/00007890-199505270-00001
   CAILLATZUCMAN S, 1994, HUM IMMUNOL, V41, P91, DOI 10.1016/0198-8859(94)90091-4
   Ciancio G, 2001, TRANSPLANTATION, V71, P827, DOI 10.1097/00007890-200104150-00002
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Delaney CP, 1996, J CLIN INVEST, V97, P217, DOI 10.1172/JCI118393
   DEMETRIS AJ, 1993, TRANSPL P, V25, P3337
   Elwood ET, 1997, LANCET, V349, P1358, DOI 10.1016/S0140-6736(96)09105-2
   Fisher RA, 1996, J SURG RES, V60, P181, DOI 10.1006/jsre.1996.0029
   Frede S E, 1996, Transpl Immunol, V4, P227, DOI 10.1016/S0966-3274(96)80022-0
   GarciaMorales R, 1996, TRANSPLANTATION, V62, P1149, DOI 10.1097/00007890-199610270-00021
   Hisanaga M, 1996, TRANSPLANT P, V28, P1073
   Ishida H, 1996, TRANSPLANTATION, V62, P126, DOI 10.1097/00007890-199607150-00024
   KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018
   Kawai T, 1999, CURR OPIN IMMUNOL, V11, P516, DOI 10.1016/S0952-7915(99)00009-6
   Kirk AD, 1999, CRIT REV IMMUNOL, V19, P349
   Ko S, 1999, NAT MED, V5, P1292, DOI 10.1038/15248
   Komminoth P, 1992, Diagn Mol Pathol, V1, P142, DOI 10.1097/00019606-199203000-00021
   KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035
   Lobashevsky A, 1999, TISSUE ANTIGENS, V54, P254, DOI 10.1034/j.1399-0039.1999.540306.x
   Lobashevsky AL, 2000, HUM IMMUNOL, V61, P1013, DOI 10.1016/S0198-8859(00)00177-4
   MCDANIEL DO, 1994, TRANSPLANTATION, V57, P852, DOI 10.1097/00007890-199403270-00014
   Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264
   Monaco AP, 2001, TRANSPLANT P, V33, P51, DOI 10.1016/S0041-1345(01)01916-9
   Monaco AP, 1997, TRANSPLANT P, V29, P2983, DOI 10.1016/S0041-1345(97)00754-9
   Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642
   NAGLER A, 1994, TRANSPLANTATION, V57, P1458, DOI 10.1097/00007890-199405270-00010
   REINSMOEN NL, 1995, PEDIATR NEPHROL, V9, pS35, DOI 10.1007/BF00867681
   Richter N, 1995, Transpl Immunol, V3, P74, DOI 10.1016/0966-3274(95)80010-7
   RYMASZEWSKI Z, 1990, ANAL BIOCHEM, V188, P91, DOI 10.1016/0003-2697(90)90532-E
   Serody JS, 2000, BLOOD, V96, P2973
   Shapiro R, 2001, TRANSPLANT P, V33, P1134, DOI 10.1016/S0041-1345(00)02461-1
   Sivasai KSR, 1997, TRANSPLANTATION, V64, P427, DOI 10.1097/00007890-199708150-00010
   SMITH JP, 1994, TRANSPLANTATION, V58, P324, DOI 10.1097/00007890-199408150-00013
   STARZL TE, 1993, HEPATOLOGY, V17, P1127
   STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5
   Starzl TE, 1997, CURR OPIN NEPHROL HY, V6, P292, DOI 10.1097/00041552-199705000-00015
   SUBERBIELLE C, 1994, LANCET, V343, P1468, DOI 10.1016/S0140-6736(94)92583-6
   TALMOR M, 1995, IMMUNOLOGY, V86, P448
   THOMAS J, 1987, TRANSPLANTATION, V43, P332, DOI 10.1097/00007890-198703000-00002
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007
   THOMAS JM, 2001, CURR OPIN ORGAN TRAN, V6, P95
   Tsuji A, 2000, BIOPHYS J, V78, P3260, DOI 10.1016/S0006-3495(00)76862-7
   Wekerle T, 2001, ANNU REV MED, V52, P353, DOI 10.1146/annurev.med.52.1.353
   Zhao YB, 1999, TRANSPLANTATION, V68, P1573, DOI 10.1097/00007890-199911270-00023
NR 51
TC 5
Z9 6
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2002
VL 63
IS 2
BP 108
EP 120
DI 10.1016/S0198-8859(01)00364-0
PG 13
WC Immunology
SC Immunology
GA 519QV
UT WOS:000173737700004
PM 11821158
DA 2018-12-27
ER

PT J
AU Ullmark, G
   Hallin, G
   Nilsson, O
AF Ullmark, G
   Hallin, G
   Nilsson, O
TI RETRACTED: Impacted corticocancellous allografts and cement for revision
   of the femur component in total hip arthroplasty (Retracted article. See
   vol 17, pg 673, 2002)
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article; Retracted Publication
DE total hip arthroplasty; graft impaction; cement; revision
ID FOLLOW-UP; SUBSIDENCE; SURGERY; FAILURE; MANTLE; GRAFT; STEM
AB Revision of the femur component in total hip arthroplasty using impacted morcellized bone allografts and cemented Lubinus SP-II prosthesis or Charnley standard prosthesis vas performed in patients with loss of bone stock grade 11 through IV according to the Endo-Klinik classification from 1st to 8th revision. We report the results from 57 hips in 56 patients, with a median of 64 months' follow-up, Modified Merle d'Aubigne-Postel postoperative scores increased significantly from preoperative to postoperative values for the Lubinus group and for the Charnley group. Few complications were seen in this follow-up period. Five stems had minor subsidence. Rate of mechanical failure was 4% for both groups. Radiologic examinations provided evidence of frequent trabecular remodeling of the graft, especially for the Lubinus prosthesis.
C1 Lanssjukhuset, Dept Orthopaed, S-80187 Gavle, Sweden.
RP Ullmark, G (reprint author), Lanssjukhuset, Dept Orthopaed, S-80187 Gavle, Sweden.
CR AMSTUTZ HC, 1982, CLIN ORTHOP RELAT R, V170, P21
   Buma P, 1996, ACTA ORTHOP SCAND, V67, P536, DOI 10.3109/17453679608997751
   CHARNLEY J, 1979, LOW FRICTION ARTHROP, P20
   Eldridge JDJ, 1997, J ARTHROPLASTY, V12, P535, DOI 10.1016/S0883-5403(97)90176-5
   ELTING JJ, 1995, CLIN ORTHOP RELAT R, V319, P159
   ENGELBRECHT E, 1987, KLASSIFIKATION BEHAN
   GIE GA, 1993, J BONE JOINT SURG BR, V75, P14
   GRUEN TA, 1979, CLIN ORTHOP RELAT R, P17
   HUNGERFORD DS, 1988, CLIN ORTHOP RELAT R, V235, P12
   HUNTER GA, 1979, J BONE JOINT SURG BR, V61, P419
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Karrholm J, 1999, J BONE JOINT SURG BR, V81B, P135, DOI 10.1302/0301-620X.81B1.8922
   KERSHAW CJ, 1991, J BONE JOINT SURG BR, V73, P564
   Knight JL, 2000, J ARTHROPLASTY, V15, P159, DOI 10.1016/S0883-5403(00)90088-3
   Leopold SS, 1999, J BONE JOINT SURG AM, V81A, P1080, DOI 10.2106/00004623-199908000-00004
   LINDER L, 1998, 65 ANN M AAOS NEW OR
   LING RSM, 1997, AAOS M SAN FRANC FEB
   Masterson EL, 1999, J ARTHROPLASTY, V14, P59, DOI 10.1016/S0883-5403(99)90203-6
   Masterson EL, 1997, J ARTHROPLASTY, V12, P759, DOI 10.1016/S0883-5403(97)90005-X
   Meding JB, 1997, J BONE JOINT SURG AM, V79A, P1834, DOI 10.2106/00004623-199712000-00009
   Mikhail WEM, 1999, ARCH ORTHOP TRAUM SU, V119, P288, DOI 10.1007/s004020050412
   NIVBRANT B, 1999, THESIS UMEA SWEDEN
   ORNSTEIN E, 1997, 3 ANN M ORTH RES SOC
   Pekkarinen J, 2000, J BONE JOINT SURG BR, V82B, P103, DOI 10.1302/0301-620X.82B1.9802
   PILLIAR RM, 1986, CLIN ORTHOP RELAT R, V208, P108
   Rubash H E, 1988, J Arthroplasty, V3, P241
   Schmale GA, 2000, J ARTHROPLASTY, V15, P718, DOI 10.1054/arth.2000.6623
   STOMBERG CN, 1994, J ARTHROPLASTY, V9, P595
   Stromberg C N, 1988, J Arthroplasty, V3, P47, DOI 10.1016/S0883-5403(88)80052-4
   Tagil M, 2001, ACTA ORTHOP SCAND, V72, P78, DOI 10.1080/000164701753606743
   THOREN K, 1994, THESIS U LUND SWEDEN
   Ullmark G, 1998, ARCH ORTHOP TRAUM SU, V117, P170, DOI 10.1007/s004020050221
   Ullmark G, 1999, J ARTHROPLASTY, V14, P1019, DOI 10.1016/S0883-5403(99)90019-0
   Ullmark G, 2000, ARCH ORTHOP TRAUM SU, V120, P445, DOI 10.1007/s004029900122
   ULLMARK G, 2002, J ARTHROPLASTY, V17
   van Biezen FC, 2000, ACTA ORTHOP SCAND, V71, P135, DOI 10.1080/000164700317413094
NR 36
TC 19
Z9 21
U1 4
U2 8
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD FEB
PY 2002
VL 17
IS 2
BP 140
EP 149
DI 10.1054/arth.2002.29397
PG 10
WC Orthopedics
SC Orthopedics
GA 523TK
UT WOS:000173971500002
PM 11847611
DA 2018-12-27
ER

PT J
AU Shin, SG
AF Shin, SG
TI RETRACTED: Evolution of the health of concrete structures by
   electrically conductive GFRP (glass fiber reinforced plastic) composites
   (Retracted article. See vol. 24, pg. 437, 2018)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE self-diagnosis; GFRP composites; carbon powder; electrical resistance;
   concrete pile; fracture; monitoring
AB The function and performance of self-diagnostic composites embedded in concrete blocks and piles were investigated by bending tests mid electrical resistance measurement. Carbon powder (CP) and carbon fiber (CF) were introduced into glass Fiber reinforced plastic (GFRP) composites to provide electrical conductivity. The CPGFRP composite displays generally good performance in various bending tests of concrete block and piles compared to the CFGFRP composite. The electrical resistance of the CPGFRP composite increases remarkably at small strains in response to microcrack formation at about 200 mum strain, and can be used to detect smaller deformations before crack formation. The CPGFRP composite shows continuous change in resistance up to a large strain level just before the final fracture for concrete structures reinforced by steel bars. It is concluded that self-diagnostic composites can be used to predict damage and fracture in concrete blocks and piles.
C1 Dong A Univ, Div Met & Mat & Chem Engn, Saha Ku, Bunsan 604714, South Korea.
RP Shin, SG (reprint author), Dong A Univ, Div Met & Mat & Chem Engn, Saha Ku, 840 Hadan 2 Dong, Bunsan 604714, South Korea.
CR ARAI Y, 1998, CERAM MAT SYST COMPO, V99, P551
   KERSEY D, 1994, 1 WORLD C STRUCT CON, V1, P3
   KIRKPATRICK S, 1973, REV MOD PHYS, V45, P574, DOI 10.1103/RevModPhys.45.574
   MASRI SF, 1994, J ENG MECH, V120, P1696, DOI 10.1061/(ASCE)0733-9399(1994)120:8(1696)
   MATSUBARA H, 1996, CHEM CHEM IND, V49, P40
   Merzbacher CI, 1996, SMART MATER STRUCT, V5, P196, DOI 10.1088/0964-1726/5/2/008
   MUTO N, 1993, J AM CERAM SOC, V76, P875, DOI 10.1111/j.1151-2916.1993.tb05309.x
   OKUHARA Y, 2000, T MRS J, V25, P581
   SHIN SG, IN PRESS KOR J MAT R
   SHIN SG, 1999, P 6 JPN INT SAMPE S, V2, P995
   TAKADA M, 1999, J JPN SOC COMPOS MAT, V25, P225
   YANAGIDA H, 1999, J JPN SOC MECH ENG, V102, P68
NR 12
TC 3
Z9 3
U1 2
U2 4
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD FEB
PY 2002
VL 8
IS 1
BP 63
EP 68
DI 10.1007/BF03027029
PG 6
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 549CP
UT WOS:000175427200008
DA 2018-12-27
ER

PT J
AU Baglia, FA
   Badellino, KO
   Li, CQ
   Lopez, JA
   Walsh, PN
AF Baglia, FA
   Badellino, KO
   Li, CQ
   Lopez, JA
   Walsh, PN
TI RETRACTED: Factor XI binding to the platelet glycoprotein Ib-IX-V
   complex promotes factor XI activation by thrombin (Retracted Article.
   See vol 282, pg 29067, 2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; BERNARD-SOULIER
   PLATELETS; HUMAN-BLOOD PLATELETS; VON-WILLEBRAND-FACTOR;
   VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; ALPHA-THROMBIN; HEAVY-CHAIN;
   SITE
AB Factor XI binds to high affinity sites on the surface of stimulated platelets where it is efficiently activated by thrombin. Here, we provide evidence that the factor XI binding site on platelets is in the glycoprotein (GP) Ibalpha subunit of the GP Ib-IX-V complex as follows. 1) Bernard-Soulier platelets, lacking the complex, are deficient in factor XI binding; 2) two GP Ibalpha ligands, SZ-2 (a monoclonal antibody) and bovine von Willebrand factor, inhibit factor XI binding to platelets; 3) by surface plasmon resonance, factor XI bound specifically to glycocalicin (the extracellular domain of GP Iba) in Zn2+-dependent fashion (K-d app similar to 52 nm). We then investigated whether glycocalicin could promote factor XI activation by thrombin, another GP Ibalpha ligand. In the presence of high molecular weight kininogen (45 nm), Zn2+ and Ca2+ ions, thrombin activated factor XI in the presence of glycocalicin at rates comparable with those seen in the presence of dextran sulfate (1 mug/ml). With higher high molecular weight kininogen concentrations (360 nm), the rate of thrombin-catalyzed factor XI activation in the presence of glycocalicin was comparable with that on activated platelets. Thus, factor XI binds to the GP Ib-IX-V complex, promoting its activation by thrombin.
C1 Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
   Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA.
   Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Walsh, PN (reprint author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.
EM pnw@astro.temple.edu
FU NHLBI NIH HHS [HL64796, HL56914, HL64943, HL46213, HL54218]
CR Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200
   Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200
   BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   BAGLIA FA, 1992, J BIOL CHEM, V267, P4247
   BAGLIA FA, 1990, J BIOL CHEM, V265, P4149
   Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+
   BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354
   Bradford HN, 1997, BLOOD, V90, P1508
   BRUNNEE T, 1993, BLOOD, V81, P580
   COLLER BS, 1983, BLOOD, V61, P99
   DEMARCO L, 1991, J BIOL CHEM, V266, P23776
   DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050
   Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162
   DU XP, 1987, BLOOD, V69, P1524
   FOX JEB, 1987, J BIOL CHEM, V262, P12627
   FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018
   Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050
   Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200
   Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q
   JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000
   Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982
   Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x
   KUNICKI TJ, 1978, J CLIN INVEST, V62, P716, DOI 10.1172/JCI109181
   LI CY, 1995, BLOOD, V86, P3805
   Lopez J A, 1997, Curr Opin Hematol, V4, P323
   LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615
   LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97
   MELONI FJ, 1992, BLOOD, V79, P1233
   MODDERMAN PW, 1992, J BIOL CHEM, V267, P364
   MURATA M, 1991, J BIOL CHEM, V266, P15474
   Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803
   RUAN CG, 1987, BLOOD, V69, P570
   RUGGERI ZM, 1987, BLOOD, V70, P895
   THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862
   van Zanten GH, 1998, BLOOD, V91, P2353
   WALSH PN, 1975, BRIT J HAEMATOL, V29, P639, DOI 10.1111/j.1365-2141.1975.tb02750.x
   Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c
   WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3
   WHITE JG, 1984, BLOOD, V63, P1249
   WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x
NR 44
TC 79
Z9 84
U1 5
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 18
PY 2002
VL 277
IS 3
BP 1662
EP 1668
DI 10.1074/jbc.M108319200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 514CW
UT WOS:000173421300008
PM 11696542
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
AF Fujii, Y
TI RETRACTED: Combination antiemetic regimens for prevention of
   postoperative nausea and vomiting - Focus on high-risk patients
   (Retracted article. See vol. 38, pg. 477, 2018)
SO CLINICAL DRUG INVESTIGATION
LA English
DT Review; Retracted Publication
ID MIDDLE-EAR SURGERY; GRANISETRON-DROPERIDOL COMBINATION; ONDANSETRON PLUS
   DEXAMETHASONE; MAJOR GYNECOLOGIC SURGERY; LAPAROSCOPIC CHOLECYSTECTOMY;
   GRANISETRON/DEXAMETHASONE COMBINATION; PROPHYLACTIC ONDANSETRON;
   ABDOMINAL HYSTERECTOMY; AMBULATORY SURGERY; FEMALE-PATIENTS
AB None of the available antiemetics is entirely effective, perhaps because most of them act through the blockade of one receptor. There is a possibility that a combination of antiemetics with different sites of activity would be more effective than one drug Alone for prophylaxis against postoperative nausea and vomiting (PONV).
   The clinical use of combined traditional antiemetics, including antihistamines (e.g. diphenhydramine), butyrophenones (e.g. droperidol) and benzamides (e.g. metoclopramide), for the prevention of PONV is limited because of the possibility of additive central nervous system toxicity, such as delayed emergence, drowsiness and extrapyramidal reactions. The efficacy of a combination of a serotonin 5-HT3 receptor antagonist (ondansetron, granisetron or tropisetron) and dexamethasone is superior to that of 5-HT3 receptor antagonists Alone for the prevention of PONV, suggesting that dexamethasone enhances the antiemetic efficacy of 5-HT3 receptor antagonists. The combination of a 5-HT3 receptor antagonist with a traditional antiemetic (droperidol, metoclopramide or promethazine) acting at a different emetogenic receptor is more effective in reducing the incidence of PONV than each antiemetic alone acting at one receptor site. The risk of undesirable adverse effects does not increase with the combination of a 5-HT3 receptor antagonist and a traditional antiemetic at the doses commonly used for PONV, because of the absence of drug interactions. The combination of a 5-HT3 receptor antagonist (ondansetron) with other agents (propofol and CP-122721) reduces the incidence of PONV to a greater degree than monotherapy. However, no data are available for the combination of 5-HT3 receptor antagonists and small doses of propofol for the prevention of PONV.
   Further studies are needed to evaluate the efficacy and safety of combination antiemetic regimens for PONV. Knowledge regarding combinations of these antiemetic drugs may be necessary to completely prevent PONV.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1, Tsukuba, Ibaraki 305, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR Ahmed AB, 2000, BRIT J ANAESTH, V85, P678, DOI 10.1093/bja/85.5.678
   Barst SM, 1999, CAN J ANAESTH, V46, P359, DOI 10.1007/BF03013228
   BONICA JJ, 1958, ANESTHESIOLOGY, V19, P532, DOI 10.1097/00000542-195807000-00010
   BORGEAT A, 1992, ANESTH ANALG, V74, P539
   Bugedo G, 1999, BRIT J ANAESTH, V83, P813
   DESILVA PHDP, 1995, ANESTH ANALG, V81, P139, DOI 10.1097/00000539-199507000-00028
   DOSE VA, 1987, ANESTH ANALG, V66, pS41
   Eberhart LHJ, 2000, ACTA ANAESTH SCAND, V44, P1252, DOI 10.1034/j.1399-6576.2000.441011.x
   Eberhart LHJ, 1999, EUR J ANAESTH, V16, P790, DOI 10.1046/j.1365-2346.1999.00591.x
   Fortney JT, 1998, ANESTH ANALG, V86, P731, DOI 10.1097/00000539-199804000-00011
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   Fujii Y, 1997, ANESTH ANALG, V85, P913, DOI 10.1097/00000539-199710000-00036
   Fujii Y, 1998, ANESTH ANALG, V87, P761, DOI 10.1097/00000539-199810000-00004
   Fujii Y, 1998, ANESTH ANALG, V86, P613, DOI 10.1097/00000539-199803000-00033
   Fujii Y, 1998, BRIT J ANAESTH, V81, P387, DOI 10.1093/bja/81.3.387
   Fujii Y, 1999, EUR J ANAESTH, V16, P688
   Fujii Y, 1998, CAN J ANAESTH, V45, P541, DOI 10.1007/BF03012704
   Fujii Y, 1999, J CLIN ANESTH, V11, P108, DOI 10.1016/S0952-8180(99)00011-2
   Fujii Y, 1999, PAEDIATR ANAESTH, V9, P329, DOI 10.1046/j.1460-9592.1999.00376.x
   Fujii Y, 1999, ANESTH ANALG, V88, P1346, DOI 10.1097/00000539-199906000-00028
   Fujii Y, 1996, CAN J ANAESTH, V43, P1229, DOI 10.1007/BF03013430
   Fujii Y, 1998, BRIT J ANAESTH, V81, P754, DOI 10.1093/bja/81.5.754
   Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P1038, DOI 10.1111/j.1399-6576.1998.tb05373.x
   Fujii Y, 2000, ANAESTH INTENS CARE, V28, P266
   Fujii Y, 2000, EUR J ANAESTH, V17, P64, DOI 10.1046/j.1365-2346.2000.00617.x
   Gesztesi Z, 2000, ANESTHESIOLOGY, V93, P931, DOI 10.1097/00000542-200010000-00009
   HARRINGTON RA, 1976, DRUGS, V12, P81
   Holt R, 2000, PAEDIATR ANAESTH, V10, P181, DOI 10.1046/j.1460-9592.2000.00475.x
   Honkavaara P, 1998, ACTA ANAESTH SCAND, V42, P211, DOI 10.1111/j.1399-6576.1998.tb05111.x
   Janknegt R, 1999, ANAESTHESIA, V54, P1059, DOI 10.1046/j.1365-2044.1999.01075.x
   Kathirvel S, 1999, EUR J ANAESTH, V16, P761
   Khalil S, 1999, J CLIN ANESTH, V11, P596, DOI 10.1016/S0952-8180(99)00103-8
   Koivuranta A, 1999, EUR J ANAESTH, V16, P390
   Koivuranta M, 1997, ANAESTHESIA, V52, P863, DOI 10.1111/j.1365-2044.1997.234-az0366.x
   LEESER J, 1991, ANESTH ANALG, V72, P751
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LOESER EA, 1979, CAN ANAESTH SOC J, V26, P125, DOI 10.1007/BF03013781
   Loewen PS, 2000, CAN J ANAESTH, V47, P1008, DOI 10.1007/BF03024875
   Loo C C, 1997, Med J Malaysia, V52, P264
   LopezOlaondo L, 1996, BRIT J ANAESTH, V76, P835
   MARTY M, 1989, EUR J CANCER CLIN ON, V25, pS41
   MCCARTHY BG, 1988, AVIAT SPACE ENVIR MD, V59, P63
   McKenzie R, 1996, ANESTH ANALG, V83, P1218, DOI 10.1097/00000539-199612000-00015
   MCKENZIE R, 1994, ANESTH ANALG, V79, P961
   McKenzie R, 1997, J CLIN ANESTH, V9, P15, DOI 10.1016/S0952-8180(96)00215-2
   MICHALOUDIS D, 1993, J ROY SOC MED, V86, P137
   OSTMAN PL, 1990, ANESTH ANALG, V71, P536
   Peixoto AJ, 2000, EUR J ANAESTH, V17, P611, DOI 10.1046/j.1365-2346.2000.00726.x
   Pueyo FJ, 1996, ANESTH ANALG, V83, P117, DOI 10.1097/00000539-199607000-00021
   Rajeeva V, 1999, CAN J ANAESTH, V46, P40, DOI 10.1007/BF03012512
   Riley TJ, 1998, J CLIN ANESTH, V10, P6, DOI 10.1016/S0952-8180(97)00188-8
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   SAGAR SM, 1991, CANCER TREAT REV, V18, P95, DOI 10.1016/0305-7372(91)90009-O
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   Song DJ, 1998, ANESTHESIOLOGY, V89, P838, DOI 10.1097/00000542-199810000-00007
   Steinbrook RA, 1996, ANESTH ANALG, V83, P1081, DOI 10.1097/00000539-199611000-00032
   STEWART DJ, 1990, CAN J PHYSIOL PHARM, V68, P304, DOI 10.1139/y90-045
   SWHITE PF, 1999, ANESTH ANALG, V88, P1200
   Tang J, 1996, ANESTH ANALG, V83, P304, DOI 10.1097/00000539-199608000-00018
   TURHANOGLU S, 1999, ACTA ANAESTH ITAL, V50, P193
   Warrick PD, 1999, J CLIN ANESTH, V11, P119, DOI 10.1016/S0952-8180(99)00024-0
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WATCHA MF, 1994, J CLIN ANESTH, V6, P370, DOI 10.1016/S0952-8180(05)80006-6
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
   Wu O, 2000, CAN J ANAESTH, V47, P529, DOI 10.1007/BF03018944
   YOUNG SN, 1981, BRIT J PHARMACOL, V74, P695, DOI 10.1111/j.1476-5381.1981.tb10480.x
NR 68
TC 2
Z9 2
U1 1
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-2563
EI 1179-1918
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PY 2002
VL 22
IS 9
BP 561
EP 574
DI 10.2165/00044011-200222090-00001
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 593JN
UT WOS:000177988000001
PM 29492850
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Tanaka, H
AF Fujii, Y
   Uemura, A
   Tanaka, H
TI RETRACTED: Prophylaxis of nausea and vomiting after laparoscopic
   cholecystectomy with ramosetron: Randomised controlled trial (Retracted
   article. See vol. 100, pg. 845, 2013)
SO EUROPEAN JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
DE complications; nausea; vomiting; antiemetics; ramosetron; laparoscopic
   cholecystectomy
ID POSTOPERATIVE NAUSEA
AB Objective: To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
   Design: Prospective, randomised, double-blind, placebo-controlled study.
   Setting: University and university-affiliated hospitals, Japan.
   Subjects: 100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.
   Interventions: Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.
   Main outcome measures: Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.
   Results: The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.
   Conclusions: Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 3058576, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakuba, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1998, EUR J ANAESTH, V15, P166, DOI 10.1111/j.0265-0215.1998.00267.x
   Iitomi T, 1995, Masui, V44, P1627
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   SANTON JM, 1991, ANAESTHESIA, V46, P317
   Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   White PF, 1999, ANESTH ANALG, V88, P1200
NR 11
TC 17
Z9 22
U1 3
U2 6
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1102-4151
J9 EUR J SURG
JI Eur. J. Surg.
PY 2002
VL 168
IS 11
BP 583
EP 586
DI 10.1080/11024150201680002
PG 4
WC Surgery
SC Surgery
GA 660XU
UT WOS:000181861100002
PM 12699092
DA 2018-12-27
ER

PT J
AU Hutchings, A
   Hubbard, WJ
   Thomas, FT
   Thomas, JM
AF Hutchings, A
   Hubbard, WJ
   Thomas, FT
   Thomas, JM
TI RETRACTED: STEALTH in transplantation tolerance (Retracted Article. See
   vol 40, pg 95, 2008)
SO IMMUNOLOGIC RESEARCH
LA English
DT Article; Retracted Publication
DE immunosuppression; immunotoxin; islet; kidney; lymphocyte; depletion;
   nonhuman primate; transplantation
ID NAIVE T-CELLS; DENDRITIC CELLS; DRIVEN PROLIFERATION; ANTI-CD3
   IMMUNOTOXIN; ALLOGRAFT TOLERANCE; ISLET TRANSPLANT; RHESUS MACAQUES;
   CUTTING EDGE; NKT CELLS; B-CELLS
AB Although contemporary immunosuppressive regimens are responsible for major improvements in allograft acceptance, there are indications that long-term survival may be compromised through drug toxicity and/or chronic immune deficiency. The ultimate goal for transplantation is tolerance, defined as durable, donor-specific allograft acceptance in the absence of long-term immunosuppression. This article reviews the nonhuman primate STEALTH model of tolerance recently developed by the transplant immunobiology group at University of Alabama at Birmingham. The STEALTH model was designed for future application to human transplantation and comprises a concise peritransplant treatment strategy of only 2 wk. Tolerance is induced by depletion of T cells, with concomitant inhibition of nuclear factor-kappaB/RelB-dependent proinflammatory signaling. This treatment has resulted in an unprecedented frequency of kidney allograft survival (62.5% at 3 yr), with some primate recipients remaining in good health more than 6 yr posttransplant, in the complete absence of chronic pharmacologic immunosuppression.
C1 Univ Alabama, Dept Surg, Div Transplantat Immunobiol, Birmingham, AL 35294 USA.
RP Hutchings, A (reprint author), Univ Alabama, Dept Surg, Div Transplantat Immunobiol, Birmingham, AL 35294 USA.
EM hutchina@uab.edu
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185
   Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G
   Carnaud C, 1999, J IMMUNOL, V163, P4647
   CECKA JM, 2000, CLIN TRANSPL, V14, P1
   Cho BK, 2000, J EXP MED, V192, P549, DOI 10.1084/jem.192.4.549
   Clarke SRM, 2000, J IMMUNOL, V165, P2458, DOI 10.4049/jimmunol.165.5.2458
   Contreras JL, 1999, TRANSPLANTATION, V68, P215, DOI 10.1097/00007890-199907270-00009
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Dengler TJ, 2000, J IMMUNOL, V164, P5146, DOI 10.4049/jimmunol.164.10.5146
   Donnenberg AD, 1995, ANN NY ACAD SCI, V770, P213, DOI 10.1111/j.1749-6632.1995.tb31057.x
   Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711
   Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7
   Goldrath AW, 2000, J EXP MED, V192, P557, DOI 10.1084/jem.192.4.557
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   Hubbard WJ, 2001, HUM IMMUNOL, V62, P479, DOI 10.1016/S0198-8859(01)00235-X
   HUBBARD WJ, 2000, CURR OPIN ORGAN TRAN, V5, P29
   Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163
   Kirk AD, 1999, CRIT REV IMMUNOL, V19, P349
   Knechtle SJ, 2000, CURR OPIN IMMUNOL, V12, P552, DOI 10.1016/S0952-7915(00)00137-0
   Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530
   LEVINGS MK, 2000, J ALLERGY CLIN IMMUN, V106, P109
   Li XC, 2000, CURR OPIN IMMUNOL, V12, P522, DOI 10.1016/S0952-7915(00)00133-3
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Matzinger P, 1997, TRANSPLANT P, V29, p11S, DOI 10.1016/S0041-1345(97)00848-8
   McKenna RM, 2000, TRANSPLANTATION, V69, P319, DOI 10.1097/00007890-200002150-00001
   Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733
   MURRAY JE, 1964, ANN SURG, V160, P449, DOI 10.1097/00000658-196409000-00009
   NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   NOOIJ FJM, 1986, EUR J IMMUNOL, V16, P975, DOI 10.1002/eji.1830160817
   Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   Sachs DH, 1999, J GASTROINTEST SURG, V3, P105, DOI 10.1016/S1091-255X(99)80017-1
   Salama AD, 2001, J CLIN INVEST, V108, P943, DOI 10.1172/JCI200114142
   Shapiro AMJ, 2001, TRANSPLANT P, V33, P3502, DOI 10.1016/S0041-1345(01)02416-2
   Snapper CM, 1996, J IMMUNOL, V156, P183
   Steinman RM, 1999, HUM IMMUNOL, V60, P562, DOI 10.1016/S0198-8859(99)00030-0
   Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   TEPPER MA, 1995, J IMMUNOL, V155, P2427
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   Thomas JM, 2001, IMMUNOL REV, V183, P223, DOI 10.1034/j.1600-065x.2001.1830118.x
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   Thomas JM, 2001, DIABETES, V50, P1227, DOI 10.2337/diabetes.50.6.1227
   Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007
   THOMAS JM, 1996, CHIMERISM TOLERANCE, P143
   WALDMANN H, 2000, CURR OPIN ORGAN TRAN, V5, P83
   Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909
   Wekerle T, 2001, J HEART LUNG TRANSPL, V20, P816, DOI 10.1016/S1053-2498(01)00265-0
   Womer KL, 2001, PHILOS T ROY SOC B, V356, P727, DOI 10.1098/rstb.2001.0852
   Wu J, 2001, TRANSPLANT P, V33, P278, DOI 10.1016/S0041-1345(00)02789-5
   Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4
   Zhai Y, 1999, CURR OPIN IMMUNOL, V11, P497, DOI 10.1016/S0952-7915(99)00007-2
NR 53
TC 4
Z9 4
U1 3
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
J9 IMMUNOL RES
JI Immunol. Res.
PY 2002
VL 26
IS 1-3
BP 143
EP 152
DI 10.1385/IR:26:1-3:143
PG 10
WC Immunology
SC Immunology
GA 604KU
UT WOS:000178620600015
PM 12403353
DA 2018-12-27
ER

PT J
AU Khan, A
   Aziz, T
AF Khan, A
   Aziz, T
TI RETRACTED: The numerical solution of third-order boundary-value problems
   using quintic splines (Retracted article. see vol 84, pg 1549, 2007)
SO INTERNATIONAL JOURNAL OF COMPUTER MATHEMATICS
LA English
DT Article; Retracted Publication
DE third-order boundary-value problems; quintic splines; five band system
AB We present a fourth-order method based on quintic splines for the solution of third-order linear and non-linear boundary-value problems of the form y''' = f(x, y), a less than or equal to x less than or equal to b subject to the boundary conditions y(a) = k(1), y'(a) = k(2), y(b) = k(3). Numerical examples are given to illustrate the method and their convergence.
C1 Aligarh Muslim Univ, Fac Engn & Technol, Dept Appl Math, Aligarh 202002, Uttar Pradesh, India.
RP Khan, A (reprint author), Aligarh Muslim Univ, Fac Engn & Technol, Dept Appl Math, Aligarh 202002, Uttar Pradesh, India.
EM amr002@amu.up.nic.in
CR Ahlberg J. H., 1967, THEORY SPLINES THEIR
   Caglar HN, 1999, INT J COMPUT MATH, V71, P373, DOI 10.1080/00207169908804816
   Jain M. K., 1984, NUMERICAL SOLUTION D
   RASHIDINIA J, 1994, THESIS AMU ALIGARH
   TIRMIZI IA, 1991, COMMUN APPL NUMER M, V7, P309, DOI 10.1002/cnm.1630070409
NR 5
TC 2
Z9 2
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7160
EI 1029-0265
J9 INT J COMPUT MATH
JI Int. J. Comput. Math.
PY 2002
VL 79
IS 9
BP 1025
EP 1031
DI 10.1080/00207160290033719
PG 7
WC Mathematics, Applied
SC Mathematics
GA 573PH
UT WOS:000176839700006
DA 2018-12-27
ER

PT J
AU Reuben, SS
   Fingeroth, R
   Krushell, R
   Maciolek, H
AF Reuben, SS
   Fingeroth, R
   Krushell, R
   Maciolek, H
TI RETRACTED: Evaluation of the safety and efficacy of the Perioperative
   administration of rofecoxib for total knee arthroplasty (Retracted
   article. See vol. 25, pg. 172, 2010)
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article; Retracted Publication
DE arthroplasty; rofecoxib; nonsteroidal anti-inflammatory drugs (NSAIDs);
   blood loss; osteoarthritis
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLOOD-LOSS; CYCLOOXYGENASE-2;
   ANALGESIA; SURGERY; COX-2; PAIN; REQUIREMENTS; INFLAMMATION; TRANSFUSION
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) frequently are discontinued before elective total knee arthroplasty (TKA) because of the increased incidence of perioperative bleeding. Rofecoxib, a selective cyclooxygenase 2 inhibitor, does not interfere with the coagulation system and may be a safer NSAID for patients undergoing TKA. In this study, 100 patients undergoing elective TKA discontinued their use of NSAIDs 10 days before surgery and were assigned randomly to receive either placebo (n = 50) or rofecoxib (n = 50), 25 mg daily for 5 consecutive days starting 3 days before surgery. The administration of rofecoxib resulted in improved preoperative pain scores and no significant increase in the incidence of perioperative bleeding or international normalized ratio compared with placebo. Rofecoxib does not need to be discontinued before elective TKA.
C1 Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA.
RP Reuben, SS (reprint author), Baystate Med Ctr, Dept Anesthesiol, 759 Chestnut St, Springfield, MA 01199 USA.
EM scott.reuben@bhs.org
CR An H S, 1991, J Arthroplasty, V6, P245, DOI 10.1016/S0883-5403(06)80171-3
   Benoni G, 1996, J BONE JOINT SURG BR, V78B, P434
   Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006
   Chan TYK, 1995, ANN PHARMACOTHER, V29, P1274, DOI 10.1177/106002809502901214
   CONNELLY CS, 1991, ARCH INTERN MED, V151, P1963, DOI 10.1001/archinte.151.10.1963
   CUSHNER FD, 1991, CLIN ORTHOP RELAT R, V269, P98
   EHRICH E, 1999, ARTHRITIS RHEUM, V39, P329
   Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X
   FRAGEN RJ, 1995, J BONE JOINT SURG AM, V77A, P998, DOI 10.2106/00004623-199507000-00004
   Fricke J, 1999, CLIN PHARMACOL THER, V65, P119, DOI 10.1016/S0009-9236(99)80007-1
   Greenberg HE, 1999, CLIN PHARMACOL THER, V65, P163, DOI 10.1016/S0009-9236(99)80184-2
   Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2
   MEADE EA, 1993, J BIOL CHEM, V268, P6610
   *MERCK CO, 1999, ROF PACK INS
   PAIEMENT GD, 1993, J BONE JOINT SURG AM, V75A, P893, DOI 10.2106/00004623-199306000-00010
   Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539-200011000-00032
   REUBEN SS, 2000, REG ANESTH PAIN MED, V25, P16
   Robinson C M, 1993, J Arthroplasty, V8, P607, DOI 10.1016/0883-5403(93)90007-Q
   SEIBERT K, 1994, RECEPTOR, V4, P17
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Slappendel R, 1999, ANESTH ANALG, V88, P146, DOI 10.1097/00000539-199901000-00027
NR 21
TC 55
Z9 56
U1 4
U2 16
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD JAN
PY 2002
VL 17
IS 1
BP 26
EP 31
DI 10.1054/arth.2002.27677
PG 6
WC Orthopedics
SC Orthopedics
GA 515XW
UT WOS:000173522800004
PM 11805921
DA 2018-12-27
ER

PT J
AU Ezzat, S
   Zheng, L
   Zhu, XF
   Wu, GE
   Asa, SL
AF Ezzat, S
   Zheng, L
   Zhu, XF
   Wu, GE
   Asa, SL
TI RETRACTED: Targeted expression of a human pituitary tumor-derived
   isoform of FGF receptor-4 recapitulates pituitary tumorigenesis
   (Retracted article. See vol. 125, pg. 3303, 2015)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID FIBROBLAST-GROWTH-FACTOR; BREAST-CANCER CELLS; LACTOTROPH HYPERPLASIA;
   EPITHELIAL-CELLS; DEFICIENT MICE; SPLICE VARIANT; ADENOMAS; GENE;
   SPECIFICITY; IDENTIFICATION
AB It is estimated that up to one in five individuals develop pituitary gland tumors. Despite the common occurrence of these tumors, the pathogenetic mechanisms underlying their development remain largely unknown. We report the identification of a novel pituitary tumor-derived, N-terminally truncated isoform of FGF receptor-4 (ptd-FGFR4). The corresponding mRNA results from alternative transcription initiation and encodes a polypeptide that lacks a signal peptide and the first two extracellular Ig-like domains. ptd-FGFR4 has a distinctive cytoplasmic residence, is constitutively phosphorylated, and is transforming in vitro and in vivo. Here we show that targeted expression of ptd-FGFR4, but not FGFR4, results in pituitary tumors that morphologically recapitulate the human disease.
C1 Univ Toronto, Dept Med, Toronto, ON, Canada.
   Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada.
   Univ Toronto, Dep Pathol & Lab Med, Toronto, ON, Canada.
   Mt Sinai Hosp, Freeman Ctr Endocrine Oncol, Toronto, ON M5G 1X5, Canada.
RP Asa, SL (reprint author), Ontario Canc Inst, 610 Univ Ave,Room 4-302, Toronto, ON M5G 2M9, Canada.
EM sylvia.asa@uhn.on.ca
OI Asa, Sylvia/0000-0001-8418-5054
CR Abbass SAA, 1997, J CLIN ENDOCR METAB, V82, P1160, DOI 10.1210/jc.82.4.1160
   ASA SL, 1992, ENDOCRINOLOGY, V131, P2083, DOI 10.1210/en.131.5.2083
   Asa SL, 1998, J CLIN ENDOCR METAB, V83, P3210, DOI 10.1210/jc.83.9.3210
   Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798
   Asa SL, 1999, ENDOCRINOLOGY, V140, P5348, DOI 10.1210/en.140.11.5348
   ASA SL, 1998, ATLAS TUMOR PATHOL 3
   Ezzat S, 2001, BIOCHEM BIOPH RES CO, V287, P60, DOI 10.1006/bbrc.2001.5546
   EZZAT S, 1990, J ENDOCRINOL INVEST, V13, P691, DOI 10.1007/BF03349601
   EZZAT S, 1975, J CLIN ENDOCR METAB, V80, P878
   Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8
   GIVOL D, 1992, FASEB J, V6, P3362
   GONSKY R, 1991, MOL ENDOCRINOL, V5, P1687, DOI 10.1210/mend-5-11-1687
   GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95
   Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275
   Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710
   JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0
   Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643
   JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609
   Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7
   Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6
   Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703
   LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436
   MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479
   Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4
   Olson DC, 1998, CELL GROWTH DIFFER, V9, P557
   Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Takaishi S, 2000, BIOCHEM BIOPH RES CO, V267, P658, DOI 10.1006/bbrc.1999.2010
   Tuominen H, 2001, PROTEIN EXPRES PURIF, V21, P275, DOI 10.1006/prep.2000.1375
   VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0
   van Heumen WRA, 1999, IUBMB LIFE, V48, P73, DOI 10.1080/713803466
   Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485
   YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A
   Zhuang ZP, 1997, CANCER RES, V57, P5446
NR 34
TC 130
Z9 132
U1 2
U2 16
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2002
VL 109
IS 1
BP 69
EP 78
DI 10.1172/JCI14036
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 509RZ
UT WOS:000173164600011
PM 11781352
OA Bronze
DA 2018-12-27
ER

PT S
AU Smith, RW
   Zhu, XH
   Tunnicliffe, MC
   Smith, TJN
   Misener, L
   Adamson, J
AF Smith, RW
   Zhu, XH
   Tunnicliffe, MC
   Smith, TJN
   Misener, L
   Adamson, J
BE Sadhal, SS
TI RETRACTED: The influence of gravity on the precise measurement of solute
   diffusion coefficients in dilute liquid metals and metalloids (Retracted
   article. See vol. 1176, pg. 228, 2009)
SO MICROGRAVITY TRANSPORT PROCESSES IN FLUID, THERMAL, BIOLOGICAL, AND
   MATERIALS SCIENCES
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Conference on Microgravity Transport Processes in Fluid, Thermal,
   Biological and Materials Sciences
CY SEP 30-OCT 05, 2001
CL BANFF, CANADA
SP NASA, Natl Sci Fdn, United Engn Fdn
DE impurity diffusion; liquid metals; liquid metalloids; gravity;
   microgravity; g-jitter
ID TRANSPORT
AB It is now well known that the diffusion coefficient (D) measured in a laboratory in low earth orbit (LEO) is less than the corresponding value measured in a terrestrial laboratory. However, all LEO laboratories are subject to transient accelerations (g-jitter) superimposed on the steady reduced gravity environment of the space platform. In measurements of the diffusion coefficients for dilute binary alloys of Pb-(Ag,Au,Sb), Sb-(Ga,In), Bi-(Ag,Au,Sb), Sn-(Au, Sb), Al-(Fe, Ni, Si), and In-Sb in which g-jitter was suppressed, it was found that D proportional to T (temperature) if g-jitter was suppressed, rather than D proportional to T-2 as observed by earlier workers with g-jitter present. Furthermore, when a forced g-jitter was applied to a diffusion couple, the value measured for D increased. The significance of these results is reviewed in the light of recent work in which ab initio molecular dynamics simulations predicted a D proportional to T relationship.
C1 Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
   Millenium Biologix Inc, Kingston, ON, Canada.
RP Smith, RW (reprint author), Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
EM smithrw@post.queensu.ca
CR FROHBERG G, 1986, NORD S AUG, P144
   Griesche A, 1998, REV SCI INSTRUM, V69, P315, DOI 10.1063/1.1148516
   HILDEBRAND JL, 1977, VISCOSITY DIFFUSIVIT, pCH1
   Jalbert LB, 1998, J PHYS-CONDENS MAT, V10, P7113, DOI 10.1088/0953-8984/10/32/003
   MALMEJAC Y, 1986, FLUID SCI MAT SCI SP, P159
   MONTE R, 2001, PUBL ESA SP 454, V2, P813
   MUNEJIRI S, 1908, P SPAC 2000
   SEKERKA RF, 2001, ESA SP 454, V1, P31
   SMITH RW, 2000, P 12 INT S EXP METH
   SMITH RW, 1998, 10 INT S EXP METH MI
   Zhu X, 1998, ADV SPACE RES, V22, P1253, DOI 10.1016/S0273-1177(98)80032-X
   Zhu X, 1996, MATER SCI FORUM, V215, P113, DOI 10.4028/www.scientific.net/MSF.215-216.113
NR 12
TC 20
Z9 21
U1 3
U2 12
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-423-4; 1-57331-422-6
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2002
VL 974
BP 57
EP 67
DI 10.1111/j.1749-6632.2002.tb05896.x
PG 11
WC Engineering, Chemical; Engineering, Mechanical; Multidisciplinary
   Sciences
SC Engineering; Science & Technology - Other Topics
GA BV61L
UT WOS:000179509600005
PM 12446313
DA 2018-12-27
ER

PT S
AU Yang, BJ
   Smith, RW
   Saho, M
   Sadayappan, M
AF Yang, BJ
   Smith, RW
   Saho, M
   Sadayappan, M
BE Sadhal, SS
TI RETRACTED: The influence of Marangoni flows on crack growth in cast
   metals (Retracted Article. See vol 1214, pg 213, 2010)
SO MICROGRAVITY TRANSPORT PROCESSES IN FLUID, THERMAL, BIOLOGICAL, AND
   MATERIALS SCIENCES
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Conference on Microgravity Transport Processes in Fluid, Thermal,
   Biological and Materials Sciences
CY SEP 30-OCT 05, 2001
CL BANFF, CANADA
SP NASA, Natl Sci Fdn, United Engn Fdn
DE Marangoni flow; hot tear; modeling
ID SURFACE-TENSION; LIQUID ALLOYS; MODEL
AB In previous work with copper-based alloys, the authors showed that a necessary part of the hot-tearing process is the creation of a void in association with an inclusion and its subsequent growth to form the crack observed in the as-cast state. The work reported here is an examination of hot tearing in aluminum alloy A201 and various similar Al-based aerospace alloys to determine (1) if a similar process to that seen in copper alloys takes place; (2) the extent to which buoyancy forces influence the movement of solute-enriched liquid and so contribute to the development of voids which are subsequently observed as hot tears; and (3) the influence of the local variations in liquid/void surface tension arising due to local composition and temperature changes on interdendritic fluid flow-that is, the effects of Marangoni convection on void size and movement during solidification. Hot cracking of aluminum alloy A201 has been examined under standardized experimental conditions. In addition, experiments were conducted in which fluid flow in test castings was controlled by magnetic fields. The results from these various investigations are presented in this paper. Similar experiments are planned for reduced gravity aircraft parabolic flights. To assist in the planning and interpretation of the results, numerical modeling simulations have been developed for Al-Cu alloys.
C1 Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
   Natl Resources Canada, Mat Technol Lab, CANMET, Ottawa, ON, Canada.
RP Yang, BJ (reprint author), Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
EM snuthrw@post.queensu.ca
CR BISHOP HF, 1960, AFS T, V68, P818
   Chang S, 1996, METALL MATER TRANS A, V27, P2708, DOI 10.1007/BF02652365
   FSRUP I, 2000, METALL MATER TRANS A, V31, P1461
   GOICOECHEA J, 1992, J MATER SCI, V27, P5247, DOI 10.1007/BF02403824
   HOLT M, 1992, SCRIPTA METALL MATER, V26, P1119, DOI 10.1016/0956-716X(92)90240-F
   LATY P, 1977, SURF SCI, V69, P508, DOI 10.1016/0039-6028(77)90130-3
   LIU Q, 1993, AFS T, V101, P759
   Pellini W.S., 1952, FOUNDRY, V80, P124
   POIRIER DR, 1987, METALL TRANS A, V18, P1156, DOI 10.1007/BF02668569
   Rappaz M, 1999, METALL MATER TRANS A, V30, P449, DOI 10.1007/s11661-999-0334-z
   Rosenberg R. A., 1960, AFS T, V68, P518
   SADAYAPPAN M, 2001, LIGHT MET 2001 S C M
   SADAYYAPPAN M, 2001, AFS T, V109, P579
   SPITTLE JA, 1983, MET TECHNOL, V10, P6, DOI 10.1179/030716983803291226
NR 14
TC 1
Z9 1
U1 3
U2 9
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-423-4; 1-57331-422-6
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2002
VL 974
BP 110
EP 123
DI 10.1111/j.1749-6632.2002.tb05901.x
PG 14
WC Engineering, Chemical; Engineering, Mechanical; Multidisciplinary
   Sciences
SC Engineering; Science & Technology - Other Topics
GA BV61L
UT WOS:000179509600010
PM 12446318
DA 2018-12-27
ER

PT S
AU Smith, RW
AF Smith, RW
BE Sadhal, SS
TI RETRACTED: Gravity-induced anomalies in interphase spacing reported for
   binary eutectics (Retracted article. See vol. 1176, pg. 228, 2009)
SO MICROGRAVITY TRANSPORT PROCESSES IN FLUID, THERMAL, BIOLOGICAL, AND
   MATERIALS SCIENCES
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Conference on Microgravity Transport Processes in Fluid, Thermal,
   Biological and Materials Sciences
CY SEP 30-OCT 05, 2001
CL BANFF, CANADA
SP NASA, Natl Sci Fdn, United Engn Fdn
DE eutectic growth; microgravity; spacing anomalies
ID SOLIDIFICATION; GROWTH; MICROSTRUCTURE; LAMELLAR; CU
AB It has been reasoned that desirable microstructural refinement in binary eutectics could result from freezing in reduced-gravity. It is recognized that the interphase spacing in a binary eutectic is controlled by solute transport and that, on Earth, buoyancy-driven convection may enhance this. Hence, it has been presumed that the interphase spacing ought to decrease when a eutectic alloy is frozen under conditions of much-reduced gravity, where such buoyancy effects would be largely absent. The result of such speculation has been that many workers have frozen various eutectics under reduced gravity and have reported that, although some eutectics became finer, others showed no change, and some even became coarser. This reported varied behavior Will be reviewed in the light of long term studies by the author at Queen's University, including recent microgravity studies in which samples of two eutectic alloy systems, MnBi-Bi and MnSb-Sb, were frozen under very stable conditions and showed no change in interphase spacing.
C1 Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
RP Smith, RW (reprint author), Queens Univ, Dept Mat & Met Engn, Kingston, ON K7L 3N6, Canada.
EM smithrw@post.queensu.ca
CR APAYDIN NA, 1990, THESIS QUEENS U
   BARBIERI F, 1988, METALL TRANS A, V19, P2659, DOI 10.1007/BF02645798
   BETHIN J, JM86548 NASA
   BETHIN J, 1986, NASACRR171271RE69 GR
   BRANDT WH, 1945, J APPL PHYS, V16, P139, DOI 10.1063/1.1707565
   BRANDT WH, 1946, T AM I MIN MET ENG, V167, P405
   CHEN Q, 1996, 7 INT S EXP METH MIC
   CROKER MN, 1973, P ROY SOC LOND A MAT, V335, P15, DOI 10.1098/rspa.1973.0111
   DEGOER J, 1983, INTERNAL REPORT
   FAVIER JJ, 1984, ESA, P127
   FIDLER RS, 1969, THESIS U BIRMINGHAM
   HUNT JD, 1968, PUBL ISI, V110
   JACKSON KA, 1966, T METALL SOC AIME, V236, P1129
   KAYA M, 1996, REPORT CANADIAN SPAC
   LARSON DJ, 1988, RE753 GRUMM CORP
   Li F, 2001, J CRYST GROWTH, V223, P251, DOI 10.1016/S0022-0248(00)00991-X
   LIU J, 1993, MAT SCI ENG A-STRUCT, V173, P129, DOI 10.1016/0921-5093(93)90201-O
   MULLER G, 1984, INTERNAL REPORT DFVL
   MULLER G, 1984, ESA SP222, P141
   OURDJINI A, 1994, MATER SCI TECH SER, V10, P312, DOI 10.1179/mst.1994.10.4.312
   Pacz A, 1921, U. S Patent, Patent No. 1387900
   PATUELLI C, 1993, T MAT RES SOC JPN A, V16, P607
   PIRICH RG, 1980, AIAA 18 AER SCI M PA
   Popov DI, 2001, CRYST GROWTH DES, V1, P313, DOI 10.1021/cg005538v
   Popov DI, 2000, J CRYST GROWTH, V209, P181, DOI 10.1016/S0022-0248(99)00525-4
   SMITH RW, 1969, SOLIDIFICATION METAL, P224
   Tiller W.A., 1958, LIQUID METALS SOLIDI, P276
   TRIVEDI R, 1991, MET T A, P2523
   WILCOX WR, 1994, MICROGRAVITY Q, V4, P147
   ZENER C, 1946, T AM I MIN MET ENG, V167, P550
NR 30
TC 1
Z9 1
U1 2
U2 7
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-423-4; 1-57331-422-6
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2002
VL 974
BP 176
EP 192
DI 10.1111/j.1749-6632.2002.tb05907.x
PG 17
WC Engineering, Chemical; Engineering, Mechanical; Multidisciplinary
   Sciences
SC Engineering; Science & Technology - Other Topics
GA BV61L
UT WOS:000179509600016
PM 12446324
DA 2018-12-27
ER

PT J
AU Aoki, N
   Matsuda, T
AF Aoki, N
   Matsuda, T
TI RETRACTED: A nuclear protein tyrosine phosphatase TC-PTP is a potential
   negative regulator of the PRL-mediated signaling pathway:
   Dephosphorylation and deactivation of signal transducer and activator of
   transcription 5a and 5b by TC-PTP in nucleus (Retracted article. See
   vol. 27, pg. 1982, 2013)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID GROWTH-FACTOR RECEPTOR; INSULIN SENSITIVITY; POSITIVE REGULATOR;
   PROLACTIN RECEPTOR; KINASE JAK2; CELLS; EXPRESSION; STAT5; MICE;
   IDENTIFICATION
AB In the present study we examined involvement of nuclear protein tyrosine phosphatase TC-PTP in PRL-mediated signaling. TC-PTP could dephosphorylate signal transducer and activator of transcription Sa (STAT5a) and STAT5b, but the apparent dephosphorylation activity of TC-PTP was weaker than that of cytosolic PTP1B 30 min after PRL stimulation in transfected COS-7 cells, whereas both STAT5a and STAT5b were dephosphorylated to the same extent by recombinant TC-PTP and PTP1B in vitro. Tyrosine-phosphorylated STAT5 was coimmunoprecipitated with substrate trapping mutants of TC-PTP, suggesting that STAT5 is a specific substrate of TC-PTP. These observations were further extended in mammary epithelial COMMA-1D cells stably expressing TC-PTP. A time-course study revealed that dephosphorylation of STAT5 by TC-PTP was delayed compared with that by cytosolic PTP1B due to nuclear localization of TC-PTP throughout PRL stimulation in mammary epithelial cells. Endogenous beta -casein gene expression and beta -casein gene promoter activation in COS-7 cells were largely suppressed by TC-PTP wild type as well as catalytically inactive mutants, suggesting that stable complexes formed between STAT5 and TC-PTP in the nucleus. Taken together, we conclude that TC-PTP is catalytically competent with respect to dephosphorylation and deactivation of PRL-activated STAT5 in the nucleus.
C1 Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.
RP Aoki, N (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.
EM naoki@agr.nagoya-u.ac.jp
CR Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x
   Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200
   Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422
   Aoki N, 1999, J BIOCHEM, V125, P669, DOI 10.1093/oxfordjournals.jbchem.a022335
   BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934
   Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556
   CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257
   COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280
   DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1
   DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x
   Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544
   Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400
   Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x
   Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x
   Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220
   Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5
   Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021
   LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631
   MIYASAKA H, 1992, MOL CELL BIOCHEM, V118, P91, DOI 10.1007/BF00249698
   MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499
   Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4
   RUI H, 1994, J BIOL CHEM, V269, P5364
   Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768
   Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548
   Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622
   TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030
   Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5
   Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4
   Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792
   Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392
   YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683
   Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017
NR 36
TC 88
Z9 96
U1 4
U2 12
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JAN
PY 2002
VL 16
IS 1
BP 58
EP 69
DI 10.1210/me.16.1.58
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 507HJ
UT WOS:000173020700006
PM 11773439
OA Bronze
DA 2018-12-27
ER

PT J
AU Chandra, RK
AF Chandra, RK
TI RETRACTED: Influence of multinutrient supplement on immune responses and
   infection-related illness in 50-65 year old individuals (Retracted
   article. See vol. 36, pg. 757, 2016)
SO NUTRITION RESEARCH
LA English
DT Article; Retracted Publication
DE older subjects; influenza vaccine; cell-mediated immunity; T
   lymphocytes; infection; vitamins; trace-elernents
ID RANDOMIZED CONTROLLED TRIAL; VITAMIN-E
AB The effect of a micronutrient supplement containing physiological amounts of trace-elements and vitamins on selected immune responses and infection was evaluated in 44 apparently healthy subjects aged 50-65 years for 12 months. At the baseline, 19 out of 44 (43.2%) subjects showed evidence of one or more nutrient deficiencies. In the supplemented group, all individuals except one showed normal nutrient levels when tested at 6 months; one person with iron deficiency persisting at 6 months required another 6 months of therapy and showed normal iron levels at 12 months. In the control group, there was no change in the prevalence of nutrient deficiencies. There was a significantly higher antibody response to influenza virus vaccine and an increase in the number of T lymphocytes and CD4+ helper T cells in the supplemented group compared with the placebo group. Interleukin-2 production was higher in the treated individuals compared with controls. Among the supplemented croup, the immune responses increased more in those with one or more nutrient deficiencies compared with those with normal nutrient levels. The total number of days of infection during the one year of observation was 11.1 +/- 0.8 in the supplemented group and 23.7 +/- 2.1 in the placebo group (p < 0.01). The beneficial effect on morbidity was of greater magnitude during the 7-12 month period of the trial. It is concluded that supplementation with modest amounts of vitamins and trace-elements results in higher immune responses and lower incidence of infection in the 50-65 year age group. (C) 2002 Elsevier Science Inc. All rights reserved.
C1 Janeway Child Hlth Ctr, St John, NF A1B 3V6, Canada.
   Privat Hosp, Gurgaon, India.
RP Chandra, RK (reprint author), Janeway Child Hlth Ctr, Room 2J740, St John, NF A1B 3V6, Canada.
EM rchandra@mun.ca
CR Chandra RK, 1997, JAMA-J AM MED ASSOC, V277, P1398, DOI 10.1001/jama.277.17.1398
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chandra RK, 1996, P NATL ACAD SCI USA, V93, P14304, DOI 10.1073/pnas.93.25.14304
   CHANDRA RK, 1977, NUTR IMMUNITY INFECT
   CHANDRA RK, 1984, NUTR IMMUNITY ILLNES
   CHAVANCE M, 1989, EUR J CLIN NUTR, V43, P827
   DUCHATEAU J, 1981, AM J MED, V70, P1001, DOI 10.1016/0002-9343(81)90849-4
   Gershwin M, 1984, NUTR IMMUNITY
   Jain AL, 2002, NUTR RES, V22, P85, DOI 10.1016/S0271-5317(01)00369-4
   Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380
   MILLER LT, 1990, ANN NY ACAD SCI, V587, P49
   PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169
   ROBERTST.IC, 1974, LANCET, V2, P368
   SUBOTICANEC K, 1989, INT J VITAM NUTR RES, V59, P20
   Suskind RM, 2001, NUTR IMMUNITY INFECT
   WAYNE SJ, 1990, J GERONTOL, V45, pM45, DOI 10.1093/geronj/45.2.M45
NR 16
TC 25
Z9 25
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JAN-FEB
PY 2002
VL 22
IS 1-2
SI SI
BP 5
EP 11
DI 10.1016/S0271-5317(01)00366-9
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 520UA
UT WOS:000173798700002
DA 2018-12-27
ER

PT J
AU Jain, AL
AF Jain, AL
TI RETRACTED: Influence of vitamins and trace-elements on the incidence of
   respiratory infection in the elderly (Retracted article. See vol. 36,
   pg. 758, 2016)
SO NUTRITION RESEARCH
LA English
DT Article; Retracted Publication
DE nutritional supplement; elderly; respiratory infection; bronchitis;
   pneumonia; sinusitis
ID IMMUNE-RESPONSES; NUTRITION; KNOWLEDGE
AB The influence of a supplement containing all essential vitamins and trace-elements previously demonstrated to enhance immunity and reduce infection was tested on 18 elderly individuals and 18 age-sex matched controls in the age range 51-78 years. The treated group suffered from respiratory infections for fewer days (14 +/- 2) compared with placebo controls (29-4) (p < 0.03). The number of days of antibiotic usage was also less in those receiving the supplement (27 +/- 4 days, versus 58 +/- 5 days in controls, p < 0.02). It is recommended that all older persons above 50 years of age should be given such a supplement on a regular basis. (C) 2002 Elsevier Science Inc. All rights reserved.
C1 Med Clin & Nursing Home, Jaipur, Rajasthan, India.
RP Jain, AL (reprint author), 16-1375 Southdown Rd,Suite 147, Mississauga, ON L5J 2ZI, Canada.
CR CHANDRA RK, 1983, LANCET, V1, P688
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chandra RK, 1996, P NATL ACAD SCI USA, V93, P14304, DOI 10.1073/pnas.93.25.14304
   FOX RA, 1984, IMMUNOLOGY INFECTION, P289
   Gershwin M, 1984, NUTR IMMUNITY
NR 5
TC 19
Z9 20
U1 4
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JAN-FEB
PY 2002
VL 22
IS 1-2
SI SI
BP 85
EP 87
DI 10.1016/S0271-5317(01)00369-4
PG 3
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 520UA
UT WOS:000173798700010
DA 2018-12-27
ER

PT J
AU Poaty-Mavoungou, V
   Toure, FS
   Tevi-Benissan, C
   Mavoungou, E
AF Poaty-Mavoungou, V
   Toure, FS
   Tevi-Benissan, C
   Mavoungou, E
TI RETRACTED: Enhancement of natural killer cell activation and
   antibody-dependent cellular cytotoxicity by interferon-alpha and
   interleukin-12 in vaginal mucosae SIV(mac251)-infected Macaca
   fascicularis (Retracted article. See vol. 21, pg. 277, 2008)
SO VIRAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FEMALE GENITAL-TRACT; HUMAN NK; MEDIATED
   CYTOTOXICITY; GENE-EXPRESSION; INFECTED INDIVIDUALS; ANTIGEN EXPRESSION;
   IMMUNOGLOBULIN-A; CYTO-TOXICITY; HIV-INFECTION
AB We studied the innate immune system of Cynomolgus monkeys (Macaca fascicularis) experimentally infected via the vaginal mucosae with a virulent simian immunodeficiency virus isolate SIV(mac251). Animals were evaluated for their natural killer (NK) cell activity, and for their antibody-dependent cellular cytotoxicity. NK cells from SIV(mac25)-infected macaques show impaired NK cell activity compared to cells from uninfected animals. Subsequent treatment of NK cells with interferon-alpha (IFN-alpha) or interleukin-12 (IL-12) alone partially restored the NK activity. However, either treatment of NK cells with both IFN-alpha and IL-12 completely reversed the impairment of cytotoxicity induced by simian immunodeficiency virus (SIV) infection. Incubation of NK cells from infected but not from uninfected monkeys with IFN-alpha and IL-12 for 8 days increased the percentage of CD16(+)/CD56(+) cells twofold to fivefold and enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. Thus IFN-alpha and IL-12 greatly enhance both the NK cell and ADCC activities of peripheral blood cells from SIV(mac251)-infected animals and increase the number of NK cells in longer term culture. The combined effect of IFN-alpha and IL-12 in enhancing NK cell activity may provide a novel therapeutic approach for the restoration of depressed NK cell activity observed in human immunodeficiency virus (HIV)-infected patients.
C1 Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany.
   CIRMF, Franceville, Gabon.
   CDC Atlanta, Atlanta, GA USA.
   Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
RP Poaty-Mavoungou, V (reprint author), Univ Tubingen, Inst Trop Med, Dept Parasitol, Wilhelmstr 27, D-72074 Tubingen, Germany.
EM elie.mavoungou@uni-tuebingen.de
CR AHMAD A, 1995, J ACQ IMMUN DEF SYND, V10, P115, DOI 10.1097/00042560-199510020-00002
   ALEXANDER NJ, 1990, FERTIL STERIL, V54, P1
   ALLEY CD, 1988, B LYMPHOCYTES HUMAN, P222
   AMEDEE AM, 1995, J VIROL, V69, P7982
   ARMANT M, 1995, IMMUNOLOGY, V85, P331
   BALIAN AS, 2000, EUR CYTOKINE NETW, V2, P177
   Baum LL, 1996, J IMMUNOL, V157, P2168
   BENVENISTE RE, 1988, J VIROL, V62, P2091
   BREYMER BG, 1993, CLIN EXP IMMUNOL, V93, P1425
   CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789
   CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905
   CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42
   CONLEY ME, 1987, ANN INTERN MED, V106, P892, DOI 10.7326/0003-4819-106-6-892
   CUKOWICZ G, 1979, IMMUNOL REV, V44, P13
   CUMMINS LM, 1991, BLOOD, V77, P1111
   DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300
   DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639
   FOREST BD, 1992, VACCINE RES, V1, P137
   Galon J, 1999, J IMMUNOL, V162, P7256
   GEROSA F, 1993, CELL IMMUNOL, V150, P382, DOI 10.1006/cimm.1993.1206
   GOICOA MA, 1995, SCAND J IMMUNOL, V41, P523, DOI 10.1111/j.1365-3083.1995.tb03602.x
   HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208
   HOSPEDALES J, 1989, REV INFECT DIS, V11, P663
   HU SL, 1993, HIV MOL ORG PATHOGEN, P293
   JOHNSON AM, 1988, BRIT MED J, V296, P1017, DOI 10.1136/bmj.296.6628.1017
   KELLER HC, 1992, AIDS RES HUM RETROV, V8, P1355
   Kohl S, 1996, J INFECT DIS, V174, P1105, DOI 10.1093/infdis/174.5.1105
   KOPLAN JP, 1986, ADV ALCOHOL SUBST AB, V5, P13
   Lau AS, 1996, PEDIATR RES, V39, P150, DOI 10.1203/00006450-199601000-00023
   Le Page C, 2000, Rev Immunogenet, V2, P374
   Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571
   LEGRAND R, 1994, AIDS RES HUM RETROV, V10, P1279, DOI 10.1089/aid.1994.10.1279
   LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295
   Lin SJ, 1997, CLIN IMMUNOL IMMUNOP, V82, P163, DOI 10.1006/clin.1996.4298
   LOZZIO CB, 1975, BLOOD, V45, P321
   Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084
   Mavoungou E, 1999, TROP MED INT HEALTH, V4, P719, DOI 10.1046/j.1365-3156.1999.00479.x
   Mendiratta SK, 2000, HUM GENE THER, V11, P1851, DOI 10.1089/10430340050129477
   Merrill JD, 1996, PEDIATR RES, V40, P498, DOI 10.1203/00006450-199609000-00021
   MESTECKY J, 1994, AIDS RES HUM RETROV, V10, pS11
   MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0
   Mori S, 1998, INT J ONCOL, V12, P1165
   NAIR MPN, 1984, CLIN IMMUNOL IMMUNOP, V33, P412, DOI 10.1016/0090-1229(84)90312-X
   Nair MPN, 2000, CLIN DIAGN LAB IMMUN, V7, P101, DOI 10.1128/CDLI.7.1.101-105.2000
   NAUME B, 1992, J IMMUNOL, V148, P2429
   NAUME B, 1991, J IMMUNOL, V147, P2208
   Poaty-Mavoungou V, 2001, J MED PRIMATOL, V30, P26, DOI 10.1111/j.1600-0684.2001.300104.x
   PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477
   QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379
   QUINN TC, 1986, NY STATE J MED, V5, P286
   ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7
   Sahin U, 1996, CANCER IMMUNOL IMMUN, V42, P9, DOI 10.1007/s002620050245
   Sareneva T, 2000, J IMMUNOL, V165, P1933, DOI 10.4049/jimmunol.165.4.1933
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   SCHULZE A, 1993, PEDIATR PULM, V16, P170, DOI 10.1002/ppul.1950160307
   SIRIANNI MC, 1990, IMMUNOL TODAY, V11, P81, DOI 10.1016/0167-5699(90)90032-5
   Sivori S, 2000, HUM IMMUNOL, V61, P1055, DOI 10.1016/S0198-8859(00)00201-9
   Stylianou E, 2001, CYTOKINE, V14, P56, DOI 10.1006/cyto.2000.0850
   Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416
   ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789
   VOWELS BR, 1990, AIDS RES HUM RETROV, V6, P905, DOI 10.1089/aid.1990.6.905
   ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277
NR 62
TC 10
Z9 10
U1 3
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
J9 VIRAL IMMUNOL
JI Viral Immunol.
PY 2002
VL 15
IS 1
BP 197
EP 212
DI 10.1089/088282402317340341
PG 16
WC Immunology; Virology
SC Immunology; Virology
GA 547BX
UT WOS:000175313800017
PM 11952142
DA 2018-12-27
ER

PT J
AU Aassila, M
AF Aassila, M
TI RETRACTED: Some blow-up results for a generalized Ginzburg-Landau
   equation (Retracted article. See vol. 66, pg. 497, 2015)
SO ZEITSCHRIFT FUR ANGEWANDTE MATHEMATIK UND PHYSIK
LA English
DT Article; Retracted Publication
DE Ginzburg-Landau equation; blow-up; energy method
ID PLANE POISEUILLE FLOW; EVOLUTION-EQUATIONS; NONEXISTENCE; STABILITY;
   THEOREMS
AB We investigate the blow-up of the solution to a complex Ginzburg-Landau like equation in u coupled with a Poisson equation in phi defined on the whole space R-n, n = 1 or 2.
C1 Univ Strasbourg, Inst Rech Math Avancee, F-67084 Strasbourg, France.
   CNRS, F-67084 Strasbourg, France.
RP Aassila, M (reprint author), Univ Strasbourg, Inst Rech Math Avancee, 7 Rue Rene Descartes, F-67084 Strasbourg, France.
EM aassila@math.u-strasbg.fr
CR BALL JM, 1977, Q J MATH, V28, P473, DOI 10.1093/qmath/28.4.473
   DAVEY A, 1974, J FLUID MECH, V63, P529, DOI 10.1017/S0022112074001765
   DOERING CR, 1994, PHYSICA D, V71, P285, DOI 10.1016/0167-2789(94)90150-3
   EAGLES PM, 1971, J FLUID MECH, V49, P529, DOI 10.1017/S0022112071002246
   HOCKING LM, 1972, J FLUID MECH, V51, P705, DOI 10.1017/S0022112072001326
   LEVINE HA, 1973, ARCH RATION MECH AN, V51, P371
   MISCHAIKOW K, 1994, JAPAN J IND APPL MAT, V11, P185
   SNOUSSI S, 2000, DIFFERENTIAL INTEGRA, V13, P61
   STEWARTSON K, 1971, J FLUID MECH, V48, P529, DOI 10.1017/S0022112071001733
   STUART JT, 1958, J FLUID MECH, V4, P1, DOI 10.1017/S0022112058000276
   WEISSLER FB, 1979, J FUNCT ANAL, V32, P277, DOI 10.1016/0022-1236(79)90040-5
NR 11
TC 2
Z9 2
U1 3
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0044-2275
EI 1420-9039
J9 Z ANGEW MATH PHYS
JI Z. Angew. Math. Phys.
PD JAN
PY 2002
VL 53
IS 1
BP 1
EP 11
DI 10.1007/s00033-002-8137-8
PG 11
WC Mathematics, Applied
SC Mathematics
GA 523WN
UT WOS:000173980700001
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
AF Schon, JH
   Kloc, C
TI RETRACTED: Fast organic electronic circuits based on ambipolar pentacene
   field-effect transistors (Retracted Article. See vol 82, pg 1313, 2003)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID INTEGRATED-CIRCUITS
AB Inverter circuits and ring oscillators have been prepared based on the organic semiconductor pentacene. High-purity pentacene single crystals and thin films exhibit ambipolar transport properties, i.e., n- and p-channel transistor activity. This feature is very attractive for complementary logic electronic circuits, since only one organic material has to be used. Switching frequencies up to 11 MHz have been achieved for single crystal circuits. Thin film devices prepared on flexible polyimide substrates revealed delays of 0.1 mus per stage resulting in oscillation frequencies up to 900 kHz. (C) 2001 American Institute of Physics.
C1 Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Lucent Technol, Bell Labs, Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR Baldo M, 1998, ADV MATER, V10, P1505, DOI 10.1002/(SICI)1521-4095(199812)10:18<1505::AID-ADMA1505>3.0.CO;2-G
   Bonse M, 1998, INTERNATIONAL ELECTRON DEVICES MEETING 1998 - TECHNICAL DIGEST, P249, DOI 10.1109/IEDM.1998.746347
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   Gelinck GH, 2000, APPL PHYS LETT, V77, P1487, DOI 10.1063/1.1290728
   Klauk H, 2000, SOLID STATE TECHNOL, V43, P63
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946
   Schon JH, 2000, ORG ELECTRON, V1, P57, DOI 10.1016/S1566-1199(00)00010-0
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 2001, APPL PHYS LETT, V78, P3821, DOI 10.1063/1.1379986
   Schon JH, 2001, SYNTHETIC MET, V122, P195, DOI 10.1016/S0379-6779(00)01353-9
   Schon JH, 2001, PHYS STATUS SOLIDI B, V226, P257, DOI 10.1002/1521-3951(200108)226:2<257::AID-PSSB257>3.0.CO;2-C
NR 12
TC 18
Z9 19
U1 3
U2 13
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD DEC 10
PY 2001
VL 79
IS 24
BP 4043
EP 4044
DI 10.1063/1.1426684
PG 2
WC Physics, Applied
SC Physics
GA 498BC
UT WOS:000172489100046
DA 2018-12-27
ER

PT J
AU Schon, JH
   Meng, H
   Bao, ZN
AF Schon, JH
   Meng, H
   Bao, ZN
TI RETRACTED: Field-effect modulation of the conductance of single
   molecules (Retracted Article. See vol 296, pg 1400, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID ELECTRONIC DEVICES; EFFECT TRANSISTORS; CARBON NANOTUBES; MONOLAYERS;
   GOLD; TRANSPORT; BEHAVIOR
AB Field-effect transistors based on two-component self-assembled monolayers of conjugated and insulating molecules were prepared; the conductance through them can be varied by more than three orders of magnitude by changing the applied gate bias. With very small ratios of conjugated to insulating molecules in the two-component monolayer, devices with only a few "electrically active" molecules can be achieved. At low temperatures, the peak channel conductance is quantized in units of 2e(2)/h (where e is the electron charge and h is Planck's constant). This behavior is indicative of transistor action in single molecules. On the basis of such single-molecule transistors, inverter circuits with gain are demonstrated.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Hong, Meng/T-2778-2018
OI Hong, Meng/0000-0001-5877-359X
CR AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1
   BAIN CD, 1988, J AM CHEM SOC, V110, P6560, DOI 10.1021/ja00227a044
   BAIN CD, 1989, LANGMUIR, V5, P1370, DOI 10.1021/la00090a019
   Brinkman WF, 1997, BELL LABS TECH J, V2, P57, DOI 10.1002/bltj.2083
   Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705
   Chen J, 2000, APPL PHYS LETT, V77, P1224, DOI 10.1063/1.1289650
   Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172
   Collins PC, 2001, SCIENCE, V292, P706, DOI 10.1126/science.1058782
   DERYCKE V, IN PRESS NANO LETT
   Di Ventra M, 2000, APPL PHYS LETT, V76, P3448, DOI 10.1063/1.126673
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   Donhauser ZJ, 2001, SCIENCE, V292, P2303, DOI 10.1126/science.1060294
   Emberly EG, 2000, PHYS REV B, V62, P10451, DOI 10.1103/PhysRevB.62.10451
   FOLKERS JP, 1994, J PHYS CHEM-US, V98, P563, DOI 10.1021/j100053a035
   Fujimaru K, 1996, JPN J APPL PHYS 1, V35, P2090, DOI 10.1143/JJAP.35.2090
   Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6
   Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000
   Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477
   Metzger RM, 1999, ACCOUNTS CHEM RES, V32, P950, DOI 10.1021/ar9900663
   NATORI K, 1994, J APPL PHYS, V76, P4879, DOI 10.1063/1.357263
   Reed MA, 1999, P IEEE, V87, P652, DOI 10.1109/5.752520
   Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520
   Tans SJ, 1998, NATURE, V393, P49
   Xue YQ, 2001, J CHEM PHYS, V115, P4292, DOI 10.1063/1.1391253
   Zhou CW, 2000, APPL PHYS LETT, V76, P1597, DOI 10.1063/1.126107
NR 25
TC 66
Z9 68
U1 3
U2 59
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD DEC 7
PY 2001
VL 294
IS 5549
BP 2138
EP 2140
DI 10.1126/science.1066171
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 500VQ
UT WOS:000172647700043
PM 11701891
DA 2018-12-27
ER

PT J
AU Deschenes, LA
   Bout, DAV
AF Deschenes, LA
   Bout, DAV
TI RETRACTED: Molecular motions in polymer films near the glass transition:
   a single molecule study of rotational dynamics (Retracted Article. See
   vol 110, pg 9362, 2006)
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article; Retracted Publication
ID SPATIALLY HETEROGENEOUS DYNAMICS; SUPERCOOLED O-TERPHENYL; STRUCTURAL
   RELAXATION; TRANSLATIONAL DIFFUSION; MULTIDIMENSIONAL NMR; SPECTROSCOPY;
   LIQUIDS; SCALE; FLUCTUATIONS; FLUORESCENCE
AB Single molecule spectroscopy was used to measure the rotations of fluorescent probe molecules in thin films of poly(methyl acrylate) and poly(n-butyl methacrylate) just above their glass-transition temperatures. By collecting the polarized fluorescence from isolated probe molecules, the rotational diffusion of single molecules was followed in real time. The autocorrelation of these transients yields a nonexponential decay from which the rotational correlation time can be calculated. Molecules reveal a broad distribution of correlation times, which showed a clear dependence on the length of observation. At short times, the spatially heterogeneous nature of these films was reflected in their wide range of correlation times. At longer times, environmental exchanges caused the correlation times to converge on a limiting bulk value. The dynamics were characterized by three time scales: a rotational correlation time (tau (e)), an environmental exchange time (tau (ex)), and the time scale upon which the distribution of time-averaged single-molecule correlation times converged to the ensemble-averaged limit (tau (bulk)). Both tau (ex) and tau (bulk) were much longer than tau (c). with the ensemble average tau (ex) being approximately 20 times longer than the average tau (c) and tau (bulk) roughly 125 times tau (c). All three time scales were found to have the same relatively weak temperature dependence when measured at temperatures 5, 10, and 15 K above the glass transition.
C1 Univ Texas, Dept Chem & Biochem, Ctr Nano & Mol Mat Sci & Technol, Austin, TX 78712 USA.
   Univ Texas, Texas Mat Inst, Austin, TX 78712 USA.
RP Bout, DAV (reprint author), Univ Texas, Dept Chem & Biochem, Ctr Nano & Mol Mat Sci & Technol, Austin, TX 78712 USA.
EM davandenbout@mail.utexas.edu
CR AMBROSE WP, 1991, NATURE, V349, P225, DOI 10.1038/349225a0
   Angell CA, 2000, J APPL PHYS, V88, P3113, DOI 10.1063/1.1286035
   Bartko AP, 1999, J PHYS CHEM B, V103, P3053, DOI 10.1021/jp9846330
   BASCHE T, 1995, NATURE, V373, P132, DOI 10.1038/373132a0
   Bennemann C, 1999, NATURE, V399, P246, DOI 10.1038/20406
   Bohmer R, 1996, EUROPHYS LETT, V36, P55, DOI 10.1209/epl/i1996-00186-5
   Bohmer R, 1998, J NON-CRYST SOLIDS, V235, P1, DOI 10.1016/S0022-3093(98)00581-X
   Box G. E. P, 1976, TIME SERIES ANAL FOR
   Chang I, 1997, J PHYS CHEM B, V101, P8794, DOI 10.1021/jp9640989
   Cicerone MT, 1996, J CHEM PHYS, V104, P7210, DOI 10.1063/1.471433
   CICERONE MT, 1993, J PHYS CHEM-US, V97, P10489, DOI 10.1021/j100142a037
   Cugliandolo LF, 2000, PHYS REV LETT, V85, P3448, DOI 10.1103/PhysRevLett.85.3448
   Deschenes LA, 2001, SCIENCE, V292, P255, DOI 10.1126/science.1056430
   Ediger MD, 2000, ANNU REV PHYS CHEM, V51, P99, DOI 10.1146/annurev.physchem.51.1.99
   English DS, 2000, CHEM PHYS LETT, V324, P15, DOI 10.1016/S0009-2614(00)00570-4
   Fourkas JT, 2001, OPT LETT, V26, P211, DOI 10.1364/OL.26.000211
   FOURKAS JT, 1997, ACS SYM SER, V676, P352
   Ha T, 1999, J PHYS CHEM B, V103, P6839, DOI 10.1021/jp990948j
   Ha T, 1998, PHYS REV LETT, V80, P2093, DOI 10.1103/PhysRevLett.80.2093
   HEUER A, 1995, PHYS REV LETT, V75, P2851, DOI 10.1103/PhysRevLett.75.2851
   Hinze G, 1998, EUROPHYS LETT, V44, P565, DOI 10.1209/epl/i1998-00510-7
   Hinze G, 1998, PHYS REV E, V57, P2010, DOI 10.1103/PhysRevE.57.2010
   Hou YW, 2000, J PHYS CHEM B, V104, P212, DOI 10.1021/jp992312y
   Kob W, 1997, PHYS REV LETT, V79, P2827, DOI 10.1103/PhysRevLett.79.2827
   Kuebler SC, 1997, PHYS REV E, V56, P741, DOI 10.1103/PhysRevE.56.741
   Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0
   Lu HP, 1997, J PHYS CHEM B, V101, P2753, DOI 10.1021/jp9634518
   MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46
   Ngai KL, 2000, J NON-CRYST SOLIDS, V274, P155, DOI 10.1016/S0022-3093(00)00210-6
   Ngai KL, 1999, J PHYS CHEM B, V103, P10684, DOI 10.1021/jp990554s
   Prolongo MG, 1997, POLYMER, V38, P5097, DOI 10.1016/S0032-3861(97)00057-8
   Russell EV, 2000, NATURE, V408, P695
   Russell EV, 1998, PHYS REV LETT, V81, P1461, DOI 10.1103/PhysRevLett.81.1461
   SANCHIS A, 1995, MACROMOLECULES, V28, P2693, DOI 10.1021/ma00112a014
   Schiener B, 1997, J CHEM PHYS, V107, P7746, DOI 10.1063/1.475089
   Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926
   SCHMIDT-ROHR K, 1991, PHYS REV LETT, V66, P3020, DOI 10.1103/PhysRevLett.66.3020
   Sillescu H, 1999, J NON-CRYST SOLIDS, V243, P81, DOI 10.1016/S0022-3093(98)00831-X
   Talley CE, 1999, J PHYS CHEM B, V103, P10214, DOI 10.1021/jp992639z
   Veerman JA, 1999, PHYS REV LETT, V83, P2155, DOI 10.1103/PhysRevLett.83.2155
   Wang CY, 2000, J CHEM PHYS, V112, P6933, DOI 10.1063/1.481319
   Wang CY, 2000, J PHYS CHEM B, V104, P1724, DOI 10.1021/jp993420n
   Wang CY, 1999, J PHYS CHEM B, V103, P4177, DOI 10.1021/jp984149x
   Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627
   Weston KD, 1999, CHEM PHYS LETT, V308, P58, DOI 10.1016/S0009-2614(99)00553-9
NR 45
TC 36
Z9 36
U1 3
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD DEC 6
PY 2001
VL 105
IS 48
BP 11978
EP 11985
DI 10.1021/jp012238v
PG 8
WC Chemistry, Physical
SC Chemistry
GA 499ZC
UT WOS:000172600100011
DA 2018-12-27
ER

PT J
AU Bulanova, E
   Budagian V
   Pohl, T
   Krause, H
   Durkop, H
   Paus, R
   Bulfone-Paus, S
AF Bulanova, E
   Budagian, V
   Pohl, T
   Krause, H
   Durkop, H
   Paus, R
   Bulfone-Paus, S
TI RETRACTED: The IL-15R alpha chain signals through association with Syk
   in human B cells (Retracted article. See vol. 186, pg. 2681, 2011)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID PROTEIN-TYROSINE KINASE; ACTIVATED KILLER-CELLS; COMMON GAMMA-CHAIN;
   T-CELL; IL-2 RECEPTOR; BETA-CHAIN; GROWTH-FACTOR; SRC-FAMILY;
   INTERLEUKIN-2 RECEPTOR; ANTIGEN RECEPTOR
AB The alpha -chain of the IL-15R (IL-15R alpha) serves as the specific, high-affinity receptor for IL-15. It is expressed by lymphoid and nonlymphoid cells, including B cell lymphoma lines. In this study, we have further explored IL-15R alpha -mediated signaling in activated primary B cells and in Raji cells, a human B-lymphoblastoid cell line which expresses the IL-15R alpha and IL-2R gamma chains, but lacks the IL-2R beta chain. Stimulation of Raji cells with IL-15 induces their proliferation and rescues them from C2-ceramide-induced apoptosis. By immunoprecipitation and Western blotting, we show that treatment of Raji cells and activated primary B cells with IL-15 induces coprecipitation of Syk kinase with the IL-15R alpha chain. Upon association, the activated Syk kinase phosphorylates the IL-15R alpha chain as well as phospholipase C gamma, which coprecipitates with Syk. Furthermore, transfection of Raji cells with stem-loop Syk antisense oligonucleotides prevents IL-15R alpha and phospholipase C gamma phosphorylation as well as the inhibition of apoptosis by IL-15. Mutation of a defined region of the intracellular signaling portion of IL-15R alpha (Tyr(227)) abrogates both the IL-15R alpha /Syk association and IL-15R alpha phosphorylation. Taken together, this suggests that Syk kinase physically and functionally associates with the IL-15R alpha chain in B cells and that Syk plays a key role in mediating IL-15-induced signal transduction, thus accounting for the distinct functional consequences of IL-15 vs IL-2 binding to B cells.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Free Univ Berlin, Klinikum Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany.
   Free Univ Berlin, Klinikum Benjamin Franklin, Dept Pathol, D-12200 Berlin, Germany.
   Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany.
RP Bulfone-Paus, S (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Pk Allee 22, D-23845 Borstel, Germany.
EM sbulfone@fz-borstel.de
CR ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
   Angiolillo AL, 1997, BIOCHEM BIOPH RES CO, V233, P231, DOI 10.1006/bbrc.1997.6435
   ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
   Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2
   BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x
   BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940
   BOLEN JB, 1992, FASEB J, V6, P3403
   BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935
   Carson W, 1998, BRAZ J MED BIOL RES, V31, P1
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x
   Chu DH, 1999, J IMMUNOL, V163, P2610
   Di Carlo E, 2000, J IMMUNOL, V165, P3111, DOI 10.4049/jimmunol.165.6.3111
   Doherty TM, 1996, J IMMUNOL, V156, P735
   Dooms H, 1998, J IMMUNOL, V161, P2141
   Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985
   GAZDAR AF, 1980, BLOOD, V55, P409
   GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669
   GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763
   GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x
   GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859
   Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622
   Hjorth-Hansen H, 1999, BRIT J HAEMATOL, V106, P28, DOI 10.1046/j.1365-2141.1999.01510.x
   Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x
   Jevremovic D, 1999, J IMMUNOL, V162, P2453
   Johnson E W, 1995, J Back Musculoskelet Rehabil, V5, P3, DOI 10.3233/BMR-1995-5103
   Kang JS, 1996, FEBS LETT, V399, P14, DOI 10.1016/S0014-5793(96)01276-8
   Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875
   Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668
   Kobayashi H, 2000, CANCER RES, V60, P3577
   KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9
   Krause H, 1996, CYTOKINE, V8, P667, DOI 10.1006/cyto.1996.0089
   Kuroki J, 1996, LEUKEMIA, V10, P1950
   Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3
   Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X
   Law CL, 1996, MOL CELL BIOL, V16, P1305
   LAW CL, 1994, J BIOL CHEM, V269, P12310
   Law DA, 1999, BLOOD, V93, P2645
   Lehours P, 2000, EUR CYTOKINE NETW, V11, P207
   LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x
   Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0
   Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097
   Matsuda M, 1996, MOL BIOL CELL, V7, P1095
   MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0
   Musso T, 1999, BLOOD, V93, P3531
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   OLIVER JM, 1994, J BIOL CHEM, V269, P29697
   Onu A, 1997, J IMMUNOL, V158, P255
   QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669
   Raeder EMB, 1999, J IMMUNOL, V163, P6785
   RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0
   Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453
   Ruckert R, 2000, J IMMUNOL, V165, P2240, DOI 10.4049/jimmunol.165.4.2240
   Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9
   SELDEN RF, 1994, CURRENT PROTOCOLS IM
   SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272
   Stevens AC, 1997, AM J PHYSIOL-GASTR L, V272, pG1201
   SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X
   TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517
   Trentin L, 1997, LEUKEMIA LYMPHOMA, V27, P35, DOI 10.3109/10428199709068269
   Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Warren HS, 1996, J IMMUNOL, V156, P3254
   WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255
   Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407
   Zhang J, 1998, J IMMUNOL, V161, P4366
NR 72
TC 69
Z9 70
U1 3
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2001
VL 167
IS 11
BP 6292
EP 6302
DI 10.4049/jimmunol.167.11.6292
PG 11
WC Immunology
SC Immunology
GA 494WU
UT WOS:000172309500032
PM 11714793
OA Bronze
DA 2018-12-27
ER

PT J
AU Tulin, EE
   Onoda, N
   Nakata, Y
   Maeda, M
   Hasegawa, M
   Nomura, H
   Kitamura, T
AF Tulin, EE
   Onoda, N
   Nakata, Y
   Maeda, M
   Hasegawa, M
   Nomura, H
   Kitamura, T
TI RETRACTED: SF20/IL-25, a novel bone marrow stroma-derived growth factor
   that binds to mouse thymic shared antigen-1 and supports lymphoid cell
   proliferation (Retracted Article. See vol 170, pg 1593, 2003)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MAJOR HISTOCOMPATIBILITY COMPLEX; SIGNAL-TRANSDUCING MOLECULE;
   DECAY-ACCELERATING FACTOR; PROTEIN-TYROSINE KINASES; T-CELLS; LY-6
   FAMILY; GLYCOSYL-PHOSPHATIDYLINOSITOL; SURFACE MOLECULES; HUMAN
   THYMOCYTES; IL-2 PRODUCTION
AB Using a forward genetic approach and phenotype-based complementation screening to search for factors that stimulate cell proliferation, we have isolated a novel secreted bone marrow stroma-derived growth factor, which we termed SF20/IL-25. This protein signals cells to proliferate via its receptor, which we have identified as mouse thymic shared Ag-1 (TSA-1). Enforced expression of TSA-1 in IL-3-dependent Ba/F3 cells that do not express endogenous TSA-1 rendered cells to,proliferate in a dose-dependent manner when stimulated with SF20/IL-25. FDCP2, a factor-dependent hemopoietic cell line that expresses endogenous TSA-1, could also be stimulated to proliferate with SF20/IL-25. Binding of SF20 to TSA-1 was blocked by anti-TSA-1 Ab and SF20-induced proliferation of TSA-1-expressing cells was inhibited by anti-TSA-1. In vitro assay revealed that SF20/IL-25 has no detectable myelopoietic activity but supports proliferation of cells in the lymphoid lineage.
C1 Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan.
   Chugai Res Inst Mol Med, Niihara, Ibaraki, Japan.
RP Tulin, EE (reprint author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
EM tulin@cimmed.com
CR ANTICA M, 1994, BLOOD, V84, P111
   BAMEZAI A, 1995, P NATL ACAD SCI USA, V92, P4294, DOI 10.1073/pnas.92.10.4294
   Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108
   Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465
   Chitnis T, 2001, J CLIN INVEST, V107, P575, DOI 10.1172/JCI11220
   CLASSON BJ, 1994, P NATL ACAD SCI USA, V91, P5296, DOI 10.1073/pnas.91.12.5296
   Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X
   DAVIS LS, 1988, J IMMUNOL, V141, P2246
   FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285
   FLEMING TJ, 1994, J IMMUNOL, V153, P1955
   FOX DA, 1985, J IMMUNOL, V134, P330
   Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440
   ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H
   Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x
   KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241
   Kitamura T, 1998, INT J HEMATOL, V67, P351
   KORTY PE, 1991, J IMMUNOL, V146, P4092
   KOSUGI A, 1994, INT IMMUNOL, V6, P1967, DOI 10.1093/intimm/6.12.1967
   Le Guiner S, 1998, EUR J IMMUNOL, V28, P1322, DOI 10.1002/(SICI)1521-4141(199804)28:04<1322::AID-IMMU1322>3.0.CO;2-I
   LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003
   MACNEIL I, 1993, J IMMUNOL, V151, P6913
   MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709
   Mao M, 1996, P NATL ACAD SCI USA, V93, P5910, DOI 10.1073/pnas.93.12.5910
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Onishi M, 1996, EXP HEMATOL, V24, P324
   PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1
   RAMARLI D, 1987, P NATL ACAD SCI USA, V84, P8598, DOI 10.1073/pnas.84.23.8598
   RANDLE ES, 1993, J IMMUNOL, V151, P6027
   REEM GH, 1987, J IMMUNOL, V139, P130
   ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315
   Rost B, 1996, METHOD ENZYMOL, V266, P525
   SAITOH SI, 1995, J IMMUNOL, V155, P5574
   Shan XC, 1998, J IMMUNOL, V160, P197
   SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535
   STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635
   THOMAS PM, 1992, J BIOL CHEM, V267, P12317
   TORIBIO ML, 1988, IMMUNOL REV, V104, P55, DOI 10.1111/j.1600-065X.1988.tb00759.x
   Tulin EE, 2001, J BIOL CHEM, V276, P27519, DOI 10.1074/jbc.M101781200
   WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2
   WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617
   YEH ETH, 1987, J IMMUNOL, V138, P91
NR 41
TC 20
Z9 22
U1 2
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2001
VL 167
IS 11
BP 6338
EP 6347
DI 10.4049/jimmunol.167.11.6338
PG 10
WC Immunology
SC Immunology
GA 494WU
UT WOS:000172309500037
PM 11714798
OA Bronze
DA 2018-12-27
ER

PT J
AU Shin, SG
AF Shin, SG
TI RETRACTED: Self-diagnosis of GFRP composites containing carbon powder
   and fiber as electrically conductive phases (Retracted article. See vol.
   24, pg. 435, 2018)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE self-diagnosis; CPGFRP composites; electrical resistance; smart
   materials; carbon powder; percolation structure
ID CONCRETE STRUCTURES; PERCOLATION
AB The electrical characteristics of glass fiber reinforced plastic (GFRP) composites have been investigated in order to incorporate a self-diagnosis function suitable for monitoring the health of structural materials. The electrical conductivity was introduced by adding carbon powder (CP) or carbon fibers (CF) into GFRP rods and sheets. The self-diagnosis ability of the composites was evaluated by measuring the change in electrical resistance as a function of stress (or strain) in tensile tests. The resistance of CFGFRP changed only slightly at small strain levels and increased nonlinearly with the applied stress due to cutting of the fibers at higher levels. CPGFRP showed high sensitivity to stress and the resistance changed linearly over a wide strain range. During cyclic loading tests, a residual resistance was also observed in CPGFRP composites after unloading. The residual resistance increased with maximum applied strain, showing that it can be used as an indicator of previously applied strain or stress. It is concluded that the CPGFRP composite is a promising material for simple diagnosis of dynamic damage and cumulative strain.
C1 Dong A Univ, Div Met & Mat, Saha Gu 604714, Busan, South Korea.
RP Shin, SG (reprint author), Dong A Univ, Div Met & Mat, 840 Hadan 2 Dong, Saha Gu 604714, Busan, South Korea.
CR ARAI Y, 1998, CERAM MAT SYST COMPO, V99, P511
   Chen PW, 1996, COMPOS PART B-ENG, V27, P11, DOI 10.1016/1359-8368(95)00002-X
   KERSEY AD, 1994, 1 WORLD C STRUCT CON, V3, P1
   KIRKPATRICK S, 1973, REV MOD PHYS, V45, P574, DOI 10.1103/RevModPhys.45.574
   KONSZTOWICZ KJ, 1990, J AM CERAM SOC, V73, P2809, DOI 10.1111/j.1151-2916.1990.tb06679.x
   LEAL ES, 1995, MEASUREMENT SCI TECH, V6, P188
   Leuenberger H, 1999, ADV POWDER TECHNOL, V10, P323, DOI 10.1163/156855299X00190
   MASRI SF, 1994, J ENG MECH, V120, P1696, DOI 10.1061/(ASCE)0733-9399(1994)120:8(1696)
   MATSUBARA H, 1996, CHEM CHEM IND, V49, P40
   Merzbacher CI, 1996, SMART MATER STRUCT, V5, P196, DOI 10.1088/0964-1726/5/2/008
   MUTO N, 1993, J AM CERAM SOC, V76, P875, DOI 10.1111/j.1151-2916.1993.tb05309.x
   MUTO N, 1992, J CERAM SOC JPN, V45, P574
   OKUHARA Y, 2000, T MRS J, V25, P581
   *SCI TECHN AG JAP, 1989, CONC INT MAT GUID TH, V30
   SHIN SG, IN PRESS MET MAT INT
   SHIN SG, 1999, P 6 JPN INT SAMPE S, V2, P995
   Stauffer D., 1992, INTRO PERCOLATION TH
   TAKADA M, 1999, J JPN SOC COMPOS MAT, V25, P225
   YANAGIDA H, 1999, J JPN SOC MECH ENG, V102, P68
   YANAGIDA H, 1992, INTELLIGENT MAT, V2, P6
NR 20
TC 5
Z9 5
U1 2
U2 3
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD DEC
PY 2001
VL 7
IS 6
BP 605
EP 611
DI 10.1007/BF03179259
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 512NA
UT WOS:000173329400011
DA 2018-12-27
ER

PT J
AU Schon, JH
   Dorget, M
   Beuran, FC
   Zu, XZ
   Arushanov, E
   Cavellin, CD
   Lagues, M
AF Schon, JH
   Dorget, M
   Beuran, FC
   Zu, XZ
   Arushanov, E
   Cavellin, CD
   Lagues, M
TI RETRACTED: Superconductivity in CaCuO2 as a result of field-effect
   doping (Retracted article. See vol 422 pg 92 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID INFINITE-LAYER-STRUCTURE; MOLECULAR-BEAM EPITAXY; CU-O SYSTEM;
   HIGH-PRESSURE; THIN-FILMS; TEMPERATURE; DEPENDENCE; PHASE; HOLE; SR
AB Understanding the doping mechanisms in the simplest superconducting copper oxide-the infinite-layer compound ACuO(2) (where A is an alkaline earth metal)Dis an excellent way of investigating the pairing mechanism in high-transition-temperature (high-T-c) superconductors more generally(1-4). Gate-induced modulation of the carrier concentration(5-7) to obtain superconductivity is a powerful means of achieving such understanding: it minimizes the effects of potential scattering by impurities, and of structural modifications arising from chemical dopants. Here we report the transport properties of thin films of the infinite-layer compound CaCuO2 using field-effect doping. At high hole- and electron-doping levels, superconductivity is induced in the nominally insulating material. Maximum values of T-c of 89 K and 34 K are observed respectively for hole- and electron-type doping of around 0.15 charge carriers per CuO2. We can explore the whole doping diagram of the CuO2 plane while changing only a single electric parameter, the gate voltage.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Paris, GPMD, F-94010 Creteil, France.
   Ecole Super Phys & Chim Ind Ville Paris, CNRS, Surfaces & Supracond UPR 5, F-75005 Paris, France.
   Wintici SA, F-94300 Vincennes, France.
   Moldavian Acad Sci, Inst Appl Phys, Kishinev 277028, Moldova.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Arushanov, Ernest/L-6045-2017
OI Arushanov, Ernest/0000-0002-5859-4943
CR ADACHI H, 1992, PHYSICA C, V196, P14, DOI 10.1016/0921-4534(92)90131-U
   AHN CH, 1995, SCIENCE, V269, P373, DOI 10.1126/science.269.5222.373
   Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   AZUMA M, 1992, NATURE, V356, P775, DOI 10.1038/356775a0
   Balestrino G, 1998, PHYS REV B, V58, pR8925, DOI 10.1103/PhysRevB.58.R8925
   ER G, 1991, PHYSICA C, V181, P206, DOI 10.1016/0921-4534(91)90356-4
   FEENSTRA R, 1994, PHYSICA C, V224, P300, DOI 10.1016/0921-4534(94)90267-4
   GUPTA A, 1994, PHYSICA C, V231, P389, DOI 10.1016/0921-4534(94)90650-5
   HIROI Z, 1993, PHYSICA C, V208, P286, DOI 10.1016/0921-4534(93)90200-A
   IKEDA N, 1993, PHYSICA C, V210, P367, DOI 10.1016/0921-4534(93)90979-Z
   Kawahara T, 1997, PHYSICA C, V276, P127, DOI 10.1016/S0921-4534(97)00018-X
   Kopnin EM, 1997, PHYSICA C, V282, P483, DOI 10.1016/S0921-4534(97)00339-0
   KORCZAK W, 1992, PHYSICA C, V193, P303, DOI 10.1016/0921-4534(92)90731-Q
   LAGUES M, 1996, COHERENCE HIGH TEMPE, P70
   Lombardi A, 1996, PHYS REV B, V54, P93, DOI 10.1103/PhysRevB.54.93
   Maple MB, 1998, J MAGN MAGN MATER, V177, P18, DOI 10.1016/S0304-8853(97)00999-2
   NIU CM, 1992, APPL PHYS LETT, V61, P1712, DOI 10.1063/1.108432
   NORTON DP, 1994, SCIENCE, V265, P2074, DOI 10.1126/science.265.5181.2074
   PROUTEAU C, 1994, PHYSICA C, V228, P63, DOI 10.1016/0921-4534(94)90174-0
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SHAKED H, 1995, PHYS REV B, V51, P11784, DOI 10.1103/PhysRevB.51.11784
   SIEGRIST T, 1988, NATURE, V334, P231, DOI 10.1038/334231a0
   SMITH MG, 1991, NATURE, V351, P549, DOI 10.1038/351549a0
   Vailionis A, 1997, PHYS REV B, V55, pR6152, DOI 10.1103/PhysRevB.55.R6152
   WOOTEN CL, 1992, PHYSICA C, V192, P13, DOI 10.1016/0921-4534(92)90736-V
   XIE XM, 1995, APPL PHYS LETT, V67, P1671, DOI 10.1063/1.115052
   ZHANG H, 1994, NATURE, V370, P352, DOI 10.1038/370352a0
   Zhou J.-R., 1995, IEEE COMPUT SCI ENG, V2, P30
NR 30
TC 63
Z9 63
U1 2
U2 44
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD NOV 22
PY 2001
VL 414
IS 6862
BP 434
EP 436
DI 10.1038/35106539
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 494UP
UT WOS:000172304500039
PM 11719801
DA 2018-12-27
ER

PT J
AU Rooney, JW
   Calame, KL
AF Rooney, JW
   Calame, KL
TI RETRACTED: TIF1 beta functions as a coactivator for C/EBP beta and is
   required for induced differentiation in the myelomonocytic cell line
   U937 (Retracted Article. See vol 16, pg 2170, 2002)
SO GENES & DEVELOPMENT
LA English
DT Article; Retracted Publication
DE TIF1 beta; C/EBP beta; U937 cells; macrophage; antisense
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PROMYELOCYTIC LEUKEMIA-CELLS; ZINC-FINGER
   PROTEINS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TARGETED DISRUPTION;
   HAMMERHEAD RIBOZYME; TIF1 BETA; MACROPHAGE; RECEPTOR
AB Representational difference analysis (RDA) cloning has identified transcriptional intermediary factor 1 beta (TIF1 beta) as a gene inducibly expressed early during myeloid differentiation of the promyelocytic cell lines HL-60 and U937. To assess the role of TIF1 beta, U937 cell lines were made that expressed antisense-hammerhead ribozymes targeted specifically against TIF1 beta mRNA. These cells failed to differentiate into macrophages, as determined by several criteria: a nonadherent morphology, a failure to arrest cell cycle, lowered levels of macrophage-specific cell surface markers, resistance to Legionella pneumophila infection, a loss of the ability to phagocytose and chemotax, and decreased expression of chemokine mRNAs. One way TIF1 beta acts in macrophage differentiation is to augment C/EBP beta transcriptional activity. Furthermore, we show by EMSA supershifts and coimmunoprecipitation that C/EBP beta and TIF1 beta physically interact. Although TIF1 beta is necessary for macrophage differentiation of U937 cells, it is not sufficient, based on the inability of ectopically expressed TIF1 beta to induce or augment phorbol ester-induced macrophage differentiation. We conclude that TIF1 beta plays an important role in the terminal differentiation program of macrophages, which involves the coactivation of C/EBP beta and induction of C/EBP beta -responsive myeloid genes.
C1 Columbia Univ, Sch Phys & Surg, Dept Microbiol, New York, NY 10032 USA.
RP Calame, KL (reprint author), Columbia Univ, Sch Phys & Surg, Dept Microbiol, New York, NY 10032 USA.
EM Klc1@columbia.edu
FU NHLBI NIH HHS [T32 HL007343, T32-HL07343]; PHS HHS [R01 A143567]; NIGMS
   NIH HHS [R01 GM29361]
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4
   Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412
   Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0
   Akira S, 1996, Curr Opin Hematol, V3, P87
   AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704
   Ausubel F., 1994, CURRENT PROTOCOLS MO
   BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000
   Casola A, 2001, J VIROL, V75, P6428, DOI 10.1128/JVI.75.14.6428-6439.2001
   Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880
   Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861
   Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153
   COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0
   COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458
   Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581
   DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T
   EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147
   Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5
   FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x
   Freedman LP, 1999, J NUTR, V129, p581S, DOI 10.1093/jn/129.2.581S
   Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067
   GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111
   HENDERSON AJ, 1995, J VIROL, V69, P5337
   HOHAUS S, 1995, MOL CELL BIOL, V15, P5830
   HOMANN M, 1993, NUCLEIC ACIDS RES, V21, P2809, DOI 10.1093/nar/21.12.2809
   Hormes R, 1997, NUCLEIC ACIDS RES, V25, P769, DOI 10.1093/nar/25.4.769
   HORWITZ MA, 1980, J CLIN INVEST, V66, P441, DOI 10.1172/JCI109874
   HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640
   Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6
   KLUG A, 1995, FASEB J, V9, P597
   KOEFFLER HP, 1983, BLOOD, V62, P709
   KOEFFLER HP, 1985, LEUKEMIA RES, V7, P117
   KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229
   KUNSCH C, 1994, J IMMUNOL, V153, P153
   LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x
   Lin YL, 2000, VIROLOGY, V276, P114, DOI 10.1006/viro.2000.0524
   Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723
   MARRA A, 1990, J IMMUNOL, V144, P2738
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700
   Matsumoto M, 1998, INT IMMUNOL, V10, P1825, DOI 10.1093/intimm/10.12.1825
   McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x
   Mink S, 1996, MOL CELL BIOL, V16, P1316
   Moore L L, 1986, Methods Enzymol, V132, P520
   Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859
   MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408
   NATSUKA S, 1992, BLOOD, V79, P460
   NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   PAHL HL, 1993, J BIOL CHEM, V268, P5014
   Patzel V, 1998, NAT BIOTECHNOL, V16, P64, DOI 10.1038/nbt0198-64
   PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023
   Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279
   RALPH P, 1982, CELL IMMUNOL, V71, P215, DOI 10.1016/0008-8749(82)90257-X
   RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528
   ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x
   ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801
   Rots NY, 1999, BLOOD, V93, P2721
   ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779
   Ryan RF, 1999, MOL CELL BIOL, V19, P4366
   SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504
   TABLER M, 1994, NUCLEIC ACIDS RES, V22, P3958, DOI 10.1093/nar/22.19.3958
   Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9
   TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2
   Yamamoto K, 1999, J BIOL CHEM, V274, P4646, DOI 10.1074/jbc.274.8.4646
   ZHANG DE, 1994, J BIOL CHEM, V269, P11425
   Zhang DE, 1996, MOL CELL BIOL, V16, P1231
   Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11
NR 71
TC 19
Z9 22
U1 1
U2 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD NOV 15
PY 2001
VL 15
IS 22
BP 3023
EP 3038
DI 10.1101/gad.937201
PG 16
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 495DJ
UT WOS:000172324700012
PM 11711437
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zou, ZH
   Horowitz, LF
   Montmayeur, JP
   Snapper, S
   Buck, LB
AF Zou, ZH
   Horowitz, LF
   Montmayeur, JP
   Snapper, S
   Buck, LB
TI RETRACTED: Genetic tracing reveals a stereotyped sensory map in the
   olfactory cortex (Retracted Article. See vol 452, pg 120, 2008)
SO NATURE
LA English
DT Article; Retracted Publication
ID ODORANT RECEPTOR; FUNCTIONAL EXPRESSION; MULTIGENE FAMILY; MITRAL CELLS;
   TUFTED CELLS; BULB; ORGANIZATION; PROJECTIONS; INFORMATION; PATHWAYS
AB The olfactory system translates myriad chemical structures into diverse odour perceptions. To gain insight into how this is accomplished, we prepared mice that coexpressed a transneuronal tracer with only one of about 1,000 different odorant receptors. The tracer travelled from nasal neurons expressing that receptor to the olfactory bulb and then to the olfactory cortex, allowing visualization of cortical neurons that receive input from a particular odorant receptor. These studies revealed a stereotyped sensory map in the olfactory cortex in which signals from a particular receptor are targeted to specific clusters of neurons. Inputs from different receptors overlap spatially and could be combined in single neurons, potentially allowing for an integration of the components of an odorant's combinatorial receptor code. Signals from the same receptor are targeted to multiple olfactory cortical areas, permitting the parallel, and perhaps differential, processing of inputs from a single receptor before delivery to the neocortex and limbic system.
C1 Harvard Univ, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Boston, MA 02115 USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Med Serv,Gastrointestinal Unit, Boston, MA 02114 USA.
RP Buck, LB (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Boston, MA 02115 USA.
EM lbuck@hms.harvard.edu
CR ALLISON AC, 1953, J COMP NEUROL, V98, P309, DOI 10.1002/cne.900980206
   AMSTRONG W, 1995, RAT NERVOUS SYSTEM, P377
   Araneda RC, 2000, NAT NEUROSCI, V3, P1248
   AUSUBEL FM, 2000, CURRENT PROTOCOLS MO
   BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X
   Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4
   Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505
   BUONVISO N, 1991, EUR J NEUROSCI, V3, P493, DOI 10.1111/j.1460-9568.1991.tb00836.x
   Cote S, 1993, IMMUNOHISTOCHEMISTRY, P147
   Datiche F, 1996, BRAIN RES BULL, V41, P391, DOI 10.1016/S0361-9230(96)00082-2
   Franklin K. B. J, 1997, MOUSE BRAIN STEREOTA
   HABERLY LB, 1977, BRAIN RES, V129, P152, DOI 10.1016/0006-8993(77)90978-7
   HABERLY LB, 1998, SYNAPTIC ORG BRAIN, P377
   Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595
   Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194
   JOYNER AL, 1993, GENE TARGETING, P107
   KANDEL ER, 2000, PRINCIPLES NEURAL SC, P625
   KATOH K, 1993, J NEUROPHYSIOL, V70, P2161
   KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X
   Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X
   LUSKIN MB, 1982, J COMP NEUROL, V209, P249, DOI 10.1002/cne.902090304
   Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4
   Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1
   McDonald AJ, 1998, PROG NEUROBIOL, V55, P257, DOI 10.1016/S0301-0082(98)00003-3
   Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2
   Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487
   Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711
   OJIMA H, 1984, J COMP NEUROL, V230, P77, DOI 10.1002/cne.902300107
   Price J.L., 1987, P179
   PRICE JL, 1991, J COMP NEUROL, V306, P447, DOI 10.1002/cne.903060309
   RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9
   RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G
   Risold PY, 1997, BRAIN RES REV, V24, P197, DOI 10.1016/S0165-0173(97)00007-6
   Royet JP, 1998, BRAIN RES, V788, P35, DOI 10.1016/S0006-8993(97)01504-7
   Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X
   SCOTT JW, 1986, EXPERIENTIA, V42, P223, DOI 10.1007/BF01942502
   SCOTT JW, 1980, J COMP NEUROL, V194, P519, DOI 10.1002/cne.901940304
   Shepherd GM, 1998, SYNAPTIC ORG BRAIN, P159
   Shipley MT, 1996, J NEUROBIOL, V30, P123
   Simerly Richard B., 1995, P353
   Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884
   Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857
   VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9
   VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M
   Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9
   Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5
   Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237
   ZIGMOND M, 1999, FUNDAMENTAL NEURAL S, P737
NR 48
TC 174
Z9 178
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 8
PY 2001
VL 414
IS 6860
BP 173
EP 179
DI 10.1038/35102506
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 490AY
UT WOS:000172029100038
PM 11700549
DA 2018-12-27
ER

PT J
AU Zhu, K
   Baudhuin, LM
   Hong, GY
   Williams, FS
   Cristina, KL
   Kabarowski, JHS
   Witte, ON
   Xu, Y
AF Zhu, K
   Baudhuin, LM
   Hong, GY
   Williams, FS
   Cristina, KL
   Kabarowski, JHS
   Witte, ON
   Xu, Y
TI RETRACTED: Sphingosylphosphorylcholine and lysophosphatidylcholine are
   ligands for the G protein-coupled receptor GPR4. (Retracted Article. See
   vol 280, pg 43280, 2005)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID LOW-DENSITY-LIPOPROTEIN; SPHINGOSINE 1-PHOSPHATE; ACID; IDENTIFICATION;
   ACTIVATION; CELLS; LYSOPHOSPHOLIPIDS; ATHEROSCLEROSIS; TRANSDUCTION;
   FIBROBLASTS
AB Sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) are bioactive lipid molecules involved in numerous biological processes. We have recently identified ovarian cancer G protein-coupled receptor 1 (OGR1) as a specific and high affinity receptor for SPC, and G2A as a receptor with high affinity for LPC, but low affinity for SPC. Among G protein-coupled receptors, GPR4 shares highest sequence homology with OGR1 (51%). In this work, we have identified GPR4 as not only another high affinity receptor for SPC, but also a receptor for LPC, albeit of lower affinity. Both SPC and LPC induce increases in intracellular calcium concentration in GPR4-, but not vector-transfected MCF10A cells. These effects are insensitive to treatment with BN52021, WEB-2170, and WEB-2086 (specific platelet activating factor (PAF) receptor antagonists), suggesting that they are not mediated through an endogenous PAF receptor. SPC and LPC bind to GPR4 in GPR4-transfected CHO cells with K-d/SPC = 36 nM, and K-d/LPC = 159 nM, respectively. Competitive binding is elicited only by SPC and LPC. Both SPC and LPC activate GPR4-dependent activation of serum response element reporter and receptor internalization. Swiss 3T3 cells expressing GPR4 respond to both SPC and LPC, but not sphingosine 1-phosphate (SIP), PAF, psychosine (Psy), glucosyl-beta1'1-sphingosine (Glu-Sph), galactosyl-beta1'1-ceramide (GalCer), or lactosyl-beta1'1-ceramide (Lac-Cer) to activate extracellular signal-regulated kinase mitogen-activated protein kinase in a concentration- and time-dependent manner. SPC and LPC stimulate DNA synthesis in GPR4-expressing Swiss 3T3 cells. Both extracellular signal-regulated kinase activation and DNA synthesis stimulated by SPC and LPC are pertussis toxin-sensitive, suggesting the involvement of a G(i)-heterotrimeric G protein. In addition, GPR4 expression confers chemotactic responses to both SPC and LPC in Swiss 3T3 cells. Taken together, our data indicate that GPR4 is a receptor with high affinity to SPC and low affinity to LPC, and that multiple cellular functions can be transduced via this receptor.
C1 Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Obstet & Gynecol, Cleveland, OH 44195 USA.
   Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA.
   Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.
RP Xu, Y (reprint author), Cleveland Clin Fdn, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM xuy@ccf.org
FU NCI NIH HHS [R21 CA84038-01, CA76204]
CR AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L
   An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906
   An SZ, 1999, MOL PHARMACOL, V55, P787
   Bohm SK, 1997, BIOCHEM J, V322, P1
   Carson MJ, 2001, SCIENCE, V293, P618, DOI 10.1126/science.1063516
   CHISOLM G, 1996, OXIDIZED LIPOPROTEIN
   Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1697, DOI 10.1016/S0891-5849(00)00227-6
   Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051
   Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061
   DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385
   Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095
   Goetzl EJ, 1998, FASEB J, V12, P1589
   Gomez-Munoz A, 1999, J LIPID RES, V40, P988
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25
   Hirayama T, 1998, HYPERTENS RES-CLIN E, V21, P137, DOI 10.1291/hypres.21.137
   Huang YH, 1999, CLIN EXP IMMUNOL, V116, P326
   Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429
   JALINK K, 1990, J BIOL CHEM, V265, P12232
   Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109
   Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781
   Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353
   Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013
   MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605
   MOCHIZUKI M, 1983, CURR EYE RES, V2, P621, DOI 10.3109/02713688208996363
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Murphy AA, 1998, J CLIN ENDOCR METAB, V83, P2110, DOI 10.1210/jc.83.6.2110
   Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728
   Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17
   Okajima F, 1998, BIOCHEM J, V336, P491, DOI 10.1042/bj3360491
   Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4
   Prokazova NV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P31
   Sasagawa T, 1998, J NUTR SCI VITAMINOL, V44, P809
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334
   Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377
   Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529
   Yokota T, 1995, J INTERN MED, V238, P479, DOI 10.1111/j.1365-2796.1995.tb01229.x
NR 41
TC 184
Z9 198
U1 4
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 2
PY 2001
VL 276
IS 44
BP 41325
EP 41335
DI 10.1074/jbc.M008057200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 488FM
UT WOS:000171925600126
PM 11535583
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Uemura, A
   Toyooka, H
TI RETRACTED: The dose-range effects of propofol on the contractility of
   fatigued diaphragm in dogs (Retracted article. See vol. 116, pg. 746,
   2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID MUSCLE FATIGUE; RESPIRATORY MUSCLES; VOLUNTARY; ACIDOSIS; FAILURE
AB Diaphragmatic fatigue may contribute to the development of respiratory failure. We studied the dose-range effects of propofol on the contractility of fatigued diaphragm in dogs. Animals were divided into three groups of eight each. In each group, diaphragmatic fatigue was induced by intermittent supramaximal. bilateral electrophrenic stimulation at a frequency of 20-Hz stimulation for 30 min. Immediately after the end of a fatigue-producing period, Group 1 received no study drug; Group 2 was infused with small-dose propofol (0.1 mg/kg initial dose plus 1.5 mg . kg(-1) . h(-1) maintenance dose); Group 3 was infused with large-dose propofol (0.1 mg/kg initial dose plus 6.0 mg . kg(-1) . h(-1) maintenance dose). We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). After the fatigue-producing period, in each group, Pdi at low-frequency (20-Hz) stimulation decreased from baseline values (P < 0.05), whereas there was no change in Pdi at high-frequency (100-Hz) stimulation. In Groups 2 and 3, with an infusion of propofol, Pdi at 20-Hz stimulation decreased from fatigued values (P < 0.05). Compared with Group 1, Pdi at 20-Hz stimulation decreased from fatigued values (P < 0.05) during propofol administration in Groups 2 and 3. The decrease in Pdi was more in Group 3 than in Group 2 (P < 0.05). We conclude that propofol decreases the contractility of fatigued canine diaphragm in a dose-related fashion.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   CLERGUE F, 1986, ANESTHESIOLOGY, V64, P181, DOI 10.1097/00000542-198602000-00009
   COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   Fujii Y, 1999, ANESTH ANALG, V89, P1557, DOI 10.1097/00000539-199912000-00046
   Fujii Y, 1998, ANESTH ANALG, V87, P1077, DOI 10.1097/00000539-199811000-00018
   FUJII Y, 2001, MIDAZOLAM VERSUS PRO, V86, P879
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Moxham J, 1981, Ciba Found Symp, V82, P197
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 19
TC 8
Z9 8
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD NOV
PY 2001
VL 93
IS 5
BP 1194
EP 1198
DI 10.1097/00000539-200111000-00029
PG 5
WC Anesthesiology
SC Anesthesiology
GA 486MA
UT WOS:000171820500026
PM 11682396
DA 2018-12-27
ER

PT J
AU Reyes, M
   Lund, T
   Lenvik, T
   Aguiar, D
   Koodie, L
   Verfaillie, CM
AF Reyes, M
   Lund, T
   Lenvik, T
   Aguiar, D
   Koodie, L
   Verfaillie, CM
TI RETRACTED: Purification and ex vivo expansion of postnatal human marrow
   mesodermal progenitor cells (Retracted article. See vol. 113, pg. 2370,
   2009)
SO BLOOD
LA English
DT Article; Retracted Publication
ID HEMATOPOIETIC STEM-CELLS; HUMAN BONE-MARROW; IN-VITRO; EXPRESSION; GENE;
   DIFFERENTIATION; ENGRAFTMENT; BLOOD; CYCLE; MOUSE
AB It is here reported that mesenchymal stem cells known to give rise to limb-bud mesoderm can, at the single-cell level, also differentiate into cells of visceral mesoderm and can be expanded extensively by means of clinically applicable methods. These cells were named mesodermal progenitor cells (MPCs). MPCs were selected by depleting bone marrow mononuclear cells from more than 30 healthy human donors of Cp45(+)/glycophorin-A (GlyA)(+) cells. Cells were cultured on fibronectin with epidermal growth factor and platelet-derived growth factor BB and 2% or less fetal calf serum. It was found that 1/5 x 10(3) CD45(-)GlyA(-) cells, or 1/10(6) bone marrow mononuclear cells, gave rise to clusters of small adherent cells. Cell-doubling time was 48 to 72 hours, and cells have been expanded in culture for more than 60 cell doublings. MPCs are CD34(-), CD44(low), CD45(-), CD117 (cKit)(-), class I-HLA(-), and HLA-DR(-). MPCs differentiated into cells of limb-bud mesoderm (osteoblasts, chondrocytes, adipocytes, stroma cells, and skeletal myoblasts) as well as visceral mesoderm (endothelial cells). Retroviral marking was used to definitively prove that single MPCs can differentiate into cells of limb bud and visceral mesoderm. Thus, MPCs that proliferate without obvious senescence under clinically applicable conditions and differentiate at the single-cell level not only into mesenchymal cells but also cells of visceral mesoderm may be an ideal source of stem cells for treatment of genetic or degenerative disorders affecting cells of mesodermal origin. (C) 2001 by The American Society of Hematology.
C1 Univ Minnesota, Sch Med, Dept Med, Stem Cell Inst, Minneapolis, MN 55455 USA.
   Univ Minnesota, Sch Med, Ctr Canc, Minneapolis, MN 55455 USA.
RP Verfaillie, CM (reprint author), Univ Minnesota, Sch Med, Dept Med, Stem Cell Inst, MMC 716,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM verfa001@umn.edu
OI Verfaillie, Catherine/0000-0001-7564-4079
FU NIAID NIH HHS [1F31AI/GM10291]; NCI NIH HHS [P01-CA-65493-1]
CR Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168-8278(98)80165-7
   ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114
   Bierhuizen MFA, 1997, BLOOD, V90, P3304
   Chen JCJ, 1999, CELL TISSUE RES, V296, P213, DOI 10.1007/s004410051282
   Choi K, 1998, DEVELOPMENT, V125, P725
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Dunbar CE, 1998, HUM GENE THER, V9, P2629, DOI 10.1089/hum.1998.9.17-2629
   Frankel MS, 2000, SCIENCE, V287, P1397, DOI 10.1126/science.287.5457.1397
   FRIDENSHTEIN AY, 1982, ARK PATOL, V44, P3
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   GRONTHOS S, 1994, BLOOD, V84, P4164
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.3.CO;2-7
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2
   Jiang YH, 2000, BLOOD, V95, P846
   JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I
   KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   Krivit W, 1999, Curr Opin Hematol, V6, P377, DOI 10.1097/00062752-199911000-00004
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Lewis ID, 2000, EXP HEMATOL, V28, P1087, DOI 10.1016/S0301-472X(00)00515-4
   Lewis ID, 2001, BLOOD, V97, P3441, DOI 10.1182/blood.V97.11.3441
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   Moore KA, 1997, BLOOD, V89, P4337
   Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Peters C, 1998, J PEDIATR-US, V133, P7, DOI 10.1016/S0022-3476(98)70170-2
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246
   Punzel M, 1999, BLOOD, V93, P3750
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   SCHILTZ JR, 1979, CELL DIFFER DEV, V8, P83, DOI 10.1016/0045-6039(79)90028-9
   Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726
   THOMSON JA, 1998, SCIENCE, V282, P114
   VERFAILLIE CM, 1992, BLOOD, V79, P1003
   VERFAILLIE CM, 1992, BLOOD, V79, P2821
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8
   Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247
   Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442
NR 39
TC 889
Z9 1054
U1 6
U2 37
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 1
PY 2001
VL 98
IS 9
BP 2615
EP 2625
DI 10.1182/blood.V98.9.2615
PG 11
WC Hematology
SC Hematology
GA 487CK
UT WOS:000171855900005
PM 11675329
OA Bronze
DA 2018-12-27
ER

PT J
AU Stumvoll, M
   Wahl, HG
   Jacob, S
   Rettig, A
   Machicao, F
   Haring, H
AF Stumvoll, M
   Wahl, HG
   Jacob, S
   Rettig, A
   Machicao, F
   Haring, H
TI RETRACTED: Two novel prevalent polymorphisms in the hormone-sensitive
   lipase gene have no effect on insulin sensitivity of lipolysis and
   glucose disposal (Retracted Article. See vol 43, pg 1348, 2002)
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article; Retracted Publication
DE euglycemic hyperinsulinemic clamp; glycerol; insulin resistance; stable
   isotopes
ID DEPENDENT DIABETES-MELLITUS; FATTY-ACID-METABOLISM;
   CARBOHYDRATE-METABOLISM; DINUCLEOTIDE REPEAT; MULTIPLE SITES;
   ADIPOSE-TISSUE; HUMAN OBESITY; RESISTANCE; PATHOGENESIS; NIDDM
AB Free fatty acids released during triglyceride lipolysis play an important role in obesity-associated insulin resistance of glucose disposal. Individual sensitivity of lipolysis to the suppressive effect of insulin varies greatly among healthy subjects. It is possible that genetic factors contribute to this variation. Among the many proteins involved in the regulation of lipolysis, hormone-sensitive lipase (HSL) represents a prime candidate for genetic variants contributing to the biological variation of insulin sensitivity of lipolysis. We determined the insulin sensitivity of lipolysis (suppression of isotopically [primed-continuous infusion of d(5) glycerol] measured glycerol rate of appearance) and of glucose disposal, using a three-step (n = 20) or standard (n = 53) hyperinsulinemic euglycemic clamp in 73 healthy, unrelated subjects. To assess the possible role of genetic polymorphisms, we directly sequenced the coding region of the HSL gene and the noncoding exon B from these subjects. We identified two silent mutations and three amino acid polymorphisms: Arg262Met (prevalence, 5%), Glu620Asp (prevalence, 31%) and Ser681Ile (prevalence, 22%). The latter two are located in the regulatory domain of HSL but neither had a significant impact on insulin sensitivity of lipolysis or glucose disposal (with and without adjustment for obesity and age as covariates; all P values > 0.20). We conclude that a number of genetic polymorphisms in HSL exist, some of which are highly prevalent. Neither of the polymorphisms we identified in the coding region, however, contributed measurably to the biological variation of insulin sensitivity in our lean, healthy population.
C1 Univ Tubingen, Dept Endocrinol & Metab, D-72076 Tubingen, Germany.
RP Stumvoll, M (reprint author), Univ Klin, Otfried Muller Str 10, D-72076 Tubingen, Germany.
EM michael.stumvoll@med.uni-tuebingen.de
CR Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3
   CAMPBELL PJ, 1994, AM J PHYSIOL, V266, pE600
   CAMPBELL PJ, 1992, AM J PHYSIOL, V263, pE1063
   DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445
   DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318
   DINNEEN S, 1992, NEW ENGL J MED, V327, P707
   ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9
   Ferrannini E, 1998, ENDOCR REV, V19, P477, DOI 10.1210/er.19.4.477
   Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491
   GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142
   GROOP LC, 1992, AM J PHYSIOL, V263, pE79
   HagstromToft E, 1997, DIABETOLOGIA, V40, P1070, DOI 10.1007/s001250050789
   Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365
   Klannemark M, 1998, DIABETOLOGIA, V41, P1516, DOI 10.1007/s001250051099
   LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897
   LEVIN J, 1995, J ECON PERSPECT, V9, P3, DOI 10.1257/jep.9.1.3
   Levitt R. C., 1992, Human Molecular Genetics, V1, P139, DOI 10.1093/hmg/1.2.139
   Magre J, 1998, DIABETES, V47, P284, DOI 10.2337/diab.47.2.284
   MCCULLOCH AJ, 1983, CLIN ENDOCRINOL, V19, P67, DOI 10.1111/j.1365-2265.1983.tb00744.x
   Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228
   NAKANISHI H, 1993, J BIOL CHEM, V268, P13
   Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411
   Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787
   Pajukanta P, 1997, ARTERIOSCL THROM VAS, V17, P841, DOI 10.1161/01.ATV.17.5.841
   Saltiel AR, 2000, P NATL ACAD SCI USA, V97, P535, DOI 10.1073/pnas.97.2.535
   Shimada F, 1996, METABOLISM, V45, P862, DOI 10.1016/S0026-0495(96)90160-2
   Stumvoll M, 1999, EXP CLIN ENDOCR DIAB, V107, P107, DOI 10.1055/s-0029-1212083
   Stumvoll M, 2000, J CLIN ENDOCR METAB, V85, P3740, DOI 10.1210/jc.85.10.3740
   Stumvoll M, 2001, HORM METAB RES, V33, P89, DOI 10.1055/s-2001-12403
   Stumvoll M, 2001, DIABETES, V50, P876, DOI 10.2337/diabetes.50.4.876
   Talmud PJ, 1998, BIOCHEM BIOPH RES CO, V252, P661, DOI 10.1006/bbrc.1998.9597
NR 31
TC 6
Z9 11
U1 2
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD NOV
PY 2001
VL 42
IS 11
BP 1782
EP 1788
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 498NQ
UT WOS:000172517900007
PM 11714847
DA 2018-12-27
ER

PT J
AU Liu, HP
   Zhang, HY
   McPherson, BC
   Baman, T
   Roth, S
   Shao, ZH
   Zhu, XD
   Yao, ZH
AF Liu, HP
   Zhang, HY
   McPherson, BC
   Baman, T
   Roth, S
   Shao, ZH
   Zhu, XD
   Yao, ZH
TI RETRACTED: Role of opioid delta(1) receptors, mitochondrial K-ATP
   channels, and protein kinase C during cardiocyte apoptosis (Retracted
   Article. See vol 35, pg 337, 2003)
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article; Retracted Publication
DE opioid delta-1 receptors; preconditioning; mitochondrial K-ATP channels;
   PKC isoforms; apoptosis
ID ACUTE MYOCARDIAL-INFARCTION; RAT HEARTS; REPERFUSION INJURY; CONSCIOUS
   RABBITS; CARDIAC MYOCYTES; ISCHEMIC-INJURY; PKC-DELTA; IN-VIVO;
   ACTIVATION; CARDIOPROTECTION
AB Opioids attenuate cardiac injury after ischemia and reperfusion. We wanted to determine whether the protection of opioids is mediated by blocking cardiocyte apoptosis. and if so, to describe the role of opioid delta (1) receptors and protein kinase C (PKC) in this effect. Chick embryonic cardiomyocytes were subjected to 12 h of simulated ischemia and then 12 h of re-oxygenation, which resulted in 54 +/- 3% (n = 6) of cell apoptosis (n = 6) as measured by flow cytometry. This result was consistent with DNA laddering and TUNEL assay. Preconditioning, elicited with three cycles of 1 min of simulated ischemia separated by 5 min of reoxygenation before prolonged simulated ischemia, reduced apoptosis (36 +/- 4%, n = 6*); Pretreatment with BNTX (0.1 mu mol/l), a selective opioid delta (1) receptor blocker, abolished the effects of preconditioning (57 +/- 5 %, n = 6). The selective opioid 6 receptor agonist BW373U86 (20 pmol/l) also attenuated apoptosis (39 +/- 3%, n = 6* v control). These effects were abolished by 5-hydroxydecanoate (100 muM), a selective mitochondrial K-ATP channel blocker (50 +/- 5%. n = 6) and by Go-6976 (0.1 pmol/l), a specific PKC inhibitor. Both preconditioning and BW373U86 activated the PKC 6 isoform of particulate fraction before simulated ischemia without effect on total and cytosolic fractions. Stimulation of opioid delta (1) receptors activates mitochondrial K-ATP channels and the PKC 6 isoform in cultured ventricular myocytes. This is one important signal transduction pathway through which ischemic preconditioning blocks apoptosis and preserves cardiac function. (C) 2001 Academic Press.
C1 Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC 27599 USA.
   Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA.
RP Yao, ZH (reprint author), Univ N Carolina, Dept Anesthesiol, 223 Burnett Womack Bldg,CB7010, Chapel Hill, NC 27599 USA.
EM zyao@aims.unc.edu
OI zhu, xiangdong/0000-0002-5627-8082; Roth, Steven/0000-0002-4955-9855
FU NHLBI NIH HHS [HL03881, HL67416, HL68250]
CR AMBROSIO G, 1995, J MOL CELL CARDIOL, V27, P1035, DOI 10.1016/0022-2828(95)90072-1
   BARRY WH, 1980, AM J PHYSIOL, V239, pH651
   Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CHANG KJ, 1993, J PHARMACOL EXP THER, V267, P852
   Chien GL, 1996, J MOL CELL CARDIOL, V28, P1895, DOI 10.1006/jmcc.1996.0182
   COMER SD, 1993, J PHARMACOL EXP THER, V267, P866
   Elsasser A, 2000, J MOL CELL CARDIOL, V32, P711, DOI 10.1006/jmcc.2000.1125
   Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346
   Gopalakrishna R, 1999, ARCH BIOCHEM BIOPHYS, V363, P246, DOI 10.1006/abbi.1999.1100
   GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504
   GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199
   INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0
   James TN, 1999, AM J MED, V107, P606, DOI 10.1016/S0002-9343(99)00308-3
   Kawamura S, 1998, AM J PHYSIOL-HEART C, V275, pH2266, DOI 10.1152/ajpheart.1998.275.6.H2266
   Liang BT, 1999, CIRC RES, V84, P1396
   MANN CL, 1999, APOPTOSIS INFLAMMATI, P7
   McPherson BC, 2001, CIRCULATION, V103, P290
   NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0
   NOTSU T, 1992, J PHARMACOL EXP THER, V260, P702
   Okamura T, 1999, AM J PHYSIOL-HEART C, V277, pH1997, DOI 10.1152/ajpheart.1999.277.5.H1997
   Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193
   Ping PP, 1999, AM J PHYSIOL-HEART C, V277, pH1771, DOI 10.1152/ajpheart.1999.277.5.H1771
   Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404
   Piot CA, 1997, CIRCULATION, V96, P1598, DOI 10.1161/01.CIR.96.5.1598
   Saraste A, 1997, CIRCULATION, V95, P320
   Schultz JE, 2001, PHARMACOL THERAPEUT, V89, P123, DOI 10.1016/S0163-7258(00)00106-6
   SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157
   SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777
   SOFUOGLU M, 1993, LIFE SCI, V52, P769, DOI 10.1016/0024-3205(93)90240-4
   VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334
   Wang YG, 1999, CIRC RES, V85, P731, DOI 10.1161/01.RES.85.8.731
   Wu S, 1999, CIRC RES, V84, P1388
   Yao ZH, 1999, AM J PHYSIOL-HEART C, V277, pH2504, DOI 10.1152/ajpheart.1999.277.6.H2504
NR 34
TC 20
Z9 27
U1 1
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD NOV
PY 2001
VL 33
IS 11
BP 2007
EP 2014
DI 10.1006/jmcc.2001.1464
PG 8
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 495NB
UT WOS:000172346300010
PM 11708844
DA 2018-12-27
ER

PT J
AU Cheriaux, G
   Chambaret, JP
AF Cheriaux, G
   Chambaret, JP
TI RETRACTED: Ultra-short high-intensity laser pulse generation and
   amplification (Retracted article. See vol. 19, pg. Nil_0457, 2008)
SO MEASUREMENT SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE pulse duration; wavefront distortions; spectral phase measurement;
   short-pulse generation
ID TI-SAPPHIRE LASER; GROUP-VELOCITY DISPERSION; LENS MODE-LOCKING;
   SOLID-STATE LASERS; OPTICAL PULSES; FEMTOSECOND PULSES; REGENERATIVE
   AMPLIFIER; REPETITION-RATE; DEFORMABLE MIRRORS; PHASE-CONTROL
AB Since the beginning of the 1990s the generation of high-intensity laser pulses has known an unprecedented evolution thanks to the conjunction of the possibility of the chirped pulse technique and the availability of spectrally broad-band laser media. Lasers capable of producing multi-terawatt pulses can now be built on few optical tables in a small laboratory. We review the generation and the amplification of ultra-short pulses by the chirped pulse amplification technique.
C1 Ecole Natl Super Tech Avancees, CNRS, UMR 7639, Lab Opt Appliquee,Ecole Polytech, F-91761 Palaiseau, France.
RP Cheriaux, G (reprint author), Ecole Natl Super Tech Avancees, CNRS, UMR 7639, Lab Opt Appliquee,Ecole Polytech, F-91761 Palaiseau, France.
EM cheriaux@enstay.ensta.fr
CR BACKUS S, 1995, OPT LETT, V20, P2000, DOI 10.1364/OL.20.002000
   Bagnoud V, 2000, APPL PHYS B-LASERS O, V70, pS165, DOI 10.1007/s003400000320
   Barty CPJ, 1996, OPT LETT, V21, P668, DOI 10.1364/OL.21.000668
   BARTY CPJ, 1994, OPT LETT, V19, P1442, DOI 10.1364/OL.19.001442
   Barty CPJ, 1996, OPT LETT, V21, P219, DOI 10.1364/OL.21.000219
   Bonlie JD, 2000, APPL PHYS B-LASERS O, V70, pS155, DOI 10.1007/s003400000329
   BRABEC T, 1992, OPT LETT, V17, P1292, DOI 10.1364/OL.17.001292
   Chambaret JP, 1996, OPT LETT, V21, P1921, DOI 10.1364/OL.21.001921
   Chanteloup JC, 1998, OPT LETT, V23, P475, DOI 10.1364/OL.23.000475
   Cheriaux G, 1996, OPT LETT, V21, P414, DOI 10.1364/OL.21.000414
   Cheriaux G, 2001, OPT LETT, V26, P169, DOI 10.1364/OL.26.000169
   CHRISTOV IP, 1985, OPT COMMUN, V53, P364, DOI 10.1016/0030-4018(85)90018-5
   CHRISTOV IP, 1992, OPT LETT, V17, P742, DOI 10.1364/OL.17.000742
   CHRISTOV IP, 1991, PROGR OPTICS, V29, P201
   Cundiff ST, 1996, OPT LETT, V21, P662, DOI 10.1364/OL.21.000662
   DEFRANZO AC, 1993, APPL OPTICS, V32, P2224, DOI 10.1364/AO.32.002224
   Dorrer C, 1998, OPT LETT, V23, P709, DOI 10.1364/OL.23.000709
   Druon F, 1998, OPT LETT, V23, P1043, DOI 10.1364/OL.23.001043
   Efimov A, 1998, OPT LETT, V23, P1612, DOI 10.1364/OL.23.001612
   FERRAY M, 1990, OPT COMMUN, V75, P278, DOI 10.1016/0030-4018(90)90532-X
   HERRMANN J, 1994, J OPT SOC AM B, V11, P498, DOI 10.1364/JOSAB.11.000498
   HUANG CP, 1992, OPT LETT, V17, P1289, DOI 10.1364/OL.17.001289
   Iaconis C, 1999, IEEE J QUANTUM ELECT, V35, P501, DOI 10.1109/3.753654
   JOOSEN W, 1991, J OPT SOC AM B, V8, P2087, DOI 10.1364/JOSAB.8.002087
   KNOX WH, 1987, J OPT SOC AM B, V4, P1771, DOI 10.1364/JOSAB.4.001771
   Koechner W, 1996, SOLID STATE LASER EN
   KRAUSZ F, 1992, IEEE J QUANTUM ELECT, V28, P2097, DOI 10.1109/3.159520
   KRAUSZ F, 1992, OPT LETT, V17, P204, DOI 10.1364/OL.17.000204
   LEBLANC C, 1993, OPT LETT, V18, P140, DOI 10.1364/OL.18.000140
   LENZNER M, 1995, OPT LETT, V20, P1397, DOI 10.1364/OL.20.001397
   MAINE P, 1988, IEEE J QUANTUM ELECT, V24, P398, DOI 10.1109/3.137
   MARTINEZ OE, 1986, J OPT SOC AM B, V3, P929, DOI 10.1364/JOSAB.3.000929
   MARTINEZ OE, 1984, J OPT SOC AM A, V1, P1003, DOI 10.1364/JOSAA.1.001003
   MARTINEZ OE, 1987, IEEE J QUANTUM ELECT, V23, P1385, DOI 10.1109/JQE.1987.1073518
   MARTINEZ OE, 1987, IEEE J QUANTUM ELECT, V23, P59, DOI 10.1109/JQE.1987.1073201
   Meshulach D, 1998, NATURE, V396, P239
   MOULTON PF, 1992, P IEEE, V80, P348, DOI 10.1109/5.135352
   PESSOT M, 1987, OPT COMMUN, V62, P419, DOI 10.1016/0030-4018(87)90011-3
   RUDD JV, 1993, OPT LETT, V18, P2044, DOI 10.1364/OL.18.002044
   SALIN F, 1991, OPT LETT, V16, P1964, DOI 10.1364/OL.16.001964
   SPENCE DE, 1991, OPT LETT, V16, P42, DOI 10.1364/OL.16.000042
   SQUIER J, 1992, OPT COMMUN, V92, P73, DOI 10.1016/0030-4018(92)90221-C
   STINGL A, 1994, OPT LETT, V19, P204, DOI 10.1364/OL.19.000204
   STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8
   Sutter DH, 1999, OPT LETT, V24, P631, DOI 10.1364/OL.24.000631
   TREACY EB, 1969, IEEE J QUANTUM ELECT, VQE 5, P454, DOI 10.1109/JQE.1969.1076303
   TREBINO R, 1993, J OPT SOC AM A, V10, P1101, DOI 10.1364/JOSAA.10.001101
   VAILLANCOURT G, 1990, OPT LETT, V15, P317, DOI 10.1364/OL.15.000317
   VALDMANIS JA, 1986, IEEE J QUANTUM ELECT, V22, P112, DOI 10.1109/JQE.1986.1072854
   Verluise F, 2000, OPT LETT, V25, P575, DOI 10.1364/OL.25.000575
   WYNNE K, 1994, OPT LETT, V19, P895, DOI 10.1364/OL.19.000895
   Yamakawa K, 1998, OPT LETT, V23, P1468, DOI 10.1364/OL.23.001468
   Yelin D, 1997, OPT LETT, V22, P1793, DOI 10.1364/OL.22.001793
   Zeek E, 2000, OPT LETT, V25, P587, DOI 10.1364/OL.25.000587
   Zeek E, 1999, OPT LETT, V24, P493, DOI 10.1364/OL.24.000493
   ZHOU JP, 1994, OPT LETT, V19, P1149, DOI 10.1364/OL.19.001149
NR 56
TC 13
Z9 14
U1 2
U2 17
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-0233
EI 1361-6501
J9 MEAS SCI TECHNOL
JI Meas. Sci. Technol.
PD NOV
PY 2001
VL 12
IS 11
BP 1769
EP 1776
DI 10.1088/0957-0233/12/11/303
PG 8
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA 498QW
UT WOS:000172522800004
DA 2018-12-27
ER

PT J
AU Paventi, S
   Liturri, S
   Colio, B
   Santevecchi, A
   Ranieri, R
AF Paventi, S
   Liturri, S
   Colio, B
   Santevecchi, A
   Ranieri, R
TI RETRACTED: Airway management with the Combitube during anaesthesia and
   in an emergency (Retracted Article. See vol 54, 317, 2002)
SO RESUSCITATION
LA English
DT Article; Retracted Publication
DE airway management; Dombitube; difficult intubation
ID ESOPHAGEAL-TRACHEAL COMBITUBE(R); REGURGITATION; INTUBATION
AB The oesophageal-tracheal Combitube (Kendall-Sheridan Catheter Corp., Argyle, NY) is a device designed for difficult airways and emergency intubation. The manufacturer recommends that the Combitube size 37F SA be used in patients with a height of between 122 and 152 cm. The aim of this study was to evaluate whether ventilation is effective and reliable in anaesthetized patients taller than 152 cm using the size 37F SA in the oesophageal position. We also evaluated whether airway protection is adequate and whether direct intubation of the trachea with the Combitube inserted in the oesophagus is possible. We studied 15 adult patients undergoing routine general anaesthesia and 20 patients who required emergency intubation following trauma. They were between 150 and 180 cm in height. Under direct vision, a size 37F SA Combitube was inserted into the oesophagus of all the patients undergoing routine general anaesthesia (control group). Blind insertion was performed in the emergency patients (emergency group). The pharyngeal balloon was inflated with a volume titrated to air leak and cuff pressures were measured. During surgery, a laryngoscope was inserted into the pharynx with the pharyngeal balloon deflated and the laryngoscopic view was evaluated using the Cormack-Lehane scale. Ventilation was effective and reliable in all 35 patients who were between 150 and 180 cm in height. In addition, a direct relationship between the pharyngeal balloon volume and patient height was established (P < 0.05), using linear regression models. The laryngoseopic view of the glottis was adequate to allow direct tracheal intubation in patients in the control group, so that the Combitube size 37F SA may be used in patients from 122 to 185 cm in height. The trachea could be directly intubated with the Combitube in the oesophageal position in patients with normal airways and in patients involved in trauma. In all patients in the emergency group, blind insertion of the Combitube resulted in the device being placed in the oesophagus. The airway protection appears to be adequate. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
C1 Univ Cattolica Sacro Cuore, Dept Anaesthesiol & Intens Care Med, I-00168 Rome, Italy.
   S Camillo de Lellis Hosp, Emergency Dept, Rieti, Italy.
RP Paventi, S (reprint author), Via Fabiola 9, I-00152 Rome, Italy.
EM paventi@iol.it
CR Bapat PP, 1997, ANESTH ANALG, V85, P139, DOI 10.1097/00000539-199707000-00025
   BLITT CD, 1970, ANESTH ANAL CURR RES, V49, P707
   CAPLAN RA, 1993, ANESTHESIOLOGY, V78, P597
   CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x
   Deroy R, 1998, ANESTH ANALG, V87, P1441, DOI 10.1097/00000539-199812000-00046
   Frass M., 1996, AIRWAY MANAGEMENT PR, P444
   Gaitini LA, 1999, ANESTH ANALG, V88, P193, DOI 10.1097/00000539-199901000-00036
   Kloeck W, 1997, CIRCULATION, V95, P2180, DOI 10.1161/01.CIR.95.8.2180
   Krafft P, 1998, ANESTH ANALG, V87, P1457, DOI 10.1097/00000539-199812000-00059
   Mercer MH, 1998, ANAESTHESIA, V53, P146, DOI 10.1046/j.1365-2044.1998.00302.x
   OVASSAPIAN A, 1993, ANESTH ANALG, V76, pS315
   Urtubia R, 1999, ANESTH ANALG, V89, P803, DOI 10.1097/00000539-199909000-00059
   UTURBIA RM, 2000, ANESTH ANALG, V90, P958
   Vezina D, 1998, CAN J ANAESTH, V45, P76, DOI 10.1007/BF03011999
   WAFAI Y, 1995, ANESTH ANALG, V80, P122, DOI 10.1097/00000539-199501000-00021
   Walz R, 1999, ANESTH ANALG, V88, P233, DOI 10.1097/00000539-199901000-00056
NR 16
TC 2
Z9 3
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD NOV
PY 2001
VL 51
IS 2
BP 129
EP 133
DI 10.1016/S0300-9572(01)00403-8
PG 5
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA 500FH
UT WOS:000172615000004
PM 11718967
DA 2018-12-27
ER

PT J
AU Lee, GJ
   Shin, R
   Park, CJ
   Yoo, TH
   Paek, KH
AF Lee, GJ
   Shin, R
   Park, CJ
   Yoo, TH
   Paek, KH
TI RETRACTED: Induction of a pepper cDNA encoding SAR8.2 protein during the
   resistance response to tobacco mosaic virus (Retracted article. See vol.
   35, pg. 174, 2013)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE cDNA cloning; differential screening; hot pepper (Capsicum annuum L.);
   hypersensitive response; SAR8.2; tobacco mosaic virus
ID PATHOGENESIS-RELATED PROTEINS; SYSTEMIC ACQUIRED-RESISTANCE;
   SALICYLIC-ACID; DISEASE RESISTANCE; GENE; ETHYLENE; PLANTS; EXPRESSION;
   PURIFICATION; ACTIVATION
AB A cDNA library was constructed with mRNA extracted from TMV resistant hot pepper plants 24 and 48 h after inoculation by TMV. The library was screened differentially with radio-labeled cDNA synthesized with mRNA from the leaves of either TMV-inoculated or mock-inoculated hot pepper plants. CaSAR8.2 clone was one of the clones isolated by this differential screening. The predicted amino acid sequence of CaSAR8.2 has a homology of 52% similarity to that of tobacco SAR8.2 genes. Southern blot analysis showed that a multigene family of CaSAR8.2 was present in the hot pepper genome. Transcripts homologous to CaSAR8.2 accumulated abundantly in the leaves and the flowers, but little in other tissues. CaSAR8.2 gene expression was induced by avirulent pathotype TMV-P-0 inoculation but not by virulent TMV-P-1.2 inoculation. Effects of exogenously applied abiotic elicitors on CaSAR8.2 expression were also examined. Salicylic acid and ethephon treatments caused a rapid accumulation of CaSAR8.2 transcripts in pepper leaves and methyl jasmonate treatment slightly induced the expression of CaSAR8.2. A strain of Xanthomonas campestris pv. vesicatoria (Xcv) that contains an avirulence gene avrBs2, was infiltrated into the leaves of a pepper cultivar containing the Bs2 resistance gene. A marked induction of CaSAR8.2 gene expression was observed in Xcv-infiltrated leaves. These results suggest possible roles of CaSAR8.2 as pathogenesis-related protein against varieties of pathogens including virus and bacteria.
C1 Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
RP Paek, KH (reprint author), Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
EM khpaek95@mail.korea.ac.kr
CR ALEXANDER D, 1992, MOL PLANT MICROBE IN, V5, P513, DOI 10.1094/MPMI-5-513
   Antoniw JF, 1978, BIOCHEM SOC T, V6, P248, DOI 10.1042/bst0060248
   Ausubel F, 1995, SHORT PROTOCOLS MOL
   BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553
   BOUKEMA IW, 1980, EUPHYTICA, V29, P433, DOI 10.1007/BF00025143
   CARR JP, 1989, GENETIC ENG PRINCIPL, V11, P65
   Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355
   Datta SK, 1999, PATHOGENESIS RELATED, P1
   delaCruz A, 1997, MOL PLANT MICROBE IN, V10, P107, DOI 10.1094/MPMI.1997.10.1.107
   Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2
   ECKER JR, 1995, SCIENCE, V268, P667
   Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525
   Guo AL, 2000, PLANT J, V21, P409, DOI 10.1046/j.1365-313x.2000.00692.x
   HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773
   Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251
   Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245
   OHASHI Y, 1992, PLANT CELL PHYSIOL, V33, P819
   Park CJ, 2001, MOL CELLS, V11, P122
   PENACORTES H, 1995, GENE ACTIVATION RESP, P395
   Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103
   RYALS J, 1991, BIOCH MOL BIOL INDUC, P205
   Sambrook J., 1989, MOL CLONING
   Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235
   Tai TH, 1999, P NATL ACAD SCI USA, V96, P14153, DOI 10.1073/pnas.96.24.14153
   van Loon LC, 1999, PATHOGENESIS-RELATED PROTEINS IN PLANTS, P1
   Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213
   VANKAN JAL, 1995, PLANT MOL BIOL, V27, P1205, DOI 10.1007/BF00020894
   VANLOON LC, 1987, PLANT MOL BIOL, V9, P593, DOI 10.1007/BF00020536
   WARD ER, 1991, PLANT CELL, V3, P1085
   XU Y, 1994, PLANT CELL, V6, P1077, DOI 10.1105/tpc.6.8.1077
   Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454
NR 31
TC 14
Z9 15
U1 2
U2 7
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD OCT 31
PY 2001
VL 12
IS 2
BP 250
EP 256
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 488GC
UT WOS:000171927000017
PM 11710530
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Siegrist, T
   Steigerwald, M
   Svensson, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Siegrist, T
   Steigerwald, M
   Svensson, C
   Batlogg, B
TI RETRACTED: Superconductivity in single crystals of the fullerene C-70
   (Retracted article. See vol 422 pg 92 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID ELECTRONIC TRANSPORT-PROPERTIES; X-RAY-DIFFRACTION; KXC70 THIN-FILMS;
   DOPED C-60; FULLERIDES; C-36; C60; C70
AB The observation of superconductivity in doped C-60 has attracted much attention(1-3), as these materials represent an entirely new class of superconductors. A maximum transition temperature (Tc) of 40 K has been reported(4) for electron-doped C-60 crystals, while a Tc of 52 K has been seen 5 in hole-doped crystals; only the copper oxide superconductors have higher transition temperatures. The results for C-60 raise the intriguing questions of whether conventional electron-phonon coupling alone(1) can produce such high transition temperatures, and whether even higher transition temperatures might be observed in other fullerenes(6-8). There have, however, been no conrrmed reports of superconductivity in other fullerenes, though it has recently been observed in carbon nanotubes(9). Here we report the observation of superconductivity in single crystals of electric-field-doped C-70. The maximum transition temperature of about 7 K is achieved when the sample is doped to approximately four electrons per C-70 molecule, which corresponds to a half-filled conduction band. We anticipate superconductivity in smaller fullerenes at temperatures even higher than in C-60 if the right charge density can be induced.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Konstanz, Dept Phys, D-78457 Constance, Germany.
   Agere Syst, Murray Hill, NJ 07974 USA.
   Lund Univ, S-22100 Lund, Sweden.
   Swiss Fed Inst Technol, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Batlogg, B (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM batlogg@solid.phys.ethz.ch
RI Kloc, Christian/A-2255-2011
CR Blanc E, 1996, EUROPHYS LETT, V33, P205, DOI 10.1209/epl/i1996-00322-3
   BLANC E, 1994, EUROPHYS LETT, V27, P359, DOI 10.1209/0295-5075/27/5/005
   BUERGI HB, 1992, ANGEW CHEM INT EDIT, V31, P640
   Chen XH, 2000, J AM CHEM SOC, V122, P5729, DOI 10.1021/ja993881m
   Cohen ML, 1999, AIP CONF PROC, V483, P359, DOI 10.1063/1.59602
   Devos A, 1998, PHYS REV B, V58, P8236, DOI 10.1103/PhysRevB.58.8236
   GOLDEN MS, 1995, J PHYS-CONDENS MAT, V7, P8219, DOI 10.1088/0953-8984/7/43/004
   Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575
   HADDON RC, 1991, NATURE, V350, P320, DOI 10.1038/350320a0
   HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0
   KOBAYASHI M, 1993, PHYS REV B, V48, P16877, DOI 10.1103/PhysRevB.48.16877
   Ohno K, 1996, CHEM PHYS LETT, V255, P367, DOI 10.1016/0009-2614(96)00389-2
   PALSTRA TTM, 1995, SOLID STATE COMMUN, V93, P327
   Piskoti C, 1998, NATURE, V393, P771
   Ramirez A. P., 1994, Superconductivity Review, V1, P1
   SAITO S, 1991, PHYS REV B, V44, P11532, DOI 10.1103/PhysRevB.44.11532
   SCHLUTER M, 1992, PHYS REV LETT, V68, P526, DOI 10.1103/PhysRevLett.68.526
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   SCHON JH, 2000, NATURE, V406, P704
   TAKAHASHI T, 1992, PHYSICA C, V190, P205, DOI 10.1016/0921-4534(92)90596-5
   Tang ZK, 2001, SCIENCE, V292, P2462, DOI 10.1126/science.1060470
   WANG ZH, 1993, PHYS REV B, V48, P10657, DOI 10.1103/PhysRevB.48.10657
   WANG ZH, 1993, PHYS REV B, V48, P16881, DOI 10.1103/PhysRevB.48.16881
   WANG ZH, 1994, PHYS REV B, V49, P15890, DOI 10.1103/PhysRevB.49.15890
NR 26
TC 28
Z9 29
U1 3
U2 44
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 25
PY 2001
VL 413
IS 6858
BP 831
EP 833
DI 10.1038/35101577
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 485JA
UT WOS:000171750200042
PM 11677603
DA 2018-12-27
ER

PT J
AU Thakkar, H
   Chen, XF
   Tyan, F
   Gim, S
   Robinson, H
   Lee, C
   Pandey, SK
   Nwokorie, C
   Onwudiwe, N
   Srivastava, RK
AF Thakkar, H
   Chen, XF
   Tyan, F
   Gim, S
   Robinson, H
   Lee, C
   Pandey, SK
   Nwokorie, C
   Onwudiwe, N
   Srivastava, RK
TI RETRACTED: Pro-survival function of Akt/protein kinase B in prostate
   cancer cells - Relationship with trail resistance (Retracted Article.
   See vol 277, pg 30408, 2002)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Review; Retracted Publication
ID FORKHEAD TRANSCRIPTION FACTOR; INTEGRIN-LINKED KINASE; AKT
   PROTEIN-KINASE; GROWTH-FACTOR I; NF-KAPPA-B; INDUCED APOPTOSIS;
   TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOCHROME-C; SIGNALING
   PATHWAYS
AB Tumor necrosis factor superfamily member TRAIL/ Apo-2L has recently been shown to induce apoptosis in transformed and cancer cells. Some prostate cancer cells express constitutively active Akt/protein kinase B due to a complete loss of lipid phosphatase PTEN gene, a negative regulator of phosphatidylinositol 3-kinase pathway. Constitutively active Akt promotes cellular survival and resistance to chemotherapy and radiation. We have recently noticed that some human prostate cancer cells are resistant to TRAIL. We therefore examined the intracellular mechanisms of cellular resistance to TRAIL. The cell lines expressing the highest level of constitutively active Akt were more resistant to undergo apoptosis by TRAIL than those expressing the lowest level. Down-regulation of constitutively active Akt by phosphatidylinositol 3-kinase inhibitors, wortmannin and LY294002, reversed cellular resistance to TRAIL. Treatment of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to TRAIL. Transfecting dominant negative Akt decreased Akt activity and increased TRAIL-induced apoptosis in cells with high Akt activity. Conversely, transfecting constitutively active Akt into cells with low Akt activity increased Akt activity and attenuated TRAIL-induced apoptosis. Inhibition of TRAIL sensitivity occurs at the level of BID cleavage, as caspase-8 activity was not affected. Enforced expression of anti-apoptotic protein Bcl-2 or Bcl-X-L inhibited TRAIL-induced mitochondrial dysfunction and apoptosis. We therefore identify Akt as a constitutively active kinase that promotes survival of prostate cancer cells and demonstrate that modulation of Akt activity, by pharmacological or genetic approaches, alters the cellular responsiveness to TRAIL. Thus, TRAIL in combination with agents that down-regulate Akt activity can be used to treat prostate cancer.
C1 Univ Maryland, Greenebaum Canc Ctr, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201 USA.
   NIA, Labs Clin Invest, NIH, Baltimore, MD 21224 USA.
RP Srivastava, RK (reprint author), Univ Maryland, Greenebaum Canc Ctr, Dept Pharmaceut Sci, Sch Pharm, 20 N Pine St, Baltimore, MD 21201 USA.
EM rsrivast@rx.umaryland.edu
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9
   BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412
   Bodmer JL, 2000, NAT CELL BIOL, V2, P241
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cairns P, 1997, CANCER RES, V57, P4997
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745
   Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111
   CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267
   Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x
   Crowder RJ, 1998, J NEUROSCI, V18, P2933
   Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Davies MA, 1999, CANCER RES, V59, P2551
   DEL PL, 1997, SCIENCE, V278, P687
   Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000
   French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Green D R, 1998, Results Probl Cell Differ, V24, P45
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Griffith TS, 1998, J IMMUNOL, V161, P2833
   Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0
   Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343
   Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768
   Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8
   Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936
   Ittmann MM, 1998, ONCOL REP, V5, P1329
   JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171
   Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   Keane MM, 1999, CANCER RES, V59, P734
   Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701
   Kennedy SG, 1999, MOL CELL BIOL, V19, P5800
   Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2
   Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783
   Kim EJ, 2001, INT J ONCOL, V18, P187
   Kim KH, 2000, CLIN CANCER RES, V6, P335
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5
   Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639
   Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050
   Kops GJPL, 1999, NATURE, V398, P630
   Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711
   Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Lynch DK, 1999, ONCOGENE, V18, P8024
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   Mori S, 1999, J IMMUNOL, V162, P5616
   Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   Ozes ON, 1999, NATURE, V401, P82
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697
   Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081
   Petrylak DP, 1999, UROLOGY, V54, P30, DOI 10.1016/S0090-4295(99)00452-5
   Pisters LL, 1999, SEMIN ONCOL, V26, P202
   Rasheed BKA, 1997, CANCER RES, V57, P4187
   Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5
   Rieger J, 1999, ACTA NEUROPATHOL, V97, P1, DOI 10.1007/s004010050948
   Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393
   Romashkova JA, 1999, NATURE, V401, P86
   Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   Sekulic A, 2000, CANCER RES, V60, P3504
   Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241
   Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x
   Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3
   Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265
   Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253
   Srivastava RK, 1999, MOL CELL BIOL, V19, P5659
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282
   Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741
   Tashiro H, 1997, CANCER RES, V57, P3935
   Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271
   Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699
   Vlietstra RJ, 1998, CANCER RES, V58, P2720
   Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200
   Walczak H, 1999, NAT MED, V5, P157
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587
   Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147
NR 102
TC 98
Z9 100
U1 4
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2001
VL 276
IS 42
BP 38361
EP 38369
DI 10.1074/jbc.M103321200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 484CT
UT WOS:000171673200007
PM 11461904
OA Bronze
DA 2018-12-27
ER

PT J
AU Hoffmann, B
   Zuo, WQ
   Liu, AX
   Morris, NR
AF Hoffmann, B
   Zuo, WQ
   Liu, AX
   Morris, NR
TI RETRACTED: The LIS1-related protein NUDF of Aspergillus nidulans and its
   interaction partner NUDE bind directly to specific subunits of dynein
   and dynactin and to alpha- and gamma-tubulin (Retracted Article. See vol
   279, pg 820, 2004)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SPINDLE POLE BODY; CYTOPLASMIC DYNEIN; NUCLEAR MIGRATION; HEAVY-CHAIN;
   MICROTUBULE ORGANIZATION; DROSOPHILA HOMOLOG; FILAMENTOUS FUNGI; GENE;
   LIS1; MUTATION
AB The NUDF protein of Aspergillus nidulans, which is required for nuclear migration through the fungal mycelium, closely resembles the LIST protein required for migration of neurons to the cerebral cortex in humans. Genetic experiments suggested that NUDF influences nuclear migration by affecting cytoplasmic dynein. NUDF interacts with another protein, NUDE, which also affects nuclear migration in A. nidulans. Interactions among LIST, NUDE, dynein, and gamma -tubulin have been demonstrated in animal cells. In this paper we examine the interactions of the A. nidulans NUDE and NUDE proteins with components of dynein, dynactin, and with alpha- and gamma -tubulin. We show that NUDF binds directly to alpha- and gamma -tubulin and to the first P-loop of the cytoplasmic dynein heavy chain, whereas NUDE binds directly to a- and y-tubulin, to NUDK (actin-related protein 1), and to the NUDG dynein LC8 light chain. The data suggest a direct role for NUDF in regulation of the dynein heavy chain and an effect on other dynein/dynactin subunits via NUDE. The interactions between NUDE, NUDF, and y-tubulin suggest that this protein may also be involved in the regulation of dynein function. Additive interactions between NUDE and dynein and dynactin subunits suggest that NUDE acts as a scaffolding factor between components.
C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.
RP Morris, NR (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.
EM morrisnr@umdnj.edu
FU NIGMS NIH HHS [GM52309]
CR Ahn C, 2001, J BIOL CHEM, V276, P9903, DOI 10.1074/jbc.M010233200
   CHIU YH, 1995, GENETICS, V141, P453
   Cottingham FR, 1999, J CELL BIOL, V147, P335, DOI 10.1083/jcb.147.2.335
   COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0
   Cunniff J, 1997, MECH DEVELOP, V66, P55, DOI 10.1016/S0925-4773(97)00085-3
   DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838
   Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681
   Faulkner NE, 2000, NAT CELL BIOL, V2, P784
   Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8
   Fernandez-Abalos JM, 1998, MOL MICROBIOL, V27, P121, DOI 10.1046/j.1365-2958.1998.00664.x
   Fischer R, 1999, FEMS MICROBIOL REV, V23, P39, DOI 10.1111/j.1574-6976.1999.tb00391.x
   GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879
   Geiser JR, 1997, MOL BIOL CELL, V8, P1035
   Habermann A, 2001, J CELL SCI, V114, P229
   Han GS, 2001, CURR BIOL, V11, P719, DOI 10.1016/S0960-9822(01)00200-7
   Inoue S, 1998, J CELL SCI, V111, P1555
   James P, 1996, GENETICS, V144, P1425
   Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1
   Lei YD, 2000, DEV BIOL, V226, P57, DOI 10.1006/dbio.2000.9848
   Liu Z, 2000, NAT CELL BIOL, V2, P776
   Liu Z, 1999, DEVELOPMENT, V126, P4477
   Matsumoto N, 1999, HUM GENET, V104, P498, DOI 10.1007/s004390050994
   MAY GS, 1989, J CELL BIOL, V109, P2267, DOI 10.1083/jcb.109.5.2267
   Minke PF, 1999, MOL MICROBIOL, V32, P1065, DOI 10.1046/j.1365-2958.1999.01421.x
   Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0
   Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1
   OAKLEY BR, 1980, CELL, V19, P255, DOI 10.1016/0092-8674(80)90407-9
   OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9
   Paluh JL, 2000, MOL BIOL CELL, V11, P1225, DOI 10.1091/mbc.11.4.1225
   PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139
   PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3
   PUNT PJ, 1992, METHOD ENZYMOL, V216, P447
   REINER O, 1995, GENOMICS, V30, P251, DOI 10.1006/geno.1995.9880
   Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977
   Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X
   Savoian MS, 2000, NAT CELL BIOL, V2, P948
   Sharp DJ, 2000, NAT CELL BIOL, V2, P922
   Smith DS, 2000, NAT CELL BIOL, V2, P767
   Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6
   Swan A, 1999, NAT CELL BIOL, V1, P444
   Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8
   Tinsley JH, 1996, MOL BIOL CELL, V7, P731
   Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200
   Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107
   Vierula PJ, 1997, MOL MICROBIOL, V24, P331, DOI 10.1046/j.1365-2958.1997.3461704.x
   Vorobjev I A, 2000, Membr Cell Biol, V14, P219
   Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489
   Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7
   Xiang X, 1999, CURR OPIN MICROBIOL, V2, P636, DOI 10.1016/S1369-5274(99)00034-X
   Xiang X, 1999, CURR GENET, V35, P626, DOI 10.1007/s002940050461
   XIANG X, 1995, MOL BIOL CELL, V6, P297
   XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100
NR 52
TC 29
Z9 33
U1 2
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2001
VL 276
IS 42
BP 38877
EP 38884
DI 10.1074/jbc.M106610200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 484CT
UT WOS:000171673200073
PM 11509576
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Meng, H
   Bao, Z
AF Schon, JH
   Meng, H
   Bao, Z
TI RETRACTED: Self-assembled monolayer organic field-effect transistors
   (Retracted article. See vol 422 pg 92 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID ROOM-TEMPERATURE; CARBON NANOTUBE; TRANSPORT; ELECTRONICS; MOLECULE;
   DEVICES; SINGLE; JUNCTIONS
AB The use of individual molecules as functional electronic devices was proposed in 1974 (ref. 1). Since then, advances in the field of nanotechnology have led to the fabrication of various molecule devices and devices based on monolayer arrays of molecules(2-11). Single molecule devices are expected to have interesting electronic properties, but devices based on an array of molecules are easier to fabricate and could potentially be more reliable. However, most of the previous work on array-based devices focused on two-terminal structures: demonstrating, for example, negative differential resistance(8), rectifiers(9), and re-configurable switching(10,11). It has also been proposed that diode switches containing only a few two-terminal molecules could be used to implement simple molecular electronic computer logic circuits(12). However, three-terminal devices, that is, transistors, could offer several advantages for logic operations compared to two-terminal switches, the most important of which is 'gain'-the ability to modulate the conductance. Here, we demonstrate gain for electronic transport perpendicular to a single molecular layer (similar to 10-20 Angstrom) by using a third gate electrode. Our experiments with field-effect transistors based on self-assembled monolayers demonstrate conductance modulation of more than five orders of magnitude. In addition, inverter circuits have been prepared that show a gain as high as six. The fabrication of monolayer transistors and inverters might represent an important step towards molecular-scale electronics.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI 李, 府中/H-4357-2011; Hong, Meng/T-2778-2018
OI Hong, Meng/0000-0001-5877-359X
CR Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323
   AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1
   BURSHTEIN Z, 1978, J CHEM PHYS, V68, P983, DOI 10.1063/1.435837
   Chen J, 2000, APPL PHYS LETT, V77, P1224, DOI 10.1063/1.1289650
   Chen J, 1999, CHEM PHYS LETT, V313, P741, DOI 10.1016/S0009-2614(99)01060-X
   Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172
   Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391
   Di Ventra M, 2000, APPL PHYS LETT, V76, P3448, DOI 10.1063/1.126673
   Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   Dunbar TD, 2000, J PHYS CHEM B, V104, P4880, DOI 10.1021/jp993724+
   Ellenbogen JC, 2000, P IEEE, V88, P386, DOI 10.1109/5.838115
   Emberly EG, 2000, PHYS REV B, V62, P10451, DOI 10.1103/PhysRevB.62.10451
   Forrest S, 2000, IEEE SPECTRUM, V37, P29, DOI 10.1109/6.861775
   Goldhaber-Gordon D, 1997, P IEEE, V85, P521, DOI 10.1109/5.573739
   HERGENROTHER JM, 2000, INT EL DEV M 2000, P65
   Hong S, 2000, SUPERLATTICE MICROST, V28, P289, DOI 10.1006/spmi.2000.0916
   Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U
   Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6
   Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477
   Metzger RM, 1999, ACCOUNTS CHEM RES, V32, P950, DOI 10.1021/ar9900663
   NATORI K, 1994, J APPL PHYS, V76, P4879, DOI 10.1063/1.357263
   RODGERS TJ, 1974, J SOLID STATE CIRCUI, V9, P239
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   SZE SM, 1985, SEMICONDUCTOR PHYSIC, P431
   Tans SJ, 1998, NATURE, V393, P49
   Tour JM, 1996, CHEM REV, V96, P537, DOI 10.1021/cr9500287
   Tour JM, 2000, ACCOUNTS CHEM RES, V33, P791, DOI 10.1021/er0000612
NR 30
TC 141
Z9 145
U1 7
U2 86
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 18
PY 2001
VL 413
IS 6857
BP 713
EP 716
DI 10.1038/35099520
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 482ZK
UT WOS:000171608000038
PM 11607026
DA 2018-12-27
ER

PT J
AU Makarova, TL
   Sundqvist, B
   Hohne, R
   Esquinazi, P
   Kopelevich, Y
   Scharff, P
   Davydov, VA
   Kashevarova, LS
   Rakhmanina, AV
AF Makarova, TL
   Sundqvist, B
   Hohne, R
   Esquinazi, P
   Kopelevich, Y
   Scharff, P
   Davydov, VA
   Kashevarova, LS
   Rakhmanina, AV
TI RETRACTED: Magnetic carbon (Retracted Article. See vol 440, pg 707,
   2006)
SO NATURE
LA English
DT Article; Retracted Publication
ID DOPED C-60; SUSCEPTIBILITY; GRAPHITE; PHASE; SUPERCONDUCTIVITY;
   FERROMAGNETISM; PRESSURE; POLYMER; NMR; C60
AB The discovery of nanostructured forms of molecular carbon has led to renewed interest in the varied properties of this element. Both graphite and C-60 can be electron-doped by alkali metals(1) to become superconducting; transition temperatures of up to 52 K have been attained by field-induced hole-doping of C-60 (ref. 2). Recent experiments(3,4) and theoretical studies(5,6) have suggested that electronic instabilities in pure graphite may give rise to superconducting and ferromagnetic properties, even at room temperature. Here we report the serendipitous discovery of strong magnetic signals in rhombohedral C-60. Our intention was to search for superconductivity in polymerized C-60; however, it appears that our high-pressure, high-temperature polymerization process results in a magnetically ordered state. The material exhibits features typical of ferromagnets: saturation magnetization, large hysteresis and attachment to a magnet at room temperature. The temperature dependences of the saturation and remanent magnetization indicate a Curie temperature near 500 K.
C1 AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia.
   Umea Univ, Dept Expt Phys, S-90187 Umea, Sweden.
   Tech Univ Ilmenau, Dept Chem, Inst Phys, D-98693 Ilmenau, Germany.
   Univ Leipzig, Dept Superconduct & Magnetism, D-04103 Leipzig, Germany.
   Univ Estadual Campinas, Inst Fis, BR-13083970 Campinas, SP, Brazil.
   Russian Acad Sci, Inst High Pressure Phys, Troitsk 142092, Russia.
RP Makarova, TL (reprint author), AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia.
EM tatiana.makarova@physics.umu.se
RI Davydov, Valery/P-5673-2015
OI Davydov, Valery/0000-0002-8702-0340; Esquinazi, Pablo
   David/0000-0003-0649-1472
CR ALLEMAND PM, 1991, SCIENCE, V253, P301, DOI 10.1126/science.253.5017.301
   Davydov VA, 2000, PHYS REV B, V61, P11936, DOI 10.1103/PhysRevB.61.11936
   DU G, 1993, J APPL PHYS, V73, P6566, DOI 10.1063/1.352565
   Gonzalez J, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.134421
   HADDON RC, 1991, NATURE, V350, P46, DOI 10.1038/350046a0
   Harigaya K, 2001, J PHYS-CONDENS MAT, V13, P1295, DOI 10.1088/0953-8984/13/6/309
   HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0
   IWASA Y, 1994, SCIENCE, V264, P1570, DOI 10.1126/science.264.5165.1570
   KAHASHI M, 1991, PHYS REV LETT, V67, P746
   Kempa H, 2000, SOLID STATE COMMUN, V115, P539, DOI 10.1016/S0038-1098(00)00233-7
   Kopelevich Y, 2000, J LOW TEMP PHYS, V119, P691, DOI 10.1023/A:1004637814008
   Lobach AS, 1998, FULLERENE SCI TECHN, V6, P375, DOI 10.1080/10641229809350209
   LUO WL, 1994, PHYS REV LETT, V73, P186, DOI 10.1103/PhysRevLett.73.186
   Makarova TL, 2001, SYNTHETIC MET, V121, P1099, DOI 10.1016/S0379-6779(00)00804-3
   Makarova TL, 2001, CARBON, V39, P2203, DOI 10.1016/S0008-6223(01)00036-7
   Makarova TL, 2000, MOL MATER, V13, P151
   MAKAROVA TL, 1999, RECENT ADV CHEM PHYS, V7, P628
   Miller JS, 2000, MRS BULL, V25, P21, DOI 10.1557/mrs2000.221
   Mrzel A, 1998, CHEM PHYS LETT, V298, P329, DOI 10.1016/S0009-2614(98)01184-1
   Narymbetov B, 2000, NATURE, V407, P883, DOI 10.1038/35038032
   NUNEZREGUEIRO M, 1995, PHYS REV LETT, V74, P278, DOI 10.1103/PhysRevLett.74.278
   OVCHINNIKOV AA, 1991, J MOL STRUC-THEOCHEM, V83, P133
   Panich AM, 2001, J PHYS CHEM SOLIDS, V62, P959, DOI 10.1016/S0022-3697(00)00264-X
   PEKKER S, 1994, SOLID STATE COMMUN, V90, P349, DOI 10.1016/0038-1098(94)90796-X
   Saito T, 2000, PHYS REV B, V61, P16091, DOI 10.1103/PhysRevB.61.16091
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Shul'Ga YM, 1998, MOL CRYST LIQ CRYS C, V10, P201
   Sundqvist B, 1999, ADV PHYS, V48, P1, DOI 10.1080/000187399243464
   WANG XK, 1994, J MATER RES, V9, P1578, DOI 10.1557/JMR.1994.1578
   XU CH, 1995, PHYS REV LETT, V74, P274, DOI 10.1103/PhysRevLett.74.274
NR 30
TC 469
Z9 481
U1 9
U2 155
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 18
PY 2001
VL 413
IS 6857
BP 716
EP 718
DI 10.1038/35099527
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 482ZK
UT WOS:000171608000039
PM 11607027
DA 2018-12-27
ER

PT J
AU Schon, JH
AF Schon, JH
TI RETRACTED: Plastic Josephson junctions (Retracted Article. See vol 82,
   pg 1313, 2003)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID CONJUGATED POLYMERS; INTEGRATED-CIRCUITS; HIGH-MOBILITY; DIODES
AB The electrical properties of polythiophene thin films can be varied from insulating to superconducting using the field effect. A spatial modulation of the properties can be achieved by patterning of the gate electrode leading to the preparation of Josephson junctions based on solution cast polymer films. These junctions can be used to build a polymer superconducting quantum interference device or to study the superconducting properties of the material itself. The observations are in accordance with the idea of electron-phonon-mediated superconductivity in this organic polymer. (C) 2001 American Institute of Physics.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
CR Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834
   BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0
   CHIANG CK, 1977, PHYS REV LETT, V39, P1098, DOI 10.1103/PhysRevLett.39.1098
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   Feast WJ, 1996, POLYMER, V37, P5017, DOI 10.1016/0032-3861(96)00439-9
   Forrest S, 2000, IEEE SPECTRUM, V37, P29, DOI 10.1109/6.861775
   Friend R, 1999, PHYS WORLD, V12, P35
   Gelinck GH, 2000, APPL PHYS LETT, V77, P1487, DOI 10.1063/1.1290728
   Groenendaal BL, 2000, ADV MATER, V12, P481, DOI 10.1002/(SICI)1521-4095(200004)12:7<481::AID-ADMA481>3.0.CO;2-C
   Jerome D, 2001, NATURE, V410, P162, DOI 10.1038/35065781
   Lee M, 2001, PHYS REV LETT, V86, P862, DOI 10.1103/PhysRevLett.86.862
   Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613
   Mooij JE, 1999, MICROELECTRON ENG, V47, P3, DOI 10.1016/S0167-9317(99)00131-8
   Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036
   ROTH S, 1995, ONE DIMENSIONAL META
   Sauvajol JL, 1997, SYNTHETIC MET, V84, P569, DOI 10.1016/S0379-6779(97)80862-4
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2001, SCIENCE, V292, P252, DOI 10.1126/science.1058812
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   SCHON JH, 2000, NATURE, V406, P704
   Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359
   Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123
   Wolf E. L., 1985, PRINCIPLES ELECT TUN
NR 24
TC 4
Z9 4
U1 2
U2 7
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD OCT 1
PY 2001
VL 79
IS 14
BP 2208
EP 2210
DI 10.1063/1.1408277
PG 3
WC Physics, Applied
SC Physics
GA 474YM
UT WOS:000171134900028
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Ballistic hole transport in pentacene with a mean free path
   exceeding 30 mu m (Retracted article. See Vol 90, pg 3419, 2001)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTOR; ELECTRON-TRANSPORT
AB Low temperature ballistic hole transport in high-quality pentacene single crystals is studied using macroscopic gated four-terminal van-der-Pauw geometry and two-terminal conventional field-effect transistor structures. Well-pronounced magnetic focusing peaks are observed in the magnetoresistance of van-der-Pauw samples indicating ballistic transport up to at least 45 mum. At low temperature the field-effect transistors show saturation currents independent of the channel length and proportional to the channel width. The transistor characteristics are consistently analyzed assuming ballistic transport of holes throughout the whole length of the channel. (C) 2001 American Institute of Physics.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Swiss Fed Inst Technol, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/RevModPhys.54.437
   Facer GR, 1999, PHYS REV B, V59, P4622, DOI 10.1103/PhysRevB.59.4622
   HIRAYAMA Y, 1991, APPL PHYS LETT, V58, P2672, DOI 10.1063/1.104803
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   NATORI K, 1994, J APPL PHYS, V76, P4879, DOI 10.1063/1.357263
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   SPECTOR J, 1992, SURF SCI, V263, P240, DOI 10.1016/0039-6028(92)90344-6
   SZE SM, 1981, PHYSICS SEMICONDUCTO
   TSUKAGOSHI K, 1993, APPL PHYS LETT, V62, P1609, DOI 10.1063/1.108601
   VANHOUTEN H, 1989, PHYS REV B, V39, P8556, DOI 10.1103/PhysRevB.39.8556
NR 10
TC 2
Z9 2
U1 3
U2 10
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-8979
J9 J APPL PHYS
JI J. Appl. Phys.
PD OCT 1
PY 2001
VL 90
IS 7
BP 3419
EP 3421
DI 10.1063/1.1400097
PG 3
WC Physics, Applied
SC Physics
GA 474YY
UT WOS:000171135900045
DA 2018-12-27
ER

PT J
AU Pignotti, M
   Steinberg, M
AF Pignotti, M
   Steinberg, M
TI RETRACTED: Heart rate variability as an outcome measure for Thought
   Field Therapy in clinical practice (Retracted Article. See vol 61, pg
   361, 2005)
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE Thought Field Therapy; heart rate variability; psychotherapy outcome
   measures; phobias; anxiety; depression; eating disorders; autonomic
   nervous system measures
ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; FAILURE SECONDARY; MAJOR
   DEPRESSION; ANXIETY; SCOPOLAMINE; STABILITY; MORTALITY; ASSOCIATION;
   BALANCE
AB The need for empirical, objective, clear, and practical outcome measures for therapy has long been recognized by clinicians and researchers. Pragmatic tools for objective determination of the efficacy of therapy have been scarce in clinical practice settings. Heart rate variability (HRV) is increasing in popularity for use in clinical settings as a measure of treatment success. Since HRV is stable and placebo-free, it has the potential to meet this need. Thirty-nine cases are presented from the clinical practices of the authors and three other clinicians where HRV was used as an outcome measure for Thought Field Therapy (TFT). The cases included TFT treatments which addressed a wide variety of problems including phobias, anxiety, trauma, depression, fatigue, attention deficit hyperactivity disorder, learning difficulties, compulsions, obsessions, eating disorders, anger, and physical pain. A lowering of subjective units of distress was in most cases related to an improvement in HRV. (C) 2001 John Wiley & Sons, Inc.
RP Pignotti, M (reprint author), 1186 Broadway,706, New York, NY 10001 USA.
EM pignotti@worldnet.att.net
CR ADAMOPOULOS S, 1992, AM J CARDIOL, V70, P1576, DOI 10.1016/0002-9149(92)90460-G
   ALLAHAN R, 1997, ELECT J TRAUMATOLOGY, P3
   BEUTLER LE, 2000, PREVENTION TREATMENT, V3
   BIGGER JT, 1992, AM J CARDIOL, V69, P718, DOI 10.1016/0002-9149(92)90493-I
   *BIOC TECH, 1998, HEART SCANN HEAR RAT
   Brody S, 2000, BIOL PSYCHOL, V52, P251, DOI 10.1016/S0301-0511(99)00048-4
   Callahan R., 1985, 5 MINUTE PHOBIA CURE
   CALLAHAN R, 2001, TAP HEALER
   Callahan RJ, 2001, J CLIN PSYCHOL, V57, P1153, DOI 10.1002/jclp.1082
   Callahan RJ, 2000, STOP NIGHTMARES TRAU
   CALLHAN R, 1997, THOUGHT FIELD, V3, P1
   CARNEY RM, 1995, AM J CARDIOL, V76, P562, DOI 10.1016/S0002-9149(99)80155-6
   Carney RM, 2000, PSYCHOSOM MED, V62, P84, DOI 10.1097/00006842-200001000-00013
   Casadei B, 1996, HEART, V75, P274, DOI 10.1136/hrt.75.3.274
   Cohen H, 1999, PSYCHOTHER PSYCHOSOM, V68, P59, DOI 10.1159/000012314
   Cohen H, 1998, BIOL PSYCHIAT, V44, P1054, DOI 10.1016/S0006-3223(97)00475-7
   COWAN MJ, 1991, J ELECTROCARDIOL, V23, P85, DOI 10.1016/0022-0736(90)90081-C
   Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871
   de Bruyne MC, 1999, AM J EPIDEMIOL, V150, P1282
   DEFERRARI GM, 1993, J AM COLL CARDIOL, V22, P1327, DOI 10.1016/0735-1097(93)90538-C
   Dekker JM, 2000, CIRCULATION, V102, P1239, DOI 10.1161/01.CIR.102.11.1239
   Dishman RK, 2000, INT J PSYCHOPHYSIOL, V37, P121, DOI 10.1016/S0167-8760(00)00085-4
   DOUGHERTY CM, 1992, AM J CARDIOL, V70, P441, DOI 10.1016/0002-9149(92)91187-9
   Friedman BH, 1998, BIOL PSYCHOL, V49, P303
   Friedman BH, 1998, J PSYCHOSOM RES, V44, P133, DOI 10.1016/S0022-3999(97)00202-X
   GRAHAM I, 1999, REPORT INT TFT C
   HIRSCH M, 1995, HEART RATE VARIABILI, P517
   Horsten M, 1999, PSYCHOSOM MED, V61, P49, DOI 10.1097/00006842-199901000-00009
   Huikuri HV, 1999, J AM COLL CARDIOL, V34, P1878, DOI 10.1016/S0735-1097(99)00468-4
   HULL SS, 1994, CIRCULATION, V89, P548, DOI 10.1161/01.CIR.89.2.548
   KAWACHI I, 1995, AM J CARDIOL, V75, P882, DOI 10.1016/S0002-9149(99)80680-8
   KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8
   KLEIGER RE, 1991, AM J CARDIOL, V68, P626, DOI 10.1016/0002-9149(91)90355-O
   Krittayaphong R, 1997, PSYCHOSOM MED, V59, P231, DOI 10.1097/00006842-199705000-00004
   MAGID NM, 1985, CIRCULATION, V72, P241
   Malik M, 1995, HEART RATE VARIABILI
   MIDDLETON HC, 1990, J AFFECT DISORDERS, V19, P229, DOI 10.1016/0165-0327(90)90099-T
   SINGER DH, 1995, HEART RATE VARIABILI, P429
   Stein Phyllis K., 1996, Journal of the American College of Cardiology, V27, p146A
   STEIN PK, 1995, AM HEART J, V129, P975, DOI 10.1016/0002-8703(95)90119-1
   *TAK FORC EUR SOC, 1996, CIRCULATION, V93, P1043
   Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850
   VANHOOGENHUYZE D, 1991, AM J CARDIOL, V68, P1668, DOI 10.1016/0002-9149(91)90327-H
   Venkatesh G, 1996, HEART, V76, P137, DOI 10.1136/hrt.76.2.137
   VYBIRAL T, 1993, J AM COLL CARDIOL, V22, P1320, DOI 10.1016/0735-1097(93)90537-B
   Watkins LL, 1999, PSYCHOSOM MED, V61, P334, DOI 10.1097/00006842-199905000-00012
   Wolpe J, 1969, PRACTICE BEHAV THERA
   YERAGANI VK, 1991, PSYCHIAT RES, V37, P35, DOI 10.1016/0165-1781(91)90104-W
NR 48
TC 17
Z9 18
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
EI 1097-4679
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD OCT
PY 2001
VL 57
IS 10
BP 1193
EP 1206
DI 10.1002/jclp.1086
PG 14
WC Psychology, Clinical
SC Psychology
GA 474JE
UT WOS:000171102700006
PM 11526606
DA 2018-12-27
ER

PT J
AU Bilgen, H
   Ozek, E
   Cebeci, D
   Ors, R
AF Bilgen, H
   Ozek, E
   Cebeci, D
   Ors, R
TI RETRACTED: Comparison of sucrose, expressed breast milk, and
   breast-feeding on the neonatal response to heel prick (Retracted
   Article. See vol 4, pg 415, 2003)
SO JOURNAL OF PAIN
LA English
DT Article; Retracted Publication
DE newborn; pain
ID RELIEVING PROCEDURAL PAIN; HUMAN NEWBORNS; 10-DAY-OLD RATS; INDUCED
   ANALGESIA; HYPOALGESIA; MEDIATION; EFFICACY; INFANTS; TRIAL
AB Newborns endure many heel pricks and other uncomfortable procedures during their first hospital stay. The aim of this study was to investigate the effectiveness of breast-feeding in reducing pain in newborns undergoing heel prick tests. One hundred thirty healthy term infants requiring a heel prick blood sampling for the Guthrie test were studied. Infants were randomly allocated to 1 of the following treatment groups: group 1, 25% sucrose (n = 35); group 2, breast milk (n = 33); group 3, sterile water (n = 34); and group 4, breast-feeding (n = 28). The median values of crying and recovery time and percent change in heart rate at 1, 2, and 3 minutes were recorded. A behavioral pain scale was applied according to the infant body coding system. The median crying time was 36, 62, 52, and 51 seconds in groups 1, 2, 3, and 4, respectively (P = .002). Similarly, there was a significant overall difference among groups for the duration of recovery time (P = .006) and the percent change in heart rate at 1 (P = .03), 2 (P = .01), and 3 (P = .009) minutes favoring the sucrose group. But when we compared the groups, the significance remained for the sucrose versus breast milk (P = .007) and water (P = .001) groups for the recovery time and sucrose versus all other groups for the percent change in heart rate at 3 minutes. The infant body coding system showed that babies in the sucrose group had significantly lower scores followed by the breast-fed and breast milk groups (P = .0001). Our study revealed that 25% sucrose is superior to breast-feeding in pain relief, which is reflected mainly in crying time and behavioral variables. The behavioral effects of breast-feeding did not provide any additional benefit. (C) 2001 by the American Pain Society.
C1 Marmara Univ, Sch Med, Dept Pediat, Div Neonatol, Istanbul, Turkey.
   Marmara Univ, Sch Med, Dept Publ Hlth, Istanbul, Turkey.
RP Ozek, E (reprint author), PK 195, TR-81020 Istanbul, Turkey.
EM mozek@turk.net
RI Ors, Rahmi/A-4735-2016
OI Ors, Rahmi/0000-0002-9089-1067
CR ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105
   Bell S G, 1994, Neonatal Netw, V13, P9
   Blass EM, 1996, PEDIATR RES, V39, P199, DOI 10.1203/00006450-199602000-00002
   BLASS EM, 1988, PHARMACOL BIOCHEM BE, V29, P9, DOI 10.1016/0091-3057(88)90266-3
   BLASS EM, 1993, BEHAV NEUROSCI, V107, P488, DOI 10.1037/0735-7044.107.3.488
   Blass EM, 1999, PAIN, V83, P611, DOI 10.1016/S0304-3959(99)00166-9
   BLASS EM, 1991, PEDIATRICS, V87, P215
   Blass EM, 1997, J DEV BEHAV PEDIATR, V18, P162, DOI 10.1097/00004703-199706000-00004
   Blass EM, 1997, PEDIATRICS, V99, P825, DOI 10.1542/peds.99.6.825
   BLASS EM, 1994, ACTA PAEDIATR, V83, P71, DOI 10.1111/j.1651-2227.1994.tb13268.x
   BLASS EM, 1994, MONOGRAPHS SOC RES C, V59, P1
   BUCHER HU, 1996, CURRENT TOPICS NEONA, V1, P85
   CRAIG KD, 1993, PAIN, V52, P287, DOI 10.1016/0304-3959(93)90162-I
   DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P138
   FITZGERALD M, 1991, BRIT MED BULL, V47, P667, DOI 10.1093/oxfordjournals.bmb.a072499
   Franck LS, 1998, SEMIN PERINATOL, V22, P434, DOI 10.1016/S0146-0005(98)80059-1
   Gray L, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e14
   Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7
   GUNNAR MR, 1988, DEV PSYCHOBIOL, V21, P297, DOI 10.1002/dev.420210402
   HAOUARI N, 1995, BRIT MED J, V310, P1498, DOI 10.1136/bmj.310.6993.1498
   Ors R, 1999, EUR J PEDIATR, V158, P63, DOI 10.1007/s004310051011
   OWENS ME, 1984, PAIN, V20, P213, DOI 10.1016/0304-3959(84)90012-5
   PRECHTL HFR, 1974, BRAIN RES, V76, P185, DOI 10.1016/0006-8993(74)90454-5
   Ramenghi LA, 1996, ARCH DIS CHILD, V74, pF129, DOI 10.1136/fn.74.2.F129
   Skogsdal Y, 1997, ACTA PAEDIATR, V86, P217, DOI 10.1111/j.1651-2227.1997.tb08872.x
   Stevens B, 1999, NURS RES, V48, P35, DOI 10.1097/00006199-199901000-00006
   Stevens B, 1997, ACTA PAEDIATR, V86, P837
   WELLER A, 1988, AM J PHYSIOL, V255, pR901
   Wood CM, 1998, ARCH DIS CHILD, V79, pF34, DOI 10.1136/fn.79.1.F34
NR 29
TC 40
Z9 45
U1 5
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD OCT
PY 2001
VL 2
IS 5
BP 301
EP 305
DI 10.1054/jpai.2001.23140
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 483RU
UT WOS:000171650300007
PM 14622809
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Ried, T
   Bryne, M
   Kildal, W
   Danielsen, H
   Reith, A
AF Sudbo, J
   Ried, T
   Bryne, M
   Kildal, W
   Danielsen, H
   Reith, A
TI RETRACTED: Abnormal DNA content predicts non-dysplastic ol the
   occurrence of carcinomas in al white patches (Retracted article. See vol
   43, pg 418, 2007)
SO ORAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE DNA ploidy; image cytometry; histological diagnosis; prognostication;
   oral white patches
ID SQUAMOUS-CELL CARCINOMA; ORAL-CAVITY; MALIGNANT-TRANSFORMATION; GENETIC
   PROGRESSION; LICHEN-PLANUS; NECK-CANCER; LESIONS; HEAD; LEUKOPLAKIA;
   INSTABILITY
AB The majority of oral squamous cell carcinomas (OSCCs) are preceeded by visible changes in the oral mucosa, most often white patches. Although the histological finding of dysplasia in oral white patches signals increased risk of developing OSCC, this may also occur in non-dysplastic lesions. However, no reliable markers exist to predict the occurrence of OSCC in these patients. From a total of 263 patients diagnosed with oral white patches, biopsies from 45 patients were selected on the criteria that the patients had lesions histologically proven to be non-dysplastic. The lesions were analyzed with respect to their DNA content. The clinical outcome of the patients was known from the Cancer Registry of Norway, and these data were compared to the DNA content of their lesions. Among the 45 patients, five cases (11%) later developed an OSCC. Four of the cases that subsequently developed an OSCC were among the five aneuploid (abnormal) cases (P = 0.001). One aneuploid lesion did not develop a carcinoma during a follow-up time of 120 months. The fifth case that subsequently developed an OSCC was diploid (normal), and developed into an OSCC after an observation time of 73 months (P = 0.001). In conclusion, aberrant DNA content reliably predicts the occurrence of OSCC in patients that otherwise would be regarded as at very low risk. Normal DNA content indicates low risk. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Oslo, Dept Pathol, Div Digital Pathol, Norwegian Radium Hosp, N-0310 Oslo, Norway.
   NCI, NIH, Bethesda, MD 20892 USA.
   Univ Oslo, Dept Oral Biol, Oslo, Norway.
RP Sudbo, J (reprint author), Univ Oslo, Dept Pathol, Div Digital Pathol, Norwegian Radium Hosp, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
CR ABDELSALAM M, 1988, CANCER, V62, P1981, DOI 10.1002/1097-0142(19881101)62:9<1981::AID-CNCR2820620918>3.0.CO;2-O
   BOUQUOT JE, 1986, ORAL SURG ORAL MED O, V61, P373, DOI 10.1016/0030-4220(86)90422-6
   Brunin F, 1999, HEAD NECK-J SCI SPEC, V21, P751, DOI 10.1002/(SICI)1097-0347(199912)21:8<751::AID-HED11>3.3.CO;2-W
   Califano J, 1996, CANCER RES, V56, P2488
   Califano J, 2000, CLIN CANCER RES, V6, P347
   CAWSON RA, 1975, BRIT MED BULL, V31, P164, DOI 10.1093/oxfordjournals.bmb.a071274
   Chiesa F, 2000, SURGERY, V128, P16, DOI 10.1067/msy.2000.106809
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   HEDLEY DW, 1994, METHOD CELL BIOL, V41, P231
   Hogmo A, 1996, HEAD NECK-J SCI SPEC, V18, P433, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<433::AID-HED6>3.0.CO;2-6
   Khuri FR, 2000, SEMIN ONCOL, V27, P25
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LICCIARDELLO JTW, 1989, INT J RADIAT ONCOL, V17, P467, DOI 10.1016/0360-3016(89)90096-5
   LUMERMAN H, 1995, ORAL SURG ORAL MED O, V79, P321, DOI 10.1016/S1079-2104(05)80226-4
   MASHBERG A, 1977, NEW ENGL J MED, V297, P109, DOI 10.1056/NEJM197707142970212
   MUNCKWIKLAND E, 1992, ORAL ONCOL, V28B, P135, DOI 10.1016/0964-1955(92)90042-Y
   Pindborg JJ, 1997, HISTOLOGICAL TYPING
   RICHTSMEIER WJ, 1993, NEW ENGL J MED, V328, P58, DOI 10.1056/NEJM199301073280111
   Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8
   Saito T, 1999, ORAL DIS, V5, P15
   Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   SHAFER WG, 1975, CANCER-AM CANCER SOC, V36, P1021, DOI 10.1002/1097-0142(197509)36:3<1021::AID-CNCR2820360327>3.0.CO;2-W
   SHEDD DP, 1971, J AMER MED ASSOC, V215, P955, DOI 10.1001/jama.215.6.955
   SHEMEN LJ, 1984, JAMA-J AM MED ASSOC, V252, P1857, DOI 10.1001/jama.252.14.1857
   SILVERMAN S, 1991, ORAL SURG ORAL MED O, V72, P665, DOI 10.1016/0030-4220(91)90007-Y
   Steinbeck RG, 1997, ORAL ONCOL, V33, P110, DOI 10.1016/S0964-1955(96)00068-1
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   TANKE HJ, 1980, J HISTOCHEM CYTOCHEM, V28, P1007, DOI 10.1177/28.9.6157711
   vanderWaal I, 1997, ORAL ONCOL, V33, P291, DOI 10.1016/S1368-8375(97)00002-X
   VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306
   WALDRON CA, 1975, CANCER-AM CANCER SOC, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
   Warnakulasuriya S, 2000, J PATHOL, V190, P407, DOI 10.1002/(SICI)1096-9896(200003)190:4<407::AID-PATH546>3.0.CO;2-D
   Yamasaki H, 2000, TOXICOL LETT, V112, P251, DOI 10.1016/S0378-4274(99)00278-7
NR 37
TC 45
Z9 46
U1 3
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD OCT
PY 2001
VL 37
IS 7
BP 558
EP 565
DI 10.1016/S1368-8375(00)00126-3
PG 8
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 471MM
UT WOS:000170933200004
PM 11564576
DA 2018-12-27
ER

PT J
AU Kim, A
   Jeong, IC
   Shim, YB
   Kang, SW
   Park, JS
AF Kim, A
   Jeong, IC
   Shim, YB
   Kang, SW
   Park, JS
TI RETRACTED: Modulation of the specific interaction of cardiolipin with
   cytochrome c by zwitterionic phospholipids in binary mixed bilayers: A
   H-2- and P-31-NMR study (Retracted Article. See vol 38, pg 766, 2005)
SO JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE bilayer; cardiolipin (CL); cytochrome c; H-2-NMR spectra; P-31-NMR
   spectra; zwitterionic phospholipid
ID NMR MEASUREMENTS; MODEL MEMBRANES; METAL-IONS; PHOSPHATIDYLCHOLINE;
   DEUTERIUM; OXIDASE; LIPIDS; PHOSPHATIDYLETHANOLAMINE; MITOCHONDRIA;
   HEADGROUP
AB The interaction of cytochrome c with binary phospholipid mixtures was investigated by solid-state H-2- and P-31-NMR. To examine the effect of the interaction on the glycerol backbones, the glycerol moieties of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), and cardiolipin (CL) were specifically deuterated. On the binding of cytochrome c to the binary mixed bilayers, no changes in the quadrupole splittings of each of the components were observed for the PC/PG, PE/CL and PE/PG liposomes. In contrast, the splittings of CL decreased on binding of protein to the PC/CL liposomes, although those of PC did not change at all. This showed that cytochrome c specifically interacts with CL in PC/CL bilayers, and penetrates into the lipid bilayer to some extent so as to perturb the dynamic structure of the glycerol backbone. This is distinctly different from the mode of interaction of cytochrome c with other binary mixed bilayers. In the P-31-NMR spectra, line broadening and a decrease of the chemical shift anisotropy were observed on the binding of cytochrome c for all binary mixed bilayers that were examined. These changes were more significant for the PC/CL bilayers. Furthermore, the line broadening is more significant for PC than for CL in PC/CL bilayers. Therefore, it can be concluded that with the polar head groups, not only CL but also PC are involved in the interaction with cytochrome e.
C1 Pusan Natl Univ, Dept Chem, Pusan 609735, South Korea.
   Pusan Natl Univ, Chem Inst Funct Mat, Pusan 609735, South Korea.
RP Park, JS (reprint author), Pusan Natl Univ, Dept Chem, Pusan 609735, South Korea.
EM jaspark@hyowon.cc.pusan.ac.kr
OI Shim, Yoon-Bo/0000-0002-6295-1480
CR AKUTSU H, 1981, BIOCHEMISTRY-US, V20, P7366, DOI 10.1021/bi00529a007
   AKUTSU H, 1986, BIOCHIM BIOPHYS ACTA, V854, P213, DOI 10.1016/0005-2736(86)90113-6
   AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9
   BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5
   DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2
   DEMEL RA, 1989, J BIOL CHEM, V264, P3988
   DEVAUX PF, 1986, BIOCHEMISTRY-US, V25, P3804, DOI 10.1021/bi00361a011
   GHOSH R, 1988, BIOCHEMISTRY-US, V27, P7750, DOI 10.1021/bi00420a025
   KREBS JJR, 1979, J BIOL CHEM, V254, P5308
   MACDONALD PM, 1991, BIOCHEMISTRY-US, V30, P3558, DOI 10.1021/bi00228a029
   MARASSI FM, 1991, BIOCHEMISTRY-US, V30, P10558, DOI 10.1021/bi00107a027
   PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2459, DOI 10.1021/bi00175a014
   PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2451, DOI 10.1021/bi00175a013
   PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P4896, DOI 10.1021/bi00182a018
   ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003
   SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010
   SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011
   SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037
   STOCKTON GW, 1974, BIOCHEM BIOPH RES CO, V60, P844, DOI 10.1016/0006-291X(74)90318-0
   VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456
   WALTHAM MC, 1986, BIOCHIM BIOPHYS ACTA, V862, P451, DOI 10.1016/0005-2736(86)90250-6
   YOSHIKAWA W, 1988, BIOCHIM BIOPHYS ACTA, V944, P321, DOI 10.1016/0005-2736(88)90501-9
NR 22
TC 4
Z9 4
U1 0
U2 10
PU SPRINGER SINGAPORE PTE LTD
PI SINGAPORE
PA #04-01 CENCON I, 1 TANNERY RD, SINGAPORE 347719, SINGAPORE
SN 1225-8687
J9 J BIOCHEM MOL BIOL
JI J. Biochem. Mol. Biol.
PD SEP 30
PY 2001
VL 34
IS 5
BP 446
EP 451
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 477PW
UT WOS:000171294300010
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: High-temperature superconductivity in lattice-expanded C-60
   (Retracted Article. See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID DOPED C-60; FULLERIDES; CRYSTALS
AB C-60 single crystals have been intercalated with CHCl3 and CHBr3 in order to expand the lattice. High densities of electrons and holes have been induced by gate doping in a field-effect transistor geometry. At low temperatures, the material turns superconducting with a maximum transition temperature of 117 K in hole-doped C-60/CHBr3. The increasing spacing between the C-60 molecules follows the general trend of alkali metal-doped C-60 and suggests routes to even higher transition temperatures.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Konstanz, Dept Phys, D-78457 Constance, Germany.
   Swiss Fed Inst Technol, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   Cappelluti E, 2000, PHYS REV LETT, V85, P4771, DOI 10.1103/PhysRevLett.85.4771
   GLOVER RE, 1960, PHYS REV LETT, V5, P258
   Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575
   HADDON RC, 1993, PHILOS T R SOC LON A, V343, P55
   JANSEN L, 2001, PHYSICA A
   JANSEN M, 1995, Z ANORG ALLG CHEM, V621, P14, DOI 10.1002/zaac.19956210105
   KLAPWIJK TM, 1989, SUPERCONDUCTING ELEC, P385
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001
   Marsiglio F, 1998, PHYS LETT A, V245, P172, DOI 10.1016/S0375-9601(98)00373-9
   MAZIN II, 1992, PHYS REV B, V45, P5114, DOI 10.1103/PhysRevB.45.5114
   Ramirez A. P., 1994, Superconductivity Review, V1, P1
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2001, SCIENCE, V292, P252, DOI 10.1126/science.1058812
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   SCHON JH, 2000, NATURE, V406, P704
NR 18
TC 161
Z9 171
U1 4
U2 57
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD SEP 28
PY 2001
VL 293
IS 5539
BP 2432
EP 2434
DI 10.1126/science.1064773
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 476PD
UT WOS:000171237200040
PM 11533443
DA 2018-12-27
ER

PT J
AU Yung, Y
   Yao, Z
   Aebersold, DM
   Hanoch, T
   Seger, R
AF Yung, Y
   Yao, Z
   Aebersold, DM
   Hanoch, T
   Seger, R
TI RETRACTED: Altered regulation of ERK1b by MEK1 and PTP-SL and modified
   Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory
   C-terminal sequence of ERKs (Retracted article. See vol. 292, pg. 8852,
   2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; OF-FUNCTION
   MUTATION; MAP KINASE; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION;
   GROWTH-FACTOR; INTERACTION MOTIF; PATHWAYS; CASCADES
AB ERK1b is an alternatively spliced form of ERK1, containing a 26-amino acid insertion between residues 340 and 341 of ERK1. Although under most circumstances the kinetics of ERK1b activation are similar to that of ERK1 and ERK2, we have previously found several conditions under which the activation of ERK1b by extracellular stimuli differs from that of other ERKs. We studied the molecular mechanisms that cause this differential regulation of ERK1b and found that ERK1b is altered in its ability to interact with MEK1 and this influenced its subcellular localization but not its kinetics of activation. ERK1b had a decreased ability to phosphorylate Elk1, but this did not change much the transcriptional activity of the latter. Importantly, the interaction of ERK1b with PTP-SL, which can act as a MAPK phosphatase, shortly after mitogenic stimulation, was significantly affected as well. Using mutants of ERK1b we found that the differential interaction of ERK1b with the three effectors is caused by the site of insertion that abrogates the cytosolic retention sequence/common docking motif of ERKs, and is not dependent on the actual sequence of the insert. Prolonged epidermal growth factor stimulation of Rat1 cells resulted in a differential inactivation and not activation of ERK1b as compared with ERK1 and ERK2. The reduced sensitivity to phosphatases without major differences in the kinetics of activation or activation of substrates, suggests that ERK1b plays a role in the transmission of extracellular signals under conditions of persistent stimulation, where ERK1b and MAPK phosphatases are induced, and the activity of ERK1 and ERK2 is suppressed.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM bmseger@weizmann.weizmann.ac.il
RI Aebersold, Daniel/C-2946-2013
CR AUSUBEL FM, 1994, CURR PROT MOL BIOL, V2
   BE BX, 2001, J BIOL CHEM, V276, P26509
   BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9
   BOULTON TG, 1991, CELL REGUL, V2, P357
   BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brand A, 2001, J NEUROCHEM, V76, P910, DOI 10.1046/j.1471-4159.2001.00085.x
   BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X
   Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262
   Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6
   CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Cruzalegui FH, 1999, ONCOGENE, V18, P7948
   Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901
   GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0
   GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x
   Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620
   Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X
   Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000
   MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K
   Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4
   Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6
   Oh-hora M, 1999, J IMMUNOL, V163, P1282
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Peng X, 1996, J NEUROCHEM, V66, P1191
   Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x
   Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337
   Raingeaud J, 1996, MOL CELL BIOL, V16, P1247
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200
   SEGER R, 1995, FASEB J, V9, P726
   Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631
   STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0
   Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065
   TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200
   Xu R, 1999, J IMMUNOL, V163, P1110
   Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1
   Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199
   ZHENG CF, 1993, J BIOL CHEM, V268, P23933
   Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900
NR 44
TC 33
Z9 33
U1 2
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 21
PY 2001
VL 276
IS 38
BP 35280
EP 35289
DI 10.1074/jbc.M105995200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 474LU
UT WOS:000171109300012
PM 11463794
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wu, YJ
   Dzhura, I
   Colbran, RJ
   Anderson, ME
AF Wu, YJ
   Dzhura, I
   Colbran, RJ
   Anderson, ME
TI RETRACTED: Calmodulin kinase and a calmodulin-binding 'IQ' domain
   facilitate L-type Ca2+ current in rabbit ventricular myocytes by a
   common mechanism (Retracted article. See vol. 593, pg. 2249, 2015)
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article; Retracted Publication
ID NONSELECTIVE CATION CURRENT; DEPENDENT PROTEIN-KINASE; CALCIUM-CHANNELS;
   INACTIVATION; VOLTAGE; ENHANCEMENT; CELLS
AB 1. Ca2+-calmodulin-dependent protein kinase II (CaMK) and a calmodulin (CaM)-binding 'IQ' domain (IQ) are both implicated in Ca2+-dependent regulation of L-type Ca2+ current (I-Ca). We used an IQ-mimetic peptide (IQmp), under conditions in which CaMK activity was controlled, to test the relationship between these CaM-activated signalling elements in the regulation of L-type Ca2+ channels (LTCCs) and I-Ca in rabbit ventricular myocytes.
   2. A specific CaMK inhibitory peptide nearly abolished I-Ca facilitation, but the facilitation was 'rescued' by cell dialysis with IQmp.
   3. IQmp significantly enhanced I-Ca facilitation and slowed the fast component of I-Ca inactivation, compared with an inactive control peptide. Neither effect could be elicited by a more avid CaM-binding peptide, suggesting that generalized CaM buffering did not account for the effects of IQmp.
   4. I-Ca facilitation was abolished and the fast component of inactivation eliminated by ryanodine, caffeine or thapsigargin, suggesting that the sarcoplasmic reticulum (SR) is an important source of Ca2+ for I-Ca facilitation and inactivation. IQmp did not restore I-Ca facilitation under these conditions.
   5. Engineered Ca2+-independent CaMK and IQmp each markedly increased LTCC open probability (P-o) in excised cell membrane patches. The LTCC P-o increases with CaMK and IQmp were non-additive, suggesting that CaMK and IQmp are components of a shared signalling pathway.
   6. Both CaMK and IQmp induced a modal gating shift in LTCCs that favoured prolonged openings, indicating that CaMK and IQmp affect LTCCs through a common biophysical mechanism.
   7. These findings support the hypothesis that CaMK is required for physiological I-Ca facilitation in cardiac myocytes. Both CaMK and IQmp were able to induce a modal gating shift, in LTCCs, suggesting that each of these signalling elements is important for Ca2+-CaM-dependent LTCC facilitation in cardiac myocytes.
C1 Vanderbilt Univ, Dept Internal Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Anesthesiol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.
RP Anderson, ME (reprint author), Vanderbilt Univ, Dept Internal Med, 221 Kirkland Hall, Nashville, TN 37232 USA.
EM mark.anderson@mcmail.vanderbilt.edu
OI Colbran, Roger/0000-0001-7401-8244
FU NHLBI NIH HHS [R01 HL062494, HL03727, HL62494]
CR AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435
   ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854
   BERS DM, 1994, METHOD CELL BIOL, V40, P3
   BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944
   CHAO SH, 1984, MOL PHARMACOL, V26, P75
   Dzhura I, 2000, NAT CELL BIOL, V2, P173
   GUPTA RC, 1989, BIOCHEMISTRY-US, V28, P5909, DOI 10.1021/bi00440a030
   HADLEY RW, 1991, J PHYSIOL-LONDON, V444, P257, DOI 10.1113/jphysiol.1991.sp018876
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   HRYSHKO LV, 1990, AM J PHYSIOL, V259, pH951
   MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321
   MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0
   Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200
   PAYNE ME, 1988, J BIOL CHEM, V263, P7190
   Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6
   Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435
   Rhoads AR, 1997, FASEB J, V11, P331
   SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8
   Sun H, 1997, AM J PHYSIOL-HEART C, V272, pH1625
   VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X
   Wu YJ, 2000, J PHYSIOL-LONDON, V522, P51, DOI 10.1111/j.1469-7793.2000.0051m.x
   Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168
   XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659
   YUAN WL, 1994, AM J PHYSIOL, V267, pH982
   YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753
   ZUHKE RD, 2000, J BIOL CHEM, V275, P21121
   Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287
   Zuhlke RD, 1999, NATURE, V399, P159
   ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424
NR 29
TC 47
Z9 50
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD SEP 15
PY 2001
VL 535
IS 3
BP 679
EP 687
DI 10.1111/j.1469-7793.2001.t01-1-00679.x
PG 9
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 480XJ
UT WOS:000171488300005
PM 11559766
OA Green Published
DA 2018-12-27
ER

PT J
AU Chang, G
   Roth, CB
AF Chang, G
   Roth, CB
TI RETRACTED: Structure of MsbA from E-coli: A homolog of the multidrug
   resistance ATP binding cassette (ABC) transporters (Retracted Article.
   See vol 314, pg 1875, 2006)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; PROGRAM; REFINEMENT; MOLSCRIPT
AB Multidrug resistance (MDR) is a serious medical problem and presents a major challenge to the treatment of disease and the development of novel therapeutics. ABC transporters that are associated with multidrug resistance (MDR-ABC transporters) translocate hydrophobic drugs and lipids from the inner to the outer leaflet of the cell membrane. To better elucidate the structural basis for the "flip-flop" mechanism of substrate movement across the lipid bilayer, we have determined the structure of the lipid flippase MsbA from Escherichia coli by x-ray crystallography to a resolution of 4.5 angstroms. MsbA is organized as a homodimer with each subunit containing six transmembrane alpha -helices and a nucleotide-binding domain. The asymmetric distribution of charged residues lining a central chamber suggests a general mechanism for the translocation of substrate by MsbA and other MDR-ABC transporters. The structure of MsbA can serve as a model for the MDR-ABC transporters that confer multidrug resistance to cancer cells and infectious microorganisms.
C1 Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Chang, G (reprint author), Scripps Res Inst, Dept Mol Biol, MB-9, La Jolla, CA 92037 USA.
EM gchang@scripps.edu
FU NIGMS NIH HHS [GM61905-01]
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P3
   Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361
   AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P18
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760
   Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x
   BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458
   CANOGAUCI DF, 1995, BIOCHEM BIOPH RES CO, V209, P2
   CHANG G, 1998, SCIENCE, V282, P5397
   CHEN C, 1986, CELL, V47, P3
   DIEZ J, 2001, J MOL BIOL, V305, P4
   DOERRIER WT, 2001, J BIOL CHEM, V276, P15
   Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69
   Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1
   FULLER CM, 1992, AM J PHYSIOL, V263, pC267
   Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2
   GROS P, 1987, SCIENCE, V235, P458
   HIGGINS CF, 1992, TRENDS BIOSCI, V17, P1
   HOLLAND IB, 1999, J MOL BIOL, V293, P2
   HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829
   HOPFNER KP, 2000, CELL, V101, P7
   HORIO M, 1988, P NATL ACAD SCI USA, V85, P10
   HUGHES AL, 1994, MOL BIOL EVOL, V11, P6
   HUNG LW, 1998, NATURE, V396, P6712
   KAROW M, 1993, MOL MICROBIOL, V7, P1
   KARPOWICH N, 2001, STRUCTURE, V9, P7
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407
   MARGOLLES A, 1999, BIOCHEMISTRY-US, V38, P49
   MCDONALD MK, 1997, J BACTERIOL, V179, P24
   Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9
   Pellegrini M, 1997, PROTEINS, V29, P426, DOI 10.1002/(SICI)1097-0134(199712)29:4<426::AID-PROT3>3.0.CO;2-6
   RAVIV Y, 1990, J BIOL CHEM, V265, P7
   ROST B, 1996, PROTEIN SCI, V5, P8
   SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4
   SARKADI B, 1992, J BIOL CHEM, V267, P7
   SENIOR A, 1998, BIOCHEMISTRY-US, V37, P3
   SMIT JJ, 1993, CELL, V75, P3
   SMITH AJ, 1994, FEBS LETT, V354, P3
   Thompson JD, 1994, NUCLEIC ACIDS RES, V22, P22
   Tomii K, 1998, GENOME RES, V8, P1048, DOI 10.1101/gr.8.10.1048
   TROWSDALE J, 1990, NATURE, V348, P6303
   VANHELVOORT A, 1996, CELL, V87, P3
   VANVEEN HW, 1998, NATURE, V391, P6664
   *WHO, 2000, DRUG RES THREAT REV
   ZHOU Y, 1999, ARCH BIOCHEM BIOPHYS, V367, P1
   ZHOU Z, 1998, J BIOL CHEM, V273, P20
NR 46
TC 561
Z9 570
U1 2
U2 59
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD SEP 7
PY 2001
VL 293
IS 5536
BP 1793
EP 1800
DI 10.1126/science.293.5536.1793
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 470WN
UT WOS:000170894400037
PM 11546864
DA 2018-12-27
ER

PT J
AU Fiorucci, S
   Distrutti, E
   Ajuebor, MN
   Mencarelli, A
   Mannucci, R
   Palazzetti, B
   Del Soldato, P
   Morelli, A
   Wallace, JL
AF Fiorucci, S
   Distrutti, E
   Ajuebor, MN
   Mencarelli, A
   Mannucci, R
   Palazzetti, B
   Del Soldato, P
   Morelli, A
   Wallace, JL
TI RETRACTED: NO-mesalamine protects colonic epithelial cells against
   apoptotic damage induced by proinflammatory cytokines (Retracted
   Article. See vol 297, pg G860, 2009)
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE colon cancer cells; apoptosis; death factors; nitromesalamine
ID INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE;
   ULCERATIVE-COLITIS; FAS LIGAND; CONVERTING-ENZYME; EXPRESSION;
   INHIBITION; ASPIRIN; LIVER
AB The activation of a self-amplifying cascade of caspases, of which caspase-8 is the apical. protease, mediates Fas-, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-, and TNF-alpha -induced apoptosis in colon cell lines. Nitric oxide (NO) protects from apoptosis induced by Fas and TNF-alpha. We examined whether NCX-456, an NO-releasing derivative of mesalamine, protects colon epithelial cells from cytokine-induced apoptosis. Caco-2 and HT-29 cell lines express death factor receptors and are driven to apoptosis in response to incubation with Fas-agonistic antibody, TNF-alpha /interferon-gamma, and TRAIL. The two novel observations reported here are that 1) cotreatment of cells with NCX-456, but not mesalamine, resulted in concentration-dependent protection against death factor-induced apoptosis and inhibition of caspase activity, and 2) exposure to dithiothreitol, an agent that effectively removes NO from thiol groups, resulted in a 70% recovery of caspase activity, which is consistent with S-nitrosation as a major mechanism for caspase inactivation. These data suggest that caspase S-nitrosation represents a mechanism for protection of colonic mucosal epithelial cells from death factor-induced death.
C1 Univ Perugia, Dipartimento Med Clin & Sperimentale, Clin Gastroenterol & Epatol, I-06100 Perugia, Italy.
   Univ Perugia, Dipartimento Med Clin & Sperimentale, Sez Med Interna & Sci Oncol, I-06100 Perugia, Italy.
   Univ Calgary, Mucosal Inflammat Res Grp, Calgary, AB T2N 4N1, Canada.
   Nicox, F-06906 Sophia Antipolis, France.
RP Fiorucci, S (reprint author), Univ Perugia, Monteluce Policlin, Clin Gastroenterol & Endoscopia Digest, I-06100 Perugia, Italy.
EM fiorucci@unipg.it
CR Abreu-Martin MT, 1999, AM J PHYSIOL-GASTR L, V276, pG599, DOI 10.1152/ajpgi.1999.276.3.G599
   ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147
   Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Boirivant M, 1996, J CLIN INVEST, V98, P2616, DOI 10.1172/JCI119082
   BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3
   COLTON T, 1978, STAT MED
   DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418
   Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133
   Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601
   DINARELLO CA, 1995, CURR BIOL, V5, P587, DOI 10.1016/S0960-9822(95)00116-3
   ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0
   Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6
   Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245
   Fiorucci S, 2000, GASTROENTEROLOGY, V118, P404, DOI 10.1016/S0016-5085(00)70223-X
   Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0
   Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315
   Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117
   Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415
   Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8
   Iwamoto M, 1996, J PATHOL, V180, P152
   Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174
   Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437
   Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402
   Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672
   Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651
   Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125
   MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9
   Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2
   Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160
   Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354
   Sandoval M, 1997, GASTROENTEROLOGY, V113, P1480, DOI 10.1053/gast.1997.v113.pm9352850
   Sands BE, 2000, GASTROENTEROLOGY, V118, pS68, DOI 10.1016/S0016-5085(00)70007-2
   Southey A, 1997, INT J IMMUNOPHARMACO, V19, P669
   Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Ueyama H, 1998, GUT, V43, P48, DOI 10.1136/gut.43.1.48
   Wallace JL, 1999, GASTROENTEROLOGY, V117, P557, DOI 10.1016/S0016-5085(99)70448-8
   WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4
NR 40
TC 17
Z9 18
U1 3
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
EI 1522-1547
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD SEP
PY 2001
VL 281
IS 3
BP G654
EP G665
PG 12
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 471CE
UT WOS:000170908600007
PM 11518677
DA 2018-12-27
ER

PT J
AU Piper, SN
   Kumle, B
   Maleck, WH
   Suttner, SW
   Fent, MT
   Boldt, J
AF Piper, SN
   Kumle, B
   Maleck, WH
   Suttner, SW
   Fent, MT
   Boldt, J
TI RETRACTED: Effects of postoperative sedation with propofol and midazolam
   on pancreatic function assessed by pancreatitis-associated protein
   (Retracted article. See vol. 66, pg. 646, 2011)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE sedation : propofol, midazolam pancreatitis : pancreatitis-associated
   protein
ID CRITICALLY-ILL PATIENTS; EFFICACY
AB This prospective randomised controlled study evaluated the effects of postoperative sedation with propofol and midazolam on pancreatic function. We studied 42 intensive care unit patients undergoing elective major surgery who were expected to be sedated postoperatively. Patients were randomly assigned to a propofol group (n = 21) or a midazolam group (n = 21). To assess pancreatic function, the following parameters were measured: pancreatitis-associated protein, amylase, lipase, cholesterol and triglyceride prior to start of sedation on the intensive care unit, 4 h after the sedation was started and at the first postoperative day. Patients in the propofol group received on average (SD) 1292 (430) mg propofol and were sedated for 9.03 (4.26) h. The midazolam group received 92 (36) mg midazolam and were sedated for 8.81 (4.68) h. Plasma cholesterol concentrations did not differ significantly between groups. Triglyceride plasma levels 4 h after the start of infusion were significantly higher in the propofol group (140 (54) mg.dl(-1)) than the midazolam-treated patients (81 (29) mg.dl(-1)), but were within normal limits. There were no significant differences between the two groups regarding amylase, lipase and pancreatitis-associated protein plasma concentrations at any time. No markers of pancreatic dysfunction were outside the normal range. We conclude that postoperative sedation with propofol induced a significant increase of serum triglyceride levels but that pancreatic function is unchanged with standard doses of propofol.
C1 Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Piper, SN (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM wolfgang_maleck@hotmail.com
CR BEHNE M, 1994, ANASTH INTENSIVMED, V35, P101
   CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557
   Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010
   Donmez A, 1999, EUR J ANAESTH, V16, P367, DOI 10.1046/j.1365-2346.1999.00485.x
   FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006
   GOTTARDIS M, 1989, BRIT J ANAESTH, V62, P393, DOI 10.1093/bja/62.4.393
   Hofbauer R, 1999, CRIT CARE MED, V27, P1843, DOI 10.1097/00003246-199909000-00023
   IOVANNA JL, 1994, GASTROENTEROLOGY, V106, P728, DOI 10.1016/0016-5085(94)90708-0
   KEIM V, 1984, DIGESTION, V29, P242, DOI 10.1159/000199041
   Kemppainen EAJ, 1998, ANN MED, V30, P169, DOI 10.3109/07853899808999400
   Kumar AN, 1999, CHEST, V115, P1198, DOI 10.1378/chest.115.4.1198
   LANGLEY MS, 1988, DRUGS, V35, P334, DOI 10.2165/00003495-198835040-00002
   Leisure GS, 1996, ANESTHESIOLOGY, V84, P224, DOI 10.1097/00000542-199601000-00027
   Mateu J, 1996, INTENS CARE MED, V22, P834, DOI 10.1007/BF01709533
   McLeod G, 1997, CRIT CARE MED, V25, P1976, DOI 10.1097/00003246-199712000-00012
   Miller L J, 1998, Am J Crit Care, V7, P73
   Pezzilli R, 1997, AM J GASTROENTEROL, V92, P1887
   PEZZILLI R, 1993, DIGEST DIS SCI, V38, P1265, DOI 10.1007/BF01296077
   Possidente CJ, 1998, PHARMACOTHERAPY, V18, P653
   RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656
   Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016
   Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034
   TOSKES PP, 1990, GASTROENTEROL CLIN N, V19, P783
   VanderPijl JW, 1997, TRANSPLANTATION, V63, P995, DOI 10.1097/00007890-199704150-00016
   Wingfield TW, 1996, ANESTHESIOLOGY, V84, P236, DOI 10.1097/00000542-199601000-00031
NR 25
TC 16
Z9 17
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD SEP
PY 2001
VL 56
IS 9
BP 836
EP 840
DI 10.1046/j.1365-2044.2001.02175.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 469CD
UT WOS:000170794600004
PM 11531667
OA Bronze
DA 2018-12-27
ER

PT J
AU Fontaine, AB
   Borsa, JJ
   Hoffer, EK
   Bloch, RD
   So, C
AF Fontaine, AB
   Borsa, JJ
   Hoffer, EK
   Bloch, RD
   So, C
TI RETRACTED: Stent placement in the treatment of pulmonary artery stenosis
   secondary to fibrosing mediastinitis (Retracted Article. See vol 13, pg
   680, 2002)
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article; Retracted Publication
DE mediastinitis; pulmonary arteries, stenosis or obstruction; pulmonary
   arteries, stents and prostheses
ID OBSTRUCTION
AB This article describes an initial experience with stent placement in three patients with severe pulmonary artery stenosis secondary to fibrosing mediastinitis. All three patients were severely symptomatic on admission and all three were asymptomatic after treatment and remained symptom-free approximately I year after treatment.
C1 Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA.
RP Fontaine, AB (reprint author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,RR-215, Seattle, WA 98195 USA.
EM afontain@u.washington.edu
CR ARNETT EN, 1977, AM J MED, V63, P634, DOI 10.1016/0002-9343(77)90209-1
   BERRY DF, 1986, CHEST, V89, P296, DOI 10.1378/chest.89.2.296
   CHERIS DN, 1974, AM J ROENTGENOL RADI, V122, P288
   DODDS GA, 1994, CHEST, V106, P315, DOI 10.1378/chest.106.1.315
   FARMER DW, 1984, AM J ROENTGENOL, V143, P1189, DOI 10.2214/ajr.143.6.1189
   Fontaine AB, 1998, J VASC INTERV RADIOL, V9, P965, DOI 10.1016/S1051-0443(98)70433-6
   GARRETT HE, 1986, ANN THORAC SURG, V42, P711, DOI 10.1016/S0003-4975(10)64619-X
   GUERRO A, 2001, CHEST, V19, P966
   HICKS GL, 1983, NEW YORK STATE J MED, V83, P242
   Kandzari DE, 2000, CATHETER CARDIO INTE, V49, P321, DOI 10.1002/(SICI)1522-726X(200003)49:3<321::AID-CCD20>3.0.CO;2-5
   LLOYD TV, 1979, CLIN NUCL MED, V4, P35, DOI 10.1097/00003072-197901000-00010
   LOSSEF SV, 1994, J VASC INTERV RADIOL, V5, P341, DOI 10.1016/S1051-0443(94)71499-8
   VOGEL JHK, 1966, AM J MED, V40, P331
   ZORN SK, 1978, LUNG, V155, P91, DOI 10.1007/BF02730683
NR 14
TC 15
Z9 15
U1 4
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
EI 1535-7732
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD SEP
PY 2001
VL 12
IS 9
BP 1107
EP 1111
DI 10.1016/S1051-0443(07)61600-5
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
   Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
   Cardiology
GA 471FR
UT WOS:000170918300014
PM 11535776
DA 2018-12-27
ER

PT J
AU Chandra, RK
AF Chandra, RK
TI RETRACTED: Effect of vitamin and trace-element supplementation on
   cognitive function in elderly subjects (Retracted Article. See vol 21,
   pg 286, 2005)
SO NUTRITION
LA English
DT Article; Retracted Publication
DE elderly; aging; vitamins; trace elements; cognitive function; memory;
   Alzheimer's disease
ID MEMORY
AB OBJECTIVE: To determine whether supplementation with vitamins and trace elements in modest amounts influences cognitive function in apparently healthy, elderly subjects.
   METHODS: The study was designed as a randomized, double-blind, placebo-controlled trial. Ninety-six, apparently healthy, independent men and women older than 65 y of age were recruited and randomized to receive a supplement of trace elements and vitamins or a placebo daily for 12 mo. Blood-nutrient levels were estimated at baseline and at the end of the study. The major outcome measure assessed was cognitive function consisting of immediate and long-term memory, abstract thinking, problem-solving ability, and attention.
   RESULTS: Eighty-six subjects completed the 1-y trial. The supplemented group showed a significant improvement in all cognitive tests (P < 0.001 to 0.05) except long-term memory recall (P > 0.1). Those whose blood-nutrient levels were below the reference standard showed lower responses on cognitive tests. There was no significant correlation between individual nutrient levels and performance on various cognitive function tests.
   CONCLUSIONS: Cognitive functions improved after oral supplementation with modest amounts of vitamins and trace elements. This has considerable clinical and public health significance. We recommend that such a supplement be provided to all elderly subjects because it should significantly improve cognition and thus quality of life and the ability to perform activities of daily living. Such a nutritional approach may delay the onset of Alzheimer's disease. Nutrition 2001;17:709-712. (C) Elsevier Science Inc. 2001.
C1 Mem Univ Newfoundland, St John, NF, Canada.
   Privat Hosp, Gurgaon, India.
RP Chandra, RK (reprint author), Janeway Child Hlth Ctr, St John, NF A1A 1R8, Canada.
EM rchandra@mun.ca
CR BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9
   Chandra RK, 1997, JAMA-J AM MED ASSOC, V277, P1398, DOI 10.1001/jama.277.17.1398
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chandra RK, 1996, P NATL ACAD SCI USA, V93, P14304, DOI 10.1073/pnas.93.25.14304
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GOODWIN JS, 1983, JAMA-J AM MED ASSOC, V249, P2917, DOI 10.1001/jama.249.21.2917
   HOFFER LJ, 1996, ANN RCPSC, V29, P11
   MUNRO H, 1992, NUTR ELDERLY
   Nandy K., 1997, AGING BRAIN SENILE D
   NIELSEN J, 1977, J GERONTOL, V32, P554, DOI 10.1093/geronj/32.5.554
   Reitan R.M.D, 1974, CLIN NEUROPSYCHOLOGY
   RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800
   Salthouse T. A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [10.1037/0894-4105.8.4.535, DOI 10.1037/0894-4105.8.4.535]
NR 13
TC 92
Z9 98
U1 4
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD SEP
PY 2001
VL 17
IS 9
BP 709
EP 712
DI 10.1016/S0899-9007(01)00610-4
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 468JV
UT WOS:000170755100002
PM 11527656
DA 2018-12-27
ER

PT J
AU Dhuley, JN
AF Dhuley, JN
TI RETRACTED: Nootropic-like effect of ashwagandha (Withania somnifera L.)
   in mice (Retracted Article. See vol 22, pg 1416, 2008)
SO PHYTOTHERAPY RESEARCH
LA Rumanian
DT Article; Retracted Publication
DE ashwagandha (Withania somnifera L.); passive avoidance; acquisition;
   retrieval; scopolamine; electroconvulsive shock; mice
ID ELEVATED PLUS-MAZE; SCOPOLAMINE; MEMORY; RATS; UTILITY; MODELS
AB Ashwagandha (Withania somnifera L.) root extract (50, 100 and 200 mg/kg; orally) improved retention of a passive avoidance task in a step-down paradigm in mice. Ashwagandha (50, 100 and 200 mg/kg; orally) also reversed the scopolarnine (0.3 mg/kg)-induced disruption of acquisition and retention and attenuated the amnesia produced by acute treatment with electroconvulsive shock (ECS), immediately after training. Chronic treatment with ECS, for 6 successive days at 24 h intervals, disrupted memory consolidation on day 7. Daily administration of ashwagandha for 6 days significantly improved memory consolidation in mice receiving chronic ECS treatment. Ashwagandha, administered on day 7, also attenuated the disruption of memory consolidation produced by chronic treatment with ECS. On the elevated plus-maze, ashwagandha reversed the scopolamine (0.3 mg/kg)-induced delay in transfer latency on day 1. On the basis of these findings, it is suggested that ashwagandha exhibits a nootropic-like effect in naive and amnesic mice. Copyright (C) 2001 John Wiley & Sons, Ltd.
C1 Hindustan Antibiot Ltd, Res Ctr, Lab Pharmacol & Toxicol, Pune 411018, Maharashtra, India.
RP Dhuley, JN (reprint author), Hindustan Antibiot Ltd, Res Ctr, Lab Pharmacol & Toxicol, Pune 411018, Maharashtra, India.
EM djayant@usa.net
CR [Anonymous], 1985, INDIAN PHARMACOPOEIA, V2, pA
   ASTHANA R, 1989, INDIAN DRUGS, V26, P199
   Bhardwaj S. K., 1995, Indian Journal of Experimental Biology, V33, P580
   Bhattacharya S K, 1997, Indian J Exp Biol, V35, P236
   BHATTACHARYA SK, 1993, TRADITIONAL MEDICINE, P320
   Dhuley JN, 1997, J ETHNOPHARMACOL, V58, P15, DOI 10.1016/S0378-8741(97)00072-X
   Dhuley JN, 1998, J ETHNOPHARMACOL, V60, P173, DOI 10.1016/S0378-8741(97)00151-7
   Dhuley JN, 1998, IMMUNOPHARM IMMUNOT, V20, P191, DOI 10.3109/08923979809034817
   Dhuley JN, 2000, J ETHNOPHARMACOL, V70, P57, DOI 10.1016/S0378-8741(99)00177-4
   GRANDHI A, 1994, J ETHNOPHARMACOL, V44, P131, DOI 10.1016/0378-8741(94)01119-2
   ITOH J, 1990, PSYCHOPHARMACOLOGY, V101, P27, DOI 10.1007/BF02253713
   ITOH J, 1991, EUR J PHARMACOL, V194, P71, DOI 10.1016/0014-2999(91)90125-A
   Kulkarni SK, 1996, PHYTOTHER RES, V10, P447, DOI 10.1002/(SICI)1099-1573(199608)10:5<447::AID-PTR869>3.0.CO;2-M
   PATWARDHAN B, 1988, J NATL INTEGRATED ME, V30, P7
   PRESTON GC, 1989, PSYCHOPHARMACOLOGY, V98, P487, DOI 10.1007/BF00441947
   SHARMA AC, 1990, METHOD FIND EXP CLIN, V12, P175
   SHARMA AC, 1991, DRUG DEVELOP RES, V222, P251
   SHARMA K, 1992, INDIAN DRUGS, V29, P247
   Sharma S, 1985, INDIAN DRUGS, V22, P133
   SMITH G, 1988, BRAIN RES REV, V13, P103, DOI 10.1016/0165-0173(88)90016-1
   SPANGLER EL, 1986, PHARMACOL BIOCHEM BE, V25, P673, DOI 10.1016/0091-3057(86)90158-9
   STAHL E, 1964, THIN LAYER CHROMATOG, P311
   WIRSCHING BA, 1984, PHARMACOL BIOCHEM BE, V20, P659, DOI 10.1016/0091-3057(84)90180-1
NR 23
TC 53
Z9 57
U1 3
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0951-418X
J9 PHYTOTHER RES
JI Phytother. Res.
PD SEP
PY 2001
VL 15
IS 6
BP 524
EP 528
DI 10.1002/ptr.874
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 475ZX
UT WOS:000171201000011
PM 11536383
DA 2018-12-27
ER

PT J
AU Gallouzi, IE
   Brennan, CM
   Steitz, JA
AF Gallouzi, IE
   Brennan, CM
   Steitz, JA
TI RETRACTED: Protein ligands mediate the CRM1-dependent export of HuR in
   response to heat shock (Retracted Article. See vol 9, pg 1410, 2003)
SO RNA
LA English
DT Article; Retracted Publication
DE APRIL; CRM1; ELAV; hsp70 mRNA; HuR; mRNA export; pp32
ID RNA-BINDING-PROTEINS; AU-RICH ELEMENTS; MAMMALIAN STRESS GRANULES;
   ELAV-LIKE PROTEIN; MESSENGER-RNA; NUCLEAR EXPORT; PHOSPHATASE 2A;
   MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; LEPTOMYCIN-B
AB AU-rich elements (AREs) located in the 3' UTRs of the messenger RNAs (mRNAs) of many mammalian early response genes promote rapid mRNA turnover. HuR, an RRM-containing RNA-binding protein, specifically interacts with AREs, stabilizing these mRNAs. HuR is primarily nucleoplasmic, but shuttles between the nucleus and the cytoplasm via a domain called HNS located between RRM2 and RRM3. We recently showed that HuR interacts with two protein ligands, pp32 and APRIL, which are also shuttling proteins, but rely on NES domains recognized by CRM1 for export. Here we show that heat shock induces increased association of HuR with pp32 and APRIL through protein-protein interactions and that these ligands partially colocalize with HuR in cytoplasmic foci. HuR associations with the hnRNP complex also increase, but through RNA links. CRM1 coimmunoprecipitates with HuR only after heat shock, and nuclear export of HuR becomes sensitive to leptomycin B, an inhibitor of CRM1. Export after heat shock requires the same domains of HuR (HNS and RRM3) that are essential for binding pp32 and APRIL. In situ hybridization and coimmunoprecipitation experiments show that LMB treatment blocks both hsp70 mRNA nuclear export and its cytoplasmic interaction with HuR after heat shock. Together, our results argue that upon heat shock, HuR switches its export pathway to that of its ligands pp32 and APRIL, which involves the nuclear export factor CRM1. HuR and its ligands may be instrumental in the nuclear export of heat-shock mRNAs.
C1 Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06536 USA.
RP Steitz, JA (reprint author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, 295 Congress Ave, New Haven, CT 06536 USA.
EM joan.steitz@yale.edu
FU NCI NIH HHS [CA16038]
CR Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885
   ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452
   Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866
   BANERJI SS, 1986, J BIOL CHEM, V261, P5740
   Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290
   Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854
   CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150
   CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1
   Chen TH, 1996, MOL BIOL CELL, V7, P2045
   DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179
   DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997
   Ducret C, 1999, MOL CELL BIOL, V19, P7076
   Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293
   Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448
   Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2
   FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914
   Fujita M, 1999, BIOCHEM BIOPH RES CO, V260, P646, DOI 10.1006/bbrc.1999.0957
   Fukuda M, 1997, NATURE, V390, P308
   Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073
   GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557
   Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607
   Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400
   Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322
   HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629
   Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057
   Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967
   HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455
   Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401
   Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417
   Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5
   Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x
   Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257
   Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431
   KOMIYAMA K, 1985, J ANTIBIOT, V38, P427, DOI 10.7164/antibiotics.38.427
   Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112
   LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984
   LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521
   LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y
   Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x
   Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144
   Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564
   Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265
   Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6
   MICHAEL WM, 1995, CELL, V83, P415
   Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9
   Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6
   Okano HJ, 1997, J NEUROSCI, V17, P3024
   Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461
   Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154
   PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0
   Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608
   Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845
   SADIS S, 1988, J CELL PHYSIOL, V135, P377, DOI 10.1002/jcp.1041350304
   Saito S, 1999, BIOCHEM BIOPH RES CO, V259, P471, DOI 10.1006/bbrc.1999.0790
   Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181
   SMITH PR, 1985, J IMMUNOL METHODS, V77, P63, DOI 10.1016/0022-1759(85)90184-X
   STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7
   TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8
   Vainberg IE, 2000, MOL CELL BIOL, V20, P3996, DOI 10.1128/MCB.20.11.3996-4005.2000
   van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307
   Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000
   WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330
NR 67
TC 117
Z9 118
U1 2
U2 10
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
EI 1469-9001
J9 RNA
JI RNA
PD SEP
PY 2001
VL 7
IS 9
BP 1348
EP 1361
DI 10.1017/S1355838201016089
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 471LG
UT WOS:000170930400013
PM 11565755
OA Green Published
DA 2018-12-27
ER

PT J
AU Senzaki, H
   Masutani, S
   Kobayashi, J
   Kobayashi, T
   Nakano, H
   Nagasaka, H
   Sasaki, N
   Asano, H
   Kyo, S
   Yokote, Y
AF Senzaki, H
   Masutani, S
   Kobayashi, J
   Kobayashi, T
   Nakano, H
   Nagasaka, H
   Sasaki, N
   Asano, H
   Kyo, S
   Yokote, Y
TI RETRACTED: Circulating matrix metalloproteinases and their inhibitors in
   patients with Kawasaki disease (Retracted article. See vol. 125, pg.
   E1020, 2012)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE aneurysm; coronary disease; metalloproteinases
ID TISSUE INHIBITOR; AORTIC-ANEURYSM
AB Background-Accelerated matrix breakdown caused by the increased activity of matrix metalloproteinases (MMPs) and/or the quantitative imbalance between MMP and tissue inhibitor of MMP (TIMP) have been implicated in several pathological conditions. MMP and TIMP may also be, involved in the destruction of the coronary arterial wall and the resultant coronary arterial lesions in Kawasaki disease.
   Methods and Results-Plasma levels of MMPs, neutrophil elastase, and TIMPs were measured by enzyme-linked immunoassay in 57 patients with Kawasaki disease and no coronary arterial lesions (group 1) and in 8 patients with Kawasaki disease and coronary arterial lesions (group 2). Blood samples were obtained before and after intravenous gamma globulin therapy and in the convalescent stage. Levels of MMPs, neutrophil elastase, and TIMPs were significantly higher in Kawasaki disease patients before gamma globulin therapy than in 18 age-matched afebrile control subjects and 17 age-matched febrile disease control subjects (P < 0.01). More importantly, the pre-gamma globulin MMP9 level and MMP9/TIMP2 ratio and post-gamma globulin MMP3 level and MMP3/TIMP1 ratio were significantly higher in group 2 than in group I patients (P < 0.05). Although MMP levels in febrile disease controls were significantly higher than those of afebrile controls, the MMP/TIMP ratios of febrile disease controls and afebrile controls were comparable.
   Conclusions-These data suggest that patients with Kawasaki disease and high levels of MMP and/or MMP/TIMP are susceptible to coronary arterial lesions. Studies of the effects of MMP inhibitors on coronary outcome may provide evidence that MMP is a viable therapeutic target for the prevention of coronary arterial lesions due to Kawasaki disease.
C1 Saitama Med Sch Hosp, Dept Pediat Cardiol, Saitama Heart Inst, Moroyama, Saitama 3500495, Japan.
   Saitama Med Sch Hosp, Dept Pediat, Saitama Heart Inst, Moroyama, Saitama 3500495, Japan.
RP Senzaki, H (reprint author), Saitama Med Sch Hosp, Dept Pediat Cardiol, Saitama Heart Inst, 38 Morohongo, Moroyama, Saitama 3500495, Japan.
EM hsenzaki@saitama-med.ac.jp
OI Senzaki, Hideaki/0000-0002-8289-0953
CR Allaire E, 1998, CIRCULATION, V98, P249, DOI 10.1161/01.CIR.98.3.249
   AMANO S, 1979, JPN CIRC J, V43, P633, DOI 10.1253/jcj.43.633
   Davies MJ, 1998, CIRCULATION, V98, P193, DOI 10.1161/01.CIR.98.3.193
   Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163
   OKADA Y, 1988, FEBS LETT, V229, P157, DOI 10.1016/0014-5793(88)80817-2
   Parks WC, 1998, MATRIX METALLOPROTEI, P1
   POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013
   Senzaki H, 2000, CIRC RES, V86, P807, DOI 10.1161/01.RES.86.7.807
   STRTLERSTEVENSO.WG, 1996, AM J PATHOL, V148, P1345
   VINE N, 1991, CLIN SCI, V81, P233, DOI 10.1042/cs0810233
   WOESSNER JF, 1991, FASEB J, V5, P2145
   ZHANG J, 1993, CLIN CHIM ACTA, V219, P1, DOI 10.1016/0009-8981(93)90192-7
NR 12
TC 76
Z9 86
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 21
PY 2001
VL 104
IS 8
BP 860
EP 863
DI 10.1161/hc3301.095286
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 465RB
UT WOS:000170602800004
PM 11514369
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Wildeman, J
   Hadziioannou, G
AF Schon, JH
   Kloc, C
   Wildeman, J
   Hadziioannou, G
TI RETRACTED: Gate-induced superconductivity in oligophenylenevinylene
   single crystals (Retracted Article. See vol 15, pg 478, 2003)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
ID TRANSISTORS
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Groningen, Polymer Chem Lab, NL-9747 AG Groningen, Netherlands.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   Devos A, 1998, PHYS REV B, V58, P8236, DOI 10.1103/PhysRevB.58.8236
   KLAPWIJK TM, 1989, SUPERCONDUCTING ELEC, P385
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001
   NAGAO H, IN PRESS INT J QUANT
   SCHON JC, UNPUB
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.035209
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   SCHON JH, 2000, NATURE, V406, P704
   SCHON JH, IN PRESS MAT RES SOC
NR 14
TC 5
Z9 5
U1 4
U2 16
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA PO BOX 10 11 61, D-69451 BERLIN, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD AUG 16
PY 2001
VL 13
IS 16
BP 1273
EP 1274
DI 10.1002/1521-4095(200108)13:16<1273::AID-ADMA1273>3.0.CO;2-P
PG 2
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 470ZP
UT WOS:000170902600014
OA Bronze
DA 2018-12-27
ER

PT J
AU Rakoff-Nahoum, S
   Chen, HC
   Kraus, T
   George, I
   Oei, E
   Tyorkin, M
   Salik, E
   Beuria, P
   Sperber, K
AF Rakoff-Nahoum, S
   Chen, HC
   Kraus, T
   George, I
   Oei, E
   Tyorkin, M
   Salik, E
   Beuria, P
   Sperber, K
TI RETRACTED: Regulation of class II expression in monocytic cells after
   HIV-1 infection (Retracted Article. See vol 177, pg 6561, 2006)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Review; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BARE-LYMPHOCYTE-SYNDROME; HUMAN MACROPHAGE
   HYBRIDOMAS; IMMUNE-DEFICIENCY SYNDROME; INVARIANT CHAIN COMPLEXES;
   PROMOTER BINDING-PROTEIN; DRA GENE PROMOTER; X-BOX-BINDING; NF-Y; BLOOD
   MONOCYTES
AB Human macrophage hybridoma cells were used to study HLA-DR expression after HIV-1 infection. HLA-DR surface expression was lost 2 wk after infection that was associated with decreased mRNA transcription. Transfecting HLA-DR-alpha and HLA-DR-beta cDNA driven by a nonphysiological CMV promoter restored expression, suggesting that regulatory DNA-binding proteins may be affected by HIV-1 infection. There was no protein binding to conserved class II DNA elements (W/Z/S box, X-1 and X-2 boxes, and Y box) in a HIV-1-infected human macrophage hybridoma cell line, 43(HIV), and in primary monocytes that lost HLA-DR expression after HIV-1(BaL) infection. PCR analysis of the HIV-1-infected cells that lost HLA-DR expression revealed mRNA for W/Z/S (RFX-5), X-1 (RFX-5), X-2 (hX-2BP), and one Y box DNA-binding protein (NF-YB), and CIITA, a non-DNA-binding protein necessary for class II transcription. There was no mRNA for the Y box-binding protein, NF-YA. However, HLA-DR expression could be restored by transfection with NF-YA driven by a CMV promoter, although HLA-DR failed to localize in either the late endosomes, lysosomes, or acidic compartments. This was associated with a loss of class II-associated invariant chain peptide and leupeptin-induced protein in the 43(HIV) cells. To address this further, non-HIV-1-infected 43 cells were infected with vaccinia virus containing HIV-1 gag, nef, pol, and env proteins. HLA-DR failed to localize in neither the late endosomes, lysosomes, or acidic compartments in the vaccinia-infected cells containing HIV-1 env protein. HIV-1 appears to have multiple effects on class II expression in monocytic cells that may contribute to the immune defects seen in HIV-1-infected patients.
C1 CUNY, Mt Sinai Med Ctr, Div Clin Immunol, New York, NY 10029 USA.
RP Sperber, K (reprint author), CUNY, Mt Sinai Med Ctr, Div Clin Immunol, Box 1089,1425 Madison Ave, New York, NY 10029 USA.
EM kirk.sperber@mssm.edu
FU NIAID NIH HHS [AI-45343, P0-1-AI-44236]; NCRR NIH HHS [1S10RR09145-01];
   NCI NIH HHS [CAR-29-256990]
CR BENDER BS, 1988, REV INFECT DIS, V10, P1142
   BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285
   Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x
   Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5
   CALLAHAN KM, 1993, J IMMUNOL, V151, P2928
   CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765
   CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367
   Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0
   Chen HC, 1998, J IMMUNOL, V161, P4257
   CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259
   DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6
   Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153
   DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Douhan J, 1996, J EXP MED, V183, P1063, DOI 10.1084/jem.183.3.1063
   DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839
   Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803
   ENNEN J, 1990, EUR J IMMUNOL, V20, P2451, DOI 10.1002/eji.1830201114
   FABER M, 1990, J BIOL CHEM, V265, P22243
   Fingerle-Rowson G, 1998, CLIN EXP IMMUNOL, V112, P501
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x
   GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.immunol.10.1.13
   Griscelli C, 1989, Immunodefic Rev, V1, P135
   HAAS JP, 1995, TISSUE ANTIGENS, V45, P317, DOI 10.1111/j.1399-0039.1995.tb02460.x
   HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411
   Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x
   JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683
   Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4
   KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592
   KASHANCHI F, 1994, J VIROL, V68, P561
   KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2
   KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965
   KOVATS S, 1994, J EXP MED, V179, P2017, DOI 10.1084/jem.179.6.2017
   LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018
   LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0
   Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301
   MANN DL, 1990, CLIN IMMUNOL IMMUNOP, V54, P174, DOI 10.1016/0090-1229(90)90079-6
   Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X
   McCabe A.M., 1987, Journal of Quaternary Science, V2, P11, DOI 10.1002/jqs.3390020104
   MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O
   MEYAARD L, 1993, IMMUNOL TODAY, V14, P161, DOI 10.1016/0167-5699(93)90279-T
   MORENO CS, 1995, J IMMUNOL, V155, P4313
   Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839
   Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009
   PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x
   PETIT AJC, 1987, J CLIN INVEST, V79, P1883, DOI 10.1172/JCI113032
   PETIT AJC, 1988, J IMMUNOL, V140, P1485
   Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572
   POLI G, 1985, CLIN EXP IMMUNOL, V62, P136
   Polyak S, 1997, J IMMUNOL, V159, P2177
   POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989
   PRINCE HE, 1985, J CLIN IMMUNOL, V5, P21, DOI 10.1007/BF00915164
   Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
   REITH W, 1995, IMMUNOL TODAY, V16, P539, DOI 10.1016/0167-5699(95)80048-4
   REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3
   REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554
   REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200
   RICH EA, 1988, J LAB CLIN MED, V112, P174
   RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0
   ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581
   RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565
   ROUXLOMBARD P, 1989, CLIN IMMUNOL IMMUNOP, V50, P374, DOI 10.1016/0090-1229(89)90144-X
   ROWELL JF, 1995, J IMMUNOL, V155, P473
   SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076
   Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239
   SEIDL C, 1992, J IMMUNOL, V148, P1576
   Singal DP, 1996, CLIN EXP RHEUMATOL, V14, P669
   SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624
   SLOAN JH, 1992, J IMMUNOL, V148, P2591
   SMITH PD, 1984, J CLIN INVEST, V74, P2121, DOI 10.1172/JCI111637
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91
   SPERBER K, 1990, J CLIN LAB IMMUNOL, V31, P151
   SPERBER K, 1990, J IMMUNOL METHODS, V129, P31, DOI 10.1016/0022-1759(90)90417-T
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P657, DOI 10.1089/aid.1993.9.657
   STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X
   STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021
   STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643
   SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641
   TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028
   TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433
   Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1
   Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232
   TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3
   TISHON A, 1993, VIROLOGY, V195, P397, DOI 10.1006/viro.1993.1389
   TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021
   UNANUE E, 1989, FUNDAMENTAL IMMUNOLO, P567
   UNANUE E, 1984, ANNU REV IMMUNOL, V3, P973
   VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x
   VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406
   WAHL SM, 1989, J IMMUNOL, V142, P3553
   Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055
   Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281
   WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601
   WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978
   Yoo L, 1996, J IMMUNOL, V157, P1313
   ZHU L, 1990, MOL CELL BIOL, V10, P3906, DOI 10.1128/MCB.10.8.3906
   ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167-5699(96)10029-3
   ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902
NR 101
TC 17
Z9 17
U1 1
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2001
VL 167
IS 4
BP 2331
EP 2342
DI 10.4049/jimmunol.167.4.2331
PG 12
WC Immunology
SC Immunology
GA 471VP
UT WOS:000170949600064
PM 11490022
OA Bronze
DA 2018-12-27
ER

PT J
AU Shao, ZM
   Wu, J
   Shen, ZZ
   Nguyen, M
AF Shao, ZM
   Wu, J
   Shen, ZZ
   Nguyen, M
TI RETRACTED: p53 mutation in plasma DNA and its prognostic value in breast
   cancer patients (Retracted Article. See vol 8, pg 3027, 2002)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID K-RAS MUTATIONS; MICROSATELLITE ALTERATIONS; COLORECTAL-CANCER;
   GENE-MUTATIONS; FOLLOW-UP; CARCINOMA; SERUM
AB Purpose: Tumor-specific DNA has recently been detected in the plasma of lung, head and neck, breast, and colon cancer patients. Detection of tumor-specific genetic materials in cancer patients at sites distant from the tumor, such as in the blood, may provide a unique and valuable tumor marker for diagnosis and prognosis.
   Experimental Design: The present investigation was aimed at determining the presence of p53 mutations in the peripheral blood of breast cancer patients and its prognostic value in these patients.
   Results: In this study, we found that the mean concentration of plasma DNA in healthy women was 21 ng/ml, whereas in patients with breast cancer the mean concentration was 211 ng/ml (P < 0.01). p53 mutations were detected in the primary tumors of 46 of 126 (36.5%) breast cancer patients. Of these 46 patients, 30 (65.1 %) were found to have p53 mutations in their plasma DNA. p53 mutations in plasma DNA were strongly correlated with clinical stage, tumor size, lymph node (LN) metastasis, and estrogen receptor status (P < 0.05). After a median follow-up of 29 months, univariate and multivariate analysis revealed that both primary tumor and plasma DNA p53 mutations were significant prognostic factors for both relapse-free and overall survival. Furthermore, we demonstrated that patients with both primary tumor and plasma p53 mutations have the worst survival. This outcome occurs in both LN-positive and LN-negative groups. Thirteen of the 22 (59%) patients with recurrence and/or metastasis later had detectable p53 mutations in their plasma DNA.
   Conclusions: Detection of p53 mutations in plasma DNA may be used as a prognostic factor and an early marker to indicate recurrence or distant metastasis.
C1 Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90095 USA.
   Fu Dan Univ, Inst Canc, Canc Hosp, Dept Surg, Shanghai 200032, Peoples R China.
RP Shao, ZM (reprint author), Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Box 951782, Los Angeles, CA 90095 USA.
EM zshao@ucla.edu
CR Anker P, 1997, GASTROENTEROLOGY, V112, P1114, DOI 10.1016/S0016-5085(97)70121-5
   Bast RC, 1996, J CLIN ONCOL, V14, P2843
   Castells A, 1999, J CLIN ONCOL, V17, P578, DOI 10.1200/JCO.1999.17.2.578
   Chen XQ, 1996, NAT MED, V2, P1033
   Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Jezersek B, 1996, CANCER LETT, V110, P137, DOI 10.1016/S0304-3835(96)04473-4
   KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364
   KUTE TE, 1992, CANCER RES, V50, P4901
   LEON SA, 1977, CANCER RES, V37, P646
   Linderholm B, 2000, INT J CANCER, V89, P51, DOI 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8
   MANGUES R, 1994, CANCER RES, V54, P6395
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Norberg T, 1998, INT J CANCER, V79, P376, DOI 10.1002/(SICI)1097-0215(19980821)79:4<376::AID-IJC12>3.3.CO;2-S
   ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8
   OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379
   Pectasides D, 1996, AM J CLIN ONCOL-CANC, V19, P459, DOI 10.1097/00000421-199610000-00007
   ROBERTSON JF, 1998, EUR J CANCER, V35, P47
   Silva JM, 1999, GENE CHROMOSOME CANC, V24, P160
   SILVA JM, 1999, CANCER RES, V59, P3252
   STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5
   STROUN M, 1989, ONCOLOGY, V46, P318
   THEILLET C, 1986, CANCER RES, V46, P4776
NR 25
TC 49
Z9 54
U1 4
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG
PY 2001
VL 7
IS 8
BP 2222
EP 2227
PG 6
WC Oncology
SC Oncology
GA 460VB
UT WOS:000170328300008
PM 11489795
DA 2018-12-27
ER

PT J
AU Kalia, A
   Enright, MC
   Spratt, BG
   Bessen, DE
AF Kalia, A
   Enright, MC
   Spratt, BG
   Bessen, DE
TI RETRACTED: Directional gene movement from human-pathogenic to
   commensal-like streptococci (Retracted article. See vol. 77, pg. 4688,
   2009)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID GROUP-A STREPTOCOCCI; LANCEFIELD GROUP-C; NEISSERIA-MENINGITIDIS;
   POPULATION-STRUCTURE; PROTEIN GENE; RECOMBINATION; STRAINS; BINDING;
   EPIDEMIOLOGY; DYSGALACTIAE
AB Group A streptococci (GAS) are highly pathogenic for humans, and their closest genetic relatives, group C and G streptococci (GCS and GGS, respectively), are generally regarded as commensals, although they can be found in association with human disease. As part of an effort to better understand the evolution of virulence, the phylogenetic relationships between GAS, GCS, and GGS were examined. The nucleotide sequence was determined for an internal portion of seven housekeeping (neutral) loci among >200 isolates of GAS and 34 isolates of GCS or GGS obtained from human subjects. Genotypic analysis failed to show support for the separation of GCS and GGS into two distinct populations. Unlike GAS, there was poor concordance between emm type and genetic relatedness among GCS and GGS. All housekeeping genes within GAS displayed relatively low levels of sequence diversity. In contrast, individual GCS and GGS strains had mosaic genomes, containing alleles at some loci that were similar or identical to GAS alleles, whereas the alleles at other loci were about 10 to 30% diverged. The data provide evidence for a history of recent interspecies transfer of neutral genes that exhibits a strong net directionality from GAS donors to GCS and GGS recipients. A model for the evolution of GAS and of GCS and GGS is described.
C1 Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.
   Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis Epidemiol, London W2 1PG, England.
RP Bessen, DE (reprint author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,Box 208034, New Haven, CT 06520 USA.
EM debra.bessen@yale.edu
RI Spratt, Brian/A-1676-2009
FU NIGMS NIH HHS [R01 GM060793, GM-60793]; NIAID NIH HHS [AI-28944]
CR Beall B, 1996, J CLIN MICROBIOL, V34, P953
   Bessen DE, 1999, J INFECT DIS, V179, P627, DOI 10.1086/314631
   Bessen DE, 2000, J INFECT DIS, V182, P1109, DOI 10.1086/315842
   Bisno AL, 2000, PRINCIPLES PRACTICE, P2101
   BRADLEY SF, 1991, REV INFECT DIS, V13, P270
   CARMELI Y, 1995, J CLIN MICROBIOL, V33, P2114
   Chhatwal GS, 2000, GRAM-POSITIVE PATHOGENS, P177
   CLEARY PP, 1991, INFECT IMMUN, V59, P2305
   Cockerill FR, 1997, JAMA-J AM MED ASSOC, V277, P38, DOI 10.1001/jama.277.1.38
   COLLINS CM, 1992, INFECT IMMUN, V60, P3689
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   EFSTRATIOU A, 1983, J HYG-CAMBRIDGE, V90, P71, DOI 10.1017/S0022172400063865
   Efstratiou A, 1997, J APPL MICROBIOL, V83, pS72, DOI 10.1046/j.1365-2672.83.s1.8.x
   Enright MC, 2001, INFECT IMMUN, V69, P2416, DOI 10.1128/IAI.69.4.2416-2427.2001
   Facklam R, 1999, EMERG INFECT DIS, V5, P247, DOI 10.3201/eid0502.990209
   Facklam R, 1991, MANUAL CLIN MICROBIO, P238
   Feil EJ, 2001, P NATL ACAD SCI USA, V98, P182, DOI 10.1073/pnas.98.1.182
   Gupta S, 1999, PARASITOL TODAY, V15, P497, DOI 10.1016/S0169-4758(99)01559-8
   Holmes EC, 1999, MOL BIOL EVOL, V16, P741, DOI 10.1093/oxfordjournals.molbev.a026159
   Horn DL, 1998, CLIN INFECT DIS, V26, P1341, DOI 10.1086/516375
   Huelsenbeck JP, 1997, SCIENCE, V276, P227, DOI 10.1126/science.276.5310.227
   Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68
   Johnson C., 2000, PRINCIPLES PRACTICE, P2167
   KAPLAN EL, 1980, J PEDIATR-US, V97, P337, DOI 10.1016/S0022-3476(80)80178-8
   KAPUR V, 1995, MOL MICROBIOL, V16, P509, DOI 10.1111/j.1365-2958.1995.tb02415.x
   Kehoe MA, 1996, TRENDS MICROBIOL, V4, P436, DOI 10.1016/0966-842X(96)10058-5
   Kline JB, 1996, INFECT IMMUN, V64, P2122
   LANCEFIELD RC, 1962, J IMMUNOL, V89, P307
   Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000
   Malke H, 2000, GRAM-POSITIVE PATHOGENS, P163
   MARTIN NJ, 1990, J CLIN MICROBIOL, V28, P1881
   MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384
   MILKMAN R, 1990, GENETICS, V126, P505
   Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101
   NASR B, 1994, EUR J BIOCHEM, V222, P267
   Ogunbi O, 1974, STREPTOCOCCAL DIS CO, P281
   Oster HR, 2000, GRAM-POSITIVE PATHOGENS, P184
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   SCHNITZLER N, 1995, J CLIN MICROBIOL, V33, P356
   SIMPSON WJ, 1992, INFECT IMMUN, V60, P1890
   SJOBRING U, 1989, MOL MICROBIOL, V3, P319, DOI 10.1111/j.1365-2958.1989.tb00177.x
   Smith NH, 1999, MOL BIOL EVOL, V16, P773, DOI 10.1093/oxfordjournals.molbev.a026162
   SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988
   Sriprakash KS, 1996, MICROB PATHOGENESIS, V20, P275, DOI 10.1006/mpat.1996.0026
   Turner JC, 1997, J CLIN MICROBIOL, V35, P1
   Vandamme P, 1996, INT J SYST BACTERIOL, V46, P774, DOI 10.1099/00207713-46-3-774
   Vieira VV, 1998, INT J SYST BACTERIOL, V48, P1231, DOI 10.1099/00207713-48-4-1231
   WANNAMAKER LW, 1973, J EXP MED, V137, P1338, DOI 10.1084/jem.137.6.1338
   WHATMORE E, 2000, INFECT IMMUN, V68, P1374
   Zhou JJ, 1997, MOL MICROBIOL, V23, P799, DOI 10.1046/j.1365-2958.1997.2681633.x
NR 50
TC 60
Z9 61
U1 3
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 2001
VL 69
IS 8
BP 4858
EP 4869
DI 10.1128/IAI.69.8.4858-4869.2001
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 456UP
UT WOS:000170100900021
PM 11447161
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU McNally, A
   Roe, AJ
   Simpson, S
   Thomson-Carter, FM
   Hoey, DEE
   Currie, C
   Chakraborty, T
   Smith, DGE
   Gally, DL
AF McNally, A
   Roe, AJ
   Simpson, S
   Thomson-Carter, FM
   Hoey, DEE
   Currie, C
   Chakraborty, T
   Smith, DGE
   Gally, DL
TI RETRACTED: Differences in levels of secreted locus of enterocyte
   effacement proteins between human disease-associated and bovine
   Escherichia coli O157 (Retracted Article. See vol 73, pg 2571, 2005)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID HEAT-STABLE ENTEROTOXIN; PATHOGENICITY ISLAND; MULTIPLEX PCR;
   SHIGELLA-FLEXNERI; VIRULENCE FACTORS; TOXIN; STRAINS; GENES; PROTEASE;
   EXPRESSION
AB Ongoing extensive epidemiological studies of verotoxin-carrying Escherichia coli O157 (stx(+) eae(+)) have shown this bacterial pathogen to be common in cattle herds in the United States and the United Kingdom. However, the incidence of disease in humans due to this pathogen is still very low. This study set out to investigate if there is a difference between strains isolated from human disease cases and those isolated from asymptomatic cattle which would account for the low disease incidence of such a ubiquitous organism. The work presented here has compared human disease strains from both sporadic and outbreak cases with a cross-section, as defined by pulsed-field gel electrophoresis, of E. coli O157 strains from cattle. Human (n = 22) and bovine (n = 31) strains were genotyped for carriage of the genes for Shiga-like toxin types 1, 2, and 2c; E. coli secreted protein genes espA, espB, and espP; the enterohemolysin gene; eae (intimin); ast (enteroaggregative E. coli stable toxin [EAST]); and genes for common E. coli adhesins. Strains were also phenotyped for hemolysin, EspP, Tir, and EspD expression as well as production of actin and cytoskeletal rearrangement associated with attaching and effacing (A/E) lesions on HeLa cells. The genotyping confirmed that there was little difference between the two groups, including carriage of stx(2) and stx(2c), which was similar in both sets. ast alleles were confirmed to all contain mutations that would prevent EAST expression. espP mutations were found only in cattle strains (5 of 30). Clear differences were observed in the expression of locus of enterocyte effacement (LEE)-encoded factors between strains and in different media. EspD, as an indicator of LEE4 (espA, -B, and -D) expression, and Tir levels in supernatants were measured. Virtually all strains from both sources could produce EspD in Luria-Bertani broth, although at very different levels. Standard trichloroacetic acid precipitation of secreted proteins from tissue culture medium produced detectable levels of EspD from the majority of strains of human origin (15 of 20) compared with only a few (4 of 20) bovine strains (P < 0.001), which is indicative of much higher levels of protein secretion from the human strains. Addition of bovine serum albumin carrier protein before precipitation and enhanced detection techniques confirmed that EspD could be detected after growth in tissue culture medium for all strains, but levels from strains of human origin were on average 90-fold higher than those from strains of bovine origin. In general, levels of secretion also correlated with ability to form A/E lesions on HeLa cells, with only the high-level protein secretors in tissue culture medium exhibiting a localized adherence phenotype. This research shows significant differences between human- and bovine-derived E. coli O157 (stx(+) eae(+)) strains and their production of certain LEE-encoded virulence factors. These data support the recent finding of Kim et al. (J. Kim, J. Nietfeldt, and A. K. Benson, Proc. Natl. Acad. Sci. USA 96:13288-13293, 1999) proposing different E. coli O157 lineages in cattle and humans and extend the differential to the regulation of virulence factors. Potentially only a subset of E. coli O157 isolates (stx(+) eae(+)) in cattle may be capable of causing severe disease in humans.
C1 Univ Edinburgh, Dept Vet Pathol, ZAP Labs, Edinburgh EH8 9AG, Midlothian, Scotland.
   Univ Aberdeen, Dept Med Microbiol, Aberdeen, Scotland.
   Univ Giessen, Inst Med Mikrobiol, Giessen, Germany.
RP Gally, DL (reprint author), Univ Edinburgh, Dept Vet Pathol, ZAP Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
EM dgally@ed.ac.uk
RI Smith, David/N-9743-2018
OI Smith, David/0000-0002-2484-2603
CR Al-Hasani K, 2000, INFECT IMMUN, V68, P2457, DOI 10.1128/IAI.68.5.2457-2463.2000
   Allison LJ, 2000, J CLIN MICROBIOL, V38, P1632
   Ammon A, 1999, J INFECT DIS, V179, P1274, DOI 10.1086/314715
   Bastian SN, 1998, RES MICROBIOL, V149, P457, DOI 10.1016/S0923-2508(98)80001-6
   Beltrametti F, 1999, J BACTERIOL, V181, P3409
   Bertin Y, 1996, J CLIN MICROBIOL, V34, P2921
   Blanco M, 1996, EUR J EPIDEMIOL, V12, P13, DOI 10.1007/BF00144422
   Blank VD, 1996, MOL CRYST LIQ CRYS C, V7, P251
   Boerlin P, 1999, J CLIN MICROBIOL, V37, P497
   Brunder W, 1999, MICROBIOL-UK, V145, P1005, DOI 10.1099/13500872-145-5-1005
   Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x
   Burland V, 1998, NUCLEIC ACIDS RES, V26, P4196, DOI 10.1093/nar/26.18.4196
   *CDCP, 2000, FOODB DIS ACT SURV N
   China B, 1999, FEMS MICROBIOL LETT, V178, P177, DOI 10.1016/S0378-1097(99)00352-3
   Cray WC, 1996, VET MICROBIOL, V53, P369, DOI 10.1016/S0378-1135(96)01261-8
   DeVinney R, 1999, INFECT IMMUN, V67, P2389
   Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x
   Ebel F, 1996, INFECT IMMUN, V64, P4472
   Elder RO, 2000, P NATL ACAD SCI USA, V97, P2999, DOI 10.1073/pnas.060024897
   Elliott SJ, 2000, INFECT IMMUN, V68, P6115, DOI 10.1128/IAI.68.11.6115-6126.2000
   Fagan PK, 1999, APPL ENVIRON MICROB, V65, P868
   Franck SM, 1998, J CLIN MICROBIOL, V36, P1795
   Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x
   Friedberg D, 1999, MOL MICROBIOL, V34, P941, DOI 10.1046/j.1365-2958.1999.01655.x
   Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x
   Henderson IR, 1999, INFECT IMMUN, V67, P5587
   Kim J, 1999, P NATL ACAD SCI USA, V96, P13288, DOI 10.1073/pnas.96.23.13288
   Klapproth JA, 2000, INFECT IMMUN, V68, P2148, DOI 10.1128/IAI.68.4.2148-2155.2000
   Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166
   KNUTTON S, 1989, INFECT IMMUN, V57, P1290
   Li BG, 1997, MOL CELL PROBE, V11, P397, DOI 10.1006/mcpr.1997.0132
   McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x
   Meng JH, 1998, INT J FOOD MICROBIOL, V45, P229, DOI 10.1016/S0168-1605(98)00163-9
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P142
   Perna NT, 1998, INFECT IMMUN, V66, P3810
   *PUBL HLTH LAB SER, 2000, E COL O157 DIS RAT E
   Roe AJ, 2000, CURR OPIN INFECT DIS, V13, P511, DOI 10.1097/00001432-200010000-00013
   Roe AJ, 2001, MICROBIOL-SGM, V147, P145, DOI 10.1099/00221287-147-1-145
   Savarino SJ, 1996, J INFECT DIS, V173, P1019, DOI 10.1093/infdis/173.4.1019
   Synge B, 2000, VET REC, V147, P27
   Wieler LH, 1998, J CLIN MICROBIOL, V36, P1604
   Yamamoto T, 1997, FEMS MICROBIOL LETT, V147, P89, DOI 10.1016/S0378-1097(96)00509-5
   Yamamoto T, 1996, INFECT IMMUN, V64, P1441
   Yamamoto T, 2000, FEBS LETT, V472, P22, DOI 10.1016/S0014-5793(00)01414-9
   Zhang WL, 2000, J CLIN MICROBIOL, V38, P2134
NR 45
TC 66
Z9 67
U1 4
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 2001
VL 69
IS 8
BP 5107
EP 5114
DI 10.1128/IAI.69.8.5107-5114.2001
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 456UP
UT WOS:000170100900052
PM 11447192
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Lehmann, A
   Boldt, J
   Rompert, R
   Thaler, E
   Kumle, B
   Weisse, U
AF Lehmann, A
   Boldt, J
   Rompert, R
   Thaler, E
   Kumle, B
   Weisse, U
TI RETRACTED: Target-controlled infusion or manually controlled infusion of
   propofol in high-risk patients with severely reduced left ventricular
   function (Retracted article. See vol. 25, pg. 756, 2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE target-controlled infusion; propofol; remifentanil; reduced left
   ventricular function
ID CARDIOVERTER-DEFIBRILLATOR IMPLANTATION; DIPRIFUSOR TCI; DILATED
   CARDIOMYOPATHY; INTRAVENOUS ANESTHESIA; PHARMACOKINETIC MODEL; CONSCIOUS
   SEDATION; CARDIAC-SURGERY; LEAD SYSTEMS; REMIFENTANIL; SAFETY
AB Objective: To compare hemodynamics, time to extubation, and costs of target-controlled infusion (TCI) with manually controlled infusion (MCI) of propofol in high-risk cardiac surgery patients.
   Design: Prospective, randomized.
   Setting: Major community university-affiliated hospital.
   Participants: Twenty patients undergoing first-time implantation of a cardioverter-defibrillator with severely reduced left ventricular function (left ventricular ejection fraction < 30%).
   Interventions: Anesthesia was performed using remifentanil, 0.2 to 0.3 mug/kg/min, and propofol. Propofol was used as TCI (plasma target concentration, 2 to 3 mug/mL; n = 10) or MCI (2.5 to 3.5 mg/kg/hr; n = 10).
   Measurements and Main Results: Hemodynamics were measured at 6 data points: T1, before anesthesia; T2 after intubation; T3, after skin incision; T4, after first defibrillation; T5, after third defibrillation; and T6, after extubation. There were no significant hemodynamic differences between the 2 groups. Dobutamine was required to maintain cardiac index > 2 L/min/m(2) in significantly more patients of the TCI group than of the MCI group. Mean dose of propofol was higher in the TCI patients (6.0 +/- 1.0 mg/kg/hr) than in the MCI patients (3.0 +/- 0.4 mg/kg/hr) (p < 0.05), whereas doses of remifentanil did not differ. Time to extubation was significantly shorter in the MCI (11.9 +/- 2.4 min) versus the TCI group (15.6 +/- 6.8 min). Costs were significantly lower in MCI patients ($34.73) than in TCI patients ($44.76).
   Conclusions: In patients with severely reduced left ventricular function, TCI and MCI of propofol in combination with remifentanil showed similar hemodynamics. TCI patients needed inotropic support more often than MCI-treated patients. Although extubation time was longer in TCI patients and costs were higher, both anesthesia techniques can be recommended for early extubation after implantation of a cardioverter-defibrillator. Copyright (C) 2001 by W.B. Saunders Company.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67073 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Dept Cardiac Surg, D-6700 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Postfach 21 73 52, D-67073 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR Bailey JM, 1996, ANESTHESIOLOGY, V84, P1288, DOI 10.1097/00000542-199606000-00003
   BLAKEMAN BP, 1993, J THORAC CARDIOV SUR, V106, P1040
   Casati A, 1999, ANESTH ANALG, V88, P917, DOI 10.1097/00000539-199904000-00043
   COETZEE JF, 1995, ANESTHESIOLOGY, V82, P1328, DOI 10.1097/00000542-199506000-00003
   DERSHWITZ M, 1995, ANESTH ANALG, V81, P619, DOI 10.1097/00000539-199509000-00035
   Fechner J, 1998, ANAESTHESIST, V47, P663, DOI 10.1007/s001010050611
   FITZPATRICK AP, 1994, CIRCULATION, V89, P2503, DOI 10.1161/01.CIR.89.6.2503
   FRAME R, 1993, PACE, V16, P149, DOI 10.1111/j.1540-8159.1993.tb01552.x
   Galatius S, 2000, AM J CARDIOL, V85, P843, DOI 10.1016/S0002-9149(99)00878-4
   Gray JM, 1998, ANAESTHESIA, V53, P22, DOI 10.1111/j.1365-2044.1998.53s114.x
   HACHENBERG T, 1991, ACTA ANAESTH SCAND, V35, P626, DOI 10.1111/j.1399-6576.1991.tb03361.x
   Hunt-Smith J, 1999, ANAESTH INTENS CARE, V27, P260
   Izquierdo E, 1995, Rev Esp Anestesiol Reanim, V42, P424
   Kuipers JA, 1999, ANESTHESIOLOGY, V91, P1780, DOI 10.1097/00000542-199912000-00032
   Lehmann A, 1999, J CARDIOTHOR VASC AN, V13, P15, DOI 10.1016/S1053-0770(99)90166-0
   Myles PS, 1997, ANESTH ANALG, V84, P12, DOI 10.1097/00000539-199701000-00003
   Natale A, 1996, J CARDIOVASC ELECTR, V7, P301, DOI 10.1111/j.1540-8167.1996.tb00531.x
   Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1
   Pacifico A, 1997, CIRCULATION, V95, P946
   Pacifico A, 1997, J AM COLL CARDIOL, V30, P769, DOI 10.1016/S0735-1097(97)00225-8
   Pagel PS, 1998, ANESTHESIOLOGY, V88, P180, DOI 10.1097/00000542-199801000-00026
   Phillips A S, 1994, J Cardiothorac Vasc Anesth, V8, P289, DOI 10.1016/1053-0770(94)90240-2
   RUSSELL D, 1995, BRIT J ANAESTH, V75, P562, DOI 10.1093/bja/75.5.562
   Russell D, 1998, ANAESTHESIA, V53, P42, DOI 10.1111/j.1365-2044.1998.53s113.x
   Servin FS, 1998, ANAESTHESIA, V53, P82, DOI 10.1111/j.1365-2044.1998.53s107.x
   Servin FS, 1998, ANAESTHESIA, V53, P72, DOI 10.1111/j.1365-2044.1998.53s106.x
   SHERRY KM, 1995, J CARDIOTHOR VASC AN, V9, P368, DOI 10.1016/S1053-0770(05)80089-8
   Stix G, 1996, EUR HEART J, V17, P764
   Strachan AN, 2000, BRIT J ANAESTH, V84, P489
   STRICKBERGER SA, 1994, CIRCULATION, V90, P868, DOI 10.1161/01.CIR.90.2.868
   Struys M, 1997, ANAESTHESIA, V52, P41, DOI 10.1111/j.1365-2044.1997.002-az001.x
   Swinhoe CF, 1998, ANAESTHESIA, V53, P61, DOI 10.1111/j.1365-2044.1998.53s104.x
   TRAPPE HJ, 1995, Z KARDIOL, V84, P385
   TUNG RT, 1995, AM J CARDIOL, V75, P908, DOI 10.1016/S0002-9149(99)80685-7
   Vuyk J, 1996, ANESTHESIOLOGY, V84, P288, DOI 10.1097/00000542-199602000-00006
   WHITE M, 1990, ANAESTHESIA, V45, P204, DOI 10.1111/j.1365-2044.1990.tb14685.x
NR 36
TC 16
Z9 18
U1 1
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD AUG
PY 2001
VL 15
IS 4
BP 445
EP 450
DI 10.1053/jcan.2001.24979
PG 6
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 463JY
UT WOS:000170466600008
PM 11505347
DA 2018-12-27
ER

PT J
AU D'Onofrio, M
   Cuomo, L
   Battaglia, G
   Ngomba, RT
   Storto, M
   Kingston, AE
   Orzi, F
   De Blasi, A
   Di Iorio, P
   Nicoletti, F
   Bruno, V
AF D'Onofrio, M
   Cuomo, L
   Battaglia, G
   Ngomba, RT
   Storto, M
   Kingston, AE
   Orzi, F
   De Blasi, A
   Di Iorio, P
   Nicoletti, F
   Bruno, V
TI RETRACTED: Neuroprotection mediated by glial group-II metabotropic
   glutamate receptors requires the activation of the MAP kinase and the
   phosphatidylinositol-3-kinase pathways (Retracted article. See vol. 129,
   pg. 1035, 2014)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE astrocytes; MAP kinase; mGlu receptors; neuroprotection;
   phosphatidylinositol-3-kinase; TGF-beta 1
ID GROWTH-FACTOR-BETA; RAT HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS;
   TRANSFORMING GROWTH-FACTOR-BETA-1; PHARMACOLOGICAL AGENTS; AMYLOID
   PEPTIDE; TGF-BETA-1; INHIBITOR; DEATH; NEUROTOXICITY
AB The mGlu2/3 receptor agonists 4-carboxy-3-hydroxyphenylglycine (4C3HPG) and LY379268 attenuated NMDA toxicity in primary cultures containing both neurons and astrocytes. Neuroprotection was abrogated by PD98059 and LY294002, which inhibit the mitogen activated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PI-3-K) pathways, respectively. Cultured astrocytes lost the ability to produce transforming growth factor-PI (TGF-pl) in response to mGlu2/3 receptor agonists when co-incubated with PD98059 or LY294002. As a result, the glial medium was no longer protective against NMDA toxicity. Activation of the MAPK and PI-3-K pathways in cultured astrocytes treated with 4C3HPG or LY379268 was directly demonstrated by an increase in the phosphorylated forms of ERK-1/2 and Akt. Similarly to that observed in the culture, intracerebral or systemic injections of mGlu2/3 receptor agonists enhanced TGF-beta1 formation in the rat or mouse caudate nucleus, and this effect was reduced by PD98059. PD98059 also reduced the ability of LY379268 to protect striatal neurons against NMDA toxicity. These results suggest that activation of glial mGlu2/3 receptors induces neuroprotection through the activation of the MAPK and PI-3-K pathways leading to the induction of TGF-beta.
C1 Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy.
   INM Neuromed, Pozzilli, Italy.
   Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
   Univ Roma La Sapienza, Dept Neurosci, I-00185 Rome, Italy.
   Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy.
   Univ G dAnnunzio, Dept Biomed Sci, Chieti, Italy.
RP Nicoletti, F (reprint author), Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM nicoletti@neuromed.it
RI Storto, Marianna/G-8745-2012; bruno, Valeria/F-3146-2012; Nicoletti,
   Ferdinando/K-4410-2016; Battaglia, Giuseppe/A-7709-2010
OI bruno, Valeria/0000-0003-4231-0739; Battaglia,
   Giuseppe/0000-0001-7571-3417; marianna, storto/0000-0002-0159-7449;
   NICOLETTI, Ferdinando/0000-0003-3366-7269; Ngomba,
   Richard/0000-0003-3825-3970
FU Telethon [1238]
CR Behrens MM, 1999, NEUROPHARMACOLOGY, V38, P1621, DOI 10.1016/S0028-3908(99)00098-2
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9
   BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x
   Bruno V, 1998, J NEUROSCI, V18, P9594
   Bruno V, 1997, J NEUROSCI, V17, P1891
   Buisson A, 1998, FASEB J, V12, P1683
   BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F
   CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409
   CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Copani A, 1999, FASEB J, V13, P2225
   COPANI A, 1995, MOL PHARMACOL, V47, P890
   DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545
   Docagne F, 1999, FASEB J, V13, P1315
   DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686
   FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408
   Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X
   HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609
   KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331
   Kingston AE, 1999, EUR J PHARMACOL, V377, P155, DOI 10.1016/S0014-2999(99)00397-0
   Kingston AE, 1999, ANN NY ACAD SCI, V890, P438, DOI 10.1111/j.1749-6632.1999.tb08022.x
   LEE JM, 1999, NATURE, V90, P1339
   Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2
   Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X
   Meucci O, 1996, J NEUROSCI, V16, P4080
   Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n
   PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585
   Prehn JHM, 1996, MOL PHARMACOL, V49, P319
   PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599
   Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9
   Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3
   Rose K., 1992, METHODS TOXICOLOGY, V1, P46
   Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008
   Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1
   Scorziello A, 1997, J NEUROSCI RES, V49, P600, DOI 10.1002/(SICI)1097-4547(19970901)49:5<600::AID-JNR10>3.0.CO;2-Z
   Shaeffer H.J., 1999, MOL CELL BIOL, V19, P2435
   Srivastava AK, 1998, TRENDS PHARMACOL SCI, V19, P205, DOI 10.1016/S0165-6147(98)01208-5
   Toker A, 2000, MOL PHARMACOL, V57, P652
   Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
NR 41
TC 105
Z9 105
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD AUG
PY 2001
VL 78
IS 3
BP 435
EP 445
DI 10.1046/j.1471-4159.2001.00435.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 460TZ
UT WOS:000170325800003
PM 11483646
OA Bronze
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Koomen, W
AF Stapel, DA
   Koomen, W
TI RETRACTED: When we wonder what it all means: Interpretation goals
   facilitate accessibility and stereotyping effects (Retracted article.
   See vol. 39, pg. 264, 2013)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
ID CATEGORY ACCESSIBILITY; IMPRESSION-FORMATION; ACCURACY MOTIVATION;
   INFORMATION; ACTIVATION; JUDGMENT; CONSTRUCTS; TRAITS; IMPACT
AB In four studies, the authors show that interpretation goals facilitate accessibility and stereotyping effects. Study I shows that priming traits that are descriptively inapplicable to a target stimulus affect target interpretations when an interpretation goal is primed but not when no such goal is present. Studies 2 and 3 show that the range of judgment dimensions affected by applicable trait primes increases when people are interpretation motivated. Studies 3 and 4 show that behavior that is only weakly related to stereotypical beliefs is interpreted in stereotypical terms when an interpretation goal is activated, whereas no such stereotyping effect occurs when perceivers are not so motivated. Implications for models of accessibility and stereotyping effects are discussed.
C1 Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands.
RP Stapel, DA (reprint author), Univ Groningen, Dept Social & Org Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
EM d.a.stapel@ppsw.rug.nl
CR BANAJI MR, 1993, J PERS SOC PSYCHOL, V65, P272, DOI 10.1037/0022-3514.65.2.272
   Bargh J.A, 1997, ADV SOCIAL COGNITION, V10
   BARGH JA, 1996, UNPUB SOCIAL IGNITIO
   BEM SL, 1974, J CONSULT CLIN PSYCH, V42, P155, DOI 10.1037/h0036215
   BOCK MD, 1975, MULTIVARIATE STAT ME
   Bodenhausen GV, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P271
   Bruner JS, 1957, CONT APPROACHES COGN, P41
   FISKE ST, 1990, ADV EXP SOC PSYCHOL, V23, P1, DOI 10.1016/S0065-2601(08)60317-2
   FORD TE, 1995, PERS SOC PSYCHOL B, V21, P950, DOI 10.1177/0146167295219009
   Hamilton D. L., 1994, HDB SOCIAL COGNITION, V2, P1
   HAMPSON SE, 1986, J PERS SOC PSYCHOL, V51, P37, DOI 10.1037/0022-3514.51.1.37
   HIGGINS ET, 1995, J EXP SOC PSYCHOL, V31, P218, DOI 10.1006/jesp.1995.1011
   HIGGINS ET, 1977, J EXP SOC PSYCHOL, V13, P141
   Higgins ET, 1996, SOCIAL PSYCHOL HDB B, P133
   KUNDA Z, 1990, PSYCHOL BULL, V108, P480, DOI 10.1037//0033-2909.108.3.480
   Kunda Z, 1996, PSYCHOL REV, V103, P284, DOI 10.1037/0033-295X.103.2.284
   MARTIN LL, 1990, J PERS SOC PSYCHOL, V59, P27, DOI 10.1037//0022-3514.59.1.27
   Neter J., 1985, APPL LINEAR STAT MOD
   NORUSIS MJ, 1997, SPSS 6 1 GUIDE DATA
   Petty R, 1996, ANSWERING QUESTIONS, P221
   SAGAR HA, 1980, J PERS SOC PSYCHOL, V39, P590, DOI 10.1037//0022-3514.39.4.590
   SEDIKIDES C, 1990, J PERS SOC PSYCHOL, V58, P397, DOI 10.1037/0022-3514.58.3.397
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 1998, J EXP SOC PSYCHOL, V34, P136, DOI 10.1006/jesp.1997.1346
   Stapel DA, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P229
   STAPEL DA, 1999, UNPUB DETERMINANTS D
   THOMPSON EP, 1994, J PERS SOC PSYCHOL, V66, P474, DOI 10.1037//0022-3514.66.3.474
   WYER RS, 1989, MEMORY SOCIAL COGNIT
NR 30
TC 9
Z9 9
U1 1
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD AUG
PY 2001
VL 27
IS 8
BP 915
EP 929
DI 10.1177/0146167201278001
PG 15
WC Psychology, Social
SC Psychology
GA 452XE
UT WOS:000169884300001
DA 2018-12-27
ER

PT J
AU Kabarowski, JHS
   Zhu, K
   Le, LQ
   Witte, ON
   Xu, Y
AF Kabarowski, JHS
   Zhu, K
   Le, LQ
   Witte, ON
   Xu, Y
TI RETRACTED: Lysophosphatidylcholine as a ligand for the immunoregutatory
   receptor G2A (Retracted article. See vol 307, pg 206, 2005)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID PROTEIN-COUPLED RECEPTORS; ENDOTHELIAL-CELLS; CULTURED HUMAN;
   IDENTIFICATION; ACTIVATION; LIPOPROTEINS; CYTOKINES; COMPONENT; ARTERIAL
AB Although the biological actions of the cell membrane and serum lipid lysophosphatidylcholine (LPC) in atherosclerosis and systemic autoimmune disease are well recognized, LPC has not been linked to a specific cell-surface receptor. We show that LPC is a high-affinity ligand for G2A, a lymphocyte-expressed G protein-coupled receptor whose genetic ablation results in the development of autoimmunity. Activation of G2A by LPC increased intracellular calcium concentration, induced receptor internalization, activated ERK mitogen-activated protein kinase, and modified migratory responses of Jurkat T lymphocytes. This finding implicates a role for LPC-G2A interaction in the etiology of inflammatory autoimmune disease and atherosclerosis.
C1 Lerner Res Inst, Dept Microbiol Immunol & Mol Genet, Cleveland, OH 44195 USA.
   Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.
   Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.
   Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA.
RP Witte, ON (reprint author), Lerner Res Inst, Dept Microbiol Immunol & Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM owenw@microblo.ucia.edu; xuy@ccf.org
FU NCI NIH HHS [T32 CA09056, CA76204, 1 R21 CA84038-01]
CR Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2
   BAUDHUIN LM, UNPUB
   Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051
   Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683
   HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25
   Huang YH, 1999, CLIN EXP IMMUNOL, V116, P326
   Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429
   Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52
   Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109
   Koh JS, 2000, J IMMUNOL, V165, P4190, DOI 10.4049/jimmunol.165.8.4190
   KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932
   KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047
   Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334
   Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529
   YAMAMOTO N, 1991, J IMMUNOL, V147, P273
NR 21
TC 228
Z9 237
U1 3
U2 23
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUL 27
PY 2001
VL 293
IS 5530
BP 702
EP 705
DI 10.1126/science.1061781
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 458PW
UT WOS:000170204600056
PM 11474113
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Fichou, D
   Batlogg, B
AF Schon, JH
   Kloc, C
   Fichou, D
   Batlogg, B
TI RETRACTED: Conjugation length dependence of the charge transport in
   oligothiophene single crystals - art. no. 035209 (Retracted article. See
   vol B 66, 249906, 2002)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; ORGANIC MOLECULAR-CRYSTALS; SEXITHIOPHENE
   FILMS; MODEL DESCRIPTION; THIN-FILMS; MOBILITY; GROWTH;
   SUPERCONDUCTIVITY; SEMICONDUCTORS; NAPHTHALENE
AB The intrinsic charge-transport mechanism in oligothiophene single crystals is investigated by temperature-dependent space-charge-limited current spectroscopy. The mobility for in-plane transport in these layered p-type semiconductors follows a power law behavior typical for coherent bandlike charge transport. A value as high as 80 cm(2)/V a is measured far the mobility in the high-temperature polymorph of alpha -sexithiophene at low temperatures. in contrast to that the charge transport perpendicular to the molecular planes can be described by incoherent hopping motion revealing the typical thermally activated temperature dependence. Consequently, the charge carrier can be characterized as partly delocalized between molecules of the molecular layer but localized within this molecular plane. The effective hole mass of the polaronic charge carrier increases with increasing temperature due to electron-phonon interaction. The strength of this electron-phonon interaction decreases with increasing conjugation length of the oligothiophene molecule leading to higher room temperature mobilities for alpha -octithiophene and alpha -sexithiophene than for alpha -quaterthiophene.
C1 Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.
   CEA Saclay, Serv Phys & Chim Surfaces & Interfaces, DRECAM, DSM, F-91191 Gif Sur Yvette, France.
   Univ Paris 06, UMR 7611, F-75005 Paris, France.
   ETH Honggerberg, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Schon, JH (reprint author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Fichou, Denis/K-3540-2013; Kloc, Christian/A-2255-2011
OI Fichou, Denis/0000-0002-5081-3806; 
CR Antolini L, 1998, ADV MATER, V10, P382, DOI 10.1002/(SICI)1521-4095(199803)10:5<382::AID-ADMA382>3.0.CO;2-Y
   APPEL J, 1968, SOLID STATE PHYSICS, V21
   BERG S, IN PRESS PHYS REV B
   Brocks G, 1999, SYNTHETIC MET, V102, P914, DOI 10.1016/S0379-6779(98)00958-8
   Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8
   Cornil J, 2000, ADV MATER, V12, P978, DOI 10.1002/1521-4095(200006)12:13<978::AID-ADMA978>3.0.CO;2-S
   Devos A, 1998, PHYS REV B, V58, P8236, DOI 10.1103/PhysRevB.58.8236
   Dimitrakopoulos CD, 1998, SYNTHETIC MET, V92, P47, DOI 10.1016/S0379-6779(98)80021-0
   Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736
   Fichou D, 2001, ADV MATER, V13, P555, DOI 10.1002/1521-4095(200104)13:8<555::AID-ADMA555>3.0.CO;2-#
   Fichou D, 1997, SYNTHETIC MET, V85, P1309, DOI 10.1016/S0379-6779(97)80253-6
   FIVAZ R, 1967, PHYS REV, V163, P743, DOI 10.1103/PhysRev.163.743
   Garnier F, 1996, SYNTHETIC MET, V81, P163, DOI 10.1016/S0379-6779(96)03761-7
   HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719
   Horowitz G, 1998, EUR PHYS J-APPL PHYS, V1, P361, DOI 10.1051/epjap:1998157
   Horowitz G, 1999, J APPL PHYS, V85, P3202, DOI 10.1063/1.369661
   HOROWITZ G, 1995, CHEM MATER, V7, P1337, DOI 10.1021/cm00055a010
   Karl N., 1990, DEFECT CONTROL SEMIC, V2, P1725
   Katz HE, 1995, CHEM MATER, V7, P2235, DOI 10.1021/cm00060a007
   KATZ HE, 1999, HDB OLIGO POLYTHIOPH
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Knupfer M, 2000, CHEM PHYS LETT, V318, P585, DOI 10.1016/S0009-2614(00)00033-6
   KNUPFER M, IN PRESS PHYS REV B
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Lee M, 2001, PHYS REV LETT, V86, P862, DOI 10.1103/PhysRevLett.86.862
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   PALOHEIMO J, 1990, APPL PHYS LETT, V56, P1157, DOI 10.1063/1.103182
   Pope M., 1982, ELECT PROCESSES ORGA
   Schon JH, 2000, ORG ELECTRON, V1, P57, DOI 10.1016/S1566-1199(00)00010-0
   Schon JH, 2000, NATURE, V406, P702, DOI 10.1038/35021011
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   Schon JH, 1999, APPL PHYS LETT, V74, P260, DOI 10.1063/1.123274
   Schon JH, 2001, PHYS REV LETT, V86, P3843, DOI 10.1103/PhysRevLett.86.3843
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   Schon JH, 2000, SYNTHETIC MET, V115, P75, DOI 10.1016/S0379-6779(00)00348-9
   SCHON JH, 2000, MRS S P, V598
   SCHON JH, 2001, SYNTHETIC MET, V115, P75
   Schoonveld WA, 2000, NATURE, V404, P977, DOI 10.1038/35010073
   SIEGRIST T, 1995, J MATER RES, V10, P2170, DOI 10.1557/JMR.1995.2170
   Siegrist T, 1998, ADV MATER, V10, P379, DOI 10.1002/(SICI)1521-4095(199803)10:5<379::AID-ADMA379>3.0.CO;2-A
   SILINSH EA, 1989, CHEM PHYS, V138, P347, DOI 10.1016/0301-0104(89)87141-1
   SILINSH EA, 1991, CHEM PHYS, V155, P389, DOI 10.1016/0301-0104(91)80115-X
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   Swenberg CE, 1998, CHEM PHYS LETT, V287, P535, DOI 10.1016/S0009-2614(98)00229-2
   Torsi L, 1996, SCIENCE, V272, P1462, DOI 10.1126/science.272.5267.1462
   Vrijmoeth J, 1998, J APPL PHYS, V83, P3816, DOI 10.1063/1.367145
   WARAGAI K, 1995, PHYS REV B, V52, P1786, DOI 10.1103/PhysRevB.52.1786
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
   Wu MW, 1997, CHEM PHYS LETT, V266, P363, DOI 10.1016/S0009-2614(97)00022-5
NR 50
TC 9
Z9 9
U1 2
U2 4
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD JUL 15
PY 2001
VL 64
IS 3
AR 035209
DI 10.1103/PhysRevB.64.035209
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 454UH
UT WOS:000169989800050
DA 2018-12-27
ER

PT J
AU Yang, HP
   Wang, JH
   Ou, XP
   Huang, ZZ
   Lu, SC
AF Yang, HP
   Wang, JH
   Ou, XP
   Huang, ZZ
   Lu, SC
TI RETRACTED: Cloning and analysis of the rat glutamate-cysteine ligase
   modifier subunit promoter (Retracted Article. See vol 324, pg 970, 2004)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE glutathione; H4IIE cells; glutamate-cysteine ligase; DNase I
   footprinting; transfection
ID GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ELECTROPHILE RESPONSIVE ELEMENT;
   AMINO-ACID-SEQUENCE; GENE-EXPRESSION; LIGHT SUBUNIT; GLUTATHIONE
   SYNTHESIS; HEAVY SUBUNIT; CELL-DENSITY; HEPG2 CELLS; BINDING
AB Glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione (GSH) synthesis, is made up of two subunits, a catalytic (GCLC) and a modifier (GCLM) subunit, which are differentially regulated. Increased GCLM expression occurs under certain oxidative stress conditions. To facilitate studies of GCLM transcriptional regulation, we have cloned and characterized a 1.86-kb 5 ' -flanking region of the rat GCLM (GenBank Accession No. AF311745). A TATA-like element and one transcriptional start sites are located at 364 and 93 nucleotides upstream of the translational start site, respectively. The promoter contains consensus binding sites for many transcription factors including activator protein 1 (AP-1), transcription factor 11 (TCF11), heat shock transcription factor (HSF), and nuclear factor kappa B (NF kappaB). The rat GCLM promoter was able to drive efficiently luciferase expression in H4IIE cells. Sequential deletion analysis revealed DNA regions, -649 to -154 and -1251 to -649, are involved in positive and negative gene regulation, respectively. Candidate transcription factors were identified by DNase I footprinting. (C) 2001 Academic Press.
C1 Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA.
RP Lu, SC (reprint author), Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, 2011 Zonal Ave,HMR Bldg,415, Los Angeles, CA 90033 USA.
EM shellylu@hsc.usc.edu
FU NIDDK NIH HHS [P30 DK48522, DK-45334]
CR Bijur GN, 1999, MOL BRAIN RES, V71, P69, DOI 10.1016/S0169-328X(99)00168-0
   Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167
   CAI JX, 1995, MOL PHARMACOL, V48, P212
   Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693
   Galloway DC, 1998, BIOCHEM J, V336, P535, DOI 10.1042/bj3360535
   Galloway DC, 1997, BIOCHEM J, V328, P99
   HUANG CS, 1993, J BIOL CHEM, V268, P19675
   HUANG CS, 1993, J BIOL CHEM, V268, P20578
   Huang ZZ, 1998, HEPATOLOGY, V27, P147, DOI 10.1002/hep.510270123
   Hudson FN, 2000, BBA-GENE STRUCT EXPR, V1492, P447, DOI 10.1016/S0167-4781(00)00128-7
   Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512
   Lu SC, 1999, TOXICOL APPL PHARM, V159, P161, DOI 10.1006/taap.1999.8729
   Lu SC, 1999, HEPATOLOGY, V30, P209, DOI 10.1002/hep.510300134
   LU SC, 1992, J CLIN INVEST, V90, P524, DOI 10.1172/JCI115890
   Lu SC, 1999, FASEB J, V13, P1169
   LU SC, 1992, AM J PHYSIOL, V263, pC1181
   Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683
   Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109
   Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445
   POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316
   RICHMAN PG, 1975, J BIOL CHEM, V250, P1422
   SAMBROOK J, 1989, MOL CLONING, V2, P9
   SEELIG GF, 1984, J BIOL CHEM, V259, P9345
   SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343
   Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627
   YAN N, 1990, J BIOL CHEM, V265, P1588
   Zeng ZH, 2000, BIOCHEM J, V346, P475, DOI 10.1042/0264-6021:3460475
NR 27
TC 14
Z9 14
U1 1
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 13
PY 2001
VL 285
IS 2
BP 476
EP 482
DI 10.1006/bbrc.2001.5190
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 455HF
UT WOS:000170020900048
PM 11444867
DA 2018-12-27
ER

PT J
AU Wolf, I
   Rubinfeld, H
   Yoon, S
   Marmor, G
   Hanoch, T
   Seger, R
AF Wolf, I
   Rubinfeld, H
   Yoon, S
   Marmor, G
   Hanoch, T
   Seger, R
TI RETRACTED: Involvement of the activation loop of ERK in the detachment
   from cytosolic anchoring (Retracted article. See vol. 292, pg. 8853,
   2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NUCLEAR EXPORT SIGNAL; PROTEIN MAP KINASE; GROWTH-FACTOR;
   NUCLEOCYTOPLASMIC TRANSPORT; ACTIVE-TRANSPORT; TRANSLOCATION; CASCADE;
   PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION
AB The Extracellular signal-regulated kinases (ERKs) are translocated into the nucleus in response to mitogenic stimulation. The mechanism of translocation and the residues in ERKs that govern this process are not clear as yet. Here we studied the involvement of residues in the activation loop of ERK2 in determining its subcellular localization. Substitution of residues in the activation loop to alanines indicated that residues 173-181 do not play a significant role in the phosphorylation and activation of ERK2. However, residues 176-181 are responsible for the detachment of ERK2 from MEK1 upon mitogenic stimulation. This dissociation can be mimicked by substitution of residues 176-178 to alanines and is prevented by deletion of these residues or by substitution of residues 179-181 to alanines. On the other hand, residues 176-181, as well as residues essential for ERK2 dimerization, do not play a role in the shuttle of ERK2 through nuclear pores. Thus, phosphorylation-induced conformational rearrangement of residues in the activation loop of ERK2 plays a major role in the control of subcellular localization of this protein.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM rony.seger@weizmann.ac.il
CR Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347
   Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849
   Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200
   BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9
   Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664
   Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652
   Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262
   CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X
   Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001
   Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4
   Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024
   Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642
   Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7
   LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0
   Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625
   LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8
   RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668
   SEGER R, 1995, FASEB J, V9, P726
   Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631
   Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8
   Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385
   Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065
   TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351
   Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671
   Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988
   Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1
   Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0
NR 34
TC 66
Z9 67
U1 2
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 6
PY 2001
VL 276
IS 27
BP 24490
EP 24497
DI 10.1074/jbc.M103352200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 451KF
UT WOS:000169800700011
PM 11328824
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Meyaard, L
   de Vries, ARV
   de Ruiter, T
   Lanier, LL
   Phillips, JH
   Clevers, H
AF Meyaard, L
   de Vries, ARV
   de Ruiter, T
   Lanier, LL
   Phillips, JH
   Clevers, H
TI RETRACTED: The epithelial cellular adhesion molecule (Ep-CAM) is a
   ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR)
   (Retracted Article. See vol 198, pg 1129, 2003)
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE ITIM; colon carcinoma; inhibitory receptor; intraepithelial lymphocytes;
   mucosal tolerance
ID MONOCLONAL-ANTIBODY; SURFACE GLYCOPROTEIN; INHIBITORY RECEPTORS; MR
   34,000; CELLS; NK; DIFFERENTIATION; LYMPHOCYTES; EXPRESSION; ANTIGEN
AB Human leukocyte-associated immunoglobulin-like receptor (LAIR)-1 is expressed on many cells of the immune system and is predicted to mediate inhibitory functions based on the presence of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain. Although the role of LAIR-1 in the regulation of immune responses in vivo is unknown, LAIR-1 cross-linking by monoclonal antibody inhibits various immune cell functions in vitro. Here, we identify the coloncarcinoma-associated epithelial cellular adhesion molecule (Ep-CAM) as a ligand for LAIR-1 and LAIR-2, a related soluble LAIR-1 family member. Ep-CAM interacts with the LAIR molecules through its first epidermal growth factor domain; ep-CAM-specific antibodies can abrogate the binding. Intraepithelial T lymphocytes express LAIR-1 and thus may interact with Ep-CAM present on human intestinal epithelium. We propose that LAIR-1-Ep-CAM interaction may contribute to mucosal tolerance and that LAIR-2 possibly modulate this function.
C1 Univ Utrecht, Med Ctr, Dept Immunol, NL-3584 CX Utrecht, Netherlands.
   DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA.
   Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94304 USA.
   Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94304 USA.
RP Meyaard, L (reprint author), Univ Utrecht, Med Ctr, Dept Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM l.meyaard@lab.azu.nl
FU NCI NIH HHS [R01 CA089294, CA89294-01]
CR ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573
   Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038
   Barten R, 2001, TRENDS IMMUNOL, V22, P52, DOI 10.1016/S1471-4906(00)01802-0
   BERGSAGEL PL, 1992, J IMMUNOL, V148, P590
   de Vries ARV, 1999, EUR J IMMUNOL, V29, P3160
   EDWARDS DP, 1986, CANCER RES, V46, P1306
   Huls GA, 1999, NAT BIOTECHNOL, V17, P276, DOI 10.1038/7023
   LANIER LL, 1994, J IMMUNOL, V153, P2417
   Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642
   Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337
   LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437
   Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875
   Lopez-Botet M, 2000, HUM IMMUNOL, V61, P7, DOI 10.1016/S0198-8859(99)00161-5
   LUNDQVIST C, 1992, J IMMUNOL METHODS, V152, P253, DOI 10.1016/0022-1759(92)90147-L
   Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0
   Meyaard L, 1999, J IMMUNOL, V162, P5800
   MOLDENHAUER G, 1987, BRIT J CANCER, V56, P714, DOI 10.1038/bjc.1987.276
   MOMBURG F, 1987, CANCER RES, V47, P2883
   Nelson AJ, 1996, EUR J IMMUNOL, V26, P401, DOI 10.1002/eji.1830260220
   Poggi A, 1998, EUR J IMMUNOL, V28, P2086, DOI 10.1002/(SICI)1521-4141(199807)28:07<2086::AID-IMMU2086>3.0.CO;2-T
   Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84
   Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788
   Wende H, 2000, IMMUNOGENETICS, V51, P703, DOI 10.1007/s002510000187
NR 23
TC 36
Z9 40
U1 2
U2 12
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD JUL 2
PY 2001
VL 194
IS 1
BP 107
EP 112
DI 10.1084/jem.194.1.107
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 450NJ
UT WOS:000169749800011
PM 11435477
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Sun, MF
   Baglia, FA
   Ho, D
   Martincic, D
   Ware, RE
   Walsh, PN
   Gailani, D
AF Sun, MF
   Baglia, FA
   Ho, D
   Martincic, D
   Ware, RE
   Walsh, PN
   Gailani, D
TI RETRACTED: Defective binding of factor XI-N248 to activated human
   platelets (Retracted Article. See vol 110, pg 4164, 2007)
SO BLOOD
LA English
DT Article; Retracted Publication
ID COAGULATION-FACTOR-XI; APPLE 3 DOMAIN; BLOOD-COAGULATION; FACTOR-IX;
   FEEDBACK ACTIVATION; CONTACT ACTIVATION; IDENTIFICATION; DEFICIENCY;
   THROMBIN; PLASMA
AB Variants of factor XI containing Gln226 to Arg (Q226 to R) and Ser248 to Asn (S248 to N) substitutions were first identified in an African American family with a history of excessive bleeding. The substitutions have recently been identified in unrelated individuals, suggesting they are relatively common. Both amino acids are located in the third apple domain of factor XI, an area implicated in binding interactions with factor IX and activated platelets. Recombinant factor XI-R226 and factor XI-N248 were compared with wildtype factor XI in assays for factor IX activation or platelet binding. Factor XI-R226 activates factor IX with a Michaelis- Menten constant (K-m) about B-fold greater than wild-type protein. The catalytic efficiency of factor IX activation is similar to wild-type protein, however, due to an increase in the turnover number (k(cat)) for the reaction, Iodinated factor XI-N248 binds to activated platelets with a dissociation constant (K-d) more than B-fold higher than wild-type protein (55 nRn and 10 nM, respectively). Activation of factor XI-N248 by thrombin in the presence of activated platelets is slower and does not progress to the same extent as activation of the wild-type protein under similar conditions, Factor XI-N248 activates factor IX normally in a purified protein system and has relatively normal activity in activated partial thromboplastin time (aPTT) assays. Factor XI-N248 is the first factor XI variant described with a clear functional difference compared with wild-type protein. Importantly, the defect in platelet binding would not be detected by routine clinical evaluation with an aPTT assay. (C) 2001 by The American Society of Hematology.
C1 Vanderbilt Univ, Hematol Oncol Div, Dept Pathol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA.
   Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA.
   Temple Univ, Sch Med, Dept Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19122 USA.
RP Gailani, D (reprint author), Vanderbilt Univ, Hematol Oncol Div, Dept Pathol, 538 MRB 2-2220 Pierce Ave, Nashville, TN 37232 USA.
EM dave.gailani@mcmail.vanderbilt.edu
FU NHLBI NIH HHS [HL56914, HL02917, HL46213, HL56153, HL58837]
CR ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303
   Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200
   BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+
   BELL WN, 1954, NATURE, V174, P880, DOI 10.1038/174880a0
   BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x
   BOUMA BN, 1977, J BIOL CHEM, V252, P6432
   BROZE GJ, 1993, THROMB HAEMOSTASIS, V70, P72
   Cargill M, 1999, NAT GENET, V22, P231
   DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001
   FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018
   FURIE B, 1992, NEW ENGL J MED, V326, P800
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   Gailani D, 1999, BLOOD, V94, p621A
   GAILANI D, 1993, BLOOD COAGUL FIBRIN, V4, P15, DOI 10.1097/00001721-199304010-00003
   GAILANI D, 2001, METABOLIC MOL BASIS, V3, P4433
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   HAYASHI T, 1997, THROMB HAEMOSTASIS, V78, pPS188
   Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200
   Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382
   Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q
   KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020
   MANNHALTER C, 1987, BLOOD, V70, P31
   Martincic D, 1998, BLOOD, V92, P3309
   MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008
   MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021
   RAGNI MV, 1985, BLOOD, V65, P719
   SADLER JE, 2001, MOL BASIS BLOOD DIS, P680
   SAITO H, 1985, J LAB CLIN MED, V106, P718
   SELIGSOHN U, 1993, THROMB HAEMOSTASIS, V70, P68
   Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373
   Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023
   Tarumi T, 2000, GENOMICS, V70, P269, DOI 10.1006/geno.2000.6393
   VONDEMBORNE PAK, 1995, BLOOD, V86, P3035
   Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153
NR 35
TC 21
Z9 22
U1 1
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUL 1
PY 2001
VL 98
IS 1
BP 125
EP 129
DI 10.1182/blood.V98.1.125
PG 5
WC Hematology
SC Hematology
GA 447JK
UT WOS:000169568000020
PM 11418471
OA Bronze
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Bryne, M
   Johannessen, AC
   Kildal, W
   Danielsen, HE
   Reith, A
AF Sudbo, J
   Bryne, M
   Johannessen, AC
   Kildal, W
   Danielsen, HE
   Reith, A
TI RETRACTED: Comparison of histological grading and large-scale genomic
   status (DNA ploidy) as prognostic tools in oral dysplasia (Retracted
   Article. See vol 211, pg 109, 2007)
SO JOURNAL OF PATHOLOGY
LA English
DT Article; Retracted Publication
DE oral white patch; oral mucosa; dysplasia; grading; inter-observer
   variability; large-scale genomic status; DNA ploidy; nuclear DNA
   content; prognosis
ID SQUAMOUS-CELL CARCINOMAS; MALIGNANT-TRANSFORMATION; IMAGE CYTOMETRY;
   PREMALIGNANT LESIONS; WHITE LESIONS; CANCER; LEUKOPLAKIA; INSTABILITY;
   PREDICTION; ESOPHAGUS
AB Approximately one in ten oral white patches (leukoplakia) are histologically classified as dysplasia, with a well-documented potential for developing into oral squamous cell carcinoma (OSCC), Histological grading in oral dysplasia has limited prognostic value, whereas large-scale genomic status (DNA ploidy, nuclear DNA content) is an early marker of malignant transformation in several tissues. Biopsies from 196 patients with oral leukoplakia histologically typed as dysplasia were investigated. Inter-observer agreement among four experienced pathologists performing a simplified grading was assessed by Cohen's kappa values. For 150 of the 196 cases, it was also possible to assess large-scale genomic status and compare its prognostic impact with that of histological grading. Disease-free survival was estimated by life-table methods, with a mean follow-up time of 103 months (range 4-165 months), The primary considered end-point was the subsequent occurrence of OSCC, For grading of the total of 196 cases, kappa values ranged from 0.17 to 0.33 when three grading groups (mild, moderate, and severe dysplasia) were considered, and from 0.21 to 0.32 when two groups (low grade and high grade) were considered (p = 0.41). For the 150 cases in which large-scale genomic status was also assessed, kappa values for the histological grading ranged from 0.21 to 0.33 for three grading groups and from 0.27 to 0.34 for two grading groups (p = 0.47), in survival analysis, histological grading was without significant prognostic value for any of the four observers (p 0.14-0.44), in contrast to DNA ploidy (p = 0.001). It is concluded that DNA ploidy in oral dysplasia has a practical prognostic value, unlike histological grading of the same lesions. Copyright (C) 2001 John Wiley & Sons, Ltd.
C1 Norwegian Radium Hosp, Dept Pathol, Div Digital Pathol, N-0310 Oslo, Norway.
   Univ Oslo, Dept Oral Biol, Oslo, Norway.
   Univ Bergen, Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Pathol, Div Digital Pathol, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
RI Johannessen, Anne Christine/B-8929-2017
OI Johannessen, Anne Christine/0000-0001-5403-2380
CR ABDELSALAM M, 1988, CANCER, V62, P1981, DOI 10.1002/1097-0142(19881101)62:9<1981::AID-CNCR2820620918>3.0.CO;2-O
   ABDELSALAM M, 1990, ORAL SURG ORAL MED O, V69, P345, DOI 10.1016/0030-4220(90)90297-6
   ANKFALVI A, 2000, J ORAL PATHOL MED, V7, P291
   ANNEROTH G, 1987, SCAND J DENT RES, V95, P229
   Axell T, 1996, J ORAL PATHOL MED, V25, P49, DOI 10.1111/j.1600-0714.1996.tb00191.x
   Bethwaite P, 1998, J CLIN PATHOL, V51, P450, DOI 10.1136/jcp.51.6.450
   BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204
   BOUQUOT JE, 1986, ORAL SURG ORAL MED O, V61, P373, DOI 10.1016/0030-4220(86)90422-6
   Brunin F, 1999, HEAD NECK-J SCI SPEC, V21, P751, DOI 10.1002/(SICI)1097-0347(199912)21:8<751::AID-HED11>3.3.CO;2-W
   Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831
   COTES RA, 1992, SYSTEMATIZED NOMENCL
   DEVET HCW, 1995, J CLIN EPIDEMIOL, V48, P869, DOI 10.1016/0895-4356(94)00225-F
   Ellison M D, 1999, Surg Oncol Clin N Am, V8, P725
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
   GRANT WE, 1993, J LARYNGOL OTOL, V107, P1140
   GUPTA PC, 1989, J ORAL PATHOL MED, V18, P17, DOI 10.1111/j.1600-0714.1989.tb00725.x
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   HEDLEY DW, 1994, METHOD CELL BIOL, V41, P231
   Hogmo A, 1996, HEAD NECK-J SCI SPEC, V18, P433, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<433::AID-HED6>3.0.CO;2-6
   Hogmo A, 1998, ANTICANCER RES, V18, P3645
   HONG WK, 1983, NEW ENGL J MED, V308, P75, DOI 10.1056/NEJM198301133080204
   KARABULUT A, 1995, J ORAL PATHOL MED, V24, P198, DOI 10.1111/j.1600-0714.1995.tb01166.x
   Kubler A, 1998, INT J ORAL MAX SURG, V27, P466, DOI 10.1016/S0901-5027(98)80040-4
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LICCIARDELLO JTW, 1989, INT J RADIAT ONCOL, V17, P467, DOI 10.1016/0360-3016(89)90096-5
   MUNCKWIKLAND E, 1990, ACTA OTO-LARYNGOL, V109, P155, DOI 10.3109/00016489009107428
   Nisi KW, 1998, INT J RADIAT ONCOL, V41, P371, DOI 10.1016/S0360-3016(98)00059-5
   Oh Yun, 1997, Current Opinion in Oncology, V9, P247, DOI 10.1097/00001622-199709030-00006
   PINDBORG JJ, 1996, HISTOLOGICAL TYPING
   Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8
   Saito T, 1999, ORAL DIS, V5, P15
   Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303
   Schantz Stimson P., 1994, Current Opinion in Oncology, V6, P265, DOI 10.1097/00001622-199405000-00008
   Schoelch ML, 1999, LARYNGOSCOPE, V109, P949, DOI 10.1097/00005537-199906000-00021
   Scholes AGM, 1998, CANCER RES, V58, P2003
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Seoane J, 1998, CLIN OTOLARYNGOL, V23, P136
   SILVERMAN S, 1984, CANCER, V53, P563
   Sporn MB, 1997, ANN NY ACAD SCI, V833, P137, DOI 10.1111/j.1749-6632.1997.tb48599.x
   TANKE HJ, 1980, J HISTOCHEM CYTOCHEM, V28, P1007, DOI 10.1177/28.9.6157711
   WALDRON CA, 1975, CANCER-AM CANCER SOC, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
   Warnakulasuriya S, 2000, J PATHOL, V190, P407, DOI 10.1002/(SICI)1096-9896(200003)190:4<407::AID-PATH546>3.0.CO;2-D
   WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306
NR 43
TC 44
Z9 46
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2001
VL 194
IS 3
BP 303
EP 310
DI 10.1002/1096-9896(200107)194:3<303::AID-PATH879>3.0.CO;2-Q
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA 448PJ
UT WOS:000169635600005
PM 11439362
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Hole transport in pentacene single crystals - art. no. 245201
   (Retracted article. See vol B 66, art. no. 249903, 2002)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID THIN-FILM TRANSISTORS; ORGANIC MOLECULAR-CRYSTALS; FIELD-EFFECT
   TRANSISTORS; PHYSICAL VAPOR GROWTH; ELECTRICAL CHARACTERISTICS;
   EVAPORATED PENTACENE; POLYACENE CRYSTALS; CHARGE-TRANSPORT;
   DRIFT-VELOCITY; MOBILITY
AB Hole transport in high-quality pentacene single crystals is investigated using space-charge-limited current spectroscopy in a temperature range from 2 to 500 K. The temperature and electric-field dependence of the charge-carrier mobility below room temperature indicates a bandlike charge transport. The effective electronic bandwidth at low temperatures is estimated to be on the order of 400 meV. However, due to electron-phonon interaction the bandwidth narrows significantly, leading to a localization of the charge carriers and the formation of a lattice polaron above approximately 400 K. As a result, the transport mechanism crosses over from coherent bandlike motion to incoherent hopping.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR Appel J., 1968, SOLID STATE PHYS, V21, P193
   ASCHE M, 1970, PHYS STATUS SOLIDI, V37, P433, DOI 10.1002/pssb.19700370148
   AUSTIN IG, 1971, CONDUCTION LOW MOBIL, P13
   BARBE DF, 1970, J CHEM PHYS, V52, P4046, DOI 10.1063/1.1673607
   BERG S, UNPUB
   BITTERLING K, 1987, PHYS REV B, V35, P7973, DOI 10.1103/PhysRevB.35.7973
   Bouchoms IPM, 1999, SYNTHETIC MET, V104, P175, DOI 10.1016/S0379-6779(99)00050-8
   BURLAND DM, 1977, J CHEM PHYS, V67, P319, DOI 10.1063/1.434527
   BURLAND DM, 1974, PHYS REV LETT, V33, P833, DOI 10.1103/PhysRevLett.33.833
   BURSHTEIN Z, 1977, PHYS REV B, V15, P5769, DOI 10.1103/PhysRevB.15.5769
   Conwell E. M., 1967, HIGH FIELD TRANSPORT
   Cornil J, 2000, ADV MATER, V12, P978, DOI 10.1002/1521-4095(200006)12:13<978::AID-ADMA978>3.0.CO;2-S
   CORNIL J, UNPUB
   CRUICKSHANK DWJ, 1958, REV MOD PHYS, V30, P163, DOI 10.1103/RevModPhys.30.163
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   DIMITRAKOPOULOS CD, 1996, J APPL PHYS, V80, P4
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   DOWS DA, 1973, CHEM PHYS LETT, V22, P595
   EAGLES DM, 1966, PHYS REV, V145, P645, DOI 10.1103/PhysRev.145.645
   EAGLES DM, 1969, PHYS REV, V181, P1278, DOI 10.1103/PhysRev.181.1278
   ERGINSOY C, 1950, PHYS REV, V79, P1013, DOI 10.1103/PhysRev.79.1013
   Garnier F, 1997, PHILOS T R SOC A, V355, P815, DOI 10.1098/rsta.1997.0046
   GLAESER RM, 1966, J CHEM PHYS, V44, P3797, DOI 10.1063/1.1726537
   GLARUM SH, 1963, J PHYS CHEM SOLIDS, V24, P1577, DOI 10.1016/0022-3697(63)90100-8
   Gundlach DJ, 1999, APPL PHYS LETT, V74, P3302, DOI 10.1063/1.123325
   HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719
   HOLSTEIN T, 1959, ANN PHYS-NEW YORK, V8, P325, DOI 10.1016/0003-4916(59)90002-8
   HOLSTEIN T, 1959, ANN PHYS-NEW YORK, V8, P343, DOI 10.1016/0003-4916(59)90003-X
   Horowitz G, 2000, ADV MATER, V12, P1046, DOI 10.1002/1521-4095(200007)12:14<1046::AID-ADMA1046>3.0.CO;2-W
   Horowitz G, 2000, J APPL PHYS, V87, P4456, DOI 10.1063/1.373091
   Kao K. C., 1981, ELECT TRANSPORT SOLI
   Karl N., 1990, DEFECT CONTROL SEMIC, V2, P1725
   KARL N, UNPUB
   KARL N, 1991, SYNTHETIC MET, V41, P2473
   KENKRE VM, 1989, PHYS REV LETT, V62, P1165, DOI 10.1103/PhysRevLett.62.1165
   KEPLER RG, 1960, PHYS REV, V119, P1226, DOI 10.1103/PhysRev.119.1226
   Klauk H, 1999, IEEE T ELECTRON DEV, V46, P1258, DOI 10.1109/16.766895
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7
   LEBLANC OH, 1960, J CHEM PHYS, V33, P626, DOI 10.1063/1.1731216
   Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476
   LITTLEWOOD PB, COMMUNICATION
   MINAKATA T, 1992, J APPL PHYS, V72, P5220, DOI 10.1063/1.352004
   MUNN RW, 1970, J CHEM PHYS, V52, P6391, DOI 10.1063/1.1672955
   NATKANIEC I, 1980, J PHYS C SOLID STATE, V13, P4265, DOI 10.1088/0022-3719/13/23/014
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   OTTAVIANI G, 1975, PHYS REV B, V12, P3318, DOI 10.1103/PhysRevB.12.3318
   REINEKER P, 1981, PHYS LETT A, V84, P294, DOI 10.1016/0375-9601(81)90816-1
   SCHEIN LB, 1979, PHYS REV B, V20, P1631, DOI 10.1103/PhysRevB.20.1631
   SCHEIN LB, 1978, PHYS REV LETT, V40, P197, DOI 10.1103/PhysRevLett.40.197
   Schon JH, 2000, ORG ELECTRON, V1, P57, DOI 10.1016/S1566-1199(00)00010-0
   Schon JH, 1998, APPL PHYS LETT, V73, P3574, DOI 10.1063/1.122828
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   Schon JH, 1999, APPL PHYS LETT, V74, P260, DOI 10.1063/1.123274
   Schon JH, 2001, PHYS REV LETT, V86, P3843, DOI 10.1103/PhysRevLett.86.3843
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 2001, J APPL PHYS, V89, P336, DOI 10.1063/1.1329667
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   Schon JH, 2000, SYNTHETIC MET, V115, P75, DOI 10.1016/S0379-6779(00)00348-9
   SEEGER K, 1982, SEMICONDUCTOR PHYSIC
   SHOCKLEY W, 1951, AT&T TECH J, V30, P990, DOI 10.1002/j.1538-7305.1951.tb03692.x
   SIEGRIST T, UNPUB
   SILBEY R, 1980, J CHEM PHYS, V72, P2763, DOI 10.1063/1.439425
   Silinsh E. A., 1987, Journal of Molecular Electronics, V3, P123
   Silinsh E. A., 1974, Physica Status Solidi A, V25, P339, DOI 10.1002/pssa.2210250133
   Silinsh E. A., 1994, ORGANIC MOL CRYSTALS
   Silinsh EA, 1996, CHEM LISTY, V90, P43
   SILINSH EA, 1985, CHEM PHYS, V94, P77, DOI 10.1016/0301-0104(85)85067-9
   SILINSH EA, 1989, CHEM PHYS, V138, P347, DOI 10.1016/0301-0104(89)87141-1
   SILINSH EA, 1995, CHEM PHYS, V198, P311, DOI 10.1016/0301-0104(95)00151-D
   SILINSH EA, 1982, PHYS STATUS SOLIDI B, V113, P379, DOI 10.1002/pssb.2221130141
   SINGH DC, 1974, MOL CRYST LIQ CRYST, V27, P55, DOI 10.1080/15421407408083120
   Sumi H., 1978, Solid State Communications, V28, P309, DOI 10.1016/0038-1098(78)90430-1
   SUMI H, 1981, J CHEM PHYS, V75, P2987, DOI 10.1063/1.442390
   SUZUKI M, 1968, SPECTROCHIM ACTA A-M, VA 24, P1091, DOI 10.1016/0584-8539(68)80129-1
   Swenberg CE, 1998, CHEM PHYS LETT, V287, P535, DOI 10.1016/S0009-2614(98)00229-2
   TANAKA K, 1994, SYNTHETIC MET, V62, P97, DOI 10.1016/0379-6779(94)90205-4
   Tharaud O, 1998, J CHIM PHYS PCB, V95, P1363, DOI 10.1051/jcp:1998284
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
   WARTA W, 1985, APPL PHYS A, V36, P136
   Wu MW, 1997, CHEM PHYS LETT, V266, P363, DOI 10.1016/S0009-2614(97)00022-5
NR 82
TC 33
Z9 33
U1 2
U2 17
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1098-0121
EI 1550-235X
J9 PHYS REV B
JI Phys. Rev. B
PD JUN 15
PY 2001
VL 63
IS 24
AR 245201
DI 10.1103/PhysRevB.63.245201
PG 10
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 446TX
UT WOS:000169531200035
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Hoshi, T
   Uemura, A
   Toyooka, H
AF Fujii, Y
   Hoshi, T
   Uemura, A
   Toyooka, H
TI RETRACTED: Dose-response characteristics of midazolam for reducing
   diaphragmatic contractility (Retracted article. See vol. 116, pg. 745,
   2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID HALOTHANE; VOLUNTARY; MUSCLE; DOGS
AB A sedative dose of midazolam decreases contractility of the diaphragm, but no data are available concerning the relationship between dose and diaphragmatic contractility. We studied the dose-response characteristics of midazolam for reducing the diaphragmatic contractility in dogs. Animals were divided into three groups of eight each: Group 1 received no study drug, Group 2 was infused with a sedative dose of midazolam (0.1 mg/kg initial dose plus 0.1 mg kg(-1) h(-1) maintenance dose), and Group 3 was infused with an anesthetic dose of midazolam (0.1 mg/kg initial dose plus 0.5 mg kg(-1) h(-1) maintenance dose). We assessed the diaphragmatic contractility by transdiaphragmatic pressure (Pdi). With an infusion of midazolam in Groups 2 and 3, Pdi at low-frequency (20 Hz) and high-frequency (100 Hz) stimulation decreased from the baseline values (P < 0.05), and the integrated electrical activity of diaphragm (Edi) at 100-Hz stimulation decreased from the baseline values, whereas Edi at 20-Hz stimulation did not change. Compared with Group 1, Pdi and Edi for each stimulus decreased during midazolam infusion in Groups 2 and 3 (P < 0.05). The decrease in Pdi and Edi was more in Group 3 than in Group 2 (P < 0.05). We conclude that midazolam decreases, in a dose-dependent manner, contractility of the diaphragm in dogs.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@igaku.tsukuba.ac.jp
CR DUREUIL B, 1987, J APPL PHYSIOL, V63, P1757
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   Fujii Y, 2000, ANESTH ANALG, V91, P1035, DOI 10.1097/00000539-200010000-00052
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   MOXHAM J, 1981, HUMAN MUSCLE FATIGUE, P197
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 10
TC 6
Z9 6
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUN
PY 2001
VL 92
IS 6
BP 1590
EP 1593
PG 4
WC Anesthesiology
SC Anesthesiology
GA 434WP
UT WOS:000168839100048
PM 11375852
DA 2018-12-27
ER

PT J
AU McPherson, PM
   Ross, PE
   Dettmar, PW
AF McPherson, PM
   Ross, PE
   Dettmar, PW
TI RETRACTED: An investigation into the impact of alginates and epidermal
   growth factor on endocytosis-A study in four oesophageal cell lines
   (Retracted Article)
SO GUT
LA English
DT Correction; Retracted Publication
CR Mcpherson PM, 2000, GUT, V46, pA93
NR 1
TC 0
Z9 0
U1 2
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2001
VL 48
IS 6
BP 873
EP 873
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 435UQ
UT WOS:000168900100034
DA 2018-12-27
ER

PT J
AU Haisch, G
   Boldt, J
   Krebs, C
   Suttner, S
   Lehmann, A
   Isgro, F
AF Haisch, G
   Boldt, J
   Krebs, C
   Suttner, S
   Lehmann, A
   Isgro, F
TI RETRACTED: Influence of a new hydroxyethylstarch preparation (HES
   130/0.4) on coagulation in cardiac surgical patients (Retracted article.
   See vol. 25, pg. 755, 2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE surgery; cardiac; hydroxyethylstarch; HES 130/0.4; thromboelastography;
   bleeding; volume replacement
ID LACTATED RINGERS SOLUTION; IN-VITRO; MODIFIED THROMBOELASTOGRAPHY;
   CARDIOPULMONARY BYPASS; BLOOD-COAGULATION; VOLUME THERAPY; STARCH;
   GELATIN; HEMODILUTION; PLATELET
AB Objective: To compare volume therapy with HES 130/0.4, a new hydroxyethylstarch (HES) solution with a gelatin-based fluid replacement strategy,
   Design: Prospective, randomized, safety study.
   Setting: Urban, university-affiliate hospital (single institution).
   Participants: Forty-two patients undergoing elective cardiac surgery.
   Interventions:Patients were prospectively randomized into 2 groups: In group 1 (n = 21), gelatin was given perioperatively for volume support until the Ist postoperative day to keep the central venous pressure (CVP) between 10 and 14 mmHg; in group 2 (n = 21) HES 130/0.4 was administered using the same protocol as in group 1.
   Measurements and Main Results: Standard coagulation variables and modified thromboelastography (TEG(R)) were used. Using different activators for extrinsic and intrinsic activation and heparin inactivation by heparinase, the onset of coagulation (coagulation time), kinetics of clot formation [dot formation time), and maximum clot firmness were measured. Measurements were performed after induction of anesthesia (T0), at the end of surgery (T1), 4 hours after surgery (T2), and on the morning of the Ist postoperative day (T3). A total of 3310 +/- 810 mL of gelatin and 3070 +/- 570 mt of HES 130/0.4 were used in the 2 groups during the study period. The 2 groups did not differ with regard to postoperative bleeding or in use of packed red blood cells or fresh frozen plasma. Standard coagulation variables were similar between the 2 groups. All TEG(R) variables were within the normal range at baseline. Coagulation time and clot formation time data were significantly elevated after surgery and in the intensive care unit, without showing specific differences between the 2 volume replacement groups. Intrinsic TEG(R) and heparinase TEG(R) clot formation times remained significantly higher until the end of the study period. No differences were seen between HES-treated and gelatin-treated patients.
   Conclusions:Volume replacement with the new HES preparation was as safe as gelatin-based volume replacement with regard to coagulation in cardiac surgical patients. HES 130/0.4 is an alternative plasma substitute to treat volume deficits. Copyright (C) 2001 by W.B. Saunders Company.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Clin Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
CR BOLDT J, 1993, ANESTH ANALG, V76, P1185, DOI 10.1213/00000539-199376060-00002
   Boldt J, 1999, J CARDIOTHOR VASC AN, V13, P752, DOI 10.1016/S1053-0770(99)90134-9
   CALATZIS A, 2000, MANAGEMENT BLEEDING, P215
   Cope JT, 1997, ANN THORAC SURG, V63, P78
   Egli GA, 1997, BRIT J ANAESTH, V78, P684, DOI 10.1093/bja/78.6.684
   FUNK W, 1995, ANESTHESIOLOGY, V82, P975, DOI 10.1097/00000542-199504000-00022
   Gorton H, 2000, BRIT J ANAESTH, V84, P403
   Gottumukkala VNR, 1999, ANESTH ANALG, V89, P1453, DOI 10.1097/00000539-199912000-00024
   HALJAMAE H, 1993, ACTA ANAESTH SCAND, V37, P25, DOI 10.1111/j.1399-6576.1991.tb05069.x
   Hillman K, 1997, BAILLIERE CLIN ANAES, V11, P1, DOI 10.1016/S0950-3501(97)80003-7
   Jamnicki M, 1998, ANESTH ANALG, V87, P989, DOI 10.1097/00000539-199811000-00002
   KARANKO MS, 1987, CRIT CARE MED, V15, P559, DOI 10.1097/00003246-198706000-00004
   Karoutsos S, 1999, BRIT J ANAESTH, V82, P175, DOI 10.1093/bja/82.2.175
   Konrad C, 1999, ANESTH ANALG, V88, P483, DOI 10.1097/00000539-199903000-00003
   Konrad CJ, 2000, ANESTH ANALG, V90, P274, DOI 10.1097/00000539-200002000-00007
   Miller BE, 2000, ANESTH ANALG, V90, P1324, DOI 10.1097/00000539-200006000-00011
   Mortier E, 1997, ANAESTHESIA, V52, P1061, DOI 10.1111/j.1365-2044.1997.220-az0354.x
   Nielsen VG, 2000, ANESTH ANALG, V90, P541, DOI 10.1097/00000539-200003000-00008
   Payen JF, 1998, BRIT J ANAESTH, V80, P464, DOI 10.1093/bja/80.4.464
   SANFELIPPO MJ, 1987, AM J CLIN PATHOL, V88, P653, DOI 10.1093/ajcp/88.5.653
   Shore-Lesserson L, 1999, ANESTH ANALG, V88, P312, DOI 10.1097/00000539-199902000-00016
   STRAUSS RG, 1988, J CARDIOTHORAC AN S1, V2, P24
   Tabuchi N, 1995, THROMB HAEMOSTASIS, V74, P1447
   Treib J, 1996, TRANSFUSION, V36, P450, DOI 10.1046/j.1537-2995.1996.36596282590.x
   Treib J, 1997, THROMB HAEMOSTASIS, V78, P974
   Tuman K J, 1994, J Cardiothorac Vasc Anesth, V8, P144, DOI 10.1016/1053-0770(94)90052-3
   VANOEVEREN W, 1998, BR J ANAESTH S1, V80, pA267
   WANG P, 1990, CIRC SHOCK, V32, P307
   Warren BB, 1997, ANESTH ANALG, V84, P206, DOI 10.1097/00000539-199701000-00037
   WELSBY I, 1997, BAILLIERE CLIN ANAES, V11, P105
NR 30
TC 65
Z9 71
U1 2
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD JUN
PY 2001
VL 15
IS 3
BP 316
EP 321
DI 10.1053/jcan.2001.23276
PG 6
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 446JK
UT WOS:000169510000007
PM 11426361
DA 2018-12-27
ER

PT J
AU Seino, Y
   Ito, R
   Suzuki, I
   Enzan, K
   Inaba, H
AF Seino, Y
   Ito, R
   Suzuki, I
   Enzan, K
   Inaba, H
TI RETRACTED: A Utstein-style analysis of prognostic factors related to
   survival in out-of-hospital cardiac arrests in Akita-City, Japan
   (Retracted Article. See vol 196, pg 51, 2002)
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE emergency medical service; cardiopulmonary resuscitation; automated
   external defibrillator; survival; prospective cohort study
ID CARDIOPULMONARY-RESUSCITATION; BYSTANDER CPR; SUDDEN-DEATH; INTERVAL
AB To analyze the epidemiology of out-of-hospital cardiac arrests and to elucidate modifiable factors affecting survival, we conducted a prospective cohort study in a middle-sized urban city served by a single emergency medical service (EMS) system in which emergency medical technicians use an automated external defibrillator. Data were collected from out-of-hospital cardiac arrests occurring between 1 January, 1994 and 31 December, 1998 by applying the Utstein style. The main outcome measure was survival at 1 year after hospital discharge. The overall incidence of out-of-hospital cardiac arrest was 71.7/100000 inhabitants/year. Resuscitations were attempted in 762 of. 1118 patients with confirmed cardiac arrest. Of the 762 patients, 37 (4.86%) survived. The cause of cardiac arrest was presumed to be cardiac in 340 (44.6%). Of the 340 cardiac arrests, 180 (52.9%) were witnessed by bystanders. Ventricular fibrillation (VF) was recorded as an initial rhythm in 56 (31.1%) of the 180 patients, and cardiopulmonary resuscitation (CPR) was performed by bystanders in 89 (49.4%). The survival rate was 39.2% (22/56) when cardiac arrest was bystander-witnessed and of cardiac origin with VF as an initial rhythm. VF as an initial rhythm, age of the patients and intervals of call-to-first CPR attempt and collapse-to-arrival at patient's side were major factors relating to survival in the witnessed cardiac arrests of cardiac origin. The age, and gender of the patients, place of collapse and intervals of collapse-to-first CPR and collapse-to-arrival at patient's side were representative factors affecting the incidence of VF as an initial rhythm. The survival rate in Akita-City from bystander-witnessed cardiac arrests of cardiac origin with VF as an initial rhythm was comparable to those in other regions with advanced EMS systems. However, the incidence of VF as an initial rhythm is extremely low. Reduction of intervals of call (collapse)-to-first CPR attempt and collapse-to-arrival at patient's side or authorization of use of automated external defibrillator in basic life support may increase the incidence of VF as an initial rhythm and improve the survival from witnessed cardiac arrests with cardiac origin.
C1 Akita City Fire Dept, Div Emergency Med Sci, Akita 0108540, Japan.
   Akita Kumiai Gen Hosp, Dept Emergency Med, Akita, Japan.
   Akita City Hosp, Div Cent Operat Room, Akita 0100842, Japan.
   Kanazawa Univ, Sch Med, Dept Emergency & Crit Care Med, Kanazawa, Ishikawa 9208641, Japan.
RP Seino, Y (reprint author), Akita City Fire Dept, Div Emergency Med Sci, 1-1-1 Sanno, Akita 0108540, Japan.
EM yseino@ma2.justnet.ne.jp
CR *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2212
   BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3
   CAMPBELL JC, 1991, ANN EMERG MED, V20, P433
   CRONE PD, 1995, NEW ZEAL MED J, V108, P297
   CUMMINS RO, 1991, ANN EMERG MED, V20, P861
   CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408
   DAWBER TR, 1966, CIRCULATION, V34, P553, DOI 10.1161/01.CIR.34.4.553
   DRACUP K, 1989, ARCH INTERN MED, V149, P61, DOI 10.1001/archinte.149.1.61
   EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0
   Fischer M, 1997, RESUSCITATION, V33, P233, DOI 10.1016/S0300-9572(96)01022-2
   Giraud F, 1996, RESUSCITATION, V33, P19, DOI 10.1016/S0300-9572(96)00997-5
   HASUO Y, 1989, J CLIN EPIDEMIOL, V42, P577, DOI 10.1016/0895-4356(89)90154-6
   Hayashi S, 1997, JPN CIRC J, V61, P814, DOI 10.1253/jcj.61.814
   Herlitz J, 1996, AM J EMERG MED, V14, P119, DOI 10.1016/S0735-6757(96)90116-3
   *ILCOR, 2000, CIRCULATION, V102, P22
   Kuisma M, 1996, HEART, V76, P18, DOI 10.1136/hrt.76.1.18
   Kuisma M, 1997, EUR HEART J, V18, P1122
   Moser DK, 1999, HEART LUNG, V28, P326, DOI 10.1053/hl.1999.v28.a101053
   Owada M, 1999, TOHOKU J EXP MED, V189, P245, DOI 10.1620/tjem.189.245
   RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5
   ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9
   SWOR RA, 1995, ANN EMERG MED, V25, P780, DOI 10.1016/S0196-0644(95)70207-5
   TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583
   Weston CFM, 1997, RESUSCITATION, V34, P227, DOI 10.1016/S0300-9572(96)01063-5
NR 24
TC 3
Z9 3
U1 2
U2 7
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD JUN
PY 2001
VL 194
IS 2
BP 107
EP 119
DI 10.1620/tjem.194.107
PG 13
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 478DF
UT WOS:000171327100004
PM 11642338
DA 2018-12-27
ER

PT J
AU Paventi, S
   Parafati, MA
   Di Luzio, E
   Pellegrino, CA
AF Paventi, S
   Parafati, MA
   Di Luzio, E
   Pellegrino, CA
TI RETRACTED: Safety and feasibility of two-dimensional echocardiography
   and myocardial perfusion imaging in patients with chest pain (Retracted
   Article. See vol 53, pg 492, 2002)
SO ANGIOLOGY
LA English
DT Article; Retracted Publication
ID EMERGENCY-ROOM; ISCHEMIA; INFARCTION; RISK
AB The accurate identification of patients at high risk for acute coronary syndromes among those seen in the emergency department with possible myocardial ischemia and nonischernic electrocardiograms is a problem. Two-dimensional echocardiography and myocardial perfusion imaging with 99m-technetium sestamibi can identify patients at low and high risk; however, comparative studies are lacking. The authors studied 555 patients considered at low or moderate risk for myocardial ischemia in our emergency department on the basis of the presenting history, and results of physical examination and electrocardiography. These patients underwent echocardiography and myocardial perfusion imaging within 4 hours of presentation. Endpoints included myocardial infarction, percutaneous transluminal coronary angioplasty, and positive results on stress perfusion imaging. Both imaging procedures were performed in the emergency department on 370 patients. Overall agreement between the two techniques was high (concordance, 89%) in the patients who had myocardial infarction or underwent coronary angiography. Agreement between the two techniques is high when used in patients with possible myocardial ischemia. Both techniques helped identify patients at high risk who required admission and those who could be safely discharged.
C1 Univ Roma La Sapienza, Coronary Care Unit, Internal Med Inst 2, Rome, Italy.
   Univ Roma La Sapienza, Publ Hlth Inst, Rome, Italy.
   Univ Roma La Sapienza, Nucl Med Lab, Rome, Italy.
RP Paventi, S (reprint author), Via Fabiola 9, I-00152 Rome, Italy.
CR BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2
   BILODEAU L, 1994, J AM COLL CARDIOL, V23, P1016
   FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4
   GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0
   GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301
   Kontos MC, 1998, AM HEART J, V136, P724, DOI 10.1016/S0002-8703(98)70022-5
   LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65
   PEELS CH, 1990, AM J CARDIOL, V65, P687, DOI 10.1016/0002-9149(90)90143-O
   SABIA P, 1991, CIRCULATION, V84, pI85
   SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002
   Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2
   TRIPPI JA, 1996, J AM SOC ECHOCARDIOG, V131, P32
   VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O
NR 13
TC 3
Z9 3
U1 4
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-3197
EI 1940-1574
J9 ANGIOLOGY
JI Angiology
PD MAY
PY 2001
VL 52
IS 5
BP 305
EP 309
DI 10.1177/000331970105200502
PG 5
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 436AN
UT WOS:000168914500002
PM 11386380
DA 2018-12-27
ER

PT J
AU Boldt, J
   Brosch, C
   Lehmann, A
   Haisch, G
   Lang, J
   Isgro, F
AF Boldt, J
   Brosch, C
   Lehmann, A
   Haisch, G
   Lang, J
   Isgro, F
TI RETRACTED: Prophylactic use of pentoxifylline on inflammation in elderly
   cardiac surgery patients (Retracted article. See vol. 92, pg. 411, 2011)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; MICROVASCULAR BLOOD-FLOW; CARDIOPULMONARY BYPASS;
   EXTRACORPOREAL-CIRCULATION; HEMORRHAGIC-SHOCK; SEPTIC SHOCK; SURVIVAL;
   IMPROVES; SEPSIS; TRANSCRIPTION
AB Background. Inflammation plays a pivotal role in the pathogenesis of organ injury after cardiopulmonary bypass (CPB). Elderly patients appear to be especially prone to develop general inflammation. Use of pentoxifylline (PTX) before surgery may be a promising approach to minimize the negative effects of CPB in these patients.
   Methods. In a prospective, randomized study, patients more than 80 years old undergoing aortocoronary artery bypass grafting received either PTX (n = 15) after induction of anesthesia (initial bolus of 300 mg followed by a continuous infusion of 1.5 mg . kg(-1) . h(-1) during the next 2 days) or saline as placebo (control group; n = 15). Polymorphonuclear neutrophil (PMN) elastase, C-reactive protein (CRP), and interleukins (IL-6, IL-8, IL-10) were measured from arterial blood samples before surgery (TO), at the end of surgery (T1), 5 hours after surgery (T2), and at the morning of the first (T3) and second (T4) postoperative day.
   Results. Postoperatively, PTX-treated patients less often needed catecholamines and were extubated earlier than the control patients (p < 0.05). On the intensive care unit, cardiac index inceased more in the PTX-treated (from 1.95 +/- 0.3 to 3.26 +/- 0.4 L . min(-1) . m(-2)) than in the control patients (from 1.89 +/- 0.2 to 2.78 +/- 0.3 L . min(-1) . m-2). Increase in CRP and PMN-elastase was significantly higher in the untreated control than in the PTX patients. After CPB, IL-6, IL-8, and IL-10 increased in both groups showing a significantly higher increase in the untreated control patients (IL-8 control: from 11.3 +/- 2.6 to 154.4 +/- 57 pg/mL [T1]); IL-8 PTX: from 10.9 +/- 2.7 to 71.8 +/- 23 pg/mL [T1]).
   Conclusions. In elderly cardiac surgery patients, use of PTX before surgery and continued after CPB resulted in less inflammatory response than in an untreated control group. The value of attenuating the inflammatory process by PTX on outcome in this patient population needs to be evaluated in further controlled studies. (Ann Thorac Surg 2001;71:1524-9) (C) 2001 by The Society of Thoracic Surgeons.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Clin Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM boldtj@gmx.net
CR Bacher A, 1997, CRIT CARE MED, V25, P795, DOI 10.1097/00003246-199705000-00014
   BIANCO JA, 1991, BLOOD, V78, P1205
   BODY SC, 2000, RELATIONSHIP COAGULA, P191
   BUTLER J, 1993, RESP MED, V87, P285, DOI 10.1016/0954-6111(93)90024-T
   BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R
   CASEY LC, 1993, ANN THORAC SURG, V56, pS92, DOI 10.1016/0003-4975(93)91143-B
   COCCIA MT, 1989, CRIT CARE MED, V17, P36, DOI 10.1097/00003246-198901000-00009
   DOHERTY GM, 1991, SURGERY, V110, P192
   EDWARDS MJ, 1991, SURGERY, V110, P199
   Fink MP, 1999, CRIT CARE MED, V27, P19, DOI 10.1097/00003246-199901000-00013
   FLYNN WJ, 1991, SURGERY, V110, P350
   FRERING B, 1994, J THORAC CARDIOV SUR, V108, P636
   GAER JAR, 1994, ANN THORAC SURG, V57, P371, DOI 10.1016/0003-4975(94)90999-7
   Gott JP, 1998, ANN THORAC SURG, V66, P747, DOI 10.1016/S0003-4975(98)00695-X
   Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21
   LECHNER AJ, 1993, CIRC SHOCK, V39, P306
   Lee KS, 1997, AM J PHYSIOL-GASTR L, V273, pG1094
   LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934
   Miller BE, 1997, J CARDIOTHOR VASC AN, V11, P355, DOI 10.1016/S1053-0770(97)90106-3
   NAGAOKA H, 1989, ANN THORAC SURG, V48, P798, DOI 10.1016/0003-4975(89)90673-5
   Nelson JL, 1999, CRIT CARE MED, V27, P113, DOI 10.1097/00003246-199901000-00038
   RIDELY S, 2000, YB INTENSIVE CARE EM, P837
   Royston D, 1997, J CARDIOTHOR VASC AN, V11, P341, DOI 10.1016/S1053-0770(97)90105-1
   SCHADE UF, 1990, CIRC SHOCK, V31, P171
   SEIFFGE D, 1995, INFLAMM RES, V44, P281, DOI 10.1007/BF02032569
   SEMMLER J, 1993, IMMUNOLOGY, V78, P520
   SIGURDSSON GH, 1993, ACTA ANAESTH SCAND, V37, P396, DOI 10.1111/j.1399-6576.1993.tb03736.x
   SOLIMAN MH, 1987, CRIT CARE MED, V15, P93, DOI 10.1097/00003246-198702000-00001
   Staubach KH, 1998, ARCH SURG-CHICAGO, V133, P94, DOI 10.1001/archsurg.133.1.94
   Staudinger T, 1996, INTENS CARE MED, V22, P888
   STEEB GD, 1992, SURGERY, V112, P756
   TIGHE D, 1990, CRIT CARE MED, V18, P184, DOI 10.1097/00003246-199002000-00012
   Tsang GMK, 1996, ASAIO J, V42, pM429, DOI 10.1097/00002480-199609000-00025
   Veering B T, 1999, Curr Opin Anaesthesiol, V12, P333, DOI 10.1097/00001503-199906000-00014
   WARD A, 1987, DRUGS, V34, P50, DOI 10.2165/00003495-198734010-00003
NR 35
TC 25
Z9 26
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2001
VL 71
IS 5
BP 1524
EP 1529
DI 10.1016/S0003-4975(01)02462-6
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 433AZ
UT WOS:000168734300023
PM 11383794
DA 2018-12-27
ER

PT J
AU Okorodudu, AO
   Jacobs, E
   Fogh-Andersen, N
AF Okorodudu, AO
   Jacobs, E
   Fogh-Andersen, N
TI RETRACTED: Critical care testing in the new millennium: the integration
   of point-of-care testing (Retracted Article. See vol 329, pg 157, 2003)
SO CLINICA CHIMICA ACTA
LA English
DT Editorial Material; Retracted Publication
C1 Univ Texas, Med Branch, Dept Pathol & Clin Chem, Galveston, TX 77555 USA.
   Mt Sinai Med Ctr, Stat Lab, New York, NY 10029 USA.
   Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark.
RP Okorodudu, AO (reprint author), Univ Texas, Med Branch, Dept Pathol & Clin Chem, 301 Univ Blvd, Galveston, TX 77555 USA.
EM aookorod@utmb.edu
NR 0
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAY
PY 2001
VL 307
IS 1-2
BP 1
EP 2
DI 10.1016/S0009-8981(01)00484-3
PG 2
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 439CM
UT WOS:000169093300001
PM 11369328
DA 2018-12-27
ER

PT J
AU Akagi, K
   Yamamura, K
AF Akagi, K
   Yamamura, K
TI RETRACTED: Strain-dependency of chromosomal abnormalities in lymphomas
   developed in E mu-myc transgenic mice (Retracted Article. See vol 93, pg
   229, 2002)
SO JAPANESE JOURNAL OF CANCER RESEARCH
LA English
DT Article; Retracted Publication
DE genetic instability; chromosomal abnormality; lymphoma; genetic
   background
ID NONPOLYPOSIS COLON-CANCER; WILD-TYPE P53; GENE AMPLIFICATION;
   CELL-LINES; MOUSE; PLASMACYTOMAS; MUTATIONS; LEUKEMIA; TRANSLOCATIONS;
   ASSOCIATION
AB We previously shelved that B and T cell lymphoma development in E mu (immunoglobulin heavy chain enhancer)-myc transgenic mice is dependent on the mouse strain. To determine whether any non-random chromosomal abnormality that,vas present was caused by variations in the lymphoma cell type or by a different genetic background, we crossed C3H transgenic mice with other inbred strains of mice, C57BL/6 or BALB/c, Cytogenetic analysis showed a high frequency of non-random chromosomal aberrations, namely, duplication or amplification of part of chromosome 5 containing the transgene and trisomy of chromosome 1, 6, or 12 in the genetic background of C3HxC57BL/6 mouse and C3HxBALB/c, mouse respectively, regardless of cell type of lymphoma. These results suggest that non-random chromosomal abnormalities in lymphoma cells are dependent on the genetic background of mouse, not on the tumor cell type in E mu -myc transgenic mouse.
C1 Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.
   Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Dev Genet, Kumamoto 8620976, Japan.
RP Akagi, K (reprint author), Saitama Canc Ctr, Res Inst, 818 Komura, Ina, Saitama 3620806, Japan.
EM akagi@cancer-c.pref.saitama.jp
CR AKAGI K, 1992, JPN J CANCER RES, V83, P269, DOI 10.1111/j.1349-7006.1992.tb00099.x
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Cahill DP, 1998, NATURE, V392, P300
   *COMM STAND GEN NO, 1972, J HERED, V63, P69
   ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4
   LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
   LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025
   LIU J, 1991, CANCER GENET CYTOGEN, V55, P207, DOI 10.1016/0165-4608(91)90079-A
   LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6
   Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312
   Mai S, 1996, ONCOGENE, V12, P277
   MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423
   Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549
   McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804
   NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0
   OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762
   OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5
   QI S-L, 1991, Methods in Molecular and Cellular Biology, V2, P119
   ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0
   ROWLEY JD, 1977, LANCET, V1, P549
   SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025
   SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802
   STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0
   SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232
   SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547
   TAKAHASHI E, 1990, HUM GENET, V86, P14
   TUJIMOTO Y, 1984, SCIENCE, V226, P1097
   WIRSCHUBSKY Z, 1984, INT J CANCER, V34, P249, DOI 10.1002/ijc.2910340217
   YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7
   YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711
   ZIJLSTRA M, 1986, BIOCHIM BIOPHYS ACTA, V865, P197, DOI 10.1016/0304-419X(86)90028-4
   1984, CANC GENET CYTOGENET, V11, P284
NR 36
TC 3
Z9 3
U1 3
U2 8
PU JAPANESE CANCER ASSOC
PI TOKYO
PA C/O JAPANESE FOUNDATION CANCER RESEARCH,1-37-1, KAMI-IKEBUKURO,
   TOSHIMA-KU, TOKYO, 170-0012, JAPAN
SN 0910-5050
J9 JPN J CANCER RES
JI Jpn. J. Cancer Res.
PD MAY
PY 2001
VL 92
IS 5
BP 499
EP 505
DI 10.1111/j.1349-7006.2001.tb01122.x
PG 7
WC Oncology
SC Oncology
GA 437AF
UT WOS:000168967500004
PM 11376558
OA Bronze
DA 2018-12-27
ER

PT J
AU Beech, DJ
   Sibbons, PD
   Howard, CV
   van Velzen, D
AF Beech, DJ
   Sibbons, PD
   Howard, CV
   van Velzen, D
TI RETRACTED: Lung development: Number of terminal bronchiolar duct endings
   and gas exchange surface area in victims of sudden infant death syndrome
   (Retracted article. See vol. 44, pg. 1250, 2009)
SO PEDIATRIC PULMONOLOGY
LA English
DT Article; Retracted Publication
DE development; terminal bronchiolar duct ending; gas exchange surface
   area; sudden infant death syndrome; growth; stereology
AB Previous research has demonstrated impaired renal development, particularly with respect to glomerular number, in victims of sudden infant death syndrome (SIDS). The present study used stereological principles to estimate the volume of the upper lobe of the right lung, total number of terminal bronchiolar duct endings (TBDE), and gas exchange surface area of this lobe within a group of human infants. The infants were classified according to cause of death (SIDS or non-SIDS), and further subdivided according to birth-weight: normal birth-weight (NBW) or low birth-weight (LBW).
   The results demonstrated that TBDE density was significantly reduced in SIDS compared to non-SIDS (P = 0.014), but only reduced from non-SIDS NEW values in the SIDS NEW group (P = 0.044). Total TBDE number was significantly reduced in SIDS from non-SIDS (P = 0.001), and was significantly reduced from non-SIDS NEW values in SIDS NEW (P = 0.023). Mean gas exchange surface area per TBDE was significantly increased in SIDS compared to non-SIDS cases (P = 0.049).
   The results of the present study indicate developmental delay of the lung in SIDS NEW infants who had previously not been considered growth retarded based on their normal body parameters. (C) 2001 Wiley-Liss, Inc.
C1 Univ Liverpool, Liverpool L69 7ZA, Merseyside, England.
   Northwick Pk Hosp & Clin Res Ctr, Northwick Pk Inst Med Res, Dept Surg Res, Harrow HA1 3UJ, Middx, England.
   Westeinde Ziekenhuis, Dept Pathol, NL-2501 CK The Hague, Netherlands.
RP Beech, DJ (reprint author), Univ Liverpool, Mulberry St, Liverpool L69 7ZA, Merseyside, England.
EM djbeech@liv.ac.uk
OI Howard, Charles Vyvyan/0000-0002-6151-3446
CR ANSARI T, 1996, PEDIAT PULMONOL, V22, P427
   Barker D. J. P., 1994, MOTHERS BABIES DIS L
   Beech DJ, 2000, EARLY HUM DEV, V59, P193, DOI 10.1016/S0378-3782(00)00095-5
   Beech DJ, 2000, PEDIATR DEVEL PATHOL, V3, P450, DOI 10.1007/s100240010091
   Beech DJ, 2000, J MICROSC-OXFORD, V197, P36
   BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x
   BUCHER U., 1961, THORAX, V16, P207, DOI 10.1136/thx.16.3.207
   GILBERT T, 1994, P 3 SIDS INT C STAV, P158
   HINCHLIFFE SA, 1993, PEDIATR PATHOL, V13, P333, DOI 10.3109/15513819309048221
   PACHE JC, 1993, J MICROSC-OXFORD, V170, P9, DOI 10.1111/j.1365-2818.1993.tb03319.x
   Ross M. H., 1995, HIST TEXT ATLAS
   SIBBONS PD, 1997, PEDIAT PULMONOL, V24, P448
   WILLINGER M, 1991, Pediatric Pathology, V11, P677
NR 13
TC 6
Z9 6
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD MAY
PY 2001
VL 31
IS 5
BP 339
EP 343
DI 10.1002/ppul.1056
PG 5
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 429DZ
UT WOS:000168501900002
PM 11340679
DA 2018-12-27
ER

PT J
AU Seger, R
   Hanoch, T
   Rosenberg, R
   Dantes, A
   Merz, WE
   Strauss, JF
   Amsterdam, A
AF Seger, R
   Hanoch, T
   Rosenberg, R
   Dantes, A
   Merz, WE
   Strauss, JF
   Amsterdam, A
TI RETRACTED: The ERK signaling cascade inhibits gonadotropin-stimulated
   steroidogenesis (Retracted article. See vol. 292, pg. 8847, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACUTE REGULATORY PROTEIN; OVARIAN GRANULOSA-CELLS; ARTERIAL
   SMOOTH-MUSCLE; LEYDIG TUMOR-CELLS; GROWTH-FACTOR; COUPLED RECEPTORS;
   STAR GENE; KINASE-A; ACTIVATION; HORMONE
AB The response of granulosa cells to luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is mediated mainly by cAMP/protein kinase A (PKA) signaling. Notably, the activity of the extracellular signal-regulated kinase (ERK) signaling cascade is elevated in response to these stimuli as well. We studied the involvement of the ERK cascade in LH- and FSH-induced steroidogenesis in two granulosa derived cell lines, rLHR-4 and rFSHR-17, respectively. We found that stimulation of these cells with the appropriate gonadotropin induced ERK activation as well as progesterone production downstream of PKA. Inhibition of ERR activity enhanced gonadotropin-stimulated progesterone production, which was correlated with increased expression of the steroidogenic acute regulatory protein (StAR), a key regulator of progesterone synthesis. Therefore, it is likely that gonadotropin-stimulated progesterone formation is regulated by a pathway that includes PKA and StAR, and this process is down-regulated by ERK, due to attenuation of StAR expression. Our results suggest that activation of PKA signaling by gonadotropins not only induces steroidogenesis but also activates down-regulation machinery involving the ERR cascade. The activation of ERK by gonadotropins as well as by other agents may be a key mechanism for the modulation of gonadotropin-induced steroidogenesis.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-71600 Rehovot, Israel.
   Weizmann Inst Sci, Dept Mol Cell Biol, IL-71600 Rehovot, Israel.
   Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany.
   Univ Penn, Ctr Res Reprod Womens Hlth, Philadelphia, PA 19104 USA.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-71600 Rehovot, Israel.
EM rony.seger@weizmann.ac.il; abraham.amsterdam@weizmann.ac.il
FU NICHD NIH HHS [HD-06224]
CR Aharoni D, 1997, CURR BIOL, V7, P43, DOI 10.1016/S0960-9822(06)00026-1
   Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2
   AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440
   Amsterdam A, 1997, ENDOCR REV, V18, P435, DOI 10.1210/er.18.4.435
   AMSTERDAM A, 1992, BIOL REPROD, V46, P513, DOI 10.1095/biolreprod46.4.513
   AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309
   Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339
   Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0
   Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111
   Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893
   COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367
   Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967
   DAY RN, 1989, J BIOL CHEM, V264, P431
   de Rooij J, 1998, NATURE, V396, P474
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X
   GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300
   Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186
   Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3
   HANUKOGLU I, 1990, J CELL BIOL, V111, P1373, DOI 10.1083/jcb.111.4.1373
   KARENTAL I, 1993, MOL CELL ENDOCRINOL, V95, pR1
   Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122
   Lalli E, 1998, ENDOCRINOLOGY, V139, P4237, DOI 10.1210/en.139.10.4237
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   MERZ WE, 1988, BIOCHEM BIOPH RES CO, V156, P1271, DOI 10.1016/S0006-291X(88)80770-8
   Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5
   Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531
   Pollack SE, 1997, J CLIN ENDOCR METAB, V82, P4243, DOI 10.1210/jc.82.12.4243
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324
   SEGER R, 1995, FASEB J, V9, P726
   SEGER R, 1995, J BIOL CHEM, V270, P28325
   Selvaraj N, 1996, MOL CELL ENDOCRINOL, V123, P171, DOI 10.1016/S0303-7207(96)03916-0
   Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631
   SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525
   Stocco DM, 2000, J ENDOCRINOL, V164, P247, DOI 10.1677/joe.0.1640247
   Stocco DM, 1998, REV REPROD, V3, P82, DOI 10.1530/ror.0.0030082
   Strauss JF, 1999, RECENT PROG HORM RES, V54, P369
   Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3
   SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004
   SUH BS, 1992, J CELL BIOL, V119, P439, DOI 10.1083/jcb.119.2.439
   VANLOENEN HJ, 1995, J ENDOCRINOL, V147, P367, DOI 10.1677/joe.0.1470367
   WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366
   Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x
   Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x
   Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240
   Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0
   Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199
   Zazopoulos E, 1997, NATURE, V390, P311
   Zeleznik AJ, 1999, TRENDS ENDOCRIN MET, V10, P189, DOI 10.1016/S1043-2760(98)00145-3
   Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513
NR 51
TC 196
Z9 199
U1 4
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 27
PY 2001
VL 276
IS 17
BP 13957
EP 13964
DI 10.1074/jbc.M006852200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 426PB
UT WOS:000168356600063
PM 11278318
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Liu, YF
   Paz, K
   Herschkovitz, A
   Alt, A
   Tennenbaum, T
   Sampson, SR
   Ohba, M
   Kuroki, T
   LeRoith, D
   Zick, Y
AF Liu, YF
   Paz, K
   Herschkovitz, A
   Alt, A
   Tennenbaum, T
   Sampson, SR
   Ohba, M
   Kuroki, T
   LeRoith, D
   Zick, Y
TI RETRACTED: Insulin stimulates PKC zeta-mediated phosphorylation of
   insulin receptor substrate-1 (IRS-1) - A self-attenuated mechanism to
   negatively regulate the function of IRS proteins (Retracted article. See
   vol. 293, pg. 7264, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID KINASE-C-ZETA; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT;
   SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE;
   PHOSPHOTYROSINE PROTEIN; JUXTAMEMBRANE REGION; S6 KINASE; ACTIVATION;
   DOMAIN
AB Incubation of rat hepatoma Fao cells with insulin leads to a transient rise in Tyr phosphorylation of insulin receptor substrate (IRS) proteins. This is followed by elevation in their P-Ser/Thr content, and their dissociation from the insulin receptor (IR), Wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, abolished the increase in the P-Ser/Thr content of IRS-1, its dissociation from the IR, and the decrease in its P-Tyr content following 60 min of insulin treatment, indicating that the Ser kinases that negatively regulate IRS-l function are downstream effectors of PI3K. PKC zeta fulfills this criterion, being an insulin-activated downstream effector of PI3K, Overexpression of PKC zeta in Fao cells, by infection of the cells with adenovirus-based PKC zeta construct, had no effect on its own, but it accelerated the rate of insulin-stimulated dissociation of IR IRS-1 complexes and the rate of Tyr dephosphorylation of IRS-1, The insulin-stimulated negative regulatory role of PKC zeta was specific and could not be mimic by infecting Fao cells with adenoviral constructs encoding for PKC alpha, delta, or eta. Because the reduction in P-Tyr content of IRS-1 was accompanied by a reduced association of IRS-1 with p85, the regulatory subunit of PI3K, it suggests that this negative regulatory process induced by PKC zeta has a built-in attenuation signal. Hence, insulin triggers a sequential cascade in which PI3K-mediated activation of PKC zeta inhibits IRS-1 functions, reduces complex formation between IRS-1 and PI3K, and inhibits further activation of PKC zeta itself. These findings implicate PKC zeta as a key element in a multistep negative feedback control mechanism of IRS-1 functions.
C1 Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
   Bar Ilan Univ, Gonda Goldschmied Ctr, Fac Life Sci, IL-52900 Ramat Gan, Israel.
   Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan.
   NIDDK, Mol & Cellular Endocrinol Branch, NIH, Bethesda, MD 20892 USA.
RP Zick, Y (reprint author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
EM yehiel.zick@weizmann.ac.il
RI Kuroki, Toshio/A-9500-2011
OI Kuroki, Toshio/0000-0001-6369-4351
CR Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5
   Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551
   Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x
   CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0
   Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865
   Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496
   DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400
   Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181
   Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2
   Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139
   Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208
   HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447
   HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0
   Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lallena MJ, 1999, MOL CELL BIOL, V19, P2180
   Lavan BE, 1997, J BIOL CHEM, V272, P11439
   Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403
   Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351
   MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K
   MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0
   Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320
   Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222
   MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x
   NAKANISHI H, 1993, J BIOL CHEM, V268, P13
   NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526
   PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412
   PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585
   PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0
   Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998
   Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911
   Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816
   Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593
   PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182
   PRONK GJ, 1993, J BIOL CHEM, V268, P5748
   Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200
   Romanelli A, 1999, MOL CELL BIOL, V19, P2921
   SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980
   Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772
   Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075
   SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609
   VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083
   WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407
   ZICK Y, 1983, J BIOL CHEM, V258, P75
NR 46
TC 154
Z9 157
U1 1
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 27
PY 2001
VL 276
IS 17
BP 14459
EP 14465
DI 10.1074/jbc.M007281200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 426PB
UT WOS:000168356600125
PM 11278339
OA Bronze
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Kildal, W
   Risberg, B
   Koppang, HS
   Danielsen, HE
   Reith, A
AF Sudbo, J
   Kildal, W
   Risberg, B
   Koppang, HS
   Danielsen, HE
   Reith, A
TI RETRACTED: DNA content as a prognostic marker in patients with oral
   leukoplakia (Retracted article. See vol 355, pg 1927, 2006)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID SQUAMOUS-CELL CARCINOMA; COMMON CLONAL ORIGIN; NECK-CANCER; MUTAGEN
   SENSITIVITY; GENETIC SUSCEPTIBILITY; PREMALIGNANT LESIONS; FIELD
   CANCERIZATION; SPINDLE CHECKPOINT; HEAD; TONGUE
AB Background: Oral leukoplakia may develop into squamous-cell carcinoma, which has a poor prognosis. Risk factors for oral carcinoma have been identified, but there are no reliable predictors of the outcome in individual patients with oral leukoplakia.
   Methods: We identified 150 patients with oral leukoplakia that was classified as epithelial dysplasia and measured the nuclear DNA content (ploidy) of the lesions to determine whether DNA ploidy could be used to predict the clinical outcome. Biopsy specimens obtained at annual follow-up visits were graded histologically and classified with respect to DNA content in a blinded fashion. Disease-free survival was assessed in relation to DNA ploidy and the histologic grade. The mean duration of follow-up was 103 months (range, 4 to 165).
   Results: Among 150 patients with verified epithelial dysplasia, a carcinoma developed in 36 (24 percent). Of the 150 patients, 105 (70 percent) had diploid (normal) lesions, 20 (13 percent) had tetraploid (intermediate) lesions, and 25 (17 percent) had aneuploid (abnormal) lesions at the time of the initial diagnosis. A carcinoma developed in 3 of the 105 patients with diploid lesions (3 percent), as compared with 21 of the 25 patients with aneuploid lesions (84 percent), yielding a negative predictive value of 97 percent with respect to the diploid lesions and a positive predictive value of 84 percent with respect to the aneuploid lesions. Carcinoma developed in 12 of 20 patients with tetraploid lesions (60 percent). The mean time from the initial assessment of the DNA content to the development of a carcinoma was 35 months (range, 4 to 57) in the group with aneuploid lesions and 49 months (range, 8 to 78) in the group with tetraploid lesions (P=0.02). The cumulative disease-free survival rate was 97 percent among the group with diploid lesions, 40 percent among the group with tetraploid lesions, and 16 percent among the group with aneuploid lesions (P<0.001).
   Conclusions: The DNA content in cells of oral leukoplakia can be used to predict the risk of oral carcinoma. (N Engl J Med 2001;344:1270-8.) Copyright (C) 2001 Massachusetts Medical Society.
C1 Norwegian Radium Hosp, Dept Pathol, Div Digital Pathol, N-0310 Oslo, Norway.
   Univ Oslo, Inst Clin Dent, Dept Pathol & Forens Odontol, N-0316 Oslo, Norway.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Pathol, Div Digital Pathol, Montebello, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
CR ABDELSALAM M, 1990, ORAL SURG ORAL MED O, V69, P345, DOI 10.1016/0030-4220(90)90297-6
   Bedi GC, 1996, CANCER RES, V56, P2484
   BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204
   BOUQUOT JE, 1986, ORAL SURG ORAL MED O, V61, P373, DOI 10.1016/0030-4220(86)90422-6
   Brunin F, 1999, HEAD NECK-J SCI SPEC, V21, P751, DOI 10.1002/(SICI)1097-0347(199912)21:8<751::AID-HED11>3.3.CO;2-W
   BRYNE M, 1991, J ORAL PATHOL MED, V20, P120, DOI 10.1111/j.1600-0714.1991.tb00904.x
   Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831
   Califano J, 1996, CANCER RES, V56, P2488
   Califano J, 2000, CLIN CANCER RES, V6, P347
   Cloos J, 1996, JNCI-J NATL CANCER I, V88, P530, DOI 10.1093/jnci/88.8.530
   COOPER JS, 1989, INT J RADIAT ONCOL, V17, P449, DOI 10.1016/0360-3016(89)90094-1
   COTE RA, 1979, SYSTEMATIZED NOMENCL, V1, P61
   Emilion G, 1996, BRIT J CANCER, V73, P809, DOI 10.1038/bjc.1996.142
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Friedlander PL, 1998, HEAD NECK-J SCI SPEC, V20, P363, DOI 10.1002/(SICI)1097-0347(199808)20:5<363::AID-HED1>3.3.CO;2-X
   Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
   GRANT WE, 1993, LANCET, V342, P147, DOI 10.1016/0140-6736(93)91347-O
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   Harrison LB, 1998, HEAD NECK-J SCI SPEC, V20, P668, DOI 10.1002/(SICI)1097-0347(199812)20:8<668::AID-HED2>3.0.CO;2-9
   HAYS GL, 1995, J AM DENT ASSOC, V126, P47, DOI 10.14219/jada.archive.1995.0023
   HEDLEY DW, 1994, METHOD CELL BIOL, V41, P231
   Hogmo A, 1996, HEAD NECK-J SCI SPEC, V18, P433, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<433::AID-HED6>3.0.CO;2-6
   HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401
   JONES AS, 1994, ORAL ONCOL, V30B, P8
   KARABULUT A, 1995, J ORAL PATHOL MED, V24, P198, DOI 10.1111/j.1600-0714.1995.tb01166.x
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LICCIARDELLO JTW, 1989, INT J RADIAT ONCOL, V17, P467, DOI 10.1016/0360-3016(89)90096-5
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   LUMERMAN H, 1995, ORAL SURG ORAL MED O, V79, P321, DOI 10.1016/S1079-2104(05)80226-4
   Nisi KW, 1998, INT J RADIAT ONCOL, V41, P371, DOI 10.1016/S0360-3016(98)00059-5
   Ogden GR, 1998, BRIT J ORAL MAX SURG, V36, P247, DOI 10.1016/S0266-4356(98)90707-0
   PINDBORG JJ, 1997, HISTOLOGICAL TYPING, P21
   Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8
   Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303
   SCHANTZ SP, 1990, J NATL CANCER I, V82, P1773, DOI 10.1093/jnci/82.22.1773
   Schantz SP, 1997, LARYNGOSCOPE, V107, P765, DOI 10.1097/00005537-199706000-00011
   Schantz SP, 2000, CARCINOGENESIS, V21, P1239, DOI 10.1093/carcin/21.6.1239
   Schantz SP, 1997, P SOC EXP BIOL MED, V216, P275
   Scholes AGM, 1998, CANCER RES, V58, P2003
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Seoane J, 1998, CLIN OTOLARYNGOL, V23, P136
   SHAFER WG, 1975, CANCER-AM CANCER SOC, V36, P1021, DOI 10.1002/1097-0142(197509)36:3<1021::AID-CNCR2820360327>3.0.CO;2-W
   SHEMEN LJ, 1984, JAMA-J AM MED ASSOC, V252, P1857, DOI 10.1001/jama.252.14.1857
   SILVERMAN S, 1984, CANCER, V53, P563
   SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082
   Suarez P, 1998, Adv Anat Pathol, V5, P137, DOI 10.1097/00125480-199805000-00001
   WALDRON CA, 1975, CANCER-AM CANCER SOC, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
   WARNAKULASURIYA KAAS, 1992, J ORAL PATHOL MED, V21, P404, DOI 10.1111/j.1600-0714.1992.tb01028.x
   Warnakulasuriya S, 2000, J PATHOL, V190, P407, DOI 10.1002/(SICI)1096-9896(200003)190:4<407::AID-PATH546>3.0.CO;2-D
   Weber RG, 1998, AM J PATHOL, V153, P295, DOI 10.1016/S0002-9440(10)65571-X
   Xie X, 1997, CANCER, V79, P2200, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2200::AID-CNCR19>3.0.CO;2-#
   Yamasaki H, 2000, TOXICOL LETT, V112, P251, DOI 10.1016/S0378-4274(99)00278-7
NR 54
TC 201
Z9 205
U1 3
U2 15
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 26
PY 2001
VL 344
IS 17
BP 1270
EP 1278
DI 10.1056/NEJM200104263441702
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 424UM
UT WOS:000168252400002
PM 11320386
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Universal crossover from band to hopping conduction in
   molecular organic semiconductors (Retracted Article. See vol 89, ARTN
   289902, 2002)
SO PHYSICAL REVIEW LETTERS
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; SINGLE-CRYSTALS; PENTACENE; TRANSPORT; GROWTH;
   MOBILITIES
AB The charge transport in a variety of herringbone-stacked organic molecular semiconductors is investigated in the temperature range from 10 to 550 K. A crossover from coherent bandlike charge transport with mobilities up to several thousand cm(2)/V s at low temperature to an incoherent hopping motion at high temperatures is observed. This is attributed to the localization of the charge carrier due to increased electron-phonon interaction and, finally the formation of a lattice polaron.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR Antolini L, 1998, ADV MATER, V10, P382, DOI 10.1002/(SICI)1521-4095(199803)10:5<382::AID-ADMA382>3.0.CO;2-Y
   Appel J., 1968, SOLID STATE PHYS, V21, P193
   AUSTIN IG, 1971, CONDUCTION LOW MOBIL, P13
   BERG S, IN PRESS PHYS REV B
   BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972
   CAMPBELL RB, 1961, ACTA CRYSTALLOGR, V14, P705, DOI 10.1107/S0365110X61002163
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   Garnier F, 1996, SYNTHETIC MET, V81, P163, DOI 10.1016/S0379-6779(96)03761-7
   GLARUM SH, 1963, J PHYS CHEM SOLIDS, V24, P1577, DOI 10.1016/0022-3697(63)90100-8
   HOROWITZ G, 1995, CHEM MATER, V7, P1337, DOI 10.1021/cm00055a010
   KARL N, 1991, SYNTHETIC MET, V41, P136
   Klauk H, 1999, IEEE T ELECTRON DEV, V46, P1258, DOI 10.1109/16.766895
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   POPE M, 1982, ELECT PROCESSES ORGN
   SCHON JC, UNPUB
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   Schon JH, 2000, SYNTHETIC MET, V115, P75, DOI 10.1016/S0379-6779(00)00348-9
   SCHON JH, 1999, MAT RES SOC S P, V598
   SHOCKLEY W, 1951, AT&T TECH J, V30, P990, DOI 10.1002/j.1538-7305.1951.tb03692.x
   SIEGRIST T, 1995, J MATER RES, V10, P2170, DOI 10.1557/JMR.1995.2170
   Siegrist T, 1998, ADV MATER, V10, P379, DOI 10.1002/(SICI)1521-4095(199803)10:5<379::AID-ADMA379>3.0.CO;2-A
   SILINSH EA, 1995, CHEM PHYS, V198, P311, DOI 10.1016/0301-0104(95)00151-D
   Torsi L, 1996, SCIENCE, V272, P1462, DOI 10.1126/science.272.5267.1462
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
   WARTA W, 1985, APPL PHYS A, V36, P136
   Wu MW, 1997, CHEM PHYS LETT, V266, P363, DOI 10.1016/S0009-2614(97)00022-5
NR 29
TC 58
Z9 58
U1 3
U2 28
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 0031-9007
J9 PHYS REV LETT
JI Phys. Rev. Lett.
PD APR 23
PY 2001
VL 86
IS 17
BP 3843
EP 3846
DI 10.1103/PhysRevLett.86.3843
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 426FC
UT WOS:000168338300037
PM 11329338
DA 2018-12-27
ER

PT J
AU Fogel, RB
   Malhotra, A
   Pillar, G
   Dalagiorgou, G
   Pittman, S
   Jakab, M
   Robinson, M
   White, DP
AF Fogel, RB
   Malhotra, A
   Pillar, G
   Dalagiorgou, G
   Pittman, S
   Jakab, M
   Robinson, M
   White, DP
TI RETRACTED: The effect of surgically induced weight loss on
   sleep-disordered breathing and pharyngeal anatomy (Retracted article.
   See vol. 32, pg. 445, 2009)
SO SLEEP
LA English
DT Meeting Abstract; Retracted Publication
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
CR SCHWARTZ AR, 1991, AM REV RESPIR DIS, V144, P494, DOI 10.1164/ajrccm/144.3_Pt_1.494
NR 1
TC 1
Z9 1
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1550-9109
J9 SLEEP
JI Sleep
PD APR 15
PY 2001
VL 24
SU S
MA 10
BP A7
EP A8
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 424KF
UT WOS:000168230900012
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Hwang, HY
   Batlogg, B
AF Schon, JH
   Kloc, C
   Hwang, HY
   Batlogg, B
TI RETRACTED: Josephson junctions with tunable weak links (Retracted
   Article. See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; SUPERCONDUCTIVITY; FILM
AB The electrical properties of organic molecular crystals, such as polyacenes or C(60), can be tuned from insulating to superconducting by application of an electric field. By structuring the gate electrode of such a field-effect switch, the charge carrier density, and therefore also the superfluid density, can be modulated. Hence, weak Links that behave like Josephson junctions can be fabricated between two superconducting regions. The coupling between the superconducting regions can be tuned and controlled over a wide range by the applied gate bias. Such devices might be used in superconducting circuits, and they are a useful scientific tool to study superconducting material parameters, such as the superconducting gap, as a function of carrier concentration or transition temperature.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   ETH Honggerberg, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   ARNOLD GB, 1987, J LOW TEMP PHYS, V68, P1, DOI 10.1007/BF00682620
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248
   JOSEPHSON BD, 1962, PHYS LETT, V1, P201
   KLAPWIJK TM, 1989, SUPERCONDUCTING ELEC, P385
   KLEINSASSER AW, 1989, APPL PHYS LETT, V55, P1909, DOI 10.1063/1.102166
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   LIKHAREV KK, 1979, REV MOD PHYS, V51, P101, DOI 10.1103/RevModPhys.51.101
   Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613
   Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001
   Mooij JE, 1999, MICROELECTRON ENG, V47, P3, DOI 10.1016/S0167-9317(99)00131-8
   Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036
   NISHINO T, 1985, IEEE ELECTR DEVICE L, V6, P297, DOI 10.1109/EDL.1985.26131
   ONNES HK, 1911, LEIDEN COMMUN, V1206, P1226
   Parks R. D., 1969, SUPERCONDUCTIVITY
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565
   SCHON JH, 2000, NATURE, V406, P704
   TAKAYANAGI H, 1985, PHYS REV LETT, V54, P2449, DOI 10.1103/PhysRevLett.54.2449
NR 22
TC 22
Z9 22
U1 6
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 13
PY 2001
VL 292
IS 5515
BP 252
EP 254
DI 10.1126/science.1058812
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 421QA
UT WOS:000168074000036
PM 11303093
DA 2018-12-27
ER

PT J
AU Deschenes, LA
   Vanden Bout, DA
AF Deschenes, LA
   Vanden Bout, DA
TI RETRACTED: Single-molecule studies of heterogeneous dynamics in polymer
   melts near the class transition (Retracted article. See vol 312, pg 195,
   2006)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID GLASS-TRANSITION; SUPERCOOLED LIQUIDS; TRANSLATIONAL DIFFUSION;
   TEMPERATURE-DEPENDENCE; ROTATIONAL DIFFUSION; RELAXATION; SPECTROSCOPY;
   JUMPS; SOLIDS; MOTION
AB Single-molecule spectroscopy was used to follow the orientation of a single probe molecule in a polymer film in real time. Broad spatially heterogeneous dynamics were observed on Long time scales, which result from simple diffusive rotational motions on short time scales. This diffusive behavior persists for many rotations before the molecule's local environment changes to one characterized by a new time scale. This environmental exchange occurs instantaneously on the time scale of the experiment and may arise from large-scale collective motions. The distribution of exchange times for these environments was measured for several temperatures near the glass transition.
C1 Univ Texas, Dept Chem, Ctr Nano & Mol Mat Sci & Technol, Austin, TX 78712 USA.
   Univ Texas, Texas Mat Inst, Austin, TX 78712 USA.
RP Vanden Bout, DA (reprint author), Univ Texas, Dept Chem, Ctr Nano & Mol Mat Sci & Technol, Austin, TX 78712 USA.
EM davandenbout@mail.utexas.edu
CR ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442
   Angell CA, 2000, J APPL PHYS, V88, P3113, DOI 10.1063/1.1286035
   Bartko AP, 1999, J PHYS CHEM B, V103, P3053, DOI 10.1021/jp9846330
   BASCHE T, 1995, NATURE, V373, P132, DOI 10.1038/373132a0
   Bennemann C, 1999, NATURE, V399, P246, DOI 10.1038/20406
   BOX GEP, 1976, TIME SERIES ANAL
   Chang I, 1997, J PHYS CHEM B, V101, P8794, DOI 10.1021/jp9640989
   Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966
   Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048
   Ediger MD, 1996, J PHYS CHEM-US, V100, P13200, DOI 10.1021/jp953538d
   Ediger MD, 2000, ANNU REV PHYS CHEM, V51, P99, DOI 10.1146/annurev.physchem.51.1.99
   FOURKAS JT, 1997, ACS S SERIES, V676
   Gleim T, 1998, PHYS REV LETT, V81, P4404, DOI 10.1103/PhysRevLett.81.4404
   Ha T, 1999, J PHYS CHEM B, V103, P6839, DOI 10.1021/jp990948j
   Ha T, 1998, PHYS REV LETT, V80, P2093, DOI 10.1103/PhysRevLett.80.2093
   Hall DB, 1997, PHYS REV LETT, V79, P103, DOI 10.1103/PhysRevLett.79.103
   HARRISON G, 1976, DYNAMIC PROPERTIES S
   Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0
   Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255
   MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46
   Moerner WE, 1996, ACCOUNTS CHEM RES, V29, P561
   Ngai KL, 1999, J PHYS CHEM B, V103, P10684, DOI 10.1021/jp990554s
   NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650
   Richert R, 1997, J PHYS CHEM B, V101, P6323, DOI 10.1021/jp9713219
   Russell EV, 2000, NATURE, V408, P695
   Sillescu H, 1999, J NON-CRYST SOLIDS, V243, P81, DOI 10.1016/S0022-3093(98)00831-X
   VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074
   Veerman JA, 1999, PHYS REV LETT, V83, P2155, DOI 10.1103/PhysRevLett.83.2155
   Wang CY, 2000, J PHYS CHEM B, V104, P1724, DOI 10.1021/jp993420n
   Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627
   Wendt H, 2000, PHYS REV E, V61, P1722, DOI 10.1103/PhysRevE.61.1722
NR 31
TC 190
Z9 190
U1 5
U2 56
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 13
PY 2001
VL 292
IS 5515
BP 255
EP 258
DI 10.1126/science.1056430
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 421QA
UT WOS:000168074000037
PM 11303094
DA 2018-12-27
ER

PT J
AU Day, NPJ
   Moore, CE
   Enright, MC
   Berendt, AR
   Smith, JM
   Murphy, MF
   Peacock, SJ
   Spratt, BG
   Feil, EJ
AF Day, NPJ
   Moore, CE
   Enright, MC
   Berendt, AR
   Smith, JM
   Murphy, MF
   Peacock, SJ
   Spratt, BG
   Feil, EJ
TI RETRACTED: A link between virulence and ecological abundance in natural
   populations of Staphylococcus aureus (Retracted article. See vol 295, pg
   971, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID CLONES; RESISTANCE
AB Staphylococcus aureus is a major cause of severe infection in humans and yet is carried without symptoms by a Large proportion of the population. We used multilocus sequence typing to characterize isolates of S. aureus recovered from asymptomatic nasal carriage and from episodes of severe disease within a defined population. We identified a number of frequently carried genotypes that were disproportionately common as causes of disease. even taking into account their relative abundance among carriage isolates, The existence of these ecologically abundant hypervirulent clones suggests that factors promoting the ecological fitness of this important pathogen also increase its virulence.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England.
   Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.
   Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.
   John Radcliffe Hosp, Natl Blood Serv, Oxford OX3 9DU, England.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
RP Day, NPJ (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England.
RI Spratt, Brian/A-1676-2009
CR Cockerill FR, 1997, JAMA-J AM MED ASSOC, V277, P38, DOI 10.1001/jama.277.1.38
   EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428
   Enright MC, 2000, J CLIN MICROBIOL, V38, P1008
   ENRIGHT MC, UNPUB
   Feil EJ, 2000, GENETICS, V154, P1439
   Feil EJ, 1999, MOL BIOL EVOL, V16, P1496, DOI 10.1093/oxfordjournals.molbev.a026061
   KUSTERS JG, 1994, FIMBRIAE ADHESION GE, P179
   Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140
   MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384
   MUSSER JM, 1990, P NATL ACAD SCI USA, V87, P225, DOI 10.1073/pnas.87.1.225
   MUSSER JM, 1990, MOL BIOL STAPHYLOCOC, P59
   *PUBL HLTH LAB SER, 2000, COMMUNICAB DIS REP, V10, P23
   Smith JM, 2000, BIOESSAYS, V22, P1115, DOI 10.1002/1521-1878(200012)22:12<1115::AID-BIES9>3.3.CO;2-I
   Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701
   Spratt BG, 1999, CURR OPIN MICROBIOL, V2, P312, DOI 10.1016/S1369-5274(99)80054-X
   Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255
NR 16
TC 83
Z9 86
U1 3
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 6
PY 2001
VL 292
IS 5514
BP 114
EP 116
DI 10.1126/science.1056495
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 420FU
UT WOS:000167995200051
PM 11292876
DA 2018-12-27
ER

PT J
AU Schon, JH
   Schenker, O
   Batlogg, B
AF Schon, JH
   Schenker, O
   Batlogg, B
TI RETRACTED: Solution processed CdS thin film transistors (Retracted
   Article. See vol 466, pg 351, 2004)
SO THIN SOLID FILMS
LA English
DT Article; Retracted Publication
DE thin film transistors; on/off current ratios; mobility; semiconductors
ID CHEMICAL BATH DEPOSITION; FIELD-EFFECT TRANSISTORS; SINGLE-CRYSTALS;
   HIGH-MOBILITY; PENTACENE; SURFACE
AB Thin film field-effect transistors based on solution processed CdS have been prepared. Mobilities in the range of 5 to 9 cm(2)/Vs and on/off-current ratios exceeding 10(6) are demonstrated. The device performance can be significantly enhanced by annealing in nitrogen resulting in mobilities as high as 45 cm(2)/Vs. The increase in mobility is ascribed to a reduction of trapping states at the grain boundaries of the CdS thin film, presumably desorption of oxygen or water. Solution processing (chemical bath deposition) of inorganic semiconductors might offer a path for low-cost, large-area microelectronic devices. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Konstanz, Fak Phys, D-78547 Constance, Germany.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
CR Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834
   DONA JM, 1992, J ELECTROCHEM SOC, V139, P2810, DOI 10.1149/1.2068984
   DRURY CJ, 1998, APPL PHYS LETT, V73, P1
   FROMENT M, 1995, J ELECTROCHEM SOC, V142, P2642, DOI 10.1149/1.2050067
   GROZDANOV I, 1994, SEMICOND SCI TECH, V9, P1234, DOI 10.1088/0268-1242/9/6/013
   HAERING RR, 1967, PR INST ELECTR ELECT, V55, P692, DOI 10.1109/PROC.1967.5637
   HELME K, 1967, SOLID STATE ELECT, V10, P732
   Herwig PT, 1999, ADV MATER, V11, P480, DOI 10.1002/(SICI)1521-4095(199904)11:6<480::AID-ADMA480>3.0.CO;2-U
   Kagan CR, 1999, SCIENCE, V286, P945, DOI 10.1126/science.286.5441.945
   Karl N., 1990, DEFECT CONTROL SEMIC, V2, P1725
   LEVINSON J, 1982, J APPL PHYS, V53, P1193, DOI 10.1063/1.330583
   LINCOT D, 1992, J ELECTROCHEM SOC, V139, P1880, DOI 10.1149/1.2069515
   LOKHANDE CD, 1991, MATER CHEM PHYS, V27, P1, DOI 10.1016/0254-0584(91)90158-Q
   MAUCH RH, 1991, 10 EUR PHOT SOL EN C, P791
   MICHELETTI FB, 1967, APPL PHYS LETT, V10, P136, DOI 10.1063/1.1754881
   Nair PK, 1998, SOL ENERG MAT SOL C, V52, P313, DOI 10.1016/S0927-0248(97)00237-7
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   ORTON JW, 1980, REP PROG PHYS, V43, P81
   Ridley BA, 1999, SCIENCE, V286, P746, DOI 10.1126/science.286.5440.746
   Schon JH, 1998, APPL PHYS LETT, V73, P3574, DOI 10.1063/1.122828
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SIHVONEN YT, 1967, J ELECTROCHEM SOC, V114, P98
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   SZE SM, 1981, PHYSICS SEMICONDUCTO
   Vasco E, 1995, MATER LETT, V25, P205, DOI 10.1016/0167-577X(95)00181-6
   Vigil O, 1998, PHYS STATUS SOLIDI A, V167, P143, DOI 10.1002/(SICI)1521-396X(199805)167:1<143::AID-PSSA143>3.0.CO;2-3
   WAXMAN A, 1968, ELECTRONICS, V41, P88
   WEIMER PK, 1962, P IRE, V50, P1462, DOI 10.1109/JRPROC.1962.288190
NR 28
TC 43
Z9 45
U1 2
U2 14
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD APR 2
PY 2001
VL 385
IS 1-2
BP 271
EP 274
DI 10.1016/S0040-6090(00)01908-8
PG 4
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 414KW
UT WOS:000167666600042
DA 2018-12-27
ER

PT J
AU Kim, C
   Kim, H
   Han, O
AF Kim, C
   Kim, H
   Han, O
TI RETRACTED: The role of serine-246 in cytochrome P450eryF-catalyzed
   hydroxylation of 6-deoxyerythronolide B (Retracted article. See vol. 74,
   pg. NIL_0003, 2010)
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE cytochrome P450; 6-deoxyerythronolide B hydroxylase; site-directed
   mutagenesis; proton delivery system; uncoupling of cytochrome
   P450-catalyzed reaction
ID P450ERYF; BIOSYNTHESIS; ACTIVATION; ENZYMES; RESIDUE
AB A strongly conserved threonine residue in the I-helix of cytochrome P450 enzymes participates In a proton delivery system for binding and cleavage of dioxygen molecules, 6-Deoxythronolide B hydroxylase (P450eryF) is unusual in that the conserved threonine residue is replaced by alanine in this enzyme. On the basis Of the crystal structures of substrate-hound P450eryF it has been proposed that the C-5 hydroxyl group of the substrate and serine-246 of the enzyme form hydrogen bonds with water molecules S19 and 564. respectively. This hydrogen bonding network constitutes the proton delivery. system whereby P450eryF maintains its catalytic activity in tl;e absence of a threonine hydroxyl group in the conserved position. To further assess the role in the proton delivery system of hydroxyl groups around the active site, three mutant forms of P450eryF (A245S, S246A, and A245S/S246A) were constructed and characterized. In each case, decreased catalytic activity and increased uncoupling could be correlated with changes in the hydrogen bonding environment. These results suggest bat Ser-246 does indeed indirectly participate in the proton shuttling pathway, and also strongly support our previous hypothesis that the C-5 hydroxyl group of the substrate participates in the acid-catalyzed dioxygen bond cleavage reaction.
C1 Chonnam Natl Univ, Biotechnol Res Inst, Inst Agr Sci & Technol, Dept Genet Engn,Coll Agr, Kwangju 500757, South Korea.
RP Han, O (reprint author), Chonnam Natl Univ, Biotechnol Res Inst, Inst Agr Sci & Technol, Dept Genet Engn,Coll Agr, Kwangju 500757, South Korea.
EM oshan@chonnam.chonnam.ac.kr
RI Kim, Haeyoung/C-3069-2008
CR ANDERSEN JF, 1993, BIOCHEMISTRY-US, V32, P1905, DOI 10.1021/bi00059a004
   ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992
   CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632
   CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144
   Harris DL, 1996, J AM CHEM SOC, V118, P6377, DOI 10.1021/ja954101m
   MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031
   MONTELLANO O, 1996, CYTOCHROME P450 STRU
   Oprea TI, 1997, P NATL ACAD SCI USA, V94, P2133, DOI 10.1073/pnas.94.6.2133
   RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008
   SONO WC, 1993, P NATL ACAD SCI USA, V90, P8519
   THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x
   Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f
   Yeom HY, 1997, ARCH BIOCHEM BIOPHYS, V337, P209, DOI 10.1006/abbi.1996.9763
NR 13
TC 2
Z9 2
U1 2
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD APR
PY 2001
VL 65
IS 4
BP 752
EP 757
DI 10.1271/bbb.65.752
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA 431MG
UT WOS:000168634600002
PM 11388449
DA 2018-12-27
ER

PT J
AU Piper, SN
   Triem, JG
   Maleck, WH
   Fent, MT
   Huttner, I
   Boldt, J
AF Piper, SN
   Triem, JG
   Maleck, WH
   Fent, MT
   Huttner, I
   Boldt, J
TI RETRACTED: Placebo-controlled comparison of dolasetron and
   metoclopramide in preventing postoperative nausea and vomiting in
   patients undergoing hysterectomy (Retracted article. See vol. 28, pg.
   469, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE surgery, hysterectomy; complications, nausea, vomiting; antiemetics,
   dolasetron, metoclopramide
ID PROPHYLACTIC ANTIEMETIC THERAPY; POSTANESTHESIA CARE-UNIT; DOSE-RESPONSE
   TRIAL; GYNECOLOGIC SURGERY; INTRAVENOUS DOLASETRON; ORAL DOLASETRON;
   DROPERIDOL; GRANISETRON; THYROIDECTOMY; CHEMOTHERAPY
AB Background and objective In a randomized, placebo-controlled, double-blind trial, we compared the efficacy of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in women undergoing hysterectomy.
   Methods Patients were allocated randomly to one of three groups: group A (n = 50) received 50 mg dolasetron orally, group B (n = 50) received 20 mg metoclopramide intravenously and placebo orally, group C (n = 50) received placebo orally. If patients complained of retching or vomiting, or if patients demanded an antiemetic, 1.25 mg droperidol was administrated intravenously. To quantify postoperative nausea and vomiting the following score was used: 0 = no nausea, 1 = nausea, 2 = retching, 3 = single vomiting, 4 = multiple vomiting. The Raatz test was used to analyse postoperative nausea and vomiting (PONV) scores.
   Results Dolasetron reduced the postoperative nausea and vomiting score significantly (P < 0.02 vs. metoclopramide; P < 0.0001 vs, placebo). Metoclopramide also reduced the postoperative nausea and vomiting score (P < 0.02 vs. placebo). Fisher's exact test showed a significant reduction of vomiting in the dolasetron group compared with metoclopramide-treated patients (P < 0.007) ano placebo-treated patients (P < 0.000006) and a significantly lower rate of nausea in comparison to the placebo group (P < 0.009). There were no significant differences between the metoclopramide and the placebo groups (in Fisher's exact test). The use of postoperative droperidol per patient was significantly lower in the dolasetron group (P < 0.04 vs. metoclopramide; P < 0.0001 vs. placebo) than in the metoclopramide (P < 0.02 vs. placebo) and in groups.
   Conclusions Oral dolasetron is more effective than either metoclopramide given intravenously or placebo for preventing vomiting after hysterectomy. It also was significantly superior to either metoclopramide or placebo concerning the PONV score and the need for droperidol rescue.
C1 Hosp City Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Piper, SN (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM wolfgang_maleck@hotmail.com
CR Alon E, 1996, ANESTH ANALG, V82, P338, DOI 10.1097/00000539-199602000-00022
   ANDREWS PLR, 1992, BRIT J ANAESTH, V69, pS2, DOI 10.1093/bja/69.supplement_1.2S
   Balfour JA, 1997, DRUGS, V54, P273, DOI 10.2165/00003495-199754020-00008
   CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145
   Cohen MM, 1999, ANESTHESIOLOGY, V91, P1882, DOI 10.1097/00000542-199912000-00043
   DEXTER F, 1995, ANESTHESIOLOGY, V82, P94, DOI 10.1097/00000542-199501000-00013
   Diemunsch P, 1997, CAN J ANAESTH, V44, P173, DOI 10.1007/BF03013007
   DIEMUNSCH P, 1996, EUR HOSP PHARM S1, V2, pS34
   Dixon RM, 1996, PHARMACOTHERAPY, V16, P245
   Eberhart LHJ, 1999, ANASTH INTENSIV NOTF, V34, P480
   Fragneto R Y, 1998, Curr Opin Anaesthesiol, V11, P275, DOI 10.1097/00001503-199806000-00006
   Frighetto L, 1999, CAN J ANAESTH, V46, P536, DOI 10.1007/BF03013543
   Fujii Y, 1998, ANAESTHESIA, V53, P1165, DOI 10.1046/j.1365-2044.1998.00633.x
   Fujii Y, 1999, LARYNGOSCOPE, V109, P664, DOI 10.1097/00005537-199904000-00028
   Fujii Y, 1998, BRIT J ANAESTH, V81, P526, DOI 10.1093/bja/81.4.526
   Graczyk SG, 1997, ANESTH ANALG, V84, P325, DOI 10.1097/00000539-199702000-00015
   Harter R L, 2000, Curr Opin Anaesthesiol, V13, P469, DOI 10.1097/00001503-200008000-00012
   Henzi I, 1999, BRIT J ANAESTH, V83, P761
   KAPUR PA, 1991, ANESTH ANALG, V73, P243
   KLOCKGETHERRADKE A, 1992, ANAESTHESIST, V41, P254
   Kovac A, 1996, ANESTHESIOLOGY, V85, pA1
   Morris RW, 1998, EUR J ANAESTH, V15, P69, DOI 10.1017/S0265021598000131
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   Rubenstein EB, 1997, CANCER-AM CANCER SOC, V79, P1216, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1216::AID-CNCR22>3.0.CO;2-1
   Rusch D, 1999, ANAESTHESIST, V48, P705, DOI 10.1007/s001010050774
   RUSSELL D, 1994, ANAESTHESIA S, V49, P6
   Triem JG, 1999, ANASTH INTENSIV NOTF, V34, P340, DOI 10.1055/s-1999-9974
   Warriner CB, 1997, CAN J ANAESTH, V44, P1167, DOI 10.1007/BF03013339
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Woodward DK, 1999, BRIT J ANAESTH, V83, P933, DOI 10.1093/bja/83.6.933
NR 31
TC 18
Z9 18
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD APR
PY 2001
VL 18
IS 4
BP 251
EP 256
DI 10.1046/j.0265-0215.2000.00810.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 422NH
UT WOS:000168124700007
PM 11350463
DA 2018-12-27
ER

PT J
AU Melillo, RM
   Pierantoni, GM
   Scala, S
   Batista, S
   Fedele, M
   Stella, A
   De Biasio, MC
   Chiappetta, G
   Fidanza, V
   Condorelli, G
   Santoro, M
   Croce, CM
   Viglietto, G
   Fusco, A
AF Melillo, RM
   Pierantoni, GM
   Scala, S
   Batista, S
   Fedele, M
   Stella, A
   De Biasio, MC
   Chiappetta, G
   Fidanza, V
   Condorelli, G
   Santoro, M
   Croce, CM
   Viglietto, G
   Fusco, A
TI RETRACTED: Critical role of the HMGI(Y) proteins in adipocytic cell
   growth and differentiation (Retracted article. See vol. 38, 2018)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID ENHANCER-BINDING-PROTEIN; NF-KAPPA-B; MOUSE OBESE GENE; IFN-BETA GENE;
   3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; VIRUS INDUCTION; C/EBP
   FAMILY; DNA-BINDING; HMG I(Y)
AB The high-mobility group I (HMGI) nonhistone chromosomal proteins HMGI(Y) and HMGI-C have been implicated in defining chromatin structure and in regulating the transcription of several genes. These proteins have been implicated in adipocyte homeostasis: a severe deficiency of fat tissue is found in mice with targeted disruption of the HMGI-C locus, and lipomagenesis in humans is frequently associated with somatic mutations of HMGI genes. The aim of this study was to examine the role of HMGI(Y) proteins in adipocytic cell growth and differentiation. First, we found that differentiation of the preadipocytic 3T3-L1 cell line caused early induction of HMGI(Y) gene expression. Suppression of HMGI(Y) expression by antisense technology dramatically increased the growth rate and impaired adipocytic differentiation in these cells. The process of adipogenic differentiation involves the interplay of several transcription factors, among which is the CCAAT/enhancer-binding protein (C/EBP) family of proteins. These factors are required for the transcriptional activation of adipocyte-specific genes. We also tested the hypothesis that HMGI(Y) might participate in transcriptional control of adipocyte specific promoters. We found that HMGI(Y) proteins bind C/EBP beta in vivo and in vitro. Furthermore, we show that HMGI(Y) strongly potentiates the capacity of C/EBP beta to transactivate the leptin promoter, an adipose-specific promoter. Taken together, these results indicate that the HMGI(Y) proteins play a critical role in adipocytic cell growth and differentiation.
C1 Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.
   Ist Nazl Tumori, Fdn Senatore Pascale, I-80131 Naples, Italy.
   Univ Studi Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy.
   Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
RP Fusco, A (reprint author), Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.
EM afusco@napoli.com
RI Scala, Stefania/K-1380-2016; Fedele, Monica/C-1417-2015
OI Scala, Stefania/0000-0001-9524-2616; MELILLO, Rosa
   Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197;
   Condorelli, Gianluigi/0000-0003-0481-6843
CR Abe N, 1999, CANCER RES, V59, P1169
   ASHAR HR, 1995, CELL, V82, P57
   Bandiera A, 1998, CANCER RES, V58, P426
   Battista S, 1999, CANCER RES, V59, P4793
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794
   Chiappetta G, 1998, CANCER RES, V58, P4193
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   CHIAPPETTA G, 1995, ONCOGENE, V10, P1307
   Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778
   CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323
   CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593
   CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694
   DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318
   FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894
   Fedele M, 1996, CANCER RES, V56, P1896
   GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1
   HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887
   Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873
   JOHN S, 1995, MOL CELL BIOL, V15, P1786
   JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114
   LEGER H, 1995, MOL CELL BIOL, V15, P3738
   LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0
   Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367
   MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793
   Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013
   MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021
   Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796
   Saisanit S, 1997, MOL CELL BIOL, V17, P844, DOI 10.1128/MCB.17.2.844
   Sambrook J, 1989, MOL CLONING LAB MANU
   SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x
   SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436
   STUDENT AK, 1980, J BIOL CHEM, V255, P4745
   TAMIMI Y, 1993, CANCER RES, V53, P5512
   Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432
   Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1
   THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644
   Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000
   Wu ZD, 1996, MOL CELL BIOL, V16, P4128
   Xiao S, 1997, AM J PATHOL, V150, P901
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
NR 48
TC 71
Z9 72
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD APR
PY 2001
VL 21
IS 7
BP 2485
EP 2495
DI 10.1128/MCB.21.7.2485-2495.2001
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 410QW
UT WOS:000167451500023
PM 11259597
OA Green Published
DA 2018-12-27
ER

PT J
AU Paventi, S
   Parafati, MA
   Di Luzio, E
   Pellegrino, CA
AF Paventi, S
   Parafati, MA
   Di Luzio, E
   Pellegrino, CA
TI RETRACTED: Usefulness of two-dimensional echocardiography and myocardial
   perfusion imaging for immediate evaluation of chest pain in the
   emergency department (Retracted Article. See vol 53, pg 492, 2002)
SO RESUSCITATION
LA English
DT Article; Retracted Publication
DE myocardial infarction; echocardiography; perfusion imaging; emergency
   treatment
ID ISCHEMIA; ROOM; INFARCTION; RISK
AB Background: Accurate identification of patients in the emergency department at high risk of acute coronary syndrome with possible myocardial ischaemia and a nonischaemic electrocardiogram is problematic. Both two-dimensional echocardiography and myocardial perfusion imaging with technetium-99m-sestamibi can identify patients at low and high risk. however comparative studies are lacking.;Methods and results: We studied 655 consecutively patients considered at low or moderate risk for myocardial ischaemia in our Emergency Department (ED). On the basis of the presenting history, physical examination, and electrocardiogram they underwent both echocardiography and myocardial perfusion imaging within 4 h of ED presentation. End points included myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) and positive stress perfusion imaging. Both imaging procedures were performed in the ED on 470 patients. Overall agreement between the two techniques was high (concordance 90%) in the patients who had myocardial infarction or underwent coronary angiography. Conclusions: Agreement between the two imaging techniques is high when used in patients with possible myocardial ischaemia. Both techniques identified patients at high risk who required admission and those who could be safely discharged directly from the ED. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
C1 Univ Roma La Sapienza, Emergency Dept, Rome, Italy.
   Univ Roma La Sapienza, Inst Publ Hlth, Rome, Italy.
   Univ Roma La Sapienza, Nucl Med Lab, Rome, Italy.
RP Paventi, S (reprint author), Via Fabiola 9, I-00152 Rome, Italy.
EM paventi@iol.it
CR BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2
   BILODEAU L, 1994, J AM COLL CARDIOL, V23, P1016
   FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4
   GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0
   GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301
   Kontos MC, 1998, AM HEART J, V136, P724, DOI 10.1016/S0002-8703(98)70022-5
   LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65
   PEELS CH, 1990, AM J CARDIOL, V65, P687, DOI 10.1016/0002-9149(90)90143-O
   SABIA P, 1991, CIRCULATION, V84, pI85
   SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002
   Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2
   TRIPPI JA, 1996, J AM SOC ECHOCARDIOG, V131, P32
   VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O
NR 13
TC 9
Z9 9
U1 2
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD APR
PY 2001
VL 49
IS 1
BP 47
EP 51
DI 10.1016/S0300-9572(00)00330-0
PG 5
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA 435NT
UT WOS:000168888100007
PM 11334691
DA 2018-12-27
ER

PT J
AU Pyen, JS
   Whang, K
   Hu, C
   Hong, SK
   Lee, MS
   Lee, JY
   Hong, SW
AF Pyen, JS
   Whang, K
   Hu, C
   Hong, SK
   Lee, MS
   Lee, JY
   Hong, SW
TI RETRACTED: Tic couvulsif caused by cerebellopontine angle schwannoma
   (Retracted article. See vol. 49, pg. 1060, 2008)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE Tic convulsif; schwannoma; cerebellopontine tumor
ID HEMIFACIAL SPASM; CONVULSIF; NEURALGIA
AB A case is presented of painful tic convulsif caused by schwannoma in the cerebellopontine angle (CPA), with right trigeminal neuralgia and ipsilateral hemifacial spasm. Magnetic resonance images showed a 4 cm round mass displacing the 4th ventricle and distorting the brain stem in the right CPA. The schwannoma, which compressed the fifth and seventh cranial nerves directly, was subtotally removed by suboccipital craniectomy. Postoperatively, the patient had a complete relief from the hemifacial spasm and marked improvement from trigeminal neuralgia. The painful tie convulsif in this case was probably produced by the tumor compressing and displacing the anterior cerebellar artery directly.
C1 Yonsei Univ, Wonju Coll Med, Dept Neurosurg, Wonju 220701, Wonju, South Korea.
   Yonsei Univ, Wonju Coll Med, Dept Radiol, Wonju 220701, Wonju, South Korea.
   Yonsei Univ, Wonju Coll Med, Dept Neurol, Wonju 220701, Wonju, South Korea.
   Yonsei Univ, Wonju Coll Med, Dept Pathol, Wonju 220701, Wonju, South Korea.
RP Whang, K (reprint author), Yonsei Univ, Wonju Coll Med, Dept Neurosurg, 162 Ilsan Dong, Wonju 220701, Wonju, South Korea.
EM whangkum@wonju.yonsei.ac.kr
OI Whang, Kum/0000-0002-3701-847X
CR COOK BR, 1984, J NEUROSURG, V61, P949, DOI 10.3171/jns.1984.61.5.0949
   Cushing H, 1920, AM J MED SCI, V160, P157, DOI 10.1097/00000441-192008000-00001
   JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321
   MAURICEWILLIAMS RS, 1973, POSTGRAD MED J, V49, P742, DOI 10.1136/pgmj.49.576.742
   OGASAWARA H, 1995, J NEUROSURG, V82, P895, DOI 10.3171/jns.1995.82.5.0895
   WAKABAYASHI T, 1983, SURG NEUROL, V19, P244, DOI 10.1016/S0090-3019(83)80008-1
NR 6
TC 9
Z9 9
U1 2
U2 9
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD APR
PY 2001
VL 42
IS 2
BP 255
EP 257
DI 10.3349/ymj.2001.42.2.255
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 430CP
UT WOS:000168556200016
PM 11371116
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Low-temperature transport in high-mobility polycrystalline
   pentacene field-effect transistors - art. no. 125304 (Retracted article.
   See vol B 66, art. no. 249907, 2002)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID THIN-FILM TRANSISTORS; ORGANIC TRANSISTORS; GATE VOLTAGE; BAND-TAILS;
   CONDUCTIVITY; SYSTEMS
AB The charge transport in high-mobility polycrystalline pentacene field-effect transistors is investigated in the temperature range from 1.7 to 30 K for carrier concentrations ranging from 10(11) to 5 x 10(12) cm(-2). For hole densities below 6 x 10(11) cm(-2) the conductance in the channel is thermally activated and can be described in the framework of an Anderson localization in two dimensions. The charge carriers are localized in the band tails. At low temperatures the transport mechanism crosses over to Mott-type variable-range hopping and finally to Efros-Shklovskii-type hopping due to the presence of a Coulomb gap. Above the critical concentration of 6 x 10(11) cm(-2) the conductance is more or less temperature independent. However, effects of weak localization are observed below 10 K.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR ABRAHAMS E, 1979, PHYS REV LETT, V42, P673, DOI 10.1103/PhysRevLett.42.673
   ANDO T, 1982, REV MOD PHYS, V54, P437, DOI 10.1103/RevModPhys.54.437
   BROWN AR, 1994, SYNTHETIC MET, V68, P65, DOI 10.1016/0379-6779(94)90148-1
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   de Leeuw D, 1999, PHYS WORLD, V12, P31
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   DIMITRIADIS CA, 1994, SOLID STATE PHENOM, V37, P577
   EFROS AL, 1975, J PHYS C SOLID STATE, V8, pL49, DOI 10.1088/0022-3719/8/4/003
   Horowitz G, 2000, J APPL PHYS, V87, P4456, DOI 10.1063/1.373091
   Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U
   Ishida S, 2000, PHYS STATUS SOLIDI B, V218, P89, DOI 10.1002/(SICI)1521-3951(200003)218:1<89::AID-PSSB89>3.0.CO;2-9
   KATZ HE, 1998, HDB OLIGO POLYTHIOPH
   Klauk H, 1999, IEEE T ELECTRON DEV, V46, P1258, DOI 10.1109/16.766895
   Klauk H, 2000, SOLID STATE TECHNOL, V43, P63
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   LEVINSON J, 1982, J APPL PHYS, V53, P1193, DOI 10.1063/1.330583
   LICCIARDELLO DC, 1976, SURF SCI, V58, P89, DOI 10.1016/0039-6028(76)90117-5
   MOTT N, 1975, PROC R SOC LON SER-A, V345, P169, DOI 10.1098/rspa.1975.0131
   Mott N. F., 1968, Journal of Non-Crystalline Solids, V1, P1, DOI 10.1016/0022-3093(68)90002-1
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   PEPPER M, 1974, PHYS LETT A, VA 48, P113, DOI 10.1016/0375-9601(74)90424-1
   POLLITT S, 1976, SURF SCI, V58, P79, DOI 10.1016/0039-6028(76)90116-3
   Schon JH, 2000, ORG ELECTRON, V1, P57, DOI 10.1016/S1566-1199(00)00010-0
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SCHON JH, IN PRESS J APPL PHYS
   Serikawa T, 1996, JPN J APPL PHYS 1, V35, P937, DOI 10.1143/JJAP.35.937
   van Lien N., 1995, PHYS LETT A, V207, P379
   Vissenberg MCJM, 1998, PHYS REV B, V57, P12964, DOI 10.1103/PhysRevB.57.12964
   WERNER J, 1985, PHYS REV B, V31, P6881, DOI 10.1103/PhysRevB.31.6881
NR 30
TC 12
Z9 12
U1 2
U2 13
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1098-0121
EI 1550-235X
J9 PHYS REV B
JI Phys. Rev. B
PD MAR 15
PY 2001
VL 63
IS 12
AR 125304
DI 10.1103/PhysRevB.63.125304
PG 5
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 416XW
UT WOS:000167806600071
DA 2018-12-27
ER

PT J
AU Petty, HR
   Kindzelskii, AL
AF Petty, HR
   Kindzelskii, AL
TI RETRACTED: Dissipative metabolic patterns respond during neutrophil
   transmembrane signaling (Retracted article. See vol. 107, pg. 10330,
   2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE cell polarity; nonequilibrium thermodynamics; chemotaxis
ID SPATIOTEMPORAL ORGANIZATION; PYODERMA-GANGRENOSUM; TRAVELING-WAVES;
   ENZYME MODEL; LIVING CELLS; OSCILLATIONS; BIOCHEMISTRY; ACTIVATION;
   ALPHA(X)BETA(2); GLYCOLYSIS
AB Self-organization is a common theme in biology. One mechanism of self-organization is the creation of chemical patterns by the diffusion of chemical reactants and their nonlinear interactions. We have recently observed sustained unidirectional traveling chemical redox [NAD(P)H - NAD(P)(+)] waves within living polarized neutrophils. The present study shows that an intracellular metabolic wave responds to formyl peptide receptor agonists, but not antagonists, by splitting into two waves traveling in opposite directions along a cell's long axis. Similar effects were noted with other neutrophil-activating substances. Moreover, when cells were exposed to an N-formyl-methionyl-leucyl-phenylalanine (FMLP) gradient whose source was perpendicular to the cell's long axis, cell metabolism was locally perturbed with reorientation of the pattern in a direction perpendicular to the initial cellular axis. Thus, extracellular activating signals and the signals' spatial cues are translated into distinct intracellular dissipative structures.
C1 Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.
RP Petty, HR (reprint author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.
EM hpetty@biology.biosci.wayne.edu
FU NCI NIH HHS [1RO1-CA74120, R01 CA074120]
CR Adachi Y, 1998, J INVEST DERMATOL, V111, P259, DOI 10.1046/j.1523-1747.1998.00311.x
   Adachi Y, 1999, J IMMUNOL, V163, P4367
   ALIT A, 1999, CELL IMMUNOL, V194, P47
   ATKINS PW, 1998, PHYSICAL CHEM
   BOITEUX A, 1980, BER BUNSEN PHYS CHEM, V84, P392, DOI 10.1002/bbpc.19800840420
   CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953
   FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887
   Glansdorff P., 1971, THERMODYNAMIC THEORY
   GOLDBETT.A, 1973, P NATL ACAD SCI USA, V70, P3255, DOI 10.1073/pnas.70.11.3255
   GRIMES GJ, 1973, EXP CELL RES, V79, P375, DOI 10.1016/0014-4827(73)90457-6
   Hasslacher B, 1993, CHAOS, V3, P7, DOI 10.1063/1.165967
   HERSCHKO.M, 1972, J CHEM PHYS, V56, P1890, DOI 10.1063/1.1677471
   HESS B, 1994, BER BUNSEN PHYS CHEM, V98, P1198, DOI 10.1002/bbpc.19940980926
   HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321
   IMBIHL R, 1995, CHEM REV, V95, P697, DOI 10.1021/cr00035a012
   KAY NE, 1980, J RETICULOENDOTH SOC, V28, P367
   Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0
   Kindzelskii AL, 1998, BIOPHYS J, V74, P90, DOI 10.1016/S0006-3495(98)77770-7
   Kindzelskii AL, 2000, BBA-MOL CELL RES, V1495, P90, DOI 10.1016/S0167-4889(99)00148-2
   LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747
   LEWIS RA, 1990, NEW ENGL J MED, V323, P645
   LIANG B, 1992, J CELL PHYSIOL, V152, P145, DOI 10.1002/jcp.1041520119
   LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015
   Mair T, 1996, J BIOL CHEM, V271, P627, DOI 10.1074/jbc.271.2.627
   MARMILLOT P, 1992, P NATL ACAD SCI USA, V89, P12103, DOI 10.1073/pnas.89.24.12103
   Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0
   Muller SC, 1998, BIOPHYS CHEM, V72, P37, DOI 10.1016/S0301-4622(98)00121-5
   Munuzuri AP, 1997, PHYS REV LETT, V79, P1941, DOI 10.1103/PhysRevLett.79.1941
   Nicolis G, 1989, EXPLORING COMPLEXITY
   Petty HR, 2000, PHYS REV LETT, V84, P2754, DOI 10.1103/PhysRevLett.84.2754
   PETTY HR, 2000, SELF ORG BIOL DYNAMI, P173
   ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368
   ROOS D, 1980, RETICULOENDOTHELIAL, P189
   Schroedinger E, 1944, WHAT IS LIFE
   Scott S. K., 1994, OSCILLATIONS WAVES C
   SHAW JO, 1981, J IMMUNOL, V127, P1250
   Shaya S, 1998, J INVEST DERMATOL, V111, P154, DOI 10.1046/j.1523-1747.1998.00255.x
   SHINJYO T, 1995, PHYSICA D, V84, P212, DOI 10.1016/0167-2789(95)00019-Z
   Tan AS, 1998, BLOOD, V91, P649
   TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012
   TYSON JJ, 1988, PHYSICA D, V32, P327, DOI 10.1016/0167-2789(88)90062-0
   Whitesides GM, 1999, SCIENCE, V284, P89, DOI 10.1126/science.284.5411.89
NR 42
TC 43
Z9 43
U1 3
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 13
PY 2001
VL 98
IS 6
BP 3145
EP 3149
DI 10.1073/pnas.061014298
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 411WB
UT WOS:000167521300040
PM 11248046
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Dodabalapur, A
   Bao, Z
   Kloc, C
   Schenker, O
   Batlogg, B
AF Schon, JH
   Dodabalapur, A
   Bao, Z
   Kloc, C
   Schenker, O
   Batlogg, B
TI RETRACTED: Gate-induced superconductivity in a solution-processed
   organic polymer film (Retracted article. See vol 422 pg 92 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID METAL-INSULATOR-TRANSITION; CONDUCTING POLYMERS; CHARGE-TRANSPORT;
   REGIOREGULAR POLY(3-HEXYLTHIOPHENE); CONJUGATED POLYMERS; HIGH-MOBILITY;
   TRANSISTORS; CRYSTALS; SIZE
AB The electrical and optical properties of conjugated polymers have received considerable attention in the context of potentially low-cost replacements for conventional metals and inorganic semiconductors. Charge transport in these organic materials has been characterized in both the doped-metallic and the semiconducting state(1-4), but superconductivity has not hitherto been observed in these polymers. Here we report a distinct metal-insulator transition and metallic levels of conductivity in a polymer field-effect transistor. The active material is solution-cast regioregular poly(3-hexylthiophene), which forms relatively well ordered films owing to self-organization, and which yields a high charge carrier mobility (0.05-0.1 cm(2) V-1 s(-1)) at room temperature. At temperatures below similar to2.35 K with sheet carrier densities exceeding 2.5 x 10(14) cm(-2), the polythiophene film becomes superconducting. The appearance of superconductivity seems to be closely related to the self-assembly properties of the polymer, as the introduction of additional disorder is found to suppress superconductivity. Our findings therefore demonstrate the feasibility of tuning the electrical properties of conjugated polymers over the largest range possible-from insulating to superconducting.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Konstanz, Dept Phys, D-78457 Constance, Germany.
   ETH Honggerberg, Solid State Phys Lab, CH-8093 Zurich, Switzerland.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011; Dodabalapur, Ananth/H-3043-2012
CR Ahlskog M, 1998, PHYS STATUS SOLIDI B, V205, P305, DOI 10.1002/(SICI)1521-3951(199801)205:1<305::AID-PSSB305>3.0.CO;2-B
   Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   Aleshin A, 1997, SYNTHETIC MET, V90, P61, DOI 10.1016/S0379-6779(97)81227-1
   Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834
   CHIANG CK, 1977, PHYS REV LETT, V39, P1098, DOI 10.1103/PhysRevLett.39.1098
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736
   Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575
   Horowitz G, 2000, ADV MATER, V12, P1046, DOI 10.1002/1521-4095(200007)12:14<1046::AID-ADMA1046>3.0.CO;2-W
   Ishiguro T., 1998, ORGANIC SUPERCONDUCT
   Kim JH, 1997, SYNTHETIC MET, V84, P71, DOI 10.1016/S0379-6779(96)03841-6
   Knupfer M, 1999, PHYS REV LETT, V83, P1443, DOI 10.1103/PhysRevLett.83.1443
   Kobashi M, 1998, MACROMOLECULES, V31, P7273, DOI 10.1021/ma980632u
   Lovinger AJ, 1998, CHEM MATER, V10, P3275, DOI 10.1021/cm980402u
   MARK JE, 1996, PHYSICAL PROPERTIES
   MASUBUCHI S, 1995, SYNTHETIC MET, V74, P151, DOI 10.1016/0379-6779(95)03356-4
   MCCULLOUGH RD, 1993, J AM CHEM SOC, V115, P4910, DOI 10.1021/ja00064a070
   Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036
   NALWA HS, 1997, HDB ORGANIC CONDUCTI
   Osterbacka R, 2000, SCIENCE, V287, P839, DOI 10.1126/science.287.5454.839
   Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008
   Schon JH, 2000, NATURE, V406, P702, DOI 10.1038/35021011
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2000, SYNTHETIC MET, V115, P75, DOI 10.1016/S0379-6779(00)00348-9
   SCHON JH, 2000, PHYS STATUS SOLIDI B, V121, pR4
   SCHON JH, 2000, NATURE, V287, P1022
   SIMANEK E, 1994, INHOMOGENEOUS SUPERC, P50401
   Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   SKOTHEIM TA, 1996, HDB CONJUGATED POLYM
   VERTHAMER NR, 1966, PHYS REV, V147, P295
NR 31
TC 140
Z9 145
U1 5
U2 60
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 8
PY 2001
VL 410
IS 6825
BP 189
EP 192
DI 10.1038/35065565
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 408HJ
UT WOS:000167320500040
PM 11242074
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Hoshi, T
   Toyooka, H
AF Fujii, Y
   Hoshi, T
   Toyooka, H
TI RETRACTED: Colforsin daropate improves contractility in fatigued canine
   diaphragm (Retracted article. See vol. 116, pg. 746, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RESPIRATORY MUSCLES; FAILURE; DOGS; MILRINONE; AMRINONE; ACIDOSIS
AB We studied the effects of colforsin daropate, a water-soluble forskoline derivative, on contractility in fatigued canine diaphragm. Dogs were randomly divided into 4 groups of 8 each. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min, immediately after the end of a fatigue-producing period, Group 1 received no study drug, Group 2 was infused with small-dose colforsin daropate (0.2 mug.kg(-1).min(-1)), Group 3 was infused with large-dose colforsin daropate (0.5 mug.kg(-1).min(-1)), and Group 4 was infused with nicardipne (5 mug.kg(-1).min(-1)) during colforsin daropate (0.5 mug.kg(-1).min(-1)) administration. After the fatigue-producing period, in each group transdiaphragmatic pressure (Pdi) at low-frequency (20-Hz) stimulation deceased from baseline values (P < 0.05), whereas there was no change in Pdi at high-frequency (100-Hz) stimulation. In Groups 2 and 3, during colforsin daropate administration, Pdi to each stimulus increased from fatigued values (P < 0.05). The increase in Pdi was larger in Group 3 than in Group 2 (P < 0.05). In Group 4, the augmentation of Pdi by colforsin daropate was abolished in fatigued diaphragm with an infusion of nicardipine. The integrated diaphragmatic electric activity did not change in any of the groups. We conclude that colforsin daropate improves, in a dose-dependent manner, contractility in fatigued canine diaphragm via its effect on transmembrane calcium movement.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   FUJII Y, 1995, CAN J ANAESTH, V42, P80, DOI 10.1007/BF03010577
   Fujii Y, 1998, ANESTH ANALG, V87, P1077, DOI 10.1097/00000539-199811000-00018
   Fujii Y, 1999, ANESTH ANALG, V89, P781, DOI 10.1097/00000539-199909000-00048
   FUJII Y, 1994, CAN J ANAESTH, V41, P435, DOI 10.1007/BF03009869
   FUJII Y, 1994, ANESTH RESUSCITATION, V30, P217
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   Hosoda S., 1997, JPN J CLIN PHARM THE, V28, P583
   HOSONO M, 1996, CLIN PHARMACOL THER, V6, P1061
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   IDE T, 1992, ANESTH ANALG, V74, P739
   Karlsberg RP, 1996, CLIN CARDIOL, V19, P21, DOI 10.1002/clc.4960190106
   LEJEMTEL TH, 1979, CIRCULATION, V59, P1098, DOI 10.1161/01.CIR.59.6.1098
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
NR 17
TC 4
Z9 4
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2001
VL 92
IS 3
BP 762
EP 766
DI 10.1213/00000539-200103000-00039
PG 5
WC Anesthesiology
SC Anesthesiology
GA 405JW
UT WOS:000167157100038
PM 11226115
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kawasaki, T
AF Fujii, Y
   Tanaka, H
   Kawasaki, T
TI RETRACTED: Preoperative oral granisetron for the prevention of
   postoperative nausea and vomiting after breast surgery (Retracted
   article. See vol. 100, pg. 844, 2013)
SO EUROPEAN JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
DE complications; nausea; vomiting; antiemetics; granisetron; breast
ID RECEPTOR ANTAGONIST
AB Objective: To evaluate the efficacy and safety of oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery.
   Design: Prospective, randomised, double-blind, placebo-controlled study.
   Setting: University affiliated hospital, Japan. Subjects: 100 women listed for partial or modified radical mastectomy with or without axillary dissection.
   Interventions: Patients were given either placebo or granisetron in three different doses (1 mg, 2 mg, 4 mg) orally 1 hour preoperatively (n = 25 in each group). A standard general anaesthetic technique and postoperative analgesia were used.
   Main outcome measures: All episodes of nausea and vomiting during the first 24 hours after anaesthesia.
   Results: Complete response, defined as no nausea and vomiting and no need for a "rescue" antiemetic, during the first 24 hours after anaesthesia was recorded in 13 (52%) with placebo, 14 (56%) with granisetron 1 mg, 22 (88%) with 2 mg, and 22 (88%) with 4 mg, respectively (p = 0.006, Fisher's exact test). No clinically Serious adverse events were seen in any of the groups.
   Conclusion: Preoperative oral granisetron, in doses of more than 2 mg, is effective for the prevention of postoperative nausea and vomiting in women undergoing general anaesthesia for breast surgery.
C1 Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Surg, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
EM yfujii@igaku.md.tsukuba.ac.jp
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1997, ACTA ANAESTH SCAND, V41, P1167
   Fujii Y, 1997, ACTA ANAESTH SCAND, V41, P746, DOI 10.1111/j.1399-6576.1997.tb04777.x
   JAKOBSSON J, 1991, ACTA ANAESTH SCAND, V35, P524, DOI 10.1111/j.1399-6576.1991.tb03341.x
   Maisano R, 1995, ANTICANCER RES, V15, P2287
   ODDBYMUHRBECK E, 1994, ACTA ANAESTH SCAND, V38, P52, DOI 10.1111/j.1399-6576.1994.tb03837.x
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 10
TC 14
Z9 14
U1 4
U2 8
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1102-4151
J9 EUR J SURG
JI Eur. J. Surg.
PD MAR
PY 2001
VL 167
IS 3
BP 184
EP 187
PG 4
WC Surgery
SC Surgery
GA 413EZ
UT WOS:000167598100005
PM 11316402
DA 2018-12-27
ER

PT J
AU Banerjee, AK
   Sherwood, R
   Rennie, JA
   Peters, TJ
AF Banerjee, AK
   Sherwood, R
   Rennie, JA
   Peters, TJ
TI RETRACTED: Sulphasalazine reduces indomethacin induced changes in small
   intestinal permeability in man (Retracted Article)
SO GUT
LA English
DT Correction; Retracted Publication
CR BANERJEE AK, 1990, GUT, V31, pA593
NR 1
TC 0
Z9 0
U1 2
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAR
PY 2001
VL 48
IS 3
BP 286
EP 286
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 406WQ
UT WOS:000167239500003
DA 2018-12-27
ER

PT J
AU D'Souza, MC
   Sharon, M
AF D'Souza, MC
   Sharon, M
TI RETRACTED: In vitro clonal propagation of annatto (Bixa orellana L.)
   (Retracted article. See vol. 53, pg. 73, 2017)
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-PLANT
LA English
DT Article; Retracted Publication
DE annatto; Bixa orellana; multiple shooting; micropropatation
AB A protocol for in vitro propagation of Bixa orellana is described. Plants were regenerated from shoot apex and nodal explants on B5 medium supplemented with 4.9 muM 2-isopentenyl adenine. The multiplication factor of shoot apex explants was higher (nine shoots per explant) than that of the nodal explants (five shoots per explant). Regardless of the position of the nodes, all the nodal explants gave similar responses. However, the size of the nodal explant was an important factor in producing multiple shoots: 0.5 cin nodal explants produced the maximum multiple shoots. Regenerated shoots from shoot apex explants rooted best on MS medium supplemented with 0.05 muM alpha -naphthalene acetic acid (NAA), whereas shoots regenerated from nodal explants needed 2.7 muM NAA for rooting. Eighty per cent survival of in vivo transferred plants occurred on the best potting substrate, coco peat. Since the multiplication factor was nine per explant, this protocol can be used for commercial microprogation. However, the regeneration capacity declined after 10 subcultures. Approximately, 3350 rooted plants could be generated in 10 mo. after eight subcultures, from one shoot with a shoot apex and four nodes.
C1 Gufic Appl Res & Educ Fdn, Andheri E 400093, Mumbai, India.
RP Sharon, M (reprint author), Gufic Appl Res & Educ Fdn, Gufic Bldg,11th Rd,MIDC, Andheri E 400093, Mumbai, India.
EM garef.tcl@mailcity.com
CR CAIUS JF, 1986, MED POISONOUS PLANTS, P141
   COLLINS P, 1991, PROSPECTIVES NATURAL, P1
   GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5
   GAMBORG OL, 1976, IN VITRO CELL DEV B, V12, P473
   Irobi ON, 1996, INT J PHARMACOGN, V34, P87, DOI 10.1076/phbi.34.2.87.13201
   KIRTIKAR KR, 1975, INDIAN MED PLANTS, V1, P216
   KOCHHAR SL, 1981, EC BOT TROPICS, P377
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   RIPLEY KP, 1986, PLANT CELL TISS ORG, V5, P213, DOI 10.1007/BF00040132
   SOLKAR LV, 1992, GLOSSARY INDIAN ME 1, P126
NR 10
TC 18
Z9 22
U1 3
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1054-5476
EI 1475-2689
J9 IN VITRO CELL DEV-PL
JI In Vitro Cell. Dev. Biol.-Plant
PD MAR-APR
PY 2001
VL 37
IS 2
BP 168
EP 172
DI 10.1007/s11627-001-0029-7
PG 5
WC Plant Sciences; Cell Biology; Developmental Biology
SC Plant Sciences; Cell Biology; Developmental Biology
GA 482AD
UT WOS:000171551900012
DA 2018-12-27
ER

PT J
AU Mori, N
   Ueda, A
   Geleziunas, R
   Wada, A
   Hirayama, T
   Yoshimura, T
   Yamamoto, N
AF Mori, N
   Ueda, A
   Geleziunas, R
   Wada, A
   Hirayama, T
   Yoshimura, T
   Yamamoto, N
TI RETRACTED: Induction of monocyte chemoattractant protein 1 by
   Helicobacter pylori involves NF-kappa B (Retracted article. See vol. 79,
   pg. 543, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; GASTRIC EPITHELIAL-CELLS; MESSENGER-RNA
   EXPRESSION; CAG PATHOGENICITY ISLAND; LEUKEMIA-VIRUS TYPE-1;
   INTERLEUKIN-8 PRODUCTION; FACTOR-ALPHA; ANTRAL GASTRITIS; KINASE-ALPHA;
   IKK-ALPHA
AB Helicobacter pylori stimulates secretion of monocyte chemoattractant protein 1 (MCP-1) from gastric epithelial cells. Secretion of this chemokine may be instrumental in monocyte infiltration of the gastric epithelium that characterizes H. pylori gastritis. The aim of this study was to identify the mechanism by which H. pylori induces MCP-1 production. Induction of MCP-1 mRNA was assessed by reverse transcription-PCR. We used luciferase reporter assays to monitor activation of the MCP-1 gene promoter and electrophoretic mobility shift assays to explore binding of transcription factors to this promoter. H. pylori infection increased MCP-1 mRNA expression from gastric epithelial cells. Induction of MCP-1 mRNA relies on an intact cag pathogenicity island. We identified two closely spaced NF-kappaB-binding sites within the MCP-1 distal enhancer as required for H. pylori-induced MCP-1 gene transcription. H. pylori infection led to the specific activation of NF-kappaB complexes containing p50 and p65. Kinase-deficient mutants of NF-kappaB-inducing kinase (NIK) and I kappaB kinases (IKK) caused suppression of MCP-1 distal enhancer-dependent reporter activity following H. pylori infection. H. pylori infection induces the activation of NF-kappaB via the NIK-IKK signaling complex, leading to MCP-1 gene transcription in gastric epithelial cells.
C1 Nagasaki Univ, Inst Trop Med, Dept Prevent Med & AIDS Res, Nagasaki 8528523, Japan.
   Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.
   Yokohama City Univ, Sch Med, Dept Internal Med 1, Yokohama, Kanagawa 232, Japan.
   Gladstone Inst Virol & Immunol, San Francisco, CA USA.
   NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Immunopathol Sect, Frederick, MD 21701 USA.
RP Mori, N (reprint author), Nagasaki Univ, Inst Trop Med, Dept Prevent Med & AIDS Res, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM n-mori@net.nagasaki-u.ac.jp
CR Aihara M, 1997, INFECT IMMUN, V65, P3218
   Ando T, 1996, AM J GASTROENTEROL, V91, P1150
   ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301
   BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703
   Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x
   BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   CALAM J, 1994, EUR J CLIN INVEST, V24, P501, DOI 10.1111/j.1365-2362.1994.tb01099.x
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3
   CRABTREE JE, 1993, SCAND J IMMUNOL, V37, P65, DOI 10.1111/j.1365-3083.1993.tb01666.x
   CRABTREE JE, 1995, J CLIN PATHOL, V48, P41, DOI 10.1136/jcp.48.1.41
   CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61
   CRABTREE JE, 1994, J CLIN PATHOL, V47, P945, DOI 10.1136/jcp.47.10.945
   DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493
   DIXON MF, 1995, BAILLIERE CLIN GASTR, V9, P467, DOI 10.1016/0950-3528(95)90043-8
   FAN XG, 1995, J CLIN PATHOL, V48, P133, DOI 10.1136/jcp.48.2.133
   FORMAN D, 1993, LANCET, V341, P1359
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Goebeler M, 1999, BLOOD, V93, P857
   HUANG JZ, 1995, INFECT IMMUN, V63, P1732
   ISAACSON PG, 1994, HUM PATHOL, V25, P1020, DOI 10.1016/0046-8177(94)90060-4
   Jung HC, 1997, J GASTROEN HEPATOL, V12, P473, DOI 10.1111/j.1440-1746.1997.tb00469.x
   Kasai K, 1996, FEBS LETT, V394, P137, DOI 10.1016/0014-5793(96)00935-0
   Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860
   Mori N, 2000, INFECT IMMUN, V68, P1806, DOI 10.1128/IAI.68.4.1806-1814.2000
   MOSS SF, 1994, GUT, V35, P1567, DOI 10.1136/gut.35.11.1567
   NAKATANI H, 1986, JPN J CANCER RES, V77, P849
   Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655
   NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833
   Peek RM, 1995, LAB INVEST, V73, P760
   Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4
   Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X
   Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7
   SHARMA SA, 1995, INFECT IMMUN, V63, P1681
   Shimoyama T, 1998, J CLIN PATHOL, V51, P765, DOI 10.1136/jcp.51.10.765
   Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4
   TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734
   Taub D D, 1994, Ther Immunol, V1, P229
   UEDA A, 1994, J IMMUNOL, V153, P2052
   Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092
   Valente AJ, 1998, J IMMUNOL, V161, P3719
   Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452
   Watanabe N, 1997, J PHYSIOL PHARMACOL, V48, P405
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Yamaoka Y, 1996, GASTROENTEROLOGY, V110, P1744, DOI 10.1053/gast.1996.v110.pm8964399
   Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7
NR 51
TC 25
Z9 27
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2001
VL 69
IS 3
BP 1280
EP 1286
DI 10.1128/IAI.69.3.1280-1286.2001
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 404GZ
UT WOS:000167090200006
PM 11179289
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Doree, SM
   Mulks, MH
AF Doree, SM
   Mulks, MH
TI RETRACTED: Identification of an Actinobacillus pleuropneumoniae
   consensus promoter structure (Retracted Article. See vol 185, pg 4666,
   2003)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID ESCHERICHIA-COLI; BACILLUS-SUBTILIS; DNA-SEQUENCES; COMPILATION; GENES;
   TRANSCRIPTION; EXPRESSION; ALIGNMENT; CONTACT; CLONING
AB Actinobacillus pleuropneumoniae promoter-containing clones were isolated from a genomic DNA library constructed in our IVET promoter trap vector pTF86. The promoter-containing clones were identified by their ability to drive expression of the promoterless luxAB genes of Vibrio harveyi. The degree of expression was quantifiable, and only high-expression or "hot" promoters were used for this study. Nine clones were sequenced, and their transcriptional start sites were determined by primer extension. The sequences upstream of the start site were aligned, and a consensus promoter structure for A. pleuropneumoniae was identified. The consensus promoter sequence for A. pleuropneumoniae was found to be TATAAT and TTG/AAA, centered approximately 10 and 35 bp upstream of the transcriptional start site, respectively. A comparison of the A. pleuropneumoniae consensus with other prokaryotic consensus promoters showed that the A. pleuropneumoniae consensus promoter is similar to that found in other eubacteria in terms of sequence, with an identical -10 element and a similar but truncated -35 element. However, the A. pleuropneumoniae consensus promoter is unique in the spacing between the -10 and -35 elements. The promoter spacing was analyzed by site-directed mutagenesis, which demonstrated that optimal spacing for an A. pleuropneumoniae promoter is shorter than the spacing identified for Escherichia coli and Bacillus subtilis promoters.
C1 Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.
RP Mulks, MH (reprint author), Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.
EM mulks@pilot.msu.edu
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Bannantine JP, 1997, MICROBIOL-UK, V143, P921, DOI 10.1099/00221287-143-3-921
   CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881
   DEWHIRST FE, 1992, J BACTERIOL, V174, P2002, DOI 10.1128/jb.174.6.2002-2013.1992
   FREY J, 1994, GENE, V142, P97, DOI 10.1016/0378-1119(94)90361-1
   Fuller TE, 1996, INFECT IMMUN, V64, P4659
   Fuller TE, 1999, MICROB PATHOGENESIS, V27, P311, DOI 10.1006/mpat.1999.0309
   *GEN COMP GROUP, 1994, PROGR MAN WISC PACK
   Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x
   HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343
   HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237
   HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351
   HUNNEMAN WA, 1986, VET QUART, V8, P83, DOI 10.1080/01652176.1986.9694024
   Jensen PR, 1998, APPL ENVIRON MICROB, V64, P82
   Langford PR, 1996, INFECT IMMUN, V64, P5035
   LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507
   MALAKOOTI J, 1995, J BACTERIOL, V177, P4372, DOI 10.1128/jb.177.15.4372-4376.1995
   Maniatis T., 1982, MOL CLONING LAB MANU
   NICOLET J, 1992, DIS SWINE, P401
   Patek M, 1996, MICROBIOL-SGM, V142, P1297, DOI 10.1099/13500872-142-5-1297
   Ross W, 1998, J BACTERIOL, V180, P5375
   SEBUNYA TNK, 1983, J AM VET MED ASSOC, V182, P1331
   STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961
   VOSKUIL MI, 1995, MOL MICROBIOL, V17, P271, DOI 10.1111/j.1365-2958.1995.mmi_17020271.x
   WEST SEH, 1995, GENE, V160, P81, DOI 10.1016/0378-1119(95)00236-Y
   Wosten MMSM, 1998, J BACTERIOL, V180, P594
   XIONG XF, 1991, J BACTERIOL, V173, P4570, DOI 10.1128/jb.173.15.4570-4577.1991
NR 27
TC 11
Z9 11
U1 2
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
EI 1098-5530
J9 J BACTERIOL
JI J. Bacteriol.
PD MAR
PY 2001
VL 183
IS 6
BP 1983
EP 1989
DI 10.1128/JB.183.6.1983-1989.2001
PG 7
WC Microbiology
SC Microbiology
GA 407FJ
UT WOS:000167261300017
PM 11222596
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Schlegel, A
   Lisanti, MP
AF Schlegel, A
   Lisanti, MP
TI RETRACTED: Caveolae and their coat proteins, the caveolins: From
   electron microscopic novelty to biological launching pad (Retracted
   Article. See vol 191, pg 366, 2002)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review; Retracted Publication
ID GIRDLE MUSCULAR-DYSTROPHY; PLASMA-MEMBRANE CAVEOLAE; GPI-ANCHORED
   PROTEINS; ROUS-SARCOMA-VIRUS; ONCOGENICALLY TRANSFORMED-CELLS; SRC
   TYROSINE KINASES; TRANS-GOLGI-NETWORK; HUMAN BREAST-CANCER; C-TERMINAL
   DOMAIN; IN-VIVO
AB Caveolins are a family of proteins that coat the cytoplasmic face of caveolae, vesicular invaginations of the plasma membrane. These proteins are central to the organization of the proteins and lipids that reside in caveolae. Caveolins transport cholestrol to and from caveolae, and they regulate the activity of signaling proteins that reside in caveolae. Studying the genes encoding the caveolae coat proteins, we have learned much about how they perform these multiple functions. (C) 2001 Wiley-Liss, Inc.
C1 Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA.
   Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA.
RP Lisanti, MP (reprint author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM lisanti@aecom.yu.edu
RI Lisanti, Michael/C-6866-2013; Lisanti, Michael/B-6131-2018
FU NIGMS NIH HHS [T32-GM07288]
CR ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359
   Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j
   Atshaves BP, 2000, J BIOL CHEM, V275, P36852, DOI 10.1074/jbc.M003434200
   Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127
   Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291
   CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728
   CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421
   Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429
   Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525
   DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838
   DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x
   Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0
   Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172
   Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448
   Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374
   Field FJ, 1998, J LIPID RES, V39, P1938
   Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o
   Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382
   FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004
   FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655
   FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O
   Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099
   Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097
   Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200
   Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633
   Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632
   GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401
   GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517
   GLENNEY JR, 1989, J BIOL CHEM, V264, P20163
   GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X
   Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043
   Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200
   Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3
   IUTTENBOGAARD A, 2000, J BIOL CHEM, V275, P25595
   KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381
   Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003
   KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003
   Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750
   Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661
   Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568
   Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4
   Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647
   LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   Li SW, 1996, J BIOL CHEM, V271, P3863
   Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7
   LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595
   LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111
   Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443
   MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582
   MAYOR S, 1995, MOL BIOL CELL, V6, P929
   McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871
   Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365
   MONIER S, 1995, MOL BIOL CELL, V6, P911
   Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708
   Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925
   MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339
   Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200
   Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419
   PALADE GE, 1953, J APPL PHYS, V24, P1424
   Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718
   Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353
   Razani B, 2000, J CELL SCI, V113, P2103
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z
   SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407
   SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789
   Scheel J, 1999, NAT CELL BIOL, V1, P127
   Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795
   Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131
   Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200
   Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660
   SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128
   SEVERS NJ, 1988, J CELL SCI, V90, P341
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104
   SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427
   Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690
   Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160
   Song KS, 1997, CELL MOL BIOL, V43, P293
   Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398
   Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200
   Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255
   Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366
   Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025
   Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123
   Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525
   Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9
   WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7
   Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5
   YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445
NR 95
TC 49
Z9 50
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2001
VL 186
IS 3
BP 329
EP 337
DI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1045>3.0.CO;2-0
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 397VT
UT WOS:000166719000002
PM 11169971
DA 2018-12-27
ER

PT J
AU Park, CJ
   Shin, R
   Park, JM
   Lee, GJ
   Yoo, TH
   Paek, KH
AF Park, CJ
   Shin, R
   Park, JM
   Lee, GJ
   Yoo, TH
   Paek, KH
TI RETRACTED: A hot pepper cDNA encoding a pathogenesis-related protein 4
   is induced during the resistance response to tobacco mosaic virus
   (Retracted article. See vol. 35, pg. 173, 2013)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE cDNA cloning; differential screening; hypersensitive response;
   pathogenesis-related protein 4; pepper (Capsicum annuum L.); tobacco
   mosaic virus
ID SYSTEMIC ACQUIRED-RESISTANCE; SALICYLIC-ACID; DIFFERENTIAL DISPLAY;
   BIOLOGICAL FUNCTION; GENE-EXPRESSION; INDUCTION; THAUMATIN; LEAVES;
   IDENTIFICATION; PURIFICATION
AB Hot pepper (Capsicum annuum) plants exhibit a hypersensitive response (HR) against infection by many tobamoviruses. A clone (CaPR-4 encoding a putative pathogenesis-related protein 4 was isolated by differential screening of a cDNA library prepared from resistant pepper plant leaves inoculated with tobacco mosaic virus (TMV) pathotype P-0. The predicted amino acid sequence of CaPR-4 is very similar to those of other plant PR-4s, Southern blot analysis showed that small gene families of PR-4-related sequences were present in the pepper genome. Hot pepper cultivar Bugang, resistant to TMV-P-0 and susceptible to TMV-P-1.2, induced CaPR-4 expression by pathotype P-0 inoculation in inoculated and systemic leaves, but not by pathotype P-1.2. Effects of exogenously applied abiotic elicitors upon the CaPR-4 expression were also examined. The expression of the CaPR-4 gene was stimulated by methyl jasmonate (MeJA), ethephon and wounding treatment. However, application of salicylic acid (SA) did not trigger the expression. Evidence is emerging that jasmonic acid and ethylene play key roles in the SA-independent pathways of plant-pathogen interaction. Taken together, these results suggest that the CaPR-4 gene is one of the defense-related genes conferring resistance on pepper plants by the SA-independent pathway and the cross-talk between signaling compounds, jasmonic acid and ethylene could have a great regulatory potential in a plant's defense against TMV.
C1 Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
RP Paek, KH (reprint author), Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea.
EM khpaek95@mail.korea.ac.kr
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Antoniw JF, 1978, BIOCHEM SOC T, V6, P248, DOI 10.1042/bst0060248
   Ausubel F, 1995, SHORT PROTOCOLS MOL
   BERZALHERRANZ A, 1995, VIROLOGY, V209, P498, DOI 10.1006/viro.1995.1282
   BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553
   BOUKEMA IW, 1982, CAPSICUM NEWSL, V3, P47
   CORNELISSEN BJC, 1986, NATURE, V321, P531, DOI 10.1038/321531a0
   Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2
   GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776
   KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x
   LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750
   LEON J, 1993, PLANT PHYSIOL, V103, P323, DOI 10.1104/pp.103.2.323
   Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245
   PENNINCHX IA, 1996, PLANT CELL, V8
   PIERPOINT WS, 1987, PHYSIOL MOL PLANT P, V31, P291, DOI 10.1016/0885-5765(87)90072-5
   Pieterse CMJ, 1996, PLANT CELL, V8, P1225
   Poirier GMC, 1997, NUCLEIC ACIDS RES, V25, P913, DOI 10.1093/nar/25.4.913
   RICHARDSON M, 1987, NATURE, V327, P432, DOI 10.1038/327432a0
   Sambrook J., 1989, MOL CLONING
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235
   UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692
   VANLOON LC, 1987, PLANT MOL BIOL, V9, P593, DOI 10.1007/BF00020536
   Vidal S, 1997, PLANT J, V11, P115, DOI 10.1046/j.1365-313X.1997.11010115.x
   Vidal S, 1998, MOL PLANT MICROBE IN, V11, P23, DOI 10.1094/MPMI.1998.11.1.23
   YUN HK, 1996, MOL CELLS, V8, P388
   Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454
NR 27
TC 45
Z9 47
U1 1
U2 11
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD FEB 28
PY 2001
VL 11
IS 1
BP 122
EP 127
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 408HC
UT WOS:000167319900020
PM 11266114
DA 2018-12-27
ER

PT J
AU Benard, O
   Naor, Z
   Seger, R
AF Benard, O
   Naor, Z
   Seger, R
TI RETRACTED: Role of dynamin, Src, and Ras in the protein kinase
   C-mediated activation of ERK by gonadotropin-releasing hormone
   (Retracted article. See vol. 292, pg. 8855, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID G-BETA-GAMMA; COUPLED RECEPTOR INTERNALIZATION; SIGNAL-REGULATED KINASE;
   MAP KINASE; TYROSINE-KINASE; DIFFERENTIAL ACTIVATION; DEPENDENT
   ACTIVATION; GROWTH-FACTOR; EGF RECEPTOR; MUSCLE-CELLS
AB G-protein-coupled receptors are a large group of integral membranal receptors, which in response to ligand binding initiate diverse downstream signaling. Here we studied the gonadotropin-releasing hormone (GnRH) receptor, which uses Gq for its downstream signaling. We show that extracellular signal-regulated kinase (ERK) activation is fully dependent on protein kinase C (PKC), but only partially dependent on Src, dynamin, and Ras. Receptor tyrosine kinases, FAK, G beta gamma, and beta -arrestin, which were implicated in some G-protein-coupled receptor signaling to MAPK cascades, do not play a role in the GnRH to ERK pathway. Our results suggest that the activation of ERK by GnRH involves two distinct signaling pathways, which converge at the level of Raf-1. The main pathway involves a direct activation of Raf-1 by PKC, and this step is partially dependent on a second pathway consisting of Ras activation, which occurs in a dynamin-dependent manner, downstream of Src.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
   Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM rony.seger@weizmann.ac.il
CR Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185
   AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309
   BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606
   Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982
   CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X
   CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259
   CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0
   Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685
   Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0
   Davis RJ, 1999, BIOCHEM SOC SYMP, P1
   DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267
   deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005
   Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0
   Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363
   GAUSE KC, 1993, J BIOL CHEM, V268, P16124
   Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251
   Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186
   Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927
   Harris D, 1997, J BIOL CHEM, V272, P13534, DOI 10.1074/jbc.272.21.13534
   Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299
   HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706
   KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0
   Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301
   Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29
   Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677
   Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4
   Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443
   Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109
   MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734
   MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015
   Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796
   Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182
   Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5
   Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489
   Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673
   Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0
   Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310
   ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531
   Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x
   Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435
   Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189
   SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H
   SEGER R, 1994, J BIOL CHEM, V269, P25699
   SEGER R, 1995, FASEB J, V9, P726
   Shacham S, 1999, ANN ENDOCRINOL-PARIS, V60, P79
   Sim Pauline, 1993, Biochemical Society Transactions, V21, p357S
   SIM PJ, 1995, MOL CELL ENDOCRINOL, V112, P257, DOI 10.1016/0303-7207(95)03616-F
   Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7
   STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462
   Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304
   VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0
   Widmann C, 1999, PHYSIOL REV, V79, P143
   Zhang J, 1997, RECEPTOR CHANNEL, V5, P193
   Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302
   Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5
NR 60
TC 88
Z9 88
U1 2
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 16
PY 2001
VL 276
IS 7
BP 4554
EP 4563
DI 10.1074/jbc.M006995200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 428WH
UT WOS:000168484300007
PM 11083862
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Boldt, J
   Kumle, B
   Suttner, S
   Haisch, G
AF Boldt, J
   Kumle, B
   Suttner, S
   Haisch, G
TI RETRACTED: Point-of-care (POC) testing of lactate in the intensive care
   patient - Accuracy, reliability, and costs of different measurement
   systems (Retracted article. See vol. 55, pg. 903, 2011)
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE critically ill; point-of-care (POC); lactate; accuracy; costs; outcome;
   hypoperfusion
ID CLINICAL MEASUREMENT; BLOOD LACTATE; ANALYZER; SHOCK
AB Background: Point-of-care (POC) monitoring may facilitate diagnostic and therapeutic interventions in the critically ill. In a prospective study reliability and costs of two POC lactate testing devices were compared to the central laboratory lactate monitoring method.
   Methods: From arterial whole blood and capillary blood samples of 40 intensive care unit (ICU) patients lactate concentrations were measured using either a battery-powered handheld lactate analyser (Accusport(R)) or a bench-top blood gas analyser (Chiron 865 series) and compared with lactate measured by the hospital's central laboratory ('reference' method). Measurements were carried out on the day of inclusion in the study ('baseline'), 8 h later, and in the morning of the 1st, 2nd, and 3rd days thereafter. Costs for blood lactate measurements were analysed for each method.
   Results: A total of 197 lactate measurements were done with each system. Lactate measured from arterial blood using the Accusport(R) and the central laboratory showed excellent agreement (bias: -0.15 mmol/l; relative error: -2.74%). Lactate measured by the blood gas analyser had also excellent agreement with the reference method (bias: 0.09 mmol/l; relative error: 2.24%) and the hand-held device (bias: -0.24 mmol/l; relative error: -5.06%). Time from blood sampling to availability of data was significantly longer for the central laboratory (85+/-35 min [range: 45-168 min]) than for both POC systems (range: 1-10 [range: 45-168 min]) than for both POC systems (range: 1-10 min). Total cost for measuring blood lactate was lowest using the Accusport(R) device.
   Conclusion: The trend towards miniaturizing laboratory monitoring devices will continue, resulting in greater flexibility of management of the critically ill. Blood lactate can rapidly, easily, accurately, and economically be measured at the bedside with the hand-held monitor apparatus Accusport(R) and the bench-top blood gas analyser.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014
   BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956
   BLAND JM, 1986, LANCET, V1, P307
   BRODER G, 1964, SCIENCE, V143, P1457, DOI 10.1126/science.143.3613.1457
   Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023
   CASTRO JH, 1995, AM J CLIN PATHOL S1, V104, pS95
   DECRESCE RP, 1995, ARCH PATHOL LAB MED, V119, P898
   DESPOTIS GJ, 1994, J THORAC CARDIOV SUR, V107, P271
   JACOBS E, 1995, AM J CLIN PATHOL, V104, pS33
   KEFFER JH, 1995, AM J CLIN PATHOL, V104, pS107
   Kellum JA, 1998, CRIT CARE MED, V26, P1783, DOI 10.1097/00003246-199811000-00010
   KOST GJ, 1993, CRIT REV CL LAB SCI, V30, P153, DOI 10.3109/10408369309084667
   Lamb L S Jr, 1995, Am J Crit Care, V4, P429
   Mantha S, 2000, ANESTH ANALG, V90, P593, DOI 10.1097/00000539-200003000-00018
   Marecaux G, 1996, INTENS CARE MED, V22, P404, DOI 10.1007/BF01712155
   MIZOCK BA, 1992, CRIT CARE MED, V20, P80, DOI 10.1097/00003246-199201000-00020
   Moomey CB, 1999, CRIT CARE MED, V27, P154, DOI 10.1097/00003246-199901000-00044
   Muller MM, 1999, ANAESTHESIST, V48, P3, DOI 10.1007/s001010050661
   Noordally O, 1999, INTENS CARE MED, V25, P508, DOI 10.1007/s001340050889
   OBERHARDT BJ, 1991, CLIN CHEM, V37, P520
   PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006
   ROSE VL, 1993, ARCH PATHOL LAB MED, V117, P611
   Shoemaker WC, 1996, CRIT CARE MED, V24, pS12
   Slomovitz BM, 1998, CRIT CARE MED, V26, P1523, DOI 10.1097/00003246-199809000-00019
   VINCENT JL, 1998, INT J INTENSIVE CARE, P49
   ZALOGA GP, 1990, CHEST, V97, pS185
NR 26
TC 42
Z9 42
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD FEB
PY 2001
VL 45
IS 2
BP 194
EP 199
DI 10.1034/j.1399-6576.2001.450210.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 398VX
UT WOS:000166778100010
PM 11167165
OA Bronze
DA 2018-12-27
ER

PT J
AU Reuben, SS
AF Reuben, SS
TI RETRACTED: Ambulatory anesthesia for knee arthroscopy (Retracted
   article. See vol. 121, pg. 1404, 2015)
SO ANESTHESIA AND ANALGESIA
LA English
DT Letter; Retracted Publication
ID LOCAL-ANESTHESIA; ANALGESIA; MORPHINE
C1 Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA.
RP Reuben, SS (reprint author), Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA.
CR BUCKLEY JR, 1989, J BONE JOINT SURG BR, V71, P126
   FRUENSGAARD S, 1990, INT ORTHOP, V14, P37
   HUTLIN J, 1992, ARTHROSCOPY, V8, P239
   Joshi W, 2000, ANESTH ANALG, V90, P1102, DOI 10.1097/00000539-200005000-00018
   Mulroy MF, 2000, ANESTH ANALG, V91, P860, DOI 10.1097/00000539-200010000-00017
   Reuben SS, 1996, ANESTH ANALG, V82, P1036, DOI 10.1097/00000539-199605000-00027
   YACOBUCCI G N, 1990, Arthroscopy, V6, P311, DOI 10.1016/0749-8063(90)90062-I
NR 7
TC 3
Z9 3
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD FEB
PY 2001
VL 92
IS 2
BP 556
EP 556
DI 10.1213/00000539-200102000-00051
PG 1
WC Anesthesiology
SC Anesthesiology
GA 396RF
UT WOS:000166649800051
PM 11159269
DA 2018-12-27
ER

PT J
AU Yamashita, J
   Itoh, M
   Kuro, T
   Kobayashi, Y
   Ogata, M
   Takaoka, M
   Matsumura, Y
AF Yamashita, J
   Itoh, M
   Kuro, T
   Kobayashi, Y
   Ogata, M
   Takaoka, M
   Matsumura, Y
TI RETRACTED: Pre- or post- ischemic treatment with a novel Na+/Ca2+
   exchange inhibitor, KB-R7943, shows renal protective effects in rats
   with ischemic acute renal failure (Retracted article. See vol. 349, pg.
   344, 2014)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID ENDOTHELIN RECEPTOR SUBTYPES; INTRACELLULAR CALCIUM; SELECTIVE LIGANDS;
   ET(A) RECEPTOR; UP-REGULATION; REVERSE MODE; CELLS; ANTAGONIST;
   IDENTIFICATION; PHOSPHORAMIDON
AB We investigated the effects of pre- or post-ischemic treatment with KB-R7943, a new Na+/Ca2+ exchange inhibitor, on ischemic acute renal failure (ARF) in rats, and these were compared with the effects of verapamil. Ischemic ARF was induced by clamping the left renal pedicle for 45-min followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal function markedly decreased 24 h after reperfusion. Pre-ischemic treatment with KB-R7943 or verapamil attenuated the ARF-induced renal dysfunction. The ischemia/reperfusion-induced renal dysfunction was overcome by post-ischemic treatment with KB-R7943 but not with verapamil. Histopathological examination of the kidney of ARF rats revealed severe renal damage, and suppression of the damage was seen with post-ischemic treatment with KB-R7943. KB-R7943 markedly suppressed the increment of endothelin-1 (ET-1) content in the kidney at 2, 6, and 24 h after reperfusion. No significant changes in Na+/Ca2+ exchanger protein expression in renal tissue were observed with 45-min ischemia, 6 h after reperfusion and KB-R7943 treatment. These results suggest that Ca2+ overload via the reverse mode of Na+/Ca2+ exchange, followed by ET-1 overproduction, seems to play an important role in the pathogenesis of the ischemia/reperfusion-induced ARF. KB-R7943, which is effective in both cases of pre- and post-ischemic treatments, may prove to be an effective therapeutic agent for cases of ischemic ARF.
C1 Osaka Univ Pharmaceut Sci, Dept Pharmacol, Osaka 5691094, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Osaka 5691094, Japan.
EM matumrh@oysun01.oups.ac.jp
CR ALLEN DG, 1993, ADV EXP MED BIOL, V346, P19
   Birck R, 1998, J CARDIOVASC PHARM, V32, P80, DOI 10.1097/00005344-199807000-00013
   BIRD JE, 1995, PHARMACOLOGY, V50, P9
   Crosignani B, 1998, RIV NUOVO CIMENTO, V21, P1, DOI 10.1007/BF02874290
   CROSS HR, 1995, MAGNET RESON MED, V34, P673, DOI 10.1002/mrm.1910340505
   DAI LJ, 1994, PFLUGERS ARCH, V425, P1
   DENNIS SC, 1990, CIRC RES, V66, P1156, DOI 10.1161/01.RES.66.4.1156
   FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915
   FUJITA K, 1995, BRIT J PHARMACOL, V114, P925, DOI 10.1111/j.1476-5381.1995.tb13292.x
   GELLAI M, 1995, J PHARMACOL EXP THER, V275, P200
   GOLDFARB D, 1983, P SOC EXP BIOL MED, V172, P389
   Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391
   Kuro T, 1999, JPN J PHARMACOL, V81, P247, DOI 10.1254/jjp.81.247
   Kuro T, 2000, JPN J PHARMACOL, V82, P307, DOI 10.1254/jjp.82.307
   Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868
   LAZDUNSKI M, 1985, J MOL CELL CARDIOL, V17, P1029, DOI 10.1016/S0022-2828(85)80119-X
   MATSUMURA Y, 1990, BIOCHEM BIOPH RES CO, V167, P203, DOI 10.1016/0006-291X(90)91751-D
   MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S
   MINO N, 1992, EUR J PHARMACOL, V221, P77
   Nakamura Aki, 1998, Folia Pharmacologica Japonica, V111, P105, DOI 10.1254/fpj.111.105
   NAMBI P, 1992, MOL PHARMACOL, V42, P336
   NAMBI P, 1992, ENDOCRINOLOGY, V131, P1081, DOI 10.1210/en.131.3.1081
   Pogwizd SM, 1999, CIRC RES, V85, P1009
   Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250
   REILLY RF, 1993, AM J PHYSIOL, V265, pF327
   SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x
   SCHRIER RW, 1987, KIDNEY INT, V32, P313, DOI 10.1038/ki.1987.211
   SCHRIER RW, 1984, AM J PHYSIOL, V247, pF365
   SHIBOUTA Y, 1990, LIFE SCI, V46, P1611
   SHIMIZU T, 1990, J PHARMACOL EXP THER, V255, P484
   SOLEZ K, 1974, KIDNEY INT, V6, P24, DOI 10.1038/ki.1974.74
   TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045
   VEMULAPALLI S, 1993, PHARMACOLOGY, V47, P188, DOI 10.1159/000139096
   VERDONCK L, 1993, CARDIOVASC RES, V27, P349
   Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x
   Wilhelm SM, 1999, KIDNEY INT, V55, P1011, DOI 10.1046/j.1523-1755.1999.0550031011.x
   WILSON DR, 1984, KIDNEY INT, V25, P519, DOI 10.1038/ki.1984.48
   WONG SME, 1986, AM J PHYSIOL, V250, pC841
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
   YU ASL, 1992, AM J PHYSIOL, V263, pF680
NR 40
TC 35
Z9 41
U1 6
U2 12
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD FEB
PY 2001
VL 296
IS 2
BP 412
EP 419
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 393HG
UT WOS:000166462700024
PM 11160625
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Kobayashi, N
AF Fujii, Y
   Saitoh, Y
   Kobayashi, N
TI RETRACTED: Prevention of vomiting after tonsillectomy in children:
   Granisetron versus ramosetron (Retracted article. See vol. 127, Pg E334,
   2017)
SO LARYNGOSCOPE
LA English
DT Article; Retracted Publication
DE tonsillectomy; nausea; vomiting; antiemetics; ramosetron; granisetron
ID STRABISMUS SURGERY; POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST;
   ONDANSETRON; EMESIS; DIMENHYDRINATE; PLACEBO
AB Objective/Hypothesis: Granisetron, a selective 8-hydroxytryptamine type 3 receptor antagonist, is effective for the prevention of vomiting after tonsillectomy in children. Ramosetron (Nasea; Yamanouchi; Tokyo, Japan), another new antagonist of 5-hydroxytryptamione type 3 receptor, has more potent and longer-acting properties than granisetron (Kytril; Smith Kline Beecham, London, UK) against cisplatin-induced emesis. This study was undertaken to compare the efficacy and safety of granisetron and ramosetron for the prevention of vomiting after pediatric tonsillectomy. Study Design: Prospective, randomized, double-blinded study. Methods: Ninety pediatric patients, aged 4 to 10 years, received intravenously granisetron 40 mug/kg or ramosetron 6 mug/kg (n = 45 each) at the end of surgery. The same standard general anesthetic technique and postoperative analgesia were used throughout. Emetic episodes and safety assessment were performed during the first 24-hour period and the next 24-hour period after anesthesia. Results: The rates of patients being emesis-free during the period from 0 to 24 hours after anesthesia were 89% with granisetron and 93% with ramosetron, respectively (P = .357); the corresponding rates during the period from 24 to 48 hours after anesthesia were 71% and 93%, respectively (P = .006). No clinically serious adverse events attributable to the study drugs were observed in any of the groups. Conclusion: Ramosetron is a better antiemetic than granisetron for the long-term prevention of postoperative vomiting in children undergoing general anesthesia for tonsillectomy.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Tosride City, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Otolaryngol, Tosride City, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJIBARA A, 1996, KISO TO RINSHO, V30, P1965
   Fujii Y, 1998, PAEDIATR ANAESTH, V8, P241, DOI 10.1046/j.1460-9592.1998.00206.x
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P1095, DOI 10.1007/BF03011834
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   Fujii Y, 1999, LARYNGOSCOPE, V109, P1988, DOI 10.1097/00005537-199912000-00017
   FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005
   Hamid SK, 1998, ANESTH ANALG, V86, P496, DOI 10.1097/00000539-199803000-00008
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   KUMAKURA H, 1990, J CLIN THER MED, V5, P25
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556
   Vener DF, 1996, ANESTH ANALG, V82, P728, DOI 10.1097/00000539-199604000-00009
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 20
TC 9
Z9 9
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2001
VL 111
IS 2
BP 255
EP 258
DI 10.1097/00005537-200102000-00013
PG 4
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 400VG
UT WOS:000166891900013
PM 11210871
DA 2018-12-27
ER

PT J
AU Nezhat, C
   Pennington, E
   Nezhat, F
AF Nezhat, C
   Pennington, E
   Nezhat, F
TI RETRACTED: Laparoscopically assisted anterior rectal wall resection and
   reanastomosis for deeply infiltrating endometriosis (Retracted Article)
SO SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES
LA English
DT Correction; Retracted Publication
CR Nezhat C, 1991, Surg Laparosc Endosc, V1, P106
   Nezhat F, 1992, Surg Laparosc Endosc, V2, P212
   2000, SURG LAPAROSC ENDOSC, V10, P191
NR 3
TC 2
Z9 2
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1530-4515
EI 1534-4908
J9 SURG LAPARO ENDO PER
JI Surg. Laparosc. Endosc. Pct. Tech.
PD FEB
PY 2001
VL 11
IS 1
BP 1
EP 1
PG 1
WC Surgery
SC Surgery
GA 406AM
UT WOS:000167192800001
DA 2018-12-27
ER

PT J
AU Muenchen, HJ
   Poncza, PJ
   Pienta, KJ
AF Muenchen, HJ
   Poncza, PJ
   Pienta, KJ
TI RETRACTED: Different docetaxel-induced apoptotic pathways are present in
   prostate cancer cell lines LNCaP and PC-3 (Retracted Article. See vol
   61, pg 1293, 2003)
SO UROLOGY
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; CLUSTERIN; PROTEASE; OVEREXPRESSION; ACTIVATION;
   EXPRESSION; CASPASES; MOUSE; CED-3; FAS
AB Objectives. To investigate the molecular machinery of docetaxel (Taxotere)-initiated death signaling on prostate cancer cell lines LNCaP and PC-3. Taxotere is a member of the taxane family of chemotherapeutic agents. It has been shown to disrupt microtubule dynamics causing mitotic arrest, which leads to cell death. Taxotere has demonstrated induction of cell death in LNCaP and PC-3 cells. However, the pathways by which apoptosis occurs differ in each cell line.
   Methods. The prostate cancer cell lines, LNCaP and PC-3, were treated with 40 nM Taxotere for Various lengths of time (0.5 to 24 hours). Western blot analysis was used for protein analysis.
   Results. LNCaP cells demonstrated caspase-3 and caspase-7 cleavage, and PC-3 cells demonstrated only caspase-8 and BH3-interacting domain death agonist cleavage. Only LNCaP cells were observed to express clusterin expression; PC-3 cells expressed a novel apoptosis inhibitor, survivin.
   Conclusions. In this study, we demonstrated two distinctly different Taxotere-induced apoptotic pathways in LNCaP and PC-3 cells that may be of clinical importance when treating prostate cancer. UROLOGY 57: 366-370, 2001. (C) 2001, Elsevier Science Inc.
C1 Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
RP Muenchen, HJ (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, 1500 E Med Ctr Dr,7303 CCGC, Ann Arbor, MI 48109 USA.
OI Pienta, Kenneth/0000-0002-4138-2186
FU NCI NIH HHS [P50 CA69568]
CR BLASCHUK O, 1983, J BIOL CHEM, V258, P7714
   BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3
   Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621
   Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720
   Escuin D, 1999, Clin Lung Cancer, V1, P138, DOI 10.3816/CLC.1999.n.011
   FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464
   Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3
   Haldar S, 1997, CANCER RES, V57, P229
   Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Marcelli M, 1999, CANCER RES, V59, P382
   Michel D, 1997, J CELL SCI, V110, P1635
   Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687
   Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   Panvichian R, 1998, CANCER RES, V58, P4667
   ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M
   Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4
   SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561
   SENSIBAR JA, 1995, CANCER RES, V55, P2431
   Sintich SM, 1999, PROSTATE, V39, P87
   YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9
NR 23
TC 27
Z9 32
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD FEB
PY 2001
VL 57
IS 2
BP 366
EP 370
DI 10.1016/S0090-4295(00)00935-3
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 403BU
UT WOS:000167023300039
PM 11182366
DA 2018-12-27
ER

PT J
AU Krishnamoorthy, RR
   Agarwal, P
   Prasanna, G
   Vopat, K
   Lambert, W
   Sheedlo, HJ
   Pang, IH
   Shade, D
   Wordinger, RH
   Yorio, T
   Clark, AF
   Agarwal, N
AF Krishnamoorthy, RR
   Agarwal, P
   Prasanna, G
   Vopat, K
   Lambert, W
   Sheedlo, HJ
   Pang, IH
   Shade, D
   Wordinger, RH
   Yorio, T
   Clark, AF
   Agarwal, N
TI RETRACTED: Characterization of a transformed rat retinal ganglion cell
   line (Retracted article. See vol. 1544, pg. 62, 2014)
SO MOLECULAR BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE Thy-1; glial fibrillary acidic protein; glaucoma; psi 2E1A virus; serum
   deprivation; apoptosis; neurotrophin; excitotoxicity
ID PRIMARY CONGENITAL GLAUCOMA; OPEN-ANGLE GLAUCOMA; NEONATAL-RAT;
   IN-VITRO; THY-1 ANTIGEN; PHOTORECEPTOR CELLS; NEUROTROPHIC FACTOR;
   CYTOCHROME P4501B1; APOPTOSIS; SURVIVAL
AB The purpose of the present study was to establish a rat retinal ganglion cell line by transformation of rat retinal cells. For this investigation, retinal cells were isolated from postnatal day 1 (PN1) rats and transformed with the psi2 E1A virus. In order to isolate retinal ganglion cells (RGC), single cell clones were chosen at random from the transformed cells. Expression of Thy-1 (a marker for RGC), glial fibrillary acidic protein (GFAP, a positive marker for Muller cells), HPC-1/syntaxin (a marker for amacrine cells), 8A1 (a marker for horizontal and ganglion cells) and neurotrophins was studied using reverse transcriptase-polymerase chain reaction (RT-PCR), immunoblotting and immunocytochemistry. One of the retinal cell clones, designated RGC-5, was positive for Thy-1, Brn-3C, Neuritin, NMDA receptor, GABA-B receptor, and synaptophysin expression and negative for GFAP, HPC-1, and 8A1, suggesting that it represented a putative RGC clone. The results of RT-PCR analysis were confirmed by immunocytochemistry for Thy-1 and GFAP. Upon further characterization by immunoblotting, the RGC-5 clone was positive for Thy-1, negative for GFAP, 8A1 and syntaxin. RGC 5 cells were also positive for the expression of neurotrophins and their cognate receptors. To establish the physiological relevance of RGC-5, the effects of serum/trophic factor deprivation and glutamate toxicity were analyzed to determine if these cells would undergo apoptosis. The protective effects of neurotrophins on RGC-5 after serum deprivation was also investigated. Apoptosis was studied by terminal deoxynucleotidyl transferase-mediated fluoresceinated dUTP nick end labeling (TUNEL). Serum deprivation resulted in apoptosis and supplementation with both BDNF and NT-4 in the growth media, protected the RGC-5 cells from undergoing apoptosis. On differentiation with succinyl concanavaIin A (sConA), RGC-5 cells became sensitive to glutamate toxicity, which could be reversed by inclusion of ciplizone (MK801). In conclusion, a transformed rat retinal cell line, RGC-5, has certain characteristics of retinal ganglion cells based on Thy-1 and Brn-3C expression and its sensitivity to glutamate excitotoxicity and neurotrophin withdrawal. These cells may be valuable in understanding of retinal ganglion cell biology and physiology including in vitro manipulations in experimental models of glaucoma. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 UNT Hlth Sci Ctr, Dept Pathol & Anat, Ft Worth, TX 76107 USA.
   UNT, Texas Acad Math & Sci, Denton, TX USA.
   UNT Hlth Sci Ctr, Dept Pharmacol, Ft Worth, TX 76107 USA.
   Alcon Res Ltd, Ft Worth, TX USA.
RP Agarwal, N (reprint author), UNT Hlth Sci Ctr, Dept Pathol & Anat, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM nagarwal@hsc.unt.edu
RI Wordinger, Robert/A-6811-2009
OI Wordinger, Robert/0000-0002-2861-8967
CR Agarwal N, 1997, BIOCHEM BIOPH RES CO, V230, P251, DOI 10.1006/bbrc.1996.5937
   Agarwal N, 1996, BIOCHEM BIOPH RES CO, V225, P84, DOI 10.1006/bbrc.1996.1134
   Aguayo AJ, 1996, CIBA F SYMP, V196, P135
   Atkinson J, 1999, DEV BRAIN RES, V112, P173, DOI 10.1016/S0165-3806(98)00165-5
   BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7
   BARNSTABLE CJ, 1996, BRAIN RES, V352, P286
   BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4
   BEALE R, 1982, NEUROCHEM INT, V4, P587, DOI 10.1016/0197-0186(82)90049-3
   BERKELAAR M, 1994, J NEUROSCI, V14, P4368
   BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3
   BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223
   COHEN A, 1994, J NEUROBIOL, V25, P953, DOI 10.1002/neu.480250805
   DEARAUJO EG, 1990, BRAZ J MED BIOL RES, V23, P743
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   EISENFELD AJ, 1984, INVEST OPHTH VIS SCI, V25, P1321
   Frade JM, 1997, DEVELOPMENT, V124, P3313
   GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408
   GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   GUENTHER E, 1994, J NEUROSCI METH, V51, P177, DOI 10.1016/0165-0270(94)90008-6
   Hu DN, 1997, J GLAUCOMA, V6, P37
   JOHNSON JE, 1986, J NEUROSCI, V6, P3031
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEIFER D, 1984, SCIENCE, V224, P303, DOI 10.1126/science.6143400
   LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916
   MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632
   MCCAFFERY CA, 1984, DEV BIOL, V104, P441, DOI 10.1016/0012-1606(84)90100-3
   MORRIS RJ, 1989, CELL SURFACE ANTIGEN, P121
   Otori Y, 1998, INVEST OPHTH VIS SCI, V39, P972
   Pang IH, 1999, INVEST OPHTH VIS SCI, V40, P1170
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   RABACCHI SA, 1994, NEUROSCIENCE, V63, P969, DOI 10.1016/0306-4522(94)90565-7
   RABACCHI SA, 1994, J NEUROSCI, V14, P5292
   RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5
   ROQUE RS, 1990, GLIA, V3, P464, DOI 10.1002/glia.440030605
   SARTHY PV, 1983, J NEUROSCI, V3, P2532
   SCHMID S, 1995, NEUROSCI LETT, V199, P91, DOI 10.1016/0304-3940(95)12020-5
   Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66
   SEIGEL GM, 1992, EXP CELL RES, V199, P240, DOI 10.1016/0014-4827(92)90430-G
   Sheedlo HJ, 1996, DEV BRAIN RES, V93, P88, DOI 10.1016/0165-3806(96)00008-9
   SHIOSAKA S, 1984, J NEUROSCI METH, V10, P229, DOI 10.1016/0165-0270(84)90059-1
   Stoilov I, 1998, AM J HUM GENET, V62, P573, DOI 10.1086/301764
   Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   TAKAHASHI N, 1991, EXP EYE RES, V53, P565, DOI 10.1016/0014-4835(91)90214-Y
   TASCHENBERGER H, 1995, J NEUROSCI, V15, P2240
   Wadia JS, 1998, J NEUROSCI, V18, P932
   XIANG MQ, 1995, J NEUROSCI, V15, P4762
NR 52
TC 284
Z9 293
U1 3
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-328X
J9 MOL BRAIN RES
JI Mol. Brain Res.
PD JAN 31
PY 2001
VL 86
IS 1-2
BP 1
EP 12
DI 10.1016/S0169-328X(00)00224-2
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 397WP
UT WOS:000166721100003
PM 11165366
DA 2018-12-27
ER

EF